

**APRIL 3, 1991**

**OLYMPIA, WASHINGTON**

**ISSUE 91-07**



---

## **IN THIS ISSUE**

Agriculture, Department of  
Attorney General, Office of the  
Building Code Council  
Community Development, Department of  
Convention and Trade Center  
Ecology, Department of  
Edmonds Community College  
Engineers and Land Surveyors Registration  
Board  
Fisheries, Department of  
Forest Practices Board  
Gambling Commission  
Governor, Office of the  
Hardwoods Commission  
Health, Board of  
Health, Department of  
Hearing Aid Council  
Higher Education Personnel Board  
Information Services, Department of

Insurance Commissioner, Office of  
Labor and Industries, Department of  
Licensing, Department of  
Lottery Commission  
Nursing, Board of  
Parks and Recreation Commission  
Personnel Board  
Pharmacy, Board of  
Public Disclosure Commission  
Public Instruction, Superintendent of  
Real Estate Commission  
Revenue, Department of  
Secretary of State  
Social and Health Services, Department of  
Tax Appeals, Board of  
Transportation Commission  
Utilities and Transportation Commission  
Walla Walla Community College  
Washington State Patrol

(Subject/Agency index at back of issue)  
This issue contains documents officially  
filed not later than March 20, 1991

## CITATION

Cite all material in the Washington State Register by its issue number and sequence within that issue, preceded by the acronym WSR. Example: the 37th item in the August 5, 1981, Register would be cited as WSR 81-15-037.

## PUBLIC INSPECTION OF DOCUMENTS

A copy of each document filed with the code reviser's office, pursuant to chapter 34.05 RCW, is available for public inspection during normal office hours. The code reviser's office is located on the ground floor of the Legislative Building in Olympia. Office hours are from 8 a.m. to 5 p.m., Monday through Friday, except legal holidays. Telephone inquiries concerning material in the Register or the Washington Administrative Code (WAC) may be made by calling (206) 753-7470 (SCAN 234-7470).

## REPUBLICATION OF OFFICIAL DOCUMENTS

All documents appearing in the Washington State Register are prepared and printed at public expense. There are no restrictions on the republication of official documents appearing in the Washington State Register. All news services are especially encouraged to give wide publicity to all documents printed in the Washington State Register.

## CERTIFICATE

Pursuant to RCW 34.08.040, the publication of rules or other information in this issue of the Washington State Register is hereby certified to be a true and correct copy of such rules or other information, except that headings of public meeting notices have been edited for uniformity of style.

DENNIS W. COOPER  
Code Reviser

---

---

## STATE MAXIMUM INTEREST RATE

The maximum allowable interest rate applicable for the month of April 1991 pursuant to RCW 19.52.020 is twelve point zero percent (12.00%).

**NOTICE: FEDERAL LAW PERMITS FEDERALLY INSURED FINANCIAL INSTITUTIONS IN THE STATE TO CHARGE THE HIGHEST RATE OF INTEREST THAT MAY BE CHARGED BY ANY FINANCIAL INSTITUTION IN THE STATE. THE MAXIMUM ALLOWABLE RATE OF INTEREST SET FORTH ABOVE MAY NOT APPLY TO A PARTICULAR TRANSACTION.**

The maximum allowable retail installment contract service charge applicable for calendar year 1991 pursuant to RCW 63.14.130(1)(a) is thirteen point seven five percent (13.75%).

The maximum allowable retail installment contract service charge for the purchase of a motor vehicle pursuant to RCW 63.14.130(2)(a) is twelve point two five percent (12.25%) for the second calendar quarter of 1991.

The maximum allowable retail installment contract service charge for the purchase of a vessel pursuant to RCW 63.14.130(3)(a) is twelve point zero percent (12.0%) for the second calendar quarter of 1991.

---

---

# WASHINGTON STATE REGISTER

(ISSN 0164-6389) is published twice each month by the Statute Law Committee, Office of the Code Reviser, Olympia, WA 98504, pursuant to RCW 34.08.020. Subscription rate is \$161.85 per year, sales tax included, post-paid to points in the United States. Second-class postage paid at Olympia, Washington.

POSTMASTER: SEND ADDRESS CHANGES TO:

WASHINGTON STATE REGISTER  
Code Reviser's Office  
Legislative Building  
Olympia, WA 98504

The Washington State Register is an official publication of the state of Washington. It contains proposed, emergency, and permanently adopted administrative rules, as well as other documents filed with the code reviser's office pursuant to RCW 34.08.020 and 42.30.075. Publication of any material in the Washington State Register is deemed to be official notice of such information.

Raymond W. Haman  
*Chairman, Statute Law Committee*

Kerry S. Radcliff  
*Editor*

Dennis W. Cooper  
*Code Reviser*

Joyce Matzen  
*Subscription Clerk*

Gary Reid  
*Chief Assistant Code Reviser*

## STYLE AND FORMAT OF THE WASHINGTON STATE REGISTER

### 1. ARRANGEMENT OF THE REGISTER

Documents are arranged within each issue of the Register according to the order in which they are filed in the code reviser's office during the pertinent filing period. The three part number in the heading distinctively identifies each document, and the last part of the number indicates the filing sequence within an issue's material.

### 2. PROPOSED, ADOPTED, AND EMERGENCY RULES OF STATE AGENCIES AND INSTITUTIONS OF HIGHER EDUCATION

The three types of rule-making actions taken under the Administrative Procedure Act (chapter 34.05 RCW) may be distinguished by the size and style of type in which they appear.

- (a) **Proposed rules** are those rules pending permanent adoption by an agency and are set forth in eight point type.
- (b) **Adopted rules** have been permanently adopted and are set forth in ten point type.
- (c) **Emergency rules** have been adopted on an emergency basis and are set forth in ten point oblique type.

### 3. PRINTING STYLE—INDICATION OF NEW OR DELETED MATERIAL

RCW 34.05.395 requires the use of certain marks to indicate amendments to existing agency rules. This style quickly and graphically portrays the current changes to existing rules as follows:

- (a) In amendatory sections—
  - (i) underlined material is new material;
  - (ii) deleted material is (~~lined out and bracketed between double parentheses~~);
- (b) Complete new sections are prefaced by the heading NEW SECTION;
- (c) The repeal of an entire section is shown by listing its WAC section number and caption under the heading REPEALER.

### 4. EXECUTIVE ORDERS, COURT RULES, NOTICES OF PUBLIC MEETINGS

Material contained in the Register other than rule-making actions taken under the APA does not necessarily conform to the style and format conventions described above. The headings of these other types of material have been edited for uniformity of style; otherwise the items are shown as nearly as possible in the form submitted to the code reviser's office.

### 5. EFFECTIVE DATE OF RULES

- (a) Permanently adopted agency rules normally take effect thirty days after the rules and the agency order adopting them are filed with the code reviser's office. This effective date may be delayed or advanced and such an effective date will be noted in the promulgation statement preceding the text of the rule.
- (b) Emergency rules take effect upon filing with the code reviser's office unless a later date is provided by the agency. They remain effective for a maximum of one-hundred-twenty days from the date of filing.
- (c) Rules of the state Supreme Court generally contain an effective date clause in the order adopting the rules.

### 6. EDITORIAL CORRECTIONS

Material inserted by the code reviser's office for purposes of clarification or correction or to show the source or history of a document is enclosed in [brackets].

### 7. INDEX AND TABLES

A combined subject matter and agency index and a table of WAC sections affected may be found at the end of each issue.

1990 – 1991

DATES FOR REGISTER CLOSING, DISTRIBUTION, AND FIRST AGENCY ACTION

Issue No.	Closing Dates <sup>1</sup>			Distribution Date	First Agency Hearing Date <sup>3</sup>
	Non-OTS & 30 p. or more	Non-OTS & 11 to 29 p.	OTS <sup>2</sup> or 10 p. max. Non-OTS		
<i>For Inclusion in—</i>	<i>File no later than—</i>			<i>Count 20 days from—</i>	<i>For hearing on or after</i>
90-14	Jun 7	Jun 21	Jul 5	Jul 18	Aug 7
90-15	Jun 20	Jul 5	Jul 18	Aug 1	Aug 21
90-16	Jul 5	Jul 18	Aug 1	Aug 15	Sep 4
90-17	Jul 25	Aug 8	Aug 22	Sep 5	Sep 25
90-18	Aug 8	Aug 22	Sep 5	Sep 19	Oct 9
90-19	Aug 22	Sep 5	Sep 19	Oct 3	Oct 23
90-20	Sep 5	Sep 19	Oct 3	Oct 17	Nov 6
90-21	Sep 26	Oct 10	Oct 24	Nov 7	Nov 27
90-22	Oct 10	Oct 24	Nov 7	Nov 21	Dec 11
90-23	Oct 24	Nov 7	Nov 21	Dec 5	Dec 25
90-24	Nov 7	Nov 21	Dec 5	Dec 19	Jan 8, 1991
91-01	Nov 21	Dec 5	Dec 19, 1990	Jan 2, 1991	Jan 22
91-02	Dec 5	Dec 19, 1990	Jan 2, 1991	Jan 16	Feb 5
91-03	Dec 26, 1990	Jan 9, 1991	Jan 23	Feb 6	Feb 26
91-04	Jan 9	Jan 23	Feb 6	Feb 20	Mar 12
91-05	Jan 23	Feb 6	Feb 20	Mar 6	Mar 26
91-06	Feb 6	Feb 20	Mar 6	Mar 20	Apr 9
91-07	Feb 20	Mar 6	Mar 20	Apr 3	Apr 23
91-08	Mar 6	Mar 20	Apr 3	Apr 17	May 7
91-09	Mar 20	Apr 3	Apr 17	May 1	May 21
91-10	Apr 3	Apr 17	May 1	May 15	Jun 4
91-11	Apr 24	May 8	May 22	Jun 5	Jun 25
91-12	May 8	May 22	Jun 5	Jun 19	Jul 9
91-13	May 22	Jun 5	Jun 19	Jul 3	Jul 23
91-14	Jun 5	Jun 19	Jul 3	Jul 17	Aug 6
91-15	Jun 26	Jul 10	Jul 24	Aug 7	Aug 27
91-16	Jul 10	Jul 24	Aug 7	Aug 21	Sep 10
91-17	Jul 24	Aug 7	Aug 21	Sep 4	Sep 24
91-18	Aug 7	Aug 21	Sep 4	Sep 18	Oct 8
91-19	Aug 21	Sep 4	Sep 18	Oct 2	Oct 22
91-20	Sep 4	Sep 18	Oct 2	Oct 16	Nov 5
91-21	Sep 25	Oct 9	Oct 23	Nov 6	Nov 26
91-22	Oct 9	Oct 23	Nov 6	Nov 20	Dec 10
91-23	Oct 23	Nov 6	Nov 20	Dec 4	Dec 24
91-24	Nov 6	Nov 20	Dec 4	Dec 18	Jan 7, 1992

<sup>1</sup>All documents are due at the code reviser's office by 5:00 p.m. on or before the applicable closing date for inclusion in a particular issue of the Register; see WAC 1-21-040.

<sup>2</sup>A filing of any length will be accepted on the closing dates of this column if it has been prepared and completed by the order typing service (OTS) of the code reviser's office; see WAC 1-21-040. Agency-typed material is subject to a ten page limit for these dates; longer agency-typed material is subject to the earlier non-OTS dates.

<sup>3</sup>At least twenty days before the rule-making hearing, the agency shall cause notice of the hearing to be published in the Register; see RCW 34.05.320(1). These dates represent the twentieth day after the distribution date of the applicable Register.



**WSR 91-05-029**

**ERRATA**

**DEPARTMENT OF HEALTH**

[Order 134—Filed February 12, 1991, 2:35 p.m.]

**Reviser's note:** The following recodification section was adopted by the Department of Licensing in Order 134 and was filed in the code reviser's office on February 12, 1991. Through a clerical error, the incorrect recodification section was published. The recodification section as it appears below is exactly as filed by the department. Pursuant to RCW 34.05.380(2), the effective date of the recodification section is March 15, 1991.

**RECODIFICATION SECTION**

The following section is being recodified:

308-31-055 as 246-922-990

**WSR 91-07-001**

**ATTORNEY GENERAL OPINION**

**Cite as: AGO 1991 No. 7**

[March 4, 1991]

**DEPARTMENT OF REVENUE—TAXATION—PROPERTY—  
PUBLIC FUNDS—PUBLIC ASSISTANCE**

1. Article 7, section 1, of the Washington Constitution, provides that all taxes on real property be uniform. House Bill 1297 which authorizes payments to certain people, calculated with reference to the taxes levied on their primary residence, does not violate the uniformity requirement.
2. Article 11, section 9, of the Washington Constitution, prohibits releasing or discharging state taxes on a county, its inhabitants or its property. The payment of assistance from funds appropriated for that purpose by the Legislature in House Bill 1297 does not constitute a release or discharge of the state property tax levied for the support of the common schools.
3. Article 8, sections 5 and 7, of the Washington Constitution, prohibits gifts of public funds. The payment of assistance to certain citizens authorized by House Bill 1297 is a gift of public funds because the payments do not carry out a fundamental governmental function and there is no consideration for the payments.
4. Article 8, sections 5 and 7, of the Washington Constitution, do not prohibit gifts of public funds that are necessary for the support of the poor. House Bill 1297 authorized assistance to persons with \$30,000 or less of combined disposable income. The question of whether House Bill 1297 constitutes assistance to the poor is, to some degree, a factual question and we cannot say precisely where the court will draw the line between assistance to the poor and an impermissible gift. Some people with incomes of less than \$30,000 are, undoubtedly, poor. However, there is substantial doubt whether an individual with an annual income of \$30,000 and no dependents is poor. It is unlikely that a court would permit such a

person to receive assistance pursuant to House Bill 1297.

Requested by:

The Honorable Jean Silver  
State Representative, District 5  
413 John L. O'Brien Building  
Olympia, Washington 98504

**WSR 91-07-002**

**EMERGENCY RULES**

**SECRETARY OF STATE**

[Filed March 7, 1991, 9:39 a.m.]

Date of Adoption: March 5, 1991.

Purpose: Due to the enactment on March 1, 1991, of SHB 1511, chapter 1, Laws of 1991, which defers the effective date of SSB 6880, chapter 256, Laws of 1990, to April 19, 1991, the emergency rules implementing SSB 6880 are repealed.

Citation of Existing Rules Affected by this Order: Repealing WAC 434-42-900 through 434-42-985.

Statutory Authority for Adoption: RCW 42.17.310 (1)(bb).

Pursuant to RCW 34.05.350 the agency for good cause finds that immediate adoption, amendment, or repeal of a rule is necessary for the preservation of the public health, safety, or general welfare, and that observing the time requirements of notice and opportunity to comment upon adoption of a permanent rule would be contrary to the public interest.

Reasons for this Finding: Requirements of RCW 42.17.310 (1)(bb) become effective on April 19, 1991, and the proposed emergency rule is no longer necessary to provide for this measure's implementation.

Effective Date of Rule: Immediately.

March 5, 1991  
Donald F. Whiting  
Assistant Secretary of State

**REPEALER**

The following sections of the Washington Administrative Code are repealed:

- WAC 434-42-900 INTENT
- WAC 434-42-905 DEFINITIONS
- WAC 434-42-910 APPLICANT
- QUALIFICATIONS
- WAC 434-42-915 CONTENTS OF AN APPLICATION
- WAC 434-42-920 DESIGNATION OF THE SECRETARY OF STATE TO SERVE AS AGENT
- WAC 434-42-925 OATH
- WAC 434-42-930 PENALTY
- WAC 434-42-935 STANDARD APPLICATION FORM
- WAC 434-42-940 APPLICATION ASSISTANTS
- WAC 434-42-945 SUBMISSION OF APPLICATIONS
- WAC 434-42-950 CERTIFICATION AND NOTIFICATION

WAC 434-42-955 AGENCY USE OF PROTECTED RECORDS  
 WAC 434-42-960 PROTECTED RECORD ACCESS BY AGENCIES  
 WAC 434-42-965 PROTECTED RECORD ACCESS BY BUSINESS  
 WAC 434-42-970 REQUESTS FOR COPIES OF PUBLIC RECORDS  
 WAC 434-42-975 ABSENTEE VOTING  
 WAC 434-42-980 SERVICE OF PROCESS  
 WAC 434-42-985 CONFIDENTIALITY OF RECORDS RELATING TO THE ADMINISTRATION OF CHAPTER 256, LAWS OF 1990

**WSR 91-07-003**  
**WITHDRAWAL OF PROPOSED RULES**  
**SECRETARY OF STATE**  
 [Filed March 7, 1991, 9:47 a.m.]

In WSR 91-03-125, the office of the Secretary of State gave notice of the intention to adopt rules to implement chapter 1, Laws of 1990 2nd ex. sess., which amended RCW 42.17.310 (1)(bb). On February 26, a public hearing was held to allow comment on these proposed rules. The amendment to this RCW became effective on March 1, 1991.

On March 1 (after chapter 1, Laws of 1990 2nd ex. sess. became effective), the legislature approved and the governor signed into law chapter 1, Laws of 1991, (SHB 1511) which amends chapter 1, Laws of 1990 2nd ex. sess. and delays the implementation of that 1990 act until April 19, 1991.

Accordingly, the office of the Secretary of State has decided to discontinue its consideration of the proposed rules for which notice was given in WSR 91-03-125 and to withdraw those proposed rules.

Donald F. Whiting  
 Assistant Secretary of State

**WSR 91-07-004**  
**EXECUTIVE ORDER**  
**OFFICE OF THE GOVERNOR**  
 [EO 91-02]

CREATING THE GOVERNOR'S COUNCIL ON HIV/AIDS

WHEREAS, infection with the human immunodeficiency virus (HIV), the virus which causes AIDS, is one of the most significant public health issues facing the citizens of Washington state; and

WHEREAS, the public issues around HIV infection and AIDS are constantly changing as the epidemic progresses in our state; and

WHEREAS, government, private industry, schools, health professions, community groups and citizens must each play a role in preventing the spread of infection and in assuring the availability of humane social and health care for individuals infected with HIV; and

WHEREAS, an advisory council comprised of individuals from varied backgrounds and expertise will improve cooperation between diverse segments of the state in preventing the spread of HIV by raising public awareness of the epidemic and by improving services to those already infected; and

WHEREAS, the AIDS Advisory Council established in 70.24.410 RCW is scheduled to terminate on June 30, 1991,

NOW, THEREFORE, I, Booth Gardner, Governor of the State of Washington, do hereby establish the Governor's Advisory Council on HIV/AIDS, as follows:

- 1) The Advisory Council has the following duties:
  - assist the Governor in developing sound state policies on the HIV epidemic,
  - review and make recommendations about proposed HIV/AIDS related programs and legislation developed or presented by government agencies or other groups,
  - identify gaps in existing HIV/AIDS programs and services and
  - provide the Governor with a forum in which to debate issues related to HIV/AIDS.
- 2) The Advisory Council shall be composed of not more than thirty members, appointed by the Governor. Members shall be representative of persons with HIV/AIDS, public health, health care professions, state/local government, educators, citizens groups, community-based service agencies, the Regional AIDSNETs and other interested persons from the public and private sectors. Four members of the Legislature, two from the House and two from the Senate, shall serve as ex-officio members of the Council.
- 3) Terms of membership shall be three years, with the exception that original members will be appointed for staggered terms in order to assure continuity of the Council: one third shall be appointed for one-year terms, one third shall be appointed for two-year terms, and one third shall be appointed for three-year terms. Members may be appointed for subsequent terms. If a member resigns before completion of a term, a new member may be appointed to serve out the remainder of that term. Members shall serve at the pleasure of the Governor.
- 4) The Council shall appoint a chair from among the voting members, shall determine its organization and shall adopt any procedural rules. The Council may create sub-committees as needed to address specific issues related to HIV/AIDS. Sub-committees may include non-members.
- 5) The Department of Health shall provide administrative support to the Council.

This Executive Order is effective immediately.

IN WITNESS WHERE-  
OF, I have hereunto set my  
hand and caused the Seal of  
the State of Washington to  
be affixed at Olympia this  
5th day of March, A.D.,  
nineteen hundred and nine-  
ty-one.

Booth Gardner

Governor of Washington

BY THE GOVERNOR:

Ralph Munro

Secretary of State

**WSR 91-07-005**  
**PERMANENT RULES**  
**DEPARTMENT OF ECOLOGY**  
[Order 90-42—Filed March 7, 1991, 2:43 p.m.]

Date of Adoption: March 7, 1991.

Purpose: Chapter 173-303 WAC is being amended to incorporate federal changes, resolve state-level issues, and clarify existing requirements.

The Dangerous Waste Regulations, chapter 173-303 WAC, establish requirements for generators, transporters, and management facilities handling dangerous waste in Washington state. These regulations reflect both federal requirements and state concerns. As the federal provisions change, the state must update its regulations to remain equivalent to the federal program. Local concerns and experiences have also been addressed. These proposed amendments are a combination of EPA-required and ecology-proposed changes, corrections and clarifications. WAC 173-303-016, alphabetized definitions. All of the specific numbers in WAC 173-303-040 have been removed so that the section could be alphabetized. See proposed WAC 173-303-040; WAC 173-303-016, delete (5)(b)(i)(C), it is redundant; WAC 173-303-017, alphabetized definitions, see WAC 173-303-040; WAC 173-303-040, definitions put in alphabetical order. Many sections of the regulation will be affected by this change. The numbering system for individual definitions has been deleted and the definitions put in alphabetical order; WAC 173-303-040, commercial chemical product, add definition; WAC 173-303-040, definitions added to this section from other places in the chapter. The intent is to have all definitions appear in WAC 173-303-040. The following definitions have been added: From WAC 173-303-071, "domestic sewage"; from WAC 173-303-140, "Dangerous waste constituents," "ignitable waste," "land disposal," "leachable inorganic waste," "organic/carbonaceous waste," "reactive waste," and "solid acid waste"; from WAC 173-303-420, to be added when siting regulations are finalized; and from WAC 173-303-515, "used oil" and "off-specification used oil fuel"; WAC 173-303-040, add definition for "environment"; WAC 173-303-

040, add a revised definition for "domestic sewage" found in WAC 173-303-071. The revised definition encompasses only those sanitary wastes which are generated from household or residential sources. This will make ecology's rules consistent with EPA's current interpretation of the scope of the term "domestic sewage". The definition is also revised to state that domestic sewage must flow to a publicly-owned treatment works (POTW) for treatment. This makes the term more compatible with the existing "POTW" definitions found in 40 CFR 260.10 and WAC 173-303-040(71), and intent of the domestic sewage exclusion; WAC 173-303-040 and WAC 173-303-071 (3)(u), add definition for "special incinerator ash." Clarify that if ash from the incineration of municipal solid waste is a state-only dangerous waste, then it must be managed under chapter 70.138 RCW; WAC 173-303-040, clarify definition of "final closure" to ensure that generator-only areas may continue to operate after treatment, storage, and disposal facilities have been closed; WAC 173-303-040, a "transfer facility," is a facility that stores a waste for more than 10 days and is required to have a permit (see WAC 173-303-950 and WAC 173-303-040(62) "permit"); WAC 173-303-045, change date of incorporation of the federal rules. This change will primarily affect interim status dangerous waste management facilities. Also, refer to the complete federal rules (HSWA [HSWA stands for the hazardous and solid waste amendments. Passed by the United States Congress in 1984, HSWA gave EPA and authorized states broader powers to regulate hazardous waste handlers.] and non-HSWA) that are referenced in this chapter (e.g. interim status standards - WAC 173-303-400). Ecology is making this change because it has become impractical to reference only non-HSWA rules. This regulatory change will pave the way for ecology to implement HSWA regulations in the future. HSWA corrective action, because of its broad workload implications, will be dealt with as a separate issue; WAC 173-303-070 (2)(a), a person who generates a waste from the recycling, treatment, storage, or disposal of a dangerous waste needs to provide representative samples and accurately describe the waste over time before that waste can be exempted from this chapter. This amendment is designed to prevent variable waste streams from being exempted because one unrepresentative sample passes the characteristics or criteria tests. It attempts to clarify that the burden of proof remains with the generator of the waste to show that the waste is not dangerous. For example, if eight out of ten samples of a waste stream (from recycling, treatment, storage, or disposal of a dangerous waste) designate as dangerous, than the waste stream would still be considered dangerous. (Under the old language, it might be construed that if one sample passed the designation tests, then the waste stream could be considered solid waste.) The waste stream as a whole would not be exempted until it could be shown that the wastes consistently passed the designation tests. Thus, if the waste stream was quite variable, then the number of samples tested would have to be increased to demonstrate that truly dangerous waste was not being disposed of improperly. Alternatively, if tests showed that the

waste stream was uniform, then the number of samples needed would be smaller. WAC 173-303-070 (2)(a)(ii) and (iii), clarify that a listed waste must be delisted (by both ecology and United States EPA) to be exempted from this chapter. (Note: TIM 85-1 discusses waste delistings in Washington.); WAC 173-303-070 (3)(c), amend so that generators must go through the lists, mixtures, and characteristics when designating their wastes (in accordance with the federal land disposal restrictions, 40 CFR 268). All applicable waste codes and treatment codes must be used on the manifest; WAC 173-303-070 (8)(b), specify that small quantity generator (SQG) waste managed in accordance with the local hazardous waste management plan (moderate risk waste plan) would be exempt from dangerous waste standards. Conversely, SQG waste that is not managed in accordance with local plan would not be exempted; WAC 173-303-071(3), add WAC 173-303-145, because it applies to hazardous substances, and WAC 173-303-960, because it always applies; WAC 173-303-071 (3)(a), domestic sewage exclusion, clarify that this exclusion applies to waste from domestic sources only. The change to the definition of "domestic sewage" at WAC 173-303-071 (3)(a) means that sanitary wastes and sanitary wastes mixtures generated on-site at business or industrial sources, will no longer be eligible for the domestic sewage exclusion. (Note: If dangerous wastes generated by business or industrial sources that have been managed pursuant to the permit by rule provisions of WAC 173-303-802(5) are not dangerous wastes at the point that they are discharged into the sanitary sewer system, they are not subject to further requirements of the dangerous waste regulations.) The word "storage" is added to the last sentence of WAC 173-303-071 (3)(a). This revision is meant to remove any confusion over the intended scope of the exclusion. In other words, any management of dangerous wastes is regulated (either under TSD provisions or permit by rule) prior to discharge into a sanitary sewage system; WAC 173-303-071 (3)(b), industrial wastewater discharge exclusion, ecology is amending WAC 173-303-071 (3)(b) to clarify the applicability of the industrial wastewater discharge exclusion. This exclusion applies only to the actual point source, end-of-pipe, discharges subject to regulation under Section 402 of the Clean Water Act (NPDES). It does not exclude industrial wastewaters while they are collected, stored, or treated before discharge, nor does it exclude wastewater treatment sludges. The reference to WAC 173-303-802(5) is provided to show the relationship to permit by rule provisions. Both WAC 173-303-071 (3)(b) and 173-303-802(5) currently apply to industrial discharges; WAC 173-303-171 (3)(g), narrow this exclusion to apply to arsenically treated wood only. This change is being made to become consistent with federal rules. Waste wood containing pentachlorophenol, creosote, or chromium above the new TC thresholds would not be excluded and thus would be regulated as dangerous wastes when discarded. (Note: See revised TIM 87-1 for more information.); WAC 173-303-071 (3)(k)(i), change PCB waste exemption so that it refers to TCLP not EP toxicity; WAC 173-303-071 (3)(l),

apply USPS or DOT shipping requirements to dangerous waste samples while accumulating them prior to shipment. Delete the (A) after (l)(i) so that the shipping requirements apply before and after testing; WAC 173-303-071 (3)(n), reword this awkward paragraph. Split into more than one sentence; WAC 173-303-071 (3)(r), WAC 173-303-040 alpha order; WAC 173-303-071 (3)(r), the department may approve, on a case-by-case basis, treatability studies for state-only dangerous waste at cleanup sites for quantities up to 10,000 Kg. This exemption from permitting requirements may be especially useful at cleanup sites where bioremediation could be a viable treatment option; WAC 173-303-071 (3)(s), typo, "... one MTU"; WAC 173-303-071 (3)(t), EPA has decided to defer, from hazardous waste regulation, petroleum contaminated soils that are subject to Underground Storage Tank (UST) corrective action rules. EPA's exclusion is limited to the new TC constituents, D018 - D043. Similarly, ecology is, for the time being, exempting petroleum contaminated soils that fail the TC for D018 - D043 only, from dangerous waste rules; WAC 173-303-072 (3)(c), correct this language to state that state-only solid corrosive wastes may be evaluated for exemption through a petition; WAC 173-303-072 (5)(d), replace reference to EP Tox with TCLP; WAC 173-303-081, clarify that residues, inner liners and containers are regulated unless empty as described in WAC 173-303-160; WAC 173-303-084 (5), there are problems with the current use of the EPA spill table as a reference for determining toxic categories for constituents in a waste. For example, the spill table categories reflect hazards other than acute toxicity. Thus, a compound might be category X because it is carcinogenic or reactive. Obviously, using this data to determine toxicity values is inappropriate. There are also benefits to using the spill table as a resource, namely, that it is very convenient, updated frequently, and inexpensive compared to the NIOSH registry. To resolve potential conflicts, the rules have been amended so that where there is a discrepancy between toxic categories listed for a certain substance via EPA's spill table and the NIOSH registry, the NIOSH registry will take precedence; WAC 173-303-084(5), the state of knowledge regarding the toxicity of chemical substances is rapidly developing. The spill table is updated quite frequently and the NIOSH registry, is updated on microfiche, quarterly. Ecology proposes to rely on the most recently published versions of these documents for designation purposes; WAC 173-303-084(7), update terminology to be consistent with IARC (International Agency on the Research of Cancer). Human and Animal, Positive and Suspected changed to "Human and Animal, Sufficient and Limited" throughout this subsection; WAC 173-303-090, new toxicity characteristic (TC, a federal rule) incorporated. This change adds 25 new organic chemicals to the old EP toxicity list. The EP toxic metals and pesticides are retained in the TC with the same thresholds as before. Generators who know their wastes contain one or more of the new constituents should designate (test or use their knowledge) these wastes to determine their status. EPA's rule will take effect on September 25, 1990, for large quantity generators and March 29, 1991,

for generators of less than 2200 pounds per month, nation-wide. For further information see the March 29, 1990, Federal Register, (55 FR 11798), call the RCRA hotline 1-800-424-9346, or call the nearest ecology regional office; WAC 173-303-103, update terminology to be consistent with IARC. Human and Animal, Positive and Suspected changed to "Human and Animal, Sufficient and Limited" throughout WAC 173-303-103; WAC 173-303-110, add reference to new Biological Testing Methods Booklet, 1991 Edition. This booklet includes the revised aquatic bioassay testing procedure. Available from the department; WAC 173-303-110, add reference to new ASTM standard D2234-86 for fly ash-like material; WAC 173-303-120 (2)(viii)(B) and (C), change reference from WAC 173-303-515 (1)(e) to (1)(d) so that it includes Table 1; WAC 173-303-120(4), specify that "immediate" recycling means placing recyclable materials received from off-site into an active recycling process within 24 hours. The phrase "active process" does not include storage tanks or containers used for settling or phase separation. Thus, recycling operations using settling or phase separation procedures lasting longer than 24 hours must necessarily take place at a TSD facility; WAC 173-303-120(4), "immediate" recycling facilities. Discussion: Recent inspections have shown environmental problems at facilities that recycle dangerous waste "immediately" (without prior storage - and therefore without a permit); Some of the problems and threats at these facilities can be characterized as "housekeeping" in nature. Ecology is also concerned that waste may be improperly managed because of lack of adequate analysis and recordkeeping. Because these facilities are essentially exempt from the regulations, problems at recycling facilities may only be addressed after the fact (e.g. spills, releases to the environment, storage without a permit, etc.). This is not consistent with the preventative philosophy of RCRA and the state Hazardous Waste Management Act. This proposed amendment would require that these facilities must comply with many of general TSD standards of this chapter, but would not require a permit. The following lists the general TSD standards that are being proposed and briefly describes their intended purpose. 283 Performance standards, general design, construction, operation, and maintenance standards that a dangerous waste management facility must meet. These standards provide a broad measure of environmental and human health protection; 290 Required notices, requiring communication in the following instances; Importing dangerous waste from a foreign source, transferring ownership or operational control of the facility and off-site waste acceptance; 310 Security, access to a facility must be controlled; 320 General inspection, routine examination of the facility to prevent malfunction, deterioration, operator error, and discharges; 330 Personnel training, required to ensure that facility personnel acquire expertise in their assigned areas to reduce the potential for mistakes which might threaten human health or the environment; 340 Preparedness and prevention, intended to minimize the possibility of fire, release, or explosion; 350 Contingency plan and emergency procedures, intended to lessen the potential impact of an

emergency; 360 Emergencies, requires that an emergency coordinator must be appointed and that procedures are in place that allow for coordinated responses to an emergency situation; 370 Manifest system, details how the waste tracking system operates; 380 Facility record-keeping, requires that an operating record would be kept at the facility. This shows what happens to wastes that are processed at the facility; 390 Facility reporting, required so that waste from generators could be tracked and the method of management (treatment, storage, or disposal) known; 395 Other general requirements, precautions for ignitable, reactive, and incompatible wastes and miscellaneous requirements; 630 Container storage provisions, requires that containers of dangerous waste be managed properly and stored in a bermed area; and 640 Tank system requirements, requires integrity assessments, engineer certifications, and secondary containment for tanks holding dangerous wastes. Would not be required of recycling process units. Sets new compliance dates for tank systems at these facilities. In addition, in lieu of WAC 173-303-300, Waste analysis, immediate recycling facilities must periodically verify the designation data that they receive from generators; WAC 173-303-145, notification of spills. Clarify that all unpermitted spills and discharges are to be reported to the department. The only exception are spills of less than 10 gallons to secondary containment (meeting the requirements of chapter 173-303 WAC) and account of which can be written to the facility files, instead of calling the department. In all other cases, the owner or operator would place a telephone call to the department immediately following a spill or discharge of dangerous waste or a hazardous substance; WAC 173-303-160, if cloth container liners are permeated with dangerous waste, they are considered to be waste. This is covered by the existing definition of "empty" and needs no rule amendment at this time; WAC 173-303-160, definitions in alpha order; WAC 173-303-200 (1)(b), fix applicability to 640 re: generators. Clarify that large quantity generators must meet the final facility tank standards, such as secondary containment and engineer certified integrity assessments, but do not have to prepare closure plans, cost estimates for closure, nor provide financial assurance for closure; WAC 173-303-201, definitions in alpha order; WAC 173-303-210(2), specify that a generator must keep a copy of his or her notification; WAC 173-303-210(6), specifies that all generator records, including plans required by this chapter, shall be made available and furnished upon request by the director; WAC 173-303-210, specifies that generator records are required to be kept for 5 years. This is consistent with the timeframe for recordkeeping under the federal land disposal restrictions (40 CFR 268); WAC 173-303-220(3), specifies that the department may require a generator to furnish additional reports, including engineering reports, plans, and specifications, concerning the quantities and disposition of dangerous waste; WAC 173-303-230, reference the federal export requirements located in 40 CFR Part 262 SubPart E. Specify that copies of all forms shall be submitted to ecology (as well

as to United States EPA); WAC 173-303-320, reference new WAC 173-303-680 Standards for miscellaneous units; WAC 173-303-360 (2)(d), indicate that on-site releases, fires, or explosions that could threaten human health or the environment must be reported; WAC 173-303-380 (2)(f), reference new WAC 173-303-680 Standards for miscellaneous units. Also specify that corrective action must be documented in the operating record where applicable; WAC 173-303-390(3), specifies that the owner or operator must submit engineering reports, plans, and specifications required by the department; WAC 173-303-400, domestic sewage/permit by rule changes. Interim status facility standards; WAC 173-303-400 (2)(c)(iii), the applicability language found at WAC 173-303-400 (2)(c)(iii) is revised to clearly state that POTW's must meet permit by rule provisions under WAC 173-303-802(4) in lieu of interim status standards. In other words, owner/operators of POTW's may treat, store, or dispose of dangerous wastes without having to comply with interim status standards for TSD's, provided they have a permit by rule. This amendment simply ties two applicable and existing sections together; WAC 173-303-400 (2)(c)(iv), the wording of WAC 173-303-400 (2)(c)(iv) has been revised for clarity and consistency. Owner/operators of totally enclosed treatment facilities, elementary neutralization, or wastewater treatment units may still meet permit-by-rule provisions of WAC 173-303-802(5), and qualify for the exclusion from interim status standards for TSD's; WAC 173-303-400(3), correction on tank dates. Interim status tanks that are underground and cannot be inspected are core-RCRA and not HSWA as the present date implies; WAC 173-303-400 (3)(c)(ix), partial closures must be certified within 60 days of completion of partial closure not at final closure; WAC 173-303-500, definitions in alpha order; WAC 173-303-525, correct two spelling errors; WAC 173-303-550, definitions in alpha order; WAC 173-303-600(1), final facility standards. Change reference to include new WAC 173-303-680, miscellaneous units; WAC 173-303-600 (3)(c), final facility standards and domestic sewage/permit by rule changes. The language found at WAC 173-303-600 (3)(c) which excludes owner/operators of POTW's that treat, store, or dispose of dangerous waste from final facility standards, provided they meet the permit-by-rule provisions of WAC 173-303-802(4), is revised for clarity and consistency. The basic requirement is unchanged; WAC 173-303-600 (3)(j), final facility standards and industrial wastewater, permit by rule. In a manner similar to the change in WAC 173-303-600 (3)(c) above, the language of WAC 173-303-600 (3)(j) is revised for clarity and consistency. The basic requirement is unchanged; WAC 173-303-610 (2)(b), (3)(a), (5), and (6), new WAC 173-303-680 conforming changes; WAC 173-303-610 (3)(b) and (8)(d), permit modifications (see WAC 173-303-830) conforming changes; WAC 173-303-610(4), delay of closure period for hazardous waste management units. This federal rule allows hazardous waste management units at TSD facilities to remain open for the purpose of accepting non-hazardous wastes. The facility owner or operator is required to submit information to

the department justifying the delay. If the department approves the application according to criteria spelled out in the rule, then the unit is allowed to receive non-hazardous waste for a specified period of time. (See 54 FR 33393.); WAC 173-303-610(6), partial closures must be certified within 60 days of completion of partial closure not at final closure; WAC 173-303-620 (1)(b), (3)(a), and (5)(a), new WAC 173-303-680 conforming changes; WAC 173-303-620 (2)(h), correct reference to federal financial assurance definitions; WAC 173-303-620(3), owners or operators of miscellaneous units must prepare a cost estimate for facility closure (federal requirement); WAC 173-303-620(5), owners or operators of miscellaneous units must prepare a cost estimate for facility post-closure monitoring and maintenance (federal requirement); WAC 173-303-620 (8)(a), correct reference to federal financial assurance liability rules; WAC 173-303-620 (8)(b), miscellaneous units used for disposal must demonstrate financial responsibility for liability to third parties; WAC 173-303-630(2), make reporting of spills consistent with 145 and 360. WAC 173-303-630 (5)(c), specify that a minimum 30-inch aisle space is required at areas storing or accumulating dangerous waste. Also, clarify that a row of drums may be two drums wide. This requirement, as proposed will apply to TSD facilities and generators. This requirement is being proposed because there has been confusion in the past regarding what constitutes "adequate aisle space." An aisle space is necessary for people to move easily up and down aisles of drums to inspect drums and drum labels and check for leaking or corroded drums. The department considers that a 3-foot aisle space is optimum for large storage areas. Indeed, we fully expect that permitted storage areas containing more than a few dozen drums will have at least a 3 foot aisle space between rows of drums. However, since this requirement applies to generators as well as TSDs, we have specified 30 inches as the minimum to accommodate smaller accumulation areas at generator accumulation areas. Stacking or securing small containers on shelves can be a perfectly acceptable method of storing waste, if the label and the condition of the container are readily visible. If, however, containers are arranged in rows (a row may be two drums wide, or drums may be arranged two-by-two on a pallet) there must be at least a thirty-inch separation between rows. Portable storage containers may be used if the containers' labels and condition are visible at all times. Loading and unloading areas not exempt from this requirement. Of course, if the fire code rules require a larger aisle space for certain wastes, then the fire code requirements must also be met. WAC 173-303-645, change title and applicability so that releases from solid waste management units are addressed under this section. See subsection (12); WAC 173-303-645, change groundwater statistical methods to conform with recent federal changes, (see 53 FR 39720); WAC 173-303-645 (1)(d), new WAC 173-303-680, conforming changes; WAC 173-303-645 (2)(a), defining terms related to groundwater statistical methods; WAC 173-303-645 (8)(c), reference chapter 173-160 WAC for construction and maintenance of groundwater monitoring wells; WAC 173-303-645(12), add that corrective

action must be performed for all releases of dangerous waste or constituents at solid waste management units (regardless of the time the waste was placed in the unit) at TSD facilities seeking a final status permit. If corrective action cannot be completed prior to issuance of the permit, the permit will contain a compliance schedule identifying how and when corrective action will be accomplished. Financial responsibility for completing corrective action is also required; WAC 173-303-680, new section setting standards for miscellaneous units. These standards will allow the department to write permits for those facilities managing dangerous waste that are new technologies or are not already defined (e.g. thermal treatment units, open burning/open detonation units, etc.) See December 10, 1987, Federal Register for further details. WAC 173-303-800(7), permit exemption for Model Toxics Control Act (chapter 70.105 RCW) cleanups: The intent of this amendment is to provide an exemption for on-site cleanups under MTCA similar to the exemption in CERCLA. The exemption is linked to an approved (signed) consent agreement or order issued by ecology. It does not include voluntary or independent cleanup actions taken without department involvement. There are cases where a dangerous waste permit is warranted or desirable at cleanup sites, even where a consent agreement or order is in place. For example, a permit may be desired where long term storage or long-term treatment will occur (on-site) and the prescriptive and site-specific requirements of a dangerous waste permit would be appropriately applied. Ecology could decide not to grant an exemption in these cases, especially where the process of obtaining a permit would not delay the cleanup or risk reducing action. Thus, the exemption as written is optional and will be made through a "conscious decision" by ecology. It is envisioned that boilerplate exemption language could easily be incorporated into an MTCA consent decree or order; and departmental on-site cleanup actions would be exempted under this amendment; WAC 173-303-800(8), add a provision to this section so that dangerous waste permits contain terms and conditions that the department determines are necessary to protect human health and the environment. The federal rules also contain such language; WAC 173-303-802 (4) and (5), permit by rule (see domestic sewage exclusion); WAC 173-303-802, permits by rule. The permit by rule provisions for owner/operators of POTW's under WAC 173-303-802 (4)(c) is amended to specifically include compliance with the performance standards of WAC 173-303-283. While compliance with performance standards is already required for POTW permit by rule facilities (see WAC 173-303-283(2)), the reference is added here for clarity: An addition is made to WAC 173-303-802 (5)(a) to specify that the permit by rule facility treats dangerous wastes. Thus, permit by rule status is not available for facilities that only store or dispose of dangerous waste. (Note: The definitions for totally enclosed treatment facility, elementary neutralization, and wastewater treatment unit (WAC 173-303-040) all involve treatment.) In addition, a requirement to designate wastes pursuant to WAC 173-303-070, is added to WAC 173-303-802(5). This amendment reaffirms a fundamental assumption

that owner/operators must know the status of the wastes they plan to treat, either through knowledge or testing, in order to manage them appropriately under permit by rule. The structure of WAC 173-303-802(5) is revised such that it is now a positive requirement for the owner/operator to actually have an appropriate water quality permit (or permits) in order to qualify for permit by rule. Thus, the owner/operator must have, and be in compliance with, a National Pollution Discharge Elimination System (NPDES), state waste discharge, or pretreatment permit (or written discharge authorization). The language also states that the discharge permit or authorization must provide for all known, available, and reasonable methods to prevent, control, and treat pollution prior to discharge. This language is added to ensure consistency with the provisions and intent of chapter 90.48 RCW. The amendments rearrange and consolidate two existing subsections, WAC 173-303-802 (5)(a) and (b), into one. However, the existing notification, general facility, and performance standard requirements remain the same. The above amendments are intended to make it clear that business or industrial generators discharging dangerous waste without the appropriate water quality NPDES, state waste discharge, or pretreatment permit (or written discharge authorization), and without meeting the requirements of WAC 173-303-802(5), do not qualify for permit by rule. They will be required to collect their wastes appropriately and send them off-site to a permitted TSD or recycling facility. Generators and owner/operators may bear additional costs of compliance if they were not previously meeting the permit by rule requirements. This would include the notification, recordkeeping, annual reporting, emergency procedures, etc., for generators, and collection and transportation costs to a TSD or legitimate recycler. In no case will generators or TSD facilities be allowed to discharge untreated or unpermitted dangerous wastes to sewer systems. (Note: The proposed amendments will not directly impact small quantity generators (SQG's). Under existing rules, SQG's do not have the option of sewerage their small volumes of dangerous or extremely hazardous wastes (see WAC 173-303-070(8)), unless the receiving facility has a permit by rule pursuant to WAC 173-303-802. If the receiving facility has a permit by rule, discharge by the SQG may continue); WAC 173-303-805(7), change to update and be consistent with federal rules. The proposed amendment allows TSD owners and operators to make changes at their facilities that are necessary to comply with the recently adopted tank system standards, federal, state, and local requirements; an interim status corrective action order under section 3008 (h) of RCRA, and the land disposal restrictions of 40 CFR Part 268. Also changes would be allowed if necessary to continue to handle newly listed wastes and during closure if the changes are in accordance with an approved closure plan. None of the above changes would count toward the "50% reconstruction limit." This is an optional federal change because it is less stringent than present rules, (see 54 FR 9596); WAC 173-303-805 (7)(a), interim status TSD facilities would be required to submit a written explanation of how they intend to treat, store, or dispose of new dangerous wastes (or how



they intend to use new units for newly listed or identified wastes) not already specified in their original Part A permit application. The department has sixty days from receipt of the revised application to deny the changes. For example, if a TSD applied to change their Part A permit so that they could accept dioxin wastes for treatment, but did not have adequate treatment systems for dioxin wastes in place, then the department could deny the application and the owners or operators would not be able to accept such wastes at their facility; WAC 173-303-805 (7)(d), clarify to make it clear that previous owners need to provide liability coverage for a facility during and after transfer of ownership, until the new owners comply, so that continuous protection is afforded the public in all cases; WAC 173-303-806, conforming changes, 680 miscellaneous units; WAC 173-303-806(4) changes to attain consistency with WAC 173-303-140; WAC 173-303-806(4), typo, change reference to appendix IX; WAC 173-303-807, 173-303-808 and 173-303-810, conforming changes, permit modifications, WAC 173-303-830; WAC 173-303-830, replace the current major/minor permit modification scheme with the new federal scheme which classifies permits changes into one of three classes. This new scheme streamlines permit changes and allows for an increase in public participation associated with permit modifications, (see 53 FR 37912 and 53 FR 41649); WAC 173-303-9904, K064, K065, and K066: Add wastes from the primary production of copper lead and zinc to the dangerous waste sources list. K088: Add spent potliner from primary aluminum production to the dangerous waste sources list. K090 and K091: Ferrochromium-silicon and ferrochromium production wastes are added to the dangerous waste sources list. W001: Add bushing to W001 definition; WAC 173-303-9906 and 173-303-9907, change the toxic waste mixtures graph and the persistent waste graph. The amended graphs indicate that wastes that designate as "dangerous" or "extremely hazardous" are regulated unless the generator is a small quantity generator. Thus, for example, if 20 pounds of toxic waste mixture (designated by the 9906 graph) were generated along with 400 pounds of listed solvent wastes, all of the wastes would be regulated. If, however, 20 pounds of toxic waste mixture material were generated at a site where the total wastes generated and accumulated on-site were less than 220 pounds, the 20 pounds of waste would be small quantity generator waste subject to WAC 173-303-070(8). These graphs are not to scale. The department will furnish copies of these graphs with the correct scale upon request.

Not adopting: WAC 173-303-9903, Iron Dextran U139 and Strongtium Sulphide P107 have been removed from the federal list of commercial chemical products because EPA has determined that the evidence for listing these chemicals is insufficient, (See 53 FR 43878 and 43 FR 43881, respectively). The department is not adopting this change (i.e. the chemicals are staying on the list) because the evidence that we have reviewed is inconclusive to date.

Citation of Existing Rules Affected by this Order: Amending chapter 173-303 WAC.

Statutory Authority for Adoption: Chapters 70.105 and 70.105D RCW.

Other Authority: 40 CFR Part 271.3 and RCRA (42 U.S.C. 3251) Sec. 3006.

Pursuant to notice filed as WSR 90-20-101 on October 2, 1990.

Changes Other than Editing from Proposed to Adopted Version: WAC 173-303-040 Definition of director, this definition was amended to clarify the meaning of the term and to include "or his designee." Rationale for change: This change was made to be consistent with the definition in chapter 70.105 RCW and so that the director of the department can take actions necessary to implement this chapter without actually having to do everything him/herself.

WAC 173-303-070 (3)(c) Waste designation, the phrase "lists of characteristics" was changed to "lists and characteristics." Rationale for change: This change was made to make the designation rules consistent with federal hazardous waste land disposal restrictions. Federal regulations require that generators use all applicable waste codes, and abide by all applicable treatment standards for those codes. Under the amended rule, generators will have to go on to designate their wastes through the sections on lists, mixtures, and characteristics. Previously, generators could have stopped after reaching a designation through, say, one of [the] lists and did not have to proceed with the other two sections. The entire land disposal restrictions rules will be added to this chapter in the future. The change above will reduce confusion between now and the future amendment.

WAC 173-303-017 (3)(k)(iii)(A), PCB waste accumulation, in response to public comment, the change made in the proposed rule is deleted. Rationale for change: This was done to reduce confusion. We sought, in the draft rules, to relieve generators from preparing a closure plan for their W001 wastes that were stored in TSCA regulated areas. A recent change in 40 CFR 761.65 requires that all PCB wastes in TSCA storage-for-disposal areas must comply with closure plans and financial assurance for closure. We were attempting to give generators a third option for managing W001 waste, namely, to set up a separate area for 90-day accumulation of W001 within a TSCA regulated area. However, it seems best (and least confusing) to delete the new language from the proposal and let generators decide between TSCA rules and dangerous waste rules. In other words, in the final rules, a generator of W001 waste will have two options: Manage W001 wastes as dangerous waste; or manage W001 as TSCA-regulated wastes. The latter will mean (since the federal TSCA rule changes) including such wastes in the closure plans and financial assurance requirements that apply at TSCA PCB storage-for-disposal areas.

WAC 173-303-071 (3)(t) Petroleum-contaminated media deferral, EPA clarified in a correction notice published in the June 29, 1990 Federal Register that their petroleum-contaminated media deferral (40 CFR 261.4 (a)(10)) only applied to the new TC constituents (D018 to D043 only). Likewise, ecology narrowed the exclusion in WAC 173-303-071 (3)(t) to be consistent with the federal rules.



WAC 173-303-084(5) Waste mixtures designation, we are adding to WAC 173-303-084(5): "If EPA's spill table and the NIOSH registry do not agree on the same category, then the category arrived at through the NIOSH registry will take precedence." Rationale for change: This change was done to eliminate the problem caused by inconsistencies with EPA spill table. It is difficult to obtain the background information necessary to determine the reason for a certain category used in EPA's spill table. Since EPA's spill table uses other data besides acute toxicity to determine a category, it would be easiest to rely on the NIOSH registry for such data. Therefore we are adding to WAC 173-303-084(5): "If EPA's spill table and the NIOSH registry do not agree on the same category, then the category arrived at through the NIOSH registry will take precedence."

WAC 173-303-120(4) Recycling facility requirements, compliance dates for tank systems at dangerous waste recycling facilities have been added to the final proposed rule. Rationale for change: Since these tanks need to meet secondary containment and certification standards and since many of these dates have already passed, new dates for compliance appear in the final rule.

WAC 173-303-145 Spills and discharges, in accordance with our aim to have almost all spills and releases of dangerous waste and hazardous substances reported to the department by telephone, we have changed the structure of this section. The terms "environment" and "affecting human health and the environment" have been deleted. Thus, spills and releases to the ground, groundwater, surface water, asphalt pavement, and concrete, etc., including spills of to secondary containment systems (if they meet or exceed 10 gallons), must be reported to the department. The only exception to the reporting requirement is for small spills to secondary containment areas that meet the requirements of the chapter. These spills may be reported to the department or an account of the spill must be written into the operating record (for a TSD facility) or the inspection log or a separate spill log (for a generator). Generators have a choice of which system to use. Thus, for example, a spill of less than ten gallons that occurs in a tank system's secondary containment area (if the secondary containment meets the applicable requirements of chapter 173-303 WAC) need not be reported, if an account is written in accordance with subsection (2)(d). Of course, container storage or accumulation areas would have to meet the requirements of WAC 173-303-630(7) or 173-303-400, whichever applies. Rationale for change: After considering several options, it was decided that the easiest way for the regulated community to report spills or releases was to pick up the phone and call the appropriate regional office of ecology (or the toll free Department of Emergency Management phone number). If the spill is truly insignificant, then spill staff can say "thank you very much for calling." Alternatively, spill staff can and do advise callers on a course of action for containing and cleaning up spills and releases. Further, the frequency and circumstances surrounding spills at facilities can be an important indicator of operational or compliance

problems. If these events are not reported, then important opportunities for environmental protection are lost. One of the primary goals of this chapter is to assure that sites do not become contaminated. Unless the department is aware of "routine" or accidental spills and discharges, this goal cannot be fulfilled. Many industrial solvents can migrate through concrete and other such "barriers." The affect of changes in this section is to clarify that all spills and releases of dangerous waste and hazardous substances are reportable. However, we do not consider a phone call — so that we can keep industrial sites clean — to be too much to require. For releases from tank systems, generators and TSD facility owners and operators do not have to report spills of less than one pound, if they are immediately contained and cleaned up.

WAC 173-303-200 (1)(e) Accumulating dangerous waste on-site, WAC 173-303-200 (1)(e) is less stringent than the federal rules (40 CFR 262.34) in that it allows a generator to evade the accumulation standards if he/she gets of his/her waste 10 days. The federal rules contain no such exemption. Rationale for change: This is a problem which risks loss of state authorization under RCRA. Therefore, ecology has deleted this paragraph in the final rule.

WAC 173-303-515 Burning used oil for energy recovery, the amendments to WAC 173-303-515 (4)(b)(vii) of the October 16, 1990, draft has been deleted from the final rule. Rationale for change: Because of the uncertain secondary impacts on the used-oil collection market that may result from increased regulation of used-oil storage facilities, ecology is withdrawing its proposal in the final rules. We will continue to research the economic and environmental aspects of this situation. However, we suspect that there may be unacceptable environmental and human health threats that are associated with the processing, storage, and burning of used-oil fuels. Specifically, we suspect that used-oil that is contaminated with metals and/or chlorinated organic solvents is being burned in marine diesel engines and used-oil fired space heaters. We will reconsider amendments that strengthen testing, recordkeeping, and other operational requirements in the near future.

WAC 173-303-610 Closure, we have added the "delay of closure" rule to the final proposed amendments. This change was made so that the department would have the flexibility to allow hazardous waste units to delay closure and accept nonhazardous waste under certain conditions and with prior approval of the department. This is a change that EPA has made in the federal rules. However, since it is a less stringent change, ecology had the option of adopting or not adopting this change. Ecology has decided to adopt the delay of closure rule. Rationale for change: We proposed not to adopt this change in the draft rule. However, because of public comment and the desire for flexibility within the department we are adding this rule to the proposed final regulation. There may be situations where we would allow, under the strict conditions set forth in the rule (and perhaps other conditions set forth in a TSD permit), and with prior approval from the department, nonhazardous waste to be treated or disposed of at hazardous waste

management units. For example, if the available alternative management methods were not as environmentally protective, it may be prudent to allow management of nonhazardous waste in this way. This change primarily affects WAC 173-303-610, but there are conforming changes that occur in other sections as well.

WAC 173-303-630 (5)(c) Container management standards, we proposed a minimum aisle space requirement of three feet in the proposed rule. This has been changed to 30 inches in the final proposed rule. Rationale for change: We are changing this minimum requirement to 30 inches in the proposed final rule primarily because of concerns that in some cases, especially at generator facilities where less than a few dozen drums are being accumulated for 90 days or less, 30 inches may be adequate aisle space. We fully expect, however, that a three foot aisle space will be required at TSD facilities where numerous drums occupy the storage area. We see that a three foot aisle space is optimum for most storage areas, and expect that the three-foot requirement will be written into permits for most if not all TSDs. However, since WAC 173-303-630 also applies to generators, some special circumstances may exist such that 30 inches would be a more appropriate distance between rows of drums containing dangerous waste. Thus, the rule, which is intended to be a minimum (indeed, the Uniform Fire Code requires more than a three foot separation in some cases), says 30 inches. Effective Date of Rule: Thirty-one days after filing.

March 7, 1991  
 Fred Olson  
 Deputy Director

Chapter 173-303 WAC  
 DANGEROUS WASTE REGULATIONS

WAC

- 173-303-016 Identifying solid waste.
- 173-303-017 Recycling processes involving solid waste.
- 173-303-040 Definitions.
- 173-303-045 References to EPA's hazardous waste and permit regulations.
- 173-303-070 Designation of dangerous waste.
- 173-303-071 Excluded categories of waste.
- 173-303-072 Procedures and bases for exempting and excluding wastes.
- 173-303-081 Discarded chemical products.
- 173-303-084 Dangerous waste mixtures.
- 173-303-090 Dangerous waste characteristics.
- 173-303-103 Carcinogenic dangerous wastes.
- 173-303-110 Sampling and testing methods.
- 173-303-120 Recycled, reclaimed, and recovered wastes.
- 173-303-145 Spills and discharges ((into the environment)).
- 173-303-160 Containers.
- 173-303-200 Accumulating dangerous waste on-site.
- 173-303-201 Special accumulation standards.
- 173-303-210 Generator recordkeeping.
- 173-303-220 Generator reporting.

- 173-303-230 Special conditions.
- 173-303-320 General inspection.
- 173-303-360 Emergencies.
- 173-303-380 Facility recordkeeping.
- 173-303-390 Facility reporting.
- 173-303-400 Interim status facility standards.
- 173-303-500 Recycling requirements for state-only dangerous waste.
- 173-303-510 Special requirements for dangerous wastes burned for energy recovery.
- 173-303-515 Special requirements for used oil burned for energy recovery.
- 173-303-520 Special requirements for reclaiming spent lead acid battery wastes.
- 173-303-525 Special requirements for recyclable material utilized for precious metal recovery.
- 173-303-550 Special requirements for facilities managing special waste.
- 173-303-560 Minimum standards for facilities managing special waste.
- 173-303-600 Final facility standards.
- 173-303-610 Closure and postclosure.
- 173-303-620 Financial requirements.
- 173-303-630 Use and management of containers.
- 173-303-645 ((Ground water protection)) Releases from solid waste management units.
- 173-303-650 Surface impoundments.
- 173-303-680 Miscellaneous units.
- 173-303-800 Permit requirements for dangerous waste management facilities.
- 173-303-802 Permits by rule.
- 173-303-805 Interim status permits.
- 173-303-806 Final facility permits.
- 173-303-807 Trial burns for dangerous waste incinerator final facility permits.
- 173-303-808 Demonstrations for dangerous waste land treatment final facility permits.
- 173-303-810 General permit conditions.
- 173-303-830 Permit changes.
- 173-303-9903 Discarded chemical products list.
- 173-303-9904 Dangerous waste sources list.
- 173-303-9906 Toxic dangerous waste mixtures graph.
- 173-303-9907 Persistent dangerous waste mixtures graph.

AMENDATORY SECTION (Amending Order DE-85-10, filed 6/3/86)

WAC 173-303-016 IDENTIFYING SOLID WASTE. (1) Purpose and applicability.

(a) The purpose of this section is to identify those materials that are and are not solid wastes.

(b) (i) The definition of solid waste contained in this section applies only to wastes that also are dangerous for purposes of the regulations implementing chapter 70.105 RCW. For example, it does not apply to materials (such as nondangerous scrap, paper, textiles, or rubber) that are not otherwise dangerous wastes and that are recycled.

(ii) This section identifies only some of the materials which are solid wastes and dangerous wastes under

chapter 70.105 RCW. A material which is not defined as a solid waste in this section, or is not a dangerous waste identified or listed in this section, is still a solid waste and a dangerous waste for purposes of these sections if reason and authority exists under chapter 70.105 RCW and WAC 173-303-960. Within the constraints of chapter 70.105 RCW, this shall include but not be limited to any material that: Is accumulated, used, reused, or handled in a manner that poses a threat to public health or the environment; or, due to the dangerous constituent(s) in it, when used or reused would pose a threat to public health or the environment.

(c) Certain materials are solid wastes but are excluded from the requirements of this chapter by WAC 173-303-071.

(2) The following terms are used and shall have the meanings as defined in WAC 173-303-040:

- |  |                                    |
|--|------------------------------------|
| (a) Boiler                               | <del>((WAC 173-303-040(8)))</del>  |
| (b) By-product                           | <del>((WAC 173-303-040(9)))</del>  |
| (c) Incinerator                          | <del>((WAC 173-303-040(41)))</del> |
| (d) Industrial furnace                   | <del>((WAC 173-303-040(43)))</del> |
| (e) Reclaim                              | <del>((WAC 173-303-040(72)))</del> |
| (f) Recover                              | <del>((WAC 173-303-040(73)))</del> |
| (g) Recycle                              | <del>((WAC 173-303-040(74)))</del> |
| (h) Used or reused<br>(see reuse or use) | <del>((WAC 173-303-040(77)))</del> |
| (i) Sludge                               | <del>((WAC 173-303-040(81)))</del> |
| (j) Scrap metal                          | <del>((WAC 173-303-040(82)))</del> |
| (k) Spent material                       | <del>((WAC 173-303-040(83)))</del> |

(3) Definition of solid waste.

(a) A solid waste is any discarded material that is not excluded by WAC 173-303-017(2) or that is not excluded by variance granted under WAC 173-303-017(5).

(b) A discarded material is any material which is:

(i) Abandoned, as explained in subsection (4) of this section; or

(ii) Recycled, as explained in subsection (5) of this section; or

(iii) Considered inherently waste-like, as explained in subsection (6) of this section.

(4) Materials are solid waste if they are abandoned by being:

(a) Disposed of; or

(b) Burned or incinerated; or

(c) Accumulated, stored, or treated (but not recycled) before or in lieu of being abandoned by being disposed of, burned, or incinerated.

(5) Materials are solid wastes if they are recycled—or accumulated, stored, or treated before recycling—as specified in (a) through (d) of this subsection.

(a) Used in a manner constituting disposal. Materials noted with a "\*" in column 1 of Table 1 are solid wastes when they are:

(i)(A) Applied to or placed on the land in a manner that constitutes disposal; or

(B) Used to produce products that are applied to or placed on the land or are otherwise contained in products that are applied to or placed on the land (in which cases the product itself remains a solid waste).

(ii) However, commercial chemical products listed in WAC 173-303-9903 or which exhibit any of the criteria or characteristics listed in WAC 173-303-100 are not solid wastes if they are applied to the land and that is their ordinary manner of use.

(b) Burning for energy recovery. Materials noted with a "\*" in column 2 of Table 1 are solid wastes when they are:

(i)~~((A))~~ Burned to recover energy;

~~((B))~~ (ii) Used to produce a fuel or are otherwise contained in fuels (in which cases the fuel itself remains a solid waste).

~~((C))~~ Contained in fuels (in which case the fuel itself remains a solid waste):

~~((ii))~~ However, commercial chemical products listed in WAC 173-303-9903 or which exhibit any of the criteria or characteristics listed in WAC 173-303-100 are not solid wastes if they are themselves fuels.

(c) Reclaimed. Materials noted with a "\*" in column 3 of Table 1 are solid wastes when reclaimed.

(d)(i) Accumulated speculatively. Materials noted with a "\*" in column 4 of Table 1 are solid wastes when accumulated speculatively.

(ii) A material is "accumulated speculatively" if it is accumulated before being recycled. A material is not accumulated speculatively, however, if the person accumulating it can show that the material is potentially recyclable and has a feasible means of being recycled; and that—during the calendar year (commencing on January 1)—the amount of material that is recycled, or transferred to a different site for recycling, equals at least seventy-five percent by weight or volume of the amount of that material accumulated at the beginning of the period. In calculating the percentage of turnover, the seventy-five percent requirement is to be applied to each material of the same type (e.g., slags from a single smelting process) that is recycled in the same way (i.e., from which the same material is recovered or that is used in the same way). Materials accumulating in units that would be exempt from regulation under WAC 173-303-071 (3)(n) are not to be included in making the calculation. (Materials that are already defined as solid wastes also are not to be included in making the calculation.) Materials are no longer in this category once they are removed from accumulation for recycling, however.

TABLE I

	Use constituting disposal WAC 173-303- 016 (5)(a)	Energy recovery/ fuel WAC 173-303- 016 (5)(b)	Reclamation WAC 173-303- 016 (5)(c)	Speculative accumulation WAC 173-303- 016 (5)(d)
Spent materials	(*)	(*)	(*)	(*)
Commercial chemical products	(*)	(*)	_____	_____
By-products listed in WAC 173-303-9904	(*)	(*)	(*)	(*)
Sludges listed in WAC 173-303-9904	(*)	(*)	(*)	(*)
By-products exhibiting a characteristic <sup>1</sup> or criteria <sup>2</sup>	(*)	(*)	_____	(*)
Sludges exhibiting a characteristic <sup>1</sup> or criteria <sup>2</sup>	(*)	(*)	_____	(*)
Scrap metal	(*)	(*)	(*)	(*)

Note: The terms "spent materials," "sludges," "by-products," and "scrap metal" are defined in WAC 173-303-040.  
<sup>1</sup> The characteristics of dangerous waste are described in WAC 173-303-090.  
<sup>2</sup> The dangerous waste criteria are described in WAC 173-303-084 and 173-303-101 through 173-303-103.

(6) Inherently waste-like materials. The following materials are solid wastes when they are recycled in any manner:

(a) Dangerous Waste Nos. F020, F021 (unless used as an ingredient to make a product at the site of generation), F022, F023, F026, and F028.

(b) The department will use the following criteria to add wastes to (a) of this subsection:

(i)(A) The materials are ordinarily disposed of, burned, or incinerated; or

(B) The materials contain toxic constituents listed in WAC 173-303-9905 and these constituents are not ordinarily found in raw materials or products for which the materials substitute (or are found in raw materials or products in smaller concentrations) and are not used or reused during the recycling process; and

(ii) The material may pose a substantial hazard to human health or the environment when recycled.

(7) Documentation of claims that materials are not solid wastes or are conditionally exempt from regulation. Respondents in actions to enforce regulations implementing chapter 70.105 RCW who raise a claim that a certain material is not a solid waste, or is conditionally exempt from regulation, must demonstrate that there is a known market or disposition for the material, and that they meet the terms of the exclusion or exemption. In doing so, they must provide appropriate documentation (such as contracts showing that a second person uses the material as an ingredient in a production process) to demonstrate that the material is not a waste, or is exempt from regulation. In addition, owners or operators of facilities claiming that they actually are recycling materials must show that they have the necessary equipment to do so.

**AMENDATORY SECTION** (Amending Order DE-87-4, filed 6/26/87)

WAC 173-303-017 RECYCLING PROCESSES INVOLVING SOLID WASTE. (1) The purpose of this section is to identify those materials that are and are not solid wastes when recycled. Certain materials, as described in subsection (2) of this section, would not typically be considered to involve waste management and are exempt from the requirements of this chapter. All recycling processes not exempted by subsection (2) of this section are subject to the recycling requirements of WAC 173-303-120.

(2) General categories of materials that are not solid waste when recycled.

(a) Except as provided in subsection (3) of this section, materials are not solid wastes when they can be shown to be recycled by being:

(i) Used or reused as ingredients in an industrial process to make a product provided the materials are not being reclaimed; or

(ii) Used or reused as effective substitutes for commercial products; or

(iii) Returned to the original process from which they are generated without first being reclaimed. The material must be returned as a substitute for raw material feedstock, and the process must use raw materials as principal feedstocks.

(b) Except as provided in subsection (3) of this section, the department has determined that the following materials when used as described are not solid wastes:

(i) Pulping liquors (i.e., black liquor) that are reclaimed in a pulping liquor recovery furnace and then reused in the pulping process;

(ii) Spent pickle liquor which is reused in wastewater treatment at a facility holding a national pollutant discharge elimination system (NPDES) permit, or which is being accumulated, stored, or treated before such reuse;

(iii) Spent sulfuric acid used to produce virgin sulfuric acid.

(3) The following materials are solid wastes, even if the recycling involves use, reuse, or return to the original process (as described in subsection (2)(a) of this section):

(a) Materials used in a manner constituting disposal, or used to produce products that are applied to the land; or

(b) Materials burned for energy recovery, used to produce a fuel, or contained in fuels; or

(c) Materials accumulated speculatively as defined in WAC 173-303-016 (5)(d)(ii); or

(d) Materials listed in WAC 173-303-016(6); or

(e) Any materials that the department determines are being accumulated, used, reused or handled in a manner that poses a threat to public health or the environment.

(4) Documentation of claims that materials are not solid wastes or are conditionally exempt from regulation. Respondents in actions to enforce regulations implementing chapter 70.105 RCW who raise a claim that a certain material is not a solid waste, or is conditionally exempt from regulation, must demonstrate that there is a known market or disposition for the material, and that they meet the terms of the exclusion or exemption. In doing so, they must provide appropriate documentation (such as contracts showing that a second person uses the material as an ingredient in a production process) to demonstrate that the material is not a waste, or is exempt from regulation. In addition, owners or operators of facilities claiming that they actually are recycling materials must show that they have the necessary equipment to do so.

(5) Variances from classification as a solid waste.

(a) In accordance with the standards and criteria in (b) of this subsection and the procedures in subsection (7) of this section, the department may determine on a case-by-case basis that the following recycled materials are not solid wastes:

(i) Materials that are accumulated speculatively without sufficient amounts being recycled (as defined in WAC 173-303-016 (5)(d)(ii));

(ii) Materials that are reclaimed and then reused within the original primary production process in which they were generated;

(iii) Materials that have been reclaimed but must be reclaimed further before the materials are completely recovered;

(iv) State-only dangerous materials (not regulated as hazardous wastes (defined in WAC 173-303-040((39))) by EPA) which serve as an effective substitute for a commercial product or raw material.

(b) Standards and criteria for variances from classification as a solid waste.

(i) The department may grant requests for a variance from classifying as a solid waste those materials that are accumulated speculatively without sufficient amounts being recycled if the applicant demonstrates that sufficient amounts of the material will be recycled or transferred for recycling in the following year. If a variance is granted, it is valid only for the following year, but can

be renewed, on an annual basis, by filing a new application. The department's decision will be based on the following standards and criteria:

(A) The manner in which the material is expected to be recycled, when the material is expected to be recycled, and whether this expected disposition is likely to occur (for example, because of past practice, market factors, the nature of the material, or contractual arrangements for recycling);

(B) The reason that the applicant has accumulated the material for one or more years without recycling seventy-five percent of the volume accumulated at the beginning of the year;

(C) The quantity of material already accumulated and the quantity expected to be generated and accumulated before the material is recycled;

(D) The extent to which the material is handled to minimize loss;

(E) Other relevant factors.

(ii) The department may grant requests for a variance from classifying as a solid waste those materials that are reclaimed and then reused as feedstock within the original primary production process in which the materials were generated if the reclamation operation is an essential part of the production process. This determination will be based on the following criteria:

(A) How economically viable the production process would be if it were to use virgin materials, rather than reclaimed materials;

(B) The prevalence of the practice on an industry-wide basis;

(C) The extent to which the material is handled before reclamation to minimize loss;

(D) The time periods between generating the material and its reclamation, and between reclamation and return to the original primary production process;

(E) The location of the reclamation operation in relation to the production process;

(F) Whether the reclaimed material is used for the purpose for which it was originally produced when it is returned to the original process, and whether it is returned to the process in substantially its original form;

(G) Whether the person who generates the material also reclaims it;

(H) Other relevant factors.

(iii) The department may grant requests for a variance from classifying as a solid waste those materials that have been reclaimed but must be reclaimed further before recovery is completed if, after initial reclamation, the resulting material is commodity-like (even though it is not yet a commercial product, and has to be reclaimed further). This determination will be based on the following factors:

(A) The degree of processing the material has undergone and the degree of further processing that is required;

(B) The value of the material after it has been reclaimed;

(C) The degree to which the reclaimed material is like an analogous raw material;

(D) The extent to which an end market for the reclaimed material is guaranteed;

(E) The extent to which the reclaimed material is handled to minimize loss;

(F) Other relevant factors.

(iv) The department may grant requests for a variance from classifying as a solid waste those materials that serve as an effective substitute for a commercial product or raw material, when such material is not regulated as hazardous waste (defined in WAC 173-303-040~~((39))~~) by EPA, if the materials are recycled in a manner such that they more closely resemble products or raw materials rather than wastes. This determination will be based on the following factors:

(A) The effectiveness of the material for the claimed use;

(B) The degree to which the material is like an analogous raw material or product;

(C) The extent to which the material is handled to minimize loss or escape to the environment;

(D) The extent to which an end market for the reclaimed material is guaranteed;

(E) The time period between generating the material and its recycling;

(F) Other factors as appropriate.

(6) Variance to be classified as a boiler.

In accordance with the standards and criteria in WAC 173-303-040~~((8))~~ (definition of "boiler"), and the procedures in subsection (7) of this section the department may determine on a case-by-case basis that certain enclosed devices using controlled flame combustion are boilers, even though they do not otherwise meet the definition of boiler contained in WAC 173-303-040~~((8))~~, after considering the following criteria:

(a) The extent to which the unit has provisions for recovering and exporting thermal energy in the form of steam, heated fluids, or heated gases; and

(b) The extent to which the combustion chamber and energy recovery equipment are of integral design; and

(c) The efficiency of energy recovery, calculated in terms of the recovered energy compared with the thermal value of the fuel; and

(d) The extent to which exported energy is utilized; and

(e) The extent to which the device is in common and customary use as a "boiler" functioning primarily to produce steam, heated fluids, or heated gases; and

(f) Other factors, as appropriate.

(7) Procedures for variances from classification as a solid waste or to be classified as a boiler.

The department will use the following procedures in evaluating applications for variances from classification as a solid waste or applications to classify particular enclosed flame combustion devices as boilers:

(a) The applicant must apply to the department. The application must address the relevant criteria contained in subsections (5)(b) or (6) of this section.

(b) The department will evaluate the application and issue a draft public notice tentatively granting or denying the application. Notification of this tentative decision will be provided by newspaper advertisement and radio broadcast in the locality where the recycler is located. The department will accept comment on the tentative decision for thirty days, and may also hold a public

hearing upon request or at its discretion. The department will issue a final decision after receipt of comments and after the hearing (if any), and this decision may not be appealed to the department.

#### AMENDATORY SECTION (Amending Order 88-24, filed 1/4/89)

WAC 173-303-040 DEFINITIONS. When used in this regulation, the following terms have the meanings given below.

~~((1))~~ "Aboveground tank" means a device meeting the definition of "tank" in this section and that is situated in such a way that the entire surface area of the tank is completely above the plane of the adjacent surrounding surface and the entire surface area of the tank (including the tank bottom) is able to be visually inspected.

"Active life" of a facility means the period from the initial receipt of dangerous waste at the facility until the department receives certification of final closure.

"Active portion" means that portion of a facility which is not a closed portion (~~subsection (11) of this section~~), and where dangerous waste recycling, reuse, reclamation, transfer, treatment, storage or disposal operations are being or have been conducted after:

~~((a))~~ The effective date of the waste's designation by 40 CFR Part 261; and

~~((b))~~ March 10, 1982, for wastes designated only by this chapter and not designated by 40 CFR Part 261. (See also "closed portion" and "inactive portion.")

~~((2))~~ "Acutely hazardous waste" means dangerous waste sources (listed in WAC 173-303-9904) F020, F021, F022, F023, F026, or F027, and discarded chemical products (listed in WAC 173-303-9903) that are identified with a dangerous waste number beginning with a "P" or that show an "X" or "A" in the reason for designation column.

~~((3))~~ "Ancillary equipment" means any device including, but not limited to, such devices as piping, fittings, flanges, valves, and pumps, that is used to distribute, meter, or control the flow of dangerous waste from its point of generation to a storage or treatment tank(s), between dangerous waste storage and treatment tanks to a point of disposal on-site, or to a point of shipment for disposal off-site.

"Aquatic LC<sub>50</sub>" (same as TLM<sub>96</sub>) means a concentration in mg/L (ppm) which kills in 96 hours half of a group of ten or more of a medium sensitivity warm water species of fish such as Lepomis macrochirus (bluegill) or Pimephales promelas (flathead minnow), or cold water species such as salmonidae, when using the testing method described in WAC 173-303-110.

~~((4))~~ "Aquifer" means a geologic formation, group of formations, or part of a formation capable of yielding a significant amount of ground water to wells or springs.

~~((5))~~ "Asbestos containing waste material" means any waste that contains more than one percent asbestos by weight and that can be crumbled, pulverized, or reduced to powder when dry, by hand pressure.

~~((6))~~ "Batch" means any waste which is generated less frequently than once a month.

~~((7))~~ "Berm" means the shoulder of a dike.

~~((8))~~ "Boiler" means an enclosed device using controlled flame combustion and having the following characteristics:

~~((a)(i))~~ The unit must have physical provisions for recovering and exporting thermal energy in the form of steam, heated fluids, or heated gases; and

~~((ii))~~ The unit's combustion chamber and primary energy recovery section(s) must be of integral design. To be of integral design, the combustion chamber and the primary energy recovery section(s) (such as waterwalls and superheaters) must be physically formed into one manufactured or assembled unit. A unit in which the combustion chamber and the primary energy recovery section(s) are joined only by ducts or connections carrying flue gas is not integrally designed; however, secondary energy recovery equipment (such as economizers or air preheaters) need not be physically formed into the same unit as the combustion chamber and the primary energy recovery section. The following units are not precluded from being boilers solely because they are not of integral design: Process heaters (units that transfer energy directly to a process stream), and fluidized bed combustion units; and

~~((iii))~~ While in operation, the unit must maintain a thermal energy recovery efficiency of at least sixty percent, calculated in terms of the recovered energy compared with the thermal value of the fuel; and

~~((iv))~~ The unit must export and utilize at least seventy-five percent of the recovered energy, calculated on an annual basis. In this calculation, no credit shall be given for recovered heat used internally in the same unit. (Examples of internal use are the preheating of fuel or combustion air, and the driving of induced or forced draft fans or feedwater pumps); or

~~((b))~~ The unit is one which the department has determined, on a case-by-case basis, to be a boiler, after considering the standards in WAC 173-303-017(6).

~~((9))~~ "By-product" means a material that is not one of the primary products of a production process and is not solely or separately produced by the production process. Examples are process residues such as slags or distillation column bottoms. The term does not include a co-product that is produced for the general public's use and is ordinarily used in the form it is produced by the process.

~~((10))~~ "Carcinogenic" means a material known to contain an IARC positive or suspected, human or animal carcinogen.

~~((11))~~ "Closed portion" means that portion of a facility which an owner or operator has closed, in accordance with the approved facility closure plan and all applicable closure requirements.

~~((12))~~ "Closure" means the requirements placed upon all TSD facilities to ensure that all such facilities are closed in an acceptable manner (see also "post-closure").

~~((13))~~ "Commercial chemical product or manufacturing chemical intermediate" refers to a chemical substance which is manufactured or formulated for commercial or manufacturing use which consists of the commercially pure grade of the chemical, any technical grades of the chemical that are produced or marketed,

and all formulations in which the chemical is the sole active ingredient.

"Compliance procedure" shall mean any proceedings instituted pursuant to the Hazardous Waste Disposal Act as amended in 1980 and 1983, and chapter 70.105A RCW, or regulations issued under authority of state law, which seeks to require compliance, or which is in the nature of an enforcement action or an action to cure a violation. A compliance procedure includes a notice of intention to terminate a permit pursuant to WAC 173-303-830(5), or an application in the state superior court for appropriate relief under the Hazardous Waste Management Act. A compliance procedure is considered to be pending from the time a notice of violation or of intent to terminate a permit is issued or judicial proceedings are begun, until the department notifies the owner or operator in writing that the violation has been corrected or that the procedure has been withdrawn or discontinued.

~~((14))~~ "Component" means either the tank or ancillary equipment of a tank system.

"Constituent" or "dangerous waste constituent" means a chemically distinct component of a dangerous waste stream or mixture.

~~((15))~~ "Container" means any portable device in which a material is stored, transported, treated, disposed of, or otherwise handled.

~~((16))~~ "Contingency plan" means a document setting out an organized, planned, and coordinated course of action to be followed in case of a fire, explosion, or release of dangerous waste or dangerous waste constituents which could threaten the public health or environment.

~~((17))~~ "Contract" means the written agreement signed by the department and the state operator.

~~((18))~~ "Corrosion expert" means a person who, by reason of his knowledge of the physical sciences and the principles of engineering and mathematics, acquired by a professional education and related practical experience, is qualified to engage in the practice of corrosion control on buried or submerged metal piping systems and metal tanks. Such a person must be certified as being qualified by the National Association of Corrosion Engineers (NACE) or be a registered professional engineer who has certification or licensing that includes education and experience in corrosion control on buried or submerged metal piping systems and metal tanks.

"Dangerous waste constituents" means those constituents listed in WAC 173-303-9905 and any other constituents that have caused a waste to be a dangerous waste under this chapter.

"Dangerous waste management unit" is a contiguous area of land on or in which dangerous waste is placed, or the largest area in which there is a significant likelihood of mixing dangerous waste constituents in the same area. Examples of dangerous waste management units include a surface impoundment, a waste pile, a land treatment area, a landfill cell, an incinerator, a tank and its associated piping and underlying containment system and a container storage area. A container alone does not constitute a unit; the unit includes containers and the land or pad upon which they are placed.



"Dangerous wastes" means those solid wastes designated in WAC 173-303-070 through 173-303-103 as dangerous or extremely hazardous waste. As used in this chapter, the words "dangerous waste" will refer to the full universe of wastes regulated by this chapter (including dangerous and extremely hazardous waste), while the abbreviation "DW" will refer to that part of the regulated universe which is dangerous only, and not extremely hazardous. (See also "extremely hazardous waste" and "hazardous waste" definitions.)

~~((19))~~ "Department" means the department of ecology.

~~((20))~~ "Dermal LD<sub>50</sub>" means the single dosage in milligrams per kilogram (mg/kg) body weight which, when dermally (skin) applied for 24 hours, within 14 days kills half of a group of ten rabbits each weighing between 2.0 and 3.0 kilograms.

~~((21))~~ "Designated facility" means the facility designated by the generator on the manifest to receive a dangerous waste shipment and which is authorized pursuant to this chapter or RCRA to recycle or manage dangerous waste.

~~((22))~~ "Dike" means an embankment or ridge of natural or man-made materials used to prevent the movement of liquids, sludges, solids, or other substances.

~~((23))~~ "Director" means the director of the department of ecology or his designee.

~~((24))~~ "Discharge" or "dangerous waste discharge" means the accidental or intentional release of hazardous substances, dangerous waste or dangerous waste constituents such that the substance, waste or a waste constituent may enter or be emitted into the environment. Release includes, but is not limited to, the actions of: Spilling, leaking, pumping, pouring, emitting, dumping, emptying, depositing, placing, or injecting.

~~((25))~~ "Disposal" means the discharging, discarding, or abandoning of dangerous wastes or the treatment, decontamination, or recycling of such wastes once they have been discarded or abandoned. This includes the discharge of any dangerous wastes into or on any land, air, or water.

"Domestic sewage" means untreated sanitary wastes from residential sources that pass through a sewer system to a publicly owned treatment works (POTW) for treatment.

~~((26))~~ "Draft permit" means a document prepared under WAC 173-303-840 indicating the department's tentative decision to issue or deny, modify, revoke and reissue, or terminate a permit. A notice of intent to terminate or deny a permit are types of draft permits. A denial of a request for modification, revocation and reissuance, or termination as discussed in WAC 173-303-830 is not a draft permit.

~~((27))~~ "Elementary neutralization unit" means a device which:

~~((a))~~ Is used for neutralizing wastes which are dangerous wastes only because they exhibit the corrosivity characteristics defined in WAC 173-303-090 or are listed in WAC 173-303-081, or in 173-303-082 only for this reason; and

~~((b))~~ Meets the definition of tank, tank system, container, transport vehicle, or vessel.

~~((28))~~ "Environment" means any air, land, water, or ground water.

"EPA/state identification number" or "EPA/state ID#" means the number assigned by EPA or by the department of ecology to each generator, transporter, and TSD facility.

~~((29))~~ "Existing tank system" or "existing component" means a tank system or component that is used for the storage or treatment of dangerous waste and that is in operation, or for which installation has commenced on or prior to February 3, 1989. Installation will be considered to have commenced if the owner or operator has obtained all federal, state, and local approvals or permits necessary to begin physical construction of the site or installation of the tank system and if either:

A continuous on-site physical construction or installation program has begun; or

The owner or operator has entered into contractual obligations, which cannot be cancelled or modified without substantial loss, for physical construction of the site or installation of the tank system to be completed within a reasonable time.

"Existing TSD facility" means a facility which was in operation or for which construction commenced on or before November 19, 1980, for wastes designated by 40 CFR Part 261, or August 9, 1982, for wastes designated only by this chapter and not designated by 40 CFR Part 261. A facility has commenced construction if the owner or operator has obtained permits and approvals necessary under federal, state, and local statutes, regulations, and ordinances and either:

A continuous on-site, physical construction program has begun; or

The owner or operator has entered into contractual obligation, which cannot be cancelled or modified without substantial loss, for physical construction of the facility to be completed within a reasonable time.

"Extremely hazardous waste" means those dangerous wastes designated in WAC 173-303-070 through 173-303-103 as extremely hazardous. The abbreviation "EHW" will be used in this chapter to refer to those dangerous wastes which are extremely hazardous. (See also "dangerous waste" and "hazardous waste" definitions.)

~~((30))~~ "Facility" means all contiguous land, and structures, other appurtenances, and improvements on the land used for recycling, reusing, reclaiming, transferring, storing, treating, or disposing of dangerous waste. Unless otherwise specified in this chapter, the terms "facility," "treatment, storage, disposal facility," "TSD facility," "dangerous waste facility" or "waste management facility" shall be used interchangeably.

~~((31))~~ "Final closure" means the closure of all dangerous waste management units at the facility in accordance with all applicable closure requirements so that dangerous waste management activities under WAC 173-303-400 and 173-303-600 through 173-303-670 are no longer conducted at the facility. Areas only subject to generator standards WAC 173-303-170 through 173-303-230 need not be included in final closure.



"Food chain crops" means tobacco, crops grown for human consumption, and crops grown to feed animals whose products are consumed by humans.

((32)) "Freeboard" means the vertical distance between the top of a tank or surface impoundment dike, and the surface of the waste contained therein.

((33)) "Fugitive emissions" means the emission of contaminants from sources other than the control system exit point. Material handling, storage piles, doors, windows and vents are typical sources of fugitive emissions.

((34)) "Generator" means any person, by site, whose act or process produces dangerous waste or whose act first causes a dangerous waste to become subject to regulation.

((35)) "Genetic properties" means those properties which cause or significantly contribute to mutagenic, teratogenic, or carcinogenic effects in man or wildlife.

((36)) "Ground water" means water which fills voids below the land surface and in the earth's crust.

((37)) "Halogenated hydrocarbons" (HH) means any organic compounds which, as part of their composition, include one or more atoms of fluorine, chlorine, bromine, iodine, or astatine. The requirements of this chapter apply to only those halogenated hydrocarbons which can be obtained using the testing method described in WAC 173-303-110, testing methods, and which are persistent dangerous wastes.

((38)) "Hazardous substances" means any liquid, solid, gas, or sludge, including any material, substance, product, commodity, or waste, regardless of quantity, that exhibits any of the physical, chemical or biological properties described in WAC 173-303-090, 173-303-101, 173-303-102, or 173-303-103.

((39)) "Hazardous wastes" means those solid wastes designated by 40 CFR Part 261, and regulated as hazardous waste by the United States EPA. This term will never be abbreviated in this chapter to avoid confusion with the abbreviations "DW" and "EHW." (See also "dangerous waste" and "extremely hazardous waste" definitions.)

"Ignitable waste" means a dangerous waste that exhibits the characteristic of ignitability described in WAC 173-303-090(5).

((40)) "Inactive portion" means that portion of a facility which has not recycled, treated, stored, or disposed dangerous waste after:

((a)) The effective date of the waste's designation, for wastes designated under 40 CFR Part 261; and

((b)) March 10, 1982, for wastes designated only by this chapter and not designated by 40 CFR Part 261.

((41)) "Incinerator" means any enclosed device using controlled flame combustion that neither meets the criteria for classification as a boiler nor is listed as an industrial furnace.

((42)) "Incompatible waste" means a dangerous waste which is unsuitable for placement in a particular device or facility because it may corrode or decay the containment materials, or is unsuitable for mixing with another waste or material because the mixture might produce heat or pressure, fire or explosion, violent reaction, toxic dusts, fumes, mists, or gases, or flammable fumes or gases.

((43)) "Industrial-furnace" means any of the following enclosed devices that are integral components of manufacturing processes and that use controlled flame devices to accomplish recovery of materials or energy; cement kilns, lime kilns, aggregate kilns, phosphate kilns, blast furnaces, smelting, melting, and refining furnaces (including pyrometallurgical devices such as cupolas, reverberator furnaces, sintering machines, roasters and foundry furnaces), titanium dioxide chloride process oxidation reactors, coke ovens, methane reforming furnaces, combustion devices used in the recovery of sulfur values from spent sulfuric acid, and pulping liquor recovery furnaces. The department may decide to add devices to this list on the basis of one or more of the following factors:

((a)) The device is designed and used primarily to accomplish recovery of material products;

((b)) The device burns or reduces secondary materials as ingredients in an industrial process to make a material product;

((c)) The device burns or reduces secondary materials as effective substitutes for raw materials in processes using raw materials as principal feedstocks;

((d)) The device burns or reduces raw materials to make a material product;

((e)) The device is in common industrial use to produce a material product; and

((f)) Other factors, as appropriate.

((44)) "Infectious waste" means organisms or materials listed in WAC 173-303-083, infectious dangerous wastes.

((45)) "Inground tank" means a device meeting the definition of "tank" in this section whereby a portion of the tank wall is situated to any degree within the ground, thereby preventing visual inspection of that external surface area of the tank that is in the ground.

"Inhalation LC<sub>50</sub>" means a concentration in milligrams of substance per liter of air which, when administered to the respiratory tract for 4 hours or less, kills within 14 days half of a group of ten rats each weighing between 200 and 300 grams.

((46)) "Inner liner" means a continuous layer of material placed inside a tank or container which protects the construction materials of the tank or container from the waste or reagents used to treat the waste.

((47)) "Installation inspector" means a person who, by reason of his knowledge of the physical sciences and the principles of engineering, acquired by a professional education and related practical experience, is qualified to supervise the installation of tank systems.

"Interim status permit" means a temporary permit given to TSD facilities which qualify under WAC 173-303-805.

"Land disposal" means placement in a facility or on the land with the intent of leaving the dangerous waste at closure, and includes, but is not limited to, placement for disposal purposes in a: Landfill; surface impoundment; waste pile; injection well; land treatment facility; salt dome or salt bed formation; underground mine or cave; concrete vault; bunker; or miscellaneous unit.

((48)) "Landfill" means a disposal facility, or part of a facility, where dangerous waste is placed in or on

land and which is not a land treatment facility, a surface impoundment, or an underground injection well, a salt dome formation, a salt bed formation, an underground mine, or a cave.

~~((49))~~ "Land treatment" means the practice of applying dangerous waste onto or incorporating dangerous waste into the soil surface so that it will degrade or decompose. If the waste will remain after the facility is closed, this practice is disposal.

"Leachable inorganic waste" means solid dangerous waste (i.e., passes paint filter test) that is not an organic/carbonaceous waste and exhibits the toxicity characteristic (dangerous waste numbers D004 to D011, only) under WAC 173-303-090(8).

~~((50))~~ "Leachate" means any liquid, including any components suspended in the liquid, that has percolated through or drained from dangerous waste.

~~((51))~~ "Leak-detection system" means a system capable of detecting the failure of either the primary or secondary containment structure or the presence of a release of dangerous waste or accumulated liquid in the secondary containment structure. Such a system must employ operational controls (e.g., daily visual inspections for releases into the secondary containment system of aboveground tanks) or consist of an interstitial monitoring device designed to detect continuously and automatically the failure of the primary or secondary containment structure or the presence of a release of dangerous waste into the secondary containment structure.

"Legal defense costs" means any expenses that an insurer incurs in defending against claims of third parties brought under the terms and conditions of an insurance policy.

~~((52))~~ "Liner" means a continuous layer of man-made or natural materials which restrict the escape of dangerous waste, dangerous waste constituents, or leachate through the sides, bottom, or berms of a surface impoundment, waste pile, or landfill.

~~((53))~~ "Major facility" means a facility or activity classified by the department as major.

~~((54))~~ "Manifest" means the shipping document, prepared in accordance with the requirements of WAC 173-303-180, which is used to identify the quantity, composition, origin, routing, and destination of a dangerous waste while it is being transported to a point of transfer, disposal, treatment, or storage.

~~((55) (Reserved))~~

~~((56))~~ "Manufacturing process unit" means a unit which is an integral and inseparable portion of a manufacturing operation, processing a raw material into a manufacturing intermediate or finished product, reclaiming spent materials or reconditioning components.

"New tank system" or "new tank component" means a tank system or component that will be used for the storage or treatment of dangerous waste and for which installation has commenced after February 3, 1989; except, however, for purposes of WAC 173-303-640 (4)(g)(ii) and 173-303-400(3), a new tank system is one for which construction commences after February 3, 1989. (See also "existing tank system.")

"New TSD facility" means a facility which began operation or for which construction commenced after November 19, 1980, for wastes designated by 40 CFR Part 261, or August 9, 1982, for wastes designated only by this chapter and not designated by 40 CFR Part 261.

"Miscellaneous unit" means a dangerous waste management unit where dangerous waste is treated, stored, or disposed of and that is not a container, tank, surface impoundment, pile, land treatment unit, landfill, incinerator, boiler, industrial furnace, underground injection well with appropriate technical standards under 40 CFR Part 146, or unit eligible for a research, development, and demonstration permit under WAC 173-303-809.

"NIOSH registry" means the registry of toxic effects of chemical substances which is published by the National Institute for Occupational Safety and Health.

~~((57))~~ "Nonsudden accident" or "nonsudden accidental occurrence" means an unforeseen and unexpected occurrence which takes place over time and involves continuous or repeated exposure.

~~((58))~~ "Occurrence" means an accident, including continuous or repeated exposure to conditions, which results in bodily injury or property damage which the owner or operator neither expected nor intended to occur.

~~((59))~~ "Off-specification used oil fuel" means used oil fuel that exceeds any specification level described in Table I in WAC 173-303-515.

"Onground tank" means a device meeting the definition of "tank" in this section and that is situated in such a way that the bottom of the tank is on the same level as the adjacent surrounding surface so that the external tank bottom cannot be visually inspected.

"On-site" means the same, geographically contiguous, or bordering property. Travel between two properties divided by a public right of way, and owned, operated, or controlled by the same person, shall be considered on-site travel if: ~~((a))~~ The travel crosses the right of way at a perpendicular intersection; or, ~~((b))~~ the right of way is controlled by the property owner and is inaccessible to the public.

~~((60))~~ "Operator" means the person responsible for the overall operation of a facility. (See also "state operator.")

~~((61))~~ "Oral LD<sub>50</sub>" means the single dosage in milligrams per kilogram (mg/kg) body weight, when orally administered, which, within 14 days, kills half a group of ten or more white rats each weighing between 200 and 300 grams.

~~((62))~~ "Organic/carbonaceous waste" means a dangerous waste that contains combined concentrations of greater than ten percent organic/carbonaceous constituents in the waste; organic/carbonaceous constituents are those substances that contain carbon-hydrogen, carbon-halogen, or carbon-carbon chemical bonding.

"Partial closure" means the closure of a dangerous waste management unit in accordance with the applicable closure requirements of WAC 173-303-400 and 173-303-600 through 173-303-670 at a facility that contains other active dangerous waste management

units. For example, partial closure may include the closure of a tank (including its associated piping and underlying containment systems), landfill cell, surface impoundment, waste pile, or other dangerous waste management unit, while other units of the same facility continue to operate.

"Permit" means an authorization which allows a person to perform dangerous waste transfer, storage, treatment, or disposal operations, and which typically will include specific conditions for such facility operations. Permits must be issued by one of the following:

((a)) The department, pursuant to this chapter;

((b)) United States EPA, pursuant to 40 CFR Part 270; or

((c)) Another state authorized by EPA, pursuant to 40 CFR Part 271.

((63)) "Permit-by-rule" means a provision of this chapter stating that a facility or activity is deemed to have a dangerous waste permit if it meets the requirements of the provision.

((64)) "Persistence" means the quality of a material which retains more than half of its initial activity after one year (365 days) in either a dark anaerobic or dark aerobic environment at ambient conditions.

((65)) "Person" means any person, firm, association, county, public or municipal or private corporation, agency, or other entity whatsoever.

((66)) "Pesticide" means but is not limited to: Any substance or mixture of substances intended to prevent, destroy, control, repel, or mitigate any insect, rodent, nematode, mollusk, fungus, weed, and any other form of plant or animal life, or virus (except virus on or in living man or other animal) which is normally considered to be a pest or which the department of agriculture may declare to be a pest; any substance or mixture of substances intended to be used as a plant regulator, defoliant, or desiccant; any substance or mixture of substances intended to be used as spray adjuvant; and, any other substance intended for such use as may be named by the department of agriculture by regulation. Herbicides, fungicides, insecticides, and rodenticides are pesticides for the purposes of this chapter.

((67)) "Pile" means any noncontainerized accumulation of solid, nonflowing dangerous waste that is used for treatment or storage.

((68)) "Point source" means any confined and discrete conveyance from which pollutants are or may be discharged. This term includes, but is not limited to, pipes, ditches, channels, tunnels, wells, cracks, containers, rolling stock, concentrated animal feeding operations, or watercraft, but does not include return flows from irrigated agriculture.

((69)) "Polycyclic aromatic hydrocarbons" (PAH) means those hydrocarbon molecules composed of two or more benzene rings. For the purposes of this chapter, the PAH of concern for designation are only those PAH with more than three rings and less than seven rings.

((70)) "Post-closure" means the requirements placed upon disposal facilities (e.g., landfills, impoundments closed as disposal facilities, etc.) after closure to ensure their environmental safety for a number of years after closure. (See also "closure.")

((71)) "Publicly owned treatment works" or "POTW" means any device or system, owned by the state or a municipality, which is used in the treatment, recycling, or reclamation of municipal sewage or liquid industrial wastes. This term includes sewers, pipes, or other conveyances only if they convey wastewater to a POTW.

"Reactive waste" means a dangerous waste that exhibits the characteristic of reactivity described in WAC 173-303-090(7).

((72)) "Reclaim" means to process a material in order to recover useable products, or to regenerate the material. Reclamation is the process of reclaiming.

((73)) "Recover" means extract a useable material from a solid or dangerous waste through a physical, chemical, biological, or thermal process. Recovery is the process of recovering.

((74)) "Recycle" means to use, reuse, or reclaim a material.

((75)) "Regulated unit" means any new or existing surface impoundment, landfill, land treatment area or waste pile that receives any dangerous waste after:

((a)) January 26, 1983 for wastes regulated by 40 CFR Part 261;

((b)) October 31, 1984 for wastes designated only by this chapter and not regulated by 40 CFR Part 261; or

((c)) The date six months after a waste is newly identified by amendments to 40 CFR Part 261 or this chapter which cause the waste to be regulated.

((76)) "Representative sample" means a sample which can be expected to exhibit the average properties of the sample source.

((77)) "Reuse or use" means to employ a material either:

((a)) As an ingredient (including use as an intermediate) in an industrial process to make a product (for example, distillation bottoms from one process used as feedstock in another process). However, a material will not satisfy this condition if distinct components of the material are recovered as separate end products (as when metals are recovered from metal-containing secondary materials); or

((b)) In a particular function or application as an effective substitute for a commercial product (for example, spent pickle liquor used as phosphorous precipitant and sludge conditioner in wastewater treatment).

((78)) "Run-off" means any rainwater, leachate, or other liquid which drains over land from any part of a facility.

((79)) "Run-on" means any rainwater, leachate, or other liquid which drains over land onto any part of a facility.

((80)) "Schedule of compliance" means a schedule of remedial measures in a permit including an enforceable sequence of interim requirements leading to compliance with this chapter.

((81)) "Scrap metal" means bits and pieces of metal parts (e.g., bars, turnings, rods, sheets, wire) or metal pieces that may be combined together with bolts or soldering (e.g., radiators, scrap automobiles, railroad box cars), which when worn or superfluous can be recycled.

"Sludge" means any solid, semisolid, or liquid waste generated from a municipal, commercial, or industrial wastewater treatment plant, water supply treatment plant, or air pollution control facility. This term does not include the treated effluent from a wastewater treatment plant.

~~((82)) "Scrap metal" means bits and pieces of metal parts (e.g., bars, turnings, rods, sheets, wire) or metal pieces that may be combined together with bolts or soldering (e.g., radiators, scrap automobiles, railroad box cars), which when worn or superfluous can be recycled.~~

((83)) "Solid acid waste" means a dangerous waste that exhibits the characteristic of low pH under the corrosivity tests of either WAC 173-303-090 (6)(a)(ii) or (b).

"Special incinerator ash" means ash residues resulting from the operation of incineration or energy recovery facilities managing municipal solid waste from residential, commercial and industrial establishments, if the ash residues are designated as dangerous waste only by this chapter and not designated as hazardous waste by 40 CFR Part 261.

"Special waste" means any dangerous waste that is solid only (nonliquid, nonaqueous, nongaseous), that is not a regulated hazardous waste under 40 CFR Part 261, and that is designated as only DW in WAC 173-303-090, 173-303-101, 173-303-102, or 173-303-103. Any solid waste that is EHW or that is regulated by the United States EPA as hazardous waste cannot be a special waste.

"Spent material" means any material that has been used and as a result of contamination can no longer serve the purpose for which it was produced without processing.

"Stabilization" and "solidification" means a technique that limits the solubility and mobility of dangerous waste constituents. Solidification immobilizes a waste through physical means and stabilization immobilizes the waste by bonding or chemically reacting with the stabilizing material.

~~((84)) "State operator" means the person responsible for the overall operation of the state's extremely hazardous waste facility on the Hanford Reservation.~~

~~((85)) "Storage" means the holding of dangerous waste for a temporary period. "Accumulation" of dangerous waste, by the generator on the site of generation, is not storage as long as the generator complies with the applicable requirements of WAC 173-303-200 and 173-303-201.~~

~~((86)) "Sudden accident" means an unforeseen and unexpected occurrence which is not continuous or repeated in nature.~~

~~((87)) "Sump" means any pit or reservoir that meets the definition of tank and those troughs/trenches connected to it that serves to collect dangerous waste for transport to dangerous waste storage, treatment, or disposal facilities.~~

"Surface impoundment" means a facility or part of a facility which is a natural topographic depression, man-made excavation, or diked area formed primarily of earthen materials (although it may be lined with man-

made materials), and which is designed to hold an accumulation of liquid dangerous wastes or dangerous wastes containing free liquids. The term includes holding, storage, settling, and aeration pits, ponds, or lagoons, but does not include injection wells.

~~((88)) "Tank" means a stationary device designed to contain an accumulation of dangerous waste, and which is constructed primarily of nonearthen materials to provide structural support.~~

~~((89)) "Tank system" means a dangerous waste storage or treatment tank and its associated ancillary equipment and containment system.~~

"Thermal treatment" means the use of a device which uses primarily elevated temperatures to treat a dangerous waste.

~~((90)) "TLM<sub>96</sub>" means the same as "Aquatic LC<sub>50</sub>."~~

~~((91)) "Totally enclosed treatment facility" means a facility for treating dangerous waste which is directly connected to a production process and which prevents the release of dangerous waste or dangerous waste constituents into the environment during treatment.~~

~~((92)) "Toxic" means having the properties to cause or to significantly contribute to death, injury, or illness of man or wildlife.~~

~~((93)) "Transfer facility" or "collection facility" means a facility at which dangerous waste shipments are collected, consolidated, and stored for more than ten days before transfer to a storage, treatment, or disposal facility.~~

~~((94)) "Transportation" means the movement of dangerous waste by air, rail, highway, or water.~~

~~((95)) "Transporter" means a person engaged in the off-site transportation of dangerous waste.~~

~~((96)) "Travel time" means the period of time necessary for a dangerous waste constituent released to the soil (either by accident or intent) to enter any on-site or off-site aquifer or water supply system.~~

~~((97)) "Treatability study" means a study in which a dangerous waste is subjected to a treatment process to determine: Whether the waste is amenable to the treatment process; what pretreatment (if any) is required; the optimal process conditions needed to achieve the desired treatment; the efficiency of a treatment process for a specific waste or wastes; or the characteristics and volumes of residuals from a particular treatment process. Also included in this definition for the purpose of the exemptions contained in WAC 173-303-071 (3)(r) and (s), are liner compatibility, corrosion, and other material compatibility studies and toxicological and health effects studies. A "treatability study" is not a means to commercially treat or dispose of dangerous waste.~~

"Treatment" means the physical, chemical, or biological processing of dangerous waste to make such wastes nondangerous or less dangerous, safer for transport, amenable for energy or material resource recovery, amenable for storage, or reduced in volume.

~~((98)) "Treatment zone" means a soil area of the unsaturated zone of a land treatment unit within which dangerous wastes are degraded, transformed or immobilized.~~

~~((99))~~ "Triple rinsing" means the cleaning of containers in accordance with the requirements of WAC 173-303-160 (2)(b), containers.

~~((100))~~ "Underground injection" means the subsurface emplacement of fluids through a bored, drilled, or driven well, or through a dug well, where the depth of the dug well is greater than the largest surface dimension.

~~((101))~~ "Underground tank" means a device meeting the definition of "tank" in this section whose entire surface area is totally below the surface of and covered by the ground.

"Unfit-for-use tank system" means a tank system that has been determined through an integrity assessment or other inspection to be no longer capable of storing or treating dangerous waste without posing a threat of release of dangerous waste to the environment.

"Unsaturated zone" means the zone between the land surface and the water table.

~~((102))~~ "Uppermost aquifer" means the geological formation nearest the natural ground surface that is capable of yielding ground water to wells or springs. It includes lower aquifers that are hydraulically interconnected with this aquifer within the facility property boundary.

~~((103))~~ "Used oil" means oil that has been refined from crude oil, used, and, as a result of such use, is contaminated by physical or chemical impurities.

"Waste water treatment unit" means a device which: Is part of a waste water treatment facility which is subject to regulation under either:

Section 402 or section 307(b) of the Federal Clean Water Act; or

Chapter 90.48 RCW, State Water Pollution Control Act, provided that any dangerous waste treated at the facility is designated only by this chapter, chapter 173-303 WAC, and is not regulated as hazardous waste under 40 CFR Part 261; and

Handles dangerous waste as defined in WAC 173-303-070 through 173-303-103 in either of the following manner:

Receives and treats or stores an influent dangerous waste water; or

Generates and accumulates or treats or stores a dangerous waste water treatment sludge; and

Meets the definition of tank or tank system in this section.

"Water or rail (bulk shipment)" means the bulk transportation of dangerous waste which is loaded or carried on board a vessel or railcar without containers or labels.

~~((104))~~ "Waste water treatment unit" means a device which:

(a) Is part of a waste water treatment facility which is subject to regulation under either:

(i) Section 402 or section 307(b) of the Federal Clean Water Act; or

(ii) Chapter 90.48 RCW, State Water Pollution Control Act, provided that any dangerous waste treated at the facility is designated only by this chapter 173-303 WAC and is not regulated as hazardous waste under 40 CFR Part 261; and

~~(b) Handles dangerous waste as defined in WAC 173-303-070 through 173-303-103 in either of the following manner:~~

~~(i) Receives and treats or stores an influent dangerous waste water; or~~

~~(ii) Generates and accumulates or treats or stores a dangerous waste water treatment sludge; and~~

~~(c) Meets the definition of tank or tank system in WAC 173-303-040.~~

~~(105) "Existing TSD facility" means a facility which was in operation or for which construction commenced on or before November 19, 1980, for wastes designated by 40 CFR Part 261, or August 9, 1982, for wastes designated only by this chapter and not designated by 40 CFR Part 261. A facility has commenced construction if the owner or operator has obtained permits and approvals necessary under federal, state and local statutes, regulations and ordinances and either:~~

~~(a) A continuous on-site, physical construction program has begun; or~~

~~(b) The owner or operator has entered into contractual obligation, which cannot be cancelled or modified without substantial loss, for physical construction of the facility to be completed within a reasonable time.~~

~~(106) "New TSD facility" means a facility which began operation or for which construction commenced after November 19, 1980, for wastes designated by 40 CFR Part 261, or August 9, 1982, for wastes designated only by this chapter and not designated by 40 CFR Part 261.~~

~~(107) "Special waste" means any dangerous waste that is solid only (nonliquid, nonaqueous, nongaseous), that is not a regulated hazardous waste under 40 CFR Part 261, and that is designated as only DW in WAC 173-303-090, 173-303-101, 173-303-102, or 173-303-103. Any solid waste that is EHW or that is regulated by the United States EPA as hazardous waste cannot be a special waste.~~

~~(108) "Active life" of a facility means the period from the initial receipt of dangerous waste at the facility until the department receives certification of final closure.~~

~~(109) "Final closure" means the closure of all dangerous waste management units at the facility in accordance with all applicable closure requirements so that dangerous waste management activities under WAC 173-303-400 and 173-303-600 through 173-303-670 are no longer conducted at the facility unless subject to the provisions in WAC 173-303-200.~~

~~(110) "Partial closure" means the closure of a dangerous waste management unit in accordance with the applicable closure requirements of WAC 173-303-400 and 173-303-600 through 173-303-670 at a facility that contains other active dangerous waste management units. For example, partial closure may include the closure of a tank (including its associated piping and underlying containment systems), landfill cell, surface impoundment, waste pile, or other dangerous waste management unit, while other units of the same facility continue to operate.~~

~~(111) "Dangerous waste management unit" is a contiguous area of land on or in which dangerous waste is placed, or the largest area in which there is a significant~~

likelihood of mixing dangerous waste constituents in the same area. Examples of dangerous waste management units include a surface impoundment, a waste pile, a land treatment area, a landfill cell, an incinerator, a tank and its associated piping and underlying containment system and a container storage area. A container alone does not constitute a unit; the unit includes containers and the land or pad upon which they are placed.

(112) "Aboveground tank" means a device meeting the definition of "tank" in subsection (88) of this section and that is situated in such a way that the entire surface area of the tank is completely above the plane of the adjacent surrounding surface and the entire surface area of the tank (including the tank bottom) is able to be visually inspected.

(113) "Ancillary equipment" means any device including, but not limited to, such devices as piping, fittings, flanges, valves, and pumps, that is used to distribute, meter, or control the flow of dangerous waste from its point of generation to a storage or treatment tank(s); between dangerous waste storage and treatment tanks to a point of disposal on-site, or to a point of shipment for disposal off-site.

(114) "Component" means either the tank or ancillary equipment of a tank system.

(115) "Corrosion expert" means a person who, by reason of his knowledge of the physical sciences and the principles of engineering and mathematics, acquired by a professional education and related practical experience, is qualified to engage in the practice of corrosion control on buried or submerged metal piping systems and metal tanks. Such a person must be certified as being qualified by the National Association of Corrosion Engineers (NACE) or be a registered professional engineer who has certification or licensing that includes education and experience in corrosion control on buried or submerged metal piping systems and metal tanks.

(116) "Existing tank system" or "existing component" means a tank system or component that is used for the storage or treatment of dangerous waste and that is in operation, or for which installation has commenced on or prior to February 3, 1989. Installation will be considered to have commenced if the owner or operator has obtained all federal, state, and local approvals or permits necessary to begin physical construction of the site or installation of the tank system and if either:

(a) A continuous on-site physical construction or installation program has begun; or

(b) The owner or operator has entered into contractual obligations, which cannot be canceled or modified without substantial loss, for physical construction of the site or installation of the tank system to be completed within a reasonable time.

(117) "Inground tank" means a device meeting the definition of "tank" in subsection (88) of this section whereby a portion of the tank wall is situated to any degree within the ground, thereby preventing visual inspection of that external surface area of the tank that is in the ground.

(118) "Installation inspector" means a person who, by reason of his knowledge of the physical sciences and the

principles of engineering, acquired by a professional education and related practical experience, is qualified to supervise the installation of tank systems.

(119) "Leak detection system" means a system capable of detecting the failure of either the primary or secondary containment structure or the presence of a release of dangerous waste or accumulated liquid in the secondary containment structure. Such a system must employ operational controls (e.g., daily visual inspections for releases into the secondary containment system of aboveground tanks) or consist of an interstitial monitoring device designed to detect continuously and automatically the failure of the primary or secondary containment structure or the presence of a release of dangerous waste into the secondary containment structure.

(120) "New tank system" or "new tank component" means a tank system or component that will be used for the storage or treatment of dangerous waste and for which installation has commenced after February 3, 1989, except, however, for purposes of WAC 173-303-640 (4)(g)(ii) and 173-303-400(3), a new tank system is one for which construction commences after February 3, 1989. (See also "existing tank system.")

(121) "Onground tank" means a device meeting the definition of "tank" in subsection (88) of this section and that is situated in such a way that the bottom of the tank is on the same level as the adjacent surrounding surface so that the external tank bottom cannot be visually inspected.

(122) "Sump" means any pit or reservoir that meets the definition of tank and those troughs/trenches connected to it that serves to collect dangerous waste for transport to dangerous waste storage, treatment, or disposal facilities.

(123) "Tank system" means a dangerous waste storage or treatment tank and its associated ancillary equipment and containment system.

(124) "Underground tank" means a device meeting the definition of "tank" in subsection (88) of this section whose entire surface area is totally below the surface of and covered by the ground.

(125) "Unfit-for-use tank system" means a tank system that has been determined through an integrity assessment or other inspection to be no longer capable of storing or treating dangerous waste without posing a threat of release of dangerous waste to the environment.

(126)) "Zone of engineering control" means an area under the control of the owner/operator that, upon detection of a dangerous waste release, can be readily cleaned up prior to the release of dangerous waste or dangerous constituents to ground water or surface water.

((127) "Treatability study" means a study in which a dangerous waste is subjected to a treatment process to determine: Whether the waste is amenable to the treatment process; what pretreatment (if any) is required; the optimal process conditions needed to achieve the desired treatment; the efficiency of a treatment process for a specific waste or wastes; or the characteristics and volumes of residuals from a particular treatment process. Also included in this definition for the purpose of the exemptions contained in WAC 173-303-071 (3)(r) and (s), are liner compatibility, corrosion, and other material

compatibility studies and toxicological and health effects studies. A "treatability study" is not a means to commercially treat or dispose of dangerous waste.

~~(128) "Manufacturing process unit" means a unit which is an integral and inseparable portion of a manufacturing operation, processing a raw material into a manufacturing intermediate or finished product, reclaiming spent materials or reconditioning components:)~~

Any terms used in this chapter which have not been defined in this section shall have either the same meaning as set forth in Title 40 CFR Parts 260, 264, 270, and 124 or else shall have their standard, technical meaning.

As used in this chapter, words in the masculine gender also include the feminine and neuter genders, words in the singular include the plural, and words in the plural include the singular.

AMENDATORY SECTION (Amending Order 88-24, filed 1/4/89)

WAC 173-303-045 REFERENCES TO EPA'S HAZARDOUS WASTE AND PERMIT REGULATIONS. Any references in this chapter to any parts, subparts, or sections from EPA's hazardous waste regulations, including 40 CFR Parts 260 through 280 and Part 124, shall be in reference to those rules as they existed on ~~((October 1, 1988, with the exception of rules adopted by EPA pursuant to the Hazardous and Solid Waste Amendments of 1984 (HSWA), Public Law 98-616, amending RCRA))~~ July 1, 1990. Copies of the appropriate referenced federal requirements are available upon request from the department.

AMENDATORY SECTION (Amending Order 88-24, filed 1/4/89)

WAC 173-303-070 DESIGNATION OF DANGEROUS WASTE. (1) Purpose and applicability.

(a) This section describes the procedures for determining whether or not a solid waste is DW or EHW.

(b) The procedures in this section are applicable to any person who generates a solid waste (including recyclable materials) that is not exempted or excluded by this chapter or by the department. Any person who must determine whether or not his solid waste is designated must follow the procedures set forth in subsection (3) of this section. Any person who determines by these procedures that his waste is designated DW or EHW shall be subject to all applicable requirements of this chapter.

(2)(a) Once a material has been determined to be a dangerous waste, then any solid waste generated from the recycling, treatment, storage, or disposal of that dangerous waste is a dangerous waste unless and until:

(i) The generator has been able to accurately describe the variability or uniformity of the waste over time, and has been able to obtain demonstration samples which are representative of the waste's variability or uniformity; and

(ii)(A) It does not exhibit any of the characteristics of WAC 173-303-090; and

(B) If it was a listed waste under WAC 173-303-080 through 173-303-083 ~~((which))~~, it also has been exempted pursuant to WAC 173-303-910(3); or

~~((iii))~~ (iii) If originally designated only through WAC 173-303-084 or 173-303-101 through 173-303-103, it does not exhibit any of the criteria of WAC 173-303-101 through 173-303-103.

Such solid waste shall include but not be limited to any sludge, spill residue, ash emission control dust, leachate, or precipitation run-off. Precipitation run-off will not be considered a dangerous waste if it can be shown that the run-off has not been contaminated with the dangerous waste, or that the run-off is adequately addressed under existing state laws (e.g. chapter 90.48 RCW), or that the run-off does not exhibit any of the criteria or characteristics described in WAC 173-303-100.

(b) Materials that are reclaimed from solid wastes and that are used beneficially (as provided in WAC 173-303-016 and 173-303-017) are not solid wastes and hence are not dangerous wastes under this section unless the reclaimed material is burned for energy recovery or used in a manner constituting disposal.

(3) Designation procedures.

(a) To determine whether or not his waste is designated a person shall check his waste against the following sections, and in the following order:

(i) First, Discarded chemical products, WAC 173-303-081;

(ii) Second, Dangerous waste sources, WAC 173-303-082;

(iii) Third, Infectious dangerous wastes, WAC 173-303-083;

(iv) Fourth, Dangerous waste mixtures, WAC 173-303-084; and

(v) Last, Dangerous waste characteristics, WAC 173-303-090.

(b) In addition to the designation procedures specified in (a) of this subsection, a person may choose or may be required under subsection (4) of this section to check his waste against the following sections, and in the following order:

(i) First, Toxic dangerous wastes, WAC 173-303-101;

(ii) Second, Persistent dangerous wastes, WAC 173-303-102;

(iii) Last, Carcinogenic dangerous wastes, WAC 173-303-103.

(c) A person shall check each section, in the order set forth, until he determines that his waste is designated. Once his waste is designated through the lists, mixtures ~~((or))~~ and characteristics, he need not determine any other designations for his waste, except as required by subsection (4) or (5) of this section. For the purposes of designating through the criteria, if a person determines that his waste is designated DW, then he must assure that it is not also EHW by checking it against the remaining sections. If the designation procedures identify a waste as both EHW and DW (e.g., a waste may be DW for corrosivity and EHW for EP toxicity), the waste must be designated EHW. If a person has checked his waste against each section that he is required by this section to check and his waste is not designated, then his waste is not subject to the requirements of chapter 173-303 WAC.



Any person who wishes to seek an exemption for a waste which has been designated DW or EHW shall comply with the requirements of WAC 173-303-072.

(4) Criteria designation required. Notwithstanding any other provisions of this chapter, the department may require any person to determine whether or not his waste is designated under the dangerous waste criteria, WAC 173-303-100 through 173-303-103, if the department has reason to believe that his waste would be designated DW or EHW by the dangerous waste criteria, or if the department has reason to believe that his waste is designated improperly (e.g., the waste has been designated DW but should actually be designated EHW by the criteria). If a person, pursuant to the requirements of this subsection, determines that his waste is a dangerous waste or that its designation must be changed, then he shall be subject to the applicable requirements of this chapter 173-303 WAC. The department shall base a requirement to designate a waste by the dangerous waste criteria on evidence that includes, but is not limited to:

(a) Test information indicating that the person's waste may be DW or EHW;

(b) Evidence that the person's waste is very similar to another persons' already designated DW or EHW;

(c) Evidence that the persons' waste has historically been a DW or EHW; or

(d) Evidence or information about a person's manufacturing materials or processes which indicate that his wastes may be DW or EHW.

(5) Special knowledge. If a generator has designated his waste under the dangerous waste lists, WAC 173-303-080 through 173-303-082, or mixtures, WAC 173-303-084, and has knowledge that his waste also exhibits any of the dangerous waste characteristics, WAC 173-303-090, or that his waste also meets any of the dangerous waste criteria, WAC 173-303-101 through 173-303-103, or both, then he shall also designate his waste in accordance with those dangerous waste characteristics, or criteria, or both.

(6) Dangerous waste numbers. When a person is reporting or keeping records on a dangerous waste, he shall use all the dangerous waste numbers which he knows are assignable to his waste from the dangerous waste lists, characteristics, or criteria. For example, if his waste is ignitable and contains extremely hazardous concentrations of halogenated hydrocarbons, he shall use the dangerous waste numbers of D001 and WP01. This shall not be construed as requiring a person to designate his waste beyond those designation requirements set forth in subsections (2), (3), (4), and (5) of this section.

(7) Quantity exclusion limits; aggregated waste quantities.

(a) Quantity exclusion limits. In each of the designation sections describing the lists, characteristics, and criteria, quantity exclusion limits (QEL) are identified. The QEL are used to distinguish when a dangerous waste is only subject to the small quantity generator provisions, and when a dangerous waste is fully subject to the requirements of this chapter. Any solid waste which is not excluded or exempted and which is listed by or exhibits the characteristics or criteria of this chapter is a dangerous waste. Small quantity generators who produce

dangerous waste below the QEL are subject to certain requirements described in subsection (8) of this section.

(b) Aggregated waste quantities. A person may be generating, accumulating, or storing more than one kind of dangerous waste identified by this chapter. In such cases, the person must consider the aggregate quantity of his wastes when determining whether or not his waste amounts exceed the specific quantity exclusion limits (QEL). Waste quantities must be aggregated for all wastes with common QEL's. For the purposes of this subsection, when aggregating waste quantities, a person shall include in his calculation dangerous wastes produced by on-site treatment or recycling of dangerous wastes and dangerous wastes being accumulated or stored. For example, if a person generates, accumulates, or stores 300 pounds of an ignitable waste and 300 pounds of a persistent waste, then both wastes are regulated because their aggregate waste quantity (600 pounds) exceeds their common QEL of 220 pounds. On the other hand, if a person generates, accumulates, or stores one pound of an EHW discarded chemical product and 300 pounds of a corrosive waste, their quantities would not be aggregated because they do not share a common QEL (2.2 pounds and 220 pounds, respective QEL's). Additional guidance on aggregating waste quantities is available from the department.

(c) The following are categories of waste that are excluded from the quantity determination and need not be aggregated as required by (b) of this subsection when calculating total waste quantities.

(i) Dangerous waste that is recycled and that is excluded from regulation under WAC 173-303-120 (2)(a), (3)(d) or (e) is not included in the quantity determinations of this section and is not subject to any requirements of this section.

(ii) Spent materials that are generated, reclaimed, and subsequently reused on-site, so long as such spent materials have been counted once.

(8) Small quantity generators.

(a) A person is a small quantity generator and is subject to the requirements of this subsection if his waste is designated under subsection (3) of this section, and the quantity of waste that he generates, accumulates, or stores (or the aggregated quantity if he generates more than one kind of waste) does not exceed the quantity exclusion limit for such waste (or wastes). If a person generates, accumulates, or stores any dangerous wastes that exceed the QEL, then all dangerous waste generated, accumulated, or stored by that person is subject to the requirements of this chapter. For example, if a person generates four pounds of an EHW discarded chemical product (QEL is 2.2 pounds) and 200 pounds of an ignitable waste (QEL is 220 pounds), then both wastes are fully regulated, and the person is not a small quantity generator for either waste. A small quantity generator may accumulate such listed or characteristic waste on-site, however when the quantity (or aggregate quantity) on-site at any time exceeds the quantity exclusion limit for such waste (or wastes) he will not be a small quantity generator and will be subject to all applicable requirements of this chapter. A small quantity generator who generates, accumulates, or stores waste in excess of



the quantity exclusion limit and becomes subject to the full requirements of this chapter cannot again be a small quantity generator until after all dangerous waste on-site at the time he became fully regulated have been removed, treated, or disposed.

(b) A small quantity generator will not be subject to the requirements of this chapter if he:

(i) Complies with subsections (1), (2), (3), and (4) of this section; and

(ii) Either treats or disposes of his dangerous waste in an on-site facility, or ensures delivery to an off-site facility, either of which is:

(A) Permitted (including permit-by-rule, interim status, or final status) under WAC 173-303-800 through 173-303-840;

(B) Authorized to manage dangerous waste by another state with a hazardous waste program approved under 40 CFR Part 271, or by EPA under 40 CFR Part 270;

(C) ~~((Permitted to manage municipal or industrial solid waste in accordance with state or local regulations, or in accordance with another state's solid waste laws if the waste is sent out of state, or))~~ Permitted to manage moderate-risk waste under chapter 173-304 WAC (Minimum functional standards for solid waste handling), operated in accordance with state and local regulations, and consistent with the applicable local hazardous waste plan that has been approved by the department;

(D) A facility that beneficially uses or reuses, or legitimately recycles or reclaims his dangerous waste, or that treats his waste prior to such recycling activities; ~~((and))~~ or

(E) Permitted to manage municipal or industrial solid waste in accordance with state or local regulations, or in accordance with another state's solid waste laws if the waste is sent out of state; and

(iii) Submits an annual report in accordance with WAC 173-303-220 if he has obtained an EPA/state identification number pursuant to WAC 173-303-060.

#### AMENDATORY SECTION (Amending Order 88-24, filed 1/4/89)

WAC 173-303-071 EXCLUDED CATEGORIES OF WASTE. (1) Purpose. Certain categories of waste have been excluded from the requirements of chapter 173-303 WAC, except for WAC 173-303-050, because they generally are not dangerous waste, are regulated under other state and federal programs, or are recycled in ways which do not threaten public health or the environment. WAC 173-303-071 describes these excluded categories of waste.

(2) Excluding wastes. Any persons who generate a common class of wastes and who seek to categorically exclude such class of wastes from the requirements of this chapter shall comply with the applicable requirements of WAC 173-303-072. No waste class will be excluded if any of the wastes in the class are regulated as hazardous waste under 40 CFR Part 261.

(3) Exclusions. The following categories of waste are excluded from the requirements of chapter 173-303 WAC, except for WAC 173-303-050, 173-303-145, and 173-303-960:

(a) ~~Domestic sewage~~ ~~((, and any mixture of domestic sewage and other wastes that passes through a sewer system to a publicly owned treatment works (POTW) for treatment))~~. "Domestic sewage" means untreated sanitary wastes from residential sources that pass through a sewer system to a publicly owned treatment works (POTW) for treatment. This exclusion does not apply to the generation, treatment, storage, recycling, or other management of dangerous wastes prior to discharge into the sanitary sewage system. Owners or operators of POTWs managing dangerous wastes may qualify for a permit-by-rule pursuant to WAC 173-303-802(4);

(b) Industrial wastewater discharges that are point-source discharges subject to regulation under Section 402 of the Clean Water Act. This exclusion does not apply to the collection, storage, or treatment of industrial waste-waters prior to discharge, nor to sludges that are generated during industrial wastewater treatment. Owners or operators of certain wastewater treatment facilities managing dangerous wastes may qualify for a permit-by-rule pursuant to WAC 173-303-802(5);

(c) Household wastes, including household waste that has been collected, transported, stored, or disposed. Wastes which are residues from or are generated by the management of household wastes (e.g., leachate, ash from burning of refuse-derived fuel) are not excluded by this provision. "Household wastes" means any waste material (including garbage, trash, and sanitary wastes in septic tanks) derived from households (including single and multiple residences, hotels and motels, bunkhouses, ranger stations, crew quarters, campgrounds, picnic grounds, and day-use recreation areas);

(d) Agricultural crops and animal manures which are returned to the soil as fertilizers;

(e) Asphaltic materials designated only for the presence of PAHs by WAC 173-303-084(6) or 173-303-102. For the purposes of this exclusion, asphaltic materials means materials intended and used for structural and construction purposes (e.g., roads, dikes, paving) which are produced from mixtures of oil and sand, gravel, ash or similar substances;

(f) Roofing tars and shingles, except that these wastes are not excluded if mixed with wastes listed in WAC 173-303-081 or 173-303-082, or if they exhibit any of the characteristics specified in WAC 173-303-090;

(g) ~~Waste wood or wood products ((treated with preservatives))~~ that fails the test for the toxicity characteristic solely for arsenic and which is not a dangerous waste for any other reason or reasons, if the waste is generated by persons who utilize the arsenical-treated wood or wood products for these materials' intended end use;

(h) Irrigation return flows;

(i) Materials subjected to in-situ mining techniques which are not removed from the ground during extraction;

(j) Mining overburden returned to the mining site;

(k) Polychlorinated biphenyl (PCB) wastes;

(i) PCB wastes whose disposal is regulated by EPA under 40 CFR 761.60 and that are dangerous either because they fail the test for toxicity characteristic (WAC

173-303-090(8), Dangerous waste codes D018 through D043 only) or because they are designated only by this chapter and not designated by 40 CFR Part 261, are exempt from regulation under this chapter except for WAC 173-303-510, 173-303-515, and 173-303-960;

(ii) Wastes that would be designated as dangerous waste under this chapter solely because they are listed as W001 under WAC 173-303-9904 when, using EPA's PCB testing method 600/4-81-045, the waste can be shown to contain less than one part per million (ppm) PCB or when, using ASTM method D 4059-86, the waste can be shown to contain less than two parts per million (ppm) PCB;

(iii) Wastes that would be designated as dangerous waste under this chapter solely because they are listed as W001 under WAC 173-303-9904 when such wastes are:

(A) Stored in a manner equivalent to the requirements of 40 CFR 761.65; and

(B) Within one year of removal from service, disposed of either in an incinerator that complies with 40 CFR 761.70, in a chemical waste landfill that complies with 40 CFR 761.75, in a high efficiency boiler that complies with 40 CFR 761.60 (a)(2)(iii) or (a)(3)(iii), or in a facility otherwise approved in accordance with 40 CFR 761.60(e);

(l) Samples:

(i) Except as provided in (l)(ii) of this subsection, a sample of solid waste or a sample of water, soil, or air, which is collected for the sole purpose of testing to determine its characteristics or composition, is not subject to any requirements of this chapter, when:

(A) The sample is being transported to a lab for testing or being transported to the sample collector after testing; or

(B) The sample is being stored by the sample collector before transport, by the laboratory before testing, or by the laboratory after testing prior to return to the sample collector; or

(C) The sample is being stored temporarily in the laboratory after testing for a specific purpose (for example, until conclusion of a court case or enforcement action).

(ii) In order to qualify for the exemptions in (l)(i)((~~A~~)) of this subsection, a sample collector shipping samples to a laboratory and a laboratory returning samples to a sample collector must:

(A) Comply with United States Department of Transportation (DOT), United States Postal Service (USPS), or any other applicable shipping requirements; or

(B) Comply with the following requirements if the sample collector determines that DOT or USPS, or other shipping requirements do not apply:

(I) Assure that the following information accompanies the sample:

(AA) The sample collector's name, mailing address, and telephone number;

(BB) The laboratory's name, mailing address, and telephone number;

(CC) The quantity of the sample;

(DD) The date of shipment;

(EE) A description of the sample; and

(II) Package the sample so that it does not leak, spill, or vaporize from its packaging.

(iii) This exemption does not apply if the laboratory determines that the waste is dangerous but the laboratory is no longer meeting any of the conditions stated in (l)(i) of this subsection;

(m) Asbestos wastes or asbestos containing wastes which would be designated only as respiratory carcinogens by WAC 173-303-084 or 173-303-103, and any other inorganic wastes which are designated only under WAC 173-303-084 or 173-303-103 because they are respiratory carcinogens, if these wastes are managed in compliance with or in a manner equivalent to the asbestos management procedures of 40 CFR Part 61;

(n) Dangerous waste (~~(which is)~~) generated in a product or raw material storage tank, a product or raw material transport vehicle or vessel, a product or raw material pipeline, or in a manufacturing process unit or an associated nonwaste-treatment-manufacturing unit until it exits the unit in which it was generated (~~(unless the unit is a)~~). This exclusion does not apply to surface impoundments, ((or unless)) nor does it apply if the dangerous waste remains in the unit more than ninety days after the unit ceases to be operated for manufacturing, or for storage or transportation of product or raw materials;

(o) Waste pickle liquor sludge generated by lime stabilization of spent pickle liquor from the iron and steel industry (SIC codes 331 and 332), except that these wastes are not excluded if they exhibit one or more of the dangerous waste criteria (WAC 173-303-100 through 173-303-103) or characteristics (WAC 173-303-090);

(p) Wastes from burning any of the materials exempted from regulation by WAC 173-303-120 (2)(a)(v), (vi), (vii), (viii), or (ix);

(q) As of January 1, 1987, secondary materials that are reclaimed and returned to the original process or processes in which they were generated where they are reused in the production process provided:

(i) Only tank storage is involved, and the entire process through completion of reclamation is closed by being entirely connected with pipes or other comparable enclosed means of conveyance;

(ii) Reclamation does not involve controlled flame combustion (such as occurs in boilers, industrial furnaces, or incinerators);

(iii) The secondary materials are never accumulated in such tanks for over twelve months without being reclaimed;

(iv) The reclaimed material is not used to produce a fuel, or used to produce products that are used in a manner constituting disposal; and

(v) The generator ensures that any residues (e.g., sludges, filters, etc.) produced from the collection, reclamation, and reuse of the secondary materials are delivered to a dangerous waste treatment, storage, or disposal facility or legitimate recycler. The generator must be able to provide documentation of such delivery. If the generator can demonstrate that the residues do not exhibit any of the dangerous waste characteristics (WAC

173-303-090) and criteria (WAC 173-303-100 through 173-303-103), then he is exempt from the requirements of this condition in this item (v).

(r) Treatability study samples.

(i) Except as provided in (r)(ii) of this subsection, persons who generate or collect samples for the purpose of conducting treatability studies as defined in WAC 173-303-040((H2)) are not subject to the requirements of WAC 173-303-180, 173-303-190, and 173-303-200 (1)(a), nor are such samples included in the quantity determinations of WAC 173-303-070 (7) and (8) and 173-303-201 when:

(A) The sample is being collected and prepared for transportation by the generator or sample collector; or

(B) The sample is being accumulated or stored by the generator or sample collector prior to transportation to a laboratory or testing facility; or

(C) The sample is being transported to the laboratory or testing facility for the purpose of conducting a treatability study; or

(D) The sample or waste residue is being transported back to the original generator from the laboratory or testing facility.

(ii) The exemption in (r)(i) of this subsection is applicable to samples of dangerous waste being collected and shipped for the purpose of conducting treatability studies provided that:

(A) The generator or sample collector uses (in "treatability studies") no more than 1000 kg of any dangerous waste, 1 kg of acutely hazardous waste, or 250 kg of soils, water, or debris contaminated with acutely hazardous waste for each process being evaluated for each generated waste stream; and

(B) The mass of each sample shipment does not exceed 1000 kg of dangerous waste, 1 kg of acutely hazardous waste, or 250 kg of soils, water, or debris contaminated with acutely hazardous waste; and

(C) The sample must be packaged so that it will not leak, spill, or vaporize from its packaging during shipment and the requirements of (r)(ii)(C)(I) or (II) of this subsection are met.

(I) The transportation of each sample shipment complies with United States Department of Transportation (DOT), United States Postal Service (USPS), or any other applicable shipping requirements; or

(II) If the DOT, USPS, or other shipping requirements do not apply to the shipment of the sample, the following information must accompany the sample:

(AA) The name, mailing address, and telephone number of the originator of the sample;

(BB) The name, address, and telephone number of the laboratory or testing facility that will perform the treatability study;

(CC) The quantity of the sample;

(DD) The date of shipment; and

(EE) A description of the sample, including its dangerous waste number.

(D) The sample is shipped, within ninety days of being generated or of being taken from a stream of previously generated waste, to a laboratory or testing facility which is exempt under (s) of this subsection or has an appropriate final facility permit or interim status; and

(E) The generator or sample collector maintains the following records for a period ending three years after completion of the treatability study:

(I) Copies of the shipping documents;

(II) A copy of the contract with the facility conducting the treatability study;

(III) Documentation showing:

(AA) The amount of waste shipped under this exemption;

(BB) The name, address, and EPA/state identification number of the laboratory or testing facility that received the waste;

(CC) The date the shipment was made; and

(DD) Whether or not unused samples and residues were returned to the generator.

(F) The generator reports the information required under (r)(ii)(E)(III) of this subsection in its annual report.

(iii) The department may grant requests, on a case-by-case basis, for quantity limits in excess of those specified in (r)(ii)(A) of this subsection, for up to an additional 500 kg of nonacute hazardous waste, 1 kg of acute hazardous waste, and 250 kg of soils, water, or debris contaminated with acute hazardous waste or for up to an additional 10,000 kg of wastes regulated only by this chapter and not regulated by 40 CFR Part 261, to conduct further treatability study evaluation when: There has been an equipment or mechanical failure during the conduct of a treatability study; there is a need to verify the results of previously conducted treatability study; there is a need to study and analyze alternative techniques within a previously evaluated treatment process; or there is a need to do further evaluation of an ongoing treatability study to determine final specifications for treatment. The additional quantities allowed are subject to all the provisions in (r)(i) and (ii)(B) of this subsection. The generator or sample collector must apply to the department in the state where the sample is collected and provide in writing the following information:

(A) The reason the generator or sample collector requires additional quantity of sample for the treatability study evaluation and the additional quantity needed;

(B) Documentation accounting for all samples of dangerous waste from the waste stream which have been sent for or undergone treatability studies including the date each previous sample from the waste stream was shipped, the quantity of each previous shipment, the laboratory or testing facility to which it was shipped, what treatability study processes were conducted on each sample shipped, and the available results of each treatability study;

(C) A description of the technical modifications or change in specifications which will be evaluated and the expected results;

(D) If such further study is being required due to equipment or mechanical failure, the applicant must include information regarding the reason for the failure or breakdown and also include what procedures or equipment improvements have been made to protect against further breakdowns; and

(E) Such other information that the department considers necessary.

(s) Samples undergoing treatability studies at laboratories and testing facilities. Samples undergoing treatability studies and the laboratory or testing facility conducting such treatability studies (to the extent such facilities are not otherwise subject to chapter 70.105 RCW) are not subject to the requirements of this chapter, except WAC 173-303-050, 173-303-145, and 173-303-960 provided that the conditions of (s)(i) through (xiii) of this subsection are met. A mobile treatment unit (MTU) may qualify as a testing facility subject to (s)(i) through (xiii) of this subsection. Where a group of MTUs are located at the same site, the limitations specified in (s)(i) through (xiii) of this subsection apply to the entire group of MTUs collectively as if the group were ~~((one))~~ one MTU.

(i) No less than forty-five days before conducting treatability studies the laboratory or testing facility notifies the department in writing that it intends to conduct treatability studies under this subsection.

(ii) The laboratory or testing facility conducting the treatability study has an EPA/state identification number.

(iii) No more than a total of 250 kg of "as received" dangerous waste is subjected to initiation of treatment in all treatability studies in any single day. "As received" waste refers to the waste as received in the shipment from the generator or sample collector.

(iv) The quantity of "as received" dangerous waste stored at the laboratory or testing facility for the purpose of evaluation in treatability studies does not exceed 1000 kg, the total of which can include 500 kg of soils, water, or debris contaminated with acutely hazardous waste or 1 kg of acutely hazardous waste. This quantity limitation does not include:

(A) Treatability study residues; and

(B) Treatment materials (including nondangerous solid waste) added to "as received" dangerous waste.

(v) No more than ninety days have elapsed since the treatability study for the sample was completed, or no more than one year has elapsed since the generator or sample collector shipped the sample to the laboratory or testing facility, whichever date first occurs.

(vi) The treatability study does not involve the placement of dangerous waste on the land or open burning of dangerous waste.

(vii) The laboratory or testing facility maintains records for three years following completion of each study that show compliance with the treatment rate limits and the storage time and quantity limits. The following specific information must be included for each treatability study conducted:

(A) The name, address, and EPA/state identification number of the generator or sample collector of each waste sample;

(B) The date the shipment was received;

(C) The quantity of waste accepted;

(D) The quantity of "as received" waste in storage each day;

(E) The date the treatment study was initiated and the amount of "as received" waste introduced to treatment each day;

(F) The date the treatability study was concluded;

(G) The date any unused sample or residues generated from the treatability study were returned to the generator or sample collector or, if sent to a designated TSD facility, the name of the TSD facility and its EPA/state identification number.

(viii) The laboratory or testing facility keeps, on-site, a copy of the treatability study contract and all shipping paper associated with the transport of treatability study samples to and from the facility for a period ending three years from the completion date of each treatability study.

(ix) The laboratory or testing facility prepares and submits a report to the department by March 15 of each year that estimates the number of studies and the amount of waste expected to be used in treatability studies during the current year, and includes the following information for the previous calendar year:

(A) The name, address, and EPA/state identification number of the laboratory or testing facility conducting the treatability studies;

(B) The types (by process) of treatability studies conducted;

(C) The names and addresses of persons for whom studies have been conducted (including their EPA/state identification numbers);

(D) The total quantity of waste in storage each day;

(E) The quantity and types of waste subjected to treatability studies;

(F) When each treatability study was conducted;

(G) The final disposition of residues and unused sample from each treatability study.

(x) The laboratory or testing facility determines whether any unused sample or residues generated by the treatability study are dangerous waste under WAC 173-303-070 and if so, are subject to the requirements of this chapter, unless the residues and unused samples are returned to the sample originator under the exemption in (r) of this subsection.

(xi) The laboratory or testing facility notifies the department by letter when it is no longer planning to conduct any treatability studies at the site.

(xii) The date the sample was received, or if the treatability study has been completed, the date of the treatability study, is marked and clearly visible for inspection on each container.

(xiii) While being held on site, each container and tank is labeled or marked clearly with the words "dangerous waste" or "hazardous waste." Each container or tank must also be marked with a label or sign which identifies the major risk(s) associated with the waste in the container or tank for employees, emergency response personnel and the public.

Note: If there is already a system in use that performs this function in accordance with local, state, or federal regulations, then such system will be adequate.

(t) Petroleum-contaminated media and debris that fail the test for the toxicity characteristic of WAC 173-303-090(8) (dangerous waste numbers D018 through

D043 only) and are subject to the corrective action regulations under 40 CFR Part 280.

(u) Special incinerator ash (as defined in WAC 173-303-040).

**AMENDATORY SECTION** (Amending Order DE 84-22, filed 6/27/84)

**WAC 173-303-072 PROCEDURES AND BASES FOR EXEMPTING AND EXCLUDING WASTES.**  
(1) Purpose and applicability.

(a) The purpose of this section is to describe the procedures that will be followed by generators and the department when wastes are considered for exemption or exclusion from the requirements of this chapter. Any person(s) whose waste is exempted or excluded will not be subject to the requirements of this chapter unless the department revokes the exemption or exclusion.

(b) Any person seeking a waste exemption must submit a petition to the department according to the procedures of WAC 173-303-910(3). A petition for exemption will be assessed against the applicable bases for exemption described in subsections (3), (4), and (5) of this section.

(c) Any persons seeking to categorically exclude a class of wastes must submit a petition to the department according to the procedures of WAC 173-303-910(4). A petition for exclusion will be assessed against the applicable bases for exclusion described in subsection (6) of this section.

(2) Department procedures. When considering, granting, or denying a petition for exemption or exclusion, the department shall follow the appropriate procedures described in WAC 173-303-910(1).

(3) Bases for exempting wastes. To successfully petition the department to exempt a waste, the petitioner must demonstrate to the satisfaction of the department that:

(a) He has been able to accurately describe the variability or uniformity of his waste over time, and has been able to obtain demonstration samples which are representative of his waste's variability or uniformity; and, either

(b) The representative demonstration samples of his waste are not designated DW or EHW by the dangerous waste criteria, WAC 173-303-100 through 173-303-103; or

(c) It can be shown, from information developed by the petitioner through consultation with the department, that his waste does not otherwise pose a threat to public health or the environment(~~(, except that)~~). However, this basis for exemption is not applicable to wastes ((which)) that exhibit any of the characteristics specified in WAC 173-303-090, except 173-303-090 (6)(a)(iii).

(4) Additional bases for exempting listed wastes. In addition to the demonstrations required by subsections (3)(a) and (b) of this section, for wastes listed in WAC 173-303-081 or 173-303-082 the petitioner must also demonstrate to the satisfaction of the department that his waste is not capable of posing a substantial present or potential threat to public health or the environment when improperly treated, stored, transported, disposed of

or otherwise managed. The following factors will be considered by the department when assessing such a demonstration:

(a) Whether or not the listed waste contains the constituent or constituents which caused it to be listed. (For the purposes of this subsection, the constituents referred to will include any of the dangerous waste constituents listed in WAC 173-303-9905);

(b) The nature of the threat posed by the waste constituent(s);

(c) The concentration of the constituent(s) in the waste;

(d) The potential of the constituent(s) or any degradation product of the constituent(s) to migrate from the waste into the environment under the types of improper management considered in (h) of this subsection;

(e) The persistence of the constituent(s) or any degradation product of the constituent(s);

(f) The potential for the constituent(s) or any degradation product of the constituent(s) to degrade into nonharmful constituents and the rate of degradation;

(g) The degree to which the constituent(s) or degradation product of the constituent(s) bioaccumulates in ecosystems;

(h) The plausible types of improper management to which the waste could be subjected;

(i) The quantities of the waste generated at individual generation sites or on a state-wide basis. Under this factor, the department will also consider whether or not the waste is listed under WAC 173-303-081 as a discarded chemical product and occurs in a relatively pure form. Any waste discarded chemical product which exceeds the quantity exclusion limit specified in WAC 173-303-081(2) for that waste will not be exempted;

(j) The nature and severity of the public health and environmental damage that has occurred as a result of the improper management of wastes containing the constituent(s);

(k) Actions taken by other governmental agencies or regulatory programs based on the health or environmental threat posed by the waste or waste constituent(s); and

(l) Such other factors as may be appropriate.

(5) Bases for exempting wastes designated solely for the presence of chromium. The department will exempt a waste which is designated because of the presence of chromium if the petitioner can demonstrate that:

(a) The waste is not designated for any other characteristic under WAC 173-303-090, or for any of the criteria specified in WAC 173-303-101, 173-303-102 or 173-303-103;

(b) The waste is not listed in WAC 173-303-081 or 173-303-082 due to the presence of any constituent from WAC 173-303-9905 other than chromium;

(c) The waste is typically and frequently managed in nonoxidizing environments or under nonoxidizing conditions; and

(d) Either of the following demonstrations can be made:

(i) The waste is generated from a process which uses trivalent chromium exclusively (or nearly exclusively), the process does not generate hexavalent chromium, and

the chromium in the waste is exclusively (or nearly exclusively) trivalent chromium; or

(ii) Under test procedures approved by the department, the ((EP)) toxicity characteristic extract of the waste can be shown to contain less than five milligrams per liter (5 mg/L) of hexavalent chromium.

(6) Bases for categorically excluding classes of wastes. This subsection does not apply to any waste class that includes hazardous waste regulated under 40 CFR Part 261. To successfully petition the department to categorically exclude a class of wastes, petitioners must demonstrate to the satisfaction of the department that the petition or petitions for exclusion:

(a) Accurately describe the class of wastes for which categorical exclusion is sought and show that the class of wastes does not include any wastes which would be regulated as hazardous waste under 40 CFR Part 261;

(b) Describe the variability or uniformity of the class of wastes over time and in relation to the individual wastes that comprise the class of waste;

(c) Discuss the generators and their individual wastes that belong to the class of wastes and, to the extent practical, any generators or individual wastes that, although belonging to the class of wastes, are not represented by the petition or petitions; and

(d) For each individual waste within the class of wastes, provide the demonstration described by subsection (3) of this section, except that where it is determined by consultation with the department to be impractical to provide the demonstration for each individual waste, the petitioner or petitioners shall provide the demonstration for samples of the individual wastes determined by consultation with the department to be representative of the class of wastes.

#### AMENDATORY SECTION (Amending Order DE-87-4, filed 6/26/87)

WAC 173-303-081 DISCARDED CHEMICAL PRODUCTS. (1) A waste shall be designated as a dangerous waste if it is handled in any of the manners described in (e) of this subsection, and if it is a residue from the management of:

(a) A commercial chemical product or manufacturing chemical intermediate which has the generic name listed in the discarded chemical products list, WAC 173-303-9903;

(b) An off-specification commercial chemical product or manufacturing chemical intermediate which if it had met specifications would have the generic name listed in the discarded chemical products list, WAC 173-303-9903;

(c) Any containers ((or)), inner liners ((~~that have been used to hold~~)), or residue remaining in a container or in an inner liner removed from a container that has held any commercial chemical product or manufacturing chemical intermediate that has, or any off-specification commercial chemical product or manufacturing chemical intermediate which if it had met specifications would have, the generic name listed on the acutely dangerous chemical products list of WAC 173-303-9903, unless the containers or inner liners are empty ((~~and have been triple rinsed~~)) as described in WAC 173-303-160(2);

(d) Any residue or contaminated soil, water, or other debris resulting from the cleanup of a spill of a commercial chemical product or manufacturing chemical intermediate which has, or of an off-specification commercial chemical product or manufacturing chemical intermediate which if it had met specifications would have, the generic name listed in the discarded chemical products list, WAC 173-303-9903;

(e) The materials or items described in (a), (b), (c), and (d) of this subsection are dangerous wastes when they are:

(i) Discarded or intended to be discarded as described in WAC 173-303-016 (3)(b)(i);

(ii) Burned for purposes of energy recovery in lieu of their original intended use;

(iii) Used to produce fuels in lieu of their original intended use;

(iv) Applied to the land in lieu of their original intended use; or

(v) Contained in products that are applied to the land in lieu of their original intended use.

(2) Quantity exclusion limits:

(a) A person with a waste or wastes (including residues from the management of wastes) identified in subsection (1) of this section, shall be a dangerous waste generator (and may not be considered a small quantity generator as provided in WAC 173-303-070(8)) if the amount of his waste exceeds the following quantity exclusion limits:

(i) For chemicals designated on the acutely dangerous chemical products list of WAC 173-303-9903 - 2.2 lbs. (1.0 kg) per month or per batch. Such wastes are designated EHW;

(ii) For chemicals and for residues from the cleanup of spills involving chemicals designated on the moderately dangerous chemical products list of WAC 173-303-9903 - 220 lbs. (100 kg) per month or per batch. Such wastes are designated DW;

(iii) For containers or inner liners which held any chemical designated on the acutely dangerous chemical products list of WAC 173-303-9903 - 2.2 lbs. (1.0 kg) of residue remaining in the containers or inner liners per month or per batch unless the containers or inner liners meet the definition of empty and have been triple rinsed as described in WAC 173-303-160(2);

(iv) For residues, contaminated soil, water, or other debris from the cleanup of a spill of any chemical designated on the acutely dangerous chemical products list of WAC 173-303-9903 - 220 lbs. (100 kg) per month or per batch. Such wastes are designated EHW.

(b) A person's total monthly waste quantity shall be the sum of all his wastes which share a common quantity exclusion limit (e.g., the total quantity of all EHW discarded chemical products, the total quantity of all residues contaminated by EHW discarded chemical products, etc.) which were generated during a month or a batch operation at each specific waste generation site.

(3) Dangerous waste numbers and mixtures. A waste which has been designated as a discarded chemical product dangerous waste shall be assigned the dangerous waste number or numbers listed in WAC 173-303-9903 next to the generic chemical or chemicals which caused

the waste to be designated. If a person mixes a solid waste with a waste that would be designated as a discarded chemical product under this section, then the entire mixture shall be designated. The mixture designation shall be the same as the designation for the discarded chemical product which was mixed with the solid waste. For example, a mixture containing 2.2 lbs. (1 kg) of Aldrin (dangerous waste number P004; EHW designation) and 22 lbs. (10 kg) of a solid waste, would be designated as an EHW, and would have the dangerous waste number P004.

(4) For the purposes of this chapter, the term "acutely hazardous waste" shall include discarded chemical products (listed in WAC 173-303-9903) that are identified with a dangerous waste number beginning with a "P" or that show an "X" or "A" in the reason for designation column.

#### AMENDATORY SECTION (Amending Order DE-87-4, filed 6/26/87)

**WAC 173-303-084 DANGEROUS WASTE MIXTURES.** (1) Purpose. It is the purpose of this section to describe the means for designating a waste mixture containing dangerous wastes which are not listed in WAC 173-303-081 through 173-303-083.

(2) References. The National Institute for Occupational Safety and Health's (NIOSH) Registry of Toxic Effects of Chemical Substances (Registry) is adopted by reference. The table in the United States EPA's regulations 40 CFR Table 302.4 (Spill Table) is adopted by reference.

(3) Waste mixture defined. For the purposes of this section, a waste mixture shall be any waste about which some or all of its constituents and concentrations are known, and which has not been designated as:

(a) A discarded chemical product under WAC 173-303-081;

(b) A dangerous waste source under WAC 173-303-082;

(c) An infectious dangerous waste under WAC 173-303-083; or

(d) A dangerous waste that has been designated by the criteria of WAC 173-303-101 through 173-303-103.

(4) A person who has a waste mixture shall use data which is available to him, and, when such data is inadequate for the purposes of this section, shall refer to the NIOSH Registry and/or to the EPA Spill Table to determine:

(a) Toxicity data or category for each known constituent in his waste;

(b) Whether or not each known constituent of his waste is a halogenated hydrocarbon or a polycyclic aromatic hydrocarbon with greater than three rings and less than seven rings; and,

(c) Whether or not each known constituent of his waste is an International Agency for Research on Cancer (IARC) human or animal, positive or suspected carcinogen.

(5) Toxicity.

(a) If a person has toxic constituents in his waste, he shall determine the toxic category for each known toxic

constituent. The toxic category for each constituent may be determined directly from EPA'S Spill Table, or by obtaining data from the NIOSH Registry and checking this data against the toxic category table, below. If data is available for more than one of the four toxicity criteria (aquatic, oral, inhalation, or dermal), then the data of severest toxicity shall be used, and the most acutely toxic category shall be assigned to the constituent. If EPA's Spill Table and the NIOSH Registry do not agree on the same category, then the category arrived at using the NIOSH Registry will take precedence. If toxicity data for a constituent cannot be found in EPA'S Spill Table, NIOSH Registry, or other source reasonably available to a person, then he need not determine the toxic category for that constituent.

TOXIC CATEGORY TABLE

Category	TLm96 (Fish) or, Aquatic (Fish) LC50(ppm)	Oral (Rat) LD50(mg/kg)	Inhalation (Rat) LC50(mg/L)	Dermal (Rabbit) LD50(mg/kg)
X	<.1	<.5	<.02	< 2
A	.1 - 1	.5 - 5	.02 - .2	2 - 20
B	1 - 10	5 - 50	.2 - 2	20 - 200
C	10 - 100	50 - 500	2 - 20	200 - 2000
D	100 - 1000	500 - 5000	20 - 200	2000 - 20,000

(b) A person whose waste mixture contains one or more toxic constituents shall determine the equivalent concentration for his waste from the following formula:

$$\text{Equivalent Concentration(\%)} = \frac{\Sigma X\%}{10} + \frac{\Sigma A\%}{100} + \frac{\Sigma B\%}{1000} + \frac{\Sigma C\%}{10000} + \frac{\Sigma D\%}{10,000}$$

where  $\Sigma(X,A,B,C, \text{ or } D) \%$  is the sum of all the concentration percentages for a particular toxic category.

Example 1. A person's waste mixture contains: Aldrin (X Category) - .01%; Diuron (B Category) - 1%; Benzene (C Category) - 4%; Phenol (C Category) - 2%; Cyclohexane (C Category) - 5%; Water (nontoxic) - 87%. His equivalent concentration (E.C.) would be:

$$\text{E.C. (\%)} = \frac{.01\%}{10} + \frac{0\%}{100} + \frac{1\%}{1000} + \frac{(4\% + 2\% + 5\%)}{10000} + \frac{0\%}{10,000}$$

$$= .01\% + 0\% + .01\% + .011\% + 0\% = .031\%$$

So his equivalent concentration equals .031%.

(c) A person whose waste mixture contains toxic constituents shall determine his designation from the toxic dangerous waste mixtures graph in WAC 173-303-9906 by finding the equivalent concentration percentage for his waste along the abscissa, finding his total waste mixture quantity along the ordinate, and plotting the point on the graph where the horizontal line drawn from his total waste mixture quantity intersects the vertical line drawn from his waste mixture's equivalent concentration. If the plotted point is in the area marked DW, he shall designate his waste as DW; if the plotted point is in the area marked EHW, he shall designate his waste as EHW.

(d) If a person knows only some of the toxic constituents in his waste mixture, or only some of the constituent concentrations, and if his waste is undesignated for those known constituents or concentrations, then his waste is not designated for toxicity under this subsection.



(e) Toxic dangerous waste mixtures graph. The toxic dangerous waste mixtures graph appears in WAC 173-303-9906.

(6) Persistence.

(a) A person whose waste mixture contains one or more halogenated hydrocarbons for which the concentrations are known shall determine his total halogenated hydrocarbon concentration by summing the concentration percentages for all of those halogenated hydrocarbons for which he knows the concentrations in his waste mixture.

Example 2. A person's waste mixture contains: Carbon tetrachloride - .009%; DDT - .012%; 1,1,1-trichloroethylene - .02%. His total halogenated hydrocarbon concentration would be:

Total HH Concentration (%) = .009% + .012% + .02% = .041%

(b) A person whose waste mixture contains one or more polycyclic aromatic hydrocarbons with more than three rings and less than seven rings for which the concentrations are known shall determine his total polycyclic aromatic hydrocarbon concentration by summing the concentration percentages for all of those polycyclic aromatic hydrocarbons with more than three rings and less than seven rings about which he knows the concentration in his waste mixture.

Example 3. A person's waste mixture contains: Chrysene - .08%; 3, 4 - benzopyrene - 1.22%. His total polycyclic aromatic hydrocarbon concentration would be:

Total PAH Concentration (%) = .08% + 1.22% = 1.3%

(c) A person whose waste mixture contains halogenated hydrocarbons shall determine his designation from the persistent dangerous waste mixtures graph in WAC 173-303-9907 by finding the total halogenated hydrocarbon concentration for his waste along the abscissa, finding his total waste mixture quantity along the ordinate, and plotting the point on the graph where the horizontal line drawn from his total waste mixture quantity intersects the vertical line drawn from his waste mixture's total halogenated hydrocarbon concentration. If the plotted point is in the area marked DW, then he shall designate his waste DW; if the plotted point is in the area marked EHW, then he shall designate his waste EHW.

(d) A person whose waste mixture contains polycyclic aromatic hydrocarbons with more than three rings and less than seven rings shall determine his designation from the persistent dangerous waste mixtures graph in WAC 173-303-9907 by finding the total polycyclic aromatic hydrocarbon concentration of his waste along the abscissa, finding his total waste mixture quantity along the ordinate, and plotting the point on the graph where the horizontal line drawn from his total waste mixture quantity intersects the vertical line drawn from his waste mixture's total polycyclic aromatic hydrocarbon concentration. If the plotted point is in the area marked EHW, then he shall designate his waste EHW. If the plotted

point is outside of the area marked EHW, then his waste is not designated.

(e) If a person knows only some of the persistent constituents in his waste mixture, or only some of the constituent concentrations, and if his waste is undesignated for those known constituents or concentrations, then his waste is not designated for persistence under this subsection.

(f) Persistent dangerous waste mixtures graph. The persistent dangerous waste mixtures graph appears in WAC 173-303-9907.

(7) Carcinogens. Any person whose waste mixture contains one or more IARC human or animal, (~~positive or suspected~~) sufficient or limited carcinogen(s) shall designate his waste DW if:

(a) The total concentration of carcinogen(s) in his waste exceeds 1.0% of the waste quantity; and

(b) The monthly or batch waste quantity exceeds 220 lbs. (100 kg).

(c) For designation purposes, any IARC human or animal, (~~positive or suspected~~) sufficient or limited carcinogen that is so rated because of studies involving implantation of the substance into test animals as sole cause for the IARC rating, shall not be carcinogenic. This additional information is available in the IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans.

(8) Assigning dangerous waste numbers. A person whose waste is a dangerous waste mixture shall assign a dangerous waste number from the generic dangerous waste numbers table in WAC 173-303-104, Generic dangerous waste numbers. He shall assign the dangerous waste number from the table which corresponds to the designation for his dangerous waste.

#### AMENDATORY SECTION (Amending Order DE-87-4, filed 6/26/87)

WAC 173-303-090 DANGEROUS WASTE CHARACTERISTICS. (1) Purpose. The purpose of this section is to set forth characteristics which a solid waste might exhibit and which would cause that waste to be a dangerous waste.

(2) Representative samples. The department will consider a sample obtained using any of the applicable sampling methods described in WAC 173-303-110(2), sampling and testing methods, to be a representative sample.

(3) Equivalent test methods. The testing methods specified in this section shall be the only acceptable methods, unless the department approves an equivalent test method in accordance with WAC 173-303-910(2).

(4) Quantity exclusion limit. A solid waste is a dangerous waste if it exhibits one or more of the dangerous waste characteristics described in subsections (5), (6), (7), and (8) of this section. If a person's solid waste exhibits one or more of these characteristics, then he shall be a dangerous waste generator (and may not be considered a small quantity generator as provided in WAC 173-303-070(8)) if the quantity of his waste exceeds 220 lbs. (100 kg) per month or per batch.

(5) Characteristic of ignitability.



(a) A solid waste exhibits the characteristic of ignitability if a representative sample of the waste has any of the following properties:

(i) It is a liquid, other than an aqueous solution containing less than 24 percent alcohol by volume, and has a flash point less than 60 degrees C (140 degrees F), as determined by a Pensky-Martens Closed Cup Tester, using the test method specified in ASTM Standard D-93-79 or D-93-80, or a Setaflash Closed Cup Tester, using the test method specified in ASTM Standard D-3278-78;

(ii) It is not a liquid and is capable, under standard temperature and pressure, of causing fire through friction, absorption of moisture or spontaneous chemical changes and, when ignited, burns so vigorously and persistently that it creates a hazard;

(iii) It is an ignitable compressed gas as defined in 49 CFR 173.300 and as determined by the test methods described in that regulation; or,

(iv) It is an oxidizer as defined in 49 CFR 173.151.

(b) A solid waste that exhibits the characteristic of ignitability, but is not designated as a dangerous waste under any of the dangerous waste lists, WAC 173-303-080 through 173-303-084, or dangerous waste criteria, WAC 173-303-101 through 173-303-103, shall be designated DW, and shall be assigned the dangerous waste number of D001.

(6) Characteristic of corrosivity.

(a) A solid waste exhibits the characteristic of corrosivity if a representative sample of the waste has any one or more of the following properties:

(i) It is aqueous, and has a pH less than or equal to 2, or greater than or equal to 12.5, as determined by a pH meter using Method 5.2 in Test Methods for the Evaluation of Solid Waste, Physical/Chemical Methods, available from the department;

(ii) It is liquid, and corrodes steel (SAE 1020) at a rate greater than 0.250 inch (6.35 mm) per year at a test temperature of 55 degrees C (130 degrees F) as determined by the test method specified in NACE (National Association of Corrosion Engineers) Standard TM-01-69 as standardized in Test Methods for the Evaluation of Solid Waste, Physical/Chemical Methods. The NACE Standard is available from the department; or

(iii) It is solid or semi-solid, and when mixed with an equal weight of water results in a solution, the liquid portion of which has the property specified in (a)(i) of this subsection. Procedures for preparing and extracting the solution and liquid are described in the test procedures of WAC 173-303-110 (3)(a).

(b) A solid waste that exhibits the characteristic of corrosivity, but is not designated as a dangerous waste under any of the dangerous waste lists, WAC 173-303-080 through 173-303-084, or dangerous waste criteria, WAC 173-303-101 through 173-303-103, shall be designated DW, and shall be assigned the dangerous waste number of D002.

(7) Characteristic of reactivity.

(a) A solid waste exhibits the characteristic of reactivity if a representative sample of the waste has any of the following properties:

(i) It is normally unstable and readily undergoes violent change without detonating;

(ii) It reacts violently with water;

(iii) It forms potentially explosive mixtures with water;

(iv) When mixed with water, it generates toxic gases, vapors or fumes in a quantity sufficient to present a danger to human health or the environment;

(v) It is a cyanide or sulfide bearing waste which, when exposed to pH conditions between 2 and 12.5 can generate toxic gases, vapors or fumes in a quantity sufficient to present a danger to human health or the environment;

(vi) It is capable of detonation or explosive reaction if it is subjected to a strong initiating source or if heated under confinement;

(vii) It is readily capable of detonation or explosive decomposition or reaction at standard temperature and pressure; or

(viii) It is a forbidden explosive as defined in 49 CFR 173.51, or a Class A explosive as defined in 49 CFR 173.53, or a Class B explosive as defined in 49 CFR 173.88.

(b) A solid waste that exhibits the characteristic of reactivity, but is not designated as a dangerous waste under any of the dangerous waste lists, WAC 173-303-080 through 173-303-084, or dangerous waste criteria, WAC 173-303-101 through 173-303-103, shall be designated DW, and shall be assigned the dangerous waste number of D003.

(8) ~~((Characteristic of EP))~~ Toxicity Characteristic.

(a) A solid waste exhibits the ~~((characteristic of EP))~~ Toxicity Characteristic if, using ~~((Extraction Procedure Test Methods - 1981 on file with the department))~~ the Toxicity Characteristic Leaching Procedure (TCLP, found in Appendix II of 40 CFR Part 261 or available upon request from the department) or equivalent methods approved by the department under WAC 173-303-110(5), the extract from a representative sample of the waste contains any of the contaminants listed in the ~~((EP))~~ Toxicity Characteristic List in (c) of this subsection, at concentrations equal to or greater than the respective value given in the list. When the waste contains less than 0.5 percent filterable solids, the waste itself, after filtering using the methodology outlined in the TCLP, is considered to be the extract for the purposes of this subsection.

(b) A solid waste that exhibits the ~~((characteristic of EP))~~ Toxicity Characteristic, but is not designated as a dangerous waste under any of the dangerous waste lists, WAC 173-303-080 through 173-303-084, or dangerous waste criteria, WAC 173-303-101 through 173-303-103, has the dangerous waste number specified in the list which corresponds to the toxic contaminant causing it to be dangerous.

(c) ~~((EP))~~ Toxicity Characteristic List. Two levels of concentration are established for the contaminants listed. Any waste containing one or more contaminants with concentrations ~~((m))~~ at or above the EHW ~~((range))~~ threshold shall cause that waste to be designated EHW.

Any waste containing contaminants which occur at concentrations ((m)) at or above the DW ((range)) threshold only (i.e., no EHW contaminants), shall be designated DW.

((EP TOXICITY LIST

Dangerous Waste Number	Contaminant	EHW Maximum Concentration In Extract (mg/L)	DW Maximum Concentration In Extract (mg/L)
D004	Arsenic	> 500	5
D005	Barium	> 10,000	100
D006	Cadmium	> 100	1
D007	Chromium	> 500	5
D008	Lead	> 500	5
D009	Mercury	> 20	0.2
D010	Selenium	> 100	1
D011	Silver	> 500	5
D012	Endrin	> 2	0.02
D013	Lindane	> 40	0.4
D014	Methoxychlor	> 1,000	10
D015	Toxaphene	> 50	0.5
D016	2,4-D	> 1,000	10
D017	2,4,5-TP Silvex	> 100	1

TOXICITY CHARACTERISTICS LIST:

Maximum Concentration of Contaminants for the Toxicity Characteristic

Dangerous Waste Number	Contaminant	(Chemical Abstracts Services #)	EHW (mg/L)	DW (mg/L)
D004	Arsenic	(7440-38-2)	500	5.0
D005	Barium	(7440-39-3)	10,000	100.0
D018	Benzene	(71-43-2)	50	0.5
D006	Cadmium	(7440-43-9)	100	1.0
D019	Carbon tetrachloride	(56-23-5)	50	0.5
D020	Chlordane	(57-74-9)	3.0	0.03
D021	Chlorobenzene	(108-90-7)	10,000	100.0
D022	Chloroform	(67-66-3)	600	6.0
D007	Chromium	(7440-47-3)	500	5.0
D023	o-Cresol	(95-48-7)	/1/	20,000 200.0
D024	m-Cresol	(108-39-4)	/1/	20,000 200.0
D025	p-Cresol	(106-44-5)	/1/	20,000 200.0
D026	Cresol	/1/	/1/	200.0
D016	2,4-D	(94-75-7)	1,000	10.0
D027	1,4-Dichlorobenzene	(106-46-7)	750	7.5
D028	1,2-Dichloroethane	(107-06-2)	50	0.5
D029	1,1-Dichloroethylene	(75-35-4)	70	0.7
D030	2,4-Dinitrotoluene	(121-14-2)	/2/	13 0.13
D012	Endrin	(72-20-8)	2	0.02
D031	Heptachlor (and its epoxide)	(76-44-8)	0.8	0.008
D032	Hexachlorobenzene	(118-74-1)	/2/	13 0.13
D033	Hexachlorobutadiene	(87-68-3)	50	0.5
D034	Hexachloroethane	(67-72-1)	300	3.0
D008	Lead	(7439-92-1)	500	5.0
D013	Lindane	(58-89-9)	40	0.4
D009	Mercury	(7439-97-6)	20	0.2
D014	Methoxychlor	(72-43-5)	1,000	10.0
D035	Methyl ethyl ketone	(78-93-3)	20,000	200.0
D036	Nitrobenzene	(98-95-3)	200	2.0
D037	Pentachlorophenol	(87-86-5)	10,000	100.0
D038	Pyridine	(110-86-1)	/2/	500 5.0
D010	Selenium	(7782-49-2)	100	1.0
D011	Silver	(7440-22-4)	500	5.0
D039	Tetrachloroethylene	(127-18-4)	70	0.7
D015	Toxaphene	(8001-35-2)	50	0.5
D040	Trichloroethylene	(79-01-6)	50	0.5
D041	2,4,5-Trichlorophenol	(95-95-4)	40,000	400.0
D042	2,4,6-Trichlorophenol	(88-06-2)	200	2.0
D017	2,4,5-TP (Silvex)	(93-72-1)	100	1.0
D043	Vinyl chloride	(75-01-4)	20	0.2

/1/ If o-, m-, and p-Cresol concentrations cannot be differentiated, the total cresol (D026) concentration is used. The DW level for

total cresol is 200 mg/L and the EHW level for total cresol is 20,000 mg/L.

/2/ Quantitation limit is greater than the calculated regulatory level. The quantitation limit therefore becomes the regulatory level.

AMENDATORY SECTION (Amending Order DE-87-4, filed 6/26/87)

WAC 173-303-103 CARCINOGENIC DANGEROUS WASTES. (1) Criteria. A substance which is listed in the National Institute for Occupational Safety and Health (NIOSH) document Registry of Toxic Effects of Chemical Substances (Registry), or any other scientific or technical documents, as an IARC (International Agency for Research on Cancer) human or animal, ((positive or suspected)) sufficient or limited carcinogen, shall be a carcinogenic substance for the purposes of this section. Any IARC identified substance which is an inorganic, respiratory carcinogen shall be a carcinogenic substance only if it occurs in a friable format (i.e., if it is in a waste which easily crumbles and forms dust which can be inhaled).

(2) Designation. Any person whose waste contains one or more IARC carcinogen(s) shall designate his waste if:

(a) The monthly or batch waste quantity exceeds 220 lbs. (100 kg); and either

(b)(i) The concentration of any one IARC ((positive)) sufficient (human or animal) carcinogen exceeds 1.0% of the waste quantity. Such waste shall be designated EHW, and such designation shall take precedence over any DW designation determined by (b)(ii) or (iii) of this subsection; or

(ii) The concentration of any one IARC ((positive)) sufficient (human or animal) carcinogen exceeds 0.01% of the waste quantity. Such waste shall be designated DW; or

(iii) The total concentration summed for all IARC ((positive and suspected)) sufficient and limited (human and animal) carcinogens exceeds 1.0% of the waste quantity. Such waste shall be designated DW.

(c) For designation purposes, any IARC human or animal, ((positive or suspected)) sufficient or limited carcinogen that is so rated because of studies involving implantation of the substance into test animals as sole cause for the IARC rating, shall not be carcinogenic. This additional information is available in the IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans.

AMENDATORY SECTION (Amending Order 88-24, filed 1/4/89)

WAC 173-303-110 SAMPLING AND TESTING METHODS. (1) Purpose. This section describes the testing methods which may be used in the process of designating a dangerous waste.

(2) Representative samples.

(a) The methods and equipment used for obtaining representative samples of a waste will vary with the type and form of the waste. The department will consider samples collected using the sampling methods below, for wastes with properties similar to the indicated materials, to be representative samples of the wastes:

- (i) Crushed or powdered material – ASTM Standard D346-75;
- (ii) Extremely viscous liquid – ASTM Standard D140-70;
- (iii) Fly ash-like material – ASTM Standard ~~(D2234-76)~~ D2234-86;
- (iv) Soil-like material – ASTM Standard D1452-65;
- (v) Soil or rock-like material – ASTM Standard D420-69;
- (vi) Containerized liquid wastes – "COLIWASA" described in Test Methods for the Evaluation of Solid Waste, Physical/Chemical Methods, SW-846, revised July 1982, as amended by Update 1 (April 1984) and Update 2 (April 1985); and,
- (vii) Liquid waste in pits, ponds, lagoons, and similar reservoirs – "Pond Sampler" described in Test Methods for the Evaluation of Solid Waste, Physical/Chemical Methods, SW-846, revised July 1982, as amended by Update 1 (April 1984) and Update 2 (April 1985).

(b) Copies of these representative sampling methods are available from the department except for the ASTM standards which can be obtained by writing to:

ASTM  
1916 Race Street  
Philadelphia, PA 19103.

(3) Test procedures. Copies of the test procedures listed in this subsection can be obtained from the department by writing to the appropriate address below:

For copies of WDOE test methods:

Attn: Test Procedures  
Hazardous Waste Section, PV-11  
Department of Ecology  
Olympia, Washington 98504

For copies of SW 846:

Superintendent of Documents  
U.S. Government Printing Office  
Washington, D.C. 20401

For copies of ASTM methods:

ASTM  
1916 Race Street  
Philadelphia, PA 19103

The document titles and included test procedures are as follows:

- (a) Chemical Testing Methods for Complying with the Dangerous Waste Regulation, March 1982, revised July 1983, describing methods for testing:
  - (i) Ignitability;
  - (ii) Corrosivity, including the addendum, Test Method for Determining pH of Solutions in Contact with Solids, March 1984;
  - (iii) Reactivity;
  - (iv) EP Toxicity;
  - (v) Halogenated hydrocarbons; and
  - (vi) Polycyclic aromatic hydrocarbons;
- (b) Biological Testing Methods, ~~((revised July 1981))~~ the latest revision, describing procedures for:
  - (i) Static acute fish toxicity test; and

(ii) Acute oral rat toxicity test;

(c) Test Methods for Evaluating Solid Waste, Physical/Chemical Methods, SW-846 (the most recent edition and all updates) is adopted by reference. This includes:

(i) Method 9095 (Paint Filter Liquids Test), demonstrating the absence or presence of free liquids in either a containerized or bulk waste;

(ii) Reserved;

(d) 40 CFR Part 261 Appendix X is adopted by reference for the purpose of analysis for chlorinated dibenzo-p-dioxins and dibenzofurans;

(e)(i) The determination of Polychlorinated Biphenyls in Transformer Fluids and Waste Oils, EPA-600/4-81-045; and

(ii) Analysis of Polychlorinated Biphenyls in Mineral Insulating Oils by Gas Chromatography, ASTM Standard D 4059-86.

(4) Substantial changes to the testing methods described above shall be made only after the department has provided adequate opportunity for public review and comment on the proposed changes. The department may, at its discretion, schedule a public hearing on the proposed changes.

(5) Equivalent testing methods. Any person may request the department to approve an equivalent testing method by submitting a petition, prepared in accordance with WAC 173-303-910(2), to the department.

#### AMENDATORY SECTION (Amending Order 88-29, filed 9/6/88)

WAC 173-303-120 RECYCLED, RECLAIMED, AND RECOVERED WASTES. (1) This section describes the requirements for persons who recycle materials that are solid wastes and dangerous. Except as provided in subsections (2) and (3) of this section, dangerous wastes that are recycled are subject to the requirements for generators, transporters, and storage facilities of subsection (4) of this section. Dangerous wastes that are recycled will be known as "recyclable materials."

(2)(a) The following recyclable materials are solid wastes and sometimes are dangerous wastes. However, they are subject only to the requirements of (b) of this subsection, WAC 173-303-050, 173-303-145 and 173-303-960:

(i) Industrial ethyl alcohol that is reclaimed;

(ii) Used batteries (or used battery cells) returned to a battery manufacturer for regeneration;

(iii) Used oil that exhibits one or more of the characteristics or criteria of dangerous waste and is recycled in some manner other than:

(A) Being burned for energy recovery; or

(B) Being used in a manner constituting disposal, except when such use is by the generator on his own property;

(iv) Scrap metal;

(v) Fuels produced from the refining of oil-bearing dangerous wastes along with normal process streams at a petroleum refining facility if such wastes result from normal petroleum refining, production, and transportation practices;

(vi) Oil reclaimed from dangerous waste resulting from normal petroleum refining, production, and transportation practices, which oil is to be refined along with normal process streams at a petroleum refining facility;

(vii) Coke and coal tar from the iron and steel industry that contains dangerous waste from the iron and steel production process;

(viii)(A) Dangerous waste fuel produced from oil-bearing dangerous wastes from petroleum refining, production, or transportation practices, or produced from oil reclaimed from such dangerous wastes, where such dangerous wastes are reintroduced into a process that does not use distillation or does not produce products from crude oil so long as the resulting fuel meets the used oil specification under WAC 173-303-515 (1)(d) and so long as no other dangerous wastes are used to produce the dangerous waste fuel;

(B) Dangerous waste fuel produced from oil-bearing dangerous waste from petroleum refining production, and transportation practices, where such dangerous wastes are reintroduced into a refining process after a point at which contaminants are removed, so long as the fuel meets the used oil fuel specification under WAC 173-303-515 (1)((~~e~~)) (d); and

(C) Oil reclaimed from oil-bearing dangerous wastes from petroleum refining, production, and transportation practices, which reclaimed oil is burned as a fuel without reintroduction to a refining process, so long as the reclaimed oil meets the used oil fuel specification under WAC 173-303-515 (1)(e); and

(ix) Petroleum coke produced from petroleum refinery dangerous wastes containing oil at the same facility at which such wastes were generated, unless the resulting coke product exhibits one or more of the characteristics of dangerous waste in WAC 173-303-090.

(b) Any recyclable material listed in (a) of this subsection will be subject to the applicable requirements listed in subsection (4) of this section if the department determines, on a case-by-case basis, that:

(i) It is being accumulated, used, reused, or handled in a manner that poses a threat to public health or the environment; or

(ii) Due to the dangerous constituent(s) in it, any use or reuse would pose a threat to public health or the environment. Such recyclable material will be listed in WAC 173-303-016(6).

(3) The following recyclable materials are not subject to the requirements of this section but are subject to the requirements of WAC 173-303-070 through 173-303-110, 173-303-160, 173-303-500 through 173-303-525, and all applicable provisions of WAC 173-303-800 through 173-303-840:

(a) Recycling requirements for state-only dangerous wastes (see WAC 173-303-500);

(b) Recyclable materials used in a manner constituting disposal (see WAC 173-303-505);

(c) Dangerous wastes burned for energy recovery in boilers and industrial furnaces that are not regulated under Subpart O of 40 CFR Part 265 or WAC 173-303-670 (see WAC 173-303-510);

(d) Used oil that is burned for energy recovery in boilers and industrial furnaces that are not regulated

under Subpart O of 40 CFR Part 265 or WAC 173-303-670, if such used oil:

(i) Exhibits one or more of the characteristics of a dangerous waste; or

(ii) Is designated as DW solely through WAC 173-303-084 or 173-303-101 through 173-303-103; or

(iii) Is designated solely as W001, (see WAC 173-303-515);

(e) Spent lead-acid batteries that are being reclaimed (see WAC 173-303-520);

(f) Recyclable materials from which precious metals are reclaimed (see WAC 173-303-525).

(4) Those recycling processes not specifically discussed in subsections (2) and (3) of this section are generally subject to regulation only up to and including storage prior to recycling. For the purpose of this section, recyclable materials received from off-site shall be considered stored unless they are moved into an active recycling process within twenty-four hours after being received. An active recycling process refers to a dynamic recycling operation that occurs within a recycling unit such as a distillation or centrifuge unit. The phrase does not refer to passive storage-like activities that occur, for example, when tanks or containers are used for phase separation or for settling impurities. Passive storage-like activities are not eligible for the recycling exemption under this subsection.

The recycling process itself is generally exempt from regulation unless the department determines, on a case-by-case basis, that the recycling process poses a threat to public health or the environment.

Unless specified otherwise in subsections (2) and (3) of this section:

(a) Generators of recyclable materials are subject to all applicable requirements of this chapter including, but not limited to, WAC 173-303-170 through 173-303-230;

(b) Transporters of recyclable materials are subject to all applicable requirements of this chapter including, but not limited to, WAC 173-303-240 through 173-303-270;

(c) Owners or operators of facilities that receive recyclable materials from off-site and recycle these recyclable materials without storing them before they are recycled are subject to the following requirements:

(i) WAC 173-303-060, (~~and~~)

(ii) WAC (~~173-303-370~~) 173-303-283 through 173-303-290,

(iii) WAC 173-303-310 through 173-303-395,

(iv) WAC 173-303-630 (2) through (10), and

(v) WAC 173-303-640 (2) through (10), except 173-303-640 (8)(c) and the second sentence of WAC 173-303-640 (8)(a) (i.e., a recycler, unless otherwise required to do so, does not have to prepare a closure plan, a cost estimate for closure, or provide financial responsibility for his tank system to satisfy the requirements of this section). In lieu of the dates in WAC 173-303-640 (2) and (4), for existing tank systems regulated under this subsection, owners and operators must complete the assessment of the tank system's integrity by June 1,

1992, and must meet the secondary containment requirements of WAC 173-303-640(4) by January 12, 1993;

(vi) The owner or operator must obtain data, by screening-type analysis if necessary, confirming the designation of each waste stream, such that each dangerous waste received can be effectively recycled without jeopardizing human health or the environment. The owner or operator must verify the waste designation periodically, so that it is accurate and current, but at least once every six months or on a batch basis if shipments of a specific waste stream are less frequent. Copies of all analyses and data must be retained for at least five years and made available to the department upon request.

(d) Owners or operators of facilities that store recyclable materials before they are recycled are subject to the following requirements including, but not limited to:

(i) For all recyclers, the applicable provisions of:

(A) WAC 173-303-280 through 173-303-395,

(B) WAC 173-303-420,

(C) WAC 173-303-800 through 173-303-840;

(ii) For recyclers with interim status permits, the applicable storage provisions of WAC 173-303-400 including Subparts F through L of 40 CFR Part 265;

(iii) For recyclers with final facility permits, the applicable storage provisions of:

(A) WAC 173-303-600 through 173-303-650, and

(B) WAC 173-303-660.

#### AMENDATORY SECTION (Amending Order DE 83-36, filed 4/18/84)

WAC 173-303-145 SPILLS AND DISCHARGES ((~~INTO THE ENVIRONMENT~~)). (1) Purpose and applicability. This section sets forth the requirements for any person responsible for a spill or discharge ((~~into the environment~~)), except when such release is otherwise permitted under state or federal law. For the purposes of complying with this section, a transporter who spills or discharges dangerous waste or hazardous substances during transportation will be considered the responsible person. This section shall apply when any dangerous waste or hazardous substance is intentionally or accidentally spilled or discharged ((~~into the environment~~)) (unless otherwise permitted) ((~~such that public health or the environment are threatened~~)), regardless of the quantity of dangerous waste or hazardous substance.

(2) Notification. Any person who is responsible for a nonpermitted spill or discharge shall immediately notify the individuals and authorities described for the following situations:

(a) For spills or discharges onto the ground or into groundwater or surface water, notify all local authorities in accordance with the local emergency plan. If necessary, check with the local emergency service coordinator and the fire department to determine all notification responsibilities under the local emergency plan. Also, notify the appropriate regional office of the department of ecology; ((~~and~~))

(b) For spills or discharges which result in emissions to the air, notify all local authorities in accordance with the local emergency plan. If necessary, check with the

local emergency service coordinator and the fire department to determine all notification responsibilities under the local emergency plan. Also, in western Washington notify the local air pollution control authority, or in eastern Washington notify the appropriate regional office of the department of ecology.

(c) Notify the appropriate regional office of the department of ecology in the following circumstances:

(i) For spills or discharges occurring outside of secondary containment meeting the requirements of this chapter, regardless of quantity; and

(ii) For spills or discharges occurring and contained in secondary containment meeting the requirements of this chapter, if the quantity of dangerous waste or hazardous substance meets or exceeds ten gallons.

(d) In lieu of notification under (c) of this subsection, for spills or discharges below ten gallons occurring and contained in secondary containment meeting the requirements of this chapter, a brief account must immediately be entered into the operating record, for a TSD facility, or into the inspection log or separate spill log, for a generator. This account must include: The time and date of the spill; the location and cause of the spill; the type and quantity of material spilled; and a brief description of any response actions taken or planned.

(3) Mitigation and control. The person responsible for a nonpermitted spill or discharge shall take appropriate immediate action to protect human health and the environment (e.g., diking to prevent contamination of state waters, shutting of open valves).

(a) In addition, the department may require the person responsible for a spill or discharge to:

(i) Clean up all released dangerous wastes or hazardous substances, or to take such actions as may be required or approved by federal, state, or local officials acting within the scope of their official responsibilities. This may include complete or partial removal of released dangerous wastes or hazardous substances as may be justified by the nature of the released dangerous wastes or hazardous substances, the human and environmental circumstances of the incident, and protection required by the Water Pollution Control Act, chapter 90.48 RCW;

(ii) Designate and treat, store or dispose of all soils, waters, or other materials contaminated by the spill or discharge in accordance with this chapter 173-303 WAC. The department may require testing in order to determine the amount or extent of contaminated materials, and the appropriate designation, treatment, storage, or disposal for any materials resulting from clean-up; and

(iii) If the property on which the spill or discharge occurred is not owned or controlled by the person responsible for the incident, restore the area impacted by the spill or discharge, and replenish resources (e.g., fish, plants) in a manner acceptable to the department.

(b) Where immediate removal or temporary storage of spilled or discharged dangerous wastes or hazardous substances is necessary to protect human health or the environment, the department may direct that removal be accomplished without a manifest, by transporters who do not have EPA/state identification numbers.

(4) Nothing in WAC 173-303-145 shall eliminate any obligations to comply with reporting requirements which may exist in a permit or under other state or federal regulations.

**AMENDATORY SECTION** (Amending Order DE-85-10, filed 6/3/86)

WAC 173-303-160 CONTAINERS. (1) Waste quantity. Containers and inner liners shall not be considered as a part of the waste when measuring or calculating the quantity of a dangerous waste. Only the weight of the residues in nonempty or nonrinsed containers or inner liners will be considered when determining waste quantities.

(2) A container or inner liner is "empty" when:

(a) All wastes in it have been taken out that can be removed using practices commonly employed to remove materials from that type of container or inner liner (e.g., pouring, pumping, aspirating, etc.) and, whichever quantity is least, either less than one inch of waste remains at the bottom of the container or inner liner, or the volume of waste remaining in the container or inner liner is equal to one percent or less of the container's total capacity, or, if the container's total capacity is greater than one hundred ten gallons, the volume of waste remaining in the container or inner liner is no more than 0.3 percent of the container's total capacity. A container which held compressed gas is empty when the pressure inside the container equals or nearly equals atmospheric pressure; and

(b) If the container or inner liner held acutely hazardous waste, as defined in WAC 173-303-040((2)), or pesticides bearing the danger or warning label, the container or inner liner has been rinsed at least three times with an appropriate cleaner or solvent. The volume of cleaner or solvent used for each rinsing shall be ten percent or more of the container's or inner liner's capacity. In lieu of rinsing for containers that might be damaged or made unusable by rinsing with liquids (e.g., fiber or cardboard containers without inner liners), an empty container may be vacuum cleaned, struck, with the open end of the container up, three times (e.g., on the ground, with a hammer or hand) to remove or loosen particles from the inner walls and corners, and vacuum cleaned again. Equipment used for the vacuum cleaning of residues from containers or inner liners must be decontaminated before discarding, in accordance with procedures approved by the department.

Any rinsate or vacuumed residue which results from the cleaning of containers or inner liners shall whenever possible be reused in a manner consistent with the original intended purpose of the substance in the container or inner liner. In the case of a farmer, if the rinsate is a pesticide residue then the rinsate shall be managed or reused in a manner consistent with the instructions on the pesticide label, provided that when the label instructions specify disposal or burial, such disposal or burial must be on the farmer's own (including rented, leased or tenanted) property. Otherwise, the rinsate shall be checked against the designation requirements (WAC 173-303-070 through 173-303-103) and, if designated, managed according to the requirements of this chapter.

(3) Any residues remaining in containers or inner liners that are "empty" as described in subsection (2) of this section will not be subject to the requirements of this chapter, and will not be considered as accumulated wastes for the purposes of calculating waste quantities.

(4) A person may petition the department to approve alternative container rinsing processes in accordance with WAC 173-303-910(1).

**AMENDATORY SECTION** (Amending Order 88-24, filed 1/4/89)

WAC 173-303-200 ACCUMULATING DANGEROUS WASTE ON-SITE. (1) A generator, not to include transporters as referenced in WAC 173-303-240(3), may accumulate dangerous waste on-site without a permit for ninety days or less after the date of generation, provided that:

(a) All such waste is shipped off-site to a designated facility or placed in an on-site facility which is permitted by the department under WAC 173-303-800 through 173-303-845 in ninety days or less. The department may, on a case-by-case basis, grant a maximum thirty day extension to this ninety day period if dangerous wastes must remain on-site due to unforeseen, temporary and uncontrollable circumstances. A generator who accumulates dangerous waste for more than ninety days is an operator of a storage facility and is subject to the facility requirements of this chapter and the permit requirements of this chapter as a storage facility unless he has been granted an extension to the ninety day period allowed pursuant to this subsection;

(b) The waste is placed in containers and the generator complies with WAC 173-303-630 (2), (3), (4), (5), (6), (8), and (9), or the waste is placed in tanks and the generator complies with WAC 173-303-640 (2) through (10), except WAC 173-303-640 (8)(c)(~~-, except that~~) and the second sentence of WAC 173-303-640 (8)(a). (Note: A generator, unless otherwise required to do so, does not have to prepare a closure plan, a cost estimate for closure, or provide financial responsibility for his tank system to satisfy the requirements of this section.)

In lieu of the "sufficient freeboard" requirement of WAC 173-303-640 (5)(b)(iii) for uncovered tanks, the generator must maintain a minimum freeboard of two feet. Such a generator is exempt from the requirements of WAC 173-303-620 and 173-303-610, except for WAC 173-303-610 (2) and (5). For container accumulation (including satellite areas as described in subsection (2)(c) of this section), the department may require that the accumulation area include secondary containment in accordance with WAC 173-303-630(7), if the department determines that there is a potential threat to public health or the environment due to the nature of the wastes being accumulated, or due to a history of spills or releases from accumulated containers. In addition, any new container accumulation areas (but not including new satellite areas, unless required by the department) constructed or installed after September 30, 1986, must comply with the provisions of WAC 173-303-630(7);

(c) The date upon which each period of accumulation begins is marked and clearly visible for inspection on each container;

(d) While being accumulated on site, each container and tank is labeled or marked clearly with the words "dangerous waste" or "hazardous waste." Each container or tank must also be marked with a label or sign which identifies the major risk(s) associated with the waste in the container or tank for employees, emergency response personnel and the public (Note—If there is already a system in use that performs this function in accordance with local, state, or federal regulations, then such system will be adequate); and

(e) The generator complies with the requirements for facility operators contained in WAC 173-303-330 through 173-303-360 (personnel training, preparedness and prevention, contingency plan and emergency procedures, and emergencies), and WAC 173-303-320 (1), (2)(a), (b), (d), and (3) (general inspection)~~((:PROVIDED, That if none of the dangerous wastes he generates are regulated as EHW under WAC 173-303-081 and no quantity of dangerous wastes he generates in one month or one batch ever exceeds 2200 pounds (1000 kilograms), then the generator need comply with the aforementioned requirements of WAC 173-303-320 through 173-303-360 only if:~~

~~(i) He accumulates dangerous waste on-site for ten or more calendar days; or~~

~~(ii) He is directed by the department to so comply, due to potential threats to public health or the environment. In such case, the department may require that he comply with all of or only parts of WAC 173-303-330 through 173-303-360, as necessary to mitigate the potential threats to public health or the environment)).~~

(2) For the purposes of this section, the ninety-day accumulation period begins on the date that:

(a) The generator first generates a dangerous waste; or

(b) The quantity (or aggregated quantity) of dangerous waste being accumulated by a small quantity generator first exceeds the quantity exclusion limit for such waste (or wastes); or

(c) The quantity of dangerous waste being accumulated in containers in a satellite area exceeds fifty-five gallons of dangerous waste or one quart of acutely hazardous waste (see WAC 173-303-040~~((2))~~). For the purposes of this section, a satellite area shall be a location at or near any point of generation where wastes initially accumulate, which is under the control of the operator of the process generating the waste.

#### AMENDATORY SECTION (Amending Order DE-87-4, filed 6/26/87)

WAC 173-303-201 SPECIAL ACCUMULATION STANDARDS. (1) This section applies to persons who generate less than 2200 pounds (1000 kg) per month and do not accumulate on-site more than 2200 pounds (1000 kg) of dangerous waste. The special provisions of this section do not apply to any acutely hazardous wastes (as defined in WAC 173-303-040~~((2))~~) that are being generated or accumulated by the generator.

(2) For purposes of accumulating dangerous waste on-site, persons who generate per month and accumulate on-site less than 2200 pounds (1000 kg) per month

of dangerous waste are subject to all applicable provisions of WAC 173-303-200 except as follows:

(a) In lieu of the ninety-day accumulation period, dangerous wastes may be accumulated for one hundred eighty days or less. The department may, on a case-by-case basis, grant a maximum ninety-day extension to this one hundred eighty-day period if the generator must transport his waste, or offer his waste for transportation, over a distance of two hundred miles or more for off-site treatment, storage, or disposal, and the dangerous wastes must remain on-site due to unforeseen, temporary and uncontrollable circumstances;

(b) The generator need not comply with WAC 173-303-330 (Personnel training); and

(c) In lieu of the contingency plan and emergency procedures required by WAC 173-303-350 and 173-303-360, the generator must comply with the following:

(i) At all times there must be at least one employee either on the premises or on call (i.e., available to respond to an emergency by reaching the facility within a short period of time) with the responsibility for coordinating all emergency response measures specified in (c)(iv) of this subsection. This employee is the emergency coordinator.

(ii) The generator must post the following information next to all emergency communication devices (including telephones, two-way radios, etc.):

(A) The name and telephone number of the emergency coordinator;

(B) Location of fire extinguishers and spill control material, and, if present, fire alarm; and

(C) The telephone number of the fire department, unless the facility has a direct alarm.

(iii) The generator must ensure that all employees are thoroughly familiar with proper waste handling and emergency procedures, relevant to their responsibilities during normal facility operations and emergencies;

(iv) The emergency coordinator or his designee must respond to any emergencies that arise. The applicable responses are as follows:

(A) In the event of a fire, call the fire department or attempt to extinguish it using a fire extinguisher;

(B) In the event of a spill, contain the flow of dangerous waste to the extent possible, and as soon as is practicable, clean up the dangerous waste and any contaminated materials or soil;

(C) In the event of a fire, explosion, or other release which could threaten human health outside the facility or when the generator has knowledge that a spill has reached waters of the state, the generator must immediately notify the department and either the government official designated as the on-scene coordinator, or the National Response Center (using their twenty-four hour toll free number 800/424-8802). The report must include the following information:

(I) The name, address, and EPA/state identification number of the generator;

(II) Date, time, and type of incident (e.g., spill or fire);

(III) Quantity and type of hazardous waste involved in the incident;

(IV) Extent of injuries, if any; and



(V) Estimated quantity and disposition of recovered materials, if any.

**AMENDATORY SECTION** (Amending Order DE-85-10, filed 6/3/86)

WAC 173-303-210 GENERATOR RECORD-KEEPING. (1) The generator shall keep a copy of each manifest signed by the initial transporter in accordance with WAC 173-303-180(3), manifest procedures, for three years, or until he receives a signed copy from the designated facility which received the waste. The signed facility copy shall be retained for at least ~~((three))~~ five years from the date the waste was accepted by the initial transporter.

(2) The generator shall keep a copy of each annual report and exception report as required by WAC 173-303-220 for a period of at least ~~((three))~~ five years from the due date of each report. The generator shall keep a copy of his most recent notification (Form 2) until he is no longer defined as a generator under this chapter.

(3) The generator shall keep records of any test results, waste analyses, or other determinations made in accordance with WAC 173-303-170(1) for designating dangerous waste for at least ~~((three))~~ five years from the date that the waste was last transferred for on-site or off-site ~~((TSD))~~ treatment, storage, or disposal.

(4) Any other records required for generators accumulating wastes on-site as described in WAC 173-303-170 (4)(b) or 173-303-200 must be retained for at least ~~((three))~~ five years, including, but not limited to such items as inspection logs and operating records.

(5) The periods of retention for any records described in this section shall be automatically extended during the course of any unresolved enforcement action requiring those records or upon request by the director.

(6) All generator records, including plans required by this chapter, shall be made available and furnished upon request by the director.

**AMENDATORY SECTION** (Amending Order DE-87-4, filed 6/26/87)

WAC 173-303-220 GENERATOR REPORTING. The generator shall submit the following reports to the department by the specified due date for each report, or within the time period allowed for each report.

(1) Annual reports.

(a) A generator or any person who has obtained an EPA/state identification number pursuant to WAC 173-303-060 shall submit an annual report to the department, on the Generator Annual Dangerous Waste Report - Form 4 according to the instructions on the form (copies are available from the department), no later than March 1 for the preceding calendar year.

(b) In addition, any generator who stores, treats, or disposes of dangerous waste on-site shall comply with the annual reporting requirements of WAC 173-303-390, Facility reporting.

(2) Exception reports.

(a) A generator who does not receive a copy of the manifest with the handwritten signature of the owner/operator of the designated facility within thirty-

five days of the date the waste was accepted by the initial transporter must contact the transporter(s) and/or facility to determine the status of the dangerous waste shipment.

(b) A generator must submit an exception report to the department if he has not received a copy of the manifest with the handwritten signature of the owner/operator of the designated facility within forty-five days of the date the waste was accepted by the initial transporter.

(c) The exception report must include:

(i) A legible copy of the manifest for which the generator does not have confirmation of delivery; and

(ii) A cover letter signed by the generator or his representative explaining the efforts taken to locate the waste and the results of those efforts.

(d) The department may require a generator to submit exception reports in less than forty-five days if it finds that the generator frequently or persistently endangers public health or the environment through improper waste shipment practices.

(3) Additional reports. The director, as he deems necessary under chapter 70.105 RCW, may require a generator to furnish additional reports (including engineering reports, plans, and specifications) concerning the quantities and disposition of ~~((his))~~ the generator's dangerous waste.

**AMENDATORY SECTION** (Amending Order DE-87-4, filed 6/26/87)

WAC 173-303-230 SPECIAL CONDITIONS. (1) Exporting dangerous waste.

Federal export requirements, administered by EPA, are set forth in 40 CFR ~~((262.50))~~ 262 Subpart E and specify the procedures applicable to generators of hazardous waste (as defined in WAC 173-303-040~~((39))~~). Copies of any forms or reports submitted to the administrator of United States EPA as required by 40 CFR ~~((262.50))~~ 262 Subpart E shall also be submitted to the department.

(2) Importing dangerous waste. When importing dangerous waste from a foreign country into Washington state, the United States importer shall comply with all the requirements of this chapter for generators, including the requirements of WAC 173-303-180(1), except that:

(a) In place of the generator's name, address and EPA/state identification number, the name and address of the foreign generator and the importer's name, address and EPA/state identification number shall be used; and

(b) In place of the generator's signature on the certification statement, the United States importer or his agent shall sign and date the certification and obtain the signature of the initial transporter.

(3) Empty containers. For the purposes of this chapter, a person who stores, treats, disposes, transports, or offers for transport empty containers of dangerous waste that were for his own use shall not be treated as a generator or as a facility owner/operator if the containers are empty as defined in WAC 173-303-160(2), and either:



(a) The rinsate is not a dangerous waste under this chapter; or

(b) He reuses the rinsate in a manner consistent with the original product or, if he is a farmer and the rinsate contains pesticide residues, he reuses or manages the rinsate in a manner consistent with the instructions on the pesticide label, provided that when the label instructions specify disposal or burial, such disposal or burial must be on the farmer's own (including rented, leased or tenanted) property.

(4) Tank cars. A person rinsing out dangerous waste tote tanks, truck or railroad tank cars shall handle the rinsate according to this chapter, and according to chapter 90.48 RCW, Water pollution control.

AMENDATORY SECTION (Amending Order DE 83-36, filed 4/18/84)

WAC 173-303-320 GENERAL INSPECTION.

(1) The owner or operator shall inspect his facility to prevent malfunctions and deterioration, operator errors, and discharges which may cause or lead to the release of dangerous waste constituents to the environment, or a threat to human health. The owner or operator must conduct these inspections often enough to identify problems in time to correct them before they harm human health or the environment.

(2) The owner or operator shall develop and follow a written schedule for inspecting all monitoring equipment, safety and emergency equipment, security devices, and operating and structural equipment that help prevent, detect, or respond to hazards to the public health or the environment. In addition:

(a) He must keep the schedule at the facility;

(b) The schedule must identify the types of problems which are to be looked for during inspections;

(c) The schedule shall indicate the frequency of inspection for specific items. The frequency should be based on the rate of possible deterioration of equipment, and the probability of an environmental or human health incident. Areas subject to spills must be inspected daily when in use. The inspection schedule shall also include the applicable items and frequencies required for the specific waste management methods described in 40 CFR Part 265 Subparts F through R for interim status facilities and in WAC 173-303-630 through (~~(+73-303-670)~~) 173-303-680 for final status facilities; and

(d) The owner or operator shall keep an inspection log or summary, including at least the date and time of the inspection, the printed name and the handwritten signature of the inspector, a notation of the observations made, an account of spills or discharges in accordance with WAC 173-303-145, and the date and nature of any repairs or remedial actions taken. The log or summary must be kept at the facility for at least (~~(three)~~) five years from the date of inspection.

(3) The owner or operator shall remedy any problems revealed by the inspection, on a schedule which prevents hazards to the public health and environment. Where a hazard is imminent or has already occurred, remedial action must be taken immediately.

AMENDATORY SECTION (Amending Order DE-87-4, filed 6/26/87)

WAC 173-303-360 EMERGENCIES. (1) Emergency coordinator. At all times, there must be at least one employee either on the facility premises or on call with the responsibility for coordinating all emergency response measures. This emergency coordinator must be thoroughly familiar with all aspects of the facility's contingency plan, required by WAC 173-303-350(2), all operations and activities at the facility, the location and properties of all wastes handled, the location of all records within the facility, and the facility layout. In addition, this person must have the authority to commit the resources needed to carry out the contingency plan.

(2) Emergency procedures. The following procedures shall be implemented in the event of an emergency.

(a) Whenever there is an imminent or actual emergency situation, the emergency coordinator (or his designee when the emergency coordinator is on call) must immediately:

(i) Activate internal facility alarms or communication systems, where applicable, to notify all facility personnel; and

(ii) Notify appropriate state or local agencies with designated response roles if their help is needed.

(b) Whenever there is a release, fire, or explosion, the emergency coordinator must immediately identify the character, exact source, amount, and areal extent of any released materials.

(c) Concurrently, the emergency coordinator shall assess possible hazards to human health and the environment (considering direct, indirect, immediate, and long-term effects) that may result from the release, fire, or explosion.

(d) If the emergency coordinator determines that the facility has had a release, fire, or explosion which could threaten human health or the environment (~~(outside the facility)~~), he must report his findings as follows:

(i) If his assessment indicates that evacuation of local areas may be advisable, he must immediately notify appropriate local authorities. He must be available to help appropriate officials decide whether local areas should be evacuated; and

(ii) He must immediately notify the department and either the government official designated as the on-scene coordinator, or the National Response Center (using their 24-hour toll free number (800) 424-8802).

(e) His assessment report must include:

(i) Name and telephone number of reporter;

(ii) Name and address of facility;

(iii) Time and type of incident (e.g., release, fire);

(iv) Name and quantity of material(s) involved, to the extent known;

(v) The extent of injuries, if any; and

(vi) The possible hazards to human health or the environment outside the facility.

(f) During an emergency, the emergency coordinator must take all reasonable measures necessary to ensure that fires, explosions, and releases do not occur, recur, or spread to other dangerous waste at the facility. These

measures must include, where applicable, stopping processes and operations, collecting and containing released waste, and removing or isolating containers.

(g) If the facility stops operations in response to a fire, explosion, or release, the emergency coordinator must monitor for leaks, pressure buildup, gas generation, or ruptures in valves, pipes, or other equipment, wherever this is appropriate.

(h) Immediately after an emergency, the emergency coordinator must provide for treating, storing, or disposing of recovered waste, contaminated soil or surface water, or any other material that results from a release, fire, or explosion at the facility.

(i) The emergency coordinator must ensure that, in the affected area(s) of the facility:

(i) No waste that may be incompatible with the released material is treated, stored, or disposed of until cleanup procedures are completed; and

(ii) All emergency equipment listed in the contingency plan is cleaned and fit for its intended use before operations are resumed.

(j) The owner or operator must notify the department, and appropriate local authorities, that the facility is in compliance with (i) of this subsection before operations are resumed in the affected area(s) of the facility.

(k) The owner or operator must note in the operating record the time, date, and details of any incident that requires implementing the contingency plan. Within fifteen days after the incident, he must submit a written report on the incident to the department. The report must include:

(i) Name, address, and telephone number of the owner or operator;

(ii) Name, address, and telephone number of the facility;

(iii) Date, time, and type of incident (e.g., fire, explosion);

(iv) Name and quantity of material(s) involved;

(v) The extent of injuries, if any;

(vi) An assessment of actual or potential hazards to human health or the environment, where this is applicable;

(vii) Estimated quantity and disposition of recovered material that resulted from the incident;

(viii) Cause of incident; and

(ix) Description of corrective action taken to prevent reoccurrence of the incident.

**AMENDATORY SECTION** (Amending Order DE-85-10, filed 6/3/86)

**WAC 173-303-380 FACILITY RECORDKEEPING.** (1) Operating record. The owner or operator of a facility shall keep a written operating record at his facility. The following information shall be recorded, as it becomes available, and maintained in the operating record until closure of the facility:

(a) A description of and the quantity of each dangerous waste received or managed on-site, and the method(s) and date(s) of its treatment, storage, or disposal at the facility as required by subsection (2) of this section, recordkeeping instructions;

(b) The location of each dangerous waste within the facility and the quantity at each location. For disposal facilities, the location and quantity of each dangerous waste must be recorded on a map or diagram of each cell or disposal area. For all facilities, this information must include cross-references to specific manifest document numbers, if the waste was accompanied by a manifest;

(c) Records and results of waste analyses required by WAC 173-303-300, General waste analysis;

(d) Summary reports and details of all incidents that require implementing the contingency plan, as specified in WAC 173-303-360 (2)(k);

(e) Records and results of inspections as required by WAC 173-303-320 (2)(d), General inspection (except such information need be kept only for ((three)) five years);

(f) Monitoring, testing, or analytical data, and corrective action where required by 40 CFR Part 265 Subparts F through R for interim status facilities, and by WAC 173-303-630 through ((173-303-670)) 173-303-680 for final status facilities;

(g) All closure and post-closure cost estimates required for the facility; and

(h) For off-site facilities, copies of notices to generators informing them that the facility has all appropriate permits, as required by WAC 173-303-290, Required notices.

(2) Recordkeeping instructions. This paragraph provides instructions for recording the portions of the operating record which are related to describing the types, quantities, and management of dangerous wastes at the facility. This information shall be kept in the operating record, as follows:

(a) Each dangerous waste received or managed shall be described by its common name and by its dangerous waste number(s) from WAC 173-303-080 through 173-303-104. Where a dangerous waste contains more than one process waste or waste constituent the waste description must include all applicable dangerous waste numbers. If the dangerous waste number is not listed then the waste description shall include the process which generated the waste;

(b) The waste description shall include the waste's physical form (i.e., liquid, solid, sludge, or gas);

(c) The weight, or volume and density, of the dangerous waste shall be recorded, using one of the units of measure specified in Table 1, below;

TABLE 1

Unit of Measure	Symbol	Density
Pounds . . . . .	P	
Short tons (2000 lbs) . . . . .	T	
Gallons (U.S.) . . . . .	G	P/G
Cubic yards . . . . .	Y	T/Y
Kilograms . . . . .	K	
Tonnes (1000 kg) . . . . .	M	
Liters . . . . .	L	K/L
Cubic meters . . . . .	C	M/C

(d) And, the date(s) and method(s) of management for each dangerous waste received or managed (treated, recycled, stored, or disposed of) shall be recorded, using the handling code(s) specified in Table 2, below.

TABLE 2

- |   |   |
|---|---|
| <p>1. Storage</p> <p>S01 Container (barrel, drum, etc.)</p> <p>S02 Tank</p> <p>S03 Waste pile</p> <p>S04 Surface impoundment</p> <p>S05 Other (specify)</p> <p>2. Treatment</p> <p>(a) Thermal treatment</p> <p>T06 Liquid injection incinerator</p> <p>T07 Rotary kiln incinerator</p> <p>T08 Fluidized bed incinerator</p> <p>T09 Multiple hearth incinerator</p> <p>T10 Infrared furnace incinerator</p> <p>T11 Molten salt destructor</p> <p>T12 Pyrolysis</p> <p>T13 Wet air oxidation</p> <p>T14 Calcination</p> <p>T15 Microwave discharge</p> <p>T16 Cement kiln</p> <p>T17 Lime kiln</p> <p>T18 Other (specify)</p> <p>(b) Chemical treatment</p> <p>T19 Absorption mound</p> <p>T20 Absorption field</p> <p>T21 Chemical fixation</p> <p>T22 Chemical oxidation</p> <p>T23 Chemical precipitation</p> <p>T24 Chemical reduction</p> <p>T25 Chlorination</p> <p>T26 Chlorinolysis</p> <p>T27 Cyanide destruction</p> <p>T28 Degradation</p> <p>T29 Detoxification</p> <p>T30 Ion exchange</p> <p>T31 Neutralization</p> <p>T32 Ozonation</p> <p>T33 Photolysis</p> <p>T34 Other (specify)</p> <p>(c) Physical treatment</p> <p>(i) Separation of components</p> <p>T35 Centrifugation</p> <p>T36 Clarification</p> <p>T37 Coagulation</p> <p>T38 Decanting</p> <p>T39 Encapsulation</p> <p>T40 Filtration</p> <p>T41 Flocculation</p> <p>T42 Flotation</p> <p>T43 Foaming</p> <p>T44 Sedimentation</p> <p>T45 Thickening</p> <p>T46 Ultrafiltration</p> <p>T47 Other (specify)</p> | <p>(ii) Removal of specific components</p> <p>T48 Absorption-molecular sieve</p> <p>T49 Activated carbon</p> <p>T50 Blending</p> <p>T51 Catalysis</p> <p>T52 Crystallization</p> <p>T53 Dialysis</p> <p>T54 Distillation</p> <p>T55 Electrodialysis</p> <p>T56 Electrolysis</p> <p>T57 Evaporation</p> <p>T58 High gradient magnetic separation</p> <p>T59 Leaching</p> <p>T60 Liquid ion exchange</p> <p>T61 Liquid-liquid extraction</p> <p>T62 Reverse osmosis</p> <p>T63 Solvent recovery</p> <p>T64 Stripping</p> <p>T65 Sand filter</p> <p>T66 Other (specify)</p> <p>(d) Biological treatment</p> <p>T67 Activated sludge</p> <p>T68 Aerobic lagoon</p> <p>T69 Aerobic tank</p> <p>T70 Anaerobic lagoon or tank</p> <p>T71 Composting</p> <p>T72 Septic tank</p> <p>T73 Spray irrigation</p> <p>T74 Thickening filter</p> <p>T75 Trickling filter</p> <p>T76 Waste stabilization pond</p> <p>T77 Other (specify)</p> <p>T78-79 (Reserved)</p> <p>3. Disposal</p> <p>D80 Underground injection</p> <p>D81 Landfill</p> <p>D82 Land treatment</p> <p>D83 Ocean disposal</p> <p>D84 Surface impoundment<br/>(to be closed as a landfill)</p> <p>D85 Other (specify)</p> <p>(3) Availability, retention and disposition of records.</p> <p>(a) All facility records, including plans, required by this chapter must be furnished upon request, and made available at all reasonable times for inspection, by any officer, employee, or representative of the department who is designated by the director.</p> <p>(b) The retention period for all facility records required under this chapter is extended automatically during the course of any unresolved enforcement action regarding the facility or as requested by the director.</p> <p>(c) A copy of records of waste disposal locations and quantities under this section must be submitted to the United States EPA regional administrator, the department, and the local land use and planning authority upon closure of the facility.</p> |
|---|---|

AMENDATORY SECTION (Amending Order DE-85-10, filed 6/3/86)

WAC 173-303-390 FACILITY REPORTING.  
The owner or operator of a facility is responsible for

preparing and submitting the reports described in this section.

(1) Unmanifested waste reports. If a facility accepts any dangerous waste from an off-site source without an accompanying manifest or shipping paper, and if the waste is not excluded from the manifest requirements of this chapter 173-303 WAC, then the owner or operator must prepare and submit a single copy of a report to the department within fifteen days after receiving the waste. The report form and instructions in the Unmanifested Dangerous Waste Report - Form 6 (which may be obtained from the department) must be used for this report. The report must include at least the following information:

- (a) The EPA/state identification number, name, and address of the facility;
- (b) The date the facility received the waste;
- (c) The EPA/state identification number, name, and address of the generator and the transporter, if available;
- (d) A description and the quantity of each unmanifested dangerous waste the facility received;
- (e) The method of management for each dangerous waste;
- (f) The certification signed by the owner or operator of the facility or his authorized representative; and
- (g) A brief explanation of why the waste was unmanifested, if known.

(2) Annual reports. The owner or operator of a facility that holds an active EPA/state identification number shall prepare and submit a single copy of an annual report to the department by March 1 of each year. The report form and instructions in the TSD Facility Annual Dangerous Waste Report - Form 5 (which may be obtained from the department) must be used for this report. In addition, any facility which ships dangerous waste off-site must comply with the annual reporting requirements of WAC 173-303-220. The annual report must cover facility activities during the previous calendar year and must include, but is not limited to the following information:

- (a) The EPA/state identification number, name, and address of the facility;
- (b) The calendar year covered by the report;
- (c) For off-site facilities, the EPA/state identification number of each dangerous waste generator from which the facility received a dangerous waste during the year. For imported shipments, the report must give the name and address of the foreign generator;
- (d) A description and the quantity of each dangerous waste the facility received during the year. For off-site facilities, this information must be listed by EPA/state identification number of each generator;
- (e) The method of treatment, storage, or disposal for each dangerous waste;
- (f) The most recent closure cost estimate under WAC 173-303-620(3) (or 40 CFR 265.142 for interim status facilities), and for disposal facilities, the most recent post-closure cost estimate under WAC 173-303-620(5) (or 40 CFR 265.144 for interim status facilities); and
- (g) The certification signed in accordance with the requirements of WAC 173-303-810(12).

(3) Additional reports. The owner or operator shall also report to the department releases of dangerous wastes, fires, and explosions as specified in WAC 173-303-360 (2)(k) and interim status groundwater monitoring data, as specified in 40 CFR 265.94 (a)(2) and (b)(2).

In addition, the owner or operator shall submit any other reports (including engineering reports, plans, and specifications) required by the department.

#### AMENDATORY SECTION (Amending Order 88-24, filed 1/4/89)

WAC 173-303-400 INTERIM STATUS FACILITY STANDARDS. (1) Purpose. The purpose of WAC 173-303-400 is to establish standards which define the acceptable management of dangerous waste during the period of interim status and until certification of final closure or, if the facility is subject to post-closure requirements, until post-closure responsibilities are fulfilled.

(2) Applicability.

(a) The interim status standards apply to owners and operators of facilities which treat, store, transfer, and/or dispose of dangerous waste. For purposes of this section, interim status shall apply to all facilities which comply fully with the requirements for interim status under Section 3005(e) of the Federal Resource Conservation and Recovery Act or WAC 173-303-805. The interim status standards shall also apply to those owners and operators of facilities in existence on November 19, 1980, for RCRA wastes and those facilities in existence on August 9, 1982, for state only wastes who have failed to provide the required notification pursuant to WAC 173-303-060 or failed to file Part A of the permit application pursuant to WAC 173-303-805 (4) and (5). Interim status shall end after final administrative disposition of the Part B permit application is completed, or may be terminated for the causes described in WAC 173-303-805(7).

(b) Interim status facilities must meet the interim status standards by November 19, 1980, except that:

(i) Interim status facilities which handle only state designated wastes (i.e., not designated by 40 CFR Part 261) must meet the interim status standards by August 9, 1982; and

(ii) Interim status facilities must comply with the additional state interim status requirements specified in subsection (3)(c)(ii), (iii) and (v), of this section, by August 9, 1982.

(c) The requirements of the interim status standards do not apply to:

(i) Persons disposing of dangerous waste subject to a permit issued under the Marine Protection, Research and Sanctuaries Act;

(ii) Persons disposing of dangerous waste by underground injection which is permitted under the Safe Drinking Water Act;

(iii) The owner or operator of a POTW who treats, stores, or disposes of dangerous wastes, provided that he has a permit by rule pursuant to the requirements of WAC 173-303-802(4);

(iv) The owner or operator of a totally enclosed treatment facility or elementary neutralization or wastewater treatment units as defined in WAC 173-303-040, provided that he (~~complies with the~~) has a permit by rule pursuant to the requirements of WAC 173-303-802(5);

(v) Generators accumulating waste for less than ninety days except to the extent WAC 173-303-200 provides otherwise; and

(vi) The addition, by a generator, of absorbent material to waste in a container, or of waste to absorbent material in a container, provided that these actions occur at the time the waste is first placed in containers and the generator complies with WAC 173-303-200 (1)(b) and 173-303-395 (1)(a) and (b).

(d) The owner or operator of an interim status facility which manages special waste may comply with the special requirements selected under WAC 173-303-550 through 173-303-560 in lieu of the interim status facility standards of this section, but only for those special wastes which he manages and only after the owner or operator has requested and the department has issued a notice of interim status modification.

### (3) Standards.

(a) Interim status standards shall be standards set forth by the Environmental Protection Agency in 40 CFR Part 265 Subparts F through R which are incorporated by reference into this regulation (including, by reference, any EPA requirements specified in those subparts which are not otherwise explicitly described in this chapter), and:

(i) The land disposal restrictions of WAC 173-303-140 and the facility requirements of WAC 173-303-280 through 173-303-440;

(ii) WAC 173-303-630(3), for containers. In addition, for container storage, the department may require that the storage area include secondary containment in accordance with WAC 173-303-630(7), if the department determines that there is a potential threat to public health or the environment due to the nature of the wastes being stored, or due to a history of spills or releases from stored containers. Any new container storage areas constructed or installed after September 30, 1986, must comply with the provisions of WAC 173-303-630(7).

(iii) WAC 173-303-640 (5)(d), for tanks; and

(iv) WAC 173-303-805.

(b) For purposes of applying the interim status standards of 40 CFR Part 265 Subparts F through R to the state of Washington facilities, the federal terms shall have (and in the case of the wording used in the financial instruments referenced in Subpart H of Part 265, shall be replaced with) the following state of Washington meanings:

(i) "Regional administrator" shall mean the "department";

(ii) "Hazardous" shall mean "dangerous"; and

(iii) "Compliance procedure" shall have the meaning set forth in WAC 173-303-040, Definitions.

(c) In addition to the changes described in (b) of this subsection, the following modifications shall be made to

interim status standards of 40 CFR Part 265 Subparts F through R:

(i) The words "the effective date of these regulations" shall mean:

(A) November 19, 1980, for facilities which manage any wastes designated by 40 CFR Part 261;

(B) For wastes which become designated by 40 CFR Part 261 subsequent to November 19, 1980, the effective date shall be the date on which the wastes become regulated;

(C) March 12, 1982, for facilities which manage wastes designated only by WAC 173-303-080 through 173-303-103 and not designated by 40 CFR Part 261;

(D) For wastes which become designated only by WAC 173-303-080 through 173-303-103 and not designated by 40 CFR Part 261 subsequent to March 12, 1982, the effective date shall be the date on which the wastes become regulated.

(ii) "Subpart N - landfills" shall have an additional section added which reads: "An owner/operator shall not landfill an organic carcinogen or an EHW, as defined by WAC 173-303-080 to 173-303-103, except at the EHW facility at Hanford";

(iii) "Subpart R - underground injection" shall have an additional section which reads: "Owners and operators of wells are prohibited from disposing of EHW or an organic carcinogen designated under WAC 173-303-080 through 173-303-103";

(iv) "Subpart M - land treatment," section 265.273(b) shall be modified to replace the words "Part 261, Subpart D of this chapter" with "WAC 173-303-080";

(v) "Subpart F - ground water monitoring," section 265.91(c) shall include the requirement that: "Ground-water monitoring wells shall be designed, constructed, and operated so as to prevent groundwater contamination. Chapter 173-160 WAC may be used as guidance in the installation of wells";

(vi) "Subpart H - financial requirements" shall have an additional section which reads: "Any owner or operator who can provide financial assurances and instruments which satisfy the requirements of WAC 173-303-620 will be deemed to be in compliance with 40 CFR Part 265 Subpart H"; and

(vii) "Subpart J - tank systems" section 265.193(a) shall be modified so that the dates by which secondary containment (which meets the requirements of that section) must be provided are the same as the dates in WAC 173-303-640 (4)(a).

(viii) "Subpart J - tank systems" section 265.191(a) shall be modified so that the date((s)) by which an assessment of a tank system's integrity must be completed (~~are the same as the dates in WAC 173-303-640 (2)(a))~~) is January 12, 1990.

(ix) "Subpart G - closure and post-closure" section 265.115 shall be modified to read "Within 60 days of completion of closure of each dangerous waste management unit (including tank systems and container storage areas) and within 60 days of completion of final closure...."

AMENDATORY SECTION (Amending Order DE-85-10, filed 6/3/86)

WAC 173-303-500 RECYCLING REQUIREMENTS FOR STATE-ONLY DANGEROUS WASTE. (1) Applicability. This section applies to the recycling of state-only dangerous waste that are not regulated as hazardous wastes (defined in WAC 173-303-040(~~(39)~~)) by EPA.

(2) Standards.

(a) If state-only dangerous wastes are recycled in any of the ways described in WAC 173-303-505 through 173-303-525, then such recycling is subject to the respective requirements of WAC 173-303-505 through 173-303-525, except as provided in (c) of this subsection.

(b) If state-only dangerous wastes are recycled in any way not specifically described in WAC 173-303-505 through 173-303-525, then such recycling is subject to the requirements of WAC 173-303-120(4), except as provided in (c) of this subsection.

(c) Recyclers who receive state-only dangerous wastes from off-site and who store the wastes in containers or tanks may, in lieu of the provisions for storing dangerous wastes prior to recycling, comply with:

(i) WAC 173-303-060;

(ii) WAC 173-303-370 (if the dangerous waste received must be accompanied by a manifest); and

(iii) The following requirements, provided that the dangerous waste is recycled within ninety days of the date it is received by the recycler:

(A) WAC 173-303-330 through 173-303-360;

(B) WAC 173-303-630 (2), (3), (4), (5), (6), (8) and (9), for containers;

(C) WAC 173-303-640 (3), (4), (5), (6) and (7), for tanks; and

(D) WAC 173-303-630(7) for new container areas installed after September 30, 1986, and WAC 173-303-640(2) for new tanks installed after September 30, 1986.

(d) The department may require a recycler who is storing his waste under the provisions of (c) of this subsection to comply with the provisions for storing dangerous waste prior to recycling specified in WAC 173-303-505 through 173-303-525 and 173-303-120(4) if:

(i) The recycler fails to comply with the requirements of (c) of this subsection; or

(ii) The department determines, on a case-by-case basis, that the requirements of (c) of this subsection do not adequately protect public health or the environment.

(3) Relief from standards. The owner/operator of a facility recycling dangerous wastes under the provisions of this section may ask the department to provide relief from any of the applicable requirements of this section. Requests for relief must be submitted as described in (a) of this subsection. Requests for relief will be approved or denied as described in (b) of this subsection.

(a) A request for relief must be submitted by the recycler to the department in writing and must describe the standards from which the recycler is seeking relief. The request must include:

(i) The facility name, EPA/state identification number, address, telephone number, and a contact person at the facility;

(ii) The waste(s) managed at the facility and the type(s) recycling;

(iii) The specific standards from which the owner/operator seeks relief;

(iv) A description, for each standard, demonstrating:

(A) Why the owner/operator believes the standard to be unnecessary;

(B) How public health and the environment will continue to be protected if the standard is not applied to the facility; and

(C) Any evidence supporting the contention that public health and the environment will be adequately protected if the standard is not applied (e.g., test data, diagrams, experiences at similar facilities, records, reports, etc.); and

(v) The following certification, signed and dated by a person who would be authorized to sign a report under WAC 173-303-810 (12)(b):

"I certify under penalty of law that I have personally examined and am familiar with the information submitted in this request and all attachments and that, based on my inquiry of those individuals immediately responsible for obtaining the information, I believe that the information is true, accurate, and complete. I am aware that there are significant penalties for submitting false information, including the possibility of fine and imprisonment."

The department may ask for any additional information it deems necessary, and will not consider approval of the owner's/operator's request until all necessary information has been submitted. Failure to provide any of the information required may result in the department's denying the owner's/operator's request.

(b) The department will review any requests submitted pursuant to (a) of this subsection, and based on the adequacy of the information provided in the request will approve or deny all or any part of the request. The department will notify the recycler of its decision in writing. If the department decides to approve all or part of the request and the recycler agrees with the department's decision, then the department will proceed to grant the approval as described below. No approval shall be effective until the procedures described below have been completed.

(i) For facilities which are required to have a final facility permit, the department shall follow the procedures for issuing (or, for facilities which already have a final facility permit, the procedures for modifying) a final facility permit, as described in WAC 173-303-806. The new or modified final facility permit shall include the standards the owner/operator must meet.

(ii) For all other types of recycling facilities, the department shall issue a notice of modification stating what standards will be applied. Before issuing the notice of modification, the department shall provide public notice of its intent, shall allow thirty days for public comment, and shall hold a public hearing if there is a significant degree of public interest or there is written notice of opposition and the department receives a request for a

hearing during the comment period. Notice of a public hearing shall be provided at least fifteen days in advance, and the public comment period shall be extended to include the date of the hearing if it will occur after the initial thirty-day comment period. Within fifteen days of the end of the public comment period the department shall, based on comments received, issue, modify and issue, or deny the notice of modification.

(c) Failure to comply with the conditions and standards as stated in the permit or notice of modification issued under (b) of this subsection shall form a basis for modifying or revoking the permit or notice of modification.

**READOPTED SECTION** (Readopting Order 88-29, filed 9/6/88)

**WAC 173-303-510 SPECIAL REQUIREMENTS FOR DANGEROUS WASTES BURNED FOR ENERGY RECOVERY.** (1) Applicability.

(a) This section applies to dangerous wastes that are burned for energy recovery in any boiler or industrial furnace that is not regulated under Subpart O of 40 CFR Part 265 or WAC 173-303-670, except as provided by (b) of this subsection. Such dangerous wastes burned for energy recovery are termed "dangerous waste fuel." Fuel produced from dangerous waste by processing, blending, or other treatment is also dangerous waste fuel. (These regulations do not apply, however, to gas recovered from dangerous waste management activities when such gas is burned for energy recovery.)

(b) The following dangerous wastes are not subject to regulation under this section:

(i) Used oil burned for energy recovery if it is a dangerous waste because it:

(A) Exhibits a characteristic of dangerous waste identified in WAC 173-303-090; or

(B) Is designated as DW only through the criteria of WAC 173-303-101 through 173-303-103; or

(C) Is a dangerous waste designated solely as W001.

Such used oil is subject to regulation under WAC 173-303-515 rather than this section.

Note: Used oil burned for energy recovery containing a listed waste (unless such listed waste is only state source W001) or a waste designated as EHW through the criteria of WAC 173-303-101 through 173-303-103 is subject to this section.

(ii) (Reserved.)

(2) Prohibitions.

(a) A person may market dangerous waste fuel only:

(i) To persons who have notified the department of their dangerous waste fuel activities under WAC 173-303-060 and have an EPA/state identification number; and

(ii) If the fuel is burned, to persons who burn the fuel in boilers or industrial furnaces identified in (b) of this subsection.

(b) Dangerous waste fuel may be burned for energy recovery in only the following devices:

(i) Industrial furnaces identified in WAC 173-303-040;

(ii) Boilers, as defined in WAC 173-303-040, that are identified as follows:

(A) Industrial boilers located on the site of a facility engaged in a manufacturing process where substances are transformed into new products, including the component parts of products, by mechanical or chemical processes; or

(B) Utility boilers used to produce electric power, steam, or heated or cooled air or other gases or fluids for sale.

(c) No fuel which contains any dangerous waste may be burned in any cement kiln which is located within the boundaries of any incorporated municipality with a population greater than five hundred thousand (based on the most recent census statistics) unless such kiln fully complies with regulations under this chapter that are applicable to incinerators.

(3) Standards applicable to generators of dangerous waste fuel.

(a) Generators of dangerous waste that is used as a fuel or used to produce a fuel are subject to WAC 173-303-170 through 173-303-230.

(b) Generators who market dangerous waste fuel to a burner also are subject to subsection (5) of this section.

(c) Generators who are burners also are subject to subsection (6) of this section.

(4) Standards applicable to transporters of dangerous waste fuel. Transporters of dangerous waste fuel (and dangerous waste that is used to produce a fuel) are subject to the requirements of WAC 173-303-240 through 173-303-270.

(5) Standards applicable to marketers of dangerous waste fuel.

Persons who market dangerous waste fuel are termed "marketers," and are subject to the following requirements. Marketers include generators who market dangerous waste fuel directly to a burner, persons who receive dangerous waste from generators and produce, process, or blend dangerous waste fuel from these dangerous wastes, and persons who distribute but do not process or blend dangerous waste fuel.

(a) Prohibitions. The prohibitions under subsection (2) of this section;

(b) Notification. Notification requirements under WAC 173-303-060 for dangerous waste fuel activities. Even if a marketer has previously notified the department of his dangerous waste management activities and obtained an EPA/state identification number, he must renotify to identify his dangerous waste fuel activities.

(c) Storage.

(i) For short term accumulation by generators who are marketers of dangerous waste fuel, the applicable provisions of WAC 173-303-200 or 173-303-201;

(ii) For all marketers who store dangerous waste fuel, the applicable storage provisions of:

(A) WAC 173-303-280 through 173-303-395;

(B) WAC 173-303-420; and

(C) WAC 173-303-800 through 173-303-840;

(iii) For marketers with interim status permits who store dangerous waste fuel, the applicable storage provisions of WAC 173-303-400 including Subparts F through L of 40 CFR Part 265;

(iv) For marketers with final status permits who store dangerous waste fuel, the applicable storage provisions of:

- (A) WAC 173-303-600 through 173-303-650; and
- (B) WAC 173-303-660.

(d) Off-site shipment. The standards for generators in WAC 173-303-170 through 173-303-230 when a marketer initiates a shipment of dangerous waste fuel;

(e) Required notices.

(i) Before a marketer initiates the first shipment of dangerous waste fuel to a burner or another marketer, he must obtain a one-time written and signed notice from the burner or marketer certifying that:

(A) The burner or marketer has notified the department under WAC 173-303-060 and identified his waste-as-fuel activities; and

(B) If the recipient is a burner, the burner will burn the dangerous waste fuel only in an industrial furnace or boiler identified in subsection (2)(b) of this section.

(ii) Before a marketer accepts the first shipment of dangerous waste fuel from another marketer, he must provide the other marketer with a one-time written and signed certification that he has notified the department under WAC 173-303-060 and identified his dangerous waste fuel activities; and

(f) Recordkeeping. In addition to the applicable recordkeeping requirements of WAC 173-303-210 and 173-303-380, a marketer must keep a copy of each certification notice he receives or sends for three years from the date he last engages in a dangerous waste fuel marketing transaction with the person who sends or receives the certification notice.

(6) Standards applicable to burners of dangerous waste fuel.

Owners and operators of industrial furnaces and boilers identified in subsection (2)(b) of this section that burn dangerous fuel are "burners" and are subject to the following requirements:

(a) Prohibitions. The prohibitions under subsection (2)(b) of this section;

(b) Notification. Notification requirements under WAC 173-303-060 for dangerous waste fuel activities. Even if a burner has previously notified the department of his dangerous waste management activities and obtained an EPA/state identification number, he must renotify to identify his dangerous waste fuel activities.

(c) Storage.

(i) For short term accumulation by generators who burn their dangerous waste fuel on site, the applicable provisions of WAC 173-303-200 or 173-303-201.

(ii) For all burners who store dangerous waste fuel, the applicable provisions of:

- (A) WAC 173-303-280 through 173-303-395;
- (B) WAC 173-303-420; and
- (C) WAC 173-303-800 through 173-303-840;

(iii) For burners under interim status permits, the applicable storage provisions of WAC 173-303-400 including Subparts F through L of 40 CFR Part 265;

(iv) For burners with final facility permits, the applicable storage provisions of:

- (A) WAC 173-303-600 through 173-303-650; and

(B) WAC 173-303-660.

(d) Required notices. Before a burner accepts the first shipment of dangerous waste fuel from a marketer, he must provide the marketer a one-time written and signed notice certifying that:

(i) He has notified the department under WAC 173-303-060 and identified his waste-as-fuel activities; and

(ii) He will burn the fuel only in a boiler or furnace identified in subsection (2)(b) of this section.

(e) Recordkeeping. In addition to the applicable recordkeeping requirements of WAC 173-303-380, a burner must keep a copy of each certification notice that he sends to a marketer for three years from the date he last receives dangerous waste fuel from that marketer.

(f) Local requirements. Any person who burns dangerous waste for energy recovery must comply with air emission requirements of the local air pollution control authority (or department of ecology if no local authority with jurisdiction exists).

#### READOPTED SECTION (Readopting Order 88-24, filed 1/4/89)

#### WAC 173-303-515 SPECIAL REQUIREMENTS FOR USED OIL BURNED FOR ENERGY RECOVERY. (1) Applicability.

(a) This section applies to used oil that is burned for energy recovery in any boiler or industrial furnace that is not regulated under Subpart O of 40 CFR Part 265 or WAC 173-303-670, if such used oil:

(i) Exhibits any characteristic of a dangerous waste identified in WAC 173-303-090; or

(ii) Is designated as DW solely through WAC 173-303-084 or 173-303-101 through 173-303-103; or

(iii) Is designated solely as W001.

(b)(i) This section does not apply to used oil burned for energy recovery that is mixed with a listed waste (except as provided in (a)(iii) of this subsection) or that is designated as EHW through WAC 173-303-084 or 173-303-101 through 173-303-103. Such used oil is subject to the requirements of WAC 173-303-510.

(ii) Used oil containing more than 1000 ppm of total halogens is presumed to be a dangerous waste because it has been mixed with halogenated dangerous waste listed in WAC 173-303-9903 or 173-303-9904. Such dangerous wastes are subject to the requirements of WAC 173-303-510. Persons may rebut this presumption by demonstrating that the used oil does not contain dangerous waste (for example, by showing that the used oil does not contain significant concentrations of halogenated dangerous constituents listed in WAC 173-303-9905).

(iii) This section does not apply to used oil that is designated for any reason other than being listed as W001 if such used oil is burned for energy recovery by the generator of the used oil in his own marine or diesel engines.

(c) If a used oil subject to this section does not exceed any of the specifications of Table 1, it is subject only to the analysis and recordkeeping requirements under subsection (4)(b)(i) and (vi) of this section; otherwise, it is subject to all applicable provisions of this section.

(d) For the purposes of this chapter:



- (i) "Used oil" means any oil that has been refined from crude oil, used, and, as a result of such use, is contaminated by physical or chemical impurities;
- (ii) Used oil fuel includes any fuel produced from used oil by processing, blending, or other treatments;
- (iii) Used oil fuel that exceeds any specification level (described in Table 1) is termed "off-specification used oil fuel."

TABLE 1

USED OIL EXCEEDING ANY SPECIFICATION LEVEL IS SUBJECT TO THIS SECTION WHEN BURNED FOR ENERGY RECOVERY

Constituent/property	Allowable level
Arsenic.....	5 ppm maximum
Cadmium.....	2 ppm maximum
Chromium .....	10 ppm maximum
Lead.....	100 ppm maximum
Flash point.....	100° F minimum
Total halogens.....	4,000 ppm maximum*
Polychlorinated Biphenyls .....	2 ppm maximum

\*Used oil containing more than 1,000 ppm total halogens is presumed to be a dangerous waste under the rebuttable presumption provided under (b)(ii) of this subsection. Such used oil is subject to WAC 173-303-510 rather than this section when burned for energy recovery unless the presumption of mixing can be successfully rebutted.

(2) Prohibitions.

(a) A person may market off-specification used oil for energy recovery only:

(i) To burners or other marketers who have notified the department of their used oil management activities stating the location and general description of such activities, and who have an EPA/state identification number; and

(ii) To burners who burn the used oil in an industrial furnace or boiler identified in (b) of this subsection.

(b) Off-specification used oil may be burned for energy recovery in only the following devices:

(i) Industrial furnaces identified in WAC 173-303-040; or

(ii) Boilers, as defined in WAC 173-303-040 that are identified as follows:

(A) Industrial boilers located on the site of a facility engaged in a manufacturing process where substances are transformed into new products, including the component parts of products, by mechanical or chemical processes;

(B) Utility boilers used to produce electric power, steam, or heated or cooled air or other gases or fluids for sale; or

(C) Used oil-fired space heaters provided that:

(I) The heater burns only used oil that the owner or operator generates or used oil received from do-it-yourself oil changers who generate used oil as household waste;

(II) The heater is designed to have a maximum capacity of not more than 0.5 million Btu per hour; and

(III) The combustion gases from the heater are vented to the ambient air.

(3) Standards applicable to generators of used oil burned for energy recovery.

(a) Except as provided in (b) and (c) of this subsection generators of used oil are not subject to this section.

(b) Generators who market used oil directly to a burner are subject to subsection (4) of this section.

(c) Generators who burn used oil are subject to subsection (5) of this section.

(4) Standards applicable to marketers of used oil burned for energy recovery.

(a) Persons who market used oil fuel are termed "marketers." However, the following persons are not marketers subject to this section:

(i) Used oil generators, and collectors who transport used oil received only from generators, unless the generator or collector markets the used oil directly to a person who burns it for energy recovery. However, persons who burn some used oil fuel for purposes of processing or other treatment to produce used oil fuel for marketing are considered to be burning incidentally to processing. Thus, generators and collectors who market to such incidental burners are not marketers subject to this section;

(ii) Persons who market only used oil fuel that meets the specification under Table 1 of subsection (1) of this section and who are not the first person to claim the oil meets the specification (i.e., marketers who do not receive used oil from generators or initial transporters and marketers who neither receive nor market off-specification used oil fuel).

(b) Marketers are subject to the following requirements:

(i) Analysis of used oil fuel. Used oil fuel is subject to regulation under this section unless the marketer obtains analyses or other information documenting that the used oil fuel meets the specification provided under Table 1 of subsection (1) of this section.

(ii) Prohibitions. The prohibitions under subsection (2)(a) of this section;

(iii) Notification. Notification to the department stating the location and general description of used oil management activities. Even if a marketer has previously notified the department of his dangerous waste management activities under WAC 173-303-060 and obtained an EPA/state identification number, he must renotify to identify his used oil management activities.

(iv) Invoice system. When a marketer initiates a shipment of off-specification used oil, he must prepare and send the receiving facility an invoice containing the following information:

(A) An invoice number;

(B) His own EPA/state identification number and the EPA/state identification number of the receiving facility;

(C) The names and addresses of the shipping and receiving facilities;

(D) The quantity of off-specification used oil to be delivered;

(E) The date(s) of shipment or delivery; and

(F) The following statement: "This used oil subject to Washington state department of ecology regulation under WAC 173-303-515;

Note: Used oil that meets the definition of combustible liquid (flash point below 200°F but at or greater than 100°F) or flammable liquid (flash point below 100°F) is subject to Department of Transportation Hazardous Materials Regulations at 49 CFR Parts 100-177.

(v) Required notices.

(A) Before a marketer initiates the first shipment of off-specification used oil to a burner or other marketer, he must obtain a one-time written and signed notice from the burner or marketer certifying that:

(I) The burner or marketer has notified the department stating the location and general description of his used oil management activities; and

(II) If the recipient is a burner, the burner will burn the off-specification used oil only in an industrial furnace or boiler identified in subsection (2)(b) of this section; and

(B) Before a marketer accepts the first shipment of off-specification used oil from another marketer subject to the requirements of this subsection, he must provide the marketer with a one-time written and signed notice certifying that he has notified the department of his used oil management activities; and

(vi) Recordkeeping.

(A) Used oil fuel that meets the specification. A marketer who first claims under (b)(i) of this subsection that used oil fuel meets the specification must keep copies of analysis (or other information used to make the determination) of used oil for three years. Such marketers must also record in an operating log and keep for three years the following information on each shipment of used oil fuel that meets the specification. Such used oil fuel is not subject to further regulation, unless it is subsequently mixed with dangerous waste or unless it is mixed with used oil so that it no longer meets the specification.

(I) The name and address of the facility receiving the shipment;

(II) The quantity of used oil fuel delivered;

(III) The date of shipment or delivery; and

(IV) A cross-reference to the record of used oil analysis (or other information used to make the determination that the oil meets the specification) required under (b)(vi)(A) of this subsection.

(B) Off-specification used oil fuel. A marketer who receives or initiates an invoice under the requirements of this section must keep a copy of each invoice for three years from the date the invoice is received or prepared. In addition, a marketer must keep a copy of each certification notice that he receives or sends for three years from the date he last engages in an off-specification used oil fuel marketing transaction with the person who sends or receives the certification notice.

(5) Standards applicable to burners of used oil burned for energy recovery.

Owners and operators of facilities that burn used oil fuel are "burners" and are subject to the following requirements:

(a) Prohibition. The prohibition under subsection (2)(b) of this section;

(b) Notification. Burners of off-specification used oil fuel must notify the department stating the location and general description of used oil management activities, except that owners and operators of used oil-fired space heaters that burn used oil fuel under the provisions of subsection (2)(b)(ii) of this section are exempt from these notification requirements. Even if a burner has previously notified the department of his dangerous waste management activities under WAC 173-303-060 and obtained an identification number, he must renotify to identify his used oil management activities.

(c) Required notices. Before a burner accepts the first shipment of off-specification used oil fuel from a marketer, he must provide the marketer a one-time written and signed notice certifying that:

(i) He has notified the department stating the location and general description of his used oil management activities; and

(ii) He will burn the used oil only in an industrial furnace or boiler identified in subsection (2)(b) of this section; and

(d) Used oil fuel analysis.

(i) Used oil fuel burned by the generator is subject to regulation under this section unless the burner obtains analysis (or other information) documenting that the used oil meets the specification provided under Table 1 of subsection (1) of this section.

(ii) Burners who treat off-specification used oil fuel by processing, blending, or other treatment to meet the specification provided under Table 1 of subsection (1) of this section must obtain analyses (or other information) documenting that the used oil meets the specification.

(e) Recordkeeping. A burner who receives an invoice under the requirements of this section must keep a copy of each invoice for three years from the date the invoice is received. Burners must also keep for three years copies of analyses of used oil fuel as may be required by (d) of this subsection. In addition, he must keep a copy of each certification notice that he sends to a marketer for three years from the date he last receives off-specification used oil from that marketer.

(f) Local requirements. Any person who burns used oil for energy recovery, except for burning in used oil-fired space heaters that meet the provisions of subsection (2)(b)(ii) of this section, must comply with the air emission requirements of the local air pollution control authority (or department of ecology if no local authority with jurisdiction exists).

**READOPTED SECTION** (Readopting Order 88-29, filed 9/6/88)

WAC 173-303-520 SPECIAL REQUIREMENTS FOR RECLAIMING SPENT LEAD ACID BATTERY WASTES. This section applies to persons who reclaim spent lead-acid batteries that are recyclable materials ("spent batteries").

(1) Persons who generate, transport, or who store spent batteries but do not reclaim them are subject only to the requirements of WAC 173-303-050, 173-303-

145 and 173-303-960 if such spent batteries are going to a battery reclaimer.

(2) Owners and operators of battery reclaiming facilities that store spent lead acid batteries prior to reclaiming them are subject to the following requirements:

(a) For all reclaimers, the applicable storage provisions of:

- (i) WAC 173-303-280 (2) and (3);
- (ii) WAC 173-303-283;
- (iii) WAC 173-303-290;
- (iv) WAC 173-303-310 through 173-303-360;
- (v) WAC 173-303-380;
- (vi) WAC 173-303-390 (2) and (3);
- (vii) WAC 173-303-395;
- (viii) WAC 173-303-420; and
- (ix) WAC 173-303-800 through 173-303-840.

(b) For reclaimers with interim status permits, the applicable storage provisions of WAC 173-303-400 including Subparts F through L of 40 CFR Part 265;

(c) For reclaimers with final facility permits, the applicable storage provisions of:

- (i) WAC 173-303-600 through 173-303-650; and
- (ii) WAC 173-303-660.

#### AMENDATORY SECTION (Amending Order DE-85-10, filed 6/3/86).

WAC 173-303-525 SPECIAL REQUIREMENTS FOR RECYCLABLE MATERIAL UTILIZED FOR PRECIOUS METAL RECOVERY. (1) Applicability and requirements.

(a) This section applies to recyclable materials that are reclaimed to recover economically significant amounts of gold, silver, platinum, (~~paladium, irridium~~) palladium, iridium, osmium, rhodium, ruthenium, or any combination of these.

(b) Persons who generate, transport, or store recyclable materials that are regulated under this section are subject to the following requirements:

(i) Notification requirements under WAC 173-303-060;

(ii) WAC 173-303-180 (for generators), 173-303-250 (for transporters), and 173-303-370 (for persons who store).

(c) Persons who store recycled materials that are regulated under this section must keep the following records to document that they are not accumulating these materials speculatively (as defined in WAC 173-303-016 (5)(d)(ii));

(i) Records showing the volume of these materials stored at the beginning of the calendar year;

(ii) The amount of these materials generated or received during the calendar year; and

(iii) The amount of materials remaining at the end of the calendar year.

(d) Recyclable materials that are regulated under this section that are accumulated speculatively (as defined in WAC 173-303-016 (5)(d)(ii)) are dangerous wastes and are subject to all applicable provisions of this chapter.

(2) Additional regulation of recyclable materials utilized for precious metal recovery on a case-by-case basis.

The department may decide on a case-by-case basis that persons accumulating or storing recyclable materials utilized for precious metal recovery should be regulated under WAC 173-303-120(4). The basis for this decision is that the materials are being accumulated or stored in a manner that does not protect human health and the environment because the materials or their toxic constituents have not been adequately contained, or because the materials being accumulated or stored together are incompatible. In making this decision, the department will consider the following factors:

(a) The types of materials accumulated or stored and the amounts accumulated or stored;

(b) The method of accumulation or storage;

(c) The length of time the materials have been accumulated or stored before being reclaimed;

(d) Whether any contaminants are being released into the environment, or are likely to be so released; and

(e) Other relevant factors.

The procedures for this decision are set forth in subsection (3) of this section.

(3) Procedures for case-by-case regulation of recyclable materials utilized for precious metal recovery.

The department will use the following procedures when determining whether to regulate recyclable materials utilized for precious metal recovery under the provisions of WAC 173-303-120(4), rather than under the provisions of subsection (1) of this section.

(a) If a generator is accumulating the waste, the department will issue a notice setting forth the factual basis for the decision and stating that the person must comply with the applicable requirements of WAC 173-303-170 and 173-303-190 through 173-303-230. The notice will become final within thirty days, unless the person served requests a public hearing to challenge the decision. Upon receiving such a request, the department will hold a public hearing. The department will provide notice of the hearing to the public and allow public participation at the hearing. The department will issue a final order after the hearing stating whether or not compliance with WAC 173-303-170 and 173-303-190 through 173-303-230 is required. The order becomes effective thirty days after service of the decision unless the department specifies a later date or unless review by the department is requested. The order may be appealed to the pollution control hearings board, in accordance with WAC 173-303-845, by any person who participated in the public hearing.

(b) If the person is accumulating the recyclable material as a storage facility, the notice will state that the person must obtain a permit in accordance with all applicable provisions of WAC 173-303-800 through 173-303-840. The owner or operator of the facility must apply for a permit within no less than sixty days and no more than six months of notice, as specified in the notice. If the owner or operator of the facility wishes to challenge the department's decision he may do so in his permit application, in a public hearing held on the draft permit, or in comments filed on the draft permit or on the notice of intent to deny the permit. The fact sheet accompanying the permit will specify the reasons for the department's determination. The question of whether the

department's decision was proper will remain open for consideration during the public comment period discussed under WAC 173-303-840 (4)(d) and in any subsequent hearing.

**AMENDATORY SECTION** (Amending Order 88-24, filed 1/4/89)

**WAC 173-303-550 SPECIAL REQUIREMENTS FOR FACILITIES MANAGING SPECIAL WASTE.**

(1) Purpose. Special wastes (as defined in WAC 173-303-040(~~(+07)~~)) pose less risk to public health and the environment than do other dangerous wastes, therefore, they do not require as high a level of regulation. The purpose of WAC 173-303-550 through 173-303-560 is to set forth those mandatory standards which are minimally acceptable for managing special waste, and the criteria and selective standards which will be applied based on the specific risks posed by such wastes.

(2) Applicability. The requirements of WAC 173-303-550 through 173-303-560 apply to owners and operators of facilities which manage special waste, and are only applicable to such special wastes as are being managed. Whenever a special waste is shipped from a facility, the owner or operator must comply with WAC 173-303-170 through 173-303-230, requirements for generators.

(3) Standards. The owner/operator of a facility managing special wastes must comply with all applicable standards of this chapter unless he requests (as described in subsection (4) of this section) and the department approves (as described in subsection (5) of this section) the application of less stringent standards to his facility. The owner/operator may request relief from any standards except those minimum standards specified in WAC 173-303-560. Failure to comply with an approval issued by the department pursuant to subsection (5) of this section, will be a violation of this chapter. Failure to comply with all applicable requirements of this chapter while the department is considering a request or after a request has been denied will be a violation of this chapter.

(4) Request. The owner/operator may request that less stringent standards be applied to his special waste management activities in any manner or form that he chooses. His request must be submitted in writing to the department, and must include:

(a) The facility name, EPA/state identification #, address, telephone number, and a contact person at the facility;

(b) The special waste(s) managed at the facility and the type(s) of management applied to them;

(c) The specific standards from which the owner/operator seeks relief;

(d) A description, for each standard, demonstrating:

(i) Why the owner/operator believes the standard to be unnecessary;

(ii) How public health and the environment will continue to be protected if the standard is not applied to the facility; and

(iii) Any evidence supporting the contention that public health and the environment will be adequately protected if the standard is not applied (e.g., test data, diagrams, experiences at similar facilities, records, reports, etc.); and

(e) The following certification, signed and dated by a person who would be authorized to sign a report under WAC 173-303-810 (12)(b):

"I certify under penalty of law that I have personally examined and am familiar with the information submitted in this request and all attachments and that, based on my inquiry of those individuals immediately responsible for obtaining the information, I believe that the information is true, accurate, and complete. I am aware that there are significant penalties for submitting false information, including the possibility of fine and imprisonment."

The department may ask for any additional information it deems necessary, and will not consider approval of the owner's/operator's request until all necessary information has been submitted. Failure to provide any of the information required by this subsection may result in the department's denying the owner's/operator's request.

(5) Approval or denial. The department will review any requests submitted pursuant to subsection (4) of this section, and based on the adequacy of the information provided in the request will approve or deny all or any part of the request. The department will notify the owner/operator of its decision in writing. Approval of a request will not be final until the permit has been modified or issued as described in (a) or (b) of this subsection. If the department decides to approve all or part of the request and the owner/operator agrees with the department's decision, then the department will proceed to grant such approval as follows:

(a) Interim status facilities. For a facility which qualifies for interim status (as described in WAC 173-303-805), the department shall issue a notice of interim status modification in accordance with WAC 173-303-805(9) stating what standards the owner/operator must meet;

(b) Final facilities.

(i) For facilities which are required to have a final facility permit, the department shall follow the procedures for issuing (or, for facilities which already have a final facility permit, the procedures for modifying) a final facility permit, as described in WAC 173-303-806. The new or modified final facility permit shall include the standards the owner/operator must meet.

(ii) The department may request that an applicant for a final facility permit submit his planned special waste demonstrations (prepared in accordance with subsection (4) of this section) a maximum of three months prior to submittal of his Part B application.

**READOPTED SECTION** (Readopting Order 88-29, filed 9/6/88)

**WAC 173-303-560 MINIMUM STANDARDS FOR FACILITIES MANAGING SPECIAL WASTE.** In no case will the department approve standards for facilities managing special waste which do not include, at a minimum, the following applicable requirements:

- (1) WAC 173-303-060;
- (2) WAC 173-303-283;
- (3) WAC 173-303-350;
- (4) WAC 173-303-360;
- (5) WAC 173-303-370;
- (6) WAC 173-303-380; and
- (7) WAC 173-303-390.

**AMENDATORY SECTION** (Amending Order 88-29, filed 9/6/88)

**WAC 173-303-600 FINAL FACILITY STANDARDS.** Purpose, scope, and applicability.

(1) The purpose of WAC 173-303-600 through ~~((173-303-670))~~ 173-303-680, is to establish minimum state-wide standards which describe the acceptable management of dangerous waste. In addition to WAC 173-303-600 through ~~((173-303-670))~~ 173-303-680, the final facility standards include WAC 173-303-280 through 173-303-395 and 173-303-420.

(2) The final facility standards apply to owners and operators of all facilities which treat, store or dispose of dangerous waste, and which are not exempted by subsection (3) of this section.

(3) The final facility standards do not apply to:

(a) Persons whose disposal activities are permitted under the Marine Protection, Research and Sanctuaries Act, except that storage, or treatment facilities where dangerous waste is loaded onto an ocean vessel for incineration or disposal at sea are subject to final facility standards;

(b) Persons whose disposal activities are permitted under the underground injection control program of the Safe Drinking Water Act, except that storage, or treatment facilities needed to handle dangerous wastes are subject to final facility standards;

(c) The owner(s) or operator(s) of a POTW(s) which treats, stores, or disposes of dangerous waste provided ~~((they follow the permit by rule))~~ he has a permit by rule pursuant to the requirements of WAC 173-303-802(4);

(d) A generator accumulating waste on site in compliance with WAC 173-303-200;

(e) The owner or operator of a facility which is permitted to manage solid waste pursuant to chapter 173-304 WAC, if the only dangerous waste the facility manages is excluded from regulation under this chapter by WAC 173-303-070(8);

(f) A farmer disposing of waste pesticides from his own use provided he complies with WAC 173-303-160 (2)(b);

(g) A transporter storing a manifested shipment of dangerous waste for ten days or less in accordance with WAC 173-303-240(5);

(h) Any person, other than an owner or operator who is already subject to the final facility standards, who is carrying out an immediate or emergency response to contain or treat a discharge or potential discharge of a dangerous waste or hazardous substance;

(i) The owner or operator of a facility which is in compliance with the interim status requirements of WAC 173-303-400 and 173-303-805, until final administrative disposition of his final facility permit;

(j) The owner or operator of a totally enclosed treatment facility or elementary neutralization or wastewater treatment unit as defined in WAC 173-303-040, provided that he ~~((complies with the))~~ has a permit by rule pursuant to the requirements of WAC 173-303-802(5); and

(k) The addition, by a generator, of absorbent material to waste in a container, or of waste to absorbent material in a container, provided that these actions occur at the time the waste is first placed in containers and the generator complies with WAC 173-303-200 (1)(b) and 173-303-395 (1)(a) and (b).

(4) The owner or operator of a final status TSD facility which manages special waste may comply with the special requirements selected under WAC 173-303-550 through 173-303-560 in lieu of the final facility standards of WAC 173-303-600 through 173-303-670, but only for those special wastes which he manages and only after the department has issued or modified his final facility permit in accordance with WAC 173-303-800 through 173-303-840 to incorporate the special requirements.

(5) The owner or operator of a facility which recycles dangerous waste may, for such recycled wastes only, comply with the applicable recycling standards specified in WAC 173-303-120 and 173-303-500 through 173-303-525 in lieu of the final facility standards.

(6) The owner or operator must comply with the special land disposal restrictions for certain dangerous wastes in WAC 173-303-140.

**AMENDATORY SECTION** (Amending Order 88-24, filed 1/4/89)

**WAC 173-303-610 CLOSURE AND POSTCLOSURE.** (1) Applicability.

(a) Subsections (2) through (6) of this section, (which concern closure), apply to the owners and operators of all dangerous waste facilities.

(b) Subsections (7) through (11) of this section, (which concern postclosure care), apply to the owners and operators of all regulated units (as defined in WAC 173-303-040~~((75))~~) at which dangerous waste will remain after closure, to tank systems that are required under WAC 173-303-640(8) to meet the requirements of landfills, to surface impoundments ~~((and))~~, waste piles, and miscellaneous units as specified in WAC 173-303-650(6) ~~((and))~~, 173-303-660(9), and 173-303-680(4), respectively and, unless otherwise authorized by the department, to the owners and operators of all facilities which, at closure, cannot meet the removal or decontamination limits specified in subsection (2)(b) of this section.

(c) For the purposes of the closure and postclosure requirements, any portion of a facility which closes is subject to the applicable closure and postclosure standards even if the rest of the facility does not close and continues to operate.

(2) Closure performance standard. The owner or operator must close the facility in a manner that:

- (a)(i) Minimizes the need for further maintenance;
- (ii) Controls, minimizes or eliminates to the extent necessary to protect human health and the environment,

postclosure escape of dangerous waste, dangerous constituents, leachate, contaminated run-off, or dangerous waste decomposition products to the ground, surface water, ground water, or the atmosphere; and

(iii) Returns the land to the appearance and use of surrounding land areas to the degree possible given the nature of the previous dangerous waste activity.

(b) Where the closure requirements of this section, or of WAC 173-303-630(10), 173-303-640(8), 173-303-650(6), 173-303-655(8), 173-303-660(9), ((~~or~~)) 173-303-670(8), or 173-303-680 (2) through (4) call for the removal or decontamination of dangerous wastes, waste residues, or equipment, bases, liners, soils or other materials containing or contaminated with dangerous wastes or waste residue, then such removal or decontamination must assure that the levels of dangerous waste or dangerous waste constituents or residues do not exceed:

(i) Background environmental levels, for any dangerous waste, managed at the facility, which either is listed under WAC 173-303-081 or 173-303-082 or is designated by the characteristics of WAC 173-303-090; and

(ii) At least the designation limits of WAC 173-303-084, or 173-303-101 through 173-303-103 for any dangerous waste, managed at the facility, which is not listed under WAC 173-303-081 or 173-303-082 and is not designated by the characteristics of WAC 173-303-090. In addition to these limits, the department may specify in the closure plan for a facility any lower limits for removal or decontamination which the department deems appropriate.

(3) Closure plan; amendment of plan.

(a) The owner or operator of a dangerous waste management facility must have a written closure plan. In addition, certain surface impoundments and waste piles from which the owner or operator intends to remove or decontaminate the dangerous waste at partial or final closure are required by WAC 173-303-650(6) and 173-303-660(9) to have contingent closure plans. The plan must be submitted with the permit application, in accordance with WAC 173-303-806(4), and approved by the department as part of the permit issuance procedures under WAC 173-303-840. The approved closure plan will become a condition of any permit. The department's decision must assure that the approved closure plan is consistent with subsections (2), (3), (4), (5), and (6) of this section, and the applicable requirements of WAC 173-303-630(10), 173-303-640(8), 173-303-650(6), 173-303-655(8), 173-303-660(9), 173-303-665(6), ((~~and~~)) 173-303-670(8), and 173-303-680(2). A copy of the approved plan and all revisions to the plan must be furnished to the department upon request, including request by mail until final closure is completed and certified in accordance with subsection (6) of this section. The plan must identify steps necessary to perform partial and/or final closure of the facility at any point during its active life. The closure plan must include at least:

(i) A description of how each dangerous waste management unit at the facility will be closed in accordance with subsection (2) of this section;

(ii) A description of how final closure of the facility will be conducted in accordance with subsection (2) of

this section. The description must identify the maximum extent of the operation which will be unclosed during the active life of the facility;

(iii) An estimate of the maximum inventory of dangerous wastes ever on-site over the active life of the facility. (Any change in this estimate is a minor modification under WAC 173-303-830(4));

(iv) A detailed description of the methods to be used during partial closures and final closure, including, but not limited to, methods for removing, transporting, treating, storing, or disposing of all dangerous wastes, and identification of the type(s) of the off-site dangerous waste management units to be used, if applicable;

(v) A detailed description of the steps needed to remove or decontaminate all dangerous waste residues and contaminated containment system components, equipment, structures, and soils during partial and final closure, including, but not limited to, procedures for cleaning equipment and removing contaminated soils, methods for sampling and testing surrounding soils, and criteria for determining the extent of decontamination required to satisfy the closure performance standard;

(vi) A detailed description of other activities necessary during the closure period to ensure that all partial closures and final closure satisfy the closure performance standards, including, but not limited to, ground water monitoring, leachate collection, and run-on and run-off control; and

(vii) A schedule for closure of each dangerous waste management unit and for final closure of the facility. The schedule must include, at a minimum, the total time required to close each dangerous waste management unit and the time required for intervening closure activities which will allow tracking of the progress of partial and final closure. (For example, in the case of a landfill unit, estimates of the time required to treat or dispose of all dangerous waste inventory and of the time required to place a final cover must be included.) Additionally, for facilities that use trust funds to establish financial assurance under WAC 173-303-620 (4) or (6) and that are expected to close prior to the expiration of the permit, an estimate of the expected year of final closure.

(b) The owner or operator must submit a written notification of or request for a permit modification to authorize a change in operating plans, facility design, or the approved closure plan in accordance with the applicable procedures in WAC 173-303-800 through 173-303-840. The written notification of or request must include a copy of the amended closure plan for review or approval by the department.

(i) The owner or operator may submit a written notification of or request to the department for a permit modification to amend the closure plan at any time prior to the notification of partial or final closure of the facility.

(ii) The owner or operator must submit a written notification of or request for a permit modification to authorize a change in the approved closure plan whenever:

(A) Changes in operating plans or facility design affect the closure plan; or

(B) There is a change in the expected year of closure, if applicable; or

(C) In conducting partial or final closure activities, unexpected events require a modification of the approved closure plan.

(iii) The owner or operator must submit a written request for a permit modification including a copy of the amended closure plan for approval at least sixty days prior to the proposed change in facility design or operation, or no later than sixty days after an unexpected event has occurred which has affected the closure plan. If an unexpected event occurs during the partial or final closure period, the owner or operator must request a permit modification no later than thirty days after the unexpected event. An owner or operator of a surface impoundment or waste pile that intends to remove all dangerous waste at closure and is not otherwise required to prepare a contingent closure plan under WAC 173-303-650(6) or 173-303-660(9), must submit an amended closure plan to the department no later than sixty days from the date that the owner or operator or department determines that the dangerous waste management unit must be closed as a landfill, subject to the requirements of WAC 173-303-665, or no later than thirty days from that date if the determination is made during partial or final closure. The department will approve, disapprove, or modify this amended plan in accordance with the procedures in WAC 173-303-800 through 173-303-840. The approved closure plan will become a condition of any permit issued.

(iv) The department may request modifications to the plan under the conditions described in (b)(ii) of this subsection. The owner or operator must submit the modified plan within sixty days of the department's request, or within thirty days if the change in facility conditions occurs during partial or final closure. Any modifications requested by the department will be approved in accordance with the procedures in WAC 173-303-800 through 173-303-840.

(c) Notification of partial closure and final closure.

(i) The owner or operator must notify the department in writing at least sixty days prior to the date on which he expects to begin closure of a surface impoundment, waste pile, land treatment, or landfill unit, or final closure of a facility with such a unit. The owner or operator must notify the department in writing at least forty-five days prior to the date on which he expects to begin final closure of a facility with only treatment or storage tanks, container storage, or incinerator units to be closed.

(ii)(A) The date when he "expects to begin closure" must be either no later than thirty days after the date on which any dangerous waste management unit receives the known final volume of dangerous wastes or, if there is a reasonable possibility that the dangerous waste management unit will receive additional dangerous wastes, no later than one year after the date on which the unit received the most recent volume of dangerous waste. If the owner or operator of a dangerous waste management unit can demonstrate to the department that the dangerous waste management unit or facility has the capacity to receive additional dangerous wastes and he has taken, and will continue to take, all steps to prevent threats to human health and the environment,

including compliance with all applicable permit requirements, the department may approve an extension to this one-year limit.

(B) For units meeting the requirements of subsection (4)(d) of this section, no later than thirty days after the date on which the dangerous waste management unit receives the known final volume of nondangerous wastes, or if there is a reasonable possibility that the dangerous waste management unit will receive additional nondangerous wastes, no later than one year after the date on which the unit received the most recent volume of nondangerous wastes. If the owner or operator can demonstrate to the department that the dangerous waste management unit has the capacity to receive additional nondangerous wastes and he has taken, and will continue to take, all steps to prevent threats to human health and the environment, including compliance with all applicable permit requirements, the department may approve an extension to this one-year limit.

(iii) If the facility's permit is terminated, or if the facility is otherwise ordered, by judicial decree or final order to cease receiving dangerous wastes or to close, then the requirements of (c) of this subsection do not apply. However, the owner or operator must close the facility in accordance with the deadlines established in subsection (4) of this section.

(iv) Removal of wastes and decontamination or dismantling of equipment. Nothing in this subsection shall preclude the owner or operator from removing dangerous wastes and decontaminating or dismantling equipment in accordance with the approved partial or final closure plan at any time before or after notification of partial or final closure.

(4) Closure; time allowed for closure.

(a) Within ninety days after receiving the final volume of dangerous wastes, or the final volume of nondangerous wastes if the owner or operator complies with all applicable requirements in (d) and (e) of this subsection, at a dangerous waste management unit or facility, the owner or operator must treat, remove from the unit or facility, or dispose of on site, all dangerous wastes in accordance with the approved closure plan. The department may approve a longer period if the owner or operator complies with all applicable requirements for requesting a modification to the permit and demonstrates that he has taken and will continue to take all steps to prevent threats to human health and the environment, including compliance with all applicable permit requirements, and either:

(i) The activities required to comply with this paragraph will, of necessity, take longer than ninety days to complete; or

(ii)(A) The dangerous waste management unit or facility has the capacity to receive additional dangerous wastes, or has the capacity to receive nondangerous wastes if the owner or operator complies with (d) and (e) of this subsection;

(B) There is a reasonable likelihood that he or another person will recommence operation of the dangerous waste management unit or the facility within one year; and



(C) Closure of the dangerous waste management unit or facility would be incompatible with continued operation of the site.

(b) The owner or operator must complete partial and final closure activities in accordance with the approved closure plan and within one hundred eighty days after receiving the final volume of dangerous wastes, or the final volume of nondangerous wastes if the owner or operator complies with all applicable requirements in (d) and (e) of this subsection, at the dangerous waste management unit or facility. The department may approve an extension to the closure period if the owner or operator complies with all applicable requirements for requesting a modification to the permit and demonstrates that he has taken and will continue to take all steps to prevent threats to human health and the environment from the unclosed but not operating dangerous waste management unit or facility, including compliance with all applicable permit requirements, and either:

(i) The partial or final closure activities will, of necessity, take longer than one hundred eighty days to complete; or

(ii)(A) The dangerous waste management unit or facility has the capacity to receive additional dangerous wastes, or has the capacity to receive nondangerous wastes if the owner or operator complies with (d) and (e) of this subsection;

(B) There is reasonable likelihood that he or another person will recommence operation of the dangerous waste management unit or the facility within one year; and

(C) Closure of the dangerous waste management unit or facility would be incompatible with continued operation of the site.

(c) The demonstrations referred to in (a) and (b) of this subsection must be made as follows: The demonstrations in (a) of this subsection must be made at least thirty days prior to the expiration of the specified ninety-day period; and the demonstration in (b) of this subsection must be made at least thirty days prior to the expiration of the specified one hundred eighty-day period unless the owner or operator is otherwise subject to the deadlines in (d) of this subsection.

(d) The department may allow an owner or operator to receive only nondangerous wastes in a landfill, land treatment, or surface impoundment unit after the final receipt of dangerous wastes at that unit if:

(i) The owner or operator requests a permit modification in compliance with all applicable requirements in WAC 173-303-830 and 40 CFR Part 124 and in the permit modification request demonstrates that:

(A) The unit has the existing design capacity as indicated on the part A application to receive nondangerous wastes; and

(B) There is a reasonable likelihood that the owner or operator or another person will receive nondangerous wastes in the unit within one year after the final receipt of dangerous wastes; and

(C) The nondangerous wastes will not be incompatible with any remaining wastes in the unit, or with the facility design and operating requirements of the unit or facility under this part; and

(D) Closure of the dangerous waste management unit would be incompatible with continued operation of the unit or facility; and

(E) The owner or operator is operating and will continue to operate in compliance with all applicable permit requirements; and

(ii) The request to modify the permit includes an amended wastes analysis plan, ground water monitoring and response program, human exposure assessment required under RCRA section 3019, and closure and postclosure plan, and updated cost estimates and demonstrations of financial assurance for closure and postclosure care as necessary and appropriate, to reflect any changes due to the presence of dangerous constituents in the nondangerous wastes, and changes in closure activities, including the expected year of closure if applicable under subsection (3)(a)(vii) of this section, as a result of the receipt of nondangerous wastes following the final receipt of dangerous wastes; and

(iii) The request to modify the permit includes revisions, as necessary and appropriate, to affected conditions of the permit to account for the receipt of nondangerous wastes following receipt of the final volume of dangerous wastes; and

(iv) The request to modify the permit and the demonstration referred to in (d)(i) and (ii) of this subsection are submitted to the department no later than one hundred twenty days prior to the date on which the owner or operator of the facility receives the known final volume of dangerous wastes at the unit, or no later than ninety days after the effective date of this rule in the state in which the unit is located, whichever is later.

(e) In addition to the requirements in (d) of this subsection, an owner or operator of a dangerous wastes surface impoundment that is not in compliance with the liner and leachate collection system requirements in 42 U.S.C. 3004 (o) (2) or (3) or 3005 (j) (2), (3), (4) or (13) must:

(i) Submit with the request to modify the permit:

(A) A contingent corrective measures plan, unless a corrective action plan has already been submitted under WAC 173-303-645(10); and

(B) A plan for removing dangerous wastes in compliance with (e)(ii) of this subsection; and

(ii) Remove all dangerous wastes from the unit by removing all dangerous liquids, and removing all dangerous sludges to the extent practicable without impairing the integrity of the liner(s), if any.

(iii) Removal of dangerous wastes must be completed no later than ninety days after the final receipt of dangerous wastes. The department may approve an extension to this deadline if the owner or operator demonstrates that the removal of dangerous wastes will, of necessity, take longer than the allotted period to complete and that an extension will not pose a threat to human health and the environment.

(iv) If a release that is a statistically significant increase (or decrease in the case of pH) over background values for detection monitoring parameters of constituents specified in the permit or that exceeds the facility's ground water protection standard at the point of compliance, if applicable, is detected in accordance with the



requirements in subpart F of this part, the owner or operator of the unit:

(A) Must implement corrective measures in accordance with the approved contingent corrective measures plan required by (e)(i) of this subsection no later than one year after detection of the release, or approval of the contingent corrective measures plan, whichever is later;

(B) May continue to receive wastes at the unit following detection of the release only if the approved corrective measures plan includes a demonstration that continued receipt of wastes will not impede corrective action; and

(C) May be required by the department to implement corrective measures in less than one year or to cease the receipt of wastes until corrective measures have been implemented if necessary to protect human health and the environment.

(v) During the period of corrective action, the owner or operator shall provide semiannual reports to the department that describe the progress of the corrective action program, compile all ground water monitoring data, and evaluate the effect of the continued receipt of non-dangerous wastes on the effectiveness of the corrective action.

(vi) The department may require the owner or operator to commence closure of the unit if the owner or operator fails to implement corrective action measures in accordance with the approved contingent corrective measures plan within one year as required in (e)(iv) of this subsection, or fails to make substantial progress in implementing corrective action and achieving the facility's ground water protection standard or background levels if the facility has not yet established a ground water protection standard.

(vii) If the owner or operator fails to implement corrective measures as required in (e)(iv) of this subsection or if the department determines that substantial progress has not been made pursuant to (e)(vi) of this subsection the department shall:

(A) Notify the owner or operator in writing that the owner or operator must begin closure in accordance with the deadline in (a) and (b) of this subsection and provide a detailed statement of reasons for this determination; and

(B) Provide the owner or operator and the public, through a newspaper notice, the opportunity to submit written comments on the decision no later than twenty days after the date of the notice.

(C) If the department receives no written comments, the decision will become final five days after the close of the comment period. The department will notify the owner or operator that the decision is final, and that a revised closure plan, if necessary, must be submitted within fifteen days of the final notice and that closure must begin in accordance with the deadlines in (a) and (b) of this subsection.

(D) If the department receives written comments on the decision, it shall make a final decision within thirty days after the end of the comment period, and provide the owner or operator in writing and the public through a newspaper notice, a detailed statement of reasons for the final decision. If the department determines that

substantial progress has not been made, closure must be initiated in accordance with the deadlines in (a) and (b) of this subsection.

(E) The final determinations made by the department under (e)(vii)(C) and (D) of this subsection are not subject to administrative appeal.

(5) Disposal or decontamination of equipment, structures and soils. During the partial and final closure periods, all contaminated equipment, structures and soils must be properly disposed of or decontaminated unless otherwise specified in WAC 173-303-640(8), 173-303-650(6), 173-303-655(8), 173-303-660(9), 173-303-665(6), or under the authority of WAC 173-303-680 (2) and (4). By removing any dangerous wastes or dangerous constituents during partial and final closure, the owner or operator may become a generator of dangerous waste and must handle that waste in accordance with all applicable requirements of WAC 173-303-170 through 173-303-230.

(6) Certification of closure. Within sixty days of completion of closure of each dangerous waste ((~~surface impoundment, waste pile, land treatment, and landfill~~) management unit (including tank systems and container storage areas), and within sixty days of the completion of final closure, the owner or operator must submit to the department by registered mail, a certification that the dangerous waste management unit or facility, as applicable, has been closed in accordance with the specifications in the approved closure plan. The certification must be signed by the owner or operator and by an independent registered professional engineer. Documentation supporting the independent registered professional engineer's certification must be furnished to the department upon request until it releases the owner or operator from the financial assurance requirements for closure under WAC 173-303-620(4).

(7) Postclosure care and use of property.

(a) Postclosure care for each dangerous waste management unit subject to postclosure requirements must begin after completion of closure of the unit and continue for thirty years after that date and must consist of at least the following:

(i) Ground water monitoring and reporting as applicable; and

(ii) Maintenance and monitoring of waste containment systems as applicable.

(b) Any time preceding partial closure of a dangerous waste management unit subject to postclosure care requirements or final closure, or any time during the postclosure period for a particular unit, the department may, in accordance with the permit modification procedures in WAC 173-303-800 through 173-303-840:

(i) Shorten the postclosure care period applicable to the dangerous waste management unit, or facility, if all disposal units have been closed, if it finds that the reduced period is sufficient to protect human health and the environment (e.g., leachate or ground water monitoring results, characteristics of the dangerous waste, application of advanced technology, or alternative disposal, treatment, or reuse techniques indicate that the dangerous waste management unit or facility is secure); or

(ii) Extend the postclosure care period applicable to the dangerous waste management unit or facility if it finds that the extended period is necessary to protect human health and the environment (e.g., leachate or ground water monitoring results indicate a potential for migration of dangerous waste at levels which may be harmful to human health and the environment).

(c) The department may require, at partial or final closure, continuation of any of the security requirements of WAC 173-303-310 during part or all of the postclosure period when:

(i) Dangerous wastes may remain exposed after completion of partial or final closure; or

(ii) Access by the public or domestic livestock may pose a hazard to human health.

(d) Postclosure use of property on or in which dangerous wastes remain after partial or final closure must never be allowed to disturb the integrity of the final cover, liner(s), or any other components of any containment system, or the function of the facility's monitoring systems, unless the department finds that the disturbance:

(i) Is necessary to the proposed use of the property, and will not increase the potential hazard to human health or the environment; or

(ii) Is necessary to reduce a threat to human health or the environment.

(e) All postclosure care activities must be in accordance with the provisions of the approved postclosure plan as specified in subsection (8) of this section.

(8) Postclosure plan; amendment of plan.

(a) The owner or operator of a dangerous waste disposal unit must have a written postclosure plan. In addition, certain surface impoundments and certain piles from which the owner or operator intends to remove or decontaminate the dangerous wastes at partial or final closure are required by WAC 173-303-650 and 173-303-660, respectively, to have written contingent postclosure plans. Owners or operators of surface impoundments and waste piles not otherwise required to prepare contingent postclosure plans under WAC 173-303-650 or 173-303-660 must submit a postclosure plan to the department within ninety days from the date that the owner or operator or department determines that the dangerous waste management unit must be closed as a landfill, subject to the postclosure requirements. The plan must be submitted with the permit application, in accordance with WAC 173-303-806, and approved by the department as part of the permit issuance procedures under WAC 173-303-840. The approved postclosure plan will become a condition of any permit issued.

(b) For each dangerous waste management unit subject to the requirements of this subsection, the postclosure plan must identify the activities which will be carried on after closure and the frequency of these activities, and include at least:

(i) A description of the planned ground water monitoring activities and frequencies at which they will be performed;

(ii) A description of the planned maintenance activities, and frequencies at which they will be performed, to ensure:

(A) The integrity of the cap and final cover or other containment structures where applicable; and

(B) The function of the facility monitoring equipment;

(iii) And the name, address, and phone number of the person or office to contact about the dangerous waste disposal unit or facility during the postclosure care period.

(c) Until final closure of the facility, a copy of the approved postclosure plan must be furnished to the department upon request, including request by mail. After final closure has been certified, the person or office specified in (b)(iii) of this subsection must keep the approved postclosure plan during the remainder of the postclosure period.

(d) Amendment of plan. The owner or operator must submit a written notification of or request for a permit modification to authorize a change in the approved postclosure plan in accordance with the applicable requirements of WAC 173-303-800 through 173-303-840. The written notification or request must include a copy of the amended postclosure plan for review or approval by the department.

(i) The owner or operator may submit a written notification or request to the department for a permit modification to amend the postclosure plan at any time during the active life of the facility or during the postclosure care period.

(ii) The owner or operator must submit a written notification of or request for a permit modification to authorize a change in the approved postclosure plan whenever:

(A) Changes in operating plans or facility design affect the approved postclosure plan; or

(B) There is a change in the expected year of final closure, if applicable; or

(C) Events which occur during the active life of the facility, including partial and final closures, affect the approved postclosure plan.

(iii) The owner or operator must submit a written request for a permit modification at least sixty days prior to the proposed change in facility design or operation, or no later than sixty days after an unexpected event has occurred which has affected the postclosure plan. An owner or operator of a surface impoundment or waste pile that intends to remove all dangerous waste at closure and is not otherwise required to submit a contingent postclosure plan under WAC 173-303-650 or 173-303-660 must submit a postclosure plan to the department no later than ninety days after the date that the owner or operator or department determines that the dangerous waste management unit must be closed as a landfill, subject to the requirements of WAC 173-303-665. The department will approve, disapprove, or modify this plan in accordance with the procedures in WAC 173-303-800 through 173-303-840. The approved postclosure plan will become a permit condition.

(iv) The department may request modifications to the plan under the conditions described in (d)(ii) of this subsection. The owner or operator must submit the modified plan no later than sixty days after the department's request, or no later than ninety days if the unit is

a surface impoundment or waste pile not previously required to prepare a contingent postclosure plan. Any modifications requested by the department will be approved, disapproved, or modified in accordance with the procedures in WAC 173-303-800 through 173-303-840.

(9) Notice to local land authority. No later than the submission of the certification of closure of each dangerous waste disposal unit, the owner or operator of a disposal facility must submit to the local zoning authority or the authority with jurisdiction over local land use and to the department a survey plat indicating the location and dimensions of landfill cells or other dangerous waste disposal units with respect to permanently surveyed benchmarks. This plat must be prepared and certified by a professional land surveyor. The plat filed with the local zoning authority or the authority with jurisdiction over local land use must contain a note, prominently displayed, which states the owner's or operator's obligation to restrict disturbance of the dangerous waste disposal unit in accordance with the applicable requirements of this section. In addition, no later than sixty days after certification of closure of each dangerous waste disposal unit, the owner or operator must submit to the local zoning authority or the authority with jurisdiction over local land use and to the department, a record of the type, location, and quantity of dangerous wastes disposed of within each cell or other disposal unit of the facility. For wastes disposed of before November 19, 1980 (March 12, 1982, for facilities subject to this chapter but not subject to 40 CFR Part 264), the owner or operator must identify the type, location, and quantity of the dangerous wastes to the best of his knowledge and in accordance with any records he has kept.

(10) Notice in deed to property.

(a) No later than sixty days after certification of closure of each dangerous waste disposal unit, the owner or operator must submit to the local zoning authority, or the authority with jurisdiction over local land use, and to the department a record of the type, location, and quantity of dangerous wastes disposed of within each cell or other disposal unit of the facility. For hazardous wastes (as defined in WAC 173-303-040((39))) disposed of before January 12, 1981, the owner or operator must identify the type, location, and quantity of the dangerous wastes to the best of his knowledge and in accordance with any records he has kept.

(b) Within sixty days of certification of closure of the first dangerous waste disposal unit and within sixty days of certification of closure of the last dangerous waste disposal unit, the owner or operator must:

(i) Record, in accordance with state law, a notation on the deed to the facility property, or on some other instrument which is normally examined during title search, that will in perpetuity notify any potential purchaser of the property that:

(A) The land has been used to manage dangerous wastes;

(B) Its use is restricted under this section; and

(C) The survey plat and record of the type, location, and quantity of dangerous wastes disposed of within each cell or other dangerous waste disposal unit of the

facility required in subsection (9) of this section have been filed with the local zoning authority, or the authority with jurisdiction over local land use, and with the department; and

(ii) Submit a certification, signed by the owner or operator, that he has recorded the notation specified in (b)(i) of this subsection, including a copy of the document in which the notation has been placed, to the department.

(c) If the owner or operator or any subsequent owner of the land upon which a dangerous waste facility was located wishes to remove dangerous wastes and dangerous waste residues, the liner, if any, or contaminated soils, he must request a modification to the postclosure permit in accordance with the applicable requirements in WAC 173-303-800 through 173-303-840. The owner or operator must demonstrate that the removal of dangerous wastes will satisfy the criteria of subsection (7)(d) of this section. By removing dangerous waste, the owner or operator may become a generator of dangerous waste and must manage it in accordance with all applicable requirements of this chapter. If he is granted a permit modification or otherwise granted approval to conduct such removal activities, the owner or operator may request that the department approve either:

(i) The removal of the notation on the deed to the facility property or other instrument normally examined during title search; or

(ii) The addition of a notation to the deed or instrument indicating the removal of the dangerous waste.

(11) Certification of completion of postclosure care. No later than sixty days after completion of the established postclosure care period for each dangerous waste disposal unit, the owner or operator must submit to the department, by registered mail, a certification that the postclosure care period for the dangerous waste disposal unit was performed in accordance with the specifications in the approved postclosure plan. The certification must be signed by the owner or operator and an independent registered professional engineer. Documentation supporting the independent registered professional engineer's certification must be furnished to the department upon request until he releases the owner or operator from the financial assurance requirements for postclosure care under WAC 173-303-620(6).

#### AMENDATORY SECTION (Amending Order 88-24, filed 1/4/89)

#### WAC 173-303-620 FINANCIAL REQUIREMENTS. (1) Applicability.

(a) The requirements of subsections (3), (4), (7), (8), (9), and (10) of this section, apply to owners and operators of all dangerous waste facilities, except as provided otherwise in this section.

(b) The requirements of subsections (5) and (6) of this section apply only to owners and operators of dangerous waste disposal facilities, to tank systems that are required under WAC 173-303-640(8) to meet the requirements of landfills, to miscellaneous units as specified in WAC 173-303-680(4), and to piles and surface impoundments to the extent that WAC 173-303-650

and 173-303-660, respectively, require that such facilities comply with this section.

(c) States and the federal government are exempt from the requirements of this section, except that operators of facilities who are under contract with the state or federal government must meet the requirements of this section.

(2) Definitions. As used in this section, the following listed or referenced terms shall have the meanings given below:

(a) "Closure plan" means the plan for closure prepared in accordance with the requirements of WAC 173-303-610(3);

(b) "Current closure cost estimate" means the most recent of the estimates prepared in accordance with subsection (3) of this section;

(c) "Current postclosure cost estimate" means the most recent of the estimates prepared in accordance with subsection (5) of this section;

(d) "Parent corporation" means a corporation which directly owns at least fifty percent of the voting stock of the corporation which is the facility owner or operator; the latter corporation is deemed a "subsidiary" of the parent corporation;

(e) "Postclosure plan" means the plan for postclosure care prepared in accordance with the requirements of WAC 173-303-610 (7), (8), (9), and (10);

(f) "Regional administrator" means the department;

(g) "Hazardous waste" means dangerous waste; and

(h) The additional terms listed and defined in 40 CFR 264.141 (f) (~~and~~), (g), and (h) are adopted by reference.

(3) Cost estimate for facility closure.

(a) The owner or operator must have a detailed written estimate, in current dollars, of the cost of closing the facility in accordance with the requirements in WAC 173-303-610 (2) through (6), and applicable closure requirements in WAC 173-303-630(10), 173-303-640(5), 173-303-650(6), 173-303-655(8), 173-303-660(9), 173-303-665(6), (~~and~~) 173-303-670(8), and 173-303-680 (2) through (4). The closure cost estimate:

(i) Must equal the cost of closure at the point in the facility's operating life when the extent and manner of its operation would make closure the most expensive, as indicated by its closure plan (see WAC 173-303-610 (3)(a));

(ii) Must be based on the costs to the owner or operator of hiring a third party to close the facility. A third party is a party who is neither a parent nor a subsidiary of the owner or operator. (See definition of parent corporation in subsection (2)(d) of this section.) The owner or operator may use costs for on-site disposal if he can demonstrate that on-site disposal capacity will exist at all times over the life of the facility;

(iii) May not incorporate any salvage value that may be realized with the sale of dangerous wastes, or nondangerous wastes if applicable under WAC 173-303-610 (4)(d), facility structures or equipment, land, or other assets associated with the facility at the time of partial or final closure; and

(iv) May not incorporate a zero cost for dangerous wastes, or nondangerous wastes if applicable under

WAC 173-303-610 (4)(d), that might have economic value.

(b) During the active life of the facility, the owner or operator must revise the closure cost estimate no later than thirty days after the department has approved the request to modify the closure plan, if the change in the closure plan increases the cost of closure. The revised closure cost estimate must be adjusted for inflation as specified in (c)(i) and (ii) of this subsection.

(c) During the active life of the facility, the owner or operator must adjust the closure cost estimate for inflation within sixty days prior to the anniversary date of the establishment of the financial instrument(s) used to comply with this section. For owners and operators using the financial test or corporate guarantee, the closure cost estimate must be updated for inflation within thirty days after the close of the firm's fiscal year and before submission of updated information to the department as specified in subsection (4) of this section. The adjustment may be made by recalculating the maximum costs of closure in current dollars, or by using an inflation factor derived from the most recent Implicit Price Deflator for Gross National Product as published by the United States Department of Commerce in its survey of current business. The inflation factor is the result of dividing the latest published annual deflator by the deflator for the previous year.

(i) The first adjustment is made by multiplying the closure cost estimate by the inflation factor. The result is the adjusted closure cost estimate.

(ii) Subsequent adjustments are made by multiplying the latest adjusted closure cost estimate by the latest inflation factor.

(d) During the operating life of the facility, the owner or operator must keep at the facility the latest closure cost estimate prepared in accordance with (a) and (b) of this subsection, and, when this estimate has been adjusted in accordance with (c) of this subsection, the latest adjusted closure cost estimate.

(4) Financial assurance for facility closure.

(a) An owner or operator of a TSD facility must establish financial assurance for closure of the facility. The owner or operator must choose from the following options or combination of options:

(i) Closure trust fund;

(ii) Surety bond guaranteeing payment into a closure trust fund;

(iii) Surety bond guaranteeing performance of closure;

(iv) Closure letter of credit;

(v) Closure insurance; or

(vi) Financial test and corporate guarantee for closure.

(b) In satisfying the requirements of financial assurance for facility closure in this subsection, the owner or operator shall meet all the requirements set forth in 40 CFR 264.143.

(5) Cost estimate for postclosure monitoring and maintenance.

(a) The owner or operator of a facility subject to postclosure monitoring or maintenance requirements must have a detailed written estimate, in current dollars,

of the annual cost of postclosure monitoring and maintenance of the facility in accordance with the applicable postclosure regulations in WAC 173-303-610 (7) through (10), 173-303-650(6), 173-303-655(8), 173-303-660(9), ~~((and))~~ 173-303-665(6), and 173-303-680(4). The postclosure cost estimate must be based on the costs to the owner or operator of hiring a third party to conduct postclosure care activities. A third party is a party who is neither a parent nor a subsidiary of the owner or operator. (See definition of parent corporation in subsection (2)(d) of this section.) The postclosure cost estimate is calculated by multiplying the annual postclosure cost estimate by the number of years of postclosure care required by WAC 173-303-610.

(b) During the active life of the facility, the owner or operator must revise the postclosure cost estimate within thirty days after the department has approved the request to modify the postclosure plan, if the change in the postclosure plan increases the cost of postclosure care. The revised postclosure cost estimate must be adjusted for inflation as specified in (c)(i) and (ii) of this subsection.

(c) During the active life of the facility, the owner or operator must adjust the postclosure cost estimate for inflation within sixty days prior to the anniversary date of the establishment of the financial instrument(s) used to comply with subsection (6) of this section. For owners or operators using the financial test or corporate guarantee, the postclosure cost estimate must be updated for inflation within thirty days after the close of the firm's fiscal year and before the submission of updated information to the department as specified in subsection (6) of this section. The adjustment may be made by recalculating the postclosure cost estimate in current dollars or by using an inflation factor derived from the most recent Implicit Price Deflator for Gross National Product as published by the United States Department of Commerce in its Survey of Current Business. The inflation factor is the result of dividing the latest published annual deflator by the deflator for the previous year.

(i) The first adjustment is made by multiplying the postclosure cost estimate by the inflation factor. The result is the adjusted postclosure cost estimate.

(ii) Subsequent adjustments are made by multiplying the latest adjusted postclosure cost estimate by the latest inflation factor.

(d) During the operating life of the facility, the owner or operator must keep at the facility the latest postclosure cost estimate prepared in accordance with (a) and (b) of this subsection, and, when this estimate has been adjusted in accordance with (c) of this subsection, the latest adjusted postclosure cost estimate.

(6) Financial assurance for postclosure monitoring and maintenance.

(a) An owner or operator of a facility subject to postclosure monitoring or maintenance requirements must establish financial assurance for postclosure care in accordance with the approved postclosure care plan. He must choose from the following options or combination of options:

(i) Postclosure trust fund;

(ii) Surety bond guaranteeing payment into a postclosure trust fund;

(iii) Surety bond guaranteeing performance of postclosure care;

(iv) Postclosure letter of credit;

(v) Postclosure insurance; or

(vi) Financial test and corporate guarantee for postclosure care.

(b) In satisfying the requirements of financial assurance for facility postclosure care in this subsection, the owner or operator shall meet all the requirements set forth in 40 CFR 264.145.

(7) Use of a mechanism for financial assurance of both closure and postclosure care. An owner or operator may satisfy the requirements for financial assurance for both closure and postclosure care for one or more facilities by using a trust fund, surety bond, letter of credit, insurance, financial test, or corporate guarantee that meets the specifications for the mechanism in both 40 CFR 264.143 and 264.145. The amount of funds available through the mechanism must be no less than the sum of funds that would be available if a separate mechanism had been established and maintained for financial assurance of closure and of postclosure care.

(8) Liability requirements.

(a) An owner or operator of a TSD facility or a group of such facilities must demonstrate financial responsibility for bodily injury and property damages to third parties caused by sudden accidental occurrences arising from operations of the facility or group of facilities. The owner or operator must meet the requirements of 40 CFR 264.147(a) ~~((or, when applicable, (g)))~~.

(b) An owner or operator of a facility with a regulated unit or units (as defined in WAC 173-303-040~~((75)))~~ or a disposal miscellaneous unit or units used to manage dangerous waste or a group of such facilities must demonstrate financial responsibility for bodily injury and property damage to third parties caused by nonsudden accidental occurrences arising from operations of the facility or group of facilities. The owner or operator must meet the requirements of 40 CFR 264.147(b) ~~((or, when applicable, (g)))~~.

(c) Request for variance. If an owner or operator can demonstrate to the satisfaction of the department that the levels of financial responsibility required by (a) or (b) of this subsection are not consistent with the degree and duration of risk associated with treatment, storage, or disposal at the facility or group of facilities, the owner or operator may obtain a variance from the department. The request for a variance must be submitted to the department as part of the application under WAC 173-303-806(4) for a facility that does not have a permit, or pursuant to the procedures for permit modification under WAC 173-303-830 for a facility that has a permit. If granted, the variance will take the form of an adjusted level of required liability coverage, such level to be based on the department's assessment of the degree and duration of risk associated with the ownership or operation of the facility or group of facilities. The department may require an owner or operator who requests a variance to provide such technical and engineering information as is

deemed necessary by the department to determine a level of financial responsibility other than that required by (a) or (b) of this subsection. Any request for a variance for a permitted facility will be treated as a request for a permit modification under WAC 173-303-830.

(d) Adjustments by the department. If the department determines that the levels of financial responsibility required by (a) or (b) of this subsection are not consistent with the degree and duration of risk associated with treatment, storage, or disposal at the facility or group of facilities, the department may adjust the level of financial responsibility required under (a) or (b) of this subsection as may be necessary to protect human health and the environment. This adjusted level will be based on the department's assessment of the degree and duration of risk associated with the ownership or operation of the facility or group of facilities. In addition, if the department determines that there is a significant risk to human health and the environment from nonsudden accidental occurrences resulting from the operations of a facility that has no regulated units (as defined in WAC 173-303-040((75))), it may require that the owner or operator of the facility comply with (b) of this subsection. An owner or operator must furnish to the department within a reasonable time, any information which the department requests to determine whether cause exists for such adjustments of level or type of coverage. Any adjustments of level or type of coverage for a facility that has a permit will be treated as a permit modification under WAC 173-303-830.

(e) Period of coverage. An owner or operator must continuously provide liability coverage for a facility as required by this subsection until certifications of closure of the facility, as specified in WAC 173-303-610(6), are received by the department.

(9) Incapacity of owners or operators, guarantor or financial institutions.

(a) An owner or operator must notify the department by certified mail of the commencement of a voluntary or involuntary proceeding under Title 11 (Bankruptcy), United States Code, naming the owner or operator as debtor, within ten days after commencement of the proceeding. A guarantor of a corporate guarantee as specified in 40 CFR 264.143(f) and 264.145(f) must make such a notification if he is named as debtor, as required under the terms of the corporate guarantee (40 CFR 264.151(h)).

(b) An owner or operator who fulfills the requirements of 40 CFR 264.143, 264.145, or 264.147 (a) or (b) by obtaining a trust fund, surety bond, letter of credit, or insurance policy will be deemed to be without the required financial assurance or liability coverage in the event of bankruptcy of the trustee or issuing institution, or a suspension or revocation of the authority of the trustee institution to act as trustee or of the institution issuing the surety bond, letter of credit, or insurance policy to issue such instruments. The owner or operator must establish other financial assurance or liability coverage within sixty days after such an event.

(10) Wording of the instruments. The financial instruments required by this section shall contain the wording specified by 40 CFR 264.151, except that:

(a) The words "regional administrator" and "environmental protection agency" must be replaced with the word "department";

(b) The words "hazardous waste" must be replaced with the words "dangerous waste"; and

(c) Any other words specified by the department shall be changed as necessary to assure financial responsibility of the facility in accordance with the requirements of this section.

Copies of the financial instruments with the appropriate word changes will be available from the department by June 30, 1984.

#### AMENDATORY SECTION (Amending Order DE-85-10, filed 6/3/86)

WAC 173-303-630 USE AND MANAGEMENT OF CONTAINERS. (1) Applicability. The regulations in this section apply to owners and operators of all dangerous waste facilities that store containers of dangerous waste.

(2) Condition of containers. If a container holding dangerous waste is not in good condition (e.g., severe rusting, apparent structural defects) or if it begins to leak, the owner or operator must transfer the dangerous waste from the container to a container that is in good condition or manage the waste in some other way that complies with the requirements of chapter 173-303 WAC. In addition, the owner or operator must address leaks and spills in accordance with the applicable provisions of WAC 173-303-145 and 173-303-360.

(3) Identification of containers. The owner or operator must label containers in a manner which adequately identifies the major risk(s) associated with the contents of the containers for employees, emergency response personnel and the public (Note—If there is already a system in use that performs this function in accordance with local, state or federal regulations, then such system will be adequate). The owner or operator must affix labels upon transfer of dangerous wastes from one container to another. The owner or operator must destroy or otherwise remove labels from the emptied container, unless the container will continue to be used for storing dangerous waste at the facility. The owner or operator must ensure that labels are not obscured, removed, or otherwise unreadable in the course of inspection required under WAC 173-303-320.

(4) Compatibility of waste with containers. The owner or operator must use a container made of or lined with materials which will not react with, and are otherwise compatible with, the dangerous waste to be stored, so that the ability of the container to contain the waste is not impaired.

(5) Management of containers.

(a) A container holding dangerous waste must always be closed, except when it is necessary to add or remove waste.

(b) A container holding dangerous waste must not be opened, handled, or stored in a manner which may rupture the container or cause it to leak.

(c) A minimum thirty-inch separation is required between aisles of containers holding dangerous waste(s). A row of drums must be no more than two drums wide.

(6) Inspections. At least weekly, the owner or operator must inspect areas where containers are stored, looking for leaking containers and for deterioration of containers and the containment system caused by corrosion, deterioration, or other factors.

(7) Containment.

(a) Container storage areas must have a containment system that is capable of collecting and holding spills and leaks. In addition to the necessary leak containment capacity, uncovered storage areas must be capable of holding the additional volume that would result from the precipitation of a maximum twenty-five year storm of twenty-four hours duration. The containment system must:

(i) Have a base underlying the containers which is free of cracks or gaps and is sufficiently impervious to contain leaks, spills, and accumulated rainfall until the collected material is detected and removed. The base must be sloped or the containment system must be otherwise designed and operated to drain and remove liquids resulting from leaks, spills, or precipitation, unless the containers are elevated or are otherwise protected from contact with accumulated liquids;

(ii) Be designed for positive drainage control (such as a locked drainage valve) to prevent release of contaminated liquids and so that uncontaminated precipitation can be drained promptly for convenience of operation. Spilled or leaked waste and accumulated precipitation must be removed from the containment system in as timely a manner as is necessary to prevent overflow; and

(iii) Have sufficient capacity to contain ten percent of the volume of all containers or the volume of the largest container, whichever is greater. Only containers holding free liquids, or holding wastes designated as F020, F021, F022, F023, F026, or F027 need to be considered in this determination.

(b) Run-on into the containment system must be prevented, unless the department waives this requirement in the permit after determining that the collection system has sufficient excess capacity in addition to that required in (a)(iii) of this subsection to accommodate any run-on which might enter the system.

(c) Storage areas that store containers holding only wastes that do not contain free liquids, do not exhibit either the characteristic of ignitability or reactivity as described in WAC 173-303-090 (5) or (7), and are not designated as F020, F021, F022, F023, F026, or F027, need not have a containment system as described in this subsection: PROVIDED, That:

(i) The storage area is sloped or is otherwise designed and operated to drain and remove liquid resulting from precipitation; or

(ii) The containers are elevated or are otherwise protected from contact with accumulated liquids.

(d) EHW in containers must be protected from the elements by means of a building or other protective covering that otherwise allows adequate inspection under subsection (6) of this section.

(8) Special requirements for ignitable or reactive waste.

(a) Containers holding reactive waste exhibiting a characteristic specified in WAC 173-303-090 (7)(a)(vi),

(vii) or (viii) must be stored in a manner equivalent to the Uniform Fire Code's "American Table of Distances for Storage of Explosives," Table 77-201, 1979 edition.

(b) The owner or operator shall design, operate, and maintain ignitable waste and reactive waste (other than a reactive waste which must meet (a) of this subsection) container storage in a manner equivalent with the Uniform Fire Code. Where no specific standard or requirements are specified in the Uniform Fire Code, or in existing state or local fire codes, applicable sections of the NFPA Pamphlet # 30, "Flammable and Combustible Liquids Code," shall be used. The owner/operator shall also comply with the requirements of WAC 173-303-395 (1)(d).

(9) Special requirements for incompatible wastes.

(a) Incompatible wastes, or incompatible wastes and materials must not be placed in the same container, unless WAC 173-303-395 (1)(b) is complied with.

(b) Dangerous waste must not be placed in an unwashed container that previously held an incompatible waste or material.

(c) A storage container holding a dangerous waste that is incompatible with any waste or other materials stored nearby in other containers, piles, open tanks, or surface impoundments must be separated from the other materials or protected from them by means of a dike, berm, wall, or other device. Containment systems for incompatible wastes shall be separate.

(10) Closure. At closure, all dangerous waste and dangerous waste residues must be removed from the containment system. Remaining containers, liners, bases, and soil containing or contaminated with dangerous waste or dangerous waste residues must be decontaminated or removed.

AMENDATORY SECTION (Amending Order 88-24, filed 1/4/89)

WAC 173-303-645 ((GROUND WATER PROTECTION)) RELEASES FROM SOLID WASTE MANAGEMENT UNITS. (1) Applicability.

(a)(i) Except as provided in (b) of this subsection, the regulations in this section apply to owners and operators of facilities that treat, store, or dispose of dangerous waste ((in surface impoundments, waste piles, land treatment units, or landfills)). The owner or operator must satisfy the requirements ((of this section)) identified in (a)(ii) of this subsection for all wastes (or constituents thereof) contained in ((any such waste management unit at the facility that is a "regulated unit" (as defined in WAC 173-303-040(75))). Any waste or waste constituent migrating beyond the waste management area under subsection (6)(b) of this section, is assumed to originate from a regulated unit unless the owner or operator can prove to the satisfaction of the department that such waste or waste constituent originated from another source.

(b) The owner or operator is not subject to regulation under this section if:

(i) He designs and operates a surface impoundment in compliance with WAC 173-303-650(3) (except as provided for surface impoundments treating or storing EHW), a pile in compliance with WAC 173-303-660



~~(1)(c), (3), or (4), or a landfill in compliance with WAC 173-303-665(3);~~

~~((ii)) solid waste management units at the facility, regardless of the time at which waste was placed in such units.~~

~~((ii)) All solid waste management units must comply with the requirements in subsection (12) of this section. Regulated units (as defined in WAC 173-303-040) must comply with the requirements of subsections (2) through (11) of this section, in lieu of subsection (12) of this section, for purposes of detecting, characterizing, and responding to releases to the uppermost aquifer. The financial responsibility requirements of subsection (12) of this section apply to regulated units.~~

~~(b) The owner or operator's regulated unit or units are not subject to regulation for releases into the uppermost aquifer under this section if:~~

~~(i) The owner or operator is exempted under WAC 173-303-600; or~~

~~(ii) He operates a unit which the department finds:~~

~~(A) Is an engineered structure;~~

~~(B) Does not receive or contain liquid waste or waste containing free liquids;~~

~~(C) Is designed and operated to exclude liquid, precipitation, and other run-on and run-off;~~

~~(D) Has both inner and outer layers of containment enclosing the waste;~~

~~(E) Has a leak detection system built into each containment layer;~~

~~(F) The owner or operator will provide continuing operation and maintenance of these leak detection systems during the active life of the unit and the closure and post-closure care periods; and~~

~~(G) To a reasonable degree of certainty, will not allow dangerous constituents to migrate beyond the outer containment layer prior to the end of the post-closure care period.~~

~~((iii)) The department finds, pursuant to WAC 173-303-655 (8)(d), that the treatment zone of a land treatment unit does not contain levels of dangerous constituents that are above background levels of those constituents by an amount that is statistically significant, and if an unsaturated zone monitoring program meeting the requirements of WAC 173-303-655(6) has not shown a statistically significant increase in dangerous constituents below the treatment zone during the operating life of the unit. An exemption under this subsection can only relieve an owner or operator of responsibility to meet the requirements of this section during the postclosure care period; or~~

~~((((iii))) (iv) The department finds that there is no potential for migration of liquid from a regulated unit to the uppermost aquifer during the active life of the regulated unit (including the closure period) and the postclosure care period. This demonstration must be certified by a qualified geologist or geotechnical engineer. In order to provide an adequate margin of safety in the prediction of potential migration of liquid, the owner or operator must base any predictions made under this subsection on assumptions that maximize the rate of liquid migration.~~

(c) The regulations under this section apply during the active life of the regulated unit (including the closure period). After closure of the regulated unit, the regulations in this section:

(i) Do not apply if all waste, waste residues, contaminated containment system components, and contaminated subsoils are removed or decontaminated at closure in accordance with the removal or decontamination limits specified in WAC 173-303-610 (2)(b);

(ii) Apply during the postclosure care period if the owner or operator is conducting a detection monitoring program under subsection (9) of this section; and

(iii) Apply during the compliance period under subsection (7) of this section, if the owner or operator is conducting a compliance monitoring program under subsection (10) of this section, or a corrective action program under subsection (11) of this section.

~~(d) Regulations in this section may apply to miscellaneous units when necessary to comply with WAC 173-303-680 (2) through (4).~~

~~(2) Required programs.~~

(a) Owners and operators subject to this section must conduct a monitoring and response program as follows:

(i) Whenever dangerous constituents under subsection (4) of this section, from a regulated unit are detected at the compliance point under subsection (6) of this section, the owner or operator must institute a compliance monitoring program under subsection (10) of this section. Detected is defined as statistically significant evidence of contamination as described in subsection (9)(g) of this section;

(ii) Whenever the ground water protection standard under subsection (3) of this section, is exceeded, the owner or operator must institute a corrective action program under subsection (11) of this section. Exceeded is defined as statistically significant evidence of increased contamination as described in subsection (10)(h) of this section;

(iii) Whenever dangerous constituents under subsection (4) of this section, from a regulated unit exceed concentration limits under subsection (5) of this section, in ground water between the compliance point under subsection (6) of this section and the downgradient facility property boundary, the owner or operator must institute a corrective action program under subsection (11) of this section; and

(iv) In all other cases, the owner or operator must institute a detection monitoring program under subsection (9) of this section.

(b) The department will specify in the facility permit the specific elements of the monitoring and response program. The department may include one or more of the programs identified in (a) of this subsection, in the facility permit as may be necessary to protect human health and the environment and will specify the circumstances under which each of the programs will be required. In deciding whether to require the owner or operator to be prepared to institute a particular program, the department will consider the potential adverse effects on human health and the environment that might occur



before final administrative action on a permit modification application to incorporate such a program could be taken.

(3) Ground water protection standard. The owner or operator must comply with conditions specified in the facility permit that are designed to ensure that dangerous constituents under subsection (4) of this section, ~~((entering))~~ detected in the ground water from a regulated unit do not exceed the concentration limits under subsection (5) of this section, in the uppermost aquifer underlying the waste management area beyond the point of compliance under subsection (6) of this section, during the compliance period under subsection (7) of this section. To the extent practical, the department will establish this ground water protection standard in the facility permit at the time the permit is issued. If the department determines that an established standard is not protective enough, or if the department decides that it is not practical to establish standards at the time of permit issuance, the department will establish the groundwater protection standard in the facility permit when dangerous constituents have ~~((entered))~~ been detected in the ground water from a regulated unit.

(4) Dangerous constituents.

(a) The department will specify in the facility permit the dangerous constituents to which the ground water protection standard of subsection (3) of this section, applies. Dangerous constituents are constituents identified in 40 CFR Part 264 Appendix IX (this list is available from the department upon request), and any other constituents not listed there which have caused a waste to be regulated under this chapter, that may be or have been detected in ground water in the uppermost aquifer underlying a regulated unit and that are reasonably expected to be in or derived from waste contained in a regulated unit, unless the department has excluded them under (b) of this subsection.

The department may also specify in the permit indicator parameters (e.g., specific conductance, pH, total organic carbon (TOC), total organic halogen (TOX), or heavy metals), waste constituents or reaction products as identified in the detection monitoring program under subsection (9)(a) of this section, that provide a reliable indication of the presence of dangerous constituents in the ground water.

(b) The department will exclude a 40 CFR Part 264 Appendix IX, or other identified constituent from the list of dangerous constituents specified in the facility permit if it finds that the constituent is not capable of posing a substantial present or potential hazard to human health or the environment. In deciding whether to grant an exemption, the department will consider the following:

(i) Potential adverse effects on ground water quality, considering:

(A) The physical and chemical characteristics of the waste in the regulated unit, including its potential for migration;

(B) The hydrogeological characteristics of the facility and surrounding land;

(C) The quantity of ground water and the direction of ground water flow;

(D) The proximity and withdrawal rates of ground water users;

(E) The current and future uses of ground water in the area;

(F) The existing quality of ground water, including other sources of contamination and their cumulative impact on the ground water quality;

(G) The potential for health risks caused by human exposure to waste constituents;

(H) The potential damage to wildlife, crops, vegetation, and physical structures caused by exposure to waste constituents; and

(I) The persistence and permanence of the potential adverse effects;

(ii) Potential adverse effects on hydraulically-connected surface water quality, considering:

(A) The volume and physical and chemical characteristics of the waste in the regulated unit;

(B) The hydrogeological characteristics of the facility and surrounding land;

(C) The quantity and quality of ground water, and the direction of ground water flow;

(D) The patterns of rainfall in the region;

(E) The proximity of the regulated unit to surface waters;

(F) The current and future uses of surface waters in the area and any water quality standards established for those surface waters;

(G) The existing quality of surface water, including other sources of contamination and the cumulative impact on surface water quality;

(H) The potential for health risks caused by human exposure to waste constituents;

(I) The potential damage to wildlife, crops, vegetation, and physical structures caused by exposure to waste constituents; and

(J) The persistence and permanence of the potential adverse effects; and

(iii) Any identification of underground sources of drinking water and exempted aquifers made pursuant to chapter 90.48 RCW, chapter 270, Laws of 1983, and other applicable state laws and regulations.

(5) Concentration limits.

(a) The department will specify in the facility permit concentration limits in the ground water for dangerous constituents established under subsection (4) of this section. The concentration of a dangerous constituent:

(i) Must not exceed the background level of that constituent in the ground water at the time that limit is specified in the permit; or

(ii) For any of the constituents listed in Table 1 of this subsection, must not exceed the respective value given in that table if the background level of the constituent is below the value given in Table 1; or

(iii) Must not exceed an alternate limit established by the department under (b) of this subsection.

Table 1. Maximum Concentration of Constituents for Ground Water Protection

Constituent	Maximum Concentration <sup>1</sup>
Arsenic	0.05
Barium	1.0
Cadmium	0.01
Chromium	0.05
Lead	0.05
Mercury	0.002
Selenium	0.01
Silver	0.05
Endrin	0.0002
Lindane	0.004
Methoxychlor	0.1
Toxaphene	0.005
2,4-D	0.1
2,4,5-TP Silvex	0.01

<sup>1</sup>Milligrams per liter.

(b) The department will establish an alternate concentration limit for a dangerous constituent if it finds that the constituent will not pose a substantial present or potential hazard to human health or the environment as long as the alternate concentration limit is not exceeded. In establishing alternate concentration limits, the department will consider the same factors listed in subsection (4)(b) (i) through (iii) of this section.

(6) Point of compliance.

(a) The department will specify in the facility permit the point of compliance at which the ground water protection standard of subsection (3) of this section, applies and at which monitoring must be conducted. The point of compliance is a vertical surface located at the hydraulically downgradient limit of the waste management area that extends down into the uppermost aquifer underlying the regulated units. Alternatively, the point of compliance may be any closer points identified by the department at the time the permit is issued, considering the risks of the facility, the wastes and constituents managed there, the potential for waste constituents to have already migrated past the alternate compliance point, and the potential threats to ground and surface waters.

(b) The waste management area is the limit projected in the horizontal plane of the area on which waste will be placed during the active life of a regulated unit. The waste management area includes horizontal space taken up by any liner, dike, or other barrier designed to contain waste in a regulated unit. If the facility contains more than one regulated unit, the waste management area is described by an imaginary line circumscribing the several regulated units.

(7) Compliance period.

(a) The department will specify in the facility permit the compliance period during which the ground water protection standard of subsection (3) of this section applies. The compliance period is the number of years

equal to the active life of the waste management area (including any waste management activity prior to permitting, and the closure period).

(b) The compliance period begins when the owner or operator initiates a compliance monitoring program meeting the requirements of subsection (10) of this section.

(c) If the owner or operator is engaged in a corrective action program at the end of the compliance period specified in (a) of this subsection, the compliance period is extended until the owner or operator can demonstrate that the ground water protection standard of subsection (3) of this section, has not been exceeded for a period of three consecutive years.

(8) General ground water monitoring requirements.

The owner or operator must comply with the requirements of this subsection for any ground water monitoring program developed to satisfy subsections (9), (10), or (11) of this section.

(a) The ground water monitoring system must consist of a sufficient number of wells, installed at appropriate locations and depths to yield ground water samples from the uppermost aquifer that:

(i) Represent the quality of background water that has not been affected by leakage from a regulated unit; ~~(and)~~

(A) A determination of background quality may include sampling of wells that are not hydraulically upgradient of the waste management area where:

(I) Hydrogeologic conditions do not allow the owner or operator to determine what wells are hydraulically upgradient; and

(II) Sampling at other wells will provide an indication of background ground water quality that is representative or more representative than that provided by the upgradient wells; and

(ii) Represent the quality of ground water passing the point of compliance.

(iii) Allow for the detection of contamination when dangerous waste or dangerous constituents have migrated from the waste management area to the uppermost aquifer.

(b) If a facility contains more than one regulated unit, separate ground water monitoring systems are not required for each regulated unit, provided that provisions for sampling the ground water in the uppermost aquifer will enable detection and measurement at the compliance point of dangerous constituents from the regulated units that have entered the ground water in the uppermost aquifer.

(c) All monitoring wells must be cased in a manner that maintains the integrity of the monitoring well bore hole. This casing must allow collection of representative ground water samples. Wells must be constructed in such a manner as to prevent contamination of the samples, the sampled strata, and between aquifers and water bearing strata. Wells must meet the requirements set forth in Parts 1 and 3 of chapter 173-160 WAC, "Minimum standards for construction and maintenance of wells."

(d) The ground water monitoring program must include at a minimum, procedures and techniques for:

(i) Decontamination of drilling and sampling equipment;

(ii) Sample collection;

(iii) Sample preservation and shipment;

(iv) Analytical procedures and quality assurance; and

(v) Chain of custody control.

(e) The ground water monitoring program must include consistent sampling and analytical methods that ensure reliable ground water sampling, accurately measure dangerous constituents and indicator parameters in ground water samples, and provide a reliable indication of groundwater quality below the waste management area.

(f) The ground water monitoring program must include a determination of the ground water surface elevation each time ground water is sampled.

(g) (Where appropriate, the ground water monitoring program must establish background ground water quality for each of the dangerous constituents or monitoring parameters or constituents specified in the permit.

(i) In the detection monitoring program under subsection (9) of this section, background ground water quality for a monitoring parameter or constituent must be based on data from quarterly sampling of wells upgradient from the waste management area for one year:

(ii) In the compliance monitoring program under subsection (10) of this section, background ground water quality for a dangerous constituent must be based on data from upgradient wells that:

(A) Is available before the permit is issued;

(B) Accounts for measurement errors in sampling and analysis; and

(C) Accounts, to the extent feasible, for seasonal fluctuations in background ground water quality if such fluctuations are expected to affect the concentration of the dangerous constituent.

(iii) Background ground water quality may be based on sampling of wells that are not upgradient from the waste management area where:

(A) Hydrogeologic conditions do not allow the owner or operator to determine what wells are upgradient; or

(B) Sampling at other wells will provide an indication of background ground water quality that is as representative or more representative than that provided by the upgradient wells.

(iv) In developing the data base used to determine a background value for each parameter or constituent, the owner or operator must take a minimum of one sample from each well and a minimum of four samples from the entire system used to determine background ground water quality, each time the system is sampled:

(h) The owner or operator must use the following statistical procedure in determining whether background values or concentration limits have been exceeded:

(i) If, in a detection monitoring program, the level of a constituent at the compliance point is to be compared to the constituent's background value and that background value has a sample coefficient of variation less than 1.00:

(A) The owner or operator must take at least four portions from a sample at each well at the compliance point and determine whether the difference between the

mean of the constituent at each well (using all portions taken) and the background value for the constituent is significant at the 0.05 level using the Cochran's Approximation to the Behrens-Fisher Student's t-test as described in Appendix IV of 40 CFR Part 264. If the test indicates that the difference is significant, the owner or operator must repeat the same procedure (with at least the same number of portions as used in the first test) with a fresh sample from the monitoring well. If this second round of analyses indicates that the difference is significant, the owner or operator must conclude that a statistically significant change has occurred; or

(B) The owner or operator may use an equivalent statistical procedure for determining whether a statistically significant change has occurred. The department will specify such a procedure in the facility permit if it finds that the alternative procedure reasonably balances the probability of falsely identifying a noncontaminating regulated unit and the probability of failing to identify a contaminating regulated unit in a manner that is comparable to that of the statistical procedure described in (h)(i)(A) of this subsection; and

(ii) In all other situations in a detection monitoring program and in a compliance monitoring program, the owner or operator must use a statistical procedure providing reasonable confidence that the migration of dangerous constituents from a regulated unit into and through the aquifer will be indicated. The department will specify a statistical procedure in the facility permit that it finds:

(A) Is appropriate for the distribution of the data used to establish background values or concentration limits; and

(B) Provides a reasonable balance between the probability of falsely identifying a noncontaminating regulated unit and the probability of failing to identify a contaminating regulated unit.) In detection monitoring or where appropriate in compliance monitoring, data on each dangerous constituent specified in the permit will be collected from background wells and wells at the compliance point(s). The number and kinds of samples collected to establish background shall be appropriate for the form of statistical test employed, following generally accepted statistical principles. The sample size shall be as large as necessary to ensure with reasonable confidence that a contaminant release to ground water from a facility will be detected. The owner or operator will determine an appropriate sampling procedure and interval for each hazardous constituent listed in the facility permit which shall be specified in the unit permit upon approval by the department. This sampling procedure shall be:

(i) A sequence of at least four samples, taken at an interval that assures, to the greatest extent technically feasible, that an independent sample is obtained, by reference to the uppermost aquifer's effective porosity, hydraulic conductivity and hydraulic gradient, and the fate and transport characteristics of the potential contaminants; or

(ii) An alternate sampling procedure proposed by the owner or operator and approved by the department.

(h) The owner or operator will specify one of the following statistical methods to be used in evaluating ground water monitoring data for each hazardous constituent which, upon approval by the department, will be specified in the unit permit. The statistical test chosen shall be conducted separately for each dangerous constituent in each well. Where practical quantification limits (pql's) are used in any of the following statistical procedures to comply with (i)(v) of this subsection, the pql must be proposed by the owner or operator and approved by the department. Use of any of the following statistical methods must be protective of human health and the environment and must comply with the performance standards outlined in (i) of this subsection.

(i) A parametric analysis of variance (ANOVA) followed by multiple comparisons procedures to identify statistically significant evidence of contamination. The method must include estimation and testing of the contrasts between each compliance well's mean and the background mean levels for each constituent.

(ii) An analysis of variance (ANOVA) based on ranks followed by multiple comparisons procedures to identify statistically significant evidence of contamination. The method must include estimation and testing of the contrasts between each compliance well's median and the background median levels for each constituent.

(iii) A tolerance or prediction interval procedure in which an interval for each constituent is established from the distribution of the background data, and the level of each constituent in each compliance well is compared to the upper tolerance or prediction limit.

(iv) A control chart approach that gives control limits for each constituent.

(v) Another statistical test method submitted by the owner or operator and approved by the department.

(i) Any statistical method chosen under (h) of this subsection for specification in the unit permit shall comply with the following performance standards, as appropriate:

(i) The statistical method used to evaluate ground water monitoring data shall be appropriate for the distribution of chemical parameters or dangerous constituents. If the distribution of the chemical parameters or dangerous constituents is shown by the owner or operator to be inappropriate for a normal theory test, then the data should be transformed or a distribution-free theory test should be used. If the distributions for the constituents differ, more than one statistical method may be needed.

(ii) If an individual well comparison procedure is used to compare an individual compliance well constituent concentration with background constituent concentrations or a ground water protection standard, the test shall be done at a Type I error level no less than 0.01 for each testing period. If a multiple comparisons procedure is used, the Type I experimentwise error rate for each testing period shall be no less than 0.05; however, the Type I error of no less than 0.01 for individual well comparisons must be maintained. This performance standard does not apply to tolerance intervals, prediction intervals, or control charts.

(iii) If a control chart approach is used to evaluate ground water monitoring data, the specific type of control chart and its associated parameter values shall be proposed by the owner or operator and approved by the department if it is protective of human health and the environment.

(iv) If a tolerance interval or a prediction interval is used to evaluate ground water monitoring data, the levels of confidence and, for tolerance intervals, the percentage of the population that the interval must contain, shall be proposed by the owner or operator and approved by the department if it finds these parameters to be protective of human health and the environment. These parameters will be determined after considering the number of samples in the background data base, the data distribution, and the range of the concentration values for each constituent of concern.

(v) The statistical method shall account for data below the limit of detection with one or more statistical procedures that are protective of human health and the environment. Any practical quantification limit (pql) approved by the department under (h) of this subsection that is used in the statistical method shall be the lowest concentration level that can be reliably achieved within specified limits of precision and accuracy during routine laboratory operating conditions that are available to the facility.

(vi) If necessary, the statistical method shall include procedures to control or correct for seasonal and spatial variability as well as temporal correlation in the data.

(j) Ground water monitoring data collected in accordance with (g) of this subsection including actual levels of constituents must be maintained in the facility operating record. The department will specify in the permit when the data must be submitted for review.

(9) Detection monitoring program. An owner or operator required to establish a detection monitoring program under this subsection must, at a minimum, discharge the responsibilities described in this subsection.

(a) The owner or operator must monitor for indicator parameters (e.g., pH, specific conductance, total organic carbon (TOC), total organic halogen (TOX), or heavy metals), waste constituents, or reaction products that provide a reliable indication of the presence of dangerous constituents in ground water. The department will specify the parameters or constituents to be monitored in the facility permit, after considering the following factors:

(i) The types, quantities, and concentrations of constituents in wastes managed at the regulated unit;

(ii) The mobility, stability, and persistence of waste constituents or their reaction products in the unsaturated zone beneath the waste management area;

(iii) The detectability of indicator parameters, waste constituents, and reaction products in ground water; and

(iv) The concentrations or values and coefficients of variation of proposed monitoring parameters or constituents in the ground water background.

(b) The owner or operator must install a ground water monitoring system at the compliance point, as specified under subsection (6) of this section. The ground water monitoring system must comply with subsection (8)(a)(ii), (b), and (c) of this section.

(c) The owner or operator must ~~((establish a background value for each monitoring parameter or constituent specified in the permit pursuant to (a) of this subsection. The permit will specify the background values for each parameter or specify the procedures to be used to calculate the background values. The owner or operator must comply with subsection (8)(g) of this section, in developing the data base used to determine background values. The owner or operator must express background values in a form necessary for the determination of statistically significant increases under subsection (8)(h) of this section. In taking samples used in the determination of background values, the owner or operator must use a ground water monitoring system that complies with subsection (8)(a)(i), (b), and (c) of this section.~~

~~(d) The owner or operator must determine ground water quality at each monitoring well at the compliance point at least semiannually during the active life of a regulated unit (including the closure period) and the postclosure care period. The owner or operator must express the ground water quality at each monitoring well in a form necessary for the determination of statistically significant increases under subsection (8)(h) of this section.)~~ conduct a ground water monitoring program for each chemical parameter and dangerous constituent specified in the permit pursuant to (a) of this subsection in accordance with subsection (8)(g) of this section. The owner or operator must maintain a record of ground water analytical data as measured and in a form necessary for the determination of statistical significance under subsection (8)(h) of this section.

(d) The department will specify the frequencies for collecting samples and conducting statistical tests to determine whether there is statistically significant evidence of contamination for any parameter or dangerous constituent specified in the permit under (a) of this subsection in accordance with subsection (8)(g) of this section. A sequence of at least four samples from each well (background and compliance wells) must be collected at least semiannually during detection monitoring.

(e) The owner or operator must determine the ground water flow rate and direction in the uppermost aquifer at least annually.

(f) The owner or operator must ~~((use procedures and methods for sampling and analysis that meet the requirements of subsection (8)(d) and (e) of this section.~~

~~(g) The owner or operator must determine whether there is a statistically significant increase over background values for any parameter or constituent specified in the permit pursuant to (a) of this subsection, each time he determines ground water quality at the compliance point under (d) of this subsection.~~

~~(i) In determining whether a statistically significant increase has occurred, the owner or operator must compare the ground water quality at each monitoring well at the compliance point for each parameter or constituent to the background value for that parameter or constituent, according to the statistical procedure specified in the permit under subsection (8)(h) of this section.~~

~~(ii) The owner or operator must determine whether there has been a statistically significant increase at each~~

~~monitoring well at the compliance point within a reasonable time period after completion of sampling. The department will specify that time period in the facility permit, after considering the complexity of the statistical test and the availability of laboratory facilities to perform the analysis of ground water samples.~~

~~(h) If the owner or operator determines, pursuant to (g) of this subsection, that there is a statistically significant increase for parameters or constituents specified pursuant to (a) of this subsection, at any monitoring well at the compliance point, he must:~~

~~(i) Notify the department of this finding in writing within seven days. The notification must indicate what parameters or constituents have shown statistically significant increases;~~

~~(ii) Immediately sample the ground water in all monitoring wells and determine the concentration of all constituents identified in 40 CFR Part 264 Appendix IX, and all other dangerous constituents not listed in 40 CFR Part 264 Appendix IX, but which are specified in the facility permit pursuant to subsection (4)(a) of this section, that are present in ground water;~~

~~(iii) Establish a background value for each constituent identified in 40 CFR Part 264 Appendix IX, and all other dangerous constituents not listed in 40 CFR Part 264 Appendix IX, but which are specified in the facility permit pursuant to subsection (4)(a) of this section, that has been found at the compliance point under (h)(ii) of this subsection, as follows:~~

~~(A) The owner or operator must comply with subsection (8)(g) of this section, in developing the data base used to determine background values;~~

~~(B) The owner or operator must express background values in a form necessary for the determination of statistically significant increases under subsection (8)(h) of this section; and~~

~~(C) In taking samples used in the determination of background values, the owner or operator must use a ground water monitoring system that complies with subsection (8)(a)(i), (b), and (c) of this section;~~

~~(iv) Within a maximum of forty-five days, submit to the department an application for a permit modification to establish a compliance monitoring program meeting the requirements of subsection (10) of this section. The application must include the following information:~~

~~(A) An identification of the concentration of any constituents identified in 40 CFR Part 264 Appendix IX, and any other dangerous constituents not listed in 40 CFR Part 264 Appendix IX, but which are specified in the facility permit pursuant to subsection (4)(a) of this section, found in the ground water at each monitoring well at the compliance point;~~

~~(B) Any proposed changes to the ground water monitoring system at the facility necessary to meet the requirements of subsection (10) of this section;~~

~~(C) Any proposed changes to the monitoring frequency, sampling and analysis procedures or methods, or statistical procedures used at the facility necessary to meet the requirements of subsection (10) of this section;~~

~~(D) For each dangerous constituent found at the compliance point, a proposed concentration limit under subsection (5)(a)(i) or (ii) of this section, or a notice of~~

~~intent to seek a variance under subsection (5)(b) of this section; and~~

~~(v) Within ninety days, submit to the department:~~

~~(A) All data necessary to justify any variance sought under subsection (5)(b) of this section; and~~

~~(B) An engineering feasibility plan necessary to meet the requirements of subsection (11) of this section, unless:~~

~~(I) All dangerous constituents identified under (h)(ii) of this subsection, are listed in Table 1 of subsection (5) of this section, and their concentrations do not exceed the respective values given in that table; or~~

~~(II) The owner or operator has sought a variance under subsection (5)(b) of this section, for every dangerous constituent identified under (h)(ii) of this subsection:~~

~~(i) If the owner or operator determines, pursuant to (g) of this subsection, that there is a statistically significant increase of parameters or constituents specified pursuant to (a) of this subsection, at any monitoring well at the compliance point, he may demonstrate that a source other than a regulated unit caused the increase or that the increase resulted from error in sampling, analysis, or evaluation. While the owner or operator may make a demonstration under this subsection in addition to, or in lieu of, submitting a permit modification application under (h)(iv) of this subsection, he is not relieved of the requirement to submit a permit modification application within the time specified in (h)(iv) of this subsection, unless the demonstration made under this subsection successfully shows that a source other than his regulated unit(s) caused the increase or that the increase resulted from error in sampling, analysis, or evaluation. In making a demonstration under this subsection, the owner or operator must:~~

~~(i) Notify the department in writing within seven days of determining a statistically significant increase at the compliance point that he intends to make a demonstration under this subsection;~~

~~(ii) Within forty-five days, submit a report to the department which demonstrates that a source other than a regulated unit caused the increase, or that the increase resulted from error in sampling, analysis, or evaluation;~~

~~(iii) Within forty-five days, submit to the department an application for a permit modification to make any appropriate changes to the detection monitoring program at the facility; and~~

~~(iv) Continue to monitor in accordance with the detection monitoring program established under this section:~~

~~(j) If the owner or operator determines that the detection monitoring program no longer satisfies the requirements of this section, he must, within forty-five days, submit an application for a permit modification to make any appropriate changes to the program.~~

~~(k) The owner or operator must assure that monitoring and corrective action measures necessary to achieve compliance with the ground water protection standard under subsection (3) of this section, are taken during the term of the permit:)) determine whether there is statistically significant evidence of contamination for any chemical parameter of dangerous constituent specified in~~

the permit pursuant to (a) of this subsection at a frequency specified under (d) of this subsection.

(i) In determining whether statistically significant evidence of contamination exists, the owner or operator must use the method(s) specified in the permit under subsection (8)(h) of this section. These method(s) must compare data collected at the compliance point(s) to the background ground water quality data.

(ii) The owner or operator must determine whether there is statistically significant evidence of contamination at each monitoring well as the compliance point within a reasonable period of time after completion of sampling. The department will specify in the facility permit what period of time is reasonable after considering the complexity of the statistical test and the availability of laboratory facilities to perform the analysis of ground water samples.

(g) If the owner or operator determines pursuant to (f) of this subsection that there is statistically significant evidence of contamination for chemical parameters or dangerous constituents specified pursuant to (a) of this subsection at any monitoring well at the compliance point, he or she must:

(i) Notify the department of this finding in writing within seven days. The notification must indicate what chemical parameters or dangerous constituents have shown statistically significant evidence of contamination:

(ii) Immediately sample the ground water in all monitoring wells and determine whether constituents in the list of Appendix IX of Part 264 are present, and if so, in what concentration.

(iii) For any Appendix IX compounds found in the analysis pursuant to (g)(ii) of this subsection, the owner or operator may resample within one month and repeat the analysis for those compounds detected. If the results of the second analysis confirm the initial results, then these constituents will form the basis for compliance monitoring. If the owner or operator does not resample for the compounds found pursuant to (g)(ii) of this subsection, the dangerous constituents found during this initial Appendix IX analysis will form the basis for compliance monitoring.

(iv) Within ninety days, submit to the department an application for a permit modification to establish a compliance monitoring program meeting the requirements of subsection (10) of this section. The application must include the following information:

(A) An identification of the concentration or any Appendix IX constituent detected in the ground water at each monitoring well at the compliance point;

(B) Any proposed changes to the ground water monitoring system at the facility necessary to meet the requirements of subsection (10) of this section;

(C) Any proposed additions or changes to the monitoring frequency, sampling and analysis procedures or methods, or statistical methods used at the facility necessary to meet the requirements of subsection (10) of this section;

(D) For each dangerous constituent detected at the compliance point, a proposed concentration limit under subsection (5)(a)(i) or (ii) of this section, or a notice of

intent to seek an alternate concentration limit under subsection (5)(b) of this section; and

(v) Within one hundred eighty days, submit to the department:

(A) All data necessary to justify and alternate concentration limit sought under subsection (5)(b) of this section; and

(B) An engineering feasibility plan for a corrective action program necessary to meet the requirement of subsection (11) of this section unless:

(I) All dangerous constituents identified under (g)(ii) of this subsection are listed in Table I of subsection (5) of this section and their concentrations do not exceed the respective values given in that Table; or

(II) The owner or operator has sought an alternate concentration limit under subsection (5)(b) of this section for every dangerous constituent identified under (g)(ii) of this subsection.

(vi) If the owner or operator determines, pursuant to (f) of this subsection, that there is a statistically significant difference for chemical parameters or dangerous constituents specified pursuant to (a) of this subsection at any monitoring well at the compliance point, he or she may demonstrate that a source other than a regulated unit caused the contamination or that the detection is an artifact caused by an error in sampling, analysis, or statistical evaluation or natural variation in the ground water. The owner operator may make a demonstration under this subsection in addition to, or in lieu of, submitting a permit modification application under (g)(iv) of this subsection; however, the owner or operator is not relieved of the requirement to submit a permit modification application within the time specified in (g)(iv) of this subsection unless the demonstration made under this subsection successfully shows that a source other than a regulated unit caused the increase, or that the increase resulted from error in sampling, analysis, or evaluation. In making a demonstration under this subsection, the owner or operator must:

(A) Notify the department in writing within seven days of determining statistically significant evidence of contamination at the compliance point that he intends to make a demonstration under this subsection;

(B) Within ninety days, submit a report to the department which demonstrates that a source other than a regulated unit caused the contamination or that the contamination resulted from error in sampling, analysis, or evaluation;

(C) Within ninety days, submit to the department an application for a permit modification to make any appropriate changes to the detection monitoring program facility; and

(D) Continue to monitor in accordance with the detection monitoring program established under this section.

(h) If the owner or operator determines that the detection monitoring program no longer satisfies the requirements of this section, he or she must, within ninety days, submit an application for a permit modification to make any appropriate changes to the program.

(10) Compliance monitoring program. An owner or operator required to establish a compliance monitoring

program under this section must, at a minimum, discharge the responsibilities described in this subsection.

(a) The owner or operator must monitor the ground water to determine whether regulated units are in compliance with the ground water protection standard under subsection (3) of this section. The department will specify the ground water protection standard in the facility permit, including:

(i) A list of the dangerous constituents and parameters identified under subsection (4) of this section;

(ii) Concentration limits under subsection (5) of this section for each of those dangerous constituents and parameters;

(iii) The compliance point under subsection (6) of this section; and

(iv) The compliance period under subsection (7) of this section.

(b) The owner or operator must install a ground water monitoring system at the compliance point as specified under subsection (6) of this section. The ground water monitoring system must comply with subsection (8)(a)(ii), (b), and (c) of this section.

~~(c) ((Where a concentration limit established under (a)(ii) of this subsection, is based on background ground water quality, the department will specify the concentration limit in the permit as follows:~~

~~(i) If there is a high temporal correlation between upgradient and compliance point concentrations of the dangerous constituents and parameters, the owner or operator may establish the concentration limit through sampling at upgradient wells each time ground water is sampled at the compliance point. The department will specify the procedures used for determining the concentration limit in this manner in the permit. In all other cases, the concentration limit will be the mean of the pooled data on the concentration of the dangerous constituent or parameter;~~

~~(ii) If a dangerous constituent from Table I under subsection (5) of this section is identified and the difference between the respective concentration limit in Table I and the background value of that constituent under subsection (8)(g) of this section is not statistically significant, the owner or operator must use the background value of the constituent as the concentration limit. In determining whether this difference is statistically significant, the owner or operator must use an approved statistical procedure providing reasonable confidence that a real difference will be indicated. The statistical procedure must:~~

~~(A) Be appropriate for the distribution of the data used to establish background values; and~~

~~(B) Provide a reasonable balance between the probability of falsely identifying a significant difference and the probability of failing to identify a significant difference; and~~

~~(iii) The owner or operator must:~~

~~(A) Comply with subsection (8)(g) of this section, in developing the data base used to determine background values;~~

~~(B) Express background values in a form necessary for the determination of statistically significant increases under subsection (8)(h) of this section; and~~



~~(c) Use a ground water monitoring system that complies with subsection (8)(a)(i), (b), and (c) of this section.~~

~~(d) The owner or operator must determine the concentration of dangerous constituents and parameters in ground water at each monitoring well at the compliance point at least quarterly during the compliance period. The owner or operator must express the concentration at each monitoring well in a form necessary for the determination of statistically significant increases under subsection (8)(h) of this section.)) The department will specify the sampling procedures and statistical methods appropriate for the constituents and the facility, consistent with subsection (8)(g) and (h) of this section.~~

~~(i) The owner or operator must conduct a sampling program for each chemical parameter or dangerous constituent in accordance with subsection (8) (g) of this section.~~

~~(ii) The owner or operator must record ground water analytical data as measured and in form necessary for the determination of statistical significance under subsection (8)(h) of this section for the compliance period of the facility.~~

~~(d) The owner or operator must determine whether there is statistically significant evidence of increased contamination for any chemical parameter or dangerous constituent specified in the permit, pursuant to (a) of this subsection, at a frequency specified under (f) of this subsection.~~

~~(i) In determining whether statistically significant evidence of increased contamination exists, the owner or operator must use the method(s) specified in the permit under subsection (8)(h) of this section. The method(s) must compare data collected at the compliance point(s) to a concentration limit developed in accordance with subsection (5) of this section.~~

~~(ii) The owner or operator must determine whether there is statistically significant evidence of increased contamination at each monitoring well at the compliance point within a reasonable time period after completion of sampling. The department will specify that time period in the facility permit, after considering the complexity of the statistical test and the availability of laboratory facilities to perform the analysis of ground water samples.~~

~~(e) The owner or operator must determine the rate and direction of ground water flow in the uppermost aquifer at least annually.~~

~~(f) The ((owner or operator must analyze samples from all monitoring wells at the compliance point for constituents identified in 40 CFR Part 264 Appendix IX, and any other dangerous constituents not listed in 40 CFR Part 264 Appendix IX, but which are specified in the facility permit pursuant to subsection (4)(a) of this section at least annually to determine whether additional dangerous constituents are present in the uppermost aquifer. If the owner or operator finds constituents identified in 40 CFR Part 264 Appendix IX, and any other dangerous constituents not listed in 40 CFR Part 264 Appendix IX, but which are specified in the facility permit pursuant to subsection (4)(a) of this section in the ground water that are not identified in the permit as~~

~~dangerous constituents, he must report the concentrations of these additional constituents to the department within seven days after completion of the analysis.~~

~~(g) The owner or operator must use procedures and methods for sampling and analysis that meet the requirements of subsection (8)(d) and (e) of this section.~~

~~(h) The owner or operator must determine whether there is a statistically significant increase over the concentration limits for any dangerous constituents specified in the permit each time he determines the concentration of dangerous constituents in ground water at the compliance point.~~

~~(i) In determining whether a statistically significant increase has occurred, the owner or operator must compare the ground water quality at each monitoring well at the compliance point for each dangerous constituent to the concentration limit for that constituent according to the statistical procedures specified in the permit under subsection (8)(h) of this section.~~

~~(ii) The owner or operator must determine whether there has been a statistically significant increase at each monitoring well at the compliance point, within a reasonable time period after completion of sampling. The department will specify that time period in the facility permit, after considering the complexity of the statistical test and the availability of laboratory facilities to perform the analysis of ground water samples.~~

~~(i)) department will specify the frequencies for collecting samples and conducting statistical tests to determine statistically significant evidence of increased contamination in accordance with subsection (8)(g) of this section. A sequence of at least four samples from each well (background and compliance wells) must be collected at least semiannually during the compliance period of the facility.~~

~~(g) The owner or operator must analyze samples from all monitoring wells at the compliance point for all constituents contained in Appendix IX of Part 264 at least annually to determine whether additional dangerous constituents are present in the uppermost aquifer and, if so, at what concentration, pursuant to procedures in (f) of this subsection. If the owner or operator finds Appendix IX constituents in the ground water that are not already identified in the permit as monitoring constituents, the owner or operator may resample within one month and repeat the Appendix IX analysis. If the second analysis confirms the presence of new constituents, the owner or operator must report the concentration of these additional constituents to the department within seven days after the completion of the second analysis and add them to the monitoring list. If the owner or operator chooses not to resample, then he or she must report the concentrations of these additional constituents to the department within seven days after completion of the initial analysis and add them to the monitoring list. If the owner or operator determines, pursuant to ((h)) (d) of this subsection, that ((the ground water protection standard is)) any concentration limits under subsection (5) of this section are being exceeded at any monitoring well at the point of compliance, he must:~~

(i) Notify the department of this finding in writing within seven days. The notification must indicate what concentration limits have been exceeded;

(ii) Submit to the department an application for a permit modification to establish a corrective action program meeting the requirements of subsection (11) of this section, within ninety days, or within sixty days if an engineering feasibility study has been previously submitted to the department under subsection (9)(h)(v) of this section. For regulated units managing EHW, time frames of sixty days and forty-five days, respectively will apply. However, if the department finds that the full extent of the ninety/sixty-day or the sixty/forty-five-day time periods will increase the likelihood to cause a threat to public health, or the environment, it can at its discretion reduce their duration. In specifying shorter limits, the department will consider the following factors:

(A) The physical and chemical characteristics of the dangerous constituents and parameters in the ground water;

(B) The hydrogeological characteristics of the facility and of the surrounding land;

(C) The rate of movement and direction of flow of the affected ground water;

(D) The proximity to and withdrawal rates of ground water users downgradient; and

(E) The current and future uses of ground water in the concerned area; and

(iii) The application must at a minimum include the following information:

(A) A detailed description of corrective actions that will achieve compliance with the ground water protection standard specified in the permit; and

(B) A plan for a ground water monitoring program that will demonstrate the effectiveness of the corrective action.

~~((f)) (i) If the owner or operator determines, pursuant to ((h)) (d) of this subsection, that the ground water ((protection standard is)) concentration limits under this section are being exceeded at any monitoring well at the point of compliance, he may demonstrate that a source other than a regulated unit caused the ((increase or that the increase resulted from)) contamination or that the detection is an artifact caused by an error in sampling, analysis, or statistical evaluation((: While the owner or operator may make a demonstration under this subsection in addition to, or in lieu of, submitting a permit modification application under (i)(ii) of this subsection, he is not relieved of the requirement to submit a permit modification application within the time specified in (i)(ii) of this subsection, unless the demonstration made under this paragraph successfully shows that a source other than a regulated unit caused the increase or that the increase resulted from error in sampling, analysis, or evaluation)) or natural variation in the ground water. In making a demonstration under this subsection, the owner or operator must:~~

(i) Notify the department in writing within seven days that he intends to make a demonstration under this subsection;

(ii) Within forty-five days, submit a report to the department which demonstrates that a source other than a

regulated unit caused the standard to be exceeded or that the apparent noncompliance with the standards resulted from error in sampling, analysis, or evaluation;

(iii) Within forty-five days, submit to the department an application for a permit modification to make appropriate changes to the compliance monitoring program at the facility; and

(iv) Continue to monitor in accord with the compliance monitoring program established under this section.

~~((k)) (j) If the owner or operator determines that the compliance monitoring program no longer satisfies the requirements of this section, he must, within forty-five days, submit an application for a permit modification to make any appropriate changes to the program.~~

~~((l) The owner or operator must assure that monitoring and corrective action measures necessary to achieve compliance with the ground water protection standard under subsection (3) of this section, are taken during the term of the permit.))~~

(11) Corrective action program. An owner or operator required to establish a corrective action program under this section must, at a minimum, discharge the responsibilities described in this subsection.

(a) The owner or operator must take corrective action to ensure that regulated units are in compliance with the ground water protection standard under subsection (3) of this section. The department will specify the ground water protection standard in the facility permit, including:

(i) A list of the dangerous constituents and parameters identified under subsection (4) of this section;

(ii) Concentration limits under subsection (5) of this section, for each of those dangerous constituents and parameters;

(iii) The compliance point under subsection (6) of this section; and

(iv) The compliance period under subsection (7) of this section.

(b) The owner or operator must implement a corrective action program that prevents dangerous constituents and parameters from exceeding their respective concentration limits at the compliance point by removing the dangerous waste constituents and parameters or treating them in place. The permit will specify the specific measures that will be taken.

(c) The owner or operator must begin corrective action within a reasonable time period after the ground water protection standard is exceeded. The department will specify that time period in the facility permit. If a facility permit includes a corrective action program in addition to a compliance monitoring program, the permit will specify when the corrective action will begin and such a requirement will operate in lieu of subsection (10)(i)(ii) of this section.

(d) In conjunction with a corrective action program, the owner or operator must establish and implement a ground water monitoring program to demonstrate the effectiveness of the corrective action program. Such a monitoring program may be based on the requirements for a compliance monitoring program under subsection (10) of this section, and must be as effective as that

program in determining compliance with the ground water protection standard under subsection (3) of this section, and in determining the success of a corrective action program under (e) of this subsection, where appropriate.

(e) In addition to the other requirements of this section, the owner or operator must conduct a corrective action program to remove or treat in place any dangerous constituents or parameters under subsection (4) of this section, that exceed concentration limits under subsection (5) of this section, in ground water between the compliance point under subsection (6) of this section, and the downgradient facility property boundary. The permit will specify the measures to be taken.

(i) Corrective action measures under this subsection must be initiated at the effective date of the modified permit and completed without time delays considering the extent of contamination.

(ii) Corrective action measures under this subsection may be terminated once the concentration of dangerous constituents and parameters under subsection (4) of this section, is reduced to levels below their respective concentration limits under subsection (5) of this section.

(f) The owner or operator must continue corrective action measures during the compliance period to the extent necessary to ensure that the ground water protection standard is not exceeded. If the owner or operator is conducting corrective action at the end of the compliance period, he must continue that corrective action for as long as necessary to achieve compliance with the ground water protection standard. The owner or operator may terminate corrective action measures taken beyond the period equal to the active life of the waste management area (including the closure period) if he can demonstrate, based on data from the ground water monitoring program under (d) of this subsection, that the ground water protection standard of subsection (3) of this section, has not been exceeded for a period of three consecutive years.

(g) The owner or operator must report in writing to the department on the effectiveness of the corrective action program. The owner or operator must submit these reports semiannually.

(h) If the owner or operator determines that the corrective action program no longer satisfies the requirements of this section, he must, within forty-five days, submit an application for a permit modification to make any appropriate changes to the program.

(12) Corrective action for solid waste management units.

(a) The owner or operator of a facility seeking a permit for the treatment, storage, or disposal of dangerous waste must institute corrective action as necessary to protect human health and the environment for all releases of dangerous waste or constituents from any solid waste management unit at the facility, regardless of the time at which waste was placed in such unit.

(b) Corrective action will be specified in the permit. The permit will contain schedules of compliance for such corrective action (where such corrective action cannot be

completed prior to issuance of the permit) and assurances of financial responsibility for completing such corrective action.

(c) The owner or operator must implement corrective actions beyond the facility property boundary, where necessary to protect human health and the environment, unless the owner or operator demonstrates to the satisfaction of the department that, despite the owner's or operator's best efforts, the owner or operator was unable to obtain the necessary permission to undertake such actions. The owner/operator is not relieved of all responsibility to clean up a release that has migrated beyond the facility boundary where off-site access is denied. On-site measures to address such releases will be determined on a case-by-case basis. Assurances of financial responsibility for such corrective action must be provided.

READOPTED SECTION (Readopting Order 88-29, filed 9/6/88)

WAC 173-303-650 SURFACE IMPOUNDMENTS. (1) Applicability. The regulations in this section apply to owners and operators of facilities that use surface impoundments to treat, store, or dispose of dangerous waste.

(2) Design and operating requirements.

(a)(i) A surface impoundment (except for an existing portion of a surface impoundment) must have a liner that is designed, constructed, and installed to prevent any migration of wastes out of the impoundment to the adjacent subsurface soil or ground water or surface water at any time during the active life (including the closure period) of the impoundment. The liner may be constructed of materials that may allow wastes to migrate into the liner (but not into the adjacent subsurface soil or ground water or surface water) during the active life of the facility, provided that the impoundment is closed in accordance with subsection (6)(a)(i) of this section. For impoundments that will be closed in accordance with subsection (6)(a)(ii) of this section, the liner must be constructed of materials that can prevent wastes from migrating into the liner during the active life of the facility. The liner must be:

(A) Constructed of materials that have appropriate chemical properties and sufficient strength and thickness to prevent failure due to pressure gradients (including static head and external hydrogeologic forces), physical contact with the waste or leachate to which they are exposed, climatic conditions, the stress of installation, and the stress of daily operation;

(B) Placed upon a foundation or base capable of providing support to the liner and resistance to pressure gradients above and below the liner to prevent failure of the liner due to settlement, compression, or uplift;

(C) Installed to cover all surrounding earth likely to be in contact with the waste or leachate; and

(D) For EHW management, the owner or operator shall submit an engineering report with his permit application under WAC 173-303-806(4) stating the basis for selecting the liner(s). The report shall be certified by a licensed professional engineer.

(ii) The owner or operator of a new surface impoundment installed after October 31, 1984, and in which liquid EHW is managed must:

(A) Install a double lined system which incorporates the specifications of subsection (3)(a), (b), and (c) of this section; and

(B) Must comply with either the ground water monitoring requirements of WAC 173-303-645, or the unsaturated zone monitoring requirements of WAC 173-303-655(6).

(b) The owner or operator will be exempted from the requirements of (a) of this subsection, if the department finds, based on a demonstration by the owner or operator, that alternate design and operating practices, together with location characteristics, will prevent the migration of any dangerous constituents listed in WAC 173-303-9905, or which otherwise cause his wastes to be regulated under this chapter, into the ground water or surface water at any future time. In deciding whether to grant an exemption, the department will consider:

(i) The nature and quantity of the wastes;

(ii) The proposed alternate design and operation;

(iii) The hydrogeologic setting of the facility, including the attenuative capacity and thickness of the liners and soils present between the impoundment and ground water or surface water; and

(iv) All other factors which would influence the quality and mobility of the leachate produced and the potential for it to migrate to ground water or surface water.

(c) A surface impoundment must be designed, constructed, maintained, and operated to prevent overtopping resulting from normal or abnormal operations; overfilling; wind and wave action; rainfall; run-on; malfunctions of level controllers, alarms, and other equipment; and human error.

(d) A surface impoundment must be designed so that any flow of waste into the impoundment can be immediately shut off in the event of overtopping or liner failure.

(e) A surface impoundment must be designed to repel birds.

(f) A surface impoundment must have dikes that are designed, constructed, and maintained with sufficient structural integrity to prevent their failure. In ensuring structural integrity, it must not be presumed that the liner system will function without leakage during the active life of the unit.

(g) Earthen dikes must be kept free of:

(i) Perennial woody plants with root systems which could weaken its structural integrity; and

(ii) Burrowing mammals which could weaken its structural integrity or create leaks through burrows.

(h) Earthen dikes must have a protective cover, such as grass, shale or rock to minimize wind and water erosion and to preserve their structural integrity.

(i) The department will specify in the permit all design and operating practices that are necessary to ensure that the requirements of this subsection are satisfied.

(3) Double-lined surface impoundments; exemption from WAC 173-303-645, ground water protection requirements.

(a) Except as provided in subsection (2)(a)(ii) of this section, the owner or operator of a double-lined surface

impoundment is not subject to regulation under WAC 173-303-645 if the following conditions are met:

(i) The impoundment (including its underlying liners) must be located entirely above the seasonal high water table;

(ii) The impoundment must be underlain by two liners which are designed and constructed in a manner that prevents the migration of liquids into or out of the space between the liners. Both liners must meet all the specifications of subsection (2)(a)(i) of this section;

(iii) A leak detection system must be designed, constructed, maintained, and operated between the liners to detect any migration of liquids into the space between the liners; and

(iv) A leachate detection, collection and removal system must be designed and operated to remove accumulated liquids from the system as quickly as possible so as to avoid unnecessary buildup of hydrostatic pressure in the system.

(b) If liquid leaks into the leak detection system, the owner or operator must:

(i) Notify the department of the leak in writing within seven days after detecting the leak; and

(ii)(A) Within a period of time specified in the permit, remove accumulated liquid, repair or replace the liner which is leaking to prevent the migration of liquids through the liner, and obtain a certification from a qualified engineer that, to the best of his knowledge and opinion, the leak has been stopped; or

(B) If a detection monitoring program pursuant to WAC 173-303-645(9) has already been established in the permit (to be complied with only if a leak occurs), begin to comply with that program and any other applicable requirements of WAC 173-303-645 within the period of time specified in the permit.

(c) The department will specify in the permit all design and operating practices that are necessary to ensure that the requirements of this section are satisfied.

(4) Monitoring and inspection.

(a) During construction and installation, liners (except in the case of existing portions of surface impoundments exempt from subsection (2)(a)(i) of this section) and cover systems (e.g., membranes, sheets, or coatings) must be inspected for uniformity, damage, and imperfections (e.g., holes, cracks, thin spots, or foreign materials). Immediately after construction or installation:

(i) Synthetic liners and covers must be inspected to ensure tight seams and joints and the absence of tears, punctures, or blisters; and

(ii) Soil-based and admixed liners and covers must be inspected for imperfections including lenses, cracks, channels, root holes, or other structural nonuniformities that may cause an increase in the permeability of the liner or cover.

(b) While a surface impoundment is in operation, it must be inspected weekly and after storms to detect evidence of any of the following:

(i) Deterioration, malfunctions, or improper operation of overtopping control systems;

(ii) Sudden drops in the level of the impoundment's contents;

(iii) The presence of liquids in leak detection systems, where installed to comply with subsection (3) of this section; and

(iv) Severe erosion or other signs of deterioration in dikes or other containment devices.

(c) Prior to the issuance of a permit, and after any extended period of time (at least six months) during which the impoundment was not in service, the owner or operator must obtain a certification from a qualified engineer that the impoundment's dike, including that portion of any dike which provides freeboard, has structural integrity. The certification must establish, in particular, that the dike:

(i) Will withstand the stress of the pressure exerted by the types and amounts of wastes to be placed in the impoundment; and

(ii) Will not fail due to scouring or piping, without dependence on any liner system included in the surface impoundment construction.

(5) Emergency repairs; contingency plans.

(a) A surface impoundment must be removed from service in accordance with (b) of this subsection when:

(i) Unexpected changes of liquid levels occur; or

(ii) The dike leaks.

(b) When a surface impoundment must be removed from service as required by (a) of this subsection, the owner or operator must:

(i) Immediately shut off the flow or stop the addition of wastes into the impoundment;

(ii) Immediately contain any surface leakage which has occurred or is occurring;

(iii) Immediately stop the leak;

(iv) Take any other necessary steps to stop or prevent catastrophic failure;

(v) Empty the impoundment, if a leak cannot be stopped by any other means; and

(vi) Notify the department of the problem in writing within seven days after detecting the problem.

(c) As part of the contingency plan required in WAC 173-303-340 through 173-303-360, the owner or operator must specify:

(i) A procedure for complying with the requirements of (b) of this subsection; and

(ii) A containment system evaluation and repair plan describing: Testing and monitoring techniques; procedures to be followed to evaluate the integrity of the containment system in the event of a possible failure; description of a schedule of actions to be taken in the event of a possible failure; and the repair techniques and materials (and their availability) to be used in the event of leakage due to containment system failure or deterioration which does not require the impoundment to be removed from service.

(d) No surface impoundment that has been removed from service in accordance with the requirements of this section may be restored to service unless the portion of the impoundment which was failing is repaired and the following steps are taken:

(i) If the impoundment was removed from service as the result of actual or imminent dike failure, the dike's structural integrity must be recertified in accordance with subsection (4)(c) of this section;

(ii) If the impoundment was removed from service as the result of a sudden drop in the liquid level, then:

(A) For any existing portion of the impoundment, a liner must be installed in compliance with subsection (2)(a)(i) or (3) of this section; and

(B) For any other portion of the impoundment, the repaired liner system must be certified by a qualified engineer as meeting the design specifications approved in the permit.

(e) A surface impoundment that has been removed from service in accordance with the requirements of this section and that is not being repaired must be closed in accordance with the provisions of subsection (6) of this section.

(6) Closure and post-closure care.

(a) At closure, the owner or operator must:

(i) Remove or decontaminate all dangerous waste and dangerous waste residues, contaminated containment system components (liners, etc.), contaminated subsoils, and structures and equipment contaminated with dangerous waste and leachate, and manage them as dangerous waste; or

(ii) If the surface impoundment will be closed as a landfill, except that this option is prohibited if EHW would remain in the closed unit(s):

(A) Eliminate free liquids by removing liquid wastes or solidifying the remaining wastes and waste residues;

(B) Stabilize remaining wastes to a bearing capacity sufficient to support a final cover; and

(C) Cover the surface impoundment with a final cover designed and constructed to:

(I) Provide long-term minimization of the migration of liquids through the closed impoundment with a material that has a permeability less than or equal to the permeability of any bottom liner system or natural subsoils present;

(II) Function with minimum maintenance;

(III) Promote drainage and minimize erosion or abrasion of the final cover; and

(IV) Accommodate settling and subsidence so that the cover's integrity is maintained.

(b) If some waste residues or contaminated materials are left in place at final closure (except that no EHW may ever be left in place), the owner or operator must comply with all post-closure requirements contained in WAC 173-303-610 (7), (8), (9), and (10), including maintenance and monitoring throughout the post-closure care period (specified in the permit). The owner or operator must:

(i) Maintain the integrity and effectiveness of the final cover, including making repairs to the cap as necessary to correct the effects of settling, subsidence, erosion, or other events;

(ii) Maintain and monitor the leak detection system in accordance with subsection (3) of this section, where such a system is present between double liner systems;

(iii) Maintain and monitor the ground water monitoring system and comply with all applicable requirements of WAC 173-303-645; and

(iv) Prevent run-on and run-off from eroding or otherwise damaging the final cover.

(c)(i) If an owner or operator plans to close a surface impoundment in accordance with (a)(i) of this subsection, and the impoundment does not comply with the liner requirements of subsection (2)(a)(i) of this section, and is not exempt from them in accordance with subsection (2)(b) of this section, then:

(A) The closure plan for the impoundment under WAC 173-303-610(3) must include both a plan for complying with (a)(i) of this subsection, and a contingent plan for complying with (a)(ii) of this subsection in case not all contaminated subsoils can be practicably removed at closure; and

(B) The owner or operator must prepare a contingent post-closure plan under WAC 173-303-610(8) for complying with (b) of this subsection in case not all contaminated subsoils can be practicably removed at closure.

(ii) The cost estimates calculated under WAC 173-303-620 (3) and (5) for closure and post-closure care of an impoundment subject to (c) of this subsection must include the cost of complying with the contingent closure plan and the contingent post-closure plan, but are not required to include the cost of expected closure under (a)(i) of this subsection.

(d) During the post-closure care period, if liquids leak into a leak detection system installed under subsection (3) of this section, the owner or operator must notify the department of the leak in writing within seven days after detecting the leak. The department will then modify the permit to require compliance with applicable requirements of WAC 173-303-645, or, if so requested by the owner or operator, to require removal of all materials in accordance with (a)(i) of this subsection.

(7) Special requirements for ignitable or reactive waste. Ignitable or reactive waste must not be placed in a surface impoundment, unless:

(a) The waste is treated, rendered, or mixed before or immediately after placement in the impoundment so that:

(i) The resulting waste, mixture, or dissolution of material no longer meets the definition of ignitable or reactive waste under WAC 173-303-090; and

(ii) WAC 173-303-395 (1)(b) is complied with; or

(b) The waste is managed in such a way that it is protected from any material or conditions which may cause it to ignite or react; or

(c) The surface impoundment is used solely for emergencies.

(8) Special requirements for incompatible wastes. Incompatible wastes and materials must not be placed in the same surface impoundment, unless WAC 173-303-395 (1)(b) is complied with.

(9) Special requirements for dangerous wastes F020, F021, F022, F023, F026, and F027.

(a) The wastes F020, F021, F022, F023, F026, or F027 must not be placed in a surface impoundment unless the owner or operator operates the surface impoundment in accordance with a management plan for these wastes that is approved by the department pursuant to the standards set out in this subsection, and in accord with all other applicable requirements of this section. The factors to be considered are:

(i) The volume, physical, and chemical characteristics of the wastes, including their potential to migrate through soil or to volatilize or escape into the atmosphere;

(ii) The attenuative properties of underlying and surrounding soils or other materials;

(iii) The mobilizing properties of other materials co-disposed with these wastes; and

(iv) The effectiveness of additional treatment, design, or monitoring techniques.

(b) The department may determine that additional design, operating, and monitoring requirements are necessary in order to reduce the possibility of migration of these wastes to ground water, surface water, or air so as to protect human health and the environment.

#### NEW SECTION

##### WAC 173-303-680 MISCELLANEOUS UNITS.

(1) Applicability. The requirements of this section apply to owners and operators of facilities that treat, store, or dispose of dangerous waste in miscellaneous units, except as WAC 173-303-600 provides otherwise.

(2) Environmental performance standards. A miscellaneous unit must be located, designed, constructed, operated, maintained, and closed in a manner that will ensure protection of human health and the environment. Permits for miscellaneous units are to contain such terms and provisions as necessary to protect human health and the environment, including, but not limited to, as appropriate, design and operating requirements, detection and monitoring requirements, and requirements for responses to releases of dangerous waste or dangerous constituents from the unit. Permit terms and provisions shall include those requirements in WAC 173-303-630 through 173-303-670, 173-303-806, and 40 CFR Part 146 that are appropriate for the miscellaneous units being permitted. Protection of human health and the environment includes, but is not limited to:

(a) Prevention of any releases that may have adverse effects on human health or the environment due to migration of wastes constituents in the ground water or subsurface environment, considering:

(i) The volume and physical and chemical characteristics of the waste in the unit, including its potential for migration through soil, liners, or other containing structures;

(ii) The hydrologic and geologic characteristics of the unit and the surrounding area;

(iii) The existing quality of ground water, including other sources of contamination and their cumulative impact on the ground water;

(iv) The quantity and direction of ground water flow;

(v) The proximity to and withdrawal rates of current and potential ground water users;

(vi) The patterns of land use in the region;

(vii) The potential for deposition or migration of waste constituents into subsurface physical structures, and into the root zone of food-chain crops and other vegetation;

(viii) The potential for health risks caused by human exposure to waste constituents; and

(ix) The potential for damage to domestic animals, wildlife, crops, vegetation, and physical structures caused by exposure to waste constituents.

(b) Prevention of any release that may have adverse effects on human health or the environment due to migration of waste constituents in surface water, or wetlands or on the soil surface considering:

(i) The volume and physical and chemical characteristics of the waste in the unit;

(ii) The effectiveness and reliability of containing, confining, and collecting systems and structures in preventing migration;

(iii) The hydrologic characteristics of the unit and the surrounding area, including the topography of the land around the unit;

(iv) The patterns of precipitation in the region;

(v) The quantity, quality, and direction of ground water flow;

(vi) The proximity of the unit to surface waters;

(vii) The current and potential uses of nearby surface waters and any water quality standards established for those surface waters;

(viii) The existing quality of surface waters and surface soils, including other sources of contamination and their cumulative impact on surface waters and surface soils;

(ix) The patterns of land use in the region;

(x) The potential for health risks caused by human exposure to waste constituents; and

(xi) The potential for damage to domestic animals, wildlife, crops, vegetation, and physical structures caused by exposure to waste constituents.

(c) Prevention of any release that may have adverse effects on human health or the environment due to migration of waste constituents in the air, considering:

(i) The volume and physical and chemical characteristics of the waste in the unit, including its potential for the emission and dispersal of gases, aerosols and particulates;

(ii) The effectiveness and reliability of systems and structures to reduce or prevent emissions of dangerous constituents to the air;

(iii) The operating characteristics of the unit;

(iv) The atmospheric, meteorologic, and topographic characteristics of the unit and the surrounding area;

(v) The existing quality of the air, including other sources of contamination and their cumulative impact on the air;

(vi) The potential for health risks caused by human exposure to waste constituents; and

(vii) The potential for damage to domestic animals, wildlife, crops, vegetation, and physical structures caused by exposure to waste constituents.

(3) Monitoring, analysis, inspection, response, reporting, and corrective action. Monitoring, testing, analytical data, inspections, response, and reporting procedures and frequencies must ensure compliance with subsection (2) of this section, WAC 173-303-320, 173-303-340(1), 173-303-380(3), 173-303-390 (1) and (3), and 173-303-645(12) as well as meet any additional requirements needed to protect human health and the environment as specified in the permit.

(4) Postclosure care. A miscellaneous unit that is a disposal unit must be maintained in a manner that complied with subsection (2) of this section during the postclosure care period. In addition, if a treatment or storage unit has contaminated soils or ground water that cannot be completely removed or decontaminated during closure, then that unit must also meet the requirements of subsection (2) of this section during postclosure care. The postclosure plan under WAC 173-303-610(8) must specify the procedures that will be used to satisfy this requirement.

AMENDATORY SECTION (Amending Order 88-29, filed 9/6/88)

WAC 173-303-800 PERMIT REQUIREMENTS FOR DANGEROUS WASTE MANAGEMENT FACILITIES. (1) The purpose of WAC 173-303-800 through 173-303-840 is to establish the requirements for permits which will allow a dangerous waste facility to operate without endangering the public health and the environment.

(2) The owner/operator of a dangerous waste facility that transfers, treats, stores, or disposes (TSD) or recycles dangerous waste shall, when required by this chapter, obtain a permit covering the active life, closure period, ground water protection compliance period, and for any regulated unit (as defined in WAC 173-303-040((75))), and for any facility which at closure does not meet the removal or decontamination limits of WAC 173-303-610 (2)(b), post-closure care period in accordance with WAC 173-303-800 through 173-303-840.

(3) TSD facility permits will be granted only if the objectives of the siting and performance standards set forth in WAC 173-303-420 and 173-303-283 are met.

(4) Permits shall be issued according to the requirements of all applicable TSD facility standards.

(5) The owner/operator of a TSD facility is responsible for obtaining all other applicable federal, state, and local permits authorizing the development and operation of the TSD facility.

(6) The terms used in regard to permits which are not defined in WAC 173-303-040 shall have the same meanings as set forth in 40 CFR 270.2.

(7) Exemptions.

(a) A permit for an on-site cleanup action may be exempted as provided in a consent decree or order signed by the department and issued pursuant to chapter 70.105D RCW.

(b) A permit is not required for an on-site cleanup action performed by the department pursuant to chapter 70.105D RCW.

(8) Each permit issued under this chapter shall contain terms and conditions as the department determines necessary to protect human health and the environment.

AMENDATORY SECTION (Amending Order 88-29, filed 9/6/88)

WAC 173-303-802 PERMITS BY RULE. (1) Purpose and applicability. This section provides for permit by rule for particular facilities and activities managing dangerous wastes, provided that certain conditions



are met. These facilities, activities, and conditions are listed in this section. Owners and operators of facilities with permits by rule are not required to submit an application for a dangerous waste facility permit.

(2) Ocean disposal barges or vessels. The owner or operator of a barge or other vessel which accepts dangerous waste for ocean disposal, shall have a permit by rule if the owner or operator:

(a) Has a permit for ocean dumping issued under 40 CFR Part 220 (Ocean Dumping, authorized by the Marine Protection, Research, and Sanctuaries Act, as amended, 33 U.S.C. § 1420 et seq.);

(b) Complies with the conditions of that permit; and

(c) Complies with the following dangerous waste regulations:

(i) WAC 173-303-060, notification and identification numbers;

(ii) WAC 173-303-170 through 173-303-230 when initiating shipments of dangerous waste;

(iii) WAC 173-303-370, manifest system;

(iv) WAC 173-303-380 (1)(a), operating record;

(v) WAC 173-303-390(2), annual report; and

(vi) WAC 173-303-390(1), unmanifested waste report.

(3) Underground injection wells. Underground injection wells with an underground injection control (UIC) permit for underground injection shall have a permit by rule if the owner or operator has a UIC permit issued by the department under a federally approved program for underground injection control, and complies with the conditions of the permit and requirements of 40 CFR 144.14 and applicable state waste discharge rules. All underground injection wells must comply with WAC 173-303-060, notification and identification numbers. However, underground injection wells disposing of EHW are prohibited.

(4) Publicly owned treatment works (POTW). The owner or operator of a POTW which accepts dangerous waste for treatment, shall have a permit by rule if the owner or operator:

(a) Has a National Pollutant Discharge Elimination System (NPDES) permit;

(b) Complies with the conditions of that permit;

(c) Complies with the following regulations:

(i) WAC 173-303-060, notification and identification numbers;

(ii) WAC 173-303-170 through 173-303-230 when initiating shipments of dangerous waste;

(iii) WAC 173-303-283, performance standards;

(iv) WAC 173-303-370, manifest system;

~~((iv))~~ (v) WAC 173-303-380 (1)(a), operating record;

~~((v))~~ (vi) WAC 173-303-390(2), annual report; and

~~((vi))~~ (vii) WAC 173-303-390(1), unmanifested waste reports;

(d) Accepts the waste only if it meets all federal, state, and local pretreatment requirements which would be applicable to the waste if it were being discharged into the POTW through a sewer, pipe, or similar conveyance; and

(e) Accepts no EHW for disposal at the POTW.

(5) Totally enclosed treatment facilities or elementary neutralization or wastewater treatment units.

(a) The owner or operator of a totally enclosed treatment facility or an elementary neutralization or wastewater treatment unit that treats dangerous wastes shall have a permit by rule, except as provided in (b) ~~((or (c)))~~ of this subsection, if he ~~((complies with))~~:

(i) ~~((WAC 173-303-060, notification and identification numbers;~~

~~((ii) WAC 173-303-310, 173-303-350, 173-303-360, 173-303-370, 173-303-380 (1)(d), and 173-303-390 of the general facility standards; and~~

~~((iii) WAC 173-303-283, performance standards.~~

~~(b) A facility is not required to have a permit by rule under this subsection if the owner or operator can demonstrate to the department's satisfaction that:~~

~~(i) The facility already has an existing permit (or permits) issued under federal, state or local authority (such as NPDES, state waste discharge, pretreatment, etc.); and~~

~~(ii) The permit (or permits) include, either separately or jointly in the case of multiple permits, all requirements specified in (a) of this subsection.~~

~~(c)) Has a NPDES permit, state waste discharge permit, pretreatment permit (or written discharge authorization from the local sewerage authority) and the permit or authorization provides effluent limits for the hazardous constituents, and provides for the use of all known, available, and reasonable methods of prevention, control, and treatment of pollution pursuant to chapter 90.48 RCW, prior to discharge;~~

~~((ii) Complies with the conditions of that permit;~~

~~((iii) Complies with the following regulations:~~

~~(A) WAC 173-303-060, notification and identification numbers;~~

~~(B) WAC 173-303-070, designation of dangerous waste;~~

~~(C) WAC 173-303-283, performance standards;~~

~~(D) WAC 173-303-310, security;~~

~~(E) WAC 173-303-350, contingency plan and emergency procedures;~~

~~(F) WAC 173-303-360, emergencies;~~

~~(G) WAC 173-303-370, manifest system;~~

~~(H) WAC 173-303-380 (1)(d), operating record;~~

~~(I) WAC 173-303-390, facility reporting.~~

~~(b) The department may require the owner or operator of a totally enclosed treatment facility or an elementary neutralization or wastewater treatment unit subject to either (a) ~~((or (b)))~~ of this subsection to apply for and obtain a final facility permit in accordance with WAC 173-303-800 through 173-303-840, if:~~

~~(i) The owner or operator violates the general facility or performance requirements specified in (a) of this subsection;~~

~~(ii) The owner or operator is conducting other activities which require him to obtain a final facility permit;~~

~~(iii) The department determines that the general facility or performance requirements specified in (a) of this subsection, are not sufficient to protect public health or the environment and that additional requirements under this chapter are necessary to provide such protection;~~

or

(iv) The owner or operator does not comply with applicable local, state or federal requirements established pursuant to sections 402 or 307(b) of the Federal Clean Water Act, or chapter 90.48 RCW.

**AMENDATORY SECTION** (Amending Order 88-24, filed 1/4/89)

WAC 173-303-805 INTERIM STATUS PERMITS. (1) Applicability. This section applies to all facilities eligible for an interim status permit. When a facility is owned by one person but is operated by another person, it is the operator's duty to qualify for interim status, except that the owner must also sign an interim status application. Prior to submittal of an interim status permit application the requirements of WAC 173-303-281 must be met.

(2) Failure to qualify for interim status. If the department has reason to believe upon examination of a Part A application that it fails to provide the required information, it shall notify the owner or operator in writing of the apparent deficiency. Such notice shall specify the grounds for the department's belief that the application is deficient. The owner or operator shall have thirty days from receipt to respond to such a notification and to explain or cure the alleged deficiency in his Part A application. If, after such notification and opportunity for response, the department determines that the application is deficient it may take appropriate enforcement action.

(3) Interim status for facilities under RCRA interim status. Any existing facility operating under interim status gained under section 3005 of RCRA shall be deemed to have an interim status permit under this chapter provided that the owner/operator complies with the applicable requirements of WAC 173-303-400 and this section.

(4) Interim status for facilities managing state-designated (non-RCRA) dangerous wastes. Any existing facility which does not satisfy subsection (3) of this section, but which is only managing dangerous wastes that are not hazardous wastes under 40 CFR Part 261, shall be deemed to have an interim status permit provided that the owner/operator of the facility has complied with the notification requirements of WAC 173-303-060 by May 11, 1982 and has submitted Part A of his permit application by August 9, 1982. If an existing facility becomes subject to this chapter due to amendments to this chapter and the facility was not previously subject to this chapter, then the owner/operator of an existing facility may qualify for an interim status permit by complying with the notification requirements of WAC 173-303-060 within three months, and submitting Part A of his permit application within six months, after the adoption date of the amendments which cause the facility to be subject to the requirements of this chapter. Facilities qualifying for interim status under this subsection shall not be deemed to have interim status under section 3005 of RCRA, and may only manage non-RCRA wastes until they either qualify separately for interim status under section 3005 of RCRA or receive a final status facility permit allowing them to manage RCRA wastes.

(5) Maintaining the interim status permit.

(a) Timely notification and submission of a Part A application qualifies the owner/operator of the existing TSD facility for the interim status permit, until the department terminates interim status pursuant to subsection (8) of this section.

(b) Interim status for the existing TSD facility shall be maintained while the department makes final administrative disposition of a final facility permit pursuant to WAC 173-303-806 if:

(i) The owner/operator has submitted his final facility permit application (as described in WAC 173-303-806) within six months of the written request by the department to submit such application; and

(ii) Grounds for terminating interim status (as described in subsection (8) of this section) do not exist.

(c) The owner/operator of an interim status facility must update his Part A whenever he is managing wastes that are newly regulated under this chapter, and as necessary to comply with subsection (7) of this section. Failure to comply with this updating requirement is a violation of interim status.

(6) Prohibitions for interim status permits. Facilities with an interim status permit shall not:

(a) Treat, store, or dispose of dangerous waste not specified in Part A of the permit application;

(b) Employ processes not specified in Part A of the permit application; or

(c) Exceed the design capacities specified in Part A of the permit application.

(7) Changes during interim status.

~~((a) Dangerous wastes not previously identified in Part A of the application may be treated, stored, or disposed at a facility with interim status if the owner/operator submits to the department a revised Part A permit application prior to accepting the new dangerous wastes.~~

~~(b) Increases in the design capacity of processes used at a facility with interim status may be made if the owner or operator submits a revised Part A permit application prior to such a change, the requirements of WAC 173-303-281 are met and the department approves the change because of a lack of available treatment, storage, or disposal capacity at other permitted TSD facilities.~~

~~(c) Changes in the processes for the treatment, storage, or disposal of dangerous waste may be made at a facility with interim status, or additional processes may be added if the owner or operator submits a revised Part A permit application prior to such changes, the requirements of WAC 173-303-281 are met and the department approves the change because:~~

~~(i) It is necessary to prevent a threat to public health or the environment because of an emergency situation; or~~

~~(ii) It is necessary to comply with state, local, or federal regulations.~~

~~(d) Changes in the ownership or operational control of a facility with interim status may be made if the new owner or operator submits a revised Part A permit application no later than ninety days prior to the scheduled change. When a transfer of ownership or operational~~

~~control of a facility occurs, the old owner or operator shall comply with the interim status financial requirements of 40 CFR Part 265 subpart H (as referenced in WAC 173-303-400), until the new owner or operator has demonstrated to the department that he is complying with the financial requirements. The new owner or operator must demonstrate compliance with the financial requirements within six months of the date of the change in the ownership or operational control of the facility. All other interim status duties are transferred effective immediately upon the date of the change of ownership or operational control of the facility. Upon demonstration to the department by the new owner or operator of compliance with the interim status financial requirements, the department shall notify the old owner or operator in writing that he no longer needs to comply with the interim status financial requirements as of the date of demonstration.~~

~~(c) In no event shall changes be made to a TSD facility under the interim status permit which amount to reconstruction of the facility. Reconstruction occurs when the capital investment in the changes to the facility exceeds fifty percent of the capital cost of a comparable entirely new TSD facility.~~

~~(f) Any revisions to an existing interim status permit must be made on the applicable Part A form(s), (forms 1 or 3 are available from the department). The owner and operator certification page must be signed and included with those sections completed.~~

~~(g) Changes under this subsection do not include changes made solely for the purpose of complying with requirements of WAC 173-303-640(4) for tanks and ancillary equipment:))~~

~~(a) Except as provided in (b) of this subsection, the owner or operator of an interim status facility may make the following changes at the facility:~~

~~(i) Treatment, storage, or disposal of new dangerous wastes not previously identified in Part A of the permit application (and, in the case of newly listed or identified wastes, addition of the units being used to treat, store, or dispose of the dangerous wastes on the effective date of the listing or identification) if the owner or operator submits a revised Part A permit application prior to such treatment, storage, or disposal (along with a justification detailing the equipment and process or processes that the owner or operator will use to treat, store, or dispose of the new dangerous wastes) and if the department does not explicitly deny the changes within sixty days of receipt of the revised application;~~

~~(ii) Increases in the design capacity of processes used at the facility if the owner or operator submits a revised Part A permit application prior to such a change (along with a justification explaining the need for the change), the requirements of WAC 173-303-281 are met, and the department approves the changes because:~~

~~(A) There is a lack of available treatment, storage, or disposal capacity at other dangerous waste management facilities; or~~

~~(B) The change is necessary to comply with a federal, state, or local requirement.~~

(iii) Changes in the processes for the treatment, storage, or disposal of dangerous waste or addition of processes if the owner or operator submits a revised Part A permit application prior to such change (along with a justification explaining the need for the change) and the department approves the change because:

(A) The change is necessary to prevent a threat to human health and the environment because of an emergency situation; or

(B) The change is necessary to comply with a federal, state, or local requirement.

(iv) Changes in the ownership or operational control of a facility if the new owner or operator submits a revised Part A permit application no later than ninety days prior to the scheduled change. When a transfer of operational control of a facility occurs, the old owner or operator shall comply with the interim status financial requirements of 40 CFR Part 265, Subpart H (as referenced in WAC 173-303-400), until the new owner or operator has demonstrated to the department that he is complying with the financial requirements. Upon demonstration to the department by the new owner or operator of compliance with the interim status financial requirements, the department shall notify the old owner or operator in writing that he no longer needs to comply with the interim status financial requirements as of the date of demonstration. The new owner or operator must demonstrate compliance with the financial requirements within six months of the date of the change in ownership or operational control of the facility. All other interim status duties are transferred effective immediately upon the date of the change in ownership or operational control of the facility.

(v) Changes made in accordance with an interim status corrective action order issued by EPA under section 3008(h) of RCRA or other federal authority, by the department under chapter 70.105 RCW or other state authority, or by a court in a judicial action brought by EPA or by the department. Changes under this subsection (7)(a)(v) are limited to the treatment, storage, or disposal of solid waste from releases that originate within the boundary of the facility.

(b) Except as specifically allowed under this subsection (7)(b), changes listed under (a) of this subsection may not be made if they amount to reconstruction of the dangerous waste management facility. Reconstruction occurs when the capital investment in the changes to the facility exceeds fifty percent of the capital cost of a comparable entirely new dangerous waste management facility. If all other requirements are met, the following changes may be made even if they amount to a reconstruction:

(i) Changes made solely for the purposes of complying with the requirements of WAC 173-303-640(4) for tanks and ancillary equipment.

(ii) If necessary to comply with federal, state, or local requirements, changes to an existing unit, changes solely involving tanks or containers, or addition of replacement surface impoundments that satisfy the standards of section 3004(o) of RCRA.

(iii) Changes that are necessary to allow owners or operators to continue handling newly listed or identified

dangerous wastes that have been treated, stored, or disposed of at the facility prior to the effective date of the rule establishing the new listing or identification.

(iv) Changes during closure of a facility or of a unit within a facility made in accordance with an approved closure plan.

(v) Changes necessary to comply with an interim status corrective action order issued by EPA under section 3008(h) or other federal authority, by an authorized state under comparable state authority, or by a court in a judicial proceeding brought by EPA or an authorized state, provided that such changes are limited to the treatment, storage, or disposal of solid waste from releases that originate within the boundary of the facility.

(vi) Changes to treat or store, in tanks or containers, hazardous wastes subject to land disposal restrictions imposed by 40 CFR Part 268 or RCRA section 3004, provided that such changes are made solely for the purpose of complying with 40 CFR Part 268 or RCRA section 3004.

(8) Termination of interim status permit. The following are causes for terminating an interim status permit, or for denying a revised permit application:

(a) Final administrative disposition of a final facility permit application is made pursuant to WAC 173-303-806;

(b) When the department on examination or reexamination of a Part A application determines that it fails to meet the applicable standards of this chapter, it may notify the owner or operator that the application is deficient and that the interim status permit has been revoked. The owner or operator will then be subject to enforcement for operating without a permit;

(c) Failure to submit a requested Part B application on time, or to provide in full the information required in the Part B application;

(d) Violation of applicable interim status standards; or

(e) A determination that the permit applicant has failed to satisfy the performance standards of WAC 173-303-283.

(9) Special waste facilities. If the department determines, pursuant to WAC 173-303-550 through 173-303-560, that interim status standards can be reduced, the department will issue a notice of interim status modification stating what standards will be applied. Failure to comply with the conditions and standards as stated in the notice of modification or with the requirements of this section shall form a basis for revoking the notice. Upon revocation of the notice of interim status modification by the department, the owner or operator shall be subject to all of the requirements applicable to interim status dangerous waste management facilities. Before issuing the notice of modification, the department shall provide public notice of its intent, shall allow thirty days for public comment, and shall hold a public hearing if there is a significant degree of public interest or there is written notice of opposition and the department receives a request for a hearing during the comment period. Notice of a public hearing shall be provided at least fifteen days in advance, and the public comment period shall be extended to include the date of the hearing if it will occur after the initial thirty-day comment period.

Within fifteen days of the end of the public comment period the department shall, based on comments received, issue, modify and issue, or deny the notice of interim status modification.

**AMENDATORY SECTION** (Amending WSR 90-20-016, filed 9/21/90, effective 10/22/90)

**WAC 173-303-806 FINAL FACILITY PERMITS.** (1) Applicability. This section applies to all dangerous waste facilities required to have a final facility permit. The final facility permit requirements are applicable to:

(a) Final status TSD facilities;

(b) Special waste management facilities; and

(c) Certain recycling facilities that are not exempt from the permit requirements.

(2) Application. Any person subject to the permit requirements of this section who intends to operate a new TSD facility must comply with WAC 173-303-281 and apply for a final facility permit. The department may, at any time, require the owner or operator of an existing TSD facility to apply for a final facility permit. Such owner or operator will be allowed one hundred eighty days to submit his application; the department may extend the length of the application period if it finds that there are good reasons to do so. The owner or operator of an existing TSD facility may voluntarily apply for a final facility permit at any time. Any person seeking a final facility permit shall complete, sign, and submit an application to the department. An application shall consist of a Part A permit form (which can be obtained from the department), and the contents of Part B as specified in subsection (4) of this section.

(3) Effective regulations. A final facility permit will include all applicable requirements of this chapter which are in effect on the date that the permit is issued by the department. WAC 173-303-840(7) provides a means for reopening permit proceedings at the discretion of the department where new requirements become effective during the permitting process and are of sufficient magnitude to make additional proceedings desirable. Any other changes to the final facility permit will be in accordance with the permit modification requirements of WAC 173-303-830.

(4) Contents of Part B. Part B of a permit application shall consist of the information required in (a) through ~~((h))~~ (i) of this subsection.

(a) General requirements. Part B of the permit application consists of the general information requirements of this subsection, and the specific information requirements in (b) through (h) of this subsection as applicable to the facility. The Part B information requirements presented in (a) through (h) of this subsection, reflect the standards promulgated in WAC 173-303-600. These information requirements are necessary in order for the department to determine compliance with WAC 173-303-600 through 173-303-670. If owners and operators of TSD facilities can demonstrate that the information prescribed in Part B cannot be provided to the extent required, the department may make allowance for submission of such information on a case-by-case basis. Information required in Part B shall be submitted to the

department and signed in accordance with requirements in WAC 173-303-810(12). Certain technical data, such as design drawings and specifications, and engineering studies shall be certified by a registered professional engineer. The following information is required for all TSD facilities, except as WAC 173-303-600(3) provides otherwise.

(i) A general description of the facility.

(ii) Chemical, biological, and physical analyses of the dangerous waste to be handled at the facility. At a minimum, these analyses shall contain all the information which must be known to treat, store, or dispose of the wastes properly in accordance with WAC 173-303-600.

(iii) A copy of the waste analysis plan required by WAC 173-303-300(5) and, if applicable WAC 173-303-300 (5)(g).

(iv) A description of the security procedures and equipment required by WAC 173-303-310, or a justification demonstrating the reasons for requesting a waiver of this requirement.

(v) A copy of the general inspection schedule required by WAC 173-303-320(2): Include where applicable, as part of the inspection schedule, specific requirements in WAC 173-303-395 (1)(d), 173-303-630(6), 173-303-640 (4) and (6), 173-303-650(4), 173-303-655(4), 173-303-660 (4) and (5), 173-303-665(4), ((and)) 173-303-670(7), and 173-303-680(3).

(vi) A justification of any request for a waiver(s) of the preparedness and prevention requirements of WAC 173-303-340, or a description of the procedures used to comply with these requirements.

(vii) A copy of the contingency plan required by WAC 173-303-350: Include, where applicable, as part of the contingency plan, specific requirements in WAC 173-303-640(8), 173-303-650(5) and 173-303-660(6).

(viii) A description of procedures, structures, or equipment used at the facility to:

(A) Prevent hazards and contain spills in unloading/loading operations (for example, ramps, berms, pavement, special forklifts);

(B) Prevent run-off from dangerous waste handling areas to other areas of the facility or environment, or to prevent flooding (for example, berms, dikes, trenches);

(C) Prevent contamination of water supplies;

(D) Mitigate effects of equipment failure and power outages; and

(E) Prevent undue exposure of personnel to dangerous waste (for example, protective clothing).

(ix) A description of precautions to prevent accidental ignition or reaction of ignitable, reactive, or incompatible wastes as required to demonstrate compliance with WAC 173-303-395 including documentation demonstrating compliance with WAC 173-303-395 (1)(c).

(x) Traffic pattern, estimated volume (number, types of vehicles) and control (for example, show turns across traffic lanes, and stacking lanes (if appropriate); describe access road surfacing and load bearing capacity; show traffic control signals).

(xi) Seismic risk consideration. The owner/operator of a proposed facility or expansion of an existing facility shall identify the seismic risk zone in which the facility is intended to be located. Where state or local maps are

not available, United States Geological Survey Open File Report number 82-1033 may be used to identify seismic risk zones. The owner/operator shall demonstrate that the facility can and will be designed to resist seismic ground motion and that the design is sufficient to withstand the maximum horizontal acceleration of a design earthquake specified in the demonstration.

(xii) An outline of both the introductory and continuing training programs by owners or operators to prepare persons to operate or maintain the TSD facility in a safe manner as required to demonstrate compliance with WAC 173-303-330. A brief description of how training will be designed to meet actual job tasks in accordance with requirements in WAC 173-303-330 (1)(d).

(xiii) A copy of the closure plan and, where applicable, the post-closure plan required by WAC 173-303-610 (3) and (8). Include, where applicable, as part of the plans, specific requirements in WAC 173-303-630(10), 173-303-640(5), 173-303-650(6), 173-303-655(8), 173-303-660(9), ((and)) 173-303-665(6), and 173-303-680 (2) and (4).

(xiv) For dangerous waste disposal units that have been closed, documentation that notices required under WAC 173-303-610(10) have been filed.

(xv) The most recent closure cost estimate for the facility prepared in accordance with WAC 173-303-620(3) and a copy of the documentation required to demonstrate financial assurance under WAC 173-303-620(4). For a new facility, a copy of the required documentation may be submitted sixty days prior to the initial receipt of dangerous wastes, if that is later than the submission of the Part B.

(xvi) Where applicable, the most recent post-closure cost estimate for the facility prepared in accordance with WAC 173-303-620(5) plus a copy of the documentation required to demonstrate financial assurance under WAC 173-303-620(6). For a new facility, a copy of the required documentation may be submitted sixty days prior to the initial receipt of dangerous wastes, if that is later than the submission of the Part B.

(xvii) Where applicable, a copy of the insurance policy or other documentation which comprises compliance with the requirements of WAC 173-303-620(8). For a new facility, documentation showing the amount of insurance meeting the specification of WAC 173-303-620 (8)(a) and, if applicable, WAC 173-303-620 (8)(b), that the owner or operator plans to have in effect before initial receipt of dangerous waste for treatment, storage, or disposal. A request for a variance in the amount of required coverage, for a new or existing facility, may be submitted as specified in WAC 173-303-620 (8)(c).

(xviii) A topographic map showing a distance of one thousand feet around the facility at a scale of 2.5 centimeters (1 inch) equal to not more than 61.0 meters (200 feet). Contours must be shown on the map. The contour interval must be sufficient to clearly show the pattern of surface water flow in the vicinity of and from each operational unit of the facility. For example, contours with an interval of 1.5 meters (5 feet), if relief is greater than 6.1 meters (20 feet), or an interval of 0.6 meters (2 feet), if relief is less than 6.1 meters (20 feet). Owners and operators of TSD facilities located in mountainous

areas should use large contour intervals to adequately show topographic profiles of facilities. The map shall clearly show the following:

- (A) Map scale and date;
- (B) One hundred-year floodplain area;
- (C) Surface waters including intermittent streams;
- (D) Surrounding land uses (residential, commercial, agricultural, recreational);
- (E) A wind rose (i.e., prevailing windspeed and direction);
- (F) Orientation of the map (north arrow);
- (G) Legal boundaries of the TSD facility site;
- (H) Access control (fences, gates);
- (I) Injection and withdrawal wells both on-site and off-site;
- (J) Buildings; treatment, storage, or disposal operations; or other structure (recreation areas, run-off control systems, access and internal roads, storm, sanitary, and process sewerage systems, loading and unloading areas, fire control facilities, etc.);
- (K) Barriers for drainage or flood control; and
- (L) Location of operational units within the TSD facility site, where dangerous waste is (or will be) treated, stored, or disposed (include equipment clean-up areas).

(Note - For large TSD facilities the department will allow the use of other scales on a case-by-case basis.)

(ix) Applicants may be required to submit such information as may be necessary to enable the department to carry out its duties under other state or federal laws as required.

(xx) Additional information requirements. The following additional information regarding protection of ground water is required from owners or operators of dangerous waste surface impoundments, waste piles, land treatment units, and landfills except as otherwise provided in WAC 173-303-645 (1)(b):

(A) A summary of the ground water monitoring data obtained during the interim status period under 40 CFR 265.90 through 265.94, where applicable;

(B) Identification of the uppermost aquifer and aquifers hydraulically interconnected beneath the facility property, including ground water flow direction and rate, and the basis for such identification (i.e., the information obtained from hydrogeologic investigations of the facility area);

(C) On the topographic map required under (a)(xviii) of this subsection, a delineation of the waste management area, the property boundary, the proposed "point of compliance" as defined under WAC 173-303-645(6), the proposed location of ground water monitoring wells as required under WAC 173-303-645(8), and, to the extent possible, the information required in (a)(xx)(B) of this subsection;

(D) A description of any plume of contamination that has entered the ground water from a regulated unit at the time that the application was submitted that:

(I) Delineates the extent of the plume on the topographic map required under (a)(xviii) of this subsection;

(II) Identifies the concentration of each constituent throughout the plume or identifies the maximum concentrations of each constituent in the plume. (Constituents are those listed in WAC 173-303-9905, and any

other constituents not listed there which have caused a managed waste to be regulated under this chapter.);

(E) Detailed plans and an engineering report describing the proposed ground water monitoring program to be implemented to meet the requirements of WAC 173-303-645(8);

(F) If the presence of dangerous constituents has not been detected in the ground water at the time of permit application, the owner or operator must submit sufficient information, supporting data, and analyses to establish a detection monitoring program which meets the requirements of WAC 173-303-645(9). This submission must address the following items specified under WAC 173-303-645(9):

(I) A proposed list of indicator parameters, waste constituents, or reaction products that can provide a reliable indication of the presence of dangerous constituents in the ground water;

(II) A proposed ground water monitoring system;

(III) Background values for each proposed monitoring parameter or constituent, or procedures to calculate such values; and

(IV) A description of proposed sampling, analysis and statistical comparison procedures to be utilized in evaluating ground water monitoring data;

(G) If the presence of dangerous constituents has been detected in the ground water at the point of compliance at the time of permit application, the owner or operator must submit sufficient information, supporting data, and analyses to establish a compliance monitoring program which meets the requirements of WAC 173-303-645(10). The owner or operator must also submit an engineering feasibility plan for a corrective action program necessary to meet the requirements of WAC 173-303-645(11) except as provided in WAC 173-303-645(9)(h)(v). Alternatively, the owner or operator can obtain written authorization in advance from the department to submit a proposed permit schedule for development and submittal of such information. To demonstrate compliance with WAC 173-303-645(10), the owner or operator must address the following items:

(I) A description of the wastes previously handled at the facility;

(II) A characterization of the contaminated ground water, including concentrations of dangerous constituents and parameters;

(III) A list of constituents and parameters for which compliance monitoring will be undertaken in accordance with WAC 173-303-645 (8) and (10);

(IV) Proposed concentration limits for each dangerous constituent and parameter, based on the criteria set forth in WAC 173-303-645 (5)(a), including a justification for establishing any alternate concentration limits;

(V) Detailed plans and an engineering report describing the proposed ground water monitoring system, in accordance with the requirements of WAC 173-303-645(8); and

(VI) A description of proposed sampling, analysis and statistical comparison procedures to be utilized in evaluating ground water monitoring data; and

(H) If dangerous constituents or parameters have been measured in the ground water which exceed the

concentration limits established under WAC 173-303-645(5), Table 1, or if ground water monitoring conducted at the time of permit application under 40 CFR 265.90 through 265.94 at the waste boundary indicates the presence of dangerous constituents from the facility in ground water over background concentrations, the owner or operator must submit sufficient information, supporting data, and analyses to establish a corrective action program which meets the requirements of WAC 173-303-645(11). However, an owner or operator is not required to submit information to establish a corrective action program if he demonstrates to the department that alternate concentration limits will protect human health and the environment after considering the criteria listed in WAC 173-303-645(5). An owner or operator who is not required to establish a corrective action program for this reason must instead submit sufficient information to establish a compliance monitoring program which meets the requirements of WAC 173-303-645(10) and (a)(xx)(F) of this subsection. To demonstrate compliance with WAC 173-303-645(11), the owner or operator must address, at a minimum, the following items:

(I) A characterization of the contaminated ground water, including concentrations of dangerous constituents and parameters;

(II) The concentration limit for each dangerous constituent and parameter found in the ground water as set forth in WAC 173-303-645(5);

(III) Detailed plans and an engineering report describing the corrective action to be taken;

(IV) A description of how the ground water monitoring program will demonstrate the adequacy of the corrective action; and

(V) The permit may contain a schedule for submittal of the information required in (a)(xx)(H)(III) and (IV) of this subsection, provided the owner or operator obtains written authorization from the department prior to submittal of the complete permit application.

(xxi) Contingent ground water protection program. The following actions are required for owners or operators of proposed land-based facilities and may be required for owners/operators of existing land-based facilities, except as provided in WAC 173-303-645 (1)(b).

(A) Contingent ground water protection program. The owner or operator shall develop a contingent ground water protection program. The purpose of this program will be to prevent the migration of dangerous waste or dangerous waste constituents from waste management units to the nearest hydraulically downgradient receptor at any time during the life of the facility. For the purposes of this subsection, the downgradient receptor shall be the facility property line, perennial surface water or domestic well, whichever is nearest to the dangerous waste management unit. The contingent ground water protection program shall at a minimum:

(I) Define the local and regional hydrogeologic characteristics. The contingent ground water protection program shall be based on a sufficient understanding of site geology, hydrology, and other factors to allow evaluation of its adequacy by the department. Site characterization shall be performed in sufficient detail to provide, at a

minimum, the following information: Site geostratigraphy; site hydrostratigraphy; identification of aquifers, aquitards, and aquicludes; flow models for each stratum (i.e., porous media or fracture flow); the distribution of vertical and horizontal hydraulic conductivity; effective porosity; horizontal and vertical hydraulic gradients; ground water travel time to receptors; and heterogeneity for each stratigraphic unit. Site interpretative models shall include ranges of tested values: The provisions of WAC 173-303-806 (4)(a)(xx) and 173-303-645, shall be used as guidance in the development of the contingent ground water protection program.

(II) Identify the range of potential release scenarios that could occur during facility operation and the postclosure care period. The scenarios shall incorporate the intended design(s) of the dangerous waste management unit(s), wastes to be placed in the dangerous waste management unit(s), waste and leachate chemistry, waste, and soil and rock geochemical interactions, and the results of site characterization pursuant to WAC 173-303-806 (4)(a)(xx) and (xxi);

(III) Include specific physical action to be taken if dangerous waste or dangerous waste constituents are detected in one or more of the monitoring wells. The physical actions shall be based upon engineering feasibility studies describing remedial actions established from site specific conditions and waste features. Such actions may include installation of a pump and treat system between the monitoring well and the receptor or installation of a section of slurry wall to decrease ground water travel times. The description of the systems shall also provide how the remediation system will achieve cleanup, its efficiency, and the timeframes involved;

(IV) Incorporate the design, construction, and sampling methods outlined in WAC 173-303-645 (8)(c), (d), (e), (f), and (g);

(V) Demonstrate to the satisfaction of the department that the owner/operator of the dangerous waste management facility has the financial capability to implement the proposed ground water protection plan; and

(VI) Include reporting procedures to the department.

(B) The response actions identified in WAC 173-303-806 (4)(a)(xxi)(A)(III) shall be activated if the presence of dangerous waste or dangerous waste constituents have been detected at the point of compliance in accordance with WAC 173-303-645 (9)(g), and shall continue until the concentration of dangerous waste or dangerous waste constituents under WAC 173-303-645(4) are reduced to levels below their respective concentration limits specified in WAC 173-303-645(5).

(C) If the owner/operator does not demonstrate that the ground water protection program will prevent the migration of dangerous waste or its constituents to the nearest receptor, the department will require corrections to be made in the protection program, increase setbacks from the nearest receptor, or deny the permit.

(xxii) Additional requirements for incineration facilities. The following actions regarding the protection of human health and the environment must be taken by owners/operators of proposed hazardous waste incineration facilities and may be required for owners or operators of existing incineration facilities.



(A) Ambient monitoring program. The owner/operator shall be required to develop an ambient monitoring program. The purpose of this ambient monitoring program will be to: Gather baseline environmental information characterizing on-site and off-site environmental conditions prior to facility operation; and, to identify and measure changes in the environment which may be linked to the construction and operation of the facility. The ambient monitoring program shall, at a minimum:

(I) Include a characterization of facility emission sources and pathways of contaminant transport.

(II) Characterize local and regional ecosystems, including agricultural, and their sensitivity to the potential contaminants from the facility.

(III) Incorporate the findings of the environmental impact statement's health risk assessment and/or other assessments specific to the proposal or available to the scientific community regarding emissions from dangerous waste management facilities and their potential human health and environmental effects.

(IV) Identify sensitive indicator plants and animals for biomonitoring, identify specific chemical constituents of concern, sampling locations, sampling frequency, sampling and analytical methods, chain of custody procedures, quality assurance/quality control procedures, reporting times, recordkeeping procedures, and data evaluation procedures.

(B) Environmental review procedures. The owner/operator shall establish procedures to allow for public review of facility operation and all monitoring data required by the facility's permit. In developing this process, the owner/operator shall, at a minimum:

(I) Coordinate this effort with the public and interested local organizations;

(II) Identify the informational needs of the community and develop a public information process which meets these needs; and

(III) Develop procedures allowing full access by the public to all monitoring data required by the permit.

(C) Impact mitigation plan. Prior to the department issuing a permit, the owner/operator shall submit an impact mitigation plan which demonstrates to the satisfaction of the department that the owner/operator will mitigate all probable significant adverse impacts, including economic, due to facility location and operations. The owner/operator shall use as a basis for identifying probable significant adverse economic impacts those probable economic impacts identified during a public review process, such as the environmental impact statement scoping process, if applicable.

The plan must include, but is not limited to, a description of what the owner/operator will do to reduce or prevent any probable significant impacts before they occur, to mitigate such impacts should they occur, and to ensure the owner/operator has and will have the financial capability to implement such preventative and mitigative measures. Mitigation measures may include, as an element, financial compensation to adversely affected parties.

This plan may be submitted with environmental reports the department requires for compliance with the State Environmental Policy Act, with the written citizen

proponent negotiation report and agreements, or with the Part B permit application. If the plan does not demonstrate that the owner/operator is capable of adequately mitigating the identified probable significant adverse economic impacts, the department will require modification of the plan or of the proposed facility location, or will deny the permit application. The department must be satisfied with the plan prior to the issuance of the permit.

(b) Specific Part B information requirements for containers. Except as otherwise provided in WAC 173-303-600(3), owners or operators of facilities that store containers of dangerous waste must provide the following additional information:

(i) A description of the containment system to demonstrate compliance with WAC 173-303-630(7). Show at least the following:

(A) Basic design parameters, dimensions, and materials of construction including allowance for a twenty-five-year, twenty-four-hour storm;

(B) How the design promotes positive drainage control or how containers are kept from contact with standing liquids in the containment system;

(C) Capacity of the containment system relative to the volume of the largest container to be stored;

(D) Provisions for preventing or managing run-on;

(E) How accumulated liquids can be analyzed and removed to prevent overflow; and

(F) A description of the building or other protective covering for EHW containers;

(ii) For storage areas that store containers holding wastes that do not contain free liquids, a demonstration of compliance with WAC 173-303-630 (7)(c), including:

(A) Test procedures and results or other documentation or information to show that the wastes do not contain free liquids; and

(B) A description of how the storage area is designed or operated to drain and remove liquids or how containers are kept from contact with standing liquids;

(iii) A description of the procedures for labeling containers;

(iv) Sketches, drawings, or data demonstrating compliance with WAC 173-303-630(8) (location of buffer zone and containers holding ignitable or reactive wastes) and WAC 173-303-630 (9)(c) (location of incompatible wastes), where applicable; and

(v) Where incompatible wastes are stored or otherwise managed in containers, a description of the procedures used to ensure compliance with WAC 173-303-630 (9)(a) and (b), and 173-303-395 (1)(b) and (c).

(c) Specific Part B information requirements for tanks. Except as otherwise provided in WAC 173-303-600(3), owners and operators of facilities that use tanks to store or treat dangerous waste must provide the following information:

(i) A written assessment that is reviewed and certified by an independent, qualified, registered professional engineer as to the structural integrity and suitability for handling dangerous waste of each tank system, as required under WAC 173-303-640 (2) and (3);

(ii) Dimensions and capacity of each tank;

(iii) Description of feed systems, safety cutoff, bypass systems, and pressure controls (e.g., vents);

(iv) A diagram of piping, instrumentation, and process flow for each tank system;

(v) A description of materials and equipment used to provide external corrosion protection, as required under WAC 173-303-640 (3)(a)(iii)(B);

(vi) For new tank systems, a detailed description of how the tank system(s) will be installed in compliance with WAC 173-303-640 (3)(b), (c), (d), and (e);

(vii) Detailed plans and a description of how the secondary containment system for each tank system is or will be designed, constructed, and operated to meet the requirements of WAC 173-303-640 (4)(a), (b), (c), (d), (e), and (f);

(viii) For tank systems for which a variance from the requirements of WAC 173-303-640(4) is sought (as provided by WAC 173-303-640 (4)(g)):

(A) Detailed plans and engineering and hydrogeologic reports, as appropriate, describing alternate design and operating practices that will, in conjunction with location aspects, prevent the migration of any dangerous waste or dangerous constituents into the ground water or surface water during the life of the facility; or

(B) A detailed assessment of the substantial present or potential hazards posed to human health or the environment should a release enter the environment.

(ix) Description of controls and practices to prevent spills and overflows, as required under WAC 173-303-640 (5)(b);

(x) For tank systems in which ignitable, reactive, or incompatible wastes are to be stored or treated, a description of how operating procedures and tank system and facility design will achieve compliance with the requirements of WAC 173-303-640 (9) and (10);

(xi) A description of the marking and/or labeling of tanks; and

(xii) Tank design to prevent escape of vapors and emissions of acutely or chronically toxic (upon inhalation) EHW.

(d) Specific Part B information requirements for surface impoundments. Except as otherwise provided in WAC 173-303-600(3), owners and operators of facilities that store, treat, or dispose of dangerous waste in surface impoundments must provide the following additional information:

(i) A list of the dangerous wastes placed or to be placed in each surface impoundment;

(ii) Detailed plans and an engineering report describing how the surface impoundment is or will be designed, constructed, operated and maintained to meet the requirements of WAC 173-303-650(2). This submission must address the following items as specified in WAC 173-303-650(2):

(A) The liner system (except for an existing portion of a surface impoundment), including the certification required by WAC 173-303-650 (2)(a)(i)(D) for EHW management. If an exemption from the requirement for a liner is sought as provided by WAC 173-303-650 (2)(b), submit detailed plans and engineering and

hydrogeologic reports, as appropriate, describing alternate design and operating practices that will, in conjunction with location aspects, prevent the migration of any dangerous constituents into the ground water or surface water at any future time;

(B) Prevention of overtopping; and

(C) Structural integrity of dikes;

(iii) If any exemption from WAC 173-303-645 is sought, as provided by WAC 173-303-650(3), detailed plans and an engineering report explaining the location of the saturated zone in relation to the surface impoundment, and the design of a double-liner system that incorporates a leak detection system between the liners;

(iv) A description of how each surface impoundment, including the liner and cover systems and appurtenances for control of overtopping, will be inspected in order to meet the requirements of WAC 173-303-650 (4)(a) and (b). This information should be included in the inspection plan submitted under (a)(v) of this subsection;

(v) A certification by a qualified engineer which attests to the structural integrity of each dike, as required under WAC 173-303-650 (4)(c). For new units, the owner or operator must submit a statement by a qualified engineer that he will provide such a certification upon completion of construction in accordance with the plans and specifications;

(vi) A description of the procedure to be used for removing a surface impoundment from service, as required under WAC 173-303-650 (5)(b) and (c). This information should be included in the contingency plan submitted under (a)(vii) of this subsection;

(vii) A description of how dangerous waste residues and contaminated materials will be removed from the unit at closure, as required under WAC 173-303-650 (6)(a)(i). For any wastes not to be removed from the unit upon closure, the owner or operator must submit detailed plans and an engineering report describing how WAC 173-303-650 (6)(a)(ii) and (b) will be complied with. This information should be included in the closure plan and, where applicable, the post-closure plan submitted under (a)(xiii) of this subsection;

(viii) If ignitable or reactive wastes are to be placed in a surface impoundment, an explanation of how WAC 173-303-650(7) will be complied with;

(ix) If incompatible wastes, or incompatible wastes and materials will be placed in a surface impoundment, an explanation of how WAC 173-303-650(8) will be complied with; and

(x) Where applicable, a waste management plan for Dangerous Waste Nos. F020, F021, F022, F023, F026, or F027 describing how the surface impoundment is or will be designed to meet the requirements of WAC 173-303-650(9).

(e) Specific Part B information requirements for waste piles. Except as otherwise provided in WAC 173-303-600(3), owners and operators of facilities that store or treat dangerous waste in waste piles must provide the following additional information:

(i) A list of dangerous wastes placed or to be placed in each waste pile;

(ii) If an exemption is sought to WAC 173-303-660(2), and 173-303-645 as provided by WAC 173-

303-660 (1)(c), an explanation of how the standards of WAC 173-303-660 (1)(c) will be complied with;

(iii) Detailed plans and an engineering report describing how the pile is or will be designed, constructed, operated, and maintained to meet the requirements of WAC 173-303-660(2). This submission must address the following items as specified in WAC 173-303-660(2):

(A) The liner system (except for an existing portion of a pile), including the licensed engineer's certification when required by WAC 173-303-660 (2)(c). If an exemption from the requirement for a liner is sought, as provided by WAC 173-303-660 (2)(d), the owner or operator must submit detailed plans and engineering and hydrogeologic reports, as applicable, describing alternate design and operating practices that will, in conjunction with location aspects, prevent the migration of any hazardous constituents into the ground water or surface water at any future time;

(B) Control of run-on;

(C) Control of run-off;

(D) Management of collection and holding units associated with run-on and run-off control systems; and

(E) Control of wind dispersal of particulate matter, where applicable;

(iv) If an exemption from WAC 173-303-645 is sought as provided by WAC 173-303-660 (3) or (4), submit detailed plans and an engineering report describing how the requirements of WAC 173-303-660 (3)(a) or (4)(a) will be complied with;

(v) A description of how each waste pile, including the liner and appurtenances for control of run-on and run-off, will be inspected in order to meet the requirements of WAC 173-303-660(5). This information should be included in the inspection plan submitted under (a)(v) of this subsection. If an exemption is sought to WAC 173-303-645 pursuant to WAC 173-303-660(4), describe in the inspection plan how the inspection requirements of WAC 173-303-660 (4)(a)(iii) will be complied with;

(vi) If treatment is carried out on or in the pile, details of the process and equipment used, and the nature and quality of the residuals;

(vii) If ignitable or reactive wastes are to be placed in a waste pile, an explanation of how the requirements of WAC 173-303-660(7) will be complied with;

(viii) If incompatible wastes, or incompatible wastes and materials will be placed in a waste pile, an explanation of how WAC 173-303-660(8) will be complied with;

(ix) A description of how dangerous waste, waste residues and contaminated materials will be removed from the waste pile at closure, as required under WAC 173-303-660 (9)(a). For any waste not to be removed from the waste pile upon closure, the owner or operator must submit detailed plans and an engineering report describing how WAC 173-303-665 (6)(a) and (b) will be complied with. This information should be included in the closure plan and, where applicable, the post-closure plan submitted under (a)(xiii) of this subsection;

(x) Where applicable, a waste management plan for Dangerous Waste Nos. F020, F021, F022, F023, F026, or F027 describing how a waste pile that is not enclosed

(as defined in WAC 173-303-660 (1)(c)) is or will be designed, constructed, operated, and maintained to meet the requirements of WAC 173-303-660(10).

(f) Specific Part B information requirements for incinerators. Except as WAC 173-303-670(1) provides otherwise, owners and operators of facilities that incinerate dangerous waste must fulfill the informational requirements of (f) of this subsection.

(i) When seeking an exemption under WAC 173-303-670 (1)(b) (ignitable or reactive wastes only):

(A) Documentation that the waste is listed as a dangerous waste in WAC 173-303-080, solely because it is ignitable; or

(B) Documentation that the waste is listed as a dangerous waste in WAC 173-303-080, solely because it is reactive for characteristics other than those listed in WAC 173-303-090 (7)(a)(iv) and (v), and will not be burned when other dangerous wastes are present in the combustion zone; or

(C) Documentation that the waste is a dangerous waste solely because it possesses the characteristic of ignitability, as determined by the tests for characteristics of dangerous waste under WAC 173-303-090; or

(D) Documentation that the waste is a dangerous waste solely because it possesses the reactivity characteristics listed in WAC 173-303-090 (7)(a)(i), (ii), (iii), (vi), (vii), and (viii), and that it will not be burned when other dangerous wastes are present in the combustion zone.

(ii) Submit a trial burn plan or the results of a trial burn, including all required determinations, in accordance with WAC 173-303-807.

(iii) In lieu of a trial burn, the applicant may submit the following information;

(A) An analysis of each waste or mixture of wastes to be burned including:

(I) Heating value of the waste in the form and composition in which it will be burned;

(II) Viscosity (if applicable), or description of physical form of the waste, and specific gravity of the waste;

(III) An identification of any dangerous organic constituents listed in WAC 173-303-9905 or, if not listed, which cause the waste(s) to be regulated, which are present in the waste to be burned, except that the applicant need not analyze for constituents which would reasonably not be expected to be found in the waste. The constituents excluded from analysis must be identified and the basis for their exclusion stated. The waste analysis must rely on analytical techniques specified in WAC 173-303-110(3), or their equivalent;

(IV) An approximate quantification of the dangerous constituents identified in the waste, within the precision produced by the analytical methods specified in WAC 173-303-110(3); and

(V) A quantification of those dangerous constituents in the waste which may be designated as principal organic dangerous constituents (PODC's) based on data submitted from other trial or operational burns which demonstrate compliance with the performance standards in WAC 173-303-670(4);

(B) A detailed engineering description of the incinerator, including:

(I) Manufacturer's name and model number of incinerator;

(II) Type of incinerator;

(III) Linear dimension of incinerator unit including cross sectional area of combustion chamber;

(IV) Description of auxiliary fuel system (type/feed);

(V) Capacity of prime mover;

(VI) Description of automatic waste feed cutoff system(s);

(VII) Stack gas monitoring and pollution control monitoring system;

(VIII) Nozzle and burner design;

(IX) Construction materials; and

(X) Location and description of temperature, pressure, and flow indicating devices and control devices;

(C) A description and analysis of the waste to be burned compared with the waste for which data from operational or trial burns are provided to support the contention that a trial burn is not needed. The data should include those items listed in (f)(iii)(A) of this subsection. This analysis should specify the principal organic dangerous constituents (PODC's) which the applicant has identified in the waste for which a permit is sought, and any differences from the PODC's in the waste for which burn data are provided;

(D) The design and operating conditions of the incinerator unit to be used, compared with that for which comparative burn data are available;

(E) A description of the results submitted from any previously conducted trial burn(s) including:

(I) Sampling and analysis techniques used to calculate performance standards in WAC 173-303-670(4); and

(II) Methods and results of monitoring temperatures, waste feed rates, carbon monoxide, and an appropriate indicator of combustion gas velocity (including a statement concerning the precision and accuracy of this measurement);

(F) The expected incinerator operation information to demonstrate compliance with WAC 173-303-670 (4) and (6), including:

(I) Expected carbon monoxide (CO) level in the stack exhaust gas;

(II) Waste feed rate;

(III) Combustion zone temperature;

(IV) Indication of combustion gas velocity;

(V) Expected stack gas volume, flow rate, and temperature;

(VI) Computed residence time for waste in the combustion zone;

(VII) Expected hydrochloric acid removal efficiency;

(VIII) Expected fugitive emissions and their control procedures; and

(IX) Proposed waste feed cutoff limits based on the identified significant operating parameters;

(G) Such supplemental information as the department finds necessary to achieve the purposes of this subsection;

(H) Waste analysis data, including that submitted in (f)(iii)(A) of this subsection, sufficient to allow the department to specify as permit principal organic dangerous constituents (permit PODC's) those constituents for

which destruction and removal efficiencies will be required; and

(I) Test protocols and sampling and analytical data to demonstrate the designation status under WAC 173-303-070 of:

(I) Incinerator ash residues, if any; and

(II) Residues from the air pollution control devices.

(iv) The department shall approve a permit application without a trial burn if the department finds that:

(A) The wastes are sufficiently similar; and

(B) The incinerator units are sufficiently similar, and the data from other trial burns are adequate to specify (under WAC 173-303-670(6)) operating conditions that will ensure that the performance standards in WAC 173-303-670(4) will be met by the incinerator.

(g) Specific Part B information requirements for land treatment facilities. Except as otherwise provided in WAC 173-303-600(3), owners and operators of facilities that use land treatment to dispose of dangerous waste must provide the following additional information:

(i) A description of plans to conduct a treatment demonstration as required under WAC 173-303-655(3). The description must include the following information:

(A) The wastes for which the demonstration will be made and the potential dangerous constituents in the waste;

(B) The data sources to be used to make the demonstration (e.g., literature, laboratory data, field data, or operating data);

(C) Any specific laboratory or field test that will be conducted, including:

(I) The type of test (e.g., column leaching, degradation);

(II) Materials and methods, including analytical procedures;

(III) Expected time for completion; and

(IV) Characteristics of the unit that will be simulated in the demonstration, including treatment zone characteristics, climatic conditions, and operating practices;

(ii) A description of a land treatment program, as required under WAC 173-303-655(2). This information must be submitted with the plans for the treatment demonstration, and updated following the treatment demonstration. The land treatment program must address the following items:

(A) The wastes to be land treated;

(B) Design measures and operating practices necessary to maximize treatment in accordance with WAC 173-303-655 (4)(a) including:

(I) Waste application method and rate;

(II) Measures to control soil pH;

(III) Enhancement of microbial or chemical reactions; and

(IV) Control of moisture content;

(C) Provisions for unsaturated zone monitoring, including:

(I) Sampling equipment, procedures, and frequency;

(II) Procedures for selecting sampling locations;

(III) Analytical procedures;

(IV) Chain of custody control;

(V) Procedures for establishing background values;

(VI) Statistical methods for interpreting results; and

(VII) The justification for any dangerous constituents recommended for selection as principal dangerous constituents, in accordance with the criteria for such selection in WAC 173-303-655 (6)(a);

(D) A list of dangerous constituents reasonably expected to be in, or derived from, the wastes to be land treated based on waste analysis performed pursuant to WAC 173-303-300;

(E) The proposed dimensions of the treatment zone;

(iii) A description of how the unit is or will be designed, constructed, operated, and maintained in order to meet the requirements of WAC 173-303-655(4). This submission must address the following items:

(A) Control of run-on;

(B) Collection and control of run-off;

(C) Minimization of run-off of dangerous constituents from the treatment zone;

(D) Management of collection and holding facilities associated with run-on and run-off control systems;

(E) Periodic inspection of the unit. This information should be included in the inspection plan submitted under (a)(v) of this subsection; and

(F) Control of wind dispersal of particulate matter, if applicable;

(iv) If food-chain crops are to be grown in or on the treatment zone of the land treatment unit, a description of how the demonstration required under WAC 173-303-655(5) will be conducted including:

(A) Characteristics of the food-chain crop for which the demonstration will be made;

(B) Characteristics of the waste, treatment zone, and waste application method and rate to be used in the demonstration;

(C) Procedures for crop growth, sample collection, sample analysis, and data evaluation;

(D) Characteristics of the comparison crop including the location and conditions under which it was or will be grown; and

(E) If cadmium is present in the land treated waste, a description of how the requirements of WAC 173-303-655 (5)(b) will be complied with;

(v) A description of the vegetative cover to be applied to closed portions of the facility, and a plan for maintaining such cover during the post-closure care period, as required under WAC 173-303-655 (8)(a)(viii) and (c)(ii). This information should be included in the closure plan and, where applicable, the post-closure care plan submitted under (a)(xiii) of this subsection;

(vi) If ignitable or reactive wastes will be placed in or on the treatment zone, an explanation of how the requirements of WAC 173-303-655(9) will be complied with; and

(vii) If incompatible wastes, or incompatible wastes and materials, will be placed in or on the same treatment zone, an explanation of how WAC 173-303-655(10) will be complied with.

(viii) Where applicable, a waste management plan for Dangerous Waste Nos. F020, F021, F022, F023, F026, or F027 describing how a land treatment facility is or will be designed, constructed, operated, and maintained to meet the requirements of WAC 173-303-655(12).

(h) Specific Part B information requirements for landfills. Except as otherwise provided in WAC 173-303-600(3), owners and operators of facilities that dispose of dangerous waste in landfills must provide the following additional information;

(i) A list of the dangerous wastes placed or to be placed in each landfill or landfill cell;

(ii) Detailed plans and an engineering report describing how the landfill is or will be designed, constructed, operated and maintained to comply with the requirements of WAC 173-303-665(2). This submission must address the following items as specified in WAC 173-303-665(2):

(A) The liner system and leachate collection and removal system (except for an existing portion of a landfill), including the licensed engineer's certification required by WAC 173-303-665 (2)(a)(i). If an exemption from the requirements for a liner and a leachate collection and removal system is sought, as provided by WAC 173-303-665 (2)(b), submit detailed plans and engineering and hydrogeologic reports, as appropriate, describing alternate design and operating practices that will, in conjunction with location aspects, prevent the migration of any dangerous constituent into the ground water or surface water at any future time;

(B) Control of run-on;

(C) Control of run-off;

(D) Management of collection and holding facilities associated with run-on and run-off control systems; and

(E) Control of wind dispersal of particulate matter, where applicable;

(iii) If an exemption from WAC 173-303-645 is sought, as provided by WAC 173-303-665(3), the owner or operator must submit detailed plans and an engineering report explaining the location of the saturated zone in relation to the landfill, the design of a double-liner system that incorporates a leak detection system between the liners, and a leachate collection and removal system above the liners;

(iv) A description of how each landfill, including the liner and cover systems, will be inspected in order to meet the requirements of WAC 173-303-665(4). This information should be included in the inspection plan submitted under (a)(v) of this subsection;

(v) Detailed plans and an engineering report describing the final cover which will be applied to each landfill or landfill cell at closure in accordance with WAC 173-303-665 (6)(a), and a description of how each landfill will be maintained and monitored after closure in accordance with WAC 173-303-665 (6)(b) and (c). This information should be included in the closure and post-closure plans submitted under (a)(xiii) of this subsection;

(vi) ~~((If ignitable or reactive wastes will be landfilled, an explanation of how the standards of WAC 173-303-665(7) will be complied with;~~

~~(vii))~~ If incompatible wastes, or incompatible wastes and materials will be landfilled, an explanation of how WAC 173-303-665(~~((8)))~~ (7) will be complied with;

~~((viii) If bulk of noncontainerized liquid waste or wastes containing free liquids is to be landfilled, an explanation of how the requirements of WAC 173-303-665(9) will be complied with;~~

~~(ix) If containers of dangerous waste are to be landfilled, an explanation of how the requirements of WAC 173-303-665(10) will be complied with; and~~

~~(x) Where applicable, a waste management plan for Dangerous Waste Nos. F020, F021, F022, F023, F026, or F027 describing how a landfill is or will be designed, constructed, operated, and maintained to meet the requirements of WAC 173-303-665(11).)~~

(vii) A description of how each landfill will be designed and operated in order to comply with WAC 173-303-140.

(i) Specific Part B information requirements for miscellaneous units. Except as otherwise provided in WAC 173-303-680(1), owners and operators of facilities that treat, store, or dispose of dangerous waste in miscellaneous units must provide the following additional information:

(i) A detailed description of the unit being used or proposed for use, including the following:

(A) Physical characteristics, materials of construction, and dimensions of the unit;

(B) Detailed plans and engineering reports describing how the unit will be located, designed, constructed, operated, maintained, monitored, inspected, and closed to comply with the requirements of WAC 173-303-680 (2) and (3); and

(C) For disposal units, a detailed description of the plans to comply with the postclosure requirements of WAC 173-303-680(4).

(ii) Detailed hydrologic, geologic, and meteorologic assessments and land-use maps for the region surrounding the site that address and ensure compliance of the unit with each factor in the environmental performance standards of WAC 173-303-680(2). If the applicant can demonstrate that he does not violate the environmental performance standards of WAC 173-303-680(2) and the department agrees with such demonstration, preliminary hydrologic, geologic, and meteorologic assessments will suffice.

(iii) Information on the potential pathways of exposure of humans or environmental receptors to dangerous waste or dangerous constituents and on the potential magnitude and nature of such exposures.

(iv) For any treatment unit, a report on a demonstration of the effectiveness of the treatment based on laboratory or field data.

(v) Any additional information determined by the department to be necessary for evaluation of compliance of the unit with the environmental performance standards of WAC 173-303-680(2).

(5) Construction. A person may begin physical construction of a new facility, or of new portions of an existing facility if the new portions would amount to reconstruction under interim status (WAC 173-303-805(7)), only after complying with WAC 173-303-281, submitting Part A and Part B of the permit application

and receiving a final facility permit. All permit applications must be submitted at least one hundred eighty days before physical construction is expected to begin.

(6) Reapplications. Any dangerous waste facility with an effective final facility permit shall submit a new application one hundred eighty days prior to the expiration date of the effective permit, unless the department grants a later date provided that such date will never be later than the expiration date of the effective permit.

(7) Continuation of expiring permits.

(a) When the owner/operator submits a timely application for a final facility permit and the application is determined by the department to be complete pursuant to subsection (8) of this section, the facility is allowed to continue operating under the expiring or expired permit until the effective date of the new permit.

(b) When the facility is not in compliance with the conditions of the expiring or expired permit, the department may choose to do any of the following:

(i) Initiate enforcement action based upon the permit which has been continued;

(ii) Issue a notice of intent to deny the new permit. If the permit is denied, the owner or operator would then be required to cease the activities authorized by the continued permit or be subject to enforcement action for operating without a permit;

(iii) Issue a new permit with appropriate conditions; and/or

(iv) Take other actions authorized by this chapter.

(8) Completeness. The department shall not issue a final facility permit before receiving a complete application, except for permits by rule or emergency permits. An application for a permit is complete when the application form and any supplemental information has been submitted to the department's satisfaction. The completeness of any application for a permit shall be judged independently of the status of any other permit application or permit for the same facility or activity.

(9) Recordkeeping. Applicants shall keep records of all data used to complete the permit applications, and any supplemental information submitted to the department for a period of at least three years from the date the application is signed.

(10) General permit conditions. All final facility permits shall contain general permit conditions described in WAC 173-303-810.

(11) Permit duration.

(a) Final facility permits shall be effective for a fixed term not to exceed ten years.

(b) The department may issue any final facility permit for a duration that is less than the full allowable term.

(c) The term of a final facility permit shall not be extended beyond ten years, unless otherwise authorized under subsection (7) of this section.

(12) Grounds for termination. The following are causes for terminating a final facility permit during its term:

(a) Noncompliance by the permittee with any condition of the permit;

(b) The permittee's failure in the application or during the permit issuance process to disclose fully all relevant facts, or the permittee's misrepresentation of any relevant facts at any time; or

(c) A determination that the permitted activity endangers public health or the environment and the hazard can only be controlled by permit modification or termination.

(13) Grounds for denial. A permit application shall be denied if it is determined that the proposed location and/or activity endangers public health and the environment as demonstrated by the permit applicant's failure to satisfy the performance standards of WAC 173-303-283.

(14) Permit changes. All final facility permits shall be subject to the requirements of permit changes, WAC 173-303-830.

(15) Procedures for decision making. Issuance of final facility permits will be subject to the procedures for decision making described in WAC 173-303-840.

(16) Other requirements for final special waste and recycling facility permits. In lieu of issuing a final special waste or recycling facility permit, the department may, after providing opportunity for public comment in accordance with WAC 173-303-840, defer to a permit already issued under other statutory authority administered by the department (such as the State Water Pollution Control Act, chapter 90.48 RCW, the State Clean Air Act, chapter 70.94 RCW, etc.) which incorporates the requirements of this section, and WAC 173-303-500 through 173-303-525 for recycling facilities or WAC 173-303-550 through 173-303-560 for special waste facilities.

**AMENDATORY SECTION** (Amending Order DE 83-36, filed 4/18/84)

WAC 173-303-807 TRIAL BURNS FOR DANGEROUS WASTE INCINERATOR FINAL FACILITY PERMITS. (1) Purpose and applicability. For purposes of determining operational readiness and establishing conditions in final facility permits for dangerous waste incinerators, the department may approve trial burns. Trial burns shall not exceed seven hundred twenty hours operating time, except that the department may extend the duration of this operational period once, up to seven hundred twenty additional hours, at the request of the owner/operator of the incinerator when good cause is shown. The permit may be modified to reflect the extension according to WAC 173-303-830(4). The procedures for requesting and approving trial burns are described in:

(a) Subsection (10) of this section for existing incinerators with interim status permits; and

(b) Subsection (11) of this section for new incinerators and for incinerators with final facility permits in which the owner/operator wishes to burn new wastes not currently included in the permit.

(2) Trial burn plan. The trial burn must be conducted in accordance with a trial burn plan prepared by the applicant and approved by the department. The trial burn plan will then become a condition of the permit and will include the following information:

(a) An analysis of each waste or mixture of waste to be burned which includes:

(i) Heating value of the waste in the form and composition in which it will be burned;

(ii) Viscosity (if applicable), or description of physical form of the waste, and specific gravity of the waste;

(iii) An analysis identifying any dangerous organic constituents listed in WAC 173-303-9905, and any other dangerous constituents which, although not listed, caused the waste to be regulated as a dangerous waste, which are reasonably expected to be present in the waste to be burned. The constituents excluded from analysis must be identified and the basis for their exclusion stated. The waste analysis must rely on analytical techniques specified or referenced in WAC 173-303-110, or their equivalent;

(iv) An approximate quantification of the dangerous constituents identified in the waste, within the precision produced by the analytical methods specified or referenced in WAC 173-303-110; and

(v) A quantification of those dangerous constituents in the waste which may be designated as principal organic dangerous constituents (PODC) based on data submitted from other trial or operational burns which demonstrate compliance with the performance standard in WAC 173-303-670(4);

(b) A detailed engineering description of the incinerator for which the trial burn permit is sought including:

(i) Manufacturer's name and model number of incinerator (if available);

(ii) Type of incinerator;

(iii) Linear dimensions of the incinerator unit including the cross sectional area of the combustion chamber;

(iv) Description of the auxiliary fuel system (type/feed);

(v) Capacity of the prime air mover;

(vi) Description of automatic waste feed cutoff system(s);

(vii) Stack gas monitoring and pollution control equipment;

(viii) Nozzle and burner design;

(ix) Construction materials; and

(x) Location and description of temperature, pressure, and flow indicating and control devices;

(c) A detailed description of sampling and monitoring procedures, including sampling and monitoring locations in the system, the equipment to be used, sampling and monitoring frequency, and planned analytical procedures for sample analysis;

(d) A detailed test schedule for each waste for which the trial burn is planned including date(s), duration, quantity of waste to be burned, and other factors relevant to the department's decision under subsection (5) of this section;

(e) A detailed test protocol, including, for each waste identified, the ranges of temperature, waste feed rate, air feed rate, use of auxiliary fuel, and other relevant parameters that will be varied to affect the destruction and removal efficiency of the incinerator;

(f) A description of, and planned operating conditions for, any emission control equipment which will be used;



(g) Procedures for rapidly stopping waste feed, shutting down the incinerator, and controlling emissions in the event of an equipment malfunction;

(h) A detailed test protocol to sample and analyze the following for designation under WAC 173-303-070:

(i) Any incinerator ash residue collected in the incinerator; and

(ii) Any residues collected in the air pollution control devices; and

(i) Such other information as the department reasonably finds necessary to determine whether to approve the trial burn plan in light of the purposes of this section.

(3) Additional information required. The department, in reviewing the trial burn plan, shall evaluate the adequacy of the information provided and may require the applicant to supplement this information, if necessary, to achieve the purposes of this section.

(4) Trial PODCs. Based on the waste analysis data in the trial burn plan, the department will specify as trial principal organic dangerous constituents (trial PODCs) those constituents for which destruction and removal efficiencies must be calculated during the trial burn. These trial PODCs will be specified by the department based on its estimate of the difficulty of incineration of the constituents identified in the waste analysis, the concentration or mass in the waste feed, and the dangerous waste constituent or constituents identified in WAC 173-303-9905, or identified as causing the waste to be regulated as a dangerous waste.

(5) Approval of the plan. The department shall approve a trial burn plan if it finds that:

(a) The trial burn is likely to determine whether the incinerator performance standard required by WAC 173-303-670(4) can be met;

(b) The trial burn itself will not present an imminent hazard to public health or the environment;

(c) The trial burn will help the department to determine operating requirements to be specified under WAC 173-303-670(6); and

(d) The information sought in (a), (b), and (c) of this subsection cannot reasonably be developed through other means.

(6) Trial burns. During each approved trial burn (or as soon after the burn as is practicable), the applicant must make the following determinations:

(a) A quantitative analysis of the trial PODCs in the waste feed to the incinerator;

(b) A quantitative analysis of the exhaust gas for the concentration and mass emissions of the trial PODCs, O<sub>2</sub>, hydrogen chloride (HCl), carbon monoxide (CO) and dangerous combustion byproducts, including the total mass emission rate of byproducts as a percent of the total mass feed rate of PODCs fed to the incinerator;

(c) A quantitative analysis of the scrubber water (if any), ash residues, and other residues, for the purpose of estimating the fate of the trial PODCs and whether they are designated according to WAC 173-303-070;

(d) A total mass balance of the trial PODCs in the waste;

(e) A computation of destruction and removal efficiency (DRE), in accordance with the DRE formula specified in WAC 173-303-670 (4)(a);

(f) If the HCl emission rate exceeds 1.8 kilograms of HCl per hour (4 pounds per hour), a computation of HCl removal efficiency in accordance with WAC 173-303-670 (4)(c)(i);

(g) A computation of particulate emissions, in accordance with WAC 173-303-670 (4)(c)(ii);

(h) An identification of sources of fugitive emissions and their means of control;

(i) A measurement of average, maximum, and minimum temperatures, and combustion gas velocity;

(j) A continuous measurement of carbon monoxide in the exhaust gas;

(k) An identification of any existing air emission standards where a state or local air pollution control authority has established emission standards and such standards are applicable to the incinerator; and

(l) Such other information as the department may specify as necessary to ensure that the trial burn will determine compliance with the performance standard of WAC 173-303-670(4), and to establish the operating conditions required by WAC 173-303-670(6).

(7) Certification. The applicant shall submit to the department a certification that the trial burn has been carried out in accordance with the approved trial burn plan, and must submit the results of all determinations required by subsection (6) of this section. This submission shall be made within thirty days of the completion of the trial burn, or later if approved by the department.

(8) Submission of data. All data collected during any trial burn must be submitted to the department following the completion of the trial burn.

(9) Signatures required. All submissions required under this section shall be certified on behalf of the applicant by the signature of a person authorized to sign a permit application under WAC 173-303-810(12).

(10) Existing incinerators with interim status permits.

(a) The owner/operator of an existing incinerator currently operating under an interim status permit may, when required by the department (or when he chooses) to apply for a final facility permit, request the department to approve of a trial burn. The trial burn may be requested for the purposes of determining feasibility of compliance with the performance standards of WAC 173-303-670(4) and the operating conditions of WAC 173-303-670(6). If a trial burn is requested, the owner/operator shall prepare and submit a trial burn plan and, upon approval by the department, perform a trial burn in accordance with subsections (2) through (9) of this section.

(b) If the department approves the trial burn, it shall issue a notice of interim status modification granting such approval and specifying the conditions applicable to the trial burn. The notice of modification shall be a condition of the interim status permit. Note: The national emission standards for hazardous air pollutants may require review for a notice of construction. Owners and operators should consult chapter 173-400 WAC or local air pollution control agency regulations for applicability.

(c) If the trial burn is approved before submitting a final facility permit application, the owner/operator shall complete the trial burn and submit the information described in subsection (6) of this section, with Part B of

the permit application. If completion of this process conflicts with the date set for submission of Part B of the final facility permit application, the owner/operator must contact the department to extend the date for submitting the Part B or the trial burn results. If the applicant submits a trial burn plan with Part B of the final facility permit application, the department will specify in the notice of interim status modification issued under (b) of this subsection, a time period for conducting the trial burn and submitting the results.

(11) New incinerators and new wastes.

(a)(i) The owner/operator of a new incinerator may submit with Part B of a final facility permit application a request for approval of a trial burn. This request shall include a statement of why the trial burn is desirable, and a trial burn plan prepared in accordance with subsection (2) of this section.

(ii) The department shall proceed to issue a final facility permit in accordance with WAC 173-303-806. The permit shall include the trial burn plan, and shall establish operating conditions for the trial burn including but not limited to those described in WAC 173-303-670(6). The time period for conducting the trial burn and submitting the results shall also be specified in the permit.

(iii) After the trial burn has been completed and the results submitted to the department, the final facility permit shall be modified in accordance with WAC 173-303-830 ~~((including minor modifications, if applicable))~~ (4) to establish the final operating requirements and performance standards for the incinerator.

(b) The owner/operator of an incinerator with a final facility permit who wishes to burn new wastes not currently included in his permit may request approval of a trial burn for the new wastes. The request and approval shall be handled in the same way as described in (a) of this subsection, except that in lieu of issuing an entirely new final facility permit the department will modify the existing final facility permit in accordance with WAC 173-303-830.

**AMENDATORY SECTION** (Amending Order DE 83-36, filed 4/18/84)

**WAC 173-303-808 DEMONSTRATIONS FOR DANGEROUS WASTE LAND TREATMENT FINAL FACILITY PERMITS.** (1) Purpose and applicability. This section is applicable to the owner/operator of a land treatment facility who must demonstrate that his proposed treatment will be successful. The purpose of this section is to allow the department to issue a land treatment demonstration permit.

(2) Permit issuance. The department may issue a land treatment demonstration permit either in advance of or as part of a final facility permit so that the owner/operator of a land treatment facility can make the demonstration required in WAC 173-303-655(3). If issued in advance of the final facility permit, the land treatment demonstration permit shall be issued as described in subsection (3) of this section, as a demonstration permit only. If issued as part of the final facility permit, the

land treatment demonstration and final facility permit shall be issued as described in subsection (4) of this section, as a phased permit. The determination for which procedure to follow will be made by the department based on the information submitted by the owner/operator in Part B of the final facility permit application.

(3) Demonstration permit only.

(a) If the department finds that the Part B does not contain enough information regarding the proposed treatment to allow the department to establish permit conditions necessary for compliance with all requirements of WAC 173-303-655, it may issue a land treatment demonstration permit only. The demonstration permit will be issued in accordance with the decision-making procedures of WAC 173-303-840. The demonstration permit may be issued either as a treatment or disposal permit, will cover only the field test or laboratory analyses, shall contain only those requirements necessary to meet the standards in WAC 173-303-655(3), and shall provide a specific time period for the demonstration. The department may extend the demonstration period as a modification (or minor modification, if applicable) to the demonstration permit.

(b) Within thirty days (unless the department approves a later date) of the end of the treatment demonstration, the owner/operator shall submit a revised Part B to the department containing the results of the field tests or laboratory analyses and all data developed during the demonstration period. The department shall then use the information and Part B to determine whether or not there is adequate information to issue a final facility permit which will incorporate conditions sufficient to provide compliance with all requirements of WAC 173-303-655. If the information is adequate, the department will proceed under WAC 173-303-806 to issue a final facility permit. If the information is not adequate, the department may, as the situation warrants, either issue a modification to the demonstration permit in accordance with the procedures of subsection (3)(a) of this section, or deny the final facility permit application.

(4) Phased permit.

(a) The department may issue a two-phase final facility permit if it finds that, based on information submitted in Part B of the permit application, substantial (although incomplete and inconclusive) information exists upon which to base the issuance of a final facility permit. The phased permit will be issued in the same manner as a final facility permit under WAC 173-303-806, except that it shall contain a first phase for making a land treatment demonstration, and a second phase (to become effective after completion of the first phase) for establishing conditions for operation of the land treatment facility.

(b) If the department finds that a phased permit may be issued, it will establish, as requirements in the first phase of the facility permit, conditions for conducting the field tests or laboratory analyses. These permit conditions will include design and operating parameters (including the duration of the tests or analyses and, in the case of field tests, the horizontal and vertical dimensions of the treatment zone), monitoring procedures, post-

demonstration cleanup activities, and any other conditions which the department finds may be necessary under WAC 173-303-655 (3)(c). The department will include conditions in the second phase of the facility permit to attempt to meet all WAC 173-303-655 requirements pertaining to unit design, construction, operation, and maintenance. The department will establish these conditions in the second phase of the permit based upon the substantial but incomplete or inconclusive information contained in the Part B application.

(i) The first phase of the permit will be effective as provided in WAC 173-303-840 (8)(b).

(ii) The second phase of the permit will be effective as provided in (d) of this subsection.

(c) When the owner or operator who has been issued a two-phase permit has completed the treatment demonstration, he must submit to the department a certification, signed by a person authorized to sign a permit application or report under WAC 173-303-810(12), that the field tests or laboratory analyses have been carried out in accordance with the conditions specified in phase one of the permit for conducting such tests or analyses. The owner or operator must also submit all data collected during the field tests or laboratory analyses within thirty days of completion of those tests or analyses unless the department approves a later date.

(d) If the department determines that the results of the field tests or laboratory analyses meet the requirements of WAC 173-303-655(3), it will modify the second phase of the permit to incorporate any requirements necessary for operation of the facility in compliance with WAC 173-303-655, based upon the results of the field tests or laboratory analyses.

(i) This permit modification may proceed (~~as a minor modification~~) under WAC 173-303-830(4) (~~provided any such change is minor~~), or otherwise will proceed as a modification under WAC 173-303-830 (3)(a)(ii). If such modifications are necessary, the second phase of the permit will become effective only after those modifications have been made.

(ii) If no modifications of the second phase of the permit are necessary (~~or if only minor modifications are necessary and have been made~~), the department will give notice of its final decision to the permit applicant and to each person who submitted written comments on the phased permit or who requested notice of the final decision on the second phase of the permit. The second phase of the permit then will become effective as specified in WAC 173-303-840 (8)(b).

(iii) If modifications under WAC 173-303-830(3) are necessary, the second phase of the permit will become effective only after those modifications have been made.

(e) If the department determines that the results of the field tests or laboratory analyses do not meet the requirements of WAC 173-303-655(3), the second phase of the permit will not become effective, and the department will, as the situation warrants, either:

(i) Modify the permit according to WAC 173-303-830(3) to allow for additional field tests or laboratory analyses; or

(ii) Proceed to terminate the permit according to WAC 173-303-840.

#### AMENDATORY SECTION (Amending Order DE-87-4, filed 6/26/87)

WAC 173-303-810 GENERAL PERMIT CONDITIONS. (1) Purpose and applicability. This section sets forth the general permit conditions that are applicable to all permits, except interim status permits and permits by rule, to assure compliance with this chapter. If the conditions of this section are incorporated in a permit by reference, a specific citation to this section must be given in the permit.

(2) Duty to comply. The permittee must comply with all conditions of his permit. Any permit noncompliance constitutes a violation and is grounds for enforcement action; for permit termination, revocation and reissuance, or modification; or for denial of a permit renewal application. The permittee need not comply with the conditions of his permit to the extent and for the duration such noncompliance is authorized in an emergency permit.

(3) Duty to reapply. If the permittee wishes to continue an activity regulated by the permit after its expiration date, the permittee must apply for and obtain a new permit.

(4) Duty to halt or reduce activity. A permittee who has not complied with his permit, and who subsequently is subject to enforcement actions, may not argue that it would have been necessary to halt or reduce the permitted activities in order to maintain compliance with the conditions of the permit.

(5) Duty to mitigate. The permittee shall take all steps required by the department to minimize or correct any adverse impact on the environment resulting from noncompliance with the permit.

(6) Proper operation and maintenance. The permittee shall at all times properly operate and maintain all facilities and systems of treatment and control which are installed or used by the permittee to achieve compliance with the conditions of the permit. Proper operation and maintenance includes effective performance, adequate funding, adequate operator staffing and training, and adequate laboratory and process controls, including appropriate quality assurance procedures. This provision requires the operation of back-up or auxiliary facilities or similar systems only when necessary to achieve compliance with the conditions of the permit.

(7) Permit actions. The permit may be modified, revoked and reissued, or terminated for cause. The filing of a request by the permittee for a permit modification, revocation and reissuance, termination, notification of planned changes, or anticipated noncompliance, does not stay any permit condition.

(8) Effect of a permit. The issuance of a permit does not convey any property rights of any sort, or any exclusive privilege. The issuance of a permit does not authorize any injury to persons or property or invasion of other private rights, or any infringement of state or local laws or regulations.

(9) Duty to provide information. The permittee shall furnish to the department, within a reasonable time, any information which it may request to determine whether cause exists for modifying, revoking and reissuing, or

terminating a permit, or to determine compliance with a permit. The permittee shall also furnish to the department, upon request, copies of records required to be kept by the permit.

(10) Inspection and entry. The permittee shall allow representatives of the department, upon the presentation of proper credentials, to:

(a) Enter upon the permittee's premises where a regulated facility or activity is located or conducted, or where records must be kept under the conditions of the permit;

(b) Have access to and copy, at reasonable times, any records that must be kept under the conditions of the permit;

(c) Inspect at reasonable times any facilities, equipment (including monitoring and control equipment), practices, or operations regulated or required under the permit; and

(d) Sample or monitor at reasonable times, for the purposes of assuring permit compliance or as otherwise authorized by chapter 173-303 WAC, any substances or parameters at any location.

(11) Monitoring and monitoring records.

(a) All permits shall specify:

(i) Requirements concerning the proper use, maintenance, and installation, when appropriate, of monitoring equipment or methods; and

(ii) Required monitoring including type, intervals, and frequency sufficient to yield data which are representative of the monitored activity including, when appropriate, continuous monitoring.

(b) Samples and measurements taken for the purpose of monitoring shall be representative of the monitored activity.

(c) The permittee shall retain records of all monitoring information, including all calibration and maintenance records and all original strip chart recordings for continuous monitoring instrumentation, copies of all reports required by this permit, and records of all data used to complete the application for this permit, for a period of at least three years from the date of the sample, measurement, report, or application. This period may be extended by request of the department at any time.

(d) Records of monitoring information shall include:

(i) The date, exact place, and time of sampling or measurements;

(ii) The individual(s) who performed the sampling or measurements;

(iii) The date(s) analyses were performed;

(iv) The individual(s) who performed the analyses;

(v) The analytical techniques or methods used; and

(vi) The results of such analyses.

(e) The permittee shall maintain all records of ground water quality and ground water surface elevations for the active life of the facility, and for the post-closure period as well.

(12) Signatory requirement. All applications, reports, or information submitted to the department shall be signed in accordance with this subsection and shall be certified according to subsection (13) of this section.

(a) Applications. When a dangerous waste facility is owned by one person, but is operated by another person, then the operator shall be the permit applicant and responsible for developing the permit application and all accompanying materials, except that the owner must also sign and certify the permit application. Permit applications shall be signed as follows:

(i) For a corporation: By a responsible corporate officer. For the purposes of this subsection, a responsible corporate officer means:

(A) A president, secretary, treasurer, or vice president of the corporation in charge of a principal business function, or any other person who performs similar policy or decision-making functions for the corporation; or

(B) The manager of one or more manufacturing, production or operating facilities employing more than two hundred fifty persons or having gross annual sales or expenditures exceeding twenty-five million dollars (in second-quarter 1980 dollars), if authority to sign documents has been assigned or delegated to the manager in accordance with corporate procedures;

(ii) For a partnership or sole proprietorship: By a general partner or the proprietor, respectively; or

(iii) For a municipality, state, federal, or other public agency: By either a principal executive officer or ranking elected official. For purposes of this subsection, a principal executive officer of a federal agency includes:

(A) The chief executive officer of the agency; or

(B) A senior executive officer having responsibility for the overall operations of a principal geographic unit of the agency.

(b) Reports. All reports required by permits and other information requested by the department shall be signed by a person described in (a) of this subsection, or by a duly authorized representative of that person. A person is a duly authorized representative only if:

(i) The authorization is made in writing by a person described in (a) of this subsection;

(ii) The authorization specifies either an individual or a position having responsibility for overall operation of the regulated facility or activity such as the position of plant manager, operator of a well or a well field, superintendent, or position of equivalent responsibility. (A duly authorized representative may thus be either a named individual or any individual occupying a named position); and

(iii) The written authorization is submitted to the department.

(c) Changes to authorization. If an authorization under (b) of this subsection is no longer accurate because a different individual or position has responsibility for the overall operation of the facility, a new authorization satisfying the requirements of (b) of this subsection must be submitted to the department prior to or together with any reports, information, or applications to be signed by an authorized representative.

(13) Certification.

(a) Except as provided in (b) of this subsection, any person signing the documents required under (a) or (b) of subsection (12) of this section shall make the following certification:

"I certify under penalty of law that this document and all attachments were prepared under my direction or supervision in accordance with a system designed to assure that qualified personnel properly gather and evaluate the information submitted. Based on my inquiry of the person or persons who manage the system, or those persons directly responsible for gathering the information, the information submitted is, to the best of my knowledge and belief, true, accurate, and complete. I am aware that there are significant penalties for submitting false information, including the possibility of fine and imprisonment for knowing violations."

(b) When a dangerous waste facility is owned by one person, but is operated by another person, then the permit application must be certified as follows:

(i) The operator must make the certification described under (a) of this subsection; and

(ii) The owner must make the following certification:

"I certify under penalty of law that I own the real property described in, and am aware of the contents of, this permit application, and that I have received a copy of this application. As owner of the real property, I understand that I am responsible for complying with any requirements of chapter 173-303 WAC with which only I am able to comply, and that there are significant penalties for failure to comply with such requirements."

(14) Reporting. The following reports shall be provided:

(a) Planned changes. The permittee shall give notice to the department as soon as possible of any planned physical alterations or additions to the permitted facility. For a new TSD facility and for a facility being modified, the permittee may not treat, store, or dispose of dangerous waste in the new or modified portion of the facility until:

(i) The permittee has submitted to the department by certified mail or hand delivery a letter signed by the permittee and a registered professional engineer stating that the facility has been constructed or modified in compliance with the permit; and either

(ii) The department has inspected the modified or newly constructed facility and finds it is in compliance with the conditions of the permit; or

(iii) Within fifteen days of the date of submission of the letter, the permittee has not received notice from the department of its intent to inspect, prior inspection is waived and the permittee may commence treatment, storage, or disposal of dangerous waste.

(b) Anticipated noncompliance. The permittee shall give advance notice to the department of any planned changes in the permitted facility or activity which may result in noncompliance with permit requirements. For a new facility, the permittee may not treat, store, or dispose of dangerous waste; and for a facility being modified, the permittee may not treat, store, or dispose of dangerous waste in the modified portion of the facility except as provided in WAC 173-303-830(4).

(c) Transfers. The permit is not transferable to any person except after notice to the department. The department may require modification or revocation and reissuance of the permit to change the name of the permittee and incorporate such other requirements as may be necessary.

(d) Monitoring reports. Monitoring results (including monitoring of the facility's impacts as required by the applicable sections of this chapter) shall be reported at the intervals specified elsewhere in the permit.

(e) Compliance schedules. Reports of permit compliance or noncompliance or any progress reports on interim and final permit requirements contained in any compliance schedule shall be submitted no later than fourteen days following each scheduled date.

(f) Immediate reporting. The permittee shall immediately report any noncompliance which may endanger health or the environment. Information shall be provided orally to the department as soon as the permittee becomes aware of the circumstances. A written submission shall also be provided within five days of the time the permittee becomes aware of the circumstances provided that the department may waive the written submission requirement in favor of a written report, to be submitted within fifteen days. The written submission shall contain a description of the noncompliance and its cause; the period of noncompliance, including exact dates and times, and if the noncompliance has not been corrected, the anticipated time it is expected to continue; and steps taken or planned to reduce, eliminate, and prevent recurrence of the noncompliance.

Information which must be reported immediately shall include:

(i) Release of dangerous waste that may cause an endangerment to drinking water supplies or ground or surface waters;

(ii) Any information of a release or discharge of dangerous waste, fire, or explosion from the permitted facility which could threaten the environment or human health outside the facility;

(iii) The following description of any such occurrence:

(A) Name, address, and telephone number of the owner or operator;

(B) Name, address, and telephone number of the facility;

(C) Date, time, and type of incident;

(D) Name and quantity of material(s) involved;

(E) The extent of injuries, if any;

(F) An assessment of actual or potential hazards to the environment and human health outside the facility, where this is applicable; and

(G) Estimated quantity and disposition of recovered material that resulted from the incident.

(g) Other noncompliance. The permittee shall report all instances of noncompliance not reported under (d), (e), and (f) of this subsection, at the time monitoring reports are submitted. The reports shall contain the information listed in (f) of this subsection.

(h) Other information. Where the permittee becomes aware that he failed to submit any relevant facts in a permit application, or submitted incorrect information in

a permit application or in any report to the department, he shall promptly submit this information.

(i) Other reports. In addition, the following reports are required when appropriate:

(i) Manifest discrepancy report as required by WAC 173-303-370(5);

(ii) Unmanifested waste report as required by WAC 173-303-390(1); and

(iii) Annual report as required by WAC 173-303-390(2).

(15) Confidentiality.

(a) Information submitted by the owner/operator of a facility identified as confidential will be treated in accordance with chapter 42.17 RCW and RCW 43.21A.160.

(b) Proprietary information can be held confidential if the owner/operator indicates to the department the degree of harm if the information is made to the public.

(c) Claims of confidentiality for permit application information must be substantiated at the time the application is submitted and in the manner prescribed in the application instructions. Claims of confidentiality for the name and address of any permit applicant will be denied.

(d) If a submitter does not provide substantiation, the department will notify the owner/operator by certified mail of the requirement to do so. If the department does not receive the substantiation within ten days after the submitter receives the notice, the department shall place the unsubstantiated information in the public file.

(e) The department will determine if the owner/operator's request meets the confidential information criteria.

#### AMENDATORY SECTION (Amending Order 88-24, filed 1/4/89)

WAC 173-303-830 PERMIT CHANGES. (1) Purpose and applicability. This section describes the types of permit changes that may be made to all permits issued by the department. This section does not apply to permits by rule or interim status permits.

(2) Transfer of permits.

(a) A permit may be transferred by the permittee to a new owner or operator only if the permit has been modified or revoked and reissued (under (b) of this subsection or subsection (3) of this section)~~((or a minor modification has been made))~~ to identify the new permittee and incorporate such other requirements as ~~((stipulated under subsection (4) of this section))~~ may be necessary under the appropriate act.

(b) Changes in the ownership or operational control of a facility may be made as a Class 1 modification with prior written approval of the department in accordance with subsection (4) of this section. The new owner or operator must submit a revised permit application no later than ninety days prior to the scheduled change. A written agreement containing a specific date for transfer of permit responsibility between the current and new permittees must also be submitted to the department. When a transfer of ownership or operational control occurs, the old owner or operator shall comply with the

requirements of WAC 173-303-620 (Financial requirements) until the new owner or operator has demonstrated that he or she is complying with the financial requirements. The new owner or operator must demonstrate compliance with the financial requirements within six months of the date of the change of ownership or operational control of the facility. Upon demonstration to the department by the new owner or operator of compliance with the financial requirements, the department shall notify the old owner or operator that he or she no longer needs to comply with the financial requirements as of the date of demonstration.

(3) Modification or revocation and reissuance of permits. When the department receives any information (for example, inspects the facility, receives information submitted by the permittee as required in the permit, receives a request for ~~((modification or))~~ revocation and reissuance, or conducts a review of the permit file), the department may determine whether or not one or more of the causes listed in (a) and (b) of this subsection for modification or revocation and reissuance or both exist. If cause exists, the department may modify or revoke and reissue the permit accordingly, subject to the limitations of (c) of this subsection, and may request an updated application if necessary. When a permit is modified, only the conditions subject to modification are reopened. If a permit is revoked and reissued, the entire permit is reopened and subject to revision and the permit is reissued for a new term. If cause does not exist under this subsection ~~((3) or (4) of this section)),~~ the department shall not modify or revoke and reissue the permit, except on request of the permittee. If a permit modification ~~((satisfies the criteria in subsection (4) of this section for "minor modifications," the permit may be modified without a draft permit or public review))~~ is requested by the permittee, the department shall approve or deny the request according to the procedures of subsection (4) of this section. Otherwise, a draft permit must be prepared and public review provided in accordance with WAC 173-303-840.

(a) Causes for modification. The following are causes for modification but not revocation and reissuance of permits, unless agreed to or requested by the permittee:

(i) Alterations. There are material and substantial alterations or additions to the permitted facility or activity which occurred after permit issuance which justify the application of permit conditions that are different or absent in the existing permit;

(ii) Information. Permits may be modified during their terms if the department receives information that was not available at the time of permit issuance and which would have justified the application of different permit conditions at the time of issuance;

(iii) New regulations. The standards or regulations on which the permit was based have been changed by statute, through promulgation of amended standards or regulations or by judicial decision after the permit was issued. Permits may be modified during their terms for this cause only when:

(A) The permit condition requested to be modified was based on an effective regulation; and

(B) The department has revised, withdrawn, or modified that portion of the regulation on which the permit condition was based; and either

(I) The department decides to modify the permit because there would be a potential threat to public health or the environment if the permit does not incorporate the requirements of the amended regulation; or

(II) A permittee requests modification within ninety days after the date the regulation amendments are adopted;

(iv) Compliance schedules. The department determines good cause exists for modification of a compliance schedule, such as an act of God, strike, flood, or materials shortage, or other events over which the permittee has little or no control and for which there is no reasonably available remedy;

(v) Closure plans or postclosure. When modification of a closure or postclosure plan is required under WAC 173-303-610 (3) or (8);

(vi) Revocation of changes approved prior to notice of closure. After the department receives the notification of expected closure under WAC 173-303-610(3), the department may determine that previously approved changes are no longer warranted. These include:

(A) Extension of the ninety or one hundred eighty day periods under WAC 173-303-610(4);

(B) Modification of the thirty year postclosure period under WAC 173-303-610(7);

(C) Continuation of security requirements under WAC 173-303-610(7); or

(D) Permission to disturb the integrity of the containment system under WAC 173-303-610(7);

(vii) When the permittee has filed a request under WAC 173-303-620 for a variance to the level of financial responsibility or when the department demonstrates under WAC 173-303-620 that an upward adjustment of the level of financial responsibility is required;

(viii) When the corrective action program specified in the permit under WAC 173-303-645 has not brought the regulated unit into compliance with the ground water protection standard within a reasonable period of time;

(ix) To include a detection monitoring program meeting the requirements of WAC 173-303-645, when the owner or operator has been conducting a compliance monitoring program under WAC 173-303-645 or a corrective action program under WAC 173-303-645 and compliance period ends before the end of the postclosure care period for the unit;

(x) When a permit requires a compliance monitoring program under WAC 173-303-645, but monitoring data collected prior to permit issuance indicate that the facility is exceeding the ground water protection standard;

(xi) To include conditions applicable to units at a facility that were not previously included in the facility's permit; or

(xii) When a land treatment unit is not achieving complete treatment of dangerous constituents under its current permit conditions.

(b) Causes for modification or revocation and reissuance. The following are causes to modify, or alternatively, revoke and reissue a permit:

(i) Cause exists for termination under WAC 173-303-806 (12) for final facility permits, and the department determines that modification or revocation and reissuance is appropriate; or

(ii) The department has received notification of a proposed transfer of the permit.

(c) Facility siting. Suitability of the facility location will not be considered at the time of permit modification or revocation and reissuance unless new information or standards indicate that a threat to human health or the environment exists which was unknown at the time of permit issuance.

~~((4) Minor modifications of permits. Unless the permittee indicates otherwise, the department may modify a permit to make the corrections or allowances for changes in the permitted activity listed in this section without following the procedures of WAC 173-303-840. Any permit modification not processed as a minor modification under this section must be made for cause and with a draft permit and public notice as required in WAC 173-303-840. Minor modifications may only be made to:~~

~~(a) Correct typographical errors;~~

~~(b) Require more frequent monitoring or reporting by the permittee;~~

~~(c) Change an interim compliance date in a schedule of compliance, provided the new date is not more than one hundred twenty days after the date specified in the existing permit and does not interfere with attainment of the final compliance date requirement;~~

~~(d) Allow for a change in ownership or operational control of a facility where the department determines that no other change in the permit is necessary, provided that a written agreement containing a specific date for transfer of permit responsibility between the current and new permittees has been submitted to the department. Changes in the ownership or operational control of a facility may be made if the new owner or operator submits a revised permit application no later than ninety days prior to the scheduled change. When a transfer of ownership or operational control of a facility occurs, the old owner or operator shall comply with the requirements of WAC 173-303-620 (Financial requirements), until the new owner or operator has demonstrated to the department that he is complying with the requirements of that section. The new owner or operator must demonstrate compliance with financial requirements within six months of the date of the change in the ownership or operational control of the facility. Upon demonstration to the department by the new owner or operator of compliance with WAC 173-303-620, the department shall notify the old owner or operator in writing that he no longer needs to comply with the financial requirements as of the date of demonstration;~~

~~(e) Change the lists of facility emergency coordinators or equipment in the permit's contingency plan;~~

~~(f) Change the following:~~

~~(i) Estimates of maximum inventory under WAC 173-303-610 (3)(a) (iii);~~

~~(ii) Estimates of expected year of closure or schedules for final closure under WAC 173-303-610 (3)(a)(vii); or~~



~~(iii) Approve periods longer than ninety days or one hundred eighty days under WAC 173-303-610 (4)(a) or (b);~~

~~(g) Change the ranges of the operating requirements set in the permit to reflect the results of the trial burn, provided that the change is minor;~~

~~(h) Change the operating requirements set in the permit for conducting a trial burn, provided that the change is minor;~~

~~(i) Grant one extension of the time period for determining operational readiness following completion of construction, for up to seven hundred twenty hours operating time for treatment of dangerous waste in an incinerator;~~

~~(j) Change the treatment program requirements for land treatment units under WAC 173-303-655(2) to improve treatment of dangerous constituents, provided that the change is minor;~~

~~(k) Change any conditions specified in the permit for land treatment units to reflect the results of field tests or laboratory analyses used in making a treatment demonstration in accordance with WAC 173-303-808, provided that the change is minor; and~~

~~(l) Allow a second treatment demonstration for land treatment to be conducted when the results of the first demonstration have not shown the conditions under which the waste or wastes can be treated completely as required by WAC 173-303-655, provided that the conditions for the second demonstration are substantially the same as the conditions for the first demonstration.)~~

(4) Permit modification at the request of the permittee.

(a) Class 1 modifications.

(i) Except as provided in (a)(ii) of this subsection, the permittee may put into effect Class 1 modifications listed in Appendix I of this section under the following conditions:

(A) The permittee must notify the department concerning the modification by certified mail or other means that establish proof of delivery within seven calendar days after the change is put into effect. This notice must specify the changes being made to permit conditions or supporting documents referenced by the permit and must explain why they are necessary. Along with the notice, the permittee must provide the applicable information required by WAC 173-303-806(4), 173-303-807, and 173-303-808.

(B) The permittee must send a notice of the modification to all persons on the facility mailing list, maintained by the department in accordance with WAC 173-303-840 (3)(e)(i)(D), and the appropriate units of state and local government, as specified in WAC 173-303-840 (3)(e)(i)(E). This notification must be made within ninety calendar days after the change is put into effect. For the Class 1 modifications that require prior department approval, the notification must be made within ninety calendar days after the department approves the request.

(C) Any person may request the department to review, and the department may for cause reject, any Class 1 modification. The department must inform the permittee by certified mail that a Class 1 modification

has been rejected, explaining the reasons for the rejection. If a Class 1 modification has been rejected, the permittee must comply with the original permit conditions.

(ii) Class 1 permit modifications identified in Appendix I by an asterisk may be made only with the prior written approval of the department.

(iii) For a Class 1 permit modification, the permittee may elect to follow the procedures in (b) of this subsection for Class 2 modifications instead of the Class 1 procedures. The permittee must inform the department of this decision in the notice required in (b)(i) of this subsection.

(b) Class 2 modifications.

(i) For Class 2 modifications, listed in Appendix I of this section, the permittee must submit a modification request to the department that:

(A) Describes the exact change to be made to the permit conditions and supporting documents referenced by the permit;

(B) Identifies that the modification is a Class 2 modification;

(C) Explains why the modification is needed; and

(D) Provides the applicable information required by WAC 173-303-806(4), 173-303-807, and 173-303-808.

(ii) The permittee must send a notice of the modification request to all persons on the facility mailing list maintained by the department and to the appropriate units of state and local government as specified in WAC 173-303-840 (3)(e)(i)(E) and must publish this notice in a major local newspaper of general circulation. This notice must be mailed and published within seven days before or after the date of submission of the modification request, and the permittee must provide to the department evidence of the mailing and publication. The notice must include:

(A) Announcement of a sixty-day comment period, in accordance with (b)(v) of this subsection, and the name and address of a departmental contact to whom comments must be sent;

(B) Announcement of the date, time, and place for a public meeting held in accordance with (b)(iv) of this subsection;

(C) Name and telephone number of the permittee's contact person;

(D) Name and telephone number of a departmental contact person;

(E) Location where copies of the modification request and any supporting documents can be viewed and copied; and

(F) The following statement: "The permittee's compliance history during the life of the permit being modified is available from the department of ecology contact person."

(iii) The permittee must place a copy of the permit modification request and supporting documents in a location accessible to the public in the vicinity of the permitted facility.

(iv) The permittee must hold a public meeting no earlier than fifteen days after the publication of the notice required in (b)(ii) of this subsection and no later

than fifteen days before the close of the sixty-day comment period. The meeting must be held to the extent practicable in the vicinity of the permitted facility.

(v) The public shall be provided sixty days to comment on the modification request. The comment period will begin on the date the permittee publishes the notice in the local newspaper. Comments should be submitted to the department of ecology contact identified in the public notice.

(vi)(A) No later than ninety days after receipt of the notification request, the department must:

(I) Approve the modification request, with or without changes, and modify the permit accordingly;

(II) Deny the request;

(III) Determine that the modification request must follow the procedures in (c) of this subsection for Class 3 modifications for the following reasons:

(AA) There is significant public concern about the proposed modification; or

(BB) The complex nature of the change requires the more extensive procedures of Class 3;

(IV) Approve the request, with or without changes, as a temporary authorization having a term of up to one hundred eighty days; or

(V) Notify the permittee that he or she will decide on the request within the next thirty days.

(B) If the department notifies the permittee of a thirty-day extension for a decision, the department must, no later than one hundred twenty days after receipt of the modification request:

(I) Approve the modification request, with or without changes, and modify the permit accordingly;

(II) Deny the request; or

(III) Determine that the modification request must follow the procedures in (c) of this subsection for Class 3 modifications for the following reasons:

(AA) There is significant public concern about the proposed modification; or

(BB) The complex nature of the change requires the more extensive procedures of Class 3.

(IV) Approve the request, with or without changes, as a temporary authorization having a term of up to one hundred eighty days.

(C) If the department fails to make one of the decisions specified in (b)(vi)(B) of this subsection by the one hundred twentieth day after receipt of the modification request, the permittee is automatically authorized to conduct the activities described in the modification request for up to one hundred eighty days, without formal departmental action. The authorized activities must be conducted as described in the permit modification request and must be in compliance with all appropriate standards of 40 CFR Part 265 (as referenced by WAC 173-303-400). If the department approves, with or without changes, or denies the modification request during the term of the temporary or automatic authorization provided for in (b)(vi)(A), (B), or (C) of this subsection, such action cancels the temporary or automatic authorization.

(D)(I) In the case of an automatic authorization under (b)(vi)(C) of this subsection, or a temporary authorization under (b)(vi)(A)(IV) or (B)(IV) of this subsection, if the department has not made a final approval or denial of the modification request by the date fifty days prior to the end of the temporary or automatic authorization, the permittee must within seven days of that time send a notification to persons on the facility mailing list, and make a reasonable effort to notify other persons who submitted written comments on the modification request, that:

(AA) The permittee has been authorized temporarily to conduct the activities described in the permit modification request; and

(BB) Unless the department acts to give final approval or denial of the request by the end of the authorization period, the permittee will receive authorization to conduct such activities for the life of the permit.

(II) If the owner/operator fails to notify the public by the date specified in (b)(vi)(D)(I) of this subsection, the effective date of the permanent authorization will be deferred until fifty days after the owner/operator notifies the public.

(E) Except as provided in (b)(vi)(G) of this subsection, if the department does not finally approve or deny a modification request before the end of the automatic or temporary authorization period or reclassify the modification as a Class 3, the permittee is authorized to conduct the activities described in the permit modification request for the life of the permit unless modified later under subsection (3) or (4) of this section. The activities authorized under this subsection (b)(vi)(E) must be conducted as described in the permit modification request and must be in compliance with all appropriate standards of 40 CFR Part 265 (as referenced by WAC 173-303-400).

(F) In making a decision to approve or deny a modification request, including a decision to issue a temporary authorization or to reclassify a modification as a Class 3, the department must consider all written comments submitted during the public comment period and must respond in writing to all significant comments in his or her decision.

(G) With the written consent of the permittee, the department may extend indefinitely or for a specified period the time periods for final approval or denial of a modification request or for reclassifying a modification as a Class 3.

(vii) The department may deny or change the terms of a Class 2 permit modification request under (b)(6)(i) through (iii) of this subsection for the following reasons:

(A) The modification request is incomplete;

(B) The requested modification does not comply with the appropriate requirements of WAC 173-303-283 through 173-303-395 and 173-303-600 through 173-303-680 or other applicable requirements; or

(C) The conditions of the modification fail to protect human health and the environment.

(viii) The permittee may perform any construction associated with a Class 2 permit modification request beginning sixty days after the submission of the request

unless the department establishes a later date for commencing construction and informs the permittee in writing before day sixty.

(c) Class 3 modifications.

(i) For Class 3 modifications listed in Appendix I of this section, the permittee must submit a modification request to the department that:

(A) Describes the exact change to be made to the permit conditions and supporting documents referenced by the permit;

(B) Identifies that the modification is a Class 3 modification;

(C) Explains why the modification is needed; and

(D) Provides the applicable information required by WAC 173-303-806(4), 173-303-807, and 173-303-808.

(ii) The permittee must send a notice of the modification request to all persons on the facility mailing list maintained by the department and to the appropriate units of state and local government as specified in WAC 173-303-840 (3)(e)(i)(E) and must publish this notice in a major local newspaper of general circulation. This notice must be mailed and published within seven days before or after the date of submission of the modification request, and the permittee must provide to the department evidence of the mailing and publication. The notice must include:

(A) Announcement of a sixty-day comment period, and a name and address of an agency contact to whom comments must be sent;

(B) Announcement of the date, time, and place for a public meeting on the modification request, in accordance with (c)(4) of this subsection;

(C) Name and telephone number of the permittee's contact person;

(D) Name and telephone number of a departmental contact person;

(E) Location where copies of the modification request and any supporting documents can be viewed and copied; and

(F) The following statement: "The permittee's compliance history during the life of the permit being modified is available from the department of ecology contact person."

(iii) The permittee must place a copy of the permit modification request and supporting documents in a location accessible to the public in the vicinity of the permitted facility.

(iv) The permittee must hold a public meeting no earlier than fifteen days after the publication of the notice required in (c)(ii) of this subsection and no later than fifteen days before the close of the sixty-day comment period. The meeting must be held to the extent practicable in the vicinity of the permitted facility.

(v) The public shall be provided at least sixty days to comment on the modification request. The comment period will begin on the date the permittee publishes the notice in the local newspaper. Comments should be submitted to the department of ecology contact identified in the notice.

(vi) After the conclusion of the sixty-day comment period, the department must grant or deny the permit

modification request according to the permit modification procedures of WAC 173-303-840. In addition, the department must consider and respond to all significant written comments received during the sixty-day comment period.

(d) Other modifications.

(i) In the case of modifications not explicitly listed in Appendix I of this section, the permittee may submit a Class 3 modification request to the department, or he or she may request a determination by the department that the modification should be reviewed and approved as a Class 1 or Class 2 modification. If the permittee requests that the modification be classified as a Class 1 or 2 modification, he or she must provide the department with the necessary information to support the requested classification.

(ii) The department shall make the determination described in (d)(i) of this subsection as promptly as practicable. In determining the appropriate class for a specific modification, the department shall consider the similarity of the modification to other modifications codified in Appendix I and the following criteria:

(A) Class 1 modifications apply to minor changes that keep the permit current with routine changes to the facility or its operation. These changes do not substantially alter the permit conditions or reduce the capacity of the facility to protect human health or the environment. In the case of Class 1 modifications, the department may require prior approval.

(B) Class 2 modifications apply to changes that are necessary to enable a permittee to respond, in a timely manner, to:

(I) Common variations in the types and quantities of the wastes managed under the facility permit;

(II) Technological advancements; and

(III) Changes necessary to comply with new regulations, where these changes can be implemented without substantially changing design specifications or management practices in the permit.

(C) Class 3 modifications substantially alter the facility or its operation.

(e) Temporary authorizations.

(i) Upon request of the permittee, the department may, without prior public notice and comment, grant the permittee a temporary authorization in accordance with this subsection. Temporary authorizations must have a term of not more than one hundred eighty days.

(ii)(A) The permittee may request a temporary authorization for:

(I) Any Class 2 modification meeting the criteria in (e)(iii)(B) of this subsection; and

(II) Any Class 3 modification that meets the criteria in (e)(iii)(B)(I) or (II) of this subsection; or that meets the criteria in (e)(iii)(B)(III) through (V) of this subsection and provides improved management or treatment of a dangerous waste already listed in the facility permit.

(B) The temporary authorization request must include:

(I) A description of the activities to be conducted under the temporary authorization;

(II) An explanation of why the temporary authorization is necessary; and

(III) Sufficient information to ensure compliance with the standards in WAC 173-303-280 through 173-303-395 and 173-303-600 through 173-303-680.

(C) The permittee must send a notice about the temporary authorization request to all persons on the facility mailing list maintained by the department and to appropriate units of state and local governments as specified in WAC 173-303-840 (3)(e)(i)(E). This notification must be made within seven days of submission of the authorization request.

(iii) The department shall approve or deny the temporary authorization as quickly as practical. To issue a temporary authorization, the department must find:

(A) The authorized activities are in compliance with the standards of WAC 173-303-280 through 173-303-395 and 173-303-600 through 173-303-680.

(B) The temporary authorization is necessary to achieve one of the following objectives before action is likely to be taken on a modification request:

(I) To facilitate timely implementation of closure or corrective action activities;

(II) To allow treatment or storage in tanks or containers of restricted wastes in accordance with 40 CFR Part 268;

(III) To prevent disruption of ongoing waste management activities;

(IV) To enable the permittee to respond to sudden changes in the types or quantities of the wastes managed under the facility permit; or

(V) To facilitate other changes to protect human health and the environment.

(iv) A temporary authorization may be reissued for one additional term of up to one hundred eighty days provided that the permittee has requested a Class 2 or 3 permit modification for the activity covered in the temporary authorization, and:

(A) The reissued temporary authorization constitutes the department's decision on a Class 2 permit modification in accordance with (b)(vi)(A)(IV) or (B)(IV) of this subsection; or

(B) The department determines that the reissued temporary authorization involving a Class 3 permit modification request is warranted to allow the authorized activities to continue while the modification procedures of (c) of this subsection are conducted.

(f) Public notice and appeals of permit modification decisions.

(i) The department shall notify persons on the facility mailing list and appropriate units of state and local government within ten days of any decision under this section to grant or deny a Class 2 or 3 permit modification request. The department shall also notify such persons within ten days after an automatic authorization for a Class 2 modification goes into effect under (b)(vi)(C) or (E) of this subsection.

(ii) The department's decision to grant or deny a Class 2 or 3 permit modification request under this section may be appealed under the permit appeal procedures of WAC 173-303-845.

(iii) An automatic authorization that goes into effect under (b)(vi)(C) or (E) of this subsection may be appealed under the permit appeal procedures of WAC

173-303-845; however, the permittee may continue to conduct the activities pursuant to the automatic authorization until the appeal has been granted pursuant to WAC 173-303-845, notwithstanding the provisions of WAC 173-303-840 (8)(b).

(g) Newly listed or identified wastes.

(i) The permittee is authorized to continue to manage wastes listed or identified as dangerous under WAC 173-303-070 if he or she:

(A) Was in existence as a dangerous waste facility with respect to the newly listed or identified waste on the effective date of the final rule listing or identifying the waste;

(B) Submits a Class 1 modification request on or before the date on which the waste becomes subject to the new requirements;

(C) Is in compliance with the standards of 40 CFR Part 265 (as referenced in WAC 173-303-400);

(D) In the case of Classes 2 and 3 modifications, also submits a complete permit modification request within one hundred eighty days after the effective date of the rule listing or identifying the waste; and

(E) In the case of land disposal units, certifies that such unit is in compliance with all applicable Part 265 ground water monitoring and financial responsibility requirements (as referenced in WAC 173-303-400) on the date twelve months after the effective date of the rule identifying or listing the waste as dangerous. If the owner or operator fails to clarify compliance with these requirements, he or she shall lose authority to operate under this section.

(ii) New wastes or units added to a facility's permit under this subsection do not constitute expansions for the purpose of the twenty-five percent capacity expansion limit for Class 2 modifications.

(h) Permit modification list. The department must maintain a list of all approved permit modifications and must publish a notice once a year in a state-wide newspaper that an updated list is available for review.

APPENDIX I

Modifications                      Class

A. General Permit Provisions

<u>1. Administrative and informational changes . . . . .</u>	<u>1</u>
<u>2. Correction of typographical errors . . . . .</u>	<u>1</u>
<u>3. Equipment replacement or upgrading with functionally equivalent components (e.g., pipes, valves, pumps, conveyors, controls) . . . . .</u>	<u>1</u>
<u>4. Changes in the frequency of or procedures for monitoring, reporting, sampling, or maintenance activities by the permittee:</u>	
<u>a. To provide for more frequent monitoring, reporting, sampling, or maintenance . . . . .</u>	<u>1</u>
<u>b. Other changes . . . . .</u>	<u>2</u>
<u>5. Schedule of compliance:</u>	
<u>a. Changes in interim compliance dates, with prior approval of the Director . . . . .</u>	<u>1</u>
<u>b. Extension of final compliance date . . . . .</u>	<u>3</u>
<u>6. Changes in expiration date of permit to allow earlier permit termination, with prior approval of the Director . . . . .</u>	<u>1</u>

<u>Modifications</u>	<u>Class</u>
7. Changes in ownership or operational control of a facility, provided the procedures of subsection (2)(b) of this section are followed . . . . .	1
<b>B. General Facility Standards</b>	
1. Changes to waste sampling or analysis methods:	
a. To conform with agency guidance or regulations . . . . .	1
b. Other changes . . . . .	2
2. Changes to analytical quality assurance/control plan:	
a. To conform with agency guidance or regulations . . . . .	1
b. Other changes . . . . .	2
3. Changes in procedures for maintaining the operating record . . . . .	1
4. Changes in frequency or content of inspection schedules . . . . .	2
5. Changes in the training plan:	
a. That affect the type or decrease the amount of training given to employees . . . . .	2
b. Other changes . . . . .	1
6. Contingency plan:	
a. Changes in emergency procedures (i.e., spill or release response procedures) . . . . .	2
b. Replacement with functionally equivalent equipment, upgrade, or relocate emergency equipment listed . . . . .	1
c. Removal of equipment from emergency equipment list . . . . .	2
d. Changes in name, address, or phone number of coordinators or other persons or agencies identified in the plan . . . . .	1
<b>Note:</b> When a permit modification (such as introduction of a new unit) requires a change in facility plans or other general facility standards, that change shall be reviewed under the same procedures as the permit modification.	
<b>C. Ground Water Protection</b>	
1. Changes to wells:	
a. Changes in the number, location, depth, or design of upgradient or downgradient wells of permitted ground water monitoring system . . . . .	2
b. Replacement of an existing well that has been damaged or rendered inoperable, without change to location, design, or depth of the well . . . . .	1
2. Changes in ground water sampling or analysis procedures or monitoring schedule, with prior approval of the Director . . . . .	1
3. Changes in statistical procedure for determining whether a statistically significant change in ground water quality between upgradient and downgradient wells has occurred, with prior approval of the Director . . . . .	1
4. Changes in point of compliance . . . . .	2
5. Changes in indicator parameters, hazardous constituents, or concentration limits (including ACLs):	
a. As specified in the ground water protection standard . . . . .	3
b. As specified in the detection monitoring program . . . . .	2
6. Changes to a detection monitoring program as required by WAC 173-303-645 (9)(j), unless otherwise specified in this appendix . . . . .	2
7. Compliance monitoring program:	
a. Addition of compliance monitoring program as required by WAC 173-303-645 (9)(h)(iv) and (10) . . . . .	3

<u>Modifications</u>	<u>Class</u>
b. Changes to a compliance monitoring program as required by WAC 173-303-645 (10)(k), unless otherwise specified in this appendix . . . . .	2
8. Corrective action program:	
a. Addition of a corrective action program as required by WAC 173-303-645 (10)(j)(ii) and (11) . . . . .	3
b. Changes to a corrective action program as required by WAC 173-303-645 (11)(h), unless otherwise specified in this appendix . . . . .	2
<b>D. Closure</b>	
1. Changes to the closure plan:	
a. Changes in estimate of maximum extent of operations or maximum inventory of waste on-site at any time during the active life of the facility, with prior approval of the Director . . . . .	1
b. Changes in the closure schedule for any unit, changes in the final closure schedule for the facility, or extension of the closure period, with prior approval of the Director . . . . .	1
c. Changes in the expected year of final closure, where other permit conditions are not changed, with prior approval of the Director . . . . .	1
d. Changes in procedures for decontamination of facility equipment or structures, with prior approval of the Director . . . . .	1
e. Changes in approved closure plan resulting from unexpected events occurring during partial or final closure, unless otherwise specified in this appendix . . . . .	2
f. Extension of the closure period to allow a landfill, surface impoundment, or land treatment unit to receive nondangerous wastes after final receipt of dangerous wastes under WAC 173-303-610 (4)(d) and (e) . . . . .	2
2. Creation of a new landfill unit as part of closure . . . . .	3
3. Addition of the following new units to be used temporarily for closure activities:	
a. Surface impoundments . . . . .	3
b. Incinerators . . . . .	3
c. Waste piles that do not comply with WAC 173-303-660 (1)(c) . . . . .	3
d. Waste piles that comply with WAC 173-303-660 (1)(c) . . . . .	2
e. Tanks or containers (other than specified below) . . . . .	2
f. Tanks used for neutralization, dewatering, phase separation, or component separation, with prior approval of the Director . . . . .	1
<b>E. Post-Closure</b>	
1. Changes in name, address, or phone number of contact in post-closure plan . . . . .	1
2. Extension of post-closure care period . . . . .	2
3. Reduction in the post-closure care period . . . . .	3
4. Changes to the expected year of final closure, where other permit conditions are not changed . . . . .	1
5. Changes in post-closure plan necessitated by events occurring during the active life of the facility, including partial and final closure . . . . .	2
<b>F. Containers</b>	
1. Modification or addition of container units:	
a. Resulting in greater than 25% increase in the facility's container storage capacity, except as provided in F(1)(c) and F(4)(a) below . . . . .	3

Modifications                      Class

b. Resulting in up to 25% increase in the facility's container storage capacity, except as provided in F(1)(c) and F(4)(a) below ..... 2

c. Or treatment processes necessary to treat wastes that are restricted from land disposal to meet some or all of the applicable treatment standards or to treat wastes to satisfy (in whole or in part) the standard of "use of practically available technology that yields the greatest environmental benefit" contained in 40 CFR 268.8(a)(2)(ii), with prior approval of the department. This modification may also involve addition of new waste codes or narrative descriptions of wastes. It is not applicable to dioxin-containing wastes (F020, 021, 022, 023, 026, 027, and 028) ..... 1

2:  
a. Modification of a container unit without increasing the capacity of the unit ..... 2

b. Addition of a roof to a container unit without alteration of the containment system ..... 1

3. Storage of different wastes in containers:

a. That require additional or different management practices from those authorized in the permit, except as provided in F(4) below ..... 3

b. That do not require additional or different management practices from those authorized in the permit... 2

Note: See (g) of this subsection for modification procedures to be used for the management of newly listed or identified wastes.

4. Storage of treatment of different wastes in containers:

a. That require addition of units or change in treatment process or management standards, provided that the wastes are restricted from land disposal and are to be treated to meet some or all of the applicable treatment standards, or that are to be treated to satisfy (in whole or in part) the standard of "use of practically available technology that yields the greatest environmental benefit" contained in 40 CFR 268.8(a)(2)(ii). This modification is not applicable to dioxin-containing wastes (F020, 021, 022, 023, 026, 027, and 028)..... 1

b. That do not require the addition of units or a change in the treatment process or management standards, and provided that the units have previously received wastes of the same type (e.g., incinerator scrubber water). This modification is not applicable to dioxin-containing wastes (F020, 021, 022, 023, 026, 027, and 028) ..... 1

G. Tanks

1:  
a. Modification or addition of tank units resulting in greater than 25% increase in the facility's tank capacity, except as provided in G(1)(c), G(1)(d), and G(1)(e) below ..... 3

b. Modification or addition of tank units resulting in up to 25% increase in the facility's tank capacity, except as provided in G(1)(d) and G(1)(e) below ..... 2

c. Addition of a new tank that will operate for more than 90 days using any of the following physical or chemical treatment technologies: neutralization, dewatering, phase separation, or component separation.... 2

Modifications                      Class

d. After prior approval of the department, addition of a new tank that will operate for up to 90 days using any of the following physical or chemical treatment technologies: neutralization, dewatering, phase separation, or component separation ..... 1

e. Modification or addition of tank units or treatment processes necessary to treat wastes that are restricted from land disposal to meet some or all of the applicable treatment standards or to treat wastes to satisfy (in whole or in part) the standard of "use of practically available technology that yields the greatest environmental benefit" contained in 40 CFR 268.8(a)(2)(ii), with prior approval of the department. This modification may also involve addition of new waste codes. It is not applicable to dioxin-containing wastes (F020, 021, 022, 023, 026, 027, and 028) ..... 1

2. Modification of a tank unit or secondary containment system without increasing the capacity of the unit ..... 2

3. Replacement of a tank with a tank that meets the same design standards and has a capacity within +/- 10% of the replaced tank provided ..... 1

-The capacity difference is no more than 1500 gallons,

-The facility's permitted tank capacity is not increased, and

-The replacement tank meets the same conditions in the permit.

4. Modification of a tank management practice .... 2

5. Management of different wastes in tanks:

a. That require additional or different management practices, tank design, different fire protection specifications, or significantly different tank treatment process from that authorized in the permit, except as provided in G(5)(c) below ..... 3

b. That do not require additional or different management practices, tank design, different fire protection specifications, or significantly different tank treatment process than authorized in the permit, except as provided in G(5)(d) ..... 2

c. That require addition of units or change in treatment processes or management standards, provided that the wastes are restricted from land disposal and are to be treated to meet some or all of the applicable treatment standards or that are to be treated to satisfy (in whole or in part) the standard of "use of practically available technology that yields the greatest environmental benefit" contained in 40 CFR 268.8(a)(2)(ii). The modification is not applicable to dioxin-containing wastes (F020, 021, 022, 023, 026, 027, and 028) .... 1

Note: See (g) of this subsection for modification procedures to be used for the management of newly listed or identified wastes.

H. Surface Impoundments

1. Modification or addition of surface impoundment units that result in increasing the facility's surface impoundment storage or treatment capacity..... 3

2. Replacement of a surface impoundment unit.... 3

<u>Modifications</u>	<u>Class</u>
3. Modification of a surface impoundment unit without increasing the facility's surface impoundment storage or treatment capacity and without modifying the unit's liner, leak detection system, or leachate collection system . . . . .	2
4. Modification of a surface impoundment management practice . . . . .	2
5. Treatment, storage, or disposal of different wastes in surface impoundments:	
a. That require additional or different management practices or different design of the liner or leak detection system than authorized in the permit . . . . .	3
b. That do not require additional or different management practices or different design of the liner or leak detection system than authorized in the permit . . . . .	2
c. That are wastes restricted from land disposal that meet the applicable treatment standards or that are treated to satisfy the standard of "use of practically available technology that yields the greatest environmental benefit" contained in 40 CFR 268.8(a)(2)(ii), and provided that the unit meets the minimum technological requirements stated in 40 CFR 268.5(h)(2). This modification is not applicable to dioxin-containing wastes (F020, 021, 022, 023, 026, 027, and 028) . . . . .	1
d. That are residues from wastewater treatment or incineration, provided that disposal occurs in a unit that meets the minimum technological requirements stated in 40 CFR 268.5(h)(2), and provided further that the surface impoundment has previously received wastes of the same type (for example, incinerator scrubber water). This modification is not applicable to dioxin-containing wastes (F020, 021, 022, 023, 026, 027, and 028) . . . . .	1

Note: See (g) of this subsection for modification procedures to be used for the management of newly listed or identified wastes.

**I. Enclosed Waste Piles.** For all waste piles except those complying with WAC 173-303-660 (1)(c), modifications are treated the same as for a landfill. The following modifications are applicable only to waste piles complying with WAC 173-303-660 (1)(c).

1. Modification or addition of waste pile units:	
a. Resulting in greater than 25% increase in the facility's waste pile storage or treatment capacity . . . . .	3
b. Resulting in up to 25% increase in the facility's waste pile storage or treatment capacity . . . . .	2
2. Modification of waste pile unit without increasing the capacity of the unit . . . . .	2
3. Replacement of a waste pile unit with another waste pile unit of the same design and capacity and meeting all waste pile conditions in the permit . . . . .	1
4. Modification of a waste pile management practice . . . . .	2
5. Storage or treatment of different wastes in waste piles:	
a. That require additional or different management practices or different design of the unit . . . . .	3
b. That do not require additional or different management practices or different design of the unit . . . . .	2

Note: See (g) of this subsection for modification procedures to be used for the management of newly listed or identified wastes.

<u>Modifications</u>	<u>Class</u>
J. Landfills and Unenclosed Waste Piles	
1. Modification or addition of landfill units that result in increasing the facility's disposal capacity . . . . .	3
2. Replacement of a landfill . . . . .	3
3. Addition or modification of a liner, leachate collection system, leachate detection system, run-off control, or final cover system . . . . .	3
4. Modification of a landfill unit without changing a liner, leachate collection system, leachate detection system, run-off control, or final cover system . . . . .	2
5. Modification of a landfill management practice . . . . .	2
6. Landfill different wastes:	
a. That require additional or different management practices, different design of the liner, leachate collection system, or leachate detection system . . . . .	3
b. That do not require additional or different management practices, different design of the liner, leachate collection system, or leachate detection system . . . . .	2
c. That are wastes restricted from land disposal that meet the applicable treatment standards or that are treated to satisfy the standard of "use of practically available technology that yields the greatest environmental benefit" contained in 40 CFR 268.8(a)(2)(ii), and provided that the landfill unit meets the minimum technological requirements stated in 40 CFR 268.5(h)(2). This modification is not applicable to dioxin-containing wastes (F020, 021, 022, 023, 026, 027, and 028) . . . . .	1
d. That are residues from wastewater treatment or incineration, provided that disposal occurs in a landfill unit that meets the minimum technological requirements stated in 40 CFR 268.5(h)(2), and provided further that the landfill has previously received wastes of the same type (for example, incinerator ash). This modification is not applicable to dioxin-containing wastes (F020, 021, 022, 023, 026, 027, and 028) . . . . .	1

Note: See (g) of this subsection for modification procedures to be used for the management of newly listed or identified wastes.

**K. Land Treatment**

1. Lateral expansion of or other modification of a land treatment unit to increase areal extent . . . . .	3
2. Modification of run-on control system . . . . .	2
3. Modify run-off control system . . . . .	3
4. Other modifications of land treatment unit component specifications or standards required in permit . . . . .	2
5. Management of different wastes in land treatment units:	
a. That require a change in permit operating conditions or unit design specifications . . . . .	3
b. That do not require a change in permit operating conditions or unit design specifications . . . . .	2

Note: See (g) of this subsection for modification procedures to be used for the management of newly listed or identified wastes.

6. Modification of a land treatment unit management practice to:	
a. Increase rate or change method of waste application . . . . .	3
b. Decrease rate of waste application . . . . .	2



Modifications                      Class

- 7. Modification of a land treatment unit management practice to change measures of pH or moisture content, or to enhance microbial or chemical reactions . . . . . 2
- 8. Modification of a land treatment unit management practice to grow food chain crops, to add to or replace existing permitted crops with different food chain crops, or to modify operating plans for distribution of animal feeds resulting from such crops . . . . . 3
- 9. Modification of operating practice due to detection of releases from the land treatment unit pursuant to WAC 173-303-655 (6)(g)(ii) . . . . . 3
- 10. Changes in the unsaturated zone monitoring system, resulting in a change to the location, depth, number of sampling points, or replace unsaturated zone monitoring devices or components of devices with devices or components that have specifications different from permit requirements . . . . . 3
- 11. Changes in the unsaturated zone monitoring system that do not result in a change to the location, depth, number of sampling points, or that replace unsaturated zone monitoring devices or components of devices with devices or components having specifications different from permit requirements . . . . . 2
- 12. Changes in background values for hazardous constituents in soil and soil-pore liquid . . . . . 2
- 13. Changes in sampling, analysis, or statistical procedure . . . . . 2
- 14. Changes in land treatment demonstration program prior to or during the demonstration . . . . . 2
- 15. Changes in any condition specified in the permit for a land treatment unit to reflect results of the land treatment demonstration, provided performance standards are met, and the Director's prior approval has been received . . . . . 2
- 16. Changes to allow a second land treatment demonstration to be conducted when the results of the first demonstration have not shown the conditions under which the wastes can be treated completely, provided the conditions for the second demonstration are substantially the same as the conditions for the first demonstration and have received the prior approval of the Director . . 2
- 17. Changes to allow a second land treatment demonstration to be conducted when the results of the first demonstration have not shown the conditions under which the wastes can be treated completely, where the conditions for the second demonstration are not substantially the same as the conditions for the first demonstration . . . . . 3
- 18. Changes in vegetative cover requirements for closure . . . . . 2

L. Incinerators

- 1. Changes to increase by more than 25% any of the following limits authorized in the permit: A thermal feed rate limit, a waste feed rate limit, or an organic chlorine feed rate limit. The Director will require a new trial burn to substantiate compliance with the regulatory performance standards unless this demonstration can be made through other means . . . . . 3

Modifications                      Class

- 2. Changes to increase by up to 25% any of the following limits authorized in the permit: A thermal feed rate limit, a waste feed limit, or an organic chlorine feed rate limit. The Director will require a new trial burn to substantiate compliance with the regulatory performance standards unless this demonstration can be made through other means . . . . . 2
- 3. Modification of an incinerator unit by changing the internal size or geometry of the primary or secondary combustion units, by adding a primary or secondary combustion unit, by substantially changing the design of any component used to remove HCl or particulate from the combustion gases, or by changing other features of the incinerator that could affect its capability to meet the regulatory performance standards. The Director will require a new trial burn to substantiate compliance with the regulatory performance standards unless this demonstration can be made through other means . . . . . 3
- 4. Modification of an incinerator unit in a manner that would not likely affect the capability of the unit to meet the regulatory performance standards but which would change the operating conditions or monitoring requirements specified in the permit. The Director may require a new trial burn to demonstrate compliance with the regulatory performance standards . . . . . 2
- 5. Operating requirements:
  - a. Modification of the limits specified in the permit for minimum combustion gas temperature, minimum combustion gas residence time, or oxygen concentration in the secondary combustion chamber. The Director will require a new trial burn to substantiate compliance with the regulatory performance standards unless this demonstration can be made through other means . . . . . 3
  - b. Modification of any stack gas emission limits specified in the permit, or modification of any conditions in the permit concerning emergency shutdown or automatic waste feed cutoff procedures or controls . . . . . 3
  - c. Modification of any other operating condition or any inspection or recordkeeping requirement specified in the permit . . . . . 2
- 6. Incineration of different wastes:
  - a. If the waste contains a POHC that is more difficult to incinerate than authorized by the permit or if incineration of the waste requires compliance with different regulatory performance standards than specified in the permit. The Director will require a new trial burn to substantiate compliance with the regulatory performance standards unless this demonstration can be made through other means . . . . . 3
  - b. If the waste does not contain a POHC that is more difficult to incinerate than authorized by the permit and if incineration of the waste does not require compliance with different regulatory performance standards than specified in the permit . . . . . 2

Note: See (g) of this subsection for modification procedures to be used for the management of newly listed or identified wastes.

7. Shakedown and trial burn:

Modifications                      Class

- a. Modification of the trial burn plan or any of the permit conditions applicable during the shakedown period for determining operational readiness after construction, the trial burn period, or the period immediately following the trial burn . . . . . 2
- b. Authorization of up to an additional 720 hours of waste incineration during the shakedown period for determining operational readiness after construction, with the prior approval of the Director . . . . . 1
- c. Changes in the operating requirements set in the permit for conducting a trial burn, provided the change is minor and has received the prior approval of the Director . . . . . 1
- d. Changes in the ranges of the operating requirements set in the permit to reflect the results of the trial burn, provided the change is minor and has received the prior approval of the Director . . . . . 1
- 8. Substitution of an alternate type of fuel that is not specified in the permit . . . . . 1

<sup>1</sup> Class 1 modifications requiring prior Agency approval.

(5) Permit termination. The department shall follow the applicable procedures in WAC 173-303-840, procedures for decision making, in terminating any permit. The following are causes for terminating a permit during its term or for denying a permit renewal application:

- (a) Noncompliance by the permittee with any condition of the permit;
- (b) The permittee's failure in the application or during the permit issuance process to disclose fully all relevant facts, or the permittee's misrepresentation of any relevant facts at any time; or
- (c) A determination that the permitted activity endangers public health or the environment and can only be regulated to acceptable levels by permit modification or termination.
- (6) Schedules of compliance.
  - (a) General. The permit may, when appropriate, specify a schedule of compliance leading to compliance with chapter 173-303 WAC.
  - (b) Time for compliance. Any schedules of compliance under this section shall require compliance as soon as possible.
  - (c) Interim dates. If a permit establishes a schedule of compliance which exceeds one year from the date of permit issuance, the schedule shall set forth interim requirements and the dates for their achievement as follows:
    - (i) The time between interim dates shall not exceed one year; or
    - (ii) If the time necessary for completion of any interim requirement (such as the construction of a control facility) is more than one year and is not readily divisible into stages for completion, the permit shall specify interim dates for the submission of reports of progress toward completion of the interim requirements and indicate a projected completion date.
  - (d) Reporting. The permit shall be written to require that no later than fourteen days following each interim date and the final date of compliance, the permittee shall notify the department in writing of its compliance or noncompliance with the interim or final requirements.

**AMENDATORY SECTION** (Amending Order 88-24, filed 1/4/89)

**WAC 173-303-9903 DISCARDED CHEMICAL PRODUCTS LIST.**

DISCARDED CHEMICAL PRODUCTS LIST

Dangerous Waste No.	Substance	WDOE Hazard Designation	Reason for Designation*
<b>ACUTELY DANGEROUS CHEMICAL PRODUCTS</b>			
P023	Acetaldehyde, chloro-	EHW	B H
U001	Acetaldehyde	EHW	C
U034	Acetaldehyde, trichloro-	EHW	H
P002	Acetamide, N-(aminothioxomethyl)-	EHW	B
P057	Acetamide, 2-fluoro-	EHW	B H
P058	Acetic acid, fluoro-, sodium salt	EHW	A H
U144	Acetic acid, lead salt	EHW	D EP
P066	Acetimidic acid, N-[(methylcarbamoyl)oxy]thio-, methyl ester	EHW	B
U003	Acetonitrile	EHW	C I
P001	3-(alpha-Acetylbenzyl)-4-hydroxycoumarin and salts	EHW	A
P002	1-Acetyl-2-thiourea	EHW	B
U006	Acetyl chloride	EHW	C H O R
P003	Acrolein	EHW	X I
U007	Acrylamide	EHW	C
U008	Acrylic acid	EHW	C O I
U009	Acrylonitrile	EHW	C + I
P070	Aldicarb	EHW	B
P004	Aldrin	EHW	X H
P005	Allyl alcohol	EHW	B I
P006	Aluminum phosphide (R,T)	EHW	B R
P007	5-(Aminomethyl)-3-isoxazolol	EHW	B
P008	4-alpha-Aminopyridine	EHW	B
P009	Ammonium picrate	EHW	R
P119	Ammonium vanadate	EHW	B
U012	Aniline	EHW	C I
P010	Arsenic acid	EHW	B
P012	Arsenic (III) oxide	EHW	B +
P011	Arsenic (V) oxide	EHW	B
P011	Arsenic pentoxide	EHW	B
P012	Arsenic trioxide	EHW	B +
P038	Arsine, diethyl-	EHW	B
U015	Azaserine	EHW	C +
P054	Aziridine	EHW	B +
U010	Azirino(2',3':3,4)pyrrolo(1,2a)indole-4,7-dione, 6-amino-8-[(aminocarbonyloxy)methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-	EHW	B +
P013	Barium cyanide	EHW	A
U157	Benz[j]aceanthrylene, 1,2-dihydro-3-methyl-	EHW	H P
U017	Benzal chloride	EHW	D H
U018	Benz[a]anthracene	EHW	P +
U018	1,2-Benzanthracene	EHW	P +
U094	1,2-Benzanthracene, 7,12-dimethyl-	EHW	C P
U012	Benzenamine	EHW	C I
P024	Benzenamine, 4-chloro-	EHW	C H
U049	Benzenamine, 4-chloro-2-methyl-	EHW	H
U093	Benzenamine, N, N-dimethyl-4-(phenylazo)-	EHW	C +
U158	Benzenamine, 4,4-methylenebis(2-chloro-	EHW	H +
P077	Benzenamine, 4-nitro-	EHW	D ?
P028	Benzene, (chloromethyl)-	EHW	B H +
U019	Benzene	EHW	C + I
U038	Benzenecetic acid, 4-chloro-alpha-(4-chlorophenyl)-alpha-hydroxy, ethyl ester	EHW	H
U030	Benzene, 1-bromo-4-phenoxy-	EHW	H
U037	Benzene, chloro-	EHW	B H I
U190	1,2-Benzenedicarboxylic acid anhydride	EHW	C
U070	Benzene, 1,2-dichloro-	EHW	B H
U071	Benzene, 1,3-dichloro-	EHW	B H
U072	Benzene, 1,4-dichloro-	EHW	B H
U017	Benzene, (dichloromethyl)-	EHW	D H
U223	Benzene, 1,3-diisocyanatomethyl-	EHW	B R
U239	Benzene, dimethyl-	EHW	C I
U201	1,3-Benzenediol	EHW	C
U127	Benzene, hexachloro-	EHW	H
U056	Benzene, hexahydro-	EHW	C I
U188	Benzene, hydroxy-	EHW	C
U220	Benzene, methyl-	EHW	C I
U105	Benzene, 1-methyl-2,4-dinitro	EHW	C
U106	Benzene, 1-methyl-2,6-dinitro-	EHW	C
U055	Benzene, (1,methylethyl)-	EHW	C I
U169	Benzene, nitro-	EHW	C I
U183	Benzene, pentachloro	EHW	H
U185	Benzene, pentachloronitro-	EHW	D H +

Dangerous Waste No.	Substance	WDOE Hazard Designation	Reason for Designation*	Dangerous Waste No.	Substance	WDOE Hazard Designation	Reason for Designation*
U020	Benzenesulfonic acid chloride	EHW	D H O R	U130	1,3-Cyclopentadiene, 1,2,3,4,5,5-hexa-chloro-	EHW	X H
U020	Benzenesulfonyl chloride	EHW	D H O R	U058	Cyclophosphamide	EHW	C H + I
U207	Benzene, 1,2,4,5-tetrachloro-	EHW	D H	U240	2,4-D, salts and esters	EHW	B H
U023	Benzene, (trichloromethyl)-	EHW	H O R	U060	DDD	EHW	C H +
P042	1,2-Benzenediol, 4-[1-hydroxy-2-(methyl-amino)ethyl]-	EHW	B	U061	DDT	EHW	X H +
P014	Benzenethiol	EHW	A	U142	Decachlorooctahydro-1,3,4-metheno-2H-cyclobuta[c,d]-pentalen-2-one	EHW	X H
U021	Benzidine	EHW	B +	U062	Diallate	EHW	C H +
U022	Benzo[a]pyrene	EHW	P +	U133	Diamine	EHW	B + R
U022	3,4-Benzopyrene	EHW	P +	U063	Dibenz[a,h]anthracene	EHW	A P +
U197	p-Benzoquinone	EHW	C	U063	1,2:5,6-Dibenzanthracene	EHW	P + A
U023	Benzotrithloride	EHW	H O R	U064	1,2:7,8-Dibenzopyrene	EHW	P +
U050	1,2-Benzphenanthrene	EHW	P +	U064	Dibenz[a,i]pyrene	EHW	P +
P028	Benzyl chloride	EHW	B H +	U066	1,2-Dibromo-3-chloropropane	EHW	C H +
P015	Beryllium dust	EHW	C +	U062	S-(2,3-Dichloroallyl) diisopropylthiocarbamate	EHW	C H +
U085	2,2'-Bioxirane	EHW	B I	U070	o-Dichlorobenzene	EHW	B H
U021	'1,1'-Biphenyl)-4,4'-diamine	EHW	B +	U071	m-Dichlorobenzene	EHW	B H
U073	(1,1'-Biphenyl-4,4'-diamine, 3,3'-dichloro-	EHW	H +	U072	p-Dichlorobenzene	EHW	B H
U095	(1,1'-Biphenyl)-4,4'-diamine, 3,3'-dimethyl-	EHW	C +	U073	3,3'-Dichlorobenzidine	EHW	H +
U024	Bis(2-chloroethoxy) methane	EHW	C H	U074	1,4-Dichloro-2-butene	EHW	C H I
U027	Bis(2-chloroisopropyl) ether	EHW	C H O	U075	Dichlorodifluoromethane	EHW	H
P016	Bis(chloromethyl) ether	EHW	B H +	U060	Dichloro diphenyl dichloroethane	EHW	C H +
U246	Bromine cyanide	EHW	C H	U061	Dichloro diphenyl trichloroethane	EHW	X H +
P017	Bromoacetone	EHW	C H	U078	1,1-Dichloroethylene	EHW	C H +
U225	Bromoform	EHW	H	U079	1,2-Dichloroethylene	EHW	D H
U030	4-Bromophenyl phenyl ether	EHW	H	U025	Dichloroethyl ether	EHW	C H
P018	Brucine	EHW	A	U081	2,4-Dichlorophenol	EHW	D H
U128	1,3-Butadiene, 1,1,2,3,4,4-hexachloro-	EHW	C H	U082	2,6-Dichlorophenol	EHW	D H
U035	Butanoic acid, 4-[bis(2-chloroethyl) amino] benzene-	EHW	H +	U240	2,4-Dichlorophenoxyacetic acid, salts and esters	EHW	B H
U160	2-Butanone peroxide	EHW	B R	P036	Dichlorophenylarsine	EHW	B H
U053	2-Butenal	EHW	B I	U083	1,2-Dichloropropane	EHW	C H I
U074	2-Butene, 1,4-dichloro-	EHW	C H I	U084	1,3-Dichloropropene	EHW	C H
U032	Calcium chromate	EHW	C + EP	P037	Dieldrin	EHW	X H +
P021	Calcium cyanide	EHW	B	U085	1,2:3,4-Diepoxybutane	EHW	B I
P123	Camphene, octachloro-	EHW	X H	P038	Diethylarsine	EHW	B
U178	Carbamic acid, methylnitroso-, ethyl ester	EHW	C +	P039	O,O-Diethyl S-[2-(ethylthio)ethyl] phosphorodithioate	EHW	A
U176	Carbamide, N-ethyl-N-nitroso-	EHW	C +	U087	O,O-Diethyl-S-methyl-dithiophosphate	EHW	B
U177	Carbamide, N-methyl-N-nitroso-	EHW	C +	P041	Diethyl-p-nitrophenyl phosphate	EHW	A
U219	Carbamide, thio-	EHW	C +	P040	O,O-Diethyl O-pyrazenyl phosphorothioate	EHW	A
P103	Carbamimidoseleonic acid	EHW	B	P043	Diisopropyl fluorophosphate	EHW	B H
U097	Carbamoyl chloride, dimethyl-	EHW	D H +	P044	Dimethoate	EHW	A
P022	Carbon bisulfide	EHW	D I ?	U092	Dimethylamine	EHW	C I
P022	Carbon disulfide	EHW	D I ?	U093	Dimethylaminoazobenzene	EHW	C +
U156	Carbonochloridic acid, methyl ester	EHW	B H I	U094	7,12-Dimethylbenz[a]anthracene	EHW	C P
U033	Carbon oxyfluoride	EHW	B H R	U095	3,3'-Dimethylbenzidine	EHW	C +
U211	Carbon tetrachloride	EHW	C H +	U096	alpha, alpha-Dimethylbenzylhydroperoxide	EHW	C R
P095	Carbonyl chloride	EHW	B H	U097	Dimethylcarbamoyl chloride	EHW	D H +
U033	Carbonyl fluoride	EHW	B H R	U099	1,2-Dimethylhydrazine	EHW	C + I
U035	Chlorambucil	EHW	H +	P045	3,3-Dimethyl-1-(methylthio)-2-butanone, O-[(methylamino)carbonyl] oxime	EHW	B
U036	Chlordane, technical	EHW	X H	P071	O,O-Dimethyl O-p-nitrophenyl phosphorothioate	EHW	A
P033	Chlorine cyanide	EHW	A H	P082	Dimethylnitrosamine	EHW	B +
U026	Chloronaphazine	EHW	H +	P046	alpha, alpha-Dimethylphenethylamine	EHW	C
P023	Chloroacetaldehyde	EHW	B H	U103	Dimethyl sulfate	EHW	C O +
P024	p-Chloroaniline	EHW	C H	P047	4,6-Dinitro-o-cresol and salts	EHW	B
U037	Chlorobenzene	EHW	B H I	P034	4,6-Dinitro-o-cyclohexylphenol	EHW	C
U039	4-Chloro-m-cresol	EHW	H	P048	2,4-Dinitrophenol	EHW	B
U041	1-Chloro-2,3-epoxypropane	EHW	C H + I	U105	2,4-Dinitrotoluene	EHW	C
U042	2-Chloroethyl vinyl ether	EHW	C H	U106	2,6-Dinitrotoluene	EHW	C
U044	Chloroform	EHW	C H +	P020	Dinoseb	EHW	B
U046	Chloromethyl methyl ether	EHW	D H + I	U109	1,2-Diphenylhydrazine	EHW	C
U047	beta-Chloronaphthalene	EHW	D H	P035	Diphosphoramidate, octamethyl	EHW	?
U048	o-Chlorophenol	EHW	D H	U110	Dipropylamine	EHW	C I
P026	1-(o-Chlorophenyl)thiourea	EHW	A H	U111	Di-n-propylnitrosamine	EHW	C +
P027	3-Chloropropionitrile	EHW	B H	P039	Disulfoton	EHW	A
U049	4-Chloro-o-toluidine, hydrochloride	EHW	H	P049	2,4-Dithiobiuret	EHW	A
U032	Chromic acid, calcium salt	EHW	C + EP	P109	Dithiopyrophosphoric acid, tetraethyl ester	EHW	A
U050	Chrysene	EHW	P +	P050	Endosulfan	EHW	X H
P029	Copper cyanides	EHW	B	P088	Endothall	EHW	B
U052	Cresols	EHW	B	P051	Endrin	EHW	X H
U052	Cresylic acid	EHW	B I	P042	Epinephrine	EHW	B
U053	Crotonaldehyde	EHW	C I	U001	Ethanal	EHW	C
U055	Cummene	EHW	C I	U174	Ethanamine, N-ethyl-N-nitroso-	EHW	C +
P030	Cyanides (soluble cyanide salts), not elsewhere specified	EHW	A	P046	Ethanamine, 1,1-dimethyl-2-phenyl-	EHW	C
P031	Cyanogen	EHW	B I	U067	Ethane, 1,2-dibromo-	EHW	C H +
U246	Cyanogen bromide	EHW	C H	U076	Ethane, 1,1-dichloro-	EHW	D H
P033	Cyanogen chloride	EHW	A H	U077	Ethane, 1,2-dichloro-	EHW	D H
U197	1,4-Cyclohexadienedione	EHW	C	U114	1,2-Ethanediyldis-carbamodithioic acid	EHW	B
U056	Cyclohexane	EHW	C I	U131	Ethane, 1,1,1,2,2,2-hexachloro-	EHW	H
U057	Cyclohexanone	EHW	C I				

Dangerous Waste No.	Substance	WDOE Hazard Designation	Reason for Designation*	Dangerous Waste No.	Substance	WDOE Hazard Designation	Reason for Designation*
U024	Ethane, 1,1'-[methylenebis(oxy)]bis[2-chloro-	EHW	C H	P016	Methane, oxybis(chloro)-	EHW	B H +
U247	Ethane, 1,1,1-trichloro-2,2-bis(p-methoxy phenyl)	EHW	D H	P112	Methane, tetranitro-	EHW	A R
U003	Ethanenitrile	EHW	C	U029	Methane, bromo-	EHW	H
U025	Ethane, 1,1'-oxybis[2-chloro-	EHW	C H	U045	Methane, chloro-	EHW	H I
U184	Ethane, pentachloro-	EHW	A H	U046	Methane, chloromethoxy-	EHW	D H + I
U208	Ethane, 1,1,1,2-tetrachloro-	EHW	H	U068	Methane, dibromo-	EHW	C H +
U209	Ethane, 1,1,2,2-tetrachloro-	EHW	H	U080	Methane, dichloro-	EHW	C H
U227	Ethane, 1,1,2-trichloro-	EHW	C H	U075	Methane, dichlorodifluoro-	EHW	H
P084	Ethenamine, N-methyl-N-nitroso	EHW	B +	U138	Methane, iodo-	EHW	H +
U043	Ethene, chloro-	EHW	D H +	U211	Methane, tetrachloro-	EHW	C H +
U042	Ethane, 2-chloroethoxy-	EHW	C H	P118	Methanethiol, trichloro-	EHW	H
U078	Ethene, 1,1-dichloro-	EHW	C H +	U153	Methanethiol	EHW	B I
U079	Ethene, trans-1,2-dichloro-	EHW	D H	U225	Methane, tribromo	EHW	H
U210	Ethene, 1,1,2,2-tetrachloro-	EHW	C H	U121	Methane, trichlorofluoro-	EHW	H
U006	Ethanoyl chloride	EHW	C H O R	U044	Methane, trichloro-	EHW	C H +
P101	Ethyl cyanide	EHW	B	P059	4,7-Methano-1H-indene, 1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro-	EHW	X H +
U038	Ethyl 4,4'-dichlorobenzilate	EHW	D H	U036	4,7-Methanoindan, 1,2,4,5,6,7,8,8-octa-chloro-3a,4,7,7a-tetrahydro-	EHW	X H
U114	Ethylenebis(dithiocarbamic acid), salts and esters	EHW	B	P066	Methomyl	EHW	B
U067	Ethylene dibromide	EHW	C H	P067	2-Methylaziridine	EHW	B + I
U077	Ethylene dichloride	EHW	D H	P068	Methyl hydrazine	EHW	A I
U115	Ethylene oxide	EHW	C I	P064	Methyl isocyanate	EHW	I ?
P054	Ethylenimine	EHW	B +	P069	2-Methylactonitrile	EHW	A
U076	Ethylidene dichloride	EHW	D H	P071	Methyl parathion	EHW	A
P097	Famphur	EHW	A	U029	Methyl bromide	EHW	H
P056	Fluorine	EHW	B	U045	Methyl chloride	EHW	H I
P057	Fluoroacetamide	EHW	B H	U156	Methyl chlorocarbonate	EHW	B H I
P058	Fluoroacetic acid, sodium salt	EHW	A H	U226	Methylchloroform	EHW	C H
U122	Formaldehyde	EHW	C	U157	3-Methylcholanthrene	EHW	H P
P065	Fulminic acid, mercury (II) salt	EHW	R ?	U158	4,4'-Methylenebis(2-chloroaniline)	EHW	H +
U125	2-Furancarboxaldehyde	EHW	C I	U132	2,2'-Methylenebis(3,4,6-trichlorophenol)	EHW	C H
U147	2,5-Furandione	EHW	C	U068	Methylene bromide	EHW	C H +
U125	Furfural	EHW	C I	U080	Methylene chloride	EHW	C H
U126	Glycidylaldehyde	EHW	C +	U122	Methylene oxide	EHW	C
U163	Guanidine, N-nitroso-N-methyl-N'nitro-	EHW	C +	U160	Methyl ethyl ketone peroxide	EHW	B R
P059	Heptachlor	EHW	X H +	U138	Methyl iodide	EHW	H +
U127	Hexachlorobenzene	EHW	H	U163	N-Methyl-N'-nitro-N-nitrosoguanidine	EHW	C + R
U128	Hexachlorobutadiene	EHW	C H	U010	Mitomycin C	EHW	B +
U129	Hexachlorocyclohexane (gamma isomer)	EHW	H +	U165	Naphthalene	EHW	B
U130	Hexachlorocyclopentadiene	EHW	X H	U047	Naphthalene, 2-chloro-	EHW	D H
P051	1,2,3,4,10,10-Hexachloro-6,7-epoxy-1,4,4a,5,6,7,8,8a-octahydro-endo, endo-1,4,5,8-dimethanophthalene	EHW	X H	U166	1,4-Naphthalenedione	EHW	C
P037	1,2,3,4,10,10-Hexachloro-6,7-epoxy-1,4,4a,5,6,7,8,8a-octahydro-endo, exo-1,4,5,8-dimethanophthalene	EHW	X H +	U236	2,7-Naphthalenedisulfonic acid, 3,3'-[(3,3'-dimethyl-(1,1'-biphenyl)-4,4'diyl)]-bis (azo)bis(5-amino-4-hydroxy)-, tetrasodium salt	EHW	H +
U131	Hexachloroethane	EHW	H	U166	1,4-Naphthoquinone	EHW	C
P060	1,2,3,4,10,10-Hexachloro-1,4,4a,5,8,8a-hexahydro-1,4:5,8-endo, endo-dimethanonaphthalene	EHW	B H	U167	1-Naphthylamine	EHW	B +
P004	1,2,3,4,10,10-Hexachloro-1,4,4a,5,8,8a-hexahydro-1,4,5,8-endo, exodimethanonaphthalene	EHW	B H	U168	2-Naphthylamine	EHW	B +
P060	Hexachlorohexahydro-endo, endo-dimethanonaphthalene	EHW	B H	U167	alpha-Naphthylamine	EHW	B +
U132	Hexachlorophene	EHW	C H	U168	beta-Naphthylamine	EHW	B +
U243	Hexachloropropene	EHW	H	U026	2-Naphthylamine, N,N-bis(2-chloro-ethyl)-	EHW	H +
P062	Hexaethyl tetraphosphate	EHW	B	P072	alpha-Naphthylthiourea	EHW	B
U133	Hydrazine	EHW	B + R	P073	Nickel carbonyl	EHW	B
P116	Hydrazinecarbothioamide	EHW	B	P074	Nickel cyanide	EHW	D R ?
U099	Hydrazine, 1,2-dimethyl-	EHW	C + I	P074	Nickel (II) cyanide	EHW	D R ?
U109	Hydrazine, 1,2-diphenyl-	EHW	C	P073	Nickel tetracarbonyl	EHW	B
P068	Hydrazine, methyl-	EHW	A I	P075	Nicotine and salts	EHW	B
P063	Hydrocyanic acid	EHW	A	P076	Nitric oxide	EHW	B
P063	Hydrogen cyanide	EHW	A	P077	p-Nitroaniline	EHW	D ?
P096	Hydrogen phosphide	EHW	B I	U169	Nitrobenzene	EHW	C I
U135	Hydrogen sulfide	EHW	B I	P078	Nitrogen dioxide	EHW	A
U096	Hydroperoxide, 1-methyl-1-phenylethyl-	EHW	C R	P076	Nitrogen (II) oxide	EHW	B
U245	Indomethacin	EHW	B H	P078	Nitrogen (IV) oxide	EHW	A
P064	Isocyanic acid, methyl ester	EHW	I ?	P081	Nitroglycerine	EHW	R ?
P007	3(2H)-Isoxazolone, 5-(aminomethyl)-	EHW	B	U170	p-Nitrophenol	EHW	C
U142	Kepon	EHW	X H	U171	2-Nitropropane	EHW	C I
U143	Lasiocarpine	EHW	C +	U174	N-Nitrosodiethylamine	EHW	C +
U144	Lead acetate	EHW	D EP	P082	N-Nitrosodimethylamine	EHW	B +
U129	Lindane	EHW	H +	U176	N-Nitroso-N-ethylurea	EHW	C +
U147	Maleic anhydride	EHW	C	U177	N-Nitroso-N-methylurea	EHW	C +
U149	Malononitrile	EHW	C	U178	N-Nitroso-N-methylurethane	EHW	C +
U151	Mercury	EHW	EP	P084	N-Nitrosomethylvinylamine	EHW	B +
P092	Mercury, (acetato-O)phenyl-	EHW	B	U179	N-Nitrosopiperidine	EHW	C +
P065	Mercury fulminate	EHW	R ?	U111	N-Nitroso-n-propylamine	EHW	C +
U152	Methacrylonitrile	EHW	B I	P050	5-Norbornene-2,3-dimethanol, 1,4,5,6,7,7-hexachloro, cyclic sulfite	EHW	X H
U092	Methanamine, N-methyl-	EHW	C I	P085	Octamethylpyrophosphoramide	EHW	A
				P087	Osmium oxide	EHW	B
				P087	Osmium tetroxide	EHW	B
				P088	7-Oxabicyclo[2.2.1]heptane-2,3-dicarboxylic acid	EHW	B

Dangerous Waste No.	Substance	WDOE Hazard Designation	Reason for Designation*	Dangerous Waste No.	Substance	WDOE Hazard Designation	Reason for Designation*
U058	2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloro ethyl)amino]tetrahydro-, 2-oxide	EHW	C H I +	P075	Pyridine, (S)-3-(1-methyl-2-pyrrolidinyl)-, and salts	EHW	B
U115	Oxirane	EWH	C I	U196	Pyridine	EHW	C I
U041	Oxirane, 2-(chloromethyl)-	EHW	C H + I	U179	Pyridine, hexahydro-N-nitroso-	EHW	C +
P089	Parathion	EHW	X	U191	Pyridine, 2-methyl-	EHW	C
U183	Pentachlorobenzene	EHW	H	P111	Pyrophosphoric acid, tetraethyl ester	EHW	A
U184	Pentachloroethane	EHW	A H	U201	Resorcinol	EHW	C
U185	Pentachloronitrobenzene	EHW	D H +	P103	Selenourea	EHW	B
See F027	Pentachlorophenol	EHW	A H	U015	L-Serine, diazoacetate (ester)	EHW	C +
U188	Phenol	EHW	C	P104	Silver cyanide	EHW	C
P034	Phenol, 2-cyclohexyl-4,6-dinitro-	EHW	C	See F027	Silvex	EHW	B H
P048	Phenol, 2,4-dinitro-	EHW	B	P105	Sodium azide	EHW	A
P047	Phenol, 2-methyl-4,6 dinitro-, and salts	EHW	B	P106	Sodium cyanide	EHW	A
P020	Phenol, 2,4-dinitro-6-(1-methylpropyl)-	EHW	B	P107	Strontium sulfide	EHW	R
P009	Phenol, 2,4,6-trinitro-, ammonium salt	EHW	R	P108	Strychnidin-10-one, and salts	EHW	B
U048	Phenol, 2-chloro-	EHW	D H	P108	Strychnine and salts	EHW	B
U039	Phenol, 4-chloro-3-methyl-	EHW	H	U135	Sulfur hydride	EHW	B I
U081	Phenol, 2,4-dichloro-	EHW	D H	U103	Sulfuric acid, dimethyl ester	EHW	C O +
U082	Phenol, 2,6-dichloro-	EHW	D H	P115	Sulfuric acid, thallium (I) salt	EHW	B
U170	Phenol, 4-nitro-	EHW	C	U189	Sulfur phosphide	EHW	B I R
See F027	Phenol, pentachloro-	EHW	A H	See F027	2,4,5-T	EHW	B H +
See F027	Phenol, 2,3,4,6-tetrachloro-	EHW	C H	See F027	1,2,4,5-Tetrachlorobenzene	EHW	D H
See F027	Phenol, 2,4,5-trichloro-	EHW	A H	U208	1,1,1,2-Tetrachloroethane	EHW	H
See F027	Phenol, 2,4,6-trichloro-	EHW	A H	U209	1,1,2,2-Tetrachloroethane	EHW	H
P036	Phenyl dichloroarsine	EHW	B H	U210	Tetrachloroethylene	EHW	C H +
P092	Phenylmercuric acetate	EHW	B	U212	2,3,4,6-Tetrachlorophenol	EHW	C H
P093	N-Phenylthiourea	EHW	A	P109	Tetraethylthiopyrophosphate	EHW	A
P094	Phorate	EHW	X	P110	Tetraethyl lead	EHW	A
P095	Phosgene	EHW	B H	P111	Tetraethylpyrophosphate	EHW	A
P096	Phosphine	EHW	B I	P112	Tetranitromethane	EHW	A R
P041	Phosphoric acid, diethyl p-nitrophenyl ester	EHW	A	P062	Tetraphosphoric acid, hexaethyl ester	EHW	B
P044	Phosphorodithioic acid, O,O-dimethyl S-[2-(methylamino)-2-oxoethyl] ester	EHW	A	P113	Thallic oxide	EHW	B
P043	Phosphorofluoric acid, bis(1-methyl-ethyl)ester	EHW	B H	P113	Thallium (III) oxide	EHW	B
P094	Phosphorothioic acid, O,O-diethyl S-(ethylthio)methyl ester	EHW	X	P114	Thallium (I) selenide	EHW	C
P097	Phosphorothioic acid, O,O-dimethyl O-[p-(dimethylamino)-sulfonyl]phenyl ester	EHW	A	P115	Thallium (I) sulfate	EHW	B
P089	Phosphorothioic acid, O,O-diethyl O-(p-nitrophenyl)ester	EHW	X	P045	Thiofanox	EHW	B
P040	Phosphorothioic acid, O,O-diethyl O-pyra-zinyl ester	EHW	A	P049	Thioimidodicarbonic diamide	EHW	A
U189	Phosphorus sulfide	EHW	B I R	U153	Thiomethanol	EHW	B I
U190	Phthalic anhydride	EHW	C	P014	Thiophenol	EHW	A
U191	2-Picoline	EHW	C	P116	Thiosemicarbazide	EHW	B H +
P110	Plumbane, tetraethyl-	EHW	A	U219	Thiourea	EHW	C +
P098	Potassium cyanide	EHW	A	P026	Thiourea, (2-chlorophenyl)-	EHW	A H
P099	Potassium silver cyanide	EHW	A	P072	Thiourea, 1-naphthalenyl-	EHW	B
P070	Propanal, 2-methyl-2(methylthio)-O-[(methylamino)carbonyl]oxime	EHW	B	P093	Thiourea, phenyl-	EHW	A
U194	1-Propanamine	EHW	C I	U220	Toluene	EHW	C I
U110	1-Propanamine, N-propyl-	EHW	C I	U223	Toluene diisocyanate	EHW	B R
U066	Propane, 1,2-dibromo-3-chloro-	EHW	C H +	P123	Toxaphene	EHW	X H
U149	Propanedinitrile	EHW	C	U226	1,1,1-Trichloroethane	EHW	C H
P101	Propanenitrile	EHW	B	U227	1,1,2-Trichloroethane	EHW	C H
P027	Propanenitrile, 3-chloro-	EHW	B H	U228	Trichloroethene	EHW	C H +
P079	Propanenitrile, 2-hydroxy-2-methyl-	EHW	A	U228	Trichloroethylene	EHW	C H +
U171	Propane, 2-nitro-	EHW	C I	P118	Trichloromethanethiol	EHW	H
U027	Propane, 2,2'-oxybis[2-chloro-	EHW	C H O	U121	Trichloromonofluoromethane	EHW	H
P081	1,2,3-Propanetriol, trinitrate-	EHW	R ?	See F027	2,4,5-Trichlorophenol	EHW	A H
U235	1-Propanol, 2,3-dibromo-, phosphate (3:1)	EHW	D H	See F027	2,4,6-Trichlorophenol	EHW	A H
U126	1-Propanol, 2,3-epoxy-	EHW	C +	U232	2,4,5-Trichlorophenoxy-acetic acid, salts and esters	EHW	B H +
P017	2-Propanone, 1-bromo-	EHW	C H	U233	2,4,5-Trichlorophenoxy-propionic acid, salts and esters	EHW	B H +
P102	Propargyl alcohol	EHW	X	U235	Tris(2,3-disbromopropyl) phosphate	EHW	D H
P003	2-Propenal	EHW	X	U236	Trypan blue	EHW	H +
U007	2-Propenamide	EHW	C	U237	Uracil, 5[bis(2-chloroethyl)amino]-	EHW	B H +
U084	Propene, 1,3-dichloro-	EHW	C H	U237	Uracil mustard	EHW	B H +
U243	1-Propene, 1,1,2,3,3,3-hexachloro-	EHW	H	P119	Vanadic acid, ammonium salt	EHW	B
U009	2-Propenenitrile	EHW	C + I	P120	Vanadium pentoxide	EHW	B
U152	2-Propenenitrile, 2-methyl-	EHW	B I	P120	Vanadium (V) oxide	EHW	B
U008	2-Propenoic acid	EHW	C O I	U043	Vinyl chloride	EHW	D H +
P005	2-Propen-1-ol	EHW	B I	P001	Warfarin	EHW	A
See F027	Propionic acid, 2-(2,4,5-trichlorophenoxy)-	EHW	B H	U239	Xylene	EHW	C I
U194	n-Propylamine	EHW	C I	P121	Zinc cyanide	EHW	C
U083	Propylene dichloride	EHW	C H I	P122	Zinc phosphide	EHW	B R
P067	1,2-Propylenimine	EHW	B + I				
P102	2-Propyn-1-ol	EHW	X	<b>MODERATELY DANGEROUS CHEMICAL PRODUCTS</b>			
P008	4-Pyridinamine	EHW	B	U187	Acetamide, N-(4-ethoxyphenyl)-	DW	D +
				U005	Acetamide, N-9H-fluoren-2-yl-	DW	?
				U112	Acetic acid, ethyl ester	DW	D I
				U214	Acetic acid, thallium(I) salt	DW	?
				U002	Acetone	DW	D I
				U004	Acetophenone	DW	D
				U005	2-Acetylaminofluorene	DW	?

Dangerous Waste No.	Substance	WDOE Hazard Designation	Reason for Designation*	Dangerous Waste No.	Substance	WDOE Hazard Designation	Reason for Designation*
U150	Alanine, 3-[p-bis(2-chloroethyl)amino]phenyl-, L-	DW	+	U140	Isobutyl alcohol	DW	D I
U328	2-Amino-1-methylbenzene	DW	D +	U141	Isosafrole	DW	D +
U353	4-Amino-1-methylbenzene	DW	D	U145	Lead phosphate	DW	+
U011	Amitrole	DW	D +	U146	Lead subacetate	DW	+
U014	Auramine	DW	+	U148	Maleic hydrazide	DW	D
U016	Benz[c]acridine	DW	+	U150	Melphalan	DW	+
U016	3,4-Benzacridine	DW	+	U119	Methanesulfonic acid, ethyl ester	DW	+
U014	Benzenamine, 4,4-carbonimidoylbis(N,N-dimethyl-	DW	+	U123	Methanoic acid	DW	D O
U222	Benzenamine, 2-methyl-, hydrochloride	DW	D +	U154	Methanol	DW	D I
U181	Benzenamine, 2-methyl-5-nitro	DW	D	U155	Methapyrilene	DW	D
U028	1,2-Benzenedicarboxylic acid, [bis(2-ethyl-hexyl)] ester	DW	?	U154	Methyl alcohol	DW	D I
U069	1,2-Benzenedicarboxylic acid, dibutyl ester	DW	D	U186	1-Methylbutadiene	DW	D I
U088	1,2-Benzenedicarboxylic acid, diethyl ester	DW	?	U159	Methyl ethyl ketone	DW	D I
U102	1,2-Benzenedicarboxylic acid, dimethyl ester	DW	?	U161	Methyl isobutyl ketone	DW	D I
U107	1,2-Benzenedicarboxylic acid, di-n-octyl ester	DW	?	U162	Methyl methacrylate	DW	D I
U203	Benzene, 1,2-methylenedioxy-4-allyl-	DW	D +	U161	4-Methyl-2-pentanone	DW	+
U141	Benzene, 1,2-methylenedioxy-4-propenyl-	DW	D +	U164	Methylthiouacil	DW	+
U090	Benzene, 1,2-methylenedioxy-4-propyl-	DW	D +	U059	5,12-Naphthacenedione, (8S-cis)-8-acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-	DW	+
U234	Benzene, 1,3,5-trinitro-	DW	D R	U172	N-Nitrosodi-n-butylamine	DW	D +
U202	1,2-Benzisothiazilin-3-one, 1,1-dioxide, and salts	DW	+	U173	N-Nitrosodiethanolamine	DW	+
U120	Benzo[j,k]fluorene	DW	D	U180	N-Nitrosopyrrolidine	DW	D +
U091	(1,1'-Biphenyl)-4,4'-diamine, 3,3'-dimethoxy-	DW	D +	U181	5-Nitro-o-toluidine	DW	D
U244	Bis(dimethylthiocarbomoyl) disulfide	DW	D	U193	1,2-Oxathiolane, 2,2-dioxide	DW	+
U028	Bis(2-ethoxy) phthalate	DW	?	U182	Paraldehyde	DW	D I
U172	1-Butanamine, N-butyl-N-nitroso-	DW	D +	U186	1,3-Pentadiene	DW	D I
U031	1-Butanol	DW	D I	U187	Phenacetin	DW	D +
U159	2-Butanone	DW	D I	U101	Phenol, 2,4-dimethyl-	DW	D
U031	n-Butyl alcohol	DW	D I	U137	1,10-(1,2-Phenylene)pyrene	DW	+
U136	Cacodylic acid	DW	D	U145	Phosphoric acid, lead salt	DW	+
U238	Carbamic acid, ethyl ester	DW	+	U087	Phosphorodithioic acid, O,O-diethyl-, S-methyl ester	DW	?
U215	Carbonic acid, dithallium(I) salt	DW	?	U192	Pronamide	DW	?
U051	Creosote	DW	D	U193	1,3-Propane sultone	DW	+
U059	Daumomycin	DW	+	U140	1-Propanol, 2-methyl-	DW	D I
U221	Diaminotoluene	DW	?	U002	2-Propanone	DW	D I
U069	Dibutyl phthalate	DW	D	U113	2-Propenoic acid, ethyl ester	DW	D I
U192	3,5-Dichloro-N-(1,1-dimethyl-2-propynyl) benzamide	DW	?	U118	2-Propenoic acid, 2-methyl-, ethyl ester	DW	I
U108	1,4-Diethylene dioxide	DW	D +	U162	2-Propenoic acid, 2-methyl-, methyl ester	DW	D I
U086	N,N-Diethylhydrazine	DW	+	U155	Pyridine, 2-[(2dimethylamino) ethyl]- 2-phenylamino	DW	+
U088	Diethyl phthalate	DW	?	U164	4(1H)-Pyrimidinone, 2,3-dihydro-6-methyl-2-thioxo-	DW	+
U089	Diethylstilbestrol	DW	+	U180	Pyrrrole, tetrahydro-N-nitroso-	DW	D +
U148	1,2-Dihydro-3-,6-pyridizinedione	DW	D	U200	Reserpine	DW	?
U090	Dihydrosafrole	DW	D +	U202	Saccharin and salts	DW	+
U091	3,3'-Dimethoxybenzidine	DW	D +	U203	Safrole	DW	D +
U098	1,1-Dimethylhydrazine	DW	+	U204	Selenious acid	DW	O
U101	2,4-Dimethylphenol	DW	D	U204	Selenium dioxide	DW	O
U102	Dimethyl phthalate	DW	?	U205	Selenium disulfide	DW	R
U107	Di-n-octyl phthalate	DW	?	U089	4,4'-Stilbene diol, alpha, alpha'-diethyl-	DW	+
U108	1,4-Dioxane	DW	D +	U206	Streptozotocin	DW	+
U117	Ethane, 1,1'-oxybis-	DW	D I	U205	Sulfur selenide	DW	R
U218	Ethanethioamide	DW	+	U213	Tetrahydrofuran	DW	I
U173	Ethanol, 2,2-(nitrosoimino)bis-	DW	+	U214	Thallium(I) acetate	DW	?
U004	Ethanone, 1-phenyl-	DW	D	U215	Thallium(I) carbonate	DW	?
U112	Ethyl acetate	DW	D I	U216	Thallium(I) chloride	DW	?
U113	Ethyl acrylate	DW	D I	U217	Thallium(I) nitrate	DW	?
U238	Ethyl carbamate (urethan)	DW	+	U218	Thioacetamide	DW	+
U116	Ethylene thiourea	DW	D +	U244	Thiran	DW	D
U117	Ethyl ether	DW	D I	U221	Toluenediamine	DW	?
U118	Ethyl methacrylate	DW	I	U328	o-Toluidine	DW	D +
U119	Ethyl methanesulfonate	DW	+	U353	p-Toluidine	DW	D
U139	Ferric dextran	DW	+	U222	o-Toluidine hydrochloride	DW	D +
U120	Fluoranthene	DW	D	U011	1H-1,2,4-Triazol-3-amine	DW	D +
U123	Formic Acid	DW	D O	U234	sym-Trinitrobenzene	DW	D R
U124	Furan	DW	I	U182	1,3,5-Trioxane, 2,4,6-trimethyl-	DW	D I
U213	Furan, tetrahydro-	DW	I	U200	Yohimban-16-carboxylic acid, 11,17-dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-, methyl ester	DW	?
U124	Furfuran	DW	I				
U206	D-Glucopyranose, 2-deoxy-2(3-methyl-3-nitrosoureido)-	DW	+				
U086	Hydraxine, 1,2-diethyl-	DW	+				
U098	Hydrazine, 1,1-dimethyl-	DW	+				
U134	Hydrofluoric acid	DW	D O				
U134	Hydrogen fluoride	DW	D O				
U136	Hydroxydimethylarsine oxide	DW	D				
U116	2-Imidazolidinethione	DW	D +				
U137	Indeno[1,2,3-cd]pyrene	DW	+				
U139	Iron dextran	DW	+				

\* EHW = Extremely Hazardous Waste  
 DW = Dangerous Waste  
 X = Toxic, Category X  
 A = Toxic, Category A  
 B = Toxic, Category B  
 C = Toxic, Category C  
 D = Toxic, Category D  
 ? = Toxic, Category not determined  
 H = Persistent, Halogenated Hydrocarbon

- O = Corrosive
- P = Persistent, Polycyclic Aromatic Hydrocarbon
- + = IARC Animal or Human, ((Positive or Suspected)) Sufficient or Limited Carcinogen
- I = Ignitable
- R = Reactive
- EP = ((Extraction Procedure)) Toxicity Characteristic

**AMENDATORY SECTION** (Amending Order 88-24, filed 1/4/89)

**WAC 173-303-9904 DANGEROUS WASTE SOURCES LIST.**

**DANGEROUS WASTE SOURCES LIST**

Dangerous Waste No.	Sources
Nonspecific Sources	
Generic:	
F001	The following spent halogenated solvents used in degreasing: Tetrachloroethylene, trichloroethylene, methylene chloride, 1,1,1-trichloroethane, carbon tetrachloride, and chlorinated fluorocarbons; and sludges from the recovery of these solvents in degreasing operations. (See footnote 1, below.)
F002	The following spent halogenated solvents: Tetrachloroethylene, methylene chloride, trichloroethylene, 1,1,1-trichloroethane, chlorobenzene, 1,1,2-trichloro-1,2,2-trifluoroethane, ortho-dichlorobenzene, ((and)) trichlorofluoromethane and 1,1,2-trichloroethane; and the still bottoms from the recovery of these solvents. (See footnote 1, below.)
F003	The following spent nonhalogenated solvents: Xylene, acetone, ethyl acetate, ethyl benzene, ethyl ether, methyl isobutyl ketone, n-butyl alcohol, cyclohexanone, and methanol; and the still bottoms from the recovery of these solvents.
F004	The following spent nonhalogenated solvents: Cresols and cresylic acid, nitrobenzene; and the still bottoms from the recovery of these solvents.
F005	The following spent nonhalogenated solvents: Toluene, methyl ethyl ketone, carbon disulfide, isobutanol, pyridine, benzene, 2-ethoxyethanol, 2-nitropropane; and the still bottoms from the recovery of these solvents.
F006	Wastewater treatment sludges from electroplating operations except from the following processes: (1) Sulfuric acid anodizing of aluminum; (2) tin plating on carbon steel; (3) zinc plating (segregated basis) on carbon steel; (4) aluminum or zinc-aluminum plating on carbon steel; (5) cleaning/stripping associated with tin, zinc, and aluminum plating on

Dangerous Waste No.	Sources
	carbon steel; and (6) chemical etching and milling of aluminum.
F019	Wastewater treatment sludges from the chemical conversion coating of aluminum.
F007	Spent cyanide plating bath solutions from electroplating operations.
F008	Plating bath residues from the bottom of plating baths from electroplating operations where cyanides are used in the process.
F009	Spent stripping and cleaning bath solutions from electroplating operations where cyanides are used in the process.
F010	Quenching bath residues from oil baths from metal heat treating operations where cyanides are used in the process.
F011	Spent cyanide solutions from salt bath pot cleaning from metal heat treating operations.
F012	Quenching wastewater treatment sludges from metal heat-treating operations where cyanides are used in the process.
F020	Wastes (except wastewater and spent carbon from hydrogen chloride purification) from the production or manufacturing use (as a reactant, chemical intermediate, or component in a formulating process) of tri- or tetrachlorophenol, or of intermediates used to produce their pesticide derivatives. (This listing does not include wastes from the production of hexachlorophene from highly purified 2,4,5-trichlorophenol.) (See footnote 2, below.)
F021	Wastes (except wastewater and spent carbon from hydrogen chloride purification) from the production or manufacturing use (as a reactant, chemical intermediate, or component in a formulating process) of pentachlorophenol, or of intermediates used to produce its derivatives. (See footnote 2, below.)
F022	Wastes (except wastewater and spent carbon from hydrogen chloride purification) from the manufacturing use (as a reactant, chemical intermediate, or component in a formulating process) of tetra-, penta-, or hexachlorobenzenes under alkaline conditions. (See footnote 2, below.)
F023	Wastes (except wastewater and spent carbon from hydrogen chloride purification) from the production of materials on equipment previously used for the production or manufacturing use (as a reactant, chemical intermediate, or component in a formulating process) of tri- and tetrachlorophenols. (See footnote 2, below.) (This listing does not include wastes from equipment used only for the production



Dangerous Waste No.	Sources	Dangerous Waste No.	Sources
	or use of hexachlorophene from highly purified 2,4,5-trichlorophenol.)	K007	Wastewater treatment sludge from the production of iron blue pigments.
F026	Wastes (except wastewater and spent carbon from hydrogen chloride purification) from the production of materials on equipment previously used for the manufacturing use (as a reactant, chemical intermediate, or component in a formulating process) of tetra-, penta-, or hexachlorobenzene under alkaline conditions. (See footnote 2, below.)	K008	Oven residue from the production of chrome oxide green pigments.
F027	Discarded unused formulations containing tri-, tetra-, or pentachlorophenol or discarded unused formulations containing compounds derived from these chlorophenols. (See footnote 2, below.) (This listing does not include formulations containing hexachlorophene synthesized from prepurified 2,4,5-trichlorophenol as the sole component.)	<b>Organic Chemicals:</b>	
F028	Residues resulting from the incineration or thermal treatment of soil contaminated with nonspecific sources wastes F020, F021, F022, F023, F026 and F027.	K009	Distillation bottoms from the production of acetaldehyde from ethylene.
F024	Wastes, including but not limited to, distillation residues, heavy ends, tars, and reactor cleanout wastes from the production of chlorinated aliphatic hydrocarbons, having carbon content from one to five, utilizing free radical catalyzed processes. (See footnote 1, below.) (This listing does not include light ends, spent filters and filter aids, spent dessicants, wastewater, wastewater treatment sludges, spent catalysts, and wastes listed under specific sources, below.)	K010	Distillation side cuts from the production of acetaldehyde from ethylene.
	Specific Sources	K011	Bottom stream from the wastewater stripper in the production of acrylonitrile.
<b>Wood Preservation:</b>		K013	Bottom stream from the acetonitrile column in the production of acrylonitrile.
K001	Bottom sediment sludge from the treatment of wastewaters from wood preserving processes that use creosote and/or pentachlorophenol. (See footnote 1, below.)	K014	Bottoms from the acetonitrile purification column in the production of acrylonitrile.
<b>Inorganic Pigments:</b>		K015	Still bottoms from the distillation of benzyl chloride. (See footnote 1, below.)
K002	Wastewater treatment sludge from the production of chrome yellow and orange pigments.	K016	Heavy ends or distillation residues from the production of carbon tetrachloride. (See footnote 1, below.)
K003	Wastewater treatment sludge from the production of molybdate orange pigments.	K017	Heavy ends (still bottoms) from the purification column in the production of epichlorohydrin. (See footnote 1, below.)
K004	Wastewater treatment sludge from the production of zinc yellow pigments.	K018	Heavy ends from the fractionation column in ethyl chloride production. (See footnote 1, below.)
K005	Wastewater treatment sludge from the production of chrome green pigments.	K019	Heavy ends from the distillation of ethylene dichloride in ethylene dichloride production. (See footnote 1, below.)
K006	Wastewater treatment sludge from the production of chrome oxide green pigments (anhydrous and hydrated).	K020	Heavy ends from the distillation of vinyl chloride in vinyl chloride monomer production. (See footnote 1, below.)
		K021	Aqueous spent antimony catalyst waste from fluoromethanes production. (See footnote 1, below.)
		K022	Distillation bottom tars from the production of phenol/acetone from cumene.
		K023	Distillation light ends from the production of phthalic anhydride from naphthalene.
		K024	Distillation bottoms from the production of phthalic anhydride from naphthalene.
		K093	Distillation light ends from the production of phthalic anhydride from ortho-xylene.
		K094	Distillation bottoms from the production of phthalic anhydride from ortho-xylene.
		K025	Distillation bottoms from the production of nitrobenzene by the nitration of benzene.
		K026	Stripping still tails from the production of methyl ethyl pyridines.

Dangerous Waste No.	Sources
K027	Centrifuge and distillation residues from toluene diisocyanate production.
K028	Spent catalyst from the hydrochlorinator reactor in the production of 1,1,1-trichloroethane. (See footnote 1, below.)
K029	Waste from the product steam stripper in the production of 1,1,1-trichloroethane. (See footnote 1, below.)
K095	Distillation bottoms from the production of 1,1,1-trichloroethane. (See footnote 1, below.)
K096	Heavy ends from the heavy ends column from the production of 1,1,1-trichloroethane. (See footnote 1, below.)
K030	Column bottoms or heavy ends from the combined production of trichloroethylene and perchloroethylene. (See footnote 1, below.)
K083	Distillation bottoms from aniline production.
K103	Process residues from aniline extraction from the production of aniline.
K104	Combined wastewater streams generated from nitrobenzene/aniline production.
K085	Distillation of fractionation column bottoms from the production of chlorobenzenes. (See footnote 1, below.)
K105	Separated aqueous stream from the reactor product washing step in the production of chlorobenzenes. (See footnote 1, below.)
K111	Product washwaters from the production of dinitrotoluene via nitration of toluene.
K112	Reaction by-product water from the drying column in the production of toluenediamine via hydrogenation of dinitrotoluene.
K113	Condensed liquid light ends from the purification of toluenediamine in the production of toluenediamine via hydrogenation of dinitrotoluene.
K114	Vicinals from the purification of toluenediamine in the production of toluenediamine via hydrogenation of dinitrotoluene.
K115	Heavy ends from the purification of toluenediamine in the production of toluenediamine via hydrogenation of dinitrotoluene.
K116	Organic condensate from the solvent recovery column in the production of toluene diisocyanate via phosgenation of toluenediamine. (See footnote 1, below.)

## Explosives:

K044	Wastewater treatment sludges from the manufacturing and processing of explosives.
------	---

Dangerous Waste No.	Sources
K045	Spent carbon from the treatment of wastewater containing explosives.
K046	Wastewater treatment sludges from the manufacturing, formulation and loading of lead-based initiating compounds.
K047	Pink/red water from TNT operations.
Inorganic Chemicals:	
K071	Brine purification muds from the mercury cell process in chlorine production, where separately prepurified brine is not used.
K073	Chlorinated hydrocarbon waste from the purification step of the diaphragm cell process using graphite anodes in chlorine production. (See footnote 1, below.)
K106	Wastewater treatment sludge from the mercury cell process in chlorine production.
Petroleum Refining:	
K048	Dissolved air flotation (DAF) float from the petroleum refining industry.
K049	Slop oil emulsion solids from the petroleum refining industry.
K050	Heat exchanger bundle cleaning sludge from the petroleum refining industry.
K051	API separator sludge from the petroleum refining industry.
K052	Tank bottoms (leaded) from the petroleum refining industry.
Iron and Steel:	
K061	Emission control dust/sludge from the primary production of steel in electric furnaces.
K062	Spent pickle liquor generated by steel finishing operations of facilities within the iron and steel industry (SIC Codes 331 and 332).
Pesticides:	
K031	Byproduct salts generated in the production of MSMA and cacodylic acid.
K032	Wastewater treatment sludge from the production of chlordane. (See footnote 3, below.)
K033	Wastewater and scrub water from the chlorination of cyclopentadiene in the production of chlordane. (See footnote 3, below.)
K034	Filter solids from the filtration of hexachlorocyclopentadiene in the production of chlordane. (See footnote 3, below.)
K097	Vacuum stripper discharge from the chlordane chlorinator in the production of chlordane. (See footnote 3, below.)

Dangerous Waste No.	Sources
K035	Wastewater treatment sludges generated in the production of creosote.
K036	Still bottoms from toluene reclamation distillation in the production of disulfoton.
K037	Wastewater treatment sludges from the production of disulfoton.
K038	Wastewater from the washing and stripping of phorate production. (See footnote 3, below.)
K039	Filter cake from the filtration of diethylphosphorodithioic acid in the production of phorate. (See footnote 3, below.)
K040	Wastewater treatment sludge from the production of phorate. (See footnote 3, below.)
K041	Wastewater treatment sludge from the production of toxaphene. (See footnote 3, below.)
K098	Untreated process wastewater from the production of toxaphene. (See footnote 3, below.)
K042	Heavy ends or distillation residues from the distillation of tetrachlorobenzene in the production of 2,4,5-T. (See footnote 1, below.)
K043	2,6-Dichlorophenol waste from the production of 2,4-D. (See footnote 1, below.)
K099	Untreated wastewater from the production of 2,4-D. (See footnote 1, below.)
K123	Process wastewater (including supernates, filtrates, and wastewaters) from the production of ethylenebisdithiocarbamic acid and its salts.
K124	Reactor vent scrubber water from the production of ethylenebisdithiocarbamic acid and its salts.
K125	Filtration, evaporation, and centrifugation solids from the production of ethylenebisdithiocarbamic acid and its salts.
K126	Baghouse dust and floor sweepings in milling and packaging operations from the production or formulation of ethylenebisdithiocarbamic acid and its salts.

Primary Copper:

<u>K064</u>	<u>Acid plant blowdown slurry/sludge resulting from the thickening of blowdown slurry from primary copper production.</u>
-------------	---

Primary Lead:

<u>K065</u>	<u>Surface impoundment solids contained in and dredged from surface impoundments at primary lead smelting facilities.</u>
-------------	---

Dangerous Waste No.	Sources
<u>Primary Zinc:</u>	
<u>K066</u>	<u>Sludge from treatment of process wastewater and/or acid plant blowdown from primary zinc production.</u>
<u>Primary Aluminum:</u>	
<u>K088</u>	<u>Spent potliners from primary aluminum reduction.</u>
<u>Ferroalloys:</u>	
<u>K090</u>	<u>Emission control dust or sludge from ferrochromium-silicon production.</u>
<u>K091</u>	<u>Emission control dust or sludge from ferrochromium production.</u>
<u>Secondary Lead:</u>	
K069	Emission control dust/sludge from secondary lead smelting.
K100	Waste leaching solution from acid leaching of emission control dust/sludge from secondary lead smelting.
<u>Veterinary Pharmaceuticals:</u>	
K084	Wastewater treatment sludges generated during the production of veterinary pharmaceuticals from arsenic or organo-arsenic compounds.
K101	Distillation tar residues from the distillation of aniline-based compounds in the production of veterinary pharmaceuticals from arsenic or organo-arsenic compounds.
K102	Residue from the use of activated carbon for decolorization in the production of veterinary pharmaceuticals from arsenic or organo-arsenic compounds.
<u>Ink Formulation:</u>	
K086	Solvent washes and sludges, caustic washes and sludges, or water washes and sludges from cleaning tubs and equipment used in the formulation of ink from pigments, driers, soaps, and stabilizers containing chromium and lead.

Coking:

K060	Ammonia still-lime sludge from coking operations.
K087	Decanter tank tar sludge from coking operations.

## Footnotes

- 1 These wastes contain or may contain halogenated hydrocarbons. Although WAC 173-303-082 states that these wastes are DW, WAC 173-303-070(5), special knowledge, requires generators who know that their waste

Dangerous  
Waste No.

## Sources


- 
- contains greater than one percent of these listed halogenated hydrocarbons to designate their waste EHW.
- 2 For wastes listed with the dangerous waste numbers F020, F021, F022, F023, F026, or F027 the quantity exclusion limit is 2.2 lbs. (1 kg) per month or per batch.
- 3 These wastes contain or may contain X Category toxic constituents. Although WAC 173-303-082 states that these wastes are DW, WAC 173-303-070(5), special knowledge, requires generators who know that their waste contains greater than 0.1 percent of these listed toxic constituents to designate their waste EHW.

## State Sources


- W001 The following wastes generated from the salvaging, rebuilding, or discarding of transformers, bushing, or capacitors which contain polychlorinated biphenyls (PCB): Cooling and insulating fluids; cores, including core papers, from unrinsed transformers and capacitors; transformers and capacitors which will no longer be used for their intended use, except for those transformers or capacitors which have been rinsed; and, rinsate from the rinsing of transformers and capacitors. For the purposes of this listing, the rinsing of PCB containing items shall be conducted as follows: First, the item is drained of all free flowing liquid; second, the item is filled with solvent and allowed to stand for at least eighteen hours; last, the item is drained thoroughly and the solvent is collected. Solvents may include kerosene, xylene, toluene and other solvents in which PCB are readily soluble. (Note—Certain PCB wastes are excluded from this listing under WAC 173-303-071 (3)(k). The generator should check that section to determine if his PCB waste is excluded from the requirements of chapter 173-303 WAC.)

AMENDATORY SECTION (Amending Order DE-87-4, filed 6/26/87)

WAC 173-303-9906 TOXIC DANGEROUS WASTE MIXTURES GRAPH.




# WAC 173-303-9906 TOXIC DANGEROUS WASTE MIXTURES GRAPH




AMENDATORY SECTION (Amending Order DE-87-4, filed 6/26/87)

WAC 173-303-9907 PERSISTENT DANGEROUS WASTE MIXTURES GRAPH.





# WAC 173-303-9907 PERSISTENT DANGEROUS WASTE MIXTURES GRAPH



**WSR 91-07-006**  
**PERMANENT RULES**  
**SUPERINTENDENT OF**  
**PUBLIC INSTRUCTION**  
 [Order 44—Filed March 7, 1991, 3:37 p.m.]

Date of Adoption: October 17, 1990.

Purpose: To implement chapter 103, Laws of 1990 which give the Superintendent of Public Instruction authority to withhold basic education allocations to school districts to facilitate repayment of moneys to the federal government.

Citation of Existing Rules Affected by this Order: WAC 392-121-500.

Statutory Authority for Adoption: RCW 28A.150.290.

Other Authority: Chapter 103, Laws of 1990.

Pursuant to notice filed as WSR 90-18-088 on September 5, 1990.

Effective Date of Rule: Thirty-one days after filing.

March 7, 1991  
 Judith A. Billings  
 Superintendent of  
 Public Instruction

**WITHHOLDING FOR REPAYMENT OF  
 FEDERAL MONEYS**

**NEW SECTION**

WAC 392-121-500 WITHHOLDING FOR REPAYMENT OF FEDERAL MONEYS—APPLICABLE PROVISIONS. The provisions of WAC 392-121-500 through 392-121-545 apply to the withholding of basic education allocations pursuant to chapter 103, Laws of 1990 to facilitate repayment of school district expenditures to the federal government pursuant to WAC 392-115-140 or a federal audit resolution process.

**NEW SECTION**

WAC 392-121-505 WITHHOLDING FOR REPAYMENT OF FEDERAL MONEYS—DEFINITION—DISALLOWED COSTS. As used in WAC 392-121-500 through 392-121-545, "disallowed costs" means the same as defined in WAC 392-115-110.

**NEW SECTION**

WAC 392-121-510 WITHHOLDING FOR REPAYMENT OF FEDERAL MONEYS—DEFINITION—MANAGEMENT DECISION LETTER. As used in WAC 392-121-500 through 392-121-545, "management decision letter" means the same as defined in WAC 392-115-137.

**NEW SECTION**

WAC 392-121-515 WITHHOLDING FOR REPAYMENT OF FEDERAL MONEYS—DEFINITION—ACCEPTABLE REPAYMENT PLAN. As used in WAC 392-121-500 through 392-121-545, "acceptable repayment plan" means a plan agreed to by the superintendent of public instruction for repayment of

disallowed costs plus accrued interest as determined by the federal government.

**NEW SECTION**

WAC 392-121-520 WITHHOLDING FOR REPAYMENT OF FEDERAL MONEYS—DEFINITION—SUBSTANTIAL IMPAIRMENT. As used in WAC 392-121-500 through 392-121-545, "substantial impairment" means that after reducing the school district's current school year basic education allocation by the amount of disallowed costs plus accrued interest the school district is likely to incur a negative unreserved general fund balance as of August 31 of the current school year and is unlikely to be able to balance the school district general fund budget for the ensuing school year without requesting the superintendent of public instruction for permission to budget receivables pursuant to WAC 392-123-060.

**NEW SECTION**

WAC 392-121-525 WITHHOLDING FOR REPAYMENT OF FEDERAL MONEYS—DETERMINATION OF SUBSTANTIAL IMPAIRMENT. If any school district does not repay disallowed costs plus accrued interest or commit to an acceptable repayment plan within thirty calendar days of issuance of the management decision letter, the superintendent of public instruction shall determine if substantial impairment exists.

**NEW SECTION**

WAC 392-121-530 WITHHOLDING FOR REPAYMENT OF FEDERAL MONEYS—NOTICE OF SUBSTANTIAL IMPAIRMENT. If the superintendent of public instruction determines pursuant to WAC 392-121-525 that substantial impairment exists, the superintendent of public instruction shall notify the school district in writing that:

(1) No withholding shall occur until such time as substantial impairment no longer exists;

(2) Unless the school district repays disallowed costs plus accrued interest or agrees to an acceptable repayment plan, the superintendent of public instruction, at least once every twelve months, or sooner at the request of the school district, shall determine if substantial impairment exists pursuant to WAC 391-121-525; and

(3) Interest will continue to accrue until the amount of disallowed costs plus accrued interest are repaid to the federal government.

**NEW SECTION**

WAC 392-121-535 WITHHOLDING FOR REPAYMENT OF FEDERAL MONEYS—NOTICE OF INTENT TO WITHHOLD BASIC EDUCATION ALLOCATIONS. If the superintendent of public instruction determines pursuant to WAC 392-121-525 that substantial impairment does not exist, the superintendent of public instruction shall notify the school district in writing of intent to withhold basic education allocations.

NEW SECTION

WAC 392-121-540 WITHHOLDING FOR REPAYMENT OF FEDERAL MONEYS—WITHHOLDING OF BASIC EDUCATION ALLOCATIONS. If the school district does not repay disallowed costs plus accrued interest or commit to an acceptable repayment plan within thirty calendar days of the notice provided pursuant to WAC 392-121-535, the superintendent of public instruction shall withhold from the school district's next basic education apportionment payment an amount equal to the disallowed costs plus accrued interest. After the initial withholding the superintendent of public instruction shall withhold amounts for additional interest accruing on disallowed costs.

NEW SECTION

WAC 392-121-545 WITHHOLDING FOR REPAYMENT OF FEDERAL MONEYS—PAYMENT OF WITHHELD BASIC EDUCATION ALLOCATIONS. Moneys withheld pursuant to WAC 392-121-540 shall be restored to the school district or paid to the federal government as provided in this section.

(1) If the school district repays disallowed costs plus accrued interest to the federal government or commits to an acceptable repayment plan before the close of the state biennium in which withholding occurred the superintendent of public instruction shall restore withheld moneys to the school district's basic education allocation.

(2) If the school district does not repay or commit to repay pursuant to subsection (1) of this section, the superintendent of public instruction shall request the legislature for reappropriation of basic education moneys for the purpose of repaying the federal government. The requested reappropriation shall include amounts for interest accruing on disallowed costs up to the anticipated date of repayment to the federal government.

(3) Upon reappropriation of moneys pursuant to subsection (2) of this section, the superintendent of public instruction shall pay an amount equal to the disallowed costs plus accrued interest to the federal government.

**WSR 91-07-007**  
**PERMANENT RULES**  
**SUPERINTENDENT OF**  
**PUBLIC INSTRUCTION**

[Order 91-04—Filed March 8, 1991, 11:03 a.m.]

Date of Adoption: March 8, 1991.

Purpose: To set forth the policies and procedures in accordance with federal requirements for the resolution of monetary and nonmonetary audit findings against a subrecipient receiving federal moneys administered by the superintendent of public instruction.

Citation of Existing Rules Affected by this Order: Chapter 392-115 WAC.

Statutory Authority for Adoption: RCW 28A.300.070.

Pursuant to notice filed as WSR 91-03-001 on January 3, 1991.

Effective Date of Rule: Thirty-one days after filing.

March 8, 1991  
 Judith A. Billings  
 Superintendent of  
 Public Instruction

Chapter 392-115 WAC  
 FINANCE—AUDIT RESOLUTION PROCESS

NEW SECTION

WAC 392-115-005 AUTHORITY. The authority for this chapter is RCW 28A.300.070 which authorizes the superintendent of public instruction to receive and administer federal moneys in accordance with federal acts—to wit;

(1) U.S. Public Law 98-502 (the Single Audit Act of 1984) and its implementing federal rules and regulations that require the superintendent of public instruction to resolve audit findings against governmental organizations receiving federal moneys that the superintendent of public instruction receives and administers;

(2) U.S. Public Law 89-64 and amendments thereto (Child Nutrition Act of 1966) and its implementing rules and regulations that require the superintendent of public instruction to resolve audit findings against those organizations operating child care programs and receiving federal moneys received and administered by the superintendent of public instruction; or

(3) U.S. Office of Management and Budget Circular A-110 and successor circular A-133 that require the superintendent of public instruction to resolve audit findings against those organizations receiving federal moneys administered and received by the superintendent of public instruction.

(4) U.S. Public Law 100-297 (Elementary and Secondary School Improvement Act of 1988) and implementing rules and regulations that require the superintendent of public instruction to consider audit findings to be prima facie evidence, and the burden of proof to set aside an audit finding rests with the subrecipient.

NEW SECTION

WAC 392-115-010 PURPOSE. The purpose of this chapter is to set forth the policies and procedures in accordance with federal requirements for the resolution of monetary and nonmonetary audit findings against a subrecipient receiving federal moneys administered by the superintendent of public instruction.

NEW SECTION

WAC 392-115-015 DEFINITION—SUBRECIPIENT. As used in this chapter, "subrecipient" means a public or nonpublic entity receiving federal moneys administered and disbursed by the superintendent of public instruction.

NEW SECTION

WAC 392-115-020 DEFINITION—PROGRAM AUDIT. As used in this chapter, "program audit" means an examination of a subrecipient to determine

compliance with the federal laws and regulations governing the operation of a specific program.

#### NEW SECTION

WAC 392-115-025 DEFINITION—SINGLE AUDIT. As used in this section, "single audit" means an organization-wide examination conducted under the Single Audit Act of 1984 encompassing the entire financial operation of a subrecipient reporting whether:

(1) All financial statements present fairly the financial position and results of financial operations in accordance with generally accepted accounting principles;

(2) All laws and regulations having a material effect upon the financial statements or major federal assistance programs have been complied with; and

(3) All internal control systems provide reasonable assurance that federal financial assistance programs are managed in compliance with applicable laws and regulations.

#### NEW SECTION

WAC 392-115-030 DEFINITION—AUDIT REPORT. As used in this chapter, "audit report" means the report issued by either the office of the state auditor or a certified public accountant disclosing the results of either a single audit or program audit.

#### NEW SECTION

WAC 392-115-035 DEFINITION—QUESTIONED COSTS. As used in this chapter, "questioned costs" means the estimated cost presented in a schedule of questioned cost, associated with one or more of the following:

(1) An alleged violation of a law, regulation, contract, grant, cooperative agreement, or other agreement governing the expenditure of moneys.

(2) Lack of adequate documentation of the expenditure of moneys.

(3) The unnecessary or unreasonable expenditure of the moneys.

#### NEW SECTION

WAC 392-115-040 DEFINITION—MONETARY AUDIT FINDING. As used in this chapter, "monetary audit finding" means a questioned cost associated with a weakness, irregularity, or error.

#### NEW SECTION

WAC 392-115-045 DEFINITION—NON-MONETARY AUDIT FINDING. As used in this chapter, "nonmonetary audit finding" means a weakness, error, or irregularity not associated with a questioned cost but associated with:

(1) Inadequacy of internal controls;

(2) Lack of compliance with federal laws or rules and regulations; or

(3) Improper financial statements of the subrecipient.

#### NEW SECTION

WAC 392-115-050 DEFINITION—AUDIT FINDING. As used in this chapter, "audit finding" means either a monetary or nonmonetary audit finding clearly designated as an audit finding in the audit report of a subrecipient pertaining to federal moneys administered by the superintendent of public instruction.

#### NEW SECTION

WAC 392-115-055 DEFINITION—DISALLOWED COSTS. As used in this chapter, "disallowed costs" means those questioned costs associated with an audit finding that the superintendent of public instruction has determined should not be charged to the federal government.

#### NEW SECTION

WAC 392-115-060 DEFINITION—ALLOWED COSTS. As used in this chapter, "allowed costs" means a questioned cost that the superintendent of public instruction has determined is properly charged to the federal government. Such determination includes but is not limited to the following reasons: Clerical error; inappropriate methodology; noncompliance with generally accepted auditing standards and incorrect interpretation or application of law, rules, or regulations.

#### NEW SECTION

WAC 392-115-065 DEFINITION—RESOLVED AUDIT FINDING. As used in this chapter, "resolved audit finding" means an audit finding subject to provisions of a management decision letter.

#### NEW SECTION

WAC 392-115-070 DEFINITION—MANAGEMENT DECISION LETTER. As used in this chapter, "management decision letter" means a letter that represents resolution of the audit finding for the purposes of this chapter.

#### NEW SECTION

WAC 392-115-075 DEFINITION—DESK REVIEW. As used in this chapter, "desk review" means a review of an audit report to assure that it meets applicable reporting standards and single audit reporting requirements.

#### NEW SECTION

WAC 392-115-080 REOPENING OF RESOLVED AUDIT FINDINGS. The superintendent of public instruction shall recover from the subrecipient moneys resulting from an audit resolution pursuant to this chapter, and any subsequent events that result in a liability of the subrecipient, including the reopening of resolved audit findings. Basic education allocation may be withheld to facilitate recovery as provided by section 1, chapter 103, Laws of 1990.

NEW SECTION

WAC 392-115-085 **AUDIT FINDING AGAINST SPI CONSIDERED TO BE AN AUDIT FINDING AGAINST A SUBRECIPIENT.** An audit finding contained in an audit report of the superintendent of public instruction resulting from failure of a subrecipient to comply with federal law or rules and regulations, shall be considered an audit finding against the subrecipient and resolved pursuant to this chapter.

NEW SECTION

WAC 392-115-090 **LACK OF COMPLIANCE WITH THE AUDIT RESOLUTION PROCESS.** Any subrecipient failing to comply with the process or procedures of this chapter may be subject to the withholding or recovery of federal moneys. The superintendent of public instruction may recover moneys or withhold future funding as necessary to implement management decision letters or final action plans. Money withheld may be released upon corrective action.

NEW SECTION

WAC 392-115-095 **DESK REVIEW OF AUDIT REPORTS.** As required by 34 C.F.R. Part 74, Appendix G, upon receipt of an audit report from the office of the state auditor or a certified public accountant, a desk review of the audit report shall be conducted by the superintendent of public instruction. Audit reports that pass the desk review shall be forwarded for resolution of any audit findings. Audit reports that are determined by such review to be deficient shall be rejected. The superintendent of public instruction may consult with auditors prior to the rejection of audit reports.

NEW SECTION

WAC 392-115-100 **SUBRECIPIENT TO BE INFORMED OF AUDIT FINDING.** The superintendent of public instruction shall inform, by letter, the affected subrecipient of an audit finding or findings within thirty calendar days after an audit report has passed desk review, as required by WAC 392-115-095. If the audit contains a monetary audit finding such letter shall be notice under P.L. 100-297 of a prima facie case for the recovery of funds, that unless rebutted, is sufficient to sustain the conclusion drawn in the audit. If the audit contains a nonmonetary finding, the audit shall be a prima facie case that sustains the audit finding unless rebutted. Audit findings are sustained under this chapter unless the subrecipient can prove that the audit is deficient as specified in WAC 392-115-140.

NEW SECTION

WAC 392-115-105 **SUBRECIPIENT CONCURRENCE WITH AUDIT FINDING.** The subrecipient shall inform the superintendent of public instruction, by letter, whether it concurs or does not concur with an audit finding within thirty calendar days of the date of the notice by the superintendent of public instruction. If the

subrecipient concurs with the audit finding(s), the superintendent of public instruction shall follow the process and procedures set forth in WAC 392-115-110 through 392-115-130. In the event a subrecipient elects not to respond to the notice within thirty calendar days of the date of said notice, such failure will be considered concurrence with audit finding(s). If the subrecipient does not concur with the audit finding, the subrecipient and the superintendent of public instruction shall follow the process and procedures set forth in WAC 392-115-140 through 392-115-150.

NEW SECTION

WAC 392-115-110 **MANAGEMENT DECISION LETTER DEVELOPED.** The superintendent of public instruction shall prepare and forward to the superecipient a management decision letter setting forth:

- (1) Any corrective actions to be taken by the subrecipient;
- (2) Any disallowed costs to be recovered from non-federal sources;
- (3) Any allowed costs chargeable to federal sources;
- (4) Any corrective action to be taken by the subrecipient;
- (5) The due date for submission to the superintendent of public instruction of any final action plan.

The superintendent of public instruction shall issue the management decision letter no later than one hundred eighty calendar days after the receipt of the audit report setting forth an audit finding against the subrecipient.

NEW SECTION

WAC 392-115-115 **FINAL ACTION PLAN.** The subrecipient shall develop a final action plan, as required in the management decision letter, setting forth:

- (1) The corrective actions; and
- (2) The schedule for implementation of corrective actions.

NEW SECTION

WAC 392-115-120 **SPI REVIEWS FINAL ACTION PLAN.** The superintendent of public instruction shall review and approve the final action plan and implementation schedule as proposed by the subrecipient for compliance with the required actions set forth in the management decision letter. If the final action plan or its implementation schedule does not comply with the requirements of the management decision letter, the superintendent shall require the subrecipient to modify the final action plan accordingly. The auditor (the office of the state auditor or a certified public accountant) has the responsibility to review the subrecipient's actions to determine if the corrective actions called for in the final action plan have taken place and assess the adherence to the final action plan in making audit determinations.

NEW SECTION

WAC 392-115-125 **SPI INFORMS SUBRECIPIENT OF THE RESULTS OF REVIEW.**

The superintendent of public instruction shall inform the subrecipient, by letter, of:

- (1) The results of its review of the final action plan;
- (2) Any modification required to be made by the subrecipient; and
- (3) The implementation schedule of the final action plan.

#### NEW SECTION

WAC 392-115-130 SUBRECIPIENT IMPLEMENTS FINAL ACTION PLAN. The subrecipient shall implement the final action plan, with any required modifications, by the date(s) specified by the superintendent of public instruction.

#### NEW SECTION

WAC 392-115-135 SUBRECIPIENT NONCONCURRENCE WITH AUDIT FINDING. The subrecipient shall state the basis of its nonconcurrency with the audit finding by letter, within sixty calendar days (inclusive of the thirty calendar days allowed the subrecipient to notify the superintendent of public instruction of its concurrence or nonconcurrency provided in WAC 392-115-105) of notification from the superintendent of public instruction of the audit finding. The letter shall set forth in full the reasons for the nonconcurrency and be the basis for any subsequent review by the superintendent of public instruction. The subrecipient shall have the burden of proof in cases of disputed audit findings.

#### NEW SECTION

WAC 392-115-140 SPI REVIEW OF AUDIT FINDING AS RESULT OF NONCONCURRENCE. The superintendent of public instruction shall review the subrecipient's letter of nonconcurrency and such review shall be limited to proof of one or more of the following:

- (1) Error or omission by the auditor;
- (2) Application of inappropriate methodology by the auditor;
- (3) Noncompliance with generally accepted auditing standards by the auditor;
- (4) Incorrect interpretation or application by the auditor of federal law or rules and regulations.

#### NEW SECTION

WAC 392-115-145 SPI DEVELOPS MANAGEMENT DECISION LETTER. The superintendent of public instruction shall issue a management decision letter pursuant to WAC 392-115-115 incorporating the results of its review of the subrecipient's nonconcurrency with an audit finding.

#### NEW SECTION

WAC 392-115-150 SUBRECIPIENT APPEAL OF MANAGEMENT DECISION LETTER. The subrecipient may, in writing, appeal the management decision letter within thirty calendar days after the date of the management decision letter to the superintendent of public instruction.

#### NEW SECTION

WAC 392-115-155 MODIFICATION OF MANAGEMENT DECISION LETTER. The superintendent of public instruction shall include any judgments or decisions resulting from a fully exhausted appeals process in a revised management decision letter developed pursuant to WAC 392-115-110.

**WSR 91-07-008**  
**PERMANENT RULES**  
**DEPARTMENT OF**  
**LABOR AND INDUSTRIES**

[Filed March 8, 1991, 11:10 a.m., effective May 1, 1991]

Date of Adoption: March 8, 1991.

Purpose: To change the rules regarding payment for health care services, updating the coding system and modifying the relative value units.

Citation of Existing Rules Affected by this Order: Amending WAC 296-20-200, 296-21-013, 296-21-015, 296-21-026, 296-21-027, 296-21-047, 296-21-050, 296-21-0501, 296-21-066, 296-21-075, 296-21-086, 296-22-202 through 296-22-475, 296-23-015 through 296-23-130, 296-23-204 through 296-23-232, 296-23-50002, 296-23A-240 through 296-23A-268, and 296-23A-325 through 296-23A-360.

Reasons for Adopting Rules: To change the rules regarding payment for health care services, updating the coding system, and modifying the relative value units.

Statutory Authority for Adoption: RCW 51.04.020(4) and 51.04.030.

Pursuant to notice filed as WSR 91-01-123 on December 19, 1990.

Changes Other than Editing from Proposed to Adopted Version: The following rules were proposed for adoption, but will not be adopted: WAC 296-21-011, 296-22-010, and 296-23-01006. Rationale: The rules not adopted would have changed the percentages paid for the technical and professional components of magnetic resonance imaging and computerized tomography. The department decided not to adopt these rules in response to correspondence received as a result of the public hearing process.

Effective Date of Rule: May 1, 1991.

March 8, 1991  
Joseph A. Dear  
Director

AMENDATORY SECTION (Amending Order 74-32, filed 6/21/74, effective 10/1/74)

WAC 296-20-200 GENERAL INFORMATION. (1) The department of labor and industries has promulgated the following rules and categories to provide a comprehensive system of classifying unspecified permanent partial disabilities in the proportion they reasonably bear to total bodily impairment. The department's objectives are to reduce litigation and establish more certainty and uniformity in the rating of unspecified permanent partial disabilities pursuant to RCW 51.32.080(2).

(2) The following system of rules and categories directs the examining physician's attention to the actual conditions (~~(he finds)~~) found and establishes a uniform system for conducting rating examinations and reporting (~~(his)~~) findings and conclusions in accord with broadly accepted medical principles.

The evaluation of bodily impairment must be made by medical experts. This system recognizes and provides for this. After conducting (~~(his)~~) the examination, the examining physician will choose the appropriate category for each bodily area or system involved in the particular claim and include this information in (~~(his)~~) the report. (~~(He)~~) The physician will, therefore, in addition to describing the (~~(workmen's)~~) worker's condition in (~~(his)~~) the report, submit (~~(his)~~) the conclusions as to the relative severity of the impairment by giving it in terms of a defined condition rather than a personal opinion as to a percentage figure. In the final section of this system of categories and rules are some rules for determining disabilities and the classification of disabilities in bodily impairment is listed for each category. These last provisions are for the department's administrative use in acting upon the medical opinions which have been submitted to it.

(3) In preparing this system, the department has complied with its duty to enact rules classifying unspecified disabilities in light of statutory references to nationally recognized standards or guides for determining various bodily impairments. Accordingly, the department has obtained and acted upon sound established medical opinion in thus classifying unspecified disabilities in the reasonable proportion they bear to total bodily impairment. In framing descriptive language of the categories and in assigning a percentage of disability, careful consideration has been given to nationally recognized medical standards and guides. Both are matters calling for the use of expert medical knowledge. For this reason, the meaning given the words used in this set of categories and accompanying rules, unless the text or context clearly indicates the contrary, is the meaning attached to the words in normal medical usage.

(4) The categories describe levels of physical and mental impairment. Impairment is anatomic or functional abnormality or loss of function after maximum medical rehabilitation has been achieved. This is the meaning of "impairment" as the word is used in the guides mentioned above. This standard applies to all persons equally, regardless of factors other than loss of physical or mental function. Impairment is evaluated without reference to the nature of injury or the treatment therefore, but is based on the functional loss due to the injury or occupational disease. The categories have been framed to include conditions in other bodily areas which derive from the primary impairment. The categories also include the presence of pain, tenderness and other complaints. (~~(Workmen)~~) Workers with comparable loss of function thus receive comparable awards.

(5) These rules and categories (WAC 296-20-200 through 296-20-690) shall only be applicable to compensable injuries occurring on or after the effective date of these rules and categories.

(6) These rules and categories (WAC 296-20-200 through 296-20-690) shall be applicable only to cases of permanent partial disability. They have no applicability to determinations of permanent total disability.

AMENDATORY SECTION (Amending Order 86-19, filed 2/28/86, effective 4/1/86)

WAC 296-23-50002 TRANSPORTATION SERVICES. Specify place of departure, destination, purpose of trip and mileage as applicable.

The codes listed in this rule will be paid at current department rates.

- M 0001 Base rate - Ground or air
  - M 0002 Ambulance - Each additional patient
  - M 0003 Ambulance-one-way mileage - Per mile
  - M 0004 Ambulance-return pickup - Same patient, same day
  - M 0005 Ambulance-return pickup one-way mileage - Per mile
  - M 0006 Ambulance-return pickup - Additional patient
  - M 0007 Ambulance - night call
  - M 0008 Ambulance - Oxygen administration
  - M 0009 Ambulance-waiting time - Per minute
  - M 0010 Bridge and ferry tolls
  - M 0011 Chartered air transportation
  - M 0012 Advanced life support - Ground or air
  - M 0023 Ambulance - Extra attendant
  - M 0024 Ambulance - Monitoring
  - M 0025 Cabulance - One-way mileage - Per mile
  - M 0026 Cabulance - Waiting time - Per minute
  - M 0027 Cabulance - Base rate
  - M 0028 Private transportation (~~(=18¢ Per mile)~~)
  - M 0029 Commercial transportation
  - M 0030 Taxi - One-way time or mileage
  - M 0036 Licensed air ambulance - One-way mileage
  - M 0060 Ambulance - Suction catheter
  - M 0061 Ambulance - Oxygen mask
  - M 0062 Ambulance - Oxygen cannula
  - M 0063 Ambulance - Airway
  - M 0064 Ambulance - Cardboard splint
  - M 0065 Ambulance - Disposable cervical collar
  - M 0066 Ambulance - Dressing
  - M 0067 Ambulance - Triangular bandage
  - M 0068 Ambulance - Backboard, stretcher
  - M 0069 Ambulance - Ice packs
  - M 0070 Ambulance - Trauma pads
  - M 0071 Ambulance - Burn kit
  - M 0072 Ambulance - Mast trouser
  - M 0073 Ambulance - Heart/lung resuscitation
  - M 0074 Ambulance - IV administration - Per IV
  - M 0075 Lodging - Receipt required
  - M 0076 Breakfast - Receipt required ((~~\$-5.00~~))
  - M 0077 Lunch - Receipt required ((~~\$-5.00~~))
  - M 0078 Dinner - Receipt required ((~~\$10.00~~))
  - M 0079 Per diem lodging/meals ((~~\$50.00~~))
  - M 0080 Parking
  - M 0081 Interpreter
  - M 0099 Unlisted transportation item or service.
- TAX 00

**AMENDATORY SECTION** (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

WAC 296-21-013 SPECIAL SERVICES AND BILLING PROCEDURES. The following services are generally part of the basic services listed in the maximum fee schedule but do involve additional expenses to the physician for materials, for his time or that of his employees. These services are generally provided as an adjunct to common medical services and should be used only when circumstances clearly warrant an additional charge over and above the usual charges for the basic services.

	Unit Value
90696 Telephone call or conference with department claims manager, vocational or medical staff, adjudicator, or employer, relative to an individual case (each 15 minutes) .....	16.0
99000 Handling and/or conveyance of specimen for transfer from the physician's office to a laboratory .....	6.0
99001 Handling and/or conveyance of specimen for transfer from the patient in other than a physician's office to a laboratory (distance may be indicated) .....	8.0
99002 Handling, conveyance, and/or any other service in connection with the implementation of an order involving devices (e.g., designing, fitting, packaging, handling, delivery or mailing) when devices such as orthotics, protectives, prosthetics are fabricated by an outside laboratory or shop but which items have been designed, and are to be fitted and adjusted by the attending physician .....	12.0
(For routine collection of venous blood, use 36415)	
99013 Telephone call for consultation or medical management; simple or brief, under 15 minutes .....	5.0
(e.g., to report on tests and/or laboratory results; to clarify or alter previous instructions; to adjust therapy)	
99014 intermediate, 15 - 30 minutes .....	10.0
(e.g., to provide advice to an established patient on a new problem; to initiate therapy that can be handled by telephone; to discuss results of tests in detail)	
99015 lengthy or complex .....	15.0
(e.g., lengthy counseling session with anxious or distraught patient; detailed or prolonged discussion with family member regarding seriously ill patient)	
99024 Postoperative follow-up visit, included in global service .....	BR
(See WAC 296-22-010)	
99025 Initial (new patient) visit when asterisk (*) surgical procedure constitutes major service at that visit .....	20.0
99030 Mileage, one way, each mile beyond 7 mile radius of point of origin (office or home), per mile .....	2.0
99040 Completion of certificate of disability card .....	2.0
99044 Doctor's estimate of physical capacities .....	10.0
99050 Services requested after office hours in addition to basic service .....	10.0
99052 Services requested between 10:00 p.m. and 8:00 a.m. in addition to basic services provided the office is closed during this period of time .....	12.0
99054 Services requested on Sundays and holidays in addition to basic services .....	12.0

99056 Services provided at request of patient in a location other than physician's office which are normally provided in the office .....	BR
99058 Office services provided on an emergency basis .....	BR
(For hospital-based emergency care facility services, see 90500 et seq.)	
99062 Emergency care facility services: When the non-hospital-based physician is in the hospital but is involved in patient care elsewhere and is called to the emergency facility to provide emergency services .....	8.0
(For hospital-based emergency care facility services, see 90500 et seq.)	
99064 Emergency care facility services: When the non-hospital-based physician is called to the emergency facility from outside the hospital to provide emergency services; not during regular office hours .....	25.0
99065 during regular office hours .....	16.0
99070 Supplies and materials (except spectacles) provided by the physician over and above those usually included with the office visit or other services rendered (list drugs, trays, supplies or materials cast room and/or casting supplies provided). Bill at cost .....	BR
(For spectacles, see 92390-92395)	
99075 Medical testimony approved in advance by office of attorney general. First hour .....	240.0
99076 Each additional 30 minutes .....	80.0
99080 Special reports as insurance forms, sixty-day report, or the review of medical data to clarify a patient's status—more than the information conveyed in the usual medical communications or standard reporting form at department request (see WAC 296-20-06101 for reporting requirements) .....	BR
99082 Unusual travel (e.g., transportation and escort of patient) per mile .....	2.0
99083 Copies of medical records requested by the department or self-insurance or their representative(s), not required to support billing for services rendered, per page .....	0.2
99084 Maximum allowed per claim .....	4.6
99085 Physician called on to convey instructions by telephone to hospital emergency room or nurse practitioner clinic—to be paid only to initial attending physician upon completion of report of accident form .....	12.0
99095 Deposition approved in advance by office of attorney general. First hour .....	200.0
99096 Each additional 30 minutes .....	67.0
99150 <del>((Detention, prolonged, with patient requiring physician attendance beyond usual service (e.g., critically ill patient, 30 minutes to one hour)))</del> <u>Prolonged physician attendance requiring physician detention beyond usual service (e.g., operative standby, monitoring ECG, EEG intrathoracic pressures, intravascular pressures, blood gases during surgery, standby for newborn care following cesarean section, or material-fetal monitoring); 30 minutes to one hour</u> .....	25.0
99151 more than one hour .....	50.0

**CRITICAL CARE**

Critical care includes the care of critically ill patients in a variety of medical emergencies that requires the constant attention of the physician (cardiac arrest, shock, bleeding, respiratory failure, postoperative complications, critically ill neonate). Critical care is usually, but



not always, given in a critical care area, such as the coronary care unit, intensive care unit, respiratory care unit, or the emergency care facility. The descriptors for critical care are intended to include cardiopulmonary resuscitation and a variety of services attendant to this procedure as well as other acute emergency situations. Separate procedure codes for services performed during this period, such as placement of catheters, cardiac output measurement, management of dialysis, control of gastrointestinal hemorrhage, electrical conversion of arrhythmia, etc., are included when this descriptor is used on a per hour basis. (The physician may list his services separately if he desires.)

Unit  
Value

- 99195 Phlebotomy, therapeutic (separate procedure) ..... 20.0
- 99199 Unlisted special service or report. .... BR

(For physicians assigned to critical care units or other long-term attendance, use special reports)

**DEFINITIONS**

Definitions and items of commonality. Terms and phrases common to the practice of medicine are defined as follows and apply to procedures 90000 through 90696.

(1) **NEW PATIENT:** A patient who is new to the physician or a known patient with a new industrial injury or condition, and whose medical and administrative record need to be established.

(2) **ESTABLISHED PATIENT:** A patient known to the physician and/or whose records are usually available.

(3) **INITIAL VISIT:** Initial care, including physical examination and initiation of diagnostic and treatment program, for a condition regardless of whether the patient is known to the physician.

(4) **FOLLOW-UP VISIT:** Subsequent care for a patient and condition known to the physician.

(5) **CONSULTATION:** A consultation includes services rendered by a physician whose opinion or advice is requested by a physician or other appropriate source for the further evaluation and/or management of the patient. When the consulting physician assumes responsibility for the continuing care of the patient, any subsequent service rendered by him will cease to be a consultation. The consulting physician cannot assume care without the concurrence of the patient or the referring doctor. See WAC 296-20-051. Five levels of consultation are recognized: Limited, intermediate, extensive, comprehensive, and complex consultation. See WAC 296-21-030 for description.

(6) **REFERRAL:** (Transfer) A referral is the transfer of the total or specific care of a patient from one physician to another and does not constitute a consultation. Initial evaluation and subsequent services are designated as listed below in levels of service.

(7) **LEVELS OF SERVICE:** Examinations, evaluations, treatment, counseling, conferences with or concerning patients, and services which necessitate wide variations in skill, effort and time required for the diagnosis and treatment of illness and the promotion of optimal health. Six levels are recognized:

**MINIMAL:** A level of service including injections, dressings, minimal care, etc., not necessarily requiring the presence of the physician.

For example:

- (a) Routine immunization for tetanus administered by a nurse.
- (b) Blood pressure determination by a nurse for medication control.
- (c) Removal of sutures from laceration.

**BRIEF:** A level of service requiring a brief period of time, with minimal effort by the physician.

	Unit Value
99154 Daily hospital management of epidural or subarachnoid drug administration .....	BR
99160 Critical care, initial, including the diagnostic and therapeutic services and direction of care of the critically ill or multiple injured or comatose patient, requiring the prolonged presence of the physician; each hour .....	100.0
99162 additional 30 minutes .....	50.0
(For monitoring cardiac output, see 78470, 93561, 93562)	
(For monitoring intra-aortic balloon counter pulsation, see 33972)	
(For subsequent visits, see appropriate critical care visit, 99171-99174 or hospital visits, 90200-90280)	
99170 Gastric intubation, and aspiration or lavage for treatment (e.g., for ingested poisons) .....	SV
99171 Critical care, subsequent follow-up visit; brief examination, evaluation and/or treatment for same illness .....	SV
99172 limited examination, evaluation and/or treatment, same or new illness .....	SV
99173 intermediate examination, evaluation and/or treatment, same or new illness .....	SV
99174 extended reexamination, reevaluation and/or treatment, same or new illness .....	SV

**OTHER SERVICES**

99175 Ipecac or similar administration for individual emesis and continued observation until stomach adequately emptied of poison .....	SV
(For diagnostic intubation, see 82926-82932, 89130-89141)	
(For gastric lavage for diagnostic purposes, see 91055)	
99180 Hyperbaric oxygen pressurization; initial .....	12.0
99182 Subsequent .....	3.0
99185 Hypothermia; regional .....	BR
99186 total body .....	BR
99190 Assembly and operation of pump with oxygenator or heat exchanger (with or without ECG and/or pressure monitoring); each hour .....	60.0
99191 3/4 hour .....	45.0
99192 1/2 hour .....	30.0

For example:

- (a) Certification of time loss in a stable or chronic case.
- (b) Reexamination of minor trauma (e.g., contusion or abrasion).
- (c) Examination of conjunctiva by the physician in a patient with subconjunctival hemorrhage, irrigation, medication and removal of foreign body with instrument.
- (d) Review of interval history, physical status, and adjustment of medication in patient with compensated arteriosclerotic heart disease on chronic diuretic therapy.

**LIMITED:** A level of service requiring limited effort or judgment, such as abbreviated or interval history, limited examination or discussion of findings and/or treatment.

For example:

- (a) Review and examination of uncomplicated sprains and strains with initiation, continuation and/or change of treatment.
- (b) Examination of an extremity fracture not requiring reduction.
- (c) Postoperative care in instances where the unit value is for surgical procedure only.

**INTERMEDIATE:** A level of service such as a complete history and physical examination of one or more organ systems, complicated with a new diagnostic or management problem not necessarily relating to the primary diagnosis that necessitates the obtaining and evaluation of pertinent history and physical or mental status findings, diagnostic tests and procedures, and the ordering of appropriate therapeutic management or an in depth counseling or discussion of the findings, but not requiring a comprehensive examination of the patient as a whole.

For example:

- (a) Review of interval history; examination of neck veins, lungs, heart, abdomen and extremities, discussion of findings and prescription of treatment in decompensated arteriosclerotic heart disease.
- (b) Review of interval history, examination of musculoskeletal system, discussion of findings, and adjustment of therapeutic program in low back and/or arthritic disorders.
- (c) Review of recent illness: Examination of pharynx, neck, axilla, groin, and abdomen; interpretation of laboratory tests and prescription of treatment in infectious mononucleosis.
- (d) Evaluation of a chest, post trauma, with impaired respiration with development of shock.

**EXTENDED:** A level of service requiring an unusual amount of effort or judgment with report to include a detailed history, review of medical records, examination, conclusions of x-ray or laboratory studies, diagnosis and recommendations for treatment, and a formal conference with patient or family. This service may, or may not involve a complete examination of the patient as a whole.

For example:

- (a) Reexamination of neurological findings, detailed review of hospital studies and course, and formal conference with patient and family jointly concerning findings and plans in a diagnostic problem of suspected intracranial disease in a young adult.

(b) Detailed intensive review of studies and hospital course and thorough reexamination of pertinent physical findings of a patient with a recent coronary infarct with complications requiring constant physician bedside attention.

(c) Review of results of diagnostic evaluation, performance of a detailed examination and a thorough discussion of physical findings, laboratory studies, x-ray examinations, diagnostic conclusions and recommendations for treatment of complicated chronic pulmonary disease.

(d) Detailed review of studies and hospital course and thorough reexamination of pertinent physical findings of a patient with a recent coronary infarct and formal conference with patient or family to review findings and prognosis.

(e) Reevaluation of a psychotic delusional patient who develops severe and acute abdominal pain involving a mental status reassessment but not a psychiatric diagnostic interview, and a conference with the consulting surgeon and nursing personnel.

(f) Detailed intensive review of studies and hospital course and thorough reexamination of pertinent findings of a patient with a recently diagnosed uterine adenocarcinoma who also has a pulmonary coin lesion under consideration for thoracotomy; this service involves several abbreviated conferences with consultants, and family or patient.

**COMPREHENSIVE:** A level of service providing an in depth evaluation of the patient with a new or existing problem requiring the development or complete reevaluation of medical data. This procedure includes the recording of a chief complaint(s), and present illness, family history, past medical history, personal history, system review, a complete physical examination, and the ordering of appropriate diagnostic tests and procedures.

#### AMENDATORY SECTION (Amending Order 87-18, filed 7/23/87)

**WAC 296-21-015 OFFICE VISITS.** The following codes (90000-90097) are to be used to report the services provided for patients in the physician's office or in an outpatient or other ambulatory facility, including the emergency department when the physician is not assigned to the emergency department. (See also codes 99062, 99064, 99065.) A patient is considered an outpatient until inpatient admission is made to a health care facility. (For services provided by physicians assigned to the emergency department, see codes 90500-90580.) (For physicians not assigned to the emergency department, use 90000-90097 and see also 99062, 99064, 99065.)

These codes are also used to report the medical services provided by a physician to a patient in an OBSERVATION AREA of a hospital.

(See introduction for definitions and examples of levels of service)

	Unit Value
<b>INITIAL VISIT</b>	
90000 BRIEF evaluation, history, examination and/or treatment and submission of a report .....	20.0
90001 Completion of report of accident .....	12.0
90010 Initial LIMITED history and physical examination, including initiation of diagnostic and treatment program and submission of a report. (Routine visit involving a single region or organ system) .....	30.0
90015 Initial INTERMEDIATE history and physical examination, including initiation of diagnostic and treatment program and submission of a report. (Serious or complicated case involving one or more regions or organ systems. Complexity or complication must be indicated in report) .....	50.0
90017 Extended-initial office visit including history and physical exam, and initiation of treatment program with submission of a report in addition to the report of accident .....	60.0
90020 Initial COMPREHENSIVE history and physical examination, including initiation of diagnostic and treatment program with submission of a report in addition to the report of accident. (A complex case requiring an unusual amount of time, skill or judgment and an evaluation of the patient as a whole and accompanied with a detailed report) .....	70.0
<b>FOLLOW-UP VISITS</b>	
90030 MINIMAL service (e.g., Injection, immunization, minimal dressing) (Independent procedure) .....	8.0
90040 BRIEF examination, evaluation and/or treatment with office notes .....	12.0
90050 LIMITED examination, evaluation and/or treatment with office notes .....	16.0
90060 INTERMEDIATE examination, evaluation and/or treatment. (Serious or complicated case involving one or more regions and/or organ systems, and accompanied with a detailed report) .....	20.0
90070 EXTENDED reexamination or reevaluation requiring an unusual amount of time, skill or judgment, but not necessitating a complete examination or reexamination of the patient as a whole accompanied by a detailed report .....	30.0
90080 COMPREHENSIVE reexamination or reevaluation requiring complete reevaluation of the patient as a whole accompanied by a detailed report .....	50.0
90097 Completion of a reopening application. An initial office visit fee will be paid for this reopening examination when justified by a report. Diagnostic studies and x-ray studies associated with the reopening examination will be allowed in addition to this fee .....	12.0

(For special narrative reports, at department or self-insurer request, see code 99080.)

**AMENDATORY SECTION** (Amending Order 87-18, filed 7/23/87)

~~WAC 296-21-027 EMERGENCY ROOM SERVICE. The following ((values apply for services performed in the emergency room when the physician is assigned to emergency room duty or is present in the emergency room because of other activity there, or if the physician elects to use the emergency room as a substitute for his office)) listings may be used by the physician~~

to report his services when he is assigned to the emergency department. (For physicians not assigned to the emergency department, use 90000-90097 and see also 99062-99065.)

For medical services provided by a physician assigned to the emergency department to a patient in an OBSERVATION AREA of a hospital, see 90000-90097.

	Unit Value
<b>INITIAL VISIT</b>	
90500 MINIMAL service (i.e. injection, etc.) .....	10.0
90505 BRIEF evaluation, history, examination and/or treatment. (Not payable when other fees are payable except as indicated by modifiers) .....	20.0
90510 Initial LIMITED history and physical examination, including initiation of diagnostic and treatment program. (Routine case involving a single region and/or organ system) (Not payable when other fees are payable except as indicated by modifiers) .....	30.0
90515 Initial INTERMEDIATE history and physical examination, including initiation of diagnostic and treatment program and submission of a detailed report. (Serious or complicated case involving one or more regions and/or organ systems) (Not payable when other fees are payable except as indicated by modifiers) .....	50.0
90517 Initial EXTENDED history and physical examination, including initiation of diagnostic and treatment program and submission of a detailed report in addition to the report of accident .....	60.0
90520 Initial COMPREHENSIVE history and physical examination, including initiation of diagnostic and treatment program and submission of a report in addition to the report of accident. A complex case requiring an unusual amount of time, skill or judgment and an evaluation of the patient as a whole and accompanied with a report .....	70.0
<b>FOLLOW-UP VISIT</b>	
90530 MINIMAL service (e.g., injection, minimal dressing, suture removal, minor laceration) (Not payable when other fees are applicable except as indicated by modifiers) .....	8.0
90540 BRIEF examination, evaluation and/or treatment. (Not payable when other fees are applicable except as indicated by modifiers) .....	12.0
90550 LIMITED examination, evaluation and/or treatment. (Routine follow up care) (Not payable when other fees are applicable except as indicated by modifiers) .....	16.0
90560 INTERMEDIATE examination, evaluation and/or treatment accompanied by a detailed report. (Case involving one or more regions and/or organ systems) (Not payable when other fees are payable except as indicated by modifiers) .....	20.0
90570 EXTENDED reexamination or reevaluation and/or treatment requiring an unusual amount of time, skill or judgment but not necessitating evaluation of the man as a whole accompanied by a detailed report. (Not payable when other fees are applicable except as indicated by modifiers) .....	30.0
90580 COMPREHENSIVE reexamination or reevaluation and/or treatment requiring complete reevaluation of the patient as a whole, accompanied by a detailed report .....	50.0
90590 Physician direction of emergency medical systems (EMS) emergency care, advanced life support, while located in a hospital emergency or critical care unit and is in two-way voice communication with rescue personnel outside the hospital .....	15.0

**AMENDATORY SECTION** (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

**WAC 296-21-047 THERAPEUTIC INJECTIONS.**

(For cost of drugs supplied by physician, see 99070)

(For injections performed as an independent procedure, see 90030)

(For allergy testing, see WAC 296-21-075)

(For skin testing, see 86450-86585)

	Unit Value
90782 Therapeutic or <u>diagnostic</u> injection of medication (specify <u>material injected</u> ); subcutaneous or intramuscular .....	6.0
90783 intra-arterial .....	10.0
90784 intravenous .....	8.0
(90782-90784 do not include injections for allergen immunotherapy. For allergen immunotherapy injections, see 95115-95117)	
90788 Intramuscular injection of antibiotic (specify) .....	6.0
90798 Intravenous therapy for severe or intractable allergic disease in physician's office or institution with theophyllines, corticosteroids, antihistamines .....	11.0
90799 Unlisted therapeutic or <u>diagnostic</u> injection .....	BR

(For allergy immunizations, see 9500 et seq.)

**AMENDATORY SECTION** (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

**WAC 296-21-050 PSYCHIATRIC SERVICES.**

**NOTES**

Treatment of mental conditions to workers is to be goal directed, time limited, intensive, and limited to conditions caused or aggravated by the industrial condition. Psychiatric services to workers are limited to those provided by psychiatrists and licensed psychologists, and according to department policy. For purposes of this rule, the term "psychiatric" refers to treatment by psychologists as well as psychiatrists.

Initial evaluation, and subsequent treatment must be authorized by department staff, as outlined by department policy. The report of initial evaluation, including test results, and treatment plan are to be sent to the worker's attending provider, as well as the department. A copy of sixty day narrative reports to the department is also to be sent to the attending provider.

All providers are bound by the medical aid rules in chapter 296-20 WAC. Reporting requirements are defined in chapter 296-20 WAC. In addition, the following are required: Testing results with scores, scales and profiles; report of raw data sufficient to allow reassessment by a panel or independent medical examiner. Use of the current Diagnostic and Statistical Manual of the American Psychiatric Association axis format in the initial evaluation and sixty day narrative reports, and explanation of the numerical scales are required.

A report to the department will contain, at least, the following elements:

Subjective complaints;

Objective observations;

Assessment of the worker's condition and goals accomplished; and

Plan of care.

Hospital care by the attending physician in treating a psychiatric inpatient may be initial or subsequent in nature (see 90200-90280) and may include exchanges with nursing and ancillary personnel. Hospital care services involve a variety of responsibilities unique to the medical management of inpatients, such as physician hospital orders, interpretation of laboratory or other medical diagnostic studies and observations, review of activity therapy reports, supervision of nursing and ancillary personnel, and the programming of all hospital resources for diagnosis and treatment.

When services include not only a visit to the patient, but also activity in leadership or direction of a treatment team as related to that patient, a code may be selected based upon the services provided that day.

Some patients receive hospital care services only and others receive hospital care services and other procedures. If other procedures such as electroconvulsive therapy or ((~~medical~~)) psychotherapy are rendered in addition to hospital care services, these should be listed separately (i.e., hospital care service plus electroconvulsive therapy or plus ((~~medical~~)) psychotherapy if rendered).

Psychiatric care may be reported without time dimensions according to the procedure or service as are other medical or surgical procedures. ((~~In reporting medical psychotherapy procedures, time is only one aspect and may be expressed as is customary in the local area. For example, the usual appointment length of an individual medical psychotherapy procedure may be signified by the procedure code alone. The modifier '-52' may be used to signify a service that is reduced or less extensive than the usual procedure. The modifier '-22' may be used to indicate a more extensive service. Thus medical psychotherapy procedures may be reported by the procedure code alone or by the procedure code with a modifier. If appropriate and customary in the local area, codes 90841, 90843 or 90844 may be used.~~))

Other medical services, such as 90050—Limited office medical service or other patient encounters, may be described as listed in the section on medicine if appropriate.) Anesthesia services, when needed will be paid per department policy.

**CONSULTATION**

Consultation for psychiatric evaluation of a patient. Includes examination of patient and exchange of information with primary physician and other informants such as nurses or family members, and preparation of report. These consultation services (90600-90643) are limited to initial or follow-up evaluation and do not involve psychiatric treatment. For treatment, see 90200 et seq. or 90841 et seq.

GENERAL CLINICAL PSYCHIATRIC DIAGNOSTIC OR EVALUATIVE INTERVIEW PROCEDURES

	Unit ((Basic ValueAmes@))
90801 Psychiatric diagnostic interview examination including history, mental status, or disposition (may include communication with family or other sources, ordering and medical interpretation of laboratory or other ((medical)) diagnostic studies; in certain circumstances other informants will be seen in lieu of the patient). Report required. ....	70.0

SPECIAL CLINICAL PSYCHIATRIC DIAGNOSTIC OR EVALUATIVE PROCEDURE

90825 Psychiatric evaluation of hospital records, other psychiatric reports, psychometric and/or projective tests, and other accumulated data for ((medical)) diagnostic purposes (without other informants or patient interview) .....	30.0
90830 Psychological testing by physician, with written report, per hour (See testing codes below)((.....BR)) <span style="display: block; text-align: right;"><u>noncovered procedure</u></span>	BR
<del>((90831 Telephone consultation with or about patient for psychiatric therapeutic or diagnostic purposes .....</del>	<del>20.0))</del>
90835 Narcosynthesis for psychiatric diagnostic and therapeutic purposes, e.g., sodium amobarbital (Amytal) interview .....	50.0
<del>((90840 Psychologic testing, psychometric and/or projective tests, with written report, given by or under supervision of physician, per hour .....</del>	<del>45.0))</del>

Testing codes:

W0050 Structured personality test, i.e., MMPI, CPI; list test conducted, report required .....	35
W0051 Neuropsychological evaluation (the complete battery ONLY): Cognitive evaluation, including intelligence, verbal comprehension, verbal reasoning, memory and learning, visual/spatial abilities, problem solving, motor abilities, and auditory, tactile and visual perception tests. Emotional and social assessments, including medication history, with positive or negative history of drug use, (including alcohol) that might impair cognitive functioning. REPORT AND PRIOR AUTHORIZATION REQUIRED .....	542
W0052 Testing other than structured personality test or complete neuropsychological evaluation, list test(s) conducted, report required .....	BR

PSYCHIATRIC THERAPEUTIC PROCEDURES ((MEDICAL)) PSYCHOTHERAPY

90841 Individual ((medical)) psychotherapy with continuing ((medical)) diagnostic evaluation, and drug management when indicated, including psychoanalysis, insight oriented, behavior modifying or supportive psychotherapy; ((each)) up to 15 minutes with report .....	20.0
90843 approximately ((20)) 16 TO 30 minutes with report .....	42.4
90844 approximately ((45-OR)) 31 TO 50 minutes with report .....	70.0
90845 Medical psychoanalysis .....	<u>noncovered procedure</u>
90846 Family medical psychotherapy (without the patient present) .....	<u>noncovered procedure</u>

90847 Family ((medical)) psychotherapy (conjoint psychotherapy) .....	50.0
90849 Multiple-family group medical psychotherapy Report required.....	((50.0)) <u>noncovered procedure</u>
90850 Inpatient care including psychotherapy and supervision of milieu team (e.g., occupational therapy, psychiatric nursing, etc.) or conference with family, 50 minutes, with report .....	70.0
90851 25 minutes, with report .....	45.0
90852 15 minutes, with report .....	20.0
90853 Group ((medical)) psychotherapy (other than of a multiple-family group) Report required. ....	50.0

PSYCHIATRIC SOMATOTHERAPY

90862 ((Chemotherapy)) Pharmacologic management, including prescription, use, and review of medication with no more than minimal ((medical)) psychotherapy((.....per hour.....60.0)) <span style="display: block; text-align: right;"><u>20.00</u></span>	60.0
90870 Electroconvulsive therapy (includes necessary monitoring); single seizure .....	50.0
90871 Multiple seizures, per day .....	75.0

OTHER PSYCHIATRIC THERAPY

90880 ((Medical)) Hypnotherapy .....	35.0
90882 Environmental intervention for medical management purposes on a psychiatric patient's behalf with agencies, employers, or institutions .....	30.0
90887 Interpretation or explanation of results of psychiatric, other medical examinations and procedures, or other accumulated data to family or other responsible persons, or advising them how to assist patient .....	30.0
90889 Preparation of report of patient's psychiatric status, history, treatment, or progress (other than for legal or consultative purposes) for other ((physicians)) providers, agencies, or insurance carriers .....	50.0

(For psychiatric consultation see 90600-90630)

~~((90898 If a claimant fails to appear for the initial psychiatric treatment interview and the psychiatrist, through investigation, including contact with the patient, files a useful report including recommendations, he is entitled to a full hour's fee .....~~

OTHER PROCEDURES

90899 Unlisted psychiatric service or procedure CLEARLY DOCUMENT SERVICES RENDERED .....	BR
--	----

AMENDATORY SECTION (Amending Order 86-36, filed 10/1/86, effective 11/1/86)

WAC 296-21-0501 BIOFEEDBACK RULES. Procedures listed under WAC ((296-20-0502)) 296-21-0502 are for use by ((M.D.'s, D.O.'s, and certified)) medical doctors, osteopathic physicians and licensed psychologists. Procedures listed under ((WAC 296-23-910)) chapter 296-23 WAC are for use by ((certified registered nurses. RPT's and LPT's must use rules and procedures listed under WAC 296-23-710 through 296-23-725)) other qualified providers as determined by department policy. All providers of biofeedback are bound by the rules and fee schedule of biofeedback WAC 296-21-0501 and 296-21-0502.

Administration of biofeedback treatment is limited to those practitioners who are certified by the Biofeedback Certification Institute of America or who meet the minimum education, experience, and training qualifications to be so certified. Those practitioners wishing to administer biofeedback treatment to ~~((injured))~~ workers, must submit a copy of their biofeedback certification or supply evidence of their qualifications to the department ~~((of))~~ or self-insurer ~~((as the case may be))~~.

(1) The department will authorize biofeedback treatment for the following conditions when accepted under the industrial insurance claim:

- (a) Idiopathic Raynaud's disease
- (b) Temporomandibular joint dysfunction
- (c) Myofascial pain dysfunction syndrome (MPD)
- (d) Tension headaches
- (e) Migraine headaches
- (f) Tinnitus
- (g) Torticollis

(h) Neuromuscular reeducation as result of neurological damage in CVA or spinal cord injury

(i) Inflammatory and/or musculoskeletal disorders causally related to the accepted condition.

(2) Twelve biofeedback treatments in a ninety day period will be authorized for the above conditions when the following is presented:

- (a) An evaluation report documenting:
  - (i) The basis for the claimant's condition;
  - (ii) the condition's relationship to the industrial injury;
  - (iii) an evaluation of the claimant's current functional measurable modalities (i.e., range of motion, up time, walking tolerance, medication intake, etc.);
  - (iv) an outline of the proposed treatment program;
  - (v) an outline of the expected restoration goals.

(b) No further biofeedback treatments will be authorized or paid for without substantiation of evidence of improvement in measurable, functional modalities (i.e., range of motion, up time, walking tolerance, medication intake, etc.). Only one additional treatment block of twelve treatments per ninety days will be authorized. Requests for biofeedback treatment beyond twenty-four treatments or one hundred eighty days will be granted only after file review by and on the advice of the department's medical consultant.

(c) In addition to treatment, pretreatment and periodic evaluation will be authorized. Follow-up evaluation can be authorized at one, three, six, and twelve months posttreatment.

(d) At the department's option, a concurring opinion may be required regarding relationship of the condition to the industrial injury and/or need for biofeedback treatment.

**AMENDATORY SECTION** (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

WAC 296-21-066 **CARDIOVASCULAR.** Values for items 92950-93799 include laboratory procedure(s), interpretation and physician's services (except surgical and anesthesia services as listed in the section on surgery), unless otherwise stated.

		Unit Value	Basic Anes@
<b>THERAPEUTIC SERVICES</b>			
92950	Cardiopulmonary resuscitation (e.g., in cardiac arrest) .....	SV	
	(See also critical care services, 99160)		
92953	Temporary transcutaneous pacing .....	BR	
	(For physician direction of ambulance or rescue personnel outside of the hospital, see 90590)		
92960	Cardioversion, elective, electrical conversion of arrhythmia, external .....	100.0	4.0
92970	Cardioassist-method of circulatory assist; internal .....	BR	
92971	external .....	BR	
	(For balloon atrial-septostomy, see 33738)		
	(For placement of catheters for use in circulatory assist devices such as intra-aortic balloon pumping, see 33970)		
92975	Thrombolysis, coronary; by intracoronary infusion, including selective, coronary angiography .....	BR	
92977	by intravenous infusion .....	BR	
92982	Percutaneous transluminal coronary angioplasty; single vessel .....	BR	
92984	each additional vessel .....	BR	
<b>CARDIOGRAPHY</b>			
	(For echocardiography, see 93300-93320)		
93000	Electrocardiogram, with interpretation and report; routine ECG with at least 12 leads ..	30.0	
93005	tracing only, without interpretation and report .....	20.0	
93010	interpretation and report only .....	15.0	
	(For ECG monitoring, see 99150, 99151)		
93012	Telephonic or telemetric transmission of electrocardiogram, rhythm strip; .....	BR	
93014	physician review with interpretation and report <u>only</u> .....	BR	
93015	Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise; continuous electrocardiographic monitoring, with interpretation and report .....	50.0	
93017	tracing only, without interpretation and report .....	30.0	
93018	interpretation and report only .....	25.0	
93024	Ergonovine provocation test .....	BR	
93040	Rhythm ECG, one to three leads; with interpretation and report .....	30.0	
93041	tracing <u>only</u> without interpretation and report .....	15.0	
93042	interpretation and report only .....	20.0	
<del>((93045</del>	<del>esophageal lead (includes placement and interpretation) .....</del>	<del>50.0))</del>	
93201	Phonocardiogram with ECG lead; with supervision during recording with interpretation and report (when equipment is supplied by the physician) .....	50.0	
93202	tracing only, without interpretation and report (when equipment is supplied by the hospital, clinic, etc.) .....	15.0	
93204	interpretation and report .....	25.0	
93205	Phonocardiogram with ECG lead, with indirect carotid artery and/or jugular vein tracing, and/or apex cardiogram; with interpretation and report .....	60.0	
93208	tracing only, without interpretation and report .....	15.0	
93209	interpretation and report only .....	30.0	
93210	Phonocardiogram, intracardiac .....	70.0	

	Unit Value	Basic Anes@		Unit Value	Basic Anes@
93220	50.0		<b>ECHOCARDIOGRAPHY</b>		
93221	15.0		<del>(93300)</del> Echocardiography, M-Mode, complete	90.7	
93222	25.0		93305 limited (e.g., follow-up or limited study)	BR))	
93224			93307 Echocardiography, real-time ((scan)) with image documentation (2D) with or without M-mode recording; complete	80.5	
			93308 follow-up or limited study	BR	
			<del>(93309)</del> Echocardiography, M-mode and real time with image documentation (2D)	190.7))	
93225		BR	93312 Echocardiography, real time with image documentation (2D) (with or without M Mode recording), transesophageal		BR
93226		BR	93320 Doppler echocardiography, pulsed wave and/or continuous wave with spectral display; complete		BR
93227		BR	93321 follow-up or limited study		BR
93230			93325 Doppler color flow velocity mapping (list separately in addition to code for echocardiography 93307, 93308, 93320, 93321)		BR
			93350 Echocardiography, real-time with image documentation (2D), with or without M-mode recording, during rest and cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, including electrocardiographic monitoring, with interpretation and report		BR
93231		BR	(Procedure 93320 is often performed in combination with M-Mode or 2-dimensional echocardiography)		
93232		BR	(For echocardiography as a radiologic procedure, see 76620-76632)		
93233		BR	<b>Cardiac catheterization</b>		
93235			Cardiac catheterization procedure includes introduction, positioning, and repositioning of catheter(s), when necessary, recording of intracardiac and intravascular pressure, obtaining blood samples for measurement of blood gases and/or dye (or other) dilution curves and cardiac output measurement (dye dilution, Fick or other method, with or without rest and exercises and/or other studies) with or without electrode catheter placement, final evaluation and report.		
93236		BR	(For radiological procedures, see 75500-75767)		
93237		BR	Listed values are for the physician's services only and include usual preassessment of cardiac problem and recording of intra-cardiac pressure.		
93255		BR	(For consultation services, see 90600-90630)		
<del>(93258)</del>			93501	350.0	5.0
93259		BR	Right heart catheterization((only))		
93262		BR	(For bundle of His recording, see 93600)		
93263	200.0	BR	93503	200.0	5.0
93266			Insertion and placement of flow directed catheter (e.g., Swan-Ganz)((with or without balloon tip, when placed)) for monitoring purposes((collection of blood, and/or angiography))		
93268		BR	(For subsequent monitoring, see 99150, 99151)		
<del>(93269)</del>		BR))	93505	200.0	5.0
			93510	200.0	5.0
			93511	200.0	5.0
			93514	200.0	5.0
			93524	400.0	5.0
			93526	450.0	5.0
			(For chest fluoroscopy, see 71034, 76000)		
<b>CARDIAC FLUOROSCOPY</b>					
93280		BR			

	Unit Value	Basic Anes@		Unit Value	Basic Anes@
93527 Combined right heart catheterization and transeptal left heart catheterization through intact septum (with or without retrograde left heart catheterization) . . . . .	400.0	5.0	93550 with selective visualization of bypass graft (this code number is to be used when procedure 93549 is combined with procedure 93551) . . . . .		BR
93528 Combined right heart catheterization with left ventricular puncture (with or without retrograde left heart catheterization) . . . . .	400.0	5.0	93551 Selective opacification of aortocoronary bypass grafts, one or more coronary arteries (injection of radiopaque material may be made by hand) . . . . .		BR
93529 Combined right heart catheterization and left heart catheterization through existing septal opening (with or without retrograde left heart catheterization) . . . . .		BR	93552 Combined left heart catheterization, selective coronary angiography, one or more coronary arteries, selective left ventricular cineangiography and visualization of bypass grafts; (this code number is to be used when procedure ((93550)) 93551 is combined with procedure 93547) . . . . .		BR
93536 Percutaneous insertion of intra-aortic balloon catheter . . . . .		BR	93553 with aortic root aortography (this code number is to be used when procedure 93548 is combined with procedure ((93550)) 93551) . . . . .		BR
(For removal of balloon catheter, see 33971)			(For radiographic procedures only, see 75762-75767)		
When injection procedures are performed in conjunction with cardiac catheterization, these services do not include introduction of catheters but do include repositioning of catheters when necessary and use of automatic power injectors. The technical details of angiography, supervision of filing and processing, interpretation and report are not included. For radiological services, see appropriate section.			Codes 93561 and 93562 are not to be used with cardiac catheterization codes.		
93541 Injection procedure during cardiac catheterization; for pulmonary angiography . . . . .	290.0		93561 Indicator dilution studies such as dye or thermal dilution, including arterial and/or venous catheterization; with cardiac output measurement (separate procedure) . . . . .	50.0	
(For radiological procedures, see 75741-75748)			93562 subsequent measurement of cardiac output . . . . .	20.0	
93542 for selective right ventricular or right atrial angiography . . . . .	290.0		(For radioisotope method of cardiac output, see 78470)		
93543 for selective left ventricular or left atrial angiography . . . . .	290.0		(For unlisted cardiac catheterization procedure, see 93799)		
(For radiological procedures, see 75500-75509)					
93544 for aortography . . . . .	290.0		<b>INTRACARDIAC ELECTROPHYSIOLOGICAL PROCEDURES</b>		
(For radiological procedures, see 75600-75628)			93600 Bundle of His recording . . . . .	200.0	
93545 for selective coronary angiography (injection of radiopaque material may be by hand) . . . . .	290.0		93602 Intra-atrial recording . . . . .	BR	
(For radiological procedures, see 75750-75755)			93603 Right ventricular recording . . . . .	BR	
Codes 93546-93553 include the introduction of catheter (percutaneous or cutdown), placement or repositioning, and injection of the contrast media or dye.			((93605 with mapping) . . . . .	BR))	
93546 Combined left heart catheterization and left ventricular angiography . . . . .	290.0		93607 Left ventricular recording . . . . .	BR	
93547 Combined left heart catheterization, selective coronary angiography, one or more coronary arteries, and selective left ventricular angiography (this code number is to be used when procedure 93510 is combined with procedures 93543 and 93545) . . . . .	350.0		((93608 with mapping) . . . . .	BR))	
93548 Combined left heart catheterization, selective coronary angiography, one or more coronary arteries, selective left ventriculography, with aortic root aortography . . . . .	300.0		93609 Intra-atrial recording and/or intra-atrial mapping of tachycardia site(s) with catheter manipulation to record from multiple sites to identify origin of tachycardia . . . . .	BR	
93549 Combined right and left heart catheterization, selective coronary angiography, one or more coronary arteries, selective left ventricular angiography; (this code number is to be used when procedure 93547 is combined with right heart catheterization) . . . . .	400.0		93610 Intra-atrial pacing . . . . .	BR	
			93612 Intra-atrial pacing . . . . .	BR	
			((93614 Bundle of His pacing) . . . . .	BR))	
			93615 Esophageal recording of atrial electrogram with or without ventricular electrogram(s); . . . . .	BR	
			93616 with pacing . . . . .	BR	
			93618 Induction of arrhythmia by electrical pacing . . . . .	BR	
			(For intracardiac phonocardiogram, see 93210)		
			((93630 Left ventricular endocardial resection, with or without cryoablation, with intra-operative mapping) . . . . .	BR))	
			93620 Comprehensive electrophysiologic evaluation with right atrial pacing and recording, right ventricular pacing and recording, His bundle recording, and induction of arrhythmia, (This code is to be used when 93600 is combined with 93602, 93603, 93610, 93612, and 93618); . . . . .	BR	
			93621 with left atrial recordings from coronary sinus or left atrium with or without pacing . . . . .	BR	
			93622 with left ventricular recordings with or without pacing . . . . .	BR	



	Unit Value	Basic Anes@
93623 <u>Programmed stimulation and pacing after intravenous drug infusion (Use this code with 93620, 93621, 93622) . . . . .</u>	BR	
93624 <u>Electrophysiologic follow-up study with pacing and recording to test effectiveness of therapy . . . . .</u>	BR	
93631 <u>Intra-operative cardiac pacing and mapping</u>	BR	
93640 <u>Electrophysiologic evaluation of cardioverter-defibrillator lead and/or device</u>	BR	
93650 <u>Intracardiac catheter ablation of arrhythmogenic focus or tract(s), including intracardiac mapping, with or without temporary pacemaker placement . . . . .</u>	BR	
Other vascular studies		
(For arterial cannulization and recording of direct arterial pressure, see 36620)		
(For radiographic injection procedures, see 36000-36299)		
(For vascular cannulization for hemodialysis, see 36800-36820)		
(For chemotherapy for malignant disease, see 96500-96549)		
(For penile plethysmography, see 54240)		
93720 Plethysmography, total body with interpretation and report . . . . .	30.0	
93721 tracing only, without interpretation and report . . . . .	10.0	
93722 interpretation and report only . . . . .	25.0	
(For regional plethysmography, see 93850-93910)		
93731 Electronic analysis of dual-chamber internal pacemaker system (may include rate, pulse amplitude and duration, configuration of wave form, and/or testing of sensory function of pacemaker); without reprogramming . . .	BR	
93732 with reprogramming . . . . .	75.0	
93733 telephonic analysis . . . . .	15.00	
93734 Electronic analysis of single-chamber internal pacemaker system (may include rate, pulse amplitude and duration, configuration of wave form, and/or testing of sensory function of pacemaker); without reprogramming .	BR	
93735 with reprogramming . . . . .	50.0	
93736 telephonic analysis . . . . .	15.00	
93740 Temperature gradient studies . . . . .	BR	
93760 Thermogram; cephalic . . . . .	BR	
93762 peripheral . . . . .	noncovered procedure	
93770 Venous pressure determination . . . . .	10.0	
(For central venous cannulization and pressure measurements, see 36488-36491, 36500)		
93784 Ambulatory blood pressure monitoring, utilizing a system such as magnetic tape and/or computer disc, for 24 hours; including recording, scanning analysis, interpretation and report . . . . .	BR	
93786 recording only . . . . .	BR	
93788 scanning analysis with report . . . . .	BR	
93790 physician review with interpretation and report . . . . .	BR	
OTHER PROCEDURES		
93797 <u>Physician services for outpatient cardiac rehabilitation; without continuous ECG monitoring (per session) . . . . .</u>	BR	

	Unit Value	Basic Anes@
93798 <u>with continuous ECG monitoring (per session) . . . . .</u>	BR	
93799 Unlisted cardiovascular service or procedure.	BR	
<b>NONINVASIVE PERIPHERAL VASCULAR DIAGNOSTIC STUDIES</b>		
Peripheral vascular studies include patient care required to perform the studies, supervision of the studies and interpretation of study results with copies for patient records of hard copy output or imaging when provided.		
<b>CEREBROVASCULAR ARTERIAL STUDIES</b>		
93850 Noninvasive studies of cerebral arteries other than carotid (e.g., periorbital flow direction with arterial compression, periorbital photoplethysmography with arterial compression, ocular plethysmography with brachial blood pressure, ocular and ear pulse wave timing) . . . . .		BR
93860 Noninvasive studies of carotid arteries, nonimaging (e.g., phonoangiography with or without spectrum analysis, flow velocity pattern evaluation, analog velocity wave form analysis, diastolic flow evaluation, vertebral arteries flow direction measurement) . . . . .		BR
93870 Noninvasive studies of carotid arteries, imaging (e.g., flow imaging by ultrasonic arteriography, high resolution B-scan with or without pulsed Doppler flow evaluation, Doppler flow or duplex scan with spectrum analysis) .	175.4	
<b>LIMB ARTERIAL STUDIES (INCLUDING DIGITS)</b>		
93890 Noninvasive studies of upper extremity arteries (e.g., segmental blood pressure measurements, continuous wave Doppler analog wave form analysis, evocative pressure response to exercise or reactive hyperemia, photoplethysmographic or pulse volume digit wave form analysis, flow velocity signals) . . .		114.4
93910 Noninvasive studies of lower extremity arteries (e.g., segmental blood pressure measurements, continuous wave Doppler analog wave form analysis, evocative pressure response to exercise or reactive hyperemia, photoplethysmography or pulse volume digit wave form analysis, flow velocity signals) . . .		80.0
<b>VENOUS STUDIES</b>		
93950 Noninvasive studies of extremity veins (e.g., Doppler studies with evaluation of venous flow patterns and responses to compression and other maneuvers, phleborheography, impedance plethysmography) . . . . .		76.3
93960 Quantitative venous flow studies (e.g., capacitance and outflow measurement of calf, measurement of calf venous reflux, quantitative photoplethysmography) . . . . .		BR

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-21-075 ALLERGY AND CLINICAL IMMUNOLOGY.**

**NOTES**

**ALLERGY SENSITIVITY TESTS:** Allergy testing and treatment require prior authorization. The performance and evaluation of selective cutaneous and mucous membrane tests in correlation with the history, physical examination, and other observations of the patient. The

number of tests performed should be judicious and dependent upon the history, physical findings, and clinical judgment. All patients should not necessarily receive the same tests nor the same number of sensitivity tests.

**IMMUNOTHERAPY (DESENSITIZATION, HYPOSENSITIZATION):** The parenteral administration of allergenic extracts as antigens at periodic intervals, usually on an increasing dosage scale to a dosage which is maintained as maintenance therapy. Indications for immunotherapy are determined by appropriate diagnostic procedures coordinated with clinical judgment and knowledge of the natural history of allergic diseases.

**OTHER THERAPY:** For medical conferences on the use of mechanical and electronic devices (precipitators, air conditioners, air filters, humidifiers, dehumidifiers), climatotherapy, physical therapy, occupational and recreational therapy, see 95105.

(For definitions of LEVELS OF SERVICE, see the Introduction)

(For medical service procedures, see 90000-90699)

(For skin testing of bacterial, viral, fungal extracts, etc., see 86450-86585)

**SPECIAL DIAGNOSTIC PROCEDURES (ALLERGY TESTING)**

	Unit Value
95000 Percutaneous tests (scratch, puncture, prick) with allergenic extracts; up to 30 tests	10.0
95001 31-60 tests each test	1.0
95002 61-90 tests each test	1.5
95003 more than 90 tests each test	2.0
95005 Percutaneous tests (scratch, puncture, prick) with antibiotics, biologicals, stinging insects; 1-5 tests	10.0
95006 6-10 tests each test	1.0
95007 11-15 tests each test	1.5
95011 more than 15 tests each test	2.0
95014 Intracutaneous (intradermal) tests, with antibiotics, biologicals, stinging insects, immediate reaction 15-20 minutes; 1-5 tests	15.0
95016 6-10 tests each test	2.0
95017 11-15 tests each test	2.5
95018 more than 15 tests each test	3.0
95020 Intracutaneous (interdermal) tests with allergenic extracts, immediate reaction—15 to 20 minutes; up to 10 tests	15.0
95021 11-20 tests, each test	2.0
95022 21-30 tests each test	2.0
95023 more than 30 tests each test	2.5
95027 Skin end point titration	BR
95030 Intracutaneous (intradermal) tests with allergenic extracts, delayed reaction—24 to 72 hours, including reading; 2 tests	20.0
95031 3-4 tests each test	2.0
95032 5-6 tests each test	2.5
95033 7-8 tests each test	3.0
95034 more than 8 tests each test	3.5
95040 Patch test, one to ten tests	10.0
95041 11-20 tests each test	2.0
95042 21-30 tests each test	2.5
95043 more than 30 tests each test	3.0
95050 Photo-patch test, one to ten tests	10.0
95051 more than 10 tests each test	4.0
95056 Photo test	10.0
95060 Mucous membrane test ophthalmic	10.0
95065 Direct nasal mucous membrane test	10.0
95070 Inhalation bronchial challenge testing (not including necessary pulmonary function tests); with histamine, methacholine, or similar compounds	BR

95071 with antigens or gases, specify	BR
(For pulmonary function tests, see 94060, 94070)	
95075 Ingestion challenge test (e.g., metabisulfite)	BR
95078 Provocative testing (e.g., Rinkel test)	BR
95080 Passive transfer test one to ten tests	100.0
95081 11-20 tests each test	2.0
95082 more than 20 tests each test	3.0

(For allergy laboratory tests, see 86000-86699)

(For intravenous therapy for severe or intractable allergic disease, see 90798)

(For preparation of antigens, materials supplied by physician, etc., see 99070)

95105 Medical conference services (e.g., use of mechanical and electronic devices, climatotherapy, breathing exercises and/or postural drainage)	50.0
--	------

(For summary conference or for therapeutic conference by physician following completion of diagnostic workup, including discussion, avoidance, elimination, symptomatic treatment, and immunotherapy, see 90040-90070)

(For prolonged conference, see 99155-99156)

**ALLERGY IMMUNOTHERAPY**

95115 Professional services for allergen immunotherapy not including provision of allergenic extracts; single injection	8.1
95117 multiple injections	9.7
95120 Immunotherapy, in prescribing physician's office or institution, including provision of allergenic extract; single antigen	20.0
95125 multiple antigens (specify number of injections)	30.0
95130 single stinging insect venom	20.0
95131 two stinging insect venoms	BR
95132 three stinging insect venoms	BR
95133 four stinging insect venoms	BR
95134 five stinging insect venoms	BR
95135 Professional services for the supervision and provision of antigens for allergen immunotherapy (specify number of vials); single antigen, single dose vials	20.0
95140 multiple antigens, single dose vials	30.0
95145 Professional services for the supervision and provision of antigens for allergen immunotherapy (specify number of treatments or total volume); single stinging insect venom, multiple dose vials	20.0
95146 two single stinging insect venoms, multiple dose vials	BR
95147 three single stinging insect venoms, multiple dose vials	BR
95148 four single stinging insect venoms, multiple dose vials	BR
95149 five single stinging insect venoms, multiple dose vials	BR
95150 Professional services for the supervision and provision of antigens for allergen immunotherapy (specify number of treatments or total volume); single or multiple antigens, one multiple dose vial	25.0
95155 single or multiple antigens, two or more multiple dose vials	35.0

(For allergy injection(s) by other than the prescribing physician, see 90782)

95170 whole body extract of biting insect or other arthropod	BR
95180 Rapid desensitization procedure, each hour (e.g., insulin, penicillin, horse serum)	BR
95199 Unlisted allergy/clinical immunologic service or procedure	BR

(For skin testing of bacterial, viral, fungal extracts, see 95030-95034, 86455-86585)

(For special reports on allergy patients, see 99080)

(For testing procedures such as radioallergosorbent testing (RAST), rat mast cell technique (RMCT), mast cell degranulation test (MCDT), lymphocytic transformation test (LTT), leukocyte histamine release (LHR), migration inhibitory factor test (MIF), transfer factor test (TFT), nitroblue tetrazolium dye test (NTD), see Immunology section in Pathology or use 95199)

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

WAC 296-21-086 CHEMOTHERAPY INJECTIONS. Procedures ((96500)) 96400-96549 are independent of the patient's office visit. Either may occur independently from the other on any given day, or they may occur sequentially on the same day. Intravenous chemotherapy injections are administered by a physician or by a qualified assistant under supervision of the physician.

Preparation of chemotherapy agent(s) is included in the service for administration of the agent.

Regional (isolation) chemotherapy perfusion should be reported using existing codes describing complex arterial chemotherapy. Placement of the catheter should be reported using the appropriate code from the cardiovascular surgery section. Adjunctive procedures such as lymph node dissection, wide local excision and skin grafts should also be identified separately.

	Unit Value
<del>(96500 Chemotherapy injection, intravenous, single premixed agent, administered by qualified assistant under supervision of physician or by physician; by push technique</del> .....	<del>BR</del>
<del>96501 by infusion technique</del> .....	<del>BR</del>
<del>96504 Chemotherapy injection, intravenous, multiple premixed agents, administered by qualified assistant under supervision of physician or by physician; by push technique</del> .....	<del>BR</del>
<del>96505 by infusion technique</del> .....	<del>BR</del>
<del>96508 Chemotherapy injection, intravenous, complex, using one or more agents requiring mixing, administered by qualified assistant under supervision of physician or by physician; by push technique</del> .....	<del>BR</del>
<del>96509 by infusion technique</del> .....	<del>BR</del>
<del>96510 by infusion technique, prolonged, requiring attendance up to one hour</del> .....	<del>BR</del>
<del>96511 by infusion technique, prolonged, each additional hour up to a total of eight hours</del> .....	<del>BR</del>
<del>96512 by infusion technique, prolonged, up to a total of several days, involving the use of portable pump</del> .....	<del>BR</del>
<del>(Use 96512 in addition to code for intravenous catheterization; see 36000-36010, 36400-36425, 36488-36491))</del>	
<del>(Report separate codes for each parenteral method of administration employed when chemotherapy is administered by different techniques.)</del>	
<u>96400 Chemotherapy administration; subcutaneous or intramuscular, with or without local anesthesia</u> ..	<u>BR</u>
<u>96408 Chemotherapy administration, intravenous; push technique</u> .....	<u>BR</u>
<u>96410 infusion technique, up to one hour</u> .....	<u>BR</u>

<u>96412 infusion technique, one to 8 hours, each additional hour</u> .....	<u>BR</u>
<u>96414 infusion technique, initiation of prolonged infusion (more than 8 hours), requiring the use of a portable or implantable pump</u> .....	<u>BR</u>
<u>(For pump or reservoir refilling, see 96520, 96530)</u>	
<u>96420 Chemotherapy administration, intra-arterial; push technique</u> .....	<u>BR</u>
<u>96422 infusion technique, up to one hour</u> .....	<u>BR</u>
<u>96423 infusion technique, one to 8 hours, each additional hour</u> .....	<u>BR</u>
<u>96425 infusion technique, initiation of prolonged infusion (more than 8 hours), requiring the use of a portable or implantable pump</u> .....	<u>BR</u>
<u>(For pump or reservoir refilling, see 96520, 96530)</u>	
<u>96440 Chemotherapy administration into pleural cavity, requiring thoracentesis</u> .....	<u>BR</u>
<u>96445 Chemotherapy administration into peritoneal cavity, requiring paracentesis</u> .....	<u>BR</u>
<u>96450 Chemotherapy administration, into CNS (e.g., intrathecal), requiring lumbar puncture</u> .....	<u>BR</u>
<u>(For intravesical (bladder) chemotherapy administration, see 51720)</u>	
<u>(For insertion of subarachnoid catheter for infusion of drug, see 63750, 63780)</u>	
<u>96520 Portable pump refilling and maintenance (use 96520 in addition to 96512)</u> .....	<u>BR</u>
<del>((96524 Chemotherapy injection, complex, administered by physician, arterial infusion technique</del> .....	<del>BR</del>
<del>96526 Chemotherapy injection, complex, administered by physician, prolonged intra-arterial therapy infusion technique, up to several months</del> .....	<del>BR))</del>
<u>(Use 96526 in addition to code for intra-arterial catheterization; see 36100-36299, 36640-36660)</u>	
<u>(For monitoring of an intra-arterial chemotherapy, drip or forced infusion, see 36620-36625)</u>	
<u>(For implantation of infusion pump in hepatic artery system for liver chemotherapy, see 36260-36262)</u>	
<u>96530 ((Implantable pump filling and maintenance)) Refilling and maintenance of implantable pump or reservoir</u> .....	<u>BR</u>
<u>((Use 96530 in addition to 96526)</u>	
<u>96535 Chemotherapy injection, complex, requiring thoracentesis and/or paracentesis, administered by physician, intracavitary</u> .....	<u>BR</u>
<u>96538 Chemotherapy injection, requiring lumbar puncture, administered by physician</u> .....	<u>BR</u>
<u>96540 Chemotherapy injection, intrathecal via reservoir, single or multiple agents, administered by physician</u> .....	<u>BR))</u>
<u>(Access of pump port is included in filling of implantable pump)</u>	
<u>(For insertion of subarachnoid catheter for infusion of drug, see 63750)</u>	
<u>96545 Provision of chemotherapy agent</u> .....	<u>BR</u>
<u>(For radioactive isotope therapy see 79000-79999)</u>	
<u>96549 Unlisted chemotherapy procedure</u> .....	<u>BR</u>

**AMENDATORY SECTION** (Amending Order 86-19, filed 2/28/86, effective 4/1/86)

**WAC 296-22-020 SKIN, SUBCUTANEOUS AND AREOLAR TISSUES.**

	Unit Value	Follow-up Days=	Basic Anes@
<b>INCISION</b>			
*10000 Incision and drainage of infected or noninfected subaceous cyst; one lesion . . . . .	<del>(0.4)</del> 0.7	0	3.0
10001 second lesion . . . . .	<del>(0.2)</del> 0.4	0	3.0
10002 more than two lesions . . . . .	<del>(0.1)</del> 0.2	0	3.0
10003* Incision and drainage of infected or noninfected epithelial inclusion cyst ("sebaceous cyst") with complete removal of sac and treatment of cavity . . . . .	<del>(0.8)</del> 0.9	0	3.0
(For excision, see 11400, et seq.)			
*10020 Incision and drainage of furuncle . . . . .	<del>(0.4)</del> 0.7	0	3.0
*10040 Acne surgery: (e.g., marsupialization, opening, or removal of multiple milia, comedones, cysts, pustules) . . . . .	<del>(0.3)</del> 0.4	0	3.0
*10060 Incision and drainage of abscess (e.g., carbuncle, suppurative hidradenitis, and other cutaneous or subcutaneous abscesses); simple . . . . .	<del>(0.4)</del> 0.7	0	3.0
10061 complicated . . . . .	<del>(BR+)</del> 1.4	0	3.0
*10080 Incision and drainage of pilonidal cyst; simple . . . . .	<del>(0.4)</del> 0.7	0	3.0
10081 complicated . . . . .	<del>(BR+)</del> 1.1	0	3.0
(For excision of pilonidal cyst, see 11770-11772)			
*10100 Incision and drainage of onychia or paronychia, single or simple . . . . .	<del>(0.4)</del> 0.8	0	3.0
10101 multiple or complicated . . . . .	<del>(BR+)</del> 1.4	0	3.0
*10120 Incision and removal of foreign body, subcutaneous tissues; simple . . . . .	<del>(0.4)</del> 0.7	0	3.0
10121 complicated . . . . .	<del>(BR+)</del> 1.8	0	3.0
*10140 Incision and drainage of hematoma, simple . . . . .	<del>(0.4)</del> 0.7	0	3.0
10141 complicated . . . . .	<del>(BR+)</del> 1.4	0	3.0
*10160 Puncture aspiration of abscess, hematoma, bulla, or cyst . . . . .	<del>(0.3)</del> 0.5	0	3.0
10180 Incision and drainage, complex, postoperative wound infection . . . . .	BR		3.0
(For secondary closure of surgical wound, see 12020, 12021, 13160)			

**AMENDATORY SECTION** (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

**WAC 296-22-021 EXCISION-DEBRIDEMENT.**

	Unit Value	Follow-up Days=	Basic Anes@
<b>DEBRIDEMENT</b>			
(For dermabrasions, see 15780-15791)			
(For nail debridement, see 11700-11711)			
(For burn(s), see 16000-16035)			
*11000 Debridement of extensive eczematous or infected skin; up to 10% of body surface . . . . .	<del>(0.4)</del> 0.5	0	3.0
11001 each additional 10% of the body surface . . . . .	<del>(0.2)</del> 0.3	0	3.0
11040 Debridement; skin, partial thickness . . . . .	<del>(BR+)</del> 0.5	0	3.0
11041 skin, full thickness . . . . .	<del>(BR)</del> 1.1	0	3.0
11042 skin and subcutaneous tissue . . . . .	<del>(BR)</del> 1.4	0	3.0
11043 skin, subcutaneous tissue, and muscle . . . . .	<del>(BR)</del> 2.1	0	3.0
11044 skin, subcutaneous tissue, muscle, and bone . . . . .	<del>(BR)</del> 3.4	0	3.0
<b>PARING, CURETTMENT, OR SHAVING</b>			
11050* Paring, curettment, or shaving of benign lesion with or without chemical cauterization (such as verrucae or clavi); single lesion . . . . .	0.5	0	3.0
11051 two to four lesions . . . . .	<del>(0.6)</del> 0.2	0	3.0
11052 more than four lesions . . . . .	<del>(0.7)</del> 0.2	0	3.0
<b>EXCISION AND SIMPLE CLOSURE</b>			
(Not reconstructive surgery; for reconstructive surgery see repair-complex)			
(For electro-surgical and other methods, see 17000 et seq.)			
<b>BIOPSY</b>			
11100 Biopsy of skin, subcutaneous tissue and/or mucous membrane (including simple closure), unless otherwise listed (separate procedure); one lesion . . . . .	<del>(0.6)</del> 0.9	7	3.0
11101 each additional lesion . . . . .	<del>(0.2)</del> 0.6	7	3.0
(For biopsy of conjunctiva, see 68100; eyelid, see 67810)			
<b>EXCISION-BENIGN LESIONS</b>			
Excision (including simple closure) of benign lesions of skin or subcutaneous tissues (e.g., cicatricial, fibrous, inflammatory, congenital, cystic lesions), including local anesthesia. See appropriate size and area below.			

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
(For electro-surgical and other methods see 17000 et seq.)				11450	Excision of skin and subcutaneous tissue for hidradenitis, axillary; with primary suture . . . . . (( <del>DR</del> ))		
*11200	Excision (including simple closure or ligature strangulation), skin tags, multiple fibrocuteaneous tags, any area; up to 15. . . . .	<del>(+0.4)</del> <u>0.6</u>	<del>(-0)</del> <u>7</u>	3.0			
11201	each additional 10 lesions . . . . .	<del>(+0.2)</del> <u>0.4</u>	<del>(-0)</del> <u>7</u>	3.0	11451	with other closure . . . . .	<del>(+0.9)</del> <u>1.4</u> 15 3.0
(For electro-surgical destruction, see 17200, 17201)				11462	Excision of skin and subcutaneous tissue for hidradenitis, inguinal; with primary suture . . . . . (( <del>DR</del> ))		
11400	Excision, benign lesion, except skin tag (unless listed elsewhere), trunk, arms or legs; lesion diameter 0.5 cm or less . . . . .	<del>(+0.6)</del> <u>0.7</u>	15	3.0	11463	with other closure . . . . .	<del>(+1.4)</del> <u>1.8</u> 15 3.0
11401	lesion diameter 0.6 to 1.0 cm . . . . .	<del>(+0.8)</del> <u>0.9</u>	15	3.0	11470	Excision of skin and subcutaneous tissue for hidradenitis, perianal, perineal, or umbilical; with primary closure . . . . . (( <del>DR</del> ))	<del>(+1.8)</del> <u>2.3</u> 15 3.0
11402	lesion diameter 1.1 to 2.0 cm . . . . .	<del>(+1.0)</del> <u>1.1</u>	15	3.0	11471	with other closure . . . . .	<del>(+2.3)</del> <u>2.3</u> 15 3.0
11403	lesion diameter 2.1 to 3.0 cm . . . . .	<del>(+1.2)</del> <u>1.4</u>	15	3.0	(When skin graft or flap is used for closure, use appropriate procedure code in addition)		
11404	lesion diameter 3.1 to 4.0 cm . . . . .	<del>(+1.4)</del> <u>1.6</u>	15	3.0	(For bilateral procedure, add modifier -50)		
11406	lesion diameter over 4.0 cm . . . . .	<del>(+1.6)</del> <u>1.9</u>	15	3.0	<b>EXCISION-MALIGNANT LESIONS</b>		
(For unusual or complicated excision, add modifier -22)				Excision (including simple closure) or treatment by any other method (except radiation or chemosurgery) of malignant lesion of skin, including local anesthesia, each lesion:			
11420	Excision, benign lesion, except skin tag (unless listed elsewhere), scalp, neck, hands, feet, genitalia; lesion diameter 0.5 cm or less . . . . .	<del>(+0.8)</del> <u>0.7</u>	15	3.0	11600	Excision, malignant; lesion, trunk, arms, or legs; lesion diameter 0.5 cm or less . . . . .	1.2 90 3.0
11421	lesion diameter 0.6 to 1.0 cm . . . . .	<del>(+1.0)</del> <u>0.9</u>	15	3.0	11601	lesion diameter 0.6 to 1.0 cm . . . . .	<del>(+1.6)</del> <u>1.5</u> 90 3.0
11422	lesion diameter 1.1 to 2.0 cm . . . . .	<del>(+1.2)</del> <u>1.3</u>	15	3.0	11602	lesion diameter 1.1 to 2.0 cm . . . . .	<del>(+2.0)</del> <u>1.9</u> 90 3.0
11423	lesion diameter 2.1 to 3.0 cm . . . . .	<del>(+1.4)</del> <u>1.6</u>	15	3.0	11603	lesion diameter 2.1 to 3.0 cm . . . . .	<del>(+2.4)</del> <u>2.2</u> 90 3.0
11424	lesion diameter 3.1 to 4.0 cm . . . . .	<del>(+1.6)</del> <u>2.0</u>	15	3.0	11604	lesion diameter 3.1 to 4.0 cm . . . . .	<del>(+2.8)</del> <u>2.5</u> 90 3.0
11426	lesion diameter over 4.0 cm . . . . .	<del>(+1.8)</del> <u>2.3</u>	15	3.0	11606	lesion diameter over 4.0 cm . . . . .	<del>(+3.2)</del> <u>2.9</u> 90 3.0
(For unusual or complicated excision, add modifier -22)				11620	Excision, malignant lesion, scalp, neck, hands, feet, genitalia; lesion diameter 0.5 cm or less . . . . . (( <del>2-0</del> ))		
11440	Excision, other benign lesion (unless listed elsewhere), face, ears, eyelids, nose, lips, mucous membrane; lesion diameter 0.5 cm or less . . . . .	<del>(+1.0)</del> <u>0.9</u>	15	3.0	11621	lesion diameter 0.6 to 1.0 cm . . . . .	<del>(+3.0)</del> <u>2.7</u> 90 3.0
11441	lesion diameter 0.6 to 1.0 cm . . . . .	<del>(+1.2)</del> <u>1.3</u>	15	3.0	11622	lesion diameter 1.1 to 2.0 cm . . . . .	<del>(+4.0)</del> <u>3.6</u> 90 3.0
11442	lesion diameter 1.1 to 2.0 cm . . . . .	<del>(+1.4)</del> <u>1.6</u>	15	3.0	11623	lesion diameter 2.1 to 3.0 cm . . . . .	<del>(+5.0)</del> <u>4.5</u> 90 3.0
11443	lesion diameter 2.1 to 3.0 cm . . . . .	<del>(+1.6)</del> <u>2.0</u>	15	3.0	11624	lesion diameter 3.1 to 4.0 cm . . . . .	<del>(+6.0)</del> <u>5.4</u> 90 3.0
11444	lesion diameter 3.1 to 4.0 cm . . . . .	<del>(+1.8)</del> <u>2.3</u>	15	3.0	11626	lesion diameter over 4.0 cm . . . . .	<del>(+7.0)</del> <u>6.3</u> 90 3.0
11446	lesion diameter over 4.0 cm . . . . .	<del>(+2.0)</del> <u>2.7</u>	15	3.0	11640	Excision, malignant lesion, face, ears, eyelids, nose, lips; lesion diameter 0.5 cm or less . . . . . (( <del>3-0</del> ))	<del>(+3.0)</del> <u>2.7</u> 90 3.0
(For unusual or complicated excision, add modifier -22)				11641	lesion diameter 0.6 to 1.0 cm . . . . . (( <del>4.0</del> ))		
(For eyelids involving more than skin, see also 67800 et seq.)				11642	lesion diameter 1.1 to 2.0 cm . . . . . (( <del>5.0</del> ))		
				11643	lesion diameter 2.1 to 3.0 cm . . . . . (( <del>6.0</del> ))		
				11644	lesion diameter 3.1 to 4.0 cm . . . . . (( <del>7.0</del> ))		

	Unit Value	Follow-up Days=	Basic Anes@
11646 lesion diameter over 4.0 cm . . . . .	<del>((8-0))</del> 7.2	90	3.0
(For eyelids involving more than skin, see also 67800 et seq.)			
<b>NAILS</b>			
(For drainage of paronychia or onychia, see 10100, 10101)			
*11700 Debridement nails, manual, five or less . . . . .	<del>((*0-3))</del> 0.4	0	3.0
11701 each additional five or less . . . . .	<del>((0-15))</del> 0.3	0	3.0
*11710 Debridement of nails, electric grinder, five or less . . . . .	<del>((*0-4))</del> 0.5	0	3.0
11711 each additional five or less . . . . .	<del>((0-2))</del> 0.4	0	3.0
*11730 Avulsion of nail plate, partial or complete, simple; single . . . . .	<del>((*0-4))</del> 0.7	0	3.0
11731 second nail plate . . . . .	<del>((0-2))</del> 0.5	0	3.0
11732 each additional nail plate . . . . .	<del>((0-1))</del> 0.5	0	3.0
11740 Evacuation of subungual hematoma . . . . .	<del>((0-3))</del> 0.5	0	3.0
11750 Excision of nail and nail matrix, partial or complete (e.g., ingrown or deformed nail), for permanent removal . . . . .	<del>((2-0-30))</del> 2.3	0	3.0
11752 with amputation of tuft of distal phalanx . . . . .	<del>((3-0-30))</del> 3.4	0	3.0
(For skin graft, if used, see 15050)			
11760 Reconstruction of nail bed; simple . . . . .	<del>((2.5-0))</del> 2.7	60	3.0
11762 complicated . . . . .	<del>((3-0-0))</del> 4.1	90	3.0
11765 Wedge excision of skin of nail fold (e.g., for ingrown toenail) . . . . .	<del>((1-2-0))</del> 1.1	60	3.0
<b>MISCELLANEOUS</b>			
(For incision of pilonidal cyst, see 10080, 10081)			
11770 Excision of pilonidal cyst or sinus, simple . . . . .	2.0	30	3.0
11771 extensive . . . . .	<del>((7-0))</del> 5.9	60	3.0
11772 complicated . . . . .	<del>((BR-1))</del> 7.2	60	3.0
(For hemangioma, see 11400-11446, 13100-15730)			
(For hidradenitis, see 10060-10061, 11450-11471)			
(For lipoma, see 11400-11446, 13100-15730)			
(For lymph node dissection, see 38700-38780)			
(For ulcer, vascular or inflammatory, see 11400-11446, 13100-15730)			

**AMENDATORY SECTION** (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

**WAC 296-22-022 INTRODUCTION.**

	Unit Value	Follow-up Days=	Basic Anes@
*11900 Injection, intralesional; up to and including seven lesions . . . . .	<del>((*0-4))</del> 0.5	0	3.0
*11901 more than seven lesions . . . . .	<del>((*0-72))</del> 0.5	0	3.0
(For veins, see 36470, 36471)			
11920 Tattooing, intradermal introduction of insoluble opaque pigments to correct color defects of skin; 6.0 sq cm or less . . . . .	<del>((BR))</del> 4.5	90	3.0
11921 6.1 to 20.0 sq cm . . . . .	<del>((BR))</del> 9.0	90	3.0
11922 each additional 20.0 sq cm . . . . .	<del>((BR))</del> 4.5	90	3.0
11950 Subcutaneous injection of "filling" material (e.g., silicone); 1 cc or less . . . . .	<del>((BR))</del> 1.8	30	3.0
11951 1.1 to 5 cc . . . . .	<del>((BR))</del> 3.6	30	3.0
11952 5.1 to 10 cc . . . . .	<del>((BR))</del> 7.2	30	3.0
11954 over 10 cc . . . . .	<del>((BR))</del> BR	30	3.0
11960 Insertion of tissue expander(s) . . . . .	<del>((BR))</del> 11.3	90	3.0
11970 Replacement of tissue expander with permanent prosthesis . . . . .	<del>((BR))</del> 13.6	90	3.0
11971 Removal of tissue expander(s) without insertion of prosthesis . . . . .	<del>((2-0))</del> 1.8	30	3.0

**AMENDATORY SECTION** (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

**WAC 296-22-023 REPAIR.** The repair of wounds may be classified as simple, intermediate or complex.

**SIMPLE REPAIR** is used when the wound is superficial; i.e., involving skin and/or subcutaneous tissues, without significant involvement of deeper structures, and which requires simple suturing. For closure with adhesive strips, list appropriate visit only.

**INTERMEDIATE REPAIR** includes the repair of wounds that, in addition to the above, require layer closure. Such wounds usually involve deeper layers such as fascia or muscle, to the extent that at least one of deeper layers requires separate closure.

**COMPLEX REPAIR** includes the repairs of wounds requiring reconstructive surgery, complicated wound closures, skin grafts or unusual and time consuming techniques of repair to obtain the maximum functional and cosmetic result. It may include creation of the defect and necessary preparation for repairs or the debridement and repair of complicated lacerations or avulsions.

Instructions for listing services at time of wound repair.

1. The repaired wound(s) should be measured and recorded in centimeters, whether curved, angular or stellate.

2. When multiple wounds are repaired, add together the lengths of those in the same classification (see above) and report as a single item.

When more than one classification of wounds is repaired, list the more complicated as the primary procedure and the less complicated as the secondary procedure, using modifier '-51'.

3. Decontamination and/or debridement: Debridement is considered a separate procedure only when gross contamination requires prolonged cleansing when appreciable amounts of devitalized or contaminated tissue are removed, or when debridement is carried out separately without immediate primary closure. (For extensive debridement of soft tissue and/or bone, see 11040-11044.)

4. Involvement of nerves, blood vessels and tendons: Report under appropriate system (nervous, cardiovascular, musculoskeletal) for repair of these structures. The repair of the associated wound is included in the primary procedure unless it qualifies as a complex wound, in which case modifier '-51' applies.

Simple ligation of vessels in an open wound is considered as part of any wound closure.

Simple "exploration" of nerves, blood vessels or tendons exposed in an open wound is also considered part of the essential treatment of the wound and is not a separate procedure unless appreciable dissection is required.

	Unit	Follow-	
	Value	up	Basic
		Days=	Anes@

**REPAIR-SIMPLE**

(Sum of lengths of repairs)

12001*	Simple repair of superficial wounds of scalp, neck, axillae, external genitalia, trunk and/or extremities (including hands and feet); 2.5 cm or less . . . . .	((0.4 — 0)) 0.9 7	3.0
12002*	2.6 cm to 7.5 cm . . . . .	((0.6 — 0)) 1.3 7	3.0
12004*	7.6 cm to 12.5 cm . . . . .	((0.8 — 0)) 1.6 7	3.0
12005	12.6 cm to 20.0 cm . . . . .	((1.0 — 0)) 2.0 7	3.0
12006	20.1 cm to 30.0 cm . . . . .	((1.2 — 0)) 2.3 7	3.0
12007	over 30.0 cm . . . . .	((BR)) 2.7 7	3.0
12011*	Simple repair of superficial wounds of face, ears, eyelids, nose, lips and/or mucous membranes; 2.5 cm or less . . . . .	((0.6 — 0)) 1.0 7	3.0
12013*	2.6 cm to 5.0 cm . . . . .	((0.8 — 0)) 1.3 7	3.0
12014	5.1 cm to 7.5 cm . . . . .	((1.0 — 0)) 1.5 7	3.0
12015	7.6 cm to 12.5 cm . . . . .	((1.2 — 0)) 1.8 7	3.0
12016	12.6 cm to 20.0 cm . . . . .	((1.4 — 0)) 2.1 7	3.0
12017	20.1 cm to 30.0 cm . . . . .	((1.6 — 0)) 2.5 7	3.0
12018	over 30.0 cm . . . . .	((BR)) 3.0 7	3.0
12020	Treatment of superficial wound dehiscence; simple closure . . . . .	((BR)) 1.4 7	3.0

12021	with packing . . . . .	((BR)) 1.6 7	3.0
-------	------------------------	-----------------	-----

(For extensive or complicated secondary wound closure, see 13160)

**REPAIR-INTERMEDIATE**

12031*	Layer closure of wounds of scalp, axillae, trunk and/or extremities (excluding hands and feet); 2.5 cm or less . . . . .	((0.6 — 0)) 1.1 15	3.0
12032*	2.6 cm to 7.5 cm . . . . .	((0.8 — 0)) 1.5 15	3.0
12034	7.6 cm to 12.5 cm . . . . .	((1.0 — 0)) 2.0 15	3.0
12035	12.6 cm to 20.0 cm . . . . .	((1.2 — 0)) 2.4 15	3.0
12036	20.1 cm to 30.0 cm . . . . .	((1.4 — 0)) 2.9 15	3.0
12037	over 30.0 cm . . . . .	((BR)) 3.3 15	3.0
12041*	Layer closure of wounds of neck, hands, feet and/or external genitalia; 2.5 cm or less . . . . .	((0.8 — 0)) 1.4 15	3.0
12042	2.6 cm to 7.5 cm . . . . .	((1.0 — 0)) 1.8 15	3.0
12044	7.6 cm to 12.5 cm . . . . .	((1.2 — 0)) 2.3 15	3.0
12045	12.6 cm to 20.0 cm . . . . .	((1.4 — 0)) 2.7 15	3.0
12046	20.1 cm to 30.0 cm . . . . .	((1.6 — 0)) 3.2 15	3.0
12047	over 30.0 cm . . . . .	((BR)) 3.6 15	3.0
12051*	Layer closure of wounds of face, ears, eyelids, nose, lips and/or mucous membranes; 2.5 cm or less . . . . .	((1.0 — 0)) 1.4 15	3.0
12052	2.6 cm to 5.0 cm . . . . .	((1.2 — 0)) 2.0 15	3.0
12053	5.1 cm to 7.5 cm . . . . .	((1.4 — 0)) 2.5 15	3.0
12054	7.6 cm to 12.5 cm . . . . .	((1.6 — 0)) 3.1 15	3.0
12055	12.6 cm to 20.0 cm . . . . .	((1.8 — 0)) 3.6 15	3.0
12056	20.1 cm to 30.0 cm . . . . .	((2.0 — 0)) 4.2 15	3.0
12057	over 30.0 cm . . . . .	((BR)) 4.7 15	3.0

**AMENDATORY SECTION** (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

**WAC 296-22-024 REPAIR-COMPLEX.**

(Reconstructive procedures, complicated wound closure, skin grafts, pedicle flaps)

(For full thickness repair of lip or eyelid, see respective anatomical subsections)

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@		
13100	Repair, complex, trunk; 1.1 cm to 2.5 cm	1.2	30	3.0	14001	defect 10.1 sq cm to 30 sq cm	<del>(6-0)</del> 6.8	60	3.0
	(For 1.0 cm or less, see simple or intermediate repairs)				14020	Adjacent tissue transfer or rearrangement, scalp, arms and/or legs; defect up to 10 sq cm	<del>(6-0)</del> 6.8	90	4.0
13101	2.6 cm to 7.5 cm	<del>(3-0)</del> 2.7	30	3.0	14021	defect 10 sq cm to 30 sq cm	<del>(8-0)</del> 8.6	90	4.0
13120	Repair, complex, scalp, arms, and/or legs; 1.1 cm to 2.5 cm	<del>(1-8)</del> 2.3	30	3.0	14040	Adjacent tissue transfer or rearrangement, forehead, cheeks, chin, mouth, neck, axillae, genitalia, hands and/or feet; defect up to 10 sq cm	<del>(8-0)</del> 8.6	60	4.0
	(For 1.0 cm or less, see simple or intermediate repairs)				14041	defect 10 sq cm to 30 sq cm	<del>(10-0)</del> 10.8	60	4.0
13121	2.6 cm to 7.5 cm	<del>(4-0)</del> 3.6	30	3.0	14060	Adjacent tissue transfer or rearrangement, eyelids, nose, ears and/or lips; defect up to 10 sq cm	<del>(10-0)</del> 12.2	60	4.0
13131	Repair, complex, forehead, cheeks, chin, mouth, neck, axillae, genitalia, hands and/or feet; 1.1 cm to 2.5 cm	<del>(2-4)</del> 2.7	30	4.0	14061	defect 10 sq cm to 30 sq cm	14.0	<del>(6-0)</del> 120	4.0
	(For 1.0 cm or less, see simple or intermediate repairs)					(For eyelid, full thickness, see 67961 et seq.)			
13132	2.6 cm to 7.5 cm	<del>(6-0)</del> 4.5	30	4.0	14300	Adjacent tissue transfer or rearrangement, more than 30 sq cm, unusual or complicated, any area	BR	120	4.0
13150	Repair, complex, eyelids, nose, ears and/or lips; 1.0 cm or less	<del>(2-0)</del> 2.3	30	4.0	14350	Filletted finger or toe flap, including preparation of recipient site	<del>(BR)</del> 7.2	60	3.0
	(See also 40650-40654, 67961-67975)								
13151	1.1 cm to 2.5 cm	<del>(3-0)</del> 3.6	30	4.0					
13152	2.6 cm to 7.5 cm	<del>(8-0)</del> 5.4	30	4.0					
13160	Secondary closure of surgical wound or dehiscence, extensive or complicated	<del>(BR)</del> 2.3	30	4.0					
	(For packing or simple secondary wound closure, see 12020, 12021)								
13300	Repair, unusual, complicated, over 7.5 cm, any area	BR		4.0					

**ADJACENT TISSUE TRANSFER OR REARRANGEMENT**

(For full thickness repair of lip or eyelid, see respective anatomical subsections)

Excision and/or repair by adjacent tissue transfer or rearrangement (e.g., Z-plasty, W-plasty, V-Y plasty, rotation flap, advancement flap, double pedicle flap). When applied in repairing lacerations, the procedures listed must be developed by the surgeon to accomplish the repair. They do not apply when direct closure or rearrangement of traumatic wounds incidentally result in these configurations.

(Skin graft necessary to close secondary defect considered an additional procedure)

14000	Adjacent tissue transfer or rearrangement, trunk; defect 10 sq cm or less	<del>(4-0)</del> 5.9	60	3.0
-------	---	-------------------------	----	-----

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-025 FREE SKIN GRAFTS.** Identify by the size and location of the defect (recipient area) and the type of graft; includes simple debridement of granulations or recent avulsion.

When a primary procedure such as orbitectomy, radical mastectomy or deep tumor removal requires skin graft for definitive closure, see appropriate anatomical subsection for primary procedure and this section for skin graft.

(Repair of donor site requiring skin graft or local flaps to be added as additional procedure)

	Unit Value	Follow-up Days=	Basic Anes@	
*15000	Excisional preparation or creation of recipient site by excision of essentially intact skin (including subcutaneous tissue), scar, or other lesion prior to repair with free skin graft (list as separate service in addition to skin graft)	<del>(3-6)</del> BR	0	3.0



	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@	
(For appropriate skin grafts, see 15050-15261; list the free graft separately by its procedure number when the graft, immediate or delayed is applied)				(For eyelids, see also 67961 et seq.)				
*15050	Pinch graft, single or multiple, to cover small ulcer, tip of digit or other minimal open area (except on face), defect size 2 cm diameter	<del>(1.2)</del> 3.6	<del>0)</del> 30	3.0	15350	Application of allograft (homograft), skin	<del>(5.0-45)</del> 1.8 0	3.0
15100	Split graft, trunk, scalp, arms, legs, hands and/or feet (except multiple digits); 100 sq cm or less, or each one percent of body area of infants and children (except 15050)	<del>(6.0)</del> 5.5	45	4.0	15400	Application of xenograft (heterograft), skin	<del>(6.0-45)</del> 1.8 0	3.0
15101	each additional 100 sq cm, or each one percent of body area of infants and children, or part thereof	<del>(1.2)</del> 2.0	60	4.0	15410	Free transplantation of skin flap by microsurgical technique, including microvascular anastomosis; 100 sq cm or less	<del>(5.0-45)</del> 10.8 120	3.0
15120	Split graft, face, eyelids, mouth, neck, ears, orbits, genitalia, and/or multiple digits; 100 sq cm or less, or each one percent of body area of infants and children (except 15050)	<del>(1.0)</del> 9.9	45	4.0	15412	between 101 and 160 sq cm	<del>(6.0-45)</del> 16.3 120	3.0
15121	Each additional 100 sq cm, or each one percent of body area of infants and children, or part thereof	<del>(2.0)</del> 3.7	90	4.0	15414	between 161 and 230 sq cm	<del>(7.0-45)</del> 21.7 120	3.0
(For eyelids, see also 67961 et seq.)				PEDICLE FLAPS (SKIN AND DEEP TISSUES)				
15200	Full thickness graft, free, including direct closure of donor site, trunk; 20 sq cm or less	<del>(4.0)</del> 4.3	45	3.0	Regions listed refer to the recipient area (not donor site) when flap is being attached in transfer or to final site.			
15201	each additional 20 sq cm	<del>(2.0)</del> 1.8	30		Regions listed refer to donor site when tube is formed for later transfer or when "delay" of flap is prior to transfer.			
15220	Full thickness graft, free, including direct closure of donor site, scalp, arms and/or legs; 20 sq cm or less	<del>(6.0)</del> 5.7	45	3.0	Procedures 15500-15730 do not include extensive immobilization, e.g., large plaster casts and other immobilizing devices are considered additional separate procedures.			
15221	each additional 20 sq cm	<del>(3.0)</del> 2.7	60		(Repair of donor site requiring skin graft or local flaps is considered an additional separate procedure)			
15240	Full thickness graft, free, including direct closure of donor site, forehead, cheeks, chin, mouth, neck, axillae, genitalia, hands and/or feet; 20 sq cm or less	<del>(8.0-45)</del> 8.6	90	4.0	15500	Formation of tube pedicle without transfer, or major "delay" of large flap without transfer; on trunk	<del>(7.0)</del> 7.2	45 3.0
(For finger tip graft, see 15050)				15505 on scalp, arms or legs				<del>(7.0)</del> 7.2 45 3.0
(For repair of syndactyly, fingers, see 26560-26562)				15510 on forehead, cheeks, chin, mouth, neck, axillae, genitalia, hands or feet				<del>(7.0)</del> 7.7 45 3.0
15241	each additional 20 sq cm	<del>(4.0)</del> 3.6	90	4.0	15515	on eyelids, nose, ears or lips	<del>(7.0)</del> 7.7 45 3.0	
15260	Full thickness graft, free, including direct closure of donor site, nose, ears, eyelids, and/or lips; 20 cm or less	<del>(10.0-45)</del> 10.8	90	4.0	15540	Primary attachment of open or tubed pedicle flap to recipient site requiring minimal preparation; to trunk	<del>(9.0)</del> 7.7 45 3.0	
15261	each additional 20 sq cm	<del>(5.0)</del> 5.4	90		15545	to scalp, arms and legs	<del>(9.0)</del> 8.3 45 3.0	
				15550 to forehead, cheeks, chin, mouth, neck, axillae, genitalia, or hands, feet				<del>(9.0)</del> 8.3 45 3.0
				(For cross finger pedicle flap, see 15580)				
				15555 to eyelids, nose, ears and lips				<del>(9.0)</del> 8.3 45 3.0

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@		
15580	cross finger pedicle flap, including free graft to donor site	<del>((9-0))</del> 8.1	45	3.0	15775	Punch graft for hair transplant; 1 to 15 punch grafts	0.5	90	3.0
					15776	more than 15 punch grafts	<del>((BR+))</del> 0.3		3.0
	(For major debridement or excisional preparation of recipient area at the time of attachment of pedicle flap, see 15700-15730)				(For strip transplant, 15220)				
<b>MISCELLANEOUS PROCEDURES</b>									
15600	Intermediate "delay" of any flap, primary "delay" of small flap, or sectioning pedicle of tubed or direct flap; at trunk	<del>((4-0-45))</del> 4.5	60	3.0	15780	Dermabrasion; total face (e.g., for acne scarring, fine wrinkling, rhytids, general keratosis)	<del>((+2-0))</del> 9.0	90	3.0
15610	at scalp, arms and legs	<del>((5-0))</del> 4.5	45	3.0	15781	segmental, face	<del>((3-5))</del> 3.6	90	3.0
15620	at forehead, cheeks, chin, neck, axillae, genitalia, hands (except 15625), or feet	<del>((6-0))</del> 4.5	45	3.0	15782	regional, other than face	<del>((3-5))</del> 3.6	90	3.0
15625	section pedicle of cross finger flap	<del>((6-0-45))</del> 4.5	60	3.0	15783	superficial, any site (e.g., tattoo removal)	<del>((2-0-0))</del> 1.8	60	3.0
15630	at eyelids, nose, ears and lips	<del>((6-0))</del> 6.8	45	3.0	15786*	Abrasion; single lesion (e.g., keratosis, scar)	<del>((0.5-0))</del> 0.4	30	3.0
15650	Transfer, intermediate, of any pedicle flap (e.g., abdomen to wrist, "Walking" tube), any location	BR((+))	60	3.0	15787	each additional four lesions or less	<del>((0-3))</del> 0.7	30	3.0
15700	Excision of lesion and/or excisional preparation of recipient site and attachment of direct or tubed pedicle flap; trunk	<del>((9-0))</del> 8.3	45	3.0	15790	Chemical peel (chemexfoliation); total face	<del>((7-0))</del> 7.2	60	
15710	scalp, arms and legs	<del>((+1-0))</del> 9.9	45	4.0	15791	regional, face, neck, or elsewhere	<del>((BR+))</del> 2.3	60	3.0
15720	forehead, cheeks, chin, mouth, neck, axillae, genitalia, hands or feet	<del>((+6-0))</del> 14.5	45	4.0	15810	Salabrasion; up to 20 sq cm	<del>((BR))</del> 0.7	30	3.0
15730	eyelids, nose, ears or lips	<del>((+6-0))</del> 14.5	45	4.0	15811	over 20 sq cm	<del>((BR))</del> 1.8	30	3.0
15732	Muscle, myocutaneous, or fasciocutaneous flap; head and neck (e.g., temporalis, masseter, sternocleidomastoid, levator scapulae)	BR			15819	Cervicoplasty	<del>((+6-5))</del> 16.9	60	3.0
15734	trunk	BR			15820	Blepharoplasty, lower eyelids;	<del>((+2-0-30))</del> 9.0	60	3.0
15736	upper extremity	BR			15821	with extensive herniated fat pads	<del>((+4-0-30))</del> 9.5	60	3.0
15738	lower extremity	BR			15822	Blepharoplasty; upper eyelids	<del>((8-0))</del> 7.7	30	3.0
	(For eyelids, nose, ears, or lips, see also anatomical area)				15823	with excessive skin weighting down lids	<del>((+2-0-30))</del> 8.1	60	3.0
	(For revision, defatting or rearranging of transferred pedicle flap or skin graft, see 13100-14300)				(For bilateral blepharoplasty, add modifier -50)				
<b>OTHER GRAFTS</b>					(See also 67916, 67917, 67923, 67924)				
15740	Graft, island pedicle flap	<del>((+2-0))</del> 9.9	90	3.0	15824	Rhytidectomy; forehead	<del>((+0-0))</del> 10.7	30	3.0
<del>((+15745</del>	myocutaneous flap	<del>BR</del>	<del>90</del>	<del>3.0)</del>	15825	neck with platysmal tightening (platysmal flap, 'P-flap')	<del>((+6-0))</del> 9.2	30	3.0
15750	neurovascular pedicle flap	<del>((+0-0))</del> 10.8	90	4.0	15826	glabellar frown	<del>((8-0))</del> 8.7	30	3.0
15755	free flap (microvascular transfer)	BR	90	4.0	15828	cheeks, chin and neck	<del>((30-0-45))</del> 29.8	60	3.0
15760	composite (full thickness of external ear or nasal ala), including primary closure, donor area	<del>((+0-0))</del> 8.1	45	4.0	15829	subcutaneous musculoaponeurotic system (SMAS) flap	BR	60	3.0
15770	derma-fat-fascia	<del>((+2-0))</del> 10.8	60	3.0	(For bilateral rhytidectomy, add modifier -50)				
					15831	Excision, excessive skin and subcutaneous tissue (including lipectomy); abdomen (abdominoplasty)	<del>((30-0-45))</del> 18.1	60	3.0

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
15832 thigh	<del>(25.0)</del> 27.1	<del>(45)</del> 60	3.0	15922 with local or regional skin flap closure	<del>((BR))</del> 7.7	90	3.0
15833 leg	<del>(30.0)</del> 27.1	<del>(45)</del> 60	3.0	15931 Excision, sacral decubitus ulcer; with primary suture	<del>((13.0))</del> 5.9	90	3.0
15834 hip	<del>(30.0)</del> 27.1	<del>(45)</del> 60	3.0	15933 with osteotomy	<del>((BR))</del> 9.9	120	3.0
15835 buttock	<del>(30.0)</del> 27.1	<del>(45)</del> 60	3.0	15934 Excision, sacral pressure ulcer, with local or regional skin flap closure (e.g., advancement, rotation, rhomboid, bipedicle)	<del>((20.0))</del> 7.7	90	3.0
15836 arm	<del>(25.0)</del> 16.3	<del>(45)</del> 60	3.0	15935 with osteotomy	<del>((BR))</del> 11.7	90	3.0
15837 forearm	<del>(25.0)</del> 13.6	<del>(45)</del> 60	3.0	15936 Excision, sacral pressure ulcer, with other flap closure;	<del>((BR))</del> 9.0	90	3.0
15838 submental fat pad	<del>((BR))</del> 7.2	60	3.0	15937 with osteotomy	<del>((BR))</del> 13.1	120	3.0
15839 other area				(To identify other flap closure, use also code number for specific flap)			
(For bilateral procedure, add modifier -50)	BR	60	3.0	15940 Excision, ischial decubitus ulcer; with primary suture	<del>((BR))</del> 7.2	120	3.0
15840 Graft for facial nerve paralysis; free fascia graft, (including obtaining fascia)	<del>((30.0))</del> 21.7	90	3.0	15941 with osteotomy (ischiectomy)	<del>((BR))</del> 7.2	120	3.0
(For bilateral procedure, add modifier -50)				15944 Excision, ischial pressure ulcer, with local or regional skin flap closure	<del>((BR))</del> 9.0	90	3.0
15841 free muscle graft (including obtaining graft)	<del>((35.0)</del> 25.3	<del>(45)</del> 120	3.0	15945 with osteotomy	<del>((BR))</del> 10.8	90	3.0
15842 free muscle graft by microsurgical technique	<del>((35.0)</del> 31.6	<del>(45)</del> 120	3.0	15946 Excision, ischial pressure ulcer, with osteotomy, with muscle flap or myocutaneous flap closure	<del>((BR))</del> 9.0	90	3.0
15845 regional muscle transfer	<del>((BR+))</del> 22.6	90	3.0	(To identify muscle or myocutaneous flap closure, use also code number for specific flap)			
(For intravenous fluorescein examination of blood flow in graft or flap, see 15860)				15950 Excision, trochanteric pressure ulcer; with primary suture	<del>((BR))</del> 1.9	60	3.0
(For nerve transfers, decompression, or repair, see 64830-64876, 64905-64907, 69720-69725, 69740-69745, 69955)				15951 with osteotomy	<del>((BR))</del> 5.4	60	3.0
15850 Removal of sutures under anesthesia (other than local) same surgeon	<del>((1.2)</del> 5.4	<del>(0))</del> 30	3.0	15952 Excision, trochanteric pressure ulcer, with local rotation skin flap closure	<del>((BR))</del> 7.2	90	3.0
15851 Removal of sutures under anesthesia (other than local) other surgeon	<del>((BR))</del> 6.3	30	3.0	15953 with osteotomy	<del>((BR))</del> 9.0	90	3.0
15852 Dressing change (for other than burns) under anesthesia (other than local)	<del>((1.4)</del> 3.2	<del>(0))</del> 30	3.0	15954 Excision, trochanteric pressure ulcer, with bipedicle flap closure	<del>((BR))</del> 9.0	90	3.0
15860 Intravenous injection of agent (e.g., fluorescein) to test blood flow in flap or graft	<del>((BR))</del> 18.1	0	3.0	15955 with osteotomy	<del>((BR))</del> 10.8	90	3.0
<del>((15875 Suction assisted lipectomy, any site(s)</del>	<del>BR</del>	<del>30</del>	<del>3.0))</del>	15956 Excision, trochanteric pressure ulcer, with muscle or myocutaneous flap closure	<del>((BR))</del> 10.4	90	3.0
15876 Suction assisted lipectomy; head and neck	BR		3.0	15958 with osteotomy	<del>((BR))</del> 12.2	120	3.0
15877 trunk	BR		3.0	(To identify muscle or myocutaneous flap closure, use also code number for specific flap)			
15878 upper extremity	BR		3.0				
15879 lower extremity	BR		3.0				

PRESSURE ULCERS (DECUBITUS ULCERS)

	Unit Value	Follow-up Days=	Basic Anes@
15960 Excision, heel pressure ulcer; with primary suture .....	BR	90	3.0
15961 with ostectomy .....	BR	120	3.0
15964 Excision, heel pressure ulcer, with local skin flap closure ...	BR	90	3.0
15965 with ostectomy .....	BR	120	3.0
15966 Excision, heel pressure ulcer, with other flap closure .....	BR	90	3.0
15967 with ostectomy .....	BR	90	3.0
(To identify other flap closure, use also code number for specific flap)			
15970 Excision, leg pressure ulcer, with primary suture .....	BR	90	3.0
15971 with ostectomy .....	BR	90	3.0
15972 Excision, leg pressure ulcer, with local skin flap(s) .....	BR	90	3.0
15973 with ostectomy .....	BR	90	3.0
15974 Excision, leg pressure ulcer, with muscle or myocutaneous flap closure; .....	BR	90	3.0
15975 with ostectomy .....	BR	90	3.0
(To identify muscle or myocutaneous flap closure, use also code number for specific flap)			
15980 Excision, knee pressure ulcer, with local skin flap closure .....	BR	90	3.0
15981 with ostectomy .....	BR	90	3.0
15982 Excision, knee pressure ulcer, with other flap closure .....	BR	90	3.0
15983 with ostectomy .....	BR	90	3.0
(To identify other flap closure, use also code number for specific flap)			
15999 Unlisted procedure, excision pressure ulcer .....	BR		3.0
(For free skin graft to close ulcer or donor site, see 15000 et seq.)			

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-026 BURNS, LOCAL TREATMENT.**

Procedures 16000-16030 refer to local treatment of burned surface only.

List percentage of body surface involved and depth of burn.

(For skin graft, see 15100-15730)

(For necessary related medical services (e.g., hospital visits, detention) in management of burned patients, see appropriate services in medicine section.)

	Unit Value	Follow-up Days=	Basic Anes@
16000 Initial treatment, first degree burn, when no more than local treatment is required .....	((0-3)) 0.5	0	3.0

	Unit Value	Follow-up Days=	Basic Anes@
16010 Dressings and/or debridement, initial or subsequent; under anesthesia, small .....	((0-8)) 0.9	0	3.0
16015 under anesthesia, medium or large, or with major debridement .....	((2-0)) 1.8	0	3.0
*16020 without anesthesia, office or hospital, small .....	((0-4)) 0.5	0	
*16025 without anesthesia, medium (e.g., whole face or whole extremity) .....	((0-6)) 0.9	0	
16030 without anesthesia, large (e.g., more than one extremity) .....	((0-8)) 1.8	0	
16035 Escharotomy .....	((BR)) 4.5	0	3.0

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-027 DESTRUCTION.**

	Unit Value	Follow-up Days=	Basic Anes@
(For electrosurgical destruction of malignant skin lesions, see 11600-11646)			
(For condylomata, see 46900-46924, 54050-54065, 56501-56515)			
*17000 Destruction by any method, with or without surgical curettment, all facial lesions or premalignant lesions in any location, including local anesthesia; one lesion .....	((0-6)) 0.8	0	3.0
17001 second and third lesions, each .....	((0-3)) 0.5	0	
17002 over 3 lesions, each additional lesion .....	((0-15)) 0.2	0	
17010 complicated lesion(s) .....	((BR)) 2.4	0	3.0
*17100 Destruction by any method of benign skin lesions on any area other than the face, including local anesthesia; one lesion .....	((0-4)) 0.5	0	3.0
17101 second lesion .....	((0-2)) 0.4	0	
17102 over two lesions, each additional lesion up to 15 lesions ..	((0-1)) 0.2	0	
17104 15 or more lesions .....	((0-1)) 2.9	0	
17105 complicated lesions .....	((BR)) 2.3	0	3.0
*17110 Destruction by any method of flat (plane, juvenile) warts or molluscum contagiosum, milia, up to 15 lesions .....	((0-4)) 0.5	0	3.0
(Retreatment same as office visit)			

	Unit Value	Follow-up Days=	Basic Anes@
*17200 Electrosurgical destruction of multiple tags; up to 15 lesions . . . . . (( <del>0.4</del> ))	0.5	0	3.0
17201 each additional 10 lesions . . . . . (( <del>0.2</del> ))	0.5	0	3.0
(For excision of fibrocuteaneous tags, see 11200, 11201)			
*17250 Chemical cauterization of a wound . . . . . ((BR))	0.7	0	3.0
(17300-17302 have been deleted. To report use 17303-17310)			
17303 Chemosurgery (Moh's technique), first stage, fixed tissue technique, including the removal of all gross tumor and application of fixative . . . . . ((BR))	4.5	0	3.0
17304 Chemosurgery (Moh's technique); first stage, fresh tissue technique, including the removal of all gross tumor and delineation of margins by means of up to five horizontal, microscopic specimens . . . . . ((BR))	4.5	0	3.0
17305 second stage, fixed or fresh tissue, up to 5 specimens . . . . . ((BR))	2.7	0	3.0
17306 third stage, fixed or fresh tissue, up to 5 specimens . . . . . ((BR))	2.7	0	3.0
17307 additional stage(s), up to 5 specimens, each stage . . . . . ((BR))	2.7	0	3.0
17310 more than 5 specimens, fixed or fresh tissue, any stage . . . . . BR	0	0	3.0
(For initiation or follow-up care of topical chemotherapy (e.g. 5-FU or similar agents), see appropriate office visits)			
*17340 Cryotherapy (CO <sub>2</sub> slush, liquid N <sub>2</sub> ) . . . . . (( <del>0.3</del> ))	0.5	0	
*17360 Chemical exfoliation for acne (e.g., acne paste, acid) . . . . . (( <del>0.3</del> ))	0.4	0	
*17380 Electrolysis epilation, each 1/2 hour . . . . . *0.6	0	0	
(For actinotherapy, see 96900)			
17999 Unlisted procedure, skin, mucous membrane and subcutaneous tissue . . . . . BR			3.0

**AMENDATORY SECTION** (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

**WAC 296-22-030 BREAST.**

	Unit Value	Follow-up Days=	Basic Anes@
<b>INCISION</b>			
(For needle localization of breast nodules, see 76096 and 76097)			
*19000 Puncture aspiration of cyst . . . . . (( <del>0.4</del> ))	1.1	0	

	Unit Value	Follow-up Days=	Basic Anes@
19001 each additional cyst . . . . . (( <del>0.4</del> ))	0.3	0	
19020 Mastotomy with exploration or drainage of abscess, deep . . . . . (( <del>2.6</del> - 1.4))	2.7	0	3.0
19030 Injection procedure only for mammary ductogram or galactogram . . . . . (( <del>0.4</del> ))	0.6	0	3.0

**AMENDATORY SECTION** (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

**WAC 296-22-031 BREAST.**

	Unit Value	Follow-up Days=	Basic Anes@
<b>EXCISION</b>			
(All codes for bilateral procedures have been deleted. To report, add modifier -50)			
*19100 Biopsy of breast, needle (separate procedure) . . . . . (( <del>0.6</del> - 0))	1.0	30	
19101 incisional . . . . . (( <del>3.6</del> ))	3.2	30	3.0
19110 Nipple exploration, with or without excision of a solitary lactiferous duct or a papilloma lactiferous duct . . . . . BR			
19112 Excision of lactiferous duct fistula . . . . . BR			
19120 Excision of cyst, fibroadenoma or other benign or malignant tumor, aberrant breast tissue, duct lesion or nipple lesion (except 19140), male or female, one or more lesions . . . . . (( <del>5.0</del> ))	4.5	30	3.0
19140 Mastectomy for gynecomastia through circumareolar or other incision . . . . . (( <del>8.0</del> ))	6.3	60	3.0
19160 Mastectomy, partial . . . . . (( <del>6.0</del> ))	5.4	60	3.0
19162 with axillary lymphadenectomy . . . . . ((BR))	15.4		3.0
19180 Mastectomy, simple complete . . . . . (( <del>8.0</del> - 45))	9.4	60	3.0
(For immediate or delayed insertion of implant, use 19340 or 19342)			
(For gynecomastia, see 19140, 19141)			
19182 Mastectomy, subcutaneous . . . . . (( <del>10.0</del> ))	9.0	60	3.0

(When performed in conjunction with reduction mammoplasty, use also 19318)

(For supplemental skills of two surgeons, see WAC 296-22-010 item 5 and modifier -62)

(For supply of prosthetic implant, see 99070)

	Unit Value	Follow-up Days=	Basic Anes@
19200 Mastectomy, radical, including breast, pectoral muscles, axillary lymph nodes .....	<del>((18.0—60))</del> 17.2	90	3.0
19220 Mastectomy, radical, including breast, pectoral muscles, axillary and internal mammary lymph nodes (Urban type operation) ..	<del>((26.0—60))</del> 23.5	120	11.0
19240 Mastectomy, modified radical, <del>((with modified axillary dissection but leaving pectoral muscles))</del> including axillary lymph nodes and pectoralis minor muscle, but excluding pectoralis major muscle .....	<del>((16.0))</del> 17.2	60	3.0
(For supply of prosthetic implant, see 99070)			
19260 Excision of chest wall tumor including ribs .....	<del>((BR+))</del> 15.4	90	9.0
19271 Excision of chest wall tumor involving ribs, with plastic reconstruction; without mediastinal lymphadenectomy .....	<del>((BR+))</del> 25.3	120	9.0
19272 with mediastinal lymphadenectomy	<del>((BR))</del> 31.6	120	9.0

**REPAIR AND RECONSTRUCTION**

(All codes for bilateral procedures have been deleted. To report, add modifier -50)

19316 Mastopexy .....	<del>((BR))</del> 14.5	90	3.0
19318 Reduction mammoplasty .....	BR	90	3.0
19324 Mammoplasty, augmentation; without prosthetic implant .....	<del>((BR))</del> 4.5	90	3.0
19325 with prosthetic implant .....	<del>((BR))</del> 4.5	90	3.0
(For flap or graft, use also appropriate number)			
19328 Removal of intact mammary implant .....	BR	<del>((30))</del> 90	3.0
19330 Removal of mammary implant material .....	<del>((BR—30))</del> 3.6	60	3.0
19340 Immediate insertion of breast prosthesis following mastopexy, mastectomy or in reconstruction	<del>((BR—30))</del> 14.5	90	3.0
19342 Delayed insertion of breast prosthesis following mastopexy, mastectomy or in reconstruction .....	<del>((BR—30))</del> 9.0	90	3.0
(For supply of implant, use 99070)			
(For preparation of custom breast implant, see 19396)			
19350 Reconstruction of nipple and/or areola .....	<del>((BR—30))</del> 8.6	90	3.0
19355 Correction of inverted nipples ...	BR		3.0

	Unit Value	Follow-up Days=	Basic Anes@
19360 Breast reconstruction with muscle or myocutaneous flap .....	BR	90	3.0
(Use also code number for specific flap)			
19364 Breast reconstruction with free flap .....	BR	90	3.0
(Use also code number for specific flap)			
19366 Breast reconstruction with other technique .....	BR	90	3.0
(For microsurgical technique, add modifier -20)			
(For insertion of prosthesis, use also 19340 or 19342)			
19370 Open periprosthetic capsulotomy, breast .....	<del>((BR))</del> 4.3	90	3.0
19371 Periprosthetic capsulectomy, breast .....	BR	90	3.0
19380 Revision of reconstructed breast ..	BR	90	3.0
19396 Preparation of moulage for custom breast implant .....	BR	90	3.0
19499 Unlisted procedure, breast .....	BR		3.0

**AMENDATORY SECTION (Amending Order 87-18, filed 7/23/87)**

**WAC 296-22-036 GENERAL.**

	Unit Value	Follow-up Days=	Basic Anes@
<b>INCISION</b>			
*20000 Incision of soft tissue abscess, secondary to osteomyelitis; superficial .....	<del>((0.4—0))</del> 0.9	7	3.0
20005 deep or complicated .....	<del>((BR))</del> 3.6	21	3.0

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-037 EXCISION.**

	Unit Value	Follow-up Days=	Basic Anes@
(For aspiration of bone marrow, see 85095)			
20200 Biopsy, muscle; superficial .....	<del>((1-2))</del> 1.0	7	3.0
20205 deep .....	<del>((2-4))</del> 2.2	15	3.0
20206* Biopsy, muscle, percutaneous needle .....	<del>((BR))</del> 1.0	15	3.0
(For CT guidance, see 76360, 76361; for ultrasonic guidance, see 76942, 76943)			
(For fine needle aspiration, preparation, and interpretation of smears, see 88170-88173)			

	Unit Value	Follow-up Days=	Basic Anes@
(For excision of muscle tumor, deep, see specific anatomic section)			
20220 Biopsy, bone, trocar or needle; superficial (e.g., ilium, sternum, spinous process, ribs) . . . . .	<del>((1.2-7))</del> 1.3	15	3.0
20225 deep (vertebral body, femur) . . . . .	4.0	15	3.0
20240 Biopsy, excisional; superficial (e.g., ilium, sternum, spinous process, ribs,) trochanter of femur . . . . .	<del>((3-0))</del> 3.6	21	3.0
20245 deep (e.g., humerus, ischium, femur) . . . . .	<del>((5-0))</del> 4.5	30	3.0
20250 Biopsy, vertebral body, open; thoracic . . . . .	<del>((BR))</del> 17.6	45	3.0
20251 lumbar or cervical . . . . .	<del>((BR))</del> 14.5	45	3.0
(For sequestrectomy, osteomyelitis or drainage of bone abscess, see anatomical area)			

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-038 INTRODUCTION OR REMOVAL.**

	Unit Value	Follow-up Days=	Basic Anes@
(For injection procedure for arthrography, see anatomical area)			
20500 Injection of sinus tract; therapeutic (separate procedure) . . . . .	0.4	0	
20501* diagnostic (sinogram) (separate procedure) . . . . .	<del>((1-0))</del> 0.9	0	
*20520 Removal of foreign body in muscle or tendon sheath; simple . . . . .	<del>((1.2-0))</del> 1.5	15	3.0
20525 deep or complicated . . . . .	<del>((BR+))</del> 3.2	30	3.0
*20550 Injection, tendon sheath, ligament, trigger points, or ganglion cyst . . . . .	*0.4	0	
*20600 Arthrocentesis, aspiration and/or injection; small joint, bursa, or ganglion cyst (e.g., fingers, toes) . . . . .	<del>((1-0-3))</del> 0.4	0	
*20605 intermediate joint, bursa, or ganglion cyst (e.g., temporomandibular, acromioclavicular, wrist, elbow or ankle; olecranon bursa) . . . . .	<del>((1-0-4))</del> 0.5	0	
*20610 major joint or bursa (e.g., shoulder, hip, knee joint, subacromial bursa) . . . . .	<del>((1-0-6))</del> 0.5	0	
20615 Aspiration and injection for treatment of bone cyst . . . . .	<del>((0-6))</del> 3.6	60	3.0

	Unit Value	Follow-up Days=	Basic Anes@
*20650 Insertion of wire or pin with application of skeletal traction, including removal (separate procedure) . . . . .	<del>((1.2-0))</del> 1.4	21	3.0
20660 Application of cranial tongs, caliper, or stereotactic frame including removal (separate procedure) . . . . .	<del>((3-0-0))</del> 2.7	21	3.0
20661 Application of halo, including removal; cranial . . . . .	<del>((3-0-0))</del> 3.3	21	3.0
20662 pelvic . . . . .	<del>((3-0-0))</del> 4.5	21	3.0
20663 femoral . . . . .	<del>((3-0-0))</del> 4.5	21	3.0
*20665 Removal of tongs or halo applied by another physician . . . . .	<del>((0-3-0))</del> 0.4	15	
*20670 Removal of implant; superficial, (e.g., buried wire, pin or rod) (separate procedure) . . . . .	<del>((1-0-6-0))</del> 1.4	15	3.0
20680 deep (e.g., buried wire, pin, screw, metal band, nail, rod or plate) . . . . .	3.6	21	4.0
20690 Application of external fixation system (e.g., Hoffmann apparatus), including removal . . . . .	<del>((BR))</del> 4.5	21	3.0

(List number 20690 in addition to code for treatment of closed or open fracture)

**REPAIR**

(For debridement as a separate procedure (e.g., in traumatic wound) involving soft tissue and/or bone, see 11042, 11044)

**AMENDATORY SECTION (Amending Order 87-18, filed 7/23/87)**

**WAC 296-22-039 REIMPLANTATION.**

	Unit Value	Follow-up Days=	Basic Anes@
<b>REIMPLANTATION</b>			
20802 Replantation, arm (includes surgical neck of humerus through elbow joint); complete (amputation) . . . . .	<del>((BR))</del> 58.7	180	3.0
20804 incomplete (amputation devascularized extremity with soft tissue pedicle) . . . . .	BR	180	3.0
20805 Replantation, forearm (includes radius and ulna to radial carpal joint); complete amputation . . . . .	<del>((BR))</del> 58.7	180	3.0
20806 incomplete amputation (devascularized extremity with soft tissue pedicle) . . . . .	BR	180	3.0
20808 Replantation, hand (includes hand through metacarpophalangeal joints); complete amputation . . . . .	<del>((BR))</del> 54.2	180	3.0

		Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
20812	incomplete (amputation devascularized extremity with soft tissue pedicle) . . . . .	BR	<u>180</u>	3.0	20910	Cartilage graft, costochondral . . . . .	0	3.0
						<del>((4-8))</del> 4.3		
20816	Replantation, digit excluding thumb (includes metacarpophalangeal joint to insertion of flexor sublimis tendon); complete amputation . . . . .	<del>((BR))</del> <u>18.1</u>	<u>180</u>	3.0	20912	nasal septum . . . . .	0	3.0
						<del>((4-2))</del> 4.3		
20820	incomplete (amputation devascularized extremity with soft tissue pedicle) . . . . .	BR	<u>180</u>	3.0		(For ear cartilage, see 21235)		
20822	Replantation, digit, excluding thumb (includes distal tip to sublimis tendon insertion); complete amputation . . . . .	<del>((BR))</del> <u>12.2</u>	<u>180</u>	3.0	20920	Fascia lata graft; by stripper . . . . .	0	3.0
						<del>((2-0))</del> 1.8		
20823	incomplete amputation (devascularized extremity with soft tissue pedicle) . . . . .	BR	<u>180</u>	3.0	20922	by incision and area exposure, complex or sheet . . . . .	0	3.0
20824	Replantation, thumb (includes carpometacarpal joint to MP joint); complete amputation . . . . .	<del>((BR))</del> <u>24.8</u>	<u>180</u>	3.0		<del>((4-0))</del> 3.6		
20826	incomplete amputation (devascularized extremity with soft tissue pedicle) . . . . .	<del>((BR))</del> <u>18.1</u>	<u>180</u>	3.0	20924	Tendon graft, from a distance (e.g., palmaris, toe extensor, plantaris) . . . . .	<u>15</u>	3.0
20827	Replantation, thumb (includes distal tip to MP joint); complete amputation . . . . .	BR	<u>180</u>	3.0		<del>((BR))</del> 1.8		
20828	incomplete amputation (devascularized extremity with soft tissue pedicle) . . . . .	BR	<u>180</u>	3.0	20926	Tissue grafts, other (e.g., paratenon, fat, dermis, etc.) . . . . .	<u>15</u>	3.0
20832	Replantation, leg; complete amputation . . . . .	<del>((BR))</del> <u>63.3</u>	<u>180</u>	3.0		<del>((BR))</del> 1.8		
20834	(incomplete amputation devascularized extremity with soft tissue pedicle) . . . . .	BR	<u>180</u>	3.0	<b>MISCELLANEOUS</b>			
20838	Replantation, foot; complete amputation . . . . .	<del>((BR))</del> <u>58.7</u>	<u>180</u>	3.0	20950	Monitoring of interstitial fluid pressure (includes insertion of device e.g., wick catheter technique, needle manometer technique) in detection of muscle compartment syndrome . . . . .	<u>180</u>	3.0
20840	incomplete (amputation devascularized extremity with soft tissue pedicle) . . . . .	BR	<u>180</u>	3.0		<del>((BR))</del> 1.4		
					20955	Bone graft with microvascular anastomosis; fibula . . . . .	<u>180</u>	3.0
						<del>((BR))</del> 55.1		
					20960	rib . . . . .	<u>180</u>	3.0
					20962	other bone graft (specify) . . . . .	<u>180</u>	3.0
					20969	Free osteocutaneous flap with microvascular anastomosis; other than iliac crest, rib, metatarsal, or great toe . . . . .	BR	<u>180</u>
						<del>((BR))</del> 28.6		
					20970	Free osteocutaneous graft with microvascular anastomosis; iliac crest . . . . .	<u>180</u>	3.0
						<del>((BR))</del> 28.6		
					20971	rib . . . . .	<u>180</u>	3.0
					20972	metatarsal . . . . .	<u>180</u>	3.0
					20973	great toe with web space . . . . .	<u>180</u>	3.0
					20974	Electrical stimulation to aid bone healing; noninvasive (nonoperative) . . . . .	0	3.0
						<del>((BR))</del> 2.7		

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-040 GRAFTS (OR IMPLANTS).**

Codes for obtaining autogenous bone, cartilage, tendon, fascia lata grafts, or other tissues, through separate incisions are to be used only when graft is not already listed as part of basic procedure. Listed value applies and WAC 296-22-010, item 7 is not to be applied to procedures 20900-20922.

(For alloplastic or heterologous grafts, see instructions, WAC 296-22-035)

		Unit Value	Follow-up Days=	Basic Anes@
20900	Bone graft, any donor area; minor or small (e.g., dowel or button) . . . . .	<del>((2-4))</del> 2.2	0	3.0
20902	major or large . . . . .	<del>((4-8))</del> 4.3	0	3.0

	(use 20974 in addition to code for appropriate bony procedure when applicable)			
20975	invasive (operative) . . . . .	<del>((BR))</del> 4.1	<u>90</u>	3.0
	(use 20975 in addition to code for appropriate bony procedure when applicable)			
20976	percutaneous insertion of electrodes . . . . .	<del>((BR))</del> 2.7	0	3.0
	(use 20976 in addition to code for appropriate bony procedure when applicable)			
20999	Unlisted procedure, musculoskeletal system, general . . . . .	BR		3.0

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-042 HEAD.**



(Skull, facial bones and temporomandibular joint)

INCISION

(For drainage of superficial abscess and hematoma, see 20000)  
 (For removal of embedded foreign body from dentoalveolar structure, see 41805, 41806)

	Unit Value	Follow-up Days=	Basic Anes@
21010 Arthrotomy, temporomandibular joint(( <del>unilateral</del> ))	((BR))	90	3.0
	11.7		
(( <del>21011</del> bilateral	<del>BR</del>	<del>3.0</del> )	

EXCISION

(For biopsy, see 20220, 20240)

21025 Excision of bone (e.g., for osteomyelitis or bone abscess); mandible	((BR))	90	
	8.1		
21026 facial bone(s)	((BR))	90	
	9.0		
21030 Excision of benign tumor or cyst of facial bone other than mandible	((BR))	90	5.0
	11.7		
21031 Excision of torus mandibularis	BR		
21032 Excision of maxillary torus palatinus	BR		
21034 Excision of malignant tumor of facial bone other than mandible	((BR))	90	5.0
	14.5		
21040 Excision of benign cyst or tumor of mandible; simple	(( <del>5-0</del> ))	90	5.0
	7.2		
21041 complex	((BR))	90	5.0
	11.3		
21044 Excision of malignant tumor of mandible	((BR))	90	5.0
	14.4		
21045 radical resection	((BR))	90	5.0
	35.2		

(For bone graft, see 21215)

21050 Condylectomy, temporomandibular joint (separate procedure)	(( <del>18-0</del> ))	90	5.0
	16.7		
(21051 has been deleted. To report bilateral procedure, use modifier -50)			
21060 Meniscectomy, partial or complete, temporomandibular joint (separate procedure)	(( <del>18-0</del> ))	90	5.0
	13.6		
(21061 has been deleted, to report, use modifier -50)			
21070 Coronoidectomy (separate procedure)(( <del>unilateral</del> ))	(( <del>18-0</del> ))	90	5.0
	17.2		
(( <del>21071</del> bilateral	<del>20.0</del>	<del>90</del>	<del>5.0</del> )

INTRODUCTION OR REMOVAL

(For application or removal of caliper or tongs, see 20660, 20665)

*21100 Application of halo type appliance for maxillofacial fixation, includes removal (separate procedure)	(( <del>2-0</del> —0))		3.0
	11.7	30	

Unit Value Follow-up Days= Basic Anes@

21110 Application of interdental fixation device for conditions other than fracture or dislocation, includes removal	(( <del>8-0</del> —90))		3.0
	5.9	30	

(For removal of interdental fixation by another physician, see 20670-20680)

21116 Injection procedure for temporomandibular joint arthrotopography	((BR))		0
	1.2		
(For temporomandibular arthrotopography, see 70332)			

REPAIR, REVISION OR RECONSTRUCTION

(For cranioplasty, see 62140-62145)

21200 Osteotomy (e.g., for prognathism, micrognathism, apertognathism or for reconstruction); mandible, total or horizontal	(( <del>30-0</del> ))	90	5.0
	36.0		
21202 mandible, segmental	((BR))	90	5.0
	17.2		
21203 mandibular ramus (osteotomy)	((BR))	90	5.0
	38.9		
21204 maxilla, total	((BR))	90	5.0
	31.6		
21206 maxilla, segmental	((BR))	90	5.0
	20.8		
21208 Osteoplasty, facial bones; augmentation (autograft, allograft, or prosthetic implant)	((BR))	90	
	11.7		
21209 reduction	((BR))	90	
	17.2		
21210 Graft, bone; nasal, maxillary and malar areas (includes obtaining graft)	(( <del>20-0</del> ))	120	5.0
	18.1		

(For cleft palate repair, see 42200-42225)

21215 mandible (includes obtaining graft)	(( <del>20-0</del> —120))		5.0
	22.6	60	
21230 Graft; rib cartilage, autogenous, to face, chin, nose or ear (includes obtaining graft)	(( <del>18-0</del> ))	120	5.0
	17.2		
21235 ear cartilage to nose or ear (includes obtaining graft)	(( <del>12-0</del> ))	60	5.0
	11.7		
21240 Arthroplasty, temporomandibular joint, with or without autograft	((BR+))	90	5.0
	19.0		

(If bone or cartilage graft is used for temporomandibular joint arthroplasty, use 20900-20910)

21242 Arthroplasty, temporomandibular joint, with allograft	BR	90	5.0
21243 Arthroplasty, temporomandibular joint, with prosthetic joint replacement	(( <del>24-5</del> ))	90	4.5
	25.3		

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
21244 Reconstruction of mandible, extramural, with transosteal bone plate (e.g., mandibular staple bone plate) . . . . .	BR			21330 complicated, with internal and/or external skeletal fixation . . . . .	((9-5)) 7.6	90	3.0
21245 Reconstruction of mandible or maxilla, subperiosteal implant; partial . . . . .	BR			21335 with concomitant open of fractured septum . . . . .	((+7-0)) 16.3	90	3.0
21246 complete . . . . .	BR			21337 Treatment of closed nasal septal fracture . . . . .	((BR)) 1.5	90	3.0
21248 Reconstruction of mandible or maxilla, endosteal implant (e.g., blade, cylinder); partial . . . . .	BR			21338 Open treatment of nasoethmoid fracture; without external fixation . . . . .	((BR)) 13.6	90	3.0
21249 complete . . . . .	BR			21339 with external fixation . . . . .	((BR)) 15.5	90	3.0
21250 Osteoplasty of maxilla and/or other facial bones for midface hypoplasia or retrusion (LeFort type operation); without bone graft . . . . .	((BR)) 25.3	90	5.0	21340 Treatment of closed or open nasoethmoid complex fracture, with splint, wire or headcap fixation, including repair of canthal ligaments and/or the nasolacrimal apparatus . . . . .	((BR)) 15.4	90	3.0
21254 with bone graft . . . . .	((BR)) 46.1	90	5.0	21343 Open treatment of closed or open depressed frontal sinus fracture . . . . .	BR	90	
21260 Periorbital osteotomies for orbital hypertelorism, with bone grafts; extracranial approach . . . . .	((BR)) 35.2	90	5.0	21345 Treatment of nasomaxillary complex fracture (LeFort II type), with interdental wire fixation or fixation of denture or splint . . . . .	BR	90	3.0
21261 combined intra- and extracranial approach . . . . .	((BR)) 58.7	90	5.0	21346 Open treatment of nasomaxillary complex fracture (LeFort II type); with wiring and/or local fixation . . . . .	((BR)) 13.6	90	3.0
21263 with forehead advancement . . . . .	((BR)) 58.7	90	5.0	21347 with multiple approaches . . . . .	((BR)) 15.5	90	3.0
21267 Orbital repositioning, periorbital osteotomies, unilateral, with bone grafts; extracranial approach . . . . .	((BR)) 35.2	90	5.0	*21355 Manipulative treatment of closed or open fracture of malar area, including zygomatic arch and malar tripod, towel clip technique . . . . .	((+1-0)) 6.8	((2)) 45	3.0
21268 combined intra- and extracranial approach . . . . .	((BR)) 58.7	90	5.0	21360 Open treatment of closed or open depressed malar fracture, including zygomatic arch and malar tripod . . . . .	((7-0)) 12.0	90	3.0
21270 Malar augmentation, bone or alloplastic material . . . . .	((BR)) 51.5	90	5.0	21365 Open treatment of closed or open complicated (e.g., multiple fractures) of malar area, including zygomatic arch and malar tripod, with internal skeletal fixation and multiple surgical approaches . . . . .	((+3-0)) 13.6	90	5.0
21275 Secondary revision for orbito-craniofacial reconstruction . . . . .	BR	90	5.0	21385 Open treatment of orbital floor "blowout" fracture; transanal approach (Caldwell-Luc type operation) . . . . .	((+2-0)) 12.3	90	3.0
(For reconstruction of skull by bone flaps, see 61555)				21386 periorbital approach . . . . .	((+3-0)) 16.3	90	3.0
21280 Medial canthoplasty . . . . .	BR	90	5.0	21387 combined approach . . . . .	((+5-0)) 16.3	90	3.0
21282 Lateral canthopexy . . . . .	BR	90	5.0	21390 periorbital approach, with alloplastic or other implant . . . . .	((+4-0)) 15.4	90	3.0
21295 Reduction of masseter muscle (e.g., treatment of benign masseteric hypertrophy); extra-oral approach . . . . .	BR	90	5.0	21395 periorbital approach with bone graft (includes obtaining graft) . . . . .	((+8-0)) 23.3	90	3.0
21296 intraoral approach . . . . .	BR	90	5.0				
<b>FRACTURE AND/OR DISLOCATION</b>							
21300 Treatment of closed skull fracture without operation . . . . .	((Sv-8)) 1.2	0					
(For operative repair, see 62000-62010)							
21310 Treatment of closed or open nasal fracture without manipulation . . . . .	((Sv-8)) 1.0	0					
*21315 Manipulative treatment nasal bone fracture; without stabilization . . . . .	*1.1	((0)) 7	3.0				
21320 with stabilization . . . . .	((3-0)) 4.1	90	3.0				
21325 Open treatment of nasal fracture; uncomplicated . . . . .	((4-0)) 3.6	90	3.0				

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
21400 Treatment of fracture of orbit, except "blowout"; without manipulation .....	<del>(SV)</del> 1.2	0		21462 with interdental fixation ..	<del>(+6.0)</del> 15.5	90	5.0
21401 with manipulation .....	<del>(6.0)</del> 12.7	90	3.0	21465 Open treatment of mandibular condylar fracture .....	<del>(BR)</del> 13.1	90	5.0
21406 Open treatment of fracture of orbit, except "blowout"; without implant .....	<del>(7.0)</del> 14.5	90	3.0	21470 Open treatment of complicated closed or open mandibular fracture by multiple surgical approaches including internal fixation, interdental fixation, and/or wiring of dentures or splints ....	<del>(BR)</del> 17.2	90	5.0
21407 with implant .....	<del>(8.0)</del> 14.5	90	3.0	21480 Uncomplicated treatment of temporomandibular dislocation, initial or subsequent .....	<del>(Sv. &amp;)</del> 3.6	30	3.0
21421 Treatment of palatal or alveolar ridge fractures (LeFort I type); closed manipulation with interdental wire fixation or fixation of denture or splint .....	<del>(7.0)</del> 11.3	90	3.0	21485 Complicated manipulate treatment of temporomandibular dislocation, initial or subsequent ...	<del>(BR)</del> 4.5	90	3.0
21422 open treatment .....	<del>(+2.0)</del> 11.3	90	3.0	21490 Open treatment of temperomandibular dislocation .....	<del>(BR)</del> 11.7	90	3.0
21431 Treatment of craniofacial separation (LeFort III type) using interdental wire fixation of denture or splint .....	<del>(8.0)</del> 14.5	90	4.0	(For interdental wire fixation, see 21462)			
21432 Open treatment of craniofacial separation (LeFort III type); with wiring and/or local fixation .....	<del>(BR)</del> 17.2	90	4.0	21493 Treatment of closed or open hyoid fracture; without manipulation .....	<del>(SV)</del> 1.2	0	
21433 complicated (e.g., multiple approaches) .....	<del>(BR)</del> 19.9	90	5.0	21494 with manipulation .....	<del>(7.0)</del> 12.7	90	3.0
21435 complicated, fixation by head cap, halo device, multiple surgical approaches, internal fixation, and/or wiring teeth .....	<del>(BR)</del> 21.7	90	5.0	21495 Open treatment of closed or open hyoid fracture .....	<del>(8.0)</del> 17.2	90	3.0
(For removal of internal or external fixation device, see 20670)				(For treatment of fracture of larynx, see 31584-31586)			
21440 Manipulative treatment of alveolar ridge fracture (separate procedure) .....	<del>(BR)</del> 11.7	30	5.0	21497 Interdental wiring, for condition other than fracture .....	<del>(BR)</del> 11.7	90	3.0
21445 Open treatment of alveolar ridge fracture (separate procedure) ...	<del>(BR)</del> 14.5	30	5.0	21499 Unlisted procedure, head .....	BR	90	3.0
21450 Treatment of closed or open mandibular fracture without manipulation .....	<del>(Sv. &amp;)</del> 1.1	90		<b>AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)</b>			
21451 with manipulation, may include external fixation .....	<del>(BR)</del> 1.7	90	5.0	<b>WAC 296-22-051 NECK (SOFT TISSUES) AND THORAX.</b>			
21452 Treatment of open mandibular fracture; without manipulation ..	<del>(BR)</del> 1.1	90	5.0	(For cervical spine, see 22100, et seq.)			
21453 with manipulation .....	<del>(BR)</del> 1.9	90	5.0	(For injection of fracture site or trigger point, see 20550)			
21454 Open treatment of closed or open mandibular fracture with external fixation .....	<del>(BR)</del> 4.5	90	5.0	<b>INCISION</b>			
21455 Closed manipulative treatment by interdental fixation of closed or open mandibular fracture .....	<del>(8.0)</del> 10.4	90	5.0	(For incision and drainage of abscess or hematoma, superficial, see 10060)			
21461 Open treatment of closed or open mandibular fracture; with or without interdental fixation .....	<del>(+6.0)</del> 13.1	90	5.0	21501 Incision and drainage, deep abscess or hematoma; soft tissues of neck or thorax .....	<del>(5.0-30)</del> 4.1	21	3.0
				21502 with partial rib osteotomy .....	<del>(6.0)</del> 5.7	30	3.0
				21510 Incision, deep, with opening of bone cortex for osteomyelitis or bone abscess .....	<del>(7.0-30)</del> 3.6	21	3.0

	Unit Value	Follow-up Days=	Basic Anes@
<b>EXCISION</b>			
21550 Biopsy, soft tissue of neck or thorax.....	<del>(7.0)</del> 1.2	<del>30</del> 0	3.0
(For needle biopsy of soft tissue, see 20206)			
21555 Excision tumor, soft tissue of neck or thorax; subcutaneous ...	<del>(7.0)</del> 1.2	<del>30</del> 15	3.0
21556 deep, subfascial, intramuscular .....	<del>(8.0)</del> 2.3	<del>30</del> 15	3.0
21557 Radical resection of tumor (e.g., malignant neoplasm), soft tissue of neck or thorax .....	13.6	180	
21600 Excision of rib, partial .....	<del>(6.0)</del> 5.0	60	5.0
(For radical resection of chest wall and rib cage for tumor, see 19260)			
(For radical debridement of chest wall and rib cage for injury, see 11040-11044)			
21610 Costotransversectomy (separate procedure) .....	<del>(BR)</del> 18.1	60	5.0
21615 Excision first and/or cervical rib for outlet compression syndrome or other cause .....	<del>(16.6)</del> 14.5	<del>60</del> 30	
21616 with sympathectomy .....	<del>(BR)</del> 4.0	30	
21620 Osteotomy of sternum, partial ..	<del>(BR)</del> 18.1	60	5.0
21627 Sternal debridement .....	BR	60	5.0
21630 Radical resection of sternum for tumor .....	<del>(BR)</del> 22.6	60	5.0
21632 with mediastinal lymphadenectomy .....	<del>(BR)</del> 36.1	60	5.0
21633 for osteomyelitis .....	BR		5.0
<b>REPAIR, REVISION OR RECONSTRUCTION</b>			
(For superficial wound, see general section under Repair-Simple)			
21700 Division of scalenus anticus; without resection of cervical rib .....	<del>(10.0)</del> 5.9	60	3.0
21705 with resection of cervical rib ..	<del>(12.0)</del> 11.3	60	5.0
21720 Division of sternocleidomastoid for torticollis, open operation; without cast application .....	<del>(8.0)</del> 5.9	60	3.0
(For transection of spinal accessory and cervical nerves, see 63191, 63192, 64722)			
21725 with cast application .....	<del>(9.0)</del> 7.7	60	3.0
21740 Reconstructive repair of pectus excavatum or carinatum .....	<del>(26.0)</del> 22.6	120	11.0

	Unit Value	Follow-up Days=	Basic Anes@
<b>FRACTURE AND/OR DISLOCATION</b>			
21800 Treatment of rib fracture; closed, uncomplicated, each .....	<del>(5.0)</del> 0.9	30	
21805 open or complicated, each ...	<del>(BR)</del> 9.0	60	5.0
21810 closed or open requiring external fixation ("flail chest") .....	<del>(BR)</del> 21.7	60	5.0
21820 Treatment of sternum fracture; closed .....	<del>(5.0)</del> 2.3	30	
21825 open .....	<del>(BR)</del> 9.0	60	5.0
(For sternoclavicular dislocation, see 23520-23532)			

	Unit Value	Follow-up Days=	Basic Anes@
<b>MISCELLANEOUS</b>			
21899 Unlisted procedure, neck or thorax .....	BR	30	5.0

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-052 BACK AND FLANK.**

	Unit Value	Follow-up Days=	Basic Anes@
<b>EXCISION</b>			
21920 Biopsy, soft tissue of back or flank; superficial .....	<del>(1.3)</del> 1.2	30	0
21925 deep .....	<del>(2.0)</del> 2.3	60	0
21930 Excision, tumor, soft tissue of back or flank .....	<del>(7.0)</del> 7.2	60	0
21935 Radical resection of tumor (e.g., malignant neoplasm), soft tissue of back or flank .....	<del>(13)</del> 13.6	180	0

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-053 SPINE (VERTEBRAL COLUMN).**

	Unit Value	Follow-up Days=	Basic Anes@
(Cervical, thoracic, and lumbar spine)			
<b>EXCISION</b>			
(For injection procedure for myelography, see 63510-63520)			
(For injection procedure for discography, see 63530-63535)			
22100 Partial resection of vertebral component, spinous processes; cervical .....	<del>(8.0)</del> 7.2	90	8.0
22101 thoracic .....	<del>(8.0)</del> 5.9	<del>90</del> 30	7.0

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
22102 lumbar	<del>((8-0))</del> 6.3	<del>90</del> 30	7.0	22210 Osteotomy of spine, posterior approach, for correction of deformity, single segment; cervical	<del>((35-0))</del> 36.1	180	7.0
22105 Partial resection of vertebral component for tumor (e.g., partial facetectomy without primary grafting); cervical	<del>((12-0))</del> 10.8	90	8.0	22212 thoracic	<del>((35-0))</del> 36.1	180	7.0
22106 thoracic	<del>((12-0))</del> 8.1	<del>90</del> 30	7.0	22214 lumbar	<del>((28-0))</del> 28.9	180	7.0
22107 lumbar	<del>((12-0))</del> 8.1	<del>90</del> 30	7.0	22220 Osteotomy of spine, anterior approach, for correction of deformity, single section; cervical			
22110 Partial excision of vertebrae (e.g., for osteomyelitis), cervical	<del>((BR))</del> 9.0	90	8.0	22222 thoracic	BR	180	
22112 thoracic	<del>((BR))</del> 9.0	30	7.0	22224 lumbar	BR	180	
22114 lumbar	<del>((BR))</del> 9.0	30	7.0	22230 Osteotomy of spine for correction of deformity, each additional segment	<del>((8-5))</del> 9.0	180	0

**INTRODUCTION**

(For injection procedure for myelography, see 62284)

(For injection procedure for diskography, see 62290, 62291)

(For injection procedure, chemonucleolysis, single or multiple levels, see 62292)

(For injection procedure for facet joints, see 64442, 64443, 64622, 64623)

(For needle or trocar biopsy, see 20220-20225)

**REPAIR, REVISION, RECONSTRUCTION**

(For radical resection of vertebral body, see vertebral corpectomy, 63081-63091)

(For prosthetic replacement of vertebrae, see 22150-22152)

22140 Reconstruction of spine with bone graft (autograft, allograft, and/or methylmethacrylate) following resection of single vertebral body; cervical ~~((28-0))~~ 90 9.0

22141 thoracic ~~((28-0))~~ 90 9.0

22142 lumbar ~~((28-0))~~ 90 7.0

22145 Reconstruction of spine following vertebral body resection, each additional vertebral body BR

22148 Harvesting of bone autograft for vertebral reconstruction following vertebral corpectomy BR

(List separately in addition to codes 22140-22145)

22150 Reconstruction of spine with prefabricated prosthetic replacement following resection of one or more vertebral bodies; cervical ~~((24-0))~~ 90 25.3

22151 thoracic ~~((24-0))~~ 90 25.3

22152 lumbar ~~((24-0))~~ 90 25.3

(For osteotomy of spine, see 22210-22230)

(For vertebral corpectomy, see 63081-63091. For spinal instrumentation, see 22840-22845. For reconstruction following vertebral corpectomy, see 22140-22152)

**FRACTURE AND/OR DISLOCATION**

22305 Closed treatment of vertebral process fracture(s) ~~((5v-8))~~ 90 2.3

22310 Closed treatment of vertebral body fracture(s); without manipulation ~~((5v-8))~~ 90 6.5

22315 Closed treatment of vertebral fracture and/or dislocation, with or without anesthesia, by manipulation or traction, each ~~((7-0))~~ 180 3.0 6.7

22325 Open treatment of vertebral fracture and/or dislocation; lumbar, each ~~((24-0))~~ 180 7.0 21.7

22326 cervical, each ~~((24-0))~~ 180 8.0 21.7

22327 thoracic, each ~~((24-0))~~ 180 7.0 21.7

**MANIPULATION**

(22500 Manipulation of spine not requiring anesthesia has been deleted. To report, use 97260)

\*22505 Manipulation of spine requiring anesthesia, any region \*1.4 0 5.0

**ARTHRODESIS**

(Arthrodesis procedures, 22548-22812, include either an allograft or an autograft. Use procedure code 22820 for the harvesting of autograft in addition to the code for arthrodesis)

**ARTHRODESIS, ANTERIOR OR ANTEROLATERAL APPROACH TECHNIQUE**

(Procedure codes 22554-22558 are for SINGLE interspace arthrodesis (2 adjacent vertebral segments); for additional interspaces or segments, use 22585)

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
22548 Arthrodesis, anterior transoral or extraoral technique, clivus-C1-C2 (atlas-axis), with bone graft, with or without excision of odontoid process.....	<del>((26.0))</del> <u>27.1</u>	180	9.0	22630 Arthrodesis, posterior interbody technique, with local bone or bone allograft and/or internal wire fixation, lumbar .....	<del>((22.0))</del> <u>180</u>	<del>180</del>	<del>7.0))</del> <u>noncovered procedure</u>
(For intervertebral disk excision by laminotomy or laminectomy, see 63020-63042. For arthrodesis, see 22548-22650)				22650 Arthrodesis, posterior, posterolateral, or lateral transverse process technique, each additional interspace .....	<del>((5.5))</del> <u>5.7</u>	180	8.0
22554 Arthrodesis, anterior interbody technique; cervical below C2, with bone graft .....	<del>((23.0))</del> <u>23.8</u>	180	9.0	(List separately in addition to code for single level arthrodesis, 22590-22630)			
22556 thoracic, with local bone (e.g., rib) and/or bone allograft ...	<del>((26.0))</del> <u>27.1</u>	180	7.0	<b>ARTHRODESIS FOR SPINE DEFORMITY (E.G., SCOLIOSIS, KYPHOSIS)</b>			
22558 lumbar, with bone graft .....	<del>((5.5))</del> <u>23.8</u>	180	7.0	22800 Arthrodesis, posterior, for spinal deformity, with or without cast, with bone graft; 6 or less vertebrae .....	<del>((29.0))</del> <u>27.1</u>	180	13.0
22585 Arthrodesis, anterior or anterolateral, each additional interspace (list separately in addition to single level arthrodesis) .....	<del>((22.0))</del> <u>5.7</u>	180	9.0	22802 7 or more vertebrae .....	<del>((BR))</del> <u>36.1</u>	<u>180</u>	13.0
(Procedure codes 22548-22585 exclude reconstruction following vertebral corpectomy)				22810 Arthrodesis, anterior, for spinal deformity, with or without cast, with bone graft; 4 to 7 vertebrae or more vertebrae .....	<del>((BR))</del> <u>BR</u>	<del>BR</del>	<del>BR</del>
<b>ARTHRODESIS, POSTERIOR, POSTEROLATERAL, OR LATERAL TRANSVERSE PROCESS TECHNIQUE</b>				<b>ARTHRODESIS, MISCELLANEOUS</b>			
(Procedure codes 22590-22630 are for SINGLE interspace arthrodesis (2 adjacent vertebral segments); for additional interspaces or segments, see 22650)				22820 Harvesting of bone autograft (e.g., ilium, fibula, etc.) for arthrodesis .....	<del>((3.5))</del> <u>3.8</u>	180	11.5
22590 Arthrodesis, posterior technique, craniocervical (occiput-C2), with bone graft and/or internal fixation .....	<del>((35.0))</del> <u>36.1</u>	180	9.0	22830 Exploration of spinal fusion .....	<del>((BR))</del> <u>BR</u>		
22595 Arthrodesis, posterior technique, atlas-axis (C1-C2) with bone graft and/or internal fixation ..	<del>((26.0))</del> <u>27.1</u>	180	9.0	<b>SPINAL INSTRUMENTATION</b>			
(For supplemental skills of two surgeons, see WAC 296-22-010, item 5b and modifier -62.)				(List separately, in addition to code for fracture, dislocation, or arthrodesis of the spine, 22305-22812)			
22600 Arthrodesis, posterior technique, cervical below C2 segment, local bone or bone allograft and/or internal fixation .....	<del>((24.0))</del> <u>21.7</u>	180	8.0	22840 Posterior instrumentation; without segmental fixation (e.g., single Harrington rods technique) ..	<del>((50.0))</del> <u>40.7</u>	180	13.0
22610 Arthrodesis, posterior or posterolateral technique, with local bone or bone allograft and/or internal fixation; thoracic .....	<del>((22.0))</del> <u>22.6</u>	180	7.0	22842 segmental fixation (e.g., pedicle fixation, dual rods with multiple hooks and sublaminar wires) .....	<del>((42))</del> <u>27.1</u>	180	13.0
22612 lumbar .....	<del>((22.0))</del> <u>22.6</u>	180	7.0	22845 Anterior instrumentation .....	<del>((BR))</del> <u>45.2</u>	<u>180</u>	7.0
22625 Arthrodesis, lateral transverse process technique, with local bone or bone allograft and/or internal wire fixation, lumbar ..	<del>((22.0))</del> <u>22.6</u>	180	7.0	22849 Reinsertion of spinal fixation device .....	<del>((BR))</del> <u>9.0</u>	<u>180</u>	7.0
				22850 Removal of posterior nonsegmental instrumentation ..	<del>((BR))</del> <u>9.0</u>	<u>180</u>	8.0
				22852 Removal of posterior segmental instrumentation .....	<del>((1+0))</del> <u>11.3</u>	180	3.5
				22855 Removal of anterior instrumentation .....	<del>((BR))</del> <u>19.9</u>	<u>180</u>	8.0
				(For spinal cord monitoring, use 95925)			
				<b>MISCELLANEOUS</b>			
				22899 Unlisted procedure, spine .....	<del>BR</del>	<u>180</u>	7.0

**AMENDATORY SECTION** (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

**WAC 296-22-061 ABDOMEN.**

	Unit Value	Follow-up Days=	Basic Anes@
<b>EXCISION</b>			
22900 Excision, abdominal wall tumor, subfascial (e.g., desmoid) . . . . .	<del>((10.0))</del> 4.5	90	4.0
<b>MISCELLANEOUS</b>			
22999 Unlisted procedure, abdomen, musculoskeletal system . . . . .	BR		5.0

**AMENDATORY SECTION** (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

**WAC 296-22-063 SHOULDER.**

(Clavicle, scapula, humerus head and neck, sternoclavicular joint, acromioclavicular joint and shoulder joint)

	Unit Value	Follow-up Days=	Basic Anes@
<b>INCISION</b>			
23000 Removal of subdeltoid (or intratendinous) calcareous deposits, open method . . . . .	<del>((6.0))</del> 5.6	60	3.0
23020 Capsular contracture release (Sever type procedure) for Erb's palsy . . . . .	<del>((11.0))</del> 10.3	60	3.0
(For incision and drainage procedures, superficial, see 10000-10160)			
23030 Incision and drainage; shoulder area deep abscess or hematoma . . . . .	<del>((BR))</del> 3.6	15	3.0
23031 infected bursa . . . . .	<del>((BR))</del> 3.2	15	3.0
23035 Incision, deep, with opening of cortex (e.g., shoulder area) for osteomyelitis or bone abscess . . . . .	<del>((BR))</del> 10.8	30	3.0
23040 Arthrotomy, glenohumeral joint, for infection, with exploration, drainage, or removal of foreign body . . . . .	<del>((11.0))</del> 10.3	60	5.0
23044 Arthrotomy, acromioclavicular, sternoclavicular joint, for infection, with exploration, drainage, or removal of foreign body . . . . .	<del>((10.0-60))</del> 6.3	45	5.0

	Unit Value	Follow-up Days=	Basic Anes@
<b>EXCISION</b>			
23065 Biopsy, soft tissue of shoulder area; superficial . . . . .	<del>((1.2-7))</del> 1.8	0	3.0
23066 deep . . . . .	<del>((2.4-15))</del> 2.9	0	3.0

(For needle biopsy of soft tissue use 20206)

	Unit Value	Follow-up Days=	Basic Anes@
23075 Excision, tumor; shoulder area subcutaneous . . . . .	<del>((3.0))</del> 1.8	7	3.0
23076 deep, subfascial or intramuscular . . . . .	<del>((4.0))</del> 3.6	15	3.0
23077 Radical resection of tumor (e.g., malignant neoplasm), soft tissue of shoulder area . . . . .	<del>((BR))</del> 13.6	180	
23100 Arthrotomy for biopsy, glenohumeral joint . . . . .	<del>((11.0))</del> 10.3	60	3.0
23101 Arthrotomy for biopsy or for excision of torn cartilage, acromioclavicular, sternoclavicular joint . . . . .	<del>((11.0))</del> 10.3	60	4.0
23105 Arthrotomy for synovectomy; glenohumeral joint . . . . .	<del>((BR))</del> 13.6	90	5.0
23106 sternoclavicular joint . . . . .	<del>((BR))</del> 10.8	90	4.0
23107 Arthrotomy, glenohumeral joint, with joint exploration, with or without removal of loose foreign body . . . . .	<del>((BR))</del> 10.8	90	
23120 Claviclectomy; partial . . . . .	<del>((8.5))</del> 7.2	60	5.0
23125 total . . . . .	<del>((16.0))</del> 14.5	60	5.0
23130 Acromioplasty or acromiectomy, partial ((or total)) . . . . .	<del>((8.5))</del> 7.2	60	5.0
23140 Excision or curettage of bone cyst or benign tumor of clavicle or scapula . . . . .	<del>((6.0))</del> 5.6	60	3.0
23145 with primary autogenous graft (includes obtaining graft) . . . . .	<del>((9.0))</del> 8.4	120	3.0
23146 with homogenous or other nonautogenous graft . . . . .	<del>((11.0-120))</del> 6.8	90	3.0
23150 Excision or curettage of bone cyst or benign tumor of proximal humerus . . . . .	<del>((6.0-120))</del> 10.8	30	3.0
23155 with primary autogenous graft (includes obtaining graft) . . . . .	<del>((9.0))</del> 13.6	120	3.0
23156 with homogenous or other nonautogenous graft . . . . .	<del>((11.0))</del> 11.7	120	3.0
23170 Sequestrectomy (e.g., for osteomyelitis or bone abscess), clavicle . . . . .	<del>((BR))</del> 5.4	120	3.0
23172 Sequestrectomy (e.g., for osteomyelitis or bone abscess), scapula . . . . .	<del>((BR))</del> 5.4	30	3.0
23174 Sequestrectomy (e.g., for osteomyelitis or bone abscess), humeral head to surgical neck . . . . .	<del>((BR))</del> 11.0	120	3.0
23180 Partial excision of bone (craterization, saucerization or diaphysectomy) for osteomyelitis, clavicle . . . . .	<del>((5.0-60))</del> 6.8	120	3.0

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
23182 Partial excision of bone (craterization, saucerization, or diaphysectomy) for osteomyelitis, scapula.....	<del>((6.0—60))</del> 5.4	30	4.0	23410 Repair of ruptured supraspinatus tendon (rotator cuff) or musculotendinous cuff; acute ..	<del>((14.0))</del> 12.7	120	5.0
23184 Partial excision (craterization, saucerization, or diaphysectomy) of bone (e.g., for osteomyelitis), proximal humerus .....	<del>((6.0—60))</del> 9.0	30	4.0	23412 chronic .....	<del>((16.0—120))</del> 13.7	60	5.0
23190 Osteotomy of scapula, partial (e.g., superior medial angle)....	<del>((7.0))</del> 5.9	60	3.0	23415 Coracoacromial ligament release, with or without acromioplasty, for chronic ruptured supraspinatus tendon (rotator cuff) .....	<del>((6.5))</del> 9.0	60	5.0
23195 Resection humeral head .....	<del>((BR))</del> 13.6		3.0	23420 Repair of complete shoulder (rotator) cuff avulsion, chronic (includes acromioplasty) .....	<del>((18.0))</del> 17.2	120	5.0
(For replacement with implant, see 23470)				23430 Tenodesis for rupture of long tendon of biceps.....	<del>((12.0))</del> 10.8	90	5.0
23200 Radical resection for tumor; clavicle.....	<del>((BR))</del> 10.8	30	3.0	23440 Resection or transplantation of long tendon of biceps, for chronic tenosynovitis.....	<del>((12.0))</del> 10.8	90	5.0
23210 scapula .....	<del>((BR))</del> 14.5	30	3.0	23450 Capsulorrhaphy for recurrent dislocation, anterior; Putti-Platt procedure or Magnuson type operation .....	<del>((17.0))</del> 15.2	90	5.0
23220 Radical resection for tumor, proximal humerus .....	<del>((BR))</del> 14.5	30	3.0	23455 Bankart type operation with or without stapling .....	<del>((19.0))</del> 17.1	90	5.0
23221 with autogenous bone graft, (includes obtaining graft) ....	<del>((BR))</del> 16.3	120	3.0	23460 Capsulorrhaphy for recurrent dislocation, anterior, any type; with bone block .....	<del>((20.0))</del> 18.3	120	5.0
23222 with prosthetic replacement ..	<del>((BR))</del> 16.3	120	3.0	23462 with coracoid process transfer .....	<del>((18.0—120))</del> 17.2	90	5.0
<b>INTRODUCTION OR REMOVAL</b>				23465 Capsulorrhaphy for recurrent dislocation, posterior, with or without bone graft.....	<del>((17.0))</del> 17.2	90	5.0
(For arthrocentesis or needling of bursa, see 20610)				(For sternoclavicular and acromioclavicular reconstruction, see 23530 or 23550)			
(For K wire or pin insertion or removal, see 20650, 20670, 20680)				23466 Capsulorrhaphy for recurrent dislocation with any type multidirectional instability .....	<del>((BR))</del> 18.1	90	3.0
23330 Removal of foreign body, shoulder; subcutaneous .....	<del>((8.0))</del> 8.1	60	3.0	23470 Arthroplasty with proximal humeral implant (e.g., Neer type operation) .....	<del>((20.0))</del> 18.1	120	6.0
23331 deep (e.g., neer prosthesis removal).....	<del>((11.0))</del> 9.9	60	3.0	23472 Arthroplasty with glenoid and proximal humeral replacement (e.g., total shoulder) .....	<del>((BR))</del> 31.6	180	6.0
23332 complicated, including "total shoulder" .....	BR	60	3.0	(For removal of total shoulder implants, see 23331, 23332)			
23350 Injection procedure for shoulder arthrography .....	<del>((0.6))</del> 0.7	0	3.0	(For osteotomy proximal humerus, see 24400)			
(For shoulder arthrography, see 73040)				23480 Osteotomy, clavicle, with or without internal fixation .....	<del>((10.0))</del> 9.0	90	3.0
<b>REPAIR, REVISION OR RECONSTRUCTION</b>				23485 with bone graft for nonunion or malunion (includes obtaining graft and/or necessary fixation) .....	<del>((13.0))</del> 11.7	120	3.0
23395 Muscle transfer, any type for paralysis of shoulder or upper arm; single.....	<del>((20.0—90))</del> 9.5	60	5.0				
23397 multiple .....	<del>((BR—90))</del> 11.3	60	5.0				
23400 Scapulopexy (e.g., Sprengel's deformity or for paralysis) .....	<del>((22.0—90))</del> 13.6	60	5.0				
23405 Tenotomy; shoulder area single.....	<del>((7.0))</del> 7.7	60	5.0				
23406 multiple through same incision .....	<del>((13.0))</del> 10.6	60	5.0				



	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
23490 Prophylactic treatment (nailing, pinning, plating, or wiring) with or without methyl methacrylate; clavicle	<del>(DR)</del> 6.3	90		23610 Treatment of open humeral (surgical or anatomical neck) fracture, with uncomplicated soft tissue closure	<del>(7-0)</del> 6.1	90	3.0
23491 proximal humerus and humeral head	<del>(DR)</del> 8.1	90		23615 Open treatment of closed or open humeral (surgical or anatomical neck) fracture, with or without internal or external skeletal fixation	<del>(+2-0)</del> 10.8	90	3.0
<b>FRACTURE AND/OR DISLOCATION</b>				23620 Treatment of closed greater tuberosity fracture; without manipulation	<del>(Sv-6)</del> 1.2	90	
23500 Treatment of closed clavicular fracture; without manipulation	<del>(Sv-6)</del> 2.0	0		23625 with manipulation	<del>(3-5)</del> 2.3	90	3.0
23505 with manipulation	<del>(3-0)</del> 3.2	90	3.0	23630 Open treatment of closed or open greater tuberosity fracture, with or without internal or external skeletal fixation	<del>(9-0-90)</del> 8.2	30	3.0
23510 Treatment of open clavicular fracture, with uncomplicated soft tissue closure	5.0	90	3.0	23650 Treatment of closed shoulder dislocation, with manipulation; without anesthesia	<del>(Sv-6)</del> 2.4	30	
23515 Open treatment of closed or open clavicular fracture, with or without internal or external skeletal fixation	<del>(9-0)</del> 8.1	90	3.0	*23655 requiring anesthesia	<del>(+1-2-0)</del> 3.5	30	3.0
23520 Treatment of closed sternoclavicular dislocation; without manipulation	<del>(Sv-6)</del> 1.8	0		23658 Treatment of open shoulder dislocation, with uncomplicated soft tissue closure	<del>(DR)</del> 7.2	90	3.0
23525 with manipulation	<del>(2-0)</del> 2.2	90	3.0	23660 Open treatment of closed or open shoulder dislocation	<del>(+2-0)</del> 10.4	90	3.0
23530 Open treatment of closed or open Sternoclavicular dislocation, acute or chronic	<del>(+0-0)</del> 7.2	90	5.0	23665 Treatment of closed shoulder dislocation, with fracture of greater tuberosity, with manipulation	<del>(3-0)</del> 2.7	90	3.0
23532 with fascial graft (includes obtaining graft)	<del>(+2-0)</del> 9.9	90	5.0	23670 Open treatment of closed or open shoulder dislocation, with fracture of greater tuberosity	<del>(+2-0)</del> 10.4	90	3.0
23540 Treatment of closed acromioclavicular dislocation, without manipulation	<del>(Sv-6)</del> 1.2	0		23675 Treatment of closed shoulder dislocation, with surgical or anatomical neck fracture, with manipulation	<del>(4-0)</del> 4.1	90	3.0
23545 with manipulation	<del>(2-4-45)</del> 2.2	60	3.0	23680 Open treatment of closed or open shoulder dislocation, with surgical or anatomical neck fracture	<del>(+4-0)</del> 13.1	90	3.0
23550 Open treatment of closed or open acromioclavicular dislocation, acute or chronic	<del>(+2-0)</del> 10.4	90	5.0	<b>MANIPULATION</b>			
23552 with fascial graft (includes obtaining graft)	<del>(+5-0)</del> 11.7	90	5.0	*23700 Manipulation under anesthesia, shoulder joint including application of fixation apparatus (dislocation excluded)	<del>(+1-2-0)</del> 2.7	15	4.0
23570 Treatment of closed scapular fracture; without manipulation	<del>(Sv-6)</del> 1.4	90		<b>ARTHRODESIS</b>			
23575 with manipulation (with or without shoulder joint involvement)	<del>(2-8)</del> 2.5	90	3.0	23800 Arthrodesis, shoulder joint, with or without local bone graft	<del>(20-0)</del> 18.1	120	5.0
23580 Treatment of open scapular fracture, with uncomplicated soft tissue closure	<del>(5-0)</del> 3.9	90	3.0	23802 with primary autogenous graft (includes obtaining graft)	<del>(24-0)</del> 19.0	120	5.0
23585 Open treatment of closed or open scapular fracture juxtaarticular	<del>(+2-0)</del> 10.4	90	3.0				
23600 Treatment of closed humeral (surgical or anatomical neck) fracture; without manipulation	<del>(Sv-6)</del> 1.8	90					
23605 with manipulation	<del>(5-0)</del> 4.5	90	3.0				

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
<b>AMPUTATION</b>				24105	Excision, olecranon bursa . . . . .	<del>((4-8))</del> 4.5	60 3.0
23900	Intertoroscaspular amputation (forequarter) . . . . .	<del>((24-0))</del> 24.4	90 11.0	24110	Excision or curettage of bone cyst or benign tumor, humerus..	<del>((9-5))</del> 9.0	60 3.0
23920	Disarticulation of shoulder . . . . .	<del>((18-0))</del> 17.2	90 5.0	24115	with primary autogenous graft (includes obtaining graft) . . . . .	<del>((12-5))</del> 12.2	120 3.0
23921	secondary closure or scar revision . . . . .	<del>((5-0))</del> 4.5	30 3.0	24116	with homogenous or other nonautogenous graft . . . . .	<del>((13-0))</del> 9.9	120 3.0

**MISCELLANEOUS**

23929 Unlisted procedure, shoulder . . . BR 5.0

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-067 HUMERUS (UPPER ARM) AND ELBOW.**

(Elbow area includes head and neck of radius and olecranon process.)

**INCISION**

(For incision and drainage procedures, superficial, see 10000-10160)

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
23930	Incision and drainage; deep abscess or hematoma . . . . .	<del>((5-0 — 15))</del> 3.2	30 3.0	24125	with primary autogenous graft (includes obtaining graft) . . . . .	<del>((10-0))</del> 9.3	120 3.0
23931	infected bursa . . . . .	<del>((5-0 — 15))</del> 2.3	0 3.0	24126	with homogenous or other nonautogenous graft . . . . .	<del>((11-0))</del> 8.1	120 3.0
23935	Incision, deep, with opening of cortex (e.g., for osteomyelitis or bone abscess) humerus or elbow . . . . .	<del>((8-0 — 15))</del> 5.4	0 3.0	24130	Excision, radial head . . . . .	<del>((8-0))</del> 7.7	60 3.0
24000	Arthrotomy, elbow, for infection, with exploration, drainage, or removal of foreign body . . . . .	<del>((10-0))</del> 9.9	60 3.0		(For replacement with implant, see 24366)		
				24134	Sequestrectomy (e.g., for osteomyelitis or bone abscess), shaft or distal humerus . . . . .	<del>((BR))</del> 10.8	30 3.0
				24136	Sequestrectomy (e.g., for osteomyelitis or bone abscess), radial head or neck . . . . .	<del>((BR))</del> 10.8	30 3.0
				24138	Sequestrectomy (e.g., for osteomyelitis or bone abscess), olecranon process . . . . .	<del>((BR))</del> 10.8	30 3.0
				24140	Partial excision (craterization, saucerization or diaphysectomy), of bone (e.g., for osteomyelitis), humerus . . . . .	<del>((7-0))</del> 10.8	60 3.0
				24145	Partial excision (craterization, saucerization or diaphysectomy.) of bone (e.g., for osteomyelitis), radial head or neck . . . . .	<del>((7-0 — 6-0))</del> 7.2	30 3.0
				24147	Partial excision (craterization, saucerization or diaphysectomy) of bone (e.g., for osteomyelitis), olecranon process . . . . .	<del>((7-0))</del> 6.8	60 3.0
				24150	Radical resection for tumor, shaft or distal humerus . . . . .	<del>((BR))</del> 15.4	0 3.0
				24151	with autogenous bone graft (includes obtaining graft) . . . . .	<del>((BR))</del> 17.2	0 3.0
				24152	Radical resection for tumor, radial head or neck . . . . .	<del>((BR))</del> 13.6	0 3.0
				24153	with autogenous bone graft (includes obtaining graft) . . . . .	<del>((BR))</del> 18.1	0 3.0
				24155	Resection of elbow joint (arthrectomy) . . . . .	<del>((BR))</del> 11.2	60 3.0

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
<b>INTRODUCTION OR REMOVAL</b>				24361	with distal humeral prosthetic replacement	<del>((BR))</del> <u>120</u>	3.0
(For K wire or pin insertion or removal, see 20650, 20670, 20680)				24362	with implant and fascia lata ligament reconstruction	<del>((BR))</del> <u>120</u>	3.0
(For arthrocentesis or needling of bursa or joint, see 20605)				24363	with distal humerus and proximal ulnar prosthetic replacement ("total elbow")	<del>((BR))</del> <u>120</u>	3.0
24160	Implant removal; elbow joint	<del>((6-0))</del> <u>8.8</u>	60	3.0			
24164	radial head	<del>((4-8-60))</del> <u>7.7</u>	<u>30</u>	3.0			
24200	Removal of foreign body; upper arm or elbow area subcutaneous	<del>((BR))</del> <u>2.0</u>	<u>30</u>	3.0	24365	Arthroplasty, radial head;	<del>((10-0-120))</del> <u>9.0</u>
24201	deep	<del>((BR))</del> <u>3.5</u>	<u>30</u>	3.0	24366	with implant	<del>((BR))</del> <u>9.9</u>
24220	Injection procedure for elbow arthrography	<del>((BR))</del> <u>0.9</u>	<u>0</u>	3.0	24400	Osteotomy, humerus, with or without internal fixation	<del>((12-0))</del> <u>12.3</u>
(For elbow arthrography, see 73085)				24410	Multiple osteotomies with realignment on intramedullary rod humeral shaft (Sofield type procedure)	14.0	90
(For injection of tennis elbow, see 20550)				24420	Osteoplasty, humerus (e.g., shortening or lengthening) (excluding 64876)	<del>((BR))</del> <u>14.0</u>	90
<b>REPAIR, REVISION, AND RECONSTRUCTION</b>				24430	Repair of nonunion or malunion, humerus; without graft (e.g., compression technique, etc.)	<del>((17-0))</del> <u>15.4</u>	90
24301	Muscle or tendon transfer, any type, upper arm or elbow area single (excluding 24320-24331)	<del>((BR))</del> <u>12.7</u>	<u>30</u>	3.0	24435	with iliac or other autogenous bone graft (includes obtaining graft)	<del>((20-0))</del> <u>18.1</u>
24305	Tendon lengthening; upper arm or elbow area single, each	<del>((7-0))</del> <u>5.2</u>	<u>60</u>	3.0	(For proximal radius and/or ulna, see 25400-25420)		
24310	Tenotomy, open, elbow to shoulder, single, each	<del>((5-0))</del> <u>4.5</u>	30	3.0	24470	Hemiepiphyseal arrest (e.g., for cubitus varus or valgus, distal humerus)	<del>((7-0))</del> <u>7.7</u>
24320	Tenoplasty, with muscle transfer, with or without free graft, elbow to shoulder, single (Seddon-Brookes type procedure)	<del>((BR))</del> <u>15.4</u>	<u>90</u>	3.0	24495	Decompression fasciotomy, forearm, with brachial artery exploration	<del>((BR))</del> <u>10.8</u>
24330	Flexor-plasty, elbow (e.g., Steindler type advancement)	<del>((8-0))</del> <u>9.9</u>	90	3.0	24498	Prophylactic treatment (nailing, pinning, plating or wiring) with or without methyl methacrylate; humerus	<del>((BR))</del> <u>9.0</u>
24331	with extensor advancement	<del>((8-0))</del> <u>12.9</u>	90	3.0	<b>FRACTURE AND/OR DISLOCATION</b>		
24340	Tenodesis for rupture of biceps tendon at elbow	<del>((14-0))</del> <u>12.7</u>	90	3.0	24500	Treatment of closed humeral shaft fracture; without manipulation	<del>((5-0))</del> <u>1.2</u>
24342	Reinsertion of ruptured biceps tendon, distal, with or without tendon graft (includes obtaining graft)	<del>((14-0))</del> <u>12.7</u>	90	3.0	24505	with manipulation	<del>((5-0))</del> <u>4.8</u>
24350	Fasciotomy, lateral or medial (e.g., "tennis elbow" or epicondylitis)	<del>((6-0))</del> <u>4.5</u>	30	3.0	24506	percutaneous insertion of rod or pin	<del>((BR))</del> <u>6.3</u>
24351	with extensor origin detachment	<del>((5-0))</del> <u>5.4</u>	30	3.0	24510	Treatment of open humeral shaft fracture, with uncomplicated soft tissue closure	<del>((7-0))</del> <u>6.3</u>
24352	with annular ligament resection	<del>((6-0))</del> <u>7.2</u>	30	3.0	24515	Open treatment of closed or open humeral shaft fracture, with or without internal or external skeletal fixation	<del>((11-0))</del> <u>9.9</u>
24354	with stripping	<del>((7-0))</del> <u>6.3</u>	<u>30</u>	3.0			
24356	with partial osteotomy	<del>((BR))</del> <u>7.2</u>	<u>30</u>	3.0			
24360	Arthroplasty, elbow, with membrane	<del>((BR))</del> <u>19.9</u>	<u>90</u>	3.0			

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
24530 Treatment of closed supracondylar or transcondylar fracture, without manipulation . . . . .	<del>(Sv.&amp;)</del> 2.3	90		24585 Open treatment of closed or open comminuted elbow fracture (fracture distal humerus and/or proximal ulna/radius), with or without internal or external skeletal fixation . . . . .	<del>(+2.0)</del> 13.9	90	3.0
24531 with traction (pin or skin) . . . . .	<del>(BR)</del> 5.9	90	3.0	24586 with elbow resection . . . . .	<del>(BR)</del> 13.9	90	3.0
24535 Treatment of closed supracondylar or transcondylar fracture, with manipulation . . . . .	<del>(5.0)</del> 4.8	90	3.0	24587 with implant . . . . .	<del>(BR)</del> 19.9	90	3.0
24536 with traction (pin or skin) . . . . .	<del>(9.0)</del> 6.1	90	3.0	(See also 24361)			
24538 with percutaneous skeletal fixation . . . . .	<del>(+0.0)</del> 8.1	90	3.0	24588 with implants and fascia lata ligament reconstruction . . . . .	<del>(BR)</del> 20.8	90	3.0
24540 Treatment of open supracondylar or transcondylar fracture, with uncomplicated soft tissue closure . . . . .	<del>(7.0)</del> 8.1	90	3.0	(See also 24362)			
24542 with traction (pin or skin) . . . . .	<del>(+1.0)</del> 8.6	90	3.0	24600 Treatment of closed elbow dislocation; without anesthesia . . . . .	<del>(Sv.&amp;)</del> 2.3	60	
24545 Open treatment of closed or open humeral supracondylar or transcondylar fracture, with or without internal or external skeletal fixation . . . . .	<del>(+0.0)</del> 11.3	90	3.0	*24605 requiring anesthesia . . . . .	<del>(+1.0)</del> 2.9	60	3.0
24560 Treatment of closed epicondylar fracture, medial or lateral; without manipulation . . . . .	<del>(Sv.&amp;)</del> 2.0			24610 Treatment of open elbow dislocation, with uncomplicated soft tissue closure . . . . .	<del>(6.0)</del> 5.4	45	3.0
24565 with manipulation . . . . .	<del>(4.0)</del> 3.6	90	3.0	24615 Open treatment of closed or open elbow dislocation . . . . .	<del>(+2.0)</del> 9.6	90	3.0
24570 Treatment of open humeral epicondylar fracture, medial or lateral with uncomplicated soft tissue closure . . . . .	<del>(6.0)</del> 5.0	90	3.0	24620 Treatment of closed Monteggia type of fracture dislocation at elbow (fracture proximal end of ulna with dislocation of radial head) . . . . .	<del>(4.0)</del> 5.4	90	3.0
24575 Open treatment of closed or open epicondylar fracture, medial or lateral, with or without internal or external skeletal fixation . . . . .	9.0	90	3.0	24625 Treatment of open Monteggia type of fracture dislocation at elbow (fracture proximal end of ulna with dislocation of the radial head), with uncomplicated soft tissue closure . . . . .	<del>(6.0)</del> 5.9	90	3.0
24576 Treatment of closed humeral condylar fracture, medial or lateral; without manipulation . . . . .	<del>(Sv)</del> 1.2	60		24635 Open treatment of closed or open Monteggia type fracture dislocation at elbow (fracture proximal end of ulna with dislocation of radial head), with or without internal or external skeletal fixation . . . . .	<del>(+2.0)</del> 10.8	90	3.0
24577 with manipulation . . . . .	<del>(4.0)</del> 3.6	90	3.0	*24640 Treatment of radial head subluxation in child, "nursemaid elbow," with manipulation . . . . .	<del>(Sv.&amp;)</del> 1.8	60	
24578 Treatment of open condylar fracture, medial or lateral, with uncomplicated soft tissue closure . . . . .	5.0	90	3.0	24650 Treatment of closed radial head or neck fracture; without manipulation . . . . .	<del>(Sv.&amp;)</del> 1.8	60	
24579 Open treatment of closed or open condylar fracture, medial or lateral, with or without internal or external skeletal fixation . . . . .	<del>(7.0)</del> 9.0	90	3.0	24655 with manipulation . . . . .	<del>(3.0)</del> 3.2	90	3.0
24580 Treatment of closed comminuted elbow fracture (fracture distal humerus and/or proximal ulna and/or proximal radius), treatment with traction, (pin or skin); without manipulation . . . . .	<del>(Sv)</del> 10.8	90		24660 Treatment of open radial head or neck fracture, with uncomplicated soft tissue closure . . . . .	<del>(4.0)</del> 4.5	90	3.0
24581 with manipulation . . . . .	<del>(8.0)</del> 7.2	90	3.0	24665 Open treatment of closed or open radial head or neck fracture, with or without internal fixation or radial head excision . . . . .	<del>(8.0)</del> 7.2	90	3.0
24583 Treatment of open comminuted elbow fracture (fracture distal humerus and/or proximal ulna and/or proximal radius), with uncomplicated soft tissue closure . . . . .	9.0	90	3.0	24666 with implant . . . . .	<del>(9.0)</del> 8.4	90	3.0

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
24670 Treatment of closed ulnar fracture, proximal end (olecranon process); without manipulation . . . . .	<del>(5-8)</del> 1.8	60		25005 at wrist for other stenosing tenosynovitis . . . . .	<del>(4-0)</del> 4.1	30	3.0
24675 with manipulation . . . . .	<del>(3-0)</del> 4.1	90	3.0	(For decompression median nerve or for carpal tunnel syndrome, see 64721)			
24680 Treatment of open ulnar fracture, proximal end (olecranon process), with uncomplicated soft tissue closure . . . . .	<del>(4-0)</del> 4.5	90	3.0	25020 Decompression fasciotomy, wrist flexor and/or extensor compartment . . . . .	<del>(3-5)</del> 5.0	30	3.0
24685 Open treatment of closed or open ulnar fracture proximal end (olecranon process), with or without internal or external skeletal fixation . . . . .	<del>(8-0)</del> 7.5	90	3.0	25023 with debridement of nonviable muscle and/or nerve . . . . .	<del>(4-0)</del> 5.4	30	3.0

MANIPULATION

(24700 has been deleted; use 24999)

ARTHRODESIS

24800 Arthrodesis, elbow joint; with or without local or homogenous bone graft . . . . .	<del>(16-0)</del> 14.9	120	3.0
24802 with primary autogenous bone graft (includes obtaining graft) . . . . .	<del>(16-0)</del> 18.1	120	3.0

AMPUTATION

24900 Amputation, arm through humerus; with primary closure . . . . .	<del>(10-0)</del> 9.0	90	3.0
24920 open, circular (guillotine) . . . . .	<del>(9-0)</del> 8.2	90	3.0
24925 secondary closure or scar revision . . . . .	<del>(3-0)</del> 2.8	30	3.0
24930 reamputation . . . . .	<del>(10-0)</del> 8.1	90	3.0
24931 with implant . . . . .	<del>(10-0)</del> 10.4	90	3.0
24935 Stump elongation . . . . .	<del>(3-0)</del> 13.6	90	3.0
24940 Cineplasty, upper extremity, complete procedure . . . . .	<del>(BR)</del> 13.6	90	3.0

MISCELLANEOUS

24999 Unlisted procedure, humerus or elbow . . . . .	BR		4.0
--	----	--	-----

AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

WAC 296-22-071 FOREARM AND WRIST.

(Radius, ulna, carpal bones and joints)

INCISION

25000 Tendon sheath incision; at radial styloid for De Quervain's disease . . . . .	<del>(4-4)</del> 4.1	30	3.0
---	-------------------------	----	-----

(For decompression median nerve or for carpal tunnel syndrome, see 64721)			
25020 Decompression fasciotomy, wrist flexor and/or extensor compartment . . . . .	<del>(3-5)</del> 5.0	30	3.0
25023 with debridement of nonviable muscle and/or nerve . . . . .	<del>(4-0)</del> 5.4	30	3.0
(For decompression fasciotomy with brachial artery exploration, see 24495)			
(For incision and drainage procedures, superficial, see 10000-10160)			
(For debridement, see also 11000-11044)			
25028 Incision and drainage; forearm and/or wrist deep abscess or hematoma . . . . .	<del>(1-0)</del> 3.6	30	3.0
25031 infected bursa . . . . .	<del>(1-5)</del> 1.8	30	3.0
25035 Incision, deep, with opening of cortex (e.g., for osteomyelitis or bone abscess); forearm or wrist . . . . .	<del>(2-0-30)</del> 4.5 60		3.0
25040 Arthrotomy, radiocarpal, or mediocarpal joint, for infection, with exploration, drainage, or removal of foreign body . . . . .	5.0	60	3.0

EXCISION

25065 Biopsy, soft tissues; superficial . . . . .	<del>(2-0-7)</del> 1.8 0		3.0
25066 deep . . . . .	<del>(3-0-15)</del> 2.8 0		3.0
(For needle biopsy of soft tissue, use 20206)			
25075 Excision, tumor; forearm and/or wrist area subcutaneous . . . . .	<del>(4-0-15)</del> 2.7 30		3.0
25076 deep, subfascial or intramuscular . . . . .	<del>(4-0-15)</del> 4.5		3.0
25077 Radical resection of tumor (e.g., malignant neoplasm) soft tissue of forearm and/or wrist area . . . . .	<del>(BR)</del> 10.8 180		
25085 Capsulotomy, wrist (e.g., for contracture) . . . . .	<del>(4-0-15)</del> 4.9 60		3.0
25100 Arthrotomy, wrist joint, for biopsy . . . . .	<del>(5-0)</del> 4.5	60	3.0
25101 with joint exploration, with or without biopsy, with or without removal of loose or foreign body . . . . .	<del>(7-0)</del> 5.3	60	3.0
25105 for synovectomy . . . . .	<del>(8-0-90)</del> 7.2 60		3.0

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
25107 Arthrotomy, distal radioulnar joint for repair of triangular cartilage complex	<del>((9-0))</del> 6.3	60	3.0	25170 Radical resection for tumor, radius or ulna	<del>((BR))</del> 13.6	60	3.0
25110 Excision, lesion of tendon sheath forearm and/or wrist	<del>((3-0))</del> 3.2	30	3.0	25210 Carpectomy, one bone	<del>((7-0))</del> 6.3	60	3.0
25111 Excision of ganglion, wrist (dorsal or volar); primary	<del>((5-0))</del> 3.6	30	3.0	(For carpectomy with implant, see 25441-25445)			
25112 recurrent	<del>((4-0))</del> 5.2	30	3.0	25215 all bones of proximal row	<del>((10-0))</del> 9.0	60	3.0
(For hand or finger, see 26160)				25230 Radial styloidectomy (separate procedure)	<del>((5-0))</del> 4.9	60	3.0
25115 Radical excision of bursa synovia of wrist, or forearm tendon sheaths (e.g., tenosynovitis, fungus, Tbc., or other granulomas, rheumatoid arthritis); flexors	<del>((10-0))</del> 9.0	60	3.0	25240 Excision distal ulna (Darrach type procedure)	<del>((6-0))</del> 4.9	60	3.0
25116 extensors (with or without transposition of dorsal retinaculum)	<del>((10-0))</del> 9.0	60	3.0	(For implant replacement, distal ulna, see 25442)			
(For finger synovectomies, see 26145)				(For obtaining fascia for interposition, see 20920, 20922)			
25118 Synovectomy, extensor tendon sheaths, wrist, single compartment;	<del>((10-0))</del> 9.0	60	3.0	<b>INTRODUCTION OR REMOVAL</b>			
25119 with resection of distal ulna	<del>((11-0))</del> 9.0	60	3.0	(For K wire, pin, or rod insertion or removal, see 20650, 20670, 20680)			
25120 Excision or curettage of bone cyst or benign tumor of radius or ulna (excluding head or neck of radius and olecranon process)	<del>((7-0))</del> 7.5	60	3.0	25246 Injection procedure for wrist arthrography	<del>((BR))</del> 1.2	0	
(For head or neck of radius or olecranon process, see 24120, 24126)				(For wrist arthrography, see 73115)			
25125 with primary autogenous graft (includes obtaining graft)	<del>((10-0))</del> 9.5	120	3.0	(For foreign body removal, superficial see 20520)			
25126 with homogenous or other nonautogenous graft	<del>((10-0))</del> 8.6	120	3.0	25248 Exploration for removal of deep foreign body forearm or wrist	<del>((BR))</del> 4.5	60	
25130 Excision or curettage of bone cyst or benign tumor of carpal bones	<del>((5-0))</del> 4.5	60	3.0	25250 Removal of wrist prosthesis; (separate procedure)	<del>((BR))</del> 9.0	30	3.0
25135 with primary autogenous graft (includes obtaining graft)	<del>((7-0))</del> 6.3	120	3.0	25251 complicated, including "total wrist"	<del>((BR))</del> 13.6	30	3.0
25136 with homogenous or other nonautogenous graft	<del>((7-0))</del> 5.4	120	3.0	<b>REPAIR, REVISION OR RECONSTRUCTION</b>			
25145 Sequestrectomy (e.g., for osteomyelitis or bone abscess); forearm and/or wrist	<del>((BR))</del> 10.8	120	3.0	25260 Repair, tendon or muscle, flexor; forearm and/or wrist primary, single, each tendon or muscle	<del>((7-0-90))</del> 7.2 60		3.0
25150 Partial excision (craterization, saucerization or diaphysectomy) of bone (e.g., for osteomyelitis), ulna	<del>((5-0))</del> 5.8	60	3.0	25263 secondary, single, each tendon or muscle	<del>((1.5-90))</del> 7.7 60		3.0
25151 radius	<del>((5-0))</del> 6.8	60	3.0	25265 secondary, with free graft (includes obtaining graft), each tendon or muscle	<del>((3-0))</del> 9.0	90	3.0
(For head or neck of radius or olecranon process, see 24145-24147)				25270 Repair, tendon or muscle, extensor; forearm and/or wrist primary, single, each tendon or muscle	<del>((5-0-90))</del> 4.5 60		3.0
				25272 secondary, single, each tendon or muscle	<del>((1.5-90))</del> 4.7 60		3.0
				25274 Repair, tendon or muscle, extensor, secondary, with tendon graft (includes obtaining graft), forearm and/or wrist, each tendon or muscle	<del>((8-0))</del> 7.6	90	3.0

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
25280 Lengthening or shortening of flexor or extensor tendon, forearm and/or wrist single, each tendon . . . . .	<del>(7.0-90)</del> 6.5	60	3.0	25391 lengthening with autogenous bone graft . . . . .	<del>(BR)</del> 12.5	90	3.0
25290 Tenotomy, open, single, flexor or extensor tendon, forearm and/or wrist single, each tendon . . . . .	<del>(4.0-90)</del> 3.9	60	3.0	25392 Osteoplasty, radius AND ulna; shortening (excluding 64876) . . . . .	<del>(BR)</del> 13.6	90	3.0
25295 Tenolysis, single flexor or extensor tendon, forearm and/or wrist single, each tendon . . . . .	<del>(1.0-90)</del> 3.9	60	3.0	25393 lengthening with autogenous bone graft . . . . .	<del>(BR)</del> 14.5	120	3.0
25300 Tenodesis, at wrist; flexors of fingers . . . . .	<del>(8.0)</del> 8.6	90	3.0	25400 Repair of nonunion or malunion, radius OR ulna; without graft (e.g., compression technique, etc.) . . . . .	<del>(14.0)</del> 10.8	90	3.0
25301 extensors of fingers . . . . .	<del>(6.0)</del> 7.7	90	3.0	25405 with iliac or other autogenous bone graft (includes obtaining graft) . . . . .	<del>(17.0)</del> 13.1	120	3.0
25310 Tendon transplantation or transfer, flexor or extensor, forearm and/or wrist single, each tendon . . . . .	<del>(9.5)</del> 8.9	90	3.0	25415 Repair of nonunion or malunion, radius AND ulna; without graft (e.g., compression technique, etc.) . . . . .	<del>(20.0)</del> 15.4	90	3.0
25312 with tendon graft(s) (includes obtaining graft), each tendon . . . . .	<del>(8.0)</del> 10.8	90	3.0	25420 with iliac or other autogenous bone graft (includes obtaining graft) . . . . .	<del>(23.0)</del> 17.9	120	3.0
25315 Flexor origin slide for cerebral palsy; forearm and/or wrist . . . . .	<del>(8.0)</del> 9.9	90	3.0	25425 Repair of defect with autogenous bone graft; radius OR ulna . . . . .	<del>(14.0)</del> 12.3	120	3.0
25316 with tendon(s) transfer . . . . .	<del>(9.0)</del> 11.7	90	3.0	25426 radius AND ulna . . . . .	<del>(20.0)</del> 17.2	120	3.0
25317 Flexor origin slide for Volkmann contracture . . . . .	<del>(12.0)</del> 8.4	120	3.0	25440 Repair of nonunion, scaphoid (navicular) bone, with or without radial styloidectomy (includes obtaining graft and necessary fixation) . . . . .	<del>(14.0)</del> 12.2	120	3.0
25318 with tendon(s) transfer . . . . .	<del>(13.0-120)</del> 9.8	90	3.0	25441 Arthroplasty with prosthetic replacement; distal radius . . . . .	<del>(18.0)</del> 12.7	120	3.0
25320 Capsulorrhaphy or reconstruction, capsulectomy, wrist (includes synovectomy, resection of capsule, tendon insertions) . . . . .	<del>(21.1-120)</del> 13.6	90	3.0	25442 distal ulna . . . . .	<del>(12.5)</del> 8.1	120	3.0
25330 Arthroplasty, wrist . . . . .	<del>(8.0)</del> 8.1	120	3.0	25443 scaphoid (navicular) . . . . .	<del>(15.5)</del> 9.9	120	3.0
25331 with implant . . . . .	<del>(BR)</del> 8.9	120	3.0	25444 lunate . . . . .	<del>(15.5)</del> 9.9	120	3.0
25332 pseudarthrosis type with internal fixation . . . . .	<del>(BR)</del> 9.5	120	3.0	25445 trapezium . . . . .	<del>(15.5)</del> 9.9	120	3.0
(For obtaining fascia for interposition, see 20920-20922)				25446 distal radius and partial or entire carpus ("total wrist") . . . . .	<del>(20.0)</del> 20.3	120	3.0
25335 Centralization of wrist on ulna (e.g., radial club hand) . . . . .	<del>(BR)</del> 20.3	180	3.0	25447 Interposition arthroplasty; intercarpal or carpometacarpal . . . . .	<del>(BR)</del> 13.6	120	3.0
25350 Osteotomy, radius, distal third . . . . .	<del>(10.0)</del> 9.3	90	3.0	25449 Revision of arthroplasty, including removal of implant wrist joint . . . . .	<del>(BR)</del> 9.0	120	3.0
25355 middle or proximal third . . . . .	<del>(12.0)</del> 11.1	90	3.0	25450 Epiphyseal arrest by epiphysiodesis or stapling; distal radius OR ulna . . . . .	<del>(6.0)</del> 5.5	120	3.0
25360 Osteotomy, ulna . . . . .	<del>(10.0)</del> 9.3	90	3.0	25455 distal radius AND ulna . . . . .	<del>(8.0)</del> 7.7	120	3.0
25365 radius and ulna . . . . .	<del>(14.0)</del> 13.0	90	3.0	25490 Prophylactic treatment (nailing, pinning, plating or wiring) with or without methyl methacrylate; radius . . . . .	<del>(BR)</del> 5.4	120	3.0
25370 Multiple osteotomies, with realignment on intramedullary rod (Sofield type procedure), radius OR ulna . . . . .	<del>(12.0)</del> 10.8	90	3.0	25491 ulna . . . . .	<del>(BR)</del> 5.4	120	3.0
25375 radius AND ulna . . . . .	<del>(18.0)</del> 16.3	90	3.0				
25390 Osteoplasty, radius OR ulna; shortening . . . . .	<del>(BR+)</del> 10.0	90	3.0				

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
25492 radius and ulna .....	<del>((BR))</del> 5.4	120		25615 Treatment of open distal radial fracture (e.g., Colles or Smith type) or epiphyseal separation, without fracture of ulnar styloid, with uncomplicated soft tissue closure .....	<del>((5-0))</del> 6.7	90	3.0
<b>FRACTURE AND/OR DISLOCATION</b>							
25500 Treatment of closed radial shaft fracture; without manipulation .....	<del>((Sv.&amp;))</del> 2.0	60		25620 Open treatment of closed or open distal radial fracture (e.g., Colles or Smith type) or epiphyseal separation, with or without fracture of the ulnar styloid, with or without internal or external skeletal fixation .....	<del>((8-0))</del> 8.1	90	3.0
25505 with manipulation .....	<del>((4-2))</del> 3.9	90	3.0	25622 Treatment of closed carpal scaphoid (navicular) fracture; without manipulation .....	<del>((Sv.&amp;))</del> 3.2	60	
25510 Treatment of open radial shaft fracture, with uncomplicated soft tissue closure .....	<del>((5-0))</del> 5.1	90	3.0	25624 with manipulation .....	<del>((4-0))</del> 3.6	90	3.0
25515 Open treatment of closed or open radial shaft fracture, with or without internal or external skeletal fixation .....	<del>((8-0))</del> 8.2	90	3.0	25626 Treatment of open carpal scaphoid (navicular) fracture, with uncomplicated soft tissue closure .....	<del>((5-0))</del> 4.5	90	3.0
25530 Treatment of closed ulnar shaft fracture; without manipulation .....	<del>((Sv.&amp;))</del> 3.0	60		25628 Open treatment of closed or open carpal scaphoid (navicular) fracture, with or without skeletal fixation .....	<del>((8-0))</del> 5.4	90	3.0
25535 with manipulation .....	<del>((4-0))</del> 3.6	90	3.0	25630 Treatment of closed carpal bone fracture (excluding carpal scaphoid (navicular)); without manipulation, each bone .....	<del>((Sv.&amp;))</del> 3.2	60	
25540 Treatment of open ulnar shaft fracture with uncomplicated soft tissue closure .....	<del>((5-0))</del> 5.4	90	3.0	25635 with manipulation, each bone .....	<del>((4-0-90))</del> 3.5	60	3.0
25545 Open treatment of closed or open ulnar shaft fracture, with or without internal or external skeletal fixation .....	<del>((8-0))</del> 8.1	90	3.0	25640 Treatment of open carpal bone fracture (excluding carpal scaphoid (navicular)); with uncomplicated soft tissue closure, each bone .....	<del>((5-0))</del> 4.6	90	3.0
25560 Treatment of closed radial and ulnar shaft fractures; without manipulation .....	<del>((Sv.&amp;))</del> 2.6	60		25645 Open treatment of closed or open carpal bone fracture (excluding carpal scaphoid (navicular)), each bone .....	<del>((6-0))</del> 5.7	90	3.0
25565 with manipulation .....	<del>((5-4-90))</del> 5.3	60	3.0	25650 Treatment of closed ulnar styloid fracture .....	<del>((BR))</del> 5.2		3.0
25570 Treatment of open radial and ulnar shaft fractures, with uncomplicated soft tissue closure .....	<del>((6-0))</del> 6.8	90	3.0	25660 Treatment of closed radiocarpal or intercarpal dislocation, one or more bones, with manipulation .....	<del>((1-2-0))</del> 2.7	30	3.0
25575 Open treatment of closed or open radial and ulnar shaft fractures, with or without internal or external skeletal fixation .....	<del>((1-2-0))</del> 11.7	90	3.0	25665 Treatment of open radiocarpal or intercarpal dislocation, one or more bones, with uncomplicated soft tissue closure .....	<del>((4-0))</del> 2.7	45	3.0
25600 Treatment of closed distal radial fracture (e.g., Colles or Smith type) or epiphyseal separation, with or without fracture of ulnar styloid, without manipulation .....	<del>((Sv.&amp;))</del> 2.7	60		25670 Open treatment of closed or open radiocarpal or intercarpal dislocation, one or more bones .....	<del>((8-0))</del> 7.1	90	3.0
25605 with manipulation .....	<del>((4-0))</del> 4.1	90	3.0	25675 Treatment of closed distal radioulnar dislocation with manipulation .....	<del>((3-2))</del> 2.8	60	3.0
25610 Treatment of closed, complex, distal radial fracture (e.g., Colles or Smith type) or epiphyseal separation, with or without fracture of ulnar styloid, requiring manipulation; without external skeletal fixation or percutaneous pinning .....	<del>((6-0))</del> 6.7	90	3.0				
25611 percutaneous pinning or pins and plaster technique .....	<del>((8-0-120))</del> 7.7	90	3.0				



**AMENDATORY SECTION** (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

**WAC 296-22-073 HAND AND FINGERS.**

	Unit Value	Follow-up Days=	Basic Anes@
25676 Open treatment of closed or open distal radioulnar dislocation, acute or chronic .....	<del>((6-0))</del> 7.2	90	3.0
25680 Treatment of closed trans-scaphoperilunar type of fracture dislocation, with manipulation ..	<del>((6-0-45))</del> 1.8	60	3.0
25685 Open treatment of closed or open trans-scaphoperilunar type of fracture dislocation .....	<del>((+2-0))</del> 9.9	90	3.0
25690 Treatment of lunate dislocation, with manipulation .....	<del>((+0))</del> 4.6	90	3.0
25695 Open treatment of lunate dislocation .....	<del>((8-0-90))</del> 9.0	60	3.0

**MANIPULATION**

(25700 has been deleted, use 25999)

**ARTHRODESIS**

25800 Arthrodesis, wrist joint (including radiocarpal and/or ulnocarpal fusion), without bone graft .....	<del>((+2-0))</del> 11.3	120	3.0
25805 with sliding graft .....	<del>((+4-0))</del> 14.2	120	3.0
25810 with iliac or other autogenous distant bone graft (includes obtaining graft) .....	<del>((+6-0))</del> 14.6	120	4.0
25820 Intercarpal fusion, without bone graft .....	<del>((BR))</del> 10.8	120	3.0
25825 with autogenous bone graft (includes obtaining graft) ....	<del>((BR))</del> 14.5	120	3.0

**AMPUTATION**

25900 Amputation, forearm, through radius and ulna .....	<del>((9-0))</del> 8.4	90	3.0
25905 open, circular (guillotine) ...	<del>((8-0))</del> 7.2	90	3.0
25907 secondary closure or scar revision .....	<del>((3-0))</del> 2.8	30	3.0
25909 reamputation .....	<del>((9-0))</del> 8.4	90	3.0
25915 Krukenberg procedure .....	<del>((9-0-90))</del> 9.5	60	3.0
25920 Disarticulation through wrist ...	<del>((8-0))</del> 7.5	90	3.0
25922 secondary closure or scar revision .....	<del>((3-0-90))</del> 2.9	30	3.0
25924 reamputation .....	<del>((9-0))</del> 7.6	90	3.0
25927 Transmetacarpal amputation; ..	<del>((+0-0))</del> 9.0	90	3.0
25929 secondary closure or scar revision .....	<del>((3-0-90))</del> 2.8	30	3.0
25931 reamputation .....	<del>((+0-0))</del> 9.0	90	3.0

**MISCELLANEOUS**

25999 Unlisted procedure, forearm or wrist .....	BR		3.0
--	----	--	-----

	Unit Value	Follow-up Days=	Basic Anes@
--	------------	-----------------	-------------

**INCISION**

*26010 Drainage of finger tip abscess; simple .....	<del>((+0.72-0))</del> 0.7	7	3.0
*26011 complicated (e.g., felon, etc.) ..	<del>((BR))</del> 2.7	30	3.0
26020 Drainage of tendon sheath, one digit and/or palm .....	<del>((+0))</del> 4.6	30	3.0
26025 Drainage of palmar bursa; single, ulnar or radial .....	5.0	30	3.0
26030 multiple or complicated .....	<del>((BR))</del> 8.1		3.0
26034 Incision, deep, with opening of cortex (e.g., for osteomyelitis or bone abscess) hand or finger ....	<del>((+0))</del> 5.4	30	3.0
26035 Decompression fingers and/or hand, injection injury (e.g., grease gun, etc.) .....	<del>((BR))</del> 13.1	60	
<u>26037 Decompressive fasciotomy, hand (excludes 26035) .....</u>	<u>BR</u>		
<u>(For infection injury, see 26035)</u>			
26040 Fasciotomy, palmar, for Dupuytren's contracture; closed (subcutaneous) .....	<del>((3-6-60))</del> 2.7	30	3.0
26045 open, partial .....	<del>((5-0))</del> 4.5	60	3.0
(For fasciectomy, see 26120-26128)			
26055 Tendon sheath incision for trigger finger .....	<del>((5-0))</del> 4.1	30	3.0
26060 Tenotomy, subcutaneous, single, each digit .....	<del>((+2-0))</del> 2.3	15	3.0
26070 Arthrotomy, for infection, with exploration, drainage or removal of foreign body; carpometacarpal joint .....	<del>((5-0-60))</del> 4.6	30	3.0
26075 metacarpophalangeal joint ...	<del>((5-0-60))</del> 4.5	30	3.0
26080 interphalangeal joint, each ...	<del>((+0))</del> 4.1	60	3.0

**EXCISION**

26100 Arthrotomy for synovial biopsy; carpometacarpal joint .....	<del>((5-0-60))</del> 4.6	30	3.0
26105 metacarpophalangeal joint ...	<del>((5-0-60))</del> 4.5	30	3.0
26110 interphalangeal joint, each ...	<del>((+0-60))</del> 4.1	30	3.0
26115 Excision, tumor or vascular malformation, hand or finger; subcutaneous .....	<del>((+0-15))</del> 2.7	30	3.0
26116 deep, subfascial, intramuscular .....	<del>((+0))</del> 4.7	30	3.0
26117 Radical resection of tumor (e.g., malignant neoplasm), soft tissue of hand or finger .....	BR		

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@	
<del>((26120 Fasciectomy palmar, simple, for Dupuytren's contracture, partial excision</del>	<del>6.0</del>	<del>60</del>	<del>3.0</del>	26210	Excision or curettage of bone cyst or benign tumor of proximal, middle or distal phalanx; of finger	<del>(5.0)</del>	60	3.0
26122 up to 1/2 palmar fascia, with single digit involvement, with or without Z-plasty or other local tissue rearrangement	10.0	60	3.0))	26215	with autogenous graft (includes obtaining graft)	<del>(6.0)</del>	120	3.0
(For fasciotomy, see 26040-26045)				26230	Partial excision (craterization, saucerization, or diaphysectomy) of bone (e.g., for osteomyelitis), metacarpal	<del>(6.0)</del>	60	3.0
26121 Fasciectomy, palmar, with or without z-plasty, other local tissue rearrangement, or skin grafting (includes obtaining graft);			BR	26235	proximal or middle phalanx of finger	<del>(5.0)</del>	60	3.0
26123 partial excision with release of single digit including proximal interphalangeal joint			BR	26236	distal phalanx of finger	<del>(5.0)</del>	60	3.0
26125 partial excision with release of each additional digit, including proximal interphalangeal joint			BR	26250	Radical resection (ostectomy) for tumor, metacarpal	<del>(12.0)</del>	120	3.0
<del>((26124 Fasciectomy, palmar, complicated, requiring skin grafting (includes obtaining graft), with single digit involvement</del>	<del>14.0</del>	<del>90</del>	<del>3.0</del>	26255	with autogenous graft (includes obtaining graft)	<del>(12.0)</del>	120	3.0
26126 each additional digit	18.0	90	3.0	26260	Radical resection (ostectomy) for tumor, proximal or middle phalanx of finger	<del>(10.0)</del>	120	3.0
26128 each finger joint release			BR))	26261	with autogenous graft (includes obtaining graft)	<del>(10.0)</del>	120	3.0
26130 Synovectomy, carpometacarpal joint	<del>(10.0)</del>	90	3.0	26262	Radical resection (ostectomy) for tumor, distal phalanx of finger	<del>(BR)</del>	120	3.0
26135 Synovectomy, metocarpophalangeal joint including intrinsic release and extensor hood reconstruction, each digit	7.2					9.0		
26140 Synovectomy, proximal interphalangeal joint, including extensor reconstruction, each interphalangeal joint	<del>(5.0)</del>	90	3.0	INTRODUCTION OR REMOVAL				
26145 Synovectomy, tendon sheath, radical (tenosynovectomy), flexor, palm or finger, single, each digit	6.3			26320	Removal of implant from finger or hand	<del>(BR)</del>	30	3.0
(For tendon sheath synovectomies at wrist, see 25115, 25116)						4.5		
26160 Excision of lesion of tendon sheath or capsule (e.g., cyst or ganglion) hand or finger	<del>(2.4)</del>	30	3.0					
(For wrist ganglion, see 25111, 25112)	3.6							
(For trigger digit, see 26055)				REPAIR, REVISION OR RECONSTRUCTION				
26170 Excision of tendon, palm, flexor, single (separate procedure), each	<del>(BR)</del>	30	3.0	26350	Flexor tendon repair or advancement, single, not in "no man's land"; primary or secondary without free graft, each tendon	<del>(7.0)</del>	120	3.0
26180 Excision of tendon, finger, flexor (separate procedure)	4.1			26352	secondary with free graft (includes obtaining graft), each tendon	<del>(BR+)</del>	120	3.0
26200 Excision or curettage of bone cyst or benign tumor of metacarpal	<del>(6.0)</del>	60	3.0	26356	Flexor tendon repair or advancement, single, in "no man's land"; primary, each tendon	<del>(7.0)</del>	120	3.0
26205 with autogenous graft (includes obtaining graft)	5.6			26357	secondary, each tendon	9.5		
	6.8	120	3.0	26358	secondary with free graft (includes obtaining graft), each tendon	<del>(BR)</del>	120	3.0
				26370	Profundus tendon repair or advancement, with intact sublimis; primary	<del>(11.8)</del>		
				26372	secondary with free graft (includes obtaining graft)	<del>(BR)</del>	60	3.0
				26373	secondary without free graft	<del>(BR)</del>	120	3.0

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
26390 Flexor tendon excision, implantation of plastic tube or rod for delayed tendon graft hand or finger	<del>((BR))</del> 7.7	120	3.0	26449 Tenolysis, complex, extensor tendon, dorsum of hand or finger, including hand and forearm	<del>((BR))</del> 7.2	60	3.0
26392 Removal of tube or rod and insertion of flexor tendon graft (includes obtaining graft) hand or finger	<del>((BR))</del> 9.9	60	3.0	(For fascia or other implant, see 20920, 20922)			
26410 Extensor tendon repair, dorsum of hand, single, primary or secondary; without free graft, each tendon	<del>((3.0-120))</del> 4.2	60	3.0	26450 Tenotomy, flexor, single, palm, open each	<del>((4.0))</del> 3.6	30	3.0
26412 with free graft (includes obtaining graft); each tendon	<del>((BR))</del> 6.3	60	3.0	26455 Tenotomy, flexor, single, finger, open, each	<del>((5.0))</del> 4.5	30	3.0
26415 Extension tendon excision, implantation of plastic tube or rod for delayed extensor tendon graft, hand or finger	BR			26460 Tenotomy, extensor, hand or finger, single, open, each	<del>((BR+))</del> 3.2	30	3.0
26416 Removal of tube or rod and insertion of extensor tendon graft (includes obtaining graft), hand or finger	BR			26471 Tenodesis; for proximal interphalangeal joint stabilization	<del>((8.0))</del> 6.4	120	3.0
26418 Extensor tendon repair, dorsum of finger, single, primary or secondary; without free graft, each tendon	<del>((4.0))</del> 4.5	120	3.0	26474 for distal joint stabilization	<del>((7.0-120))</del> 4.7	90	3.0
26420 with free graft (includes obtaining graft) each tendon	<del>((BR))</del> 6.3	120	3.0	26476 Tendon lengthening, extensor, hand or finger single, each	<del>((8.0-120))</del> 4.5	90	3.0
26426 Extensor tendon repair, central slip repair, secondary (boutonniere deformity); using local tissues	<del>((4.0-120))</del> 6.6	90	3.0	26477 Tendon shortening, extensor, hand or finger single, each	<del>((8.0-120))</del> 4.5	90	3.0
26428 with free graft (includes obtaining graft)	<del>((BR))</del> 8.1	90	3.0	26478 Tendon lengthening, flexor, hand or finger single, each	<del>((BR))</del> 5.4	90	3.0
26432 Extensor tendon repair, distal insertion ("mallet finger"), closed, splinting with or without percutaneous pinning	<del>((5.0-120))</del> 5.4	30	3.0	26479 Tendon shortening, flexor, hand or finger single, each	<del>((BR))</del> 5.4	90	3.0
26433 Extensor tendon repair, distal insertion ('mallet finger'), open, primary or secondary repair; without graft	<del>((6.0-120))</del> 5.4	30	3.0	26480 Tendon transfer or transplant, carpometacarpal area or dorsum of hand, single; without free graft, each	<del>((8.0))</del> 8.1	90	3.0
26434 with free graft (includes obtaining graft)	<del>((BR))</del> 7.2	90	3.0	26483 with free tendon graft (includes obtaining graft), each tendon	<del>((11.0))</del> 10.8	90	3.0
(For tenovagotomy for trigger finger, see 26055)				26485 Tendon transfer or transplant, palmar, single, each tendon, without free tendon graft	<del>((10.0))</del> 9.3	90	3.0
26437 Extensor tendon realignment, hand	<del>((BR))</del> 5.4	60	3.0	26489 with free tendon graft (includes obtaining graft), each tendon	<del>((11.0))</del> 11.1	90	3.0
26440 Tenolysis, simple, flexor tendon, palm, OR finger, single, each tendon	<del>((5.0))</del> 4.6	60	3.0	26490 Opponens plasty, sublimis tendon transfer type	<del>((9.5))</del> 9.2	120	3.0
26442 palm AND finger, each tendon	<del>((6.0))</del> 5.4	60	3.0	26492 tendon transfer with graft (includes obtaining graft)	<del>((11.0))</del> 11.1	120	3.0
26445 Tenolysis, extensor tendon, dorsum of hand or finger; each tendon	<del>((6.0))</del> 5.4	60	3.0	26494 hypothenar muscle transfer	<del>((12.0))</del> 10.8	120	3.0
				26496 other methods	<del>((BR))</del> 12.7	120	3.0
				(For thumb fusion in opposition, see 26820)			
				26497 Tendon transfer to restore intrinsic function; ring and small finger	<del>((BR))</del> 10.8	120	3.0
				26498 all four fingers	<del>((BR))</del> 14.9	120	3.0
				26499 Correction claw finger, other methods	<del>((BR))</del> 14.9	120	3.0

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
26500 Tendon pulley reconstruction; with local tissues (separate procedure).....	<del>((6-0))</del> 5.7	90	3.0	26560 Repair of syndactyly (web finger), each web space; with skin flaps .....	<del>((9-5))</del> 9.0	45	3.0
26502 with tendon or fascial graft (includes obtaining graft) (separate procedure) .....	<del>((8-0))</del> 7.2	90	3.0	26561 with skin flaps and grafts ...	<del>((+2-5))</del> 10.8	45	3.0
26504 with tendon prosthesis (separate procedure) .....	BR			26562 complex, involving bone, nails, etc. ....	<del>((BR))</del> 13.6	90	3.0
26508 Thenar muscle release for thumb contracture .....	<del>((8-0))</del> 7.2	90	3.0	26565 Osteotomy for correction of deformity; metacarpal .....	<del>((8-0))</del> 7.7	90	3.0
26510 Cross intrinsic transfer .....	BR	90	3.0	26567 phalanx .....	<del>((5-0))</del> 6.3	90	3.0
26516 Capsulodesis for M-P joint stabilization; single digit .....	<del>((6-0))</del> 6.8	90	3.0	26568 Osteoplasty for lengthening of metacarpal or phalanx .....	<del>((BR))</del> 8.3	90	3.0
26517 two digits .....	<del>((8-0))</del> 8.1	90	3.0	<del>((26570 Bone graft, (includes obtaining graft); metacarpal.....</del>	<del>10-0</del>	<del>120</del>	<del>3-0</del>
26518 three or four digits.....	<del>((+0-0))</del> 10.1	90	3.0	26574 phalanx .....	7-0	120	3-0
26520 Capsulectomy or capsulotomy, for contracture, metacarpophalangeal joint, single, each .....	<del>((7-0))</del> 6.8	90	3.0	26580 Repair cleft hand .....	<del>((BR))</del> 18.1	180	
26525 interphalangeal joint, single, each .....	<del>((7-0))</del> 6.3	90	3.0	26585 Repair bifid digit .....	<del>((BR))</del> 8.1	90	
26527 Arthroplasty, carpometacarpal joint .....	<del>((BR))</del> 10.8	90	3.0	26587 ((Repair)) Reconstruction of supernumerary digit, soft tissue and bone .....	BR		
26530 Arthroplasty, metacarpophalangeal joint, single, each .....	<del>((7-0))</del> 7.2	90	3.0	(For excision of supernumerary digit, soft tissue only, use 11200)			
26531 with prosthetic implant, single, each .....	9.0	90	3.0	26590 Repair macrodactylia .....	<del>((BR))</del> 7.2	90	
26535 Arthroplasty interphalangeal joint; single, each.....	<del>((8-0))</del> 7.2	90	3.0	26591 Repair, intrinsic muscles of hand (specify) .....	<del>((BR))</del> 6.3	90	3.0
26536 with prosthetic implant, single, each .....	<del>((+1-3))</del> 9.0	90	3.0	(For microsurgical technique, use modifier -20)			
26540 Primary repair of collateral ligament, metacarpophalangeal joint .....	<del>((+0-0))</del> 9.5	90	3.0	26593 Release, intrinsic muscles of hand (specify) .....	<del>((BR))</del> 5.4	90	3.0
26541 with tendon or fascial graft (includes obtaining graft) ...	<del>((+2-0))</del> 10.4	90	3.0	(For microsurgical technique, use modifier -20)			
26542 with local tissue (e.g., adductor advancement) .....	<del>((BR))</del> 9.0	90	3.0	26596 Excision of constricting ring with multiple Z-plasties .....	BR	90	3.0
26545 Reconstruction, collateral ligament, interphalangeal joint, single, including graft, each joint ..	<del>((8-0))</del> 6.8	90	3.0	26597 Release of scar contracture, flexor or extensor, with skin grafts, rearrangement flaps, or Z-plasties, hand and/or finger ..	BR	90	3.0
26548 Repair and reconstruction, finger, volar plate, interphalangeal joint .....	<del>((7-0))</del> 7.2	90	2.5	<b>FRACTURES AND/OR DISLOCATION</b>			
26550 Pollicization of a digit .....	<del>((BR))</del> 15.4	120	3.0	26600 Treatment of closed metacarpal fracture, single; without manipulation, each bone .....	<del>((Sv-0))</del> 1.4	60	
26552 Reconstruction thumb with toe..	<del>((BR))</del> 18.1	120		26605 with manipulation, each bone ..	<del>((2-4))</del> 2.3	90	3.0
26555 Positional change of other finger .....	<del>((BR))</del> 10.8	120	3.0	26607 with manipulation, with skeletal fixation, each bone .....	<del>((BR))</del> 4.5	60	3.0
26557 Toe to finger transfer; first stage .....	<del>((BR))</del> 7.2	120	3.0	26610 Treatment of open metacarpal fracture, single, with uncomplicated soft tissue closure, each bone .....	<del>((3-0))</del> 3.2	90	3.0
26558 each delay .....	<del>((BR))</del> 4.5	120	3.0	26615 Open treatment of closed or open metacarpal fracture, single, with or without internal or external skeletal fixation, each bone .....	<del>((7-0))</del> 6.3	90	3.0
26559 second stage .....	<del>((BR))</del> 9.0	120	3.0				

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
26641 Treatment of carpometacarpal dislocation, thumb, with manipulation . . . . .	<del>(Sv.&amp;))</del> 1.8	60		26725 with manipulation, each . . . . .	<del>((+6))</del> 1.9	45	3.0
26645 Treatment of closed carpometacarpal fracture dislocation, thumb (Bennett fracture), with manipulation . . . . .	<del>((4-0))</del> 3.6	45	3.0	26727 Treatment of unstable phalangeal shaft fracture, proximal or middle phalanx, finger or thumb, with manipulation, requiring traction or fixation, each . . . . .	<del>((2-0))</del> 2.9	45	3.0
26650 with skeletal fixation . . . . .	<del>((6-0))</del> 5.4	45	3.0	26730 Treatment of open phalangeal shaft fracture, proximal or middle phalanx, finger or thumb, with uncomplicated soft tissue closure, each . . . . .	<del>((2-2))</del> 3.2	45	3.0
26655 Treatment of open carpometacarpal fracture dislocation, thumb (Bennett fracture), with uncomplicated soft tissue closure . . . . .	<del>((5-0))</del> 4.5	45	3.0	26735 Open treatment of closed or open phalangeal shaft fracture, proximal or middle phalanx, finger or thumb, with or without internal or external skeletal fixation, each . . . . .	<del>((4-0))</del> 5.4	60	3.0
26660 with skeletal fixation . . . . .	<del>((7-0))</del> 6.4	45	3.0	26740 Treatment of closed articular fracture, involving metacarpophalangeal or proximal interphalangeal joint; without manipulation, each . . . . .	<del>((Sv-))</del> 2.3	60	
26665 Open treatment of closed or open carpometacarpal fracture dislocation, thumb (Bennett fracture), with or without internal or external skeletal fixation . . . . .	<del>((10-0))</del> 9.5	90	3.0	26742 with manipulation, each . . . . .	<del>((2-0))</del> 3.2	60	3.0
26670 Treatment of closed carpometacarpal dislocation, other than Bennett fracture, single, with manipulation; without anesthesia . . . . .	<del>((0.72-0))</del> 1.4	30		26744 Treatment of open articular fracture, involving metacarpophalangeal or proximal interphalangeal joint, with uncomplicated soft tissue closure, each . . . . .	<del>((+5))</del> 3.6	60	3.0
26675 requiring anesthesia . . . . .	<del>((2-0))</del> 2.3	45	3.0	26746 Open treatment of closed or open articular fracture, involving metacarpophalangeal or proximal interphalangeal joint, each . . . . .	<del>((6-0))</del> 5.4	60	3.0
26676 with percutaneous pinning . . . . .	<del>((BR))</del> 2.3	45	3.0	26750 Treatment of closed distal phalangeal fracture, finger or thumb; without manipulation, each . . . . .	<del>((Sv.&amp;))</del> 0.7	45	
26680 Treatment of open carpometacarpal dislocation, other than Bennett fracture, single, with uncomplicated soft tissue closure . . . . .	<del>((3-0))</del> 2.7	45	3.0	26755 with manipulation, each . . . . .	<del>((0.72-0))</del> 0.9	30	3.0
26685 Open treatment of closed or open carpometacarpal dislocation, other than Bennett fracture; single, with or without internal or external skeletal fixation . . . . .	<del>((6-0))</del> 5.4	90	3.0	26756 with percutaneous pinning . . . . .	<del>((BR))</del> 1.4	30	3.0
26686 complex, multiple or delayed reduction . . . . .	<del>((BR))</del> 7.2	60		26760 Treatment of open distal phalangeal fracture, finger or thumb, with uncomplicated soft tissue closure, each . . . . .	1.2	30	3.0
26700 Treatment of closed metacarpophalangeal dislocation, single, with manipulation; without anesthesia . . . . .	<del>((0.72-0))</del> 1.7	30		26765 Open treatment of closed or open distal phalangeal fracture, finger or thumb, each . . . . .	<del>((2.0-45))</del> 3.6	30	3.0
26705 requiring anesthesia . . . . .	2.0	45	3.0	26770* Treatment of closed interphalangeal joint dislocation, single, with manipulation; without anesthesia . . . . .	<del>((+0.72-0))</del> 0.9	30	
26706 with percutaneous pinning . . . . .	<del>((BR))</del> 3.6	45	3.0	26775 requiring anesthesia . . . . .	<del>((+2))</del> 1.4	45	3.0
26710 Treatment of open metacarpophalangeal dislocation, single, with uncomplicated soft tissue closure . . . . .	<del>((3-0))</del> 2.9	45	3.0	26776 with percutaneous pinning . . . . .	<del>((+5))</del> 1.4	45	2.5
26715 Open treatment of closed or open metacarpal phalangeal dislocation, single, with or without internal or external skeletal fixation . . . . .	<del>((6-0))</del> 6.3	90	3.0	26780 Treatment of open interphalangeal joint dislocation, single, with uncomplicated soft tissue closure . . . . .	<del>((+6))</del> 2.3	45	3.0
26720 Treatment of closed phalangeal shaft fracture, proximal or middle phalanx, finger or thumb; without manipulation, each . . . . .	<del>((Sv.&amp;))</del> 1.4	45					

**AMENDATORY SECTION** (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

**WAC 296-22-079 PELVIS AND HIP JOINT.**

(Including head and neck of femur)

**INCISION**

(For incision and drainage procedures, superficial, see 10000-10160)

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
26785	Open treatment of closed or open interphalangeal joint dislocation, single	<del>(2-4)</del> 2.7	60	3.0			
<b>ARTHRODESIS</b>							
26820	Fusion in opposition, thumb, with autogenous graft (includes obtaining graft)	<del>(+0-0)</del> 10.7	120	3.0			
26841	Arthrodesis, carpometacarpal joint, thumb, with or without internal fixation	<del>(8-0)</del> 7.2	120	3.0	26990	Incision and drainage; pelvis or hip joint area, deep abscess or hematoma	<del>(BR)</del> 3.6 30
26842	with autogenous graft (includes obtaining graft)	<del>(+0-0)</del> 9.1	120	3.0	26991	infected bursa	<del>(BR)</del> 1.0 30
26843	Arthrodesis, carpometacarpal joint, digits, other than thumb	<del>(8-0)</del> 7.2	120	3.0	26992	Incision, deep, with opening of bone cortex (e.g., for osteomyelitis or bone abscess); pelvis and/or hip joint	<del>(BR)</del> 4.5 30
26844	with autogenous graft (includes obtaining graft)	<del>(+0-0)</del> 9.1	120	3.0	27000	Tenotomy, adductor [abductor], subcutaneous, closed (separate procedure)	<del>(+0-0)</del> 1.8 30
26850	Arthrodesis metacarpophalangeal joint, with or without internal fixation	7.0	120	3.0	27001	Tenotomy, adductor [abductor], of hip subcutaneous, open ( <del>(- unilateral)</del> )	<del>(3-0-45)</del> 2.7 30
26852	with autogenous graft (includes obtaining graft)	<del>(8-0)</del> 8.1	120	3.0	<del>(27002)</del>	<del>bilateral</del>	<del>4.0-45-3.0</del>
26860	Arthrodesis, interphalangeal joint, with or without internal fixation	<del>(5-0)</del> 5.2	120	3.0	27003	Tenotomy, adductor [abductor], subcutaneous, open; with obturator neurectomy ( <del>(- unilateral)</del> )	<del>(5-0)</del> 6.3 45
26861	each additional interphalangeal joint	<del>(4-0)</del> 1.8	120	3.0	<del>(27004)</del>	<del>bilateral</del>	<del>6.0-45-3.0</del>
26862	with autogenous graft (includes obtaining graft)	<del>(6-0)</del> 7.0	120	3.0	27005	Tenotomy, iliopsoas, open (separate procedure)	<del>(6-0-45)</del> 5.4 60
26863	with autogenous graft (includes obtaining graft), each additional joint	<del>(5-0)</del> 2.7	120	3.0	27006	Tenotomy, abductors, of hip open (separate procedure)	<del>(6-0)</del> 6.3 60
<b>AMPUTATION</b>							
	(For hand through metacarpal bones, see 25927)				27010	Gluteal-iliotibial fasciotomy (Ober type procedure)	<del>(6-0)</del> 5.4 45
26910	Amputation, metacarpal, with finger or thumb (ray amputation), single, with or without interosseous transfer	<del>(7-0)</del> 7.2	90	3.0	27015	Iliac crest fasciotomy (Soutter or Campbell type procedure), stripping of ilium	<del>(8-0)</del> 7.2 90
	(For repositioning, see 26550-26555)				27025	Ober-Yount fasciotomy, combined with spica cast, pins in tibia, wedging the cast, etc. ( <del>(- unilateral)</del> )	<del>(+0-0)</del> 9.1 90
26951	Amputation, finger or thumb, primary or secondary, any joint or phalanx, single, including neurectomies; with direct closure	<del>(3-5)</del> 5.0	45	3.0	<del>(27026)</del>	<del>bilateral</del>	<del>12.0-90-3.0</del>
26952	with local advancement flaps (V-Y, hood)	<del>(5-0)</del> 6.3	45	3.0	27030	Arthrotomy, hip, for infection, with drainage	<del>(+4-0)</del> 12.7 90
	(For repair of soft tissue defect requiring split or full thickness graft or other pedicle grafts, see 15050-15750)				27033	Arthrotomy, hip, for exploration or removal of loose or foreign body	<del>(+6-0)</del> 12.7 90
26952	with local advancement flaps (V-Y, hood)	<del>(5-0)</del> 6.3	45	3.0	27035	Hip joint denervation, intrapelvic or extrapelvic intra-articular branches of sciatic, femoral or obturator nerves	<del>(+7-0-60)</del> 15.5 90
<b>MISCELLANEOUS</b>							
26989	Unlisted procedure, hands or fingers	BR		3.0			

(For obturator neurectomy, see 64763-64768)

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
<b>EXCISION</b>				27080	Coccygectomy primary	<del>((6-0))</del> 5.4	90 3.0
27040	Biopsy, soft tissues of pelvis and hip area; superficial	<del>((1-2-7))</del> 1.1 0	3.0		(For pressure (decubitus) ulcer, see 15920-15922 and 15931-15958)		
27041	deep	<del>((2-4-15))</del> 2.2 0	3.0	<b>INTRODUCTION AND/OR REMOVAL</b>			
	(For needle biopsy of soft tissue, use 20206)			27086*	Removal of foreign body; pelvis or hip subcutaneous tissue	<del>((BR))</del> 1.1	7 3.0
27047	Excision, tumor; pelvis and hip area subcutaneous	<del>((3-0))</del> 1.7	7 3.0	27087	deep	<del>((BR))</del> 2.1	30 3.0
27048	deep, subfascial, intramuscular	<del>((4-0))</del> 3.5	15 3.0	27090	Removal of hip prosthesis; separate procedure	<del>((14-0))</del> 12.7	90 3.0
27049	Radical resection of tumor (e.g., malignant neoplasm); soft tissue of pelvis and hip area	<del>((BR))</del> 13.6	180	27091	complicated, including "total hip" and methylmethacrylate, when applicable	<del>((BR))</del> 36.1	120 7.0
27050	Arthrotomy, for biopsy; sacroiliac joint	<del>((6-0))</del> 5.4	90 3.0	27093	Injection procedure for hip arthrography; without anesthesia	<del>((BR))</del> 1.2	0 3.0
27052	hip joint	<del>((14-0))</del> 12.2	90 3.0	27095	with anesthesia	<del>((BR))</del> 3.6	0 3.0
27054	Arthrotomy for synovectomy, hip joint	<del>((20-0))</del> 18.3	90 3.0		(For hip arthrography, see 73525)		
27060	Excision; ischial bursa	5.0	60 3.0	<b>REPAIR, REVISION OR RECONSTRUCTION</b>			
27062	trochanteric bursa or calcification	<del>((4-0))</del> 3.6	60 3.0	27097	Hamstring recession, proximal	<del>((BR))</del> 5.4	90 3.0
	(For arthrocentesis or needling of bursa, see 20610)			27098	Adductor transfer to ischium	<del>((BR))</del> 10.8	120 3.0
27065	Excision of bone cyst or benign tumor; superficial (wing of ilium, symphysis pubis or greater trochanter of femur) with or without autogenous bone graft	<del>((5-0-120))</del> 4.5 60	3.0	27100	Transfer external oblique muscle to greater trochanter including fascial or tendon extension (graft)	<del>((15-0))</del> 13.1	120 5.0
27066	deep, with or without bone graft	<del>((9-5))</del> 8.6	120 3.0	27105	Transfer paraspinal muscle to hip (includes fascial or tendon extension graft)	<del>((16-0))</del> 14.0	120 3.0
27067	with bone graft requiring separate incision	<del>((10-0))</del> 10.8	120 3.0	27110	Transfer iliopsoas to greater trochanter	<del>((18-0))</del> 16.7	120 3.0
27070	Partial excision (craterization, saucerization), (e.g., for osteomyelitis); superficial (e.g., wing of ilium, symphysis pubis or greater trochanter of femur)	<del>((6-0))</del> 5.4	60 3.0	27111	to femoral neck	<del>((15-0))</del> 17.2	120 3.0
27071	deep	<del>((12-0))</del> 10.8	60 3.0	27120	Acetabuloplasty; (Whittman or Colonna type procedure)	<del>((24-0))</del> 21.7	120 6.0
27075	Radical resection for tumor or infection; wing of ilium; one pubic or ischial ramus or symphysis pubis	<del>((BR))</del> 16.3	60 5.0	27122	resection femoral head (Girdlestone procedure)	<del>((20-0))</del> 18.1	120 7.0
27076	ilium, including acetabulum, both pubic rami, or ischium and acetabulum	<del>((BR))</del> 28.9	120 3.0	27125	<del>((Hemiarthroplasty, of hip (partial hip replacement) prosthesis (e.g., Austin-Moore, bipolar arthroplasty))) Partial hip replacement (hemiarthroplasty); prosthesis (e.g., femoral stem prosthesis, bipolar arthroplasty)</del>	<del>((28-0-180))</del> 24.4 120	7.0
27077	innominate bone, total	<del>((BR))</del> 40.7	120 3.0		(For prosthetic replacement following fracture of the hip, use 27236)		
27078	ischial tuberosity and greater trochanter of femur	<del>((BR))</del> 10.8	90 3.0	27126	cup	<del>((26-0-180))</del> 27.1 120	6.0
27079	ischial tuberosity and greater trochanter of femur, with skin flaps	<del>((BR))</del> 12.7	90 3.0	27127	cup with acetabuloplasty	<del>((34-0))</del> 29.4	180 7.0

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@		
27130	Arthroplasty, acetabular and proximal femoral prosthetic replacement (total hip replacement), with or without autograft or allograft . . . . .	<del>(40.0)</del> 32.1	180	10.0	27181	osteotomy and internal fixation . . . . .	<del>(24.0)</del> 21.9	120	5.0
27132	Conversion of previous hip surgery to total hip replacement, with or without autograft or allograft . . . . .	<del>(BR)</del> 39.8	180	7.0	27185	Epiphyseal arrest by epiphysodes or stapling, greater trochanter . .	5.0	120	3.0
27134	Revision of total hip arthroplasty; both components, with or without autograft or allograft . . . . .	<del>(BR)</del> 36.1	180	7.0	27187	Prophylactic treatment (nailing, pinning, plating, or wiring) with or without methyl methacrylate, femoral neck and proximal femur . . . . .	<del>(BR)</del> 31.6	180	
27137	acetabular component only, with or without autograft or allograft . . . . .	<del>(BR)</del> 31.6	180	7.0	FRACTURES AND/OR DISLOCATIONS				
27138	femoral component only, with or without allograft . . . . .	<del>(BR)</del> 31.6	180	7.0	27190	Treatment of closed sacral fracture . . . . .	<del>(Sv.&amp;)</del> 4.5	60	
27140	Osteotomy and transfer of greater trochanter (separate procedure) . . . . .	<del>(+2.0)</del> 11.0	90	3.0	27192	Open treatment of closed or open sacral fracture . . . . .	<del>(BR)</del> 14.5	90	3.0
27146	Osteotomy, iliac, acetabular or innominate bone . . . . .	<del>(24.0)</del> 20.8	120	4.0	27195	Treatment of sacroiliac and/or symphysis pubis dislocation, without manipulation . . . . .	<del>(Sv.&amp;)</del> 2.7	90	
27147	with open reduction of hip . . . . .	23.5			27196	Treatment of sacroiliac and/or symphysis pubis dislocation, with anesthesia and with manipulation . . . . .	<del>(BR)</del> 11.7	90	3.0
27151	with femoral osteotomy . . . . .	<del>(27.0)</del> 23.5	120	4.0	27200	Treatment of closed coccygeal fracture . . . . .	<del>(Sv.&amp;)</del> 1.4	60	
27156	with femoral osteotomy and with open reduction of hip . . . . .	<del>(30.0)</del> 26.2	120	4.0	27201	Treatment of open coccygeal fracture . . . . .	<del>(BR)</del> 1.8	90	3.0
27157	Acetabular augmentation (Wilson procedure) . . . . .	<del>(BR)</del> 17.2	120	5.0	27202	Open treatment of closed or open coccygeal fracture . . . . .	<del>(BR)</del> 2.7	90	3.0
27158	Osteotomy, pelvis, bilateral for congenital malformation . . . . .	<del>(BR)</del> 20.8		5.0	27210	Treatment of closed iliac, pubic or ischial fracture . . . . .	4.5	90	
27161	Osteotomy, femoral neck, (separate procedure) . . . . .	<del>(20.0)</del> 16.3	120	3.0	27212	Treatment of open iliac, pubic or ischial fracture, with uncomplicated soft tissue closure . . . . .	<del>(Sv.&amp;)</del> 7.7	90	3.0
27165	Osteotomy, intertrochanteric or subtrochanteric including internal or external fixation and/or cast . . . . .	<del>(24.0)</del> 21.0	120	5.0	27214	Open treatment of closed or open iliac, pubic or ischial fracture, with or without internal skeletal fixation . . . . .	<del>(BR)</del> 15.4	90	4.0
27170	Bone graft for nonunion, femoral head, neck, intertrochanteric or subtrochanteric area (includes obtaining bone graft) . . . . .	<del>(24.0)</del> 22.0	120	6.0	(For external fixation, see 20690-20691)				
27175	Treatment of slipped femoral epiphysis; by traction, without reduction . . . . .	<del>(Sv.&amp;)</del> 9.9			27220	Treatment of closed acetabulum (hip socket) fracture(s); without manipulation . . . . .	<del>(Sv.&amp;)</del> 2.7	90	
27176	by single or multiple pinning, in situ . . . . .	<del>(20.0)</del> 19.4	120	3.0	27222	with manipulation with or without skeletal traction . . . . .	<del>(8.0)</del> 7.2	90	3.0
27177	Open treatment of slipped femoral epiphysis; single or multiple pinning or bone graft (includes obtaining graft) . . . . .	<del>(22.0)</del> 20.3	120	5.0	27224	Open treatment of closed or open acetabulum (hip socket) fracture(s), with or without internal or external fixation, simple . . . . .	<del>(22.0)</del> 20.0	90	6.0
27178	closed manipulation with single or multiple pinning . . . . .	<del>(21.0)</del> 20.6	120	5.0	27225	complicated, intrapelvic approach . . . . .	<del>(BR)</del> 21.7	90	10.0
27179	osteoplasty of femoral neck (Heyman type procedure) . . . . .	<del>(+6.0)</del> 14.9	120	5.0	27230	Treatment of closed femoral fracture, proximal end, neck; without manipulation . . . . .	<del>(Sv.&amp;)</del> 1.8	90	



	Unit Value	Follow-up Days=	Basic Anes@
27232 with manipulation including skeletal traction . . . . .	<del>((9.5))</del> 9.0	90	3.0
27234 Treatment of open femoral fracture, proximal end, neck; with uncomplicated soft tissue closure, with manipulation (including skeletal traction) . . . . .	<del>((12.0))</del> 10.9	90	3.0
27235 Treatment of closed or open femoral fracture, proximal end, neck, in situ pinning of undisplaced or impacted fracture . . . . .	<del>((20.0—180))</del> 19.0	90	4.0
27236 Open treatment of closed or open femoral fracture, proximal end, neck, internal fixation or prosthetic replacement . . . . .	<del>((22.0))</del> 24.4	120	6.0
27238 Treatment of closed intertrochanteric, petrochanteric or subtrochanteric femoral fracture; without manipulation . . . . .	<del>((Sv.&amp;))</del> 1.8	90	
27240 with manipulation (including skeletal traction). . . . .	<del>((9.5))</del> 9.9	90	3.0
27242 Treatment of open intertrochanteric, petrochanteric or subtrochanteric femoral fracture, with uncomplicated soft tissue closure (including traction) . . . . .	<del>((12.0—90))</del> 12.7	120	3.0
27244 Open treatment of closed or open intertrochanteric, petrochanteric or subtrochanteric femoral fracture, with internal fixation . . . . .	<del>((20.0))</del> 21.7	120	6.0
27246 Treatment of closed greater trochanteric fracture, without manipulation . . . . .	<del>((Sv.&amp;))</del> 1.8	0	
27248 Open treatment of closed or open greater trochanteric fracture, with or without internal or external skeletal fixation . . . . .	<del>((7.0))</del> 6.4	90	5.0
27250 Treatment of closed hip dislocation, traumatic; without anesthesia . . . . .	<del>((Sv.&amp;))</del> 3.2	60	
27252 requiring anesthesia . . . . .	<del>((4.8))</del> 4.3	120	3.0
27253 Open treatment of closed or open hip dislocation, traumatic, without internal fixation . . . . .	<del>((15.0—180))</del> 15.4	120	5.0
27254 Open treatment of closed or open hip dislocation, traumatic, with acetabular lip fixation, with or without internal or external skeletal fixation . . . . .	<del>((17.0))</del> 15.4	120	5.0
27255 complicated or late . . . . .	<del>((22.0—180))</del> 23.5	120	5.0
*27256 Treatment of congenital hip dislocation, by abduction, splint or traction; any method . . . . .	<del>((Sv.&amp;))</del> 11.7	360	3.0
*27257 with manipulation requiring anesthesia . . . . .	<del>((4.5—45))</del> 13.6	360	3.0

	Unit Value	Follow-up Days=	Basic Anes@
27258 Open treatment of congenital hip dislocation; replacement of femoral head in acetabulum (including tenotomy, etc.) . . . . .	<del>((17.0))</del> 16.3	120	5.0
27259 with femoral shaft shortening . . . . .	<del>((BR))</del> 17.2	120	5.0
27265 Treatment of atraumatic hip dislocation (e.g., post-total hip arthroplasty); without anesthesia . . . . .	BR		
27266 requiring general anesthesia . . . . .	BR		

MANIPULATION

*27275 Manipulation, hip joint, requiring general anesthesia . . . . .	<del>((1.2—0))</del> 2.7	120	3.0
--	-----------------------------	-----	-----

ARTHRODESIS

27280 Arthrodesis, sacroiliac joint (including obtaining graft) . . . . .	<del>((14.0))</del> 12.7	120	5.0
27282 Arthrodesis, symphysis pubis (including obtaining graft) . . . . .	<del>((BR))</del> 16.3		4.0
27284 Arthrodesis, hip joint (including obtaining graft) . . . . .	<del>((24.0))</del> 22.6	180	5.0
27286 with subtrochanteric osteotomy . . . . .	<del>((26.0))</del> 23.5	180	5.0

AMPUTATION

27290 Interpelviabdominal amputation (hind quarter amputation) . . . . .	<del>((29.0))</del> 31.6	120	11.0
27295 Disarticulation of hip . . . . .	<del>((24.0))</del> 24.4	120	8.0

MISCELLANEOUS

27299 Unlisted procedure, pelvis or hip joint . . . . .	BR		7.0
---	----	--	-----

Reviser's note: The brackets and enclosed material in the text of the above section occurred in the copy filed by the agency and appear in the Register pursuant to the requirements of RCW 34.08.040.

AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

WAC 296-22-082 FEMUR (THIGH REGION) AND KNEE JOINT.

(Including tibial plateaus)

	Unit Value	Follow-up Days=	Basic Anes@
INCISION			
(For incision and drainage of abscess or hematoma, superficial, see 10000-10160)			
27301 Incision and drainage of deep abscess, infected bursa, or hematoma thigh or knee region . . . . .	<del>((BR))</del> 2.7	30	3.0
27303 Incision, deep, with opening of bone cortex (e.g., for osteomyelitis or bone abscess) femur or knee . . . . .	<del>((BR))</del> 3.6	30	3.0

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
27305 Fasciotomy, iliotibial (tenotomy), open	<del>(6.0)</del> 5.4	45	3.0	27357 with primary autogenous graft (includes obtaining graft)	<del>(+4.0)</del> 13.6	120	3.0
(For combined Ober-Yount fasciotomy, see 27025-27026)				27358 with internal fixation (list in addition to 27355, 27356, or 27357)	<del>(+5.0)</del> 14.5	120	3.0
27306 Tenotomy, subcutaneous, closed, adductor or hamstring, (separate procedure); single	<del>(+2.0)</del> 2.2		3.0	27360 Partial excision, (craterization, saucerization or diaphysectomy), of bone (e.g., osteomyelitis), femur, proximal tibia and/or fibula	<del>(+0.0)</del> 9.0		3.0
27307 multiple	<del>(4.0)</del> 2.7		3.0	27365 Radical resection for tumor (femur or bone)	<del>(BR)</del> 16.3	120	3.0
27310 Arthrotomy, knee, for infection, with exploration, drainage or removal of foreign body	<del>(+2.0)</del> 11.3	90	3.0	(For radical resection of tumor, soft tissue, use 27329)			
27315 Neurectomy, hamstring muscle	<del>(+1.0)</del> 9.9	30	3.0	<b>INTRODUCTION AND/OR REMOVAL</b>			
27320 Neurectomy, popliteal (gastrocnemius)	<del>(+1.0)</del> 9.9	30	3.0	27370 Injection procedure for knee arthrography	0.6	0	
<b>EXCISION</b>				(For knee arthrography, see 73580, 73581)			
27323 Biopsy, soft tissue of thigh or knee area; superficial	<del>(+2.0)</del> 1.1		3.0	27372 Removal foreign body, deep thigh region or knee area	<del>(BR)</del> 4.7	30	
27324 deep	<del>(2.4)</del> 2.2		3.0	(For removal of knee prosthesis including "total" knee, see 27488)			
27327 Excision, tumor; thigh or knee area subcutaneous	<del>(3.0)</del> 2.3		3.0	<b>REPAIR, REVISION OR RECONSTRUCTION</b>			
27328 deep, subfascial, or intramuscular	<del>(4.0)</del> 3.6	15	3.0	27380 Suture of infrapatellar tendon; primary	<del>(+1.0)</del> 9.9	90	3.0
27329 Radical resection of tumor (e.g., malignant neoplasm); soft tissue of thigh or knee area	<del>(BR)</del> 12.7	90		27381 secondary reconstruction, including fascial or tendon graft	<del>(BR)</del> 11.7	90	
27330 Arthrotomy, knee; for synovial biopsy only	<del>(+2.0)</del> 11.3	90	3.0	27385 Suture of quadriceps or hamstring muscle rupture; primary	<del>(+3.0)</del> 11.8	90	3.0
27331 with joint exploration, with or without biopsy, with or without removal of loose or foreign bodies	<del>(+3.0)</del> 12.2	90	3.0	27386 secondary reconstruction, including fascial or tendon graft	<del>(+5.0)</del> 14.5	90	3.0
27332 Arthrotomy, knee, for excision of semilunar cartilage (meniscectomy); medial OR lateral	<del>(+4.0)</del> 14.5	90	3.0	27390 Tenotomy, open, hamstring, knee to hip; single	<del>(6.0)</del> 5.4		3.0
27333 medial AND lateral	<del>(20.0)</del> 14.5	90	3.0	27391 multiple, one leg	<del>(6.0)</del> 7.2		3.0
27334 Arthrotomy, knee, for synovectomy; anterior OR posterior	<del>(+7.0)</del> 16.3	120	3.0	27392 multiple, bilateral	<del>(8.0)</del> BR	45	3.0
27335 anterior AND posterior including popliteal area	<del>(+4.0)</del> 17.2	120	3.0	27393 Lengthening of hamstring tendon; single	<del>(8.0)</del> 6.3		3.0
27340 Excision, prepatellar bursa	<del>(5.0)</del> 7.2	60	3.0	27394 multiple, one leg	<del>(+2.0)</del> 8.1		3.0
27345 Excision of synovial cyst of popliteal space (Baker's cyst)	<del>(8.0)</del> 8.1	60	3.0	27395 multiple, bilateral	<del>(+6.0)</del> BR	120	3.0
27350 Patellectomy or hemipatellectomy	<del>(+2.0)</del> 10.8		3.0	27396 Transplant, hamstring tendon to patella; single	<del>(+6.0)</del> 14.6	120	3.0
27355 Excision or curettage of bone cyst or benign tumor of femur	<del>(+1.0)</del> 9.9	60	3.0	27397 multiple	<del>(+4.0)</del> 16.2	120	3.0
27356 with homogenous graft	<del>(+2.0)</del> 12.7		3.0	27400 Tendon or muscle transfer, hamstrings to femur (Eggers type procedure)	<del>(+6.0)</del> 13.6	120	3.0
		120		27403 Arthrotomy with open meniscus repair	<del>(+4.0)</del> 15.4		3.0

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
(For arthroscopic repair, use 29882)				27446	Arthroplasty, knee, condyle and plateau; medial OR lateral compartment	<del>((43.5))</del> 23.5	120 5.0
27405 Repair, primary, torn ligament, and/or capsule, knee; collateral	<del>((+4.0))</del> 12.7	120	3.0	27447	medial AND lateral compartments with or without patella resurfacing (*total knee replacement")	<del>((40.0))</del> 36.1	120 5.0
27407 cruciate	<del>((+6.0))</del> 15.4	120	3.0				
(27408 has been deleted, use 27427)					(For revision of total knee arthroplasty, see 27487)		
27409 collateral and cruciate ligaments	<del>((+8.0))</del> 18.1	120	3.0		(For revision of total knee prosthesis, see 27488)		
27418 Anterior tibial tubercle plasty for chondromalacia patellae (Maquet procedure)	<del>((+4.0))</del> 19.0	120	3.0	27448	Osteotomy, femur, shaft or supracondylar, without fixation	<del>((+3.0 - 120))</del> 16.7 90	3.0
27420 Reconstruction for recurrent dislocating patella; (Hauser type procedure)	14.0	120	3.0	27450	with fixation	19.0 90	3.0
27422 with extensor realignment and/or muscle advancement or release (Campbell, Goldthwaite, etc., type procedure)	<del>((+5.0))</del> 14.0	120	3.0	27454	Osteotomy, multiple, femoral shaft, with realignment on intramedullary rod (Sofield type procedure)	<del>((20.0))</del> 18.5	90 3.0
27424 with patellectomy	<del>((+7.0))</del> 14.9	120	3.0	27455	Osteotomy, proximal tibia, including fibular excision or osteotomy (includes correction of genu varus (bowleg) or genu valgus (knock knee)), before epiphyseal closure	<del>((+2.0 - 90))</del> 11.7 120	3.0
27425 Lateral retinacular release (any method)	<del>((6.0))</del> 16.3	120	3.0	27457	After epiphyseal closure	14.0 120	3.0
27427 Ligamentous reconstruction (augmentation) knee; extra-articular	<del>((+4.0))</del> 17.2	120	3.0	27465	Osteoplasty, femur; shortening (excluding 64876)	<del>((20.0))</del> 18.5	180 3.0
27428 intraarticular (open)	<del>((+6.0))</del> 24.4	120	3.0	27466	lengthening	<del>((26.0))</del> 23.9	180 3.0
27429 intraarticular (open) and extra-articular	<del>((23.0))</del> 27.1	120	3.0	27468	combined, lengthening and shortening with femoral segment transfer	<del>((40.0))</del> 34.8	180 4.0
(When performed with primary repair, use in addition to the code for the primary repair)				27470	Repair, nonunion or malunion, femur, distal to head and neck; without graft (e.g., compression technique, etc.)	<del>((20.0))</del> 18.5	120 3.0
27430 Quadriceps plasty (Bennett or Thompson type)	<del>((+5.0))</del> 14.0	120	3.0	27472	with iliac or other autogenous bone graft (includes obtaining graft)	<del>((23.0))</del> 20.8	120 3.0
27435 Capsulotomy, knee, posterior capsular release	<del>((+4.0))</del> 13.0	90	3.0	27475	Epiphyseal arrest by epiphysiodesis or stapling; distal femur	<del>((+4.0))</del> 12.7	120 3.0
(27436 has been deleted, see 29887)				27477	tibia and fibula, proximal	<del>((+6.0))</del> 14.5	120 3.0
27437 Arthroplasty, patella; without prosthesis	<del>((BR))</del> 13.6		3.0	27479	combined, distal femur, proximal tibia and fibula	<del>((20.0))</del> 18.5	120 3.0
27438 with prosthesis	<del>((22.0))</del> 18.1	120	3.0	27485	Arrest, hemiepiphyseal, distal femur or proximal leg (e.g., for genu varus or valgus)	<del>((+1.0))</del> 10.0	120 3.0
27440 Arthroplasty, knee, tibial plateau	<del>((20.0))</del> 19.0	120	3.0	27486	Revision of total knee arthroplasty; with or without allograft; one component	BR	120 3.0
27441 with debridement and partial synovectomy	<del>((BR))</del> 19.9	120	3.0	27487	all components	<del>((BR))</del> 32.7	120
27442 Arthroplasty, knee, femoral condyles or tibial plateaus	<del>((24.0))</del> 20.8	120	3.0	27488	Removal of knee prosthesis, including "total knee", methylmethacrylate and insertion of spacer, when applicable	<del>((BR))</del> 11.3	90
27443 with debridement and partial synovectomy	<del>((BR))</del> 19.9	120	3.0				
27445 Arthroplasty, knee, constrained, prosthesis (e.g., Waldius type)	<del>((20.0))</del> 25.3	120	3.0				

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
27495 Prophylactic treatment (nailing, pinning, plating or wiring) with or without methyl methacrylate, femur.....	<del>((BR))</del> 12.7	120		27532 with manipulation .....	<del>((5-0))</del> 4.7	90	3.0
<b>FRACTURES AND/OR DISLOCATION</b>				27534 Treatment of open tibial fracture, proximal (plateau), with uncomplicated soft tissue closure .....	<del>((8-0))</del> 7.2	90	3.0
27500 Treatment of closed femoral shaft fracture (including supracondylar); without manipulation (includes traction) .....	<del>((Sv.&amp;))</del> 4.5	90		27536 Open treatment of closed or open tibial fracture, proximal (plateau), with or without internal or external skeletal fixation .....	<del>((14-0))</del> 12.9	90	3.0
27502 with manipulation .....	<del>((7-0))</del> 6.8	90	3.0	27537 with autogenous graft (includes obtaining graft) .....	<del>((16-0-120))</del> 15.4	90	3.0
27504 Treatment of open femoral shaft fracture (including supracondylar), with uncomplicated soft tissue closure .....	<del>((11-0))</del> 9.9	90	3.0	27538 Treatment of closed intercondylar spine(s) fracture(s) of knee .....	<del>((Sv.&amp;))</del> 2.7	90	
27506 Open treatment of closed or open femoral shaft fracture (including supracondylar), with or without internal or external skeletal fixation .....	<del>((19-0))</del> 18.1	90	4.0	27540 Open treatment of closed or open intercondylar spine(s) fractures(s), of knee with internal fixation ...	<del>((14-0))</del> 12.9	90	3.0
27508 Treatment of closed femoral fracture, distal end, medial or lateral condyle; without manipulation ..	<del>((Sv.&amp;))</del> 5.4	90		27550 Treatment of closed knee dislocation; without anesthesia .....	<del>((Sv.&amp;))</del> 2.1	45	
27510 with manipulation .....	<del>((8-0))</del> 7.6	90	3.0	27552 requiring anesthesia .....	<del>((3-6))</del> 3.0	45	3.0
27512 Treatment of open femoral fracture, distal end, medial or lateral condyle, with uncomplicated soft tissue closure .....	<del>((12-0))</del> 10.8	90	3.0	27554 Treatment of open knee dislocation, with uncomplicated soft tissue closure .....	<del>((7-0))</del> 6.4	45	3.0
27514 Open treatment of closed or open femoral fracture, distal end, medial or lateral condyle, with or without internal or external skeletal fixation .....	<del>((20-0))</del> 18.1	90	4.0	27556 Open treatment of closed or open knee dislocation, with or without internal or external skeletal fixation; without primary ligamentous repair .....	<del>((15-0))</del> 14.0	90	3.0
27516 Treatment of closed distal femoral epiphyseal separation; without manipulation (includes traction) ..	<del>((Sv))</del> 6.3			27557 with primary ligamentous repair .....	<del>((BR-120))</del> 15.4	90	3.0
27517 with manipulation .....	<del>((7-0))</del> 8.5	120	3.0	27560 Treatment of closed patellar dislocation; without anesthesia .....	<del>((Sv.&amp;))</del> 2.1	45	
27518 Treatment of open distal femoral epiphyseal separation, with uncomplicated soft tissue closure ...	<del>((8-0))</del> 11.7	120	3.0	(For recurrent dislocation, see 27420-27424)			
27519 Open treatment of closed or open distal femoral epiphyseal separation, with or without internal or external skeletal fixation .....	<del>((18-0))</del> 20.8	120	4.0	27562 requiring anesthesia .....	<del>((3-6))</del> 3.2	45	3.0
27520 Treatment of closed patellar fracture, without manipulation .....	<del>((Sv.&amp;))</del> 2.3	60		27564 Treatment of open patellar dislocation, with uncomplicated soft tissue closure .....	<del>((5-0))</del> 4.5	45	3.0
27522 Treatment of open patellar fracture, with uncomplicated soft tissue closure .....	<del>((4-0))</del> 4.3	90	3.0	27566 Open treatment of closed or open patellar dislocation, with or without partial or total patellectomy.	<del>((12-0))</del> 10.9	90	3.0
27524 Open treatment of closed or open patellar fracture, with repair and/or excision .....	<del>((12-0))</del> 10.8	90	3.0	<b>MANIPULATION</b>			
27530 Treatment of closed tibial fracture, proximal (plateau); without manipulation .....	<del>((Sv.&amp;))</del> 2.7	90		*27570 Manipulation of knee joint under general anesthesia (includes application of traction or other fixation devices) .....	<del>((12-0))</del> 2.7	30	3.0
				<b>ARTHRODESIS</b>			
				27580 Fusion of knee, any technique ..	<del>((20-0))</del> 19.0	120	3.0
				<b>AMPUTATION</b>			
				27590 Amputation, thigh, through femur, any level .....	<del>((14-5))</del> 13.1	120	4.0

	Unit Value	Follow-up Days=	Basic Anes@
27591 immediate fitting technique including first cast	<del>((BR 30))</del> 13.6	120	3.0
27592 open, circular (guillotine)	<del>((14.0))</del> 14.5	120	4.0
27594 secondary closure or scar revision	<del>((SV 6))</del> 4.5	120	3.0
27596 reamputation	<del>((BR 1))</del> 12.7	45	4.0
27598 Disarticulation at knee	<del>((14.0))</del> 12.7	120	4.0

MISCELLANEOUS

27599 Unlisted procedure, femur or knee	BR		4.0
---	----	--	-----

AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

WAC 296-22-087 LEG (TIBIA AND FIBULA) AND ANKLE JOINT.

	Unit Value	Follow-up Days=	Basic Anes@
<b>INCISION</b>			
27600 Decompression fasciotomy, leg (for closed space decompression); anterior compartment only	<del>((5.0))</del> 5.4	30	3.0
27601 posterior compartment only	<del>((BR))</del> 8.9	30	3.0
27602 anterior and posterior compartments	<del>((7.0))</del> 11.7	30	3.0
(For incision and drainage procedures, superficial, see 10000-10160)			
27603 Incision and drainage; leg or ankle deep abscess or hematoma	<del>((BR))</del> 4.5	60	3.0
27604 infected bursa	<del>((SV))</del> 1.0	30	3.0
*27605 Tenotomy, Achilles tendon, subcutaneous (separate procedure); local anesthesia	<del>((1.0 0))</del> 2.3	30	3.0
27606 general anesthesia	<del>((2.0 0))</del> 2.7	30	3.0
27607 Incision, deep, with opening of bone cortex (e.g., for osteomyelitis or bone abscess); leg or ankle	<del>((BR))</del> 3.6	30	3.0
27610 Arthrotomy, ankle, for infection with exploration, drainage or removal of foreign body	<del>((9.0))</del> 8.2	60	3.0
27612 Arthrotomy, ankle, posterior capsular release, with or without Achilles tendon lengthening	<del>((10.0))</del> 9.0	60	3.0
(See also 27685)			
<b>EXCISION</b>			
27613 Biopsy, soft tissues; superficial	<del>((1.2 7))</del> 2.7	0	3.0
27614 deep	<del>((2.4 15))</del> 4.5	0	3.0

	Unit Value	Follow-up Days=	Basic Anes@
27615 Radical resection of tumor (e.g., malignant neoplasm); soft tissue of leg or ankle area	<del>((BR))</del> 11.3	90	3.0
27618 Excision, tumor; leg or ankle subcutaneous	<del>((3.0 7))</del> 3.6	21	3.0
27619 deep, subfascial or intramuscular	<del>((4.0 15))</del> 7.2	30	3.0
27620 Arthrotomy, ankle, with joint exploration, with or without biopsy, with or without removal of loose or foreign body	<del>((9.0))</del> 8.2	60	3.0
27625 Arthrotomy, ankle, for synovectomy	<del>((12.0))</del> 10.8	90	3.0
27626 including tenosynovectomy	<del>((14.0))</del> 11.7	90	3.0
27630 Excision of lesion of tendon, sheath or capsule (e.g., cyst or ganglion leg and/or ankle)	<del>((3.6))</del> 3.3	30	3.0
27635 Excision, or curettage, of bone cyst or benign tumor, tibia or fibula	<del>((10.0))</del> 9.5	60	3.0
27637 with primary autogenous graft (includes obtaining graft)	<del>((13.0))</del> 11.7	120	3.0
27638 with primary homogenous graft	<del>((14.0))</del> 11.7	120	3.0
27640 Excision, partial, (craterization, saucerization or diaphysectomy) of bone (e.g., for osteomyelitis or exostosis; tibia	<del>((12.0 60))</del> 11.3	120	3.0
27641 fibula	<del>((10.0))</del> 10.8	60	3.0
27645 Resection for tumor, radical; tibia	<del>((BR))</del> 17.2	120	3.0
27646 fibula	<del>((BR))</del> 11.7	120	3.0
27647 talus or calcaneus	<del>((BR))</del> 16.3	120	3.0

INTRODUCTION OR REMOVAL

27648 Injection procedure for ankle arthrography	<del>((BR))</del> 1.2		
(For ankle arthrography, see 73615)			
(For ankle arthroscopy, see 29890-29898)			

REPAIR, REVISION OR RECONSTRUCTION

27650 Repair, primary, open or percutaneous, ruptured Achilles tendon	<del>((11.0))</del> 9.9	120	3.0
27652 with graft (includes obtaining graft)	<del>((14.0))</del> 12.7	120	3.0
27654 Repair, secondary, ruptured Achilles tendon, with or without graft	<del>((14.0))</del> 14.5	120	3.0
27656 Repair, fascial defect of leg	<del>((6.0))</del> 5.4	45	3.0

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@		
27658	Repair or suture of flexor tendon of leg; primary, without graft, single, each	<del>((6-0))</del> 5.9	90	3.0	27707	fibula	<del>((7-0))</del> 6.3	90	3.0
27659	secondary with or without graft, single tendon, each	<del>((8-0))</del> 7.2	90	3.0	27709	tibia and fibula	<del>((14-0))</del> 13.6	90	3.0
27664	Repair or suture of extensor tendon of leg; primary, without graft, single, each	<del>((4-0))</del> 3.9	90	3.0	27712	multiple, with realignment on intramedullary rod (Sofield type procedure)	<del>((18-0))</del> 16.4	90	3.0
27665	secondary with or without graft, single tendon, each	<del>((6-0))</del> 5.4	90	3.0		(For osteotomy to correct genu varus (bowleg) or genu valgus (knock-knee), see 27455-27457)			
27675	Repair for dislocating peroneal tendons; without fibular osteotomy	5.0	<del>((90))</del> 30	3.0	27715	Osteoplasty, tibia and fibula, lengthening	<del>((24-0))</del> 22.1	90	3.0
27676	with fibular osteotomy	<del>((6-0-90))</del> 5.9	<del>90</del> 60	3.0	27720	Repair of nonunion or malunion, tibia, without graft (e.g., compression technique, etc.)	<del>((18-0))</del> 16.3	90	3.0
27680	Tenolysis, including tibia, fibula and ankle flexor, single	<del>((5-0))</del> 4.5	60	3.0	27722	with sliding graft	<del>((20-0))</del> 17.6	120	3.0
27681	multiple (through same incision), each	<del>((6-0))</del> 5.4	60	3.0	27724	with iliac or other autogenous bone graft (includes obtaining graft)	<del>((22-0))</del> 19.0	120	3.0
27685	Lengthening or shortening of tendon; single (separate procedure)	<del>((7-0))</del> 6.4	90	3.0	27725	by synostosis, with fibula, any method	<del>((BR))</del> 25.3	120	3.0
27686	multiple (through same incision), each	<del>((8-0-120))</del> 7.2	<del>120</del> 90	3.0	27727	Repair of congenital pseudarthrosis, tibia	<del>((BR))</del> 19.9	120	3.0
27687	Gastrocnemius recession (e.g., Strayer procedure)	<del>((7-0-120))</del> 6.9	<del>120</del> 90	3.0	27730	Epiphyseal arrest by epiphysiodesis or stapling, distal tibia	<del>((12-0))</del> 10.4	120	3.0
	(Toe extensors are considered as a group to be a single tendon when transplanted into midfoot)				27732	distal fibula	<del>((6-0))</del> 5.6	120	3.0
27690	Transfer or transplant of single tendon (with muscle redirection or rerouting); superficial (e.g., anterior tibial extensors into midfoot)	<del>((8-0))</del> 7.2	120	3.0	27734	distal tibia and fibula	<del>((14-0))</del> 12.3	120	3.0
27691	anterior tibial or posterior tibial through interosseous space	<del>((10-0))</del> 9.0	120	3.0	27740	Epiphyseal arrest by epiphysiodesis or stapling, combined, proximal and distal tibia and fibula	<del>((18-0))</del> 16.7	120	3.0
27692	each additional tendon	<del>((2-0))</del> 1.8			27742	and distal femur	<del>((22-0))</del> 20.3	120	3.0
27695	Suture, primary, torn, ruptured or severed ligament, ankle; collateral	<del>((10-0))</del> 9.0	120	3.0		(For epiphyseal arrest of proximal tibia and fibula, see 27477)			
27696	both collateral ligaments	<del>((14-0))</del> 12.7	120	3.0	27745	Prophylactic treatment (nailing, pinning, plating or wiring), with or without methyl methacrylate, tibia	<del>((BR))</del> 13.7	120	
27698	Suture, secondary repair, torn, ruptured or severed ligament; ankle, collateral (e.g., Watson-Jones procedure)	14.0	120	3.0		<b>FRACTURES AND/OR DISLOCATIONS</b>			
27700	Arthroplasty, ankle	<del>((BR))</del> 18.1	90	3.0	27750	Treatment of closed tibial shaft fracture; without manipulation	<del>((Sw-@))</del> 3.3	120	
27702	with implant ("total ankle")	<del>((BR))</del> 28.0	120	3.0	27752	with manipulation	5.0	<del>((90))</del> 120	3.0
27703	secondary reconstruction, total ankle	<del>((BR))</del> 26.7	90	3.0	27754	Treatment of open tibial shaft fracture, with uncomplicated soft tissue closure	<del>((6-5-90))</del> 6.3	120	3.0
27704	Removal of ankle implant	<del>((BR))</del> 9.9	30		27756	Open treatment of closed or open tibial shaft fracture, with internal skeletal fixation; simple	<del>((12-0-90))</del> 10.8	<del>120</del> 120	3.0
27705	Osteotomy; tibia	<del>((12-0))</del> 11.3	90	3.0	27758	complicated	<del>((17-9))</del> 19.0	120	3.0

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
27760	Treatment of closed distal tibial fracture (medial malleolus); without manipulation .....(( <del>Sw.&amp;</del> ))	90		27814	Open treatment of closed or open bimalleolar ankle fracture, with or without internal skeletal fixation ..... (( <del>+2.0</del> ))	90	3.0
	2.4				11.3		
27762	with manipulation ..... (( <del>3.0</del> ))	90	3.0	27816	Treatment of closed trimalleolar ankle fracture; without manipulation .....(( <del>Sw.&amp;</del> ))		
	3.1				2.7		
27764	Treatment of open distal tibial fracture (medial malleolus) with uncomplicated soft tissue closure (( <del>4.4</del> ))	90	3.0	27818	with manipulation ..... (( <del>6.6</del> ))	90	3.0
	6.3				5.9		
27766	Open treatment of closed or open distal tibial fracture (medial malleolus), with fixation ..... (( <del>9.0</del> ))	90	3.0	27820	Treatment of open trimalleolar ankle fracture, with uncomplicated soft tissue closure ..... (( <del>7.0</del> ))	90	3.0
	8.1				6.3		
27780	Treatment of closed proximal fibula or shaft fracture; without manipulation .....(( <del>Sw.&amp;</del> ))	90		27822	Open treatment of closed or open trimalleolar ankle fracture, with or without internal or external skeletal fixation, medial and/or lateral malleolus; only ..... (( <del>+4.5</del> ))	90	3.0
	1.8				13.1		
27781	with manipulation ..... (( <del>3.0</del> ))	90	3.0	27823	including internal skeletal fixation of posterior lip (malleolus) ..... (( <del>+8.0</del> — <del>+20</del> ))		3.0
	2.7				14.1	90	
27782	Treatment of open proximal fibula or shaft fracture, with uncomplicated soft tissue closure .. (( <del>4.0</del> ))	90	3.0	27830	Treatment of proximal tibiofibular joint dislocation; without anesthesia .....(( <del>Sw.&amp;</del> ))	90	
	3.6				2.3		
27784	Open treatment of closed or open proximal fibula or shaft fracture, with or without internal or external skeletal fixation ..... (( <del>8.0</del> ))	90	3.0	27831	requiring anesthesia ..... (( <del>DR</del> ))	30	3.0
	7.5				2.7		
27786	Treatment of closed distal fibular fracture (lateral malleolus); without manipulation .....(( <del>Sw.&amp;</del> ))			27832	Open treatment of proximal tibiofibular joint dislocation with fixation or excision ..... (( <del>8.0</del> ))	90	3.0
	2.7				7.3		
27788	with manipulation ..... (( <del>3.0</del> ))	90	3.0	27840	Treatment of ankle dislocation; without anesthesia .....(( <del>Sw.&amp;</del> ))	45	
	3.6				1.6		
27790	Treatment of open distal fibular fracture (lateral malleolus), with uncomplicated soft tissue closure (( <del>4.0</del> ))	90	3.0	27842	requiring anesthesia ..... (( <del>2.0</del> ))	45	3.0
	3.8				2.4		
27792	Open treatment of closed or open distal fibular fracture (lateral malleolus), with fixation ..... (( <del>9.0</del> ))	90	3.0	27844	Treatment of open ankle dislocation, with uncomplicated soft tissue closure ..... 3.2	45	3.0
	8.1			27846	Open treatment of closed or open ankle dislocation ..... (( <del>+2.0</del> ))	90	3.0
27800	Treatment of closed tibia and fibula fractures, shafts; without manipulation .....(( <del>Sw.&amp;</del> ))	90			11.0		
	3.5			27848	with fixation ..... (( <del>9.0</del> ))	90	3.0
27802	with manipulation ..... (( <del>6.5</del> ))	90	3.0		9.9		
	4.5			<b>ARTHROSCOPY</b>			
27804	Treatment of open tibia and fibula fractures, shafts, with uncomplicated soft tissue closure (e.g., "pins above and below") .. (( <del>8.0</del> — <del>90</del> ))		3.0	<b>MANIPULATION</b>			
	8.6	120		*27860	Manipulation of ankle under general anesthesia (includes application of traction or other fixation apparatus) ..... (( <del>+1.0</del> — <del>0</del> ))		3.0
27806	Open treatment of closed or open tibia and fibula fractures, shafts, with or without internal or external skeletal fixation ..... (( <del>+4.5</del> — <del>90</del> ))		3.0		1.3	30	
	13.6	120		<b>ARTHRODESIS</b>			
27808	Treatment of closed bimalleolar ankle fracture, (including Potts); without manipulation .....(( <del>Sw.&amp;</del> ))	90		27870	Arthrodesis, ankle any method . (( <del>+7.0</del> ))	120	3.0
	2.7				15.7		
27810	with manipulation ..... (( <del>5.0</del> ))	90	3.0	27871	Arthrodesis, tibiofibular joint, proximal or distal ..... (( <del>DR</del> ))	120	3.0
	4.5				4.1		
27812	Treatment of open bimalleolar ankle fracture, with uncomplicated soft tissue closure ..... (( <del>6.5</del> ))	90	3.0	<b>AMPUTATION</b>			
	5.9			27880	Amputation, leg, through tibia and fibula ..... (( <del>+2.0</del> — <del>90</del> ))		4.0
					13.1	120	
				27881	with immediate fitting technique including application of first cast ..... (( <del>+2.0</del> — <del>90</del> ))		4.0
					14.5	120	

	Unit Value	Follow-up Days=	Basic Anes@
27882 open, circular (guillotine) ...	<del>((10.5-90))</del> 9.5	120	4.0
*27884 secondary closure or scar revision .....	<del>((Sw.6))</del> 4.5	45	3.0
27886 reamputation .....	<del>((BR))</del> 13.6	45	4.0
27888 Amputation, ankle, through malleoli of tibia and fibula (Syme, Pirogoff type procedures), with plastic closure and resection of nerves .....	<del>((12.0))</del> 10.4	90	3.0
27889 Ankle disarticulation .....	<del>((12.0-120))</del> 10.4	90	3.0

MISCELLANEOUS

27899 Unlisted procedure, leg or ankle .	BR		4.0
--	----	--	-----

**AMENDATORY SECTION** (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

WAC 296-22-091 FOOT.

INCISION

(For incision and drainage procedures, superficial, see 10000-10160)

	Unit Value	Follow-up Days=	Basic Anes@
*28001 Incision and drainage, infected bursa .....	<del>((Sw))</del> 0.7	15	
*28002 Deep dissection below fascia, requiring deep dissection, with or without tendon sheath involvement; single bursal space, specify .....	<del>((BR))</del> 1.2	21	3.0
28003 multiple areas .....	<del>((BR))</del> 1.8	21	3.0
28005 Incision, deep, with opening of bone cortex (e.g., for osteomyelitis or bone abscess); foot .....	<del>((BR))</del> 3.6	45	3.0
28008 Fasciotomy, <del>((plantar))</del> foot and/or <del>((toe, subcutaneous))</del> .....	<del>((2.4))</del> 2.2	60	3.0
(See also 28060, 28062, 28250)			
*28010 Tenotomy, subcutaneous, toe; single .....	<del>((0.8-0))</del> 0.9	30	3.0
*28011 multiple .....	<del>((1.2-0))</del> 1.4	30	3.0
(For open tenotomy, see 28230, 28234)			
28020 Arthrotomy, with exploration, drainage or removal of loose or foreign body; intertarsal or tarsometatarsal joint .....	<del>((6.0))</del> 5.6	60	3.0
28022 metatarsophalangeal joint .....	<del>((3.6))</del> 3.3	60	3.0
28024 interphalangeal joint .....	<del>((2.4))</del> 2.3	60	3.0
28030 Neurectomy of intrinsic musculature of foot .....	<del>((BR))</del> 10.8	60	3.0

	Unit Value	Follow-up Days=	Basic Anes@
28035 Tarsal tunnel release (posterior tibial nerve decompression) .....	<del>((8.0-60))</del> 9.0	30	3.0

(For other nerve entrapments, see 64704 and 64722)

EXCISION

28043 Excision, tumor foot; subcutaneous .....	<del>((3.0-7))</del> 2.7	21	3.0
28045 deep, subfascial, intramuscular .	<del>((4.0-15))</del> 4.5	21	3.0
28046 Radical resection of tumor (e.g., malignant neoplasm); soft tissue of foot .....	BR		
28050 Arthrotomy for synovial biopsy; intertarsal or tarsometatarsal joint .....	<del>((6.0))</del> 5.6	60	3.0
28052 metatarsophalangeal joint .....	<del>((3.6))</del> 3.3	60	3.0
28054 interphalangeal joint .....	<del>((2.4))</del> 2.3	60	3.0
28060 Faciectomy, excision of plantar fascia; partial (separate procedure) .....	<del>((6.0))</del> 5.0	60	3.0
28062 radical (separate procedure) ...	<del>((BR))</del> 10.4	90	3.0
(For plantar fasciotomy, see 28008, 28250)			
28070 Synovectomy, intertarsal or tarsometatarsal joint, each .....	<del>((6.0))</del> 5.6	90	3.0
28072 metatarsophalangeal joint, each .....	<del>((3.6))</del> 3.3	90	3.0
28080 Excision of interdigital (Morton) neuroma, single, each .....	<del>((3.6))</del> 4.1	30	3.0
28086 Synovectomy, tendon sheath; foot flexor .....	<del>((6.0-90))</del> 9.0	60	3.0
28088 extensor .....	<del>((6.0-90))</del> 4.8	60	3.0
28090 Excision of lesion of tendon or fibrous sheath or capsule (including synovectomy) (cyst or ganglion); foot .....	3.6	<del>((30))</del> 45	3.0
28092 toes .....	<del>((2.4))</del> 2.3	30	3.0
28100 Excision or curettage of bone cyst or benign tumor, talus or calcaneus .....	<del>((6.0))</del> 5.6	60	3.0
28102 with iliac or other autogenous bone graft (includes obtaining graft) .....	<del>((7.0))</del> 6.3	120	3.0
28103 with homogenous bone graft ...	<del>((8.0))</del> 5.4	120	3.0
28104 Excision or curettage of bone cyst or benign tumor, tarsal or metatarsal bones, except talus or calcaneus .....	<del>((4.8))</del> 4.4	60	3.0
28106 with iliac or other autogenous bone graft (includes obtaining graft) .....	<del>((5.6))</del> 5.4	120	3.0



	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
28107	with homogenous bone graft ... <del>((6-6))</del> <u>4.5</u>	120	3.0	28175	phalanx of toe ... <del>((BR))</del> <u>6.3</u>	<u>120</u>	3.0
28108	Excision or curettage of bone cyst or benign tumor, phalanges of foot ... 3.6	60	3.0		(For talus or calcaneus, see 27647)		
	(For ostectomy, partial (e.g., hallux valgus, Silver type procedure) see 28290)			INTRODUCTION AND/OR REMOVAL			
28110	Ostectomy, partial excision, fifth metatarsal head (bunionette) (separate procedure) ... <del>((2-4))</del> <u>2.2</u>	60	3.0	*28190	Remove foreign body; foot subcutaneous ... <del>((BR))</del> <u>1.2</u>		3.0
28111	Ostectomy; complete excision of first metatarsal head ... <del>((7-0-90))</del> <u>4.1</u> <u>30</u>		3.0	28192	deep ... <del>((BR))</del> <u>2.3</u>	<u>15</u>	3.0
28112	other metatarsal head (second, third or fourth) ... <del>((4-0))</del> <u>3.6</u>	60	3.0	28193	complicated ... <del>((BR))</del> <u>3.6</u>	<u>21</u>	3.0
28113	fifth metatarsal head ... <del>((1-0-90))</del> <u>4.5</u> <u>30</u>		3.0	REPAIR, REVISION OR RECONSTRUCTION			
28114	all metatarsal heads with proximal phalangectomy partial excluding first metatarsal (Clayton type procedure) ... <del>((12-0))</del> <u>10.8</u>	60	3.0	28200	Repair or suture of tendon, foot, flexor, single; primary or secondary, without free graft, each tendon ... <del>((6-0))</del> <u>5.4</u>	90	3.0
28116	Ostectomy, excision of tarsal coalition ... <del>((7-0))</del> <u>6.3</u>	60	3.0	28202	secondary with free graft, each tendon (includes obtaining graft) ... <del>((8-0))</del> <u>7.2</u>	90	3.0
28118	Ostectomy, calcaneus ... <del>((7-0))</del> <u>6.3</u>	60	3.0	28208	Repair or suture of tendon, foot, extensor, single; primary or secondary, each tendon ... <del>((2-0))</del> <u>2.7</u>	90	3.0
28119	for spur, with or without plantar fascial release ... <del>((BR))</del> <u>4.5</u>	<u>60</u>	3.0	28210	secondary with free graft, each tendon (includes obtaining graft) ... <del>((4-4))</del> <u>4.0</u>	90	3.0
28120	Partial excision (craterization, saucerization, sequestrectomy, or diaphysectomy) of bone (e.g., for osteomyelitis or talar bossing), talus or calcaneus ... <del>((6-0))</del> <u>5.4</u>	60	3.0	28220	Tenolysis, flexor, single ... <del>((5-0))</del> <u>4.5</u>	60	3.0
28122	Partial excision (craterization, saucerization, or diaphysectomy) of bone (e.g., for osteomyelitis or tarsal bossing), tarsal or metatarsal bone, except talus or calcaneus ... <del>((4-8))</del> <u>4.3</u>	60	3.0	28222	multiple (through same incision) ... <del>((BR))</del> <u>5.4</u>	60	3.0
28124	Partial excision (craterization, saucerization, or diaphysectomy) of bone (e.g., for osteomyelitis or dorsal bossing), phalanx of toe ... <del>((3-6))</del> <u>3.3</u>	60	3.0	28225	Tenolysis, extensor; foot single ... <del>((2-0))</del> <u>2.5</u>	60	3.0
28126	Condylectomy, phalangeal base, single toe, each ... <del>((8-0))</del> <u>1.0</u>	60	3.0	28226	multiple (through same incision) ... <del>((BR))</del> <u>3.3</u>	60	3.0
28130	Talectomy (astragalectomy) ... <del>((10-0))</del> <u>9.0</u>	120	3.0	28230	Tenotomy, open, flexor, foot, single or multiple (separate procedure) ... <del>((3-0))</del> <u>2.7</u>	30	3.0
28140	Metatarsectomy ... <del>((6-0))</del> <u>5.4</u>	60	3.0	28232	toe, single (separate procedure) ... <del>((1-4))</del> <u>1.3</u>	30	3.0
28150	Phalangectomy, single, each ... <del>((3-6))</del> <u>3.2</u>	30	3.0	28234	Tenotomy, open, extensor, foot or toe ... <del>((1-0))</del> <u>0.9</u>	30	3.0
28153	Resection, head of phalanx, toe ... <del>((6-0))</del> <u>1.8</u>	30	3.0	28236	Transfer of tendon, anterior tibial into tarsal bone ... <del>((5-0-120))</del> <u>5.9</u> <u>60</u>		3.0
28160	Hemiphalangectomy or interphalangeal joint excision, toe single, each ... <del>((3-0))</del> <u>1.8</u>	30	3.0	28238	Advancement of posterior tibial tendon with excision of accessory navicular bone (Kidner type procedure) ... <del>((7-0-120))</del> <u>6.2</u> <u>60</u>		3.0
28171	Radical resection for tumor; tarsal (except talus or calcaneus) ... <del>((BR))</del> <u>9.0</u>	<u>120</u>	3.0		(For subcutaneous tenotomy, see 28010, 28011)		
28173	metatarsal ... <del>((BR))</del> <u>9.0</u>	<u>120</u>	3.0		(For transfer or transplant of tendon with muscle redirection or rerouting, see 27690-27692)		
					(For extensor hallucis longus transfer, great toe, IP fusion (Jones procedure), see 28760)		

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
28240 Tenotomy lengthening or release, abductor hallucis muscle . . . . .	<del>(3.6)</del> 3.3	60	3.0	28300 Osteotomy; calcaneus (Dwyer or Chambers type procedure) with or without internal fixation . . . . .	<del>(9.5)</del> 8.7	90	3.0
28250 Division of plantar fascia and muscle ("Steindler stripping") (separate procedure) . . . . .	<del>(6.0)</del> 5.4	60	3.0	28302 talus . . . . .	<del>(9.0)</del> 8.1	90	3.0
28260 Capsulotomy, midfoot; medial release only (separate procedure) . . . . .	<del>(BR)</del> 8.5	60	3.0	28304 Osteotomy, midtarsal bones, other than calcaneus or talus . . . . .	<del>(8.0)</del> 7.3	90	3.0
28261 with tendon lengthening . . . . .	<del>(BR)</del> 9.7	60	3.0	28305 with autogenous graft (includes obtaining graft) (Fowler type) . . . . .	9.0	<del>(120)</del> 90	3.0
28262 extensive, including posterior talotibial capsulotomy and tendon(s) lengthening as for resistant clubfoot deformity . . . . .	<del>(BR)</del> 18.1	90	3.0	28306 Osteotomy, metatarsal, base or shaft, single, with or without lengthening for shortening or angular correction; first metatarsal . . . . .	<del>(7.0)</del> 6.5	90	3.0
28264 Capsulotomy, midtarsal (Heyman type procedure) . . . . .	<del>(12.0)</del> 10.9	90	3.0	28307 first metatarsal with bone graft . . . . .	BR		
28270 Capsulotomy for contracture, metatarsophalangeal joint, with or without tenorrhaphy, single, each joint (separate procedure) . . . . .	<del>(3.0)</del> 1.4	60	3.0	28308 other than first metatarsal . . . . .	<del>(5.6)</del> 5.1	90	3.0
28272 interphalangeal joint, single, each joint (separate procedure) . . . . .	<del>(1.4)</del> 1.5	60	3.0	28309 Osteotomy, metatarsals, multiple, for cavus foot (Swanson type procedure) . . . . .	<del>(BR-120)</del> 6.3	60	3.0
28280 Webbing operation (create syndactylism of toes) for soft corn (Kelikian type procedure) . . . . .	<del>(3.6-46)</del> 3.1	45	3.0	28310 Osteotomy for shortening, angular or rotational correction; proximal phalanx, first toe (separate procedure) . . . . .	2.8	90	3.0
28285 Hammer toe operation, one toe (e.g., interphalangeal fusion, filleting, phalangectomy) (separate procedure) . . . . .	<del>(4.8-90)</del> 4.3	60	3.0	28312 other phalanges, any toe . . . . .	<del>(2.0)</del> 1.8	90	3.0
28286 for cock-up fifth toe with plastic skin closure, (Ruiz-Mora type procedure) . . . . .	<del>(3.6-120)</del> 2.2	60	3.0	28313 Reconstruction, angular deformity of toe (overlapping second toe, fifth toe, curly toes), soft tissue procedures only . . . . .	BR		
28288 Osteotomy, partial, exostectomy or condylectomy, single, metatarsal head, first through fifth, each metatarsal head, (separate procedure) . . . . .	<del>(7.0-120)</del> 6.3	60	3.0	28315 Sesamoidectomy, first toe (separate procedure) . . . . .	<del>(BR)</del> 3.6	90	3.0
28290 Hallux valgus (bunion) correction, with or without sesamoidectomy; simple exostectomy (Silver type procedure) . . . . .	<del>(4.8-60)</del> 4.3	90	3.0	28320 Repair of nonunion or malunion; tarsal bones (calcaneus, talus, etc.) . . . . .	<del>(BR)</del> 7.2	120	3.0
28292 Keller, McBride or Mayo type procedure . . . . .	<del>(7.0)</del> 6.9	90	3.0	28322 metatarsal, with or without bone graft (includes obtaining graft) . . . . .	<del>(4.8)</del> 4.4	120	3.0
28293 resection of joint with implant . . . . .	<del>(8.0)</del> 7.4	120	3.0	28340 Reconstruction, toe, macrodactyly; soft tissue resection . . . . .	BR		
28294 with tendon transplants (Joplin type procedure) . . . . .	<del>(9.5)</del> 8.6	90	3.0	28341 requiring bone resection . . . . .	BR		
28296 with metatarsal osteotomy (Mitchell Chevron or concentric type procedure) . . . . .	<del>(9.5-120)</del> 11.3	90	3.0	28344 Reconstruction, toe(s); polydactyly . . . . .	BR		
28297 Lapidus type procedure . . . . .	<del>(9.5-120)</del> 8.6	90	3.0	28345 syndactyly, with or without skin graft(s), each web . . . . .	BR		
28298 by phalanx osteotomy . . . . .	<del>(7.0-120)</del> 3.6	90	3.0	28360 Reconstruction, cleft foot . . . . .	BR		
28299 by other methods (e.g., double osteotomy) . . . . .	<del>(BR)</del> 11.3	90	3.0	<b>FRACTURE AND/OR DISLOCATION</b>			
				28400 Treatment of closed calcaneal fracture; without manipulation . . . . .	<del>(Sw. &amp;)</del> 2.3	120	
				28405 with manipulation including Cotton or Bohler type reductions . . . . .	<del>(BR)</del> 3.6	120	3.0
				28406 with manipulation and skeletal fixation . . . . .	<del>(BR)</del> 5.0	120	3.0
				28410 Treatment of open calcaneal fracture, with uncomplicated soft tissue closure . . . . .	<del>(4.0-90)</del> 3.8	120	3.0

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@		
28415	Open treatment of closed or open calcaneal fracture, with or without internal or external skeletal fixation . . . . .	<del>(+0-0)</del> 9.2	90	3.0	28496	with manipulation and percutaneous pinning, each . . . . .	<del>(BR)</del> 1.2	30	
28420	with primary iliac or other autogenous bone graft (includes obtaining graft) . . . . .	<del>(+4-5)</del> 12.7	90	3.0	28500	Treatment of open fracture great toe, phalanx or phalanges, with uncomplicated soft tissue closure . . . . .	<del>(+8)</del> 1.6	30	3.0
28430	Treatment of closed talus fracture; without manipulation . . . . .	<del>(Sv-6)</del> 2.4	90	3.0	28505	Open treatment of closed or open fracture great toe, phalanx or phalanges, with or without internal or external skeletal fixation . . . . .	<del>(3-6)</del> 3.3	45	3.0
28435	with manipulation . . . . .	<del>(3-0)</del> 3.3	90	3.0	28510	Treatment of closed fracture, phalanx or phalanges, other than great toe; without manipulation, each . . . . .	<del>(Sv-6)</del> 0.6	30	
28436	with manipulation and percutaneous pinning . . . . .	<del>(BR)</del> 3.5	90	3.0	28515	with manipulation, each . . . . .	1.0	30	3.0
28440	Treatment of open talus fracture, with uncomplicated soft tissue closure . . . . .	<del>(4-0)</del> 3.7	90	3.0	28520	Treatment of open fracture, phalanx or phalanges, other than great toe, with uncomplicated soft tissue closure, each . . . . .	<del>(+6-30)</del> 1.5	45	3.0
28445	Open treatment of closed or open talus fracture, with or without internal or skeletal fixation . . . . .	<del>(+0-0)</del> 9.2	90	3.0	28525	Open treatment of closed or open fracture, phalanx or phalanges; other than great toe, with or without internal or external skeletal fixation, each . . . . .	<del>(3-0)</del> 2.8	45	3.0
28450	Treatment of closed tarsal bone fracture (except talus and calcaneus); without manipulation, each . . . . .	<del>(Sv-6)</del> 2.3	90	3.0	28530	Treatment of closed sesamoid fracture . . . . .	BR		
28455	with manipulation, each . . . . .	<del>(2-0)</del> 2.9	90	3.0	*28540	Treatment of closed tarsal bone dislocation; without anesthesia . . . . .	<del>(*0-72-0)</del> 2.7	45	
28456	with manipulation reduction and percutaneous pinning, each . . . . .	<del>(BR)</del> 3.3	90	3.0	28545	requiring anesthesia . . . . .	<del>(2-0)</del> 2.7	45	3.0
28460	Treatment of open tarsal bone fracture (except talus and calcaneus), with uncomplicated soft tissue closure, each . . . . .	<del>(3-0)</del> 3.2	90	3.0	28546	Treatment of closed tarsal bone dislocation, with percutaneous skeletal fixation . . . . .	<del>(2-0)</del> 3.6	45	
28465	Open treatment of closed or open tarsal bone fracture (except talus and calcaneus), with or without internal or external skeletal fixation, each . . . . .	<del>(6-0)</del> 5.5	90	3.0	28550	Treatment of open tarsal bone dislocation, with uncomplicated soft tissue closure . . . . .	2.8	45	3.0
28470	Treatment of closed metatarsal fracture; without manipulation, each . . . . .	<del>(Sv-6)</del> 2.0	60		28555	Open treatment of closed or open tarsal bone dislocation, with or without internal or external skeletal fixation . . . . .	<del>(6-0)</del> 5.2	90	3.0
28475	with manipulation, each . . . . .	<del>(2-2-90)</del> 2.3	60	3.0	*28570	Treatment of closed talotarsal joint dislocation; without anesthesia . . . . .	<del>(*1-0-0)</del> 2.2	45	
28476	with manipulation and percutaneous pinning, each . . . . .	<del>(BR)</del> 2.3	60	3.0	28575	requiring anesthesia . . . . .	<del>(2-4)</del> 2.2	45	3.0
28480	Treatment of open metatarsal fracture, with uncomplicated soft tissue closure, each . . . . .	<del>(3-0)</del> 2.8	90	3.0	28580	Treatment of open talotarsal joint dislocation, with uncomplicated soft tissue closure . . . . .	3.2	45	3.0
28485	Open treatment of closed or open metatarsal fracture, with or without internal or external skeletal fixation, each . . . . .	<del>(6-0)</del> 5.5	90	3.0	28585	Open treatment of closed or open talotarsal joint dislocation, with or without internal or external skeletal fixation . . . . .	<del>(+0-0)</del> 9.0	90	3.0
28490	Treatment of closed fracture great toe, phalanx or phalanges; without manipulation . . . . .	<del>(Sv-6)</del> 0.9	30		*28600	Treatment of closed tarsometatarsal joint dislocation, without anesthesia . . . . .	<del>(*0-72-0)</del> 1.8	45	
28495	with manipulation . . . . .	<del>(+2)</del> 1.0	30	3.0	28605	requiring anesthesia . . . . .	<del>(2-0)</del> 2.3	45	3.0
					28606	Treatment of closed tarsometatarsal joint dislocation, with percutaneous skeletal fixation . . . . .	<del>(3-0)</del> 5.4	45	3.0

	Unit Value	Follow-up Days=	Basic Anes@
28610 Treatment of open tarsometatarsal joint dislocation, with uncomplicated soft tissue closure . . . . .	<del>((2-0))</del> 4.1	45	3.0
28615 Open treatment of closed or open tarsometatarsal joint dislocation, with or without internal or external skeletal fixation . . . . .	<del>((6-0))</del> 5.6	90	3.0
*28630 Treatment of closed metatarsophalangeal joint dislocation; without anesthesia . . . . .	<del>((*0.72-0))</del> 1.6	45	3.0
28635 requiring anesthesia . . . . .	<del>((1-4))</del> 1.6	45	3.0
28640 Treatment of open metatarsophalangeal joint dislocation, with uncomplicated soft tissue closure . . . . .	<del>((2-0))</del> 2.3	45	3.0
28645 Open treatment of closed or open metatarsophalangeal joint dislocation . . . . .	<del>((4-0))</del> 3.8	90	3.0
*28660 Treatment of closed interphalangeal joint dislocation; without anesthesia . . . . .	<del>((*0.72-0))</del> 1.1	45	3.0
28665 requiring anesthesia . . . . .	<del>((1-2))</del> 1.1	45	3.0
28670 Treatment of open interphalangeal joint dislocation, with uncomplicated soft tissue closure . . . . .	<del>((1-6))</del> 1.5	45	3.0
28675 Open treatment of closed or open interphalangeal joint dislocation . . . . .	<del>((2-4))</del> 2.3	60	3.0
<b>ARTHRODESIS</b>			
28705 Pantalar arthrodesis . . . . .	<del>((19-0))</del> 16.3	120	3.0
28715 Triple arthrodesis . . . . .	<del>((15-0))</del> 13.6	120	3.0
28725 Subtalar arthrodesis . . . . .	<del>((BR))</del> 10.8	120	3.0
28730 Arthrodesis, midtarsal or tarsometatarsal, multiple or transverse . . . . .	<del>((11-0))</del> 9.9	120	3.0
28735 with osteotomy as for flat foot correction . . . . .	<del>((14-0))</del> 12.7	120	3.0
28737 Arthrodesis, midtarsal navicular-cuneiform, with tendon lengthening and advancement (Miller type procedure) . . . . .	<del>((7-0))</del> 10.8	120	3.0
28740 Arthrodesis, midtarsal or tarsometatarsal, single joint . . . . .	<del>((9-0))</del> 8.1	120	3.0
28750 Arthrodesis, great toe; metatarsophalangeal joint . . . . .	<del>((7-0))</del> 6.4	120	3.0
28755 interphalangeal joint . . . . .	<del>((4-0))</del> 4.3	120	3.0
28760 Arthrodesis, great toe, interphalangeal joint, with extensor hallucis longus transfer to first metatarsal neck (Jones type procedure) . . . . .	<del>((6-0))</del> 5.6	120	3.0

(For hammertoe operation or interphalangeal fusion, see 28285)

**AMPUTATION**

	Unit Value	Follow-up Days=	Basic Anes@
28800 Amputation, foot; midtarsal (Chopart type procedure) . . . . .	<del>((10-0))</del> 9.1	90	3.0
28805 transmetatarsal . . . . .	<del>((10-0))</del> 9.1	90	3.0
28810 Amputation, metatarsal, with toe, single . . . . .	<del>((6-0))</del> 5.6	90	3.0
28820 Amputation, toe; metatarsophalangeal joint . . . . .	<del>((3-0))</del> 2.8	45	3.0
28825 interphalangeal joint . . . . .	<del>((2-0))</del> 2.2	45	3.0

(For amputation of tuft of distal phalanx use 11752)

**MISCELLANEOUS**

28899 Unlisted procedure, foot or toes . . . . .	BR		3.0
--	----	--	-----

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-095 APPLICATION OF CASTS AND STRAPPING.**

The listed procedures apply when the cast application or strapping is a replacement procedure used during or after the period of follow-up care. Additional visits are reportable only if significant identifiable further services are provided at the time of the cast application or strapping.

If cast application or strapping is provided as an initial procedure in which no surgery is performed (e.g., casting of a sprained ankle or knee), use the appropriate level of office visit in addition to 99070 for supplies.

Listed procedures include removal of cast or strapping.

	Unit Value	Follow-up Days=	Basic Anes@
<b>BODY AND UPPER EXTREMITY CASTS</b>			
29000 Application of halo type body cast (see 20661-20663 for insertion) . . . . .	<del>((5-0))</del> 4.5	2	3.0
29010 Application of Risser jacket, localizer, body; only . . . . .	<del>((3-0))</del> 2.9	2	3.0
29015 including head . . . . .	<del>((3-6))</del> 3.5	2	3.0
29020 Application of turnbuckle jacket, body; only . . . . .	<del>((3-0))</del> 2.9	2	3.0
29025 including head . . . . .	<del>((3-6))</del> 3.5	2	3.0
29035 Application of body cast, shoulder to hips . . . . .	1.6	2	3.0
29040 including head, Minerva type . . . . .	<del>((2-2))</del> 2.5	2	3.0
29044 including one thigh . . . . .	2.0	2	3.0
29046 including both thighs . . . . .	2.2	2	3.0
29049 Application; plaster figure of eight . . . . .	<del>((0-6))</del> 1.2	2	3.0
29055 shoulder spica . . . . .	1.8	2	3.0

	Unit Value	Follow-up Days=	Basic Anes@
29058 plaster Velpeau .....	<del>((0-8))</del> 1.2	2	3.0
29065 shoulder to hand (long arm) ..	<del>((0-8))</del> 0.7	2	3.0
29075 elbow to fingers (short arm) ..	<del>((0-6))</del> 0.5	2	3.0
29085 hand and lower forearm (gauntlet) .....	<del>((0-6))</del> 0.5	2	3.0

**SPLINTS**

29105 Application of long arm splint (shoulder to hand) .....	<del>((0-6))</del> 0.5	2	3.0
29125 Application of short arm (forearm and hand); static .....	0.5	2	3.0
29126 dynamic .....	<del>((0-8))</del> 1.2	2	3.0
29130 Application of finger splint; static .....	<del>((0-3))</del> 0.5	2	3.0
29131 dynamic .....	<del>((0-4))</del> 1.2	2	3.0

**STRAPPING—ANY AGE**

29200 Strapping; thorax .....	0.4	0	
29220 low back .....	0.5	0	
29240 shoulder (eg, Velpeau) ....	<del>((0-6))</del> 0.5	0	
29260 elbow or wrist .....	<del>((0-24))</del> 0.3	0	
29280 hand or finger .....	<del>((0-2))</del> 0.3	0	

**LOWER EXTREMITY CASTS**

29305 Application of hip spica cast; ( <del>unilateral</del> ) <u>one leg</u> .....	<del>((2-0))</del> 1.8	2	3.0
29325 ( <del>bilateral, or</del> ) <u>one and one-half spica or both legs</u> .	<del>((2-4))</del> 2.0	2	3.0

(For hip spica (body) cast, including thighs only, see 29046)

29345 Application of long leg cast (thigh to toes) .....	<del>((+))</del> 1.0	2	3.0
29355 walking or ambulatory type	<del>((+3))</del> 1.2	2	3.0
29358 Application of long leg cast brace .....	<del>((BR))</del> 0.9		
29365 Application of cylinder cast (thigh to ankle) .....	<del>((+0))</del> 0.9	2	3.0
29405 Application of short leg (below knee to toes) .....	<del>((0-8))</del> 0.7	2	3.0
29425 walking or ambulatory type	<del>((+0))</del> 0.9	2	3.0
29435 Application of patellar tendon bearing (PTB) cast .....	<del>((+2))</del> 1.4	2	3.0
29440 Adding walker to previously applied cast .....	0.3	1	
29450 Application of clubfoot cast with molding or manipulation, long or short leg ( <del>unilateral</del> ) .....	0.4	2	3.0
<del>((29455 bilateral</del> .....	<del>0.8</del>	<del>2</del>	<del>3.0</del> )

(If over age 24 months, see other lower extremity casts)

**SPLINTS**

29505 Application of long leg splint (thigh to ankle or toes) .....	<del>((0-72))</del> 0.6	2	3.0
29515 Application of short leg splint (calf to foot) .....	<del>((0-6))</del> 0.5	2	3.0

**STRAPPING—ANY AGE**

29520 Strapping; hip .....	0.5	0	
29530 Knee .....	0.4	0	
29540 Ankle .....	0.3	0	
29550 toes .....	0.3	0	
29580 Unna boot .....	<del>((0-4))</del> 0.5	0	
29590 Denis-Browne splint strapping ..	<del>((0-4))</del> 1.2	0	

**REMOVAL OR REPAIR**

(Codes for cast removals should be employed only for casts applied by another physician)

29700 Removal or bivalving; gauntlet, boot or body cast .....	0.4	0	
29705 full arm or full leg cast .....	0.4	0	
29710 shoulder or hip spica, Minerva or Risser jacket, etc. ....	0.5	0	
29715 turnbuckle jacket .....	<del>((0-7))</del> 0.6	0	
29720 Repair of spica, body cast or jacket .....	<del>((0-24))</del> 0.3	0	
29730 Windowing of cast .....	<del>((0-24))</del> 0.3	0	
29740 Wedging of cast (except clubfoot casts) .....	0.3	0	
29750 Wedging of clubfoot cast ( <del>unilateral</del> ) .....	0.3	0	
<del>((29751 bilateral</del> .....	<del>0.4</del>	<del>0</del> )	

**MISCELLANEOUS**

29799 Unlisted procedure, casting or strapping .....	BR		3.0
--	----	--	-----

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-097 ARTHROSCOPY.**

Surgical arthroscopy always includes a diagnostic arthroscopy. When arthroscopy is performed in conjunction with arthrotomy, add modifier -51.

	Unit Value	Follow-up Days=	Basic Anes@
29815 Arthroscopy, shoulder, diagnostic, with or without synovial biopsy (separate procedure) .....	<del>((7-0-60))</del> 4.5	0	3.0
29819 Arthroscopy, shoulder, surgical; with removal of loose body or foreign body .....	<del>((7-5))</del> 10.8	60	3.0
29820 synovectomy, partial .....	<del>((8-0))</del> 11.7	60	3.0
29821 synovectomy, complete .....	<del>((9-9))</del> 14.5	60	3.0
29822 debridement, limited .....	<del>((7-5))</del> 13.6	60	3.0

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@		
29823	debridement, extensive	<del>((9-9))</del> 14.0	60	3.0	29880	with meniscectomy (medial AND lateral, including any meniscal shaving)	<del>((16-0))</del> 16.4	60	3.5
29825	with lysis and resection of adhesions with or without manipulation	<del>((9-9))</del> 6.3	60	3.0	29881	with meniscectomy (medial or lateral including any meniscal shaving)	<del>((16-6-90))</del> 12.7	60	3.0
29826	<u>decompression of subacromial space with partial acromioplasty with or without coracoacromial release</u>	BR			29882	with meniscus repair (medial or lateral)	<del>((16-8-90))</del> 15.8	60	3.0
29830	Arthroscopy, elbow, diagnostic, with or without synovial biopsy (separate procedure)	<del>((4-7-60))</del> 4.5		3.0	29883	with meniscus repair (medial AND lateral)	<del>((18-5))</del> 19.0	60	3.5
29834	Arthroscopy, elbow, surgical; with removal of loose body or foreign body	<del>((5-0))</del> 9.0	60	3.0	29884	with lysis of adhesions with or without manipulation (separate procedure)	<del>((15-2-90))</del> 5.4	60	3.0
29835	synovectomy, partial	<del>((7-1))</del> 10.8	60	3.0	29885	drilling for osteochondritis dissecans with bone grafting with or without internal fixation (including debridement of base of lesion)	BR	60	
29836	synovectomy, complete	<del>((8-2))</del> 14.5	60	3.0	29886	drilling for intact osteochondritis dissecans lesion	<del>((16-4-90))</del> 14.5	60	3.0
29837	debridement, limited	<del>((7-2))</del> 9.0	60	3.0	29887	drilling for intact osteochondritis dissecans lesion with internal fixation	<del>((16-8-90))</del> 15.8	60	3.0
29838	debridement, extensive	<del>((8-0))</del> 9.5	60	3.0	29888	Arthroscopy aided anterior cruciate ligament repair/augmentation or reconstruction	<del>((27-0))</del> 28.0	60	3.5
29840	Arthroscopy, wrist, diagnostic, with or without synovial biopsy (separate procedure)	6.5	60	3.0	29889	Arthroscopy aided posterior cruciate ligament repair/augmentation or reconstruction	<del>((27-0))</del> 28.0	60	3.5
29843	Arthroscopy, wrist, surgical; for infection, lavage and drainage	<del>((6-5))</del> 6.8	60	3.0	<del>((29890</del> Arthroscopy, ankle, diagnostic, with or without synovial biopsy (separate procedure)	6.0	<del>90</del>	<del>3.0))</del>	
29844	synovectomy, partial	<del>((6-5))</del> 6.9	60	3.0	29894	Arthroscopy, ankle (tibiotalar and fibulotalar joints), surgical; with removal of loose body or foreign body	<del>((9-0-90))</del> 8.1	60	3.0
29845	synovectomy, complete	<del>((8-0))</del> 8.1	60	3.0	29895	synovectomy, partial	<del>((9-4-90))</del> 8.1	60	3.0
29846	excision of triangular fibrocartilage and/or joint debridement	<del>((8-5))</del> 8.9	60	3.0	<del>((29896</del> synovectomy, complete	9.9	<del>90</del>	<del>3.0))</del>	
29847	internal fixation for fracture or instability	<del>((8-5))</del> 9.0	60	3.0	29897	debridement, limited	<del>((9-4-90))</del> 8.1	60	3.0
29870	Arthroscopy, knee, diagnostic, with or without synovial biopsy (separate procedure)	<del>((6-1-30))</del> 4.5		3.0	29898	debridement, extensive	<del>((9-9-90))</del> 9.0	60	3.0
29871	Arthroscopy, knee, surgical; for infection, lavage and drainage	<del>((7-4-90))</del> 6.8	60	3.0	29909	Unlisted procedure, arthroscopy	BR		3.0
<del>((29872</del> for infection, lavage and drainage with suction irrigation	7.6	<del>90</del>	<del>3.0))</del>						
29874	for removal of loose body or foreign body (e.g., osteochondritis dissecans fragmentation, chondral fragmentation)	<del>((13-0-90))</del> 9.0		3.0					
29875	synovectomy, limited (e.g., plica or shelf resection) (separate procedure)	<del>((16-2-90))</del> 12.7	60	3.0					
29876	synovectomy, major, two or more compartments (e.g., medial or lateral)	<del>((16-6-90))</del> 14.5	60	3.0					
29877	debridement/shaving of articular cartilage (chondroplasty)	<del>((16-4-90))</del> 12.7	60	3.0					
29879	abrasion arthroplasty (includes chondroplasty where necessary) or multiple drilling	<del>((16-8-90))</del> 12.7	60	3.0					

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-100 RESPIRATORY SYSTEM.**

	Unit Value	Follow-up Days=	Basic Anes@
NOSE			
INCISION			
(For simple furuncle, see 10020)			
*30000 Drainage abscess or hematoma, nasal, internal approach	*1.2	0	3.0
(For external approach, see 10020, 10060, 10140)			

	Unit Value	Follow-up Days=	Basic Anes@
*30020 Drainage of abscess or hematoma, nasal septum . . . . .	<del>(1.4)</del> <u>1.3</u>	0	3.0
(For lateral rhinotomy, see specific application, e.g., 30118, 30320)			

EXCISION

30100 Biopsy, intranasal . . . . .	0.6	<del>(7)</del> <u>0</u>	3.0
(For biopsy skin of nose, see 11100, 11101)			
30110 Excision of nasal polyp(s) simple( <del>unilateral</del> ) . . . . .	<del>(1.4-15)</del> <u>2.2</u>	<u>7</u>	3.0
<del>(30111 bilateral . . . . .)</del>	<del>BR</del>	<del>3.0</del>	

(30110, 30111 would normally be completed in an office setting)

30115 Excision, nasal polyp(s), extensive( <del>unilateral</del> ) . . . . .	<del>(4.0-30)</del> <u>4.6</u>	<u>15</u>	3.0
<del>(30116 bilateral . . . . .)</del>	<del>BR</del>	<del>3.0</del>	

(30115, 30116 would normally require the facilities available in a hospital setting)

30117 Excision, intranasal lesion; internal approach . . . . .	<del>(BR)</del> <u>1.5</u>	<u>7</u>	
30118 external approach (lateral rhinotomy) . . . . .	<del>(BR)</del> <u>6.4</u>	<u>30</u>	

30120 Excision or surgical planing of skin of nose for rhinophyma . . . . .	<del>(10.0)</del> <u>10.8</u>	60	3.0
---	----------------------------------	----	-----

30124 Excision dermoid cyst, nose; simple, skin, subcutaneous . . . . .	<del>(2.5-0)</del> <u>1.5</u>	<u>30</u>	4.0
---	----------------------------------	-----------	-----

30125 complex, under bone or cartilage . . . . .	<del>(BR)</del> <u>7.7</u>	30	4.0
--	-------------------------------	----	-----

30130 Excision turbinate, partial or complete . . . . .	<del>(2.0)</del> <u>1.8</u>	30	3.0
---	--------------------------------	----	-----

30140 Submucous resection turbinate, partial or complete . . . . .	<del>(6.0)</del> <u>5.2</u>	90	3.0
--	--------------------------------	----	-----

(For submucous resection of nasal septum, see 30500)

30150 Rhinectomy; partial . . . . .	<del>(BR)</del> <u>5.6</u>	<u>90</u>	3.0
-------------------------------------	-------------------------------	-----------	-----

30160 total . . . . .	<del>(BR)</del> <u>12.6</u>	<u>90</u>	3.0
-----------------------	--------------------------------	-----------	-----

(For closure and/or reconstruction, primary or delayed, see integumentary System, 13150-13152, 14060-14300, 15120-15730, 15760, 20900-20910)

INTRODUCTION

*30200 Injection into turbinate(s), therapeutic . . . . .	<del>(0.48-0)</del> <u>0.5</u>	<u>30</u>	
---	-----------------------------------	-----------	--

30210* Displacement therapy (Proetz type) . . . . .	<del>(0.2-0)</del> <u>1.0</u>	<u>30</u>	4.0
---	----------------------------------	-----------	-----

30220 Insertion, nasal septal prosthesis (button) . . . . .	<del>(BR)</del> <u>0.4</u>	<u>30</u>	4.0
---	-------------------------------	-----------	-----

ENDOSCOPY

(For nasal endoscopy, see 31250-31258)

REMOVAL OF FOREIGN BODY

*30300 Removal of foreign body; intranasal; office type procedure . . . . .	<del>(0.4-0)</del> <u>0.9</u>	<u>7</u>	3.0
---	----------------------------------	----------	-----

30310 requiring general anesthesia . . . . .	<del>(2.0)</del> <u>2.3</u>	<u>7</u>	3.0
--	--------------------------------	----------	-----

30320 by lateral rhinotomy . . . . .	<del>(BR)</del> <u>5.6</u>	<u>30</u>	3.0
--------------------------------------	-------------------------------	-----------	-----

REPAIR

(For obtaining tissues for graft, see 20900-20926, 21210)

30400 Rhinoplasty, primary, lateral and alar cartilages and/or elevation of nasal tip . . . . .	<del>(2.0)</del> <u>14.2</u>	180	3.0
---	---------------------------------	-----	-----

(For columellar reconstruction, see 13150 et seq.)

30410 complete, external parts including bony pyramid, lateral and alar cartilages, and/or elevation of nasal tip . . . . .	<del>(18.0)</del> <u>21.3</u>	180	3.0
---	----------------------------------	-----	-----

30420 including major septal repair . . . . .	<del>(20.0)</del> <u>24.6</u>	180	3.0
---	----------------------------------	-----	-----

30430 Rhinoplasty, secondary; minor revision (small amount of nasal tip work) . . . . .	<del>(3.0)</del> <u>5.7</u>	45	3.0
---	--------------------------------	----	-----

30435 intermediate revision (bony work with osteotomies) . . . . .	<del>(BR)</del> <u>4.1</u>	45	3.0
--	-------------------------------	----	-----

30450 major revision (nasal tip work and osteotomies) . . . . .	<del>(BR)</del> <u>5.4</u>	<u>45</u>	4.0
---	-------------------------------	-----------	-----

(For submucous resection of turbinates, see 30140)

30520 Septoplasty or submucous resection with or without cartilage scoring, contouring or replacement with graft . . . . .	<del>(10.0)</del> <u>9.0</u>	90	5.0
--	---------------------------------	----	-----

30540 Repair choanal atresia; intranasal . . . . .	<del>(1.0)</del> <u>12.4</u>	60	5.0
--	---------------------------------	----	-----

30545 transpalatine . . . . .	<del>(20.0-365)</del> <u>15.7</u>	<u>60</u>	5.0
-------------------------------	--------------------------------------	-----------	-----

*30560 Lysis intranasal synechia . . . . .	<del>(0.4-0)</del> <u>0.8</u>	<u>7</u>	3.0
--	----------------------------------	----------	-----

30580 Repair fistula; oromaxillary (combine with 31030 if antrotomy is included) . . . . .	<del>(10.0)</del> <u>9.0</u>	90	3.0
--	---------------------------------	----	-----

30600 oronasal . . . . .	<del>(BR+)</del> <u>9.0</u>	<u>90</u>	3.0
--------------------------	--------------------------------	-----------	-----

30620 Reconstruction, functional, internal nose (septal or other septal dermatoplasty) (does not include obtaining graft) . . . . .	<del>(10.0)</del> <u>9.0</u>	90	3.0
---	---------------------------------	----	-----

	Unit Value	Follow-up Days=	Basic Anes@
30630 Repair nasal septal perforations	<del>((BR))</del> 9.0	90	3.0

DESTRUCTION

*30800 Cauterization turbinates, unilateral or bilateral (separate procedure); superficial	<del>((*0.4-0))</del> 0.7	7	3.0
30805 intramural	1.4	<del>((7))</del> 30	3.0
30820 Cryosurgery of turbinates, unilateral or bilateral	<del>((BR))</del> 2.8	30	3.0

OTHER PROCEDURES

*30901 Control nasal hemorrhage, anterior, simple (cauterization)(; unilateral)	<del>((*0.6))</del> 1.2	0	
<del>((*30902 bilateral</del>	<del>*0.6</del>	<del>0</del>	
*30903 Control nasal hemorrhage, anterior, complex (cauterization with local anesthesia and packaging)(; unilateral)	<del>((BR))</del> 1.2	7	
<del>((*30904 bilateral</del>	<del>BR</del>		
*30905 Control nasal hemorrhage, posterior, with posterior nasal packs and/or cauterization; initial	*2.4	0	3.0
*30906 subsequent	<del>((*1.6))</del> 2.1	0	3.0
30915 Ligation, arteries, ethmoidal	<del>((+0.0))</del> 11.3	30	3.0
30920 internal maxillary artery, transantral	<del>((BR))</del> 12.4	30	3.0
(For ligation external carotid artery, see 37600)			
30930 Fracture nasal turbinate(s) therapeutic	<del>((BR))</del> 0.9	30	3.0
30999 Unlisted procedure, nose	BR		3.0

AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

WAC 296-22-105 ACCESSORY SINUSES.

	Unit Value	Follow-up Days=	Basic Anes@
INCISION			
*31000 Lavage by cannulation; maxillary sinus(; unilateral) (antrum puncture or natural ostium)	<del>((*0.4))</del> 0.9	0	3.0
<del>((*31001 maxillary sinuses, bilateral</del>	<del>*0.6</del>	<del>0</del>	<del>3.0</del>
31002* sphenoid sinus	<del>((0.0))</del> 0.9	0	3.0
31020 Sinusotomy, maxillary (antrotomy); intranasal(; unilateral)	<del>((3.0))</del> 5.4	90	3.0
<del>((31021 intranasal, bilateral</del>	<del>6.0</del>	<del>90</del>	<del>3.0</del>
31030 radical(; unilateral) (Caldwell-Luc) without removal of antrochoanal polyps	<del>((+0.0))</del> 12.2	90	3.0

	Unit Value	Follow-up Days=	Basic Anes@
<del>((31031 radical, bilateral (Caldwell-Luc) without removal of antrochoanal polyps</del>	<del>12.0</del>	<del>90</del>	<del>3.0</del>
31032 radical (unilateral) (Caldwell-Luc) with removal of antrochoanal polyps	<del>((+1.0-3.0))</del> 14.5	90	
<del>((31033 radical, bilateral (Caldwell-Luc) with removal of antrochoanal polyps</del>	<del>16.0</del>	<del>3.0</del>	
31040 Pterygomaxillary fossa surgery, any approach	<del>((+7.5))</del> 18.1	90	4.5
(For transantral ligation of internal maxillary artery, see 30920)			
31050 Sinusotomy, sphenoid, with or without biopsy	<del>((+1.0-3.0))</del> 7.7	90	3.0
31051 with mucosal stripping or removal of polyp(s)	<del>((+4.0-3.0))</del> BR		3.0
31070 Sinusotomy, frontal; external, simple (trephine operation)	<del>((+0.0))</del> 9.5	30	3.0
31075 transorbital, unilateral (for mucocele or osteoma, Lynch type)	<del>((+6.0))</del> 14.5	180	3.0
31080 obliterative without osteoplastic flap, brow incision (includes ablation)	<del>((24.0))</del> 14.9	180	3.0
31081 obliterative, without osteoplastic flap, coronal incision (includes ablation)	<del>((BR))</del> 14.9	180	3.0
31084 obliterative, with osteoplastic flap, brow incision	<del>((BR))</del> 21.7	180	3.0
31085 obliterative, with osteoplastic flap, coronal incision	<del>((BR))</del> 21.7	180	3.0
31086 nonobliterative, with osteoplastic flap, brow incision	<del>((BR))</del> 16.3	90	3.0
31087 nonobliterative, with osteoplastic flap, coronal incision	<del>((BR))</del> 16.3	90	3.0
31090 Sinusotomy combined, three or more sinuses	<del>((26.0))</del> 22.6	180	3.0
EXCISION			
31200 Ethmoidectomy; intranasal, anterior	<del>((6.0))</del> 6.3	90	3.0
31201 intranasal, total	<del>((+0.0))</del> 10.4	90	3.0
31205 extranasal total	<del>((+3.0))</del> 13.1	90	3.0
31225 Maxillectomy; without orbital exenteration	<del>((24.0))</del> 20.3	180	3.0
31230 with orbital exenteration (en bloc)	<del>((24.0))</del> 25.3	180	3.0
(For orbital exenteration as an independent procedure, see 65110 et seq.)			



	Unit Value	Follow-up Days=	Basic Anes@
(For skin grafts, see 15120 et seq.)			
<b>ENDOSCOPY</b>			
For endoscopic procedures, code appropriate endoscopy of each anatomic site examined.			
31250 Nasal endoscopy, diagnostic (includes examination of the medial meatus, infundibulum, and sinus ostia) .....	1.0	((0))	3.0
31252 Nasal endoscopy, surgical; with nasal polypectomy .....	<del>(3.0)</del> 2.9	<del>(30)</del>	3.0
31254 with ethmoidectomy, partial ..	<del>(8.0)</del> 8.5	<del>(60)</del>	3.0
31255 with ethmoidectomy, anterior and posterior .....	<del>(13.5)</del> 13.8	<del>(60)</del>	3.0
31256 with maxillary antrostomy ..	<del>(14.0)</del> 14.5	<del>(30)</del>	3.0
31258 with removal of foreign body(s) .....	<del>(1.5)</del> 1.4	<del>(30)</del>	3.0
31260 Maxillary sinus endoscopy, diagnostic with or without biopsy ...	<del>(5.0)</del> 5.1	<del>(30)</del>	3.0
31263 Maxillary sinus endoscopy, surgical; with removal of foreign body(s) .....	<del>(6.5)</del> 6.6	<del>(30)</del>	3.0
31265 with removal of cyst .....	<del>(5.0)</del> 5.1	<del>(30)</del>	3.0
31267 with removal of mucous membrane and/or polyps .....	<del>(10.0)</del> 10.1	<del>(30)</del>	3.0
31268 with removal of fungus ball ..	<del>(10.0)</del> 10.1	<del>(30)</del>	3.0
31270 Sphenoid endoscopy, diagnostic ..	<del>(3.0)</del> 3.1	<del>(30)</del>	3.0
31275 Sphenoid endoscopy, surgical; including sphenoidotomy .....	<del>(5.0)</del> 5.1	<del>(30)</del>	3.0
31277 with removal of mucous membrane .....	<del>(5.5)</del> 5.6	<del>(30)</del>	3.0

**OTHER PROCEDURES**

(For hypophysectomy, transnasal or transeptal approach, see 61548)

(For transcranial hypophysectomy, see 61546)

31299 Unlisted procedure, accessory sinuses .....	BR		3.0
---	----	--	-----

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-110 LARYNX.**

	Unit Value	Follow-up Days=	Basic Anes@
<b>EXCISION</b>			
31300 Laryngotomy (thyrotomy, laryngofissure); with removal of tumor or laryngocele, cordectomy .....	<del>(16.0)</del> 13.1	90	6.0

	Unit Value	Follow-up Days=	Basic Anes@
31320 diagnostic .....	<del>(8.0)</del> 7.2	60	6.0
31360 Laryngectomy; total, without radical neck dissection .....	<del>(26.0)</del> 22.6	180	6.0
31365 total, with radical neck dissection .....	<del>(34.0)</del> 32.5	180	6.0
31367 subtotal supraglottic, without radical neck dissection .....	<del>(30.0)</del> 22.6	60	6.0
31368 subtotal supraglottic, with radical neck dissection .....	<del>(30.0)</del> 32.5	60	6.0
31370 Partial laryngectomy (hemilaryngectomy); horizontal .....	<del>(30.0)</del> 26.2	180	6.0
31375 laterovertical .....	<del>(20.0)</del> 20.8	180	6.0
31380 anterovertical .....	<del>(20.0)</del> 20.8	180	6.0
31382 antero-latero-vertical .....	<del>(20.0)</del> 20.8	60	6.0
31390 Pharyngolaryngectomy, with radical neck dissection; without reconstruction .....	<del>(BR)</del> 28.0	60	6.0
31395 with reconstruction .....	<del>(BR)</del> 34.8	60	6.0
31400 Arytenoidectomy or arytenoidopexy, external approach .....	<del>(20.0)</del> 18.1	180	6.0
(For endoscopic arytenoidectomy, see 31560)			
31420 Epiglottidectomy .....	<del>(16.0)</del> 14.5	60	6.0

**INTRODUCTION**

31500 Intubation, endotracheal, emergency procedure .....	1.4	0	
(For injection procedure for bronchography, see 31656, 31708, 31710)			

**ENDOSCOPY**

For endoscopic procedures, code appropriate endoscopy of each anatomic site examined.

31505 Laryngoscopy, indirect (separate procedure); diagnostic .....	<del>(BR)</del> 1.4	0	
31510 with biopsy .....	<del>(BR)</del> 1.4	0	
31511 with removal of foreign body ..	<del>(BR)</del> 1.4	0	
31512 with removal of lesion .....	<del>(BR)</del> 1.4	0	
31513 with vocal cord injection .....	<del>(BR)</del> 0.9	0	
31515 Laryngoscopy, direct, with or without tracheoscopy; for aspiration .....	0.6	0	
31520 diagnostic, newborn .....	<del>(2.4)</del> 2.2	0	4.0
31525 diagnostic, except newborn .....	<del>(4.0)</del> 3.6	0	4.0
31526 diagnostic, with operating microscope .....	<del>(BR)</del> 4.0		4.0

		Unit Value	Follow- up Days=	Basic Anes@
31527	with insertion of obturator ...	<del>(BR)</del>		
		6.8		4.0
31528	with dilatation, initial .....	<del>(BR)</del>		
		4.1		4.0
31529	with dilatation, subsequent ...	<del>(BR)</del>		
		2.3		4.0
31530	Laryngoscopy, operative, with foreign body removal .....	<del>(6.0)</del>		
		5.4	30	4.0
31531	with operating microscope ...	<del>(BR)</del>		
		6.8	7	4.0
31535	Laryngoscopy, operative, with bi- opsy .....	<del>(6.0)</del>		
		5.4	30	4.0
31536	with operating microscope ...	<del>(BR)</del>		
		6.8		
31540	Laryngoscopy, operative, with excision of tumor and/or strip- ping of vocal cords or epiglottis .	<del>((6.0-90))</del>		
		5.6	30	4.0
31541	with operating microscope ...	<del>(BR)</del>		
		6.8	30	4.0
31560	Laryngoscopy, operative, with arytenoidectomy .....	<del>((15.0-90))</del>		
		14.0	60	4.0
31561	with operating microscope ...	<del>(BR)</del>		
		16.3	60	4.0
31570	Laryngoscopy with injection into vocal cord(s), therapeutic .....	<del>((6.0-90))</del>		
		7.2	60	4.0
31571	with operating microscope ...	<del>(BR)</del>		
		9.0	60	4.0
31575	Laryngoscopy, flexible fiberoptic, diagnostic .....	<del>((BR-90))</del>		
		1.6	7	4.0
31576	with biopsy .....	<del>(BR-90)</del>		
		2.6	7	4.0
31577	with removal of foreign body .	<del>(BR-90)</del>		
		6.3	7	4.0
31578	with removal of lesion .....	<del>(BR-90)</del>		
		7.0	7	4.0
31579	with stroboscopy .....	BR	<del>((90))</del>	4.0

REPAIR

31580	Laryngoplasty; for laryngeal web, two stage, with keel inser- tion and removal .....	<del>(BR)</del>		
		22.6	90	4.0
31582	for laryngeal stenosis, with graft or core mold, including tracheotomy .....	<del>(BR)</del>		
		22.1	90	4.0
31584	with open reduction of frac- ture .....	<del>(BR)</del>		
		22.1	90	4.0
31585	Treatment of closed laryngeal fracture; without manipulation..	<del>(BR)</del>		
		1.8	0	4.0
31586	with closed manipulative re- duction .....	<del>(BR)</del>		
		3.6	0	4.0
31587	Laryngoplasty, cricoid split ....	BR		4.0
31588	<u>Laryngoplasty, not otherwise specified (e.g., for burns, recon- struction after partial laryngectomy) .....</u>	BR		
31590	Laryngeal reinnervation by neur- omuscular pedicle .....	<del>((BR-90))</del>		
		18.1	180	4.0

DESTRUCTION

31595	Section recurrent laryngeal nerve, therapeutic (separate pro- cedure), unilateral .....	<del>((BR-90))</del>		
		14.5	180	4.0

OTHER PROCEDURES

31599	Unlisted procedure, larynx .....	BR		4.0
-------	----------------------------------	----	--	-----

AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

WAC 296-22-115 TRACHEA AND BRONCHI.

	Unit Value	Follow- up Days=	Basic Anes@
<b>INCISION</b>			
31600	Tracheostomy, planned (separate procedure); .....	<del>((5.4-15))</del>	
		4.7	14
31601	under two years .....	<del>((6.0-15))</del>	
		5.9	14
31603	Tracheostomy, emergency proce- dure, transtracheal .....	<del>((BR-90))</del>	
		5.9	14
31605	Cricothyroid membrane .....	<del>(BR)</del>	
		4.9	14
31610	Tracheostomy, fenestration proce- dure with skin flaps .....	<del>((7.0-15))</del>	
		6.3	14
	(For endotracheal intubation, see 31500)		
	(For tracheal aspiration under direct vision, see 31515)		
<u>31611</u>	<u>Construction of tracheoesophageal fistula and subsequent insertion of an alaryngeal speech prosthesis (e.g., voice button, Blom-Singer prosthesis) .....</u>	<u>BR</u>	
31612	Tracheal puncture, percutaneous for aspiration of mucus (transtra- cheal aspiration) .....	<del>((BR))</del>	
		0.3	0
31613	Tracheostoma revision; simple, without flap rotation .....	<del>((BR-30))</del>	
		4.3	60
31614	complex, with flap rotation ....	<del>((BR-30))</del>	
		9.8	60
<b>ENDOSCOPY</b>			
For endoscopic procedures, code appropriate endoscopy of each ana- tomic site examined.			
(For tracheoscopy, see laryngoscopy codes 31515- 31578)			
31615	Tracheobronchoscopy through es- tablished tracheostomy incision ..	2.3	0
31622	Bronchoscopy; diagnostic, (flexible or rigid), with or without cell washing or brushing .....	<del>((3.6))</del>	
		4.2	0
31625	with biopsy, rigid bronchoscope	<del>((5.0-30))</del>	
		4.1	7
31628	with transbronchial lung biopsy, with or without fluoroscopic guidance .....	<del>((BR))</del>	
		3.6	7

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
31629	BR		5.0	31720	Catheter aspiration (separate procedure); nasotracheobronchial ...	((0-0)) 0.3	0
31630				31725	tracheobronchial with fibero-scope, bedside ...	((1-0)) 3.2	0
31631				<b>REPAIR</b>			
				31750	Tracheoplasty; cervical ...	((BR)) 20.8	90 6.0
31635				31755	tracheopharyngeal fistulization (Asai technique), each stage ...	((BR)) 22.6	90 6.0
31640				31760	intrathoracic ...	((BR)) 22.6	90 12.0
31641				31766	Carinal reconstruction ...	BR	6.0
				31770	Bronchoplasty; graft repair ...	((BR)) 22.6	90 11.0
31645				31775	excision stenosis and anastomosis ...	((BR)) 22.6	90 11.0
31646				(For lobectomy and bronchoplas-ty, see 32485)			
				31780	Excision tracheal stenosis and anastomosis; cervical ...	((BR)) 22.6	90 11.0
				31781	cervicothoracic ...	((BR)) 25.3	90 11.0
31656	4.0	((30)) 0	4.0	31785	Excision of tracheal tumor or car-cinoma; cervical ...	((BR)) 22.6	90 11.0
				31786	thoracic ...	((BR)) 28.9	90 11.0
				<b>SUTURE</b>			
31659	BR		4.0	31800	Suture of external tracheal wound or injury; cervical ...	((BR)) 18.1	30 6.0
<b>INTRODUCTION</b>				31805	intrathoracic ...	((BR)) 19.9	30 12.0
				31820	Surgical closure tracheostomy or fistula; without plastic repair ...	((4-0-30)) 2.7	0 4.0
				31825	with plastic repair ...	((6-0-30)) 4.4	0 4.0
				(For repair of tracheoesophageal fistula, see 43305-43312)			
31700				31830	Revision of tracheostomy scar ...	((5-60-30)) 2.7	0 4.0
31708	0.9	0		31899	Unlisted procedure, trachea, bron-chi ...	BR	4.0
31710				<b>AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)</b>			
				<b>WAC 296-22-116 LUNGS AND PLEURA.</b>			
					Unit Value	Follow-up Days=	Basic Anes@
31715	0.8	0		<b>INCISION</b>			
				*32000	Thoracentesis, puncture of pleu-ral cavity for aspiration, initial or subsequent ...	((#0-72)) 1.8	0
31717							
31719							

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
<u>32002</u> Thoracentesis with insertion of tube with or without water seal (e.g., for pneumothorax) (separate procedure) . . . . .	BR			32320 Decortication and parietal pleurectomy . . . . .	<del>(28.0)</del> 21.7	90	11.0
32005 Chemical pleurodesis (e.g., for recurrent or persistent pneumothorax) . . . . .	<del>(BR)</del> 2.0	0		32400 Biopsy, pleura; percutaneous needle . . . . .	<del>((1.2-7))</del> 1.1	0	
*32020 Tube thoracostomy with or without water seal (e.g. for abscess, ((pneumothorax;)) hemothorax, empyema) (separate procedure) . . . . .	<del>((+1.2))</del> 1.4	0		(For CT guidance, see 76360, 76361; for ultrasonic guidance, see 76942, 76943; for fluoroscopic localization, see 71036, 71037)			
32035 Thoracostomy; with rib resection for empyema . . . . .	<del>((6.0-60))</del> 8.1	90	3.0	(For fine needle aspiration, preparation, and interpretation of smears, see 88170-88173)			
32036 with open flap drainage for empyema . . . . .	<del>((8.0))</del> 9.0	90	3.0	32402 open . . . . .	<del>((6.0-15))</del> 9.0	0	3.0
32095 Thoracotomy limited, for biopsy of lung or pleura . . . . .	<del>(BR)</del> 8.1	90	3.0	32405 Biopsy, lung or mediastinum, percutaneous needle . . . . .	<del>((3.0-7))</del> 3.2	0	3.0
32100 Thoracotomy, major; with exploration and biopsy . . . . .	<del>((+2.0))</del> 10.4	90	11.0	(For CT guidance, see 76360, 76361; for ultrasonic guidance, see 76942, 76943; for fluoroscopic localization, see 71036, 71037)			
32110 with control of traumatic hemorrhage and/or repair of lung tear . . . . .	<del>((+6.0))</del> 14.5	90	11.0	(For fine needle aspiration, preparation, and interpretation of smears, see 88170-88173)			
32120 for postoperative complications . . . . .	<del>((+6.0))</del> 13.6	90	11.0	*32420 Pneumonocentesis, puncture of lung for aspiration . . . . .	<del>((+1.2))</del> 1.4	0	
32124 with open intrapleural pneumolysis . . . . .	<del>((+6.0))</del> 14.5	90	11.0	32440 Pneumonectomy, total . . . . .	<del>((30.0))</del> 27.1	90	11.0
32140 with cyst(s) removal with or without a pleural procedure . . . . .	<del>((+6.0))</del> 14.5	90	11.0	32445 Pneumonectomy, extrapleural; without empyemectomy . . . . .	<del>((20.0))</del> 30.7	90	11.0
32141 with excision-plication of bullae, with or without any pleural procedure . . . . .	<del>((20.0))</del> 14.5	90	11.0	32450 with empyemectomy . . . . .	<del>((25.0))</del> 30.7	90	11.0
32150 with removal of intrapleural foreign body or fibrin deposit . . . . .	<del>((+4.0))</del> 12.7	90	11.0	32480 Lobectomy, total or segmental; . . . . .	<del>((26.0))</del> 24.4	90	11.0
32151 with removal of intrapulmonary foreign body . . . . .	<del>((+6.0))</del> 12.7	90	11.0	32485 with bronchoplasty . . . . .	<del>((30.0))</del> 27.1	90	11.0
32160 with cardiac massage . . . . .	<del>(BR)</del> 9.9	90	12.0	32490 with concomitant decortication . . . . .	<del>((30.0))</del> 27.1	90	11.0
(For segmental or other resections of lung, see 32480-32525)				32500 Wedge resection, of lung; single or multiple . . . . .	<del>((22.0))</del> 17.2	90	11.0
32200 Pneumonostomy, with open drainage of abscess or cyst . . . . .	<del>((+4.0-120))</del> 12.7	90	11.0	32520 Resection of lung; with resection of chest wall . . . . .	<del>((30.0))</del> 27.1	90	11.0
32215 Pleural scarification for repeat pneumothorax . . . . .	<del>((+6.0))</del> 12.7	90	11.0	32522 with reconstruction of chest wall, without prosthesis . . . . .	<del>((32.0))</del> 30.7	90	11.0
32220 Decortication, pulmonary, (separate procedure); total . . . . .	<del>((20.0))</del> 18.1	90	11.0	32525 with major reconstruction of chest wall, with prosthesis . . . . .	<del>((35.0))</del> 32.5	90	11.0
32225 partial . . . . .	<del>((+4.0))</del> 12.7	90	11.0	32540 Extrapleural enucleation of empyema (empyemectomy) . . . . .	<del>((20.0))</del> 18.1	90	11.0
32310 Pleurectomy; parietal (separate procedure) . . . . .	<del>((20.0))</del> 13.6	90	11.0	32545 with lobectomy . . . . .	<del>((30.0))</del> 27.1	90	11.0
32315 partial . . . . .	<del>((+5.0))</del> 12.7	90	11.0				
<b>EXCISION</b>				<b>ENDOSCOPY</b>			
				For endoscopic procedures, code appropriate endoscopy of each anatomic site examined.			
				32700 Thoracoscopy, exploratory (separate procedure) . . . . .	<del>((4.0))</del> 4.5	30	4.0
				32705 with biopsy . . . . .	<del>((4.0))</del> 0.5	30	4.0

	Unit Value	Follow-up Days=	Basic Anes@
<b>REPAIR</b>			
32800 Repair lung hernia through chest wall.....	<del>((BR))</del> 10.8	30	11.0
32810 Closure of chest wall following open flap drainage for empyema (Clagett type procedure).....	<del>((BR))</del> 18.1	60	11.0
32815 Open closure of major bronchial fistula.....	<del>((BR))</del> 27.1	60	11.0
32820 Major reconstruction, chest wall (post-traumatic).....	<del>((BR))</del> 27.1	60	11.0

**SURGICAL COLLAPSE THERAPY; THORACOPLASTY**  
(See also 32520-32525)

32900 Resection of ribs, extrapleural, all stages.....	<del>((+4.0))</del> 12.7	90	10.0
32905 Thoracoplasty, Schede type or extrapleural (all stages).....	<del>((+4.0))</del> 12.7	90	9.0
32906 with closure of bronchopleural fistula.....	<del>((+6.0))</del> 16.3	90	9.0
(For open closure of major bronchial fistula, see 32815)			
(For resection of first rib for thoracic outlet compression, see 21615, 21616)			
32940 Pneumonolysis, extrapariosteal, including filling or packing procedures.....	<del>((+4.0))</del> 12.7	90	9.0
*32960 Pneumothorax; therapeutic, intrapleural injection of air.....	<del>((+1.0))</del> 1.1	0	
32999 Unlisted procedure, lungs and pleura.....	BR		9.0

**AMENDATORY SECTION** (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

**WAC 296-22-120 HEART AND PERICARDIUM.**

	Unit Value	Follow-up Days=	Basic Anes@
<b>PERICARDIUM</b>			
33010* Pericardiocentesis; initial.....	<del>((+2))</del> 2.0	0	
33011* subsequent.....	<del>((+0))</del> 2.7	0	
33015 Tube pericardiostomy.....	<del>((BR))</del> 2.7	10	
33020 Pericardiostomy for removal of clot or foreign body (primary procedure).....	<del>((20.0))</del> 14.5	90	13.0
33025 Creation of pericardial window or partial resection for drainage....	<del>((20.0-15))</del> 15.4	90	15.0

33030 <del>((Partial resection for chronic constrictive pericarditis, without)) Pericardiectomy, subtotal or complete; without cardiopulmonary bypass.....</del>	<del>((30.0))</del> 18.1	90	15.0
<del>((33035 Complete ventricular decortication, with cardiopulmonary bypass.....</del>	<del>40.0</del>	90	<del>15.0</del>
33031 with cardiopulmonary bypass.....	BR		
33050 Excision of pericardial cyst or tumor.....	<del>((20.0))</del> 23.5	90	13.0
33100 Pericardiectomy (separate procedure).....	<del>((34.0))</del> 28.9	90	15.0

**CARDIAC TUMOR**

33120 Excision of intracardiac tumor, resection with cardiopulmonary bypass.....	<del>((50.0))</del> 45.2	90	15.0
33130 Resection of external cardiac tumor.....	<del>((25.0))</del> 27.1	90	12.0

**PACEMAKER OR DEFIBRILLATOR**

(For electronic analysis of internal pacemaker system, see 93731-93736)			
(Procedures include repositioning or replacement in first 14 days)			
(For fluoroscopy and radiography procedure with insertion of pacemaker, see 71090)			
33200 Insertion of permanent pacemaker with epicardial electrode; by thoracotomy.....	<del>((24.0))</del> 19.0	90	15.0
33201 by xiphoid approach.....	<del>((24.0))</del> 13.6	90	15.0
33206 Insertion of permanent pacemaker with transvenous electrode(s); atrial.....	<del>((BR))</del> 15.4	15	3.0
33207 ventricular.....	<del>((BR))</del> 9.9	7	3.0
33208 AV sequential.....	<del>((BR))</del> 12.7	7	3.0
33210 Insertion of temporary transvenous cardiac electrode, or pacemaker catheter (separate procedure).....	<del>((7.0-15))</del> 1.8	7	Sv.&
33212 Insertion or replacement of pacemaker pulse generator or automatic <del>((internal))</del> implantable cardioverter-defibrillator (AICD) pulse generator only.....	<del>((4.0-30))</del> 5.4	7	6.0
33216 Insertion, replacement, or repositioning of permanent transvenous electrodes only (15 days or more after initial insertion).....	<del>((8.0-30))</del> 4.5	15	6.0
33218 Repair of pacemaker; electrodes only.....	<del>((5.0-30))</del> 6.3	15	6.0
33219 with replacement of pulse generator.....	<del>((BR))</del> 7.3	15	6.0

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
33222				33408			
Revision or relocation of skin pocket for pacemaker or automatic (( <del>internal</del> )) implantable cardioverter-defibrillator (AICD) . . . . .	<del>((4.5))</del>	<del>3.0)</del>		with inflow occlusion . . . . .	<del>((BR))</del>		
	<u>BR</u>		6.0		<u>36.1</u>	<u>90</u>	15.0
33232				(For multiple valve replacement, see 33480-33492)			
Removal of permanent pacemaker . . . . .	BR		6.0	33411			
33245				Replacement aortic valve; with aortic annulus enlargement, noncoronary . . . . .	BR	<del>((90))</del>	15.0
Implantation of automatic (( <del>internal</del> )) implantable cardioverter-defibrillator (AICD) pads with or without sensing electrodes . . . . .	BR		6.0	33412			
33246				with transventricular aortic annulus enlargement (Konno procedure) . . . . .	BR	<del>((90))</del>	15.0
with insertion of automatic (( <del>internal</del> )) implantable cardioverter-defibrillator (AICD) pulse generator . . . . .	BR		6.0	33415			
33248				Resection or incision of subvalvular tissue for discrete subvalvular aortic stenosis . . . . .	<del>((40.0))</del>	<u>38.0</u>	<u>90</u>
Revision or removal of automatic (( <del>internal</del> )) implantable cardioverter-defibrillator (AICD) pads and electrodes . . . . .	BR		6.0	33416			
33250				Ventriculomyotomy (-myectomy) for idiopathic hypertrophic subaortic stenosis (e.g., asymmetric septal hypertrophy) . . . . .	<u>BR</u>		
Operative ablation of supraventricular arrhythmogenic focus or pathway (e.g., Wolff-Parkinson-White, A-V node re-entry), tract(s) and/or focus (foci); without cardiopulmonary bypass . . . . .	<u>BR</u>			33417			
33251				Aortoplasty (gusset) for supra-ventricular stenosis . . . . .	<del>((40.0))</del>	<u>38.9</u>	<u>90</u>
with cardiopulmonary bypass . . . . .	<u>BR</u>						
33260				MITRAL VALVE			
Operative ablation of arrhythmogenic focus or pathway; without cardiopulmonary bypass . . . . .	<u>BR</u>			33420			
33261				Valvotomy, mitral valve (commissurotomy); closed . . . . .	<del>((32.0))</del>	<u>28.9</u>	<u>90</u>
with cardiopulmonary bypass . . . . .	<u>BR</u>			33422			
WOUNDS OF THE HEART AND GREAT VESSELS				33425			
33300				Valvuloplasty, mitral valve, with cardiopulmonary bypass . . . . .	<del>((52.0))</del>	<u>40.7</u>	<u>90</u>
Repair of cardiac wound; without bypass . . . . .	<del>((24.0))</del>			33426			
	<u>21.7</u>	<u>90</u>	15.0	with prosthetic ring . . . . .	<u>BR</u>		
33305				33427			
with cardiopulmonary bypass . . . . .	<del>((30.0))</del>	<u>90</u>	15.0	radical reconstruction with or without ring . . . . .	<u>BR</u>		
	<u>29.8</u>	<u>90</u>	15.0	33430			
33310				Replacement, mitral valve, with cardiopulmonary bypass . . . . .	<del>((52.0))</del>	<u>40.7</u>	<u>90</u>
Cardiotomy, exploratory (includes removal of foreign body); without bypass . . . . .	<del>((22.0))</del>						
	<u>21.7</u>	<u>90</u>	15.0	TRICUSPID VALVE			
33315				<del>((33450))</del>			
with cardiopulmonary bypass . . . . .	<del>((34.0))</del>	<u>90</u>	15.0	Valvotomy, tricuspid valve (commissurotomy); closed . . . . .	<del>32.0</del>	<del>90</del>	<del>15.0)</del>
	<u>36.1</u>	<u>90</u>	15.0	33452			
33320				((open)) Valvotomy, tricuspid valve, with cardiopulmonary bypass . . . . .	<del>((50.0))</del>	<u>35.2</u>	<u>90</u>
Suture repair of aorta or great vessels; without bypass . . . . .	<del>((20.0))</del>			33460			
	<u>32.5</u>	<u>90</u>	15.0	Valvuloplasty or valvectomy, tricuspid valve, with cardiopulmonary bypass . . . . .	<del>((50.0))</del>	<u>36.1</u>	<u>90</u>
33322				33465			
with cardiopulmonary bypass . . . . .	<del>((30.0))</del>	<u>90</u>	15.0	replacement . . . . .	<del>((52.0))</del>	<u>37.0</u>	<u>90</u>
	<u>40.7</u>	<u>90</u>	15.0				
33330				(For multiple valve replacement, see 33480-33492)			
Insertion of graft; without bypass . . . . .	<del>((30.0))</del>			33468			
	<u>40.7</u>	<u>90</u>	15.0	Tricuspid valve repositioning and plication for Ebstein anomaly . . . . .	<del>((50.0))</del>	<u>36.1</u>	<u>90</u>
33335							
with cardiopulmonary bypass . . . . .	<del>((40.0))</del>	<u>90</u>	15.0	PULMONARY VALVE			
	<u>50.6</u>	<u>90</u>	15.0	33470			
33350				Valvotomy, pulmonary valve (commissurotomy); closed (transventricular) . . . . .	<del>((32.0))</del>	<u>31.6</u>	<u>90</u>
Great vessel repair with other major procedure . . . . .	BR		15.0	33471			
				transvenous balloon method . . . . .	<del>((BR))</del>	<u>31.6</u>	<u>90</u>
CARDIAC VALVES				33472			
(Aortic valve)				open, with inflow occlusion . . . . .	<del>((32.0))</del>	<u>35.2</u>	<u>90</u>
33400				33474			
Valvuloplasty, aortic valve, open, with cardiopulmonary bypass . . . . .	<del>((50.0))</del>			open, with cardiopulmonary bypass . . . . .	<del>((50.0))</del>	<u>37.5</u>	<u>90</u>
	<u>36.1</u>	<u>90</u>	15.0				
33404							
Construction of apical-aortic conduit . . . . .	BR	<del>((90))</del>	15.0				
33405							
Replacement, aortic valve with cardiopulmonary bypass . . . . .	<del>((52.0))</del>	<u>90</u>	15.0				
	<u>38.9</u>	<u>90</u>	15.0				
33407							
Valvotomy, aortic valve (commissurotomy); with cardiopulmonary bypass . . . . .	<del>((BR))</del>	<u>90</u>	15.0				
	<u>37.5</u>	<u>90</u>	15.0				

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@		
33476	Right ventricular resection for infundibular stenosis, with or without commissurotomy . . . . .	<del>((50.0))</del> 38.0	90	15.0	33528	three or more coronary grafts . . . . .	<del>((50.0))</del> 43.4	90	15.0
33478	Outflow tract augmentation (gusset), with or without commissurotomy or infundibular resection . . . . .	<del>((52.0))</del> 38.0	90	15.0	<b>POSTINFARCTION MYOCARDIAL PROCEDURES</b>				
<b>MULTIPLE VALVE PROCEDURES</b>				33542	Myocardial resection (e.g., ventricular aneurysmectomy) . . . . .	<del>((35.0))</del> 41.6	90	15.0	
33480	Replacement and/or repair, double valve procedure, by methods 33400-33465 . . . . .	<del>((70.0))</del> 45.2	90	15.0	33545	Repair of postinfarction ventricular septal defect, with or without myocardial resection . . . . .	<del>((50.0))</del> 45.2	90	15.0
33481	Single valve replacement; with commissurotomy or valvuloplasty of another valve . . . . .	<del>((56.0))</del> 43.4	90	15.0	<del>((33560))</del>	<del>Myocardial operation combined with coronary bypass procedure . . . . .</del>	<del>BR))</del>		
33482	with commissurotomy or valvuloplasty of two valves . . . . .	<del>((60.0))</del> 47.0	90	15.0	33570	Coronary angioplasty (end arterectomy, with or without gas, arterial implantation or anastomosis), with bypass . . . . .	<del>((60.0))</del> 27.1	90	15.0
33483	Double valve replacement . . . . .	<del>((65.0))</del> 45.2	90	15.0	33575	combined with vascularization . . . . .	<del>((60.0))</del> 40.7	90	15.0
33485	with commissurotomy or valvuloplasty of one valve . . . . .	<del>((67.0))</del> 47.0	90	15.0	<b>SEPTAL DEFECT</b>				
33490	Replacement and/or repair, triple valve procedure, by methods 33400 to 33465 . . . . .	<del>((80.0))</del> 54.2	90	15.0	<del>((33640))</del>	<del>Repair atrial septal defect, secundum, direct closure without cardiopulmonary bypass . . . . .</del>	<del>32.0</del>	<del>90</del>	<del>15.0))</del>
33492	Triple valve replacement . . . . .	<del>((85.0))</del> 54.2	90	15.0	33641	<del>((direct closure with cardiopulmonary bypass))</del> Repair atrial septal defect, secundum, with cardiopulmonary bypass, with or without patch . . . . .	<del>((46.0))</del> 30.7	90	15.0
<b>CORONARY ARTERY PROCEDURES</b>				<del>((33643))</del>	<del>patch closure, with or without anomalous pulmonary venous drainage . . . . .</del>	<del>30.0</del>	<del>90</del>	<del>15.0))</del>	
(Basic procedures include endarterectomy or angioplasty)				33645	Direct or patch closure, sinus venosus, with or without anomalous pulmonary venous drainage . . . . .	<del>((30.0))</del> 33.4	90	15.0	
33500	Repair of coronary arteriovenous or arteriocardiac chamber fistula . . . . .	BR			33647	Repair of atrial septal defect and ventricular septal defect, with direct or patch closure . . . . .	BR	<del>((90))</del>	15.0
33502	Anomalous coronary artery; ligation . . . . .	<del>((20.0))</del> 25.3	90	15.0	33649	Repair of tricuspid atresia (e.g., Fontan, Gago procedures) . . . . .	<del>((BR))</del> 34.3	90	15.0
33503	graft, without cardiopulmonary bypass . . . . .	<del>((25.0))</del> 28.0	90	15.0	33660	Patch closure, endocardial cushion defect, with or without repair of mitral and/or tricuspid cleft . . . . .	<del>((50.0))</del> 39.3	90	15.0
33504	graft, with cardiopulmonary bypass . . . . .	<del>((35.0))</del> 36.1	90	15.0	33665	with repair of separate ventricular septal defect . . . . .	<del>((35.0))</del> 42.5	90	15.0
33510	Coronary artery bypass, autogenous graft, (e.g., saphenous vein or internal mammary artery); single graft . . . . .	<del>((35.0))</del> 38.0	90	15.0	33670	Repair of complete atrioventricular canal, with or without prosthetic valve . . . . .	<del>((50.0))</del> 43.4	90	15.0
33511	two coronary grafts . . . . .	<del>((56.0))</del> 40.7	90	15.0	33681	Closure ventricular septal defect; <del>((direct))</del> with or without patch . . . . .	<del>((35.0))</del> 33.9	90	15.0
33512	three coronary grafts . . . . .	<del>((67.0))</del> 43.4	90	15.0	<del>((33682))</del>	<del>patch . . . . .</del>	<del>50.0</del>	<del>90</del>	<del>15.0))</del>
33513	four coronary grafts . . . . .	<del>((67.0))</del> 46.1	90	15.0	33684	with pulmonary valvotomy or infundibular resection (acyanotic) . . . . .	<del>((50.0))</del> 39.8	90	15.0
33514	five coronary grafts . . . . .	<del>((67.0))</del> 48.8	90	15.0	33688	with removal of pulmonary artery band, with or without gusset . . . . .	<del>((5.0))</del> 39.8		
33516	six or more coronary grafts . . . . .	<del>((67.0))</del> 50.6	90	15.0	33690	Banding of pulmonary artery . . . . .	<del>((15.0))</del> 21.7	90	15.0
(For separate procurement of autogenous graft, see modifier -62, services rendered by two surgeons)									
33520	Coronary artery bypass, nonautogenous graft (e.g., synthetic or cadaver); single graft . . . . .	<del>((30.0))</del> 36.1	90	15.0					
33525	two coronary grafts . . . . .	<del>((35.0))</del> 38.9	90	15.0					

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
33692 <del>((Total))</del> Complete repair tetralogy of Fallot; <del>((intact outflow tract))</del> .....	<del>((50.0))</del> 39.8	90	15.0	33785 <del>Repair transposition of great vessels, aortic pulmonary artery reconstruction (Jatene type) ..</del>	BR	90	<del>15.0))</del>
33694 with <del>((outflow tract gusset))</del> transannular patch .....	<del>((50.0))</del> 40.7	90	15.0	33774 <del>Repair of transposition of the great arteries, atrial baffle procedure (e.g., Mustard or Senning type) with cardiopulmonary bypass; .....</del>	BR		
33696 with closure of previous shunt .....	<del>((8.0))</del> 40.7	90		33775 <del>with removal of pulmonary band .....</del>	BR		
<b>SINUS OF VALSALVA</b>				33776 <del>with closure of ventricular septal defect .....</del>	BR		
33702 Repair sinus of Valsalva fistula, with cardiopulmonary bypass ...	<del>((50.0))</del> 36.6	90	15.0	33777 <del>with repair of subpulmonic obstruction .....</del>	BR		
33710 with repair of ventricular septal defect .....	<del>((35.0))</del> 39.8	90	15.0	33778 <del>Repair of transposition of the great arteries, aortic pulmonary artery reconstruction (e.g., Jatene type); .....</del>	BR		
33720 Repair sinus of Valsalva aneurysm, with cardiopulmonary bypass .....	<del>((50.0))</del> 37.0	90	15.0	33779 <del>with removal of pulmonary band .....</del>	BR		
<b>TOTAL ANOMALOUS PULMONARY VENOUS DRAINAGE</b>				33780 <del>with closure of ventricular septal defect .....</del>	BR		
33730 Complete repair of anomalous venous return (supracardiac, intracardiac, or infracardiac types) ..	<del>((50.0))</del> 37.0	90	15.0	33781 <del>with repair of subpulmonic obstruction .....</del>	BR		
(For partial anomalous return, see atrial septal defect)				<b>TRUNCUS ARTERIOSUS</b>			
<b>SHUNTING PROCEDURES</b>				33786 Total repair, truncus arteriosus (Rastelli type operation) .....	<del>((50.0))</del> 45.2	90	15.0
33735 Atrial septectomy or septostomy; closed (Blalock-Hanlon type operation) .....	<del>((32.0))</del> 23.5	90	15.0	33788 <del>((Replant pulmonary artery for hemitruncus)) Reimplantation of an anomalous pulmonary artery. ((30.0))</del>	27.1	90	15.0
33737 open, with inflow occlusion ...	<del>((40.0))</del> 30.7	90	15.0	(For pulmonary artery band, see 33690)			
33738 transvenous method, balloon, Rashkind type (includes cardiac catheterization) .....	<del>((50.0))</del> 19.9	90	15.0	<b>AORTIC ANOMALIES</b>			
33739 blade method (Sang-Park septostomy) (includes cardiac catheterization) .....	BR		15.0	33802 Division of aberrant vessel (vascular ring) .....	<del>((18.0))</del> 21.7	90	15.0
33750 Shunt; subclavian to pulmonary artery (Blalock-Taussig type operation) .....	<del>((30.0))</del> 27.1	90	15.0	33803 with reanastomosis .....	<del>((20.0))</del> 25.3	90	15.0
33755 ascending aorta to pulmonary artery (Waterston type operation) .....	<del>((30.0))</del> 27.1	90	15.0	<del>((33810) Creation of aortopulmonary window; without bypass .....</del>	20.0	90	15.0
33762 descending aorta to pulmonary artery (Potts-Smith type operation) .....	<del>((30.0))</del> 27.1	90	15.0	33812 <del>with cardiopulmonary bypass ..</del>	30.0	90	<del>15.0))</del>
33764 central, with prosthetic graft ..	BR	<del>((90))</del>	15.0	33813 <del>Obliteration of aortopulmonary septal defect; without cardiopulmonary bypass .....</del>	BR		
33766 vena cava to pulmonary artery (Glenn type operation) .....	<del>((30.0))</del> 27.1	90	15.0	33814 <del>with cardiopulmonary bypass ..</del>	BR		
<b>TRANSPOSITION OF THE GREAT VESSELS</b>				33820 Patent ductus arteriosus; ligation (primary procedure) .....	<del>((15.0))</del> 18.1	90	15.0
<del>((33782) Repair transposition of great vessels, atrial baffle procedure (Mustard or Senning type); with cardiopulmonary bypass .....</del>	<del>50.0</del>	90	15.0	33822 division, under 18 years .....	<del>((18.0))</del> 18.1	90	15.0
33783 <del>with removal of pulmonary artery band, with or without gusset .....</del>	<del>50.0</del>	90	15.0	33824 division, 18 years and older ...	<del>((20.0))</del> 22.6	90	15.0
33784 <del>with closure of ventricular septal defect .....</del>	<del>50.0</del>	90	15.0	33830 ligation or division when performed with another procedure .....	<del>((5.0))</del> 5.4		15.0
				33840 Excision of coarctation of aorta, with or without associated patent ductus arteriosus; with direct anastomosis .....	<del>((20.0))</del> 27.1	90	15.0
				33845 with graft .....	<del>((30.0))</del> 29.8	90	15.0
				33851 repair using either left subclavian artery or prosthetic material as gusset for enlargement ((of segment (Waldhausen procedure))) .....	BR	<del>((90))</del>	15.0



	Unit Value	Follow-up Days=	Basic Anes@
<u>33852</u> repair of hypoplastic or interrupted aortic arch using autogenous or prosthetic material . . . . .	<u>BR</u>		
<u>33855</u> repair of hypoplastic left heart syndrome (e.g., Norwood type) . . . . .	<u>BR</u>		
<b>THORACIC AORTIC ANEURYSM</b>			
33860 Ascending aorta graft, with cardiopulmonary bypass; with or without coronary implant, with or without valve suspension; without valve replacement . . . . .	<del>((40.0))</del> <u>40.7</u>	90	15.0
33865 with valve replacement . . . . .	<del>((50.0))</del> <u>45.2</u>	90	15.0
33870 Transverse arch graft, with cardiopulmonary bypass . . . . .	<del>((60.0))</del> <u>50.6</u>	90	15.0
33875 Descending thoracic aorta graft, with or without bypass . . . . .	<del>((20.0))</del> <u>36.1</u>	90	15.0
33877 Repair of thoracoabdominal aortic aneurysm with graft, with or without cardiopulmonary bypass . . . . .	<del>((40.0—90))</del> <u>BR</u>		15.0
<b>PULMONARY ARTERY</b>			
33910 Pulmonary artery embolectomy; with cardiopulmonary bypass . . . . .	<del>((30.0))</del> <u>34.3</u>	90	15.0
33915 without bypass . . . . .	<del>((20.0))</del> <u>24.4</u>	90	15.0
<u>33916</u> Pulmonary endarterectomy with or without embolectomy, with cardiopulmonary bypass . . . . .	<u>BR</u>		
<b>MISCELLANEOUS</b>			
33930 Donor cardiectomy-pneumectomy, with preparation and maintenance of homograft . . . . .	<u>BR</u>		15.0
33935 Heart-lung transplant with recipient cardiectomy-pneumectomy . . . . .	<u>BR</u>		
33940 Donor cardiectomy, with preparation and maintenance of homograft . . . . .	<u>BR</u>		
33945 Heart transplant, with or without recipient cardiectomy . . . . .	<u>BR</u>		
33960 Prolonged extracorporeal circulation for cardiopulmonary insufficiency . . . . .	<u>BR</u>	<u>90</u>	15.0
33970 Intraaortic balloon counterpulsation; insertion only . . . . .	<del>((BR—10))</del> <u>6.3</u>	<u>0</u>	15.0
(For percutaneous insertion use 93536)			
33971 removal of balloon including repair of artery with or without graft . . . . .	<del>((BR))</del> <u>4.5</u>		15.0
33972 monitoring only . . . . .	<del>((BR))</del> <u>1.8</u>		15.0
33999 Unlisted procedure, cardiac surgery . . . . .	<u>BR</u>		15.0

**AMENDATORY SECTION** (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

WAC 296-22-125 ARTERIES AND VEINS. Primary vascular procedure listings include establishing both inflow and outflow by whatever procedures necessary. Also included is that portion of the operative arteriogram performed by the surgeon, as indicated. Sympathectomy, when done, is included in the listed aortic procedures. For unlisted vascular procedure, use 37799.

	Unit Value	Follow-up Days=	Basic Anes@
<b>ARTERIAL EMBOLECTOMY OR THROMBECTOMY, WITH OR WITHOUT CATHETER</b>			
34001 Embolectomy or thrombectomy, with or without catheter; carotid, subclavian, or innominate artery, by neck incision . . . . .	<del>((14.0))</del> <u>9.0</u>	60	6.0
34051 innominate, subclavian artery, by thoracic incision . . . . .	<del>((14.0))</del> <u>18.1</u>	60	11.0
34101 axillary, brachial, innominate, subclavian artery, by arm incision . . . . .	<del>((14.0))</del> <u>7.2</u>	60	5.0
34111 radial or ulnar . . . . .	<del>((BR))</del> <u>7.2</u>	60	5.0
34151 renal, celiac, mesentery, aortoiliac artery, by abdominal incision . . . . .	<del>((20.0))</del> <u>13.6</u>	60	6.0
34201 femoropopliteal, aortoiliac artery, by leg incision . . . . .	<del>((14.0))</del> <u>10.8</u>	60	5.0
34203 popliteal-tibio-peroneal, by leg incision . . . . .	<del>((BR))</del> <u>10.8</u>	60	5.0
<b>VENOUS THROMBECTOMY, DIRECT OR WITH CATHETER</b>			
34401 Thrombectomy, direct or with catheter; vena cava, iliac vein, by abdominal incision . . . . .	<del>((18.0—60))</del> <u>10.8</u>	<u>90</u>	5.0
34421 vena cava, iliac, femoropopliteal vein, by leg incision . . . . .	<del>((12.0—60))</del> <u>7.2</u>	<u>90</u>	3.0
34451 vena cava, iliac, femoropopliteal vein, by abdominal and leg incision . . . . .	<del>((24.0—60))</del> <u>13.6</u>	<u>90</u>	5.0
34471 subclavian vein, by neck incision . . . . .	<del>((28.0—60))</del> <u>9.0</u>	<u>90</u>	5.0
34490 axillary and subclavian vein, by arm incision . . . . .	<del>((28.0—60))</del> <u>6.3</u>	<u>90</u>	5.0
<b>VENOUS RECONSTRUCTION</b>			
34501 Valvuloplasty, femoral vein . . . . .	<u>BR</u>		
34510 Venous valve transposition, any vein donor . . . . .	<u>BR</u>		
34520 Cross-over vein graft to venous system . . . . .	<del>((BR))</del> <u>22.6</u>	<u>90</u>	
34530 Saphenopopliteal vein anastomosis . . . . .	<u>BR</u>		

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@	
<b>DIRECT REPAIR OF ANEURYSM, OR EXCISION (PARTIAL OR TOTAL) AND GRAFT INSERTION FOR ANEURYSM, FALSE ANEURYSM, RUPTURED ANEURYSM, OR OCCLUSIVE DISEASE</b>				35112	for ruptured aneurysm, splenic artery	<del>((BR))</del> 27.1	90	
Procedures 35001-35162 include preparation of artery for anastomosis including endarterectomy.				35121	for aneurysm or occlusive disease, hepatic, celiac, renal, or mesenteric artery	<del>((40.0))</del> 22.6	90	6.0
(For intracranial aneurysm, see 61700 et seq.)				35122	for ruptured aneurysm, hepatic, celiac, renal, or mesenteric artery	<del>((BR))</del> 27.1	90	6.0
(For thoracic aortic aneurysm, see 33860-33875)				35131	for aneurysm or occlusive disease, iliac artery (common, hypogastric, external)	<del>((32.0))</del> 18.1	90	6.0
35001			Direct repair of aneurysm or excision (partial or total) and graft insertion, with or without patch graft; for aneurysm or occlusive disease, carotid, subclavian artery, by neck incision		<del>((28.0))</del> 18.1	90	6.0	
35002			for ruptured aneurysm, carotid, subclavian artery by neck incision		<del>((BR))</del> 22.6	90	6.0	
35005			for aneurysm or occlusive disease, vertebral artery		BR			
35011			for aneurysm or occlusive disease, axillary-brachial artery, by arm incision		<del>((28.0))</del> 16.3	90	5.0	
35013			for ruptured aneurysm, axillary-brachial artery, by arm incision		<del>((BR))</del> 20.8	90		
35021			for aneurysm or occlusive disease, innominate, subclavian artery, by thoracic incision		<del>((32.0))</del> 16.3	90	12.0	
35022			for ruptured aneurysm, innominate, subclavian artery, by thoracic incision		<del>((BR))</del> 20.8	90		
35045			for aneurysm or occlusive disease, radial or ulnar artery		<del>((BR))</del> 16.3	90		
35081			for aneurysm or occlusive disease, abdominal aorta		<del>((40.0))</del> 22.6	90	12.0	
35082			for ruptured aneurysm, abdominal aorta		<del>((BR))</del> 31.6	90	12.0	
35091			for aneurysm or occlusive disease, abdominal aorta involving visceral vessels (mesenteric, celiac, renal)		<del>((BR))</del> 25.3	90	12.0	
35092			for ruptured aneurysm, abdominal aorta involving visceral vessels (mesenteric, celiac, renal)		<del>((BR))</del> 34.3	90	12.0	
35102			for aneurysm or occlusive disease, abdominal aorta involving iliac vessels (common, hypogastric, external)		<del>((40.0))</del> 24.4	90	12.0	
35103			for ruptured aneurysm, abdominal aorta involving iliac vessels (common, hypogastric, external)		<del>((BR))</del> 31.6	90	12.0	
35111			for aneurysm or occlusive disease, splenic artery		<del>((24.0))</del> 18.1	90	6.0	
				35141	for aneurysm or occlusive disease, common femoral artery (profunda femoris, superficial femoral)	<del>((28.0))</del> 16.3	90	5.0
				35142	for ruptured aneurysm, common femoral artery (profunda femoris, superficial femoral)	<del>((BR))</del> 19.9	90	
				35151	for aneurysm or occlusive disease, popliteal artery	<del>((28.0))</del> 18.1	90	5.0
				35152	for ruptured aneurysm, popliteal artery	<del>((BR))</del> 22.6	90	5.0
				35161	for aneurysm or occlusive disease, other arteries	BR	90	5.0
				35162	for ruptured aneurysm, other arteries	BR		5.0
<b>REPAIR ARTERIOVENOUS FISTULA</b>				35180	Repair, congenital arteriovenous fistula; head and neck	<del>((28.0-60))</del> 18.1	90	6.0
				35182	thorax and abdomen	<del>((34.0-60))</del> 23.5	90	6.0
				35184	extremities	<del>((28.0-60))</del> 18.1	90	6.0
				35188	Repair, acquired or traumatic arteriovenous fistula; head and neck	<del>((30.0-60))</del> 19.9	90	6.0
				35189	thorax and abdomen	<del>((40.0-60))</del> 28.9	90	6.0
				35190	extremities	<del>((30.0-60))</del> 19.9	90	6.0
<b>REPAIR BLOOD VESSEL OTHER THAN FOR FISTULA, WITH OR WITHOUT PATCH GRAFT</b>				(For AV fistula repair, see 35180-35190)				
				35201	Repair blood vessels, direct; neck	<del>((28.0))</del> 19.0	60	10.0
				35206	upper extremity	<del>((28.0))</del> 19.0	60	10.0
				35207	hand and finger	<del>((BR))</del> 19.0	60	10.0
				35211	intrathoracic, with bypass	<del>((35.0-60))</del> 29.8	90	10.0
				35216	intrathoracic, without bypass	<del>((30.0-60))</del> 21.7	90	10.0
				35221	intra-abdominal	<del>((34.0))</del> 24.4	90	10.0

	Unit Value	Follow-up Days=	Basic Anes@
35226 lower extremity	<del>((28.0—60))</del> 14.6	90	8.0
35231 Repair blood vessel with vein graft; neck	<del>((30.0—60))</del> 23.5	90	6.0
35236 upper extremity	<del>((30.0—60))</del> 23.5	90	6.0
35241 intrathoracic, with bypass	<del>((40.0—60))</del> 33.4	90	6.0
35246 intrathoracic, without bypass	<del>((35.0—60))</del> 22.6	90	6.0
35251 intra-abdominal	<del>((40.0))</del> 29.4	90	6.0
35256 lower extremity	<del>((32.0—60))</del> 20.1	90	3.0
35261 Repair blood vessel with graft other than vein; neck	<del>((32.0—60))</del> 14.5	90	6.0
35266 upper extremity	<del>((32.0—60))</del> 14.5	90	6.0
35271 intrathoracic, with bypass	<del>((42.0—60))</del> 28.9	90	6.0
35276 intrathoracic, without bypass	<del>((37.0—60))</del> 19.9	90	6.0
35281 intra-abdominal	<del>((42.0))</del> 18.1	90	6.0
35286 lower extremity	<del>((34.0—60))</del> 17.2	90	3.0

**THROMBOENDARTERECTOMY**

(For coronary artery, see 33570, 33575)

35301 Thromboendarterectomy, with or without patch graft; carotid, vertebral, subclavian, by neck incision	<del>((30.0—90))</del> 13.6	60	6.0
35311 subclavian, innominate, by thoracic incision	<del>((30.0))</del> 22.6	90	11.0
35321 axillary-brachial	<del>((30.0—90))</del> 16.3	60	5.0
35331 abdominal aorta	<del>((40.0))</del> 21.7	90	12.0
35341 mesenteric, celiac, or renal	<del>((40.0))</del> 19.9	90	6.0
35351 iliac	<del>((32.0))</del> 19.9	90	6.0
35355 iliofemoral	BR	((90))	6.0
35361 combined aortoiliac	<del>((40.0))</del> 21.7	90	12.0
35363 combined aortoiliofemoral	<del>((BR))</del> 23.5	90	12.0
35371 common femoral	<del>((20.0))</del> 16.3	90	5.0
35372 deep (profunda) femoral	<del>((28.0—90))</del> BR		5.0
35381 femoral and/or popliteal, and/or tibioperoneal	<del>((20.0))</del> 18.1	90	5.0

**TRANSLUMINAL ANGIOPLASTY, INTRAOPERATIVE**

(If done as part of another operation, use modifier -51 or -52)

35450 Transluminal angioplasty, intraoperative (separate procedure); renal or other visceral artery	BR		
35452 aortic	BR		
35454 iliac	BR		
35456 femoral-popliteal	BR		
35458 subclavian-axillary	BR		

**BYPASS GRAFT—VEIN**

	Unit Value	Follow-up Days=	Basic Anes@
35501 Bypass graft, vein; carotid	<del>((30.0))</del> 13.6	90	6.0
35506 carotid-subclavian	<del>((30.0))</del> 18.1	90	6.0
35507 subclavian-carotid	<del>((30.0))</del> 18.1	90	6.0
35508 carotid-vertebral	<del>((30.0))</del> 18.1	90	11.0
35509 carotid-carotid	<del>((30.0))</del> 18.1	90	11.0
35511 subclavian-subclavian	<del>((30.0))</del> 19.9	90	11.0
35515 subclavian-vertebral	<del>((30.0))</del> 19.9	90	11.0
35516 subclavian-axillary	<del>((30.0))</del> 19.9	90	6.0
35518 axillary-axillary	<del>((30.0))</del> 19.9	90	5.0
35521 axillary-femoral	<del>((30.0))</del> 22.6	90	5.0
35526 aortosubclavian or carotid	<del>((32.0))</del> 28.9	90	12.0
35531 aortoceliac, or aortomesenteric	<del>((36.0))</del> 23.5	90	12.0
35533 axillary-femoral-femoral	<del>((BR))</del> 23.5	90	12.0
35536 splenorenal	<del>((32.0))</del> 23.5	90	10.0
35541 aortoiliac	<del>((32.0))</del> 21.7	90	12.0
35546 aortofemoral or bifemoral	<del>((32.0))</del> 23.5	90	12.0
35548 aortoiliofemoral, unilateral	<del>((32.0))</del> 23.5	90	12.0
35549 aortoiliofemoral, bilateral	<del>((40.0))</del> 25.3	90	12.0
35551 aorto-femoral-popliteal	<del>((40.0))</del> 26.2	90	12.0
35556 femoral-popliteal	<del>((20.0))</del> 23.5	90	5.0
35558 femoral-femoral	<del>((20.0))</del> 19.9	90	5.0
35560 aorto-renal	<del>((BR))</del> 23.5	90	12.0
35563 ilioiliac	<del>((30.0))</del> 21.7	90	12.0
35565 iliofemoral	<del>((32.0))</del> 23.5	90	12.0
35566 femoral-anterior tibial, posterior tibial, or peroneal artery	<del>((30.0))</del> 23.5	90	12.0
35571 popliteal-tibial or peroneal artery	<del>((32.0))</del> 22.6	90	12.0

**IN-SITU VEIN BYPASS**

35582 In-situ vein bypass; aortofemoral-popliteal (only femoral-popliteal portion in-situ)	BR	90	12.0
35583 femoral-popliteal	BR	90	12.0
35585 femoral-anterior tibial, posterior tibial, or peroneal artery	BR	90	12.0
35587 popliteal-tibial, peroneal	BR	90	12.0

**BYPASS GRAFT—WITH OTHER THAN VEIN**

35601 Bypass graft, with other than vein, carotid	<del>((40.0))</del> 21.7	90	12.0
35606 carotid-subclavian	<del>((40.0))</del> 21.7	90	12.0

	Unit Value	Follow-up Days=	Basic Anes@
35612 subclavian-subclavian . . . . .	<del>((40.0))</del> 21.7	90	12.0
35616 subclavian-axillary . . . . .	<del>((30.0))</del> 21.7	90	6.0
35621 axillary-femoral . . . . .	<del>((35.0))</del> 21.7	90	12.0
35626 aortosubclavian or carotid . . . . .	<del>((35.0))</del> 25.3	90	12.0
35631 aortoceliac, aorto mesenteric, aorto renal . . . . .	<del>((35.0))</del> 25.3	90	12.0
35636 splenorenal . . . . .	<del>((35.0))</del> 25.3	90	12.0
35637 vertebral-carotid transposition . . . . .	BR	((90))	12.0
35638 vertebral-subclavian transposition . . . . .	BR	((90))	12.0
35641 aortoiliac . . . . .	<del>((35.0))</del> 28.9	90	12.0
36642 carotid-vertebral . . . . .	<del>((BR))</del> 28.9	90	12.0
35645 subclavian-vertebral . . . . .	<del>((BR))</del> 28.9	90	12.0
35646 aortofemoral or bifemoral . . . . .	<del>((30.0))</del> 28.9	90	12.0
35650 axillary-axillary . . . . .	<del>((BR))</del> 19.9	90	
35651 aortofemoral-popliteal . . . . .	<del>((30.0))</del> 27.1	90	12.0
35654 axillary-femoral-femoral . . . . .	<del>((BR))</del> 25.3	90	
35656 femoral-popliteal . . . . .	<del>((28.0))</del> 22.6	90	5.0
35661 femoral-femoral . . . . .	<del>((28.0))</del> 18.1	90	5.0
35663 ilioiliac . . . . .	<del>((28.0))</del> 21.7	90	5.0
35665 iliofemoral . . . . .	<del>((28.0))</del> 21.7	90	5.0
35666 femoral-anterior tibial, posterior tibial, or peroneal artery . . . . .	<del>((28.0))</del> 23.5	90	5.0
35671 popliteal-tibial or peroneal artery . . . . .	<del>((28.0))</del> 18.1	90	5.0
35681 Bypass graft, composite . . . . .	BR		

**EXPLORATION (NOT FOLLOWED BY SURGICAL REPAIR) WITH OR WITHOUT LYSIS OF ARTERY**

35701 Exploration; carotid artery . . . . .	<del>((10.0-30))</del> 8.2	90	3.0
35721 femoral artery . . . . .	<del>((8.0-30))</del> 6.4	90	3.0
35741 popliteal artery . . . . .	<del>((8.0-30))</del> 6.4	90	3.0
35761 Other vessels . . . . .	<del>((BR))</del> 7.3	90	BR

**EXPLORATION FOR POSTOPERATIVE HEMORRHAGE, INFECTION OR THROMBOSIS**

35800 Exploration for postoperative hemorrhage or thrombosis; neck . . . . .	<del>((BR))</del> 9.0	90	BR
35820 chest . . . . .	<del>((BR))</del> 18.1	90	BR
35840 abdomen . . . . .	<del>((BR))</del> 13.6	90	BR
35860 extremity . . . . .	<del>((BR))</del> 8.1	90	BR
35870 Repair of graft-enteric fistula . . . . .	<del>((BR))</del> 31.6	90	

35875 Thrombectomy and/or repair of arterial or venous graft . . . . .	BR
35900 Excision of infected graft . . . . .	BR
35910 with revascularization . . . . .	BR

Introduction

VASCULAR INJECTION PROCEDURES

NOTES

Listed services for injection procedures include necessary local anesthesia, introduction of needles or catheter, injection of contrast medium with or without automatic power injection and necessary pre and postinjection care specifically related to the injection procedure.

For radiological vascular injection performed by a single physician as a complete procedure (necessary local anesthesia, placement of needle or catheter and injection of contrast media, and supervision of the study and interpretation of results), see RADIOLOGY section, code numbers 75500-75893.

Catheters, drugs and contrast media are not included in the listed service for the injection procedures.

(For injection procedures in conjunction with cardiac catheterization, see 93541-93545)

(For chemotherapy of malignant disease, see 96500-96549)

INTRAVENOUS

(An intracatheter is a sheathed combination of needle and short catheter)

36000 Introduction of needle or intracatheter, vein( <del>(unilateral)</del> ) . . . . .	<del>((1.0))</del> 0.9	0	
<del>((3600+))</del> bilateral . . . . .	<del>(1.4-0))</del> 1.4	0	
36010 Introduction of catheter; in superior or inferior vena cava, right heart or pulmonary artery . . . . .	<del>((2.0))</del> 1.8	0	3.0

(For venous catheterization for selective organ blood sampling, see 36500)

INTRA-ARTERIAL—INTRA-AORTIC

36100 Introduction of needle or intracatheter, carotid or vertebral artery( <del>(unilateral)</del> ) . . . . .	<del>((5.0))</del> 3.6	0	3.0
<del>((3610+))</del> bilateral . . . . .	<del>(6.0-0-3.0))</del> 6.0	0	3.0
36120 Introduction of needle or intracatheter; retrograde brachial artery . . . . .	<del>((5.0))</del> 3.6	0	3.0
36140 extremity artery . . . . .	<del>((2.0))</del> 2.7	0	3.0
36145 arteriovenous shunt created for dialysis (cannula, fistula or graft) . . . . .	<del>((1.0))</del> 0.5	0	3.0

(For insertion of arteriovenous cannula, see 36810-36820)

36160 Introduction of needle or intracatheter, aortic, translumbar . . . . .	<del>((3.0))</del> 2.7	0	3.0
36200 Introduction of catheter; aorta (arch, abdominal, midstream renal, aorto-iliac run-off) or selective; initial placement . . . . .	<del>((4.0))</del> 3.6	0	3.0

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
36215	each additional selective thoracic and/or cerebral artery catheter placement (e.g., vertebral or carotid)	<del>((5-8))</del> 5.6	0	3.0	36488	Placement of central venous catheter (subclavian, jugular, or other vein) (e.g., for central venous pressure, hyperalimentation, hemodialysis, or chemotherapy); percutaneous, age 2 years or under	<del>((0-8))</del> 1.4 0
36230	coronary artery, selective, unilateral or bilateral	<del>((6-0))</del> 5.9	0	7.0	36489*	percutaneous, over age 2	<del>((0-8))</del> 0.9 0
36245	each additional selective abdominal artery catheter placement (e.g., celiac artery, gastroduodenal artery, inferior mesenteric artery, renal artery)	<del>((5-0))</del> 4.2	0	3.0	*36490	Cutdown placement of central venous catheter for hyperalimentation; age 2 years or under	<del>((3-0-15))</del> 2.3 0
36260	Insertion of implantable infusion pump	<del>((BR-0))</del> 5.9 45		3.0	*36491	over age 2	<del>((2-0-15))</del> 1.6 0
36261	Revision of implanted infusion pump	BR	<del>((0))</del>	3.0			
36262	Removal of implanted infusion pump	BR	<del>((0))</del>	3.0			
36299	Unlisted procedure, vascular injection	BR		3.0			
<b>VENOUS</b>							
Venipuncture, needle or catheter for diagnostic study or intravenous therapy, percutaneous:							
36400	Venipuncture, under age 3 years; femoral, jugular or sagittal sinus	0.4	0		36495	Insertion of implantable intravenous infusion pump or venous access port	<del>((BR))</del> 5.4 0 3.0
*36405	scalp vein	<del>((0-6))</del> 0.5	0		36496	Revision of implantable intravenous infusion pump or venous access port	<del>((BR))</del> 5.4 0 3.0
*36406	other vein	<del>((0-3))</del> 0.6	0		36497	Removal of implantable intravenous infusion pump or venous access port	<del>((BR))</del> 3.6 0 3.0
*36410	Venipuncture, child over age 3 years or adult, necessitating physician's skill (separate procedure), for venography (upper extremity, vena cava, adrenal, renal, iliac, femoral, popliteal, tibial, saphenous, jugular, innominate vein). Not to be used for routine venipuncture.	0.2	0		36500	Venous catheterization for selective organ blood sampling	<del>((BR))</del> 3.2 0
*36415	Routine venipuncture for collection of specimen(s)	<del>((BR))</del> 0.2	0		*36510	Catheterization of umbilical vein for diagnosis or therapy, newborn	<del>((0.6-7))</del> 0.9 0
36420	Venipuncture, cutdown; under age 1 year	<del>((1-0))</del> 0.9	7		36520	Therapeutic apheresis (plasma and/or cell exchange)	<del>((BR))</del> 6.3 0
36425	age 1 or over	<del>((0-72))</del> 0.7	7		36522	Photopheresis, extracorporeal	BR
36430	Transfusion, blood or blood components	0.4	0		<b>ARTERIAL</b>		
*36440	Push transfusion, blood, 2 years or under	<del>((1-2))</del> 1.1	0		*36600	Arterial puncture; withdrawal of blood for diagnosis	<del>((0-2))</del> 0.4 0
36450	Exchange transfusion; newborn	<del>((7-0))</del> 6.3	0		36620	Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous	1.0 0
36455	other than newborn	<del>((BR+))</del> 9.0	0		36625	cutdown	1.4 <del>((7))</del> 0
36460	Transfusion, intrauterine, fetal	<del>((BR+))</del> 9.0	0		36640	Arterial catheterization for prolonged infusion therapy (chemotherapy), cutdown (see also 96526)	<del>((2-0-7))</del> 1.3 0
36468	Single or multiple injections of sclerosing solutions, spider veins (telangiectasia); limb or trunk	BR					
36469	face	BR					
*36470	Injection of sclerosing solution; single vein	<del>((0-28))</del> 0.5	0				
*36471	multiple veins, same leg	<del>((0-4))</del> 0.5	0		*36660	Catheterization, umbilical artery, newborn, for diagnosis or therapy	<del>((1-0-7))</del> 1.3 0

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
36680 Placement of needle for intraosseous infusion .....	<del>(1.4)</del> BR	7		<b>REPAIR, LIGATION AND OTHER PROCEDURES</b>			
<b>INTERVASCULAR CANNULIZATION OR SHUNT (SEPARATE PROCEDURE)</b>				37565 Ligation of internal jugular vein .....	<del>(BR)</del> 9.0	30	6.0
36800 Insertion of cannula for hemodialysis, other purpose; vein to vein .....	<del>(3.0)</del> 2.7	7	3.0	37600 Ligation, external carotid artery .....	<del>(10.0)</del> 6.8	30	3.0
36810 arteriovenous, external (Scribner type) .....	<del>(9.0)</del> 8.1	7	3.0	37605 internal or common carotid artery .....	<del>(10.0)</del> 7.2	30	3.0
36815 arteriovenous, external revision or closure .....	<del>(6.0)</del> 5.4	7	3.0	37606 internal or common carotid artery, with gradual occlusion, as with Selverstone or Crutchfield clamp .....	<del>(10.0)</del> 9.0	30	4.0
36820 arteriovenous, internal (Cimino type) .....	<del>(BR)</del> 12.7	7	3.0	(For ligation treatment of intracranial aneurysm, see 61703)			
36821 Arteriovenous anastomosis, direct, any site .....	<del>(10.0-60)</del> 11.7	7	4.0	37609 Ligation or biopsy, temporal artery .....	<del>(4.0-30)</del> 1.4	0	4.0
36822 Insertion of cannula(s) for prolonged extracorporeal circulation for cardiopulmonary insufficiency (ECMO) .....	<del>(12.0-7)</del> BR		3.0	37615 Ligation, major artery (e.g., post-traumatic, rupture); neck .....	<del>(BR)</del> 7.2	30	4.0
(For maintenance of prolonged extracorporeal circulation, use 33960)				37616 chest .....	<del>(BR)</del> 18.1	60	6.0
36825 Creation of arteriovenous fistula; autogenous graft .....	<del>(15.0-60)</del> 13.1	7	4.0	37617 abdomen .....	<del>(BR)</del> 13.6	60	6.0
36830 nonautogenous graft .....	<del>(12.0-60)</del> 11.7	7	4.0	37618 extremity .....	<del>(BR)</del> 9.0	60	4.0
<u>36832 Revision of an arteriovenous fistula, with or without thrombectomy, autogenous or nonautogenous graft .....</u>	BR			37620 Interruption, partial or complete, of inferior vena cava by suture, ligation, plication, clip, extravascular, intravascular (umbrella device) .....	<del>(16.0)</del> 13.6	90	5.0
36835 Insertion of Thomas shunt .....	<del>(15.0-60)</del> 11.7	7	4.0	37650 Interruption, partial or complete, of femoral vein, by ligature, intravascular device(; unilateral) .....	<del>(8.0)</del> 6.3	30	3.0
36840 Insertion mandril .....	<del>(6.0-60)</del> 5.9	7	4.0	<del>(3765+ bilateral .....</del>	<del>10.0-30-3.0)</del>		
36845 Anastomosis mandril .....	<del>(10.0-60)</del> 10.8	7	4.0	37660 Interruption, partial or complete, of common iliac vein by ligature, intravascular device .....	<del>(12.0)</del> 9.0	90	3.0
36860 Cannula declotting; without balloon catheter .....	<del>(BR)</del> 0.9	0	4.0	37700 Ligation and division of long saphenous vein at saphenofemoral junction, or distal interruptions( <del>(-unilateral)</del> ) .....	<del>(4.8)</del> 3.6	30	3.0
36861 with balloon catheter .....	<del>(BR)</del> 1.8	0	4.0	<del>(3770+ bilateral .....</del>	<del>6.0-6</del>		
37140 Anastomosis, portacaval .....	<del>(32.0)</del> 28.0	90	11.0	37720 Ligation and division and complete stripping of long or short saphenous veins( <del>(-unilateral)</del> ) .....	<del>(7.0)</del> 6.3	30	3.0
(For peritoneal-venous shunt, see 49425)				<del>(3772+ bilateral .....</del>	<del>12.0-30-3.0)</del>		
37145 renoportal .....	<del>(32.0)</del> 27.1	90	9.0	37730 Ligation and division and complete stripping of long and short saphenous veins( <del>(-unilateral)</del> ) .....	<del>(10.0)</del> 9.0	30	3.0
37160 caval-mesenteric .....	<del>(32.0)</del> 28.0	90	9.0	<del>(3773+ bilateral .....</del>	<del>14.5-30-3.0)</del>		
37180 Splenorenal, proximal .....	<del>(32.0)</del> 28.0	90	9.0	37735 Ligation and division and complete stripping of long or short saphenous veins with radical excision of ulcer and skin graft and/or interruption of communicating veins of lower leg, with excision of deep fascia( <del>(-unilateral)</del> ) .....	<del>(18.0-30)</del> 15.8	60	3.0
37181 splenorenal, distal (selective decompression of esophagogastric varices, any technique) ..	<del>(BR)</del> 36.1	90	9.0				
37190 Plastic repair of arteriovenous aneurysm .....	<del>(BR)</del> 19.0	90	9.0				

	Unit Value	Follow-up Days=	Basic Anes@
<del>((37737 bilateral</del> .....	<del>22.0</del>	<del>30</del>	<del>3.0))</del>
37760 Ligation of perforators, subfascial, radical (Linton type), with or without skin graft .....	<del>((10.0</del> <del>60))</del>		
	<u>18.1</u>	<u>120</u>	3.0
37780 Ligation and division of short saphenous vein at saphenopopliteal junction (separate procedure)((unilateral) .....	<del>((2.0))</del>		
	<u>1.8</u>	<u>30</u>	3.0
<del>((37781 bilateral</del> .....	<del>4.0</del>	<del>3</del>	<del>3.0))</del>
37785 Ligation ((and division of minor varicose vein of), division, and/or excision of recurrent or secondary varicose veins (clusters), one leg .....	<del>((1.2</del> <del>15))</del>		
	<u>1.1</u>	<u>30</u>	3.0
<del>((37787 Bilateral</del> .....	<del>1.8</del>	<del>15</del>	<del>3.0))</del>
37799 Unlisted procedure, vascular surgery .....	BR		3.0

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-130 SPLEEN.**

	Unit Value	Follow-up Days=	Basic Anes@
<b>EXCISION</b>			
38100 Splenectomy (separate procedure); total .....	14.5	45	6.0
38101 partial .....	<del>((14.5))</del>		
	<u>18.1</u>	<u>45</u>	6.0
<b>REPAIR</b>			
38115 Repair of ruptured spleen (splenorrhaphy) with or without partial splenectomy .....	<del>((13.0))</del>		
	<u>14.0</u>	<u>45</u>	6.0
<b>INTRODUCTION</b>			
38200 Injection procedure for splenoportography .....	<del>((2.0))</del>		
	<u>1.8</u>	<u>7</u>	3.0

**AMENDATORY SECTION (Amending Order 86-19, filed 2/28/86, effective 4/1/86)**

**WAC 296-22-132 BONE MARROW TRANSPLANTATION SERVICES.**

	Unit Value	Follow-up Days=	Basic Anes@
38230 Bone marrow harvesting for transplantation .....	<del>((BR))</del>		
	<u>14.9</u>	<u>30</u>	3.0
38240 Bone marrow transplantation; allogenic .....	<del>((BR))</del>		
	<u>15.8</u>	<u>30</u>	3.0
38241 autologous .....	BR		
(For compatibility studies, see 86810-86822)			

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-135 LYMPH NODES AND LYMPHATIC CHANNELS.**

	Unit Value	Follow-up Days=	Basic Anes@
<b>INCISION</b>			
*38300 Drainage of lymph node abscess or lymphadenitis, simple .....	<del>((4.0))</del>		
	<u>0.9</u>	<u>0</u>	3.0
38305 extensive .....	<del>((BR))</del>		
	<u>1.8</u>	<u>30</u>	3.0
38308 Lymphangiectomy or other operations on lymphatic channels ...	<del>((BR))</del>		
	<u>4.5</u>	<u>30</u>	3.0
38380 Suture and/or ligation of thoracic duct; cervical approach .....	<del>((BR))</del>		
	<u>4.5</u>	<u>45</u>	3.0
38381 thoracic approach .....	<del>((BR))</del>		
	<u>12.7</u>	<u>60</u>	3.0
38382 abdominal approach .....	<del>((BR))</del>		
	<u>12.7</u>	<u>60</u>	3.0

<b>EXCISION</b>			
38500 Biopsy or excision of lymph node(s); superficial (separate procedure) .....	1.4	<del>((15))</del>	
		<u>0</u>	3.0
38505 by needle, superficial (e.g., cervical, inguinal, axillary) ..	<del>((BR))</del>		
	<u>1.4</u>	<u>0</u>	
(For fine needle aspiration, use 88170)			
38510 deep, cervical node(s) .....	<del>((3.4</del> <del>30))</del>		
	<u>3.1</u>	<u>0</u>	3.0
38520 deep cervical node(s) with excision scalene fat pad .....	<del>((5.0</del> <del>30))</del>		
	<u>4.5</u>	<u>0</u>	3.0
38525 deep axillary node(s) .....	<del>((BR))</del>		
	<u>7.2</u>	<u>0</u>	
38530 internal mammary node(s) (separate procedure) .....	<del>((7.0</del> <del>60))</del>		
	<u>6.2</u>	<u>0</u>	3.0

(For percutaneous needle biopsy, retroperitoneal lymph node or mass, see 49180; for fine needle aspiration, use 88171)			
38542 Dissection deep jugular node(s) .....	<del>((BR))</del>		
	<u>5.4</u>	<u>60</u>	3.0
(For radical cervical neck dissection, see 38720, 38721)			
38550 Excision of cystic hygroma, axillary or cervical, without deep neurovascular dissection; simple .....	<del>((6.0))</del>		
	<u>5.4</u>	<u>60</u>	3.0
38555 complex .....	<del>((BR))</del>		
	<u>9.0</u>		3.0

**LIMITED LYMPHADENECTOMY FOR STAGING (SEPARATE PROCEDURE)**

38562 Limited lymphadenectomy for staging (separate procedure); pelvic and para-aortic .....	BR		
(When combined with prostatectomy, use 55812 or 55842)			

	Unit Value	Follow-up Days=	Basic Anes@
(When combined with insertion of radioactive substance into prostate, use 55862)			
38564 retroperitoneal (aortic and/or splenic) . . . . .	BR		
(When combined with prostatectomy, use 55812 or 55842)			
(When combined with insertion of radioactive substance into prostate, use 55862)			

**RADICAL LYMPHADENECTOMY (RADICAL RESECTION OF LYMPH NODES)**

	Unit Value	Follow-up Days=	Basic Anes@
(For limited pelvic and retroperitoneal lymphadenectomies, see 38562-38564)			
38700 Suprahyoid lymphadenectomy( <del>(bilateral)</del> ) . . . . .	<del>(12.0)</del>		
<del>(38701 bilateral . . . . .)</del>	<del>15.0</del>	60	4.0
38720 Cervical lymphadenectomy (complete)( <del>(unilateral)</del> ) . . . . .	19.0	60	4.0
<del>(38721 bilateral . . . . .)</del>	<del>22.0</del>	<del>60</del>	<del>4.0</del>
38724 Cervical lymphadenectomy (modified radical neck dissection) . . . . .	<del>(BR)</del>		
	19.0	60	4.0
38740 Axillary lymphadenectomy; superficial . . . . .	<del>(8.0)</del>		
	7.2	60	3.0
38745 complete . . . . .	<del>(14.0)</del>		
	12.7	60	3.0
38760 Inguinofemoral lymphadenectomy, superficial, including Cloquet's node (separate procedure)( <del>(unilateral)</del> ) . . . . .	<del>(8.0)</del>		
	7.2	60	3.0
<del>(38761 bilateral . . . . .)</del>	<del>12.0</del>	<del>60</del>	<del>3.0</del>
38765 Inguinofemoral lymphadenectomy, superficial, in continuity with pelvic lymphadenectomy, including external iliac hypogastric and obturator nodes (separate procedure)( <del>(unilateral)</del> ) . . . . .	<del>(20.0)</del>		
	16.3	60	5.0
<del>(38766 bilateral . . . . .)</del>	<del>24.0</del>	<del>60</del>	<del>5.0</del>
38770 Pelvic lymphadenectomy, including external iliac, hypogastric, and obturator nodes (separate procedure)( <del>(unilateral)</del> ) . . . . .	<del>(12.0)</del>		
	16.3	60	6.0
<del>(38771 bilateral . . . . .)</del>	<del>20.0</del>	<del>60</del>	<del>6.0</del>
38780 Retroperitoneal transabdominal lymphadenectomy, extensive, including pelvic, aortic, and renal nodes (separate procedure) . . . . .	<del>(28.0-90)</del>		
	24.4	60	7.0
(For excision and repair of lymphedematous skin and subcutaneous tissue, see 15000, 15500-15730)			

**INTRODUCTION**

38790 Injection procedure for lymphangiography( <del>(unilateral)</del> ) . . . . .	<del>(3.0-7)</del>		
	2.7	0	
<del>(38791 bilateral . . . . .)</del>	<del>4.0</del>	<del>7)</del>	

	Unit Value	Follow-up Days=	Basic Anes@
38794 Cannulation, thoracic duct . . . . .	<del>(BR)</del>		
	3.6	0	
38999 Unlisted procedure, hemic or lymphatic system . . . . .	BR		3.0

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-140 MEDIASTINUM.**

	Unit Value	Follow-up Days=	Basic Anes@
<b>INCISION</b>			
39000 Mediastinotomy with exploration, removal of foreign body or drainage; cervical approach . . . . .	<del>(6.0-90)</del>		
	5.4	0	6.0
39010 transthoracic . . . . .	<del>(12.0)</del>		
	10.8	90	12.0
39020 sternal split . . . . .	<del>(22.0)</del>		
	19.4	90	12.0
<b>EXCISION</b>			
39200 Excision of mediastinal cyst . . . . .	<del>(18.0)</del>		
	16.4	90	12.0
39220 Excision of mediastinal tumor . . . . .	<del>(18.0)</del>		
	16.4	90	12.0

(For substernal thyroidectomy, see 60270)

(For thymectomy, see 60520)

**ENDOSCOPY**

39400 Mediastinoscopy, with or without biopsy . . . . .	<del>(BR)</del>		
	5.4	0	3.0

**REPAIR**

39499 Unlisted procedure, mediastinum . . . . .	BR		3.0
---	----	--	-----

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-141 DIAPHRAGM.**

	Unit Value	Follow-up Days=	Basic Anes@
<b>REPAIR</b>			
39501 Repair, laceration of diaphragm . . . . .	<del>(BR)</del>		
	16.9	90	6.0
39502 Repair, paraesophageal hiatus hernia, transabdominal with or without fundoplasty, vagotomy, and/or pyloroplasty, except neonatal . . . . .	<del>(BR)</del>		
	15.5	90	6.0
39503 Repair, neonatal diaphragmatic hernia, <u>((including chest tube and)) with or without chest tube insertion and with or without creation of ventral hernia . . . . .</u>	<del>(BR)</del>		
	19.9	90	7.0
39520 Repair, diaphragmatic hernia (esophageal hiatal); transthoracic . . . . .	<del>(17.0)</del>		
	15.4	90	11.0



	Unit Value	Follow-up Days=	Basic Anes@
39530 combined, thoracoabdominal	<del>(19.0)</del> 17.2	90	11.0
39531 combined, thoracoabdominal, with dilation of stricture (with or without gastroplasty)	<del>(BR)</del> 17.2	90	11.0
39540 Repair, diaphragmatic hernia (other than neonatal), traumatic; acute	<del>(BR)</del> 17.2	90	13.0
39541 chronic	<del>(BR)</del> 17.2	90	11.0
39545 Imbrication of diaphragm for eventration; paralytic	<del>(22.0)</del> 10.8	90	7.0
39547 nonparalytic	<del>(BR)</del> 10.8	90	7.0
39599 Unlisted procedure, diaphragm.	BR		7.0

(For incidental repair of minor hiatal hernia, see WAC 296-22-010, item 7b)

	Unit Value	Follow-up Days=	Basic Anes@
40654 over one half vertical height, or complex	<del>(BR)</del> 5.4	30	3.0
40700 Plastic repair of cleft lip; primary, partial or complete, unilateral	<del>(16.0)</del> 14.5	90	6.0
40701 Primary bilateral, one stage procedure	<del>(20.0)</del> 19.0	90	6.0
40702 primary bilateral, one of two stages	<del>(14.0)</del> 12.7	90	6.0
40720 secondary, <del>(unilateral)</del> by recreation of defect and reclosure	<del>(16.0)</del> 14.5	90	6.0
<del>(40740) secondary, bilateral (per major stage)</del>	<del>14.0</del>	<del>90</del>	<del>6.0</del>
40761 with cross lip pedicle flap (Abbe-Estlander type), including sectioning and inserting of pedicle	<del>(BR)</del> 8.1	90	6.0

(For repair cleft palate, see 42200 et seq.)

(For other reconstructive procedures, see 14060, 14061, 15120-15261, 15515 et seq.)

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-146 LIPS.**

	Unit Value	Follow-up Days=	Basic Anes@
(For procedures on skin of lips, see 10000 et seq.)			
<b>EXCISION</b>			
40490 Biopsy of lip	<del>(0.6-7)</del> 0.5	0	3.0
40500 Vermilionectomy ("lip peel") with mucosal advancement	<del>(10.5-120)</del> 7.4	30	3.0
40510 Excision of lip; transverse wedge excision with primary closure	<del>(10.5-120)</del> 6.8	30	3.0
40520 V-excision of lesion with primary direct linear closure	<del>(6.0-120)</del> 6.2	30	3.0
40525 full thickness, reconstruction with local flap (e.g., Estlander or fan)	<del>(BR)</del> 7.1	30	3.0
40527 full thickness, reconstruction with cross lip flap (Abbe-Estlander)	<del>(BR)</del> 27.1	90	3.0
(For excision of mucous lesions, see 40810-40814)			
40530 Resection of lip, more than one-fourth, without reconstruction	<del>(6.0-120)</del> 6.3	30	3.0
(For lip reconstruction (see 13131 et seq.))			

**REPAIR (CHEILOPLASTY)**

40650 Repair lip, full thickness; vermilion only	<del>(BR)</del> 2.7	30	3.0
40652 up to half vertical height	<del>(BR)</del> 3.6	30	3.0

**OTHER PROCEDURES**

40799 Unlisted procedure, lips	BR		3.0
--------------------------------	----	--	-----

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-147 VESTIBULE OF MOUTH.**

The vestibule is the part of the oral cavity outside the dentoalveolar structures; it includes the mucosal and submucosal tissue of lips and cheeks.

	Unit Value	Follow-up Days=	Basic Anes@
<b>INCISION</b>			
40800* Drainage of abscess, cyst, hematoma, vestibule of mouth; simple	<del>(0.4)</del> 0.7	0	4.0
40801 complicated	<del>(BR)</del> 1.4	0	4.0
40804* Removal of embedded foreign body; simple	<del>(0.4)</del> 0.7	0	4.0
40805 complicated	<del>(BR)</del> 1.4	0	4.0
40806 Incision of labial frenum (frenotomy)	<del>(5v)</del> 0.5	0	4.0

**EXCISION, DESTRUCTION**

40808 Biopsy, vestibule of mouth	0.6	0	4.0
40810 Excision of lesion of mucosa and submucosa; without repair	<del>(0.6)</del> 0.5	0	4.0
40812 with simple repair	<del>(1.0)</del> 1.4	0	4.0
40814 with complex repair	<del>(BR-0)</del> 1.8	30	4.0

	Unit Value	Follow-up Days=	Basic Anes@
40816 complex, with excision of and underlying muscle	<del>((BR-0))</del> 2.7	60	4.0
40818 Excision of mucosa as donor graft	<del>((BR-0))</del> 1.8	60	4.0
40819 Excision of frenum, labial or buccal (frenulectomy, frenulectomy, frenectomy)	<del>((BR))</del> 1.4	0	4.0
40820 Destruction of lesion or scar by physical methods (e.g., laser, thermal, cryo, chemical)	<del>((BR))</del> 0.5	0	4.0
<b>REPAIR</b>			
40830 Closure of laceration; 2.5 cm or less	<del>((0.4-0))</del> 0.9	7	4.0
40831 over 2.5 cm or complex	<del>((0.4-0))</del> 1.7	30	4.0
40840 Vestibuloplasty; anterior	<del>((BR-0))</del> 7.2	90	4.0
40842 posterior, unilateral	<del>((BR-0))</del> 7.2	90	4.0
40843 posterior, bilateral	<del>((BR-0))</del> 9.0	90	4.0
40844 entire arch	<del>((BR-0))</del> 10.8	90	4.0
40845 complex (including ridge extension, muscle repositioning)	<del>((BR-0))</del> 12.7	120	4.0
(For skin grafts, see 15000 et seq.)			
<b>OTHER PROCEDURES</b>			
40899 Unlisted procedure, vestibule of mouth	BR		4.0

**AMENDATORY SECTION (Amending Order 87-18, filed 7/23/87)**

**WAC 296-22-150 TONGUE, FLOOR OF MOUTH.**

	Unit Value	Follow-up Days=	Basic Anes@
<b>INCISION</b>			
*41000 Incision and drainage of intraoral abscess, cyst, or hematoma of tongue or floor of mouth; lingual	<del>((0.4))</del> 0.7	0	3.0
41005* sublingual, superficial	<del>((0.4))</del> 0.7	0	4.0
41006 sublingual, deep, supramylohyoid	<del>((BR))</del> 0.7	0	4.0
41007 submental space	<del>((BR))</del> 0.7	0	4.0
41008 submandibular space	<del>((BR))</del> 0.7	0	4.0
41009 masticator space	<del>((BR))</del> 0.7	0	4.0
41010 Incision of lingual frenum (frenotomy)	0.4	((+5)) 0	4.0

	Unit Value	Follow-up Days=	Basic Anes@
41015 Incision and drainage of extraoral abscess, cyst, or hematoma of floor of mouth; sublingual	0.6	((+5)) 0	4.0
41016 submental	<del>((BR))</del> 0.6	0	4.0
41017 submandibular	<del>((BR))</del> 0.6	0	4.0
41018 masticator space	<del>((BR))</del> 0.6	0	4.0

(For frenoplasty, see 41520)

**EXCISION**

41100 Biopsy of tongue, anterior two-thirds	<del>((1.0-15))</del> 0.6	0	3.0
41105 posterior one-third	<del>((0.6-15))</del> 0.9	0	3.0
41108 Biopsy, floor of mouth	<del>((1.0-15))</del> 0.6	0	4.0
41110 Excision lesion of tongue; without closure	<del>((BR))</del> 0.8	7	4.0
41112 with closure, anterior two-thirds	<del>((BR))</del> 1.3	7	4.0
41113 with closure, posterior one-third	<del>((BR))</del> 1.3	7	4.0
41114 with local tongue flap	BR		4.0
(List 41114 in addition to code 41112 or 41113)			
41115 Excision of lingual frenum (frenectomy)	<del>((BR))</del> 0.5	7	4.0
41116 Excision lesion of floor of mouth	<del>((BR))</del> 1.3	7	4.0
41120 Glossectomy; less than one-half tongue	<del>((8-0))</del> 8.1	120	6.0
41130 Hemiglossectomy	<del>((12-0))</del> 9.9	120	6.0
41135 partial, with unilateral radical neck dissection	<del>((20-0))</del> 19.9	120	6.0
41140 complete or total, with or without tracheostomy, without radical neck dissection	<del>((18-0))</del> 15.8	120	6.0
41145 complete or total, with or without tracheostomy, with unilateral radical neck dissection	<del>((26-0))</del> 25.3	120	6.0
41150 composite procedure with resection floor of mouth and mandibular resection, without radical neck dissection	<del>((BR+))</del> 19.9	120	6.0
41153 composite procedure with resection floor of mouth, with suprahyoid neck dissection	<del>((BR-120))</del> 25.3		6.0
41155 composite procedure with resection floor of mouth, mandibular resection, and radical neck dissection (Commando type)	<del>((BR))</del> 27.1	120	6.0

	Unit Value	Follow-up Days=	Basic Anes@
<b>REPAIR</b>			
41250* Repair laceration 2.5 cm or less; floor of mouth and/or anterior two-thirds of tongue .....	1.0	((0)) 7	4.0
41251* posterior one-third of tongue .....	((1.0-0)) 1.4	7	4.0
41252* Repair laceration of tongue, floor of mouth, over 2.6 cm or complex .....	((BR)) 2.7	7	4.0

**OTHER PROCEDURES**

41500 Fixation tongue, mechanical, other than suture (e.g., K-wire) .....	((5.0)) 4.5	30	3.0
41510 Suture tongue to lip for micrognathia (Douglas type procedure) .....	((10.0)) 9.0	30	3.0
41520 Frenoplasty (surgical revision of frenum, e.g., with Z-plasty) ...	((BR)) 1.8	30	3.0
(For frenotomy, see 40806, 41010)			
41599 Unlisted procedure, tongue, floor of mouth .....	BR		3.0

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-155 TEETH AND GUMS.**

	Unit Value	Follow-up Days=	Basic Anes@
(For biopsy, see 11100)			
<b>INCISION</b>			
*41800 Drainage abscess, cyst, hematoma .....	((0.4)) 0.8	0	3.0
41805 Removal embedded foreign body; from soft tissues .....	((0.8)) 0.7	0	3.0
41806 from bone .....	((2.0)) 0.9	0	3.0
<b>EXCISION, DESTRUCTION</b>			
41820 Gingivectomy, excision gingiva, each quadrant .....	((BR)) 3.6	0	3.0
41821 Operculectomy, excision pericoronal tissues .....	((BR)) 0.7	0	3.0
41822 Excision fibrous tuberosities ...	((BR)) 0.9	0	3.0
41823 Excision osseous tuberosities ...	((BR)) 1.8	0	3.0
41825 Excision of lesion or tumor (except listed above); without repair .....	((BR)) 0.5	0	3.0
41826 with simple repair .....	((BR)) 0.9	0	3.0
41827 with complex repair .....	((BR)) 1.8	7	3.0

(For nonexcisional destruction, see 41850)

	Unit Value	Follow-up Days=	Basic Anes@
41828 Excision of hyperplastic alveolar mucosa, each sextant or quadrant (specify) .....	((BR)) 1.4	0	3.0
41830 Alveolectomy, including curettage of osteitis or sequestrectomy .....	BR		3.0
41850 Destruction of lesion (except excision), dentoalveolar structures .....	((BR)) 0.5	0	3.0

**OTHER PROCEDURES**

41870 Periodontal mucosal grafting ..	((BR)) 4.3	90	3.0
41872 Gingivoplasty .....	((BR)) 3.5	90	3.0
41874 Alveoplasty .....	((BR)) 3.5	90	3.0
(For closure of lacerations, see 40830, 40831)			
(For segmental osteotomy, see 21202, 21206)			
(For reduction of fractures, see 21420-21490)			
41899 Unlisted procedure, dentoalveolar structures .....	BR		3.0

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-160 PALATE, UVULA.**

	Unit Value	Follow-up Days=	Basic Anes@
<b>INCISION</b>			
*42000 Drainage of abscess of palate, uvula .....	((0.4)) 0.7	0	3.0
<b>EXCISION, DESTRUCTION</b>			
42100 Biopsy of palate, uvula .....	((0.6-7)) 0.5	0	3.0
42104 Excision lesion of palate, uvula; without closure .....	((BR)) 0.7	0	3.0
42106 with closure .....	((BR)) 1.3	0	3.0
42107 with local flap closure .....	((BR)) 14.5	90	3.0
(For skin graft, see 14040-14300)			
(For mucosal graft, see 40818)			
42120 Resection of palate or extensive resection of lesion .....	((BR+)) 19.9	90	6.0
(For reconstruction of palate with extraoral tissue, see 14040-14300, 15050, 15120, 15240, 15510-15720)			

	Unit Value	Follow-up Days=	Basic Anes@
*42140 Uvulectomy: Excision of uvula	<del>(0.6)</del> 0.9	<del>0</del> 15	3.0
42145 Palatopharyngoplasty (e.g., uvulopalatopharyngoplasty uvulopharyngoplasty)	<del>(BR)</del> 12.3	<del>90</del> 90	
<del>((42150 Removal of exostosis bony palate</del>	<del>BR</del>	<del>30)</del>	
42160 Destruction of lesion, palate or uvula (thermal, cryo or chemical)	<del>(BR)</del> 0.8	<del>0</del>	3.0

REPAIR

42180 Repair laceration of palate; up to 2 cm	<del>(BR)</del> 1.4	15	
42182 over 2 cm or complex	<del>(BR)</del> 2.7	15	
42200 Palatoplasty for cleft palate, soft and/or hard palate only	<del>(16.0)</del> 14.6	90	6.0
42205 Palatoplasty for cleft palate, with closure of alveolar ridge; soft tissue only	<del>(20.0)</del> 18.1	90	6.0
42210 with bone graft to alveolar ridge (includes obtaining graft)	<del>(22.0)</del> 20.3	90	6.0
(For obtaining bone graft by second surgeon, see WAC 296-22-010, item 5c and modifier -64)			
42215 Palatoplasty for cleft palate; major revision	<del>(16.0)</del> 14.6	90	6.0
42220 secondary lengthening procedure	<del>(17.0)</del> 15.5	90	6.0
42225 attachment pharyngeal flap	<del>(17.0)</del> 15.5	90	6.0
42226 Lengthening of palate, and pharyngeal flap	<del>(BR)</del> 15.8	90	6.0
42227 Lengthening of palate, with island flap	<del>(BR)</del> 15.8	90	6.0
42235 Repair anterior palate, including vomer flap	<del>(16.0)</del> 5.0	90	6.0
(For repair of larger defect, see 42215)			
42260 Repair nasolabial fistula	<del>(BR)</del> 5.4	90	4.0
42280 Maxillary impression for palatal prosthesis	<del>(BR)</del> 0.7	90	4.0
42281 Insertion of pin-retained palatal prosthesis	<del>(BR)</del> 0.4	90	4.0
(For repair cleft lip, see 40700 et seq.)			

OTHER PROCEDURES

42299 Unlisted procedure, palate, uvula	BR		4.0
---	----	--	-----

AMENDATORY SECTION (Amending Order 87-18, filed 7/23/87)

WAC 296-22-165 SALIVARY GLANDS AND DUCTS.

	Unit Value	Follow-up Days=	Basic Anes@
INCISION			
*42300 Drainage of abscess; parotid, simple	<del>(1.4)</del> 1.6	0	3.0
42305 parotid, complicated	<del>(BR)</del> 2.7	0	3.0
*42310 Drainage of abscess; submaxillary or sublingual, intraoral	<del>(1.0)</del> 1.1	0	3.0
42320 submaxillary, external	<del>(3.0)</del> 2.3	0	3.0
42325 Fistulization sublingual salivary cyst (ranula);	<del>(BR)</del> 0.9	30	3.0
42326 with prosthesis	<del>(BR)</del> 1.1	30	
*42330 Sialolithotomy; submandibular (submaxillary), sublingual, or parotid, uncomplicated, intraoral	<del>(0.6)</del> 0.8	15	3.0
42335 submandibular (submaxillary), complicated, intraoral	<del>(2.4)</del> 2.2	30	3.0
42340 parotid, extraoral or complicated intraoral	<del>(6.0)</del> 5.4	30	3.0

EXCISION

*42400 Biopsy salivary gland; needle	<del>(0.8)</del> 0.9	0	
42405 incisional	<del>(2.0)</del> 1.9	30	3.0
42408 Excision sublingual salivary cyst (ranula)	<del>(BR)</del> 2.7	15	3.0
42409 Marsupialization sublingual salivary cyst (ranula)	<del>(BR)</del> 2.3	15	3.0
(For fistulization of sublingual salivary cyst, see 42325)			
42410 Excision of parotid tumor or parotid gland; lateral lobe, without nerve dissection	<del>(6.0)</del> 5.6	60	3.0
42415 lateral lobe, with dissection and preservation of facial nerve	<del>(14.5)</del> 14.0	60	3.0
42420 total, with dissection and preservation of facial nerve	<del>(18.0)</del> 17.5	60	3.0
42425 total, en bloc removal with sacrifice of facial nerve	<del>(12.0)</del> 11.2	60	3.0
42426 total, with unilateral radical neck dissection	<del>(25.0)</del> 25.3	60	3.0
42440 Excision submandibular (submaxillary) gland	<del>(10.0)</del> 9.5	60	3.0
42450 Excision sublingual gland	<del>(5.5)</del> 9.5	60	3.0

	Unit Value	Follow-up Days=	Basic Anes@
<b>REPAIR</b>			
42500 Plastic repair salivary duct, (sialodochoplasty); primary or simple .....	<del>((7-0))</del> 6.4	60	3.0
42505 secondary or complicated .....	<del>((BR+))</del> 9.5	60	3.0
42507 Parotid duct diversion, bilateral (Wilke type procedure); .....	<del>((BR))</del> 11.7	60	3.0
42508 with excision of one submandibular gland .....	<del>((BR))</del> 11.7	60	3.0
42509 with excision of both submandibular glands .....	<del>((BR))</del> 19.9	60	3.0
42510 with ligation of both submandibular (Wharton's) ducts .....	<del>((BR))</del> 12.2	60	3.0

**OTHER PROCEDURES**

42550 Injection procedure for sialography .....	<del>((0-4))</del> 0.6	0	
42600 Closure salivary fistula .....	<del>((BR+))</del> 9.0	60	3.0
*42650 Dilatation salivary duct .....	<del>((0-3))</del> 0.5	0	3.0
42660* Dilatation and catheterization of salivary duct, with or without injection .....	<del>((5-))</del> 0.5	0	3.0
42665 Ligation salivary duct, intraoral .....	<del>((BR))</del> 1.1	0	3.0
42699 Unlisted procedure, salivary glands or ducts .....	BR		3.0

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-170 PHARYNX, ADENOIDS AND TONSILS.**

	Unit Value	Follow-up Days=	Basic Anes@
<b>INCISION</b>			
*42700 Incision and drainage abscess; peritonsillar .....	<del>((0-6))</del> 1.2	0	3.0
42720 retropharyngeal or parapharyngeal, intraoral approach .....	<del>((2-4))</del> 2.2	15	3.0
42725 retropharyngeal or parapharyngeal, external approach .....	<del>((BR))</del> 4.5	15	3.0

**EXCISION**

42800 Biopsy; oropharynx .....	0.8	7	3.0
42802 hypopharynx .....	1.4	7	3.0
42804 nasopharynx, visible lesion, simple .....	1.0	7	3.0
42806 nasopharynx, survey for unknown primary lesion .....	<del>((BR))</del> 1.1	7	3.0

(For laryngoscopic biopsy, see 31510, 31535, 31536)

	Unit Value	Follow-up Days=	Basic Anes@
42808 Excision of lesion of pharynx ...	<del>((BR))</del> 2.7	30	3.0
42809 Removal of foreign body from pharynx .....	<del>((BR))</del> 0.9	0	3.0
42810 Excision branchial cleft cyst, or vestige, confined to skin and subcutaneous tissues .....	<del>((4-0))</del> 3.4	30	3.0
42815 Excision branchial cleft cyst, vestige, or fistula, extending beneath subcutaneous tissues and/or into pharynx .....	<del>((10-0))</del> 9.3	30	3.0
42820 Tonsillectomy and adenoidectomy; under age 12 years .....	<del>((4-0))</del> 4.6	30	3.0
42821 age 12 or over .....	<del>((4-0))</del> 4.6	30	3.0
42825 Tonsillectomy, primary or secondary; under age 12 .....	<del>((3-5))</del> 4.6	30	3.0
42826 age 12 or over .....	<del>((4-0))</del> 4.6	30	3.0
42830 Adenoidectomy, primary; under age 12 .....	<del>((2-8))</del> 2.6	30	3.0
42831 age 12 or over .....	<del>((3-0))</del> 2.6	30	3.0
42835 Adenoidectomy, secondary; under age 12 .....	<del>((2-8))</del> 2.6	30	3.0
42836 age 12 or over .....	<del>((3-0))</del> 2.6	30	3.0
42842 Radical resection of tonsil, tonsillar pillars, and/or retromolar trigone; without closure .....	<del>((BR))</del> 13.7	30	3.0
42844 closure with local flap (e.g., tongue, buccal) .....	<del>((BR))</del> 16.4	30	3.0
42845 closure with other flap .....	<del>((BR))</del> 16.4	30	3.0

(For closure with other flap(s), use appropriate number for flap(s))

(When combined with radical neck dissection, use also 38720, 38721)

42860 Excision of tonsil tags .....	<del>((2-8))</del> 2.7	30	3.0
42870 Excision lingual tonsil (separate procedure) .....	<del>((4-8))</del> 4.3	30	3.0
42880 Excision of nasopharyngeal lesion (e.g., fibroma) .....	<del>((BR))</del> 6.3	30	3.0

(For excision and repair of hypopharyngeal diverticulum, cervical approach, see 43130; for endoscopic approach, see 43225)

42890 Limited pharyngectomy; without radical neck dissection .....	<del>((BR))</del> 10.8	60	3.0
42892 Resection of lateral pharyngeal wall or pyriform sinus, direct closure by advancement of lateral and posterior pharyngeal walls ..	<del>((BR))</del> 14.5	60	3.0

	Unit Value	Follow-up Days=	Basic Anes@
(When combined with radical neck dissection, use also 38720, 38721)			
42894 Resection of pharyngeal wall requiring closure with myocutaneous flap . . . . .	<del>((BR))</del> 17.2	60	3.0
(When combined with radical neck dissection, use also 38720, 39721)			
<b>REPAIR</b>			
42900 Suture pharynx for wound or injury . . . . .	<del>((BR))</del> 4.5	30	3.0
42950 Pharyngoplasty (plastic or reconstructive operation on pharynx) . . . . .	<del>((BR))</del> 11.3	60	3.0
(For pharyngeal flap, see 42225)			
42953 Pharyngoesophageal repair . . . . .	<del>((BR))</del> 11.3	60	3.0
(For closure with myocutaneous or other flap, use appropriate number in addition)			
<b>OTHER PROCEDURES</b>			
42955 Pharyngostomy (fistulization of pharynx, external for feeding) . . . . .	<del>((BR))</del> 4.1	0	
42960 Control oropharyngeal hemorrhage (primary or secondary, e.g., posttonsillectomy); simple . . . . .	<del>((+0))</del> 1.2	0	4.0
42961 complicated, requiring hospitalization . . . . .	<del>((BR))</del> 1.4	0	4.0
42962 with secondary surgical intervention . . . . .	<del>((BR))</del> 1.8	0	4.0
42970 Control of nasopharyngeal hemorrhage (primary or secondary, eg, postadenoidectomy); simple, with posterior nasal packs, with or without anterior packs and/or cauterization . . . . .	<del>((2-0))</del> 2.3	0	4.0
42971 complicated, requiring hospitalization . . . . .	<del>((BR))</del> 2.7	0	4.0
42972 with secondary surgical intervention . . . . .	<del>((BR))</del> 2.7	0	4.0
42999 Unlisted procedure, pharynx, adenoids, or tonsils . . . . .	BR		4.0

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-180 ESOPHAGUS.**

	Unit Value	Follow-up Days=	Basic Anes@
<b>INCISION</b>			
43000 Esophagotomy, cervical approach; without removal foreign body . . . . .	<del>((+4-0))</del> 11.9	90	6.0
43020 with removal of foreign body . . . . .	<del>((+4-0))</del> 12.7	90	6.0
43030 Cricopharyngeal myotomy . . . . .	<del>((+4-0))</del> 11.7	90	6.0
43040 Esophagotomy, thoracic approach; without removal of foreign body . . . . .	<del>((+9-0))</del> 16.3	90	12.0
43045 with removal foreign body . . . . .	<del>((+9-0))</del> 17.2	90	12.0
<b>EXCISION</b>			
43100 Excision of local lesion, esophagus, with primary repair; cervical approach . . . . .	<del>((+9-0))</del> 13.6	90	12.0
43101 thoracic approach . . . . .	<del>((20-0))</del> 19.9	90	12.0
43105 Wide excision of malignant lesion of cervical esophagus, with or without laryngectomy . . . . .	<del>((BR))</del> 21.7	90	12.0
43106 with radical neck dissection (Wookey type procedure) . . . . .	<del>((BR))</del> 28.9	90	12.0
43110 Esophagectomy: (at upper two-thirds level) and gastric anastomosis with vagotomy; with or without pyloroplasty . . . . .	<del>((30-0))</del> 25.3	90	12.0
43111 with second stage pyloroplasty . . . . .	<del>((35-0))</del> 13.6	90	12.0
43115 Esophagectomy (at upper two-thirds level) with segment replacement, one or two stages . . . . .	<del>((40-0))</del> 29.8	90	12.0
43119 Total esophagectomy with gastropharyngostomy, without thoracotomy . . . . .	BR		12.0
43120 Esophagogastrectomy (lower-third) and vagotomy, combined thoracicoabdominal with or without pyloroplasty . . . . .	<del>((29-0))</del> 27.5	90	12.0
43130 Diverticulectomy of hypopharynx or esophagus, with or without myotomy; cervical approach . . . . .	<del>((+4-0))</del> 12.2	90	6.0
43135 thoracic approach . . . . .	<del>((20-0))</del> 18.1	90	12.0
43136 Diverticulopexy of hypopharynx, with or without myotomy . . . . .	<del>((BR))</del> 10.8	90	6.0

(For endoscopic approach, see 43225)

**ENDOSCOPY**

(For endoscopic procedures, code appropriate endoscopy of each anatomic site examined)

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
43200	<del>(4.0-15)</del> 3.4	0	3.0	(For radiological guidance of percutaneous placement, see 74350, 74351)			
43202	<del>(4.0-15)</del> 4.2	0	3.0	43247	<del>(5.0-15)</del> 4.5	0	3.0
43204	5.0	((+5)) 0	3.0	43251	<del>(6.0-15)</del> 5.0	0	3.0
43215	<del>(6.0-15)</del> 5.1	0	3.0	43255	5.0	((+5)) 0	3.0
(For removal of foreign body with use of catheter see 74235)				43258	<del>(5.0-15)</del> 4.8	0	3.0
43217	<del>(6.0-15)</del> 5.3	0	3.0	(For injection sclerosis of esophageal varices, use 43204 or 43243)			
(43218 Esophagoscopy with irrigation has been deleted. To report, use 43499)				43260			
43219	<del>(4.8-15)</del> 5.9	0	3.0	Endoscopic retrograde cholangiopancreatography (ERCP), with or without biopsy, and/or collection of specimen collection	<del>(5.0-15)</del> 6.8	0	3.0
43220	4.8	((+5)) 0	3.0	43262	<del>(6.0-15)</del> 7.7	0	3.0
(For dilation, without visualization, see 43450-43456)				43263	<del>(8.7-15)</del> 7.7	0	3.0
43226	<del>(4.0-15)</del> 4.4	0	3.0	43264	<del>(7.0-15)</del> 7.7	0	3.0
43227	5.0	((+5)) 0	3.0	43265	BR		3.0
43228	<del>(5.0-15)</del> 3.6	0	3.0	(When done with sphincterotomy, also use 43262)			
(For gastroscopy, without esophagoscopy, see 43700-43714)				43267	BR		3.0
43234	<del>(BR)</del> 2.8	0	3.0	(When done with sphincterotomy, also use 43262)			
43235	<del>(5.0-15)</del> 3.8	0	3.0	43268	BR		3.0
43239	<del>(4.0-15)</del> 4.3	0	3.0	(When done with sphincterotomy, also use 43262)			
43241	<del>(BR)</del> 5.0	0	3.0	43269	BR		3.0
43243	BR			43271	BR		3.0
43245	<del>(BR-15)</del> 5.0	0	3.0	43272	BR		3.0
43246	<del>(BR-15)</del> 5.0	0	3.0	(For fluoroscopic monitoring and radiography, see 74330)			
				REPAIR			
				43300	<del>(BR)</del> 17.2	90	12.0
				43305	<del>(22.0)</del> 19.9	90	6.0

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
43310	Esophagoplasty, (plastic repair or reconstruction) thoracic approach; without repair of tracheoesophageal fistula . . . . .	<del>((30.0))</del> <u>22.6</u>	90	12.0	<b>MANIPULATION</b>		
43312	with repair of tracheoesophageal fistula . . . . .	<del>((26.0))</del> <u>26.2</u>	90	12.0	(For associated esophagogram, use 74220)		
43320	Esophagogastrostomy (cardioplasty) with or without vagotomy and pyloroplasty; abdominal approach . . . . .	<del>((22.0))</del> <u>20.8</u>	90	6.0	*43450	Dilation of esophagus, by unguided sound or bougie, single or multiple; initial session . . . . .	<del>((40.6))</del> <u>1.6</u> 0 3.0
43321	thoracic approach . . . . .	<del>((22.0))</del> <u>21.2</u>	90	11.0	*43451	subsequent session . . . . .	<del>((40.6))</del> <u>1.6</u> 0 3.0
43324	Esophago gastric fundoplasty (e.g., Nissen, Belsey IV, Hill procedures) . . . . .	<del>((BR))</del> <u>18.1</u>	90	6.0	43453	Dilation of esophagus, over guide wire or string . . . . .	<del>((3.0-15))</del> <u>2.7</u> 0 3.0
43325	Esophago gastric fundoplasty with fundic patch (Thal-Nissen procedure) . . . . .	<del>((BR))</del> <u>20.8</u>	90	6.0	(For dilation with direct visualization, see 43220)		
	(For cricopharyngeal myotomy, see 43030)				43455	Dilation of esophagus by balloon or Stark dilator; . . . . .	<del>((4.0-15))</del> <u>3.6</u> 0 3.0
43330	Esophagomyotomy (Heller type) with or without hiatal hernia repair; abdominal approach . . . . .	<del>((19.0))</del> <u>17.3</u>	90	6.0	43456	retrograde . . . . .	<del>((BR))</del> <u>3.6</u> 0 3.0
43331	thoracic approach . . . . .	<del>((19.0))</del> <u>17.3</u>	90	11.0	43460	Esophago gastric tamponade, with balloon (Sengstaaken type) . . . . .	<del>((Sv. &amp;))</del> <u>3.6</u> 0
	(For esophagoduodenostomy or esophagojejunosomy with total gastric resection, see 43620)				(For removal of esophageal foreign body by balloon catheter, use 74235)		
43340	Esophagojejunosomy (without total gastrectomy); abdominal approach . . . . .	<del>((24.0))</del> <u>21.7</u>	90	6.0	43499	Unlisted procedure, esophagus .	BR 3.0
43341	thoracic approach . . . . .	<del>((24.0))</del> <u>22.6</u>	90	11.0	<b>AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)</b>		
43350	Esophagostomy, fistulization of esophagus, external; abdominal approach . . . . .	<del>((14.0))</del> <u>13.6</u>	90	6.0	<b>WAC 296-22-190 STOMACH.</b>		
43351	thoracic approach . . . . .	<del>((14.0))</del> <u>12.7</u>	90	11.0			
43352	cervical approach . . . . .	<del>((14.0))</del> <u>12.7</u>	90	14.0			
<b>SUTURE</b>							
43400	Ligation, direct, esophageal varices . . . . .	<del>((20.0))</del> <u>18.1</u>	90	12.0	<b>INCISION</b>		
43401	Transection of esophagus with repair, for esophageal varices . .	BR			43500	Gastrotomy; with exploration or foreign body removal . . . . .	<del>((12.0))</del> <u>12.2</u> 45 5.0
43410	Suture esophageal wound or injury; cervical approach . . . . .	<del>((BR))</del> <u>13.6</u>	90	7.0	43501	with suture repair of bleeding ulcer or esophago gastric laceration . . . . .	<del>((BR))</del> <u>14.9</u> 45 5.0
43415	thoracic approach . . . . .	<del>((19.0))</del> <u>17.3</u>	90	12.0	43510	with esophageal dilation and insertion of plastic tubes . . . . .	<del>((BR))</del> <u>12.7</u> 45 5.0
43420	Closure esophagostomy or fistula; cervical approach . . . . .	<del>((14.0))</del> <u>12.2</u>	90	6.0	43520	Pyloromyotomy, cutting of pyloric muscle (Fredet-Ramstedt type operation) . . . . .	<del>((10.0))</del> <u>10.4</u> 45 6.0
43425	thoracic approach . . . . .	<del>((26.0))</del> <u>19.9</u>	90	12.0	<b>EXCISION</b>		
	(For repair of esophageal hiatal hernia, see 39500 et seq.)				43600	Biopsy of stomach; by capsule, tube, peroral (one or more specimens) . . . . .	<del>((3.0))</del> <u>1.3</u> 0
					43605	by laparotomy . . . . .	<del>((12.0))</del> <u>12.2</u> 45 5.0
					43610	Local excision of ulcer or tumor . . . . .	<del>((14.5))</del> <u>13.6</u> 45 6.0
					43620	Gastrectomy, total; including intestinal anastomosis . . . . .	<del>((28.0))</del> <u>25.3</u> 90 7.0
					43625	with repair by intestinal transplant . . . . .	<del>((34.0))</del> <u>29.8</u> 90 7.0



	Unit Value	Follow-up Days=	Basic Anes@
43630 Hemigastrectomy or distal subtotal gastrectomy including pyloroplasty, gastroduodenostomy or gastrojejunostomy; without vagotomy	19.0	60	6.0
43635 with vagotomy, any type	<del>(21.0)</del> 20.8	60	6.0
43638 Hemigastrectomy or proximal subtotal gastrectomy, thoracic or abdominal approach	<del>(19.0)</del> 25.3	60	6.0
43640 Vagotomy including pyloroplasty, with or without gastrotomy truncal or selective	<del>(17.0)</del> 16.7	60	6.0
(For pyloroplasty, see 43800)			
(For vagotomy, see 64752-64760)			
43641 parietal cell (highly selective)	BR		6.0

ENDOSCOPY

(For upper gastrointestinal endoscopy, see 43234-43258)

INTRODUCTION

43750 Percutaneous placement of gastrostomy tube	BR		5.0
*43760 Change of gastrostomy tube	BR		5.0

SUTURE

43800 Pyloroplasty	<del>(13.0)</del> 13.1	45	5.0
(For pyloroplasty and vagotomy, see 43640)			
43810 Gastroduodenostomy	<del>(14.0)</del> 13.7	45	5.0
43820 Gastrojejunostomy	<del>(14.0)</del> 13.7	45	5.0
43825 with vagotomy any type	<del>(18.0)</del> 16.5	45	6.0
43830 Gastrotomy, temporary (tube, rubber, or plastic) (separate procedure)	<del>(13.0)</del> 10.4	45	5.0
43831 neonatal, for feeding	8.0	30	5.0
(For change of gastrostomy tube, see 43760)			
43832 Gastrotomy, permanent, with construction of gastric tube	<del>(16.0)</del> 14.5	45	5.0
43840 Gastrorrhaphy, suture of perforated duodenal or gastric ulcer, wound, or injury	<del>(13.0)</del> 12.7	45	6.0
43844 Gastric bypass for morbid obesity			NONCOVERED PROCEDURE
43845 ((Gastric stapling)) Gastroplasty, any method, for morbid obesity			NONCOVERED PROCEDURE
43846 Gastric bypass with Roux-en-Y gastroenterostomy for morbid obesity			NONCOVERED PROCEDURE

	Unit Value	Follow-up Days=	Basic Anes@
43850 Revision of gastroduodenal anastomosis (gastroduodenostomy) with reconstruction, without vagotomy	<del>(20.0)</del> 18.1	60	5.0
43855 with vagotomy	<del>(23.0)</del> 20.8	60	6.0
43860 Revision of gastrojejunal anastomosis (gastrojejunostomy) with reconstruction; with or without partial gastrectomy or bowel resection; without vagotomy	<del>(20.0)</del> 18.1	60	5.0
43865 with vagotomy	<del>(23.0)</del> 20.8	60	6.0
43870 Closure of gastrotomy, surgical	<del>(12.0)</del> 9.0	45	5.0
43880 Closure of gastrocolic fistula	<del>(BR)</del> 14.5	45	5.0
43885 Anterior gastropexy for hiatal hernia (separate procedure)	<del>(BR)</del> 11.7	45	5.0
43999 Unlisted procedure, stomach	BR		5.0

AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

WAC 296-22-195 INTESTINES (EXCEPT RECTUM).

	Unit Value	Follow-up Days=	Basic Anes@
INCISION			
44005 Enterolysis (freeing of intestinal adhesion) for acute bowel obstruction	<del>(14.5)</del> 13.2	90	6.0
44010 Duodenotomy for exploration, biopsy(s), or foreign body removal	<del>(14.5)</del> 13.5	60	7.0
44015 Needle catheter jejunostomy for enteral hyperalimentation (list separately in addition to primary procedure)	BR		4.0
44020 Enterotomy, small bowel, other than duodenum, for exploration, biopsy(s); or foreign body removal	<del>(14.5)</del> 13.2	60	4.0
44021 for decompression (e.g. Baker tube)	BR	<del>(60)</del>	4.0
44025 Colotomy, for exploration, biopsy(s), or foreign body removal	<del>(15.0)</del> 14.1	60	4.0
44040 Exteriorization of intestine (Mikulicz resection with crushing of spur)	<del>(18.0)</del> 16.3	60	5.0
44050 Reduction of volvulus, intussusception, internal hernia, by laparotomy	<del>(14.0)</del> 13.1	90	5.0
44055 Correction of malrotation by lysis of duodenal bands and/or reduction of midgut volvulus (e.g., Ladd procedure)	BR	<del>(90)</del>	5.0

EXCISION			ENTEROSTOMY—EXTERNAL FISTULIZATION OF INTESTINES (SEPARATE PROCEDURE)					
	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@	
44100	Biopsy of intestine by capsule, tube, peroral (one or more specimens) . . . . .	<del>(3.0)</del> 2.3	0		44300	Enterostomy, or cecostomy, tube (e.g., for decompression of feeding) . . . . .	<del>(8.5—90)</del> 8.1 60	4.0
44110	Excision of one or more lesions of small or large bowel not requiring anastomosis, exteriorization, or fistulization; single enterotomy . . . . .	<del>(16.0)</del> 13.6	60	4.0	44305	in conjunction with other procedures . . . . .	<del>(2.0—90)</del> 2.1 60	
44111	multiple enterotomies . . . . .	<del>(BR)</del> 15.4	60	4.0	44310	Ileostomy . . . . .	<del>(14.5—90)</del> 13.1 60	4.0
44120	Enterectomy, resection of small intestine; with anastomosis . . . . .	<del>(17.0)</del> 15.9	60	6.0	44312	Revision of ileostomy; simple (release of superficial scar) . . . . .	<del>(BR)</del> 2.5 60	4.0
44125	with double-barrel enterostomy . . . . .	<del>(14.0)</del> 12.7	60	6.0	44314	complicated (reconstruction in depth) . . . . .	<del>(BR)</del> 14.5 60	4.0
44130	Enteroenterostomy, anastomosis of intestine; (separate procedure) . . . . .	<del>(14.5—90)</del> 13.6	60	5.0	44316	Continent ileostomy (Koch procedure) . . . . .	<del>(BR)</del> 19.9 60	4.0
44131	intestinal bypass for morbid obesity noncovered procedure . . . . .	10.8	90			(For fiberoptic evaluation, see 44385)		
44140	Colectomy, partial; with anastomosis . . . . .	<del>(18.0)</del> 16.7	90	5.0	44320	Colostomy or skin level cecostomy (separate procedure) . . . . .	<del>(12.0—90)</del> 10.4 60	4.0
44141	with skin level cecostomy or colostomy . . . . .	<del>(20.0)</del> 18.1	90	6.0	44322	with multiple biopsies (e.g., for Hirschsprung disease) . . . . .	BR ((90))	4.0
44143	with end colostomy and closure of distal segment (Hartmann type procedure) . . . . .	<del>(18.0)</del> 15.8	90	6.0	44340	Revision of colostomy, simple (release of superficial scar) . . . . .	<del>(12)</del> 2.3 90	4.0
44144	with resection, with colostomy or ileostomy and creation of mucofistula . . . . .	<del>(18.0)</del> 15.6	90	6.0	44345	complicated (reconstruction in depth) . . . . .	<del>(6.0)</del> 7.7 60	4.0
44145	with coloproctostomy (low pelvic anastomosis) . . . . .	<del>(24.0)</del> 19.2	90	6.0	44346	with repair of paracolostomy hernia . . . . .	BR ((66))	4.0
44146	with coloproctostomy (low pelvic anastomosis) with colostomy . . . . .	<del>(26.0—90)</del> 20.8	60	6.0		ENDOSCOPY, SMALL BOWEL AND STOMAL		
44147	abdominal and transanal approach . . . . .	BR ((90))	6.0			(For upper gastrointestinal endoscopy, see 43234-43258)		
44150	Colectomy, total, abdominal, with ileostomy or ileoproctostomy; without proctectomy . . . . .	<del>(26.0)</del> 22.6	90	6.0	44360	Small intestinal endoscopy, enteroscopy beyond second portion of duodenum; diagnostic . . . . .	<del>(3.0—7)</del> 4.1 0	3.0
44151	with continent ileostomy . . . . .	<del>(BR)</del> 24.4	90	6.0	44361	for biopsy and/or collection of specimen by brushing or washing for cytology . . . . .	<del>(2.0—7)</del> 4.7 0	3.0
44152	with rectal mucosectomy, ileoanal anastomosis, with or without loop ileostomy . . . . .	<del>(BR)</del> 28.9	90	6.0	44363	with removal of foreign body . . . . .	<del>(BR—7)</del> 4.7 0	3.0
44153	with rectal mucosectomy, ileoanal anastomosis, creation of ileal reservoir (S or J), with or without loop ileostomy . . . . .	<del>(BR)</del> 38.4	90	6.0	44364	with removal of polyps . . . . .	<del>(3.0—7)</del> 5.2 0	3.0
44155	Colectomy, total abdominal, with proctectomy and ileostomy . . . . .	<del>(30.0)</del> 27.1	90	6.0	44366	for control of hemorrhage (e.g., electrocoagulation, laser photocoagulation) . . . . .	<del>(BR)</del> 5.9 0	3.0
44156	with continent ileostomy . . . . .	<del>(BR)</del> 28.9	90	6.0	44369	for ablation of tumor or mucosal lesion (e.g., laser hot biopsy/fulguration) . . . . .	<del>(2.0—7)</del> 5.9 0	3.0
44160	Colectomy with removal of terminal ileum and ileocolostomy . . . . .	<del>(30.0—90)</del> 17.2	60	6.0	44372	for placement of percutaneous jejunostomy tube . . . . .	BR	
					44373	for conversion of percutaneous gastrostomy tube to percutaneous jejunostomy tube . . . . .	BR	
					44380	Fiberoptic ileoscopy through stoma . . . . .	<del>(4.0—7)</del> 3.0 0	3.0

	Unit Value	Follow-up Days=	Basic Anes@
44382 with biopsy and/or collection of specimen by brushing or washing .....	<del>(3.0)</del> 3.5	<del>(7)</del> 0	3.0
44385 Fiberoptic evaluation of small intestinal (cock) or pelvic pouch .	3.0	<del>(7)</del> 0	3.0
44386 for biopsy and/or collection of specimen by brushing or washing .....	BR		3.0
44388 Fiberoptic colonoscopy through colostomy .....	<del>(3.0)</del> 4.1	<del>(7)</del> 0	3.0
44389 with biopsy and/or collection of specimen by brushing or washing .....	<del>(2.5)</del> 4.4	 0	3.0
44390 with removal of foreign body	<del>(3.5)</del> 5.8	 0	3.0
44391 for control of hemorrhage (e.g., electrocoagulation, laser photocoagulation) .....	<del>(3.5)</del> 5.0	 0	3.0
44392 with removal of polypoid lesion(s) .....	<del>(3.5)</del> 5.9	 0	3.0
44393 for ablation of tumor or mucosal lesion (e.g., laser hot biopsy/fulguration) .....	BR		3.0
(For colonoscopy per rectum, see 45360-45386)			

SUTURE

44600 Suture of intestine (enterorrhaphy), large or small, for perforated ulcer, diverticulum, wound, injury or rupture; single .....	<del>(14.0)</del> 12.2	<del>(45)</del> 60	7.0
44605 with colostomy .....	<del>(16.0)</del> 14.2	<del>(90)</del> 60	7.0
44610 multiple .....	<del>(BR)</del> 15.8	 60	7.0
44620 Closure of enterostomy, large or small intestine .....	<del>(10.0)</del> 9.0	<del>(90)</del> 60	5.0
44625 with resection and anastomosis .....	<del>(14.0)</del> 13.1	<del>(90)</del> 60	6.0
44640 Closure of intestinal cutaneous fistula .....	<del>(BR)</del> 11.7	 60	4.0
44650 Closure of enteroenteric or enterocolic fistula .....	<del>(14.0)</del> 12.7	<del>(90)</del> 60	5.0
44660 Closure of enterovesical fistula; without intestinal or bladder resection .....	<del>(14.0)</del> 12.7	<del>(90)</del> 60	5.0
(For closure of renocolic fistula, see 50525, 50526)			
44661 with bowel and/or bladder resection .....	<del>(BR)</del> 19.9	 60	5.0
(For closure of gastrocolic fistula, see 43880)			
(For closure of rectovesical fistula, see 45800-45805)			

44680 Intestinal plication, (separate procedure) .....	<del>(20.0)</del> 16.3	<del>(90)</del> 60	6.0
44799 Unlisted procedure, intestine ..	BR		5.0

AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

WAC 296-22-200 MECKEL'S DIVERTICULUM AND THE MESENTERY.

	Unit Value	Follow-up Days=	Basic Anes@
EXCISION			
44800 Excision of Meckel's diverticulum (diverticulectomy) or omphalomesenteric duct .....	<del>(10.0)</del> 10.8	45	4.0
44820 Excision of lesion of mesentery (separate procedure) (with bowel resection, see 44120 or 44140 et seq.) .....	<del>(BR)</del> 9.0	45	4.0
(With bowel resection, see 44120 or 44140 et seq.)			

SUTURE

44850 Suture of mesentery (separate procedure) .....	<del>(13.0)</del> 9.5	45	4.0
(For reduction and repair of internal hernia, see 44050)			
44899 Unlisted procedure, Meckel's diverticulum and the mesentery ..	BR		4.0

AMENDATORY SECTION (Amending Order 86-19, filed 2/28/86, effective 4/1/86)

WAC 296-22-205 APPENDIX.

	Unit Value	Follow-up Days=	Basic Anes@
INCISION			
44900 Incision and drainage of appendiceal abscess, transabdominal .....	<del>(7.0)</del> 9.0	45	4.0
EXCISION			
44950 Appendectomy; .....	<del>(9.5)</del> 9.0	45	4.0
(For incidental appendectomy, see WAC 296-22-010, item 7b and modifier -52)			
44955 when done for indicated purpose at time of other major procedure (not as separate procedure) .....	<del>(6.0)</del> 0.5	45	4.0
44960 for ruptured appendix with abscess or generalized peritonitis .....	<del>(BR)</del> 9.9	45	4.0

**AMENDATORY SECTION** (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

**WAC 296-22-210 RECTUM.**

	Unit Value	Follow-up Days=	Basic Anes@
<b>INCISION</b>			
45000 Transrectal drainage of pelvic abscess .....	<del>((3.0))</del> 3.2	<del>(15)</del> 0	3.0
45005 Incision and drainage of submucous abscess, rectum....	<del>((4.5))</del> 2.2	<del>(30)</del> 15	3.0
45020 Incision and drainage of deep supralelevator, pelvirectal or retrorectal abscess (see also 46050, 46060) .....	<del>((4.0))</del> 4.1		30 3.0
<b>EXCISION</b>			
45100 Biopsy of anorectal wall, anal approach (e.g., congenital megacolon).....	<del>((4.0))</del> 3.6		15 3.0
(For endoscopic biopsy, see 45305)			
45108 Anorectal myomectomy .....	<del>((BR))</del> 7.2		90 3.0
45110 Proctectomy; complete, combined abdominoperineal, with colostomy, one or two stages .....	<del>((26.0))</del> 25.3		90 7.0
45111 partial resection of rectum ..	<del>((24.0))</del> 19.0		90 7.0
45112 Proctectomy, combined abdominoperineal, pull-through procedure, one or two stages .....	<del>((28.0))</del> 25.3		90 7.0
45114 Proctectomy, partial, with anastomosis; abdominal and transsacral approach, one or two stages .....	<del>((30.0))</del> 23.5		90 7.0
45116 transsacral approach only (Kraske type) .....	<del>((28.0))</del> 19.0		90 7.0
45120 Proctectomy, complete, (e.g., for congenital megacolon Swenson Duhamel, or Soave type operation).....	<del>((26.0))</del> 28.0		90 7.0
45121 with subtotal or total colectomy, with multiple biopsies (e.g., for colonic aganglionosis) .....	BR		
45130 Excision of rectal procidentia, with anastomosis; perineal approach .....	<del>((14.5))</del> 13.6		90 4.0
45135 abdominal and perineal approach .....	<del>((26.0))</del> 22.6		90 6.0
45150 Division of stricture of rectum .	<del>((BR))</del> 9.0		3.0
45160 Excision of rectal tumor by proctotomy, transsacral or transcoccygeal approach .....	<del>((19.0))</del> 17.2		90 3.0
45170 Excision of rectal tumor, transanal approach .....	<del>((BR))</del> 2.7		30 3.0

	Unit Value	Follow-up Days=	Basic Anes@
45180 Excision and/or electrodesiccation of malignant tumor of rectum, transanal approach .....	<del>((BR))</del> 2.7		30 3.0
<b>ENDOSCOPY</b>			
45300 Proctosigmoidoscopy; diagnostic (separate procedures) .....	0.6	0	3.0
45302 for collection of specimen by brushing or washing for cytology .....	<del>((1.0))</del> 1.1	<del>(7)</del> 0	3.0
45303 for dilation, direct, instrumental .....	<del>((1.5))</del> 0.6	<del>(7)</del> 0	3.0
45305 for biopsy, .....	<del>((1.2))</del> 1.1	<del>(7)</del> 0	3.0
45307 for removal of foreign body .	<del>((1.0))</del> 2.7	<del>(7)</del> 0	3.0
45310 for removal of polyp or papilloma .....	<del>((1.4))</del> 1.8	<del>(7)</del> 0	3.0
45315 with removal of multiple excrescences, papillomata or polyps .....	<del>((1.8))</del> 2.2	<del>(7)</del> 0	3.0
45317 for control of hemorrhage (e.g., electrocoagulation, laser photocoagulation) .....	<del>((2.0))</del> 2.7	<del>(7)</del> 0	3.0
45320 for ablation of tumor (e.g., electrocoagulation, laser photocoagulation, hot biopsy/fulguration) .....	BR		
45321 for decompression of volvulus.....	<del>((BR))</del> 2.7		0 3.0
(45325 colonoscopy has been renumbered 45355 without change in terminology)			
45330 Sigmoidoscopy, flexible fiberoptic; diagnostic .....	<del>((0.8))</del> 1.2	<del>(15)</del> 0	3.0
45331 for biopsy and/or collection of specimen by brushing or washing .....	<del>((1.4))</del> 1.6	<del>(15)</del> 0	3.0
45332 for removal of foreign body .	<del>((1.4))</del> 1.6	<del>(15)</del> 0	3.0
45333 with removal of polyp(s) ....	1.8	<del>((15))</del> 0	3.0
45334 for control of hemorrhage (e.g., electrocoagulation, laser photocoagulation) .....	<del>((BR))</del> 1.6		0 3.0
45336 for ablation of tumor or mucosal lesion (e.g., electrocoagulation, laser photocoagulation hot biopsy/fulguration) .	BR		3.0
<del>((45377))</del> <del>((45337))</del> 45337 for decompression of volvulus.....	BR		
45355 Colonoscopy, with standard sigmoidoscope, transabdominal via colotomy, single or multiple	<del>((3.0))</del> 1.4	<del>(7)</del> 0	3.0
45378 Colonoscopy, fiberoptic, beyond splenic flexure; diagnostic procedure .....	<del>((6.0))</del> 6.3	<del>(7)</del> 15	3.0

	Unit Value	Follow-up Days=	Basic Anes@
45379 with removal of foreign body	<del>((7.0-7))</del> 7.7	15	3.0
45380 with biopsy and/or collection of specimen for cytology . . . .	<del>((6.0-7))</del> 6.8	15	3.0
45382 for control of hemorrhage . . .	<del>((7.0-7))</del> 7.2	15	3.0
45383 for ablation of tumor or mucosal lesion (e.g., electrocoagulation, laser photocoagulation, hot biopsy/fulguration)	BR		3.0
45385 for removal of polypoid lesion(s) . . . . .	<del>((7.0-7))</del> 8.1	15	3.0

(For small bowel and stomal endoscopy, see 44360-44393)

REPAIR

45500 Proctoplasty, for stenosis . . . . .	<del>((10.0))</del> 9.0	90	3.0
45505 for prolapse of mucous membrane . . . . .	<del>((11.0))</del> 9.9	90	3.0
45520 Perirectal injection of sclerosing solution for prolapse( <del>(office)</del> ) . . . . .	<del>((11.0))</del> 0.7	0	
<del>((45521 hospital . . . . .</del>	<del>4.0</del>	<del>30</del>	<del>3.0</del> )
45540 Proctopexy for prolapse, abdominal approach . . . . .	<del>((18.0))</del> 15.8	90	4.0
45541 perineal approach . . . . .	<del>((18.0))</del> 16.1	90	3.0
45550 proctopexy combined with sigmoid resection, abdominal approach . . . . .	<del>((22.0))</del> 19.5	90	5.0
45560 Repair of rectocele (separate procedure) . . . . .	<del>((24.0))</del> 6.3	90	5.0

(For repair of rectocele with posterior colporrhaphy, see 57250)

SUTURE

45800 Closure of rectovesical fistula . . . . .	<del>((20.0))</del> 17.2	90	5.0
45805 with colostomy . . . . .	<del>((22.0))</del> 19.0	90	5.0
45820 Closure of rectourethral fistula . . . . .	<del>((20.0))</del> 17.2	90	3.0
45825 with colostomy . . . . .	<del>((22.0))</del> 19.0	90	4.0

(For rectovaginal fistula closure, see 57300-57308)

MANIPULATION

*45900 Reduction of procidentia (separate procedure) under anesthesia . . . . .	<del>((10.6))</del> 2.0	0	3.0
45905* Dilation of anal sphincter (separate procedure) under anesthesia other than local . . . . .	<del>((BR))</del> 1.4	0	3.0
45910 Dilation of rectal stricture (separate procedure) under anesthesia other than local . . . . .	<del>((BR))</del> 1.4	0	3.0

	Unit Value	Follow-up Days=	Basic Anes@
45915* Removal of fecal impaction or foreign body (separate procedure) under anesthesia . . . . .	<del>((BR))</del> 1.4	0	3.0
45999 Unlisted procedure, rectum . . . . .	BR		3.0

AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

WAC 296-22-215 ANUS.

	Unit Value	Follow-up Days=	Basic Anes@
--	------------	-----------------	-------------

INCISION

*46000 Fistulotomy, subcutaneous . . . . .	<del>((10.6-0))</del> 1.4	30	3.0
(For fistulectomy, see 46060, 46270-46285)			
*46030 Removal of seton, other marker . . . . .	<del>((10.6))</del> 0.5	0	
46040 Incision and drainage of ischiorectal and/or perirectal abscess (separate procedure) . . . . .	<del>((2.4))</del> 2.1	15	3.0
46045 Incision and drainage of intramural, intramuscular or submucosal abscess, transanal, under anesthesia . . . . .	<del>((2.4))</del> 2.1	15	3.0
*46050 Incision and drainage, perianal abscess, superficial (see also 45020, 46060) . . . . .	<del>((10.48))</del> 0.7	0	3.0
46060 Incision and drainage of ischiorectal or intramural abscess with fistulectomy, submuscular (see also 45020) . . . . .	<del>((9.5))</del> 9.0	90	3.0
46070 Incision, anal septum (infant) . . . . .	<del>((1.2))</del> 1.4	0	3.0

(For anoplasty, see 46700-46705)

*46080 Sphincterotomy, anal, division of anal sphincter (separate procedure) . . . . .	<del>((1.2-0))</del> 1.1	30	3.0
46083 Incision of thrombosed hemorrhoid, external . . . . .	BR		3.0

EXCISION

46200 Fissurectomy, with or without sphincterotomy . . . . .	<del>((4.8-90))</del> 3.6	60	3.0
46210 Cryptectomy, single . . . . .	1.4	30	3.0
46211 multiple, (separate procedure) . . . . .	<del>((7.0))</del> 4.5	90	3.0
46220 Papillectomy or excision of single tab, anus (separate procedure) . . . . .	<del>((0.6))</del> 0.5	15	3.0
46221 Hemorrhoidectomy, by simple ligature (rubber band) . . . . .	<del>((BR))</del> 1.8	30	3.0
46230 Excision of external hemorrhoid tags and/or multiple papillae . . . . .	<del>((1.2))</del> 1.1	15	3.0

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
46250 Hemorrhoidectomy, external, complete	<del>((4.8))</del> 4.5	90	3.0	46716 Perineal transplant of anovaginal fistula	<del>((14.0-9.0))</del> 3.2	60	4.0
46255 Hemorrhoidectomy, internal and external, simple	<del>((7.0))</del> 7.2	90	3.0	46730 Construction of anus for congenital absence; perineal or sacrococcygeal approach	<del>((16.0))</del> 14.5	90	5.0
46257 with fissurectomy	<del>((BR))</del> 7.7	90	3.0	46735 combined abdominal and perineal approach	<del>((20.0))</del> 22.6	90	7.0
46258 with fistulectomy, with or without fissurectomy	<del>((BR))</del> 8.1	90	3.0	46740 Construction of anus for congenital absence, with repair of urinary fistula	<del>((22.0))</del> 24.4	90	7.0
46260 Hemorrhoidectomy, internal and external, complex or extensive	<del>((10.0))</del> 7.7	90	3.0	46750 Sphincteroplasty, anal, for incontinence, or prolapse; adult	<del>((10.0))</del> 9.5	90	3.0
46261 with fissurectomy	<del>((BR))</del> 7.7	90	3.0	46751 child	<del>((12.0))</del> 9.8	90	4.0
46262 with fistulectomy, with or without fissurectomy	<del>((BR))</del> 8.1	90	3.0	46753 Graft (Thiersch operation) for rectal incontinence and/or prolapse	<del>((BR))</del> 13.6	90	4.0
46270 Fistulectomy; subcutaneous	<del>((2.4))</del> 2.7	30	3.0	46754 Removal of Thiersch wire or suture	<del>((BR))</del> 2.7	90	4.0
46275 submuscular	<del>((9.5))</del> 7.5	90	3.0	46760 Sphinteroplasty, anal, for incontinence, adult, muscle transplant	<del>((BR))</del> 12.7	90	4.0
46280 complex or multiple	<del>((BR+))</del> 9.0	90	3.0	46761 levator muscle imbrication (park posterior anal repair)	BR		
46285 second stage	<del>((2.0))</del> 1.8	30	3.0	46762 implantation artificial sphincter	BR		
*46320 Enucleation or excision of external thrombotic hemorrhoid	<del>((*0.72-0))</del> 1.1	15	3.0	<b>DESTRUCTION</b>			
<b>INTRODUCTION</b>				*46900 Destruction of lesion(s), anus (e.g., condyloma, papilloma, molluscum contagiosum, herpetic vessel, simple chemical	<del>((*0.48-0))</del> 0.5	7	
*46500 Injection of sclerosing solution, hemorrhoids	<del>((*0.4))</del> 0.5	0	3.0	*46910 electrodesiccation	<del>((*0.8-0))</del> 0.7	7	3.0
<b>ENDOSCOPY</b>				46916 cryosurgery	<del>((BR-0))</del> 0.6	7	3.0
*46600 Anoscopy; diagnostic (separate procedure)	<del>((*0.32))</del> 0.3	0	3.0	46917 laser surgery	BR		
46602 for collection of specimen by brushing or washing for cytology	<del>((0.5))</del> 0.3	0	3.0	46922 surgical excision	<del>((BR))</del> 0.9	7	3.0
46604 for dilation, direct, instrumental	<del>((0.7))</del> 0.3	0	3.0	46924 Destruction of lesion(s), anus (e.g., condyloma, papilloma, molluscum, contagiosum, herpetic vessel) extensive, any method	<del>((BR))</del> 4.1	7	3.0
46606 for biopsy	<del>((1.0))</del> 0.5	0	3.0	46934 Destruction of hemorrhoids, any method; internal	<del>((BR))</del> 1.5	15	
46608 for removal of foreign body	<del>((1.5))</del> 0.9	0	3.0	46935 external	<del>((BR))</del> 0.9	15	
46610 for removal of polyp	<del>((1.5))</del> 0.4	0	3.0	46936 internal and external	<del>((BR))</del> 1.3	15	
46612 for multiple polyp removal	<del>((BR))</del> 0.5	0	3.0	46937 Cryosurgery of rectal tumor; benign	<del>((BR))</del> 1.3	15	
46614 with coagulation for control of hemorrhage and/or fulguration of mucosal lesion	<del>((BR))</del> 1.8	0	3.0	46938 malignant	<del>((BR))</del> 2.7	15	3.0
<b>REPAIR</b>				46940 Curettage or cauterization of anal fissure, including dilation of anal sphincter (separate procedure); initial	<del>((BR))</del> 1.8	15	3.0
46700 Anoplasty, plastic operation for stricture; adult	<del>((9.0))</del> 8.1	90	3.0	46942 subsequent	<del>((BR))</del> 1.8	15	
46705 infant	<del>((10.0-30))</del> 9.0	3	4.0	<b>REPAIR</b>			
(For simple incision of anal septum, see 46070)				46715 Repair of congenital anovaginal fistula ("cut-back" type procedure)	<del>((+2.0))</del> 10.8	90	4.0

	Unit Value	Follow-up Days=	Basic Anes@
<b>SUTURE</b>			
46945	Ligation of internal hemorrhoids; single procedure . . . . .	<del>((BR))</del> <u>1.5</u> 15	3.0
46946	multiple procedures . . . . .	<del>((BR))</del> <u>1.3</u> 15	3.0

**OTHER PROCEDURES**

46999	Unlisted procedure, anus . . . . .	BR	3.0
-------	------------------------------------	----	-----

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-220 LIVER.**

	Unit Value	Follow-up Days=	Basic Anes@
<b>INCISION</b>			
*47000	Biopsy of liver, percutaneous needle . . . . .	<del>((+1.4))</del> <u>1.8</u> 0	3.0
	(For CT guidance, see 76360, 76361; for ultrasonic guidance, see 76942, 76943)		
	(For fine needle aspiration, preparation, and interpretation of smears, see 88170-88173)		
47010	Hepatotomy for drainage of abscess or cyst, one or two stages . . . . .	<del>((BR))</del> <u>14.5</u> 60	3.0

**EXCISION**

47100	Biopsy of liver, wedge (separate procedure) . . . . .	<del>((+0.0))</del> <u>9.0</u> 45	4.0
47120	Hepatectomy, resection of liver; partial lobectomy . . . . .	<del>((+9.0))</del> <u>26.2</u> 45	10.0
47122	trisegmentectomy . . . . .	BR	
47125	total left lobectomy . . . . .	<del>((BR))</del> <u>35.2</u> 45	13.0
47130	total right lobectomy . . . . .	<del>((BR))</del> <u>35.2</u> 45	13.0
47133	Donor hepatectomy, with preparation and maintenance of homograft . . . . .	<del>((BR))</del> <u>35.2</u> 13.0	
47135	Liver transplant, with or without recipient hepatectomy . . . . .	BR	15.0

**REPAIR**

47300	Marsupialization of cyst or abscess of liver . . . . .	14.5 60	6.0
-------	--	---------	-----

**SUTURE**

47350	Hepatorrhaphy, suture of liver wound or injury; simple . . . . .	<del>((+4.0))</del> <u>13.6</u> 45	4.0
47355	with common duct or gallbladder drainage . . . . .	<del>((+8.0))</del> <u>16.3</u> 45	7.0
47360	complex, with or without hepatic artery ligation . . . . .	<del>((BR))</del> <u>18.1</u> 45	12.0
47399	Unlisted procedure, liver . . . . .	BR	3.0

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-225 BILIARY TRACT.**

	Unit Value	Follow-up Days=	Basic Anes@
<b>INCISION</b>			
47400	Hepaticotomy or hepaticostomy with exploration, drainage, or removal of calculus . . . . .	<del>((20.0))</del> <u>19.0</u> 45	6.0
47420	Choledochotomy or choledochostomy with exploration, drainage, or removal of calculus, with or without cholecystotomy . . . . .	<del>((+7.0))</del> <u>17.2</u> 45	5.0
47425	with transduodenal sphincterotomy or sphincteroplasty . . . . .	<del>((+9.0))</del> <u>20.3</u> 45	6.0
47440	Duodenocholedochotomy, transduodenal choledocholithotomy . . . . .	<del>((+9.0))</del> <u>20.3</u> 45	6.0
47460	Transduodenal sphincterotomy or sphincteroplasty (separate procedure) . . . . .	19.0 45	6.0
47480	Cholecystotomy or cholecystostomy with exploration, drainage or removal of calculus (separate procedure) . . . . .	<del>((+2.0))</del> <u>11.3</u> 45	5.0
47490	Percutaneous cholecystostomy . . . . .	BR	

**INTRODUCTION**

47500	Injection procedure for percutaneous transhepatic cholangiography . . . . .	<del>((+6))</del> <u>2.2</u> 0	
47510	Introduction of percutaneous transhepatic catheter or stent for biliary drainage . . . . .	<del>((BR))</del> <u>6.3</u> 45	
47525	Change of percutaneous biliary drainage catheter . . . . .	BR	5.0
47530	T-tube revision and/or reinsertion . . . . .	BR	5.0
	(For radiologic guidance, see 75981, 75983)		

**ENDOSCOPY**

47550	Biliary endoscopy, intraoperative (choledochoscopy) . . . . .	<del>((BR))</del> <u>5.0</u> 45	5.0
	(Use 47550 with either 47420 or 47610)		
47552	Biliary endoscopy, percutaneous via T-tube or other tract; diagnostic . . . . .	BR	5.0
47553	for biopsy and/or collection of specimen by brushing or washing . . . . .	BR	5.0
47554	for removal of stone(s) . . . . .	BR	5.0
47555	for dilation of biliary duct stricture . . . . .	BR	5.0
	(For peroral biliary endoscopic procedure see 43260-43272)		

**EXCISION**

47600	Cholecystectomy . . . . .	<del>((+4.5))</del> <u>12.2</u> 45	5.0
47605	with cholangiography . . . . .	<del>((+5.0))</del> <u>16.3</u> 45	5.0

	Unit Value	Follow-up Days=	Basic Anes@
47610 Cholecystectomy with exploration of common duct . . . . .	<del>((17.0))</del> 18.1	<del>45</del>	6.0
47612 with choledochenterostomy .	BR	45	6.0
47620 with transduodenal sphincterotomy or sphincteroplasty [sphincteroplasty], with or without cholangiography . . . . .	<del>((20.0))</del> 19.9	45	6.0
47630 Biliary duct stone extraction, percutaneous via t-tube tract (e.g., Burhenne technique) . . . . .	<del>((BR))</del> 6.3	45	5.0
(For fluoroscopic procedure, see 74327)			
47700 Exploration for congenital atresia of bile ducts, without repair, with or without liver biopsy, with or without cholangiography . . . . .	<del>((14.5))</del> 16.3	45	6.0
47701 Portoenterostomy (e.g., Kasai procedure) . . . . .	BR		
47710 Excision of bile duct tumor, with repair . . . . .	BR		
47715 Excision of choledochal cyst . . . . .	BR		
47716 Anastomosis, choledochal cyst, without excision . . . . .	BR		
<b>REPAIR</b>			
47720 Cholecystoenterostomy; direct . . . . .	<del>((14.5))</del> 13.6	60	5.0
47721 with gastroenterostomy . . . . .	<del>((16.0))</del> 17.2	60	6.0
47740 Roux-en-y . . . . .	<del>((16.0))</del> 15.4	60	6.0
47760 Anastomosis, direct, of extrahepatic biliary ducts and gastrointestinal tract . . . . .	<del>((20.0-90))</del> 19.0	60	6.0
47765 Anastomosis, direct, of intrahepatic ducts and gastrointestinal tract . . . . .	<del>((BR))</del> 18.1	60	6.0
47780 Anastomosis, Roux-en-y of extrahepatic biliary ducts and gastrointestinal tract . . . . .	<del>((22.0-90))</del> 21.7	60	6.0
47800 Reconstruction, plastic, of extrahepatic biliary ducts with end-to-end anastomosis . . . . .	<del>((20.0-90))</del> 19.9	60	6.0
47801 Placement of choledochal stent . . . . .	BR		5.0
47802 U-tube hepaticoenterostomy . . . . .	BR		
<b>OTHER PROCEDURES</b>			
47999 Unlisted procedure, biliary tract . . . . .	BR		5.0

**AMENDATORY SECTION** (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

**WAC 296-22-230 PANCREAS.**

	Unit Value	Follow-up Days=	Basic Anes@
<b>INCISION</b>			
48000 Drainage of abdomen for pancreatitis . . . . .	<del>((13.0))</del> 11.7	60	5.0
48020 Removal of pancreatic calculus . . . . .	<del>((20.0))</del> 18.1	60	6.0
<b>EXCISION</b>			
48100 Biopsy of pancreas (separate procedure) . . . . .	<del>((14.0))</del> 13.6	60	5.0
48102 Biopsy of pancreas, needle, percutaneous . . . . .	<del>((2.5-7))</del> 2.7	0	
(For CT guidance, see 76360, 76361; for ultrasonic guidance, see 76942, 76943)			
(For fine needle aspiration, preparation, and interpretation of smears, see 88170-88173)			
48120 Excision of lesion of pancreas (e.g., cyst, adenoma) . . . . .	<del>((17.0))</del> 15.8	60	6.0
48140 Pancreatectomy, distal subtotal, with or without splenectomy . . . . .	<del>((20.0))</del> 18.1	60	6.0
48145 with pancreaticojejunostomy . . . . .	<del>((22.0))</del> 21.7	60	6.0
48148 Excision of ampulla of Vater, simple . . . . .	<del>((BR))</del> 21.7	60	6.0
48150 Pancreatectomy, proximal subtotal, with pancreaticoduodenotomy (Whipple type procedure and pancreatic jejunostomy) . . . . .	<del>((34.0))</del> 31.6	60	6.0
48151 Pancreatectomy, near-total, with preservation of duodenum (Child type procedure) . . . . .	<del>((BR))</del> 27.1	60	
48155 Pancreatectomy, total . . . . .	<del>((34.0))</del> 30.7	60	6.0
48160 with transplantation . . . . .	BR		6.0
48180 Pancreaticojejunostomy side-to-side anastomosis, Puestow type operation, (separate procedure) . . . . .	<del>((24.0))</del> 22.6	60	6.0
<b>ENDOSCOPY</b>			
(For peroral pancreatic endoscopic procedures see 43260-43272)			
<b>REPAIR</b>			
48500 Marsupialization of cyst of pancreas . . . . .	<del>((14.5))</del> 13.6	60	6.0
48510 External drainage, pseudocyst of pancreas . . . . .	BR		
48520 Internal anastomosis of pancreatic cyst to gastrointestinal tract; direct . . . . .	<del>((17.0))</del> 15.4	60	6.0



	Unit Value	Follow-up Days=	Basic Anes@
48540 Roux-en-y .....	<del>(+9.0)</del> 18.1	60	6.0
48999 Unlisted procedure, pancreas ..	BR		6.0

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-235 ABDOMEN, PERITONEUM AND OMENTUM.**

	Unit Value	Follow-up Days=	Basic Anes@
<b>INCISION</b>			
49000 Exploratory laparotomy, exploratory celiotomy with or without biopsy(s) (separate procedure) (see WAC 296-22-010, item 7b) .....	<del>(+10.0)</del> 9.0	45	6.0
49002 Reopening of recent laparotomy incision for exploration; removal of hematoma, control of bleeding .....	<del>(+10.0)</del> 7.2	45	7.0
49010 Exploration, retroperitoneal area with or without biopsy(s) (separate procedure) .....	<del>(+10.0)</del> 9.0	45	6.0
49020 Drainage of peritoneal abscess or localized peritonitis, exclusive of appendiceal abscess, transabdominal .....	<del>(+11.0)</del> 9.9	45	6.0
(For appendiceal abscess, see 44900)			
49040 Drainage of subdiaphragmatic or subphrenic abscess .....	<del>(+12.0)</del> 11.7	45	7.0
49060 Drainage of retroperitoneal abscess .....	<del>(+11.0)</del> 9.9	45	7.0
*49080 Peritoneocentesis, abdominal paracentesis or peritoneal lavage; initial .....	<del>(+10.8)</del> 1.4	0	4.0
*49081 subsequent .....	<del>(+10.6)</del> 1.2	0	4.0
49085 Removal of peritoneal foreign body .....	<del>(BR)</del> 9.0	45	6.0
(For lysis of intestinal adhesions, see 44000)			

**EXCISION AND DESTRUCTION**

*49180 Biopsy, abdominal or retroperitoneal mass, needle, percutaneous .....	<del>(2.5-7)</del> 2.7		0
(For CT guidance, see 76360, 76361, 76365, 76366; for ultrasonic guidance, see 76942, 76943)			
(For fine needle aspiration, preparation, and interpretation of smears, see 76942, 76943)			

	Unit Value	Follow-up Days=	Basic Anes@
49200 Excision or destruction by any method of intraabdominal or retroperitoneal tumors or cysts or endometriomas .....	<del>(+14.0)</del> 12.7	60	5.0
49201 extensive .....	<del>(BR)</del> 19.0	60	5.0
49215 Excision of presacral or sacrococcygeal tumor .....	BR		
49220 Staging celiotomy (laparotomy) for Hodgkin's disease or lymphoma (includes splenectomy, needle or open biopsies of both liver lobes, possibly also removal of abdominal nodes, abdominal node and/or bone marrow biopsies, ovarian repositioning) ....	<del>(BR-45)</del> 19.9	60	5.0
49250 Umbilectomy, omphalectomy, excision of umbilicus (separate procedure) .....	<del>(BR)</del> 7.2	60	5.0
49255 Omentectomy, epiploectomy, resection of omentum (separate procedure) .....	<del>(BR)</del> 9.0	60	5.0

**ENDOSCOPY**

49300 Peritoneoscopy; without biopsy ..	<del>(4.0-15)</del> 4.1	0	3.0
49301 with biopsy .....	<del>(6.0-10)</del> 4.3	0	5.0
49302 Peritoneoscopy with guided transhepatic cholangiography; without biopsy .....	<del>(7.0-10)</del> 4.5	0	5.0
49303 with biopsy .....	<del>(8.0-10)</del> 4.3	0	5.0
(For sterilization by laparoscopic technique, see 58982)			

**INTRODUCTION AND REVISION**

*49400 Pneumoperitoneum (separate procedure); initial .....	<del>(+1.0)</del> 1.1	0	3.0
*49401 subsequent .....	*0.6	0	3.0
*49420 Insertion of intraperitoneal cannula or catheter for drainage or dialysis; temporary .....	<del>(+1.0)</del> 1.4	0	3.0
49421 permanent .....	<del>(BR)</del> 2.7	0	3.0
49425 Peritoneal-venous shunt (e.g., LeVeen shunt) .....	<del>(BR)</del> 11.3	30	3.0
49426 Revision of peritoneal-venous shunt .....	BR		3.0
(For shunt patency test, see 78291)			

**REPAIR**

**HERNIOPLASTY, HERNIORRHAPHY, HERNIOTOMY**

(For reduction and repair of intra-abdominal hernia, see 44050)  
 (For debridement of abdominal wall, see 11042, 11043)  
 (All codes for bilateral procedures in hernia repair have been deleted. To report, add modifier -50)

	Unit Value	Follow-up Days=	Basic Anes@
49500 Repair inguinal hernia, under age 5 years, with or without hydrocelectomy; unilateral . . . . .	<del>((7.0))</del> 7.2	45	3.0
49505 Repair inguinal hernia, age 5 or over; unilateral . . . . .	<del>((9.0))</del> 7.7	45	4.0
49510 Repair of inguinal hernia, age 5 or over; unilateral, with orchiectomy, with or without implantation of prosthesis . . . . .	<del>((9.5))</del> 8.0	45	3.0
49515 with excision of hydrocele or spermatocele . . . . .	<del>((9.5))</del> 8.6	45	3.0
49520 recurrent . . . . .	<del>((10.0))</del> 9.9	45	4.0
49525 sliding . . . . .	<del>((10.0))</del> 8.1	45	3.0
49530 incarcerated . . . . .	<del>((12.0))</del> 9.0	45	3.0
49535 strangulated . . . . .	<del>((12.0))</del> 8.1	45	3.0
49540 Repair lumbar hernia . . . . .	<del>((10.0))</del> 9.3	45	3.0
49550 Repair femoral hernia, groin incision; unilateral . . . . .	<del>((9.0))</del> 8.0	45	3.0
49552 Repair femoral hernia, Henry approach; unilateral . . . . .	<del>((10.0))</del> 8.0	45	3.0
49555 Repair femoral hernia, recurrent, any approach . . . . .	<del>((10.0))</del> 9.5	45	3.0
49560 Repair ventral hernia (separate procedure) . . . . .	<del>((11.0))</del> 10.4	45	6.0
49565 recurrent . . . . .	<del>((12.0))</del> 11.7	45	3.0
49570 Repair epigastric hernia, peritoneal fat (separate procedure); simple . . . . .	<del>((3.0))</del> 3.6	45	3.0
49575 complex . . . . .	<del>((7.0))</del> 5.0	45	3.0
49580 Repair umbilical hernia; under age 5 years . . . . .	<del>((7.0))</del> 6.3	45	3.0
49581 age 5 or over . . . . .	<del>((8.5))</del> 7.2	45	4.0
49590 Repair spigelian hernia . . . . .	<del>((9.0))</del> 8.1	45	3.0
49600 Repair of omphalocele; small, with primary closure . . . . .	9.5	45	6.0
49605 large or gastroschisis, with or without prosthesis . . . . .	<del>((14.5))</del> 13.6	60	9.0
49606 with staged closure of prosthesis, reduction in operating room, under anesthesia . . . . .	BR		9.0
49610 Repair of omphalocele (Gross type operation); first stage . . . . .	<del>((12.0))</del> 10.8	60	8.0
49611 second stage . . . . .	<del>((12.0))</del> 10.8	60	7.0

(For diaphragmatic or hiatal hernia repair, see 39502-39541)  
(For surgical repair of omentum, use 49999)

SUTURE

	Unit Value	Follow-up Days=	Basic Anes@
49900 Suture, secondary, of abdominal wall for evisceration or dehiscence . . . . .	<del>((6.0))</del> 5.6	30	5.0
(For suture of ruptured diaphragm, see 39540-39541)			
(For debridement of abdominal wall, see 11042, 11043)			
49999 Unlisted procedure, abdomen, peritoneum and omentum . . . . .	BR		5.0

AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

WAC 296-22-245 KIDNEY.

	Unit Value	Follow-up Days=	Basic Anes@
INCISION			
(For retroperitoneal exploration, abscess, tumor, or cyst, see 49010, 49060, 49200, 49201)			
50010 Renal exploration, not necessitating other specific procedures . . . . .	<del>((17.0))</del> 13.6	90	6.0
50020 Drainage of perirenal or renal abscess (separate procedure) . . . . .	<del>((14.0))</del> 12.2	90	5.0
50040 Nephrostomy, nephrotomy with drainage . . . . .	<del>((20.0))</del> 16.3	90	5.0
50045 Nephrotomy, with exploration . . . . .	<del>((20.0))</del> 16.3	90	5.0
(For renal endoscopy performed in conjunction with this procedure, see 50570-50580)			
50060 Nephrolithotomy; removal of calculus . . . . .	<del>((20.0))</del> 18.1	90	5.0
50065 secondary surgical operation for calculus . . . . .	<del>((24.0))</del> 22.6	90	5.0
50070 complicated by congenital kidney abnormality . . . . .	<del>((24.0))</del> 22.6	90	5.0
50075 removal of large (staghorn calculus filling renal pelvis and calyces including anatomic pyelolithotomy) . . . . .	<del>((26.0))</del> 23.5	90	5.0
50080 Percutaneous nephrostolithotomy or pyelostolithotomy, with or without dilation, endoscopy, lithotripsy, stenting or basket extraction; up to 2 cm . . . . .	<del>((BR))</del> 18.1		5.0
50081 over 2 cm . . . . .	<del>((BR))</del> 20.8		5.0

(For establishment of nephrostomy without nephrostolithotomy, see 50040, 50395 or 52334)

	Unit Value	Follow-up Days=	Basic Anes@
50100 Transection or repositioning of aberrant renal vessels (separate procedure) . . . . .	<del>(17.0)</del> 14.7	90	5.0
50120 Pyelotomy; with exploration . . . . .	<del>(20.0)</del> 17.2	90	5.0
(For renal endoscopy performed in conjunction with this procedure, see 50570-50580)			
50125 with drainage, pyelostomy . . . . .	<del>(20.0)</del> 17.2	90	5.0
50130 with removal of calculus (pyelolithotomy, pelviolithotomy including coagulum pyelolithotomy) . . . . .	<del>(20.0)</del> 18.1	90	5.0
50135 complicated (e.g., secondary operation, congenital kidney abnormality) . . . . .	<del>(24.0)</del> 22.6	90	5.0

EXCISION

(For excision of retroperitoneal tumor or cyst, see 49200, 49201)

*50200 Renal biopsy, percutaneous; by trocar or needle . . . . .	<del>(2.4-7)</del> 2.5	0	0
--	---------------------------	---	---

(For CT guidance, see 76360, 76361; for fluoroscopic guidance, see 76000; for ultrasonic guidance, see 76942, 76943)

(For fine needle aspiration, preparation, and interpretation of smears, see 88170-88173)

50205 by surgical exposure of kidney . . . . .	<del>(8.0)</del> 7.2	30	5.0
50220 Nephrectomy, including partial ureterectomy, any approach including rib resection . . . . .	<del>(20.0)</del> 22.6	90	5.0
50225 complicated because of previous surgery on same kidney . . . . .	<del>(24.0)</del> 21.4	90	5.0
50230 radical, with regional lymphadenectomy . . . . .	<del>(26.0)</del> 29.4	90	5.0
50234 Nephrectomy with total ureterectomy and bladder cuff; through same incision . . . . .	<del>(24.0)</del> 21.7	90	5.0
50236 through separate incision . . . . .	<del>(24.0)</del> 22.6	90	5.0
50240 Nephrectomy, partial . . . . .	<del>(24.0)</del> 21.7	90	5.0
50280 Excision or unroofing of cyst(s) of kidney . . . . .	<del>(18.0)</del> 14.5	90	5.0
50290 Excision of perinephric cyst . . . . .	<del>(18.0)</del> 14.5	90	5.0

RENAL TRANSPLANTATION

(For dialysis, see 90941-90999)

50300 Donor nephrectomy, with preparation and maintenance of homograft; from cadaver donor, unilateral or bilateral . . . . .	<del>(BR+)</del> 27.1	0	0
---	--------------------------	---	---

50320 from living donor, unilateral . . . . .	<del>(24.0)</del> 29.4	90	5.0
50340 Recipient nephrectomy (separate procedure)( <del>(unilateral)</del> ) . . . . .	<del>(20.0)</del> 22.6	90	5.0
<del>(50341)</del> bilateral . . . . .	<del>30.0</del>	<del>90</del>	<del>5.0</del>
50360 Renal homotransplantation, implantation of graft; excluding donor and recipient nephrectomy . . . . .	<del>(30.0-180)</del> 33.9	90	6.0
50365 with ( <del>(unilateral)</del> ) recipient nephrectomy . . . . .	<del>(50.0-180)</del> 45.2	90	6.0
<del>(50366)</del> with bilateral recipient nephrectomy . . . . .	<del>50.0-180-6.0</del>		
50370 Removal of transplanted homograft (e.g., infarcted or rejected kidney) . . . . .	<del>(13.0-60)</del> 18.1	90	6.0
50380 Renal autotransplantation, reimplantation of kidney . . . . .	<del>(30.0-120)</del> 33.9	90	6.0

(For extra-corporeal "bench" surgery, use autotransplantation as the primary procedure and add the secondary procedure e.g., partial nephrectomy, nephrolithotomy, and use the modifier -51)

INTRODUCTION

*50390 Aspiration and/or injection of renal cyst or pelvis by needle, percutaneous . . . . .	<del>(2.5-7)</del> 2.3	0	0
--	---------------------------	---	---

(For CT guidance, see 76365, 76366)

(For fluoroscopic guidance, see 76000; for ultrasonic guidance, see 76938, 76939; for radiologic guidance, see 74000)

(For fine needle aspiration, preparation, and interpretation of smears, see 88170-88173)

50392 Introduction of intracatheter or catheter into renal pelvis for drainage and/or injection, percutaneous . . . . .	<del>(2.5-7)</del> 4.5	0	0
---	---------------------------	---	---

(For fluoroscopic guidance see 76000; for ultrasonic guidance see 76938)

(For radiographic procedure, see 74475, 74476)

50393 Introduction of ureteral catheter or stent into ureter through renal pelvis for drainage and/or injection, percutaneous . . . . .	<del>(2.5-7)</del> 3.6	0	3.0
---	---------------------------	---	-----

(For fluoroscopic guidance, see 76000; for ultrasonic guidance, see 76938)

(For radiographic procedure, see 74480, 74481)

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
				<b>ENDOSCOPY</b>			
				(For supplies and materials, use 99070)			
50394				50551			
Injection procedure for pyelography (as nephrostogram, pyelostogram, antegrade pyeloureterograms) through nephrostomy or pyelostomy tube, or indwelling ureteral catheter (separate procedure) . . . . .	.3	0		Renal endoscopy through established nephrostomy or pyelostomy, with or without irrigation, instillation, or ureteropyelography, exclusive of radiologic service . . . . .	<del>(2.0)</del> 2.3	<del>(3)</del> 0	
50395				50553			
Introduction of guide into renal pelvis and/or ureter with dilation to establish nephrostomy tract, percutaneous . . . . .	<del>(DR)</del> 4.5	0	3.0	with ureteral catheterization with or without dilation of ureter . . . . .	<del>(2.0)</del> 2.5	<del>(3)</del> 0	3.0
(For nephrostolithotomy, see 50080, 50081)				50555 with biopsy . . . . .			
(For retrograde percutaneous nephrostomy, use 52334)				50557 with fulguration and/or incision, with or without biopsy . . . . .			
(For endoscopic surgery, see 50551-51561)				50559 with insertion of radioactive substance with or without biopsy and/or fulguration . . . . .			
50396				50561			
Manometric studies through nephrostomy or pyelostomy tube, or indwelling ureteral catheter . . . . .	.4	0		with removal of foreign body or calculus . . . . .	<del>(2.0)</del> 2.5	<del>(3)</del> 0	3.0
50398*				When procedures 50570-50580 provide a significant identifiable service, they may be added to 50045 and 50120			
Change of nephrostomy or pyelostomy tube . . . . .	<del>(3)</del> .4	0		50570			
				Renal endoscopy through nephrotomy or pyelotomy, with or without irrigation, instillation, or ureteropyelography, exclusive of radiologic service . . . . .	<del>(1.4)</del> 1.8	<del>(3)</del> 0	
<b>REPAIR</b>				(For nephrotomy, see 50045)			
50400				(For pyelotomy, see 50120)			
Pyeloplasty; (Foley Y-pyeloplasty), plastic operation on renal pelvis, with or without plastic operation on ureter or nephropexy, nephrostomy, pyelostomy, or uretral splinting; simple . . . . .	<del>(22.0)</del> 21.2	90	5.0	50572			
50405				with ureteral catheterization with or without dilation of ureter . . . . .	<del>(1.8)</del> 2.1	<del>(3)</del> 0	
complicated (congenital kidney abnormality, secondary pyeloplasty, solitary kidney calycolplasty) . . . . .	<del>(26.0)</del> 23.5	90	5.0	50574			
				with biopsy . . . . .	<del>(1.8)</del> 2.1	<del>(3)</del> 0	
				50576			
				with fulguration and/or incision, with or without biopsy . . . . .	<del>(2.0)</del> 2.1	<del>(3)</del> 0	
				50578			
				with insertion of radioactive substance, with or without biopsy and/or fulguration . . . . .	<del>(2.4)</del> 2.1	<del>(3)</del> 0	
				50580			
				with removal of foreign body or calculus . . . . .	<del>(2.0)</del> 2.1	<del>(3)</del> 0	
<b>SUTURE</b>				<b>OTHER PROCEDURES</b>			
50500				50590			
Nephrorrhaphy, suture of kidney wound or injury . . . . .	<del>(20.0)</del> 19.9	90	8.0	Lithotripsy, extracorporeal shock wave . . . . .	<del>(DR)</del> 45.2		90
50520							
Closure of nephrocutaneous or pyelocutaneous fistula . . . . .	<del>(20.0)</del> 20.3	90	5.0				
50525							
Closure of nephrovisceral fistula e.g., including visceral repair abdominal approach . . . . .	<del>(24.0)</del> 21.7	90	5.0				
50526							
thoracic approach . . . . .	<del>(24.0)</del> 21.7	90	11.0				
(For supplemental skills of two surgeons, see WAC 296-22-010, item 5b, and modifier -62)							
50540							
Symphysiotomy for horseshoe kidney with or without pyeloplasty and/or other plastic procedure, unilateral or bilateral (one operation) . . . . .	<del>(28.0)</del> 24.8	90	5.0				

AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

WAC 296-22-250 URETER.

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
<b>INCISION</b>				50700	Ureteroplasty: Plastic operation on ureter (e.g., stricture) . . . . . ((20-0))	90	5.0
50600	Ureterotomy with exploration or drainage (separate procedure) . ((18-0))	16.7	90	5.0	18.1	90	5.0
	(For ureteral endoscopy performed in conjunction with this procedure, see 50970-50980)						
50605	Ureterotomy for insertion of indwelling stent, all types . . . . . ((BR))	16.7		5.0	16.3	90	5.0
	(For ureteral endoscopy performed in conjunction with this procedure, see 50970-50980)				24.0	<del>90</del>	<del>5.0</del>
50610	Ureterolithotomy; upper one-third or ureter . . . . . ((20-0))	17.7	90	5.0	16.3	90	5.0
	(For transvesical ureterolithotomy, see 51060)				24.0	<del>90</del>	<del>5.0</del>
50620	middle one-third of ureter . . ((18-0))	16.7	90	5.0	12.7	90	5.0
	(For cystotomy with stone basket extraction of ureteral calculus, see 51065)						
50630	lower one-third . . . . . ((20-0))	18.1	90	5.0	22.6	90	5.0
	(For endoscopic extraction or manipulation of ureteral calculus, see 50080, 50081, 50561, 50961, 50980, 52320-52330, 52336, 52337)						
<b>EXCISION</b>				50722	Ureterolysis for ovarian vein syndrome . . . . . ((16-0))	90	5.0
	(For ureterocele, see 51535, 51536, 52300)						
50650	Ureterectomy, with bladder cuff (separate procedure) . . . . . ((20-0))	18.1	90	5.0	19.9	90	5.0
	(When combined with cystourethroplasty or vasical neck revision, see 51820)						
50660	Ureterectomy, total, ectopic ureter, combination abdominal, vaginal and/or perineal approach ((22-0))	25.3	90	7.0	22.6	90	5.0
<b>INTRODUCTION</b>				50725	Ureterolysis for retrocaval ureter, with reanastomosis of upper urinary tract or vena cava . . . . . ((26-0))	90	5.0
50684	Injection procedure for ureterography or ureteropyelography through ureterostomy or indwelling ureteral catheter (separate procedure) . . . . . ((0-3))	0.4	0		22.6	90	5.0
	(For supplemental skills of two surgeons, see WAC 296-22-010, item 5b, and modifier -62)						
50686	Manometric studies through ureterostomy or indwelling ureteral catheter . . . . . ((0-4))	0.5	0		20.8	90	5.0
50688*	Change of ureterostomy tube . . ((0-3))	0.9	0		22.1	90	5.0
50690	Injection procedure for visualization of ilial conduit and/or ureteropyelography, exclusive of radiologic service (separate procedure) . . . . . ((0-4))	0.5	0		20.2	90	5.0
	(For supplemental skills of two surgeons, see WAC 296-22-010, item 5b, and modifier -62)				26.0	<del>90</del>	<del>5.0</del>
<b>REPAIR</b>				50740	Ureteropyelostomy anastomosis of ureter and renal pelvis . . . . . ((22-0))	90	5.0
	(When substantial ureteral tapering is required for the following procedures, use modifier -22)						
					19.9	90	5.0
					22.6	90	5.0
					20.8	90	5.0
					22.1	90	5.0
					20.2	90	5.0
					26.0	<del>90</del>	<del>5.0</del>
					22.1	90	5.0
					20.2	90	5.0
					26.0	<del>90</del>	<del>5.0</del>
					28.5	120	6.0
					BR		
					26.2	120	6.0
					34.0	<del>120</del>	<del>6.0</del>

	Unit Value	Follow-up Days=	Basic Anes@
50825 Continent diversion, including bowel anastomosis (Kock pouch or Camey enterocystoplasty) ..	<del>(30.0)</del> <u>BR</u>	120	6.0
(For combination of 50800-50821 with cystectomy, see 51580-51595)			
50830 Urinary undiversion (e.g., taking down of ureteroileal conduit, ureterosigmoidostomy or ureterentorostomy with ureteroureterostomy or ureteroneocystostomy).	<del>(BR)</del> <u>45.2</u>	120	6.0
50840 Replacement of all or part of ureter by bowel segment, including bowel anastomosis( <del>unilateral</del> ) ..	<del>(30.0)</del> <u>26.2</u>	120	6.0
<del>((50841 bilateral ..</del>	<del>40.0</del>	<del>120</del>	<del>6.0)</del>
50860 Ureterostomy, transplantation of ureter to skin( <del>unilateral</del> ) ..	<del>(18.0)</del> <u>16.4</u>	90	5.0
<del>((50861 bilateral ..</del>	<del>22.0</del>	<del>90</del>	<del>5.0)</del>

SUTURE

50900 Ureterorrhaphy, suture of ureter (separate procedure) ..	<del>(20.0)</del> <u>18.1</u>	90	5.0
50920 Closure of ureterocutaneous fistula ..	<del>(20.0)</del> <u>18.1</u>	90	5.0
50930 Closure of ureterovisceral fistula (including visceral repair) ..	<u>20.8</u>	90	5.0
50940 Deligation of ureter ..	<del>(BR)</del> <u>9.0</u>	0	5.0

(For ureteroplasty, ureterolysis, etc., see 50700-50861)

ENDOSCOPY

50951 Ureteral endoscopy through established ureterostomy, with or without irrigation, instillation, or ureteropyelography, exclusive of radiologic service ..	<del>(2.5-3)</del> <u>2.0</u>	0	
50953 with ureteral catheterization with or without dilation of ureter ..	<del>(2.5-3)</del> <u>2.3</u>	0	
50955 with biopsy ..	<del>(2.5-3)</del> <u>2.3</u>	0	
50957 with fulguration and/or incision, with or without biopsy ..	<del>(2.5-3)</del> <u>2.3</u>	0	
50959 with insertion of radioactive substance with or without biopsy and/or fulguration (not including provision of material) ..	<del>(2.5-3)</del> <u>2.4</u>	0	
50961 with removal of foreign body or calculus ..	<del>(2.5-3)</del> <u>2.3</u>	0	

When procedures 50970-50980 provide a significant identifiable service, they may be added to 50600

	Unit Value	Follow-up Days=	Basic Anes@
50970 Ureteral endoscopy through ureterotomy, with or without irrigation, instillation, or ureteropyelography, exclusive of radiologic service ..	<del>(1.3-3)</del> <u>2.1</u>	0	
(For ureterotomy, see 50600)			
50972 with ureteral catheterization with or without dilation of ureter ..	<del>(1.8-3)</del> <u>2.3</u>	0	
50974 with biopsy ..	<del>(1.8-3)</del> <u>2.3</u>	0	
50976 with fulguration and/or incision, with or without biopsy ..	<del>(2.0-3)</del> <u>2.3</u>	0	
50978 with insertion of radioactive substance, with or without biopsy and/or fulguration (not including provision of material) ..	<del>(2.4-3)</del> <u>2.3</u>	0	
50980 with removal of foreign body or calculus ..	<del>(2.0-3)</del> <u>2.3</u>	0	

AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

WAC 296-22-255 BLADDER.

	Unit Value	Follow-up Days=	Basic Anes@
INCISION			
51000 Aspiration of bladder by needle ..	<del>(0.4)</del> <u>0.5</u>	0	
*51005 Aspiration of bladder; by trocar or intracatheter ..	<del>(4.0)</del> <u>0.5</u>	0	
51010 with insertion of suprapubic catheter ..	<del>(2.0-30)</del> <u>1.5</u>	0	5.0
51020 Cystotomy or cystostomy; with fulguration and/or insertion of radioactive material ..	<del>(14.5)</del> <u>11.7</u>	90	5.0
51030 with cryosurgical destruction of intravesical lesion ..	<del>(14.5)</del> <u>12.0</u>	90	5.0
51040 Cystostomy, cystotomy with drainage ..	<del>(12.0)</del> <u>10.8</u>	90	5.0
51045 Cystotomy, with insertion of ureteral catheter or stent (separate procedure) ..	<del>(14.5)</del> <u>9.5</u>	90	5.0
51050 Cystolithotomy, cystotomy with removal of calculus, without vesical neck resection ..	<del>(14.5)</del> <u>10.8</u>	90	5.0
51060 Transvesical ureterolithotomy ..	<del>(19.0)</del> <u>19.9</u>	90	5.0
51065 Cystotomy, with stone basket extraction and/or ultrasonic or electro-hydraulic fragmentation of ureteral calculus ..	<del>(12.0-30)</del> <u>19.9</u>	90	5.0

	Unit Value	Follow-up Days=	Basic Anes@
51080 Drainage of perivesical or prevesical space abscess . . . . .	<del>((8-0))</del> 7.2	90	5.0
<b>EXCISION</b>			
51500 Excision of urachal cyst or sinus, with or without umbilical hernia repair . . . . .	<del>((14-0))</del> 12.7	90	5.0
51520 Cystotomy; for simple excision of vesical neck (separate procedure) . . . . .	<del>((16-0-90))</del> 13.6	30	5.0
51525 for excision of bladder diverticulum, single or multiple (separate procedure) . . . . .	<del>((20-0))</del> 18.1	90	5.0
51530 for excision of bladder tumor . . . . .	<del>((16-0))</del> 13.6	90	5.0
(For transurethral excision, see 52200-52240)			
51535 Cystotomy for excision, incision or repair of ureterocele( <del>unilateral</del> ) . . . . .	<del>((16-0))</del> 13.6	90	5.0
<del>((51536 bilateral . . . . .</del>	<del>18.0</del>	<del>90</del>	<del>5.0</del> )
(For transurethral excision, see 52300)			
51550 Cystectomy, partial; simple . . . . .	<del>((18-0))</del> 15.4	90	6.0
51555 complicated (e.g., postradiation, previous surgery, difficult location) . . . . .	<del>((20-0))</del> 18.1	90	6.0
51565 Cystectomy, partial, with reimplantation of ureter(s) into bladder (ureter- <del>oneocystostomy</del> ) . . . . .	<del>((24-0))</del> 22.1	90	6.0
51570 Cystectomy, complete; (separate procedure) . . . . .	<del>((26-0))</del> 23.0	90	6.0
51575 with bilateral pelvic lymphadenectomy, including external iliac, hypogastric and obturator nodes . . . . .	<del>((34-0))</del> 33.9	90	6.0
51580 Cystectomy, complete with ureterosigmoidotomy or ureterocutaneous transplantations . . . . .	<del>((34-0-120))</del> 36.1	70	7.0
51585 with bilateral pelvic lymphadenectomy, including external iliac, hypogastric and obturator nodes . . . . .	<del>((40-0-120))</del> 40.7	90	7.0
51590 Cystectomy, complete, with ureteroileal conduit or sigmoid bladder, including bowel anastomosis . . . . .	<del>((44-0-120))</del> 45.2	90	7.0
51595 with bilateral lymphadenectomy, including external iliac, hypogastric and obturator nodes . . . . .	<del>((50-0-120))</del> 48.8	90	7.0
51596 Cystectomy, complete, with continent diversion, including bowel anastomosis (e.g., Kock pouch, Camey enterocystoplasty . . . . .	<del>((44-0))</del> BR	120	7.0

	Unit Value	Follow-up Days=	Basic Anes@
51597 Pelvic exenteration, complete, for vesical, prostatic or urethral malignancy, with removal of bladder and ureteral transplantations, with or without hysterectomy and/or abdominoperineal resection of rectum and colon and colostomy, or any combination thereof . . . . .	<del>((BR))</del> 52.4	90	7.0

**INTRODUCTION**

(For bladder catheterization, see 53670-53675)

51600 Injection procedure for cystography or voiding urethrocystography . . . . .	<del>((0-2))</del> 0.3	0	
51605 Injection procedure and placement of chain for contrast and/or chain urethrocystography . . . . .	0.4	0	
51610 Injection procedure for retrograde urethrocystography . . . . .	0.3	0	
(For injection procedure for retroperitoneal pneumography, see 49430)			
*51700 Bladder irrigation, simple, lavage and/or instillation . . . . .	*0.2	0	
51705* Change of cystostomy tube; simple . . . . .	<del>((0-3))</del> 0.5	0	
51710* complicated . . . . .	<del>((BR))</del> 2.3	0	
51720 Bladder instillation of anticarcinogenic agent (including detention time) . . . . .	<del>((0-8))</del> 0.7	0	

**URODYNAMICS**

The following section (51725-51796) lists procedures that may be used separately or in many and varied combinations. When multiple procedures are performed in the same investigative session, modifier '-51' should be employed.

All procedures in this section imply that these services are performed by, or are under the direct supervision of, a physician and that all instruments, equipment, fluids, gases, probes, catheters, technician's fees, medications, gloves, trays, tubing and other sterile supplies be provided by the physician. When the physician only interprets the results and/or operates the equipment, a p.c. (professional component modifier '-26') should be used to identify physicians' services.

	Unit Value	Follow-up Days=	Basic Anes@
51725 Simple cystometrogram (CMG) (e.g., spinal manometer) . . . . .	<del>((BR))</del> 1.2	0	
51726 Complex cystometrogram (e.g., calibrated electronic equipment)	1.4	0	
51736 Simple uroflowmetry (UFR) (e.g., stop-watch flow rate, mechanical uroflowmeter) . . . . .	<del>((BR))</del> 0.3	0	
51739 Sound recording of external stream (e.g., Lyons type, Keitzer type) . . . . .	<del>((BR))</del> 0.3	0	

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
51741 Complex uroflowmetry (e.g., calibrated electronic equipment) . . . . .	<del>((8))</del> 0.5	0		(For closure of vesicoenteric fistula, see 44660, 44661)			
51772 Urethral pressure profile, studies (UPP) (urethral closure pressure profile), any technique gas or liquid; initial recording . . . . .	<del>((BR))</del> 1.4	0		(For closure of rectovesical fistula, see 45800-45805)			
51785 Electromyographic studies (EMG) of anal or urethral sphincter, any technique . . . . .	<del>((BR))</del> 1.9	0		51940 Closure of exstrophy (see also 54390) . . . . .	<del>((BR))</del> 40.7	90	5.0
51792 Stimulus evoked response (e.g., measurement of bulbocavernosus reflex latency time) . . . . .	<del>((BR))</del> 2.7	0		51960 Enterocystoplasty, including bowel anastomosis . . . . .	<del>((30-0))</del> 27.1	90	5.0
51795 Voiding pressure studies (VP); bladder voiding pressure, any technique . . . . .	<del>((BR))</del> 1.2	0		51980 Cutaneous vesicostomy . . . . .	<del>((18-0))</del> 16.3	90	5.0
51797 intraabdominal voiding pressure (AP) (rectal, gastric, intraperitoneal) . . . . .	1.7	0					
<b>REPAIR</b>				<b>ENDOSCOPY - CYSTOSCOPY, URETHROSCOPY, CYSTOUR-ETHROSCOPY</b>			
51800 Cystoplasty or cystourethroplasty, plastic operation on bladder and/or vesical neck (anterior Y-plasty, vesical fundus resection), any procedure, with or without wedge resection of posterior vesical neck . . . . .	<del>((20-0))</del> 18.1	90	5.0	<b>NOTES</b>			
51820 Cystourethroplasty with unilateral or bilateral ureteroneocystostomy . . . . .	<del>((30-0))</del> 27.1	90	5.0	Endoscopic descriptions are listed so that the main procedure can be identified without having to list all the minor related functions performed at the same time. For example: Meatotomy, urethral calibration and/or dilation, urethroscopy, and cystoscopy prior to a transurethral resection of prostate; ureteral catheterization following extraction of ureteral calculus; internal urethrotomy and bladder neck fulguration when performing a cystourethroscopy for the female urethral syndrome. When the secondary procedure requires significant additional time and effort, it may be identified by the addition of modifier '-22.' For example: Urethrotomy performed for a documented preexisting stricture or bladder neck contracture.			
51840 Anterior vesicourethropexy, or urethropexy (Marshall-Marchetti-Krantz type); simple . . . . .	<del>((14-5))</del> 13.1	90	4.0	52000 Cystourethroscopy (separate procedure) . . . . .	<del>((12-7))</del> 1.8	0	3.0
51841 complicated (e.g., secondary repair) . . . . .	<del>((21-0))</del> 16.3	90	4.0	52005 with ureteral catheterization, with or without irrigation, instillation, or ureteropyelography, exclusive of radiologic service . . . . .	<del>((16-7))</del> 2.7	0	3.0
(For urethropexy (Peyreya type), see 57289)				52007 with brush biopsy of ureter and/or renal pelvis . . . . .	<del>((BR-3))</del> 3.6	0	3.0
51845 Abdomino-vaginal vesical neck suspension, with or without endoscopic control (e.g., Stamey, Raz, modified Pereyra) . . . . .	<del>((BR))</del> 18.1		4.0	52010 with ejaculatory duct catheterization . . . . .	<del>((16-7))</del> 2.7	0	3.0
51860 Cystorrhaphy, suture of bladder wound, injury or rupture; simple . . . . .	<del>((14-5))</del> 13.1	90	4.0	<b>TRANSURETHRAL SURGERY (URETHRA AND BLADDER)</b>			
51865 complicated . . . . .	<del>((BR+))</del> 16.3		6.0	52204 Cystourethroscopy, with biopsy . . . . .	<del>((2-0))</del> 2.7	7	3.0
51880 Closure of cystostomy (separate procedure) . . . . .	<del>((8-0))</del> 5.9	90	3.0	52214 Cystourethroscopy, with fulguration (including cryosurgery or laser surgery) of trigone, bladder neck, prostatic fossa, urethra, or periurethral glands . . . . .	<del>((2-0))</del> 2.7	7	3.0
51900 Closure of vesicovaginal fistula, abdominal approach . . . . .	<del>((22-0))</del> 27.1	90	5.0	52224 Cystourethroscopy, with fulguration (including cryosurgery or laser surgery) or treatment of MINOR (less than 0.5 cm) lesion(s), with or without biopsy . . . . .	<del>((2-0))</del> 2.7	7	3.0
(For vaginal approach, see 57320-57330)				52234 Cystourethroscopy, with fulguration (including cryosurgery or laser surgery) and/or resection of; SMALL bladder tumor(s) (0.5 to 2.0 cm) . . . . .	<del>((5-0-30))</del> 5.2	15	3.0
51920 Closure of vesicouterine fistula . . . . .	<del>((20-0))</del> 17.2	90	5.0	52235 MEDIUM bladder tumor(s) (2.0-5.0 cm) . . . . .	<del>((12-0))</del> 10.8	30	3.0
51925 with hysterectomy . . . . .	<del>((20-0))</del> 22.6	90	5.0	52240 LARGE bladder tumor(s) . . . . .	<del>((18-0))</del> 16.3	30	5.0



	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
52250 Cystourethroscopy with insertion of radioactive substance, with or without biopsy or fulguration . . .	<del>(6.0)</del> 3.6	<del>30</del> 7	3.0	<b>TRANSURETHRAL SURGERY (URETER AND PELVIS)</b>			
52260 Cystourethroscopy, with dilation of bladder for interstitial cystitis; general or conduction (spinal) anesthesia . . . . .	<del>(3.0)</del> 2.7	<del>30</del> 7	3.0	52320 Cystourethroscopy (including ureteral catheterization); with removal of ureteral calculus . . . . .	<del>(7.0)</del> 6.8	<del>30</del> 15	3.0
52265 local anesthesia . . . . .	<del>(1.4)</del> 2.7	<del>7</del> 30	3.0	52325 with fragmentation of ureteral calculus (e.g. ultrasonic or electro-hydraulic technique) . . . . .	BR	<del>(30)</del>	3.0
52270 Cystourethroscopy, with internal urethrotomy; female . . . . .	<del>(4.0)</del> 2.7	<del>45</del> 15	3.0	52330 with manipulation, without removal of ureteral calculus . . . . .	<del>(5.0)</del> 4.5	<del>30</del> 15	3.0
52275 male . . . . .	<del>(4.0)</del> 3.2	<del>45</del> 15	3.0	52332 cystourethroscopy, with insertion of indwelling ureteral stent (e.g., Gibbons or double J type) . . . . .	<del>(BR)</del> 4.5	<del>7</del> 15	3.0
52276 Cystourethroscopy, with direct vision internal urethrotomy . . . . .	<del>(4.0)</del> 7.2	<del>45</del> 30	3.0	52334 Cystourethroscopy with insertion of ureteral guide wire through kidney to establish a percutaneous nephrostomy, retrograde . . . . .	BR		3.0
52277 Cystourethroscopy, with resection of external sphincter (sphincterotomy) . . . . .	<del>(6.0)</del> 7.7		3.0	(For percutaneous nephrostolithotomy, see 50080, 50081; for establishment of nephrostomy tract only, see 50395)			
52281 Cystourethroscopy, with calibration and/or dilation of urethral stricture or stenosis, with or without meatotomy and injection procedure for cystography, male or female . . . . .	<del>(2.4)</del> 2.7	<del>7</del> 0	3.0	52335 Cystourethroscopy, with ureteroscopy and/or pyeloscopy (includes dilation of the ureter by any method) . . . . .	<del>(4.2)</del> 11.3	<del>7</del>	3.0
52283 Cystourethroscopy, with steroid injection into stricture . . . . .	<del>(2.0)</del> 2.5	<del>7</del> 0	3.0	52336 with removal or manipulation of calculus (ureteral catheterization is included) . . . . .	<del>(BR)</del> 14.5		3.0
52285 Cystourethroscopy for treatment of the female urethral syndrome with any or all of the following: Urethral meatotomy, urethral dilation, internal urethrotomy, lysis of urethrovaginal septal fibrosis, lateral incisions of the bladder neck, and fulguration of urethral polyp(s), bladder neck, and/or trigone . . . . .	<del>(3.4)</del> 2.7	<del>7</del> 15	3.0	52337 with lithotripsy (ureteral catheterization is included) . . . . .	<del>(BR)</del> 16.3		3.0
52290 Cystourethroscopy; with ureteral meatotomy, unilateral or bilateral . . . . .	<del>(4.0)</del> 3.6	<del>30</del> 15	3.0	52338 with biopsy and/or fulguration of lesion . . . . .	<del>(BR)</del> 15.8		3.0
52300 with resection or fulguration of ureterocele, unilateral or bilateral . . . . .	<del>(6.0)</del> 5.4	<del>30</del> 15	3.0	<b>TRANSURETHRAL SURGERY (VESICAL NECK AND PROSTATE)</b>			
52305 with incision or resection of orifice of bladder diverticulum, single or multiple . . . . .	<del>(6.0)</del> 5.4	<del>30</del> 15	3.0	52340 Cystourethroscopy, with incision, fulguration or resection of bladder neck and/or posterior urethra (congenital valves, obstructive hypertrophic mucosal folds) . . . . .	<del>(6.0)</del> BR	<del>30</del> 90	3.0
52310 Cystourethroscopy, with removal of foreign body, calculus or ureteral stent from urethra or bladder (separate procedure); simple . . . . .	<del>(4.0)</del> 3.6	<del>30</del> 15	3.0	52500 Transurethral resection of bladder neck, (separate procedure) . . . . .	<del>(10.0)</del> 9.0		4.0
52315 complicated . . . . .	<del>(BR)</del> 6.8	<del>+</del> 15	3.0	52601 Transurethral resection of prostate, including control of postoperative bleeding during the hospitalization, complete (vasectomy, meatotomy, cystourethroscopy, urethral calibration and/or dilation, and internal urethrotomy are included) . . . . .	<del>(20.0)</del> 18.1	90	5.0
52317 Litholapaxy: Crushing or fragmentation of calculus by any means in bladder and removal of fragments, simple; small (less than 2.5 cm) . . . . .	<del>(BR)</del> 9.0	<del>30</del> 15	3.0	(For other approaches, see 55801-55845)			
52318 complicated or large (over 2.5 cm) . . . . .	<del>(BR)</del> 12.5	<del>30</del> 15	3.0	52606 Transurethral fulguration for postoperative bleeding occurring after the usual follow-up time . . . . .	<del>(2.4)</del> 3.4	0	

	Unit Value	Follow-up Days=	Basic Anes@
52612 Transurethral resection of prostate; first stage of two-stage resection (partial resection) . . . . .	<del>((15.0))</del> 20.8	90	5.0
52614 second stage of two-stage resection (resection completed) . . . . .	<del>((11.0))</del> 5.4	90	5.0
52620 Transurethral resection; of residual obstructive tissue after 90 days postoperative . . . . .	<del>((6.0))</del> 5.4	90	5.0
52630 of regrowth of obstructive tissue longer than one year postoperative . . . . .	<del>((20.0))</del> 18.1	90	5.0
52640 of postoperative bladder neck contracture . . . . .	<del>((10.0))</del> 9.0	90	5.0
52650 Transurethral cryosurgical removal of prostate (postoperative irrigations and aspirations of sloughing tissue included) . . . . .	<del>((20.0—120))</del> 18.1	90	5.0
52700 Transurethral drainage of prostatic abscess . . . . .	<del>((8.0))</del> 7.2	60	5.0

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-260 URETHRA.**

(For endoscopy, see cystoscopy, urethroscopy, cystourethroscopy, 52000-52700)

(For injection procedure for urethrocytography, see 51600-51610)

	Unit Value	Follow-up Days=	Basic Anes@
<b>INCISION</b>			
53000 Urethrotomy or urethrostomy, external (separate procedure) pendulous urethra . . . . .	<del>((2.4))</del> 2.2	15	3.0
53010 perineal urethra, external . . . . .	<del>((6.0))</del> 5.4	30	3.0
53020 Meatotomy, cutting of meatus (separate procedure), except infant . . . . .	<del>((1.0))</del> 1.8	15	3.0
53025 Infant . . . . .	0.6	15	3.0
53040 Drainage of deep periurethral abscess . . . . .	<del>((3.0))</del> 2.7	30	3.0
(For subcutaneous abscess, see 10060-10061)			
53060 Drainage of Skene's gland abscess or cyst . . . . .	1.2	15	3.0
53080 Drainage of perineal urinary extravasation; uncomplicated (separate procedure) . . . . .	<del>((4.0—15))</del> 3.6	0	3.0
53085 complicated . . . . .	<del>((BR+))</del> 10.8	0	5.0

**EXCISION**

53200 Biopsy of urethra . . . . .	<del>((2.0))</del> 1.8	7	3.0
53210 Urethrectomy, total, including cystostomy; female . . . . .	<del>((14.0))</del> 12.7	60	5.0
53215 male . . . . .	<del>((18.0))</del> 16.5	60	5.0
53220 Excision or fulguration of carcinoma of urethra . . . . .	<del>((BR+))</del> 9.0	60	3.0
53230 Excision of urethral diverticulum (separate procedure); female . . . . .	<del>((10.0))</del> 11.7	60	3.0
53235 male . . . . .	<del>((12.0))</del> 11.7	60	3.0
53240 Marsupialization of urethral diverticulum, male or female . . . . .	<del>((4.0—30))</del> 3.6	15	3.0
53250 Excision of bulbourethral gland (Cowper's gland) . . . . .	<del>((12.0—60))</del> 3.6	15	3.0
53260 Excision or fulguration; urethral polyp(s), distal urethra . . . . .	<del>((1.0))</del> 0.9	15	3.0
(For endoscopic approach, see 52212-52224)			
53265 urethral caruncle . . . . .	<del>((1.2))</del> 1.8	15	3.0
53270 Skene's glands . . . . .	<del>((1.2))</del> 1.8	15	3.0
53275 urethral prolapse . . . . .	<del>((3.0—30))</del> 2.8	15	3.0

**REPAIR**

(For hypospadias, see 54300-54352)			
53400 Urethroplasty; first stage, for fistula, diverticulum, or stricture, (e.g., Johanssen type) . . . . .	<del>((10.0))</del> 9.0	60	3.0
53405 second stage (formation of urethra), including urinary diversion . . . . .	<del>((14.0))</del> 13.1	60	3.0
53410 Urethroplasty, one-stage reconstruction of male anterior urethra . . . . .	<del>((16.0))</del> 14.5	60	3.0
53415 Urethroplasty, transpubic or perineal, one stage, for reconstruction or repair of prostatic or membranous urethra . . . . .	<del>((BR))</del> 21.7		3.0
53420 Urethroplasty, two-stage reconstruction or repair of prostatic or membranous urethra; first stage . . . . .	<del>((20.0))</del> 18.1	60	3.0
53425 second stage . . . . .	<del>((20.0))</del> 18.1	90	3.0
53430 Urethroplasty, reconstruction of female urethra . . . . .	<del>((14.0))</del> 12.7	90	3.0
53440 Operation for correction of male urinary incontinence, with or without introduction of prosthesis . . . . .	<del>((20.0))</del> 18.1	90	3.0

	Unit Value	Follow-up Days=	Basic Anes@
53442 Removal of perineal prosthesis introduced for continence . . . . .	<del>((BR-90))</del> 4.5	60	3.0
53443 Urethroplasty with tubularization of posterior urethra and/or lower bladder for incontinence (e.g., Tenago, Leadbetter procedure) . . . . .	<del>((BR))</del> 19.9		3.0
53445 Operation for correction of urinary incontinence with placement of inflatable urethral or bladder neck sphincter, including placement of pump and/or reservoir. . . . .	<del>((BR))</del> 24.4	90	3.0
53447 Removal, repair or replacement of inflatable sphincter including pump and/or reservoir and/or cuff . . . . .	<del>((BR-90))</del> 5.4	60	3.0
53449 Surgical correction of hydraulic abnormality of inflatable sphincter device . . . . .	<del>((BR))</del> 8.1	90	3.0
53450 Urethromeatoplasty, with mucosal advancement . . . . .	<del>((4-0))</del> 3.6	30	3.0
53460 Urethromeatoplasty, with partial excision of distal urethral segment (Richardson type procedure) . . . . .	<del>((3-4))</del> 4.5	30	3.0

SUTURE

53502 Urethrorrhaphy, suture of urethral wound or injury, female . . . . .	<del>((BR))</del> 9.2	30	3.0
53505 Urethrorrhaphy, suture of urethral wound or injury; penile . . . . .	<del>((10-0-90))</del> 9.2	30	3.0
53510 perineal . . . . .	<del>((14-0))</del> 12.2	90	3.0
53515 prostatomembranous . . . . .	<del>((20-0))</del> 18.1	90	3.0
53520 Closure of urethrostomy or urethrocutaneous fistula, male (separate procedure) . . . . .	<del>((6-0))</del> 5.4	90	3.0
(For closure of urethrovaginal fistula, see 57310)			
(For closure of urethrorectal fistula, see 45820, 45825)			

MANIPULATION

*53600 Dilation of urethral stricture by passage of sound or urethral dilator, male; initial . . . . .	<del>((*0-4))</del> 0.5	0	
*53601 subsequent . . . . .	<del>((*0-3))</del> 0.4	0	
53605 Dilation of urethral stricture or vesical neck by passage of sound or urethral dilator, male, general or conduction (spinal) anesthesia . . . . .	<del>((1-6-3))</del> 1.5	0	3.0
*53620 Dilation of urethral stricture by passage of filiform and follower, male; initial . . . . .	*0.8	0	

	Unit Value	Follow-up Days=	Basic Anes@
*53621 subsequent . . . . .	<del>((*0-6))</del> 0.5	0	
*53640 Passage of filiform and follower for acute vesical retention, male . . . . .	<del>((*0-8))</del> 0.7	0	
*53660 Dilation of female urethra including suppository and/or instillation; initial . . . . .	<del>((*0-4))</del> 0.5	0	
*53661 subsequent . . . . .	<del>((*0-3))</del> 0.4	0	
53665 dilation of female urethra, general or conduction (spinal) anesthesia . . . . .	<del>((1-5-3))</del> 1.2	0	3.0
53670* Catheterization; simple . . . . .	0.3	0	
53675* complicated (may include difficult removal of balloon catheter) . . . . .	<del>((0-7))</del> 0.5	0	
53899 Unlisted procedure, urinary system . . . . .	BR		3.0

AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

WAC 296-22-265 PENIS.

	Unit Value	Follow-up Days=	Basic Anes@
INCISION			
54000 Slitting of prepuce, dorsal or lateral, (separate procedure); newborn . . . . .	<del>((0-6-7))</del> 0.7	0	
54001 except newborn . . . . .	<del>((1-4-7))</del> 1.3	0	3.0
54015 Incision and drainage of penis, deep . . . . .	<del>((1-4-15))</del> 1.2	0	3.0
DESTRUCTION			
*54050 Destruction of lesion(s), penis, (e.g., condyloma, papilloma, molluscum, contagiosum, herpetic vesicle), simple, chemical . . . . .	<del>((*0-3))</del> 0.4	0	3.0
*54055 electrodesiccation . . . . .	<del>((*0-8-0))</del> 0.7	7	3.0
54056 cryosurgery . . . . .	<del>((BR))</del> 0.9	7	3.0
54057 laser surgery . . . . .	<del>((BR))</del> 1.8	7	3.0
*54060 surgical excision . . . . .	<del>((*1-0-0))</del> 1.8		3.0
54065 extensive, any method . . . . .	<del>((BR))</del> 2.4	7	3.0
(For destruction or excision of other lesions, see integumentary system)			
EXCISION			
54100 Biopsy of penis, cutaneous (separate procedure) . . . . .	<del>((0-6))</del> 0.9	7	3.0
54105 deep structures . . . . .	<del>((1-4-15))</del> 1.3	7	3.0

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@		
54110	Excision of penile plaque (Peyronie disease) . . . . .	<del>(7.4)</del> 7.5	30	3.0	54300	Plastic operation of penis for straightening of chordee (e.g., hypospadias), with or without mobilization of urethra . . . . .	<del>(8.0-60)</del> 7.2	30	3.0
54111	with graft to 5 cm in length . . . . .	<del>(BR)</del> 16.7	30	3.0	54304	Plastic operation on penis for correction of chordee or for first stage hypospadias repair with or without transplantation of prepuce and/or skin flaps . . . . .	<del>(BR)</del> 12.7	30	3.0
54112	with graft greater than 5 cm in length . . . . .	<del>(BR)</del> 18.5	30	3.0	54308	Urethroplasty for second stage hypospadias repair (including urinary diversion); less than 3 cm . . . . .	<del>(BR)</del> 12.7	30	3.0
54115	Removal foreign body from deep penile tissue (e.g., plastic implant) . . . . .	<del>(6.0-45)</del> 5.0	30	3.0	54312	greater than 3 cm . . . . .	<del>(BR)</del> 14.5		3.0
54120	Amputation of penis, partial . . . . .	<del>(10.0-60)</del> 9.0	30	3.0	54316	Urethroplasty for second stage hypospadias repair (including urinary diversion) with free skin graft obtained from site other than genitalia . . . . .	<del>(BR)</del> 16.3		3.0
54125	complete . . . . .	<del>(20.0-60)</del> 18.1	90	3.0	54318	Urethroplasty for third stage hypospadias repair to release penis from scrotum (e.g., third stage Cecil repair) . . . . .	<del>(BR)</del> 9.0		3.0
54130	Amputation of penis, radical; with bilateral inguino-femoral lymphadenectomy . . . . .	<del>(26.0)</del> 25.3	90	3.0	54322	One stage distal hypospadias repair (with or without chordee or circumcision); with simple meatal advancement (e.g., Magpi, V-flap) . . . . .	<del>(BR)</del> 10.8		3.0
54135	in continuity with bilateral pelvic lymphadenectomy, including external iliac, hypogastric and obturator nodes . . . . .	<del>(30.0)</del> 30.7	90	5.0	54324	with urethroplasty by local skin flaps (e.g., flip-flap, prepuce flap) . . . . .	<del>(BR)</del> 12.7		3.0
	(For lymphadenectomy (separate procedure), see 38760-38771)				54326	with urethroplasty by local skin flaps and mobilization of urethra . . . . .	<del>(BR)</del> 14.5		3.0
54150	Circumcision, clamp procedure; newborn . . . . .	<del>(0.8)</del> 0.7	15		54328	with extensive dissection to correct chordee and urethroplasty with local skin flaps, skin graft patch, and/or island flap . . . . .	<del>(BR)</del> 18.5		3.0
54152	except newborn . . . . .	<del>(1.0)</del> 0.9	15	3.0	54332	One stage proximal penile or penoscrotal hypospadias repair requiring extensive dissection to correct chordee and urethroplasty by use of skin graft tube and/or island flap . . . . .	<del>(BR)</del> 20.8		3.0
54160	Circumcision, surgical excision other than clamp or dorsal slit; newborn . . . . .	<del>(0.8)</del> 0.9	30		54336	One stage perineal hypospadias repair requiring extensive dissection to correct chordee and urethroplasty by use of skin graft tube and/or island flap . . . . .	<del>(BR)</del> 23.9		3.0
54161	except newborn . . . . .	<del>(3.0)</del> 2.7	30	3.0	54340	Repair of hypospadias complications (i.e., fistula, stricture, diverticula); by closure, incision, or excision, simple . . . . .	<del>(BR)</del> 9.5		3.0
<b>INTRODUCTION</b>					54344	requiring mobilization of skin flaps and urethroplasty with flap or patch graft . . . . .	<del>(BR)</del> 14.5		3.0
*54200	Injection procedure for Peyronie disease . . . . .	<del>(4.0)</del> 0.5	0						
54205	with surgical exposure of plaque . . . . .	<del>(7.4-30)</del> 4.5	0	3.0					
54220	Irrigation of corpora cavernosa for priapism . . . . .	<del>(BR)</del> 1.6	0	3.0					
54230	Injection procedure for corpora cavernosography . . . . .	<del>(BR)</del> 1.3	7	3.0					
54235	Injection of corpora cavernosa with pharmacological agent(s) (e.g., papaverine, phentolamine, etc.) . . . . .	<del>(+)</del> 1.3	7	2.5					
54240	penile plethysmography . . . . .	<del>(BR)</del> 1.3	7	3.0					
54250	Nocturnal penile tumescence and/or rigidity test . . . . .	<del>(BR)</del> 1.8		3.0					
<b>REPAIR</b>									
	(For other urethroplasties, see 53400-53430)								

	Unit Value	Follow-up Days=	Basic Anes@
54348 requiring extensive dissection and urethroplasty with flap, patch or tubed graft (includes urinary diversion) . . . . .	<del>(BR)</del> 18.1		3.0
54352 Repair of hypospadias cripple requiring extensive dissection and excision of previously constructed structures including re-release of chordee and reconstruction of urethra and penis by use of local skin as grafts and island flaps and skin brought in as flaps or grafts . . . . .	<del>(BR)</del> 30.3		3.0
54360 Plastic operation on penis to correct angulation . . . . .	<del>(BR)</del> 14.5	90	3.0
54380 Plastic operation on penis for epispadias distal to external sphincter . . . . .	<del>(BR+)</del> 7.2	30	3.0
54385 with incontinence . . . . .	BR	30	4.0
54390 with exstrophy of bladder . . . . .	BR	30	4.0
54400 Insertion of penile prosthesis, noninflatable (semirigid) . . . . .	<del>(+4-0)</del> 10.8	30	3.0
54401 inflatable (self-contained) . . . . .	<del>(+5)</del> BR	90	3.0
54402 Removal or replacement of noninflatable (semp-rigid) or inflatable (self-contained) penile prosthesis . . . . .	BR		
54405 Insertion of inflatable (multicomponent) penile prosthesis, including placement of pump, cylinders and/or reservoir . . . . .	<del>(BR)</del> 22.6	90	3.0
54407 Removal, repair or replacement of inflatable (multicomponent) penile prosthesis, including pump and/or reservoir and/or cylinders . . . . .	<del>(BR)</del> 5.4	90	3.0
55409 Surgical correction of hydraulic abnormality of inflatable prosthesis, including pump and/or reservoir and/or cylinders . . . . .	<del>(BR)</del> 6.8	90	3.0
54420 Corpora cavernosa-saphenous vein shunt (priapism operation), unilateral or bilateral . . . . .	<del>(+0-0)</del> 11.3	30	3.0
54430 Corpora cavernosa-corpora spongiosum shunt or corpora cavernosa-glans penis shunt (priapism operation), unilateral or bilateral . . . . .	<del>(+0-0)</del> 11.3	30	3.0
54435 Corpora cavernosa-glans penis fistulization (e.g., biopsy needle, Winter procedure, rongeur, or punch) for priapism . . . . .	<del>(BR)</del> 2.7		3.0
54440 Plastic operation of penis for injury . . . . .	BR		3.0

MANIPULATION

	Unit Value	Follow-up Days=	Basic Anes@
54450 Foreskin manipulation including lysis of preputial adhesions and stretching . . . . .	<del>(BR)</del> 0.5	0	3.0

AMENDATORY SECTION (Amending Order 83-23, filed 8/2/83)

WAC 296-22-270 TESTIS.

	Unit Value	Follow-up Days=	Basic Anes@
<b>EXCISION</b>			
54500 Biopsy of testis, needle (separate procedure) . . . . .	0.4	<del>(7)</del> 0	
54505 Biopsy of testis, incisional, (separate procedure) <del>(unilateral)</del> . . . . .	<del>(3-0)</del> 2.8	<del>15)</del> 0	3.0
<del>(54506 bilateral)</del> . . . . .	<del>4.0</del>	<del>15</del>	<del>3.0)</del>
(When combined with vasogram, seminal vesiculogram or epididymogram, see 55300)			
54510 Excision of local lesion of testis . . . . .	<del>(6-0)</del> 5.4	30	3.0
54520 Orchiectomy, simple, (including subcapsular), with or without testicular prosthesis, scrotal or inguinal approach <del>(unilateral)</del> . . . . .	<del>(6-0)</del> 5.7	30	3.0
<del>(54521 bilateral)</del> . . . . .	<del>8.0</del>	<del>30</del>	<del>3.0)</del>
54530 Orchiectomy, radical, for tumor; inguinal approach . . . . .	<del>(8-0)</del> 8.6	30	3.0
54535 with abdominal exploration . . . . .	<del>(+2-0)</del> 11.3	45	4.0
(For orchiectomy with repair of hernia, see 49510)			
(For radical retroperitoneal lymphadenectomy, see 38780)			
54550 Exploration for undescended testis (inguinal or scrotal area) <del>(unilateral)</del> . . . . .	<del>(8-0)</del> 7.5	30	4.0
<del>(54555 bilateral)</del> . . . . .	<del>12.0</del>	<del>30</del>	<del>4.0)</del>
54560 Exploration for undescended testis with abdominal exploration <del>(unilateral)</del> . . . . .	<del>(+2-0)</del> 10.4	30	4.0
<del>(54565 bilateral)</del> . . . . .	<del>15.0</del>	<del>30</del>	<del>5.0)</del>
<b>REPAIR</b>			
54600 Reduction of torsion of testis, surgical, with or without fixation of contralateral testis . . . . .	<del>(8-0)</del> 9.0	30	3.0
54620 Fixation of contralateral testis (separate procedure) . . . . .	<del>(4-0)</del> 3.6	30	3.0
54640 Orchiopexy, any type, with or without hernia repair <del>(unilateral)</del> . . . . .	<del>(+2-0)</del> 9.9	30	3.0
<del>(54641 bilateral)</del> . . . . .	<del>18.0</del>	<del>30</del>	<del>4.0)</del>
54645 second stage (Torek type) . . . . .	<del>(2-0)</del> 1.8	30	3.0

	Unit Value	Follow-up Days=	Basic Anes@
54660 Insertion of testicular prosthesis (separate procedure)((- unilateral))	<del>(4.0)</del> 3.6	30	3.0
<del>((54661 bilateral</del>	<del>6.0</del>	<del>30</del>	<del>3.0)</del>
54670 Suture or repair of testicular injury	<del>(8.0)</del> 7.2	30	3.0
54680 Transplantation of testis(es) to thigh (because of scrotal destruction)	<del>(10.0)</del> 9.0	30	3.0

**AMENDATORY SECTION (Amending Order 86-19, filed 2/28/86, effective 4/1/86)**

**WAC 296-22-275 EPIDIDYMIS.**

	Unit Value	Follow-up Days=	Basic Anes@
<b>INCISION</b>			
54700 Incision and drainage of epididymis, testis and/or scrotal space (abscess or hematoma)	<del>(1.4)</del> 1.3	7	3.0

	Unit Value	Follow-up Days=	Basic Anes@
<b>EXCISION</b>			
54800 Biopsy of epididymis, needle	0.4	7	
(For fine needle aspiration, preparation, and interpretation of smears, see 88170-88173)			
54820 Exploration of epididymis with or without biopsy	<del>(6.0)</del> 5.1	30	3.0
54830 Excision of local lesion of epididymis	<del>(6.0)</del> 5.4	30	3.0
54840 Excision of spermatocele with or without epididymectomy	<del>(8.0)</del> 7.2	45	3.0

(With hernia repair, see 49515)

54860 Epididymectomy, unilateral	<del>(8.0)</del> 7.2	45	3.0
54861 bilateral	<del>(10.0)</del> 10.8	45	3.0

	Unit Value	Follow-up Days=	Basic Anes@
<b>REPAIR</b>			
54900 Epididymovasostomy, anastomosis of epididymis to vas deferens; unilateral	<del>(10.0)</del> 18.1	90	3.0
54901 bilateral	<del>(14.0)</del> 27.1	90	3.0

(For microsurgical repair with use of operating microscope, add modifier -20)

**AMENDATORY SECTION (Amending Order 80-25, filed 12/3/80, effective 3/1/81)**

**WAC 296-22-280 TUNICA VAGINALIS.**

	Unit Value	Follow-up Days=	Basic Anes@
<b>INCISION</b>			
*55000 Puncture aspiration of hydrocele, with or without injection of medication	<del>(6.0)</del> 0.3	0	

	Unit Value	Follow-up Days=	Basic Anes@
<b>EXCISION</b>			
55040 Excision of hydrocele; unilateral	<del>(8.0)</del> 7.2	45	3.0
55041 bilateral	<del>(12.0)</del> 12.7	45	3.0

(With hernia repair, see 49515)

	Unit Value	Follow-up Days=	Basic Anes@
<b>REPAIR</b>			
55060 Repair of hydrocele (Bottle type)	<del>(6.0)</del> 5.5	45	3.0

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-285 SCROTUM.**

	Unit Value	Follow-up Days=	Basic Anes@
<b>INCISION</b>			
*55100 Drainage of scrotal wall abscess (see also 54700)	<del>(4.0)</del> 0.5	0	3.0
55110 Scrotal exploration	<del>(BR)</del> 4.5		3.0
55120 Removal of foreign body in scrotum	<del>(BR)</del> 1.8	0	3.0

	Unit Value	Follow-up Days=	Basic Anes@
<b>EXCISION</b>			
(For excision of local lesion of skin of scrotum, see integumentary system)			
55150 Resection of scrotum	<del>(BR)</del> 2.7	30	3.0

	Unit Value	Follow-up Days=	Basic Anes@
<b>REPAIR</b>			
55175 Scrotoplasty; simple	<del>(BR)</del> 7.2	30	3.0
55180 complicated	<del>(BR)</del> 10.8		3.0

**AMENDATORY SECTION (Amending Order 86-19, filed 2/28/86, effective 4/1/86)**

**WAC 296-22-290 VAS DEFERENS.**

	Unit Value	Follow-up Days=	Basic Anes@
<b>INCISION</b>			
55200 Vasotomy, cannulization with or without incision of vas, unilateral or bilateral (separate procedure)	<del>(3.6)</del> 3.3	30	3.0

	Unit Value	Follow-up Days=	Basic Anes@
<b>EXCISION</b>			
55250 Vasectomy, unilateral or bilateral (separate procedure), including postoperative semen examination(s).....	<del>((3.6))</del> <u>4.1</u>	30	3.0

	Unit Value	Follow-up Days=	Basic Anes@
<b>INTRODUCTION</b>			
55300 Vasotomy for vasograms, seminal vesiculograms, or epididymograms, unilateral or bilateral ...	<del>((3.6))</del> <u>3.3</u>	30	3.0
(When combined with 54505 or 54506, apply WAC 296-22-010, item 7a)			
(For radiographic procedure, see 74440, 74441)			

	Unit Value	Follow-up Days=	Basic Anes@
<b>REPAIR</b>			
55400 Vasovasostomy, vasovasorrhaphy( <del>(unilateral)</del> )	<del>((10.0))</del> <u>18.1</u>	90	3.0
<del>((55401 bilateral</del> .....	<del>14.0</del>	<del>90</del>	<del>3.0</del> )
(For microsurgical repair with use of operating microscope, add modifier -20)			

	Unit Value	Follow-up Days=	Basic Anes@
<b>SUTURE</b>			
55450 Ligation (percutaneous) of vas deferens, unilateral or bilateral (separate procedure) .....	1.2	30	3.0

**AMENDATORY SECTION (Amending Order 80-25, filed 12/3/80, effective 3/1/81)**

**WAC 296-22-295 SPERMATIC CORD.**

	Unit Value	Follow-up Days=	Basic Anes@
<b>EXCISION</b>			
55500 Excision of hydrocele of spermatic cord, unilateral (separate procedure) .....	<del>((6.0))</del> <u>5.4</u>	45	3.0
55520 Excision of lesion of spermatic cord (separate procedure) .....	<del>((6.0))</del> <u>5.4</u>	30	3.0
55530 Excision of varicocele or ligation of spermatic veins for varicocele; (separate procedure) .....	<del>((8.0))</del> <u>7.2</u>	45	3.0
55535 abdominal approach .....	<del>((9.5))</del> <u>8.6</u>	45	5.0
55540 with hernia repair .....	<del>((9.5))</del> <u>8.6</u>	45	3.0

**AMENDATORY SECTION (Amending Order 80-25, filed 12/3/80, effective 3/1/81)**

**WAC 296-22-300 SEMINAL VESICLES.**

	Unit Value	Follow-up Days=	Basic Anes@
<b>INCISION</b>			
55600 Vesiculotomy( <del>(unilateral)</del> ) ...	<del>((8.0))</del> <u>6.3</u>	60	5.0
<del>((55601 bilateral</del> .....	<del>12.0</del>	<del>60</del>	<del>5.0</del> )
55605 complicated .....	<del>((14.0))</del> <u>BR</u>	60	3.0

	Unit Value	Follow-up Days=	Basic Anes@
<b>EXCISION</b>			
55650 Vesiculectomy, any approach( <del>(unilateral)</del> ) .....	<del>((20.0-90))</del> <u>18.1</u>	45	5.0
<del>((55651 bilateral</del> .....	<del>20.0</del>	<del>90</del>	<del>5.0</del> )
55680 Excision of Mullerian duct cyst .....	<del>((20.0-90))</del> <u>18.1</u>	45	5.0

(For injection procedures, see 52010, 52110, 55300)

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-305 PROSTATE.**

	Unit Value	Follow-up Days=	Basic Anes@
<b>INCISION</b>			
55700 Biopsy, prostate; needle or punch, single or multiple, any approach .....	<del>((1.4))</del> <u>1.8</u>	15	3.0

(For fine needle aspiration, preparation, and interpretation of smears, see 88170-88173)

55705 incisional, any approach ....	<del>((8.0))</del> <u>7.7</u>	30	4.0
55720 Prostatotomy, external drainage of prostatic abscess, any approach; simple .....	<del>((8.0-60))</del> <u>7.7</u>	30	4.0
55725 complicated .....	<del>((14.0))</del> <u>12.7</u>	60	4.0

(For transurethral drainage, see 52700)

55740 Prostatolithotomy, removal of prostatic calculus (separate procedure) .....	<del>((20.0))</del> <u>16.3</u>	60	4.0
---	------------------------------------	----	-----

	Unit Value	Follow-up Days=	Basic Anes@
<b>EXCISION</b>			
(For transurethral removal of prostate, see 52601-52650)			
(For limited pelvic lymphadenectomy for staging (separate procedure), use 38562)			
(For independent node dissection, see 38770-38780)			

	Unit Value	Follow-up Days=	Basic Anes@
55801 Prostatectomy, perineal, subtotal (including control of postoperative bleeding, during initial hospitalization, vasectomy, meatotomy, urethral calibration and/or dilation, and internal urethrotomy) are included . . . .	<del>(26.0)</del> 19.9	90	6.0
55810 prostatectomy, perineal radical . . . . .	<del>(26.0)</del> 23.5	90	6.0
55812 with lymph node biopsy(s) (limited pelvic lymphadenopathy) . . . . .	<del>(BR)</del> 25.8		
55815 with bilateral pelvic lymphadenectomy, including external iliac, hypogastric and obturator nodes . . . . .	<del>(BR)</del> 31.6		6.0

(If 55815 is carried out on separate days, use 38771 and 55810)

55821 Prostatectomy, including control of postoperative bleeding complete (vasectomy, meatotomy, urethral calibration and/or dilation, and internal urethrotomy are included), suprapubic, subtotal, one or two stages . . . . .	<del>(26.0)</del> 18.1	90	5.0
55831 retropubic, subtotal . . . . .	<del>(26.0)</del> 18.1	90	5.0
55840 prostatectomy, retropubic radical . . . . .	<del>(26.0—90)</del> 23.5		6.0
55842 with lymph node biopsy(s) (limited pelvic lymphadenectomy) . . . . .	<del>(BR)</del> 24.8	90	
55845 with bilateral pelvic lymphadenectomy, including external iliac, hypogastric and obturator nodes . . . . .	<del>(BR)</del> 31.6	90	3.0

((with bilateral pelvic lymphadenectomy, including external iliac, hypogastric and obturator nodes))

**OTHER PROCEDURES**

(For artificial insemination, see 58310)

55899 Unlisted procedure, male genital system . . . . .	BR		3.0
---	----	--	-----

**AMENDATORY SECTION (Amending Order 86-19, filed 2/28/86, effective 4/1/86)**

**WAC 296-22-307 PERINEUM.**

	Unit Value	Follow-up Days=	Basic Anes@
<b>INCISION</b>			
*56000 Incision and drainage of perineal abscess (nonobstetrical) (see also 10060 et seq) . . . . .	*0.6	0	3.0

**EXCISION**

56100 Biopsy of perineum (separate procedure) . . . . .	<del>(6.6)</del> 0.5	7	3.0
---	-------------------------	---	-----

(For excision of local lesion, see 11420-11426, 11620-11626)

**REPAIR**

56200 Perineoplasty, repair of perineum nonobstetrical, (separate procedure) (see also 56800) . . . . .	<del>(BR)</del> 4.3	15	3.0
---	------------------------	----	-----

(For repair of wounds to genitalia, see 12001-12007, 12041-12047, 13131, 13132)

(For repair of recent injury of vagina and perineum, nonobstetrical, see 57210)

(For anal sphincteroplasty, see 46750, 46751)

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-310 VULVA AND INTROITUS.**

	Unit Value	Follow-up Days=	Basic Anes@
<b>INCISION</b>			
(For incision and drainage of sebaceous cyst, furuncle, or caruncle, see 10000-10020, 10060, 10061)			
*56400 Incision and drainage, abscess of vulva, extensive . . . . .	<del>(*0.8)</del> 0.7	0	3.0
*56420 Incision and drainage of Bartholin's gland abscess, unilateral . . . . .	<del>(*1.0)</del> 0.7	0	3.0
(For incision and drainage of Skene's gland abscess or cyst, see 53060)			
56440 Marsupialization of Bartholin's gland cyst . . . . .	<del>(4.0—30)</del> 3.6	0	3.0

**DESTRUCTION**

*56501 Destruction of lesion(s), vulva; simple, any method . . . . .	<del>(BR)</del> 0.6	0	3.0
56515 extensive, any method . . . . .	<del>(BR+)</del> 3.6	0	3.0

(For destruction of Skene's gland cyst or abscess, see 53270)

(For cautery destruction of urethral caruncle, see 53265)

**EXCISION**

56600 Biopsy of vulva (separate procedure) . . . . .	0.6	7	3.0
--	-----	---	-----



**AMENDATORY SECTION** (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

**WAC 296-22-315 VAGINA.**

	Unit Value	Follow-up Days=	Basic Anes@
(For local excision or fulguration of lesion(s) of external genitalia, see 11420-11426, 11620-11626, 17000-17302, 56500-56521)			
56620 Vulvectomy; partial( <del>(unilateral or bilateral)</del> ) (( <del>but</del> ) less than 80% of vulvar area) . . . . . (( <del>+2.0</del> ))	<u>9.9</u>	60	3.0
56625 complete (skin and subcutaneous tissue)( <del>(unilateral)</del> ) . . . . . (( <del>+5.0</del> ))	<u>14.0</u>	60	3.0
(For skin graft, see 15000 et seq)			
56630 Vulvectomy, radical; without skin graft . . . . . (( <del>20.0</del> ))	<u>19.9</u>	120	3.0
56635 with inguofemoral lymphadenectomy( <del>(unilateral)</del> ) . . . . . (( <del>24.0</del> ))	<u>24.8</u>	120	5.0
(( <del>56636</del> with inguofemoral lymphadenectomy, bilateral . . . . . <del>26.0</del> — 120 — 5.0))			
56640 vulvectomy, radical, with inguofemoral, iliac, and pelvic lymphadenectomy( <del>(unilateral)</del> ) . . . . . (( <del>26.0</del> ))	<u>29.8</u>	120	5.0
(( <del>56641</del> bilateral . . . . . <del>30.0</del> — 120 — 5.0))			
(For lymphadenectomy, see 38760-38780)			
56680 Clitoridectomy, simple . . . . . (( <del>8.0</del> ))	<u>7.2</u>	30	3.0
56685 extensive . . . . . (( <del>+2.0</del> ))	<u>10.8</u>	90	3.0
56700 Hymenectomy, partial excision of hymen . . . . . (( <del>2.4</del> ))	<u>3.2</u>	30	3.0
56710 Plastic revision of hymen . . . . . (( <del>2.4</del> ))	<u>3.6</u>	30	3.0
*56720 Hymenotomy, simple incision . . . . . (( <del>+1.4</del> ))	<u>1.0</u>	0	3.0
56740 Excision of Bartholin's gland or cyst . . . . . (( <del>4.8</del> ))	<u>3.9</u>	30	3.0
(For excision of Skene's gland, see 53270)			
(For excision of urethral caruncle, see 53265)			
(For excision or fulguration of urethral carcinoma, see 53220)			
(For excision or marsupialization of urethral diverticulum, see 53230-53240)			
<b>REPAIR</b>			
(For repair of urethra for mucosal prolapse, see 53275)			
56800 Plastic repair of introitus . . . . . (( <del>4.8</del> ))	<u>4.3</u>	30	3.0
<b>SUTURE</b>			
(For episiorrhaphy, episiperineorrhaphy for recent injury of vulva and/or perineum, nonobstetrical, see 57210)			

	Unit Value	Follow-up Days=	Basic Anes@
<b>INCISION</b>			
57000 Colpotomy with exploration . . . . . (( <del>4.0</del> ))	<u>4.1</u>	30	3.0
57010 with drainage of pelvic abscess . . . . . (( <del>BR</del> ))	<u>5.0</u>	30	
*57020 Colpocentesis (separate procedure) . . . . . (( <del>0.8</del> ))	<u>0.7</u>	0	3.0
<b>DESTRUCTION</b>			
57061 Destruction of vaginal lesion(s); simple, any method . . . . .	0.7	<u>15</u>	3.0
57065 extensive, any method . . . . .	BR		3.0
<b>EXCISION</b>			
*57100 Biopsy of vaginal mucosa; simple (separate procedure) . . . . . (( <del>0.72</del> ))	<u>0.7</u>	7	3.0
57105 extensive, requiring suture (including cysts) . . . . .	BR		3.0
57108 Colpectomy, obliteration of vagina; partial . . . . . (( <del>+2.0</del> — <del>60</del> ))	<u>9.0</u>	<u>30</u>	3.0
(For excision and/or fulguration of local lesion(s), see 11200-11660, 17000-17300)			
57110 complete . . . . . (( <del>+4.0</del> ))	<u>12.7</u>	60	3.0
57120 Colpocleisis (Le Fort type) . . . . . (( <del>+2.0</del> ))	<u>11.1</u>	60	3.0
57130 Excision of vaginal septum . . . . . (( <del>BR</del> ))	<u>4.5</u>	<u>7</u>	3.0
57135 Excision of vaginal cyst or tumor . . . . . (( <del>BR</del> ))	<u>3.4</u>	<u>30</u>	3.0
<b>INTRODUCTION</b>			
*57150 Irrigation and/or application of medicament for treatment of bacterial, parasitic or fungoid disease . . . . . (( <del>0.24</del> ))	<u>0.3</u>	0	
*57160 Insertion of pessary . . . . . (( <del>0.24</del> ))	<u>0.3</u>	0	
57170 Diaphragm fitting with instructions . . . . . (( <del>0.24</del> ))	<u>0.3</u>	<u>0</u>	
57180 Introduction of any hemostatic agent or pack for spontaneous or traumatic nonobstetrical hemorrhage (separate procedure) . . . . .	BR		3.0
<b>REPAIR</b>			
(For urethral suspension, (Marshall-Marchetti-Krantz type) abdominal approach, see 51840, 51841)			
57200 Colporrhaphy, suture of injury of vagina (nonobstetrical) . . . . . (( <del>BR</del> — <del>3.0</del> ))	<u>5.4</u>	<u>7</u>	
57210 Colpoperineorrhaphy, suture of injury of vagina and/or perineum (nonobstetrical) . . . . . (( <del>BR</del> — <del>3.0</del> ))	<u>5.9</u>	<u>7</u>	

	Unit Value	Follow-up Days=	Basic Anes@
57220 Plastic operation on urethral sphincter, vaginal approach (eg, Kelly urethral plication) (separate procedure) . . . . .	<del>((7.0—60))</del> 6.8	7	3.0
57230 Plastic repair of urethrocele (separate procedure) . . . . .	<del>((7.0—60))</del> 6.3	7	3.0
57240 Anterior colporrhaphy, repair of cystocele with or without repair of urethrocele (separate procedure) . . . . .	<del>((8.5))</del> 7.8	60	4.0
57250 Posterior colporrhaphy, repair of rectocele with or without perineorrhaphy . . . . .	<del>((7.0))</del> 7.2	60	3.0
(For repair of rectocele (separate procedure) without posterior colporrhaphy, see 45560)			
57260 Combined anteroposterior colporrhaphy . . . . .	<del>((12.0))</del> 10.8	60	3.0
57265 with enterocele repair . . . . .	<del>((14.0))</del> 12.7	60	3.0
57268 Repair of enterocele, vaginal approach (separate procedure) . . . . .	<del>((BR))</del> 9.0		
57270 Repair of enterocele, abdominal approach (separate procedure) . . . . .	<del>((14.0))</del> 11.3	60	4.0
57280 Colpopexy, abdominal approach . . . . .	<del>((14.0))</del> 12.7	60	4.0
57282 Sacrospinous ligament fixation for prolapse of vagina following hysterectomy (separate procedure) . . . . .	<del>((BR))</del> 12.7	60	3.0
57288 Sling operation for stress incontinence (e.g., fascia or synthetic) . . . . .	<del>((15.0—90))</del> 12.7	60	5.0
57289 Pereyra procedure, including anterior colporrhaphy . . . . .	<del>((13.0—90))</del> 11.3	60	3.0
57291 Construction of artificial vagina; without graft . . . . .	BR		3.0
57292 with graft . . . . .	BR		3.0
57300 Closure of rectovaginal fistula; vaginal or transanal approach . . . . .	<del>((14.5))</del> 11.7	90	3.0
57305 abdominal approach . . . . .	<del>((18.0))</del> 15.8	90	5.0
57307 abdominal approach, with concomitant colostomy . . . . .	<del>((20.0))</del> 17.6	90	5.0
57310 Closure of urethrovaginal fistula . . . . .	<del>((14.5))</del> 13.1	60	4.0
57311 with bulbo cavernous transplant . . . . .	BR	60	4.0
57320 Closure of vesicovaginal fistula, vaginal approach . . . . .	<del>((14.5))</del> 13.1	60	4.0
(For concomitant cystostomy, see 51005-51040 and WAC 296-22-010, item 7a)			
57330 transvesical and vaginal approach . . . . .	<del>((BR))</del> 14.5	60	5.0

(For abdominal approach, see 51900)

MANIPULATION

	Unit Value	Follow-up Days=	Basic Anes@
*57400 Dilation of vagina under anesthesia . . . . .	<del>((4.0-72))</del> 1.8	0	3.0
*57410 Pelvic examination under anesthesia . . . . .	<del>((4.0-72))</del> 1.8	0	3.0

ENDOSCOPY

	Unit Value	Follow-up Days=	Basic Anes@
57450 Culdoscopy, diagnostic . . . . .	<del>((4.0—15))</del> 4.5	0	3.0
57451 with biopsy and/or lysis of adhesions or tubal sterilization . . . . .	<del>((4.0))</del> 8.1	15	3.0
57452* Colposcopy; (separate procedure) . . . . .	<del>((1.0))</del> 1.8	0	
57454* with biopsies, or biopsy of the cervix . . . . .	<del>((2.0))</del> 3.6	0	

AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

WAC 296-22-325 CERVIX UTERI.

	Unit Value	Follow-up Days=	Basic Anes@
EXCISION			
(For radical surgical procedures, see 58200-58240)			
*57500 Biopsy, single or multiple, or local excision of lesion, with or without fulguration, (separate procedure) . . . . .	<del>((4.0-6))</del> 0.7	0	3.0
57505 Endocervical curettage (not done as part of a dilation and curettage) . . . . .	<del>((BR))</del> 0.9	0	3.0
*57510 Cauterization of cervix; electro or thermal . . . . .	<del>((4.0-6—0))</del> 0.7	7	
57511* cryocautery, initial or repeat . . . . .	<del>((6.6—0))</del> 0.9	45	
57513 laser surgery . . . . .	<del>((1.0))</del> 5.0	45	3.0
57520 Biopsy of cervix, circumferential (cone) with or without dilation and curettage, with or without Sturmdorff type repair (see also 58120) . . . . .	<del>((4.8))</del> 4.5	45	3.0
57530 Trachelectomy (cervicectomy), amputation of cervix (separate procedure) . . . . .	<del>((4.8))</del> 4.5	45	3.0
57540 Excision of cervical stump, abdominal approach . . . . .	<del>((12.0))</del> 10.8	45	4.0
57545 with pelvic floor repair . . . . .	<del>((BR))</del> 13.6	45	4.0
57550 Excision of cervical stump, vaginal approach . . . . .	<del>((12.0))</del> 10.8	45	3.0
57555 with anterior and/or posterior repair . . . . .	<del>((14.5))</del> 13.6	45	3.0

	Unit Value	Follow-up Days=	Basic Anes@
57556 with repair of enterocele .. ((+4.5))	<u>13.6</u>	45	4.0

**INTRODUCTION**

(For insertion of intrauterine device, see 58300)

**REPAIR**

57700 ((Tracheloplasty (Shirodkar or East type operation)) Cerclage of uterine cervix, nonobstetrical) ((6.0))	<u>8.6</u>	45	3.0
57720 Trachelorrhaphy, plastic repair of uterine cervix, vaginal approach .. ((6.0))	<u>4.5</u>	45	3.0

**MANIPULATION**

*57800 Dilation of cervical canal, instrumental (separate procedure) ... ((+0.6))	<u>0.5</u>	0	3.0
57820 Dilation and curettage of cervical stump .. ((+0.0))	<u>3.6</u>	15	3.0

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-330 CORPUS UTERI.**

	Unit Value	Follow-up Days=	Basic Anes@
--	------------	-----------------	-------------

**EXCISION**

*58100 Endometrial biopsy, suction type (separate procedure) .. ((+0.72))	<u>0.7</u>	0	3.0
58101* Endometrial washings (e.g., for cytology sampling) .. ((+0.0))	<u>0.7</u>	0	3.0
58102 Office endometrial curettage .. ((2.0))	<u>2.7</u>	0	3.0
((58103 Menstrual extraction .. (0.0))	<u>0.5</u>	0	3.0
58120 Dilation and curettage, diagnostic and/or therapeutic (obstetrical) (see also 57520 nonobstetrical) .. ((4.0-15))	<u>3.6</u>	0	3.0
(For postpartum hemorrhage, see 59160)			
58140 Myomectomy, excision of fibroid tumor of uterus, single or multiple, (procedure); abdominal approach .. ((+4.0))	<u>10.8</u>	45	5.0
58145 vaginal approach .. ((BR))	<u>8.1</u>	45	5.0
58150 Total hysterectomy (corpus and cervix), with or without removal of tube(s), with or without removal of ovary(s) .. ((+6.0))	<u>15.4</u>	45	5.0
58152 with colpo-urethrocytopexy (Marshall-Marchetti-Krantz type) .. ((BR))	<u>18.1</u>	45	5.0
(For urethrocytopexy without hysterectomy, see 51840, 51841)			

	Unit Value	Follow-up Days=	Basic Anes@
58180 Supracervical hysterectomy (subtotal hysterectomy), with or without tube(s), with or without removal of ovary(s) .. ((+6.0))	<u>13.6</u>	45	5.0

58200 Total hysterectomy, including partial vaginectomy, with limited para-aortic and pelvic lymphnode biopsy(s) .. ((20.0))	<u>18.1</u>	120	5.0
--	-------------	-----	-----

(For hysterectomy with pelvic lymphadenectomy, use 58210)

58210 Radical hysterectomy, with bilateral total pelvic and limited para-aortic lymphadenectomy .. ((30.0))	<u>31.6</u>	120	7.0
---	-------------	-----	-----

(For radical hysterectomy with ovarian transposition, use also 51597)

58240 Pelvic exenteration for gynecological malignancy, with total hysterectomy or cervicectomy, with removal of bladder and ureteral transplantsations, and/or abdominoperineal resection of rectum and colon and colostomy, or any combination thereof (pelvic exenteration) .. BR	<u>120</u>		7.0
--	------------	--	-----

(For pelvic exenteration of lower urinary tract or male genital malignancy, use 51597)

58260 Vaginal hysterectomy .. ((+6.0))	<u>16.7</u>	45	4.0
--	-------------	----	-----

58265 with plastic repair of vagina, anterior and/or posterior colporrhaphy .. ((+8.0))	<u>19.0</u>	45	4.0
---	-------------	----	-----

58267 with colpo-urethrocytopexy (Marshall-Marchetti-Krantz type, Pereyra type, with or without endoscopic control) .. ((20.0-90))	<u>19.9</u>	45	5.0
--	-------------	----	-----

58270 with repair of enterocele .. ((+8.0))	<u>18.1</u>	45	4.0
---	-------------	----	-----

58275 Vaginal hysterectomy, with total or partial colectomy .. ((+8.0))	<u>18.1</u>	45	4.0
---	-------------	----	-----

58280 with repair of enterocele .. ((+8.0))	<u>18.1</u>	45	4.0
---	-------------	----	-----

58285 Vaginal hysterectomy, radical (Schauta type operation) .. ((24.0))	<u>21.7</u>	120	7.0
--	-------------	-----	-----

**INTRODUCTION**

(For insertion of radioactive substance into corpus with or without dilation and curettage, see 77520-77550)

*58300 Insertion of intrauterine device (IUD) .. ((+1.0-0-3.0))	<u>NONCOVERED</u>		
---	-------------------	--	--

58301 Removal of intrauterine device (IUD) .. ((BR))	<u>0.5</u>	0	
--	------------	---	--

58310 Artificial insemination .. ((BR))	<u>NONCOVERED</u>		
---	-------------------	--	--

58311 with sperm washing .. ((BR))	<u>NONCOVERED</u>		
------------------------------------	-------------------	--	--

	Unit Value	Follow-up Days=	Basic Anes@
*58320 Insufflation of uterus and tubes with air and CO <sub>2</sub> . . . . .	<del>((+1.0))</del> 0.9	0	3.0
*58340 Injection procedure for hysterosalpingography . . . . .	<del>((0.8))</del> 0.9	0	
*58350* Hydrotubation of oviduct, including materials . . . . .	<del>((+0))</del> 1.1	0	

(For materials supplied by physician, see 99070)

**REPAIR**

58400 Uterine suspension, with or without shortening of round ligaments, with or without shortening of sacrouterine ligaments; (separate procedure) . . . . .	<del>((+2.0))</del> 10.9	45	4.0
58410 with presacral sympathectomy . . . . .	<del>((+4.0))</del> 14.9	45	5.0
58520 Hysterorrhaphy, repair of ruptured uterus (nonobstetrical) . . . . .	<del>((+2.0))</del> 9.9	45	4.0
58540 Hysteroplasty, repair of uterine anomaly (Strassman type) . . . . .	<del>((+4.0))</del> 14.5	45	4.0

**SUTURE**

(For closure of vesicouterine fistula, see 51920)

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-333 OVIDUCT.**

	Unit Value	Follow-up Days=	Basic Anes@
<b>INCISION</b>			
58600 Transection of fallopian tube, abdominal or vaginal approach, unilateral or bilateral . . . . .	<del>((+2.0))</del> 9.0	45	4.0
58605 Ligation or transection of fallopian tube(s), abdominal or vaginal approach, postpartum, unilateral or bilateral during same hospitalization (separate procedure) . . . . .	<del>((7.0))</del> 6.8	45	4.0
(For laparoscopic procedures, see 58980-58987)			
58611 Ligation or transection of fallopian tube(s) when done at the time of Cesarean section or intra-abdominal surgery (not a separate procedure, included in major procedure.) . . . . .	<del>((BR))</del> 3.6	45	4.0
58615 Occlusion of fallopian tube(s) by device (e.g., band, clip, Falope ring, fulguration) vaginal or suprapubic approach . . . . .	<del>((BR))</del> 9.0	45	4.0
(For laparoscopic approach, see 58983)			

**EXCISION**

58700 Salpingectomy, complete or partial, unilateral or bilateral (separate procedure) . . . . .	<del>((+2.0))</del> 9.4	45	4.0
58720 Salpingo-oophorectomy, complete or partial, unilateral or bilateral (separate procedure) . . . . .	<del>((+2.0))</del> 10.3	45	4.0

**REPAIR**

58740 Lysis of adhesions (salpingolysis, ovariolysis) . . . . .	<del>((BR))</del> 14.9	45	4.0
(For laparoscopic approach, see 58985)			
58750 Tubotubal anastomosis . . . . .	<del>((BR))</del> 19.0	45	4.0
58752 Tubouterine implantation . . . . .	<del>((BR))</del> 14.9	45	4.0
58760 Fimrioplasty . . . . .	<del>((BR))</del> 14.9	45	4.0
58770 Salpingostomy (salpingoneostomy) . . . . .	14.9	45	

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-337 OVARY.**

	Unit Value	Follow-up Days=	Basic Anes@
<b>OVARY</b>			
<b>INCISION</b>			
58800 Drainage of ovarian cyst(s), unilateral, or bilateral, (separate procedure); vaginal approach . . . . .	<del>((4.0))</del> 4.5	15	4.0
58805 abdominal approach . . . . .	<del>((+2.0))</del> 10.8	45	4.0
58820 Drainage of ovarian abscess; vaginal approach . . . . .	<del>((4.0))</del> 4.5	15	4.0
58822 abdominal approach . . . . .	<del>((6.0-15))</del> 9.0	45	4.0
58825 Transposition, ovary(s) . . . . .	BR		
<b>EXCISION</b>			
58900 Biopsy of ovary, unilateral or bilateral (separate procedure) . . . . .	<del>((+2.0))</del> 9.5	45	4.0
58920 Wedge resection or bisection of ovary, unilateral or bilateral . . . . .	<del>((+2.0))</del> 9.0	45	4.0
58925 Ovarian cystectomy, unilateral or bilateral . . . . .	<del>((+2.0))</del> 9.0	45	4.0
58940 Oophorectomy, partial or total, unilateral or bilateral . . . . .	<del>((+2.0))</del> 9.0	45	4.0
58943 for ovarian malignancy, with para-aortic and pelvic lymph node biopsies, peritoneal biopsies, diaphragmatic assessments, with or without salpingectomy(s) . . . . .	BR		

	Unit Value	Follow-up Days=	Basic Anes@
58950 Resection of ovarian malignancy with bilateral salpingo-oophorectomy and omentectomy	((14)) 14.5	60	5.0
58951 with total abdominal hysterectomy, pelvic and limited para-aortic lymphadenectomy	BR		
58952 with radical dissection for debulking	BR		
58960 Laparotomy, for staging or restaging of ovarian malignancy ('second look'), with or without omentectomy, peritoneal washings, biopsy of abdominal and pelvic peritoneum, diaphragmatic assessment with pelvic and limited para-aortic lymphadenectomy	BR		

IN VITRO FERTILIZATION

58970 Follicle puncture for oocyte retrieval, any method	NONCOVERED PROCEDURE		
58972 Culture and fertilization of oocyte(s)	NONCOVERED PROCEDURE		
58974 Embryo transfer, any method (separate procedure)	NONCOVERED PROCEDURE		
58976 Gamete intrafallopian transfer, any method	NONCOVERED PROCEDURE		

ENDOSCOPY-LAPAROSCOPY

The endoscopic descriptors in this publication are listed so that the main procedure can easily be identified without having to list all the minor related procedures that may be performed at the same time (such as lysis of adhesions and fulguration of bleeding points during laparoscopy with fulguration transection of the oviducts). When the laparoscopy requires mini-laparotomy (Hasson technique) or when secondary procedures involve significant additional time and effort, they may be reported by using modifier -22.

Operative laparoscopy and hysteroscopy may utilize many methods to accomplish the same result (e.g., hotcautery, CO2 laser, ND-YAG laser, pelviscopy). The CPT code is the same regardless which technique is employed to achieve the desired result.

(For peritoneoscopy, see 49300-49303)

58980 Laparoscopy ((for visualization of pelvic viscera), surgical; . . .)	((6.0-10)) 6.8	0	5.0
58982 with fulguration of oviducts (with or without transection)	((8.0-10)) 7.7	15	5.0
58983 with occlusion of oviducts by device (e.g., band, clip, or Falope ring)	((BR)) 7.7	15	5.0

(For vaginal or suprapubic approach, see 58615)

58984 with fulguration ((of ovarian or peritoneal lesions) or excision of lesions of the ovary, pelvic viscera, or peritoneal surface by any method)	((8.0-10)) 7.7	15	5.0
--	-------------------	----	-----

	Unit Value	Follow-up Days=	Basic Anes@
58985 with lysis of adhesions	((8.0-10)) 7.7	15	5.0
58986 with biopsy (single or multiple)	((8.0-10)) 7.7	15	5.0
58987 with aspiration (single or multiple)	((8.0-10)) 7.7	15	5.0
58988 with removal of adnexal structures (partial or total oophorectomy and/or salpingectomy)	BR		
58990 Hysteroscopy, diagnostic	((BR)) 3.6	15	3.0
((58995 therapeutic	BR		3.0)
58992 with lysis of intrauterine adhesions or resection of intrauterine septum (any method)	BR		
58994 with removal of submucous leiomyomata (any method)	BR		

OTHER PROCEDURES

58999 Unlisted procedure, female genital system nonobstetrical	BR		3.0
--	----	--	-----

AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

WAC 296-22-340 MATERNITY CARE AND DELIVERY.

NOTES

The services normally required in uncomplicated maternity cases include antepartum care, delivery and postpartum care.

Antepartum care includes usual prenatal services (initial and subsequent history, physical examinations, recording of weight, blood pressure, fetal heart tones, routine chemical urinalyses, maternity counseling).

Delivery includes vaginal delivery (with or without episiotomy, with or without forceps or breech delivery) or Cesarean section, and resuscitation of new born infant when necessary.

Postpartum care includes hospital and office visits following vaginal or Cesarean section delivery.

For medical complications of pregnancy (toxemia, cardiac problems, neurological problems or other problems requiring additional or unusual services or requiring hospitalization), see services in MEDICINE section. For surgical complications of pregnancy not listed below, see appropriate procedures in SURGERY.

If a physician provides all or part of the antepartum and/or postpartum patient care but does not perform the delivery due to termination of pregnancy by abortion or referral to another physician for delivery, see 59420-59430.

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
<b>INCISION</b>				59160	<del>((Dilation and))</del> curettage <del>((for))</del> <sub>1</sub> postpartum <del>((hemorrhage))</del> <sub>1</sub> (separate procedure) ... <del>((4-0))</del>	15	3.0
59000	Amniocentesis <del>((for diagnostic purposes, abdominal approach))</del> <sub>1</sub> any method	<del>((+0))</del>	0		3.8		
	(For ultrasonic guidance, see 76946, 76947)			<b>INTRODUCTION</b>			
<del>((59010*))</del>	<del>Amnioscopy</del>	<del>1-0</del>	<del>0</del>		(For intrauterine fetal transfusion, see 36460)		
59011*	Amnioscopy (intraovular)	BR	0))		(For introduction of hypertonic solution and/or prostaglandins to initiate labor, see 59850)		
59012	Cordocentesis (intrauterine), any method	BR		59200	Insertion of hygroscopic cervical dilator (e.g., laminaria) (separate procedure)	BR	
59015	Chorionic villus sampling, any method	BR	0	<b>REPAIR</b>			
59020*	Fetal oxytocin stress test	<del>((+0))</del>	0		(For tracheloplasty, see 57700)		
59025	Fetal nonstress test	<del>((+0))</del>	0	59300	Episiotomy or vaginal repair <del>((only))</del> , by other than <del>((delivering))</del> attending physician; <del>((simple))</del>		
59030*	Fetal scalp blood sampling	<del>((+0))</del>	0				
<del>((59031*))</del>	<del>repeat</del>	<del>0.9</del>	<del>0</del>				
59050	Initiation and/or supervision of internal fetal monitoring during labor by consultant with report (separate procedure)	<del>((+0))</del>	0	<del>((59305))</del>	extensive	<del>1.9</del>	0 3.0
		1.6	0	59320	Cerclage of cervix, during pregnancy; vaginal	BR	3.0))
<b>EXCISION</b>				59325	abdominal	BR	
59100	Hysterotomy, abdominal <del>((for removal of))</del> (e.g., for hydatidiform mole, abortion ... <del>((+4-0))</del>	14.5	45 5.0	59350	Hysterorrhaphy of ruptured uterus <del>((separate procedure))</del> ... <del>((BR))</del>	13.6	45 3.0
<del>((59101))</del>	<del>with tubal ligation</del>	<del>14.0</del>	<del>45 6.0</del>	<del>((59351))</del>	following dilation and curettage, including both procedures	BR	3.0))
59105	Hysterotomy, abdominal, for legal abortion	16.0	45 6.0	<b>DELIVERY, ANTEPARTUM AND POSTPARTUM CARE</b>			
59106	with tubal ligation	18.0	45 6.0))	59400	<del>((Total obstetrical care (all-inclusive, "global" care) includes))</del> Routine obstetric care including antepartum care, vaginal delivery (with or without episiotomy, and/or forceps <del>((or breech delivery))</del> ) and postpartum care ... <del>((8-0))</del>	15.4	45 3.0
<b>EXCISION</b>				59410	Vaginal delivery only (with or without episiotomy <del>((;))</del> and/or forceps <del>((or breech delivery))</del> ) including <del>((in-hospital))</del> postpartum care <del>((separate procedure))</del> ... <del>((4-0))</del>	11.3	45 3.0
59120	Surgical treatment of ectopic pregnancy; tubal or ovarian, requiring salpingectomy and/or oophorectomy, abdominal or vaginal approach	<del>((+4-0))</del>	12.7 45 5.0	59412	External cephalic version, with or without tocolysis (list in addition to code(s) for delivery)		<del>((NONCOVERED PROCEDURE))</del>
59121	tubal or ovarian, without salpingectomy and/or oophorectomy	<del>((BR))</del>	12.7 45 5.0			BR	45
<del>((59125))</del>	<del>ovarian, requiring oophorectomy and/or salpingectomy</del>	<del>BR</del>	<del>5.0))</del>	59414	Delivery of placenta following delivery of infant outside of hospital	BR	
59126	ovarian, without oophorectomy and/or salpingectomy	BR		59420	Antepartum care only (separate procedure)	<del>((Sv.&amp;))</del>	5.8 0
59130	abdominal pregnancy	<del>((BR))</del>	12.7 45 5.0	59430	Postpartum care only (separate procedure)	<del>((Sv.&amp;))</del>	0.9 0
59135	interstitial, uterine pregnancy requiring total hysterectomy <del>((total or subtotal))</del>	<del>((BR))</del>	15.8 45 5.0	<b>CESAREAN SECTION</b>			
59136	interstitial, uterine pregnancy with partial resection of uterus	BR			(For standby attendance of infant, see 99151)		
59140	cervical, with evacuation	<del>((BR))</del>	12.7 45 5.0	<del>((59500))</del>	Cesarean section, low cervical, including in-hospital postpartum care, (separate procedure)	10.0	7 5.0
59150	Laparoscopic treatment of ectopic pregnancy; without salpingectomy and/or oophorectomy	BR					
59151	with salpingectomy and/or oophorectomy	BR					

	Unit Value	Follow-up Days=	Basic Anes@
5950+ including antepartum and postpartum care	13.0	45	5.0
59520 Cesarean section, classic, including in-hospital postpartum care; (separate procedure)	10.0	7	5.0
5952+ including antepartum and postpartum care	13.0	45	5.0
59540 Cesarean section, extraperitoneal, including in-hospital postpartum care; (separate procedure)	12.0	7	5.0
5954+ including antepartum and postpartum care	16.0	45	5.0
59560 Cesarean section with hysterectomy, subtotal, including in-hospital postpartum care; (separate procedure)	12.0	7	6.0
5956+ including antepartum and postpartum care	16.0	45	6.0
59580 Cesarean section with hysterectomy, total, including in-hospital postpartum care; (separate procedure)	12.0	7	6.0
5958+ including antepartum and postpartum care	16.0	45	6.0))
59510 Routine obstetric care including antepartum care, cesarean delivery, and postpartum care	BR		
59515 Cesarean delivery only including postpartum care	BR		
59525 Subtotal or total hysterectomy after cesarean delivery (list in addition to 59510 or 59515)	BR		

ABORTION

((59800 Treatment of spontaneous abortion, first trimester, completed medically	Sv.&		
5980+ completed surgically (separate procedure)	4.0	45	3.0
59810 Treatment of spontaneous abortion, second trimester, completed medically	Sv.&		
5981+ completed surgically (separate procedure)	4.0	45	3.0))
59812 Treatment of spontaneous abortion, any trimester, completed surgically	BR		
59820 Treatment of missed abortion, ((any)) first trimester, completed medically or surgically	((Sv.&))		
59821 second trimester	4.1	30	3.0
59830 Treatment of septic abortion, completed surgically	BR		
59840 ((Legal (therapeutic))) Induced abortion, by dilation and curettage((, and/or vacuum extraction))	((Sv.&))		
59841 ((Legal (therapeutic))) Induced abortion, by dilation and evacuation	5.4	30	3.0
59850 ((Legal (therapeutic))) Induced abortion, by one or more intraamniotic injections (amniocentesis-injections) (including hospital admission and visits, delivery of fetus and secundines)	((Sv.&))		
59851 with dilation and curettage	6.4	30	5.0

	Unit Value	Follow-up Days=	Basic Anes@
and/or evacuation	((BR))		
59852 with hysterotomy (failed ((same time)) intra-amniotic injection)	8.1	30	
	((BR))		
	10.8	45	

OTHER PROCEDURES

59870 Uterine evacuation and curettage for hydatidiform mole	BR		
59899 Unlisted procedure, maternity care and delivery	BR		3.0

AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

WAC 296-22-350 THYROID GLAND.

	Unit Value	Follow-up Days=	Basic Anes@
INCISION			
*60000 Incision and drainage of thyroglossal cyst, infected	((0.6))	0	3.0
	0.8		
EXCISION			
*60100 Biopsy, thyroid, percutaneous needle	((1.2-7))		
	1.4	0	

(For ultrasonic guidance, see 76942, 76943)

(For fine needle aspiration, preparation, and interpretation of smears, see 88170-88173)

60200 Excision of cyst or adenoma of thyroid, or transection of isthmus	((9.5-45))	30	5.0
	9.0		
60220 Total thyroid lobectomy, unilateral	((14.0))	45	5.0
	14.5		
60225* with contralateral subtotal lobectomy, including isthmus	((14.0-45))	30	5.0
	19.0		
60240 Thyroidectomy, total or complete	((16.0-45))	30	5.0
	16.3		
60245 Thyroidectomy, subtotal or partial	((14.5-45))	30	5.0
	15.4		
60246 with removal of substernal thyroid gland, cervical approach	((BR))	30	5.0
	18.1		
60252 Thyroidectomy, total or subtotal for malignancy; with limited neck dissection	((24.0-180))	30	5.0
	23.5		
60254 with radical neck dissection	((28.0-180))	30	6.0
	26.2		
60260 Thyroidectomy, secondary((; unilateral))	((15.0-45))	30	5.0
	15.4		
((6026+ bilateral	18.0	45	5.0))
60270 Thyroidectomy, including substernal thyroid gland, sternal split or transthoric approach	((BR-45))	30	5.0
	20.8		

	Unit Value	Follow-up Days=	Basic Anes@
60280	<del>((11.0—45))</del> 10.8	30	4.0
60281	BR		4.0

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-355 PARATHYROID, THYMUS, ADRENAL GLANDS AND CAROTID BODY.**

	Unit Value	Follow-up Days=	Basic Anes@
<b>EXCISION</b>			
(For pituitary and pineal surgery, see Nervous System)			
60500	<del>((18.0))</del> 16.5	45	5.0
60502	BR		5.0
60505	<del>((24.0—60))</del> 20.8	30	12.0
60520	<del>((18.0—60))</del> 17.6	30	12.0
60540	<del>((19.0—90))</del> 17.6	30	9.0
60545	<del>((22.0—90))</del> 20.3	30	9.0
(For excision of remote or disseminated pheochromocytoma, see 49200, 49201)			
<del>((60550))</del>	<del>24.0</del>	<del>90</del>	<del>9.0</del>
60555	BR		9.0
60600	<del>((17.0—60))</del> 18.1	30	8.0
60605	<del>((24.0—60))</del> 22.1	30	8.0
60699	BR		5.0

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-365 SKULL, MENINGES, AND BRAIN.**

(For injection procedure for cerebral angiography, see 36100-36215)  
(For injection procedure for ventriculography, see 61026, 61120, 61130)

	Unit Value	Follow-up Days=	Basic Anes@
<b>PUNCTURE FOR INJECTION, DRAINAGE OR ASPIRATION</b>			
*61000	<del>((2.0))</del> 1.8		0
*61001	<del>((1.4))</del> 1.3		0
*61020	<del>((2.0))</del> 1.8		0
61026*	<del>((BR))</del> 2.7	0	7.0
*61050	<del>((1.8))</del> 2.3		0
61055*	<del>((BR))</del> 3.7	0	6.0
61070*	<del>((2.0))</del> 1.4	0	0
<b>TWIST DRILL BURR HOLE(S) OR TREPHINE</b>			
61105*	<del>((BR))</del> 9.0	30	
61106	<del>((BR))</del> 6.3	0	
61107*	<del>((8.0—30))</del> 9.7	0	7.0
61108	<del>((17.5))</del> 18.1	7	8.0
61120	<del>((10.0))</del> 9.0	30	7.0
61130	<del>((7.0))</del> 6.3	0	
61140	<del>((20.0—0))</del> 19.9	30	5.0
61150	<del>((24.0—90))</del> 19.9	30	9.0
61151	<del>((2.0))</del> 2.3	0	4.0
61154	<del>((26.0))</del> 19.9	90	9.0
<del>((61155))</del>	<del>39.0</del>	<del>90</del>	<del>9.0</del>



	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
61156 with aspiration of hematoma or cyst, intracerebral . . . . .	<del>(25.0)</del> 19.4	90	9.0	61343 Craniectomy, suboccipital with cervical laminectomy for decompression of medulla and spinal cord, with or without dural graft (e.g., Arnold-Chiari malformation) . . . . .	<del>(39.2)</del> 40.7	90	9.5
61210* for implanting ventricular catheter, reservoir, or pressure recording device (separate procedure) . . . . .	<del>(8.0-30)</del> 7.2	90	7.0	61345 Other cranial decompression, posterior fossa . . . . .	<del>(22.0)</del> 17.6	90	13.0
61215 Insertion of subcutaneous reservoir, pump or continuous infusion system for connection to ventricular catheter . . . . .	BR		7.0	(For orbital decompression by lateral wall approach, Kroenlein type, see 67440)			
61250 Burr hole(s) or trephine, supratentorial, exploratory, not followed by other surgery(; <del>unilateral</del> ) . . . . .	<del>(15.0-30)</del> 13.6	90	7.0	61440 Craniotomy for section of tentorium cerebelli (separate procedure) . . . . .	<del>(BR)</del> 23.5	90	10.0
<del>(61251 bilateral . . . . .)</del> 61253 Burr hole(s) or trephine, infratentorial, unilateral or bilateral . . . . .	<del>22.0-30</del> <del>(BR)</del> 23.0	90	7.0	61450 Craniectomy, subtemporal, for section, compression, or decompression of sensory root of gasserian ganglion . . . . .	<del>(28.0)</del> 31.6	90	10.0
(If burr hole(s) or trephine followed by craniotomy at same operative session, use 61304-61321; do not use 61250, 61251, or 61253)				61458 Craniectomy, suboccipital; for exploration or decompression of cranial nerves . . . . .	<del>(30.0)</del> 35.2	90	10.0
<b>CRANIECTOMY OR CRANIOTOMY</b>				61460 for section of one or more cranial nerves . . . . .	<del>(34.0)</del> 34.3	90	10.0
61304 Craniectomy or craniotomy, exploratory; supratentorial . . . . .	<del>(34.0)</del> 31.6	90	9.0	61470 for medullary tractotomy . . . . .	<del>(40.0)</del> 34.3	90	11.0
61305 infratentorial (posterior fossa) . . . . .	<del>(40.0)</del> 33.4	90	10.0	61480 for mesencephalic tractotomy or pedunculotomy . . . . .	<del>(40.0)</del> 34.3	90	11.0
61312 Craniectomy or craniotomy for evacuation of hematoma, supratentorial; extradural or subdural . . . . .	<del>(31.5)</del> 32.5	90	9.5	61490 Craniotomy for lobotomy, including cingulotomy(; <del>unilateral</del> ) . . . . .	<del>(24.0)</del> 22.6	90	9.0
61313 intracerebral . . . . .	<del>(33.0)</del> 34.3	90	9.5	<del>(61491 bilateral . . . . .)</del> 61500 Craniectomy; with tumor or other bone lesion of skull . . . . .	<del>36.0-90</del> <del>(BR)</del> 32.5	90	8.0
61314 Craniectomy or craniotomy for evacuation of hematoma, infratentorial; extradural or subdural . . . . .	<del>(39.0)</del> 40.7	90	9.5	61501 for osteomyelitis . . . . .	BR		8.0
61315 intracerebellar . . . . .	<del>(42.7)</del> 44.3	90	9.5	61510 Craniectomy, trephination, bone flap craniotomy; for excision of brain tumor, supratentorial; except meningioma . . . . .	<del>(34.0)</del> 36.1	90	12.0
61320 Craniectomy or craniotomy, drainage of intracranial abscess; supratentorial . . . . .	<del>(28.0)</del> 28.9	90	11.0	61512 for excision of meningioma, supratentorial . . . . .	<del>(40.0)</del> 38.0	90	11.0
61321 infratentorial . . . . .	<del>(28.0)</del> 31.6	90	13.0	61514 for excision of brain abscess, supratentorial . . . . .	<del>(32.0)</del> 33.4	90	9.0
61330 Decompression of orbit only, transcranial approach(; <del>unilateral</del> ) . . . . .	<del>(26.0)</del> 27.1	90	9.0	61516 for excision or fenestration of cyst, supratentorial . . . . .	<del>(30.0)</del> 33.4	90	11.0
<del>(61331 bilateral . . . . .)</del> 61332 Exploration of orbit (transcranial approach); with biopsy . . . . .	<del>BR-9.0)</del> <del>(BR)</del> 36.1	90	9.0	(For excision of pituitary tumor of craniopharyngioma, see 61545, 61546, 61548)			
61333 with removal of lesion . . . . .	<del>(BR)</del> 36.1	90	9.0	61518 Craniectomy for excision of brain tumor, infratentorial or posterior fossa; except meningioma or cerebellopontine angle tumor, or midline tumor at base of skull . . . . .	<del>(40.0)</del> 39.8	90	11.0
61334 with removal of foreign body . . . . .	<del>(BR)</del> 36.1	90	9.0	61519 meningioma . . . . .	<del>(44.0)</del> 45.2	90	13.0
61340 Other cranial decompression (e.g., subtemporal), supratentorial(; <del>unilateral</del> ) . . . . .	<del>(16.0)</del> 19.9	90	9.0	61520 cerebellopontine angle tumor . . . . .	<del>(40.0)</del> 45.2	90	11.0
<del>(61341 bilateral . . . . .)</del>	<del>24.0-90</del> 24.0	90	9.0				

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
61521	midline tumor at base of skull .. ((BR))			61550	Craniectomy for craniostenosis; single suture .. ((18-0))		
	<u>60.3</u>		11.0		22.6	90	9.0
61522	Craniectomy, infratentorial or posterior fossa; for excision of brain abscess .. ((30-0))			61552	multiple sutures, one stage .. ((22-0))		
	<u>39.8</u>	90	13.0		25.3	90	9.0
61524	for excision or fenestration of cyst .. ((30-0))			61553	each stage of multiple stages .. ((BR))		
	<u>39.8</u>	90	13.0		20.8	90	9.0
61526	Craniectomy, bone flap craniotomy, transtemporal (mastoid) for excision of cerebellopontine angle tumor .. ((30-0))			61555	Reconstruction of skull by multiple bone flaps .. ((BR))		
	<u>45.2</u>	90	13.0		39.8	90	9.0
61530	combined with middle/posterior fossa craniotomy/craniectomy .. ((BR))						
	<u>45.2</u>	90	13.0				
61533	craniectomy, trephination, bone flap craniotomy; for insertion of epidural electrode array .. ((BR))			61561	Reconstruction of skull by orbital advancement, including suturotomy or craniotomy ((unilateral)) .. ((BR))		
	<u>34.8</u>	90	9.0		38.0	90	9.0
				((61562	bilateral .. ((BR))		9.0
				61570	Craniectomy or craniotomy for excision of foreign body from brain .. ((BR))		
					44.3	90	9.0
61534	for excision of epileptogenic focus without electrocorticography during surgery .. ((BR))			61571	with treatment of penetrating wound of brain .. ((BR))		
	<u>34.3</u>	90	9.0		44.3	90	9.0
61535	for removal of epidural electrode array, without excision of cerebral tissue (separate procedure) .. ((BR))			61575	Transoral approach to skull base, brain stem, or upper spinal cord for biopsy, decompression, or excision of lesion .. BR	90	
	<u>26.2</u>	90	9.0	61576	requiring splitting of tongue and/or mandible (including tracheostomy) .. BR	90	
61536	for excision of cerebral, epileptogenic focus with electrocorticography during surgery (includes removal of electrode array) .. ((BR))						
	<u>37.0</u>	90	9.0				
61538	for lobectomy with electrocorticography during surgery, temporal lobe .. ((30-0))			61680	Surgery of intracranial arteriovenous malformation; supratentorial, simple .. ((52-0))		
	<u>39.8</u>	90	9.0		54.2	90	
61539	for lobectomy with electrocorticography during surgery, other than temporal lobe, partial or total .. ((30-0))			61682	supratentorial, complex .. ((61-0))		
	<u>39.8</u>	90	9.0		63.3	90	
61541	for transection of corpus callosum .. ((BR))			61684	infratentorial, simple .. ((56-5))		
	<u>52.9</u>	90	9.0		58.7	90	
61542	for total hemispherectomy .. ((48-0))			61686	infratentorial, complex .. ((65-5))		
	<u>47.9</u>	90	9.0		67.8	90	
61543	for partial or subtotal hemispherectomy .. BR	90	9.0	61690	dural, simple .. BR	90	
61544	for excision or coagulation of choroid plexus .. ((30-0))			61692	dural, complex .. BR	90	
	<u>34.3</u>	90	11.0				
61545	for excision of craniopharyngioma .. ((63-5))						
	<u>66.0</u>	90	9.5				
61546	Craniotomy for hypophysectomy; intracranial approach .. ((34-0))						
	<u>38.4</u>	90	10.0				
61548	Hypophysectomy, transnasal or transeptal approach, nonstereotactic .. ((BR))						
	<u>35.7</u>	90	4.0				

(For cranial reconstruction for orbital hypertelorism, see 21260-21263)

(For sequestrectomy for osteomyelitis, see 21020)

(For arthrodesis, use 22548)

(For sequestrectomy for osteomyelitis, see 21020)

**SURGERY FOR ANEURYSM, ARTERIOVENOUS MALFORMATION, OR VASCULAR DISEASE**

(For excision of vascular malformation, see 61532)

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
(For cervical approach for direct ligation of carotid artery, see 37600-37606)				61855	subcortical . . . . .	<del>((18-0))</del> BR	30 8.0
61705 Surgery of aneurysm, vascular malformation or carotid-cavernous fistula; by intracranial and cervical occlusion of carotid artery . . . . .	<del>((32-0))</del> 48.8	90	15.0	61860	Craniectomy or craniotomy for implantation of neurostimulator electrodes, cerebral; cortical . . . . .	<del>((15-0))</del> BR	30 6.0
61708 by intracranial electrothrombosis . . . . .	<del>((30-0))</del> 36.1	90	9.0	61865	subcortical . . . . .	<del>((18-0))</del> BR	30 6.0
61710 by intra-arterial embolization, injection procedure or balloon catheter . . . . .	<del>((24-0))</del> 9.0	90	9.0	61870	Craniectomy for implantation of neurostimulator electrodes, cerebellar; cortical . . . . .	<del>((18-0))</del> BR	30 7.0
61711 Anastomosis, arterial, extracranial-intracranial (e.g., middle cerebral/cortical) arteries . . . . .	<del>((36-0))</del> 37.0	90	15.0	61875	subcortical . . . . .	<del>((19-0))</del> BR	30 7.0
(For carotid or vertebral thromboendarterectomy, see 35301)				61880	Revision or removal of intracranial neurostimulator electrodes . . . . .	BR	7.0
61712 Microdissection, intracranial or spinal procedure (list separately in addition to code for primary procedure) . . . . .	BR		9.0	61885	Incision for subcutaneous placement of neurostimulator receiver, direct or inductive coupling . . . . .	BR	7.0
61888				61888	Revision or removal of intracranial neurostimulator receiver . . . . .	BR	7.0
					(See WAC 296-22-010, item 2)		
<b>STEREOTAXIS</b>				<b>REPAIR</b>			
61720 Stereotactic lesion, any method, including burr hole(s) and localizing and recording techniques, single or multiple stages; globus pallidus or thalamus . . . . .	<del>((38-0))</del> 31.2	90	8.0	62000	Elevation of depressed skull fracture; simple, extradural . . . . .	<del>((18-0))</del> 16.3	90 9.0
61735 subcortical structure other than globus pallidus or thalamus . . . . .	<del>((38-0))</del> 30.5	90	8.0	62005	compound or comminuted, extradural . . . . .	<del>((24-0))</del> 22.6	90 9.0
61750 Stereotactic biopsy, aspiration or excision, including burr hole(s) for intracranial lesion . . . . .	<del>((BR))</del> 26.0	90	8.0	62010	with repair of dura and/or debridement of brain . . . . .	<del>((29-0))</del> 28.0	90 11.0
61751 with computerized axial tomography . . . . .	BR	90	8.0	62100	Craniotomy for repair of dural/CSF leak, including surgery for rhinorrhea/otorrhea . . . . .	<del>((30-0))</del> 29.8	90 9.0
61770 Stereotactic localization, any method, including burr hole(s); with insertion of catheter(s) for brachytherapy . . . . .	<del>((16-5))</del> 17.2	90	8.0		(For repair of spinal dural/CSF leak, see 63708)		
61780 for introduction of subcortical electrodes . . . . .	<del>((18-0))</del> 18.4	90	8.0	62120	Repair of encephalocele, including cranioplasty . . . . .	<del>((BR))</del> 22.6	90 9.0
61790 Stereotactic lesion of gasserian ganglion, percutaneous, by neurolytic agent (e.g., alcohol, thermal, electrical, radiofrequency) . . . . .	<del>((18-0))</del> 25.3	90	7.0	62140	Cranioplasty for skull defect, up to 5 cm diameter . . . . .	<del>((20-0))</del> 21.7	90 9.0
61791 Trigeminal medullary tract . . . . .	31.2	90		62141	larger than 5 cm diameter . . . . .	<del>((BR))</del> 26.2	90 9.0
61793 Stereotactic focused proton beam or gamma radio-surgery . . . . .	BR			62142	Removal of bone flap or prosthetic plate of skull . . . . .	<del>((BR))</del> 19.0	90 9.0
61795 Stereotactic computer assisted volumetric intracranial procedure (list separately in addition to code for primary procedure) . . . . .	BR			62143	Replacement of bone flap or prosthetic of skull . . . . .	25.3	90
<b>NEUROSTIMULATORS, INTRACRANIAL</b>				62145	Cranioplasty for skull defect with reparative brain surgery . . . . .	<del>((BR+))</del> 31.6	90 11.0
61850 Burr or twist drill hole(s) for implantation of neurostimulator electrodes; cortical . . . . .	<del>((15-0-30))</del> 25.3	90	8.0	<b>CSF SHUNT</b>			
				62180	Ventriculocisternostomy (Torkildsen type operation) . . . . .	<del>((32-0-90))</del> 24.4	7 11.0
				62190	Creation of shunt; subarachnoid/subdural-atrial, -jugular, -auricular . . . . .	<del>((24-0-90))</del> 18.1	7 9.0
				62192	subarachnoid/subdural-peritoneal, -pleural, -other terminus . . . . .	<del>((22-0-90))</del> 18.1	7 9.0
				62194	Replacement or irrigation, subarachnoid/subdural catheter . . . . .	<del>((6-0-90))</del> 7.2	7 5.0

	Unit Value	Follow-up Days=	Basic Anes@
62200	Ventriculocisternostomy, third ventricle . . . . .	<del>((32.0—90))</del> 30.7	7 11.0
62201	stereotactic method . . . . .	BR	
62220	Creation of shunt; ventriculo-atrial, -jugular, -auricular . . . . .	<del>((26.0—90))</del> 20.8	7 11.0
62223	ventriculo-peritoneal, -pleural, -other terminus . . . . .	<del>((24.0—90))</del> 21.7	7 9.0
62225	Replacement or irrigation, ventricular catheter . . . . .	<del>((10.0—90))</del> 8.1	7 5.0
62230	Replacement or revision of shunt, obstructed valve, or distal catheter in shunt system . . . . .	<del>((20.0—90))</del> 16.3	7 11.0
62256	Removal of complete shunt system; without replacement . . . . .	<del>((10.0—90))</del> 8.1	7 11.0
62258	with replacement by similar or other shunt at same operation . . . . .	<del>((3.0—0))</del> 18.1	7 9.0

(For percutaneous irrigation or aspiration of shunt reservoir, see 61070)

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-370 SPINE AND SPINAL CORD.**

(For application of caliper or tongs, see 20660)  
 (For treatment of fracture or dislocation of spine, see 22305-22327)

	Unit Value	Follow-up Days=	Basic Anes@
62268*	Percutaneous aspiration, spinal cord cyst or syrxn . . . . .	<del>((BR))</del> 13.8	0
	(For CT guidance, see 76365, 76366; for ultrasonic guidance, see 76938, 76939)		
62269*	Biopsy of spinal cord, percutaneous needle . . . . .	<del>((BR))</del> 15.2	0
	(For CT guidance, see 76360, 76361; for ultrasonic guidance, see 76942, 76943)		
62270*	Spinal puncture, lumbar; diagnostic . . . . .	<del>((1.6))</del> 0.9	0
62272*	Spinal puncture, therapeutic, for drainage of spinal fluid (by needle or catheter) . . . . .	<del>((BR))</del> 0.9	0
62273*	Injection, lumbar epidural, of blood or clot patch . . . . .	<del>((2+))</del> 0.9	0
62274*	Injection of anesthetic substance including narcotics, diagnostic or therapeutic; subarachnoid or subdural, single . . . . .	<del>((2+))</del> 0.9	0

**PUNCTURE FOR INJECTION, DRAINAGE OR ASPIRATION**

	Unit Value	Follow-up Days=	Basic Anes@
62276*	subarachnoid or subdural, differential . . . . .	<del>((3.5))</del> 0.9	0
62277*	subarachnoid or subdural, continuous . . . . .	<del>((3.0))</del> 0.9	0
62278*	lumbar or caudal epidural, single . . . . .	<del>((2+))</del> 0.9	0
62279*	lumbar or caudal epidural, continuous . . . . .	<del>((3.0))</del> 0.9	0
62280*	Injection of neurolytic substance (e.g., alcohol, phenol, iced saline solutions); subarachnoid . . . . .	<del>((5.0))</del> 2.7	0
62282*	lumbar or caudal epidural . . . . .	<del>((5.0))</del> 2.7	0
62284*	Injection procedure for myelography, spinal or posterior fossa . . . . .	<del>((3.0—7))</del> 2.3	0
62288*	Injection of substance other than anesthetic, contrast, or neurolytic solutions; subarachnoid (separate procedure) . . . . .	<del>((BR))</del> 2.6	0
62289*	lumbar or caudal epidural . . . . .	<del>((2.8))</del> 2.3	0
62290*	Injection procedure for diskography, single or multiple levels; lumbar . . . . .	<del>((2.8))</del> 2.7	0
62291*	cervical . . . . .	<del>((2.8))</del> 2.7	0
62292	Injection procedure for chemonucleolysis; including diskography, intervertebral disc; one or more levels-lumbar . . . . .	<del>((13.0—180))</del> 4.5	0 4.0
62294*	Injection procedure, arterial, for occlusion of arteriovenous malformation, spinal . . . . .	<del>((2.8))</del> 2.7	0

**POSTERIOR EXTRADURAL LAMINOTOMY OR LAMINECTOMY FOR EXPLORATION/DECOMPRESSION OF NEURAL ELEMENTS OR EXCISION OF HERNIATED INTERVERTEBRAL DISKS**

63001	Laminectomy for exploration/decompression of spinal cord and/or cauda equina, one or two segments; cervical . . . . .	<del>((30.0))</del> 31.6	90 10.0
63003	thoracic . . . . .	<del>((30.0))</del> 31.6	90 10.0
63005	lumbar, except for spondylolisthesis . . . . .	<del>((24.0))</del> 29.8	90 8.0
63010	lumbar for spondylolisthesis (Gill type procedure) . . . . .	<del>((28.0))</del> 27.6	90 8.0
63011	sacral . . . . .	<del>((24.0))</del> 28.0	90 10.0
63015	Laminectomy for exploration/decompression of spinal cord and/or cauda equina, more than two segments; cervical . . . . .	<del>((BR))</del> 30.7	90 10.0
63016	thoracic . . . . .	<del>((BR))</del> 30.7	90 10.0
63017	lumbar . . . . .	<del>((BR))</del> 30.7	90 8.0

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
63020 Laminotomy (hemilaminectomy), for decompression of nerve root(s) including partial facetectomy, for aminotomy and/or excision of herniated intervertebral disk; one interspace, cervical( <del>(; unilateral)</del> )..... (( <del>26-0</del> ))	<del>28.9</del>	90	10.0	<b>ANTERIOR OR ANTEROLATERAL APPROACH FOR EXTRADURAL EXPLORATION/DECOMPRESSION</b>			
(( <del>63021</del> one interspace, cervical, bilateral)..... (( <del>28-0</del> ))	<del>28.0</del>	<del>90</del>	<del>10.0</del>	63075 Dissectomy, anterior, for decompression of spinal cord and/or nerve root(s), including osteophyctomy; cervical, single interspace..... (( <del>26-0</del> ))	<del>27.1</del>	90	8.0
63030 one interspace, lumbar( <del>(; unilateral)</del> )..... (( <del>25-0</del> ))	<del>27.1</del>	90	8.0	63076 cervical, each additional interspace..... (( <del>5-0</del> ))	<del>5.4</del>	90	9.0
(( <del>63031</del> one interspace, lumbar, bilateral)..... (( <del>27-0</del> ))	<del>27.0</del>	<del>90</del>	<del>8.0</del>	63077 thoracic, single interspace .... (( <del>26-0</del> ))	<del>27.1</del>	90	9.0
63035 each additional interspace, cervical or lumbar ..... (( <del>BR</del> ))	<del>5.4</del>	90	10.0	63078 thoracic, each additional interspace..... (( <del>5-0</del> ))	<del>5.4</del>	90	9.0
(Use 63035 only for procedures 63031-63035)				63081 Vertebral corpectomy (vertebral body resection), partial or complete, anterior approach for decompression of spinal cord and/or nerve root(s); cervical, single segment ..... (( <del>36-5</del> ))	<del>38.0</del>	90	9.0
63040 Laminotomy (hemilaminectomy), for decompression of nerve root(s) including partial facetectomy, foraminotomy and/or excision of herniated intervertebral disk; reexploration; cervical ..... (( <del>30-5</del> ))	<del>31.6</del>	90	10.0	63082 cervical, each additional segment ..... (( <del>6-0</del> ))	<del>6.3</del>	90	10.0
63042 lumbar ..... (( <del>BR</del> ))	<del>31.6</del>	90	8.0	63085 Vertebral corpectomy (vertebral body resection), partial or complete, transthoracic approach for decompression of spinal cord and/or nerve root(s); thoracic, single segment ..... (( <del>39-0</del> ))	<del>40.7</del>	90	9.0
63045 Laminectomy, including unilateral or bilateral complete facetectomy or foraminotomy for decompression of spinal cord, cauda equina and/or nerve root(s), (e.g., spinal or lateral recess stenosis), single segment; cervical ..... (( <del>30-5</del> ))	<del>31.6</del>	90	9.0	63086 thoracic, each additional segment ..... (( <del>6-0</del> ))	<del>6.3</del>	90	9.0
63046 thoracic ..... (( <del>30-5</del> ))	<del>31.6</del>	90	9.0	63087 Vertebral corpectomy (vertebral body resection), partial or complete, combined thoracolumbar approach for decompression of spinal cord, cauda equina, or nerve root(s), lower thoracic, or lumbar; single ..... (( <del>39-0</del> ))	<del>40.7</del>	90	9.0
63047 lumbar ..... (( <del>28-0</del> ))	<del>28.9</del>	90	9.0	63088 each additional segment ..... (( <del>6-0</del> ))	<del>6.3</del>	90	9.0
63048 each additional segment, cervical, thoracic, or lumbar ..... 5.0	5.0	90	9.0	63090 Vertebral corpectomy (vertebral body resection), partial or complete, transperitoneal or retroperitoneal approach for decompression of spinal cord, cauda equina, or nerve root(s), lower thoracic, lumbar, or sacral; single segment ... (( <del>36-5</del> ))	<del>38.0</del>	90	9.0
<b>TRANSPEDICULAR OR COSTOVERTEBRAL APPROACH FOR POSTEROLATERAL EXTRADURAL EXPLORATION/DECOMPRESSION</b>				63091 each additional segment ..... (( <del>6-0</del> ))	<del>6.3</del>	90	9.0
63055 Transpedicular approach for decompression of spinal cord, equina and/or nerve root(s) (e.g., herniated intervertebral disk), single segment, thoracic ..... (( <del>39-0</del> ))	<del>40.7</del>	90	9.0	(Procedures 63081-63091 include disiectomy above and/or below vertebral segment)			
63056 lumbar ..... (( <del>35-0</del> ))	<del>36.1</del>	90	9.0	(If followed by arthrodesis, see 22554-22585)			
63057 each additional segment, thoracic or lumbar ..... (( <del>5-0</del> ))	<del>5.4</del>	90	9.0	<b>INCISION</b>			
63064 Costovertebral approach for decompression of spinal cord or nerve root(s), (e.g., herniated intervertebral disk), thoracic; single segment ..... (( <del>30-0</del> ))	<del>34.3</del>	90	8.0	63170 Laminectomy for myelotomy (e.g., Bischof or DREZ type), cervical, thoracic, or thoracolumbar ..... (( <del>36-5</del> ))	<del>38.0</del>	90	8.0
63066 each additional segment ..... 5.0	5.0	90	9.0	63172 Laminectomy for drainage of intramedullary cyst/syrinx; to subarachnoid space ..... BR	BR	90	8.0
(For excision of thoracic intraspinal lesions by laminectomy, see 63266, 63271, 63276, 63281, and 63286)				63173 to peritoneal space ..... BR	BR	90	8.0

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
63180 Laminectomy and section of dentate ligaments, with or without dural graft, cervical; one or two segments	38.0	90	8.0	63275 Laminectomy for biopsy/excision of intraspinal neoplasm, extradural, cervical	<del>(35.0)</del> 36.1	90	9.0
63182 more than two segments	<del>(BR)</del> 36.1		8.0	63276 extradural, thoracic	<del>(35.0)</del> 36.1	90	9.0
63185 Laminectomy for rhizotomy; one or two segments	<del>(28.0)</del> 30.7	90	8.0	63277 extradural, lumbar	<del>(31.5)</del> 32.5	90	9.0
63190 more than two segments	<del>(BR)</del> 33.4	90	8.0	63278 extradural, sacral	<del>(31.5)</del> 32.5	90	9.0
63191 Laminectomy for section of spinal accessory nerve( <del>(-unilateral)</del> )	BR		8.0	63280 intradural, extramedullary, cervical	<del>(36.5)</del> 38.0	90	9.0
<del>(63192 bilateral)</del>	<del>BR</del>		<del>8.0)</del>	63281 intradural, extramedullary, thoracic	<del>(36.5)</del> 38.0	90	9.0
(For resection of sternocleidomastoid muscle, use 21720)				63282 intradural, extramedullary, lumbar	<del>(33.0)</del> 34.3	90	9.0
63194 Laminectomy for cordotomy, ( <del>(unilateral)</del> ) with section of one spinothalamic tract, one stage; cervical	<del>(32.0)</del> 33.4	90	8.0	63283 intradural, sacral	<del>(33.0)</del> 34.3	90	9.0
63195 thoracic	<del>(32.0)</del> 33.4	90	7.0	63285 intradural, intramedullary, cervical	<del>(43.5)</del> 45.2	90	9.0
63196 Laminectomy for cordotomy, ( <del>(bilateral)</del> ) with section of both spinothalamic tracts, one stage; cervical	<del>(32.0)</del> 33.4	90	8.0	63286 intradural, intramedullary, thoracic	<del>(43.5)</del> 45.2	90	9.0
63197 thoracic	<del>(32.0)</del> 33.4	90	7.0	63287 intradural, intramedullary, thoracolumbar	<del>(43.5)</del> 45.2	90	9.0
63198 Laminectomy for cordotomy( <del>(-bilateral)</del> ) with section of both spinothalamic tracts, two stages within fourteen days; cervical	<del>(40.0)</del> 39.3	90	8.0	63290 combined extradural-intradural lesion, any level	BR	90	9.0
63199 thoracic	<del>(40.0)</del> 39.3	90	7.0	<b>EXCISION, ANTERIOR OR ANTEROLATERAL APPROACH, INTRASPINAL LESION</b>			
<b>EXCISION BY LAMINECTOMY OF LESION OTHER THAN HERNIATED DISK</b>				(For arthrodesis, see 22548-22650)			
				(For reconstruction of spine, see 22140-22152)			
63200 Laminectomy, for release of tethered spinal cord, lumbar	<del>(32.5)</del> 33.9	90	9.0	63300 Vertebral corpectomy (vertebral body resection), partial or complete, for excision of intraspinal lesion, single segment; extradural, cervical	<del>(39.0)</del> 40.7	90	
63250 Laminectomy for excision or occlusion of arteriovenous malformation of spinal cord; cervical	<del>(BR)</del> 40.7	90	9.0	63301 extradural, thoracic by transthoracic approach	<del>(43.5)</del> 45.2	90	
63251 thoracic	<del>(BR)</del> 40.7	90	8.0	63302 extradural, thoracic by thoracolumbar approach	<del>(43.5)</del> 45.2	90	
63252 thoracolumbar	<del>(48.0)</del> 49.7	90	9.0	63303 extradural, lumbar or sacral by transperitoneal or retroperitoneal approach	<del>(43.5)</del> 45.2	90	
63265 Laminectomy for excision or intraspinal lesion other than neoplasm, extradural; cervical	<del>(35.0)</del> 36.1	90	9.0	63304 intradural, cervical	<del>(39.0)</del> 40.7	90	
63266 thoracic	<del>(35.0)</del> 36.1	90	9.0	63305 intradural, thoracic by transthoracic approach	<del>(43.5)</del> 45.2	90	
63267 lumbar	<del>(31.5)</del> 32.5	90	9.0	63306 intradural, thoracic by thoracolumbar approach	<del>(43.5)</del> 45.2	90	
63268 sacral	<del>(31.5)</del> 32.5	90	9.0	63307 intradural, lumbar, or sacral by transperitoneal or retroperitoneal approach	<del>(43.5)</del> 45.2	90	
63270 Laminectomy for excision of intraspinal lesion other than neoplasm, intradural; cervical	<del>(36.5)</del> 38.0	90	9.0	63308 each additional segment (list separately in addition to codes for single segment 63300-63307)	<del>(5.0)</del> 5.4	90	
63271 thoracic	<del>(36.5)</del> 38.0	90	9.0				
63272 lumbar	<del>(33.0)</del> 34.3	90	9.0				
63273 sacral	<del>(33.0)</del> 34.3	90	9.0				

	Unit Value	Follow-up Days=	Basic Anes@
<b>STEREOTAXIS</b>			
63600 Stereotactic lesion of spinal cord, percutaneous, any modality (including stimulation and/or recording).....	<del>(+8.0)</del> 21.7	90	7.0
63610 Stereotactic stimulation of spinal cord, percutaneous, separate procedure not followed by other surgery.....	<del>(8.0-0)</del> 21.7	90	7.0
63615 Stereotactic biopsy, aspiration, or excision of lesion, spinal cord....	<del>(BR)</del> 26.2	90	7.0
<b>NEUROSTIMULATORS, SPINAL</b>			
63650 Percutaneous implantation of neurostimulator electrodes; epidural.....	BR		8.0
63652 intradural (spinal cord).....	BR		8.0
63655 Laminectomy for implantation of neurostimulator electrodes; epidural.....	BR		10.0
63656 endodural.....	BR		10.0
63657 subdural.....	BR		10.0
63658 spinal cord (dorsal or ventral).....	BR		10.0
63660 Revision or removal of spinal neurostimulator electrodes.....	BR		10.0
63685 Incision for subcutaneous placement of neurostimulator receiver, direct or inductive coupling.....	BR		4.0
63688 Revision or removal of spinal neurostimulator receiver.....	BR		4.0
<b>REPAIR</b>			
63700 Repair of meningocele; less than 5 cm diameter.....	<del>(20.0)</del> 23.5	90	9.0
63702 larger than 5 cm diameter.....	<del>(BR)</del> 25.3	90	9.0
63704 Repair of myelomeningocele; less than 5 cm diameter.....	<del>(BR)</del> 27.1	90	9.0
63706 larger than 5 cm diameter.....	<del>(BR)</del> 28.9	90	9.0
63707 Repair of dural/CSF leak, not requiring laminectomy.....	<del>(28.0)</del> 28.9	90	7.0
63709 Repair of dural/CSF leak, or pseudomeningocele, with laminectomy.....	<del>(28.0)</del> 28.9	90	7.0
63710 Dural graft, spinal.....	<del>(BR)</del> 28.0	90	9.0
(For laminectomy and section of dentate ligaments, with or without dural graft, cervical, see 63180-63182)			
<b>SHUNT, SPINAL CSF</b>			
63740 Creation of shunt, lumbar, subarachnoid-peritoneal, -pleural or other including laminectomy.....	<del>(26.0-90)</del> 23.5	7	9.0
63744 Replacement, irrigation or revision of lumbar-subarachnoid shunt..	<del>(+8.0-90)</del> 11.7	7	5.0
63746 Removal of entire lumbosubarachnoid shunt system without replacement.....	<del>(+8.0-90)</del> 9.0	7	5.0

	Unit Value	Follow-up Days=	Basic Anes@
63750 Insertion, subarachnoid catheter with reservoir and/or pump for intermittent or continuous infusion of drug, including laminectomy.....	<del>(BR)</del> 22.1	7	5.0
63780 Insertion, subarachnoid or epidural catheter, with reservoir and/or pump for drug infusion, without laminectomy.....	<del>(+7.5)</del> 18.1	7	7.0
(For pump refilling and maintenance, see 96520 and 96530)			

**AMENDATORY SECTION** (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

**WAC 296-22-375 EXTRACRANIAL NERVES, PERIPHERAL NERVES AND AUTONOMIC NERVOUS SYSTEM.**

(For intracranial surgery on cranial nerves, see 61450, 61460, 61790)

**INTRODUCTION/INJECTION OF ANESTHETIC AGENT (NERVE BLOCK), DIAGNOSTIC OR THERAPEUTIC**

	Unit Value	Follow-up Days=	Basic Anes@
<b>SOMATIC NERVES</b>			
64400* Injection, anesthetic agent; trigeminal nerve, any division or branch.....	<del>(+3.0)</del> 2.3	0	
64402* facial nerve.....	<del>(+2.5)</del> 1.6	0	
64405* greater occipital nerve.....	<del>(+2.5)</del> 0.6	0	
64408* vagus nerve.....	<del>(+2.5)</del> 1.1	0	
64410* phrenic nerve.....	<del>(+2.5)</del> 1.1	0	
64412* spinal accessory nerve.....	<del>(+2.5)</del> 1.1	0	
64413* cervical plexus.....	<del>(+2.5)</del> 1.1	0	
64415* brachial plexus.....	<del>(+2.5)</del> 1.4	0	
64417* axillary nerve.....	<del>(+2.5)</del> 1.4	0	
64418* suprascapular nerve.....	<del>(2.0)</del> 1.4	0	
64420* intercostal nerve, single.....	<del>(+2.0)</del> 1.4	0	
64421* intercostal nerves, multiple, regional block.....	<del>(+2.5)</del> 1.4	0	
64425* ilioinguinal, iliohypogastric nerves.....	<del>(+2.0)</del> 1.4	0	
64430* pudendal nerve.....	<del>(+2.5)</del> 1.4	0	
64435* paracervical (uterine) nerve.....	<del>(+2.5)</del> 1.4	0	
64440* paravertebral nerve (thoracic, lumbar, sacral, coccygeal), single.....	<del>(+3.0)</del> 1.4	0	

	Unit Value	Follow-up Days=	Basic Anes@
64441* paravertebral nerves, multiple, regional block . . . . .	<del>(3.2)</del> 1.4	0	
64442* paravertebral facet joint nerve, lumbar, single level . . . . .	<del>(2.5)</del> 1.7	0	
64443* paravertebral facet joint nerve, lumbar, each additional level . . . . .	<del>(0.5)</del> 1.0	0	
64445* sciatic nerve . . . . .	<del>(2.5)</del> 1.4	0	
64450* other peripheral nerve or branch . . . . .	<del>(2.0)</del> 0.5	0	
(For phenol destruction, see 64600-64640)			
(For subarachnoid or subdural, see 62274-62277)			
(For epidural or caudal, see 62278, 62279)			

**SYMPATHETIC NERVES**

64505* Injection, anesthetic agent; sphenopalatine ganglion . . . . .	<del>(3.0)</del> 1.2	0	
64508* carotid sinus (separate procedure) . . . . .	<del>(2.5)</del> 1.2	0	
64510* stellate ganglion (cervical sympathetic) . . . . .	<del>(2.0)</del> 1.2	0	
64520* lumbar or thoracic (paravertebral sympathetic) . . . . .	<del>(3.0)</del> 1.4	0	
64530* celiac plexus, with or without radiologic monitoring . . . . .	<del>(4.0)</del> 1.2	0	

**NEUROSTIMULATORS, PERIPHERAL NERVE**

64550 Application of surface (transcutaneous) neurostimulator . . . . .	<del>(BR)</del> 0.9	0	
64553 Percutaneous implantation of neurostimulator electrodes; cranial nerve . . . . .	<del>(BR)</del> 3.2	0	
64555 peripheral nerve . . . . .	<del>(BR)</del> 2.5	0	
64560 autonomic nerve . . . . .	<del>(BR)</del> 2.5	0	
64565 neuromuscular . . . . .	<del>(BR)</del> 2.5	0	
64573 Incision for implantation of neurostimulator electrodes; cranial nerve . . . . .	<del>(BR)</del> 5.4	0	
64575 peripheral nerve . . . . .	<del>(BR)</del> 4.7	0	
64577 autonomic nerve . . . . .	<del>(BR)</del> 4.7	0	
64580 neuromuscular . . . . .	<del>(BR)</del> 4.7	0	
64585 Revision or removal of peripheral neurostimulator electrodes . . . . .	<del>(BR)</del> 4.1	0	
64590 Incision for subcutaneous placement of neurostimulator receiver, direct or inductive coupling . . . . .	<del>(BR)</del> 4.4	0	

	Unit Value	Follow-up Days=	Basic Anes@
64595 Revision or removal of peripheral neurostimulator receiver . . . . .	<del>(BR)</del> 3.0	0	

**DESTRUCTION BY NEUROLYTIC AGENT (E.G., CHEMICAL, THERMAL, ELECTRICAL, RADIOFREQUENCY) SOMATIC NERVES**

64600 Destruction by neurolytic agent, trigeminal nerve; supraorbital, infraorbital, mental, or inferior alveolar branch . . . . .	<del>(5.0)</del> 2.3	7	
64605 second and third division branches at foramen ovale . . . . .	<del>(5.0-30)</del> 4.1	7	
64610 second and third division branches at foramen ovale under radiologic monitoring . . . . .	5.0	<del>(30)</del> 7	
64620 Destruction by neurolytic agent; intercostal nerve . . . . .	<del>(4.0)</del> 1.4	7	
64622 paravertebral facet joint nerve, lumbar, single level . . . . .	<del>(BR)</del> 2.3	7	
64623 paravertebral facet joint nerve, lumbar, each additional level . . . . .	<del>(BR)</del> 0.5	7	
64630 pudendal nerve . . . . .	<del>(5.0)</del> 0.7	7	
64640 Other peripheral nerve or branch . . . . .	<del>(5.0)</del> 0.7	7	

**SYMPATHETIC NERVES**

64680 Destruction by neurolytic agent, celiac plexus, with or without radiologic monitoring . . . . .	<del>(6.0)</del> 2.7	7	
---	-------------------------	---	--

**NEUROPLASTY (EXPLORATION, NEUROLYSIS OR NERVE DECOMPRESSION)**

Neuroplasty is the decompression or freeing of intact nerve from scar tissue, including external neurolysis and transposition

(For internal neurolysis by dissection, see 64727)

(For facial nerve decompression, see 69720)

64702 Neuroplasty; digital, one or both, same digit . . . . .	<del>(4.0)</del> 4.5	90	3.0
64704 nerve of hand or foot . . . . .	<del>(8.0)</del> 7.2	90	3.0
64708 Neuroplasty, major peripheral nerve; arm or leg; other than specified . . . . .	<del>(12.0)</del> 9.0	90	4.0
64712 sciatic nerve . . . . .	<del>(BR)</del> 12.7	90	6.0
64713 brachial plexus . . . . .	<del>(BR)</del> 11.7	90	6.0
64714 lumbar plexus . . . . .	<del>(BR)</del> 11.7	90	6.0
64716 Neuroplasty and/or transposition; cranial nerve (specify) . . . . .	<del>(BR)</del> 13.6	90	6.0
64718 ulnar nerve at elbow . . . . .	<del>(15.0)</del> 9.9	90	3.0
64719 ulnar nerve at wrist . . . . .	<del>(9.0)</del> 7.1	90	3.0
64721 median nerve at carpal . . . . .	7.1	90	3.0



	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
tunnel	<del>((10-0))</del> 7.6	90	3.0	(For excision of tender scar, skin and subcutaneous tissues with or without tiny neuroma, see 11400-11460, 13000-13300)			
64722 Decompression; unspecified nerve(s) (specify)	<del>((BR))</del> 9.0	90					
64726 plantar digital nerve	<del>((6-0))</del> 4.3	90	3.0	<b>EXCISION-SOMATIC NERVES</b>			
64727 Internal neurolysis, requiring use of operating microscope (list separately in addition to code for neuroplasty) (neuroplasty includes external neurolysis)	BR		3.0	(For Morton neurectomy, see 28080)			
<b>TRANSECTION OR AVULSION OF NERVE</b>							
(For stereotactic lesion of gasserian ganglion, see 61790)							
64732 Transection or avulsion of; supra-orbital nerve	<del>((7-0))</del> 6.3	30	3.0	64774 Excision of neuroma; cutaneous nerve, surgically identifiable	<del>((3-0))</del> 3.6	30	3.0
64734 infraorbital nerve	<del>((7-0))</del> 6.3	30	3.0	64776 digital nerve, one or both, same digit	<del>((3-0))</del> 3.6	30	3.0
64736 mental nerve	<del>((7-0))</del> 9.0	30	3.0	64778 digital nerve, each additional digit (list separately by this number)	<del>((2-0))</del> 1.8	30	
64738 inferior alveolar nerve by osteotomy	<del>((10-0))</del> 9.0	30	3.0	64782 hand or foot, except digital nerve	<del>((6-0))</del> 5.4	30	3.0
64740 lingual nerve	<del>((BR))</del> 4.5	30	3.0	64783 hand or foot, each additional nerve, except same digit (list separately by this number)	<del>((3-0))</del> 1.9	30	3.0
64742 facial nerve, differential or complete	<del>((BR))</del> 9.0	30	3.0	64784 major peripheral nerve except sciatic	<del>((10-0))</del> 8.1	30	3.0
64744 greater occipital nerve	<del>((7-0))</del> 6.8	30	3.0	64786 sciatic nerve	<del>((BR))</del> 9.5	30	3.0
64746 phrenic nerve	<del>((5-0))</del> 4.5	30	3.0	64787 Implantation of nerve end into bone or muscle (list separately in addition to neuroma excision)	<del>((5-5))</del> 5.7	30	3.0
(For section of recurrent laryngeal nerve, see 31595)				64788 Excision of neurofibroma or neurolemmoma, cutaneous nerve	<del>((6-0))</del> 5.7	30	3.0
64752 vagus nerve (vagus), transthoracic	<del>((14-0))</del> 13.1	45	11.0	64790 major peripheral nerve	<del>((BR))</del> 8.1	60	3.0
64755 vagi limited to proximal stomach (selective proximal vagotomy, proximal gastric vagotomy, parietal cell vagotomy, supra- or highly selective vagotomy)	<del>((BR))</del> 20.8	45	3.0	64792 extensive (including malignant type)	<del>((BR))</del> 9.9	60	3.0
64760 vagus nerve (vagus), abdominal	<del>((14-0))</del> 12.7	45	6.0	64795 Biopsy of nerve	<del>((BR))</del> 2.7	0	
64761 pudendal nerve(, unilateral)	<del>((BR))</del> 4.5	45	6.0	<b>EXCISION-SYMPATHETIC NERVES</b>			
<del>((64762 pudendal nerve, bilateral</del>	<del>BR</del>		<del>6.0)</del>	64802 Sympathectomy, cervical(, unilateral)	<del>((14-5))</del> 13.1	60	6.0
64763 Transection or avulsion of obturator nerve, extrapelvic, with or without adductor tenotomy(, unilateral)	<del>((6-0))</del> 5.4	45	3.0	<del>((64803 bilateral</del>	<del>19.0</del>	<del>60</del>	<del>6.0)</del>
<del>((64764 bilateral</del>	<del>9.0</del>	<del>45</del>	<del>3.0)</del>	64804 Sympathectomy, cervicothoracic(, unilateral); one stage	<del>((20-0))</del> 18.1	60	6.0
64766 Transection or avulsion of obturator nerve, intrapelvic, with or without adductor tenotomy(, unilateral)	<del>((10-0))</del> 9.0	60	4.0	<del>((64806 bilateral or two stage unilateral</del>	<del>28.0</del>	<del>60</del>	<del>8.0)</del>
<del>((64768 bilateral</del>	<del>13.0</del>	<del>60</del>	<del>4.0)</del>	64809 Sympathectomy, thoracolumbar(, unilateral)	<del>((20-0))</del> 18.1	60	6.0
64771 Transection or avulsion of other cranial nerve, extradural	<del>((BR))</del> 9.9	30	3.0	<del>((64811 bilateral</del>	<del>28.0</del>	<del>60</del>	<del>8.0)</del>
64772 Transection or avulsion of other spinal nerve, extradural	<del>((BR))</del> 5.4	30	3.0	64818 Sympathectomy, lumbar(, unilateral)	<del>((15-0))</del> 10.8	60	5.0
				<del>((64819 bilateral</del>	<del>21.0</del>	<del>60</del>	<del>5.0)</del>
				<b>NERVE REPAIR BY SUTURE (NEURORRHAPHY)</b>			
				64830 Microdissection and/or microrepair of nerve (list separately in addition to code for nerve repair)	<del>((BR))</del> 1.8	0	4.0
				64831 Suture of digital nerve, hand or foot; one nerve	<del>((4-8))</del> 5.2	90	3.0

	Unit Value	Follow-up Days=	Basic Anes@
64832 each additional digit nerve . . . .	<del>((12.2))</del> 2.3	90	
64834 Suture of one nerve, hand or foot; common sensory nerve . . . . .	<del>((8.0))</del> 7.2	90	3.0
64835 median motor thenar . . . . .	<del>((10.0))</del> 9.0	90	3.0
64836 ulnar motor . . . . .	<del>((12.0))</del> 10.8	90	3.0
64837 Suture of each additional nerve, hand or foot . . . . .	<del>((BR))</del> 5.4	90	3.0
64840 Suture of posterior tibial nerve . . . . .	<del>((BR))</del> 10.8	90	3.0
64856 Suture of major peripheral nerve, arm or leg, except sciatic; including transposition . . . . .	<del>((14.0))</del> 10.8	90	3.0
64857 without transposition . . . . .	<del>((BR))</del> 10.8	90	3.0
64858 Suture of sciatic nerve . . . . .	<del>((BR))</del> 13.3	90	3.0
64859 Suture of each additional major peripheral nerve . . . . .	<del>((BR))</del> 3.6	90	3.0
64861 Suture of; brachial plexus . . . . .	<del>((BR))</del> 12.2	90	3.0
64862 lumbar plexus . . . . .	<del>((BR))</del> 12.2	90	3.0
64864 Suture of facial nerve; extracranial . . . . .	<del>((BR))</del> 10.8	90	3.0
64865 intratemporal, with or without grafting . . . . .	<del>((BR))</del> 10.8	90	3.0
64866 Anastomosis; facial-spinal accessory . . . . .	<del>((26.0-90))</del> 26.7	90	3.0
64868 facial-hypoglossal . . . . .	<del>((26.0))</del> 26.7	90	3.0
64870 facial-phrenic . . . . .	<del>((26.0))</del> 26.7	90	3.0
64872 Suture of nerve; requiring secondary or delayed suture (list separately in addition to code for primary neurorrhaphy) . . . . .	<del>((BR))</del> 1.8	90	3.0
64874 requiring extensive mobilization, or transposition of nerve (list separately in addition to code for nerve suture) . . . . .	<del>((BR))</del> 1.8	90	3.0
64876 requiring shortening of bone of extremity (list separately in addition to code for nerve suture) . . . . .	<del>((BR))</del> 1.8	90	3.0

**NEURORRHAPHY WITH NERVE GRAFT**

64890 Nerve graft (includes obtaining graft), single strand, hand or foot; up to 4 cm length . . . . .	<del>((BR-90))</del> 12.7 120		3.0
64891 more than 4 cm length . . . . .	<del>((BR-90))</del> 14.5 120		3.0
64892 Nerve graft (includes obtaining graft), single strand, arm or leg; up to 4 cm length . . . . .	<del>((BR-90))</del> 12.7 120		3.0
64893 more than 4 cm length . . . . .	<del>((BR-90))</del> 14.5 120		3.0

	Unit Value	Follow-up Days=	Basic Anes@
64895 Nerve graft (includes obtaining graft), multiple strands (cable), hand or foot; up to 4 cm length . . . . .	<del>((BR-90))</del> 16.3 120		3.0
64896 more than 4 cm length . . . . .	<del>((BR-90))</del> 18.1 120		3.0
64897 Nerve graft (includes obtaining graft), multiple strands (cable), arm or leg; up to 4 cm length . . . . .	<del>((BR-90))</del> 16.3 120		3.0
64898 more than 4 cm length . . . . .	<del>((BR-90))</del> 18.1 120		3.0
64901 Nerve graft, each additional nerve; single strand . . . . .	<del>((BR-90))</del> 1.8 120		3.0
64902 multiple strands (cable) . . . . .	<del>((BR-90))</del> 3.6 120		3.0
64905 Nerve pedicle transfer; first stage . . . . .	<del>((BR-90))</del> 7.2 120		3.0
64907 second stage . . . . .	<del>((BR-90))</del> 7.2 120		3.0

**OTHER PROCEDURES**

64999 Unlisted procedure, nervous system . . . . .	BR		3.0
--	----	--	-----

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-405 EYEBALL.**

	Unit Value	Follow-up Days=	Basic Anes@
<b>REMOVAL OF EYE</b>			
65091 Evisceration ocular contents; without implant . . . . .	<del>((10.0))</del> 9.0	30	3.0
65093 with implant . . . . .	<del>((12.0))</del> 11.3	30	3.0
65101 Enucleation of eye, without implant . . . . .	<del>((10.0))</del> 11.3	30	3.0
65103 with implant, muscles not attached to implant . . . . .	<del>((11.0))</del> 12.7	30	3.0
65105 with, muscles attached to implant, muscles attached to implant . . . . .	<del>((12.0))</del> 15.4	30	3.0
(For conjunctivoplasty after enucleation, see 68320 et seq)			
65110 Exenteration orbit (does not include skin graft), removal orbital contents; only . . . . .	<del>((20.0-60))</del> 18.1 30		4.0
65112 with therapeutic removal of bone . . . . .	<del>((BR))</del> 20.3 30		4.0
65114 with temporalis muscle transplant . . . . .	<del>((25.0-60))</del> 23.5 30		4.0
(For skin graft to orbit (split skin), see 15120, 15121; free, full thickness, see 15260, 15261)			
(For eyelid repair involving more than skin, see 67930 et seq)			

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
<b>SECONDARY IMPLANT PROCEDURES</b>				65235	from anterior chamber, non-magnetic extraction . . . . .	<del>((16.0))</del> 13.6	45 8.0
An ocular implant is an implant inside muscular cone; an orbital implant is an implant outside muscular cone.				65240	from lens (without extraction lens), magnetic extraction . . . . .	<del>((12.0—30))</del> 12.7	45 6.0
65130	Insertion ocular implant secondary; after evisceration, in scleral shell . . . . .	<del>((8.0))</del> 10.4	30 4.0	65245	from lens (without extraction lens), nonmagnetic extraction . . . . .	<del>((BR))</del> 12.7	45 8.0
65135	after enucleation, muscles not attached to implant . . . . .	<del>((10.0))</del> 11.3	30 4.0	(For removal implanted material anterior segment, see 65920)			
65140	after enucleation, muscles attached to implant . . . . .	<del>((14.0))</del> 13.6	30 4.0	65260	from posterior segment, magnetic extraction, anterior or posterior route . . . . .	<del>((12.0—30))</del> 18.1	45 6.0
65150	Reinsertion ocular implant; with or without conjunctival graft . . . . .	<del>((BR))</del> 9.9	30 4.0	65265	from posterior segment, non-magnetic extraction . . . . .	<del>((18.0—30))</del> 18.1	45 8.0
65155	with use of foreign material for reinforcement and/or attachment of muscles to implant . . . . .	<del>((BR))</del> 10.8	30 4.0	(For removal implanted material posterior segment, see 67120)			
65175	Removal ocular implant . . . . .	<del>((BR))</del> 6.8	30 4.0	<b>REPAIR OF LACERATION OF EYEBALL</b>			
(For orbital implant (implant outside muscle cone) insertion, see 67550; removal, see 67560)				(For fracture of orbit, see 21385 et seq.)			
<b>REMOVAL OF OCULAR FOREIGN BODY</b>				(For repair wound of eyelid, skin, linear, simple, see 12011-12018; intermediate, layered closure, see 12051-12057; linear, complex, see 13150-13300; other, see 67930-67935)			
(For removal of implanted material: Ocular implant, see 65175; anterior segment implant, see 65920; posterior segment implant, see 67120; orbital implant, see 67560)				(For repair wound of lacrimal system, see 68700)			
(For diagnostic x-ray for foreign body, see 70030-70050)				(For repair operative wound, see 66250)			
(For diagnostic echography for foreign body, see 76529)				65270*	Repair laceration; conjunctiva, with or without nonperforating laceration sclera, direct closure . . . . .	<del>((0.9—0))</del> 1.8	7 4.0
(For removal of foreign body from orbit: Frontal approach, see 67413; lateral approach, see 67430; transcranial approach, see 61334)				65272	conjunctiva, by mobilization and rearrangement, without hospitalization . . . . .	<del>((BR))</del> 2.7	7 4.0
(For removal of foreign body from eyelid, embedded, see 67938)				65273	conjunctiva, by mobilization and rearrangement, with hospitalization . . . . .	<del>((BR))</del> 4.5	7 4.0
(For removal of foreign body from lacrimal system, see 68530)				65275	cornea, nonperforating, with or without removal foreign body . . . . .	<del>((SV))</del> 6.8	60 4.0
65205*	Removal foreign body, external eye; conjunctival superficial . . . . .	<del>((0.2))</del> 0.6	0 4.0	65280	cornea and/or sclera, perforating, not involving uveal tissue . . . . .	<del>((BR—30))</del> 12.7	60 5.0
65210*	conjunctival embedded (includes concretions), subconjunctival, or scleral nonperforating . . . . .	<del>((0.6))</del> 0.7	0 4.0	65285	cornea and/or sclera, perforating, with reposition or resection of uveal tissue . . . . .	<del>((15.4—30))</del> 13.6	60 6.0
65220*	corneal, without slit lamp . . . . .	<del>((0.6))</del> 0.7	0 4.0	65286	application of tissue glue, wounds of cornea and/or sclera . . . . .	<del>((1.0))</del> BR	0 4.0
65222*	corneal, with slit lamp . . . . .	<del>((0.8))</del> 1.1	0 4.0	(Repair of laceration includes use of conjunctival flap and restoration of anterior chamber, by air or saline injection when indicated)			
(For repair of corneal laceration with foreign body, see 65275)				(For repair of iris or ciliary body; see 66680)			
65230	Removal foreign body intraocular; from anterior chamber, magnetic extraction . . . . .	<del>((12.0))</del> 11.7	45 6.0				

	Unit Value	Follow-up Days=	Basic Anes@
65290 Repair wound extraocular muscle, tendon and/or Tenon's capsule . . .	<del>((4.4))</del> 9.0	30	4.0

**AMENDATORY SECTION** (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

**WAC 296-22-410 ANTERIOR SEGMENT—CORNEA.**

**INCISION**

	Unit Value	Follow-up Days=	Basic Anes@
65300 Delimiting keratotomy . . . . .	<del>((2.0))</del> 1.8	15	3.0
(For paracentesis of cornea, see 65800-65815)			
(For removal of foreign body, cornea, see 65220-65222)			

**EXCISION**

65400 Excision lesion cornea (keratectomy, lamellar, partial), except pterygium . . . . .	<del>((8.0))</del> 7.2	30	3.0
65410* Biopsy cornea . . . . .	<del>((1.0))</del> 5.4	0	3.0
65420 Excision or transposition, pterygium; without graft . . . . .	<del>((6.0))</del> 4.5	30	3.0
65426 with graft . . . . .	<del>((BR))</del> 6.3	30	3.0

**REMOVAL OR DESTRUCTION**

65430* Scraping cornea, diagnostic, for smear and/or culture . . . . .	<del>((0.4))</del> 0.5	0	4.0
65435* Removal corneal epithelium; with or without chemocauterization (abrasion, curettage) . . . . .	<del>((1.0))</del> 0.9	0	4.0
65436 with application of chelating agent, e.g., EDTA . . . . .	<del>((BR))</del> 1.8	0	
65450 Destruction of lesion of cornea by cryotherapy; photocoagulation or thermocauterization . . . . .	<del>((1.6-7))</del> 1.2	0	4.0
65600 Tattoo of cornea, mechanical or chemical . . . . .	<del>((8.0))</del> 5.4	30	3.0

**KERATOPLASTY**

(Keratoplasty excludes refractive keratoplasty procedures, 65760, 65765, 65767)

(Corneal transplant includes preparation of donor material)

65710 Keratoplasty (corneal transplant), lamellar, includes autografts, and fresh or preserved homografts . . . . .	<del>((24.0))</del> 21.7	90	8.0
65730 Keratoplasty (corneal transplant), penetrating (except in aphakia), includes autografts, and fresh or preserved homografts . . . . .	<del>((30.0))</del> 26.7	90	8.0

65750 Keratoplasty (corneal transplant), penetrating, (in aphakia), includes autografts, and fresh or preserved homografts . . . . .	<del>((30.0))</del> 31.6	90	8.0
--	-----------------------------	----	-----

**OTHER PROCEDURES**

65760 Keratomileusis . . . . .	<del>((30.0))</del> 28.9	90	8.0
65765 Keratophakia . . . . .	<del>((30.0))</del> 31.6	90	8.0
65767 Epikeratophakia . . . . .	BR	90	8.0
65770 Keratoprosthesis . . . . .	<del>((32.0))</del> 27.1	90	8.0
65772 Corneal relaxing incision for correction of surgically induced astigmatism . . . . .	<del>((12.0))</del> BR	90	8.0
65775 Corneal wedge resection for correction of surgically induced astigmatism . . . . .	<del>((12.0))</del> BR	90	8.0
(For fitting of contact lens for treatment of disease, see 92070)			
(For unlisted procedures on cornea, see 66999)			

**AMENDATORY SECTION** (Amending Order 86-19, filed 2/28/86, effective 4/1/86)

**WAC 296-22-413 ANTERIOR SEGMENT—ANTERIOR CHAMBER.**

	Unit Value	Follow-up Days=	Basic Anes@
<b>INCISION</b>			
*65800 Paracentesis anterior chamber eye (separate procedure); with diagnostic aspiration of aqueous . . . . .	<del>((1.0))</del> 2.7	0	3.0
65805* with therapeutic release of aqueous . . . . .	<del>((1.5))</del> 2.3	0	3.0
65810 with removal of vitreous and/or discission of anterior hyaloid membrane, with or without air injection . . . . .	<del>((8.0))</del> 9.0	90	3.0
65815 with removal of blood, with or without irrigation and/or air injection . . . . .	<del>((5.6))</del> 13.6	15	3.0
(For injection, see 66020-66030)			
(For removal of blood clot, see 65930)			
65820 Goniotomy; without goniopuncture . . . . .	<del>((10.0))</del> 9.0	30	3.0
65825 with goniopuncture . . . . .	<del>((10.0))</del> 9.0	30	4.0
65830 Goniopuncture, without goniotomy . . . . .	<del>((BR))</del> 9.0	30	3.0
65850 Trabeculotomy ab externo . . . . .	<del>((BR))</del> 14.5	45	3.0

	Unit Value	Follow-up Days=	Basic Anes@
65855 Trabeculoplasty by laser surgery, one or more sessions (defined treatment series) . . . . .	<del>((BR))</del> 9.0	45	3.0

(If retreatment necessary after several months because of disease progression, a new treatment or treatment series should be reported with a modifier, if necessary, to indicate lessor or greater complexity)

(For trabeculectomy, see 66170)

OTHER PROCEDURES

65865 Severing adhesions anterior segment of eye, incisional technique (with or without injection air or liquid) (separate procedure); goniosynechia . . . . .	<del>((+0.0))</del> 9.5	30	6.0
65870 anterior synechia, except goniosynechia . . . . .	<del>((9.0))</del> BR	30	6.0
65875 posterior synechia . . . . .	<del>((9.0))</del> BR	30	6.0
65880 corneovitreal adhesions . . . . .	BR	30	3.0
65900 Removal epithelial downgrowth anterior chamber eye . . . . .	BR	0	6.0
65920 Removal implanted material anterior segment eye . . . . .	<del>((BR))</del> 18.1	30	6.0
65930 Removal of blood clot, anterior segment eye . . . . .	<del>((BR))</del> 9.0	30	6.0
66020 Injection, anterior chamber (separate procedure); air or liquid . . . . .	<del>((2.0-7))</del> 2.3	0	3.0
66030* medication . . . . .	<del>((+))</del> BR	7	3.0

(For unlisted procedures on anterior segment, see 66999)

AMENDATORY SECTION (Amending Order 86-19, filed 2/28/86, effective 4/1/86)

WAC 296-22-415 ANTERIOR SEGMENT—ANTERIOR SCLERA.

	Unit Value	Follow-up Days=	Basic Anes@
EXCISION			
(For removal of intraocular foreign body, see 65230-65235)			
(For operations on posterior sclera, see 67250-67255)			
66130 Excision lesion sclera . . . . .	<del>((BR))</del> 3.6	45	6.0
66150 Fistulization sclera for glaucoma; trephination with iridectomy . . . . .	<del>((+2.0))</del> 13.1	45	6.0
66155 thermocauterization with iridectomy . . . . .	<del>((+2.0))</del> 12.7	45	6.0
66160 sclerectomy with punch or scissors, with iridectomy . . . . .	<del>((+2.0))</del> 12.7	45	6.0

	Unit Value	Follow-up Days=	Basic Anes@
66165 iridencleisis or iridotasis . . . . .	<del>((+2.0))</del> 11.7	45	6.0
66170 trabeculectomy ab externo . . . . .	<del>((BR))</del> 14.5	45	

(For trabeculectomy ab externo, see 65850)

(For repair of operative wound, see 66250)

REPAIR

(For scleral procedures in retinal surgery, see 67102 et seq)

66220 Repair scleral staphyloma; without graft . . . . .	<del>((20.0))</del> 18.1	90	6.0
66225 with graft . . . . .	<del>((24.0))</del> 21.7	90	6.0

(For scleral reinforcement, see 67250-67255)

REVISION OPERATIVE WOUND

66250 Revision or repair operative wound anterior segment, any type, early or late, major or minor procedure . . . . .	BR		6.0
--	----	--	-----

OTHER PROCEDURES

(For unlisted procedures on anterior sclera, see 66999)

AMENDATORY SECTION (Amending Order 81-28, filed 11/30/81, effective 1/1/82)

WAC 296-22-420 ANTERIOR SEGMENT—IRIS, CILIARY BODY.

	Unit Value	Follow-up Days=	Basic Anes@
IRIDOTOMY, IRIDECTOMY			
66500 Iridotomy by stab incision (separate procedure); except transfixion . . . . .	<del>((5.0))</del> 5.9	30	3.0
66505 with transfixion as for iris bombe . . . . .	<del>((5.0))</del> 5.9	30	3.0
66600 Iridectomy, with corneoscleral or corneal section; for removal of lesion . . . . .	<del>((+4.0))</del> 12.7	45	3.0
66605 with cyclectomy . . . . .	<del>((20.0))</del> 19.9	45	3.0
66625 peripheral for glaucoma (separate procedure) . . . . .	<del>((+0.0))</del> 9.0	45	3.0
66630 sector for glaucoma (separate procedure) . . . . .	<del>((+0.0))</del> 9.0	45	3.0
66635 "optical" (separate procedure) . . . . .	<del>((+0.0))</del> 9.0	45	3.0

(For "iridotomy" by photocoagulation, see 66761)

(For "coreoplasty" by photocoagulation, see 66762)

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
<b>REPAIR</b>				66821	laser surgery (e.g., YAG laser) (one or more stages) ..... ((BR)) <u>5.0</u> 45 3.0		
66680	Repair of iris, ciliary body (as for iridodialysis)..... ((+0.0)) <u>10.8</u>	45	3.0	<b>REMOVAL CATARACT</b>			
	(For reposition or resection of uveal tissue with perforating wound of cornea or sclera, see 65285)			66830	Removal of secondary membranous cataract ("after cataract"), with corneoscleral section, with or without iridectomy (iridocapsulotomy, iridocapsulectomy) ..... ((+2.0)) <u>16.3</u> 90 3.0		
66682	Suture of iris, ciliary body (separate procedure) with retrieval of suture through small incision (e.g., McCannel suture) ..... ((BR)) <u>13.6</u>	45	3.0	66840	Removal of lens material; aspiration technique, one or more stages ..... ((+2.0 - 3.0)) <u>16.3</u> <u>90</u> 3.0		
<b>DESTRUCTION</b>				66850	phacofragmentation technique (mechanical or ultrasonic, e.g., phacoemulsification), with aspiration ..... ((+6.0)) <u>18.1</u> 90 3.0		
66700	Cyclodiathermy; initial ..... ((8.0)) <u>6.3</u>	30	3.0	66915	Expression lens, linear, one or more stages ..... ((20.0)) <u>18.1</u> 90 3.0		
66701	subsequent ..... ((4.0)) <u>6.3</u>	30	3.0	66920	Extraction lens with or without iridectomy; intracapsular, with or without enzymes ..... ((20.0)) <u>18.1</u> 90 3.0		
66720	Cyclocryotherapy; initial ..... ((6.0)) <u>6.3</u>	30	3.0	66930	intracapsular, for dislocated lens ..... ((22.0)) <u>21.7</u> 90 3.0		
66721	subsequent ..... ((3.0)) <u>6.3</u>	30	3.0	66940	extracapsular (other than 66840, 66850, 66915) ..... ((20.0)) <u>18.1</u> 90 3.0		
66740	Cyclodialysis; initial ..... ((+2.0)) <u>12.2</u>	45	3.0	Preliminary iridectomy, done as a separate procedure prior to extraction of lens, is included in the listed extraction of lens			
66741	subsequent ..... ((6.0)) <u>BR</u>	45	3.0	(For removal of intralenticular foreign body without lens extraction, see 65240-65245)			
66761	Coreoplasty ("irodotomy") by photocoagulation; for glaucoma . . . . . ((5.0 - 30)) <u>9.0</u>	45	3.0	(For repair of operative wound, see 66250)			
66762	other than for glaucoma . . . . . ((5.0)) <u>5.4</u>	30	3.0	<b>ANTERIOR SEGMENT—OTHER PROCEDURES</b>			
66770	Destruction of cyst or lesion iris or ciliary body (nonexcisional procedure) ..... ((9.0 - 45)) <u>6.8</u>	30	3.0	66983	Intracapsular cataract extraction with insertion of intraocular lens prosthesis (one stage procedure) . . . . . ((BR)) <u>25.3</u> <u>0</u> 3.0		
<b>OTHER PROCEDURES</b>				66984	Extracapsular cataract removal with insertion of intraocular lens prosthesis (one stage procedure), manual or phacoemulsification technique ..... ((BR)) <u>25.3</u> <u>90</u> 3.0		
(For unlisted procedures on iris, ciliary body, see 66999)				66985	insertion of intraocular lens subsequent to cataract extraction (separate procedure) ..... ((BR)) <u>18.1</u> <u>120</u> 3.0		
<b>AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)</b>				(For removal of implanted material from anterior segment, see 65920)			
<b>WAC 296-22-425 ANTERIOR SEGMENT—LENS.</b>				(For intraocular lens prosthesis supplied by physician, see 99070)			
	Unit Value	Follow-up Days=	Basic Anes@	(For ultrasonic determination of intraocular lens power, see 76516, 76517)			
<b>INCISION</b>				(For secondary fixation (separate procedure), see 66682)			
66800	Discission of lens capsule; incisional technique (needling of lens); initial ..... ((5.0)) <u>5.4</u>	45	3.0	66999	Unlisted procedure, anterior segment of eye ..... BR 3.0		
66801	subsequent ..... ((2.4)) <u>5.4</u>	45	3.0				
66802	laser surgery (one or more stages) ..... ((BR)) <u>5.2</u>	45	3.0				
66820	Discission of secondary membranous cataract ("after cataract") and/or anterior hyaloid; incisional technique (Ziegler or Wheeler Knife) ..... 5.0	45	3.0				

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-427 POSTERIOR SEGMENT—VITREOUS.**

	Unit Value	Follow- up Days=	Basic Anes@
67005 Removal of vitreous, anterior approach (open sky technique or limbal incision); partial removal . . . . .	((BR)) <u>16.3</u>	90	3.0
67010 subtotal removal with mechanical vitrectomy (such as VISC or rotoextractor) . . . . .	((BR)) <u>22.6</u>	90	3.0
(For removal of vitreous by paracentesis of anterior chamber, see 65810)			
(For removal of corneovitreal adhesions, see 65880)			
67015 Aspiration or release of vitreous, subretinal or choroidal fluid, pars plana approach (posterior sclerotomy) . . . . .	((9.0—15)) <u>9.9</u>	60	3.0
67025 Injection of vitreous substitute, pars plana approach (separate procedure), excludes air or balanced salt solutions . . . . .	((12.0—30)) <u>9.9</u>	60	3.0
67030 Dissection of vitreous strands (without removal), pars plana approach . . . . .	((BR)) <u>13.6</u>	45	3.0
67031 Severing of vitreous strands, vitreous face adhesions, sheets, membranes, or opacities, laser surgery (one or more stages) . . . . .	((BR)) <u>9.9</u>	45	3.0
67036 Vitrectomy, mechanical, pars plana approach . . . . .	((BR)) <u>31.6</u>	60	3.0
67038 with epiretinal membrane stripping . . . . .	((14.0)) <u>BR</u>	30	3.0
67040 with endolaser panretinal photocoagulation . . . . .	((14.0)) <u>BR</u>	30	3.0
(For associated lensectomy, see 66850)			
(For use of vitrectomy in retinal detachment surgery, see 67108)			
(For associated removal of foreign body, see 65260-65265)			
(For unlisted procedures on vitreous, see 67299)			

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-430 POSTERIOR SEGMENT—RETINAL DETACHMENT.**

**REPAIR**

(If diathermy, cryotherapy and/or photocoagulation are combined, report under principle modality used)

	Unit Value	Follow- up Days=	Basic Anes@
67101 Repair of retinal detachment, one or more sessions; cryotherapy or diathermy, with or without drainage of subretinal fluid . . . . .	((BR)) <u>22.6</u>	0	3.0
67105 photocoagulation (laser or xenon arc, one or more sessions) with or without drainage of subretinal fluid . . . . .	((22.0)) <u>20.3</u>	90	3.0
67107 scleral buckling (such as lamellar excision, imbrication, or encircling procedure), with or without implant, may include procedures 67101-67105 . . . . .	((30.0)) <u>25.3</u>	90	8.0
67108 with vitrectomy, any method, with or without air tamponade, may include procedures 67101-67107 and/or removal of lens by same technique . . . . .	((30.0—120)) <u>37.0</u>	90	5.0
67109 by technique other than 67101-67108 . . . . .	BR		3.0
67112 previously operated upon, any technique . . . . .	BR		3.0
(For aspiration or drainage of subretinal or subchoroidal fluid, see 67015)			
67115 Release of encircling material (posterior segment) . . . . .	((BR)) <u>8.1</u>	30	3.0
67120 Removal implanted material, posterior segment extraocular . . . . .	((BR)) <u>8.1</u>	30	3.0
67121 intraocular . . . . .	((BR)) <u>10.8</u>	30	3.0
(For removal from anterior segment, use 65920)			
(For removal of foreign body, see 65260, 65265)			

**PROPHYLAXIS**

Repetitive services. The services listed below are often performed in multiple sessions or groups of sessions. The methods of reporting vary. The following descriptors are intended to include all sessions in a defined treatment period:

67141 Prophylaxis of retinal detachment (e.g., retinal break, lattice degeneration), without drainage, one or more sessions; cryotherapy, diathermy . . . . .	((10.0)) <u>8.1</u>	30	3.0
67145 photocoagulation (laser or xenon arc) . . . . .	((10.0)) <u>10.8</u>	30	3.0

**POSTERIOR SEGMENT—OTHER PROCEDURES**

**DESTRUCTION—RETINA, CHOROID**

67208 Destruction of localized lesion of retina (e.g. maculopathy, choroidopathy, small tumors), one or more sessions; cryotherapy, diathermy . . . . .	((10.0—30)) <u>12.7</u>	90	3.0
67210 photocoagulation, (laser or xenon arc) . . . . .	((10.0—30)) <u>10.8</u>	90	3.0

	Unit Value	Follow-up Days=	Basic Anes@
67218 radiation by implantation of source (includes removal of source) . . . . .	<del>((BR))</del> 23.9	90	3.0
67227 Destruction of extensive or progressive retinopathy (eg, diabetic), one or more sessions; cryotherapy, diathermy . . . . .	<del>((12.0—30))</del> 13.6	90	3.0
67228 photocoagulation (laser or xenon arc) . . . . .	<del>((12.0—30))</del> 10.8	90	3.0

(For unlisted procedures on retina, see 67299)

**SCLERAL REPAIR**

(For excision lesion sclera, see 66130)

67250 Scleral reinforcement (separate procedure); without graft . . . . .	<del>((22.0))</del> 18.5	90	3.0
67255 with graft . . . . .	<del>((24.0))</del> 21.7	90	3.0

(For repair scleral staphyloma, see 66220-66225)

67299 Unlisted procedure, posterior segment . . . . .	BR		3.0
---	----	--	-----

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-435 OCULAR ADNEXA—EXTRAOCULAR MUSCLES.**

	Unit Value	Follow-up Days=	Basic Anes@
67311 Strabismus surgery on patient not previously operated on, any procedure, any muscle, (may include minor displacement, eg, for A or V pattern); one muscle . . . . .	<del>((10.0))</del> 13.6	30	3.0
67312 two muscles, one or both eyes . . . . .	<del>((10.0))</del> 16.3	30	3.0
67313 three or more muscles, one or both eyes . . . . .	<del>((12.0))</del> 17.2	30	3.0
67320 Transposition extraocular muscle (e.g., for paretic muscle), one or more stages, one or more muscles, with displacement of plane of action more than 5 mm . . . . .	<del>((18.0))</del> 17.2	30	3.0
67331 Strabismus surgery on patient previously operated on; not involving reoperation of muscles . . . . .	<del>((10.0))</del> 13.6	30	3.0
67332 involving reoperation of muscles . . . . .	<del>((BR))</del> 18.1	30	3.0
67335 Adjustable suture technique during strabismus surgery . . . . .	BR		3.0
67345 Chemodenervation of extraocular muscle . . . . .	BR		

(Use also code for conventional muscle surgery, 67311-67313, to identify number of muscles involved)

**OTHER PROCEDURES**

67350 Biopsy extraocular muscle . . . . .	<del>((4.4—15))</del> 9.0	0	3.0
---	------------------------------	---	-----

(For repair of wound extraocular muscle, tendon or Tenon's capsule, see 65290)

67399 Unlisted procedure, ocular muscle . . . . .	BR		3.0
---	----	--	-----

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-440 OCULAR ADNEXA—ORBIT.**

	Unit Value	Follow-up Days=	Basic Anes@
67400 Orbitotomy without bone flap (frontal approach); for exploration, with or without biopsy . . . . .	<del>((12.0))</del> 12.7	30	7.0
67405 drainage only . . . . .	<del>((12.0))</del> 12.7	30	7.0
67412 with removal lesion . . . . .	<del>((BR))</del> 18.1	60	7.0
67413 with removal foreign body . . . . .	<del>((BR))</del> 18.1	30	7.0
67415 Transconjunctival or aspirational biopsy . . . . .	<del>((2.2—15))</del> 3.2	0	3.0

(For exenteration, enucleation, and repair, see 65101 et seq)

67420 Orbitotomy with bone flap, lateral approach (e.g., Kroenlein); with removal of lesion . . . . .	<del>((22.0))</del> 20.8	30	7.0
67430 with removal foreign body . . . . .	<del>((22.0))</del> 19.0	30	7.0
67440 with drainage or decompression . . . . .	<del>((22.0))</del> 18.1	30	7.0
67450 for exploration, with or without biopsy . . . . .	<del>((22.0))</del> 18.1	30	7.0

(For orbitotomy, transcranial approach, see 61330-61334)

(For orbital implant, see 67550, 67560)

(For removal of eyeball or for repair after removal, see 65091-65175)

**OTHER PROCEDURES**

*67500 Retrobulbar injection; medication (separate procedure, does not include supply of medication) . . . . .	<del>((10.6))</del> 1.1	0	
67505 alcohol . . . . .	<del>((2.0))</del> 1.1	15	



	Unit Value	Follow-up Days=	Basic Anes@
67515* Injection therapeutic agent into Tenon's capsule . . . . .	0.7	<del>((0))</del> 7	3.0
(For subconjunctival injection, see 68200)			
67550 Orbital implant (implant outside muscle cone); insertion . . . . .	<del>((+5.0))</del> 10.8	30	3.0
67560 removal or revision . . . . .	<del>((BR))</del> 9.0	30	3.0
(For ocular implant (implant inside muscle cone), see 65093-65105, 65130-65175)			
(For treatment of fractures of malar area, orbit, see 21350 et seq)			
67599 Unlisted procedure, orbit . . . . .	BR		3.0

	Unit Value	Follow-up Days=	Basic Anes@
67830 incision lid margin . . . . .	<del>((BR))</del> 0.9	7	3.0
67835 incision lid margin, with free mucous membrane graft . . . . .	<del>((BR))</del> 12.7	30	3.0
67840* Excision of lesion of eyelid (except chalazion) without closure or with simple direct closure . . . . .	<del>((+6.0))</del> 1.8	30	3.0
(For excision and repair of eyelid by reconstructive surgery, see 67961-67966)			
67850* Destruction of lesion of lid margin (up to 1 cm) . . . . .	<del>((+6))</del> 1.4	0	3.0
(For chemosurgery technique of malignancies of skin, see 17300-17302)			
(For initiation or follow-up care of topical chemotherapy, e.g., 5-FU or similar agents, see appropriate office visits)			

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-445 OCULAR ADNEXA—EYELIDS.**

	Unit Value	Follow-up Days=	Basic Anes@
<b>INCISION</b>			
*67700 Blepharotomy, drainage abscess eyelid . . . . .	<del>((+0.4))</del> 1.4	0	3.0
67710 Severing tarsorrhaphy . . . . .	<del>((6.4))</del> 0.9	15	3.0
67715 Canthotomy (separate procedure) . . . . .	<del>((6.4))</del> 1.4	15	3.0
(For canthoplasty, see 67950)			
(For division symblepharon, see 68340)			

	Unit Value	Follow-up Days=	Basic Anes@
<b>TARSORRHAPHY</b>			
67880 Construction intermarginal adhesions, median tarsorrhaphy, or canthorrhaphy . . . . .	<del>((2.0))</del> 4.1	30	3.0
67882 with transposition of tarsal plate . . . . .	<del>((+4.0))</del> 5.9	30	3.0
(For severing of tarsorrhaphy, see 67710)			
(For canthoplasty, reconstruction canthus, see 67950)			
(For canthotomy, see 67715)			

**EXCISION OR REMOVAL OF LESION INVOLVING MORE THAN SKIN (I.E., INVOLVING LID MARGIN, TARSUS AND/OR PALPEBRAL CONJUNCTIVA)**

(For removal of lesion, involving mainly skin of eyelid, see 11440-11446; 11640-11646; 17000-17010)			
(For repair wounds, blepharoplasty, grafts, reconstructive surgery, see 67930-67975)			
67800 Excisionchalazion; single . . . . .	1.2	15	3.0
67801 multiple, same lid . . . . .	<del>((+4))</del> 1.5	15	3.0
67805 multiple, different lids . . . . .	<del>((+6))</del> 1.8	15	3.0
67808 under general anesthesia and/or requiring hospitalization, single or multiple . . . . .	<del>((3.2))</del> 2.7	15	3.0
67810* Biopsy eyelid . . . . .	<del>((+6.0))</del> 1.2	0	3.0
*67820 Correction trichiasis; epilation, forceps only . . . . .	*0.4	0	
*67825 epilation, (e.g., by electrosurgery or cryotherapy) . . . . .	<del>((+1.0))</del> 0.9	7	3.0

	Unit Value	Follow-up Days=	Basic Anes@
<b>REPAIR BLEPHAROPTOSIS, LID RETRACTION</b>			
67901 Repair blepharoptosis; frontalis muscle technique with suture . . . . .	<del>((+2.0))</del> 12.7	60	3.0
67902 frontalis muscle technique with fascial sling (includes obtaining fascia) . . . . .	<del>((+6.0))</del> 14.5	60	3.0
67903 (tarso) levator resection, internal approach . . . . .	<del>((+6.0))</del> 15.4	60	3.0
67904 (tarso) levator resection, external approach . . . . .	<del>((+6.0))</del> 15.4	60	3.0
67906 superior rectus technique with fascial sling (includes obtaining fascia) . . . . .	<del>((+6.0))</del> 14.5	60	3.0
67907 superior rectus tendon transplant . . . . .	<del>((+6.0))</del> 14.5	60	3.0
67908 conjunctivo-tarso-levator resection (Fasanella-Servat type) . . . . .	<del>((+2.0))</del> 10.8	30	3.0
67909 Reduction of overcorrection of ptosis . . . . .	<del>((BR))</del> 10.8	30	3.0
67911 Correction of lid retraction . . . . .	<del>((+2.0))</del> 16.3	30	3.0

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
<b>REPAIR ECTROPION, ENTROPION</b>				(For repair lacrimal canaliculi, see 68700)			
(For correction trichiasis by mucous membrane graft, see 67835)				67950	Canthoplasty (reconstruction of canthus) . . . . .	<del>((BR))</del> 10.8	45 3.0
67914	Repair ectropion; suture . . . . .	<del>((+6))</del> 3.6	15 3.0	67961	Excision and repair of eyelid, involving lid margin, tarsus, conjunctiva, canthus, or full thickness, may include preparation for skin graft or pedicle flap with adjacent tissue transfer or rearrangement; up to one-fourth of lid margin . . . . .	<del>((+2.0))</del> 13.1	60 3.0
67915	thermocauterization . . . . .	<del>((+4))</del> 1.8	15 3.0	67966	over one-fourth of lid margin . . . . .	<del>((+5.0))</del> 14.5	60 3.0
67916	blepharoplasty, excision tarsal wedge . . . . .	<del>((9.0—60))</del> 8.1	30 3.0	(For canthoplasty, see 67950)			
67917	blepharoplasty, extensive (e.g., Kuhnt-Szymanowski operation) . . . . .	<del>((+1.0—60))</del> 10.8	30 3.0	(For free skin grafts, see 15120, 15121, 15260, 15261)			
(For correction everted punctum, see 68705)				(For tubed pedicle flap preparation, see 15515; for delay, see 15630; for attachment, see 15555)			
67921	Repair entropion; suture . . . . .	<del>((+6))</del> 3.6	15 3.0	67971	Reconstruction eyelid full thickness by transfer of tarsoconjunctival flap from opposing eyelid; up to two-thirds of eyelid, one stage or first stage . . . . .	<del>((+5.0))</del> 15.4	60 3.0
67922	thermocauterization . . . . .	<del>((+4))</del> 1.8	15 3.0	67973	total eyelid, lower, one stage or first stage . . . . .	<del>((+7.0))</del> 16.3	60 3.0
67923	blepharoplasty, excision tarsal wedge . . . . .	<del>((9.0—60))</del> 8.1	30 3.0	67974	total eyelid, upper, one stage or first stage . . . . .	<del>((20.0))</del> 18.1	60 3.0
67924	blepharoplasty, extensive (e.g., Wheeler operation) . . . . .	<del>((+1.0—60))</del> 10.4	30 3.0	67975	second stage . . . . .	<del>((2.4))</del> 7.2	60 3.0
(For repair cicatricial ectropion or entropion requiring scar excision or skin graft, see also 67961 et seq.)				<b>OTHER PROCEDURES</b>			
<b>RECONSTRUCTIVE SURGERY, BLEPHAROPLASTY INVOLVING MORE THAN SKIN (I.E., INVOLVING LID MARGIN, TARSUS, AND/OR PALPEBRAL CONJUNCTIVA)</b>				67999	Unlisted procedure, eyelids . . . .	BR	3.0
67930	Suture recent wound, eyelid, involving lid margin, tarsus, and/or palpebral conjunctiva) direct closure; partial thickness . . . . .	<del>((+6—15))</del> 5.0	30 3.0	(For cicatricial ectropion or entropion requiring scar excision, skin graft, etc., see 15100-15260)			
67935	full thickness . . . . .	<del>((3.4))</del> 7.2	30 3.0	<b>AMENDATORY SECTION (Amending Order 86-19, filed 2/28/86, effective 4/1/86)</b>			
67938	Removal embedded foreign body, eyelid . . . . .	<del>((BR))</del> 0.6	0 3.0	<b>WAC 296-22-450 OCULAR ADNEXA—CONJUNCTIVA.</b>			
(For repair skin of eyelid, see 12011-12018; 12051-12057; 13150-13300)							
(For tarsorrhaphy, canthorrhaphy, see 67880-67882)							
(For repair blepharoptosis and lid retraction, see 67901-67911)							
(For blepharoplasty for entropion, ectropion, see 67916, 67917, 67923, 67924)							
(For correction blepharochalasis (blepharorhytidectomy), see 15820-15823)							
(For repair skin of eyelid, adjacent tissue transfer, see 14060, 14061; preparation for graft, see 15000; free graft, see 15120, 15121, 15260, 15261)							
(For excision lesion of eyelid, see 67800 et seq.)							
				(For removal of foreign body, see 65205 et seq.)			
				<b>INCISION, DRAINAGE</b>			
				68020	Incision conjunctiva, drainage cyst . . . . .	<del>((0.4—1.5))</del> 0.5	0 3.0
				68040	Expression conjunctival follicles, e.g., for trachoma . . . . .	<del>((SV))</del> 0.6	0

	Unit Value	Follow-up Days=	Basic Anes@
<b>EXCISION, DESTRUCTION</b>			
68100 Biopsy conjunctiva . . . . .	<del>((1.0—15))</del> 1.4	0	3.0
68110 Excision lesion conjunctiva; up to 1 cm . . . . .	<del>((1.0—15))</del> 1.8	10	3.0
68115 over 1 cm . . . . .	<del>((2.0))</del> 3.6	15	3.0
68130 with adjacent sclera . . . . .	<del>((BR))</del> 5.4	15	3.0
68135* Destruction lesion conjunctiva . . . . .	<del>((0.60—0))</del> 1.8	7	3.0
(For nevus, see 11440-11460)			

	Unit Value	Follow-up Days=	Basic Anes@
<b>INJECTION</b>			
68200 Subconjunctival injection . . . . .	<del>((0.6—7))</del> 0.9	0	
(For injection into Tenon's capsule or retrobulbar injection, see 67500-67515)			

	Unit Value	Follow-up Days=	Basic Anes@
<b>CONJUNCTIVOPLASTY</b>			
(For wound repair, see 65270-65273)			
68320 Conjunctivoplasty; with conjunctival graft or extensive rearrangement . . . . .	<del>((12.0))</del> 11.7	30	3.0
68325 with buccal mucous membrane graft (includes obtaining graft) . . . . .	<del>((14.0))</del> 12.7	30	5.0
68326 Conjunctivoplasty, reconstruction cul-de-sac; with conjunctival graft or extensive rearrangement . . . . .	<del>((BR))</del> 12.7	30	3.0
68328 with buccal mucous membrane graft (includes obtaining graft) . . . . .	<del>((BR))</del> 14.5	30	5.0
68330 Repair symblepharon; conjunctivoplasty, without graft . . . . .	<del>((BR))</del> 9.0	30	3.0
68335 with free graft conjunctiva or buccal mucous membrane (includes obtaining graft) . . . . .	<del>((BR))</del> 12.7	30	5.0
68340 division symblepharon with or without insertion of conformer or contact lens . . . . .	<del>((BR))</del> 4.1	30	3.0

	Unit Value	Follow-up Days=	Basic Anes@
<b>OTHER PROCEDURES</b>			
68360 Conjunctival flap; bridge or partial (separate procedure) . . . . .	<del>((5.0))</del> 5.4	30	3.0
68362 total (such as Gunderson thin flap or purse string flap) . . . . .	<del>((9.0))</del> 9.5	30	3.0
(For conjunctival flap for perforating injury, see 65280-65285)			
(For repair of operative wound, see 66250)			
(For removal of conjunctival foreign body, see 65205-65210)			

68399 Unlisted procedure, conjunctiva . . . . . BR 3.0  
(For repair of symblepharon without graft, see 11400-11460, 13000-14160)

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-455 OCULAR ADNEXA—LACRIMAL SYSTEM.**

	Unit Value	Follow-up Days=	Basic Anes@
<b>INCISION</b>			
68400 Incision, drainage lacrimal gland . . . . .	<del>((2.4))</del> 1.9	15	3.0
68420 Incision, drainage lacrimal sac . . . . .	<del>((2.0))</del> 1.8	15	3.0
*68440 Snip incision lacrimal punctum . . . . .	<del>((0.4—0))</del> 0.9	7	3.0

	Unit Value	Follow-up Days=	Basic Anes@
<b>EXCISION</b>			
68500 Excision of lacrimal gland: (dacryoadenectomy), except for tumor; total . . . . .	<del>((12.0))</del> 11.3	45	3.0
68505 partial . . . . .	<del>((12.0))</del> 10.8	45	3.0
68510 Biopsy lacrimal gland . . . . .	<del>((BR))</del> 1.8	0	3.0
68520 Excision of lacrimal sac (dacryocystectomy) . . . . .	<del>((12.0))</del> 11.7	45	3.0
68525 Biopsy of lacrimal sac . . . . .	<del>((BR))</del> 1.8	45	3.0
68530 Removal or foreign body or dacryolith, lacrimal passages . . . . .	<del>((SV))</del> 9.0	30	
68540 Excision of lacrimal gland tumor; frontal approach . . . . .	<del>((15.0))</del> 13.6	45	3.0
68550 involving osteotomy . . . . .	<del>((BR))</del> 15.4	45	3.0

	Unit Value	Follow-up Days=	Basic Anes@
<b>REPAIR</b>			
68700 Plastic repair canaliculi . . . . .	<del>((BR))</del> 10.8	30	3.0
68705 Correction everted punctum, cautery . . . . .	<del>((1.0—60))</del> 1.4	15	3.0
68720 Dacryocystorhinostomy (fistulization of lacrimal sac to nasal cavity) . . . . .	<del>((14.0))</del> 13.6	60	5.0
68745 Conjunctivorhmostomy (fistulization of conjunctiva to nasal cavity); without tube . . . . .	<del>((15.0))</del> 14.5	90	5.0
68750 with insertion of tube or stent . . . . .	<del>((15.0—90))</del> 15.4	15	5.0
68760 Closure of lacrimal punctum (e.g., thermocauterization, ligation, or laser photocoagulation) . . . . .	<del>((1.0))</del> 1.1	15	3.0
68770 Closure lacrimal fistula (separate procedure) . . . . .	<del>((5.0))</del> 6.8	30	3.0

	Unit Value	Follow-up Days=	Basic Anes@
<b>PROBING AND RELATED PROCEDURES</b>			
*68800 Dilation lacrimal punctum, with or without irrigation, unilateral or bilateral . . . . . (( <del>*0.4</del> ))	<u>0.7</u>	0	3.0
*68820 Probing nasolacrimal duct, with or without irrigation, unilateral or bilateral . . . . . (( <del>*0.6</del> ))	<u>1.1</u>	0	3.0
68825 requiring general anesthesia . . . . . (( <del>BR</del> ))	<u>2.3</u>	7	3.0
(See also 92018)			
68830 with insertion of tube or stent. (( <del>2.8</del> ))	<u>3.2</u>	15	3.0
*68840 Probing lacrimal canaliculi, with or without irrigation . . . . . (( <del>*0.4</del> ))	<u>0.7</u>	0	3.0
68850* Injection contrast medium for dacryocystography . . . . . (( <del>0.7</del> ))	<u>0.6</u>	0	3.0
(For dacryocystography, see 70170, 70171)			
<b>OTHER PROCEDURES</b>			
68899 Unlisted procedure, lacrimal system . . . . . BR			3.0

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-22-465 EXTERNAL EAR.**

	Unit Value	Follow-up Days=	Basic Anes@
<b>INCISION</b>			
*69000 Drainage external ear, abscess or hematoma; simple . . . . . (( <del>*0.4</del> ))	<u>0.9</u>	0	3.0
69005 complicated . . . . . (( <del>BR</del> ))	<u>3.0</u>	0	3.0
*69020 Drainage external auditory canal, abscess . . . . . (( <del>*0.4</del> ))	<u>0.9</u>	0	3.0
69090 Ear piercing . . . . . (( <del>0.6</del> —7))	<u>0.7</u>	0	
<b>EXCISION</b>			
69100 Biopsy external ear . . . . . (( <del>0.6</del> —7))	<u>0.7</u>	0	3.0
69105 Biopsy external auditory canal . . . . . (( <del>0.6</del> —7))	<u>0.7</u>	0	3.0
69110 Excision external ear; partial, simple repair . . . . . (( <del>3.0</del> ))	<u>5.4</u>	30	3.0
69120 complete amputation . . . . . (( <del>8.0</del> ))	<u>7.2</u>	90	3.0
(For reconstruction of ear, see 15120 et seq.)			
69140 Excision exostosis(es), of external auditory canal . . . . . (( <del>12.0</del> ))	<u>10.4</u>	90	3.0

	Unit Value	Follow-up Days=	Basic Anes@
69145 Excision soft tissue lesion, external auditory canal . . . . . (( <del>0.6</del> ))	<u>1.8</u>	90	3.0
69150 Radical excision external auditory canal lesion; without neck dissection . . . . . (( <del>BR</del> ))	<u>13.6</u>	90	3.0
69155 with neck dissection . . . . . (( <del>BR</del> ))	<u>21.2</u>	90	6.0
(For resection of temporal bone, see 69535)			
(For skin grafting, see 15000-15261)			

**REMOVAL FOREIGN BODY**

*69200 Removal foreign body from external auditory canal; without general anesthesia . . . . . (( <del>*0.4</del> ))	<u>0.7</u>	0	
69205 with general anesthesia . . . . . (( <del>2.0</del> —7))	<u>1.8</u>	0	3.0
69210 Removal impacted cerumen (separate procedure), one or both ears . . . . . 0.5		(( <del>0</del> ))	3.0
<u>30</u>			
69220 Debridement, mastoidectomy cavity, simple (e.g., routine cleaning)(( <del>unilateral</del> )) . . . . . (( <del>BR</del> ))	<u>0.5</u>	7	3.0
<u>BR</u> <del>3.0</del>			
(( <del>69221</del> bilateral . . . . .			
69222 Debridement, mastoidectomy cavity, complex (e.g., with anesthesia or more than routine cleaning)(( <del>unilateral</del> )) . . . . . (( <del>BR</del> ))	<u>0.9</u>	14	3.0
<u>BR</u> <del>3.0</del>			
(( <del>69223</del> bilateral . . . . .			

**REPAIR**

(For suture of wound or injury of external ear, see 12011-14300)			
69300 Otoplasty protruding ear, with or without size reduction(( <del>unilateral</del> )) . . . . . (( <del>10.0</del> ))	<u>10.8</u>	180	3.0
<u>16.0</u> <del>180</del> <del>3.0</del>			
(( <del>69301</del> bilateral . . . . .			
69310 Reconstruction of external auditory canal (meatoplasty) (eg. for stenosis due to trauma, infection), separate procedure . . . . . BR		<u>180</u>	3.0
69320 Reconstruction external auditory canal for congenital atresia, single stage . . . . . (( <del>16.0</del> ))	<u>18.1</u>	180	3.0
(For combination with middle ear reconstruction see 69631, 69641)			
(For other reconstructive procedures with grafts (skin, cartilage, bone), see 13150-15760, 21230-21235)			

**OTHER PROCEDURES**

(For otoscopy under general anesthesia, see 92502)			
69399 Unlisted procedure, external ear. BR			3.0

**AMENDATORY SECTION** (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

**WAC 296-22-470 MIDDLE EAR.**

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@
<b>INTRODUCTION</b>				(For middle fossa approach, see 69950-69970)			
69400	Eustachian tube inflation, transnasal; with catheterization . . . . .	0.3	0	69540	Excision aural polyp . . . . .	1.0	15 3.0
69401	without catheterization . . . . .	0.3	0	69550	Excision aural glomus tumor; transcanal . . . . .	<del>(BR)</del> 18.6	180 3.0
69405	Eustachian tube catheterization, transtympanic . . . . .	BR		69552	transmastoid . . . . .	<del>(BR)</del> 27.9	180 3.0
69410	Focal application of phase control substance, middle ear (baffle technique) . . . . .	BR		69554	extended (extratemporal) . . . . .	<del>(BR)</del> 37.2	180 3.0
<b>INCISION</b>				<b>REPAIR</b>			
*69420	Myringotomy, including aspiration and/or eustachian tube inflation . . . . .	<del>(0.6-0)</del> 0.9	7 3.0	69601	Revision mastoidectomy; resulting in complete mastoidectomy. . . . .	<del>(+5.0)</del> 14.0	180 6.0
69421*	Myringotomy including aspiration and/or eustachian tube inflation requiring general anesthesia . . . . .	<del>(2.0)</del> 1.9	0 3.5	69602	resulting in modified radical mastoidectomy . . . . .	<del>(20.0)</del> 16.5	180 5.0
*69424	Ventilating tube removal when originally inserted by another physician( <del>(-unilateral)</del> ) . . . . .	<del>(BR)</del> 0.7	0 3.0	69603	resulting in radical mastoidectomy . . . . .	<del>(20.0)</del> 21.5	180 5.0
<del>(69425)</del>	<del>bilateral . . . . .</del>	<del>BR</del>	<del>3.0</del>	69604	resulting in tympanoplasty . . . . .	<del>(BR)</del> 19.6	180 5.0
*69433	Tympanostomy (requiring insertion of ventilating tube); local or topical anesthesia( <del>(-unilateral)</del> ) . . . . .	<del>(1.6-7)</del> 3.9	30 3.0	(For planned secondary tympanoplasty after mastoidectomy, see 69631, 69632)			
<del>(69434)</del>	<del>bilateral . . . . .</del>	<del>1.8</del>	<del>0 3.0</del>	69605	with apicectomy . . . . .	<del>(BR)</del> 21.2	180
69436	Tympanostomy (requiring insertion of ventilating tube), general anesthesia( <del>(-unilateral)</del> ) . . . . .	<del>(2.0)</del> 3.9	30 3.0	(For skin graft, see 15120, 15121, 15260, 15261)			
<del>(69437)</del>	<del>bilateral . . . . .</del>	<del>3.0</del>	<del>3.0</del>	69610	Tympanic membrane repair, with or without site preparation or perforation preparation for closure with or without patch . . . . .	<del>(0.6-0)</del> 0.8	7 3.0
69440	Middle ear exploration through postauricular or ear canal incision . . . . .	<del>(10.0)</del> 9.9	30 3.0	<del>(69611)</del>	<del>Tympanic membrane patching with tissue graft . . . . .</del>	<del>0.6-0</del>	<del>0 3.0</del>
(For atticotomy, see 69601 et seq.)				69620	Myringoplasty, (surgery confined to drumhead and donor area) . . . . .	<del>(+3.0)</del> 15.8	180 3.0
69450	Tympanolysis, transcanal . . . . .	10.4	3.0	69631	Tympanoplasty, without mastoidectomy (including canalplasty, atticotomy and/or middle ear surgery), initial or revision; without ossicular chain reconstruction . . . . .	<del>(22.0)</del> 21.2	180 3.0
<b>EXCISION</b>				69632	with ossicular chain reconstruction, e.g., postfenestration . . . . .	<del>(22.0)</del> 23.0	180 3.0
69501	Transmastoid antrotomy ("simple" mastoidectomy) . . . . .	<del>(+2.0)</del> 11.2	180 5.0	69633	with ossicular chain reconstruction and synthetic prosthesis (e.g., partial ossicular replacement prosthesis (PORP), total ossicular replacement prosthesis, (TORP)) . . . . .	<del>(BR)</del> 23.0	180 3.0
69502	Mastoidectomy; complete . . . . .	<del>(+8.0)</del> 11.2	180 5.0	69635	Tympanoplasty with antrotomy or mastoidotomy (including canalplasty, atticotomy, middle ear surgery, and/or tympanic membrane repair); without ossicular chain reconstruction . . . . .	<del>(22.0)</del> 22.1	180 6.0
69505	modified radical . . . . .	<del>(20.0)</del> 18.6	180 6.0	69636	with ossicular chain reconstruction . . . . .	<del>(24.0)</del> 23.0	180 6.0
69511	radical . . . . .	<del>(20.0)</del> 21.4	180 6.0	(For skin graft, see 15000 et seq.)			
(For mastoidectomy cavity debridement, see 69220-69223)				(For skin graft, see 15000 et seq.)			
69530	Petrous apicectomy including radical mastoidectomy . . . . .	<del>(30.0)</del> 27.9	180 6.0	(For mastoidectomy cavity debridement, see 69220-69223)			
69535	Resection temporal bone, external approach . . . . .	<del>(BR-180)</del> 27.9	90 6.0				

	Unit Value	Follow-up Days=	Basic Anes@		Unit Value	Follow-up Days=	Basic Anes@								
69637				69711											
with ossicular chain reconstruction and synthetic prosthesis (e.g., partial ossicular replacement prosthesis, (PORP), total ossicular replacement prosthesis, (TORP))	<del>((BR—0))</del> <u>23.0</u>	180	6.0	Removal or repair of electromagnetic bone conduction hearing device in temporal bone	BR		6.0								
69641				69720											
Tympanoplasty with mastoidectomy (including canalplasty, middle ear surgery, tympanic membrane repair); without ossicular chain reconstruction	<del>((23.0))</del> <u>25.3</u>	180	5.0	Decompression, facial nerve, intratemporal; lateral to geniculate ganglion	<del>((24.0))</del> <u>23.5</u>	180	6.0								
69642				69725											
with ossicular chain reconstruction	<del>((26.0))</del> <u>28.0</u>	180	5.0	including medial to geniculate ganglion	<del>((26.0))</del> <u>36.1</u>	180	6.0								
69643				69740											
with intact or reconstructed wall, without ossicular chain reconstruction	<del>((26.0))</del> <u>27.1</u>	180	5.0	Suture facial nerve, intratemporal, with or without graft or decompression; lateral to geniculate ganglion	<del>((30.0))</del> <u>27.1</u>	180	6.0								
69644				69745											
with intact or reconstructed canal wall, with ossicular chain reconstruction	<del>((28.0))</del> <u>27.1</u>	180	5.0	including medial to geniculate ganglion	<del>((30.0))</del> <u>33.4</u>	180	6.0								
69645				(For extracranial suture of facial nerve, see 64864)											
radical or complete, without ossicular chain reconstruction	<del>((24.0))</del> <u>25.3</u>	180	5.0	69799	BR		5.0								
69646				<b>AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)</b>											
radical or complete, with ossicular chain reconstruction	<del>((26.0))</del> <u>28.0</u>	180	5.0	<b>WAC 296-22-475 INNER EAR.</b>											
69650				<table border="0"> <tr> <td></td> <td>Unit Value</td> <td>Follow-up Days=</td> <td>Basic Anes@</td> </tr> <tr> <td>Stapes mobilization</td> <td><del>((12.0—90))</del> <u>12.2</u></td> <td>180</td> <td>3.0</td> </tr> </table>					Unit Value	Follow-up Days=	Basic Anes@	Stapes mobilization	<del>((12.0—90))</del> <u>12.2</u>	180	3.0
	Unit Value	Follow-up Days=	Basic Anes@												
Stapes mobilization	<del>((12.0—90))</del> <u>12.2</u>	180	3.0												
69660				<b>INCISION, DESTRUCTION</b>											
Stapedectomy or stapedotomy with reestablishment of ossicular continuity, with or without use of foreign material	<del>((20.0—90))</del> <u>21.2</u>	180	5.0	69801											
69661				Labyrinthotomy, with or without cryosurgery or other nonexcisional destructive procedures or tack procedure; transcanal	<del>((20.0))</del> <u>19.0</u>	180	6.0								
with footplate drill out	<del>((BR—90))</del> <u>18.1</u>	180	5.0	69802											
<u>69662</u>				with mastoidectomy	<del>((BR))</del> <u>25.3</u>	180	6.0								
<u>Revision of stapedectomy or stapedotomy</u>	BR			69805											
(For revision, see 69632)				Endolymphatic sac operation; without shunt	<del>((BR))</del> <u>22.6</u>	180	6.0								
69666				69806											
Repair oval window fistula	<del>((20.0))</del> <u>18.1</u>	180	5.0	with shunt	<del>((BR))</del> <u>26.2</u>	180	6.0								
69667				69820											
Repair round window fistula	<del>((20.0))</del> <u>17.6</u>	180	5.0	Fenestration semicircular canal	<del>((22.0))</del> <u>22.6</u>	180	6.0								
69670				69840											
Mastoid obliteration (separate procedure)	<del>((BR))</del> <u>18.1</u>	180	6.0	Revision fenestration operation	<del>((11.0))</del> <u>15.4</u>	180	6.0								
(69675 Tympanic neurectomy has been revised as 69676, 69677)				<b>EXCISION</b>											
69676				69905											
Tympanic neurectomy	<del>((BR))</del> <u>16.3</u>	180	6.0	Labyrinthectomy; transcanal	<del>((BR))</del> <u>21.2</u>	180	6.0								
(69677 bilateral)	<del>((BR—180—6.0))</del>			69910											
<b>OTHER PROCEDURES</b>				with mastoidectomy	<del>((BR))</del> <u>25.3</u>	180	6.0								
69700				69915											
Closure postauricular fistula, mastoid (separate procedure)	<del>((7.0—60))</del> <u>6.3</u>	90	3.0	Vestibular nerve section, translabyrinthine approach	<del>((BR))</del> <u>35.4</u>	180	6.0								
69710				(For transcranial approach, see 69950)											
Implantation or replacement of electromagnetic bone conduction hearing device in temporal bone	BR		6.0	<b>INSERTION</b>											
(Replacement procedure includes removal of old device)				69930											
<b>OTHER PROCEDURES</b>				Cochlear device implantation, with or without mastoidectomy	BR										
				<b>OTHER PROCEDURES</b>											
				69949											
				Unlisted procedure, inner ear	BR		6.0								
				<b>TEMPORAL BONE, MIDDLE FOSSA APPROACH</b>											
				(For external approach, see 69535)											

	Unit Value	Follow-up Days=	Basic Anes@	Unit Value
69950 Vestibular nerve section, transcranial approach . . . . .	((BR)) 37.0	180	6.0	70190 Radiologic examination, optic foramina . . . . .
69955 Total facial nerve decompression and/or repair (may include graft) . . . . .	((BR)) 35.2	180	6.0	70200 orbits, complete, minimum of four views . . . . .
69960 Decompression internal auditory canal . . . . .	((BR)) 35.2	180	6.0	70210 Radiologic examination, paranasal sinuses, less than three views . . . . .
69970 Removal of tumor . . . . .	((BR)) 46.5	180	6.0	70220 Radiologic examination, sinuses, paranasal, complete, minimum of three views . . . . .
<b>OTHER PROCEDURES</b>				70240 Radiologic examination, sella turcica . . . . .
69979 Unlisted procedure, temporal bone, middle fossa approach . . . . .	BR		6.0	70250 Radiologic examination, skull, limited, less than four views, with or without stereo . . . . .
<b>AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)</b>				70260 complete, minimum of four views, with or without stereo . . . . .
<b>WAC 296-23-015 HEAD AND NECK.</b>				70300 Radiologic examination, teeth, single view . . . . .
			Unit Value	70310 partial examination, less than full mouth . . . . .
70010 Myelography, posterior fossa supervision and interpretation only . . . . .	((BR)) 27.1			70320 complete, full mouth . . . . .
70011 complete procedure . . . . .	((BR)) 67.8			70328 Radiologic examination, temporomandibular joints, unilateral, open and closed mouth . . . . .
(For injection procedure, see 61052)				70330 bilateral . . . . .
70015 Cisternography, positive contrast; supervision and interpretation only . . . . .	((BR)) 27.1			70332 Temporomandibular joint arthrography; supervision and interpretation only . . . . .
70016 complete procedure . . . . .	((BR)) 67.8			70333 complete procedure . . . . .
(For injection procedure only for cisternography, see 61053)				(For injection procedure only for arthrography, see 21116)
70030 Radiologic examination, eye, for detection of foreign body . . . . .	((BR)) 7.5			70336 Magnetic resonance (e.g., proton) imaging, temporomandibular joint . . . . .
70100 Radiologic examination, mandible, less than four views . . . . .	((BR)) 7.2			70350 Cephalogram (orthodontic) . . . . .
70110 complete, minimum of four views . . . . .	((+0-0)) 9.9			70355 Orthopantomogram . . . . .
70120 Radiologic examination, mastoid(s), less than three views per side . . . . .	6.0			70360 Radiologic examination, neck soft tissue . . . . .
70130 complete minimum of three views per side . . . . .	12.0			70370 pharynx or larynx, including fluoroscopy and/or magnification technique . . . . .
70134 Radiologic examination, internal auditory meati, complete . . . . .	((+2-0)) 9.6			70371 Complex dynamic pharyngeal and speech evaluation by cine or video recording . . . . .
70140 Radiologic examination, facial bones, less than three views . . . . .	((BR)) 5.8			70373 Laryngography, contrast; supervision and interpretation only . . . . .
70150 complete, minimum of three views . . . . .	((+0-0)) 9.6			70374 complete procedure . . . . .
70160 Radiologic examination, nasal bones complete, minimum of three views . . . . .	((BR)) 7.2			(For injection procedure only for laryngography, see 31708)
70170 Nasolacrimal duct (dacryocystography) supervision and interpretation only . . . . .	((BR)) 6.9			70380 Radiologic examination, salivary gland for calculus . . . . .
70171 complete procedure . . . . .	((+0-0)) 17.3			70390 Sialography; supervision and interpretation only . . . . .
(For injection procedure for dacryocystography, see 68850)				70391 complete procedure . . . . .
				(For injection procedure only for sialography, see 42550)

	Unit Value		Unit Value
70450 Computerized axial tomography, head or brain; without contrast material . . . . .	((58-0)) <u>55.8</u>	71020 Radiologic examination, chest, two views, frontal and lateral . . . . .	((7-0)) <u>7.2</u>
70460 with contrast material . . . . .	((64-0)) <u>65.9</u>	71021 with apical lordotic procedure . . . . .	((7-2)) <u>6.3</u>
70470 without contrast material, followed by contrast materials and further sections . . . . .	((71-0)) <u>80.8</u>	71022 with oblique projections . . . . .	((7-2)) <u>BR</u>
(For coronal, sagittal, and/or oblique sections, see 76375)		71023 with fluoroscopy . . . . .	((BR)) <u>10.3</u>
70480 Computerized axial tomography, orbit, sella, or posterior fossa or outer, middle, or inner ear; without contrast material . . . . .	((58-0)) <u>61.3</u>	71030 Radiologic examination, chest, complete, minimum of four views . . . . .	((8-0)) <u>8.2</u>
70481 with contrast material . . . . .	((64-0)) <u>71.1</u>	71034 with fluoroscopy . . . . .	((10-0)) <u>13.7</u>
70482 without contrast material, followed by contrast material and further sections . . . . .	((71-0)) <u>80.8</u>	(For separate chest fluoroscopy, see 76000)	
(For coronal, sagittal, and/or oblique sections, see 76375)		71035 Radiologic examination, chest, special views, e.g., lateral decubitus, Bucky studies . . . . .	((BR)) <u>9.6</u>
70486 Computerized axial tomography, maxillo-facial area; without contrast material . . . . .	((58-0)) <u>33.7</u>	71036 Needle biopsy of intrathoracic lesion, including follow-up films, fluoroscopic localization only . . . . .	((BR)) <u>13.5</u>
70487 with contrast material(s) . . . . .	((64-0)) <u>37.8</u>	71037 complete procedure . . . . .	((BR)) <u>48.1</u>
70488 without contrast material, followed by contrast material(s) and further sections . . . . .	((71-0)) <u>46.9</u>	71038 Fluoroscopic localization for transbronchial biopsy or brushing . . . . .	((BR)) <u>13.0</u>
(For coronal, sagittal, and/or oblique sections, see 76375)		(For biopsy procedure, see 32400, 32405)	
70490 Computerized axial tomography, soft issue neck; without contrast material . . . . .	((BR)) <u>34.9</u>	71040 Bronchography, unilateral; supervision and interpretation only . . . . .	((5-6)) <u>11.1</u>
70491 with contrast material(s) . . . . .	((BR)) <u>39.9</u>	71041 complete procedure . . . . .	((14-0)) <u>27.7</u>
70492 without contrast material followed by contrast material(s) and further sections . . . . .	((BR)) <u>49.3</u>	71060 Bronchography, bilateral; supervision and interpretation only . . . . .	((8-0)) <u>12.5</u>
(For coronal, sagittal, and/or oblique sections, see 76375)		71061 complete procedure . . . . .	((22-0)) <u>31.3</u>
(For cervical spine, see 72125, 72126)		(For injection procedure only for bronchography, see 31715, 31710)	
70540 Magnetic resonance (e.g., proton) imaging; orbit, face and neck . . . . .	((120-0)) <u>117.9</u>	71090 Insertion pacemaker, fluoroscopy and radiography, supervision and interpretation only . . . . .	((BR)) <u>6.7</u>
70551 Magnetic resonance ((imaging)) (e.g., proton) imaging, brain (including brain stem); without contrast material . . . . .	((120-0)) <u>117.9</u>	71100 Ribs, unilateral, two views . . . . .	((11-2)) <u>10.6</u>
70552 with contrast material(s) . . . . .	<u>117.9</u>	71101 including posteroanterior chest; minimum of three views . . . . .	((16-0)) <u>11.1</u>
W0060 Nonionic contrast media for magnetic resonance imaging . . . . .	<u>15.9</u>	71110 bilateral; three views . . . . .	((14-0)) <u>11.1</u>
		71111 including posteroanterior chest, minimum of four views . . . . .	((14-0)) <u>11.1</u>
		71120 Sternum, minimum of two views . . . . .	((6-0)) <u>7.2</u>
<b>AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)</b>		71130 Sternoclavicular joint(s), minimum of three views . . . . .	((6-0)) <u>7.2</u>
<b>WAC 296-23-020 CHEST.</b>		71250 Computerized tomography, thorax; without contrast material . . . . .	((77-0)) <u>61.1</u>
	Unit Value	71260 with contrast material(s) . . . . .	((84-0)) <u>75.5</u>
71010 Radiologic examination, chest, single view, frontal . . . . .	((4-0)) <u>4.8</u>	71270 without contrast material, followed by contrast material and further sections . . . . .	((90-0)) <u>78.2</u>
71015 stereo, frontal . . . . .	((5-0)) <u>7.2</u>		



(For coronal, sagittal, and/or oblique sections, see 76375)

71550	Magnetic resonance (e.g., proton) imaging, chest (e.g., for evaluation of hilar and mediastinal lymphadenopathy) . . . .	((+20.0)) <u>117.9</u>
-------	--	---------------------------

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-23-025 SPINE AND PELVIS.**

	Unit Value	
72010	Spine, entire, survey study (A-P and lateral) . . . . .	((+6.0)) <u>20.0</u>
72020	Radiologic examination, spine, single view, specify level . . . . .	((6.5)) 5.3
72040	Spine, cervical; A-P and lateral . . . . .	((6.0)) 7.2
72050	minimum of four views . . . . .	((+0.0)) <u>11.5</u>
72052	complete, including oblique and flexion and/or extension views . . . . .	((+5.2)) 14.4
72070	Spine, thoracic; A-P and lateral . . . . .	((9.0)) <u>7.2</u>
72072	thoracic, A-P and lateral, including swimmer's view of the cervicothoracic junction . . . . .	((+2.0)) <u>10.6</u>
72074	thoracic, complete inc. obliques, minimum of four views . . . . .	((+6.0)) <u>13.7</u>
72080	thoraco-lumbar, A-P and lateral . . . . .	((9.0)) <u>7.2</u>
72090	scoliosis study, including supine and erect studies . . . . .	((6.0)) 7.5
72100	Spine, lumbosacral; A-P and lateral . . . . .	((9.0)) 9.6
72110	complete, with oblique views . . . . .	((+6.0)) 10.8
72114	complete, including bending views . . . . .	((+8.5)) <u>13.0</u>
72120	bending views only, minimum of four views . . . . .	((+0.0)) <u>8.9</u>
72125	Computerized axial tomography, cervical spine; without contrast material . . . . .	((62.4)) 43.3
72126	with contrast material . . . . .	((72.8)) <u>51.7</u>
72127	without contrast material, followed by contrast material(s) and further sections . . . . .	((BR)) <u>55.3</u>
<p>(For injection procedure 72126, 72127, 72129, 72130, 72132, 72133, by intrathecal injection, also use 62284)</p>		
72128	Computerized axial tomography, thoracic spine; without contrast material . . . . .	((62.4)) 43.3
72129	with contrast material . . . . .	((72.8)) <u>51.7</u>
72130	without contrast material, followed by contrast material(s) and further sections . . . . .	((BR)) <u>55.3</u>

	Unit Value	
72131	Computerized axial tomography, lumbar spine; without contrast material . . . . .	((60.0)) 43.3
72132	with contrast material . . . . .	((70.0)) <u>51.7</u>
72133	without contrast material, followed by contrast material(s) and further sections . . . . .	((BR)) <u>55.3</u>
72141	Magnetic resonance (e.g., proton) imaging, spinal canal and contents; cervical; without contrast material . . . . .	((+20.0)) <u>117.9</u>
	<del>((72143 thoracic . . . . .</del>	<del>+20.0</del>
	<del>72144 lumbar . . . . .</del>	<del>+20.0</del>
	<del>72142 with contrast material(s) . . . . .</del>	<del>117.9</del>
72146	Magnetic resonance (e.g., proton) imaging, spinal canal and contents, thoracic; without contrast material . . . . .	117.9
	<del>72147 with contrast material(s) . . . . .</del>	<del>117.9</del>
72148	Magnetic resonance (e.g., proton) imaging, spinal canal and contents, lumbar; without contrast material . . . . .	117.9
	<del>72149 with contrast material(s) . . . . .</del>	<del>117.9</del>
72170	Pelvis, A-P only . . . . .	((5.0)) 7.2
	<del>((72180 stereo . . . . .</del>	<del>6.4</del>
72190	complete, minimum of three views . . . . .	((8.0)) <u>9.6</u>
<p>(For pelvimetry, see 74710)</p>		
72192	Computerized tomography, pelvis; without contrast material . . . . .	((60.0)) 61.3
72193	with contrast material(s) . . . . .	((70.0)) <u>78.2</u>
72194	without contrast material, followed by contrast material(s) and further sections . . . . .	((BR)) <u>81.8</u>
72196	Magnetic resonance (e.g., proton) imaging; pelvis . . . . .	((+20.0)) 132.3
72200	Sacro-iliac joints; less than three views . . . . .	((5.0)) 7.2
72202	three or more views . . . . .	((8.0)) <u>7.7</u>
72220	Sacrum and coccyx; minimum of two views . . . . .	((6.4)) <u>7.2</u>
72240	Myelography, cervical; supervision and interpretation only . . . . .	((7.2)) 23.6
72241	complete procedure . . . . .	((+8.0)) <u>58.9</u>
72255	thoracic; supervision and interpretation only . . . . .	((7.2)) 23.6
72256	complete procedure . . . . .	((+8.0)) <u>58.9</u>
72265	lumbosacral; supervision and interpretation only . . . . .	((7.2)) 23.3
72266	complete procedure . . . . .	((+8.0)) <u>58.2</u>
72270	entire spinal canal; supervision and interpretation only . . . . .	((+2.0)) 27.4
72271	complete procedure . . . . .	((30.0)) <u>68.6</u>
<p>(For injection procedures for myelography, see 61055 or 62284)</p>		

	Unit Value
72285 Diskography, cervical; supervision and interpretation only .....	(( <del>8-0</del> )) <u>37.5</u>
72286 complete procedure .....	(( <del>20-0</del> )) <u>93.8</u>
72295 lumbar; supervision and interpretation only .....	(( <del>8-0</del> )) <u>36.6</u>
72296 complete procedure .....	(( <del>20-0</del> )) <u>91.4</u>
(For injection procedures for diskography, see 62290, 62291)	
W0060 <u>Nonionic contrast media for magnetic resonance imaging .....</u>	<u>15.9</u>

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-23-030 UPPER EXTREMITIES.**

	Unit Value
73000 Clavicle, complete .....	(( <del>4-8</del> )) <u>5.3</u>
73010 Scapula, complete .....	(( <del>6-0</del> )) <u>6.5</u>
73020 Shoulder; one view .....	(( <del>4-8</del> )) <u>4.3</u>
73030 complete, minimum of two views .....	(( <del>6-0</del> )) <u>6.5</u>
73040 arthrography; supervision and interpretation only .....	(( <del>4-0</del> )) <u>11.1</u>
73041 complete procedure .....	(( <del>10-0</del> )) <u>27.7</u>
(For injection procedure for arthrography, see 23350)	
73050 Acromio-clavicular joints, bilateral, with or without weighted distraction .....	(( <del>7-0</del> )) <u>6.7</u>
73060 Humerus, minimum of two views .....	(( <del>4-8</del> )) <u>6.0</u>
73070 Elbow, limited, A-P and lateral .....	(( <del>4-8</del> )) <u>4.3</u>
73080 complete, minimum of three views .....	(( <del>6-0</del> )) <u>5.5</u>
73085 Radiologic examination, elbow, arthrography; supervision and interpretation only .....	(( <del>4-0</del> )) <u>9.1</u>
73086 complete procedure .....	(( <del>10-0</del> )) <u>22.9</u>
(For injection procedure only for arthrography, see 24220)	
73090 Forearm, A-P and lateral .....	(( <del>4-8</del> )) <u>5.3</u>
73100 Wrist, limited, A-P and lateral .....	(( <del>4-0</del> )) <u>3.8</u>
73110 complete, minimum of three views .....	(( <del>6-0</del> )) <u>5.5</u>
73115 Radiologic examination, wrist, arthrography; supervision and interpretation only .....	(( <del>4-0</del> )) <u>9.3</u>
73116 complete procedure .....	(( <del>10-0</del> )) <u>23.3</u>
(For injection procedure only for arthrography, see 25246)	

	Unit Value
73120 Hand; two views .....	(( <del>4-0</del> )) <u>5.1</u>
73130 minimum of three views .....	(( <del>6-0</del> )) <u>5.5</u>
73140 Finger(s), minimum of two views .....	(( <del>3-6</del> )) <u>3.4</u>
73200 Computerized tomography, upper extremity; without contrast material .....	(( <del>58-0</del> )) <u>62.5</u>
73201 with contrast material(s) .....	(( <del>64-0</del> )) <u>72.9</u>
73202 without contrast material, followed by contrast material(s) and further sections .....	(( <del>7-0</del> )) <u>75.8</u>
(For coronal, sagittal and oblique sections, see 76375)	

73220 Magnetic resonance (e.g., proton) imaging, upper extremity, other than joint ..	(( <del>20-0</del> )) <u>117.9</u>
73221 Magnetic resonance (e.g., proton) imaging, any joint of upper extremity .....	(( <del>20-00</del> )) <u>117.9</u>

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-23-035 LOWER EXTREMITIES.**

	Unit Value
73500 Radiologic examination, hip, unilateral, one view .....	(( <del>5-0</del> )) <u>5.3</u>
73510 complete, minimum of two views .....	(( <del>7-0</del> )) <u>7.2</u>
73520 Radiologic examination, hips, bilateral, minimum of two views of each hip, including A-P of pelvis .....	9.6
73525 Radiologic examination, hip, arthrography; supervision and interpretation only .....	((BR)) <u>8.9</u>
73526 complete procedure .....	((BR)) <u>22.4</u>
(For injection procedure only for arthrography, see 27093, 27095)	
73530 Radiologic examination, hip, during operative procedure .....	(( <del>16-0</del> )) <u>14.0</u>
73550 Radiologic examination, femur, A-P and lateral .....	(( <del>6-0</del> )) <u>6.3</u>
73560 Radiologic examination, knee, A-P and lateral .....	(( <del>4-4</del> )) <u>5.1</u>
73562 A-P and lateral, with oblique(s), minimum three views .....	(( <del>6-4</del> )) <u>6.0</u>
73564 complete, including obliques, and/or tunnel, and/or patella and/or standing views .....	(( <del>8-4</del> )) <u>7.2</u>
73580 Radiologic examination, knee, arthrography supervision and interpretation only .....	(( <del>6-4</del> )) <u>12.0</u>
73581 complete procedure .....	(( <del>16-0</del> )) <u>30.1</u>
(For injection procedure for arthrography, see 27370)	

	Unit Value
73590 Radiologic examination, tibia and fibula, A-P and lateral .....	((4-0)) <u>6.0</u>
73592 lower extremity, infant, minimum of two views .....	((4-0)) <u>6.0</u>
73600 Radiologic examination, ankle, A-P and lateral .....	((4-4)) <u>4.1</u>
73610 complete, minimum of three views ....	((6-0)) <u>5.3</u>
73615 Radiologic examination, ankle, arthrography; supervision and interpretation only.....	((4-0)) <u>9.1</u>
73616 complete procedure .....	((10-0)) <u>22.9</u>
(For injection procedure only for arthrography, see 27648)	
73620 Radiologic examination, foot, A-P and lateral .....	((4-0)) <u>3.4</u>
73630 complete, minimum of three views ....	((5-6)) <u>4.8</u>
73650 Radiologic examination, calcaneus, minimum of two views .....	((4-4)) <u>4.8</u>
73660 Toe(s), minimum of two views .....	((3-6)) <u>3.1</u>
73700 Computerized axial tomography, lower extremity; without contrast material ....	((58-0)) <u>61.3</u>
73701 with contrast material(s) .....	((64-0)) <u>71.5</u>
73702 without contrast material, followed by contrast materials and further sections .....	((71-0)) <u>74.3</u>
(For coronal, sagittal and/or oblique sections, see 76375)	
73720 Magnetic resonance (e.g., proton) imaging, lower extremity, other than joint ..	((120-0)) <u>117.9</u>
73721 Magnetic resonance (e.g., proton) imaging, any joint of lower extremity .....	((120-0)) <u>117.9</u>

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-23-040 ABDOMEN.**

	Unit Value
74000 Abdomen, single view (KUB) A-P .....	((6-0)) <u>5.5</u>
74010 with additional oblique and cone views .....	((8-0)) <u>7.7</u>
74020 complete, includes decubitus and/or erect views .....	((11-0)) <u>9.9</u>
74022 complete acute abdomen series, including supine, erect, and/or decubitus views, upright PA chest .....	((BR)) <u>9.9</u>
74150 Computerized axial tomography, abdomen; without contrast material.....	((77-0)) <u>61.3</u>
74160 with contrast material .....	((84-0)) <u>78.2</u>

74170 without contrast material, followed by contrast material and further sections .	((90-0)) <u>81.8</u>
(For coronal, sagittal and/or oblique sections, see 76375)	
74181 Magnetic resonance (e.g., proton) imaging, abdomen .....	((120-0)) <u>117.9</u>

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-23-045 GASTROINTESTINAL TRACT.**

	Unit Value
74210 Pharynx and/or cervical esophagus .....	((8-8)) <u>10.1</u>
74220 Esophagus .....	((8-8)) <u>10.8</u>
74230 Swallowing function, pharynx and/or esophagus, by cineradiography and/or video.....	((12-0)) <u>13.2</u>
74235 Removal of foreign body(s), esophageal, with use of balloon catheter under fluoroscopic guidance .....	((BR)) <u>33.7</u>
74240 Uppergastrointestinal tract, with or without delayed films, without KUB .....	((14-0)) <u>18.0</u>
74241 with or without delayed films, with KUB .....	((15-2)) <u>18.0</u>
74245 with small bowel, includes multiple serial films .....	((17-6)) <u>24.1</u>
74246 Radiological exam gastrointestinal tract, upper, air contrast, with specific high density barium, effervescent agent, with or without glucagon; with or without delayed films, without KUB .....	((BR)) <u>14.9</u>
74247 with or without delayed films, with KUB .....	((BR)) <u>29.1</u>
74249 with small bowel follow through .....	((BR)) <u>19.7</u>
74250 Small bowel, includes multiple serial films .....	((14-0)) <u>14.9</u>
74260 Duodenography, hypotonic .....	((BR)) <u>16.8</u>
74270 Colon, barium enema .....	((12-0)) <u>19.2</u>
74280 air contrast with specific high density barium with or without glucagon .....	((14-0)) <u>20.7</u>
74283 <u>Barium enema, therapeutic, for reduction of intussusception .....</u>	<u>BR</u> <u>9.6</u>
74290 Cholecystography, oral contrast .....	
74291 additional or repeat examination or multiple exam .....	4.8
74300 Cholangiography and/or pancreatography; during surgery .....	((10-0)) <u>11.5</u>
74301 additional set during surgery .....	((3-0)) <u>6.0</u>
74305 postoperative .....	((12-0)) <u>10.1</u>

	Unit Value		Unit Value
		74420 Urography retrograde, with or without KUB.....	((+2-0)) <u>14.4</u>
(For biliary duct stone extraction, percutaneous, see 47630, 74327)			
74320 percutaneous, transhepatic; supervision and interpretation only .....	((6-4)) <u>21.2</u>	74425 Urography, antegrade, (pyelostogram, nephrostogram, loopogram); supervision and interpretation only .....	((BR)) <u>8.2</u>
74321 complete procedure .....	((+6-0)) <u>52.9</u>	74426 complete procedure .....	((BR)) <u>20.4</u>
		(For injection procedure only, see 50394, 50684, 50690)	
(For injection procedure for percutaneous or transhepatic cholangiography, see 47500)		74430 Cystography, minimum of three views, supervision and interpretation only .....	((3-5)) <u>5.2</u>
74327 Postoperative biliary duct stone removal percutaneous via T-tube tract, basket or snare (e.g., Burhenne technique), fluoroscopic monitoring and radiography .....	((BR)) <u>43.3</u>	74431 Cystography, complete procedure .....	((8-8)) <u>13.0</u>
74328 Endoscopic catheterization of the biliary ductal system, fluoroscopic monitoring and radiography .....	((BR)) <u>17.3</u>	(For injection procedure for cystography, see 51600, 51605)	
74329 Endoscopic catheterization of the pancreatic ductal system, fluoroscopic monitoring and radiography .....	((BR)) <u>17.8</u>	74440 Vasography, vesiculography, or epididymography supervision and interpretation only.....	((3-5)) <u>16.1</u>
74330 Combined endoscopic catheterization of the biliary and pancreatic ductal systems, fluoroscopic monitoring and radiography .....	((BR)) <u>18.5</u>	74441 complete procedure .....	((8-8)) <u>40.2</u>
74340 Introduction of long gastrointestinal tube (e.g., Miller-Abbott), with multiple fluoroscopies and films .....	((BR)) <u>19.2</u>	(For injection procedure, see 52010, 55300)	
74350 Percutaneous placement of gastrostomy tube; radiological guidance only .....	BR	74445 Corpora cavernosography; supervision and interpretation only .....	((BR)) <u>10.1</u>
74351 complete procedure .....	((BR)) <u>73.9</u>	74446 complete procedure .....	((BR)) <u>25.3</u>
(For endoscopic approach, use 43246)		(For injection procedure only, see 54230)	
74355 Percutaneous placement of enteroclysis tube; radiologic guidance only .....	BR	74450 Urethrocystography, retrograde; supervision and interpretation only .....	((3-8)) <u>5.4</u>
74356 complete procedure .....	((BR)) <u>73.9</u>	74451 complete procedure .....	((9-6)) <u>13.5</u>
(For surgical procedure only, use 44015)		74455 voiding; supervision and interpretation only.....	((5-6)) <u>5.8</u>
74360 Intraluminal dilation of strictures and/or obstructions (e.g., esophagus or biliary tree); radiologic guidance only .....	BR	74456 complete procedure .....	((+4-0)) <u>14.4</u>
74361 complete procedure .....	((BR)) <u>77.0</u>	(For injection procedure only for voiding urethrocystography, see 51600)	
(For dilation only, use 43455 or 47555)		74470 Translumbar renal cyst study, translumbar, contrast visualization; supervision and interpretation only .....	((+4-0)) <u>17.3</u>
<b>AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)</b>		74471 complete procedure .....	((+0-0)) <u>43.3</u>
<b>WAC 296-23-050 URINARY TRACT.</b>		(For injection procedure only for translumbar renal cyst study, see 50390)	
	Unit Value	74475 Introduction of intracatheter or catheter into renal pelvis for drainage and/or injection, percutaneous, with fluoroscopic monitoring and radiography; supervision and interpretation only .....	((BR)) <u>35.6</u>
74400 Urography, (pyelography) intravenous, with or without KUB .....	((+5-2)) <u>18.0</u>	74476 complete procedure .....	((BR)) <u>89.0</u>
74405 with special hypertensive contrast concentration and/or clearance studies .....	((+6-0)) <u>21.2</u>	(For injection procedure only, see 50392-50398)	
74410 Urography, infusion, drip technique and/or bolus technique .....	((20-0)) <u>19.2</u>		
74415 with nephrotomography .....	((26-0)) <u>34.9</u>		

	Unit Value
74480 Introduction of ureteral catheter or stent into ureter through renal pelvis for drainage and/or injection, percutaneous, with fluoroscopic monitoring and radiography; supervision and interpretation only . . . .	((BR)) 38.5
74481 complete procedure . . . . .	((BR)) 96.2
(For injection procedure only, see 50392 - 50398)	
74485 Dilation of nephrostomy or ureters with fluoroscopic monitoring and radiography; supervision and interpretation only . . . .	((BR)) 36.6
74486 complete procedure . . . . .	((BR)) 91.4

**AMENDATORY SECTION (Amending Order 87-18, filed 7/23/87)**

**WAC 296-23-055 FEMALE GENITAL TRACT.**

	Unit Value
(For abdomen and pelvis, see 74000-74170, 72170-72190)	
74710 Pelvimetry with or without placental localization . . . . .	((+0-0)) 12.5
74720 Abdomen for fetal age, fetal position and/or placental localization, single view	4.0
74725 multiple views . . . . .	6.0
74740 Hysterosalpingography supervision and interpretation only . . . . .	((+3)) 11.0
74741 complete procedure . . . . .	((+0-8)) 27.4
(For injection procedure for hysterosalpingography, see 58340)	
74775 Perineogram (e.g., vaginogram, for sex determination or extent of anomalies) . . . .	18.8

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-23-065 VASCULAR SYSTEM.**

(For vascular injection procedures, see 36000-36299)

(For cardiac fluoroscopy, see 93280)

(For cardiac catheterization, see 93501- 93562)

When multiple vascular radiographic procedures are performed at the same time (e.g., aortic arch study plus renal arteriogram), the total value shall be the value for the major procedure plus 50% of the value for the lesser procedure(s) unless otherwise indicated. See modifier -50. The cost of catheters, drugs and contrast media is included in the listed value for the radiographic procedure.

**HEART**

75500 Angiocardiography, by cineradiography supervision and interpretation only . . . .	((8-8)) 42.3
75501 complete procedure (including catheterization) . . . . .	((22-0)) 105.9
75505 Angiocardiography by serialography (single plane;) supervision and interpretation only . . . . .	((9-2)) 43.3
75506 complete procedure (including catheterization) . . . . .	((23-0)) 108.3
75507 Angiocardiography by serialography, multi-plane; supervision and interpretation only . . . . .	((18-4)) 44.3
75509 complete procedure (including catheterization) . . . . .	((46-0)) 110.7
75519 Cardiac radiography, selective cardiac catheterization; right side, supervision and interpretation only . . . . .	((17-2)) 35.1
75520 complete procedure . . . . .	((43-0)) 87.8
75523 left side, supervision and interpretation only . . . . .	((8-6)) 40.9
75524 left side, complete procedure . . . . .	((21-5)) 102.2
<u>75527 Cardiac radiography, selective cardiac catheterization, right and left side; supervision and interpretation only . . . . .</u>	<u>58.2</u>
75528 <del>((Cardiac radiography, selective cardiac catheterization, right and left side;))</del> complete procedure . . . . .	((55-0)) 145.5
75552 Magnetic resonance (e.g., proton) imaging, myocardium . . . . .	((120-0)) 117.9

**AORTA AND ARTERIES**

75600 Aortography, thoracic, without serialography; supervision and interpretation only . . . . .	((8-0)) 27.4
75601 complete procedure . . . . .	((20-0)) 68.6
75605 Aortography, thoracic, by serialography; supervision and interpretation only . . . .	((11-0)) 29.8
75606 complete procedure . . . . .	((30-0)) 74.6
<del>((75620 Aortography, abdominal, translumbar, without serialography, supervision and interpretation only . . . . .</del>	<del>12.8</del>
<del>75621 complete procedure . . . . .</del>	<del>32.0</del>
<del>75622 Aortography, abdominal, catheter, without serialography, supervision and interpretation only . . . . .</del>	<del>12.8</del>
<del>75623 complete procedure . . . . .</del>	<del>32.0))</del>
75625 Aortography, abdominal, translumbar, by serialography; supervision and interpretation only . . . . .	((15-2)) 32.7
75626 complete procedure . . . . .	((40-0)) 81.8
75627 Aortography, abdominal, catheter, by serialography; supervision and interpretation only . . . . .	((17-0)) 32.7

	Unit Value		Unit Value
75628 complete procedure .....	((48-0)) <u>81.8</u>	75681 direct puncture, complete procedure ..	((50-0)) <u>168.4</u>
75630 Aortography, abdominal plus bilateral ileofemoral lower extremity, catheter, by serialography; supervision and interpreta- tion only .....	((BR)) <u>33.7</u>	75682 catheter, complete procedure .....	((54-0)) <u>175.6</u>
75631 complete procedure .....	((BR)) <u>84.2</u>	75685 Angiography, vertebral; supervision and interpretation only .....	((17-2)) <u>46.2</u>
75650 Angiography, cervicocerebral, catheter, including vessel origin; supervision and interpretation only .....	((17-2)) <u>43.3</u>	75686 direct puncture, complete procedure ..	((40-0)) <u>115.5</u>
75651 complete procedure .....	((40-0)) <u>108.3</u>	75687 catheter, complete procedure .....	((46-0)) <u>115.5</u>
75652 Angiography, cervicocerebral, selective catheter, including vessel origin; one ves- sel, supervision and interpretation only ..	((12-6)) <u>43.3</u>	75690 Angiography, vertebral, cervical, unilat- eral; supervision and interpretation only .	((17-2)) <u>46.2</u>
75653 one vessel, complete procedure .....	((36-0)) <u>108.3</u>	75692 catheter, complete procedure .....	((46-0)) <u>115.5</u>
75654 two vessels, supervision and interpreta- tion only .....	((13-3)) <u>62.5</u>	75695 Angiography, vertebral, cervical, bilater- al; supervision and interpretation only ...	((21-5)) <u>70.2</u>
75655 two vessels, complete procedure .....	((38-0)) <u>156.4</u>	75697 catheter, complete procedure .....	((54-0)) <u>175.6</u>
75656 three or four vessels, supervision and interpretation only .....	((17-2)) <u>70.2</u>	75705 Angiography, spinal, selective; supervi- sion and interpretation only .....	((9-8)) <u>75.6</u>
75657 three or four vessels, complete proce- dure .....	((40-0)) <u>175.6</u>	75706 complete procedure .....	((28-0)) <u>189.1</u>
75658 Angiography, brachial, retrograde; super- vision and interpretation only .....	((17-2)) <u>37.5</u>	75710 Angiography, extremity, unilateral, su- pervision and interpretation only .....	((10-5)) <u>31.3</u>
75659 complete procedure .....	((40-0)) <u>93.8</u>	75711 without serialography, complete proce- dure .....	((30-0)) <u>62.5</u>
75660 Angiography, external carotid, cerebral, unilateral, selective; supervision and in- terpretation only .....	((17-2)) <u>46.2</u>	75712 by serialography, complete procedure .	((32-0)) <u>78.2</u>
75661 complete procedure .....	((40-0)) <u>115.5</u>	75716 Angiography, extremity, bilateral; super- vision and interpretation only .....	((11-2)) <u>45.2</u>
75662 Angiography, external carotid, cerebral, bilateral, selective; supervision and inter- pretation only .....	((21-5)) <u>67.4</u>	75717 without serialography, complete proce- dure .....	((32-0)) <u>92.6</u>
75663 complete procedure .....	((56-0)) <u>168.4</u>	75718 by serialography, complete procedure .	((34-0)) <u>113.1</u>
75665 Angiography, carotid, cerebral, unilater- al; supervision and interpretation only ...	((17-2)) <u>46.2</u>	75722 Angiography, renal, unilateral, selective (including flush aortogram); supervision and interpretation only .....	((17-2)) <u>46.2</u>
75667 direct puncture, complete procedure ..	((40-0)) <u>115.5</u>	75723 complete procedure .....	((40-0)) <u>115.5</u>
75669 catheter, complete procedure .....	((46-0)) <u>115.5</u>	75724 Angiography, renal, bilateral, selective (including flush aortogram); supervision and interpretation only .....	((25-0)) <u>58.7</u>
75671 Angiography, carotid, cerebral, bilateral; supervision and interpretation only .....	((21-5)) <u>67.4</u>	75725 complete procedure .....	((60-0)) <u>146.8</u>
75672 direct puncture, complete procedure ..	((50-0)) <u>168.4</u>	75726 Angiography, visceral; selective or supra- selective, supervision and interpretation only .....	((19-7)) <u>52.0</u>
75673 catheter, complete procedure .....	((54-0)) <u>173.2</u>	75727 selective (with or without flush aorto- gram), complete procedure .....	((46-0)) <u>129.9</u>
75676 Angiography, carotid, cervical, unilateral; supervision and interpretation only .....	((17-2)) <u>46.2</u>	75728 supraseductive, complete procedure ....	((48-0)) <u>141.9</u>
75677 direct puncture, complete procedure ..	((46-0)) <u>115.5</u>		
75678 catheter, complete procedure .....	((46-0)) <u>115.5</u>		
75680 Angiography, carotid, cervical, bilateral; supervision and interpretation only .....	((21-5)) <u>70.2</u>		

(For selective angiography, additional  
visceral vessels studied after basic exam-  
ination, see 75772, 75773)

	Unit Value		Unit Value
75733	Angiography, adrenal, bilateral, selective; supervision and interpretation only . . . . .	( <del>(20.6)</del> )	75775 complete procedure . . . . . BR
	46.7		75790 Angiography, arteriovenous shunt (e.g., dialysis patient) . . . . . ( <del>BR</del> )
75734	complete procedure . . . . .	( <del>(48.0)</del> )	61.8
	<u>116.7</u>		
75736	Angiography, pelvic; selective or supraseductive, supervision and interpretation only . . . . .	( <del>(18.9)</del> )	<b>VEINS AND LYMPHATICS</b>
	46.2		(For injection procedure only for venous system, see 36400-36510)
75737	selective, complete procedure . . . . .	( <del>(44.0)</del> )	(For injection procedure only for lymphatic system, see 38790-38794)
	108.3		
75738	supraselective, complete procedure . . . . .	( <del>(46.0)</del> )	75801 Lymphangiography, extremity only, unilateral; supervision and interpretation only . . . . .
	<u>115.5</u>		((9.6))
75741	Angiography, pulmonary, unilateral, selective; supervision and interpretation only . . . . .	( <del>(10.5)</del> )	31.8
	11.9		( <del>(25.0)</del> )
75742	complete procedure . . . . .	( <del>(30.0)</del> )	<u>79.4</u>
	<u>84.2</u>		
75743	Angiography, pulmonary, bilateral, selective; supervision and interpretation only . . . . .	( <del>(21.5)</del> )	75802 complete procedure . . . . .
	48.1		((12.0))
75744	complete procedure . . . . .	( <del>(50.0)</del> )	43.3
	<u>120.3</u>		( <del>(35.0)</del> )
75746	Angiography, pulmonary; by nonselective catheter or venous injection, supervision and interpretation only . . . . .	( <del>(10.5)</del> )	<u>108.3</u>
	28.9		
75747	catheter, nonselective, complete procedure . . . . .	( <del>(30.0)</del> )	75803 Lymphangiography, extremity only, bilateral; supervision and interpretation only . . . . .
	72.2		((12.0))
75748	venous injection, complete procedure . . . . .	( <del>(40.0)</del> )	43.3
	<u>48.1</u>		( <del>(35.0)</del> )
75750	Angiography, coronary, root injection; supervision and interpretation only . . . . .	( <del>(25.8)</del> )	<u>108.3</u>
	46.7		
75751	complete procedure . . . . .	( <del>(60.0)</del> )	75804 complete procedure . . . . .
	<u>116.7</u>		((35.0))
75752	Angiography, coronary, unilateral selective injection, including left ventricular and supra-ventricular angiogram and pressure recording; supervision and interpretation only . . . . .	( <del>(30.0)</del> )	<u>79.4</u>
	60.1		
75753	complete procedure . . . . .	( <del>(70.0)</del> )	75805 Lymphangiography, pelvic/abdominal, unilateral; supervision and interpretation only . . . . .
	<u>150.4</u>		((12.0))
75754	Angiography, coronary, bilateral selective injection, including left ventricular and supra-ventricular angiogram and pressure recording; supervision and interpretation only . . . . .	( <del>(34.4)</del> )	31.8
	62.5		( <del>(35.0)</del> )
75755	complete procedure . . . . .	( <del>(80.0)</del> )	<u>79.4</u>
	<u>156.4</u>		
75756	Angiography, internal mammary; supervision and interpretation only . . . . .	( <del>(15.2)</del> )	75806 complete procedure . . . . .
	37.0		((12.0))
75757	complete procedure . . . . .	( <del>(40.0)</del> )	46.2
	<u>92.6</u>		( <del>(35.0)</del> )
75762	Angiography, coronary bypass, unilateral selective injection; supervision and interpretation only . . . . .	( <del>BR</del> )	<u>115.5</u>
	27.9		
75764	complete procedure . . . . .	( <del>BR</del> )	75810 Splenoportography; supervision and interpretation only . . . . .
	<u>69.8</u>		((15.2))
75766	Angiography, coronary bypass, multiple selective injection; supervision and interpretation only . . . . .	( <del>BR</del> )	18.3
	36.6		( <del>(40.0)</del> )
75767	complete procedure . . . . .	( <del>BR</del> )	<u>45.7</u>
	<u>91.4</u>		
75774	Angiography, selective, each additional vessel studied after basic examination; supervision and interpretation only . . . . .	( <del>BR</del> )	75811 complete procedure . . . . .
	BR		((8.0))
			12.5
			( <del>(16.0)</del> )
			<u>31.3</u>
			75822 Venography, extremity, bilateral; supervision and interpretation only . . . . .
			((10.0))
			18.3
			( <del>(26.0)</del> )
			<u>45.7</u>
			75823 complete procedure . . . . .
			((16.0))
			22.6
			( <del>(32.0)</del> )
			<u>56.5</u>
			75826 complete procedure . . . . .
			((30.0))
			23.1
			( <del>(35.0)</del> )
			<u>57.7</u>
			75827 Venography, caval, superior, with serialography; supervision and interpretation only . . . . .
			((12.0))
			23.1
			( <del>(35.0)</del> )
			<u>57.7</u>
			75828 complete procedure . . . . .
			((15.2))
			29.8
			( <del>(40.0)</del> )
			<u>74.6</u>
			75832 complete procedure . . . . .
			((19.5))
			36.6
			( <del>(45.0)</del> )
			<u>91.4</u>
			75833 Venography, renal, bilateral, selective; supervision and interpretation only . . . . .
			((10.8))
			31.8

	Unit Value		Unit Value
75841 complete procedure .....	(( <del>30.0</del> ) <u>79.4</u> )	75896 Transcatheter therapy, infusion, (e.g., thrombolysis other than coronary) including angiography; supervision and interpretation only .....	(( <del>15.9</del> ) <u>57.7</u> )
75842 Venography, adrenal, bilateral, selective; supervision and interpretation only .....	(( <del>12.2</del> ) <u>38.5</u> )	75897 complete procedure .....	(( <del>42.0</del> ) <u>144.3</u> )
75843 complete procedure .....	(( <del>32.0</del> ) <u>96.2</u> )	(Infusion for coronary disease, see 92975-92977)	
<del>((75845 Venography, azygos, selective or nonselective, supervision and interpretation only .....</del>	<del>10.6</del>	75898 Angiogram through existing catheter for follow-up study for transcatheter therapy, embolization or infusion .....	(( <del>10.0</del> ) <u>27.7</u> )
75846 selective, complete procedure .....	<del>30.0</del>	75940 Percutaneous placement of IVC filter; supervision and interpretation only .....	((BR) <u>51.0</u> )
75847 nonselective, complete procedure .....	<del>28.0</del>	75941 complete procedure .....	((BR) <u>127.5</u> )
75850 Venography, intraosseous; supervision and interpretation only .....	<del>12.2</del> <u>32.0</u> )	(For surgical procedure, use 37620)	
75851 complete procedure .....	<del>18.3</del>	75950 Transcatheter intravascular occlusion, (e.g., balloon) temporary, including angiography; supervision and interpretation only .....	((BR) <u>57.7</u> )
75860 Venography, sinus or jugular, catheter; supervision and interpretation only .....	(( <del>12.2</del> ) <u>18.3</u> )	75951 complete procedure .....	((BR) <u>144.3</u> )
75861 complete procedure .....	(( <del>32.0</del> ) <u>45.7</u> )	75955 Transcatheter intravascular occlusion, (e.g., balloon, coil or methacrylate) permanent, including angiography; supervision and interpretation only .....	((BR) <u>57.7</u> )
75870 Venography, superior sagittal sinus; supervision and interpretation only .....	(( <del>12.2</del> ) <u>26.0</u> )	75956 complete procedure .....	((BR) <u>144.3</u> )
75871 complete procedure, including direct puncture .....	(( <del>32.0</del> ) <u>65.0</u> )	75961 Transcatheter retrieval, percutaneous, of fractured venous or arterial catheter .....	((BR) <u>89.0</u> )
75872 Venography, epidural; supervision and interpretation only .....	((BR) <u>26.9</u> )	75962 Percutaneous transluminal angioplasty, any method, peripheral artery; supervision and interpretation only .....	BR
75873 complete procedure .....	((BR) <u>67.4</u> )	75963 complete procedure .....	BR
75880 Venography, orbital; supervision and interpretation only .....	(( <del>13.7</del> ) <u>18.3</u> )	75964 Percutaneous transluminal angioplasty, any method, each additional peripheral artery; supervision and interpretation only .....	BR
75881 complete procedure .....	(( <del>36.0</del> ) <u>45.7</u> )	75965 complete procedure .....	BR
75885 Percutaneous transhepatic portography with hemodynamic evaluation; supervision and interpretation only .....	(( <del>13.7</del> ) <u>41.4</u> )	75966 Percutaneous transluminal angioplasty, any method, renal or other visceral artery; supervision and interpretation only .....	BR
75886 complete procedure .....	(( <del>36.0</del> ) <u>103.4</u> )	75967 complete procedure .....	BR
75887 Percutaneous transhepatic portography without hemodynamic evaluation; supervision and interpretation only .....	(( <del>12.9</del> ) <u>41.4</u> )	75968 Percutaneous transluminal angioplasty, any method, each additional visceral artery; supervision and interpretation only .....	BR
75888 complete procedure .....	(( <del>34.0</del> ) <u>103.4</u> )	75969 complete procedure .....	BR
75889 Hepatic venography wedged or free, with hemodynamic evaluation; supervision and interpretation only .....	(( <del>14.4</del> ) <u>31.8</u> )	(For injection procedure only for percutaneous transluminal angioplasty, see 36100-36299)	
75890 complete procedure .....	(( <del>38.0</del> ) <u>79.4</u> )	(For percutaneous transluminal coronary angioplasty, see 92982-92984)	
75891 Hepatic venography, wedged or free, without hemodynamic evaluation; supervision and interpretation only .....	(( <del>12.9</del> ) <u>28.9</u> )	(For intraoperative transluminal angioplasty, see 35450-35458)	
75892 complete procedure .....	(( <del>34.0</del> ) <u>72.2</u> )	75970 Transcatheter biopsy; supervision and interpretation only .....	((BR) <u>36.6</u> )
75893 Venous sampling thru catheter without angiography (e.g., for parathyroid hormone, renin) .....	(( <del>5.0</del> ) <u>60.1</u> )	75971 complete procedure .....	((BR) <u>91.4</u> )
<b>TRANSCATHETER THERAPY AND BIOPSY</b>			
75894 Transcatheter therapy, embolization, (e.g., particulate or liquid) including angiography; supervision and interpretation only .....	(( <del>15.2</del> ) <u>57.7</u> )	(For transcatheter renal and ureteral biopsy, see 52007)	
75895 complete procedure .....	(( <del>40.0</del> ) <u>144.3</u> )		



Unit  
Value

**AMENDATORY SECTION** (Amending Order 89-09,  
filed 8/10/89, effective 9/10/89)

**WAC 296-23-079 MISCELLANEOUS.**

Unit  
Value

	(For percutaneous needle biopsy of pancreas, see 48102; of retroperitoneal lymph node or mass, see 49180)				
	(For injection procedure only for, see 36100-36299)				
75978	Percutaneous transluminal angioplasty, venous (e.g., subclavian stenosis); supervision and interpretation only	BR			
75979	complete procedure	BR			
75980	Percutaneous transhepatic biliary drainage with monitoring; supervision and interpretation only	((BR))	76000	Fluoroscopy (separate procedure, up to one hour physician time other than 71023 or 71034)	((3-0)) <u>12.0</u>
75981	complete procedure	48.1 ((BR)) <u>120.3</u>	76001	Fluoroscopy, physician time more than one hour, assisting a nonradiologic physician (e.g., nephrostolithotomy, ERCP, bronchoscopy, transbronchial biopsy) . . .	((11-0)) <u>27.4</u>
75982	Percutaneous placement of drainage catheter for combined internal and external biliary drainage or of a drainage stent for internal biliary drainage in patients with an inoperable mechanical biliary obstruction; supervision and interpretation only	((BR))	76003	Fluoroscopic localization for needle biopsy or aspiration	((BR)) <u>16.6</u>
75983	complete procedure	52.0 ((BR)) <u>129.9</u>		(See appropriate surgical code for location, e.g., 20220, 20225, 32400, 32405, 47000, 48100, 50200, 50390, 60100)	
75984	Change of percutaneous drainage catheter with contrast monitoring (i.e., biliary tract, urinary tract); supervision and interpretation only	((BR))	76020	Bone age studies	((6-0)) <u>7.7</u>
75985	complete procedure	10.6 ((BR)) <u>26.5</u>	76040	Bone length studies (orthoroentgenogram, scanogram)	((10-0)) <u>8.4</u>
	(For change of pyelostomy or nephrostomy tube, use 50398)		76061	Radiological examination, osseous survey; limited (e.g., for metastases)	((15-2)) <u>41.6</u>
	(For introduction procedure only for percutaneous biliary drainage, see 47510)		76062	complete (axial and appendicular skeleton)	((BR)) <u>25.3</u>
	(For percutaneous cholecystostomy, use 47490)		76065	osseous survey, infant	((13-2)) <u>24.1</u>
	(For change of percutaneous biliary drainage catheter only, use 47425)		76066	Joint survey, single view, one or more joints (specify)	((BR)) <u>7.7</u>
	(For percutaneous nephrostolithotomy or pyelostolithotomy, see 50080, 50081)		76070	Computerized tomography, bone density study	((BR)) <u>26.2</u>
75989	Radiological guidance for percutaneous drainage of abscess, or specimen collection (e.g., fluoroscopy, ultrasound or computed tomography), with or without placement of indwelling catheter; supervision and interpretation only	((BR))	76080	Fistula or sinus tract study supervision and interpretation only	((4-8)) <u>6.7</u>
75990	complete procedure	33.7 ((BR)) <u>84.2</u>	76081	complete procedure	((12-0)) <u>16.8</u>
	(75989, 75990 are neither organ nor area specific. For drainage of abscess performed without radiology or fluoroscopy, see under specific anatomic site)		76086	Mammary ductogram or galactogram, single duct; supervision and interpretation only	6.3 ((15-8)) <u>15.6</u>
			76087	complete procedure	
			76088	Mammary ductogram or galactogram, multiple ducts; supervision and interpretation only	((10-6)) <u>16.3</u>
			76089	complete procedure	((26-5)) <u>40.7</u>
				(Modifier -50 should not be used with 76086-76089. To report bilateral procedures, use 76088 or 76089)	
				(For injection procedure only for mammary ductogram or galactogram, see 19030)	
			76090	Mammography, unilateral	((8-8)) <u>10.1</u>
			76091	bilateral	((13-2)) <u>15.4</u>

	Unit Value
<u>76092 Screening mammography, bilateral (two view film study of each breast).....</u>	<u>BR</u>
76096 Localization of breast nodule or calcification before operation, with marker and confirmation of its position with appropriate imaging (e.g., ultrasound or radiologic) .....	(( <del>14.6</del> ) 13.2 (( <del>7.3</del> ) 14.9
76097 each additional localization .....	(( <del>BR</del> ) 4.8
76098 Radiological examination, breast surgical specimen.....	(( <del>13.2</del> ) 16.8
76100 Radiologic examination, single plane body section (e.g., tomography), other than with urography .....	(( <del>19.3</del> ) 16.8 (( <del>35.0</del> ) 24.1
76101 Radiologic examination, complex motion (i.e., hypercycloidal) body section (e.g., mastoid polytomography), other than with urography; unilateral .....	(( <del>BR</del> ) 24.1
76102 bilateral .....	(( <del>BR</del> ) 28.9
(For nephrotomography, see 74415)	
76120 Cineradiography, except where specifically included .....	(( <del>13.2</del> ) 10.8 (( <del>7.0</del> ) 9.6
76125 to complement routine examination ...	BR
76140 Written consultation on x-ray examination made elsewhere .....	(( <del>6.0</del> ) 12.0
76150 Xeroradiography .....	BR
76350 Subtraction in conjunction with contrast studies .....	(( <del>BR</del> ) 74.6
76355 Computerized tomography guidance for stereotactic localization.....	(( <del>BR</del> ) 19.7 (( <del>BR</del> ) 98.6
76360 Computerized tomography guidance for needle biopsy; supervision and interpretation only .....	(( <del>BR</del> ) 19.7 (( <del>BR</del> ) 98.6
76361 complete procedure .....	(( <del>BR</del> ) 33.2
76365 Computerized tomography guidance for cyst aspiration; supervision and interpretation only .....	(( <del>23.5</del> ) 29.4
76366 complete procedure .....	(( <del>20.0</del> ) 117.9 BR
76370 Computerized tomography guidance for placement of radiation therapy fields....	
76375 Computerized tomography, coronal, sagittal, multiplanar, oblique and/or 3 dimensional reconstruction.....	
76400 Magnetic resonance (e.g., proton) imaging, bone marrow blood supply.....	
76499 Unlisted diagnostic radiologic procedure .	

AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

WAC 296-23-07902 HEAD AND NECK.

	Unit Value
76506 Echoencephalography, B-mode (gray scale) complete (for determination of ventricular size, delineation of cerebral contents and detection of fluid, masses or other intracranial abnormalities), including A-mode encephalography as secondary component where indicated.....	(( <del>BR</del> ) 22.9
76511 Ophthalmic, ultrasound, echography; A-mode with amplitude quantitation .....	(( <del>22.9</del> ) 25.3
76512 contact scan B-mode.....	(( <del>22.9</del> ) 25.3 (( <del>22.9</del> ) 25.3
76513 immersion (water bath) B-scan .....	(( <del>15.4</del> ) 24.1 (( <del>BR</del> ) 24.1 (( <del>BR</del> ) 28.9
76516 Ophthalmic biometry by ultrasound echography; A-mode .....	(( <del>11.4</del> ) 14.4
76519 with intraocular lens power calculation .....	
76529 Ophthalmic ultrasound foreign body localization .	
76536 Echography, soft tissues of head and neck (e.g., thyroid, parathyroid, parotid) B-scan and/or real time with image documentation .....	

AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

WAC 296-23-07903 HEART AND CHEST.

	Unit Value
76604 Echography, chest B-scan (includes mediastinum) and/or real time with image documentation .....	(( <del>11.4</del> ) 20.4 <del>15.4</del> 7.7 11.4 9.7
<del>76620 Echocardiography, M-mode, complete .....</del>	<del>BR</del>
<del>76625 limited, e.g., follow-up or limited study .....</del>	<del>BR</del>
<del>76627 Echocardiography, real-time scan; complete .....</del>	<del>BR</del>
<del>76628 limited .....</del>	<del>BR</del>
<del>76629 Echocardiography M-mode and real time with image documentation (2D).....</del>	<del>BR</del>
76632 Doppler echocardiography .....	BR
(Procedure 76632 is often performed in combination with M-mode or 2-dimensional echocardiography)	
(For echocardiography as a cardiovascular procedure, see 93300-93320)	
76645 Echography, breast(s) (unilateral or bilateral), B-scan and/or real time with image documentation .	(( <del>19.2</del> ) 29.1

AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

WAC 296-23-07905 ABDOMEN AND RETROPERITONEUM.

	Unit Value
76700 Echography, abdominal B-scan and/or real time with image documentation complete .....	(( <del>22.9</del> ) 28.9
76705 limited, (e.g., single organ, quadrant, follow-up) .....	(( <del>15.4</del> ) 24.1

	Unit Value
76770 Echography, retroperitoneal (e.g., renal, aorta, nodes), B-scan and/or real time with image documentation complete .....	((22-9)) 28.9
76775 limited .....	((+9-2)) 24.1
76778 Echography of transplanted kidney, B-scan and/or real time with image documentation, with or without duplex Doppler studies .....	<u>BR</u>

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-23-07906 PELVIS, GENITALIA, AND EXTREMITIES.**

	Unit Value
76800 Echography, spinal canal and contents .....	<u>BR</u>
76805 Echography, pregnant uterus ((pelvic)), B-scan and/or real time with image documentation; complete (complete fetal and maternal evaluation) .....	((21-2)) 24.1
76815 limited((fetal growth rate, heart beat, anomalies, placental location)) (gestational age, heart beat, placental location, fetal position, or emergency in the delivery room) .....	((9-7)) 14.4
76816 follow-up or repeat .....	((9-7)) 15.6
76818 Fetal biophysical profile .....	((BR)) 21.7
76825 ((Echography)) Echocardiography, fetal ((heart in utero)), real time with image documentation (2D) with or without M-mode recording .....	((BR)) 24.1
76830 Echography, transvaginal .....	<u>BR</u>
76855 Echography, pelvic area (Doppler) .....	((+1-4)) 12.0
76856 Echography, pelvic, (nonobstetric), B-scan and/or real time with image documentation .....	((BR)) 21.7
76857 limited or follow-up (e.g., for follicles) .....	((BR)) 12.3

**GENITALIA**

76870 Echography, scrotum and contents .....	((BR)) 25.3
76872 Echography, prostate, transrectal .....	<u>BR</u>

**EXTREMITIES**

76880 Echography, extremity, nonvascular, B-scan and/or real time with image documentation .....	((BR)) 19.2
--	----------------

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-23-07907 VASCULAR STUDIES.**

	Unit Value
76925 ((Imaging)) Echography, peripheral vascular system (e.g., B-scan, Doppler or real time scan) .....	((BR)) 22.9
76926 ((Imaging)) Echography, head and trunk (e.g., Duplex Doppler) .....	((25-0)) 21.4

**ULTRASONIC GUIDANCE PROCEDURES**

76930 Ultrasonic guidance for pericardiocentesis; supervision and interpretation .....	((BR)) 20.2
76931 complete procedure .....	((BR)) 50.5
76932 Ultrasonic guidance for endomyocardial biopsy; supervision and interpretation only .....	<u>BR</u>
76933 complete procedure .....	<u>BR</u>
76934 Ultrasonic guidance for thoracentesis; supervision and interpretation only .....	((3-0)) 14.0
76935 complete procedure .....	((5-0)) 34.9
76938 Ultrasonic guidance for cyst (any location,) or renal pelvis aspiration; supervision and interpretation only .....	((+0)) 20.2
76939 complete procedure .....	((2-0)) 50.5
76942 Ultrasonic guidance for needle biopsy; supervision and interpretation only .....	((4-0)) 20.2
76943 complete procedure .....	((6-0)) 50.5
76946 Ultrasonic guidance for amniocentesis; supervision and interpretation only .....	((4-0)) 15.4
76947 complete procedure .....	((6-0)) 38.5
76948 Ultrasonic guidance for aspiration of ova; ((complete procedure)) supervision and interpretation only .....	((BR)) 14.3
76949 complete procedure .....	((BR)) 35.8
76950 Echography for placement of radiation therapy fields, B-scan .....	((+7-+)) 28.9
76960 Ultrasonic guidance for placement of radiation therapy fields except for B-scan echography .....	((+4-3)) 19.2

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-23-07908 MISCELLANEOUS.**

	Unit Value
76970 Ultrasound study follow-up specify .....	((+0-0)) <u>BR</u>
76986 Echography, intraoperative .....	((5-7)) 35.8
((76991) Intraluminal ultrasound study (e.g., transrectal, transvaginal) .....	<u>BR</u> )
76999 Unlisted ultrasound procedure .....	<u>BR</u>

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-23-080 THERAPEUTIC RADIOLOGY—GENERAL INFORMATION AND INSTRUCTIONS.** (1) Listings for therapeutic radiology provide for teletherapy and brachytherapy to include initial consultation, clinical treatment planning, simulation, medical radiation physics, dosimetry, treatment devices, special services, and clinical treatment management procedures. They include normal follow-up care during course

of treatment and for three months following its completion.

**CONSULTATION: CLINICAL MANAGEMENT**

Preliminary consultation, evaluation of patient prior to decision to treat, or full medical care (in addition to treatment management) when provided by the therapeutic radiologist may be identified by the appropriate procedure codes from medicine or surgery sections.

**CLINICAL TREATMENT PLANNING  
(EXTERNAL AND INTERNAL SOURCES)**

The clinical treatment planning process is a complex service including interpretation of special testing, tumor localization, treatment volume determination, treatment time/dosage determination, choice of treatment modality, determination of number and size of treatment ports, selection of appropriate treatment devices, and other procedures.

**DEFINITIONS:** Simple—planning requiring single treatment area of interest encompassed in a single port or simple parallel opposed ports with simple blocking.

Intermediate—planning requiring three or more converging ports, two separate treatment areas, special blocking, or special time dose constraints.

Complex—planning requiring highly complex blocking, tangential ports, special wedges or compensators, three or more separate treatment areas, rotational or special beam considerations.

	Unit Value
77261 Therapeutic radiology treatment planning; simple	BR
77262 intermediate	BR
77263 complex	BR
77280 Therapeutic radiology simulation-aided field setting; simple	((BR)) <u>15.6</u>
77285 intermediate	((BR)) <u>40.9</u>
77290 complex	((BR)) <u>52.9</u>
77299 Unlisted procedure, therapeutic radiology clinical treatment planning	BR

**MEDICAL RADIATION PHYSICS, DOSIMETRY, TREATMENT DEVICES AND SPECIAL SERVICES**

77300 Basic radiation dosimetry calculation, central axis depth dose, TDF, NSD, gap calculation, off axis factor, tissue inhomogeneity factors, as required during course of treatment	((4-0)) <u>9.6</u>
77305 Teletherapy, isodose plan (whether hand or computer calculated); simple (one or two parallel opposed unmodified ports directed to a single area of interest)	((3-0)) <u>10.1</u>
77310 intermediate (three or more treatment ports directed to a single area of interest)	((4-0)) <u>20.4</u>
77315 complex (mantle or inverted Y, tangential ports, the use of wedges, compensators, complex rotational blocking or special beam considerations)	((6-0)) <u>32.0</u>

77321 Special teletherapy port plan, particles, hemi-body, total body	((BR)) <u>37.3</u>
77326 Brachytherapy isodose calculation; simple (calculation made from single plane, one to four source/ribbon application)	((BR)) <u>25.3</u>
77327 intermediate (multiplane dosage calculations, application involving five to ten sources/ribbons)	((BR)) <u>34.4</u>
77328 complex (multiplane isodose plan, volume implant calculations, over ten sources/ribbons used, special spatial reconstruction)	((BR)) <u>43.8</u>
77331 Special dosimetry (e.g., TLD, microdosimetry) (specify)	((BR)) <u>14.9</u>
77332 Treatment devices, design and construction; simple (simple block, simple bolus)	((BR)) <u>15.6</u>
77333 intermediate (multiple blocks, stents, bite blocks, special bolus)	((BR)) <u>22.9</u>
77334 complex (irregular blocks, special shields, compensators, wedges, molds or casts)	BR
77336 Continuing medical radiation physics consultation in support of therapeutic radiologist, including continuing quality assurance	((BR)) <u>18.3</u> BR
77370 Special medical radiation physics consultation	BR
77399 Unlisted procedure, medical radiation physics, dosimetry and treatment devices	BR

**CLINICAL TREATMENT MANAGEMENT**

Except where specified, assumes treatment on a daily basis (4 or 5 fractions per week) with the use of megavoltage photon or high energy particle sources. Daily and weekly clinical treatment management are mutually exclusive for the same dates.

**DEFINITIONS:** Simple—single treatment area, single port or parallel opposed ports, simple blocks.

Intermediate—two separate treatment areas, three or more ports on a single treatment area, use of special blocks.

Complex—three or more separate treatment areas, highly complex blocking (mantle, inverted Y, tangential ports, wedges, compensators, or other special beam considerations).

77400 Daily megavoltage treatment management; simple	((2-0)) <u>13.2</u>
77405 intermediate	((3-0)) <u>16.8</u>
77410 complex	((4-0)) <u>19.7</u>
77415 Therapeutic radiology treatment port film interpretation and verification, per treatment course	((3-0)) <u>9.6</u>
77420 Weekly megavoltage treatment management; simple	((4-0)) <u>60.1</u>
77425 intermediate	((5-0)) <u>73.4</u>
77430 complex	((6-0)) <u>101.0</u>
(For complicated shielding devices, see treatment aids, 77600-77635)	
77465 Daily kilovoltage treatment management	((2-0)) <u>10.8</u>
77470 Special treatment procedure (e.g., total body irradiation, hemi-body irradiation, per oral, vaginal cone irradiation)	BR

Unit Value

(77470 assumes that the procedure be performed one or more times during the course of therapy, in addition to daily or weekly patient management)

77499 Unlisted procedure, therapeutic radiology clinical treatment management ..... BR

**HYPERTHERMIA**

Hyperthermia treatments as listed in this section include external (superficial and deep) and interstitial and intracavitary. Radiation therapy when given concurrently is listed separately.

Hyperthermia is used only as an adjunct to radiation therapy or chemotherapy. It may be induced by a variety of sources, e.g., microwave, ultrasound, low energy radiofrequency conduction, or by probes.

The listed treatments include management during the course of therapy and follow-up care for three months after completion. Preliminary consultation is not included (see medicine 90600-90630). Physics planning and interstitial insertion of temperature sensors, and use of external or interstitial heat generating sources are included.

77600 Hyperthermia, externally generated; superficial (i.e., heating to a depth of 4 cm or less) ..... ((BR))  
42.3

77605 deep (i.e., heating to depths greater than 4 cm) ..... ((BR))  
56.3

77610 Hyperthermia generated by interstitial probe(s); 5 or fewer interstitial applicators ..... ((BR))  
42.3

77615 more than 5 interstitial applicators ..... ((BR))  
56.3

**CLINICAL INTRACAVITARY HYPERTHERMIA**

77620 Hyperthermia generated by intracavitary probe(s) ..... ((20-0))  
42.3

**CLINICAL BRACHYTHERAPY**

Clinical brachytherapy requires the use of either natural or man-made radioelements applied into or around a treatment field of interest. The supervision of radioelements and dose interpretation are performed solely by the the therapeutic radiologist. When a procedure requires the service of a surgeon in addition, the modifier '-66' or '-80' may be used (see modifiers in radiology guidelines, page 290). Services 77750-77799 include admission to the hospital and daily visits.

**DEFINITIONS:** (Sources refer to intracavitary placement or permanent interstitial placement; ribbons refer to temporary interstitial placement)

Simple—application with one to four sources/ribbons

Intermediate—application with five to ten sources/ribbons

Complex—application with greater than ten sources/ribbons  
(Professional service component only)

77750 Infusion or instillation of radioelement solution of radioactive materials for therapy (includes handling and loading) ..... ((+2.5))  
BR

77761 Intracavitary radioelement application; simple ... ((BR))  
65.0

77762 intermediate ..... ((BR))  
93.8

77763 complex ..... BR

77776 Interstitial radioelement application; simple ..... BR

77777 intermediate ..... ((BR))  
123.7

77778 complex ..... BR

77789 Surface application of radioelement ..... ((24.75))  
17.1

77790 Supervision, handling, loading of radioelement ... ((33.5))  
17.1

77799 Unlisted procedure, clinical brachytherapy ..... BR

**AMENDATORY SECTION** (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

**WAC 296-23-125 DIAGNOSTIC.**

Unit Value

**ENDOCRINE SYSTEM**

78000 Thyroid uptake, single determination ..... ((6-0))  
8.9

78001 multiple determinations ..... ((8-0))  
11.5

78003 stimulation, suppression or discharge (not including initial uptake studies) ..... ((9-0))  
16.8

78006 Thyroid imaging, with uptake; single determination ..... ((16-0))  
25.3

78007 multiple determinations ..... ((18-0))  
27.7

78010 Thyroid imaging only ..... ((10-0))  
14.9

78011 with vascular flow ..... ((BR))  
17.8

78015 Thyroid carcinoma metastases imaging; limited area (e.g., neck and chest only) ..... ((20-0))  
23.1

78016 with additional studies (e.g., urinary recovery, etc.) ..... ((25-0))  
26.9

78017 multiple areas ..... ((BR))  
26.0

78018 whole body ..... ((BR))  
29.6

(For triiodothyronine true (TT-3), RIA, see 84480)

(For calcitonin, RIA, see 82308)

(For triiodothyronine, free (FT-3), RIA (unbound T-3 only), see 84481)

(For T-4 thyroxine, CPB or resin uptake, see 84435)

(For TT-4 thyroxine, RIA, see 84436)

(For T-4 thyroxine, neonatal, see 84437)

(For FT-4 thyroxine, free, RIA (unbound T-4 only), see 84439)

78070 Parathyroid imaging ..... BR  
(For parathormone (parathyroid hormone), RIA, see 83970)

78075 Adrenal imaging, cortical ..... ((BR))  
42.1

(For adrenal cortex antibodies, RIA, see 86681)

(For cortisol, RIA, plasma, see 82533)

(For cortisol, RIA, urine, see 82534)

(For aldosterone, double isotope technique, see 82087)

(For aldosterone, RIA, blood, see 82088)

(For aldosterone, RIA, urine, see 82089)

(For 17-ketosteroids, RIA, see 83588)

(For 17-OH ketosteroids, RIA, see 83599)

(For 17-hydroxycorticosteroids, RIA, see 83491)

(For insulin, RIA, see 83525)

(For insulin antibodies, RIA, see 86337)

(For insulin factor antibodies, RIA, see 86338)

(For proinsulin, RIA, see 84206)

	Unit Value		Unit Value
(For glucagon, RIA, see 82943)		78130 Red cell survival study (e.g., radiochromium) . . . .	(( <del>20.0</del> ) 32.5)
(For adrenocorticotrophic hormone (ACTH), RIA, see 82024)		78135 plus splenic and/or hepatic sequestration . . . .	(( <del>30.0</del> ) 54.1)
(For human growth hormone (HGH), (somatotropin), RIA, see 83003)		78140 Red cell splenic and/or hepatic sequestration . . . .	(( <del>20.0</del> ) 36.1)
(For human growth hormone antibody, RIA, see 86277)		78160 Plasma radio-iron turnover rate . . . . .	((+ <del>6.0</del> ) 34.9)
(For thyroglobulin antibody, RIA, see 86800)		78162 Radio-iron oral absorption . . . . .	BR
(For thyroid microsomal antibody, RIA, see 86376)		78170 Radio-iron red cell utilization . . . . .	(( <del>24.0</del> ) 32.5)
(For thyroid stimulating hormone (TSH), RIA, see 84443)		78172 Chelatable iron for estimation of total body iron .	((BR) 18.3)
(For thyrotropin releasing factor, RIA, see 84444)		(For hemosiderin, RIA, see 83071)	
(For plus long-acting thyroid stimulator (LATS), see 84445)		(For intrinsic factor antibodies, RIA, see 86340)	
(For follicle stimulating hormone (FSH component of pituitary gonadotropin), RIA, see 83001)		(For cyanocobalamin (vitamin B-12), RIA, see 82607)	
(For luteinizing hormone (LH component of pituitary gonadotropin), (ICSH), RIA, see 83002)		(For folic acid (folate) serum, RIA, see 82746)	
(For luteinizing releasing factor (LRH), RIA, see 83727)		(For human hepatitis antigen, nepatitis associated agent (Australian antigen) (HAA), RIA, see 86287)	
(For prolactin level (mammatropin), RIA, see 84146)		(For hepatitis A antibody (HAAb), RIA, see 86296)	
(For oxytocin level, (oxytocinase), RIA, see 83949)		(For hepatitis A virus antibody (HAVAb), see 86297)	
(For vasopressin level (antidiuretic hormone), RIA, see 84588)		(For hepatitis B core antigen (HB <sub>c</sub> Ag), RIA, see 86288)	
(For estradiol, RIA, see 82670)		(For hepatitis B core antibody (HB <sub>c</sub> Ab), RIA, see 86289)	
(For progesterone, RIA, see 84144)		(For hepatitis B surface antigen (HB <sub>s</sub> Ag), RIA, see 86287)	
(For testosterone, blood, RIA, see 84403)		(For hepatitis B surface antibody (HB <sub>s</sub> Ab), RIA, see 86291)	
(For testosterone, urine, RIA, see 84405)		(For hepatitis Be antigen (HB <sub>e</sub> Ag), RIA, see 86293)	
(For etiocholanolone, RIA, see 82696)		(For hepatitis Be antibody (HB <sub>e</sub> Ab), RIA, see 86295)	
(For chemical analysis, RIA tests, see WAC 296-23-212, chemistry and toxicology)		78185 Spleen imaging only; static . . . . .	(( <del>20.0</del> ) 24.1)
78099 Unlisted endocrine procedure, diagnostic nuclear medicine . . . . .	BR	(If combined with liver study, use procedures 78215 and 78216)	
(For chemical analysis, RIA tests, see Chemistry and Toxicology section)		78186 with vascular flow . . . . .	(( <del>25.0</del> ) 26.5)
<b>HEMATOPOIETIC, RETICULOENDOTHELIAL AND LYMPHATIC SYSTEM</b>		78191 Platelet survival . . . . .	((BR) 59.4)
78102 Bone marrow imaging; limited area . . . . .	BR	78192 White blood cell localization; limited area scanning . . . . .	((BR) 34.4)
78103 multiple areas . . . . .	BR	78193 whole body . . . . .	((BR) 79.9)
78104 whole body . . . . .	((BR) 18.8	78195 Lymphatics and lymph glands imaging . . . . .	((BR) 32.5)
78110 Plasma volume, radionuclide-dilution technique; (separate procedure) single sampling . . . . .	(( <del>8.0</del> ) 12.8	78199 Unlisted hematopoietic, R-E and lymphatic procedure, diagnostic nuclear medicine . . . . .	BR
78111 multiple sampling . . . . .	BR((+)	(For chemical analysis, RIA tests, see WAC 296-23-212, chemistry and toxicology)	
(For dye method, see 84605, 84610)		<b>GASTROINTESTINAL SYSTEM</b>	
78120 Red cell volume determination (separate procedure); single sampling . . . . .	((+ <del>2.0</del> ) 18.0	78201 Liver imaging; static only . . . . .	(( <del>20.0</del> ) 30.8)
78121 multiple sampling . . . . .	((BR+) 25.3	78202 with vascular flow . . . . .	(( <del>25.0</del> ) 39.7)
78122 Whole blood volume determination, including separate measurement of plasma volume and red cell volume (radionuclide volume-dilution technique) . . . . .	(( <del>8.0</del> ) 38.0	(For spleen imaging only, use 78185 and 78186)	
		78205 Liver imaging (SPECT) . . . . .	((BR) 50.8)

	Unit Value		Unit Value
78215 Liver and spleen imaging; static only .....	((25-0)) 28.9	78315 by three phase technique .....	((BR)) 45.2
78216 with vascular flow of liver and/or spleen .....	((30-0)) 32.5	78320 tomographic (SPECT) .....	((BR)) 55.1
78220 Liver function study with hepatobiliary agents; with serial images .....	((20-0)) 21.7	78350 Bone density (mineral content) study single photon absorptiometry .....	((BR)) 8.2
78223 Hepatobiliary ductal system imaging, including gallbladder .....	((BR)) 29.6	78351 dual photon absorptiometry .....	((BR)) 15.6
78225 Liver-lung study, imaging (e.g., subphrenic abs- cess) .....	((BR)) 28.9	78380 Joint imaging; limited area .....	((BR)) 32.5
78230 Salivary gland imaging; static .....	((14-0)) 22.9	78381 multiple areas .....	((BR)) 44.5
78231 with serial views .....	((16-0)) 28.4	78399 Unlisted musculoskeletal procedure, diagnostic nuclear medicine .....	BR
78232 Salivary gland function study .....	((BR)) 28.4	<b>CARDIOVASCULAR SYSTEM</b>	
78258 Esophageal motility .....	((BR)) 30.1	78414 Determination of ventricular ejection fraction with probe technique .....	((BR)) 60.1
78261 Gastric mucosa imaging .....	((BR)) 24.1	78415 Cardiac blood pool imaging, functional imaging (e.g., phase and amplitude analysis) .....	71.0
78262 Gastroesophageal reflux study .....	((BR)) 24.1	78425 Regurgitant index .....	((BR)) 10.8
78264 Gastric emptying study .....	((BR)) 24.1	78428 Cardiac shunt detection .....	((BR)) 39.7
78270 Vitamin B-12 absorption studies (e.g., Schilling test); without intrinsic factor .....	((10-0)) 15.6	78435 Cardiac flow study, imaging (i.e., angiocardio- graphy) .....	((BR)) 41.4
78271 with intrinsic factor .....	20.0	78445 Vascular flow study, imaging (i.e., angiography, venography) .....	((BR)) 18.0
78272 Vitamin B-12 absorption studies combined, with and without intrinsic factor .....	((25-0)) 24.1	78455 Venous thrombosis study (e.g., radioactive fibrin- ogen) .....	((BR)) 43.3
78276 Gastrointestinal aspirate blood loss localization ..	((BR)) 28.9	78457 Venous thrombosis imaging (e.g., venogram); uni- lateral .....	((BR)) 16.8
78278 Acute gastrointestinal blood loss imaging .....	((BR)) 28.9	78458 bilateral .....	((BR)) 30.1
78280 Gastrointestinal blood loss study (e.g., stool counting) .....	((16-0)) 28.9	78460 Myocardial imaging; resting only, quantitative, or qualitative .....	((27-0)) 28.1
78282 Gastrointestinal protein loss (e.g., radiochromium albumin) .....	((12-0)) 18.0	78461 exercise and redistribution, qualitative or quan- titative, with or without pharmacological inter- vention .....	((30-0)) 72.2
(For gastrin, RIA, see 82941)		78464 tomographic (SPECT), at rest only, qualitative or quantitative .....	((BR)) 64.0
(For intrinsic factor level, see 83528)		78465 tomographic (SPECT) with exercise and redis- tribution, qualitative or quantitative, with or without pharmacological intervention .....	((BR)) 101.8
(For carcinoembryonic antigen level (CEA), RIA, see 86151)		78466 Myocardial imaging, infarct avid, at rest; qualita- tive .....	((27-0)) 27.7
78290 Bowel imaging (e.g., ectopic gastric mucosa, Meckel's localization, volvulus) .....	((20-0)) 24.1	78467 quantitative .....	((27-0)) 32.0
78291 Peritoneal-venous shunt patency test (e.g., for LeVeen shunt) .....	((BR)) 33.2	78468 with first pass technique .....	((35-0)) 36.3
78299 Unlisted gastrointestinal procedure, diagnostic nu- clear medicine .....	BR	78469 with emission computed tomography .....	((50-0)) 48.8
(For chemical analysis, RIA tests, see WAC 296-23-212, chemistry and toxicology)		78470 Cardiac output .....	((BR)) 36.6
<b>MUSCULOSKELETAL SYSTEM</b>			
(Bone and joint imaging can be used in the diagnosis of a variety of infectious inflammatory diseases, e.g., osteomyelitis, as well as for lo- calization of primary and/or metastatic neoplasms)			
78300 Bone, imaging limited area (e.g., spine, pelvis, or skull, etc.) .....	((25-0)) 33.7	78471 Cardiac blood pool imaging, gated equilibrium, at rest, wall motion study plus ejection fraction .....	((21-0)) 49.1
78305 multiple areas .....	((40-0)) 40.9	78472 Cardiac blood pool imaging, gated equilibrium, at rest, wall motion study plus regional ejection frac- tion .....	((23-0)) 51.5
78306 whole body .....	((48-2)) 49.3	78474 quantitative wall motion study plus ejection fraction plus ventricular volume determination .....	((25-0)) 60.1
78310 vascular flow only .....	((BR)) 39.7		

	Unit Value		Unit Value	
78475	quantitative wall motion study, with exercise and/or pharmacological intervention . . . . .	((26-0)) <u>81.8</u>	78599 Unlisted respiratory procedure, diagnostic nuclear medicine . . . . .	BR
78476	quantitative wall motion study plus ejection fraction, with exercise and/or pharmacological intervention . . . . .	((27-0)) <u>84.9</u>	<b>NERVOUS SYSTEM</b>	
78477	quantitative wall motion study plus ejection fraction plus ventricular volume determination, with exercise and/or pharmacological intervention . . . . .	((30-0)) <u>92.1</u>	78600 Brain imaging, limited procedure; static . . . . .	((26-0)) <u>24.1</u>
78479	serial studies, any combination . . . . .	((25-0)) <u>BR</u>	78601 with vascular flow . . . . .	((31-0)) <u>30.1</u>
78481	Cardiac blood pool imaging, first pass technique, at rest; wall motion study with ejection fraction . . . . .	((20-0)) <u>49.6</u>	78605 Brain imaging, complete; static . . . . .	((30-0)) <u>32.5</u>
78484	quantitative wall motion study plus ejection fraction plus ventricular volume determination . . . . .	((25-0)) <u>55.8</u>	78606 with vascular flow . . . . .	((35-0)) <u>36.1</u>
78485	quantitative wall motion study, with exercise and/or pharmacological intervention . . . . .	((26-0)) <u>81.8</u>	78607 tomographic (ECT) . . . . .	((BR)) <u>62.3</u>
78486	quantitative wall motion study plus ejection fraction, with exercise and/or pharmacological intervention . . . . .	((27-0)) <u>84.9</u>	78610 Brain imaging, vascular flow study only . . . . .	((10-0)) <u>17.3</u>
78487	quantitative wall motion study plus ejection fraction plus ventricular volume determination, with exercise and/or pharmacological intervention . . . . .	((30-0)) <u>92.1</u>	78615 Cerebral blood flow . . . . .	((BR)) <u>32.5</u>
78489	serial studies, any combination . . . . .	((25-0)) <u>BR</u>	78630 Cerebrospinal fluid flow, imaging; cisternography (not including introduction of material) . . . . .	((35-0)) <u>37.3</u>
	(For digoxin, RIA, see 82643)		(For injection procedure, see 61000-61070; 62270-62294)	
	(For digitoxin (digitalis), RIA, see 82640)		78635 ventriculography . . . . .	((35-0)) <u>20.4</u>
	(For cerebral blood flow study, see 78615)		(For injection procedure, see 61000-61070; 62270-62294)	
78499	Unlisted cardiovascular procedure, diagnostic nuclear medicine . . . . .	BR	78645 shunt evaluation . . . . .	((35-0)) <u>18.0</u>
	(For chemical analysis, RIA tests, see WAC 296-23-212, chemistry and toxicology)		(For injection procedure, see 61000-61070; 62270-62294)	
<b>RESPIRATORY SYSTEM</b>			78650 CSF leakage detection and localization . . . . .	((32-0)) <u>20.4</u>
78580	Pulmonary perfusion imaging; particulate . . . . .	((26-0)) <u>28.9</u>	(For injection procedure, see 61000-61070; 62270-62294)	
78581	gaseous . . . . .	((BR)) <u>28.9</u>	78652 tomographic (ECT) . . . . .	((BR)) <u>53.2</u>
78582	gaseous, with ventilation, rebreathing and washout . . . . .	((BR)) <u>28.9</u>	(For myelin basic protein, CSF, RIA, see 83873)	
78584	Pulmonary perfusion imaging, particulate, with ventilation; single breath . . . . .	((BR)) <u>51.7</u>	78655 Eye tumor identification with radiophosphorus . . . . .	((BR)) <u>31.3</u>
78585	rebreathing and washout, with or without single breath . . . . .	((1-6)) <u>51.7</u>	78660 Dacryocystography (lacrima flow study) . . . . .	((BR)) <u>19.5</u>
78586	Pulmonary ventilation imaging, aerosol; single projection . . . . .	((BR)) <u>28.9</u>	78699 Unlisted nervous system procedure, diagnostic nuclear medicine . . . . .	BR
78587	multiple projections (e.g., anterior, posterior, lateral views) . . . . .	((BR)) <u>28.9</u>	<b>GENITOURINARY SYSTEM</b>	
78591	Pulmonary ventilation imaging, gaseous, single breath, single projection . . . . .	((BR)) <u>28.9</u>	78700 Kidney imaging; static only . . . . .	((18-0)) <u>22.9</u>
78593	Pulmonary ventilation imaging, gaseous, with rebreathing and washout with or without single breath; single projection . . . . .	((22-0)) <u>28.9</u>	78701 with vascular flow . . . . .	((20-0)) <u>26.5</u>
78594	multiple projections (e.g., anterior, posterior, lateral views) . . . . .	((BR)) <u>28.9</u>	78704 with function study (i.e., imaging renogram) . . . . .	((23-0)) <u>28.9</u>
			78707 with vascular flow and function study . . . . .	((30-0)) <u>31.8</u>
			(For introduction of radioactive substance in association with renal endoscopy, see 50558, 50559, 50578)	
			78710 Kidney imaging (SPECT) . . . . .	((BR)) <u>50.0</u>
			78715 Kidney vascular flow . . . . .	((BR)) <u>18.0</u>
			78725 Kidney function study only . . . . .	((BR)) <u>20.4</u>
			78726 with pharmacological intervention . . . . .	((BR)) <u>32.5</u>
			(For renin (angiotensin I), RIA, see 84244)	
			(For angiotensin II, RIA, see 82163)	



	Unit Value		Unit Value
(For beta-2 microglobulin, RIA, see 82231, 82232)		(For alpha-1 fetoprotein, RIA, see 86244)	
78727 Kidney transplant evaluation . . . . .	((BR)) <u>23.6</u>	(For antinuclear antibodies, RIA, see 86038)	
78730 Urinary bladder residual study . . . . .	((BR)) <u>20.0</u>	(For lactic dehydrogenase, RIA, see 83610)	
(For introduction of radioactive substance in association with cystotomy or cystostomy, see 51020; in association with cystourethroscopy, see 52250)		(For amikacin, see 82112)	
78740 Ureteral reflux study (radionuclide voiding cystogram) . . . . .	((BR)) <u>24.1</u>	(For aminophylline, see 82137)	
(For estradiol, RIA, see 82670)		(For amitriptyline, see 82138)	
(For estriol, RIA, see 82677, 84680)		(For amphetamine, chemical, quantitative, see 82145)	
(For progesterone, RIA, see 84144)		(For chlordiazepoxide, see 82420, 82425)	
(For prostatic acid phosphatase, RIA, see 84066)		(For chlorpromazine, see phenothiazine, urine, 84021, 84022)	
78760 Testicular imaging . . . . .	((BR)) <u>27.7</u>	(For clonazepam, see 82512)	
78761 with vascular flow . . . . .	((BR)) <u>34.6</u>	(For cocaine, quantitative, see 82520)	
(For testosterone, blood, RIA, see 84403)		(For diazepam, see 82636)	
(For testosterone, urine, RIA, see 84405)		(For dihydromorphinone, quantitative, see 82649)	
(For introduction of radioactive substance in association with ureteral endoscopy, see 50958, 50959, 50978)		(For phenytoin (diphenylhydantoin), see 84045)	
(For lactogen, placental (HPL) chorionic somatomammotropin, RIA, see 83632)		(For flucytosine, see 82741)	
(For chorionic gonadotropin beta subunit, RIA, see 84702, 84703)		(For gentamicin, see 84695)	
(For pregnanediol, RIA, see 84135)		(For lysergic acid diethylamide (LSD), RIA, see 83728)	
(For pregnantrial, RIA, see 84138)		(For morphine (heroin), RIA, see 83862)	
78799 Unlisted genitourinary procedure, diagnostic nuclear medicine . . . . .	BR	(For phencyclidine (PCP), see 83992)	
(For chemical analysis, RIA tests, see WAC 296-23-212 chemistry and toxicology)		(For phenobarbital, see barbiturates, 82205, 82210)	
<b>MISCELLANEOUS STUDIES</b>		(For tobramycin, see 84840)	
78800 Radionuclide localization of tumor (e.g., gallium, selenomethionine); limited area . . . . .	((BR)) <u>20.4</u>	(For kanamycin, see 83578)	
(For specific organ, see appropriate heading)		78890 Generation of automated data: Interactive process involving nuclear physician and/or allied health professional personnel; simple manipulations and interpretation, not to exceed 30 minutes . . . . .	((BR)) <u>7.2</u>
(For eye tumor identification, see 78655)		78891 complex manipulations and interpretation, exceeding 30 minutes . . . . .	((BR)) <u>12.0</u>
78801 multiple areas . . . . .	((BR)) <u>24.1</u>	(Use 78890 or 78891 in addition to primary procedure)	
78802 whole body . . . . .	((BR)) <u>41.9</u>	78990 Provision of diagnostic radionuclide(s) . . . . .	((+2.0)) <u>9.6</u>
78803 Tumor localization (SPECT) . . . . .	((BR)) <u>60.4</u>	78999 Unlisted miscellaneous procedure, diagnostic nuclear medicine . . . . .	BR
78805 Radionuclide localization of abscess; limited area . . . . .	((BR)) <u>33.7</u>		
78806 whole body . . . . .	((BR)) <u>39.0</u>	<b>AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)</b>	
(For imaging bone infectious inflammatory disease, see 78300-78381)		<b>WAC 296-23-130 THERAPEUTIC.</b>	
(For Rast, see 86421, 86422)			Unit Value
(For gamma-E immunoglobulin, RIA, see 82785)		79000 Radionuclide therapy, hyperthyroidism, initial including evaluation of patient . . . . .	((48.0)) <u>36.1</u>
(For gamma-G immunoglobulin, see 82784)		79001 subsequent, each therapy . . . . .	((20.0)) <u>27.4</u>
(For alpha-1 antitrypsin, RIA, see 86064)		(For follow-up visit, see 90030-90080)	
		79020 Radionuclide therapy, thyroid suppression, (euthyroid cardiac disease), including evaluation of patient . . . . .	((48.0)) <u>43.3</u>

	Unit Value		Unit Value
79030 Radionuclide ablation of gland for thyroid carcinoma .....	((BR+)) <u>51.2</u>	80002 Automated multichannel test; 1 or 2 clinical chemistry test(s) .....	((21-0)) <u>15.7</u>
79035 Radionuclide therapy for metastases of thyroid carcinoma .....	((BR)) <u>54.9</u>	80003 3 clinical chemistry tests .....	((28-0)) <u>15.7</u>
79100 Radionuclide therapy, polycythemia vera, chronic leukemia, etc., each treatment .....	((16-0)) <u>39.7</u>	80004 4 clinical chemistry tests .....	((32-0)) <u>15.7</u>
79200 Intracavitary radioactive colloid therapy .....	((24-0)) <u>51.7</u>	80005 5 clinical chemistry tests .....	((36-0)) <u>15.7</u>
79300 Interstitial radioactive colloid therapy .....	((60-0)) <u>72.2</u>	80006 6 clinical chemistry tests .....	((40-0)) <u>15.7</u>
79400 Radionuclide therapy, nonthyroid, nonhematologic e.g., for metastases to bone .....	((BR+)) <u>55.3</u>	80007 7 clinical chemistry tests .....	((44-0)) <u>15.7</u>
79420 Intravascular radionuclide therapy, particulate .....	((BR)) <u>77.0</u>	80008 8 clinical chemistry tests .....	((48-0)) <u>15.7</u>
79440 Intraarticular radionuclide therapy .....	((BR)) <u>90.2</u>	80009 9 clinical chemistry tests .....	((52-0)) <u>15.7</u>
79900 Provision of therapeutic radionuclide(s) .....	BR	80010 10 clinical chemistry tests .....	((56-0)) <u>15.7</u>
79999 Unlisted radionuclide therapeutic procedure .....	BR	80011 11 clinical chemistry tests .....	((60-0)) <u>15.7</u>

**AMENDATORY SECTION** (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

**WAC 296-23-204 PANEL OR PROFILE TESTS.**

The following list contains those tests that can be and are frequently done as groups and combinations ("profiles") on automated multichannel equipment. For any combination of tests among those listed immediately below, use the appropriate number 80002-80021. Groups of the tests listed here are distinguished from multiple tests performed individually for immediate or "stat" reporting.

The following unit values apply when three or more of the tests listed below are performed on the same blood or urine specimen under the conditions described under WAC 296-23-200(5).

(For handling of specimen, see 99000 and 99001)

- Albumin
- Albumin/globulin ratio
- Bilirubin, direct
- Bilirubin, total
- Calcium
- Carbon dioxide content
- Chloride
- Cholesterol
- Creatinine
- Globulin
- Glucose (sugar)
- Lactic dehydrogenase (LDH)
- Phosphatase, acid
- Phosphatase, alkaline
- Phosphorus
- Potassium
- Protein, total
- Sodium
- Transaminase, glutamic, oxaloacetic (SGOT)
- Transaminase, glutamic, pyruvic (SGPT)
- Urea nitrogen (BUN)
- Uric acid

80012 12 clinical chemistry tests .....	((64-0)) <u>15.7</u>
80016 13-16 clinical chemistry tests .....	((66-8)) <u>15.7</u>
80018 17-18 clinical chemistry tests .....	((69-6)) <u>15.7</u>
80019 19-24 clinical chemistry tests .....	((72-4)) <u>25.5</u>
<del>((80020-25-30 clinical chemistry tests .....</del>	<del>75.2</del>
<del>80021-31 or more clinical chemistry tests .....</del>	<del>78.0))</del>

**THERAPEUTIC DRUG MONITORING**

(e.g., antiepilepsy drugs, cardiac drugs, antibiotics, sedatives)

80031 Therapeutic quantitative drug monitoring in body fluids and/or excreta measurement one drug (if drug not specified by individual code number) ...	((BR)) <u>58.9</u>
80032 2 drugs measured .....	((BR)) <u>102.2</u>
80033 3 drugs measured .....	((BR)) <u>102.2</u>
80034 4 or more drugs measured .....	((BR)) <u>102.2</u>
80040 Serum radioimmunoassay for circulating antibiotic levels .....	((BR)) <u>68.8</u>
80042 Serum antimicrobial level, bioassay method .....	BR

**ORGAN OR DISEASE ORIENTED PANELS**

Organ "panels" as an approach to diagnosis have been developed in response to the increased use of general screening programs that are now in use in physicians' offices, health centers, clinics, and hospitals. Also included here are profiles that combine laboratory tests together under a problem oriented classification. The lack of an expanded list of laboratory tests under each number is deliberate. Because no two laboratories utilize the same array of tests in a particular panel, each laboratory should establish its own profile and accompany each reported panel by a listing of the components of that panel performed by the laboratory.

	Unit Value
80050 General health screen panel .....	BR
80052 Premarital profile .....	NONCOVERED
80053 Executive profile .....	NONCOVERED
80055 Obstetric profile .....	NONCOVERED
80056 Amenorrhea profile .....	((BR)) NONCOVERED
80057 Male infertility and/or gynecomastia profile .....	((BR)) NONCOVERED
80058 Hepatic function panel .....	((BR)) <u>45.2</u>
80059 Hepatitis panel .....	BR

	Unit Value		Unit Value
80060 Hypertension panel .....	((BR)) 80.6	89105 collection of multiple fractional specimens, with pancreatic or gallbladder stimulation, single or double lumen tube .....	((BR)) 90.4
80061 Lipid profile .....	((BR)) 55.0		
80062 Cardiac evaluation (including coronary risk) pan- el.....	((BR)) 70.7	(For chemical analyses, see Chemistry and Toxicology)	
80063 Cardiac injury panel .....	((BR)) 70.7	(For electrocardiogram, see 93000-93279)	
80064 with creatine phosphokinase (CPK) and/or lac- tic dehydrogenase (LDH) isoenzyme determi- nation .....	((BR)) 70.7	(For radiological localization, see 74340)	
80065 Metabolic panel .....	BR	(Esophagus acid perfusion test (Bernstein), see 91030)	
80066 Malabsorption panel .....	BR	89125 Fat stain, feces, urine, sputum .....	((+5.0)) 25.5
80067 Pulmonary (lung function) panel .....	BR	89130 Gastric intubation and aspiration diagnostic, each specimen, for chemical analyses or cytopathology ..	((20.0)) 37.3
80068 Lung maturity profile .....	BR	89132 after stimulation .....	((45.0)) 37.3
80070 Thyroid panel .....	((BR)) 45.2	89135 Gastric intubation, aspiration, and fractional collec- tions; for one hour (e.g., gastric secretory study) ...	((60.0)) 66.8
80071 with thyrotropin releasing hormone (TRH) ...	((BR)) 45.2	89136 two hours .....	((90.0)) 78.6
80072 Arthritis panel .....	((BR)) 112.0	89140 two hours including gastric stimulation (e.g., histalog, pentagastrin).....	((105.0)) 90.4
80073 Renal panel .....	BR	89141 three hours, including gastric stimulation .....	((120.0)) 102.2
80075 Parathyroid panel .....	BR	(For gastric lavage, therapeutic, see 96150)	
80080 Prostatic panel .....	BR	(For radiologic localization of gastric tube, see 74340)	
80082 Pancreatic panel .....	BR	(For chemical analyses, see 82926-82932)	
80084 Pituitary panel .....	BR	(For joint fluid chemistry, see Chemistry and Toxicology, this section)	
80085 Microcytic anemia panel .....	BR	89160 Meat fibers, feces .....	((12.0)) 11.8
80086 Macrocytic anemia panel .....	BR	89190 Nasal smear for eosinophils .....	((BR)) 17.7
80088 Transition panel (for management of patient with proven metastatic disease) .....	BR	89205 Occult blood, any source except feces .....	((10.5)) 11.8
80089 Muscle panel .....	BR	(Occult blood, feces, see 82270)	
80090 Antibody panel (e.g., TORCH: Toxoplasma IFA, rubella HI, cytomegalovirus CF, herpes virus CF).....	BR	(Paternity tests, see 86385, 86386)	
80099 Unlisted panel .....	BR	89300 Semen analysis, presence and/or sperm motility in- cluding Huhner test.....	((12.0)) 41.3
<b>CONSULTATIONS (CLINICAL PATHOLOGY)</b>			
A clinical pathology consultation is a service, including a written re- port, rendered by the pathologist in response to a request from an at- tending physician in relation to a test result(s) requiring additional medical interpretive judgment. Reporting of a test result(s) without medical interpretive judgment is not considered a clinical pathology consultation.			
80500 Clinical pathology consultation; limited, without review of patient's history and medical records...	BR	89310 motility and count .....	((40.0)) 19.6
80502 comprehensive, for a complex diagnostic prob- lem, with review of patient's history and medi- cal records .....	BR	89320 complete (volume, count, motility and differen- tial).....	((80.0)) 41.3
(For consultations involving the examination and evalua- tion of the patient, see 90600-90643)			
<b>AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)</b>			
<b>WAC 296-23-232 MISCELLANEOUS.</b>			
	Unit Value		
89050 Cell count, miscellaneous body fluids (except blood) (e.g., CSF, joint fluid, etc.).....	((12.0)) 13.8	89325 Sperm evaluation; hamster penetration test.....	((BR)) 25.5
89051 with differential count .....	((20.0)) 23.6	(For medicolegal identification of sperm, see 88125))	
89060 Crystal identification by compensated polarizing lens analysis, synovial fluid.....	((BR)) 23.6	89329 Sperm evaluation; hamster penetration test.....	BR
89100 Duodenal intubation and aspiration single specimen (e.g., simple bile study or afferent loop culture) plus appropriate test procedure .....	((40.0)) 112.0	89330 cervical mucus penetration test, with or without spinnbarkeit test .....	((BR)) 27.5
		(For complete spinal fluid examination, see 89070))	
		89350 Sputum, obtaining specimen, aerosol induced tech- nique (separate procedure) .....	((20.0)) 33.4
		89355 Starch granules, feces .....	((10.5)) 17.7
		89360 Sweat collection by iontophoresis .....	((BR)) 57.0
		(For chloride and sodium analysis, see 82437, 84295)	
		(Tissue culture, see 86595)	

	Unit Value
(Tissue typing, see 86810-86822)	
89365 Water load test .....	((BR)) <u>25.5</u>
89399 Unlisted miscellaneous pathology test .....	BR

**AMENDATORY SECTION** (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

**WAC 296-23-208 URINALYSIS.**

(For specific analyses, see appropriate section)

	Unit Value
81000 <u>Urinalysis</u> (( <del>routine, complete</del> )) ( <u>pH, specific gravity, protein, tests for reducing substances such as glucose</u> ); with microscopy .....	((+2.0)) <u>9.8</u>
81002 (( <del>routine</del> )) without microscopy .....	((8.0)) <u>5.9</u>
81004 <u>Urinalysis</u> ; components, single, not otherwise listed, specify .....	((5.0)) <u>5.9</u>
81005 chemical, qualitative any number of constituents ..	((8.0)) <u>9.8</u>
81007 <u>bacteriuria screen, by nonculture technique, commercial kit (specify type)</u> .....	BR
81010 concentration and dilution test .....	((+4.0)) <u>17.7</u>
81011 water deprivation test .....	((BR)) <u>15.7</u>
81012 water deprivation test with vasopressin response..	((BR)) <u>19.6</u>
81015 microscopic .....	((+0.0)) <u>11.8</u>
81020 two or three glass test .....	((+0.0)) <u>15.7</u>
81030 Quantitative sediment analysis and quantitative protein (Addis count) .....	((40.0)) <u>19.6</u>
81099 Unlisted urinalysis procedure .....	BR

**AMENDATORY SECTION** (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

**WAC 296-23-212 CHEMISTRY AND TOXICOLOGY.**

The material for examination can be from any source. Examination is quantitative unless specified. (For list of automated, multichannel tests, see 80003-80019.)

	Unit Value
82000 Acetaldehyde, blood .....	((40.0)) <u>45.2</u>
82003 Acetaminophen, urine .....	((40.0)) <u>60.9</u>
(Acetic anhydride, see volatiles, 84600)	
82005 Acetoacetic acid, serum .....	((40.0)) <u>45.2</u>
82009 Acetone, qualitative .....	((+2.0)) <u>17.7</u>
82010 quantitative .....	((+2.0)) <u>41.3</u>
(For acetone bodies, see 82009-82010, 82635, 83947)	
82011 Acetylsalicylic acid; quantitative .....	((32.0)) <u>33.4</u>
82012 qualitative .....	((32.0)) <u>27.5</u>

	Unit Value
82013 Acetylcholinesterase, .....	((40.0)) <u>45.2</u>
(Acid, gastric, see gastric acid, 82926-82932)	
(Acid phosphatase, see 84060-84065)	
82015 Acidity, titratable, urine .....	((30.0)) <u>17.7</u>
(ACTH, see 82024)	
(Adrenalin-Noradrenalin, see catecholamines, 82382-82384)	
82024 Adrenocorticotrophic hormone (ACTH), RIA ....	((+20.0)) <u>157.2</u>
82030 Adenosine; 5'-diphosphate (ADP) and 5'-monophosphate (AMP), cyclic, RIA, blood .....	((40.0)) <u>45.2</u>
82035 5'-triphosphate, blood .....	((40.0)) <u>45.2</u>
82040 Albumin, serum .....	((+20.0)) <u>19.6</u>
82042 urine, quantitative (specify method, e.g., Esbach) .....	((20.0)) <u>9.8</u>
(For albumin/globulin ratio, albumin/globulin ratio by electrophoretic method, see 84155-84200)	
82055 Alcohol (ethanol), blood, chemical .....	((30.0)) <u>58.9</u>
82060 by gas-liquid chromatography .....	((40.0)) <u>49.1</u>
82065 urine, chemical .....	((30.0)) <u>53.0</u>
82070 by gas-liquid chromatography .....	((40.0)) <u>49.1</u>
82072 Alcohol (ethanol) gelation .....	((30.0)) <u>45.2</u>
82075 breath .....	((60.0)) <u>57.0</u>
82076 Alcohol; isopropyl .....	((60.0)) <u>51.1</u>
82078 methyl .....	((60.0)) <u>58.9</u>
82085 Aldolase, blood, kinetic ultraviolet method .....	((20.0)) <u>45.2</u>
82086 colorimetric .....	((20.0)) <u>41.3</u>
82087 Aldosterone; double isotope technique .....	((+20.0)) <u>176.8</u>
82088 RIA blood .....	((+00.0)) <u>202.4</u>
82089 RIA urine .....	((+00.0)) <u>196.5</u>
82091 saline infusion test .....	((BR)) <u>196.5</u>
(Alkaline phosphatase, see 84075-84080)	
82095 Alkaloids, tissue, screening .....	((80.0)) <u>84.5</u>
82096 quantitative .....	((+20.0)) <u>174.4</u>
82100 urine, screening .....	((80.0)) <u>64.8</u>
82101 quantitative .....	((+20.0)) <u>147.4</u>
(See also 82486, 82600, 82662, 82755, 84231)	
(Alpha amino acid nitrogen, see 82126)	
(Alpha-hydroxybutyric (HBD) dehydrogenase, see 83485, 83486)	
(Alphaketoglutarate, see 83584)	
(Alpha tocopherol (Vitamin E), see 84446)	

	Unit Value		Unit Value
82108 Aluminum, blood (serum) .....	BR	82180 Ascorbic acid (Vitamin C) blood .....	((40-0)) <u>47.2</u>
82112 Amikacin .....	((BR)) <u>72.7</u>		
(Amikacin serum radioimmunoassay, see 80040)		(Aspirin, see acetylsalicylic acid, 82011, 82012)	
82126 Alpha amino acid nitrogen .....	((50-0)) <u>53.0</u>	(Atherogenic index, blood, ultracentrifugation, quantitative, see 83717)	
82128 Amino acids, qualitative .....	((40-0)) <u>31.4</u>	82205 Barbiturates quantitative .....	((60-0)) <u>60.9</u>
82130 Amino acids, urine or plasma chromatographic fractionation and quantitation, one or more .....	((180-0)) <u>17.7</u>	82210 quantitative and identification .....	((80-0)) <u>74.7</u>
82134 Aminohippurate, para (PAH) .....	((30-0)) <u>45.2</u>	(For qualitative screen, see 82486, 82660, 82662, 82755, 84231)	
(For administration, see 36410, 99070)		82225 Barium .....	((BR)) <u>82.5</u>
82135 Aminolevulinic acid, delta (ALA) .....	((50-0)) <u>74.7</u>	(Bence-Jones protein, 84185)	
82137 Aminophylline .....	((60-0)) <u>64.8</u>	82230 Beryllium, urine .....	((80-0)) <u>106.1</u>
82138 Amitriptyline .....	((60-0)) <u>86.4</u>	82231 Beta-2 microglobulin, RIA; urine .....	((BR)) <u>78.6</u>
82140 Ammonia, blood .....	((40-0)) <u>72.7</u>	82232 serum .....	((BR)) <u>78.6</u>
82141 urine .....	((40-0)) <u>43.2</u>	82235 Bicarbonate excretion, urine .....	((BR)) <u>17.7</u>
82142 Ammonium chloride loading test .....	((40-0)) <u>51.1</u>	82236 Bicarbonate loading test .....	((BR)) <u>29.5</u>
82143 Amniotic fluid scan (spectrophotometric) .....	((50-0)) <u>51.1</u>	(Bicarbonate, see 82374)	
(For L/S ratio, see 83661)		82240 Bile acids, blood, fractionated .....	((120-0)) <u>39.3</u>
(Amobarbital, see 82205-82210)		82245 Bile pigments, urine .....	((8-0)) <u>3.9</u>
82145 Amphetamine, or methamphetamine, chemical, quantitative .....	((80-0)) <u>62.9</u>	82250 Bilirubin, blood, total or direct .....	((24-0)) <u>23.6</u>
82150 Amylase, serum .....	((30-0)) <u>29.5</u>	82251 blood, total and direct .....	((30-0)) <u>25.5</u>
82156 urine (diastase) .....	((30-0)) <u>25.5</u>	82252 feces, qualitative .....	((BR)) <u>3.9</u>
82157 Androstenedione RIA .....	((80-0)) <u>123.8</u>	82260 urine, quantitative .....	((12-0)) <u>17.7</u>
82159 Androsterone .....	((50-0)) <u>117.9</u>	82265 amniotic fluid, quantitative .....	((30-0)) <u>29.5</u>
82160 RIA .....	((50-0)) <u>117.9</u>	82268 Bismuth .....	((80-0)) <u>98.2</u>
(See also 83593-83596)		82270 Blood, feces, occult, screening .....	((8-0)) <u>5.9</u>
(Angiotensin I, see renin, 84244)		82273 duodenal, gastric contents, qualitative .....	((BR)) <u>11.8</u>
82163 Angiotensin II, RIA .....	((BR)) <u>76.6</u>	(Blood urea nitrogen (BUN), see 84520-84525, 84545)	
82164 Angiotensin-converting enzyme .....	((BR)) <u>57.0</u>	(Blood volume, see 84605-84610, 78110, 78111)	
82165 Aniline .....	((BR)) <u>47.2</u>	82280 Boric acid, blood .....	((100-0)) <u>110.0</u>
(Antidiuretic hormone, RIA, see 84588)		82285 urine .....	((100-0)) <u>104.1</u>
82168 Antihistamines .....	((BR)) <u>60.9</u>	82286 Bradykinin .....	((BR)) <u>21.6</u>
82170 Antimony, urine .....	((80-0)) <u>92.3</u>	82290 Bromides, blood .....	((24-0)) <u>29.5</u>
(Antimony, screen, see 83015)		82291 urine .....	((40-0)) <u>31.4</u>
(Antitrypsin, alpha-1-, see 86329)		(For bromsulphthalein (BSP), see 84382)	
82172 Apolipoprotein .....	BR	82300 Cadmium, urine .....	((100-0)) <u>106.1</u>
82173 Arginine tolerance test .....	((BR)) <u>66.8</u>	82305 Caffeine .....	((60-0)) <u>55.0</u>
82175 Arsenic, blood, urine, gastric contents, hair or nails, quantitative .....	((80-0)) <u>86.4</u>	82306 Calcifediol (25-OH Vitamin D-3), chromatographical technique .....	((BR)) <u>141.5</u>

(For heavy metal screening, see 83015)

	Unit Value		Unit Value
82307 Calciferol (Vitamin D) RIA .....	((BR)) 104.1	82425 urine .....	((60-0)) 49.1
82308 Calcitonin, RIA .....	((80-0)) 112.0	82435 Chlorides, blood, (specify chemical or electromet- ric) .....	((20-0)) 9.8
82310 Calcium, blood, chemical .....	((22-0)) 19.6	82436 urine, (specify chemical, electrometric or Fantus test) .....	((20-0)) 25.5
82315 fluorometric .....	((22-0)) 15.7	82437 sweat (without iontophoresis) .....	((20-0)) 13.8
82320 emission flame photometry .....	((22-0)) 15.7		
82325 atomic absorption flame photometry .....	((24-0)) 25.5	(For iontophoresis, see 89360)	
82330 fractionated, diffusible .....	((60-0)) 66.8	82438 spinal fluid .....	((20-0)) 23.6
82331 after calcium infusion test .....	((24-0)) 25.5	82441 Chlorinated hydrocarbons, screen .....	((20-0)) 29.5
82335 urine, qualitative (Sulkowitch) .....	((11-0)) 19.6	82443 Chlorothiazide-hydrochlorothiazide .....	((60-0)) 86.4
82340 quantitative timed specimen .....	((32-0)) 23.6		
82355 Calculus (stone) qualitative, chemical .....	((40-0)) 55.0	(Chlorpromazine, see 84021, 84022)	
82360 quantitative, chemical .....	((60-0)) 55.0	82465 Cholesterol, serum; total .....	((22-0)) 7.9
82365 infrared spectroscopy .....	((60-0)) 55.0	82470 total and esters .....	((30-0)) 33.4
82370 X-ray diffraction .....	((50-0)) 41.3	82480 Cholinesterase, serum .....	((40-0)) 43.2
		82482 RBC .....	((60-0)) 51.1
(Carbamates, see individual listings)		82484 serum and RBC .....	((80-0)) 72.7
82372 Carbamazepine, serum .....	((BR)) 62.9	82485 Chondroitin B sulfate, quantitative .....	((BR)) 57.0
82374 Carbon dioxide, combining power or content .....	((10-0)) 9.8		
		(Chorionic gonadotropin, see gonadotropin, 84702, 84703)	
(See also 82801-82803, 82817)		82486 Chromatography; gas-liquid, compound and meth- od not elsewhere specified .....	((BR)) 76.6
82375 Carbon monoxide, (carboxyhemoglobin); quantita- tive .....	((48-0)) 60.9	82487 paper, 1-dimensional, compound and method not elsewhere specified .....	((BR)) 78.6
82376 qualitative .....	((48-0)) 15.7	82488 paper, 2-dimensional, not elsewhere specified .....	((BR)) 104.1
		82489 thin layer, not elsewhere specified .....	((BR)) 84.5
(Carbon tetrachloride, see 84600)		82495 Chromium, urine .....	((100-0)) 86.4
(Carboxyhemoglobin, see 82375, 82376)		82507 Citric acid .....	((80-0)) 119.8
82380 Carotene, blood .....	((40-0)) 39.3	82512 Clonazepam .....	((BR)) 80.6
		82520 Cocaine, quantitative .....	((60-0)) 49.1
(Carotene plus Vitamin A, see 84595)			
82382 Catecholamines (dopamine, norepinephrine, epine- phrine); total urine .....	((BR)) 68.8	(Cocaine, screen, see 82486, 82489, 82660, 82662, 82755, 84231)	
82383 blood .....	((BR)) 119.8	(Codeine, quantitative, see 82096, 82101)	
82384 fractionated .....	((BR)) 112.0	(Complement, see 86158-86164)	
		(Compound S, see 82634)	
(For urine metabolites, see 83835, 84585)		82525 Copper, blood .....	((60-0)) 60.9
82390 Ceruloplasmin, chemical (copper oxidase), blood ..	((40-0)) 45.2	82526 urine .....	((60-0)) 64.8
(For gel diffusion technique, see 86331; immunodiffusion technique, see 86329)		(Coprobilinogen, feces, 84577)	
82400 Chloral hydrate, blood .....	((60-0)) 82.5	(Coprotoporphyrins, see 84118-84121)	
82405 urine .....	((40-0)) 49.1	(Corticosteroids, see 83491-83496)	
82415 Chloramphenicol, blood .....	((40-0)) 51.1	82528 Corticosterone, RIA .....	((BR)) 72.7
82418 Chlorazepate dipotassium .....	((40-0)) 82.5		
82420 Chlordiazepoxide, blood .....	((60-0)) 94.3	(See also 83593-83597)	

	Unit Value		Unit Value
82529	Cortisol; fluorometric, plasma	( <del>36.0</del> )	(See also 83593-83596)
		55.0	
82531	CPB, plasma	( <del>75.0</del> )	(Deoxycortisol, 11- (compound S), RIA, see 82634)
		62.9	
82532	CPB, urine	( <del>75.0</del> )	82628 Desipramine
		62.9	((BR))
82533	RIA, plasma	( <del>90.0</del> )	82633 Desoxycorticosterone, 11-RIA
		62.9	((BR))
82534	RIA, urine	( <del>90.0</del> )	145.4
		72.7	(See also 83593-83596)
82536	after adrenocorticotropic hormone (ACTH) ad- ministration	((BR))	82634 Desoxycortisol, 11-(compound S), RIA
		84.5	((BR))
82537	48 hours after continuous ACTH infusion	((BR))	145.4
		84.5	(See also 83492)
82538	after metyrapone tartrate administration	((BR))	82635 Diacetic acid
		84.5	((+R))
82539	dexamethasone suppression test, plasma and/or urine	((BR))	31.4
		84.5	(Diagnex blue, tubeless gastric, see 82939)
82540	Creatine, blood	( <del>24.0</del> )	(Diastase, urine, see 82156)
		17.7	82636 Diazepam
82545	urine	( <del>40.0</del> )	((50-0))
		17.7	66.8
82546	Creatine and creatinine	( <del>50.0</del> )	82638 Dibucaine number
		37.3	((34-0))
82550	Creatine phosphokinase (CPK), blood, timed kinet- ic ultraviolet method	( <del>26.0</del> )	43.2
		29.5	82639 Dicumarol
82552	isoenzymes	( <del>30.0</del> )	((BR))
		58.9	74.7
82555	colorimetric	( <del>20.0</del> )	(Dichloroethane, see 84600)
		21.6	(Dichloromethane, see 84600)
82565	Creatinine, blood	( <del>20.0</del> )	(Diethylether, see 84600)
		23.6	82640 Digitoxin digitalis, blood RIA
82570	urine	( <del>20.0</del> )	((BR+))
		23.6	66.8
82575	clearance	( <del>40.0</del> )	82641 urine
		47.2	((BR+))
82585	Cryofibrinogen, blood	( <del>40.0</del> )	64.8
		21.6	82643 Digoxin, RIA
82595	Cryoglobulin, blood	( <del>40.0</del> )	((36-0))
		31.4	66.8
	(Crystals, pyrophosphate vs. urate, see 84208)		82646 Dihydrocodinone
82600	Cyanide, blood	((BR))	((BR))
		72.7	66.8
82601	tissue	((BR))	(Dihydrocodinone screen, see 82486-82489, 82662, 82755, 84231)
		90.4	82649 Dihydromorphinone, quantitative
82606	Cyanocobalamin (Vitamin B-12); bioassay	( <del>70.0</del> )	((75-0))
		70.7	127.7
82607	RIA	( <del>45.0</del> )	(Dihydromorphinone screen, see 82486-82489, 82662, 82755, 84231)
		74.7	82651 Dihydrotestosterone (DHT)
82608	unsaturated binding capacity	( <del>60.0</del> )	((BR))
		72.7	60.9
	(Cyclic AMP, see 82030)		82652 Dihydroxy vitamin D, 1, 25
	(Cyclic GMP, see 83008)		((BR))
	(Cyclosporine, see 83003)		218.1
82614	Cystine, blood, qualitative	((BR))	82654 Dimethadione
		43.2	((BR))
82615	Cystine, and homocystine, urine, qualitative	( <del>30.0</del> )	66.8
		31.4	(Diphenylhydantoin, see 84045)
82620	quantitative	( <del>40.0</del> )	(Dopamine, see 82382-82384)
		58.9	82656 Doxepin
82624	Cystine aminopeptidase	((BR))	((BR))
		43.2	62.9
	(D hemoglobin, see 83053)		82660 Drug screen (amphetamines, barbiturates, alka- loids)
	(Delta-aminolevulinic acid (ALA), see 82135)		((65-0))
82626	Dehydroepiandrosterone, RIA	((BR))	62.9
		108.1	(See also 82486-82489, 82662, 82755, 84231)
			(Duodenal contents, see individual enzymes; for intubation and collection, see 89100)
			((82662—Immunoassay technique for drugs..... 30-0))
			(For enzyme immunoassay for bacteria, use 86227)
			82664 Electrophoretic technique, not elsewhere specified
			((45-0))
			72.7
			82666 Epiandrosterone
			((BR))
			106.1

	Unit Value		Unit Value
(See also 83593)		82741 Flucytosine (5-fluorocytosine) . . . . .	((BR)) 72.7
(Epinephrine, see 82382-82384)		82742 Flurazepam . . . . .	((BR)) 76.6
82668 Erythropoietin, bioassay . . . . .	((BR)) 82.5	82745 Folic acid, (folate), blood bioassay . . . . .	((BR+)) 70.7
(For HI method, see 86280)		82746 RIA . . . . .	((45-0)) 70.7
82670 Estradiol, RIA (placental) . . . . .	((90-0)) 137.5	(Follicle stimulating hormone (FSH), see 83000, 83001)	
82671 Estrogens; fractionated . . . . .	((85-0)) 110.0	82750 Formimino-glutamic acid (FIGLU), urine . . . . .	((+00-0)) 125.7
82672 total . . . . .	((60-0)) 104.1	82755 Free radical assay technique for drugs (FRAT) . . . . .	((BR)) 82.5
82673 Estriol; fluorometric . . . . .	((54-0)) 21.6	82756 Free thyroxine index (T-7) . . . . .	((BR)) 17.7
82674 GLC . . . . .	((45-0)) 72.7	82757 Fructose, semen . . . . .	((BR)) 25.5
82676 Chemical . . . . .	((75-0)) 96.3	(Fructose, TLC screen, see 84375)	
82677 RIA . . . . .	((+05-0)) 94.3	82759 Galactokinase, RBC . . . . .	((BR)) 49.1
(Estrogen receptor assay, see 84233)		82760 Galactose, blood . . . . .	((40-0)) 49.1
82678 Estrone; chemical . . . . .	((75-0)) 108.1	82763 tolerance test . . . . .	((75-0)) 57.0
82679 RIA . . . . .	((90-0)) 123.8	82765 urine . . . . .	((40-0)) 33.4
(Ethanol, see 82055-82075)		82775 Galactose-1-phosphate uridyl transferase . . . . .	((60-0)) 104.1
82690 Ethchlorvynol (Placidyl), blood . . . . .	((60-0)) 96.3	(For TLC screen, see 84375)	
82691 urine . . . . .	((60-0)) 66.8	82776 screen . . . . .	((+0-0)) 17.7
82692 Ethosuximide . . . . .	((BR)) 78.6	82780 Gallium . . . . .	((BR)) 102.2
(Ethyl alcohol, see 82055-82075)		82784 Gammaglobulin, A, D, G, M nephelometric, each . . . . .	((+2-0)) 17.7
82694 Etiocholanolone . . . . .	((BR)) 110.0	82785 Gammaglobulin, E, (e.g., RIA, EIA) . . . . .	((75-0)) 58.9
(See also 83593)		82786 Gammaglobulin, salt precipitation method . . . . .	((21-0)) 29.5
(Evans blue, see blood volume, 84605-84610)		(Gammaglobulin by gel (immuno) diffusion, see 86329)	
82696 Etiocholanolone, RIA . . . . .	((50-0)) 104.1	(Gamma-glutamyl transpeptidase (GGT), see 82977)	
82705 Fat or lipids, feces, screening . . . . .	((+0-0)) 25.5	82790 Gases, blood, oxygen saturation; by calculation from pO <sub>2</sub> . . . . .	((40-0)) 41.3
82710 quantitative, 24 or 72 hour specimen . . . . .	((+00-0)) 76.6	82791 by manometry . . . . .	((40-0)) 47.2
82715 Fat differential, feces, quantitative . . . . .	((BR)) 31.4	82792 by oximetry . . . . .	((20-0)) 35.4
82720 Fatty acids, blood, esterified . . . . .	((40-0)) 47.2	82793 by spectrophotometry . . . . .	((40-0)) 47.2
82725 nonesterified . . . . .	((40-0)) 51.1	82795 by calculation from pCO <sub>2</sub> . . . . .	((6-0)) 21.6
82727 Ferric chloride, urine . . . . .	((BR)) 49.1	82800 Gases, blood, pH, only . . . . .	((20-0)) 41.3
82728 Ferritin, specify method (e.g., RIA, immunoradio- metric assay) . . . . .	((BR)) 45.2	82801 pCO <sub>2</sub> . . . . .	((24-0)) 21.6
(Fetal hemoglobin, see hemoglobin 83030, 83033, and 85460)		82802 pH, pCO <sub>2</sub> by electrode . . . . .	((42-0)) 45.2
(Fetoprotein, alpha-1, see 86329)		82803 pH, pCO <sub>2</sub> , pO <sub>2</sub> simultaneous . . . . .	((54-0)) 96.3
82730 Fibrinogen, quantitative . . . . .	((21-0)) 37.3	82804 pO <sub>2</sub> by electrode . . . . .	((40-0)) 43.2
(See also 85371, 85377)		82812 pO <sub>2</sub> by manometry . . . . .	((24-0)) 31.4
82735 Fluoride, blood . . . . .	((+00-0)) 64.8	82817 pH, pCO <sub>2</sub> by tonometry . . . . .	((24-0)) 58.9
82740 urine . . . . .	((+00-0)) 70.7	(For arterial puncture, see 36600)	



	Unit Value		Unit Value
(For blood gas studies as a part of pulmonary function studies, see 94700-94710)		(For glucose tolerance test with medication use 90784 in addition)	
82926 Gastric acid, free and total; single specimen	(( <del>11.2</del> )) <u>37.3</u>	82963 Glucosidase, beta	(( <del>BR</del> )) <u>106.1</u>
82927 each additional specimen	(( <del>9.0</del> )) <u>13.8</u>	82965 Glutamate dehydrogenase, blood	(( <del>40.0</del> )) <u>35.4</u>
82928 Gastric acid, free or total; single specimen	(( <del>9.0</del> )) <u>21.6</u>	(Glutamic oxaloacetic transaminase (SGOT), see 84450-84455)	
82929 each additional specimen	(( <del>7.5</del> )) <u>11.8</u>	(Glutamic pyruvic transaminase (SGPT), see 84460-84465)	
82931 Gastric acid, pH titration; single specimen	(( <del>24.0</del> )) <u>41.3</u>	82975 Glutamine (glutamic acid amide), spinal fluid	(( <del>80.0</del> )) <u>37.3</u>
82932 each additional specimen	(( <del>18.0</del> )) <u>27.5</u>	82977 Glutamyl transpeptidase, gamma (GGT)	(( <del>BR</del> )) <u>29.5</u>
(Gastric analysis, with stimulation, see 89140, 89141)		82978 Glutathione	(( <del>BR</del> )) <u>33.4</u>
(Gastric analysis, pepsin, see 83974)		82979 Glutathione reductase, RBC	(( <del>BR</del> )) <u>33.4</u>
(For gastric intubation, see 89130, 74340)		82980 Glutethimide	(( <del>56.2</del> )) <u>76.6</u>
(For aspiration of specimens with insulin administration (Hollander test), see 91075)		(Glycohemoglobin, see 83036)	
82938 Gastrin (serum) after secretin stimulation (e.g., for gastrinoma, Zollinger-Ellison syndrome)	(( <del>BR</del> )) <u>86.4</u>	82985 Glycoprotein electrophoresis	(( <del>60.0</del> )) <u>74.7</u>
82941 Gastrin, RIA	(( <del>48.0</del> )) <u>84.5</u>	82995 Gold, blood	(( <del>100.0</del> )) <u>80.6</u>
(GGT, see 82977)		83000 Gonadotropin, pituitary FSH; bioassay	(( <del>90.0</del> )) <u>72.7</u>
(GLC, gas liquid chromatography, see 82486)		83001 RIA	(( <del>90.0</del> )) <u>72.7</u>
82942 Globulin, serum	(( <del>10.5</del> )) <u>21.6</u>	83002 (LH)(ICSH)RIA	(( <del>90.0</del> )) <u>66.8</u>
(See also 82784, 82786, 84155-84200, 86329)		83003 Growth hormone (HGH), (somatotropin) RIA	(( <del>48.0</del> )) <u>64.8</u>
82943 Glucagon, RIA	(( <del>BR</del> )) <u>68.8</u>	83004 after glucose tolerance test	(( <del>48.0</del> )) <u>78.6</u>
82944 Glucosamine	(( <del>6.0</del> )) <u>21.6</u>	(For growth hormone secretion after arginine tolerance test, see 82173)	
82946 Glucagon tolerance test	(( <del>BR</del> )) <u>43.2</u>	(For human growth hormone antibody, RIA, see 86277)	
82947 Glucose; except urine (e.g., blood, spinal fluid, joint fluid)	(( <del>10.5</del> )) <u>7.9</u>	83008 Guanosine monophosphate (GMP) cyclic, RIA	(( <del>BR</del> )) <u>60.9</u>
82948 blood, stick test	(( <del>8.2</del> )) <u>9.8</u>	83010 Haptoglobin, chemical	(( <del>60.0</del> )) <u>17.7</u>
82949 fermentation	(( <del>22.5</del> )) <u>17.7</u>	83011 quantitative, electrophoresis	(( <del>30.0</del> )) <u>47.2</u>
82950 post glucose dose (includes glucose)	(( <del>13.5</del> )) <u>21.6</u>	83012 phenotypes, electrophoresis	(( <del>60.0</del> )) <u>84.5</u>
82951 tolerance test (GTT), three specimens (includes glucose)	(( <del>37.5</del> )) <u>19.6</u>	83015 Heavy metal screen (arsenic, bismuth, mercury, antimony); chemical (e.g., Reinsch, Gutzeit)	(( <del>30.0</del> )) <u>92.3</u>
82952 tolerance test, each additional beyond three specimens	(( <del>10.5</del> )) <u>19.6</u>	83018 chromatography, DEAE column	(( <del>BR</del> )) <u>102.2</u>
(For intravenous glucose tolerance test, see 82961)		83020 Hemoglobin, electrophoresis (includes A <sub>2</sub> , S, C, etc.)	(( <del>80.0</del> )) <u>37.3</u>
82953 tolbutamide tolerance test	(( <del>15.0</del> )) <u>74.7</u>	(Hemoglobin, carboxyhemoglobin (CO), see 82375, 82376; colorimetric, see 85018, 85031)	
(For insulin tolerance test, see 83526)		83030 F (fetal), chemical	(( <del>40.0</del> )) <u>33.4</u>
(For leucine tolerance test, see 83681)		83033 F (fetal), qualitative (APT) test, fecal	(( <del>56.0</del> )) <u>27.5</u>
82954 urine	(( <del>20.0</del> )) <u>11.8</u>	83036 glycosylated (Alc)	(( <del>60.0</del> )) <u>27.5</u>
82955 Glucose-6-phosphate dehydrogenase, erythrocyte	(( <del>60.0</del> )) <u>47.2</u>	83040 methemoglobin, electrophoretic separation	(( <del>80.0</del> )) <u>49.1</u>
82960 screen	(( <del>56.0</del> )) <u>25.5</u>	83045 qualitative	(( <del>20.0</del> )) <u>23.6</u>
82961 Glucose tolerance test, intravenous	(( <del>BR</del> )) <u>84.5</u>	83050 quantitative	(( <del>40.0</del> )) <u>35.4</u>

	Unit Value		Unit Value
83051 plasma .....	((40-0)) 11.8	83500 Hydroxy-proline, urine, free only .....	((100-0)) 121.8
83052 sickle, turbidimetric .....	((34-0)) 13.8	83505 total only .....	((100-0)) 137.5
83053 solubility, S-D, etc. ....	((40-0)) 35.4	83510 free and total .....	((100-0)) 200.4
83055 sulfhemoglobin, qualitative .....	((20-0)) 23.6	83523 Imipramine .....	((67-0)) 84.5
83060 quantitative .....	((40-0)) 41.3	(Immunoassay technique for drugs, use 82662)	
83065 thermolabile .....	((BR)) 33.4	(Immunoglobulines, see 82784, 82785, 82786, 86329, 86335)	
83068 unstable, screen .....	((BR)) 37.3	83524 Indican, urine .....	((35-0)) 23.6
83069 urine .....	((BR)) 19.6	83525 Insulin, RIA .....	((40-0)) 55.0
83070 Hemosiderin, urine .....	((12-0)) 23.6	83526 Insulin tolerance .....	((80-0)) 45.2
83071 Hemosiderin, RIA .....	((25-6)) 229.9	(For proinsulin, see 84206)	
(Heroin, screening, see 82660, 82486, 82662, 82755, 84231; quantitative, see 82096, 82101)		83528 Intrinsic factor level .....	((BR)) 78.6
(HIAA, see 83497)		(For intrinsic factor antibodies, RIA, see 86340)	
83086 Histidine; blood, qualitative .....	((BR)) 66.8	83530 Inulin clearance .....	((40-0)) 45.2
83087 urine, qualitative .....	((BR)) 55.0	(For administration, see 36410, 99070)	
83088 Histamine .....	((100-0)) 137.5	(For thyroxine, see 84435-84439)	
(Hollander test, see 91075)		(For triiodothyronine (true T-3), RIA, see 84480)	
(Homocystine, qualitative, see 82615)		83540 Iron, serum, chemical .....	((20-0)) 31.4
(Homocystine, quantitative, see 82620)		83545 automated .....	((12-0)) 25.5
83093 Homogentisic acid; blood, qualitative .....	((BR)) 39.3	83546 radioactive uptake method .....	((30-0)) 35.4
83094 Homogentisic acid, urine, qualitative .....	((20-0)) 27.5	83550 Iron binding capacity, serum; chemical .....	((20-0)) 37.3
83095 quantitative .....	((40-0)) 49.1	83555 automated .....	((12-0)) 37.3
(Hormones, see individual alphabetic listings in chemistry section)		83565 radioactive uptake method .....	((30-0)) 37.3
83150 Homo-vanillic acid (HVA), urine .....	((80-0)) 88.4	83570 Isocitric dehydrogenase (IDH), blood, kinetic ul- traviolet .....	((26-0)) 43.2
83485 Hydroxybutyric dehydrogenase, alpha (HBD), blood; kinetic ultraviolet method .....	((22-0)) 19.6	83571 colorimetric .....	((20-0)) 37.3
83486 colorimetric method .....	((20-0)) 35.4	(Isopropyl alcohol, see alcohol 82076)	
83491 Hydroxycorticosteroids, 17- (17-OHCS); RIA ...	((64-1)) 76.6	83576 Isonicotinic acid hydrazide (INH) .....	((105-0)) 127.7
83492 gas liquid chromatography (GLC) .....	((82-0)) 39.3	83578 Kanamycin .....	((49-0)) 74.7
83493 blood, Porter-Silber type .....	((45-0)) 72.7	83582 Ketogenic steroids, urine; 17-(17-KGS) .....	((45-0)) 60.9
83494 blood, fluorometric .....	((38-0)) 72.7	83583 11-desoxy: 11-oxy ratio .....	((75-0)) 114.0
83495 urine, Porter-Silber type .....	((52-0)) 72.7	83584 Ketoglutarate, alpha .....	((40-0)) 41.3
83496 urine, fluorometric .....	((52-0)) 72.7	(Ketone bodies, see 82005-82010; urine, see 81000- 81005)	
(See also 82531-82534, 82634, 84409)		83586 Ketosteroids, 17-(17-KS), blood; total .....	((30-0)) 68.8
83497 Hydroxyindolacetic acid, 5-(HIAA), urine .....	((60-0)) 62.9	83587 fractionation, alpha/beta .....	((75-0)) 137.5
(For HIAA, blood, see 84260)		83588 RIA .....	((54-0)) 84.5
83498 Hydroxyprogesterone, 17-d, RIA .....	((105-0)) 112.0	83589 Ketosteroids, 17-(17-KS), urine; total .....	((36-0)) 60.9
83499 Hydroxyprogesterone, 20- .....	((BR)) 112.0	83590 fractionation, alpha/beta .....	((60-0)) 115.9

	Unit Value		Unit Value
83593 chromatographic fractionation .....	<del>((75-0))</del> 127.7	(For feces, see 82705-82715)	
83597 11-desoxy: 11-oxy ratio .....	<del>((75-0))</del> 96.3	83715 Lipoprotein, blood; electrophoretic separation and quantitation phenotyping .....	<del>((60-0))</del> 31.4
(See also 82528, 82633, 82666, 82694))			
83599 Ketosteroids, 17-OH, RIA .....	<del>((64-1))</del> 55.0	83717 analytic ultracentrifugation separation and quantitation (atherogenic index) .....	<del>((+00-0))</del> 121.8
83600 Kynurenic acid .....	<del>((90-0))</del> 108.1	83718 Lipoprotein high density cholesterol (HDL choles- terol) by precipitation method) .....	<del>((DR))</del> 15.7
83605 Lactate, lactic acid .....	<del>((40-0))</del> 3.9	83719 Lipoprotein very low density cholesterol (VLDL cholesterol) by ultracentrifugation .....	<del>((DR))</del> 76.6
83610 Lactic dehydrogenase (LDH), RIA .....	<del>((33-7))</del> 21.6	83720 Lipoprotein cholesterol fractionation calculation by formula .....	<del>((DR))</del> 96.3
83615 Lactic dehydrogenase (LDH), blood, kinetic ultra- violet method .....	<del>((26-0))</del> 29.5	83725 Lithium, blood, quantitative .....	<del>((60-0))</del> 31.4
83620 colorimetric or fluorometric .....	<del>((20-0))</del> 25.5	(Luteinizing hormone (LH), see 83002)	
83624 heat or urea inhibition (total not included) .....	<del>((24-0))</del> 19.6	83727 Luteinizing releasing factor (LRH), RIA .....	<del>((60-0))</del> 78.6
83625 isozymes, electrophoretic separation and quanti- tation .....	<del>((60-0))</del> 17.7	83728 Lysergic acid diethylamide (LSD) RIA .....	<del>((DR))</del> 114.0
83626 chemical separation .....	<del>((20-0))</del> 55.0	83730 Macroglobulins (Sia test) .....	<del>((30-0))</del> 31.4
83628 Lactic dehydrogenase, liver (LLDH) .....	<del>((20-0))</del> 33.4	83735 Magnesium, blood; chemical .....	<del>((20-0))</del> 27.5
83629 Lactic dehydrogenase (LDH), urine .....	<del>((20-0))</del> 29.5	83740 fluorometric .....	<del>((20-0))</del> 27.5
83631 Lactic dehydrogenase (LDH), CSF .....	<del>((20-0))</del> 13.8	83750 atomic absorption .....	<del>((40-0))</del> 29.5
(For hydroxybutyric dehydrogenase (HBD), see 83485)			
83632 Lactogen, human placental (HPL) chorionic soma- tomammotropin, RIA .....	<del>((30-0))</del> 76.6	83755 urine; chemical .....	<del>((40-0))</del> 27.5
83633 Lactose, urine; qualitative .....	<del>((20-0))</del> 27.5	83760 fluorometric .....	<del>((40-0))</del> 33.4
83634 quantitative .....	<del>((20-0))</del> 57.0	83765 atomic absorption .....	<del>((40-0))</del> 33.4
(For tolerance, see 82951-82952)			
(For TLC screen, see 84375)			
83645 Lead, screening, blood .....	<del>((20-0))</del> 55.0	83775 Malate dehydrogenase, kinetic ultraviolet method .	<del>((30-0))</del> 31.4
83650 urine .....	<del>((20-0))</del> 47.2	(Maltose tolerance, see 82951, 82952)	
83655 quantitative, blood .....	<del>((60-0))</del> 47.2	(Mammotropin, see 84146)	
83660 urine .....	<del>((60-0))</del> 47.2	83785 Manganese, blood or urine .....	<del>((60-0))</del> 106.1
83661 Lecithin-sphingomyelin ratio (L/S ratio), amniotic fluid .....	<del>((75-0))</del> 31.4	83790 Mannitol clearance .....	<del>((DR))</del> 33.4
83670 Leucine amino-peptidase (LAP), blood, kinetic ul- traviolet method .....	<del>((26-0))</del> 33.4	(Marijuana, see tetrahydrocannabinol THC, 84408)	
83675 colorimetric .....	<del>((20-0))</del> 27.5	83795 Melanin, urine, quantitative .....	<del>((60-0))</del> 33.4
83680 urine .....	<del>((26-0))</del> 43.2	83799 Meperidine, quantitative .....	<del>((54-0))</del> 70.7
83681 Leucine tolerance test .....	<del>((26-0))</del> 45.2	(For screen, see 82486, 82489, 82662, 82755, 84231)	
83685 Lidocaine .....	<del>((20-0))</del> 62.9	83805 Meprobamate, blood or urine .....	<del>((60-0))</del> 80.6
83690 Lipase, blood .....	<del>((30-0))</del> 33.4	(For screen, see 82486, 82489, 84231)	
83700 Lipids, blood, total .....	<del>((30-0))</del> 43.2	83825 Mercury quantitative, blood .....	<del>((70-0))</del> 60.9
83705 fractionated (cholesterol, triglycerides, phospho- lipids) .....	<del>((60-0))</del> 51.1	83830 urine .....	<del>((70-0))</del> 60.9
		(Mercury screen, see 83015)	
		83835 Metanephrines, urine .....	<del>((52-0))</del> 74.7
		(For catecholamines, see 82382-82384)	
		83840 Methadone .....	<del>((60-0))</del> 76.6

	Unit Value		Unit Value
(Methamphetamine, see 82145)		83938 Ouabain .....	((BR)) 57.0
(Methanol, see 82078)		83945 Oxalate, urine .....	((40.0)) 57.0
83842 Methapyrilene .....	((50.0)) 84.5	(For alpha oxoglutarate, see 82120)	
83845 Methaqualone .....	((90.0)) 74.7	83946 Oxazepam .....	((40.0)) 70.7
83857 Methemalbumin .....	((32.0)) 49.1	83947 Oxybutyric acid, beta .....	((40.0)) 25.5
(Methemoglobin, see hemoglobin 83045-83050)		83948 Oxycodine .....	((52.0)) 72.7
83858 Methsuximide, serum .....	((90.0)) 66.8	(Oxygen, see gases, blood, 82790-82817)	
(Methyl alcohol, see 82078)		83949 Oxytocinase, RIA .....	((52.0)) 57.0
83859 Methyprylon .....	((90.0)) 41.3	(Para-aminohippuric acid, see 82134)	
83860 Morphine, screening .....	((80.0)) 66.8	83965 Paraaldehyde, blood, quantitative .....	((60.0)) 72.7
83861 quantitative .....	((120.0)) 106.1	83970 Parathormone (parathyroid hormone), RIA .....	((65.0)) 167.0
83862 RIA .....	((82.0)) 96.3	83971 Penicillin, urine .....	((50.0)) 57.0
83864 Mucopolysaccharides, acid, blood .....	((60.0)) 57.0	83972 Pentazocine .....	((60.0)) 62.9
83865 Mucopolysaccharides, acid, urine quantitative .....	((60.0)) 80.6	83973 Pentose, urine, qualitative .....	((13.5)) 25.5
83866 screen .....	((21.0)) 49.1	(For TLC screen, see 84375)	
83872 Mucin, synovial fluid (rope test) .....	((21.0)) 23.6	83975 Pepsinogen, blood .....	((40.0)) 60.9
83873 Myeline basic protein, CSF, RIA .....	((BR)) 98.2	83985 Pesticide, other than chlorinated hydrocarbons, blood, urine or other material .....	((BR+)) 43.2
(For oligoclonal bands, see 83916)		(Pesticide, chlorinated hydrocarbons, see 82441)	
83874 Myoglobin, electrophoresis .....	((30.0)) 47.2	83986 pH, body fluid, except blood .....	((BR)) 15.7
83875 Myoglobin, urine .....	((40.0)) 51.1	(For blood, see 82800, 82802, 82803, 82817)	
83880 Nalorphine .....	((60.0)) 94.3	83992 Phencyclidine (PCP) .....	((38.0)) 72.7
83885 Nickel, urine .....	((100.0)) 82.5	83995 Phenol, blood or urine .....	((60.0)) 70.7
83887 Nicotine .....	((75.0)) 106.1	84005 Phenolsulphonphthalein (PSP), urine .....	((20.0)) 21.6
83895 Nitrogen, urine, total, 24 hour specimen .....	((60.0)) 58.9	(For injection procedure, see 36410 for provision of mate- rials, see 99070)	
83900 feces, 24 hour specimen .....	((100.0)) 78.6	84021 Phenothiazine, urine .....	((100.0)) 41.3
83910 Nonprotein nitrogen, blood .....	((20.0)) 27.5	(See also 82486 et seq.)	
(Norepinephrine, see 82382-82384)		84022 quantitative, chemical .....	((BR)) 74.7
83912 Nucleic acid probe with electrophoresis, with ex- amination and report .....	BR	(For also individual drugs)	
83915 Nucleotidase 5'- .....	((25.0)) 55.0	84030 Phenylalanine, blood, Guthrie .....	((12.0)) 19.6
83916 Oligoclonal immune globulin (Ig), CSF, by electrophoresis .....	((BR)) 98.2	(Phenylalanine-tyrosine ratio, see 84030, 84510)	
(For myelin basic protein, CSF, see 83873)		84031 fluorometric .....	((12.0)) 25.5
83917 Organic acids; screen, qualitative .....	((30.0)) 74.7	84033 Phenylbutazone .....	((20.0)) 80.6
83918 quantitative .....	((30.0)) BR	84035 Phenylketones; blood, qualitative .....	((20.0)) 11.8
83920 Ornithine carbonyl transferase, (OCT) .....	((24.0)) 29.5	84037 urine, qualitative .....	((20.0)) 11.8
83930 Osmolality, blood .....	((20.0)) 31.4	84038 Phenylpropanolamine .....	((20.0)) 29.5
83935 urine .....	((20.0)) 31.4		

	Unit Value		Unit Value
84039 Phenylpyruvic acid; blood .....	<del>((20.0))</del> 17.7	84136 other method (specify) .....	<del>((BR))</del> 27.5
84040 Phenylpyruvic acid, urine .....	<del>((20.0))</del> 3.9	84138 Pregnanetriol; RIA .....	<del>((BR))</del> 102.2
(For qualitative chemical tests, urine, see 81005)			
84045 Phenytoin .....	<del>((61.0))</del> 64.8	84139 other method (specify) .....	<del>((BR))</del> 84.5
84060 Phosphatase, acid, blood .....	<del>((24.0))</del> 64.8	84141 Primidone .....	<del>((60.0))</del> 62.9
84065 (prostatic) fraction .....	<del>((40.0))</del> 43.2	84142 Procainamide .....	<del>((60.0))</del> 74.7
84066 prostatic fraction, RIA .....	<del>((60.0))</del> 33.4	84144 Progesterone, any method .....	<del>((105.0))</del> 49.1
84075 alkaline, blood .....	<del>((24.0))</del> 21.6	(For proinsulin, RIA, see 84206)	
84078 heat stable (total not included) .....	<del>((16.0))</del> 35.4	84146 Prolactin (mammotropin), RIA .....	<del>((225.0))</del> 96.3
84080 isoenzymes, electrophoretic method .....	<del>((BR))</del> 64.8	84147 Propoxyphene .....	<del>((60.0))</del> 96.3
84081 Phosphatidylglycerol .....	<del>((BR))</del> 82.5	(For screen, see 82486 et seq.)	
84082 Phosphates, tubular reabsorption of (TRP) .....	<del>((60.0))</del> 90.4	84149 Propranolol .....	<del>((BR))</del> 60.9
(Phosphates, inorganic, see 84100-84105)			
(Phosphates, organic, see 82480-82484)			
84083 Phosphoglucomutase, isoenzymes .....	<del>((60.0))</del> 92.3	84150 Prostaglandin, any one, RIA .....	<del>((BR))</del> 121.8
84085 Phosphogluconate, 6-, dehydrogenase, RBC .....	<del>((18.0))</del> 27.5	84155 Protein, total, serum; chemical .....	<del>((20.0))</del> 21.6
84087 Phosphohexose isomerase .....	<del>((30.0))</del> 47.2	84160 refractometric .....	<del>((12.0))</del> 21.6
84090 Phospholipids, blood .....	<del>((30.0))</del> 31.4	84165 electrophoretic fractionation and quantitation .....	<del>((60.0))</del> 45.2
(See also 83705)			
(For lecithin/sphingomyelin ratio, see 83661)			
84100 Phosphorus, blood .....	<del>((24.0))</del> 19.6	84170 Protein, total, and albumin/globulin ratio .....	<del>((40.0))</del> 35.4
84105 urine .....	<del>((24.0))</del> 19.6	(For serum albumin, see 82040, for serum globulin, 82942)	
(Pituitary gonadotropins, see 83000-83002)			
(PKU, see 81005, 84030, 84031)			
84106 Porphobilinogen, urine; qualitative .....	<del>((20.0))</del> 13.8	84175 Protein, other sources, quantitative .....	<del>((24.0))</del> 27.5
84110 Porphobilinogen, urine, quantitative .....	<del>((20.0))</del> 39.3	84176 Protein, special studies (e.g., monoclonal protein analysis) .....	<del>((BR))</del> 49.1
84118 Porphyrins, copro-, urine; quantitative .....	<del>((30.0))</del> 35.4	84180 urine; quantitative, 24 hour specimen .....	<del>((24.0))</del> 21.6
84119 qualitative .....	<del>((24.0))</del> 39.3	84185 Bence-Jones .....	<del>((12.0))</del> 31.4
84120 Porphyrins; copro- and uro-, fractionated, urine ..	<del>((64.0))</del> 68.8	84190 electrophoretic fractionation and quantitation ..	<del>((80.0))</del> 45.2
84121 uro-, copro-, and porphobilinogen, urine .....	<del>((80.0))</del> 82.5	84195 spinal fluid semi-quantitative (Pandy) .....	<del>((20.0))</del> 21.6
(For porphyrin precursors, see 82630)			
84126 feces, quantitative .....	<del>((100.0))</del> 125.7	84200 electrophoretic fractionation and quantitation ..	<del>((80.0))</del> 33.4
84128 Porphyrins, plasma .....	<del>((82.0))</del> 90.4	84201 Protirelin, thyrotropin releasing hormone (TRH) test .....	<del>((BR))</del> 78.6
(For protoporphyrin, RBC, see 84202, 84203)			
84132 Potassium, blood .....	<del>((24.0))</del> 7.9	84202 Protoporphyrin, RBC; quantitative .....	<del>((30.0))</del> 70.7
84133 urine .....	<del>((24.0))</del> 19.6	84203 screen .....	<del>((20.0))</del> 29.5
84135 Pregnanediol; RIA .....	<del>((BR))</del> 104.1	84205 Protiptylene .....	<del>((68.0))</del> 60.9
		84206 Proinsulin, RIA .....	<del>((60.0))</del> 57.0
		84207 Pyridoxine (Vitamin B-6) .....	<del>((BR))</del> 98.2
		84208 Pyrophosphate vs. urate, crystals (polarization) ...	<del>((12.0))</del> 25.5
		84210 Pyruvate, blood .....	<del>((30.0))</del> 45.2
		84220 Pyruvic-kinase, RBC .....	<del>((30.0))</del> 47.2
		84228 Quinine .....	<del>((30.0))</del> 57.0
		84230 Quinidine, blood .....	<del>((40.0))</del> 58.9

	Unit Value		Unit Value
84231 Radioimmunoassay (RIA) not elsewhere specified .	(( <del>BR</del> )) <u>64.8</u>	84403 Testosterone, blood, RIA . . . . .	(( <del>+05.0</del> )) <u>117.9</u>
(Reinsch test, see 83015)		84405 Testosterone, urine, RIA . . . . .	(( <del>+20.0</del> )) <u>121.8</u>
84232 Releasing factor . . . . .	(( <del>BR</del> )) <u>51.1</u>	84406 Testosterone, binding protein . . . . .	(( <del>BR</del> )) <u>104.1</u>
84233 Receptor assay; estrogen (estradiol) . . . . .	(( <del>BR</del> )) <u>247.6</u>	84407 Tetracaine . . . . .	(( <del>BR</del> )) <u>76.6</u>
84234 progesterone . . . . .	(( <del>BR</del> )) <u>247.6</u>	84408 Tetrahydrocannabinol THC (marijuana) . . . . .	(( <del>BR</del> )) <u>39.3</u>
84235 endocrine, other than estrogen or progesterone (specify hormone) . . . . .	(( <del>BR</del> )) <u>257.4</u>	84409 Tetrahydrocortisone or tetrahydrocortisol . . . . .	(( <del>+05.0</del> )) <u>143.4</u>
84236 progesterone and estrogen . . . . .	(( <del>BR</del> )) <u>314.4</u>	(See also 83492-83497)	
84238 nonendocrine (e.g., acetylcholine) (specify receptor) . . . . .	(( <del>BR</del> )) <u>172.9</u>	84410 Thallium, blood or urine . . . . .	(( <del>+00.0</del> )) <u>121.8</u>
84244 Renin (Angiotensin I); (RIA) . . . . .	(( <del>60.0</del> )) <u>92.3</u>	84420 Theophylline, blood or saliva . . . . .	(( <del>60.0</del> )) <u>37.3</u>
(See also 82163, angiotensin II)		84425 Thiamine (Vitamin B-1) . . . . .	(( <del>BR</del> )) <u>98.2</u>
84246 furosemide test . . . . .	(( <del>BR</del> )) <u>106.1</u>	84430 Thiocyanate, blood . . . . .	(( <del>30.0</del> )) <u>55.0</u>
84252 Riboflavin (Vitamin B-2) . . . . .	(( <del>BR</del> )) <u>84.5</u>	84434 Thioridazine . . . . .	(( <del>40.0</del> )) <u>66.8</u>
(Salicylates, see 82011, 82012)		(Thyrotropin releasing hormone (TRH) test, see 84201)	
(Saline infusion test, see 82091)		84435 Thyroxine, (T-4), CPB or resin uptake . . . . .	(( <del>33.0</del> )) <u>25.5</u>
(Secretin test, see 99070, 89100 and appropriate analyses)		84436 Thyroxine, true (TT-4), RIA . . . . .	(( <del>21.0</del> )) <u>15.7</u>
84255 Selenium, blood, urine or tissue . . . . .	(( <del>+00.0</del> )) <u>106.1</u>	84437 Thyroxine (T-4), neonatal . . . . .	(( <del>20.0</del> )) <u>23.6</u>
84260 Serotonin, blood . . . . .	(( <del>+20.0</del> )) <u>58.9</u>	84439 Thyroxine, free (FT-4), RIA (unbound T-4 only) . . . . .	(( <del>45.0</del> )) <u>25.5</u>
(For urine metabolites, see 83497)		84442 Thyroxine binding globulin (TBG) . . . . .	(( <del>52.0</del> )) <u>37.3</u>
84275 Sialic acid, blood . . . . .	(( <del>50.0</del> )) <u>66.8</u>	(Thyroxine, free thyroxine index, T-7, see 82756)	
(Sickle hemoglobin, see 83020, 83052, 83053, 85660)		(Thyroid hormones, thyroxine, etc., see 84435-84439, 84479-84481)	
84285 Silica, blood, urine or tissue . . . . .	(( <del>+00.0</del> )) <u>108.1</u>	84443 Thyroid stimulating hormone (TSH), RIA or EIA . . . . .	(( <del>60.0</del> )) <u>43.2</u>
84295 Sodium, blood . . . . .	(( <del>+24.0</del> )) <u>17.7</u>	84444 Thyrotropin releasing factor (TRF), RIA . . . . .	(( <del>BR</del> )) <u>112.0</u>
84300 urine . . . . .	(( <del>+24.0</del> )) <u>17.7</u>	84445 plus long acting (LATS) . . . . .	(( <del>BR</del> )) <u>233.8</u>
(Somatomammotropin, see 83632)		84446 Tocopherol alpha (Vitamin E) . . . . .	(( <del>38.0</del> )) <u>62.9</u>
(Somatotropin, see 83003; chorionic, see 83632)		(Tolbutamide tolerance, see 82953)	
84310 Sorbitol dehydrogenase, serum . . . . .	(( <del>26.0</del> )) <u>33.4</u>	84447 Toxicology, screen; general . . . . .	(( <del>BR</del> )) <u>68.8</u>
84315 Specific gravity (except urine) . . . . .	(( <del>0.0</del> )) <u>9.8</u>	84448 sedative (acid and neutral drugs, volatiles) . . . . .	(( <del>45.0</del> )) <u>76.6</u>
84318 Stercobilin, qualitative, feces . . . . .	(( <del>BR</del> )) <u>47.2</u>	84450 Transaminase, blood, glutamic oxaloacetic (SGOT), timed kinetic ultraviolet method . . . . .	(( <del>24.0</del> )) <u>19.6</u>
(For stone analysis see 82355-82370)		84455 colorimetric or fluorometric . . . . .	(( <del>20.0</del> )) <u>19.6</u>
84324 Strychnine . . . . .	(( <del>75.0</del> )) <u>66.8</u>	84460 glutamic pyruvic (SGPT), blood timed kinetic ultraviolet . . . . .	(( <del>24.0</del> )) <u>23.6</u>
(Sugar, see under glucose)		84465 colorimetric or fluorometric . . . . .	(( <del>20.0</del> )) <u>23.6</u>
84375 Sugars chromatographic separation . . . . .	(( <del>00.0</del> )) <u>7.9</u>	(Transferrin, see 86329)	
(Sulfhemoglobin, see hemoglobin, 83055-83060)		84472 Trichloroethanol . . . . .	(( <del>60.0</del> )) <u>88.4</u>
84395 Sulfonamide, blood chemical . . . . .	(( <del>20.0</del> )) <u>29.5</u>	84474 Trichloroacetic acid . . . . .	(( <del>36.0</del> )) <u>72.7</u>
(T-3, see 84479-84481)		(Trichloroacetaldehyde, see 82400-82405)	
(T-4, see 84435-84439)			

	Unit Value		Unit Value
84476	Trifluoperazine	.....	((36-0))
			66.8
84478	Triglycerides, blood	.....	((30-0))
			<u>15.7</u>
(See also 83705)			
84479	Triiodothyronine (T-3), resin uptake	.....	27.5
84480	Triiodothyronine, true (TT-3), RIA	.....	((36-0))
			<u>45.2</u>
84481	Triiodothyronine, free (FT-3), RIA (unbound T-3 only)	.....	((BR))
			84.5
84483	Trimethadione	.....	((36-0))
			66.8
84485	Trypsin, duodenal fluid	.....	((30-0))
			13.8
84488	Trypsin, feces, quantitative, 24 hour specimen	....	((30-0))
			13.8
84490	quantitative	.....	((30-0))
			<u>17.7</u>
(Tubular reabsorption of phosphate, blood and urine, see 84082)			
84510	Tyrosin, blood	.....	((40-0))
			<u>49.1</u>
(Ultracentrifugation, lipoprotein, see 82190)			
(Urate vs. pyrophosphate crystals, see 84208)			
84520	Urea nitrogen, blood (BUN); quantitative	.....	((22-0))
			21.6
84525	stick test	.....	((8-0))
			5.9
84540	urine	.....	((20-0))
			23.6
84545	clearance	.....	((40-0))
			33.4
84550	Uric acid, blood, chemical	.....	((20-0))
			21.6
84555	uricase, ultraviolet method	.....	((26-0))
			25.5
84560	urine	.....	((20-0))
			21.6
84565	Urobilin, urine, qualitative	.....	((12-0))
			13.8
84570	quantitative, timed specimen	.....	((24-0))
			27.5
84575	feces, quantitative	.....	((60-0))
			62.9
84577	Urobilinogen, feces, quantitative	.....	((30-0))
			60.9
84578	Urobilinogen, urine, qualitative	.....	((24-0))
			3.9
84580	quantitative, timed specimen	.....	((24-0))
			31.4
84583	semiquantitative	.....	((20-0))
			19.6
84584	Uropepsin, urine	.....	((24-0))
			<u>60.9</u>
(Uroporphyrins, see 84120, 84121)			
84585	Vanillylmandelic acid (VMA), urine	.....	((24-0))
			64.8
84588	Vasopressin (antidiuretic hormone), RIA	.....	((BR))
			104.1
84589	Viscosity, fluid	.....	((10-0))
			27.5
84590	Vitamin A, blood	.....	((40-0))
			58.9
84595	including carotene (see also 82380)	.....	((60-0))
			<u>68.8</u>
(Vitamin B-1, see 84425)			
(Vitamin B-2, see 84252)			
		(Vitamin B-6, see 84207)	
		(Vitamin B-12, blood, see 82606, 82607)	
		(Vitamin B-12, absorption (Schilling), see 78270, 78271)	
		(Vitamin C, see 82180)	
		(Vitamin D, see 82306, 82307)	
		(Vitamin E, see 84446)	
84597	Vitamin K	.....	((BR))
			<u>66.8</u>
(VMA, see 84585)			
84600	Volatiles (acetic anhydride, carbon tetrachloride, dichloroethane, dichloromethane, diethylether)	....	((45-0))
			<u>78.6</u>
(For acetaldehyde, see 82000)			
84605	Volume, blood, dye method (Evans blue)	.....	((30-0))
			<u>37.3</u>
84610	including total plasma and total blood cell volume	.....	((50-0))
			<u>55.0</u>
(Volume, blood, RISA or Cr-51, see 78110, 78111)			
84613	Warfarin	.....	((BR))
			72.7
84615	Xanthurenic acid	.....	((BR))
			153.2
84620	Xylose tolerance test, blood and/or urine	.....	((40-0))
			53.0
84630	Zinc, quantitative, blood	.....	((100-0))
			49.1
84635	urine	.....	((100-0))
			47.2
84681	C-peptide, any method	.....	BR
84695	Gentamicin	.....	((38-5))
			80.6
84702	Gonadotropin, chorionic; quantitative	.....	((30-0))
			BR
84703	qualitative	.....	((30-0))
			BR
84800	Thyroid stimulating hormone (TSH), neonatal	....	((60-0))
			74.7
84810	Tobramycin	.....	((BR))
			76.6
84999	Unlisted chemistry or toxicology procedure	.....	BR

Note: Gas-liquid chromatography, paper chromatography, electrophoresis, nuclear medicine, enzyme immunoassay and radioimmunoassay techniques are being extended constantly for the analysis of many drugs, hormones and other substances. Where these methodologies are not specifically listed under the compound in question, such tests should be coded under the listing for the specific general methodology. (For immunodiffusion, immunoprecipitin, and counter-immunoelectrophoretic methods other than enzyme and radioimmunoassay techniques, see immunology section.)

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-23-216 HEMATOLOGY.**

(Includes blood clotting (coagulation) procedures. For blood banking procedures, see under Immunology WAC 296-23-221.)

(Agglutinins, see Immunology)

(Antifactor (specific coagulation factors), see 85300-85341)

(Antiplasmin, see 85410)

	Unit Value		Unit Value
(Antiprothrombinase, see 85311)			
(Antithrombin III, see 85300)			
(Basophil count, see 85005)		85095 Bone marrow smear and/or cell block; aspiration only	((45.0)) 117.9
85000 Bleeding time Duke	((+0.0))	85097 smear interpretation only, with or without differential cell count	((BR)) 29.5
85002 Ivy or template	((24.0)) 11.8 17.7	85100 aspiration, staining, and interpretation of smears	((+40.0)) 229.9
(Blood cell morphology only, see 85548)		(For special stains, see 85535, 85540, 85560, 88312-88313)	
85005 Blood count; basophil count, direct	((+0.0)) 13.8	85101 aspiration and staining only	((75.0)) 153.2
85007 manual differential WBC count (includes RBC morphology and platelet estimation)	((7.5)) 11.8	85102 Bone marrow ( <del>needle</del> ) biopsy, needle or trocar; ...	((75.0)) 153.2
(See also 85548, 85585)		(For ( <del>trocar</del> ) bone biopsy, see 20220)	
(For other fluids, e.g., CSF, see 89051, 89190)		85103 staining and interpretation	((60.0)) 115.9
85009 differential WBC count, buffy coat	((+2.0)) 17.7	85105 interpretation only	((30.0)) 108.1
85012 eosinophil count, direct	((+0.0)) 17.7	85109 staining and preparation only	((30.0)) 53.0
(For nasal smear, see 89180)		85170 Clot retraction screen	((8.0)) 17.7
85014 hematocrit	((8.0)) 7.9	85171 quantitative	((45.0)) 37.3
85018 hemoglobin, colorimetric	((8.0)) 9.8	85172 inhibition by drugs	((BR)) 13.8
(For other hemoglobin determination, see 83020-83068)		85175 Clot lysis time, whole blood dilution	((40.0)) 17.7
85021 hemogram, automated RBC, WBC, Hgb, Hct and indices only)	((+0.5)) 19.6	(Clotting factor I (fibrinogen), see 82730, 85371-85377)	
85022 hemogram, automated, and manual differential WBC count (CBC)	((+5.0)) 27.5	85210 Clotting factor; II prothrombin, specific	((40.0)) 55.0
85023 hemogram and platelet count, automated, and manual differential WBC count (CBC)	((+7.0)) 31.4	(See also 85610-85618)	
85024 hemogram and platelet count, automated, and automated partial differential WBC (CBC)	((+7.0)) 27.1	85220 factor V (AcG or proaccelerin) labile factor	((40.0)) 84.5
85025 hemogram and platelet count, automated, and automated complete differential WBC (CBC)	((+7.0)) 27.1	85230 factor VII (proconvertin stable factor)	((40.0)) 84.5
85027 hemogram, automated, with platelet count	((+2.0)) 35.4	85240 factor VIII (AHG) one stage	((40.0)) 86.4
85029 Additional automated hemogram indices (e.g., red cell distribution width (RDW), mean platelet volume (MPV), red blood cell histogram, platelet histogram, white blood cell histogram); one to three indices	((BR)) 21.6	85242 factor VIII (AHG), two stage	((40.0)) 84.5
85030 four or more indices	((BR)) 21.6	85244 factor VIII related antigen quantitation	((BR)) 98.2
85031 blood count; hemogram, manual, complete CBC (RBC, WBC, Hgb, Hct, differential and indices)	((+6.5)) 15.7	85250 factor IX (PTC or Christmas)	((40.0)) 88.4
85041 red blood cell (RBC) only	((8.0)) 13.8	85260 factor X (Stuart-Prower)	((40.0)) 88.4
(See also 85021-85031, 89050)		85270 factor XI (PTA)	((40.0)) 88.4
85044 reticulocyte count, manual	((+2.0)) 17.7	85280 factor XII (Hagemann)	((40.0)) 88.4
85045 reticulocyte count, flow cytometry	BR	85290 factor XIII (fibrin stabilizing)	((40.0)) 80.6
85048 white blood cell (WBC)	((8.0)) 13.8	85291 factor XIII (fibrin stabilizing), screen solubility	((40.0)) 37.3
(See also 85021-85031)		85292 prekallikrein assay (Fletcher factor assay)	((BR)) 92.3
85060 Blood smear, peripheral, interpretation by physician with written report	((BR)) 29.5	((82593)) 85293 high molecular weight ( <del>kininogen</del> ) kininogen assay (Fitzgerald factor assay)	((BR)) 92.3
		85300 Clotting inhibitors or anti-coagulants, anti-thrombin	((40.0)) 53.0
		85301 antithrombin III, antigen assay	((BR)) 53.0
		85302 protein C assay	((BR)) 58.9
		85310 anti-thromboplastins	((40.0)) 49.1



	Unit Value		Unit Value
85311 anti-prothrombinase .....	(( <del>40.0</del> )) 51.1	85426 von Willebrand factor assay .....	(( <del>BR</del> )) 110.0
85320 anti-prothromboplastins .....	(( <del>40.0</del> )) 49.1		(For plasminogen activator, see 85665)
85330 anti-factor VIII .....	(( <del>40.0</del> )) 29.5		(Fragility, red blood cell, see 85547, 85555-85557)
85340 cross recalcification time (mixtures) .....	(( <del>40.0</del> )) 43.2	85441 Heinz bodies; direct .....	(( <del>9.0</del> )) 13.8
85341 PTT inhibition test .....	(( <del>BR</del> )) 21.6	85445 induced, acetyl phenylhydrazine .....	(( <del>19.5</del> )) 29.5
85345 Coagulation time (Lee and White) .....	(( <del>30.0</del> )) 21.6		(For hematocrit (pcv), see 85014, 85021-85031)
85347 Coagulation time, activated .....	(( <del>20.0</del> )) 15.7		(For hemoglobin, see 83020-83068, 85018-85031)
85348 other methods .....	(( <del>BR</del> )) 17.7	85460 Hemoglobin, fetal, differential lysis (Kleihauer) .....	(( <del>26.0</del> )) 27.5
			(See also 83030, 83033)
(Complete blood count, see 85022-85025, 85031)			(Hemogram, see 85021-85031)
(Differential count, see 85007 et seq.)			(Hemolysins, see 86006, 86281, 86282)
(Drug inhibition, clot retraction, see 85172)		85520 Heparin assay .....	(( <del>60.0</del> )) 33.4
(Duke bleeding time, see 85000)		85530 Heparin-protamine tolerance test .....	(( <del>60.0</del> )) 70.7
(Eosinophil count, direct, see 85012)		85535 Iron stain (RBC or bone marrow smears) .....	(( <del>10.0</del> )) 27.5
(Eosinophils, microscopic examination for, in various body fluids, see 89180)			(Ivy bleeding time, see 85002)
(Ethanol gel, see 85363)		85538 Leder stain (esterase) blood or bone marrow .....	(( <del>30.0</del> )) 47.2
85360 Euglobulin lysis .....	(( <del>40.0</del> )) 15.7	85540 Leucocyte alkaline phosphatase .....	(( <del>20.0</del> )) 41.3
		85544 Lupus erythematosus (LE) cell prep .....	(( <del>20.0</del> )) 41.3
(Fetal hemoglobin, see 83030-83033, 85460)			(Lysozyme, see 85549)
85362 Fibrin degradation (split) products (FDP)(FSP); agglutination, slide .....	(( <del>12.0</del> )) 33.4	85547 Mechanical fragility, RBC .....	(( <del>30.0</del> )) 43.2
85363 ethanol gel .....	(( <del>10.0</del> )) 25.5	85548 Morphology of red blood cells, only .....	(( <del>9.0</del> )) 13.8
85364 hemagglutination inhibition (Merskey), microtiter .....	(( <del>36.0</del> )) 55.0	85549 Muramidase, serum .....	(( <del>52.0</del> )) 82.5
85365 immunoelectrophoresis .....	(( <del>BR</del> )) 88.4	85555 Osmotic fragility, RBC; .....	(( <del>15.0</del> )) 31.4
85367 precipitation .....	(( <del>10.0</del> )) 27.5	85556 incubated, qualitative .....	(( <del>10.0</del> )) 41.3
85368 protamine paracoagulation (PPP) .....	(( <del>BR</del> )) 43.2	85557 incubated, quantitative .....	(( <del>60.0</del> )) 60.9
85369 staphylococcal clumping .....	(( <del>12.0</del> )) 17.7		(Packed cell volume, see 85014)
			(Partial thromboplastin time, see 85730-85732)
(Fibrinogen, quantitative, see 82730)			(Parasites, blood, e.g., malaria smears, see 87207)
85371 Fibrinogen, semiquantitative; latex .....	(( <del>40.0</del> )) 31.4	85560 Peroxidase stain, WBC .....	(( <del>15.0</del> )) 23.6
85372 turbidimetric .....	(( <del>22.5</del> )) 35.4		(Plasmin, see 85400)
85376 Fibrinogen; thrombin with plasma dilution .....	(( <del>24.0</del> )) 39.3		(Plasminogen, see 85420)
85377 thrombin time dilution .....	(( <del>36.0</del> )) 51.1		(Plasminogen activator, see 85665)
85390 Fibrinolysins, screening .....	(( <del>20.0</del> )) 13.8	85575 Platelet; adhesiveness (in vivo) .....	(( <del>45.0</del> )) 29.5
85392 with EACA control .....	(( <del>BR</del> )) 41.3	85576 aggregation (in vitro), any agent .....	(( <del>BR</del> )) 94.3
85395 semiquantitative .....	(( <del>30.0</del> )) 35.4	85577 retention (in vitro), glass bead .....	(( <del>30.0</del> )) 53.0
85398 Fibrinolysis, quantitative .....	(( <del>45.0</del> )) 21.6	85580 Platelet, count (Rees-Ecker) .....	(( <del>14.0</del> )) 21.6
85400 Fibrinolytic mechanisms, plasmin .....	(( <del>BR</del> )) 21.6	85585 estimation on smear, only .....	(( <del>10.0</del> )) 7.9
85410 alpha-2 anti-plasmin .....	(( <del>BR</del> )) 21.6		(Sec also 85007)
85420 plasminogen .....	(( <del>BR</del> )) 21.6		
85421 plasminogen, antigenic assay .....	(( <del>BR</del> )) 47.2		

	Unit Value
85590 phase microscopy .....	((20.0))
	19.6
85595 electronic technique .....	((20.0))
	15.7
85610 Prothrombin time .....	((16.0))
	11.8
(See also 85618)	
85612 Russell viper venom type (includes venom) .....	((36.0))
	41.3
85615 Prothrombin utilization (consumption) .....	((40.0))
	17.7
85618 Prothrombin-Proconvertin, P & P (Owren) .....	((18.0))
	17.7
(Red blood cell count, see 85021, 85031, 85041)	
85630 Red blood cell size (Price-Jones) .....	((40.0))
	45.2
85632 Red blood cell peroxide hemolysis .....	((30.0))
	39.3
85635 Reptilase test .....	((33.0))
	49.1
(Reticulocyte count, see 85044)	
(Rumpel-Leede test, see 85165)	
85650 Sedimentation rate (esr) Wintrobe type .....	((14.0))
	15.7
85651 Westergren type .....	((10.5))
	15.7
85660 Sickling of red blood cells reduction slide method ..	((14.0))
	17.7
(Sickling, electrophoresis, see 83020)	
(Sickling, solubility, S-D, see 83053)	
(Sickling, turbidimetric (Sickledex dithionate), see 83052)	
(Siderocytes, see 85535)	
(Smears for parasites, malaria, etc., see 87207)	
(Staphylococcal clumping test, see 85369)	
85665 Streptokinase titer (plasminogen activator) .....	((BR))
	84.5
<u>85667 T-cell depletion (any method) of bone marrow for</u>	<u>BR</u>
<u>transplantation .....</u>	<u>((20.0))</u>
85670 Thrombin time, plasma .....	((20.0))
	23.6
85675 titer .....	((12.0))
	23.6
85700 Thromboplastin generation test, screening (Hicks-Pitney) .....	((40.0))
	41.3
85710 definitive, with platelet substitute .....	((45.0))
	41.3
85711 with patient's platelets .....	((45.0))
	41.3
85720 all factors .....	((BR+))
	92.3
(For individual clotting factors, see 85210 et seq.)	
85730 Thromboplastin time, partial (PTT) plasma or whole blood .....	((30.0))
	19.6
85732 substitution plasma .....	((30.0))
	31.4
(For thromboplastin inhibition test, see 85341)	
(For tourniquet test, see 85165)	
85810 Viscosity, blood .....	((40.0))
	27.5
85820 serum or plasma .....	((40.0))
	57.0

	Unit Value
(WBC count, see 85021-85031, 85048, 89050)	
85999 Unlisted hematology procedure .....	BR

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-23-221 IMMUNOLOGY.**

(Includes serology, immuno-hematology and blood banking)	
(Acetylcholine antireceptor antibody, see 86685)	
(Acid hemolysins, see 86281)	
(Actinomycosis, see 86000-86009)	
(Adrenal cortex antibodies, RIA, see 86681)	
	Unit Value
86000 Agglutinins febrile, each antigen .....	((14.0))
	33.4
86002 febrile panel (typhoid O & H, paratyphoid A & B, brucella and Proteus OX-19) .....	((45.0))
	49.1
86004 warm .....	((36.0))
	11.8
(Agglutinins and autohemolysins, see 86004, 86011-86013, 86281-86283, 86006-86009)	
(Agglutinins, auto, see 86282-86283, 86011, 86013)	
(Agglutinins, cold, see 86006, 86013, 86282, 86283)	
(Alpha-1 antitrypsin, see 86329)	
(Alpha-1 fetoprotein, see 86329)	
(Anti-AChR (acetylcholine receptor) antibody titer, see 86685)	
86006 Antibody, <u>non-RBC</u> , qualitative ( <del>(, not otherwise specified)</del> ); first antigen, slide or tube .....	((12.0))
	25.5
86007 each additional antigen .....	((7.5))
	9.8
86008 Antibody, <u>non-RBC</u> , quantitative ( <del>(titer, not otherwise specified)</del> ); first antigen .....	((18.0))
	25.5
86009 each additional antigen .....	((12.0))
	11.8
86011 Antibody, detection, leukocyte antibody .....	((44.0))
	45.2
86012 Antibody absorption, cold auto absorption; per serum .....	((30.0))
	53.0
(For elution, see 86019)	
86013 differential .....	((45.0))
	80.6
86014 Antibody, platelet antibodies (agglutinins) .....	((45.0))
	23.6
86016 ( <del>(Antibodies, RBC, saline, high protein and antihuman globulin technique)</del> ) <u>Antibody screen, RBC, each serum</u> .....	((30.0))
	53.0
(See also 86032)	
<del>((86017</del> <u>with ABO + Rh(D) typing (for holding blood instead of complete crossmatch)</u> .....	<del>24.0</del>
86018 <u>enzyme technique including antihuman globulin</u> .....	17.0))
86019 ( <del>(elution, any method)</del> ) <u>Antibody (RBC) elution, any method, each elution</u> .....	((45.0))
	80.6

	Unit Value		Unit Value
86021	Antibody identification; leukocyte antibodies . . . . .	<del>((60.0))</del> 74.7	(For blood compatibility test using enzymes, see codes 86068, 86411)
86022	platelet antibodies . . . . .	<del>((75.0))</del> 104.1	(For enzyme technique, see <del>((86018))</del> 86016, 86411)
86023	platelet associated immunoglobulin assay . . . . .	<del>((BR))</del> 51.1	<del>((86075) Blood crossmatch, minor only (plasma, Rh immune globulin), includes recipient and donor typing and antibody screening, first unit . . . . .</del>
86024	RBC antibodies ( <del>((8-10 cell panel) standard techniques))</del> (each panel) . . . . .	<del>((38.0))</del> 64.8	86076 each additional unit . . . . . 44.0 27.0
<del>((86026) RBC antibodies (8-10 cell panel), with enzyme technique including antihuman globulin . . . . .</del>	<del>52.0))</del>	(For incompatibility problems, see 86004, 86011-86014, 86016-86026, 86031-86035, 86068-86076))	
(For absorption and elution, see 86012-86013, 86019)		(For typing, antibody screening and blood in lieu of crossmatch, see 86017)	
<del>((86028) saline or high protein, each (Rh, AB, etc.) . . . . .</del>	<del>12.0))</del>	(For blood transfusion, see 36400-36460, 36510, 36660)	
(For antibody identification using enzyme technique, see 86411, 86024)		86077 Blood bank physician services; difficult crossmatch and/or evaluation of irregular antibody(s), interpretation and written report . . . . .	<del>((BR))</del> 222.0
(Antibody to specific nuclear antigen, use 86235)		86078 investigation of transfusion reaction including suspicion of transmissible disease, interpretation and written report . . . . .	<del>((BR))</del> 222.0
(Anti-DNA, see 86225)		86079 authorization for deviation from standard blood banking procedures (e.g., use of outdated blood, transfusion of RH incompatible units), with written report . . . . .	<del>((BR))</del> 141.5
(Antideoxyribonuclease titer, see 86215)		86080 Blood typing; ABO only . . . . .	<del>((12.0))</del> 19.6
86031 Antihuman globulin test; direct (Coombs) ( <del>((1-3 dilutions))</del> (broad, IgG and non-IgG), each . . . . .	<del>((12.0))</del> 23.6	86082 ABO and Rho(D) . . . . .	<del>((18.0))</del> 19.6
86032 indirect, qualitative (broad, gamma or nongamma, each) . . . . .	<del>((15.0))</del> 9.8	<del>((86090) M-N . . . . .</del>	<del>20.0))</del>
86033 indirect, titer (broad, gamma or nongamma each) . . . . .	<del>((12.0))</del> 25.5	86083 ABO, Rh(D) and RBC antibody screening . . . . .	BR
86034 enzyme technique, qualitative . . . . .	<del>((30.0))</del> 53.0	86084 antigen screening for compatible blood unit using reagent serum, per unit screened . . . . .	BR
<del>((86035) drug sensitization, identification (e.g., penicillin) . . . . .</del>	<del>75.0))</del>	86085 antigen screening for compatible unit using patient's serum, per unit screened . . . . .	BR
(For antibody detection (screening), see 86016, 86017)		86095 <del>((Blood typing;))</del> RBC antigens, other than ABO or Rho(D) ( <del>((-antiglobulin technique, each antigen))</del> . . . . .	<del>((10.5))</del> 15.7
86038 Antinuclear antibodies (ANA), RIA . . . . .	<del>((55.0))</del> 60.9	<del>((86096) direct, slide or tube, including Rh subtypes, each antigen . . . . .</del>	<del>10.5))</del>
(Antinuclear antibodies, fluorescent technique, see 86255, 86256)		86100 Blood typing; Rho(D) only . . . . .	<del>((12.0))</del> 15.7
(Antistreptococcal antibody, anti-DNAse, see 86215)		86105 Rh genotyping, complete . . . . .	<del>((45.0))</del> 19.6
(Antistreptokinase titer, see 86590)		(For Rho variant Du, see 86095))	
86060 Antistreptolysin O titre . . . . .	<del>((20.0))</del> 17.7	86115 anti-Rh immuno-globulin testing (Rhogam type) . . . . .	<del>((60.0))</del> 45.2
86063 screen . . . . .	<del>((10.0))</del> 11.8	<del>((86120) special (Kell, Duffy, etc.) . . . . .</del>	<del>BR))</del>
86064 Antitrypsin, alpha-1; RIA . . . . .	<del>((20.0))</del> 58.9	86128 Collection, processing and storage of predeposited autologous whole blood or components . . . . .	<del>((BR))</del> 74.7
86066 Pi (Protease inhibitor) typing . . . . .	<del>((20.0))</del> 58.9	86130 Collection and processing for transfusion of inoperatively salvaged blood . . . . .	BR
86067 other method (specify) . . . . .	<del>((20.0))</del> 62.9	(For therapeutic phlebotomy, see 99195)	
(Autoagglutinins, see 86282, 86283)		(Bovine milk antibody, see 86008, 86009)	
(Autoantibodies, see specific antigens)		(Brucellosis, see 86000-86002, 86470)	
(Blastomycosis, see 86006-86009, 86460)		86140 C-reactive protein . . . . .	<del>((20.0))</del> 25.5
86068 <del>((Blood, crossmatch, complete standard technique, includes typing and antibody screening of recipient and donor, first unit))</del> Blood compatibility test; crossmatch by immediate spin and antihuman globulin technique, each unit . . . . .	<del>((60.0))</del> 51.1	(Candidiasis, see 86008)	
<del>((86069) each additional unit . . . . .</del>	<del>45.0</del>	86149 Carcinoembryonic antigen; gel diffusion . . . . .	<del>((60.0))</del> 70.7
86072 Blood crossmatch; enzyme technique . . . . .	10.5	86151 RIA or EIA . . . . .	<del>((60.0))</del> 70.7
86073 screening for compatible unit saline and/or high protein . . . . .	26.0		
86074 antiglobulin technique . . . . .	15.0))		
86070 crossmatch by immediate spin technique only . . . . .	BR		

	Unit Value		Unit Value
86155 Chemotaxis assay, specify method . . . . .	((BR)) <u>49.1</u>	86277 Growth hormone, human (HGH), antibody, RIA . . . . .	((BR)) <u>74.7</u>
(Coccidioidomycosis, see 86006-86009, 86490)		(Ham test, see 86281)	
(Cold agglutinin or hemolysin, see 86006-86013, 86282, 86283)		86280 Hemagglutination inhibition tests (HAI), each (e.g., rubella, viral) . . . . .	((60-0)) <u>21.6</u>
86158 Complement; C'1 esterase . . . . .	((52-0)) <u>58.9</u>	86281 Hemolysins, acid (for paroxysmal hemoglobinuria) (Ham test) . . . . .	((24-0)) <u>43.2</u>
86159 C'2 esterase . . . . .	((52-0)) <u>49.1</u>	86282 Hemolysins and agglutinins, auto, screen, each; . . . . .	((30-0)) <u>33.4</u>
86162 total (CH 50) . . . . .	((70-0)) <u>98.2</u>	86283 incubated with glucose (e.g., ATP) . . . . .	((75-0)) <u>55.0</u>
86163 C's esterase . . . . .	((BR)) <u>21.6</u>	(Cold, see 86006-86009, warm 86004, acid 86281)	
86164 C'4 esterase . . . . .	((BR)) <u>62.9</u>	86287 Hepatitis B surface antigen (HB <sub>s</sub> Ag) (Australian antigen, HAA), RIA or EIA . . . . .	((36-0)) <u>51.1</u>
(For complement fractions, quantitative, see 86329)		(For gel diffusion technique, see HAI, 86280)	
86171 Complement fixation tests, each antigen . . . . .	((40-0)) <u>47.2</u>	86288 Hepatitis B core antigen (HB <sub>c</sub> Ag), RIA . . . . .	((BR)) <u>53.0</u>
(Coombs test, see 86031-86035)		86289 Hepatitis B core antibody (HB <sub>c</sub> Ab), RIA or EIA . . . . .	((BR)) <u>58.9</u>
86185 Counterelectrophoresis, each antigen . . . . .	((24-0)) <u>35.4</u>	86290 IgM antibody (e.g., RIA, EIA, RPHA) . . . . .	((BR)) <u>82.5</u>
(For HAA, see 86287)		86291 Hepatitis B surface antibody (HB <sub>s</sub> Ab), (e.g., RIA, EIA, RPHA) . . . . .	((BR)) <u>45.2</u>
(Crossmatch, see 86068-86076)		86293 Hepatitis Be antigen (HB <sub>e</sub> Ag), (e.g., RIA, EIA) . . . . .	((BR)) <u>49.1</u>
(Cryptococcosis, see 86008, 86009, 86255, 86256)		86295 Hepatitis Be antibody (HB <sub>e</sub> Ab), (e.g., RIA, EIA) . . . . .	((BR)) <u>49.1</u>
86215 Deoxyribonuclease, antibody . . . . .	((36-0)) <u>64.8</u>	86296 Hepatitis A antibody (HAAb), (e.g., RIA, EIA) . . . . .	((BR)) <u>57.0</u>
86225 Deoxyribonucleic acid (DNA) antibody . . . . .	((36-0)) <u>64.8</u>	86298 IgG antibody . . . . .	((BR)) <u>53.0</u>
(Direct antiglobulin test (Coombs), see 86031)		86299 IgM antibody . . . . .	((BR)) <u>53.0</u>
(Donath-Landsteiner screen, see 86008, 86009)		86300 Heterophile antibodies, screening (includes mono-type test) slide or tube . . . . .	((20-0)) <u>19.6</u>
(Drug sensitization, RBC, see 86035)		86305 quantitative titer . . . . .	((30-0)) <u>31.4</u>
(Echinococcosis, see 86171, 86280, 86500)		86310 plus titers after absorption, beef cells and guinea pig kidney . . . . .	((30-0)) <u>35.4</u>
(For particle agglutination rapid test for infectious agent, use 86403)		(Histoplasmosis, see 86006-86009, 86171)	
(For HIV antibody tests, see 86312-86314)		(HLA typing, see 86597)	
(Eosinophils, nasal smear, use 89190)		(For hormones, see individual alphabetic listing in chemistry section)	
86235 Antibody to specific nuclear antigen, any method, each . . . . .	((30-0)) <u>47.2</u>	86311 HIV antigen test . . . . .	BR
86243 Fc receptor assay, specify method . . . . .	((BR)) <u>90.4</u>	86312 HIV antibody detection; immunoassay . . . . .	((BR)) <u>53.0</u>
86244 Feto-protein, alpha-1, RIA or EIA . . . . .	((57-0)) <u>72.7</u>	86314 confirmatory test (e.g., Western blot) . . . . .	((BR)) <u>82.5</u>
(Filariasis, see 86280)		(Human growth hormone antibody, RIA, see 86277)	
86255 Fluorescent antibody; screen . . . . .	((24-0)) <u>47.2</u>	86316 Immunoassay for tumor antigen (e.g., prostate specific antigen, cancer antigen 125) . . . . .	BR
86256 titer . . . . .	((36-0)) <u>47.2</u>	86317 Immunoassay for infectious agent antigen or antibody, each . . . . .	BR
(Fluorescent technique for antigen identification in tissue, see 88346)		(For particle agglutination rapid test for infectious agent antigen, use 86403)	
86265 Frozen blood, preparation for freezing, each unit including processing and collection; . . . . .	BR	86318 Immunoassay for chemical constituent . . . . .	BR
86266 with thawing . . . . .	BR	86319 Immunoassay technique for drugs . . . . .	BR
86267 with freezing and thawing . . . . .	BR	(For immunoassay for bacteria, use 86317)	
(FTA, see 86650)		86320 Immuno-electrophoresis, serum, each specimen	
(Gc grouping, see 86335)			
(Gel (agar) diffusion tests, see 86331)			
(Gm grouping, see 86335)			

	Unit Value		Unit Value
(plate) .....	((+00-0)) <u>88.4</u>	86382 Neutralization test, viral .....	((BR)) <u>82.5</u>
86325 other fluids (e.g., urine) with concentration, each specimen .....	((+00-0)) <u>88.4</u>	86384 Nitroblue tetrazolium dye test (NTD) .....	((BR)) <u>45.2</u>
86327 crossed (2 dimensional assay) .....	((BR)) <u>106.1</u>	(Ouchterlony diffusion, see 86331)	
86329 Immunodiffusion; quantitative, each IgA, IgG, IgM, ceruloplasmin, transferrin, alpha-2, macroglobulin, complement fractions, alpha-1 antitrypsin, or other (specify) .....	((30-0)) <u>66.8</u>	(Parietal cell antibody, see 86255, 86256)	
86331 gel diffusion, qualitative (Ouchterlony) each antigen or antibody .....	((30-0)) <u>58.9</u>	86385 Paternity testing, ABO + Rh factors + MN (per individual) .....	((37-5)) <u>149.3</u>
(For ceruloplasmin by chemical method, see 83290)		86386 each additional antigen system .....	((+5-0)) <u>21.6</u>
(IgE, RIA, see 82785; RIST, see 86423)		(Penicillin antibody RBC, see 86035)	
86332 Immune complex assay; Clq binding cell .....	BR	(Platelet antibodies (agglutinins), see 86014)	
86333 Raji cell .....	BR	(Platelet associated immunoglobulin assay, see 86023)	
86334 Immunofixation electrophoresis .....	BR	86403 Particle agglutination, rapid test for infectious agent antigen, each antigen .....	((BR)) <u>21.6</u>
86335 Immunoglobulin typing (Gc, Gm, Inv), each .....	((BR)) <u>43.2</u>	86404 Pooling of platelets or other blood products .....	BR
(Insulin antibody, see 86016)		86405 Precipitin test for blood (species identification) .....	((BR)) <u>45.2</u>
86337 Insulin antibodies, RIA .....	((BR)) <u>98.2</u>	(Pregnancy test, see 84702, 84703, 86006-86009)	
86338 Insulin factor antibodies, RIA .....	((32-0)) <u>88.4</u>	86410 Pretreatment of RBC's for use in RBC antibody detection, identification, and/or compatibility testing; incubation with chemical agents or drugs, each .....	BR
86340 Intrinsic factor antibodies, RIA .....	((32-0)) <u>70.7</u>	86411 incubation with enzymes, each .....	BR
(Intrinsic factor, antibody (fluorescent), see 86255, 86256)		86412 by density gradient separation .....	BR
(Inv grouping, see 86335)		86417 Pretreatment of serum for use in RBC antibody identification; incubation with drugs, each .....	BR
(Latex fixation, see 86403)		86418 by dilution .....	BR
(LE cell preparation, see 85544)		86419 incubation with inhibitors, each .....	BR
(LE factor, see 86006, 86007, 86255, 86256)		86420 by differential red cell absorption using patient RBC's or RBC's of known phenotype, each absorption .....	BR
(Leptospirosis, see 86006-86009, 86171)		86421 Radioallergosorbent test in vitro testing for allergen-specific IgE (e.g., RAST, MAST, FAST, IP, PRIST, etc.); up to 5 tests .....	((BR)) <u>60.9</u>
(Leukoagglutinins, see 86013, 86021)		86422 6 or more tests .....	((BR)) <u>29.5</u>
86342 Irradiation of blood products, each .....	BR	86423 Radioimmunosorbent test (RIST) IgE, quantitative .....	((BR)) <u>74.7</u>
86343 Leukocyte histamine release test (LHR) .....	((BR)) <u>58.9</u>	(Rapid plasma reagin test (RPR), see 86592)	
86344 Leukocyte phagocytosis .....	((BR)) <u>39.3</u>	86430 Rheumatoid factor latex fixation .....	((+2-0)) <u>15.7</u>
86349 Leukocyte transfusion (leukapheresis) .....	((BR)) <u>235.8</u>	(RIST, see 86423)	
(Lymphocyte culture, see 86353)		(RPR, see 86592)	
86353 Lymphocyte transformation, spontaneous blastogenesis or phytomitogen (phytohemagglutinin, PHA) or other mitogen culture (MC) (e.g., tuberculin, candida) .....	((+20-0)) <u>241.7</u>	(Rubella, CF, see 86171; HAI, see 86280)	
86357 Lymphocytes; T & B differentiation .....	((+65-0)) <u>29.5</u>	(Serologic test for syphilis (STS), see 86171, 86592, 86593)	
86358 B-cell evaluation .....	((BR)) <u>96.3</u>	86455 Skin test; allergy testing, one or more antigens .....	15.7
(Malaria, see 87207)		86490 coccidioidomycosis .....	((20-0)) <u>15.7</u>
86376 Microsomal antibody (thyroid); RIA .....	((BR)) <u>62.9</u>	86510 histoplasmosis .....	((20-0)) <u>15.7</u>
86377 other method (specify) .....	((30-0)) <u>66.8</u>	86540 mumps .....	((20-0)) <u>15.7</u>
86378 Migration inhibitory factor test (MIF) .....	((BR)) <u>82.5</u>	86580 tuberculosis, intradermal .....	((20-0)) <u>15.7</u>
(Milk antibody, anti-bovine, see 86008-86009)		86585 tuberculosis, tine test .....	((+2-0)) <u>15.7</u>
(Mitochondrial antibody, liver, see 86255)		(For skin tests for allergy testing, see 95005-95199, medicine section)	
(Mononucleosis screening slide, see 86006-86007)		(Smooth muscle antibody, see 86255, 86256)	

	Unit Value
(Sporotrichosis, see 86006-86009)	
86587 Splitting of blood or blood products, each .....	BR
86590 Streptokinase, antibody .....	<del>((27-0))</del>
	<u>33.4</u>
(Streptolysin O antibody, see antistreptolysin O, 86060-86061)	
(Streptobacillus, see 86008, 86009)	
86592 Syphilis, test; qualitative (e.g., VDRL, RPR, ART) .....	<del>((9-0))</del>
	9.8
86593 quantitative .....	<del>((15-0))</del>
	<u>19.6</u>
(Tetanus, see 86280)	
(Thyroglobulin antibody, see 86006-86009, 86171)	
(Thyroglobulin antibody, RIA, see 86800)	
(Thyroglobulin RIA, use 86318)	
86594 Thyroid autoantibodies .....	<del>((BR))</del>
	64.8
86595 Tissue; culture .....	<del>((BR))</del>
	57.0
86600 Toxoplasmosis dye test .....	<del>((80-0))</del>
	<u>62.9</u>
(For CF, see 86171; IFA, see 86255, 86256)	
86630 Transfer factor test (TFT) .....	<del>((BR))</del>
	<u>33.4</u>
86650 Treponema antibodies, fluorescent, absorbed (FTA-abs) .....	<del>((30-0))</del>
	<u>41.3</u>
86662 Treponema pallidum test, other, specify (e.g., TPIA, TPA, TPMB, TPCF, RPCF) .....	<del>((BR))</del>
	<u>64.8</u>
(Trichinosis, see 86006-86009)	
(Trypanosomiasis, see 86171, 86280)	
(Tuberculosis, see 86580, 86585, 87116-87118, 87190)	
(Vaccinia immune globulin, see 90742)	
(VDRL, see 86592)	
(Viral antibodies, see 86171, 86280, 86382)	
(Visceral larval migrans, see 86280)	
(Warm agglutinins, see 86004)	
86681 Adrenal cortex antibodies, RIA .....	<del>((31-0))</del>
	86.4
86685 Anti-AChR (acetylcholine receptor) antibody titer .....	<del>((BR))</del>
	153.2
86687 HTLV I, antibody detection; immunoassay .....	BR
86689 confirmatory test .....	BR
86800 Thyroglobulin antibody, RIA .....	<del>((31-0))</del>
	<u>76.6</u>
<b>TISSUE TYPING</b>	
(For pretransplant crossmatch, use appropriate code(s))	
86805 Lymphocytotoxicity assay, visual crossmatch; with titration .....	BR
86806 without titration .....	BR
86807 Serum screening for cytotoxic percent reactive antibody (PRA); standard method .....	BR
86808 quick method .....	BR
(86810 has been deleted)	
86812 Tissue typing; HLA typing, A, B, or C (e.g., A10, B7, B27), single antigen .....	<del>((BR))</del>
	<u>117.9</u>

	Unit Value
86813 HLA typing, A, B, and/or C (e.g., A10, B7, B27), multiple antigens .....	<del>((BR))</del>
	102.2
86816 HLA typing, DR, single antigen .....	<del>((BR))</del>
	369.4
86817 HLA typing, DR, multiple antigen .....	<del>((BR))</del>
	316.3
86821 Lymphocyte culture, mixed (MLC) .....	<del>((BR))</del>
	277.0
86822 Lymphocyte culture, primed (PLC) .....	<del>((BR))</del>
	170.9
86999 Unlisted immunology procedure .....	BR

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-23-224 MICROBIOLOGY.**

	Unit Value
(Includes bacteriology, mycology, parasitology and virology)	
87001 Animal inoculation, small animal; with observation .....	<del>((36-0))</del>
	62.9
87003 with observation and dissection .....	<del>((45-0))</del>
	<u>72.7</u>
87015 Concentration (any type) for parasites, ova or tubercle bacillus (T.B. AFB) .....	<del>((20-0))</del>
	<u>29.5</u>
87040 Culture, bacterial, definitive blood; includes anaerobic screen .....	<del>((48-0))</del>
	33.4
87045 stool .....	<del>((25-0))</del>
	41.3
87060 throat or nose .....	<del>((20-0))</del>
	15.7
87070 any other source .....	<del>((16-0))</del>
	<u>25.5</u>
(For urine, see 87086-87088)	
87072 Culture or direct bacterial identification method, each organism, by commercial kit, any source except urine .....	<del>((BR))</del>
	21.6
87075 Culture, bacterial, any source; anaerobic (isolation) .....	<del>((36-0))</del>
	<u>33.4</u>
87076 definitive identification each anaerobic organism including gas chromatography .....	<del>((60-0))</del>
	45.2
87081 Culture, bacterial, screening only, for single organisms .....	<del>((15-0))</del>
	<u>17.7</u>
87082 Culture, presumptive, pathogenic organisms, screening only, by commercial kit (specify type); for single organisms .....	<del>((BR))</del>
	21.6
87083 multiple organisms .....	<del>((BR))</del>
	33.4
87084 with colony estimation from density chart .....	<del>((BR))</del>
	43.2
87085 with colony count .....	<del>((BR))</del>
	43.2
87086 Culture, bacterial, urine; quantitative, colony count .....	<del>((15-0))</del>
	15.7
87087 commercial kit .....	<del>((12-0))</del>
	<u>31.4</u>
87088 identification, in addition to quantitative or commercial kit .....	<del>((12-0))</del>
	33.4
87101 Culture, fungi, isolation; skin .....	<del>((15-0))</del>
	37.3
87102 other source (except blood) .....	<del>((18-0))</del>
	<u>37.3</u>

	Unit Value
87103 blood.....	BR
87106 Culture, fungi, definitive identification of each fungus.....	<del>((30.0))</del> 47.2
87109 Culture, mycoplasma, any source.....	<del>((75.0))</del> 49.1
87110 Culture, Chlamydia.....	BR
87116 Culture, tubercle or other acid-fast bacilli (e.g., TB, AFB, mycobacteria); any source, isolation only.....	<del>((18.0))</del> 47.2
87117 concentration plus isolation.....	<del>((30.0))</del> 47.2
87118 culture, mycobacteria, definitive identification of each organism.....	<del>((30.0))</del> 47.2
87140 Culture, typing fluorescent method each antiserum.....	<del>((20.0))</del> 45.2
87143 gas liquid chromatography (GLC) method.....	<del>((45.0))</del> 60.9
87145 phage method.....	<del>((40.0))</del> 33.4
87147 serological method agglutination grouping, per antiserum.....	<del>((20.0))</del> 49.1
87151 serologic method, speciation.....	<del>((20.0))</del> 27.5
87155 precipitin method, grouping, per antiserum.....	<del>((12.0))</del> 17.7
87158 other methods.....	<del>((20.0))</del> 17.7
87163 Culture, any source, additional identification methods required (use in addition to primary culture code).....	<del>((BR))</del> 55.0
87164 Dark field examination, any source (e.g., penile, vaginal, oral, skin); includes specimen collection.....	<del>((60.0))</del> 45.2
87166 without collection.....	<del>((30.0))</del> 45.2
87174 Endotoxin, bacterial pyrogens; chemical.....	<del>((24.0))</del> 43.2
87175 biological assay (e.g., Limulus lysate).....	BR
87176 homogenization, tissue, for culture.....	<del>((15.0))</del> 29.5
87177 Ova and parasites, direct smears, concentration and identification.....	<del>((30.0))</del> 33.4

(Individual smears and procedures, see 87015, 87208-87211)

(Trichrome, iron hemotoxylin and other special stains, see 88312)

87178 Microbial identification, nucleic acid probes, each probe used.....	BR
(For nucleic acid probes in cytologic material, use 88365)	
87181 Sensitivity studies antibiotic, agar diffusion method, per antibiotic.....	<del>((40.0))</del> 23.6
87184 disc method, per plate (12 or less discs).....	<del>((24.0))</del> 15.7
87186 microtiter, minimum inhibitory concentration (MIC), any number of antibiotics.....	<del>((45.0))</del> 29.5
87187 minimum bactericidal concentration (MBC) (use in addition to 87186 or 87188).....	BR
87188 macrotube dilution method, each antibiotic.....	<del>((30.0))</del> 33.4
87190 Sensitivity study of tubercle bacillus, (TB, AFB), each drug.....	<del>((60.0))</del> 13.8
87192 fungi, each drug.....	BR
87197 Serum bactericidal titer (Schlichter test).....	BR

	Unit Value
87205 Smear, primary source, with interpretation; routine stain for bacteria, fungi, or cell types.....	<del>((12.0))</del> 19.6
87206 fluorescent and/or acid fast stain for bacteria, fungi, or cell types.....	<del>((18.0))</del> 27.5
87207 special stain for inclusion bodies or intracellular parasites (e.g., malaria, kala azar, herpes).....	<del>((24.0))</del> 17.7
87208 direct or concentrated, dry, for ova and parasites.....	<del>((12.0))</del> 27.5
(For concentration, see 87015; complete examination, see 87177)	
(For complex special stains, see 88312-88313)	
(For fat, meat, fibers, nasal eosinophils, and starch, see miscellaneous section)	
87210 wet mount with simple stain, for bacteria, fungi, ova, and/or parasites.....	<del>((12.0))</del> 9.8
87211 wet and dry mount, for ova and parasites.....	<del>((18.0))</del> 17.7
87220 Tissue examination for fungi (e.g., KOH slide).....	<del>((BR))</del> 21.6
87230 Toxin or antitoxin assay, tissue culture (e.g., clostridium difficile toxin).....	BR
87250 Virus identification; inoculation of embryonated eggs, or small animal, includes observation and dissection.....	<del>((12.0))</del> 35.4
87252 tissue culture, inoculation and observation.....	<del>((12.0))</del> BR
87253 tissue culture, additional studies (e.g., hemadsorption, neutralization) each isolate.....	<del>((6.0))</del> BR

(For electron microscopy, see 88348)

(For inclusion bodies in tissue sections, see 88304-88309; in smears, see 87207-87210; in fluids, see 88106)

87999 Unlisted microbiology procedure..... BR

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-23-228 ANATOMIC PATHOLOGY.**

	Unit Value
<b>POSTMORTEM EXAMINATION</b>	
(Procedures 88000 through 88099 represent physician services only. See modifier -90 for outside laboratory services.)	
88000 Necropsy (autopsy) without CNS, gross examination only.....	<del>((400.0))</del> BR
88005 with brain.....	<del>((500.0))</del> BR
88007 with brain and spinal cord.....	<del>((600.0))</del> BR
88012 infant with brain.....	<del>((300.0))</del> BR
88014 stillborn or newborn with brain.....	<del>((300.0))</del> BR
88016 macerated stillborn.....	<del>((400.0))</del> BR
88020 Necropsy (autopsy) without CNS, gross and microscopic examination.....	<del>((800.0))</del> BR
88025 with brain.....	<del>((900.0))</del> BR

	Unit Value
88027 with brain and spinal cord .....	(( <del>1000.0</del> )) BR
88028 infant with brain .....	(( <del>700.0</del> )) BR
88029 stillborn or newborn with brain .....	(( <del>700.0</del> )) BR
88036 Necropsy (autopsy), limited, gross and/or micro- scopic; regional .....	BR
88037 single organ .....	BR((+))
88040 Necropsy (autopsy); forensic examination .....	BR
88045 coroner's call .....	BR
88099 Unlisted necropsy (autopsy) procedure .....	BR

	Unit Value
(For percutaneous needle biopsy, see 32405 for lung, 47000 for liver, 48102 for pancreas, 49180 for abdominal or retroperitoneal mass)	
88172 Evaluation of fine needle aspirate with or without preparation of smears; immediate cytohistologic study to determine adequacy of specimen(s) .....	BR
88173 interpretation and report .....	BR
88180 Flow cytometry; each cell surface marker .....	BR
88182 cell cycle or DNA analysis .....	BR
88199 Unlisted cytopathology procedure .....	BR
(For electron microscopy, see 88348, 88349)	

**CYTOPATHOLOGY**

88104 Cytopathology, fluids, washings or brushings, with centrifugation except cervical or vaginal; smears with interpretation .....	(( <del>45.0</del> )) 70.7
88106 filter method only with interpretation .....	(( <del>45.0</del> )) 27.5
88107 smears and filter preparation with interpretation .....	(( <del>60.0</del> )) 72.7
88108 concentration technique, smears and interpreta- tion (e.g., Saccomanno technique) .....	(( <del>BR</del> )) 147.4

(For cervical or vaginal smears, see 88150)

(For gastric intubation with lavage, see 89130-89141,  
91055)

(For x-ray localization, see 74340)

88125 Cytopathology, forensic (e.g., sperm) .....	(( <del>75.0</del> )) 123.8
88130 Sex chromatin identification; (Barr bodies) .....	(( <del>40.0</del> )) 43.2
88140 peripheral blood smear, polymorphonuclear "drum sticks" .....	(( <del>40.0</del> )) 9.8

(For guard stain, see 88313)

88150 Cytopathology, smears, cervical or vaginal (e.g., Pa- panicolaou), screening by technician under physician supervision, up to three smears .....	(( <del>BR</del> )) 17.7 BR
88151 requiring interpretation by physician .....	BR
88155 with definitive hormonal evaluation (e.g., maturation index, karyopyknotic index, estrogenic index) .....	(( <del>40.0</del> )) 21.6
88160 Cytopathology, any other source (e.g., sputum), screening and interpretation .....	(( <del>36.0</del> )) 45.2
88161 preparation, screening and interpretation .....	(( <del>BR</del> )) 53.0
88162 extended study involving over 5 slides and/or multiple stains .....	BR

(For obtaining specimen, see percutaneous needle biopsy  
under individual organ in surgery)

(For aerosol collection of sputum, see 89350)

(For special stains, see 88312, 88313)

88170 Fine needle aspiration with or without preparation of smears; superficial tissue (e.g., thyroid, breast, pros- tate) .....	BR
--	----

(For percutaneous needle biopsy, see 60100 for thyroid,  
19100 for breast, 55700 for prostate)

88171 deep tissue under radiologic guidance .....	BR
(For CT guidance, see 76360, 76361; for ultrasonic guid- ance, see 76942, 76943; for fluoroscopic guidance use 76000)	

**CYTOGENETIC STUDIES**

(For acetylcholinesterase, see 82013)

(For alpha-fetoprotein, Serum or amniotic fluid, see  
86244)

88230 Tissue culture for chromosome analysis; lymphocyte	BR
88233 skin or other solid tissue biopsy .....	BR
88235 amniotic fluid or chorionic villus cells .....	BR
88237 bone marrow (myeloid) cells .....	BR
88239 other tissue .....	BR
88245 Chromosome analysis for breakage syndromes; score 25 cells (SCE study), count 5 cells, 1 karyotype, with banding (e.g., Bloom syndrome) .....	BR
88248 score 100 cells, count 20 cells, 2 karyotypes, with banding, (e.g., ataxia telangiectasia, Fanconi ane- mia) .....	BR
88250 Chromosome analysis for fragile X associated with fragile X-linked mental retardation; score 100 cells, count 20 cells, 2 karyotypes, with banding .....	BR
88260 Chromosome analysis for fragile X associated with fragile X-linked mental retardation; score 100 cells, count 20 cells, 2 karyotypes, with banding .....	(( <del>BR</del> )) 251.5
88261 count 5 cells, 1 karyotype, with banding .....	(( <del>BR</del> )) 503.0
88262 count 15-20 cells, 2 karyotypes, with banding .....	(( <del>BR</del> )) 756.4
88263 Count 45 cells for mosaicism, 2 karyotypes, with banding .....	(( <del>675.0</del> )) BR
88267 Chromosome analysis; amniotic fluid, or chorionic villus count 15 cells, 1 karyotype, with banding ...	(( <del>600.0</del> )) 858.6
88269 Chromosome analysis; count 5 cells, screening with banding .....	BR
88280 Chromosome analysis; additional karyotyping, each study .....	(( <del>75.0</del> )) 110.0
88283 additional specialized banding technique (e.g., NOR, C-banding) .....	BR
88285 additional cells counted, each study .....	((+ <del>5.0</del> )) 27.5
88289 additional high resolution study .....	BR
88299 Unlisted cytogenetic study .....	BR

**AMENDATORY SECTION (Amending Order 89-09,  
filed 8/10/89, effective 9/10/89)**

**WAC 296-23-231 ANATOMIC PATHOLOGY.**

	Unit Value
--	---------------

**SURGICAL PATHOLOGY**

(Procedures 88300 through 88399 include accession, han-  
dling and reporting)



	Unit Value
NOTE: Only one of the numbers 88300-88309 should be used in reporting specimens (single or multiple) that are removed during a single surgical procedure.	
88300 Surgical pathology, gross examination only.....	((20-0)) <u>45.2</u>
88302 Surgical pathology, gross and microscopic examination of presumptively normal tissue(s), for identification and record purposes.....	((60-0)) <u>96.3</u>
88304 Surgical pathology, gross and microscopic examination of presumptively abnormal tissue(s); uncomplicated specimen.....	((75-0)) <u>123.8</u>
88305 single complicated <u>specimen</u> or <u>specimen composed of multiple uncomplicated ((specimen(s))) tissues</u> , without complex dissection.....	((105-0)) <u>172.9</u>
88307 single complicated specimen requiring complex dissection or a <u>specimen composed of multiple complicated ((specimens)) tissues</u> .....	((150-0)) <u>239.7</u>
88309 complex diagnostic problem with or without extensive dissection.....	((BR)) <u>263.3</u>
(For fine needle aspiration, preparation, and interpretation of smears, see 88170-88173)	
88311 Decalcification procedure. (List separately in addition to code for surgical pathology examination) ...	((12-0)) <u>19.6</u>
88312 Special stains (list separately in addition to code for surgical pathology examination); Group I for microorganisms, (e.g., Gridley, acid fast, methenamine silver), each.....	((25-0)) <u>39.3</u>
88313 Group II, all other (e.g., iron, trichrome), except immunocytochemistry and immunoperoxidase stains, each.....	((12-0)) <u>19.6</u>
(For immunocytochemistry and immunoperoxidase tissue studies, use 88342)	
88314 Histochemical staining with frozen section(s).....	((BR)) <u>98.2</u>
88317 Interpretation and report by treating physician of previously diagnosed histologic slide (without consultation).....	BR
88318 Determinative histochemistry to identify chemical components (e.g., copper, zinc).....	BR
88319 Determinative histochemistry or cytochemistry to identify enzyme constituents, each.....	BR
88321 Consultation and report on referred slides prepared elsewhere.....	((BR)) <u>127.7</u>
88323 Consultation and report on referred material requiring preparation of slides.....	BR
88325 Consultation, comprehensive, with review of records and specimens, with report on referred material....	BR
88329 Consultation during surgery.....	BR
88331 with frozen section(s), single specimen.....	((90-0)) <u>182.7</u>
88332 each additional tissue block with frozen section(s).....	((30-0)) <u>96.3</u>
88342 Immunocytochemistry (including tissue immunoperoxidase), each antibody.....	BR
88346 Immunofluorescent study, each antibody; <u>direct method</u> .....	((BR)) <u>196.5</u>
88347 <u>indirect method</u> .....	BR
88348 Electron microscopy; diagnostic.....	BR
88349 scanning.....	BR
88355 Morphometric analysis; skeletal muscle.....	BR

88356 nerve.....	BR
88358 tumor.....	BR
88362 Nerve teasing preparations.....	BR
(For physician interpretation of peripheral blood smear, use 85060)	
88365 Tissue in situ hybridization, interpretation and report.....	BR
88399 Unlisted surgical pathology procedure.....	BR

**AMENDATORY SECTION** (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

**WAC 296-23A-240 HEAD AND NECK.**

	Unit Value
70011 Myelography, posterior fossa; complete procedure.....	((BR)) <u>67.8</u>
70016 Cisternography, positive contrast; complete procedure.....	((BR)) <u>67.8</u>
(For injection procedure only for cisternography, see 61053)	
70030 Radiologic examination, eye, for detection of foreign body.....	((8-0)) <u>7.5</u>
(70040 and 70050 have been deleted)	
70100 Radiologic examination, mandible; partial, less than four views.....	((6-0)) <u>7.2</u>
70110 complete, minimum of four views.....	((10-0)) <u>9.9</u>
70120 Radiologic examination, mastoids; less than three views per side.....	6.0
70130 complete, minimum of three views per side....	12.0
70134 Radiologic examination, internal auditory meati, complete.....	((12-0)) <u>9.6</u>
70140 Radiologic examination, facial bones; less than three views.....	((6-0)) <u>5.8</u>
70150 complete, minimum of three views.....	((10-0)) <u>9.6</u>
70160 Radiologic examination, nasal bones, complete, minimum of three views.....	((6-4)) <u>7.2</u>
70171 Dacryocystography nasolacrimal, complete procedure.....	((10-0)) <u>17.3</u>
70190 Radiologic examination; optic foramina.....	((6-0)) <u>7.2</u>
70200 orbits, complete, minimum of four views.....	((8-0)) <u>9.6</u>
70210 Radiologic examination, sinuses, paranasal, less than three views.....	((5-0)) <u>4.6</u>
70220 Radiologic examination, sinuses, paranasal, complete, minimum of three views.....	((8-0)) <u>7.2</u>
70240 Radiologic examination, sella turcica.....	((5-0)) <u>4.8</u>
70250 Radiologic examination, skull; less than four views, with or without stereo.....	6.0
70260 complete, minimum of four views, with or without stereo.....	12.0
70300 Radiologic examination, teeth; single view.....	((2-0)) <u>2.4</u>
70310 partial examination, less than full mouth.....	((4-0)) <u>4.8</u>

	Unit Value		Unit Value
70320 complete, full mouth .....	((8-0)) <u>7.2</u>	70492 without contrast material followed by contrast material(s) and further sections .....	((BR)) <u>49.3</u>
70328 Radiologic examination, temporomandibular joint, open and closed mouth; unilateral .....	((6-0)) <u>5.8</u>		
70330 bilateral .....	((8-8)) <u>9.6</u>	(For coronal, sagittal, and/or oblique sections, see 76375)	
70333 Temporomandibular joint arthrotopography (includes a contrast arthrogram and appropriate laminographic studies); complete procedure .....	((21-7)) <u>30.6</u>	(For cervical spine, see 72125, 72126)	
70336 Magnetic resonance (e.g., proton) imaging, temporomandibular joint .....	((+20-0)) <u>60.0</u>	70540 Magnetic resonance (e.g., proton) imaging; orbit, face, and neck .....	((+20-0)) <u>117.9</u>
70350 Cephalogram, orthodontic .....	((4-0)) <u>4.8</u>	70551 <u>Magnetic resonance (e.g., proton) imaging, brain (including brain stem); without contrast material</u> .....	((+20-0)) <u>117.9</u>
70355 Orthopantomogram .....	((+0-0)) <u>9.6</u>	<u>70552 with contrast material(s)</u> .....	<u>117.9</u>
70360 Radiologic examination, neck; soft tissue .....	((4-0)) <u>4.8</u>	<u>W0060 Nonionic contrast media for magnetic resonance imaging</u> .....	<u>15.9</u>
70370 pharynx or larynx, including fluoroscopy and/or magnification technique .....	((8-0)) <u>10.3</u>	<b>AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)</b>	
70371 Complex dynamic pharyngeal and speech evaluation by cine or video recording .....	((BR)) <u>25.3</u>	<b>WAC 296-23A-242 CHEST.</b>	
70374 Laryngography, contrast; complete procedure .....	((24-0)) <u>31.3</u>		Unit Value
70380 Radiologic examination, salivary gland for calculus .....	((6-4)) <u>7.2</u>	71010 Radiologic examination, chest; single view, frontal .....	((4-0)) <u>4.8</u>
70391 Sialography; complete procedure .....	((8-0)) <u>18.5</u>	71015 stereo, frontal .....	((5-0)) <u>7.2</u>
70450 Computerized axial tomography, head or brain; without contrast material .....	((50-0)) <u>55.8</u>	71020 two views, frontal and lateral .....	((7-0)) <u>7.2</u>
70460 with contrast material(s) .....	((64-0)) <u>65.9</u>	71021 apical lordotic procedure .....	((7-2)) <u>6.3</u>
70470 without contrast material, followed by contrast material(s) and further sections .....	((71-0)) <u>80.8</u>	71022 oblique projections .....	((7-2)) <u>BR</u>
(For coronal, sagittal, and/or oblique sections, see 76375)		71023 with fluoroscopy .....	((BR)) <u>10.3</u>
70480 Computerized axial tomography, orbit, sella, or posterior fossa or outer, middle, or inner ear; without contrast material .....	((50-0)) <u>61.3</u>	71030 Radiologic examination, chest, complete, minimum of four views .....	((8-0)) <u>8.2</u>
70481 with contrast material(s) .....	((64-0)) <u>71.0</u>	71034 with fluoroscopy .....	((+0-0)) <u>13.7</u>
70482 without contrast material, followed by contrast material(s) and further sections .....	((71-0)) <u>80.8</u>	(For separate chest fluoroscopy, see 76000)	
(For coronal, sagittal, and/or oblique sections, see 76375)		71035 Radiologic examination, chest, special views, e.g., lateral decubitus, Bucky studies .....	((BR)) <u>9.6</u>
70486 Computerized axial tomography, maxillofacial area; without contrast material .....	((50-0)) <u>33.7</u>	71036 Fluoroscopic localization for needle biopsy of intrathoracic lesion, including follow-up films .....	((BR)) <u>13.5</u>
70487 with contrast material(s) .....	((64-0)) <u>37.8</u>	71037 <u>Complete procedure</u> .....	<u>48.1</u>
70488 without contrast material, followed by contrast material(s) and further sections .....	((71-0)) <u>46.9</u>	71038 Fluoroscopic localization for transbronchial biopsy or brushing .....	((BR)) <u>13.0</u>
(For coronal, sagittal, and/or oblique sections, see 76375)		71041 Bronchography, unilateral; complete procedure ..	((+4-0)) <u>27.7</u>
70490 Computerized axial tomography, soft tissue neck; without contrast material .....	((BR)) <u>34.9</u>	71061 Bronchography, bilateral; complete procedure ...	((22-0)) <u>31.3</u>
70491 with contrast material(s) .....	((BR)) <u>39.9</u>	71100 Radiologic examination, ribs, unilateral; two views .....	7.2
		71101 including posteroanterior chest, minimum of three views .....	((+1-2)) <u>10.6</u>
		71110 Radiologic examination, ribs, bilateral; three views .....	((+0-0)) <u>11.1</u>
		71111 including posteroanterior chest, minimum of four views .....	((+4-0)) <u>11.1</u>
		71120 Radiologic examination; sternum, minimum of two views .....	((6-0)) <u>7.2</u>

	Unit Value		Unit Value
71130 sternoclavicular joint or joints, minimum of three views .....	((6-0)) <u>7.2</u>	72128 Computerized axial tomography, thoracic spine; without contrast material .....	((62-4)) 43.3
71250 Computerized axial tomography, thorax; without contrast material .....	((77-0)) 61.1	72129 with contrast material .....	((72-8)) <u>51.7</u>
71260 with contrast material(s) .....	((84-0)) <u>75.5</u>	72130 without contrast material, followed by contrast material(s) and further sections .....	((BR)) <u>55.3</u>
71270 without contrast material, followed by contrast material(s) and further sections .....	((90-0)) <u>78.2</u>	72131 Computerized axial tomography, lumbar spine; without contrast material .....	((60-0)) 43.3
(For coronal, sagittal, and/or oblique sections, see 76375)		72132 with contrast material .....	((70-0)) <u>51.7</u>
71550 Magnetic resonance (e.g., proton) imaging, chest (e.g., for evaluation of hilar and mediastinal lymphadenopathy) .....	((120-0)) <u>117.9</u>	(For coronal, sagittal, and/or oblique sections, see 76375)	
<b>AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)</b>		72133 without contrast material, followed by contrast material(s) and further sections .....	((BR)) <u>55.3</u>
<b>WAC 296-23A-244 SPINE AND PELVIS.</b>		72141 Magnetic resonance (e.g., proton) imaging, spinal canal and contents; cervical <u>without contrast material</u> .....	((20-0)) <u>117.9</u>
	Unit Value	<del>((72143 thoracic .....</del>	<del>117.9</del>
72010 Radiologic examination, spine, entire, survey study, anteroposterior and lateral .....	((16-0)) <u>20.0</u>	72144 <del>lumbar .....</del>	<del>120.0</del>
72020 Radiologic examination, spine, single view, specify level .....	((6-5)) <u>5.3</u>	<del>(72145 has been deleted. To report, see 72125-72132))</del>	<del>120.0</del>
72040 Radiologic examination, spine, cervical; anteroposterior and lateral .....	((6-0)) <u>7.2</u>	72142 with contrast material(s) .....	<u>117.9</u>
72050 minimum of four views .....	((10-0)) <u>11.5</u>	<del>(72143 has been deleted. To report, see 72146, 72147)</del>	
72052 complete, including oblique and flexion and/or extension studies .....	((15-2)) <u>14.4</u>	<del>(72144 has been deleted. To report, see 72148, 72149)</del>	
72070 Radiologic examination, spine; thoracic, anteroposterior and lateral .....	((9-0)) <u>7.2</u>	<del>(72145 has been deleted. To report, see 72125-72133)</del>	
72072 thoracic, anteroposterior and lateral, including swimmer's view of the cervicothoracic junction .....	((12-0)) <u>10.6</u>	72146 Magnetic resonance (e.g., proton) imaging, spinal canal and contents, thoracic; without contrast material .....	<u>117.9</u>
72074 thoracic, complete, including obliques, minimum of four views .....	((16-0)) <u>13.7</u>	72147 with contrast material(s) .....	<u>117.9</u>
72080 thoracolumbar, anteroposterior and lateral .....	((9-0)) <u>7.2</u>	72148 Magnetic resonance (e.g., proton) imaging, spinal canal and contents, lumbar; without contrast material .....	<u>117.9</u>
72090 scoliosis study, including supine and erect studies .....	((6-0)) <u>7.5</u>	72149 with contrast material(s) .....	<u>117.9</u>
72100 Radiologic examination, spine, lumbosacral; anteroposterior and lateral .....	((9-0)) <u>9.6</u>	72170 Radiologic examination, pelvis; anteroposterior only .....	((5-0)) 7.2
72110 complete with oblique views .....	((16-0)) <u>10.8</u>	<del>((72180 stereo .....</del>	<del>6-4))</del>
72114 complete, including bending views .....	((18-5)) <u>13.0</u>	72190 complete, minimum of three views .....	((8-0)) <u>9.6</u>
72120 Radiologic examination, spine, lumbosacral, bending views only, minimum of four views .....	((10-0)) <u>8.9</u>	(For pelvimetry, see 74710)	
72125 Computerized axial tomography, cervical spine; without contrast material .....	((62-4)) 43.3	72192 Computerized axial tomography, pelvis; without contrast material(s) .....	((BR)) 61.3
72126 with contrast material .....	((72-8)) <u>51.7</u>	72193 with contrast material(s) .....	((BR)) <u>78.2</u>
72127 without contrast material, followed by contrast material(s) and further sections .....	((BR)) <u>55.3</u>	72194 without contrast material, followed by contrast material(s) and further sections .....	((BR)) <u>81.8</u>
		(For coronal, sagittal, and/or oblique sections, see 76375)	
		72196 Magnetic resonance (e.g., proton) imaging, pelvis .....	((120-0)) <u>132.3</u>
		72200 Radiologic examination, sacroiliac joints; less than three views .....	((5-0)) 7.2
		72202 three or more views .....	((8-0))

	Unit Value
	<u>7.7</u>
72220 Radiologic examination, sacrum and coccyx, minimum of two views .....	(( <del>6-4</del> ))
	<u>7.2</u>
72241 Myelography, cervical; complete procedure .....	(( <del>18-0</del> ))
	<u>58.9</u>
72256 Myelography, thoracic; complete procedure .....	(( <del>18-0</del> ))
	<u>58.9</u>
72266 Myelography, lumbosacral; complete procedure ..	(( <del>18-0</del> ))
	<u>58.2</u>
72271 Myelography, entire spinal canal; complete procedure .....	(( <del>30-0</del> ))
	<u>68.6</u>
72286 Diskography, cervical; complete procedure .....	(( <del>20-0</del> ))
	<u>93.8</u>
72296 Diskography, lumbar; complete procedure .....	(( <del>20-0</del> ))
	<u>91.4</u>
<u>W0060 Nonionic contrast media for magnetic resonance imaging .....</u>	<u>15.9</u>

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-23A-246 UPPER EXTREMITIES.**

	Unit Value
73000 Radiologic examination; clavicle, complete .....	(( <del>4-8</del> ))
	<u>5.3</u>
73010 scapula, complete .....	(( <del>6-0</del> ))
	<u>6.5</u>
73020 Radiologic examination, shoulder; one view .....	(( <del>4-0</del> ))
	<u>4.3</u>
73030 complete, minimum of two views .....	(( <del>6-0</del> ))
	<u>6.5</u>
73041 Radiologic examination, shoulder, arthrography; complete procedure .....	(( <del>10-0</del> ))
	<u>27.7</u>
73050 Radiologic examination; acromioclavicular joints, bilateral, with or without weighted distraction ...	(( <del>7-0</del> ))
	<u>6.7</u>
73060 humerus, minimum of two views .....	(( <del>4-8</del> ))
	<u>6.0</u>
73070 Radiologic examination, elbow; anteroposterior and lateral views .....	(( <del>4-8</del> ))
	<u>4.3</u>
73080 complete, minimum of three views .....	(( <del>6-0</del> ))
	<u>5.5</u>
73086 Radiologic examination, elbow, arthrography; complete procedure .....	(( <del>10-0</del> ))
	<u>22.9</u>
73090 Radiologic examination; forearm, anteroposterior and lateral views .....	(( <del>4-8</del> ))
	<u>5.3</u>
73100 Radiologic examination, wrist; anteroposterior and lateral views .....	(( <del>4-0</del> ))
	<u>3.8</u>
73110 complete, minimum of three views .....	(( <del>6-0</del> ))
	<u>5.5</u>
73116 Radiologic examination, wrist, arthrography; complete procedure .....	(( <del>10-0</del> ))
	<u>23.3</u>
73120 Radiologic examination, hand; two views .....	(( <del>4-0</del> ))
	<u>5.1</u>
73130 minimum of three views .....	(( <del>6-0</del> ))
	<u>5.5</u>
73140 Radiologic examination, finger or fingers, minimum of two views .....	(( <del>3-6</del> ))
	<u>3.4</u>
73200 Computerized axial tomography, upper extremity; without contrast material .....	(( <del>58-0</del> ))
	<u>62.5</u>

	Unit Value
73201 with contrast material(s) .....	(( <del>64-0</del> ))
	<u>72.9</u>
73202 without contrast material, followed by contrast material(s) and further sections .....	(( <del>71-0</del> ))
	<u>75.8</u>
73220 Magnetic resonance (e.g., proton) imaging, upper extremity, other than joint .....	(( <del>120-0</del> ))
	<u>117.9</u>
73221 Magnetic resonance (e.g., proton) imaging, any joint of upper extremity .....	(( <del>120-0</del> ))
	<u>117.9</u>

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-23A-248 LOWER EXTREMITIES.**

	Unit Value
73500 Radiologic examination, hip; unilateral, one view .	(( <del>5-0</del> ))
	<u>5.3</u>
73510 complete, minimum of two views .....	(( <del>7-0</del> ))
	<u>7.2</u>
73520 Radiologic examination, hips, bilateral, minimum of two views of each hip, including anteroposterior view of pelvis .....	9.6
73526 Radiologic examination, hip, arthrography; complete procedure .....	(( <del>BR</del> ))
	<u>22.4</u>
73530 Radiologic examination, hip, during operative procedure .....	(( <del>16-0</del> ))
	<u>14.0</u>
73550 Radiologic examination, femur, anteroposterior and lateral views .....	(( <del>6-0</del> ))
	<u>6.3</u>
73560 Radiologic examination, knee; anteroposterior and lateral views .....	(( <del>4-4</del> ))
	<u>5.1</u>
73562 anteroposterior and lateral, with oblique(s), minimum of three views .....	(( <del>6-4</del> ))
	<u>6.0</u>
73564 complete, including oblique(s), and/or tunnel, and/or patellar, and/or standing views .....	(( <del>8-4</del> ))
	<u>7.2</u>
73581 Radiologic examination, knee, arthrography; complete procedure .....	(( <del>16-0</del> ))
	<u>30.1</u>
73590 Radiologic examination; tibia and fibula, anteroposterior and lateral views .....	(( <del>4-8</del> ))
	<u>6.0</u>
73592 lower extremity, infant, minimum of two views .....	(( <del>4-0</del> ))
	<u>6.0</u>
73600 Radiologic examination, ankle; anteroposterior and lateral views .....	(( <del>4-4</del> ))
	<u>4.1</u>
73610 complete, minimum of three views .....	(( <del>6-0</del> ))
	<u>5.3</u>
73616 Radiologic examination, ankle, arthrography; complete procedure .....	(( <del>10-0</del> ))
	<u>22.9</u>
73620 Radiologic examination, foot; anteroposterior and lateral views .....	(( <del>4-0</del> ))
	<u>3.4</u>
73630 complete, minimum of three views .....	(( <del>5-6</del> ))
	<u>4.8</u>
73650 Radiologic examination; calcaneus, minimum of two views .....	(( <del>4-4</del> ))
	<u>4.8</u>
73660 toe or toes, minimum of two views .....	(( <del>3-6</del> ))
	<u>3.1</u>
73700 Computerized axial tomography, lower extremity; without contrast material .....	(( <del>58-0</del> ))
	<u>61.3</u>

	Unit Value		Unit Value
73701 with contrast material(s) .....	(( <del>64.0</del> ) 71.5)	74241 with or without delayed films, with KUB .....	(( <del>15.2</del> ) 18.0)
73702 without contrast materials, followed by contrast material(s) and further sections .....	(( <del>71.0</del> ) 74.3)	74245 with small bowel, includes multiple serial films	(( <del>17.6</del> ) 24.1)
(For coronal, sagittal, and/or oblique sections, see 76375)		74246 Radiologic examination, gastrointestinal tract, upper, air contrast, with specific high density barium, effervescent agent, with or without glucagon; with or without delayed films, without KUB .....	((BR)) 14.9
73720 Magnetic resonance (e.g., proton) imaging, lower extremity, other than joint .....	(( <del>120.0</del> ) 117.9)	74247 with or without delayed film, with KUB .....	((BR)) 29.1
73721 Magnetic resonance (e.g., proton) imaging, any joint of lower extremity .....	(( <del>120.0</del> ) 117.9)	74249 with small bowel follow through .....	((BR)) 19.7

**AMENDATORY SECTION** (Amending Order 86-47, filed 1/8/87)

**WAC 296-23A-250 ABDOMEN.**

	Unit Value		Unit Value
74000 Radiologic examination, abdomen; single anteroposterior view .....	(( <del>6.0</del> ) 5.5)	74280 air contrast with high density barium, with or without glucagon .....	(( <del>14.0</del> ) 20.7)
74010 anteroposterior and additional oblique and cone views .....	(( <del>8.0</del> ) 7.7)	74283 <u>Barium enema, therapeutic, for reduction of intussusception</u> .....	BR 9.6
74020 complete, including decubitus and/or erect views .....	(( <del>11.0</del> ) 9.9)	74290 Cholecystography, oral contrast .....	4.8
74022 complete acute abdomen series, including supine, erect, and/or decubitus views, upright PA chest .....	((BR)) 9.9	74291 additional or repeat examination or multiple day examination .....	(( <del>10.0</del> ) 11.5)
74150 Computerized axial tomography, abdomen; without contrast material .....	(( <del>77.0</del> ) 61.3)	74300 Cholangiography and/or pancreatography; during surgery .....	(( <del>3.0</del> ) 6.0)
74160 with contrast material(s) .....	(( <del>84.0</del> ) 78.2)	74301 additional set during surgery .....	(( <del>12.0</del> ) 10.1)
74170 without contrast material, followed by contrast material(s) and further sections .....	(( <del>90.0</del> ) 81.8)	74305 postoperative .....	(For biliary duct stone extraction, percutaneous, see 74327)
(For coronal, sagittal, and/or oblique sections, see 76375)			(74310, 74315 have been deleted. To report, use 76499)
74181 Magnetic resonance (e.g., proton) imaging, abdomen .....	(( <del>120.0</del> ) 117.9)	74321 Cholangiography, percutaneous, transhepatic; complete procedure .....	(( <del>16.0</del> ) 52.9)

**AMENDATORY SECTION** (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

**WAC 296-23A-252 GASTROINTESTINAL TRACT.**

	Unit Value		Unit Value
74210 Radiologic examination; pharynx and/or cervical esophagus .....	(( <del>8.8</del> ) 10.1)	74327 Postoperative biliary duct stone removal, percutaneous via T-tube tract, basket or snare (e.g., Burhenne technique) fluoroscopic monitoring and radiography .....	((BR)) 43.3
74220 esophagus .....	(( <del>8.8</del> ) 10.8)	74328 Endoscopic catheterization of the biliary ductal system, fluoroscopic monitoring and radiography .....	((BR)) 17.3
74230 Swallowing function, pharynx and/or esophagus, with cineradiography and/or video .....	(( <del>12.0</del> ) 13.2)	74329 Endoscopic catheterization of the pancreatic ductal system, fluoroscopic monitoring and radiography .....	((BR)) 17.8
74235 Removal of foreign body(s), esophageal, with use of balloon catheter under fluoroscopic guidance ..	((BR)) 33.7	74330 Combined endoscopic catheterization of the biliary and pancreatic ductal systems, fluoroscopic monitoring and radiography .....	((BR)) 18.5
74240 Radiologic examination, gastrointestinal tract, upper; with or without delayed films, without KUB ..	(( <del>14.0</del> ) 18.0)	74340 Introduction of long gastrointestinal tube, (e.g., Miller-Abbott), with multiple fluoroscopies and films .....	((BR)) 19.2
		74351 Percutaneous placement of gastrostomy tube; complete procedure .....	((BR)) 73.9
		74356 Percutaneous placement of enteroclysis tube; complete procedure .....	((BR)) 73.9
		74361 Intraluminal dilation of strictures and/or obstructions (e.g., esophagus or biliary tree); complete procedure .....	((BR)) 77.0

**AMENDATORY SECTION** (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

**WAC 296-23A-254 URINARY TRACT.**

	Unit Value
74400 Urography (pyelography) intravenous, with or without KUB .....	((+5.2)) <u>18.0</u>
74405 with special hypertensive contrast concentration and/or clearance studies .....	((+6.0)) <u>21.2</u>
74410 Urography, infusion, drip technique and/or bolus technique .....	((20.0)) <u>19.2</u>
74415 with nephrotomography .....	((26.0)) <u>34.9</u>
74420 Urography, retrograde, with or without kidneys, ureters, and bladder .....	((+2.0)) <u>14.4</u>
74426 Urography, antegrade, (pyelostogram, nephrostogram, loopogram); complete procedure .....	((BR)) <u>20.4</u>
74431 Cystography, minimum of three views; complete procedure .....	((8.0)) <u>13.0</u>
74441 Vasography, vesiculography, or epididymography; complete procedure .....	((8.0)) <u>40.2</u>
74446 Corpora cavernosography; complete procedure ...	((BR)) <u>25.3</u>
74451 Urethrocytography, retrograde; complete procedure .....	((9.6)) <u>13.5</u>
74456 Urethrocytography, voiding; complete procedure .....	((+4.0)) <u>14.4</u>
74471 Radiologic examination, renal cyst study, translumbar, contrast visualization; complete procedure .....	((+0.0)) <u>43.3</u>
74476 Introduction of intracatheter or catheter into renal pelvis for drainage and/or injection, percutaneous, with fluoroscopic monitoring and radiography; complete procedure .....	((BR)) <u>89.0</u>
74481 Introduction of ureteral catheter or stent into ureter through renal pelvis for drainage and/or injection, percutaneous, with fluoroscopic monitoring and radiography; complete procedure .....	((BR)) <u>96.2</u>
74486 Dilation of nephrostomy or ureters with fluoroscopic monitoring and radiography; complete procedure .....	((BR)) <u>91.4</u>

**AMENDATORY SECTION** (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

**WAC 296-23A-256 GYNECOLOGICAL AND OBSTETRICAL.**

	Unit Value
(For abdomen and pelvis, see 74000-74170, 72170-72190)	
74710 Pelvimetry, with or without placental localization .....	((+0.0)) <u>12.5</u>
<del>((74720 Radiologic examination, abdomen, for fetal age, fetal position and/or placental localization; single view .....</del>	<del>4.0</del>
74725 <del>multiple views .....</del>	<del>6.0))</del>
(74731 has been deleted. To report, use 76499)	

74741 Hysterosalpingography; complete procedure .....	((+0.8)) <u>27.4</u>
74775 Perincogram (e.g., vaginogram, for sex determination or extent of anomalies) .....	((BR)) <u>18.8</u>

**AMENDATORY SECTION** (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

**WAC 296-23A-258 VASCULAR SYSTEM.**

	Unit Value
<b>HEART</b>	
75501 Angiocardiology by cineradiography; complete procedure .....	((22.0)) <u>105.9</u>
75506 Angiocardiology by serialography, single plane; complete procedure .....	((23.0)) <u>108.3</u>
75509 Angiocardiology by serialography, multiplane; complete procedure .....	((46.0)) <u>110.7</u>
75520 Cardiac radiography, selective cardiac catheterization, right side; complete procedure .....	((43.0)) <u>87.8</u>
75524 Cardiac radiography, selective cardiac catheterization, left side; complete procedure .....	((21.5)) <u>102.2</u>
75528 Cardiac radiography, selective cardiac catheterization, right and left side; complete procedure ...	((55.0)) <u>145.5</u>
75552 Magnetic resonance (e.g., proton) imaging, myocardium .....	((+20.0)) <u>117.9</u>
<b>AORTA AND ARTERIES</b>	
75601 Aortography, thoracic, without serialography; complete procedure .....	((20.0)) <u>68.6</u>
75606 Aortography, thoracic, by serialography; complete procedure .....	((30.0)) <u>74.6</u>
<del>((75621 Aortography, abdominal, translumbar, without serialography; complete procedure .....</del>	<del>32.0</del>
<del>75623 Aortography, abdominal, catheter, without serialography; complete procedure .....</del>	<del>32.0))</del>
75626 Aortography, abdominal, translumbar, by serialography; complete procedure .....	((40.0)) <u>81.8</u>
75628 Aortography, abdominal, catheter, by serialography; complete procedure .....	((48.0)) <u>81.8</u>
75631 Aortography, abdominal plus bilateral iliofemoral lower extremity, catheter, by serialography; complete procedure .....	((BR)) <u>84.2</u>
75651 Angiography, cervicocerebral, catheter, including vessel origin; complete procedure .....	((40.0)) <u>108.3</u>
75653 Angiography, cervicocerebral, selective catheter, including vessel origin; one vessel, complete procedure .....	((36.0)) <u>108.3</u>
75655 two vessels, complete procedure .....	((38.0)) <u>156.4</u>
75657 three or four vessels, complete procedure .....	((40.0)) <u>175.6</u>
75659 Angiography, brachial, retrograde; complete procedure .....	((40.0)) <u>93.8</u>

	Unit Value		Unit Value		
75661	Angiography, external carotid, cerebral, unilateral, selective; complete procedure . . . . .	((40.0)) <u>115.5</u>	75737	Angiography, pelvic; selective, complete procedure . . . . .	((44.0)) <u>108.3</u>
75663	Angiography, external carotid, cerebral, bilateral, selective; complete procedure . . . . .	((50.0)) <u>168.4</u>	75738	supraselective, complete procedure . . . . .	((46.0)) <u>115.5</u>
75667	Angiography, carotid, cerebral, unilateral; direct puncture, complete procedure . . . . .	((40.0)) <u>115.5</u>	75742	Angiography, pulmonary, unilateral, selective; complete procedure . . . . .	((30.0)) <u>84.2</u>
75669	catheter, complete procedure . . . . .	((46.0)) <u>115.5</u>	75744	Angiography, pulmonary, bilateral, selective; complete procedure . . . . .	((50.0)) <u>120.3</u>
75672	Angiography, carotid, cerebral, bilateral; direct puncture, complete procedure . . . . .	((50.0)) <u>168.4</u>	75747	Angiography, pulmonary; by catheter, nonselective, complete procedure . . . . .	((30.0)) <u>72.2</u>
75673	catheter, complete procedure . . . . .	((54.0)) <u>173.2</u>	75748	venous injection, complete procedure . . . . .	((40.0)) <u>48.1</u>
75677	Angiography, carotid, cervical, unilateral; direct puncture, complete procedure . . . . .	((40.0)) <u>115.5</u>	75751	Angiography, coronary, root injection; complete procedure . . . . .	((60.0)) <u>116.7</u>
75678	catheter, complete procedure . . . . .	((46.0)) <u>115.5</u>	75753	Angiography, coronary, unilateral selective injection, including left ventricular and supra-vascular angiogram and pressure recording; complete procedure . . . . .	((70.0)) <u>150.4</u>
75681	Angiography, carotid, cervical, bilateral; direct puncture, complete procedure . . . . .	((50.0)) <u>168.4</u>	75755	Angiography, coronary, bilateral selective injection, including left ventricular and supra-vascular angiogram and pressure recording; complete procedure . . . . .	((80.0)) <u>156.4</u>
75682	catheter, complete procedure . . . . .	((54.0)) <u>175.6</u>	75757	Angiography, internal mammary; complete procedure . . . . .	((40.0)) <u>92.6</u>
75686	Angiography, vertebral; direct puncture, complete procedure . . . . .	((40.0)) <u>115.5</u>	75764	Angiography, coronary bypass, unilateral selective injection; complete procedure . . . . .	((BR)) <u>69.8</u>
75687	catheter, complete procedure . . . . .	((46.0)) <u>115.5</u>	75767	Angiography, coronary bypass, multiple selective injection; complete procedure . . . . .	((BR)) <u>91.4</u>
	(75691 has been deleted)		75775	Angiography, coronary bypass, selective, each additional vessel studied after basic examination; complete procedure . . . . .	BR
75692	catheter, complete procedure . . . . .	((46.0)) <u>115.5</u>	75790	Angiography, arteriovenous shunt (e.g., dialysis patient) . . . . .	((BR)) <u>61.8</u>
	(75696 has been deleted)			<b>VEINS AND LYMPHATICS</b>	
75697	catheter, complete procedure . . . . .	((54.0)) <u>175.6</u>	75802	Lymphangiography, extremity only, unilateral; complete procedure . . . . .	((25.0)) <u>79.4</u>
75706	Angiography, spinal, selective; complete procedure . . . . .	((20.0)) <u>189.1</u>	75804	Lymphangiography, extremity only, bilateral; complete procedure . . . . .	((35.0)) <u>108.3</u>
75711	Angiography, extremity, unilateral; without serialography, complete procedure . . . . .	((30.0)) <u>62.5</u>	75806	Lymphangiography, pelvic/abdominal, unilateral; complete procedure . . . . .	((35.0)) <u>79.4</u>
75712	by serialography, complete procedure . . . . .	((32.0)) <u>78.2</u>	75808	Lymphangiography, pelvic/abdominal, bilateral; complete procedure . . . . .	((35.0)) <u>115.5</u>
75717	Angiography, extremity, bilateral; without serialography, complete procedure . . . . .	((32.0)) <u>92.5</u>	75811	Splenoportography; complete procedure . . . . .	((40.0)) <u>45.7</u>
75718	by serialography, complete procedure . . . . .	((34.0)) <u>113.1</u>	75821	Venography, extremity, unilateral; complete procedure . . . . .	((16.0)) <u>31.3</u>
75723	Angiography, renal, unilateral, selective, (including flush aortogram); complete procedure . . . . .	((40.0)) <u>115.5</u>	75823	Venography, extremity, bilateral; complete procedure . . . . .	((26.0)) <u>45.7</u>
75725	Angiography, renal, bilateral, selective, (including flush aortogram); complete procedure . . . . .	((60.0)) <u>146.8</u>	75826	Venography, caval, inferior, with serialography; complete procedure . . . . .	((32.0)) <u>56.5</u>
75727	Angiography, visceral; selective with or without flush aortogram, complete procedure . . . . .	((46.0)) <u>129.9</u>	75828	Venography, caval, superior, with serialography; complete procedure . . . . .	((35.0)) <u>57.7</u>
75728	supraselective, complete procedure . . . . .	((48.0)) <u>141.9</u>			
	(For selective angiography, additional visceral vessels studied after basic examination, see 75773)				
75732	Angiography, adrenal, unilateral, selective; complete procedure . . . . .	((46.0)) <u>108.3</u>			
75734	Angiography, adrenal, bilateral, selective; complete procedure . . . . .	((48.0)) <u>116.7</u>			

	Unit Value		Unit Value
75832 Venography, renal, unilateral, selective; complete procedure . . . . .	((40-0)) <u>74.6</u>	75967 Percutaneous transluminal angioplasty, any method, visceral artery; complete procedure . . . . .	BR
75834 Venography, renal, bilateral, selective; complete procedure . . . . .	((45-0)) <u>91.4</u>	75969 Percutaneous transluminal angioplasty, any method, each additional visceral artery; complete procedure . . . . .	BR <u>91.4</u>
75841 Venography, adrenal, unilateral, selective; complete procedure . . . . .	((30-0)) <u>79.4</u>	75971 Transcatheter biopsy; complete procedure . . . . .	((BR)) <u>91.4</u>
75843 Venography, adrenal, bilateral, selective; complete procedure . . . . .	((32-0)) <u>96.2</u>	75979 Percutaneous transluminal angioplasty, venous (e.g., subclavian stenosis); complete procedure . . . . .	BR
<del>((75846 Venography, azygos, selective, complete procedure . . . . .</del>	<del>30-0</del>	75981 Percutaneous transhepatic biliary drainage with contrast monitoring; complete procedure . . . . .	((BR)) <u>120.3</u>
<del>75847 nonselective, complete procedure . . . . .</del>	<del>28-0</del>	75983 Percutaneous placement of drainage catheter for combined internal and external biliary drainage or of a drainage stent for internal biliary drainage in patients with an inoperable mechanical biliary obstruction; complete procedure . . . . .	((BR)) <u>129.9</u>
<del>75851 Venography, intraosseous, complete procedure . . . . .</del>	<del>32-0</del>	75985 Change of percutaneous drainage catheter with contrast monitoring (i.e., biliary tract, urinary tract); complete procedure . . . . .	((BR)) <u>26.5</u>
75861 Venography, sinus or jugular, catheter; complete procedure . . . . .	((32-0)) <u>45.7</u>	75990 Radiologic guidance for percutaneous drainage of abscess or specimen collection (i.e., fluoroscopy, ultrasound, or computed tomography), with or without placement of indwelling catheter; complete procedure . . . . .	((BR)) <u>84.2</u>
75871 Venography, superior sagittal sinus; complete procedure, including direct puncture . . . . .	((32-0)) <u>65.0</u>		
75873 Venography, epidural; complete procedure . . . . .	((BR)) <u>67.4</u>		
75881 Venography, orbital; complete procedure . . . . .	((36-0)) <u>45.7</u>		
75886 Percutaneous transhepatic portography with hemodynamic evaluation; complete procedure . . . . .	((36-0)) <u>103.4</u>		
75888 Percutaneous transhepatic portography without hemodynamic evaluation; complete procedure . . . . .	((34-0)) <u>103.4</u>		
75890 Hepatic venography wedged or free, with hemodynamic evaluation; complete procedure . . . . .	((38-0)) <u>79.4</u>		
75892 Hepatic venography, wedged or free, without hemodynamic evaluation; complete procedure . . . . .	((34-0)) <u>72.2</u>		
75893 Venous sampling through catheter without angiography (e.g., for parathyroid hormone, renin) . . . . .	((5-0)) <u>60.1</u>		
<b>TRANSCATHETER THERAPY AND BIOPSY</b>			
75895 Transcatheter therapy, embolization (e.g., particulate or liquid), including angiography; complete procedure . . . . .	((40-0)) <u>144.3</u>		
75897 Transcatheter therapy, infusion, including angiography; complete procedure . . . . .	((42-0)) <u>144.3</u>		
75898 Angiogram through existing catheter for follow-up study for transcatheter therapy, embolization or infusion . . . . .	((10-0)) <u>27.7</u>		
75941 Percutaneous placement of IVC filter; complete procedure . . . . .	((BR)) <u>127.5</u>		
75951 Transcatheter intravascular occlusion (e.g., balloon), temporary, including angiography; complete procedure . . . . .	((BR)) <u>144.3</u>		
75956 Transcatheter intravascular occlusion (e.g., balloon, coil or methacrylate), permanent, including angiography; complete procedure . . . . .	((BR)) <u>144.3</u>		
75961 Transcatheter retrieval, percutaneous, of fractured venous or arterial catheter . . . . .	((BR)) <u>89.0</u>		
75963 Percutaneous transluminal angioplasty, any method, peripheral artery; complete procedure . . . . .	BR		
75965 Percutaneous transluminal angioplasty, any method, each additional peripheral artery; complete procedure . . . . .	BR		
		(75990 is neither organ nor area specific. For drainage of abscess performed without radiology or fluoroscopy, see under specific anatomic site.)	
		<b>AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)</b>	
		<b>WAC 296-23A-260 MISCELLANEOUS.</b>	
			Unit Value
		(For arthrography of shoulder, see 73041, elbow, see 73086, wrist, see 73116, hip, see 73526, knee, see 73581, ankle, see 73616)	
		76000 Fluoroscopy (separate procedure) up to one hour physician time, other than 71023 or 71034 . . . . .	((3-0)) <u>12.0</u>
		76001 Fluoroscopy, physician time more than one hour, assisting a nonradiologic physician (e.g., nephrostolithotomy, ERCP, bronchoscopy, transbronchial biopsy) . . . . .	((BR)) <u>27.4</u>
		76003 Fluoroscopic localization for needle biopsy or fine needle aspiration . . . . .	((BR)) <u>16.6</u>
		76020 Bone age studies . . . . .	((6-0)) <u>7.7</u>
		76040 Bone length studies (orthoroentgenogram, scanogram) . . . . .	((10-0)) <u>8.4</u>
		76061 Radiologic examination, osseous survey; limited (e.g., for metastases) . . . . .	((15-2)) <u>41.6</u>
		76062 complete (axial and appendicular skeleton) . . . . .	((BR)) <u>25.3</u>
		76065 Radiologic examination; osseous survey, infant . . . . .	((13-2)) <u>24.1</u>
		76066 Joint survey, single view, one or more joints (specify) . . . . .	((BR)) <u>7.7</u>
		76070 Computerized tomography, bone density study . . . . .	((BR)) <u>26.2</u>



	Unit Value
76081 Radiologic examination, fistula or sinus tract study; complete procedure .....	((+2-0)) <u>16.8</u>
76087 Mammary ductogram or galactogram, single duct; complete procedure .....	((+5-0)) <u>15.6</u>
76089 Mammary ductogram or galactogram, multiple ducts; complete procedure .....	((26-5)) <u>40.7</u>
76090 Mammography, unilateral .....	((8-8)) <u>10.1</u>
76091 bilateral .....	((+3-2)) <u>15.4</u>
((For xeromammography, list 76150 in addition to code for mammography))	
76092 Screening mammography, bilateral (two view film study of each breast) .....	<u>BR</u>
76096 Localization of breast nodule or calcification; before operation, with marker and confirmation of its position with appropriate imaging (e.g., ultrasound or radiologic) .....	((+4-6)) <u>13.2</u>
76097 each additional localization .....	((7-3)) <u>14.9</u>
76098 Radiologic examination, breast surgical specimen .....	((BR)) <u>4.8</u>
76100 Radiologic examination, single plane body section, (e.g., tomography), other than with urography ...	((+3-2)) <u>16.8</u>
76101 Radiologic examination, complex motion (i.e., hypercycloidal) body section (e.g., mastoid polytomography), other than with urography; unilateral .....	((+9-3)) <u>16.8</u>
76102 bilateral .....	((35-0)) <u>24.1</u>
(For nephrotomography, see 74415)	
76120 Cineradiography, except where specifically included .....	((+3-2)) <u>10.8</u>
76125 Cineradiography to complement routine examination .....	((7-0)) <u>9.6</u>
76150 Xeroradiography .....	((6-0)) <u>12.0</u>
76350 Subtraction in conjunction with contrast studies ..	<u>BR</u>
76355 Computerized tomography guidance for stereotactic localization .....	((BR)) <u>74.6</u>
76361 Computerized tomography guidance for needle biopsy; complete procedure .....	((BR)) <u>98.6</u>
76366 Computerized tomography guidance for cyst aspiration; complete procedure .....	((BR)) <u>98.6</u>
76370 Computerized tomography guidance for placement of radiation therapy fields .....	((BR)) <u>33.2</u>
76375 Computerized tomography, coronal, sagittal, multiplanar, oblique and/or 3 dimensional reconstruction .....	((23-5)) <u>29.4</u>
76400 Magnetic resonance (e.g., proton) imaging, bone marrow blood supply .....	((+20-0)) <u>117.9</u>
76499 Unlisted diagnostic radiologic procedure .....	<u>BR</u>

**AMENDATORY SECTION** (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

**WAC 296-23A-262 DIAGNOSTIC ULTRASOUND.**

- Notes
- A-mode: Implies a one-dimensional ultrasonic measurement procedure
- M-mode: Implies a one-dimensional ultrasonic measurement procedure with movement of the trace to record amplitude and velocity of moving echo-producing structures
- B-scan: Implies a two-dimensional ultrasonic scanning procedure with a two-dimensional display
- Real-time scan: Implies a two-dimensional ultrasonic scanning procedure with display of both two-dimensional structure and motion with time

Unit  
Value

**HEAD AND NECK**

76506 Echoencephalography, B-scan and/or real time with image documentation (gray scale) (for determination of ventricular size, delineation of cerebral contents and detection of fluid masses or other intracranial abnormalities), including A-mode encephalography as secondary component where indicated .....	((BR)) <u>22.9</u>
76511 Ophthalmic ultrasound, echography; A-mode with amplitude quantitation .....	((22-9)) <u>25.3</u>
76512 contact B-scan .....	((22-9)) <u>25.3</u>
76513 immersion (water bath) B-scan .....	((22-9)) <u>25.3</u>
76516 Ophthalmic biometry by ultrasound echography, A-mode .....	((+5-4)) <u>24.1</u>
76519 with intraocular lens power calculation .....	((BR)) <u>24.1</u>
76529 Ophthalmic ultrasound foreign body localization ..	((BR)) <u>28.9</u>
76536 Echography, soft tissues of head and neck (e.g., thyroid, parathyroid, parotid), B-scan and/or real time with image documentation .....	((BR)) <u>14.4</u>

**HEART**

76604 Echography, chest, B-scan (includes mediastinum) and/or real time with image documentation .....	((+1-4)) <u>20.4</u>
<del>((76620 Echocardiography, M-mode, complete .....</del>	<del>15.4</del>
<del>76625 limited, (e.g., follow-up or limited study) .....</del>	<del>7.7</del>
<del>76627 Echocardiography, real time with image documentation (2D); complete .....</del>	<del>11.4</del>
<del>76628 limited .....</del>	<del>9.7</del>
<del>76629 Echocardiography, M-mode real time with image documentation (2D) .....</del>	<del>BR</del>
<del>76632 Doppler echocardiography .....</del>	<del>BR))</del>
(Procedure 76632 is often performed in combination with M-mode or 2-dimensional echocardiography)	
76645 Echography, breast(s) (unilateral or bilateral), B-scan and/or real time with image documentation ..	((+9-2)) <u>29.1</u>

	Unit Value		Unit Value
<b>ABDOMEN AND RETROPERITONEUM</b>			
76700 Echography, abdominal, B-scan and/or real time with image documentation; complete study . . . . .	((22.9)) 28.9	76939 Ultrasonic guidance for cyst (any location) or renal pelvis aspiration; complete procedure . . . . .	((2.0)) 50.5
76705 limited (e.g., single organ, quadrant, follow-up) . . . . .	((15.4)) 24.1	76943 Ultrasonic guidance for needle biopsy; complete procedure . . . . .	((6.0)) 50.5
76770 Echography, retroperitoneal (e.g., renal, aorta, nodes) B-scan and/or real time with image documentation; complete . . . . .	((22.9)) 28.9	(76945 has been deleted. See 75990)	
76775 limited . . . . .	((19.2)) 24.1	76947 Ultrasonic guidance for amniocentesis; complete procedure . . . . .	((6.0)) 38.5
76778 Echography of transplanted kidney, B-scan and/or real time with image documentation, with or without duplex Doppler studies . . . . .	<u>BR</u>	76949 Ultrasonic guidance for aspiration of ova; complete procedure . . . . .	((BR)) 35.8
<b>SPINAL CANAL</b>			
76800 Echography, spinal canal and contents . . . . .	<u>BR</u>	76950 Echography for placement of radiation therapy fields, B-scan . . . . .	((17.1)) 28.9
<b>PELVIS</b>			
76805 Echography, pregnant uterus, B-scan and/or real time with image documentation; complete fetal and maternal evaluation . . . . .	((21.2)) 24.1	76960 Ultrasonic guidance for placement of radiation therapy fields, except for B-scan echography . . . . .	((14.3)) 19.2
76815 limited (fetal growth rate, heart beat, anomalies, placental location) (fetal position, or emergency in the delivery room) . . . . .	((9.7)) 14.4	<b>MISCELLANEOUS</b>	
76816 follow-up or repeat . . . . .	((BR)) 15.6	76970 Ultrasound study follow-up (specify) . . . . .	((10.0)) <u>BR</u>
76818 Fetal biophysical profile . . . . .	((BR)) 21.7	76986 Echography, intraoperative . . . . .	((BR)) 35.8
76825 Echocardiography, fetal ((heart in utero)), real time with image documentation (2D) with or without M-mode recording . . . . .	((BR)) 24.1	((76991) <del>Intraluminal ultrasound study (e.g., transrectal, transvaginal)</del> . . . . .	
76830 Echography, transvaginal . . . . .	<u>BR</u>	76999 Unlisted ultrasonic procedure . . . . .	<u>BR</u>
76855 Echography, pelvic area (Doppler) . . . . .	((11.4)) 12.0	<b>AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)</b>	
76856 Echography, pelvic (nonobstetric), B-scan and/or real time with image documentation; complete . . . . .	((BR)) 21.7	WAC 296-23A-264 THERAPEUTIC RADIOLOGY. Listings of therapeutic radiology provide for teletherapy and brachytherapy to include initial consultation, clinical treatment planning, simulation, medical radiation physics, dosimetry, treatment devices, special services, and clinical treatment management procedures. They include normal follow-up care during course of treatment and for three months following its completion.	
76857 limited or follow-up (e.g., for follicles) . . . . .	((BR)) 12.3	77299 Unlisted procedure, therapeutic radiology clinical treatment planning	
<b>GENITALIA</b>			
76870 Echography, scrotum and contents . . . . .	((BR)) 25.3	77399 Unlisted procedure, medical radiation physics, dosimetry and treatment devices	
76872 Echography, prostate, transrectal . . . . .	<u>BR</u>	77499 Unlisted procedure, therapeutic radiology clinical treatment management	
<b>EXTREMITIES</b>			
76880 Echography, extremity, nonvascular B-scan and/or real time with image documentation . . . . .	((BR)) 19.2	77799 Unlisted procedure, clinical brachytherapy	
<b>VASCULAR STUDIES</b>			
76925 (( <del>fmaging</del> )) Echography, peripheral, vascular system (e.g., B-scan, Doppler or real-time scan) . . . . .	((BR)) 22.9	(For treatment by injectable or ingestible isotopes, see subsection NUCLEAR MEDICINE)	
76926 (( <del>fmaging</del> )) Echography, head and trunk vascular system (e.g., Duplex Doppler) . . . . .	((BR)) 21.4	<b>CONSULTATION: CLINICAL MANAGEMENT</b>	
Preliminary consultation, evaluation of patient prior to decision to treat, or full medical care (in addition to treatment management) when provided by the therapeutic radiologist may be identified by the appropriate procedure codes from medicine or surgery sections.			
<b>ULTRASONIC GUIDANCE PROCEDURES</b>			
76931 Ultrasonic guidance for pericardiocentesis; complete procedure . . . . .	((BR)) 50.5	<b>CLINICAL TREATMENT PLANNING (EXTERNAL AND INTERNAL SOURCES)</b>	
76933 Ultrasonic guidance for endomyocardial biopsy; complete procedure . . . . .	<u>BR</u>	The clinical treatment planning process is a complex service including interpretation of special testing, tumor localization, treatment volume determination, treatment time/dosage determination, choice of treatment modality, determination of number and size of treatment ports,	
76935 Ultrasonic guidance for thoracentesis; complete procedure . . . . .	((5.0)) 34.9		

selection of appropriate treatment devices, and other procedures.

DEFINITIONS:

Simple—planning requiring single treatment area of interest encompassed in a single port or simple parallel opposed ports with simple blocking.

Intermediate—planning requiring three or more converging ports, two separate treatment areas, special blocking, or special time dose constraints.

Complex—planning requiring highly complex blocking, tangential ports, special wedges or compensators, three or more separate treatment areas, rotational or special beam considerations.

Bill procedure codes 77261-77299 only if a technical component has been performed.

	Unit Value
77261 Therapeutic radiology treatment planning; simple	BR
77262 intermediate	BR
77263 complex	BR
77280 Therapeutic radiology simulation-aided field setting (requiring simulator, with or without fluoroscopy); simple	((BR)) <u>15.6</u>
77285 intermediate	((BR)) <u>40.9</u>
77290 complex	((BR)) <u>52.9</u>
77299 Unlisted procedure, therapeutic radiology clinical treatment planning	BR

MEDICAL RADIATION PHYSICS, DOSIMETRY, TREATMENT DEVICES AND SPECIAL SERVICES

77300 Basic radiation dosimetry calculation, central axis depth dose, TDF, NSD, gap calculation off axis factor, tissue inhomogeneity factors, as required during course of treatment	((4-0)) <u>9.6</u>
77305 Teletherapy, isodose plan (whether hand or computer calculated); simple (one or two parallel opposed unmodified ports directed to a single area of interest)	((3-0)) <u>10.1</u>
77310 intermediate (three or more treatment ports directed to a single area of interest)	((4-0)) <u>20.4</u>
77315 complex (mantle or inverted Y, tangential ports, the use of wedges, compensators, complex rotational blocking or special beam considerations)	((6-0)) <u>32.0</u>
77321 Special teletherapy port plan, particles, hemi-body, total body	((BR)) <u>37.3</u>
77326 Brachytherapy isodose calculation; simple (calculation made from single plane, one to four source/ribbon application)	((BR)) <u>25.3</u>
77327 intermediate (multiplane dosage calculations, application involving five to ten sources/ribbons)	((BR)) <u>34.4</u>
77328 complex (multiplane isodose plan, volume implant calculations, over ten sources/ribbons used, special spatial reconstruction)	((BR)) <u>43.8</u>
77331 Special dosimetry (e.g., TLD, microdosimetry) (specify)	((BR)) <u>14.9</u>

	Unit Value
77332 Treatment devices, design and construction; simple (simple block, simple bolus)	((BR)) <u>15.6</u>
77333 intermediate (multiple blocks, stents, bite blocks, special bolus)	((BR)) <u>22.9</u>
77334 complex (irregular blocks, special shields, compensators, wedges, molds or casts)	BR
77336 Continuing medical radiation physics consultation in support of therapeutic radiologist, including continuing quality assurance	((BR)) <u>18.3</u> BR
77370 Special medical radiation physics consultation	BR
77399 Unlisted procedure, medical radiation physics, dosimetry and treatment devices	BR

CLINICAL TREATMENT MANAGEMENT

Except where specified, assumes a treatment on a daily basis (4 or 5 fractions per week) with the use of megavoltage photon or high energy particle sources. Daily and weekly clinical treatment management are mutually exclusive for the same dates.

DEFINITIONS: Simple—single treatment area, single port or parallel opposed ports, simple blocks.

Intermediate—two separate treatment areas, three or more ports on a single treatment area, use of special blocks.

Complex—three or more separate treatment areas, highly complex blocking (mantle, inverted Y, tangential ports, wedges, compensators, or other special beam considerations).

Bill procedure codes 77400-77499 only if a technical component has been performed.

	Unit Value
77400 Daily megavoltage treatment management; simple	((2-0)) <u>13.2</u>
77405 intermediate	((3-0)) <u>16.8</u>
77410 complex	((4-0)) <u>19.7</u>
77415 Therapeutic radiology treatment port film interpretation and verification, per treatment course	((3-0)) <u>9.6</u>
77420 Weekly megavoltage treatment management; simple	((4-0)) <u>60.1</u>
77425 intermediate	((5-0)) <u>73.4</u>
77430 complex	((6-0)) <u>101.0</u>
77465 Daily kilovoltage treatment management	((2-0)) <u>10.8</u>
77470 Special treatment procedure (e.g., total body irradiation, hemibody irradiation, per oral, vaginal cone irradiation)	BR
(77470 assumes that the procedure be performed one or more times during the course of therapy, in addition to daily or weekly patient management)	
77499 Unlisted procedure, therapeutic radiology clinical treatment management	BR

**HYPERTHERMIA**

Hyperthermia treatments as listed in this section include external (superficial and deep) and interstitial. Radiation therapy when given concurrently is listed separately.

Hyperthermia is used only as an adjunct to radiation therapy or chemotherapy. It may be induced by a variety of sources, e.g., microwave, ultrasound, low energy radio-frequency conduction, or by probes.

The listed treatments include management during the course of therapy and follow-up care for three months after completion. Preliminary consultation is not included (see WAC 296-21-030). Physics planning and interstitial insertion of temperature sensors, and use of external or interstitial heat generating sources are included.

The following descriptors are included in the treatment schedule:

	Unit Value
77600 Hyperthermia, externally generated; superficial (i.e., heating to a depth of 4 cm or less) . . . . .	((BR)) <u>42.3</u>
77605 deep (i.e., heating to depths greater than 4 cm)	((BR)) <u>56.3</u>
77610 Hyperthermia generated by interstitial probe(s); 5 or fewer interstitial applicators . . . . .	((BR)) <u>42.3</u>
77615 more than 5 interstitial applicators . . . . .	((BR)) <u>56.3</u>

**CLINICAL INTRACAVITARY HYPERTHERMIA**

77620 Hyperthermia generated by intracavitary probe(s) . . . . .	((BR)) <u>42.3</u>
--	-----------------------

**CLINICAL BRACHYTHERAPY**

Clinical brachytherapy requires the use of either natural or man-made radioelements applied into or around a treatment field of interest.

**DEFINITIONS:** (Sources refer to intracavitary placement or permanent interstitial placement; ribbons refer to temporary interstitial placement)

Simple—application with one to four sources/ribbons

Intermediate—application with five to ten sources/ribbons

Complex—application with greater than ten sources/ribbons

	Unit Value
77750 Infusion or instillation of radioelement solution . . . . .	((+2.5)) <u>BR</u>
77761 Intracavitary radioelement application; simple . . . . .	((BR)) <u>65.0</u>
77762 intermediate . . . . .	((BR)) <u>93.8</u>
77763 complex . . . . .	<u>BR</u>
77776 Interstitial radioelement application; simple . . . . .	<u>BR</u>
77777 intermediate . . . . .	((BR)) <u>123.7</u>
77778 complex . . . . .	<u>BR</u>

77789 Surface application of radioelement . . . . .	((24.75)) <u>17.1</u>
77790 Supervision, handling, loading of radioelement . . . . .	((33.5)) <u>17.1</u>
77799 Unlisted procedure, clinical brachytherapy . . . . .	<u>BR</u>

**AMENDATORY SECTION** (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

**WAC 296-23A-266 NUCLEAR MEDICINE.**

Notes: Listed procedures may be performed independently or in the course of overall medical care.

Radioimmunoassay tests are found in the clinical pathology section (codes 82000-84999). These codes can be appropriately used by any specialist performing such tests in a laboratory licensed and/or certified for radioimmunoassays. The reporting of these tests is not confined to clinical pathology laboratories alone.

**DIAGNOSTIC**

	Unit Value
<b>ENDOCRINE SYSTEM</b>	
78000 Thyroid uptake, single determination . . . . .	((6.0)) <u>8.9</u>
78001 multiple determinations . . . . .	((8.0)) <u>11.5</u>
78003 stimulation suppression or discharge (not including initial uptake studies) . . . . .	((9.0)) <u>16.8</u>
78006 Thyroid imaging, with uptake; single determination . . . . .	((16.0)) <u>25.3</u>
78007 multiple determinations . . . . .	((18.0)) <u>27.7</u>
78010 Thyroid imaging; only . . . . .	((10.0)) <u>14.9</u>
78011 with vascular flow . . . . .	((BR)) <u>17.8</u>
78015 Thyroid carcinoma metastases imaging; limited area (e.g., neck and chest only) . . . . .	((20.0)) <u>23.1</u>
78016 with additional studies (e.g., urinary recovery) . . . . .	((25.0)) <u>26.9</u>
78017 multiple areas . . . . .	((BR)) <u>26.0</u>
78018 whole body . . . . .	((BR)) <u>29.6</u>

(For triiodothyronine (true TT-3), RIA, see 84480)

(For calcitonin, RIA, see 82308)

(For triiodothyronine, fee (FT-3), RIA (unbound T-3 only), see 84481)

(For T-4 thyroxine, CPB or resin uptake, see 84435)

(For TT-4 thyroxine, RIA, see 84436)

(For T-4 thyroxine, neonatal, see 84437)

(For FT-4 thyroxine, fee, RIA (unbound T-4 only), see 84439)

(For parathormone (parathyroid hormone), RIA, see 83970)

78070 Parathyroid imaging . . . . .	<u>BR</u>
78075 Adrenal cortical imaging . . . . .	((BR)) <u>42.1</u>

(For adrenal cortex antibodies, RIA, see 86681)

	Unit Value		Unit Value
(For cortisol, RIA, plasma, see 82533)		78110 Blood or plasma volume, radionuclide-dilution technique; (separate procedure) single sampling . . .	(( <del>6-0</del> )) <u>12.8</u>
(For cortisol, RIA, urine, see 82534)		78111 multiple samplings . . . . .	<u>BR</u>
(For aldosterone, double isotope technique, see 82087)		(For dye method, see 84605, 84610)	
(For aldosterone, RIA, blood, see 82088)		78120 Red cell volume determination (separate procedure) single sampling . . . . .	(( <del>+2-0</del> )) <u>18.0</u>
(For aldosterone, RIA, urine, see 82089)		78121 multiple samplings . . . . .	(( <del>BR</del> )) <u>25.3</u>
(For 17-ketosteroids, RIA, see 83588)		78122 Whole blood volume determination including separate measurement of plasma volume and red cell volume (radionuclide volume-dilution technique) . . . . .	(( <del>8-0</del> )) <u>38.0</u>
(For 17-OH ketosteroids, RIA, see 83599)		(For dye method, see 84610)	
(For 17-hydroxycorticosteroids, RIA, see 83491)		78130 Red cell survival study . . . . .	(( <del>20-0</del> )) <u>32.5</u>
(For insulin, RIA, see 83525)		78135 with splenic and/or hepatic sequestration . . . . .	(( <del>30-0</del> )) <u>54.1</u>
(For insulin antibodies, RIA, see 86337)		78140 Red cell splenic and/or hepatic sequestration . . . . .	(( <del>20-0</del> )) <u>36.1</u>
(For insulin factor antibodies, RIA, see 86338)		78160 Plasma radioiron disappearance (turnover) rate . . . . .	(( <del>+6-0</del> )) <u>34.9</u>
(For proinsulin, RIA, see 84206)		78162 Radioiron oral absorption . . . . .	<u>BR</u>
(For glucagon, RIA, see 82943)		78170 Radioiron red cell utilization . . . . .	(( <del>24-0</del> )) <u>32.5</u>
(For adrenocorticotrophic hormone (ACTH), RIA, see 82024)		78172 Chelatable iron for estimation of total body iron . . . . .	(( <del>BR</del> )) <u>18.3</u>
(For human growth hormone (HGH), (somatotropin), RIA, see 83003)		(78180 has been deleted. To report radioiron body distribution and storage pools, use 78199)	
(For human growth antibody, RIA, see 86277)		(For hemosiderin, RIA, see 83071)	
(For thyroglobulin antibody, RIA, see 86800)		(For intrinsic factor antibodies, RIA, see 86340)	
(For thyroid microsomal antibody, RIA, see 86376)		(For cyanocobalamin (vitamin B-12), RIA, see 82607)	
(For thyroid stimulating hormone (TSH), RIA, see 84443)		(For folic acid (folate) serum, RIA, see 82746)	
(For thyrotropin releasing factor, RIA, see 84444)		(For human hepatitis antigen, hepatitis associated agent (Australian antigen) (HAA), RIA, see 86287)	
(For plus long-acting thyroid stimulator (LATS), see 84445)		(For hepatitis A antibody (HAAb), RIA, see 86296)	
(For follicle stimulating hormone (FSH component of pituitary gonadotropin), RIA, see 83001)		(For hepatitis A virus antibody (HAVAb), see 86297)	
(For luteinizing hormone (LH component of pituitary gonadotropin), (ICSH), RIA, see 83002)		(For hepatitis B core antigen (HB <sub>c</sub> Ag), RIA, see 86288)	
(For luteinizing releasing factor (LRH), RIA, see 83727)		(For hepatitis B core antibody (HB <sub>c</sub> Ab), RIA, see 86289)	
(For prolactin level (mammotropin), RIA, see 84146)		(For hepatitis B surface antigen (HB <sub>s</sub> Ab), RIA, see 86287)	
(For oxytocin level, (oxytocinase), RIA, see 83949)		(For hepatitis B surface antibody (HB <sub>s</sub> Ab), RIA, see 86291)	
(For vasopressin level (antidiuretic hormone), RIA, see 84588)		(For hepatitis Be antigen (HB <sub>e</sub> Ag), RIA, see 86293)	
(For estradiol, RIA, see 82670)		(For hepatitis Be antibody (HB <sub>e</sub> Ab), RIA, see 86295)	
(For progesterone, RIA, see 84144)		78185 Spleen imaging only . . . . .	(( <del>20-0</del> )) <u>24.1</u>
(For testosterone, blood, RIA, see 84403)		(If combined with liver study, use procedures 78215 and 78216)	
(For testosterone, urine, RIA, see 84405)		78186 with vascular flow . . . . .	(( <del>25-0</del> )) <u>26.5</u>
(For etiocholanolone, RIA, see 82696)		78191 Platelet survival . . . . .	(( <del>BR</del> )) <u>59.4</u>
78099 Unlisted endocrine procedure, diagnostic nuclear medicine . . . . .	BR	78192 White cell localization; limited area scanning . . . . .	(( <del>BR</del> )) <u>34.4</u>
(For chemical analysis, RIA tests, see Chemistry and Toxicology section)			
<b>HEMATOPOIETIC, RETICULOENDOTHELIAL AND LYMPHATIC SYSTEM</b>			
78102 Bone marrow imaging; limited area . . . . .	BR		
78103 multiple areas . . . . .	BR		
78104 whole body . . . . .	(( <del>BR</del> )) <u>18.8</u>		

	Unit Value		Unit Value
78193 whole body .....	((BR)) 79.9		
78195 Lymphatics and lymph glands imaging .....	((BR)) 32.5	(For chemical analysis, RIA tests, see Chemistry and Toxicology section)	
78199 Unlisted hematopoietic, reticuloendothelial and lymphatic procedure, diagnostic nuclear medicine (For chemical analysis, RIA tests, see Chemistry and Toxicology section)	BR		
<b>GASTROINTESTINAL SYSTEM</b>		<b>MUSCULOSKELETAL SYSTEM</b>	
78201 Liver imaging; static only .....	((20-0)) 30.8	78300 Bone imaging, limited area (e.g., skull, pelvis) ...	((25-0)) 33.7
78202 with vascular flow .....	((25-0)) 39.7	78305 multiple areas .....	((40-0)) 40.9
78205 Liver imaging (SPECT) .....	((BR)) 50.8	78306 whole body .....	((48-2)) 49.3
(For spleen imaging only, use 78185 and 78186)		78310 vascular flow only .....	((BR)) 39.7
78215 Liver and spleen imaging; static only .....	((25-0)) 28.9	78315 by three phase technique .....	((BR)) 45.2
78216 with vascular flow .....	((30-0)) 32.5	78320 tomographic (SPECT) .....	((BR)) 55.1
78220 Liver function study with hepatobiliary agents; with serial images .....	((20-0)) 21.7	78350 Bone density (bone mineral content) study; single photon absorptionmetry .....	((BR)) 8.2
78223 Hepatobiliary ductal system imaging, including gallbladder .....	((BR)) 29.6	78351 dual photon absorptionmetry .....	((BR)) 15.6
78225 Liver-lung imaging (e.g., subphrenic abscess) ...	((BR)) 28.9	78380 Joint imaging; limited area .....	((BR)) 32.5
78230 Salivary gland imaging .....	((14-0)) 22.9	78381 multiple areas .....	((BR)) 44.5
78231 with serial images .....	((16-0)) 28.4	78399 Unlisted musculoskeletal procedure, diagnostic nuclear medicine .....	BR
78232 Salivary gland function study .....	((BR)) 28.4	<b>CARDIOVASCULAR SYSTEM</b>	
78258 Esophageal motility .....	((BR)) 30.1	(78401-78412 have been deleted. To report, see 78471-78489)	
78261 Gastric mucosa imaging .....	((BR)) 24.1	78414 Determination of ventricular ejection fraction with probe technique .....	((BR)) 60.1
78262 Gastroesophageal reflux study .....	((BR)) 24.1	78415 Cardiac blood pool imaging, functional imaging (e.g., phase and amplitude analysis) .....	((BR)) 71.0
78264 Gastric emptying study .....	((BR)) 24.1	(78418-78424 have been deleted. See 78460-78469)	
78270 Vitamin B-12 absorption studies (e.g., Schilling test); without intrinsic factor (e.g., Schilling test) .....	((10-0)) 15.6	78425 Cardiac regurgitant index .....	((BR)) 10.8
78271 with intrinsic factor (e.g., Schilling test) .....	20.0	78428 Cardiac shunt detection .....	((BR)) 39.7
78272 Vitamin B-12 absorption studies combined, with and without intrinsic factor .....	((25-0)) 24.1	78435 Cardiac flow imaging (i.e., angiocardiology) ..	((BR)) 41.4
78276 Gastrointestinal aspirate blood loss localization ..	((BR)) 28.9	78445 Vascular flow imaging (i.e., angiography, venography) .....	((BR)) 18.0
78278 Acute gastrointestinal blood loss imaging .....	((BR)) 28.9	78455 Venous thrombosis study (e.g., radioactive fibrinogen) .....	((BR)) 43.3
78280 Gastrointestinal blood loss study .....	((16-0)) 28.9	78457 Venous thrombosis imaging (e.g., venogram); unilateral .....	((BR)) 16.8
78282 Gastrointestinal protein loss .....	((12-0)) 18.0	78458 bilateral .....	((BR)) 30.1
(For gastrin, RIA, see 82941)		78460 Myocardial imaging; resting only, quantitative, or qualitative .....	((BR)) 28.1
(For intrinsic factor level, see 83528)		78461 exercise and redistribution, qualitative or quantitative, with or without pharmacological intervention .....	((BR)) 72.2
(For carcinoembryonic antigen level (CEA), RIA, see 86151)		78462 quantitative, at rest only .....	BR
78290 Bowel imaging (e.g., ectopic gastric mucosa, Meckel's localization, volvulus) .....	((20-0)) 24.1	78463 quantitative, at rest plus exercise and/or pharmacological intervention .....	BR))
78291 Peritoneal-venous shunt patency test (e.g., for LeVein shunt) .....	((BR)) 33.2		
78299 Unlisted gastrointestinal procedure, diagnostic nuclear medicine .....	BR		

	Unit Value		Unit Value	
78464	tomographic (SPECT), at rest only, qualitative or quantitative . . . . .	((BR)) <u>64.0</u>	78581 gaseous . . . . .	((BR)) <u>28.9</u>
78465	tomographic (SPECT) with exercise and redistribution, qualitative or quantitative, with or without pharmacological intervention . . . . .	((BR)) <u>101.8</u>	78582 gaseous, with ventilation, rebreathing and washout . . . . .	((BR)) <u>28.9</u>
78466	Myocardial imaging, infarct avid, at rest; qualitative . . . . .	((BR)) <u>27.7</u>	78584 Pulmonary perfusion imaging, particulate, with ventilation; single breath . . . . .	((BR)) <u>51.7</u>
78467	quantitative . . . . .	((BR)) <u>32.0</u>	78585 rebreathing and washout, with or without single breath . . . . .	((+6)) <u>51.7</u>
78468	with first pass technique . . . . .	((BR)) <u>36.3</u>	78586 Pulmonary ventilation imaging, aerosol; single projection . . . . .	((BR)) <u>28.9</u>
78469	with emission computed tomography . . . . .	((BR)) <u>48.8</u>	78587 multiple projections (e.g., anterior, posterior, lateral views) . . . . .	((BR)) <u>28.9</u>
78470	Cardiac output . . . . .	((BR)) <u>36.6</u>	78591 Pulmonary ventilation imaging, gaseous, single breath, single projection . . . . .	((BR)) <u>28.9</u>
78471	Cardiac blood pool imaging, gated equilibrium, at rest, wall motion study plus ejection fraction . . . . .	((BR)) <u>49.1</u>	78593 Pulmonary ventilation imaging, gaseous, with rebreathing and washout with or without single breath; single projection . . . . .	((22-0)) <u>28.9</u>
78472	Cardiac blood pool imaging, gated equilibrium, at rest, wall motion study plus regional ejection fraction . . . . .	((BR)) <u>51.5</u>	78594 multiple projections (e.g., anterior, posterior, lateral views) . . . . .	((BR)) <u>28.9</u>
78474	quantitative wall motion study plus ejection fraction plus ventricular volume determination . . . . .	((BR)) <u>60.1</u>	78599 Unlisted respiratory procedure, diagnostic nuclear medicine . . . . .	BR
78475	quantitative wall motion study, with exercise and/or pharmacological intervention . . . . .	((BR)) <u>81.8</u>	<b>NERVOUS SYSTEM</b>	
78476	quantitative wall motion study plus ejection fraction, with exercise and/or pharmacological intervention . . . . .	((BR)) <u>84.9</u>	78600 Brain imaging, limited procedure . . . . .	((26-0)) <u>24.1</u>
78477	quantitative wall motion study plus ejection fraction plus ventricular volume determination, with exercise and/or pharmacological intervention . . . . .	((BR)) <u>92.1</u> BR	78601 with vascular flow . . . . .	((31-0)) <u>30.1</u>
78479	serial studies, any combination . . . . .		78605 Brain imaging, complete study . . . . .	((30-0)) <u>32.5</u>
78481	Cardiac blood pool imaging, first pass technique, at rest; wall motion study with ejection fraction . . . . .	((BR)) <u>49.6</u>	78606 with vascular flow . . . . .	((35-0)) <u>36.1</u>
78484	quantitative wall motion study plus ejection fraction plus ventricular volume determination . . . . .	((BR)) <u>55.8</u>	78607 tomographic (ECT) . . . . .	((BR)) <u>62.3</u>
78485	quantitative wall motion study, with exercise and/or pharmacological intervention . . . . .	((BR)) <u>81.8</u>	78610 Brain imaging, vascular flow only . . . . .	((10-0)) <u>17.3</u>
78486	quantitative wall motion study plus ejection fraction, with exercise and/or pharmacological intervention . . . . .	((BR)) <u>84.9</u>	78615 Cerebral blood flow . . . . .	((BR)) <u>32.5</u>
78487	quantitative wall motion study plus ejection fraction plus ventricular volume determination, with exercise and/or pharmacological intervention . . . . .	((BR)) <u>92.1</u> BR	78630 Cerebrospinal fluid flow, imaging (not including introduction of material); cisternography . . . . .	((35-0)) <u>37.3</u>
78489	serial studies, any combination . . . . . (For digoxin, RIA, see 82643) (For digitoxin (digitalis), RIA, see 82640) (For cerebral blood flow study, see 78615)		78635 ventriculography . . . . .	((35-0)) <u>20.4</u>
78499	Unlisted cardiovascular procedure, diagnostic nuclear medicine . . . . . (For chemical analysis, RIA tests, see Chemistry and Toxicology section)	BR	(78640 has been deleted. Use 78699)	
<b>RESPIRATORY SYSTEM</b>			78645 shunt evaluation . . . . .	((35-0)) <u>18.0</u>
78580	Pulmonary perfusion imaging; particulate . . . . .	((26-0)) <u>28.9</u>	78650 CSF leakage detection and localization . . . . .	((32-0)) <u>20.4</u>
			78652 tomographic (ECT) . . . . .	((BR)) <u>53.2</u>
			(For myelin basic protein, CSF, RIA, see 83873)	
			78655 Eye tumor identification . . . . .	((BR)) <u>31.3</u>
			78660 Dacryocystography (lacrima flow study) . . . . .	((BR)) <u>19.5</u>
			78699 Unlisted nervous system procedure, diagnostic nuclear medicine . . . . .	BR
			<b>GENITOURINARY SYSTEM</b>	
			78700 Kidney imaging; only . . . . .	((18-0)) <u>22.9</u>
			78701 with vascular flow . . . . .	((20-0)) <u>26.5</u>
			78704 with function study (i.e., imaging renogram) . . . . .	((23-0)) <u>28.9</u>

	Unit Value		Unit Value
78707 with vascular flow and function study .....	<del>((BR))</del> 31.8	(For imaging bone infectious inflammatory disease, see 78300-78381)	
78710 Kidney imaging (SPECT) .....	<del>((BR))</del> 50.0	(For Rast, see 86421, 86422)	
78715 Kidney vascular flow only .....	<del>((BR))</del> 18.0	(For gamma-E immunoglobulin, RIA, see 82785)	
78725 Kidney function study only .....	<del>((BR))</del> 20.4	(For gamma-G immunoglobulin, see 82784)	
78726 with pharmacological intervention .....	<del>((BR))</del> 32.5	(For alpha-1 antitrypsin, RIA, see 86064)	
(For renin (angiotensin I), RIA, see 84244)		(For alpha-1 fetoprotein, RIA, see 86244)	
(For angiotensin II, RIA, see 82163)		(For antinuclear antibodies, RIA, see 86038)	
(For beta-2 microglobulin, RIA, see 82231, 82232)		(For lactic dehydrogenase, RIA, see 83610)	
78727 Kidney transplant evaluation .....	<del>((BR))</del> 23.6	(For amikacin, see 82112)	
78730 Urinary bladder residual study .....	<del>((BR))</del> 20.0	(For aminophylline, see 82137)	
78740 Ureteral reflux study (radionuclide voiding cystogram) .....	<del>((BR))</del> 24.1	(For amitriptyline, see 82138)	
(For estradiol, RIA, see 82670)		(For amphetamine, chemical quantitative, see 82145)	
(For estriol, RIA, see 82677)		(For chlordiazepoxide, see 82420, 82425)	
(For progesterone, RIA, see 84144)		(For chlorpromazine, see phenothiazine, urine, 84021, 84022)	
(For prostatic acid phosphatase, RIA, see 84066)		(For clonazepam, see 82512)	
78760 Testicular imaging .....	<del>((BR))</del> 27.7	(For cocaine, quantitative, see 82520)	
78761 with vascular flow .....	<del>((BR))</del> 34.6	(For diazepam, see 82636)	
(For testosterone, blood, RIA, see 84403)		(For dihydromorphinone, quantitative, see 82649)	
(For testosterone, urine, RIA, see 84405)		(For phenytoin (diphenylhydantoin), see 84045)	
(For lactogen, human placental (HPL) chorionic somatomammotropin, RIA, see 83632)		(For flucytosine, see 82741)	
(For chorionic gonadotropin beta subunit, RIA, see 84702, 84703)		(For gentamicin, see 84695)	
(For pregnanediol, RIA, see 84135)		(For lysergic acid diethylamide (LSD), RIA, see 83728)	
(For pregnanetriol, RIA, see 84138)		(For morphine (Heroin), RIA, see 83862)	
78799 Unlisted genitourinary procedure, diagnostic nuclear medicine .....	BR	(For phencyclidine (PCP), see 83992)	
(For chemical analysis, RIA tests, see Chemistry and Toxicology section)		(For phenobarbital, see barbiturates, 82205, 82210)	
<b>MISCELLANEOUS STUDIES</b>		(For tobramycin, see 84810)	
(For specific organ, see appropriate heading)		(For kanamycin, see 83578)	
(For radiophosphorus tumor identification, ocular, see 78655)		78890 Generation of automated data: Interactive process involving nuclear physician and/or allied health professional personnel; simple manipulations and interpretation, not to exceed 30 minutes .....	<del>((BR))</del> 7.2
78800 Radionuclide localization of tumor; limited area ..	<del>((BR))</del> 20.4	78891 complex manipulations and interpretation, exceeding 30 minutes .....	<del>((BR))</del> 12.0
(For specific organ, see appropriate heading)		(use 78890 or 78891 in addition to primary procedure)	
(For eye tumor identification, see 78655)		(use 78895 in addition to primary procedure)	
78801 multiple areas .....	<del>((BR))</del> 24.1	78990 Provision of diagnostic radionuclide(s) .....	12.0
78802 whole body .....	<del>((BR))</del> 41.9	78999 Unlisted miscellaneous procedure, diagnostic nuclear medicine .....	BR
78803 Tumor localization (SPECT) .....	<del>((BR))</del> 60.4		
78805 Abscess localization; limited area .....	<del>((BR))</del> 33.7		
78806 whole body .....	<del>((BR))</del> 39.0		

**AMENDATORY SECTION (Amending Order 86-47, filed 1/8/87)**

WAC 296-23A-268 THERAPEUTIC.



	Unit Value
79000 Radionuclide therapy, hyperthyroidism, initial, including evaluation of patient .....	(( <del>48.0</del> )) <u>36.1</u>
79001 subsequent, each therapy .....	(( <del>28.0</del> )) <u>27.4</u>
79020 Radionuclide therapy, thyroid suppression (euthyroid cardiac disease), including evaluation of patient .....	(( <del>48.0</del> )) <u>43.3</u>
79030 Radionuclide ablation of gland for thyroid carcinoma .....	(( <del>BR</del> )) <u>51.2</u>
79035 Radionuclide therapy for metastases of thyroid carcinoma .....	(( <del>BR</del> )) <u>54.9</u>
79100 Radionuclide therapy, polycythemia vera, chronic leukemia, each treatment .....	(( <del>16.0</del> )) <u>39.7</u>
79200 Intracavitary radioactive colloid therapy .....	(( <del>24.0</del> )) <u>51.7</u>
79300 Interstitial radioactive colloid therapy .....	(( <del>60.0</del> )) <u>72.2</u>
79400 Radionuclide therapy, nonthyroid, nonhematologic (e.g., for metastases to bone) ...	(( <del>BR</del> )) <u>55.3</u>
79420 Intravascular radionuclide therapy, particulate ...	(( <del>BR</del> )) <u>77.0</u>
79440 Intra-articular radionuclide therapy .....	(( <del>BR</del> )) <u>90.2</u>
79900 Provision of therapeutic radionuclide(s) .....	<u>BR</u>
79999 Unlisted radionuclide therapeutic procedure .....	<u>BR</u>

**AMENDATORY SECTION** (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

**WAC 296-23A-325 PANEL OR PROFILE TESTS.**

The following list contains those tests that can be and are frequently done as groups and combinations ("profiles") on automated multichannel equipment. For any combination of tests among those listed immediately below, use the appropriate number 80002-80021. Groups of the tests listed here are distinguished from multiple tests performed individually for immediate or "stat" reporting.

The following unit values apply when three or more of the tests listed below are performed on the same blood or urine specimen, under the conditions described in WAC 296-23A-300.

- Albumin
- Albumin/globulin ratio
- Bilirubin, direct
- Bilirubin, total
- Calcium
- Carbon dioxide content
- Chlorides
- Cholesterol
- Creatinine
- Globulin
- Glucose (sugar)
- Lactic dehydrogenase (LDH)
- Phosphatase, alkaline
- Phosphorus (organic phosphate)
- Potassium
- Protein, total

	Unit Value
Sodium	
Transaminase, glutamic oxaloacetic (SGOT)	
Transaminase, glutamic pyruvic (SGPT)	
Urea nitrogen (BUN)	
Uric acid	
80002 Automated multichannel test; 1 or 2 clinical chemistry test(s) .....	(( <del>21.0</del> )) <u>15.7</u>
80003 3 clinical chemistry tests .....	(( <del>28.0</del> )) <u>15.7</u>
80004 4 clinical chemistry tests .....	(( <del>32.0</del> )) <u>15.7</u>
80005 5 clinical chemistry tests .....	(( <del>36.0</del> )) <u>15.7</u>
80006 6 clinical chemistry tests .....	(( <del>40.0</del> )) <u>15.7</u>
80007 7 clinical chemistry tests .....	(( <del>44.0</del> )) <u>15.7</u>
80008 8 clinical chemistry tests .....	(( <del>48.0</del> )) <u>15.7</u>
80009 9 clinical chemistry tests .....	(( <del>52.0</del> )) <u>15.7</u>
80010 10 clinical chemistry tests .....	(( <del>56.0</del> )) <u>15.7</u>
80011 11 clinical chemistry tests .....	(( <del>60.0</del> )) <u>15.7</u>
80012 12 clinical chemistry tests .....	(( <del>64.0</del> )) <u>15.7</u>
80016 13-16 clinical chemistry tests .....	(( <del>68.0</del> )) <u>15.7</u>
80018 17-18 clinical chemistry tests .....	(( <del>69.6</del> )) <u>15.7</u>
80019 19-24 clinical chemistry tests .....	(( <del>72.4</del> )) <u>25.5</u>
<del>((80020-25-30 clinical chemistry tests .....</del>	<del>75.2</del>
<del>80021-31 or more clinical chemistry tests .....</del>	<del>78.0</del> )

**THERAPEUTIC DRUG MONITORING**

(e.g., antiepilepsy drugs, cardiac drugs, antibiotics, sedatives)

80031 Therapeutic quantitative drug monitoring in body fluids and/or excreta; measurement one drug (if drug not specified by individual code number) ...	(( <del>BR</del> )) <u>58.9</u>
80032 2 drugs measured .....	(( <del>BR</del> )) <u>102.2</u>
80033 3 drugs measured .....	(( <del>BR</del> )) <u>102.2</u>
80034 4 or more drugs measured .....	(( <del>BR</del> )) <u>102.2</u>
80040 Serum radioimmunoassay for circulating antibiotic levels .....	(( <del>BR</del> )) <u>68.8</u>
80042 Serum antimicrobial level, bioassay method .....	<u>BR</u>

**ORGAN OR DISEASE ORIENTED PANELS**

Organ "panels" as an approach to diagnosis have been developed in response to the increased use of general screening programs that are now in use in physicians' offices, health centers, clinics, and hospitals. Also included here are profiles that combine laboratory tests together under a problem oriented classification. The lack of an expanded list of laboratory tests under each number is deliberate. Because no two laboratories utilize the same array of tests in a particular panel, each laboratory should establish its own profile and accompany each reported panel by a listing of the components of that panel performed by the laboratory.

	Unit Value
80050 General health screen panel .....	BR
80056 Amenorrhea profile .....	((BR))
	<u>noncovered procedure</u>
80057 Male infertility and/or gynecomastia profile .....	((BR))
	<u>noncovered procedure</u>
80058 Hepatic function panel .....	((BR))
	45.2
80059 Hepatitis panel .....	BR
80060 Hypertension panel .....	((BR))
	80.6
80061 Lipid profile .....	((BR))
	55.0
80062 Cardiac evaluation (including coronary risk) panel .....	((BR))
	70.7
80063 Cardiac injury panel .....	((BR))
	70.7
80064 with creatine phosphokinase (CPK) and/or lactic dehydrogenase (LDH) isoenzyme determination .....	((BR))
	70.7
80065 Metabolic panel .....	BR
80066 Malabsorption panel .....	BR
80067 Pulmonary (lung function) panel .....	BR
80068 Lung maturity profile .....	BR
80070 Thyroid panel .....	((BR))
	45.2
80071 with thyrotropin releasing hormone (TRH) .....	((BR))
	45.2
80072 Arthritis panel .....	((BR))
	112.0
80073 Renal panel .....	BR
80075 Parathyroid panel .....	BR
80080 Prostatic panel .....	BR
80082 Pancreatic panel .....	BR
80084 Pituitary panel .....	BR
80085 Microcytic anemia panel .....	BR
80086 Macrocytic anemia panel .....	BR
80089 Muscle panel .....	BR
80090 Antibody panel (e.g., TORCH: Toxoplasma IFA, rubella HI, cytomegalovirus CF, herpes virus CF) .....	BR
80099 Unlisted panel .....	BR

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-23A-330 URINALYSIS.**

(For specific analyses, see appropriate section)

	Unit Value
81000 Urinalysis; (( <u>routine</u> )) (pH, specific gravity, protein, tests for reducing substances as glucose), with microscopy .....	((+2-0))
	9.8
81002 (( <u>routine</u> )) without microscopy .....	((0-0))
	5.9
81004 urinalysis: components, single, not otherwise listed, specify .....	((5-0))
	5.9
81005 chemical, qualitative, any number of constituents .....	((0-0))
	9.8
81007 bacteriuria screen, by nonculture technique, commercial kit (specialty type) .....	BR
81010 concentration and dilution test .....	((+4-0))
	17.7
81011 water deprivation test .....	((BR))
	15.7

	Unit Value
81012 water deprivation test with vasopressin response ..	((BR))
	19.6
81015 microscopic only .....	((+0-0))
	11.8
81020 two or three glass test .....	((+0-0))
	15.7
81030 Quantitative sediment analysis and quantitative protein (Addis count) .....	((+0-0))
	19.6
81099 Unlisted urinalysis procedure .....	BR

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-23A-335 CHEMISTRY AND TOXICOLOGY.**

Notes: The material for examination may be from any source. Examination is quantitative unless specified. (For list of automated, multichannel tests, see 80003-80019)

Clinical pathology includes radioimmunoassay as one method of performing many chemistry tests. These codes can be appropriately used by any specialist performing such tests in a laboratory licensed and/or certified for radioimmunoassays. The reporting of these tests is not confined to clinical pathology laboratories alone.

	Unit Value
82000 Acetaldehyde, blood .....	((+0-0))
	45.2
82003 Acetaminophen, urine .....	((+0-0))
	60.9
	(Acetic anhydride, see volatiles, 84600)
82005 Acetoacetic acid .....	((+0-0))
	45.2
82009 Acetone, qualitative .....	((+2-0))
	17.7
82010 quantitative .....	((+2-0))
	41.3
	(For acetone bodies, see 82009-82010, 82635, 83947)
82011 Acetylsalicylic acid; quantitative .....	((32-0))
	33.4
82012 qualitative .....	((32-0))
	27.5
82013 Acetylcholinesterase .....	((+0-0))
	45.2
	(Acid, gastric, see gastric acid, 82926-82932)
	(Acid phosphatase, see 84060-84065)
82015 Acidity, titratable, urine .....	((30-0))
	17.7
	(ACTH, see 82024)
	(Adrenalin-Noradrenalin, see catecholamines, 82382-82384)
82024 Adrenocorticotrophic hormone (ACTH), RIA .....	((+20-0))
	157.2
82030 Adenosine; 5'-diphosphate (ADP) and 5'-monophosphate (AMP), cyclic, RIA, blood .....	((+0-0))
	45.2
82035 5'-triphosphate, blood .....	((+0-0))
	45.2
82040 Albumin serum .....	((20-0))
	19.6
82042 urine, quantitative (specify method, e.g., Esbach) .....	((20-0))
	9.8

	Unit Value		Unit Value
(For albumin/globulin ratio, albumin/globulin ratio by electrophoretic method, see 84155-84200)		82142 Ammonium chloride loading test	((40-0)) 51.1
82055 Alcohol (ethanol), blood; chemical	((30-0)) 58.9	82143 Amniotic fluid scan (spectrophotometric)	((50-0)) 51.1
82060 by gas-liquid chromatography	((40-0)) 49.1	(For L/S ratio, see 83661)	
82065 Alcohol (ethanol), urine; chemical	((30-0)) 53.0	(Amobarbital, see 82205-82210)	
82070 by gas-liquid chromatography	((40-0)) 49.1	82145 Amphetamine or methamphetamine, chemical, quantitative	((80-0)) 62.9
82072 Alcohol (ethanol) gelation	((30-0)) 45.2	82150 Amylase, serum	((30-0)) 29.5
82075 Alcohol (ethanol), breath	((60-0)) 57.0	(82155 has been deleted)	
82076 Alcohol; isopropyl	((60-0)) 51.1	82156 Amylase, urine (diastase)	((30-0)) 25.5
82078 methyl	((60-0)) 58.9	82157 Androstenedione RIA	((80-0)) 123.8
82085 Aldolase, blood; kinetic ultraviolet method	((26-0)) 45.2	82159 Androsterone	((50-0)) 117.9
82086 colorimetric	((20-0)) 43.1	82160 RIA	((50-0)) 117.9
82087 Aldosterone; double isotope technique	((+20-0)) 176.8	(See also 83593-83596)	
82088 RIA blood	((+00-0)) 202.4	(Angiotensin I, see renin, 84244)	
82089 RIA urine	((+00-0)) 196.5	82163 Angiotensin II, RIA	((BR)) 76.6
82091 saline infusion test	((BR)) 196.5	82164 Angiotensin-converting enzyme	((BR)) 57.0
(Alkaline phosphatase, see 84075-84080)		82165 Aniline	((BR)) 47.2
82095 Alkaloids, tissue; screening	((80-0)) 84.5	(Antidiuretic hormone, RIA, see 84588)	
82096 quantitative	((+20-0)) 147.4	82168 Antihistamines	((BR)) 60.9
82100 Alkaloids, urine, screening	((80-0)) 64.8	82170 Antimony, urine	((80-0)) 92.3
82101 quantitative	((+20-0)) 147.4	(Antimony, screen, see 83015)	
(See also 82486, 82600, 82662, 82755, 84231)		(Antitrypsin, alpha-1-, see 86329)	
(Alpha amino acid nitrogen, see 82126)		82172 Apolipoprotein	BR
(Alpha-hydroxybutyric (HBD) dehydrogenase, see 83485, 83486)		82173 Arginine tolerance test	((BR)) 66.8
(Alphaketoglutarate, see 83584)		82175 Arsenic, blood, urine, gastric contents, hair or nails, quantitative	((80-0)) 86.4
(Alpha tocopherol (Vitamin E), see 84446)		(For heavy metal screening, see 83015)	
82108 Aluminum, blood (serum)	BR	82180 Ascorbic acid (Vitamin C), blood	((40-0)) 47.2
82112 Amikacin	((BR)) 72.7	(Aspirin, see acetylsalicylic acid, 82011, 82012)	
(Amikacin serum radioimmunoassay, see 80040)		(Atherogenic index, blood, ultracentrifugation, quantitative, see 83717)	
82126 amino acid nitrogen, alpha	((50-0)) 53.0	82205 Barbiturates; quantitative	((60-0)) 60.9
82128 Amino acids, qualitative	((40-0)) 31.4	82210 quantitative and identification	((80-0)) 74.7
82130 Amino acids, urine or plasma, chromatographic fractionation and quantitation, one or more	((+80-0)) 17.7	(For qualitative screen, see 82486, 82660, 82755, 84231)	
82134 Aminohippurate, para (PAH)	((30-0)) 45.2	82225 Barium	((BR)) 82.5
82135 Aminolevulinic acid, delta (ALA)	((50-0)) 74.7	(Bence-Jones protein, 84185)	
82137 Aminophylline	((60-0)) 64.8	82230 Beryllium, urine	((80-0)) 106.1
82138 Amitriptyline	((60-0)) 86.4	(Beta-glucosidase, see 82963)	
82140 Ammonia; blood	((40-0)) 72.7	82231 Beta-2 microglobulin, RIA; urine	((BR)) 78.6
82141 urine	((40-0)) 43.2		

	Unit Value		Unit Value
82232 serum .....	((BR)) 78.6	82355 Calculus (stone), qualitative; chemical .....	((40-0)) 55.0
82235 Bicarbonate excretion, urine .....	((BR)) 17.7	82360 Calculus (stone), quantitative; chemical .....	((60-0)) 55.0
82236 Bicarbonate loading test .....	((BR)) 29.5	82365 infrared spectroscopy .....	((60-0)) 55.0
(Bicarbonate, see 82374)		82370 X-ray diffraction .....	((50-0)) 41.3
82240 Bile acids, blood, fractionated .....	((+20-0)) 39.3	(Carbamates, see individual listings)	
82245 Bile pigments, urine .....	((8-0)) 3.9	82372 Carbamazepine, serum .....	((BR)) 62.9
82250 Bilirubin; blood, total or direct .....	((24-0)) 23.6	82374 Carbon dioxide, combining power or content .....	((+60-0)) 9.8
82251 blood, total and direct .....	((30-0)) 25.5	(See also 82801-82803, 82817)	
82252 feces, qualitative .....	((BR)) 3.9	82375 Carbon monoxide, (carboxyhemoglobin); quantita- tive .....	((48-0)) 60.9
82260 urine, quantitative .....	((+2-0)) 17.7	82376 qualitative .....	((48-0)) 15.7
82265 amniotic fluid, quantitative .....	((30-0)) 29.5	(Carbon tetrachloride, see 84600)	
82268 Bismuth .....	((80-0)) 98.2	(Carboxyhemoglobin, see 82375, 82376)	
82270 Blood; occult, feces, screening .....	((8-0)) 5.9	82380 Carotene, blood .....	((40-0)) 39.3
82273 duodenal, gastric contents, qualitative .....	((BR)) 11.8	(Carotene plus Vitamin A, see 84595)	
(Blood urea nitrogen (BUN), see 84520-84525, 84545)		82382 Catecholamines (dopamine, norepinephrine, epine- phrine); total urine .....	((BR)) 68.8
(Blood volume, see 84605-84610, 78110, 78111)		82383 blood .....	((BR)) 119.8
82280 Boric acid; blood .....	((+100-0)) 110.0	82384 fractionated .....	((BR)) 112.0
82285 urine .....	((+100-0)) 104.1	(For urine metabolites, see 83835, 84585)	
82286 Bradykinin .....	((BR)) 21.6	82390 Ceruloplasmin, chemical (copper oxidase), blood ..	((40-0)) 45.2
82290 Bromides; blood .....	((24-0)) 29.5	(For gel diffusion technique, see 86331; immunodiffusion technique, see 86329)	
82291 urine .....	((40-0)) 31.4	82400 Chloral hydrate; blood .....	((60-0)) 82.5
82300 Cadmium, urine .....	((+100-0)) 106.1	82405 urine .....	((40-0)) 49.1
82305 Caffeine .....	((60-0)) 55.0	82415 Chloramphenicol; blood .....	((40-0)) 51.1
82306 Calcifediol (25-OH Vitamin D-3), chromato- graphic technique .....	((BR)) 141.5	82418 Chlorazepate dipotassium .....	((40-0)) 82.5
82307 Calciferol (Vitamin D), RIA .....	((BR)) 104.1	82420 Chlordiazepoxide; blood .....	((60-0)) 94.3
(For 1, 25-Dihydroxyvitamin D, use 82652)		82425 urine .....	((60-0)) 49.1
82308 Calcitonin, RIA .....	((80-0)) 112.0	82435 Chlorides; blood (specify chemical or electromet- ric) .....	((20-0)) 9.8
82310 Calcium, blood; chemical .....	((22-0)) 19.6	82436 urine (specify chemical, electrometric or Fantus test) .....	((20-0)) 25.5
82315 fluorometric .....	((22-0)) 15.7	82437 sweat (without iontophoresis) .....	((20-0)) 13.8
82320 emission flame photometry .....	((22-0)) 15.7	82438 spinal fluid .....	((20-0)) 23.6
82325 atomic absorption flame photometry .....	((24-0)) 25.5	82441 Chlorinated hydrocarbons, screen .....	((20-0)) 29.5
82330 fractionated, diffusible .....	((60-0)) 66.8	82443 Chlorothiazide-hydrochlorothiazide .....	((60-0)) 86.4
82331 after calcium infusion test .....	((24-0)) 25.5	(Chlorpromazine, see 84021, 84022)	
82335 Calcium, urine; qualitative (Sulkowitch) .....	((+1-0)) 19.6	82465 Cholesterol, serum; total .....	((22-0)) 7.9
82340 quantitative, timed specimen .....	((32-0)) 23.6		
(82345 has been deleted)			

	Unit Value		Unit Value
82470 total and esters .....	<del>((30.0))</del> 33.4	82538 after metyrapone tartrate administration .....	<del>((BR))</del> 84.5
82480 Cholinesterase; serum .....	<del>((40.0))</del> 43.2	82539 dexamethasone suppression test, plasma and/or urine .....	<del>((BR))</del> 84.5
82482 RBC .....	<del>((60.0))</del> 51.1	82540 Creatine; blood .....	<del>((24.0))</del> 17.7
82484 serum and RBC .....	<del>((80.0))</del> 72.7	82545 urine .....	<del>((40.0))</del> 17.7
82485 Chondroitin B sulfate, quantitative .....	<del>((BR))</del> 57.0	82546 Creatine and creatinine .....	<del>((50.0))</del> 37.3
(Chorionic gonadotropin, see gonadotropin, 84702, 84703)			
82486 Chromatography; gas-liquid, compound and meth- od not elsewhere specified .....	<del>((BR))</del> 76.6	82550 Creatine phosphokinase (CPK), blood; timed kinet- ic ultraviolet method .....	<del>((26.0))</del> 29.5
82487 paper, 1-dimensional, compound and method not elsewhere specified .....	<del>((BR))</del> 78.6	82552 isoenzymes .....	<del>((30.0))</del> 58.9
82488 paper, 2-dimensional, not elsewhere specified ...	<del>((BR))</del> 104.1	82555 colorimetric .....	<del>((20.0))</del> 21.6
82489 thin layer, not elsewhere specified .....	<del>((BR))</del> 84.5	82565 Creatinine; blood .....	<del>((20.0))</del> 23.6
(82490 has been deleted)			
82495 urine .....	<del>((100.0))</del> 86.4	82570 urine .....	<del>((20.0))</del> 23.6
(82505 has been deleted)			
82507 Citrate .....	<del>((80.0))</del> 119.8	82575 clearance .....	<del>((40.0))</del> 47.2
82512 Clonazepam .....	<del>((BR))</del> 80.6	82585 Cryofibrinogen, blood .....	<del>((40.0))</del> 21.6
82520 Cocaine, quantitative .....	<del>((60.0))</del> 49.1	82595 Cryoglobulin, blood .....	<del>((40.0))</del> 31.4
(Cocaine, screen, see 82486-82489, 82660, 82662, 82755, 84231)			
(Codeine, screen, see 82486-82489, 82660, 82662, 82755, 84231)			
(Codeine, quantitative, see 82096, 82101)			
(Complement, see 86154-86158)			
(Compound S, see 82634)			
82525 Copper; blood .....	<del>((60.0))</del> 60.9	(Crystals, pyrophosphate vs. urate, see 84208)	
82526 urine .....	<del>((60.0))</del> 64.8	82600 Cyanide; blood .....	<del>((80.0))</del> 72.7
(Coprobilinogen, feces, 84577)			
(Coproprophyrins, see 84118-84121)			
(Corticosteroids, see 83491-83496)			
82528 Corticosterone, RIA .....	<del>((BR))</del> 72.7	82601 tissue .....	<del>((80.0))</del> 90.4
(See also 83593-83597)			
82529 Cortisol; fluorometric, plasma .....	<del>((36.0))</del> 55.0	82606 Cyanocobalamin (Vitamin B-12); bioassay .....	<del>((70.0))</del> 70.7
82531 CPB, plasma .....	<del>((75.0))</del> 62.9	82607 RIA .....	<del>((45.0))</del> 74.7
82532 CPB, urine .....	<del>((75.0))</del> 62.9	82608 unsaturated binding capacity .....	<del>((60.0))</del> 72.7
82533 RIA, plasma .....	<del>((90.0))</del> 62.9	(Cyclic AMP, see 82030)	
82534 RIA, urine .....	<del>((90.0))</del> 72.7	(Cyclic GMP, see 83008)	
82536 after adrenocorticotrophic hormone (ACTH) ad- ministration .....	<del>((BR))</del> 84.5	(Cyclosporine, see 83003)	
82537 48 hours after continuous ACTH infusion .....	<del>((BR))</del> 84.5	82614 Cystine, blood, qualitative .....	<del>((BR))</del> 43.2
		82615 Cystine and homocystine, urine; qualitative .....	<del>((30.0))</del> 31.4
		82620 quantitative .....	<del>((40.0))</del> 58.9
		82624 Cystine aminopeptidase .....	<del>((BR))</del> 43.2
		(D hemoglobin, see 83053)	
		(Delta-aminolevulinic acid (ALA), see 82135)	
		82626 Dehydroepiandrosterone (DHEA), RIA .....	<del>((BR))</del> 108.1
		(See also 83593)	
		(Deoxycortisol, 11-(compound S), RIA, see 82634)	
		82628 Desipramine .....	<del>((BR))</del> 84.5
		82633 Desoxycorticosterone, 11-RIA .....	<del>((BR))</del> 145.4
		82634 Desoxycortisol, 11-(compound S), RIA .....	<del>((80.0))</del> 145.4
		(See also 83492)	
		(Dexamethasone suppression test, see 82539)	
		82635 Diacetic acid .....	<del>((18.0))</del> 31.4

	Unit Value		Unit Value
(Diastase, urine, see 82156)		82674 GLC .....	((45.0)) 72.7
82636 Diazepam .....	((50.0)) 66.8	82676 Chemical .....	((75.0)) 96.3
82638 Dibucaine number .....	((34.0)) 43.2	82677 RIA .....	((105.0)) 94.3
82639 Dicumarol .....	((BR)) 74.7	(Estrogen receptor assay, see 84233)	
(Dichloroethane, see 84600)		82678 Estrone; chemical .....	((75.0)) 108.1
(Dichloromethane, see 84600)		82679 RIA .....	((90.0)) 123.8
(Diethylether, see 84600)		(Ethanol, see 82055-82075)	
82640 Digitoxin (digitalis); blood, RIA .....	((BR)) 66.8	82690 Ethchlorvynol; blood .....	((60.0)) 96.3
82641 urine .....	((BR)) 64.8	82691 urine .....	((60.0)) 66.8
82643 Digoxin, RIA .....	((36.0)) 66.8	82692 Ethosuximide .....	((BR)) 78.6
82646 Dihydrocodinone .....	((BR)) 66.8	(Ethyl alcohol, see 82055-82075)	
(Dihydrocodinone screen, see 82486-82489, 82662, 82755, 84231)		82694 Etiocholanolone .....	((BR)) 110.0
82649 Dihydromorphinone, quantitative .....	((75.0)) 127.7	(See also 83593)	
(Dihydromorphinone screen, see 82486-82489, 82662, 82755, 84231)		(Evans Blue, see blood volume, 84605-84610)	
82651 Dihydrotestosterone (DHT) .....	((BR)) 60.9	82696 Etiocholanolone, RIA .....	((50.0)) 104.1
82652 Dihydroxyvitamin D, 1, 25- .....	((BR)) 218.1	82705 Fat or lipids, feces; screening .....	((10.0)) 25.5
82654 Dimethadione .....	((BR)) 66.8	82710 quantitative, 24 or 72 hour specimen .....	((100.0)) 76.6
(Diphenylhydantoin, see 84045)		82715 Fat differential, feces, quantitative .....	((BR)) 31.4
(Dopamine, see 82382-82384)		82720 Fatty acids, blood; esterified .....	((40.0)) 47.2
82656 Doxepin .....	((BR)) 62.9	82725 nonesterified .....	((40.0)) 51.1
82660 Drug screen (amphetamines, barbiturates, alkaloids) .....	((65.0)) 62.9	82727 Ferric chloride, urine .....	((BR)) 49.1
(See also 82486-82489, 82662, 82755, 84231)		82728 Ferritin, specify method (e.g., RIA, immunoradiometric assay) .....	((BR)) 45.2
(Duodenal contents, see individual enzymes; for intubation and collection, see 89100)		(Fetal hemoglobin, see hemoglobin 83030, 83033, and 85460)	
(Endocrine receptor assays, see 84233-84235)		(Fetoprotein, alpha-1, see 86329)	
<del>((82662 Immunoassay technique for drugs .....</del> 30.0))		82730 Fibrinogen, quantitative .....	((21.0)) 37.3
(For enzyme immunoassay for bacteria, use 86227)		(See also 85371, 85377)	
82664 Electrophoretic technique, not elsewhere specified .....	((45.0)) 72.7	82735 Fluoride; blood .....	((100.0)) 64.8
82666 Epiandrosterone .....	((BR)) 106.1	82740 urine .....	((100.0)) 70.7
(See also 83593)		82741 Flucytosine (5-fluorocytosine) .....	((BR)) 72.7
(Epinephrine, see 82382-82384)		82742 Flurazepam .....	((BR)) 76.6
82668 Erythropoietin, bioassay .....	((BR)) 82.5	82745 Folic acid (folate), blood; bioassay .....	((BR)) 70.7
(For HI method, see 86280)		82746 RIA .....	((45.0)) 70.7
82670 Estradiol, RIA (placental) .....	((90.0)) 137.5	(Follicle stimulating hormones (FSH), see 83000, 83001)	
82671 Estrogens; fractionated .....	((85.0)) 110.0	82750 Formiminoglutamic acid (FIGLU), urine .....	((100.0)) 125.7
82672 total .....	((60.0)) 104.1	82755 Free radical assay technique for drugs (FRAT) .....	((BR)) 82.5
82673 Estriol; fluorometric .....	((54.0)) 21.6	82756 Free thyroxine index (T-7) .....	((BR)) 17.7

	Unit Value		Unit Value
82757 Fructose, semen .....	((BR)) <u>25.5</u>	(For gastric intubation, see 89130, 74340)	
(Fructose, TLC screen, see 84375)		82938 Gastrin (serum) after secretin stimulation (e.g., for gastrinoma, Zollinger-Ellison syndrome) .....	((BR)) <u>86.4</u>
(Furosemide test, see 84246)		82941 Gastrin, RIA .....	((48-0)) <u>84.5</u>
82759 Galactokinase, RBC .....	((BR)) <u>49.1</u>	(Gentamicin, see 84695)	
82760 Galactose; blood .....	((40-0)) <u>49.1</u>	(GGT, see 82977)	
82763 tolerance test .....	((75-0)) <u>57.0</u>	(Gentamicin serum radioimmunoassay, see 80040)	
82765 urine .....	((40-0)) <u>33.4</u>	(GLC, gas liquid chromatography, see 82486)	
(For TLC screen, see 84375)		82942 Globulin, serum .....	((10-5)) <u>21.6</u>
82775 Galactose-1-phosphate uridyl transferase; quantitative .....	((60-0)) <u>104.1</u>	(See also 82784, 82786, 84155-84200, 86329)	
82776 screen .....	((18-0)) <u>17.7</u>	82943 Glucagon, RIA .....	((BR)) <u>68.8</u>
82780 Gallium .....	((BR)) <u>102.2</u>	82944 Glucosamine .....	((6-0)) <u>21.6</u>
82784 Gammaglobulin, A, D, G, M nephelometric, each .....	((12-0)) <u>17.4</u>	82946 Glucagon tolerance test .....	((BR)) <u>43.2</u>
82785 Gammaglobulin, E, (e.g., RIA, EIA) .....	((75-0)) <u>58.9</u>	82947 Glucose; except urine (e.g., blood, spinal fluid, joint fluid) .....	((10-5)) <u>7.9</u>
82786 Gammaglobulin, salt precipitation method .....	((21-0)) <u>29.5</u>	82948 blood, stick test .....	((8-2)) <u>9.8</u>
(Gammaglobulin by gel (immuno) diffusion, see 86329)		82949 fermentation .....	((22-5)) <u>17.7</u>
(Gamma-glutamyl transpeptidase (GGT), see 82977)		82950 post glucose dose (includes glucose) .....	((13-5)) <u>21.6</u>
82790 Gases, blood, oxygen saturation; by calculation from pO <sub>2</sub> .....	((40-0)) <u>41.3</u>	82951 tolerance test (GTT), three specimens (includes glucose) .....	((37-5)) <u>19.6</u>
82791 by manometry .....	((40-0)) <u>47.2</u>	82952 tolerance test, each additional beyond three specimens .....	((10-5)) <u>19.6</u>
82792 by oximetry .....	((20-0)) <u>35.4</u>	(For intravenous glucose tolerance test, see 82961)	
82793 by spectrophotometry .....	((40-0)) <u>47.2</u>	82953 tolbutamide tolerance test .....	((15-0)) <u>74.7</u>
82795 by calculation from pCO <sub>2</sub> .....	((6-0)) <u>21.6</u>	(For insulin tolerance test, see 83526)	
82800 Gases, blood; pH, only .....	((20-0)) <u>41.3</u>	(For leucine tolerance test, see 83681)	
82801 pCO <sub>2</sub> .....	((24-0)) <u>21.6</u>	82954 Glucose, urine .....	((20-0)) <u>11.8</u>
82802 pH, pCO <sub>2</sub> by electrode .....	((42-0)) <u>45.2</u>	82955 Glucose-6-phosphate dehydrogenase(G6PD); quantitative .....	((60-0)) <u>47.2</u>
82803 pH, pCO <sub>2</sub> , pO <sub>2</sub> simultaneous .....	((54-0)) <u>96.3</u>	82960 screen .....	((56-0)) <u>25.5</u>
82804 pO <sub>2</sub> by electrode .....	((40-0)) <u>43.2</u>	82961 Glucose tolerance test, intravenous .....	((BR)) <u>84.5</u>
82812 pO <sub>2</sub> by manometry .....	((24-0)) <u>31.4</u>	82963 Glucosidase, beta .....	((BR)) <u>106.1</u>
82817 pH, pCO <sub>2</sub> by tonometry .....	((24-0)) <u>58.9</u>	82965 Glutamate dehydrogenase, blood .....	((40-0)) <u>35.4</u>
82926 Gastric acid, free and total; single specimen .....	((11-2)) <u>37.3</u>	(Glutamic oxaloacetic transaminase (SGOT), see 84450-84455)	
82927 each additional specimen .....	((9-0)) <u>13.8</u>	(Glutamic pyruvic transaminase (SGPT), see 84460-84465)	
82928 Gastric acid, free or total; single specimen .....	((9-0)) <u>21.6</u>	82975 Glutamine (glutamic acid amide), spinal fluid .....	((80-0)) <u>37.3</u>
82929 each additional specimen .....	((7-5)) <u>11.8</u>	82977 Glutamyl transpeptidase, gamma (GGT) .....	((BR)) <u>29.5</u>
82931 Gastric acid, pH titration; single specimen .....	((24-0)) <u>41.3</u>	82978 Glutathione .....	((BR)) <u>33.4</u>
82932 each additional specimen .....	((18-0)) <u>27.5</u>	82979 Glutathione reductase, RBC .....	((BR)) <u>33.4</u>
(Gastric analysis, with stimulation, see 89140, 89141, 91052)			
(Gastric analysis, pepsin, see 83974)			

	Unit Value		Unit Value
82980	(( <del>56.2</del> )) <u>76.6</u>	83069	(( <del>BR</del> )) <u>19.6</u>
		83070	(( <del>12.0</del> )) <u>23.6</u>
	(Glycohemoglobin, see 83036)	83071	(( <del>25.6</del> )) <u>229.9</u>
82985	(( <del>60.0</del> )) <u>74.7</u>		(Heroin, screening, see 82660, 82486, 82662, 82755, 84231; quantitative, see 82096, 82101)
82995	(( <del>100.0</del> )) <u>80.6</u>		(HIAA, see 83497)
83000	(( <del>90.0</del> )) <u>72.7</u>	83086	(( <del>BR</del> )) <u>66.8</u>
83001	(( <del>90.0</del> )) <u>72.7</u>	83087	(( <del>BR</del> )) <u>55.0</u>
83002	(( <del>90.0</del> )) <u>66.8</u>	83088	(( <del>100.0</del> )) <u>137.5</u>
	(For luteinizing releasing factor (LRH), see 83727)		(Homocystine, qualitative, see 82615)
83003	(( <del>48.0</del> )) <u>64.8</u>		(Homocystine, quantitative, see 82620)
83004	(( <del>48.0</del> )) <u>78.6</u>	83093	(( <del>BR</del> )) <u>39.3</u>
	(For growth hormone secretion after arginine tolerance test, see 82173)	83094	(( <del>20.0</del> )) <u>27.5</u>
	(For human growth hormone antibody, RIA, see 86277)	83095	(( <del>40.0</del> )) <u>49.1</u>
	(83005 has been deleted)	83150	(( <del>80.0</del> )) <u>88.4</u>
83008	(( <del>BR</del> )) <u>60.9</u>		(Hormones, see individual alphabetic listings in chemistry section)
83010	(( <del>60.0</del> )) <u>17.7</u>	83485	(( <del>22.0</del> )) <u>19.6</u>
83011	(( <del>30.0</del> )) <u>47.2</u>	83486	(( <del>20.0</del> )) <u>35.4</u>
83012	(( <del>60.0</del> )) <u>84.5</u>	83491	(( <del>64.1</del> )) <u>76.6</u>
83015	(( <del>30.0</del> )) <u>92.3</u>	83492	(( <del>82.0</del> )) <u>39.3</u>
83018	(( <del>BR</del> )) <u>102.2</u>	83493	(( <del>45.0</del> )) <u>72.7</u>
83020	(( <del>80.0</del> )) <u>37.3</u>	83494	(( <del>38.0</del> )) <u>72.7</u>
	(Hemoglobin, carboxyhemoglobin (CO), see 82375, 82376; colorimetric, see 85018, 85031)	83495	(( <del>52.0</del> )) <u>72.7</u>
83030	(( <del>40.0</del> )) <u>33.4</u>	83496	(( <del>52.0</del> )) <u>72.7</u>
83033	(( <del>56.0</del> )) <u>27.5</u>		(See also 82531-82534, 82634, 84409)
83036	(( <del>60.0</del> )) <u>27.5</u>	83497	(( <del>60.0</del> )) <u>62.9</u>
83040	(( <del>80.0</del> )) <u>49.1</u>		(For HIAA, blood, see 84260)
83045	(( <del>20.0</del> )) <u>23.6</u>	83498	(( <del>105.0</del> )) <u>112.0</u>
83050	(( <del>40.0</del> )) <u>35.4</u>	83499	(( <del>BR</del> )) <u>112.0</u>
83051	(( <del>40.0</del> )) <u>11.8</u>	83500	(( <del>100.0</del> )) <u>121.8</u>
83052	(( <del>34.0</del> )) <u>13.8</u>	83505	(( <del>100.0</del> )) <u>137.5</u>
83053	(( <del>40.0</del> )) <u>35.4</u>	83510	(( <del>100.0</del> )) <u>200.4</u>
83055	(( <del>20.0</del> )) <u>23.6</u>	83523	(( <del>67.0</del> )) <u>84.5</u>
83060	(( <del>40.0</del> )) <u>41.3</u>		(Immunoassay technique for drugs, use 82662)
83065	(( <del>BR</del> )) <u>33.4</u>		(Immunoglobulins, see 82784, 82785, 82786, 86329, 86335)
83068	(( <del>BR</del> )) <u>37.3</u>	83524	(( <del>35.0</del> )) <u>23.6</u>



	Unit Value		Unit Value
83525 Insulin, RIA .....	<del>((40.0))</del> <u>55.0</u>	83615 Lactic dehydrogenase (LDH), blood; kinetic ultra-violet method .....	<del>((26.0))</del> <u>29.5</u>
(For proinsulin, see 84206)		83620 colorimetric or fluorometric .....	<del>((20.0))</del> <u>25.5</u>
83526 Insulin tolerance test .....	<del>((80.0))</del> <u>45.2</u>	83624 heat or urea inhibition (total not included) .....	<del>((24.0))</del> <u>19.6</u>
83528 Intrinsic factor level .....	<del>((BR))</del> <u>78.6</u>	83625 isoenzymes, electrophoretic separation and quantitation .....	<del>((60.0))</del> <u>17.7</u>
(For intrinsic factor antibodies, RIA, see 86340)		83626 isoenzymes, chemical separation .....	<del>((20.0))</del> <u>55.0</u>
83530 Insulin clearance .....	<del>((40.0))</del> <u>45.2</u>	83628 Lactic dehydrogenase, liver (LLDH) .....	<del>((20.0))</del> <u>33.4</u>
(For thyroxine, see 84435-84439)		83629 Lactic dehydrogenase (LDH), urine .....	<del>((20.0))</del> <u>29.5</u>
(For triiodothyronine (true T-3), RIA, see 84480)		83631 Lactic dehydrogenase (LDH), CSF .....	<del>((20.0))</del> <u>13.8</u>
83540 Iron, serum; chemical .....	<del>((20.0))</del> <u>31.4</u>	(For hydroxybutyric dehydrogenase (HBD), see 83485)	
83545 automated .....	<del>((+2.0))</del> <u>25.5</u>	83632 Lactogen, human placental (HPL) chorionic somatomammotropin, RIA .....	<del>((30.0))</del> <u>76.6</u>
83546 radioactive uptake method .....	<del>((30.0))</del> <u>35.4</u>	83633 Lactose, urine; qualitative .....	<del>((20.0))</del> <u>27.5</u>
83550 Iron binding capacity, serum; chemical .....	<del>((20.0))</del> <u>37.3</u>	83634 quantitative .....	<del>((20.0))</del> <u>57.0</u>
83555 automated .....	<del>((+2.0))</del> <u>37.3</u>	(For tolerance, see 82951-82952)	
83565 radioactive uptake method .....	<del>((30.0))</del> <u>37.3</u>	(For TLC screen, see 84375)	
83570 Isocitric dehydrogenase (IDH), blood; kinetic ultraviolet .....	<del>((26.0))</del> <u>43.2</u>	83645 Lead, screening; blood .....	<del>((20.0))</del> <u>55.0</u>
83571 colorimetric .....	<del>((20.0))</del> <u>37.3</u>	83650 urine .....	<del>((20.0))</del> <u>47.2</u>
(Isopropyl alcohol, see alcohol 82076)		83655 Lead, quantitative; blood .....	<del>((60.0))</del> <u>47.2</u>
83576 Isonicotinic acid hydrazide (INH) .....	<del>((+05.0))</del> <u>127.7</u>	83660 urine .....	<del>((60.0))</del> <u>47.2</u>
83578 Kanamycin .....	<del>((49.0))</del> <u>74.7</u>	83661 Lecithin - sphingomyelin (L/S ratio), amniotic fluid .....	<del>((75.0))</del> <u>31.4</u>
83582 Ketogenic steroids, urine; 17-(17-KGS) .....	<del>((45.0))</del> <u>60.9</u>	83670 Leucine aminopeptidase (LAP), blood; kinetic ultraviolet method .....	<del>((26.0))</del> <u>33.4</u>
83583 11-desoxy: 11-oxy ratio .....	<del>((75.0))</del> <u>114.0</u>	83675 colorimetric .....	<del>((20.0))</del> <u>27.5</u>
83584 Ketoglutarate, alpha .....	<del>((40.0))</del> <u>41.3</u>	83680 Leucine aminopeptidase (LAP), urine .....	<del>((26.0))</del> <u>43.2</u>
(Ketone bodies, see 82005-82010; urine, see 81000-81005)		83681 Leucine tolerance test .....	<del>((26.0))</del> <u>45.2</u>
83586 Ketosteroids 17-(17-KS), blood; total .....	<del>((30.0))</del> <u>68.8</u>	83685 Lidocaine .....	<del>((20.0))</del> <u>62.9</u>
83587 fractionation, alpha/beta .....	<del>((75.0))</del> <u>137.5</u>	83690 Lipase, blood .....	<del>((30.0))</del> <u>33.4</u>
83588 RIA .....	<del>((54.0))</del> <u>84.5</u>	83700 Lipids, blood; total .....	<del>((30.0))</del> <u>43.2</u>
83589 Ketosteroids, 17-(17-KS), urine; total .....	<del>((36.0))</del> <u>60.9</u>	83705 fractionated (cholesterol, triglycerides, phospholipids) .....	<del>((60.0))</del> <u>51.1</u>
83590 fractionation, alpha/beta .....	<del>((60.0))</del> <u>115.9</u>	(For feces, see 82705-82715)	
83593 chromatographic fractionation .....	<del>((75.0))</del> <u>127.7</u>	83715 Lipoprotein, blood; electrophoretic separation and quantitation (phenotyping) .....	<del>((60.0))</del> <u>31.4</u>
83597 11-desoxy: 11-oxy ratio .....	<del>((75.0))</del> <u>96.3</u>	83717 analytic ultracentrifugation separation and quantitation (atherogenic index) .....	<del>((+00.0))</del> <u>121.8</u>
(See also 82528, 82633, 82666, 82694)		83718 Lipoprotein high density cholesterol (HDL cholesterol) by precipitation method .....	<del>((BR))</del> <u>15.7</u>
83599 Ketosteroids, 17-OH, RIA .....	<del>((64.1))</del> <u>55.0</u>	83719 Lipoprotein very low density cholesterol (VLDL cholesterol) by ultracentrifugation .....	<del>((BR))</del> <u>76.6</u>
83600 Kynurenic acid .....	<del>((90.0))</del> <u>108.1</u>		
83605 Lactate, (lactic acid) .....	<del>((40.0))</del> <u>3.9</u>		
83610 Lactic dehydrogenase (LDH), RIA .....	<del>((33.7))</del> <u>21.6</u>		

	Unit Value		Unit Value
83720 Lipoprotein cholesterol fractionation calculation by formula .....	<del>((BR))</del> 96.3	83858 Methsuximide, serum .....	<del>((90-0))</del> 66.8
83725 Lithium, blood, quantitative .....	<del>((60-0))</del> 31.4	(Methyl alcohol, see 82078)	
(Luteinizing hormone (LH), see 83002)		83859 Methypylon .....	<del>((90-0))</del> 41.3
83727 Luteinizing releasing factor (LRH), RIA .....	<del>((60-0))</del> 78.6	(Microglobulin, beta-2, RIA, see 82231, 82232)	
83728 Lysergic acid diethylamide (LSD), RIA .....	<del>((BR))</del> 114.0	83860 Morphine, screening .....	<del>((80-0))</del> 66.8
83730 (Macroglobulins (Sia) test) .....	<del>((30-0))</del> 31.4	83861 quantitative .....	<del>((120-0))</del> 106.1
(Macroglobulins, alpha-2-Sia, see 86329)		83862 RIA .....	<del>((82-0))</del> 96.3
83735 Magnesium, blood; chemical .....	<del>((20-0))</del> 27.5	83864 Mucopolysaccharides, acid, blood .....	<del>((60-0))</del> 57.0
83740 fluorometric .....	<del>((20-0))</del> 27.5	83865 Mucopolysaccharides, acid, urine; quantitative .....	<del>((60-0))</del> 80.6
83750 atomic absorption .....	<del>((40-0))</del> 29.5	83866 screen .....	<del>((21-0))</del> 49.1
83755 Magnesium, urine, chemical .....	<del>((40-0))</del> 27.5	83872 Mucin, synovial fluid (Ropes test) .....	<del>((21-0))</del> 23.6
83760 fluorometric .....	<del>((40-0))</del> 33.4	83873 Myeline basic protein, CSF, RIA .....	<del>((BR))</del> 98.2
83765 atomic absorption .....	<del>((40-0))</del> 33.4	(For oligoclonal bands, see 83916)	
83775 Malate dehydrogenase, kinetic ultraviolet method .....	<del>((30-0))</del> 31.4	83874 Myoglobin, electrophoresis .....	<del>((30-0))</del> 47.2
(Maltose tolerance, see 82951, 82952)		83875 Myoglobin, urine .....	<del>((40-0))</del> 51.1
(Mamotropin, see 84146)		83880 Nalorphine .....	<del>((60-0))</del> 94.3
83785 Manganese, blood or urine .....	<del>((60-0))</del> 106.1	83885 Nickel, urine .....	<del>((100-0))</del> 82.5
83790 Mannitol clearance .....	<del>((BR))</del> 33.4	83887 Nicotine .....	<del>((75-0))</del> 106.1
(Marijuana, see tetrahydrocannabinol THC, 84408)		83895 Nitrogen, total; urine, 24-hour specimen .....	<del>((60-0))</del> 58.9
83795 Melanin, urine, qualitative .....	<del>((60-0))</del> 33.4	83900 feces, 24-hour specimen .....	<del>((100-0))</del> 78.6
83799 Meperidine, quantitative .....	<del>((54-0))</del> 70.7	83910 Nonprotein nitrogen (NPN), blood .....	<del>((20-0))</del> 27.5
(For screen, see 82486, 82489, 82662, 82755, 84231)		83912 Nucleic acid probe with electrophoresis, with examination and report .....	BR
83805 Meprobamate, blood or urine .....	<del>((60-0))</del> 80.6	(Norepinephrine, see 82382-82384)	
(For screen, see 82486, 82489, 84231)		83915 Nucleotidase 5'- .....	<del>((25-0))</del> 55.0
83825 Mercury, quantitative; blood .....	<del>((70-0))</del> 60.9	83916 Oligoclonal immune globulin (Ig), CSF, by electrophoresis .....	<del>((BR))</del> 98.2
83830 urine .....	<del>((70-0))</del> 60.9	(For myelin basic protein, CSF, see 83873)	
(Mercury screen, see 83015)		83917 Organic acids; screen, qualitative .....	<del>((30-0))</del> 74.7
83835 Metanephrines, urine .....	<del>((52-0))</del> 74.7	83918 quantitative .....	<del>((30-0))</del> BR
(For catecholamines, see 82382-82384)		83920 Ornithine carbamyl transferase (OCT) .....	<del>((24-0))</del> 29.5
83840 Methadone .....	<del>((60-0))</del> 76.6	83930 Osmolality; blood .....	<del>((20-0))</del> 31.4
(Methamphetamine, see 82145)		83935 urine .....	<del>((20-0))</del> 31.4
(Methanol, see 82078)		83938 Ouabain .....	<del>((BR))</del> 57.0
83842 Methapyrilene .....	<del>((50-0))</del> 84.5	83945 Oxalate, urine .....	<del>((40-0))</del> 57.0
83845 Methaqualone .....	<del>((90-0))</del> 74.7	(For alpha-oxoglutarate, see 83584)	
83857 Methemalbumin .....	<del>((32-0))</del> 49.1	83946 Oxazepam .....	<del>((40-0))</del> 70.7
(Methemoglobin, see hemoglobin 83045-83050)		83947 Oxybutyric acid, beta .....	<del>((40-0))</del> 25.5

	Unit Value		Unit Value
83948 Oxycodone .....	(( <del>52.0</del> )) <u>72.7</u>	84060 Phosphatase, acid; blood .....	(( <del>24.0</del> )) <u>64.8</u>
(Oxygen, see gases, blood, 82790-82817)		84065 prostatic fraction .....	(( <del>40.0</del> )) <u>43.2</u>
83949 Oxytocinase, RIA .....	(( <del>52.0</del> )) <u>57.0</u>	84066 prostatic fraction, RIA .....	(( <del>60.0</del> )) <u>33.4</u>
(Para-aminohippuric acid, see 82134)		84075 Phosphatase, alkaline, blood .....	(( <del>24.0</del> )) <u>21.6</u>
83965 Paraldehyde, blood, quantitative .....	(( <del>60.0</del> )) <u>72.7</u>	84078 heat stable (total not included) .....	(( <del>16.0</del> )) <u>35.4</u>
83970 Parathormone (parathyroid hormone), RIA .....	(( <del>165.0</del> )) <u>167.0</u>	84080 isoenzymes, electrophoretic method .....	(( <del>BR</del> )) <u>64.8</u>
(PBI, see 83533)		84081 Phosphatidylglycerol .....	(( <del>BR</del> )) <u>82.5</u>
83971 Penicillin, urine .....	(( <del>50.0</del> )) <u>57.0</u>	84082 Phosphates, tubular reabsorption of (TRP) .....	(( <del>60.0</del> )) <u>90.4</u>
83972 Pentazocine .....	(( <del>60.0</del> )) <u>62.9</u>	(Phosphates, inorganic, see 84100-84105)	
83973 Pentose, urine, qualitative .....	(( <del>13.5</del> )) <u>25.5</u>	(Phosphates, organic, see 82480-82484)	
(For TLC screen, see 84375)		84083 Phosphoglucomutase, isoenzymes .....	(( <del>60.0</del> )) <u>92.3</u>
(83974 has been deleted)		84085 Phosphogluconate, 6-, dehydrogenase, RBC .....	(( <del>18.0</del> )) <u>27.5</u>
83975 Pepsinogen, blood .....	(( <del>40.0</del> )) <u>60.9</u>	84087 Phosphohexose isomerase .....	(( <del>30.0</del> )) <u>47.2</u>
83985 Pesticide other than chlorinated hydrocarbons, blood, urine, or other material .....	(( <del>BR</del> )) <u>43.2</u>	84090 Phospholipids, blood .....	(( <del>30.0</del> )) <u>31.4</u>
(Pesticide, chlorinated hydrocarbons, see 82441)		(See also 83705)	
83986 pH, body fluid, except blood .....	(( <del>BR</del> )) <u>15.7</u>	(For lecithin/sphingomyelin ratio, see 83661)	
(For blood, see 82800, 82802, 82803, 82817)		84100 Phosphorus (phosphate); blood .....	(( <del>24.0</del> )) <u>19.6</u>
83992 Phencyclidine (PCP) .....	(( <del>38.0</del> )) <u>72.7</u>	84105 urine .....	(( <del>24.0</del> )) <u>19.6</u>
(Phenobarbital, see barbiturates 82205-82210)		(Pituitary gonadotropins, see 83000-83002)	
83995 Phenol, blood or urine .....	(( <del>60.0</del> )) <u>70.7</u>	(PKU, see 81005, 84030, 84031)	
84005 Phenolsulphonphthalein (PSP), test, urine .....	(( <del>20.0</del> )) <u>21.6</u>	84106 Porphobilinogen, urine; qualitative .....	(( <del>20.0</del> )) <u>13.8</u>
84021 Phenothiazine, urine; qualitative, chemical .....	(( <del>100.0</del> )) <u>41.3</u>	84110 quantitative .....	(( <del>20.0</del> )) <u>39.3</u>
(See also 82486 et seq.)		84118 Porphyrins, copro-, urine; quantitative .....	(( <del>30.0</del> )) <u>35.4</u>
84022 quantitative, chemical .....	(( <del>BR</del> )) <u>74.7</u>	84119 qualitative .....	(( <del>24.0</del> )) <u>39.3</u>
(See also individual drugs)		84120 Porphyrins; copro- and uro-, fractionated, urine ..	(( <del>64.0</del> )) <u>68.8</u>
84030 Phenylalanine (PKU), blood; Guthrie .....	(( <del>12.0</del> )) <u>19.6</u>	84121 uro-, copro-, and porphobilinogen, urine .....	(( <del>80.0</del> )) <u>82.5</u>
(Phenylalanine-tyrosine ratio, see 84030, 84510)		84126 Porphyrins, feces, quantitative .....	(( <del>100.0</del> )) <u>125.7</u>
84031 fluorometric .....	(( <del>12.0</del> )) <u>25.5</u>	84128 Porphyrins, plasma .....	(( <del>82.0</del> )) <u>90.4</u>
84033 Phenylbutazone .....	(( <del>20.0</del> )) <u>80.6</u>	(Porphyrin precursors, see 82135)	
84035 Phenylketones; blood, qualitative .....	(( <del>20.0</del> )) <u>11.8</u>	(For protoporphyrin, RBC, see 84202, 84203)	
84037 urine, qualitative .....	(( <del>20.0</del> )) <u>11.8</u>	84132 Potassium; blood .....	(( <del>24.0</del> )) <u>7.9</u>
84038 Phenylpropanolamine .....	(( <del>20.0</del> )) <u>29.5</u>	84133 urine .....	(( <del>24.0</del> )) <u>19.6</u>
84039 Phenylpyruvic acid; blood .....	(( <del>20.0</del> )) <u>17.7</u>	84135 Pregnanediol; RIA .....	(( <del>BR</del> )) <u>104.1</u>
84040 urine .....	(( <del>20.0</del> )) <u>3.9</u>	84136 other method (specify) .....	(( <del>BR</del> )) <u>27.5</u>
(For qualitative chemical tests, urine, see 81005)		84138 Pregnanetriol; RIA .....	(( <del>BR</del> )) <u>102.2</u>
84045 Phenytoin .....	(( <del>61.0</del> )) <u>64.8</u>	84139 other method (specify) .....	(( <del>BR</del> )) <u>84.5</u>
		84141 Primidone .....	(( <del>60.0</del> )) <u>62.9</u>
		84142 Procainamide .....	(( <del>60.0</del> )) <u>74.7</u>

	Unit Value		Unit Value
84144 Progesterone, any method .....	(( <del>105.0</del> )) <u>49.1</u>	84234 progesterone .....	(( <del>BR</del> )) <u>247.6</u>
(Progesterone receptor assay, see 84234)		84235 endocrine, other than estrogen or progesterone (specify hormone) .....	(( <del>BR</del> )) <u>257.4</u>
(For proinsulin, RIA, see 84206)		84236 progesterone and estrogen .....	(( <del>BR</del> )) <u>314.4</u>
84146 Prolactin (mammotropin), RIA .....	(( <del>225.0</del> )) <u>96.3</u>	84238 nonendocrine (e.g., acetylcholine) (specify recep- tor) .....	(( <del>BR</del> )) <u>172.9</u>
84147 Propoxyphene .....	(( <del>60.0</del> )) <u>96.3</u>	84244 Renin (angiotensin I); (RIA) .....	(( <del>60.0</del> )) <u>92.3</u>
(For screen, see 82486 et seq.)		(See also 82163, angiotensin II)	
84149 Propranolol .....	(( <del>BR</del> )) <u>60.9</u>	84246 furosemide test .....	(( <del>BR</del> )) <u>106.1</u>
84150 Prostaglandin, any one, RIA .....	(( <del>BR</del> )) <u>121.8</u>	(Renin converting enzyme, see 82164)	
84155 Protein, total, serum; chemical .....	(( <del>20.0</del> )) <u>21.6</u>	84252 Riboflavin (Vitamin B-2) .....	(( <del>BR</del> )) <u>84.5</u>
84160 refractometric .....	(( <del>12.0</del> )) <u>21.6</u>	(Salicylates, see 82011, 82012)	
84165 electrophoretic fractionation and quantitation...	(( <del>60.0</del> )) <u>45.2</u>	(Saline infusion test, see 82091)	
84170 Protein, total and albumin/globulin ratio .....	(( <del>40.0</del> )) <u>35.4</u>	(Secretin test, see 89100 and appropriate analyses)	
(For serum albumin, see 82040; serum globulin, see 82942)		84255 Selenium, blood, urine or tissue .....	(( <del>100.0</del> )) <u>106.1</u>
84175 Protein, other sources, quantitative .....	(( <del>24.0</del> )) <u>27.5</u>	84260 Serotonin, blood .....	(( <del>120.0</del> )) <u>58.9</u>
84176 Protein, special studies (e.g., monoclonal protein analysis) .....	(( <del>BR</del> )) <u>49.1</u>	(For urine metabolites, see 83497)	
84180 Protein, urine; quantitative, 24-hour specimen ...	(( <del>24.0</del> )) <u>21.6</u>	84275 Sialic acid, blood .....	(( <del>50.0</del> )) <u>66.8</u>
84185 Bence-Jones .....	(( <del>12.0</del> )) <u>31.4</u>	(Sickle hemoglobin, see 83020, 83052, 83053, 85660)	
84190 electrophoretic fractionation and quantitation...	(( <del>80.0</del> )) <u>45.2</u>	84285 Silica, blood, urine or tissue .....	(( <del>100.0</del> )) <u>108.1</u>
84195 Protein, spinal fluid; semi-quantitative (Pandy) ...	(( <del>20.0</del> )) <u>21.6</u>	84295 Sodium; blood .....	(( <del>24.0</del> )) <u>17.7</u>
84200 electrophoretic fractionation and quantitation...	(( <del>80.0</del> )) <u>33.4</u>	84300 urine .....	(( <del>24.0</del> )) <u>17.7</u>
84201 Protirelin, thyrotropin releasing hormone (TRH) test .....	(( <del>BR</del> )) <u>78.6</u>	(Somatomammotropin, see 83632)	
84202 Protoporphyrin, RBC; quantitative .....	(( <del>30.0</del> )) <u>70.7</u>	(Somatotropin, see 83003; chorionic, see 83632)	
84203 screen .....	(( <del>20.0</del> )) <u>29.5</u>	84310 Sorbitol dehydrogenase, serum .....	(( <del>20.0</del> )) <u>33.4</u>
84205 Protiptylene .....	(( <del>68.0</del> )) <u>60.9</u>	84315 Specific gravity (except urine) .....	(( <del>8.0</del> )) <u>9.8</u>
84206 Proinsulin, RIA .....	(( <del>60.0</del> )) <u>57.0</u>	(For urine specific gravity, see 81000)	
84207 Pyridoxine (Vitamin B-6) .....	(( <del>BR</del> )) <u>98.2</u>	(84317 has been deleted)	
84208 Pyrophosphate vs. urate, crystals (polarization) ...	(( <del>12.0</del> )) <u>25.5</u>	84318 Stercobilin, qualitative, feces .....	(( <del>BR</del> )) <u>47.2</u>
84210 Pyruvate, blood .....	(( <del>30.0</del> )) <u>45.2</u>	(Stone analysis, see 82355-82370)	
84220 Pyruvic kinase, RBC .....	(( <del>30.0</del> )) <u>47.2</u>	84324 Strychnine .....	(( <del>75.0</del> )) <u>66.8</u>
84228 Quinine .....	(( <del>30.0</del> )) <u>57.0</u>	(Sugar, see under glucose)	
84230 Quinidine, blood .....	(( <del>40.0</del> )) <u>58.9</u>	84375 Sugars, chromatographic, TLC or paper chroma- tography .....	(( <del>80.0</del> )) <u>7.9</u>
84231 Radioimmunoassay (RIA) not elsewhere specified .	(( <del>BR</del> )) <u>64.8</u>	(Sulfhemoglobin, see hemoglobin, 83055-83060)	
(Reinsch test, see 83015)		84395 Sulfonamide, blood, chemical .....	(( <del>20.0</del> )) <u>29.5</u>
84232 Releasing factor .....	(( <del>BR</del> )) <u>51.1</u>	(T-3, see 84435, 84479, 84480)	
84233 Receptor assay; estrogen (estradiol) .....	(( <del>BR</del> )) <u>247.6</u>	(T-4, see 84435-84439)	
		84403 Testosterone, blood, RIA .....	(( <del>105.0</del> )) <u>117.9</u>

	Unit Value		Unit Value
84405 Testosterone, urine, RIA .....	(( <del>120.0</del> )) 121.8	(Trichloroacetaldehyde, see 82400-82405)	
84406 Testosterone, binding protein .....	(( <del>BR</del> )) 104.1	84476 Trifluoperazine .....	(( <del>36.0</del> )) 66.8
84407 Tetracaine .....	(( <del>BR</del> )) 76.6	84478 Triglycerides, blood .....	(( <del>30.0</del> )) 15.7
84408 Tetrahydrocannabinol THC (marijuana) .....	(( <del>BR</del> )) 39.3	(See also 83705)	
84409 Tetrahydrocortisone or tetrahydrocortisol .....	(( <del>105.0</del> )) 143.4	84479 Triiodothyronine (T-3), resin uptake .....	(( <del>BR</del> )) 27.5
(See also 83491-83497)		84480 Triiodothyronine true (TT-3), RIA .....	(( <del>36.0</del> )) 45.2
84410 Thallium, blood or urine .....	(( <del>100.0</del> )) 121.8	84481 Triiodothyronine, free (FT-3), RIA (unbound T-3 only) .....	(( <del>BR</del> )) 84.5
84420 Theophylline, blood or saliva .....	(( <del>60.0</del> )) 37.3	84483 Trimethadione .....	(( <del>36.0</del> )) 66.8
84425 Thiamine (Vitamin B-1) .....	(( <del>BR</del> )) 98.2	84485 Trypsin, duodenal fluid .....	(( <del>30.0</del> )) 13.8
84430 Thiocyanate, blood .....	(( <del>30.0</del> )) 55.0	84488 Trypsin, feces; qualitative, 24-hour specimen .....	(( <del>30.0</del> )) 13.8
84434 Thioridazine .....	(( <del>40.0</del> )) 66.8	84490 quantitative .....	(( <del>30.0</del> )) 17.7
(Thyrotropin releasing hormone (TRH) test, see 84201)		(Tubular reabsorption of phosphate, blood and urine, see 84082)	
84435 Thyroxine, (T-4), CPB or resin uptake .....	(( <del>33.0</del> )) 25.5	84510 Tyrosine, blood .....	(( <del>40.0</del> )) 49.1
84436 Thyroxine, true (TT-4), RIA .....	(( <del>21.0</del> )) 15.7	(Ultracentrifugation, lipoprotein, see 83717)	
84437 Thyroxine (T-4), neonatal .....	(( <del>20.0</del> )) 23.6	(Urate vs. pyrophosphate crystals, see 84208)	
84439 Thyroxine, free (FT-4), RIA (unbound T-4 only) .....	(( <del>45.0</del> )) 25.5	84520 Urea nitrogen, blood (BUN); quantitative .....	(( <del>22.0</del> )) 21.6
84442 Thyroxine binding globulin (TBG) .....	(( <del>52.0</del> )) 37.3	84525 stick test .....	(( <del>8.0</del> )) 5.9
(Thyroxine, free thyroxine index, T-7, see 82756)		84540 Urea nitrogen urine .....	(( <del>20.0</del> )) 23.6
(Thyroid hormones, thyroxine, etc., see 84435-84439, 84479-84481)		84545 Urea nitrogen clearance .....	(( <del>40.0</del> )) 33.4
84443 Thyroid stimulating hormone (TSH), RIA .....	(( <del>60.0</del> )) 43.2	84550 Uric acid; blood, chemical .....	(( <del>20.0</del> )) 21.6
(Thyroid stimulating hormone (TSH), neonatal, see 84800)		84555 uricase, ultraviolet method .....	(( <del>26.0</del> )) 25.5
84444 Thyrotropin releasing factor (TRF), RIA .....	(( <del>BR</del> )) 112.0	84560 Uric acid, urine .....	(( <del>20.0</del> )) 21.6
84445 plus long acting (LATS) .....	(( <del>BR</del> )) 233.8	84565 Urobilin, urine; qualitative .....	(( <del>12.0</del> )) 13.8
(Tobramycin, see 84810)		84570 quantitative, timed specimen .....	(( <del>24.0</del> )) 27.5
84446 Tocopherol alpha (Vitamin E) .....	(( <del>30.0</del> )) 62.9	84575 Urobilin, feces, quantitative .....	(( <del>60.0</del> )) 62.9
(Tolbutamide tolerance, see 82953)		84577 Urobilinogen, feces, quantitative .....	(( <del>30.0</del> )) 60.9
84447 Toxicology, screen; general .....	(( <del>BR</del> )) 68.8	84578 Urobilinogen, urine; qualitative .....	(( <del>24.0</del> )) 3.9
84448 sedative (acid and neutral drugs, volatiles) .....	(( <del>45.0</del> )) 76.6	84580 quantitative, timed specimen .....	(( <del>24.0</del> )) 31.4
84450 Transaminase, glutamic oxaloacetic (SGOT), blood; timed kinetic ultraviolet method .....	(( <del>24.0</del> )) 19.6	84583 semiquantitative .....	(( <del>20.0</del> )) 19.6
84455 colorimetric or fluorometric .....	(( <del>20.0</del> )) 19.6	84584 Uropepsin, urine .....	(( <del>24.0</del> )) 60.9
84460 Transaminase, glutamic pyruvic (SGPT), blood; timed kinetic ultraviolet method .....	(( <del>24.0</del> )) 23.6	(Uroporphyrins, see 84120, 84121)	
84465 colorimetric or fluorometric .....	(( <del>20.0</del> )) 23.6	(Valproic acid, see 80031)	
(Transferrin, see 86329)		84585 Vanillylmandelic acid (VMA), urine .....	(( <del>24.0</del> )) 64.8
84472 Trichloroethanol .....	(( <del>60.0</del> )) 88.4	84588 Vasopressin (antidiuretic hormone), RIA .....	(( <del>BR</del> )) 104.1
84474 Trichloroacetic acid .....	(( <del>36.0</del> )) 72.7	84589 Viscosity, fluid .....	(( <del>10.0</del> )) 27.5
		84590 Vitamin A, blood .....	(( <del>40.0</del> )) 58.9

	Unit Value
84595 including carotene .....	(( <del>60.0</del> )) <u>68.8</u>
(See also 82380)	
(Vitamin B-1, see 84425)	
(Vitamin B-2, see 84252)	
(Vitamin B-6, see 84207)	
(Vitamin B-12, blood, see 82606, 82607)	
(Vitamin B-12, absorption (Schilling), see 78270, 78271)	
(Vitamin C, see 82180)	
(Vitamin D, see 82306, 82307)	
(Vitamin E, see 84446)	
84597 Vitamin K .....	(( <del>BR</del> )) <u>66.8</u>
(VMA, see 84585)	
84600 Volatiles (acetic anhydride, carbon tetrachloride, dichloroethane, dichloromethane, diethylether)....	(( <del>45.0</del> )) <u>78.6</u>
(For acetaldehyde, see 82000)	
84605 Volume, blood, dye method (Evans blue) .....	(( <del>30.0</del> )) <u>37.3</u>
84610 including total plasma and total blood cell vol- ume .....	(( <del>50.0</del> )) <u>55.0</u>
(Volume, blood, RISA or Cr-51, see 78110, 78111)	
84613 Warfarin .....	(( <del>BR</del> )) <u>72.7</u>
84615 Xanthurenic acid .....	(( <del>BR</del> )) <u>153.2</u>
84620 Xylose tolerance test, blood and/or urine .....	(( <del>40.0</del> )) <u>53.0</u>
84630 Zinc, quantitative; blood .....	(( <del>100.0</del> )) <u>49.1</u>
84635 urine .....	(( <del>100.0</del> )) <u>47.2</u>
(84645 has been deleted)	
84681 C-peptide, any method .....	BR
84695 Gentamicin .....	(( <del>38.5</del> )) <u>80.6</u>
84702 Gonadotropin, chorionic; quantitative .....	(( <del>30.0</del> )) BR
84703 qualitative .....	(( <del>30.0</del> )) BR
84800 Thyroid stimulating hormone (TSH), neonatal....	(( <del>60.0</del> )) <u>74.7</u>
84810 Tobramycin .....	(( <del>BR</del> )) <u>76.6</u>
84999 Unlisted chemistry or toxicology procedure.....	BR

Note: Gas-liquid chromatography, paper chromatography, electrophoresis, nuclear medicine, enzyme immunoassay and radioimmunoassay techniques are being extended constantly for the analysis of many drugs, hormones and other substances. Where these methodologies are not specifically listed under the compound in question, such tests should be coded under the listing for the specific general methodology. (For immunodiffusion, immunoprecipitin, and counter-immunoelectrophoretic methods other than enzyme and radioimmunoassay techniques, see immunology section.)

**AMENDATORY SECTION** (Amending Order 89-09, filed 8/10/89, effective 9/10/89)

**WAC 296-23A-340 HEMATOLOGY.**

(Includes blood clotting (coagulation) procedures. For blood banking procedures, see under Immunology WAC 296-23A-345)	
(Agglutinins, see Immunology)	
(Antifactor (specific coagulation factors), see 85300-85341)	
(Antiplasmin, see 85410)	
(Antiprothrombinase, see 85311)	
(Antithrombin III, see 85300)	
(Basophil count, see 85005)	
	Unit Value
85000 Bleeding time; Duke .....	(( <del>10.0</del> )) <u>11.8</u>
85002 Ivy or template .....	(( <del>24.0</del> )) <u>17.7</u>
(Blood cell morphology only, see 85548)	
85005 Blood count; basophil count, direct .....	(( <del>10.0</del> )) <u>13.8</u>
85007 differential WBC count (includes RBC morphology and platelet estimation) .....	(( <del>7.5</del> )) <u>11.8</u>
(See also 85548, 85585)	
(For other fluids, e.g., CSF, see 89051, 89190)	
85009 differential WBC count, buffy coat .....	(( <del>12.0</del> )) <u>17.7</u>
85012 eosinophil count, direct .....	(( <del>10.0</del> )) <u>17.7</u>
(For nasal smear, see 89180)	
85014 hematocrit .....	(( <del>8.0</del> )) <u>7.9</u>
85018 hemoglobin, colorimetric.....	(( <del>8.0</del> )) <u>9.8</u>
(For other hemoglobin determination, see 83020-83068)	
85021 hemogram, automated (RBC, WBC, Hgb, Hct and indices only) .....	(( <del>10.5</del> )) <u>19.6</u>
85022 hemogram, automated, and manual differential WBC count (CBC) .....	(( <del>15.0</del> )) <u>27.5</u>
85023 hemogram and platelet count, automated, and manual differential WBC count (CBC).....	(( <del>17.0</del> )) <u>31.4</u>
85024 hemogram and platelet count, automated, and au- tomated partial differential WBC (CBC) .....	(( <del>17.0</del> )) <u>27.1</u>
85025 hemogram and platelet count, automated, and au- tomated complete differential WBC (CBC) .....	(( <del>17.0</del> )) <u>27.1</u>
85027 hemogram, automated, with platelet count .....	(( <del>12.0</del> )) <u>35.4</u>
85029 Additional automated hemogram indices (e.g., red cell distribution width (RDW), mean platelet vol- ume (MPV), red blood cell histogram, platelet histogram, white blood cell histogram, three part differential); one to three indices .....	(( <del>BR</del> )) <u>21.6</u>
85030 four or more indices .....	(( <del>BR</del> )) <u>21.6</u>
85031 Blood count; hemogram, manual, complete CBC (RBC, WBC, Hgb, Hct, differential and indices)...	(( <del>16.5</del> )) <u>15.7</u>
85041 red blood cell count (RBC) only .....	(( <del>8.0</del> )) <u>13.8</u>

	Unit Value		Unit Value
(See also 85021-85031, 89050)		<del>((82593))</del>	
85044 reticulocyte count <u>manual</u> . . . . .	<del>((12.0))</del> 17.7	<del>((85293))</del> 85293	high molecular weight kinninogen assay (Fitzgerald factor assay) . . . . .
85045 reticulocyte count, flow cytometry . . . . .	<del>BR</del>		<del>((BR))</del> 92.3
85048 white blood cell (WBC) . . . . .	<del>((8.0))</del> 13.8	85300 Clotting inhibitors or anticoagulants; antithrombin III, except antigen assay . . . . .	<del>((40.0))</del> 53.0
(See also 85021-85031)		85301 antithrombin III, antigen assay . . . . .	<del>((BR))</del> 53.0
85095 Bone marrow smear and/or cell block; aspiration only . . . . .	<del>((45.0))</del> 117.9	85302 protein C assay . . . . .	<del>((BR))</del> 58.9
85097 Smear interpretation only, with or without differen- tial cell count . . . . .	<del>((BR))</del> 29.5	85310 antithromboplastin . . . . .	<del>((40.0))</del> 49.1
(For interpretation of smear, use 85097; for cell block in- terpretation, see 88304, 88305)		85311 antiprothrombinase . . . . .	<del>((40.0))</del> 51.1
85100 aspiration, staining and interpretation . . . . .	<del>((140.0))</del> 229.9	85320 antiprothromboplastin . . . . .	<del>((40.0))</del> 49.1
85101 aspiration and staining only . . . . .	<del>((75.0))</del> 153.2	85330 antifactor VIII . . . . .	<del>((40.0))</del> 29.5
(For special stains, see 85535, 85540, 85560, 88312- 88313)		85340 cross recalcification time (mixtures) . . . . .	<del>((40.0))</del> 43.2
85102 Bone marrow needle biopsy <u>needle or trocar</u> . . . . .	<del>((75.0))</del> 153.2	85341 PTT inhibition test . . . . .	<del>((BR))</del> 21.6
85103 staining and interpretation . . . . .	<del>((60.0))</del> 115.9	85345 Coagulation time; Lee and White . . . . .	<del>((30.0))</del> 21.6
85109 staining and preparation only . . . . .	<del>((30.0))</del> 53.0	85347 activated . . . . .	<del>((20.0))</del> 15.7
(For bone biopsy, see 20220)		85348 other methods . . . . .	<del>((BR))</del> 17.7
85170 Clot retraction; screen . . . . .	<del>((8.0))</del> 17.7	(Complete blood count, see 85021-85031)	
85171 quantitative . . . . .	<del>((45.0))</del> 37.3	(Differential count, see 85007 et seq.)	
85172 inhibition by drugs . . . . .	<del>((BR))</del> 13.8	(Drug inhibition, clot retraction, see 85172)	
85175 Clot lysis time, whole blood dilution . . . . .	<del>((40.0))</del> 17.7	(Duke bleeding time, see 85000)	
(Clotting factor I (fibrinogen), see 82730, 85371-85377)		(Eosinophil count, direct, see 85012)	
85210 Clotting factor II prothrombin, specific . . . . .	<del>((40.0))</del> 55.0	(Eosinophils, microscopic examination for, in various body fluids, see 89180)	
(See also 85610-85618)		(Ethanol gel, see 85363)	
85220 factor V (AcG or proaccelerin) labile factor . . . . .	<del>((40.0))</del> 84.5	85360 Euglobulin lysis . . . . .	<del>((40.0))</del> 15.7
85230 factor VII (proconvertin, stable factor) . . . . .	<del>((40.0))</del> 84.5	(Fetal hemoglobin, see 83030-83033, 85460)	
85240 factor VIII (AHG), one stage . . . . .	<del>((40.0))</del> 86.4	85362 Fibrin degradation (split) products (FDP)(FSP); ag- glutination, slide . . . . .	<del>((12.0))</del> 33.4
85242 factor VIII (AHG), two stage . . . . .	<del>((40.0))</del> 84.5	85363 ethanol gel . . . . .	<del>((10.0))</del> 25.5
85244 factor VIII related antigen quantitation . . . . .	<del>((BR))</del> 98.2	85364 hemagglutination inhibition (Merskey), microtiter . . . . .	<del>((36.0))</del> 55.0
85250 factor IX (PTC or Christmas) . . . . .	<del>((40.0))</del> 88.4	85365 immunoelectrophoresis . . . . .	<del>((BR))</del> 88.4
85260 factor X (Stuart-Prower) . . . . .	<del>((40.0))</del> 88.4	85367 precipitation . . . . .	<del>((18.0))</del> 27.5
85270 factor XI (PTA) . . . . .	<del>((40.0))</del> 88.4	85368 protamine paracoagulation (PPP) . . . . .	<del>((BR))</del> 43.2
85280 factor XII (Hageman) . . . . .	<del>((40.0))</del> 88.4	85369 staphylococcal clumping . . . . .	<del>((12.0))</del> 17.7
85290 factor XIII (fibrin stabilizing) . . . . .	<del>((40.0))</del> 80.6	(Fibrinogen, quantitative, see 82730)	
85291 factor XIII (fibrin stabilizing), screen solubility . . . . .	<del>((40.0))</del> 37.3	85371 Fibrinogen, semiquantitative; latex . . . . .	<del>((40.0))</del> 31.4
85292 preallikrein assay (Fletcher factor assay) . . . . .	<del>((BR))</del> 92.3	85372 turbidimetric . . . . .	<del>((22.5))</del> 35.4
		85376 Fibrinogen; thrombin with plasma dilution . . . . .	<del>((24.0))</del> 39.3
		85377 thrombin time dilution . . . . .	<del>((36.0))</del> 51.1
		85390 Fibrinolysins; screening . . . . .	<del>((20.0))</del> 13.8

	Unit Value		Unit Value
85392 with EACA control .....	((BR)) 41.3	(Plasminogen, see 85420)	
85395 semiquantitative .....	((30.0)) 35.4	(Plasminogen activator, see 85665)	
85398 Fibrinolysis, quantitative .....	((45.0)) 21.6	85575 Platelet; adhesiveness (in vivo) .....	((45.0)) 29.5
85400 Fibrinolytic mechanisms; plasmin .....	((BR)) 21.6	85576 aggregation (in vitro), any agent .....	((BR)) 94.3
85410 antiplasmin .....	((BR)) 21.6	85577 retention (in vitro), glass bead .....	((30.0)) 53.0
85420 plasminogen, except antigenic assay .....	((BR)) 21.6	85580 count (Rees-Ecker) .....	((14.0)) 21.6
(For plasminogen activator, see 85665)		85585 estimation on smear, only .....	((10.0)) 7.9
85421 plasminogen, antigenic assay .....	((BR)) 47.2	(See also 85007)	
85426 Von Willebrand factor assay .....	((BR)) 110.0	85590 phase microscopy .....	((20.0)) 19.6
(Fragility, red blood cell, see 85547, 85555-85557)		85595 electronic technique .....	((20.0)) 15.7
85441 Heinz bodies; direct .....	((9.0)) 13.8	(Protamine paracoagulation (PPP), see 85368)	
85445 induced, acetyl phenylhydrazine .....	((19.5)) 29.5	85610 Prothrombin time .....	((16.0)) 11.8
(Hematocrit (PCV), see 85014, 85021-85031)		(See also 85618)	
(Hemoglobin, see 83020-83068, 85018-85031)		85612 Russell viper venom type (includes venom) .....	((36.0)) 41.3
85460 Hemoglobin, fetal, differential lysis (Kleihauer) .....	((26.0)) 27.5	(85614 has been deleted)	
(See also 83030, 83033)		85615 Prothrombin utilization (consumption) .....	((40.0)) 17.7
(Hemogram, see 85021-85031)		85618 Prothrombin - Proconvertin, P & P (Owren) .....	((18.0)) 17.7
(Hemolysins, see 86006, 86281, 86282)		(Red blood cell count, see 85021-85031)	
85520 Heparin assay .....	((60.0)) 33.4	85630 Red blood cell size (Price-Jones) .....	((40.0)) 45.2
85530 Heparin-protamine tolerance test .....	((60.0)) 70.7	85632 Red blood cell peroxide hemolysis .....	((30.0)) 39.3
85535 Iron stain (RBC or bone marrow smears) .....	((18.0)) 27.5	85635 Reptilase test .....	((35.0)) 49.1
(Ivy bleeding time, see 85002)		(Reticulocyte count, see 85044)	
85538 Leder stain (esterase) blood or bone marrow .....	((30.0)) 47.2	(Rumpel-Leede test, see 85165)	
85540 Leucocyte alkaline phosphatase with count .....	((20.0)) 41.3	85650 Sedimentation rate (ESR); Wintrobe type .....	((14.0)) 15.7
85544 Lupus erythematosus (LE) cell prep .....	((20.0)) 41.3	85651 Westergren type .....	((10.5)) 15.7
(Lysozyme, see 85548)		85660 Sickling of RBC, reduction, slide method .....	((14.0)) 17.7
85547 Mechanical fragility, RBC .....	((30.0)) 43.2	(Sickling, electrophoresis, see 83020)	
85548 Morphology of red blood cells, only .....	((9.0)) 13.8	(Sickling, solubility, S-D, see 83053)	
85549 Muramidase, serum .....	((52.0)) 82.5	(Sickling, turbidimetric (Sickledex dithionate), see 83052)	
(Nitroblue tetrazolium dye test, see 86384)		(Siderocytes, see 85535)	
85555 Osmotic fragility, RBC .....	((15.0)) 31.4	(Smears for parasites, malaria, etc., see 87207)	
85556 incubated, qualitative .....	((18.0)) 41.3	(Staphylococcal clumping test, see 85369)	
85557 incubated, quantitative .....	((60.0)) 60.9	85665 Streptokinase titer (plasminogen activator) .....	((BR)) 84.5
(Packed cell volume, see 85014)		85667 T-cell depletion (any method) of bone marrow for transplantation .....	BR
(Partial thromboplastin time, see 85730-85732)		85670 Thrombin time; plasma .....	((20.0)) 23.6
(Parasites, blood, e.g., malaria smears, see 87207)		85675 titer .....	((12.0)) 23.6
85560 Peroxidase stain, WBC .....	((15.0)) 23.6		
(Plasmin, see 85400)			



	Unit Value
85700 Thromboplastin generation test; screening (Hicks-Pitney) .....	<del>((40-0))</del> 41.3
85710 definitive, with platelet substitute .....	<del>((45-0))</del> 41.3
85711 with patient's platelets .....	<del>((45-0))</del> 41.3
85720 all factors .....	<del>((BR))</del> 92.3
(For individual clotting factors, see 85210 et seq.)	
85730 Thromboplastin time, partial (PTT); plasma or whole blood .....	<del>((30-0))</del> 19.6
85732 substitution, plasma .....	<del>((30-0))</del> 31.4
(For thromboplastin inhibition test, see 85341)	
(Tourniquet test, see 85165)	
85810 Viscosity, blood .....	<del>((40-0))</del> 27.5
85820 serum or plasma .....	<del>((40-0))</del> 57.0
(Von Willebrand factor assay, see 85426)	
(WBC count, see 85021-85031, 85048, 89050)	
85999 Unlisted hematology procedure .....	BR

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-23A-345 IMMUNOLOGY.**

(Includes serology, immunohematology and blood banking)

(Acetylcholine antireceptor antibody, see 86685)

(Acid hemolysins, see 86281)

(Actinomycosis, see 86000-86009)

(Adrenal cortex antibodies, RIA, see 86681)

	Unit Value
86000 Agglutinins; febrile, each antigen .....	<del>((14-0))</del> 33.4
86002 febrile panel (typhoid O & H, paratyphoid A & B, brucella and Proteus OX-19) .....	<del>((45-0))</del> 49.1
86004 warm .....	<del>((36-0))</del> 11.8
(Agglutinins and autohemolysins, see 86004, 86011-86013, 86281-86283, 86006-86009)	
(Agglutinins, auto, see 86282-86283, 86011, 86013)	
(Agglutinins, cold, see 86006, 86013, 86282, 86283)	
(Alpha-1 antitrypsin, see 86064, 86067, 86329)	
(Alpha-1 feto-protein, see 86244)	
(Anti-AChR (acetylcholine receptor) antibody titer, see 86685)	
86006 Antibody, <u>non-RBC</u> qualitative, ( <del>(not otherwise specified;)</del> ) first antigen, slide or tube .....	<del>((12-0))</del> 25.5
86007 each additional antigen .....	<del>((7-5))</del> 9.8

	Unit Value
86008 Antibody, <u>non-RBC</u> quantitative titer, ( <del>(not otherwise specified;)</del> ) first antigen .....	<del>((18-0))</del> 25.5
86009 each additional antigen .....	<del>((12-0))</del> 11.8
86011 Antibody, detection, leukocyte antibody .....	<del>((44-0))</del> 45.2
86012 Antibody absorption, cold auto absorption; per serum .....	<del>((30-0))</del> 53.0
(For elution, see 86019)	
86013 differential .....	<del>((45-0))</del> 80.6
86014 Antibody, platelet antibodies (agglutinins) .....	<del>((45-0))</del> 23.6
86016 ( <del>(Antibodies, RBC, saline, high protein and antihuman globulin technique)</del> ) <u>Antibody screen, RBC, each serum</u> .....	<del>((30-0))</del> 53.0
(See also 86032)	
<del>((86017 with ABO Rh(D) typing (for holding blood instead of complete crossmatch) .....</del>	<del>24-0</del>
86018 <u>enzyme technique including antihuman globulin</u> .....	17.0)
<u>(86017 has been deleted. To report, use 86083)</u>	
<u>(For antibody screen using enzyme technique, see 86016, 86411)</u>	
86019 <u>Antibody (RBC) elution, any method, each elution</u> ..	<del>((45-0))</del> 80.6
86021 Antibody identification; leukocyte antibodies .....	<del>((60-0))</del> 74.7
86022 platelet antibodies .....	<del>((75-0))</del> 104.1
86023 platelet associated immunoglobulin assay .....	<del>((BR))</del> 51.1
86024 <u>RBC antibodies ((<del>8-10 cell panel</del>) standard technique) each panel</u> .....	<del>((38-0))</del> 64.8
<del>((86026 RBC antibodies (8-10 cell panel), with enzyme technique including antihuman globulin .....</del>	<del>52-0</del>
<u>(For absorption and elution, see 86012-86013, 86019)</u>	
<del>86028 saline or high protein, each (Rh, AB, etc.) .....</del>	<del>12-0)</del>
(Antibody to specific nuclear antigen, use 86235)	
(Anti-DNA, see 86225)	
(Anti-deoxyribonuclease titer, see 86215)	
86031 Antihuman globulin test; direct (Coombs) ( <del>(1-3 dilutions)</del> ) <u>(broad, IgG and non-IgG), each</u> .....	<del>((12-0))</del> 23.6
86032 indirect, qualitative (broad, gamma or nongamma, each) .....	<del>((15-0))</del> 9.8
86033 indirect, titer (broad, gamma or nongamma each) .....	<del>((12-0))</del> 25.5
86034 enzyme technique, qualitative .....	<del>((30-0))</del> 53.0
<del>((86035 drug sensitization, identification (e.g., penicillin) .....</del>	<del>75-0)</del>
(For antibody detection (screening), see 86016, 86017)	
86038 Antinuclear antibodies (ANA), RIA .....	<del>((55-0))</del> 60.9
(Antinuclear antibodies, fluorescent technique, see 86255, 86256)	
(86045 has been deleted)	
(Antistreptococcal antibody, anti-DNAse, see 86215)	

	Unit Value		Unit Value
(Antistreptokinase titer, see 86590)		type).....	((68-0)) 45.2
86060 Antistreptolysin O titer .....	((20-0)) 17.7	<del>((86120 special (Kell, Duffy).....</del>	<del>BR))</del>
86063 screen .....	((10-0)) 11.8	86128 Collection and processing of predeposited autologous whole blood or components .....	((BR)) 74.7
86064 Antitrypsin, alpha-1; RIA .....	((20-0)) 58.9	86130 Collection and processing for transfusion of inoperatively salvaged blood .....	BR
86066 Pi (Protease inhibitor) typing .....	((20-0)) 58.9	(Bovine milk antibody, see 86008, 86009)	
86067 other method (specify) .....	((20-0)) 62.9	(Brucellosis, see 86000-86002)	
(Autoagglutinins, see 86282, 86283)		86140 C-reactive protein .....	((20-0)) 25.5
(Autoantibodies, see specific antigens)		(Candidiasis, see 86008)	
(Blastomycosis, see 86006-86009)		86149 Carcinoembryonic antigen (CEA); gel diffusion ....	((60-0)) 70.7
86068 Blood ( <del>crossmatch, complete standard technique;</del> <del>includes typing and antibody screening of recipient</del> <del>and donor, first unit)) <u>compatibility test; crossmatch</u> <u>by immediate spin and antihuman globulin tech-</u> <u>nique, each unit .....</u></del>	((60-0)) 51.1	86151 RIA .....	((60-0)) 70.7
<del>((86069 each additional unit .....</del>	<del>45.0</del>	86155 Chemotaxis assay, specify method .....	((BR)) 49.1
86072 <del>Blood crossmatch; enzyme technique .....</del>	<del>10.5))</del>	(Coccidioidomycosis, see 86006-86009, 86171, 86490)	
(86069 has been deleted. To report, see 86068, 86070)		(Cold agglutinin or hemolysin, see 86006-86013, 86282, 86283)	
86070 <u>crossmatch by immediate spin technique only ....</u>	BR	86158 Complement; C'1 esterase .....	((52-0)) 58.9
(86072 has been deleted)		86159 C'2 esterase .....	((52-0)) 49.1
(For blood compatibility test using enzymes, see codes 86068, 86411)		86162 total (CH 50) .....	((70-0)) 98.2
<del>((86073 screening for compatible unit saline and/or high protein .....</del>	<del>26.0</del>	86163 C'3 esterase .....	((BR)) 21.6
86074 <del>antiglobulin technique .....</del>	<del>15.0))</del>	86164 C'4 esterase .....	((BR)) 62.9
(For enzyme technique, see 86018)		(For complement fractions, quantitative, see 86329)	
<del>((86075 Blood crossmatch, minor only (plasma, Rh im-</del> <del>mune globulin), includes recipient and donor typ-</del> <del>ing and antibody screening, first unit .....</del>	<del>44.0</del>	86171 Complement fixation tests, each antigen .....	((40-0)) 47.2
86076 <del>each additional unit .....</del>	<del>27.0</del>	(Coombs test, see 86031-86035)	
(For incompatibility problems, see 86004, 86011-86014, 86016-86026, 86031-86035, 86068-86076))		86185 Counterelectrophoresis, each antigen .....	((24-0)) 35.4
(For typing, antibody screening and blood in lieu of crossmatch, see 86017)		(For HAA, see 86287)	
(For transfusion, see 36400-36460, 36510, 36660)		(Crossmatch, see 86068-86076)	
86080 Blood typing; ABO only .....	((12-0)) 19.6	(Cryptococcosis, see 86008, 86009, 86255, 86256)	
86082 ABO and Rho(D) .....	((18-0)) 19.6	86215 Deoxyribonuclease, antibody .....	((36-0)) 64.8
<del>((86090 MN .....</del>	<del>20.0))</del>	86225 Deoxyribonucleic acid (DNA) antibody .....	((36-0)) 64.8
86083 <u>ABO, Rh(D) and RBC antibody screening .....</u>	BR	(86227-86229 have been deleted)	
86084 <u>antigen screening for compatible blood unit using</u> <u>reagent serum, per unit screened .....</u>	BR	(Direct antiglobulin test (Coombs), see 86031)	
86085 <u>antigen screening for compatible unit using pa-</u> <u>tient's serum, per unit screened .....</u>	BR	(Donath-Landsteiner screen, see 86008, 86009)	
(86090 has been deleted)		(Drug sensitization, RBC, see 86035)	
86095 ( <del>Blood typing;)) RBC antigens, other than ABO</del> <del>((or) and/or Rho(D))(<del>antiglobulin technique;</del></del> <del>each antigen) .....</del>	((10-5)) 15.7	(Echinococcosis, see 86171, 86280)	
<del>((86096 direct, slide or tube, including Rh subtypes,</del> <del>each antigen .....</del>	<del>10.5))</del>	(For particle agglutination rapid test for infectious agent, use 86403)	
86100 ( <del>Blood typing;)) Rho(D) only .....</del>	((12-0)) 15.7	(For HIV HTLV-III antibody tests, see 86312-86314)	
86105 Rh genotyping, complete .....	((45-0)) 19.6	(Eosinophils, nasal smear, see 89190)	
(For Rho variant Du, see 86095)		86235 Antibody to specific nuclear antigen, any method, each .....	((30-0)) 47.2
86115 anti-Rh immunoglobulin testing (RhoGAM		86243 Fc receptor assay, specify method .....	((BR)) 90.4

	Unit Value		Unit Value
86244 Feto-protein, alpha-1, RIA or EIA .....	(( <del>57.0</del> )) <u>72.7</u>	86310 plus titers after absorption with beef cells and guinea pig kidney .....	(( <del>30.0</del> )) <u>35.4</u>
(Filariasis, see 86280)		(Histoplasmosis, see 86006-86009, 86171)	
86255 Fluorescent antibody; screen .....	(( <del>24.0</del> )) <u>47.2</u>	(HLA typing, see 86812-86817)	
86256 titer .....	(( <del>36.0</del> )) <u>47.2</u>	(Hormones, see individual alphabetic listing in chemistry section)	
(Fluorescent technique for antigen identification in tissue, see 88346)		86311 HIV antigen test .....	<u>BR</u>
86265 Frozen blood, preparation for freezing, each unit including processing and collection .....	BR	86312 HIV (HTLV-III) antibody detection; immunoassay .....	(( <del>BR</del> )) <u>53.0</u>
86266 with thawing .....	BR	86314 confirmatory test (e.g., Western blot) .....	(( <del>BR</del> )) <u>82.5</u>
86267 with freezing and thawing .....	BR	(Human growth hormone antibody, RIA, see 86277)	
(FTA, see 86650)		86316 Immunoassay for tumor antigen (e.g., prostate specific antigen, cancer antigen 125) .....	BR
(Gc grouping, see 86335)		86317 Immunoassay for infectious agent antigen or antibody, each .....	BR
(Gel (agar) diffusion tests, see 86331)		(For particle agglutination rapid test for infectious agent antigen, use 86403)	
(Gm grouping, see 86335)		86318 Immunoassay for chemical constituent .....	BR
(Gonadotropins, chorionic, see 82996-82998, 84701)		86319 Immunoassay technique for drugs .....	<u>BR</u>
86277 Growth hormone, human (HGH), antibody, RIA ..	(( <del>BR</del> )) <u>74.7</u>	(For immunoassay for bacteria, use 86317)	
(Ham test, see 86281)		86320 Immunelectrophoresis, serum, each specimen (plate) .....	(( <del>100.0</del> )) <u>88.4</u>
86280 Hemagglutination inhibition tests (HAI), each (e.g., rubella, viral) .....	(( <del>60.0</del> )) <u>21.6</u>	86325 other fluids (e.g., urine) with concentration, each specimen .....	(( <del>100.0</del> )) <u>88.4</u>
86281 Hemolysins, acid (for paroxysmal hemoglobinuria) (Ham test) .....	(( <del>24.0</del> )) <u>43.2</u>	86327 crossed (2 dimensional assay) .....	(( <del>BR</del> )) <u>106.1</u>
86282 Hemolysins and agglutinins, auto, screen, each ....	(( <del>30.0</del> )) <u>33.4</u>	86329 Immunodiffusion; quantitative, each IgA, IgG, IgM, ceruloplasmin, transferrin, alpha-2, macroglobulin, complement fractions, alpha-1 antitrypsin, or other (specify) .....	(( <del>30.0</del> )) <u>66.8</u>
86283 incubated with glucose (e.g., ATP) .....	(( <del>75.0</del> )) <u>55.0</u>	86331 gel diffusion, qualitative (Ouchterlony) each antigen or antibody .....	(( <del>30.0</del> )) <u>58.9</u>
(Cold, see 86006-86009; warm, see 86004; acid, see 86281)		86332 Immune complex assay; Clq binding cell .....	BR
(86285, 86286 have been deleted)		86333 Raji cell .....	BR
86287 Hepatitis B surface antigen (HB <sub>s</sub> Ag) (Australian antigen, HAA), RIA or EIA .....	(( <del>36.0</del> )) <del>36.0</del> <u>51.1</u>	86334 Immuno fixation electrophoresis .....	BR
(For gel diffusion technique, see 86331; CF, see 86171; HAI, see 86280)		(For ceruloplasmin by chemical method, see 82390)	
86288 Hepatitis B core antigen (HB <sub>c</sub> Ag), RIA .....	(( <del>BR</del> )) <u>53.0</u>	(IgE, RIA, see 82785; RIST, see 86423)	
86289 Hepatitis B core antibody (HB <sub>c</sub> Ab), RIA or EIA ..	(( <del>BR</del> )) <u>58.9</u>	86335 Immunoglobulin typing (Gc, Gm, Inv), each .....	(( <del>BR</del> )) <u>43.2</u>
86290 IgM antibody (e.g., RIA, EIA, RPHA) .....	(( <del>BR</del> )) <u>82.5</u>	(Insulin antibody, see 86016)	
86291 Hepatitis B surface antibody (HB <sub>s</sub> Ab) (e.g., RIA, EIA, RPHA) .....	(( <del>BR</del> )) <u>45.2</u>	86337 Insulin antibodies, RIA .....	(( <del>BR</del> )) <u>98.2</u>
86293 Hepatitis Be antigen (HB <sub>e</sub> Ag) (e.g., RIA, EIA) ...	(( <del>BR</del> )) <u>49.1</u>	86338 Insulin factor antibodies, RIA .....	(( <del>32.0</del> )) <u>88.4</u>
86295 Hepatitis Be antibody (HB <sub>e</sub> Ab) (e.g., RIA, EIA) ..	(( <del>BR</del> )) <u>49.1</u>	86340 Intrinsic factor antibodies, RIA .....	(( <del>32.0</del> )) <u>70.7</u>
86296 Hepatitis A antibody (HAAb) (e.g., RIA, EIA) ...	(( <del>BR</del> )) <u>57.0</u>	(Intrinsic factor, antibody (fluorescent), see 86255, 86256)	
86298 IgG antibody .....	(( <del>BR</del> )) <u>53.0</u>	(Inv grouping, see 86335)	
86299 IgM antibody .....	(( <del>BR</del> )) <u>53.0</u>	(Latex fixation, see 86403)	
86300 Heterophile antibodies, screening (includes monotype test) slide or tube .....	(( <del>20.0</del> )) <u>19.6</u>	(LE cell preparation, see 85544)	
86305 quantitative titer .....	(( <del>30.0</del> )) <u>31.4</u>	(LE factor, see 86006, 86007, 86255, 86256)	
		(Leptospirosis, see 86006-86009)	
		(Leukoagglutinins, see 86013, 86021)	
		86342 Irradiation of blood products, each .....	<u>BR</u>

	Unit Value		Unit Value
86343 Leukocyte histamine release test (LHR) . . . . .	((BR)) 58.9	86421 Radioallergosorbent test, in vitro testing for allergen specific IgE (e.g., RAST, MAST, FAST, IP, PRIST, etc.); up to 5 tests . . . . .	((BR)) 60.9
86344 Leukocyte phagocytosis . . . . .	((BR)) 39.3	86422 6 or more tests . . . . .	((BR)) 29.5
86349 Leukocyte transfusion (leukapheresis) . . . . .	((BR)) 235.8	86423 Radioimmunosorbent test (RIST) IgE, quantitative . . . . .	((BR)) 74.7
(Lymphocyte culture, see 86353)		(Rapid plasma reagin test (RPR), see 86592)	
86353 Lymphocyte transformation, spontaneous blastogenesis or phytomitogen (phytohemagglutina- tion, PHA) or other mitogen culture (MC) (e.g., tu- berculin, candida) . . . . .	((+20-0)) 241.7	86430 Rheumatoid factor, latex fixation . . . . .	((+2-0)) 15.7
86357 Lymphocytes; T & B differentiation . . . . .	((+65-0)) 29.5	(RIST, see 86423)	
86358 B-cell evaluation . . . . .	((BR)) 96.3	(RPR, see 86592)	
(Malaria, see 87207)		(Rubella, CF, see 86171; HAI, see 86280)	
(Melioidosis, see 86280)		(Serologic test for syphilis (STS), see 86171, 86592, 86593)	
86376 Microsomal antibody (thyroid); RIA . . . . .	((BR)) 62.9	86455 Skin test; anergy testing, one or more antigens . . . . .	((BR)) 15.7
86377 other method (specify) . . . . .	((30-0)) 66.8	86490 coccidioidomycosis, each test . . . . .	((20-0)) 15.7
86378 Migration inhibitory factor test (MIF) . . . . .	((BR)) 82.5	86510 histoplasmosis . . . . .	((20-0)) 15.7
(Milk antibody, antiovine, see 86008-86009)		86540 mumps . . . . .	((20-0)) 15.7
(Mitochondrial antibody, liver, see 86255-86256)		86580 tuberculosis, patch or intradermal . . . . .	((20-0)) 15.7
(Mononucleosis screening slide, see 86006-86007)		86585 tuberculosis, tine test . . . . .	((+2-0)) 15.7
86382 Neutralization test, viral . . . . .	((BR)) 82.5	(Smooth muscle antibody, see 86255, 86256)	
86384 Nitroblue tetrazolium dye test (NTD) . . . . .	((BR)) 45.2	86587 Splitting of blood or blood products, each . . . . .	BR
(Ouchterlony diffusion, see 86331)		(Sporotrichosis, see 86006-86009)	
(Parietal cell antibody, see 86255, 86256)		86590 Streptokinase, antibody . . . . .	((27-0)) 33.4
86385 Paternity testing, ABO + Rh factors + MN (per individual) . . . . .	((37-5)) 149.3	(Streptolysin O antibody, see antistreptolysin O, 86060- 86063)	
86386 each additional antigen system . . . . .	((+5-0)) 21.6	(Streptobacillus, see 86008, 86009)	
(Penicillin antibody RBC, see 86035)		86592 Syphilis test; qualitative (e.g., VDRL, RPR, ART) . . . . .	((9-0)) 9.8
(Platelet antibodies (agglutinins), see 86014)		86593 quantitative . . . . .	((+5-0)) 19.6
(Platelet associated immunoglobulin assay, see 86023)		(Tetanus, see 86280)	
(86402 has been deleted)		(Thyroglobulin antibody, see 86006-86009, 86171)	
86403 Particle agglutination, rapid test for infectious agent antigen, each antigen . . . . .	((BR)) 21.6	(Thyroglobulin antibody, RIA, see 86800)	
86404 Pooling of platelets or other blood products . . . . .	BR	(Thyroglobulin, RIA, use 86318)	
(For immunoassay for infectious agent antigen, use 86317)		86594 Thyroid autoantibodies . . . . .	((BR)) 64.8
86405 Precipitin test for blood (species identification) . . . . .	((BR)) 45.2	86595 Tissue culture . . . . .	((BR)) 57.0
(Pregnancy test, see 84702, 84703, 86006-86009)		86600 Toxoplasmosis, dye test . . . . .	((80-0)) 62.9
86410 Pretreatment of RBC's for use in RBC antibody de- tection, identification, and/or compatibility testing; incubation with chemical agents or drugs, each . . . . .	BR BR	(For CF, see 86171; IFA, see 86255, 86256)	
86411 incubation with enzymes, each . . . . .	BR	86630 Transfer factor test (TFT) . . . . .	((BR)) 33.4
86412 by density gradient separation . . . . .	BR	86650 Treponema antibodies, fluorescent, absorbed (FTA- Abs) . . . . .	((30-0)) 41.3
86417 Pretreatment of serum for use in RBC antibody identification; incubation with drugs, each . . . . .	BR BR	(86660 has been deleted)	
86418 by dilution . . . . .	BR	86662 Treponema pallidum test, other, specify (e.g., TPIA, TPA, TPMB, TPCF, RPCF) . . . . .	((BR)) 64.8
86419 incubation with inhibitors, each . . . . .	BR	(Trichinosis, see 86006-86009)	
86420 by differential red cell absorption using patient RBC's or RBC's of known phenotype, each ab- sorption . . . . .	BR		

	Unit Value
(Trypanosomiasis, see 86171, 86280)	
(Tuberculosis, see 86580, 86585, 87116-87118, 87190)	
(VDRL, see 86592)	
(Viral antibodies, see 86171, 86280, 86382)	
(Visceral larval migrans, see 86280)	
(Warm agglutinins, see 86004)	
86681 Adrenal cortex antibodies, RIA . . . . .	((31-0)) 86.4
86685 Anti-AChR (acetylcholine receptor) antibody titer . . . . .	((BR)) 153.2
86687 HTLV I, antibody detection; immunoassay . . . . .	BR
86689 confirmatory test . . . . .	BR
86800 Thyroglobulin antibody, RIA . . . . .	((31-0)) 76.6
(For pretransplant crossmatch, use appropriate code or codes)	
86805 Lymphocytotoxicity assay, visual crossmatch; with titration . . . . .	BR
86806 without titration . . . . .	BR
86807 Serum screening for cytotoxic percent reactive antibody (PRA); standard method . . . . .	BR
86808 quick method . . . . .	BR
(86810 has been deleted)	
86812 Tissue typing; HLA typing, A, B, or C (e.g., A10, B7, B27), single antigen . . . . .	((BR)) 117.9
86813 HLA typing, A, B, and/or C (e.g., A10, B7, B27), multiple antigens . . . . .	((BR)) 102.2
86816 HLA typing, DR, single antigen . . . . .	((BR)) 369.4
86817 HLA typing, DR, multiple antigen . . . . .	((BR)) 316.3
86821 lymphocyte culture, mixed (MLC) . . . . .	((BR)) 277.0
86822 lymphocyte culture, primed (PLC) . . . . .	((BR)) 170.9
86999 Unlisted immunology procedure . . . . .	BR

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-23A-350 MICROBIOLOGY.**

	Unit Value
(Includes bacteriology, mycology, parasitology, and virology)	
87001 Animal inoculation, small animal; with observation . . . . .	((36-0)) 62.9
87003 with observation and dissection . . . . .	((45-0)) 72.7
87015 Concentration (any type), for parasites, ova, or tubercle bacillus (TB, AFB) . . . . .	((20-0)) 29.5
87040 Culture, bacterial, definitive, blood (includes anaerobic screen) . . . . .	((48-0)) 33.4
87045 stool . . . . .	((25-0)) 41.3
87060 throat or nose . . . . .	((20-0)) 15.7
87070 any other source . . . . .	((16-0)) 25.5

(For urine, see 87086-87088)

	Unit Value
87072 Culture or direct bacterial identification method, each organism, by commercial kit, any source except urine . . . . .	((BR)) 21.6
(For urine, see 87087)	
87075 Culture, bacterial, any source; anaerobic (isolation) . . . . .	((36-0)) 33.4
87076 definitive identification, each anaerobic organism, including gas chromatography . . . . .	((60-0)) 45.2
87081 Culture, bacterial, screening only, for single organisms . . . . .	((15-0)) 17.7
87082 Culture, presumptive, pathogenic organisms, screening only, by commercial kit (specify type); for single organisms . . . . .	((BR)) 21.6
87083 multiple organisms . . . . .	((BR)) 33.4
87084 with colony estimation from density chart . . . . .	((BR)) 43.2
87085 with colony count . . . . .	((BR)) 43.2
(For urine colony count, see 87086)	
87086 Culture, bacterial, urine; quantitative, colony count . . . . .	((15-0)) 15.7
87087 commercial kit . . . . .	((12-0)) 31.4
87088 identification, in addition to quantitative or commercial kit . . . . .	((12-0)) 33.1
87101 Culture, fungi, isolation; skin . . . . .	((15-0)) 37.3
87102 other source (except blood) . . . . .	((18-0)) 37.3
87103 blood . . . . .	((18-0)) BR
87106 Culture, fungi, definitive identification of each fungus . . . . .	((30-0)) 47.2
87109 Culture, mycoplasma, any source . . . . .	((75-0)) 49.1
87110 Culture, mycobacteria, definitive identification of each organism . . . . .	BR
87116 Culture, tubercle or other acid-fast bacilli (e.g., TB, AFB, mycobacteria); any source, isolation only . . . . .	((18-0)) 47.2
87117 concentration plus isolation . . . . .	((30-0)) 42.7
87118 Culture, mycobacteria, definitive identification of each organism . . . . .	((30-0)) 42.7
87140 Culture, typing; fluorescent method each antiserum . . . . .	((20-0)) 42.5
87143 gas liquid chromatography (GLC) method . . . . .	((45-0)) 60.9
87145 phage method . . . . .	((40-0)) 33.4
87147 serologic method agglutination grouping, per antiserum . . . . .	((20-0)) 49.1
87151 serologic method, speciation . . . . .	((20-0)) 27.5
87155 precipitin method, grouping, per antiserum . . . . .	((12-0)) 17.7
87158 other methods . . . . .	((20-0)) 17.7
87163 Culture, any source, additional identification methods required (use in addition to primary culture code) . . . . .	((BR)) 55.0

	Unit Value		Unit Value
87164	((60.0))	Dark field examination, any source (e.g., penile, vaginal, oral, skin); includes specimen collection	((6.0)) <u>BR</u>
	<u>45.2</u>		
87166	((36.0))	without collection	(Electron microscopy, see 88348)
	<u>45.2</u>		
87174	((24.0))	chemical	(Inclusion bodies in tissue sections, see 88304-88309; in smears, see 87207-87210; in fluids, see 88106)
	<u>43.2</u>		
87175	BR	biological assay (e.g., Limulus lysate)	87999 Unlisted microbiology procedure
87176	((15.0))	homogenization, tissue, for culture	BR
	<u>29.5</u>		
87177	((36.0))	Ova and parasites, direct smears, concentration and identification	
	<u>33.4</u>		
		(Individual smears and procedures, see 87015, 87208-87211)	
		(Trichrome, iron hemotoxylin and other special stains, see 88312)	
87178	BR	Microbial identification, nucleic acid probes, each probe used	Unit Value
		(For nucleic acid probes in cytologic material, use 88365)	
87181	((40.0))	Sensitivity studies, antibiotic; agar diffusion method, each antibiotic	88104 Cytopathology, fluids, washings or brushings, with centrifugation except cervical or vaginal; smears and interpretation
	<u>23.6</u>		((45.0)) <u>70.7</u>
87184	((24.0))	disc method, each plate (12 or less discs)	88106 filter method only with interpretation
	<u>15.7</u>		((45.0)) <u>27.5</u>
87186	((45.0))	microtiter, minimum inhibitory concentration (MIC), any number of antibiotics	88107 smears and filter preparation with interpretation
	<u>29.5</u>		((60.0)) <u>72.7</u>
87187	BR	minimum bactericidal concentration (MBC) (use in addition to 87186 or 87188)	88108 concentration technique, smears and interpretation (e.g., Saccomanno technique)
87188	((36.0))	macrotube dilution method, each antibiotic	((BR)) <u>147.4</u>
	<u>33.4</u>		
87190	((60.0))	tubercle bacillus (TB, AFB), each drug	(For cervical or vaginal smears, see 88150)
	<u>13.8</u>		(For gastric intubation with lavage, see 89130-89141)
87192	BR	fungi, each drug	(For x-ray localization, see 74340)
87197	BR	Serum bactericidal titer (Schlichter test)	
87205	((12.0))	Smear, primary source, with interpretation; routine stain for bacteria, fungi, or cell types	88125 Cytopathology, forensic (e.g., sperm)
	<u>19.6</u>		((75.0)) <u>123.8</u>
87206	((18.0))	fluorescent and/or acid fast stain for bacteria, fungi, or cell types	88130 Sex chromatin identification; (Barr bodies)
	<u>27.5</u>		((40.0)) <u>43.2</u>
87207	((24.0))	special stain for inclusion bodies or intracellular parasites (e.g., malaria, kala azar, herpes)	88140 peripheral blood smear, polymorphonuclear "drum sticks"
	<u>17.7</u>		((40.0)) <u>9.8</u>
87208	((12.0))	direct or concentrated, dry, for ova and parasites	(For guard stain, see 88313)
	<u>27.5</u>		
		(For concentration, see 87015; complete examination, see 87177)	88150 Cytopathology, smears, cervical or vaginal (e.g., Papanicolaou), screening by technician under physician supervision, up to three smears
		(For complex special stains, see 88312-88313)	((BR)) <u>17.7</u> <u>BR</u>
		(For fat, meat fibers, nasal eosinophils, and starch, see miscellaneous section)	((80151) requiring interpretation by physician)
87210	((12.0))	wet mount with simple stain, for bacteria, fungi, ova, and/or parasites	88155 with definitive hormonal evaluation (e.g., maturation index, karyopyknotic index, estrogenic index)
	<u>9.8</u>		((40.0)) <u>21.6</u>
87211	((18.0))	wet and dry mount, with interpretation, for ova and parasites	88160 Cytopathology, any other source; screening and interpretation
	<u>17.7</u>		((36.0)) <u>45.2</u>
87220	((BR))	Tissue examination for fungi (e.g., KOH slide)	88161 preparation, screening and interpretation
	<u>21.6</u>		((BR)) <u>53.0</u>
87230	BR	Toxin or antitoxin assay, tissue culture (e.g., Clostridium difficile toxin)	88162 extended study involving over 5 slides and/or multiple stains
87250	((12.0))	Virus identification; inoculation of embryonated eggs, or small animal, includes observation and dissection	BR
	<u>35.4</u>		(For obtaining specimen, see percutaneous needle biopsy under individual organ in Surgery)
87252	((12.0))	tissue culture, inoculation and observation	(For aerosol collection of sputum, see 89350)
	<u>BR</u>		(For special stains, see 88312-88314)
87253	BR	tissue culture, additional studies (e.g.,	88170 Fine needle aspiration with or without preparation of smears; superficial tissue (e.g., thyroid, breast, prostate)
			BR
			88171 deep tissue under radiologic guidance
			(For CT guidance, see 76360, 76361; for ultrasonic guidance, see 76942, 76943; for fluoroscopic guidance use 76003)

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-23A-355 CYTOPATHOLOGY.**

	Unit Value
88172 Evaluation of fine needle aspirate with or without preparation of smears; immediate cytohistologic study to determine adequacy of specimen(s) . . . . .	BR
88180 Flow cytometry; each cell surface marker . . . . .	BR
88182 cell cycle or DNA analysis . . . . .	BR
88199 Unlisted cytopathology procedure . . . . .	BR
(For electron microscopy, see 88348)	
<b>CYTOGENETIC STUDIES</b>	
(For acetylcholinesterase, see 82013)	
(For alpha-fetoprotein, serum or amniotic fluid, see 86244)	
88230 Tissue culture for chromosome analysis; lymphocyte . . . . .	BR
88233 skin or other solid tissue biopsy . . . . .	BR
88235 amniotic fluid or chorionic villus cells . . . . .	BR
88237 bone marrow (myeloid) cells . . . . .	BR
88239 other tissue . . . . .	BR
88245 Chromosome analysis for breakage syndromes; score 25 cells (SCE study), count 5 cells, 1 karyotype, with banding (e.g., Bloom syndrome) . . . . .	BR
88248 score 100 cells, count 20 cells, 2 karyotypes, with banding (e.g., ataxia telangiectasia, Fanconi anemia) . . . . .	BR
88250 Chromosome analysis for fragile X associated with fragile X-linked mental retardation; score 100 cells, count 20 cells, 2 karyotypes, with banding . . . . .	BR
88260 Chromosome analysis for fragile X associated with fragile X-linked mental retardation; score 100 cells, count 20 cells, 2 karyotypes, with banding . . . . .	((+80-0)) 251.5
88261 count 5 cells, 1 karyotype with banding . . . . .	((+375-0)) 503.0
88262 count 15-20 cells, 2 karyotypes with banding . . . . .	((+525-0)) 756.4
88263 count 45 cells for mosaicism, 2 karyotypes, with banding . . . . .	((+675-0)) BR
88267 Chromosome analysis; amniotic fluid or chorionic villus, count 15 cells, 1 karyotype with banding . . . . .	((+600-0)) 858.6
(88265, 88268, and 88270 have been deleted)	
88269 Chromosome analysis; in situ for amniotic fluid cells, count cells from 6-12 colonies, 1 karyotype with banding . . . . .	BR
88280 additional karyotyping, each study . . . . .	((+75-0)) 110.0
88283 additional specialized banding technique (e.g., NOR, C-banding) . . . . .	BR
88285 additional cells counted, each study . . . . .	((+15-0)) 27.5
88289 additional high resolution study . . . . .	BR
88299 Unlisted cytogenetic study . . . . .	BR

**SURGICAL PATHOLOGY**

(Procedures 88300 through 88399 include accession, handling and reporting)

88300 Surgical pathology, gross examination only . . . . .	((+20-0)) 45.2
Note: Only one of the numbers 88302-88309 should be used in reporting specimens (single or multiple) that are removed from a single anatomic site.	
88302 Surgical pathology, gross and microscopic examination of presumptively normal tissue(s), for identification and record purposes . . . . .	((+60-0)) 96.3

	Unit Value
88304 Surgical pathology, gross and microscopic examination of presumptively abnormal tissue(s); uncomplicated specimen . . . . .	((+75-0)) 123.8
88305 single complicated specimen or specimen composed of multiple uncomplicated ((specimen(s))) tissues, without complex dissection . . . . .	((+105-0)) 172.9
88307 single complicated specimen requiring complex dissection or a specimen composed of multiple complicated ((specimens)) tissues . . . . .	((+150-0)) 239.7
88309 complex diagnostic problem with or without extensive dissection . . . . .	((BR)) 263.3
(For fine needle aspiration, preparation and interpretation of smears, see 88170-88173)	
88311 Decalcification procedure (list separately in addition to code for surgical pathology examination) . . . . .	((+12-0)) 19.6
88312 Special stains (list separately in addition to code for surgical pathology examination); Group I for microorganisms (e.g., Gridley, acid fast, methenamine silver), each . . . . .	((+25-0)) 39.3
88313 Group II, all other (e.g., iron, trichrome) except immunocytochemistry and immunoperoxidase stains, each . . . . .	((+12-0)) 19.6
(For immunocytochemistry and immunoperoxidase tissue studies, see 88342)	
88314 histochemical staining with frozen section(s) . . . . .	((BR)) 98.2
88318 Determinative histochemistry to identify chemical components (e.g., copper, zinc) . . . . .	BR
88319 Determinative histochemistry to identify enzyme constituents, each . . . . .	BR
88323 Preparation of slides on referred material . . . . .	BR
88331 Preparation of frozen section(s), single specimen . . . . .	((BR)) 182.7
88332 each additional frozen section during same visit to surgical operating suite . . . . .	((BR)) 96.3
88342 Immunocytochemistry (including tissue immunoperoxidase), each antibody . . . . .	BR
88346 Immunofluorescent study, each antibody direct method . . . . .	((BR)) 196.5
88347 indirect method . . . . .	BR
88348 Electron microscopy; diagnostic scanning . . . . .	BR
88349 scanning . . . . .	BR
88355 Morphometric analysis; skeletal muscle . . . . .	BR
88356 nerve . . . . .	BR
88358 tumor . . . . .	BR
88362 Nerve teasing preparations . . . . .	BR
88399 Unlisted surgical pathology procedure . . . . .	BR

**AMENDATORY SECTION (Amending Order 89-09, filed 8/10/89, effective 9/10/89)**

**WAC 296-23A-360 MISCELLANEOUS.**

	Unit Value
89050 Cell count, miscellaneous body fluids (e.g., CSF, joint fluid), except blood . . . . .	((+12-0)) 13.8
89051 with differential count . . . . .	((+20-0)) 23.6
89060 Crystal identification by compensated polarizing lens analysis; synovial fluid . . . . .	((BR)) 23.6

	Unit Value
89100 Duodenal intubation and aspiration; single specimen (e.g., simple bile study or afferent loop culture) plus appropriate test procedure . . . . .	(( <del>40.0</del> )) <u>112.0</u>
89105 collection of multiple fractional specimens with pancreatic or gallbladder stimulation, single or double lumen tube . . . . .	((BR)) <u>90.4</u>
(For radiological localization, see 74340)	
(For chemical analysis, see Chemistry and Toxicology)	
89125 Fat stain, feces, urine, sputum . . . . .	((+5.0)) <u>25.2</u>
89130 Gastric intubation and aspiration, diagnostic, each specimen, for chemical analyses or cytopathology . . . . .	(( <del>20.0</del> )) <u>37.3</u>
89132 after stimulation . . . . .	(( <del>45.0</del> )) <u>37.3</u>
89135 Gastric intubation and aspiration, and fractional collections (e.g., gastric secretory study); one hour. . . . .	(( <del>60.0</del> )) <u>66.8</u>
89136 two hours . . . . .	(( <del>90.0</del> )) <u>78.6</u>
89140 two hours including gastric stimulation (e.g., histalog, pentagastrin) . . . . .	((+105.0)) <u>90.4</u>
89141 three hours, including gastric stimulation . . . . .	((+120.0)) <u>102.2</u>
(For radiologic localization of gastric tube, see 74340)	
(For chemical analyses, see 82926-82932)	
(Joint fluid chemistry, see Chemistry and Toxicology)	
89160 Meat fibers, feces . . . . .	((+12.0)) <u>11.8</u>
89190 Nasal smear for eosinophils . . . . .	((BR)) <u>17.7</u>
89205 Occult blood, any source except feces . . . . .	((+10.5)) <u>11.8</u>
(Occult blood, feces, see 82270)	
(Paternity tests, see 86385, 86386)	
89300 Semen analysis; presence and/or motility of sperm including Huhner test . . . . .	((+12.0)) <u>41.3</u>
89310 motility and count . . . . .	(( <del>40.0</del> )) <u>19.6</u>
89320 complete (volume, count, motility and differential) . . . . .	(( <del>80.0</del> )) <u>41.3</u>
(Skin tests, see 86455-86585)	
89325 Sperm antibodies . . . . .	((BR)) <u>25.5</u>
89329 Sperm evaluation, hamster penetration test . . . . .	BR
(For medicolegal identification of sperm, see 88125)	
89330 cervical mucus penetration test, with or without spinnbarkeit test . . . . .	((BR)) <u>27.5</u>
89350 Sputum, obtaining specimen, aerosol induced technique (separate procedure) . . . . .	(( <del>20.0</del> )) <u>33.4</u>
89355 Starch granules, feces . . . . .	((+10.5)) <u>17.7</u>
89360 Sweat collection by iontophoresis . . . . .	((BR)) <u>57.0</u>
(For chloride and sodium analysis, see 82437, 84295)	
(Tissue culture, see 86595)	
(Tissue typing, see 86810-86822)	

	Unit Value
89365 Water load test . . . . .	((BR)) <u>25.5</u>
89399 Unlisted miscellaneous pathology test . . . . .	BR

**WSR 91-07-009**

**NOTICE OF PUBLIC MEETINGS  
CONVENTION AND TRADE CENTER**

[Memorandum—March 5, 1991]

The Design Committee of the Washington State Convention and Trade Center will meet on Wednesday, March 13, 1991, at 11:30 a.m. in Room 601 of the Convention Center, 800 Convention Place, Seattle.

The Washington State Convention and Trade Center board of directors will meet on Wednesday, March 13, 1991, at 2:00 p.m. in Room 601 of the Convention Center, 800 Convention Place, Seattle.

If you have any questions regarding these meetings, please call 447-5000.

**WSR 91-07-010**

**NOTICE OF PUBLIC MEETINGS  
WALLA WALLA COMMUNITY COLLEGE**

[Memorandum—March 7, 1991]

**SCHEDULE OF MEETINGS FOR WALLA WALLA  
COMMUNITY COLLEGE BOARD OF TRUSTEES  
1991**

- Wednesday, January 9, 1991
- Monday, February 4, 1991
- Wednesday, March 6, 1991
- Wednesday, April 3, 1991 in Clarkston
- Wednesday, May 1, 1991
- Monday, June 3, 1991
- Wednesday, June 26, 1991
- Wednesday, August 7, 1991 (optional)
- Wednesday, September 4, 1991
- Wednesday, October 2, 1991
- Wednesday, November 6, 1991
- Wednesday, December 4, 1991

**WSR 91-07-011**

**PERMANENT RULES  
DEPARTMENT OF  
SOCIAL AND HEALTH SERVICES  
(Public Assistance)**

[Order 3150—Filed March 11, 1991, 4:50 p.m.]

Date of Adoption: March 11, 1991.

WAC 388-81-030 Purpose: To delete the reference to the Division of Medical Assistance (DMA) as a single state agency administering Title XIX. Summary: Deletes the wording referring to DMA as the single state agency administering Title XIX. Reasons: Delete the



reference to DMA as the single state agency administering Title XIX. Rule is not necessary because of administrative reasons.

**WAC 388-82-140 Purpose:** To incorporate the new income levels for qualified Medicare beneficiaries (QMB). **Summary:** Effective January 1, 1991, QMB income level is 100 percent of the 1990 federal poverty level. **Reasons:** Incorporate into rules the QMB income levels effective January 1, 1991. Rule is necessary as a result of federal law or regulation, citation: 42 U.S.C. 1396d

**WAC 388-87-010 Purpose:** To incorporate changes in the federal regulations on payment of providers for medical services when a third party is liable. **Summary:** The department shall pay for medical services when there is a liable third party if the provider bills the third party and does not receive payment within thirty days of service. The benefits are from an absent parent who is not meeting their obligation to pay as designated by a court order or by receipt of a third party payment. The department shall pay and seek reimbursement for medical services for prenatal care, labor and delivery, and post-partum care (except inpatient hospital costs) preventive pediatric service or early and periodic screening diagnosis and treatment services. **Reasons:** Add provisions to pay a provider for medical services when there is a liable third party. Rule is necessary as a result of federal law or regulation, citation: 42 CFR 433.130

**WAC 388-95-337 Purpose:** To incorporate the increase in the resource standard for the community spouse. **Summary:** Effective January 1, 1991, the resource limit for the community spouse increases to \$66,480. **Reasons:** To reflect the increase in the community spouse resource limit. Rule is necessary as a result of federal law or regulations, citation: Department of Health and Human Services Title XIX State Agency Letter No. 90-11.

**WAC 388-95-360 Purpose:** To incorporate the federal changes in shelter expense for the community spouse. **Summary:** The shelter expense for the community spouse increases January 1, 1991, to \$1,662. **Reasons:** Include in the rules the increase in the shelter expense for the community spouse. Rule is necessary as a result of federal law or regulations, citation: Department of Health and Human Services Title XIX State Agency Letter No. 90-11.

**WAC 388-99-020 Purpose:** To show an increase in the medically needy income level (MNIL). **Summary:** The MNIL is increased effective January 1, 1991. The amount of increase varies according to the size of family. **Reasons:** To reflect an increase in the MNIL. Rule is necessary for administrative reasons.

**Citation of Existing Rules Affected by this Order:** Amending WAC 388-81-030, 388-82-140, 388-87-010, 388-95-360, 388-99-020, and 388-95-337.

**Statutory Authority for Adoption:** [RCW 74.08.090].

Pursuant to notice filed as WSR 91-02-090 on December 31, 1990.

Changes Other than Editing from Proposed to Adopted Version: WAC 388-82-140, changes in content from the proposed rule and the adopted version are as follows: The monthly income figures have been increased to reflect the increase in the federal poverty income guidelines effective April 1, 1991. The principal reasons for adopting the changes are the federal poverty income guidelines increase April 1, 1991. These amounts increase accordingly; and WAC 388-95-360, changes in content from the proposed rule and the adopted version are as follows: In subsection (1)(d), the shelter expenses is increased to \$270.90 from \$256.80. In subsection (1)(e), the maintenance needs for the family member residing with the community spouse is increased to one-third of the amount \$903 exceeds the family members's income. The previous amount was \$856. The principal reasons for adopting the changes are the federal poverty income guidelines increases April 1, 1991, which requires these figures to be increases accordingly.

**Effective Date of Rule:** Thirty-one days after filing.

March 11, 1991

Rosemary Carr

Acting Director

Administrative Services

**AMENDATORY SECTION** (Amending Order 1868, filed 8/18/82)

**WAC 388-81-030 CASE EXCEPTION.** A request for an exception to policy for medical care services denied by strict application of a rule or regulation requires approval by the division of medical assistance (~~(; the single state agency for administering Title XIX)~~). See WAC 388-20-020 for exception to policy procedures.

**AMENDATORY SECTION** (Amending Order 2987, filed 5/31/90, effective 7/1/90)

**WAC 388-82-140 QUALIFIED MEDICARE BENEFICIARIES ELIGIBLE FOR MEDICARE COST SHARING.** (1) The department shall provide Medicare cost sharing under WAC 388-81-060(2) for an individual:

((+)) (a) Meeting the general nonfinancial requirements under chapter 388-83 WAC; ((and))

((+)) (b) Entitled to Medicare hospital insurance benefits, Part A, under Title XVIII of the Social Security Act; ((and))

((+)) (c) Having resources not exceeding twice the maximum supplemental security income (SSI) resource limits under chapter 388-92 WAC; and

((+)) (d) Having a total countable family income, as determined under chapter 388-92 WAC, except as specified in subsection (2) of this section, not exceeding ((ninety)) one-hundred percent of the federal poverty income guidelines as published and updated by the secretary of health and human services. ((Ninety)) Effective April 1, 1991, one-hundred percent of the ((+1990)) 1991 federal poverty income guidelines is:

	Family Size	Monthly
<del>((a))</del> (i)	One	\$ <del>((47))</del> 552
<del>((b))</del> (ii)	Two	<del>((63))</del> 740
<del>((c))</del> (iii)	Three	<del>((79))</del> 928
<del>((d))</del> (iv)	Four	<del>((95))</del> 1,117
<del>((e))</del> (v)	Five	<del>((1,13))</del> 1,305
<del>((f))</del> (vi)	Six	<del>((1,27))</del> 1,493
<del>((g))</del> (vii)	Seven	<del>((1,43))</del> 1,682
<del>((h))</del> (viii)	Eight	<del>((1,59))</del> 1,870
<del>((i))</del> (ix)	For family units with more than eight members, add \$ <del>((16))</del> 188 to the monthly income for each additional member.	

(2) Effective January 1, 1991, for applicants and recipients, the department shall not consider Social Security Cost of Living Allowance increase until April 1, of each year.

**AMENDATORY SECTION** (Amending Order 2886, filed 10/27/89, effective 11/27/89)

WAC 388-87-010 CONDITIONS OF PAYMENT—GENERAL. (1) The department shall be responsible for payment of service rendered to a recipient only when the:

- (a) ~~((The))~~ Services are within the scope of care of the medical assistance program under chapter 388-86 WAC;
- (b) ~~((The))~~ Services are properly authorized;
- (c) ~~((The))~~ Services are billed properly;
- (d) ~~((The))~~ Services are timely billed as described under WAC ~~((388-88-015))~~ 388-87-015;
- (e) ~~((The))~~ Recipient is certified as eligible; and
- (f) Third-party payment procedures are followed.

(2) The fees and rates the department establishes shall constitute the maximum allowable payment for approved medical care and services ~~((provided))~~ the providers provide to recipients ~~((by the providers))~~.

(3) ~~((An "eligible"))~~ A "recipient" shall mean a person the department finds eligible for any medical program. The provider is responsible for ascertaining whether a client has medical coverage for the dates of service.

(4) A provider shall not bill, demand, or otherwise collect reimbursement from ~~((an-eligible))~~ a recipient, or from other persons on behalf of the recipient, for any service included in the medical program's scope of benefits, and the recipient is not liable for payment for such services if the provider:

- (a) Does not properly bill the department for services the department is responsible for payment; or
- (b) Fails to satisfy department conditions of payment, including but not limited to:
  - (i) Prior approval when required;
  - (ii) Timely billing and billing according to department instructions;
  - (iii) Pursuit of third-party liability; or
  - (iv) Adequate documentation of medical necessity.
- (5) The department shall not pay for services not included in the medical program's scope of benefits.

(6) A provider may bill ~~((an-eligible))~~ a recipient for services only when the:

(a) ~~((The))~~ Recipient signs a specific written agreement with the provider before receiving the services stating the:

- (i) Specific service provided;
- (ii) Service is not covered by the medical assistance program;
- (iii) Recipient chooses to receive the specific service;
- (iv) Agreement is to pay for the services; and
- (v) Agreement is void and unenforceable and the recipient is under no obligation to pay the provider if the:

- (A) Service is covered by the medical program; or
- (B) Provider fails to satisfy department conditions of payment as described under WAC 388-87-010 (4)(b).

(b) ~~((The))~~ Recipient received reimbursement directly from a third party for services the department has no payment responsibility for; or

(c) ~~((The))~~ Bill counts toward a spenddown liability or deductible as described under WAC 388-99-030 and chapter 388-100 WAC.

(7) If a third party pays a provider the department rate, or more, for a covered service, the provider may not bill the department or the recipient for that service.

(8) The department shall pay for medical services and seek reimbursement from any liable third party, when the claim is for:

- (a) Prenatal care;
- (b) Labor, delivery, and post-partum care (except in-patient hospital costs) for a pregnant woman; or
- (c) Preventive pediatric service as covered under the early and periodic screening, diagnosis and treatment (EPSDT) program.

(9) The department shall pay for medical services and seek reimbursement from any liable third party when the provider submits to the department documentation of billing the third party and the provider has not received payment after thirty days from the date of service and:

(a) The claim is for a covered service provided to a person on whose behalf the office of support enforcement is enforcing an absent parent to pay support.

(b) For the purposes of this section, "is enforcing" means the absent parent:

- (i) Is not complying with an existing court order; or
- (ii) Received payment directly from the third party and did not pay for the medical services.

(10) If the third party pays the provider, then the provider shall refund to the department the amount of the:

- (a) Third party payment when the payment is less than the department's maximum allowable rate; or
- (b) Department's payment if the third payment is equal to or greater than the department's maximum allowable rate.

(11) The department shall not be responsible for payment of medical care or services if the third-party benefits are available to pay the recipient's medical expenses at the time the provider bills the department, except as described in subsection (8) of this section.

(12) The recipient shall not be responsible for payment except to the extent as described in subsection (6)

of this section or to the extent the recipient has directly received third-party reimbursement for such services.

~~((9))~~ (13) A provider shall not refuse to furnish covered services to ~~(an eligible)~~ a recipient because of a third party's potential liability for the services.

~~((10))~~ (14) Payment for any service a provider furnishes to a recipient may not be made to or through a factor who advances money to that provider for accounts receivable.

~~((11))~~ (15) The department shall not be responsible for payment for medical care and goods ~~(and/or)~~ or services or all three provided to a recipient:

(a) Enrolled in a department-contracted, prepaid medical plan; and

(b) Failing to use the provider under contract unless:

(i) Emergency conditions exist; or

(ii) The department has approved payment to another provider for provision of a service not covered by the prepaid plan.

~~((12))~~ (16) Payment for care under the medical assistance ~~((or limited casualty-medically needy))~~ programs ~~((are))~~ is retroactive for three months before the month of application provided the applicant was eligible when the care was received. The applicant need not be eligible at the time of actual application. The central authorization unit's (CAU) medical consultant shall approve medical services that require approval for the retroactive period.

~~((13))~~ (17) Payment for care under the limited casualty program-medically indigent may be retroactive for seven days before the date of application if applicant is otherwise eligible. Medical services that require approval shall be approved by the CAU medical consultant for the retroactive period.

~~((14))~~ (18) The department may pay a claim a provider submits for payment for services rendered to a person subsequently determined ineligible at the time of service under the following conditions only when:

(a) The ineligible person was certified at the time of service as both financially ~~((and))~~ or medically eligible;

(b) Payment was not made from sources outside the department; and

(c) A request for such payment is submitted to and approved by the division of medical assistance.

~~((15))~~ (19) The department shall pay for billed medically necessary services on the basis of usual and customary charges or the rates the department establishes, whichever is lower.

~~((16))~~ (20) The department shall not authorize payment for well-~~((baby))~~ child care except as provided under the ~~((early periodic screening, diagnosis and treatment-))~~EPSDT~~(())~~ program. See WAC 388-86-027.

~~((17))~~ (21) In counties/areas where nonambulance transportation is provided as a medical service, payment for medically necessary transportation services, provided by nonprofit organizations, shall be based on the operating costs incurred in providing the service but shall not exceed the rates established by the department. See WAC 388-87-035 for nonambulance transportation payment other than provided by a nonprofit organization.

AMENDATORY SECTION (Amending Order 3007, filed 5/31/90, effective 7/1/90)

WAC 388-95-337 AVAILABILITY OF RESOURCES.

(1) Resources are defined under WAC 388-92-005 for the SSI-related applicant or recipient and under WAC 388-22-030 for an AFDC-related applicant or recipient.

(2) The methodology and standards for determining and evaluating resources are under WAC 388-95-340, 388-95-380, and 388-95-390. Transfers of resources are evaluated under WAC 388-95-395.

(3) The department shall follow Washington state community property principles in determining the ownership of resources:

(a) For persons whose most recent period of institutionalization~~((:~~

~~((:))~~ began before October 1, 1989~~((:))~~ and ~~((:))~~ remain~~((s))~~ continuously institutionalized.

(b) For purposes of Medicaid eligibility, the department shall presume all resources are:

(i) Community resources if jointly held in the names of both the husband and wife, or in the name of the applicant/recipient only;

(ii) The separate property of the nonapplicant spouse if:

(A) Held in the separate name of the nonapplicant spouse; or

(B) Transferred between spouses as described under WAC 388-92-043(6).

(c) The department shall divide by two, the total value of the community resources the husband and wife own and assign one-half of the total value to each spouse.

(4) A person is no longer continuously institutionalized if, for thirty consecutive days, the person:

(a) Is absent from an institution; or

(b) Does not receive COPES/CAP/OBRA/CCASA/HOSPICE waived services.

(5) The department shall use the following criteria for the purpose of determining Medicaid eligibility of a person, whose most recent continuous period of institutionalization starts on or after October 1, 1989:

(a) The department shall exclude resources in WAC 388-95-380 with the exception of subsection (3) under WAC 388-95-380. One automobile per couple is totally excluded without regard to use;

(b) The department shall consider available to the community spouse, resources in the name~~((s))~~ of either the community spouse or the institutionalized spouse, except resources exceeding the greater of:

(i) ~~((Sixty-two))~~ Sixty-six thousand ~~((five))~~ four hundred eighty dollars effective January 1, 1991;

(ii) An amount established by a fair hearing under chapter 388-08 WAC if the community spouse's resource allowance is inadequate to provide a minimum monthly maintenance needs allowance; or

(iii) An amount ordered transferred to the community spouse by the court.

(c) The resources available to the community spouse shall be in the name of the community spouse or transferred to the community spouse or to another for sole benefit of the community spouse before the first regularly scheduled eligibility review after the initial eligibility determination is completed; and

(d) The department shall consider resources greater than such resources in subsection (5)(b) of this section available to the institutional spouse.

(6) The department shall consider resources of the community spouse:

(a) Unavailable to the institutionalized spouse during a continuous period of institutionalization; or

(b) When the institutionalized spouse acquires resources in excess of the one-person resource maximum, if the most recent period of institutionalization began after September 30, 1989.

**AMENDATORY SECTION** (Amending Order 3007, filed 5/31/90, effective 7/1/90)

WAC 388-95-360 ALLOCATION OF INCOME—INSTITUTIONALIZED RECIPIENT. (1) In reducing payment to the institution, the department shall consider the institutionalized recipient's income under WAC 388-95-335 (3)(a), (b), (c), and (d).

(2) The department shall deduct the following amounts, in the following order, from the institutionalized recipient's total income, including amounts excluded in determining eligibility:

(a) Specified personal needs allowance;

(b) An amount an SSI, AFDC, or FIP-related client in a medical facility receives as a cash assistance payment sufficient to bring the client's income up to the personal needs allowance;

(c) The current personal needs allowance plus wages the SSI-related client receives for work approved by the department as part of a training or rehabilitative program designed to prepare the individual for a less-restrictive placement when the total wages received plus the personal needs allowance do not exceed the one-person medically needy income level:

(i) No deductions are allowed for expenses of employment; and

(ii) The excess wages shall apply to the cost of care when the total wages received plus the initial personal needs allowance exceeds the one-person medically needy income level.

(d) An amount for the community spouse equal to the standard maintenance need of one thousand two hundred fifty-eight dollars less the separate income of the community spouse. The department shall increase the standard need maintenance amount by:

(i) Shelter expenses exceeding two hundred ~~((fifty-six))~~ seventy dollars and ~~((eighty))~~ ninety cents. The department shall calculate actual expenses for the community spouse's principal residence for:

(A) Rent;

(B) Mortgage;

(C) Taxes and insurance;

(D) Any maintenance charge for a condominium or cooperative; and

(E) A food stamp standard allowance for utilities provided the utilities are not included in the maintenance charges for a condominium or cooperative.

(ii) The total of the standard maintenance need amount and the shelter expenses shall not exceed one thousand ~~((five))~~ six hundred ~~((sixty-five))~~ sixty-two dollars, unless:

(A) A court enters an order against the institutionalized client for the community spouse support in excess of this amount; or

(B) A hearings officer determines a greater amount is needed because of exceptional circumstances resulting in extreme financial duress.

(e) An amount for the maintenance needs of a family member residing with the community spouse equal to one-third of the amount ~~((eight))~~ nine hundred ~~((fifty-six))~~ three dollars exceeds the family member's income for each:

(i) Dependent or minor child;

(ii) Dependent parent; or

(iii) Dependent sibling of the institutionalized or community spouse;

(f) If an institutional recipient does not have a community spouse, an amount for the maintenance needs of family members residing in the recipient's home is equal to the medically needy income level for the number of legal dependents in the home less the income of the dependents;

(g) Amounts for incurred medical expenses not subject to third-party payment including, but not limited to:

(i) Health insurance premiums, co-insurance, or deductible charges; and

(ii) Necessary medical care recognized under state law, but not covered under Medicaid.

(h) Maintenance of the home of a single person or couple:

(i) Up to one hundred eighty dollars per month; and

(ii) Limited to a six-month period; and

(iii) A physician has certified that either of the individuals is likely to return to the home within that period; and

(iv) Social service staff shall document initial need for the income exemption and review the person's circumstances after ninety days.

(3) The department shall not deduct specified personal needs allowance, community spouse, needy dependent maintenance needs, or home maintenance needs from a veteran's aid and attendance allowance.

(4) The recipient shall use the income remaining after allocations specified in subsection (2) of this section, toward payment of the recipient's cost of care at the department rate.

(5)(a) Effective July 1, 1988, SSI-related clients shall continue to receive total payment under 1611 (b)(1) of the Social Security Act (SSA) for the first three full calendar months of institutionalization in a public or Medicaid-approved medical institution or facility if the:

(i) Stay in the institution or facility is not expected to exceed three months; and

(ii) SSI-related clients plan to return to their former living arrangements.

(b) The department shall not consider the SSI payment when computing the participation amount.

**AMENDATORY SECTION** (Amending Order 2946, filed 3/1/90, effective 4/1/90)

WAC 388-99-020 ELIGIBILITY DETERMINATION—MEDICALLY NEEDY IN OWN HOME. (1) Effective ((January 1, 1990)) January 1, 1991, the department shall set the medically needy income level (MNIL) at:

(a) One person	\$ ((414))	<u>458</u>
(b) Two persons	\$ ((542))	<u>575</u>
(c) Three persons	\$ ((612))	<u>650</u>
(d) Four persons	\$ ((683))	<u>725</u>
(e) Five persons	\$ ((783))	<u>833</u>
(f) Six persons	\$ ((892))	<u>942</u>
(g) Seven persons	\$ ((1,025))	<u>1,092</u>
(h) Eight persons	\$ ((1,133))	<u>1,208</u>
(i) Nine persons	\$ ((1,250))	<u>1,325</u>
(j) Ten persons and above	\$ ((1,358))	<u>1,433</u>

(2) The department shall compute countable income by deducting, from gross income, amounts that would be deducted in determining:

(a) AFDC eligibility for families and children in a nondesignated FIP geographic area. The department shall not apply the earned income exemption of thirty dollars plus one-third of the remainder for ((individuals)) persons applying solely for medical assistance;

(b) SSI/SSP eligibility for aged, blind, or disabled ((individuals)) persons; and

(c) FIP eligibility for families and children.

(3) The department shall allow the following special income disregards:

(a) Health insurance premiums, except Medicare, the ((individual)) person expects to pay during the base period;

(b) An amount equal to the maintenance needs of an ineligible or nonapplying spouse not to exceed the one-person medically needy income level; and

(c) Child care payment amounts allowed as if the ((individual)) person was a FIP enrollee.

(4) If countable income is equal to or less than the appropriate MNIL, the department shall certify the family or ((individual)) person eligible.

(5) If countable income is greater than the appropriate MNIL, the department shall require the applicant to spenddown the excess countable income for the base period. The base period shall be the three-month or six-month period which corresponds to the certification period under WAC 388-99-055.

(6) The department shall consider the income and resources of the spouse or of the parent of an applicant under eighteen years of age:

(a) In the same household, available to the applicant, whether or not actually contributed; and

(b) Not in the same household, only to the extent of what is actually contributed.

(7) The department shall consider the financial responsibility of relatives for aged, blind, and disabled, under chapter 388-92 WAC.

(8) In mixed households, where more than one assistance unit exists, the department shall determine income for the:

(a) ((The)) AFDC-related assistance unit according to subsections (2)(a) and (3) of this section;

(b) ((The)) SSI-related assistance unit according to subsections (2)(b) and (3) of this section; and

(c) ((The)) FIP-related assistance unit according to subsections (2)(c) and (3) of this section.

**WSR 91-07-012**

**NOTICE OF PUBLIC MEETINGS  
FOREST PRACTICES BOARD**

[Memorandum—March 12, 1991]

There will be a special Forest Practices Board meeting held on March 13, 1991, at 1 p.m. The meeting will be held in the auditorium on first floor of the General Administration Building, Olympia, Washington. Additional information may be obtained from: Forest Practices Division, 1007 South Washington, EL-03, Olympia, WA 98504, (206) 753-5315.

**WSR 91-07-013**

**PERMANENT RULES  
DEPARTMENT OF  
SOCIAL AND HEALTH SERVICES  
(Public Assistance)**

[Order 3151—Filed March 12, 1991, 4:24 p.m.]

Date of Adoption: March 12, 1991.

Purpose: The amendatory rules contain the titles for seven sections. These section headings were incorrectly labelled in the original rules.

Citation of Existing Rules Affected by this Order: Amending chapter 388-150 WAC, Minimum licensing requirements for child day care centers.

Statutory Authority for Adoption: RCW 74.15.030.

Pursuant to notice filed as WSR 91-03-127 on January 23, 1991.

Effective Date of Rule: Thirty-one days after filing.

March 12, 1991

Rosemary Carr

Acting Director

Administrative Services

**AMENDATORY SECTION** (Amending Order 3103, filed 11/20/90, effective 12/21/90)

WAC 388-150-005 ((LICENSING)) AUTHORITY. ((Authority:)) The following rules are adopted under chapter 74.15 RCW.

**AMENDATORY SECTION** (Amending Order 3103, filed 11/20/90, effective 12/21/90)

WAC 388-150-100 ACTIVITY PROGRAM. (1) ((Activity program:)) The licensee shall implement an activity program designed to meet the developmental, cultural, and individual needs of the child served. The

licensee shall ensure the program contains a range of learning experiences for the child to:

- (a) Gain self-esteem, self-awareness, self-control, and decision making abilities;
- (b) Develop socially, emotionally, intellectually, and physically;
- (c) Learn about nutrition, health, and personal safety; and

(d) Experiment, create, and explore.

(2) The licensee shall ensure the center's program offers variety and options, including a balance between:

- (a) Child-initiated and staff-initiated activities;
- (b) Free play and organized events;
- (c) Individual and group activities; and
- (d) Quiet and active experiences.

(3) The licensee shall ensure the center's program affords the child daily opportunities for small and large muscle activities and outdoor play.

(4) The licensee shall operate the center's program under a regular schedule of activities with allowances for a variety of special events. The licensee shall implement a planned program of activities as evidenced by a current, written activity schedule, and afford staff classroom planning time.

(5) The licensee shall manage child and staff movements from one planned activity or care area to another to achieve smooth, unregimented transitions by:

- (a) Establishing familiar routines;
- (b) Contributing to learning experiences; and
- (c) Maintaining staff-to-child ratio and group size guidelines.

(6) The child may remain in care only ten hours or less per day except as necessitated by the parent's working hours and travel time from and to the center.

**AMENDATORY SECTION** (Amending Order 3103, filed 11/20/90, effective 12/21/90)

WAC 388-150-180 ((STAFFING==))STAFF PATTERN AND QUALIFICATIONS. (1) General qualifications. The licensee, staff, volunteer, and other person associated with the operation of the center who has access to the child in care shall:

- (a) Be of good character;
- (b) Demonstrate the understanding, ability, personality, emotional stability, and physical health suited to meet the cultural, emotional, mental, physical, and social needs of the child in care; and
- (c) Not have committed or been convicted of child abuse or any crime involving physical harm to another person.

(2) Center management. The licensee shall serve as or employ a director, responsible for the overall management of the center's facility and operation. The director shall:

- (a) Be twenty-one years of age or older;
- (b) Serve as administrator of the center, ensuring compliance with minimum licensing requirements;
- (c) Have knowledge of child development as evidenced by professional references, education, experience, and on-the-job performance;

(d) Have the management and supervisory skills necessary for the proper administration of the center, including:

- (i) Record maintenance;
- (ii) Financial management; and
- (iii) Maintenance of positive relationships with staff, children, parents, and the community;

(e) Have completed forty-five or more college quarter credits in early childhood education/child development, or possess an equivalent educational background, or be a certified child development associate;

(f) Have two or more years successful experience working with children of the same age level as those served by the center as evidenced by professional references and on-the-job performance;

(g) Have planning, coordination, and supervisory skills to implement a high quality, developmentally appropriate program; and

(h) Have knowledge of children and how to meet children's needs.

(3) When the director does not meet the qualifications specified in subsections (2)(e), (f), (g), and (h) of this section, the director or licensee shall employ a program supervisor, responsible for planning and supervising the center's learning and activity program. The program supervisor shall:

- (a) Be twenty-one years of age or older;
- (b) Meet the education, experience, and competency qualifications specified in subsections (2)(e), (f), (g), and (h) of this section; and
- (c) Discharge on-site program supervisory duties a minimum of twenty hours weekly.

(4) For the center serving the school age child only, the program supervisor may substitute equivalent courses in education, recreation, or physical education for required education.

(5) The director and program supervisor may be one and the same person when qualified for both positions. The director or program supervisor shall normally be on the premises while the child is in care. If temporarily absent from the center, the director and program supervisor shall leave a competent, designated staff person in charge.

(6) The director and program supervisor may also serve as child care staff when such role does not interfere with the director's or program supervisor's management and supervisory responsibilities.

(7) Center staffing. The licensee shall ensure the lead child care staff person in charge of a child or a group of children implementing the activity program:

- (a) Is eighteen years of age or older; and
- (b) Possesses a high school education or equivalent; or
- (c) Has child development knowledge and experience.

(8) The licensee may assign a child care assistant or aide to support lead child care staff. The child care assistant or aide shall be sixteen years of age or older. The child care assistant or aide shall care for the child under the direct supervision of the lead child care staff person. The licensee shall ensure no person under eighteen years

of age is assigned sole responsibility for a group of children. The assistant or aide, eighteen years of age or older, may care for a child or group of children without direct supervision by a superior for a brief period time.

(9) The licensee may arrange for a volunteer to support lead child care staff. The volunteer shall be sixteen years of age or older. The volunteer shall care for the child under the direct supervision of the lead child care staff person. The licensee may count the volunteer in the staff-to-child ratio when the volunteer meets staff qualification requirements.

(10) Support service personnel. The licensee shall provide or arrange for fulfillment of administrative, clerical, accounting, maintenance, transportation, and food service responsibilities so the child care staff is free to concentrate on program implementation.

(11) The licensee shall ensure completion of support service duties occurs in a manner allowing the center to maintain required staff-to-child ratios.

**AMENDATORY SECTION** (Amending Order 3103, filed 11/20/90, effective 12/21/90)

**WAC 388-150-210 HEALTH ((AND NUTRITION)) CARE PLAN.** (1) ((Health care plan.)) The licensee shall maintain current written health policies and procedures for staff orientation and use, and for the parent. The health care plan shall include, but not be limited to, information about the center's procedures concerning:

- (a) Communicable disease prevention, reporting, and management;
- (b) Action taken for medical emergencies;
- (c) First aid;
- (d) Care of minor illnesses;
- (e) Medication management;
- (f) General hygiene practices;
- (g) Handwashing practices;
- (h) Food and food services; and
- (i) Infant care procedures and nursing consultation, where applicable.

(2) The licensee shall use the services of an advisory physician, physician's assistant, or registered nurse to assist in the development, approval, and periodic review of the center's health care plan.

**AMENDATORY SECTION** (Amending Order 3103, filed 11/20/90, effective 12/21/90)

**WAC 388-150-280 GENERAL SAFETY, MAINTENANCE, AND ((ENVIRONMENT)) SITE.**

(1) ((General safety, maintenance, and site.)) The licensee shall operate the center:

- (a) On an environmentally safe site;
- (b) In a neighborhood free from a condition detrimental to the child's welfare; and
- (c) In a location accessible to other services to carry out the program.

(2) The licensee shall maintain the indoor and outdoor premises in a safe and sanitary condition, free of hazards, and in good repair. The licensee shall ensure furniture and equipment are safe, stable, durable, child-sized, and free of sharp, loose, or pointed parts.

(3) The licensee shall:

(a) Install handrails or safety devices at child height adjacent to steps, stairways, and ramps;

(b) Maintain a flashlight or other emergency lighting device in working condition;

(c) Ensure there is no flaking or deteriorating lead-based paint on interior and exterior surfaces, equipment, and toys accessible to the preschool age and younger child;

(d) Finish or cover rough or untreated wood surfaces; and

(e) Maintain one or more telephones in working order, accessible to staff.

(4) The licensee shall supply bathrooms and other rooms subject to moisture with washable, moisture-impermeable flooring.

(5) The licensee caring for the preschool age and younger child shall equip child-accessible electrical outlets with nonremovable safety devices or covers preventing electrical injury.

(6) The licensee shall ensure staff can gain rapid access in an emergency to a bathroom or other room occupied by the child.

(7) The licensee shall shield light bulbs and tubes in child-accessible areas.

(8) The licensee shall keep the premises free from rodents, fleas, cockroaches, and other insects and pests.

(9) The licensee shall use a housekeeping sink or another appropriate method for drawing clean mop water and disposing waste water.

(10) The licensee shall ensure the mop storage area is ventilated.

(11) The licensee shall ensure no firearm or another weapon is on the premises.

(12) The licensee shall comply with fire safety regulations adopted by the state fire marshal's office.

**AMENDATORY SECTION** (Amending Order 3103, filed 11/20/90, effective 12/21/90)

**WAC 388-150-390 ((AGENCY PRACTICES)) DISCRIMINATION PROHIBITED.** ((Discrimination prohibited.))

The licensee shall comply with federal and state regulatory and statutory requirements, defined under chapter 49.60 RCW, regarding nondiscrimination in employment practices and client services.

**AMENDATORY SECTION** (Amending Order 3103, filed 11/20/90, effective 12/21/90)

**WAC 388-150-450 CHILD RECORDS ((REPORTING)) AND ((POSTING)) INFORMATION.** ((Child records and information.))

The licensee shall maintain on the premises organized confidential records and information concerning the child in care. The licensee shall ensure the child's record contains, at a minimum:

(1) Registration data:

(a) Name, birthdate, dates of enrollment and termination, and other identifying information;

(b) Name, address, and home and business telephone number of the parent and other person to be contacted in case of emergency; and

(c) Completed enrollment application signed by the parent, guardian, or responsible relative.

(2) Authorizations:

(a) Name, address, and telephone number of the person authorized to remove from the center the child under care;

(b) Written parental consent for transportation provided by the center, including field trips and swimming, when the child participates in these activities. A parent-signed blanket consent form may authorize the child's off-site travel; and

(c) Written parental consent, or court order, for providing medical care and emergency surgery, except for such care authorized by law.

(3) Medical and health data:

(a) Date and kind of illness and injury occurring on the premises, including the treatment given by staff;

(b) Medication given indicating dosage, date, time, and name of dispensing staff person; and

(c) A health history, obtained when the licensee or staff enrolls the child for care. The history includes:

(i) The date of the child's last physical examination;

(ii) Allergies;

(iii) Special health or developmental problems and other pertinent health information;

(iv) Immunization history as required under WAC 388-150-220; and

(v) Name, address, and telephone number of the child's health care provider or facility.

**WSR 91-07-014**  
**PERMANENT RULES**  
**PARKS AND RECREATION**  
**COMMISSION**

[Filed March 12, 1991, 4:36 p.m.]

Date of Adoption: March 8, 1991.

Purpose: Allows enforcement officers to remove repeat offenders of alcohol abuse in state parks; and Dash Point and Saltwater can be closed if alcohol is being abused or causing public problems.

Citation of Existing Rules Affected by this Order: Amending WAC 352-32-200 and 352-32-210.

Statutory Authority for Adoption: RCW 43.51.040.

Pursuant to notice filed as WSR 91-03-140 on January 23, 1991.

Effective Date of Rule: Thirty-one days after filing.

March 8, 1991

Jack Shreve

Chair

**AMENDATORY SECTION** (Amending Order 9, filed 11/24/70)

WAC 352-32-200 PENALTIES. (1) In addition to the penalty provided in RCW 43.51.180, or any other existing or future law of the state of Washington, failure to comply with any section of this chapter, or of any other chapter of this title, or any other rule or regulation of the commission, or with any other federal, state, or

local law, rule, or regulation applicable under the circumstances, shall subject the person so failing to comply to ejection from any state park area.

(2) All drug or alcohol related misconduct for which a citation is issued shall additionally subject the individual to expulsion from all lands administered by the commission for the following periods:

(a) One incident shall result in a twenty-four-hour expulsion.

(b) Two incidents shall result in a thirty-day expulsion.

(c) Three incidents shall result in a one-year expulsion.

**AMENDATORY SECTION** (Amending Order 95, filed 6/24/86)

WAC 352-32-210 CONSUMPTION OF ALCOHOL IN STATE PARK AREAS. (1) Opening, possessing alcoholic beverage in an open container, or consuming any alcoholic beverages in any state park area shall be prohibited except in the following designated areas and under the following circumstances:

(a) In designated campgrounds, by registered campers or their guests;

(b) In designated picnic areas, which shall include those sites within state park areas where picnic tables, benches, fireplaces, and/or outdoor kitchens are available, even though not signed as designated picnic areas; and

(c) In any building operated and maintained under a concession agreement, wherein the concessionaire has been licensed to sell alcoholic beverages by the Washington state liquor control board, and where the dispensation of such alcoholic beverages by such concessionaire has been approved by the commission.

(2) Opening, possessing alcoholic beverage in an open container, or consuming any alcoholic beverages shall be prohibited at Dash Point State Park and Saltwater State Park except in the following designated areas and under the following circumstances:

(a) In designated campgrounds, by registered campers or their guests.

(b) In any building operated and maintained under a concession agreement wherein the concessionaire has been licensed to sell alcoholic beverages by the Washington state liquor board, and where the dispensation of such alcoholic beverages by such concessionaire has been approved by the commission.

(c) In any reservable group day use facility by any authorized group which has paid the reservation fee and applicable damage deposit and which has obtained prior permit authorization to have alcohol by the park manager.

(3) Dispensing alcoholic beverages from kegs or containers larger than two gallons is prohibited in state park areas except when authorized in writing (group use permit) by the park manager.

~~((3))~~ (4) The provisions of this rule shall not apply to any part of the Seashore Conservation Area, as designated and established by RCW 43.51.655.



~~((4))~~ (5) Opening, consuming, or storing alcoholic beverages in Fort Simcoe State Park and Squaxin Island State Park shall be prohibited.

**WSR 91-07-015**  
**WITHDRAWAL OF PROPOSED RULES**  
**DEPARTMENT OF AGRICULTURE**  
 [Filed March 13, 1991, 3:27 p.m.]

This is to officially request withdrawal of proposed rule making CR-102 filed in your office on January 18, 1991, WSR 91-03-093.

It is not our intent to refile this proposal or reschedule hearings.

There was no well established consensus agreement or support on the proposal as presented, nor was there consensus agreement proposed to amend the proposal under consideration. In light of this, it is not our intention to refile this or an amended proposal. If, after consultation with affected parties, a redraft or new proposal is drafted and submitted to the director, a new rule proposal will be filed at a later date.

J. Allen Stine  
 Assistant Director  
 Commodity Inspection Division

**WSR 91-07-016**  
**PERMANENT RULES**  
**DEPARTMENT OF AGRICULTURE**  
 [Order 2075—Filed March 13, 1991, 3:31 p.m.]

Date of Adoption: March 13, 1991.

Purpose: The amendments revise rules regarding requirements for certified seed to be used in the commercial production of potatoes.

Citation of Existing Rules Affected by this Order: Amending chapter 16-482 WAC, rules relating to seed potato quarantine.

Statutory Authority for Adoption: Chapter 17.24 RCW, Insect pests and plant diseases.

Pursuant to notice filed as WSR 91-03-105 on January 22, 1991.

Effective Date of Rule: Thirty-one days after filing.

March 13, 1991  
 Michael Schwisow  
 Deputy Director  
 for C. Alan Pettibone  
 Director

AMENDATORY SECTION (Amending Order 1126, filed 10/9/69, effective 11/10/69)

WAC 16-482-001 PROMULGATION—ESTABLISHING QUARANTINE. ~~((1) Whereas, the production of commercial potatoes in the state of Washington is one of the larger agricultural industries in the state; and~~

~~(2) Whereas, this will best serve to protect the health and welfare of the people in the state of Washington; and~~

~~(3) Whereas, the most important function to protect the commercial potato industry is securing seed potatoes that are free from injurious pests and disease and of good quality.~~

~~(4) Now, therefore, I, Donald W. Moos, director of the department of agriculture of the state of Washington, by virtue of the authority vested in me by chapter 17.24 RCW relating to insect pests and plant diseases, after public hearing held in Moses Lake, Washington, on September 23, 1969, pursuant to chapters 34.04 and 42.32 RCW, do hereby proclaim and establish a quarantine to become effective November 10, 1969, setting forth the rules for the importation and planting of seed potatoes for commercial or seed potato production.)) The commercial production of potatoes both for food and for seed in the state of Washington is one of the major agricultural industries. The introduction and spread of serious bacterial, fungal, viral and nematode diseases of potatoes represents a serious economic threat to the industry. A quarantine is established under this chapter requiring the planting of certified seed potatoes in commercial potato production areas to mitigate this threat.~~

NEW SECTION

WAC 16-482-005 REGULATED ARTICLES. All potatoes used for commercial plantings in excess of one acre or for seed potato production.

NEW SECTION

WAC 16-482-006 QUARANTINE AREA. All states and territories of the United States and all counties within the state of Washington.

NEW SECTION

WAC 16-482-007 REGULATED AREA. There is established a regulated area within the state of Washington consisting of the entire counties of Adams, Benton, Chelan, Columbia, Douglas, Ferry, Franklin, Garfield, Grant, Grays Harbor, King, Kittitas, Klickitat, Lincoln, Mason, Pend Oreille, Skagit, Snohomish, Spokane, Stevens, Thurston, Walla Walla, Whatcom, Whitman, and Yakima.

AMENDATORY SECTION (Amending Order 1126, filed 10/9/69, effective 11/10/69)

WAC 16-482-010 REGULATIONS—CERTIFIED SEED REQUIREMENT. (1) ~~((All seed potatoes must have been produced as a part of a certified seed potato program in the state or country of origin and accepted and certified by that program.~~

~~(2) Shippers of seed potatoes into the state of Washington shall give notice prior to shipment to the State Department of Agriculture, P.O. Box 310, Moses Lake, Washington 98837, telephone 509-RO5-9121.~~

~~(3) Receivers of seed potatoes in the state of Washington are required to notify the state department of agriculture through the area inspection office.~~

~~(4) Quality and condition inspection required prior to shipment of seed potatoes into the state of Washington.~~

~~(5) Shippers contemplating bulk seed shipments into the state of Washington must file advance notice with the state which would include verification of seed potatoes being shipped in bulk as being part of a certified seed program in the state of origin and accepted and certified by that program, and further indicate how the bulk shipments will be identified and sealed for proper delivery.~~

~~(6) The department will retain a sample, at no cost to it, of each lot of certified seed produced or received in this state for seed or commercial production. Such samples will be retained for entry in Washington seed lot trials.)) Except as provided in WAC 16-482-015, all seed potatoes propagated for commercial or for seed production within the regulated area shall be from certified seed, produced as a part of a certified seed potato program in the state or country of origin and accepted and certified by that program.~~

~~(2) The department may sample and test any lot of seed potatoes or conduct field inspections for the purpose of testing and verification of compliance with this chapter.~~

#### NEW SECTION

WAC 16-482-015 REGULATIONS—CERTIFIED SEED—EXCEPTIONS. The certified seed requirement shall not be applicable to:

- (1) Potatoes planted for personal use or other non-commercial purposes;
- (2) Commercial production, other than for production of seed potatoes, of not more than one acre;
- (3) Experimental or seed trial plots as provided in WAC 16-482-016.

#### NEW SECTION

WAC 16-482-016 EXCEPTIONS—PERMIT REQUIREMENT. The director may allow planting of seed potatoes, otherwise prohibited, by special permit. Such permit shall specify the conditions under which planting is allowed and shall be obtained prior to planting.

#### NEW SECTION

WAC 16-482-017 RECORDKEEPING REQUIREMENT. All commercial potato growers within the regulated area shall be responsible for obtaining certification documents or tags to verify that all seed potatoes used for propagation purposes comply with the terms of this chapter. Such documents shall be retained by the grower for a period of one calendar year and a copy provided to the department of agriculture, plant services division, upon written request to the grower. Such documents shall include the total weight of certified seed potatoes and shall be issued by an official certifying agency in the state or country of origin. Falsification of seed potato documents shall subject the grower to penalties provided in law.

AMENDATORY SECTION (Amending Order 1126, filed 10/9/69, effective 11/10/69)

WAC 16-482-020 DISPOSITION OF MATERIAL SHIPPED IN VIOLATION OF THIS QUARANTINE. ((Regulated commodities not meeting the requirements of this quarantine shall be returned to the point of origin, or destroyed at the option and expense of the owner or owners, his or their responsible agent or agents.)) (1) Seed potatoes shipped in violation of this quarantine may be returned to the point of origin, diverted to nonseed use, or destroyed at the option and expense of the owner or owners or their responsible agents.

(2) Seed potatoes planted and growing in violation of the terms of this quarantine may be destroyed or placed under quarantine, with terms and conditions for that quarantine specified by the director, at the option and expense of the grower or owners or their responsible agents. Potatoes, placed under quarantine for violation of the terms of this chapter and found to be infested or infected with a viral, fungal, bacterial or nematode disease by subsequent inspection or testing shall be destroyed at the expense of the grower, without compensation.

(3) In addition to the actions specified in subsections (1) and (2) of this section, any grower violating the terms of this quarantine shall be subject to civil and/or criminal penalties provided by laws.

#### REPEALER

The following sections of the Washington Administrative Code are repealed:

WAC 16-482-030 VIOLATION AND PENALTY.

WAC 16-482-040 EFFECTIVE DATE.

#### **WSR 91-07-017**

#### **NOTICE OF PUBLIC MEETINGS DEPARTMENT OF COMMUNITY DEVELOPMENT**

[Memorandum—March 12, 1991]

Pursuant with RCW 42.30.075, schedule of regular meetings, the following schedule of meeting dates is provided:

1st Calendar Quarter	March 15, 1991
2nd Calendar Quarter	June 14, 1991
3rd Calendar Quarter	September 13, 1991
4th Calendar Quarter	December 13, 1991

#### **WSR 91-07-018**

#### **PROPOSED RULES GAMBLING COMMISSION**

[Filed March 13, 1991, 4:18 p.m.]

Original Notice.

Title of Rule: WAC 230-30-075 Minimum percentage of prizes for certain gambling activity.

Purpose: To request an increase in the amount allowed to be expended for merchandise prizes in punchboard and pull tab games.

Statutory Authority for Adoption: RCW 9.46.070(11).

Statute Being Implemented: Chapter 9.46 RCW.

Summary: Allows an increase from \$300 to \$400 in the amount allowed to be expended for merchandise prizes.

Name of Agency Personnel Responsible for Drafting and Enforcement: Frank L. Miller, Deputy Director, Lacey, 438-7640; and Implementation: Ronald O. Bailey, Director, Lacey, 438-7640.

Name of Proponent: Washington State Licensed Beverage Association, private.

Rule is not necessitated by federal law, federal or state court decision.

Explanation of Rule, its Purpose, and Anticipated Effects: The petitioner requests an increase in the amount allowed to be expended for merchandise prizes from \$300 to \$400 in order to: Meet rising costs of quality prizes; stimulate the market; and offer better prizes to the player.

Proposal Changes the Following Existing Rules: The proposed change expands the scope of an existing rule.

No small business economic impact statement is required for this proposal by chapter 19.85 RCW.

The agency has considered whether this rule change would create an economic impact on small businesses as defined by chapter 19.85 RCW. It has determined there is no economic impact to small business as a result of these proposals.

Hearing Location: Best Western Lakeway Inn, 714 Lakeway Drive, Bellingham, WA 98226, on May 9, 1991, at 10:00.

Submit Written Comments to: Washington State Gambling Commission, 4511 Woodview Drive S.E., Olympia, WA 98504-8121, by May 8, 1991.

Date of Intended Adoption: May 9, 1991.

March 13, 1991  
Frank L. Miller  
Deputy Director

AMENDATORY SECTION (Amending Order 154, filed 10/14/85)

WAC 230-30-075 MINIMUM PERCENTAGE OF PRIZES FOR CERTAIN GAMBLING ACTIVITIES. No operator shall put out for play and no distributor or manufacturer of punchboards and pull tabs shall sell or otherwise provide to any person in this state or for use in this state any punchboard or pull tab series that does not contain the following minimum percentage in prizes:

(1) Punchboards - a minimum of 60 percent respecting each punchboard placed out for public play.

(2) Pull tabs - a minimum of 60 percent respecting each series of pull tabs placed out for public play.

(3) For the purpose of determining the percentage of prizes offered on any punchboard, or in any pull tab series under this section, total merchandise prizes shall be computed at the amount actually paid therefor by the licensed operator plus 50 percent of that actual cost.

(4) Single cash prized on punchboards/pull tabs shall not exceed:

(a) Two hundred in cash; or

(b) A merchandise prize, or combination merchandise prize, for which the operator has not expended more than (~~three~~) four hundred dollars.

(5) Multiple winners on an individual pull tab or punch shall not exceed the single cash or merchandise prize limit in (4) above.

Reviser's note: RCW 34.05.395 requires the use of underlining and deletion marks to indicate amendments to existing rules. The rule published above varies from its predecessor in certain respects not indicated by the use of these markings.

**WSR 91-07-019**

**PROPOSED RULES**

**GAMBLING COMMISSION**

[Filed March 13, 1991, 4:23 p.m.]

Continuance of WSR 91-03-062.

Title of Rule: WAC 230-02-505 Recreational gaming activity—Defined; 230-04-120 Licensing of distributors; 230-04-187 Recreational gaming activity—Permit required; 230-04-190 Issuance of license; 230-04-201 Fees; 230-12-100 Licensees shall closely monitor all activities; 230-25-110 Fund raising event—Use of equipment, lease or rental from licensee only; and 230-25-330 Recreational gaming activity—Rules for play.

Purpose: WAC 230-02-505 provides a definition of the term "recreational gaming activity" as used in current rules; WAC 230-04-120 guidelines for distributors of gambling equipment; WAC 230-04-187 provides for permit requirements to conduct a recreational gaming activity; WAC 230-04-190 allows for issuance of a permit to conduct recreational gaming activity; WAC 230-04-201 provides for a fee to conduct a recreational gaming activity; WAC 230-12-100 clarifies the responsibilities of a gambling manager; WAC 230-25-110 allows for an organization to lease its fund-raising event equipment; and WAC 230-25-330 provides for play for a recreational gaming activity.

Statutory Authority for Adoption: Chapter 9.46 RCW.

Statute Being Implemented: Chapter 9.46 RCW.

Summary: WAC 230-02-505 describes a recreational gaming activity; WAC 230-04-120 provides rules for distributors of gambling equipment and their licensing; WAC 230-04-187 allows any qualified organization to utilize fund raising event equipment for amusement only; WAC 230-04-190 describes the procedure for issuance of a permit to conduct a recreational gaming activity; WAC 230-04-201 provides license classes and fees related to recreational gaming activities; WAC 230-12-100 describes responsibilities of licensees to closely monitor all gambling activities; WAC 230-25-110 outlines the use of equipment, lease or rental of fund-raising event equipment; and WAC 230-25-330 describes rules for play of a recreational gaming activity.

Name of Agency Personnel Responsible for Drafting and Enforcement: Frank L. Miller, Deputy Director, Lacey, 438-7640; and Implementation: Ronald O. Bailey, Director, Lacey, 438-7640.

Rule is not necessitated by federal law, federal or state court decision.

Explanation of Rule, its Purpose, and Anticipated Effects: WAC 230-02-505 defines a new activity and codifies an existing policy of "fun nights"; WAC 230-04-120 allows licensed distributors to lease fund raising

event equipment for recreational gaming activities; WAC 230-04-187 allows qualified organizations to utilize professional gambling equipment for amusement only; WAC 230-04-190 allows the issuance of a permit for a nongambling activity; WAC 230-04-201 provides a fee for a permit for a new activity; WAC 230-12-100 clarifies the responsibilities of a gambling manager; WAC 230-25-110 allows qualified organizations to lease professional gambling equipment conditionally without obtaining a license; and WAC 230-25-330 outlines rules for operating a recreational gaming activity.

**Proposal Changes the Following Existing Rules:** All proposed changes expand or clarify the scope of existing rules.

No small business economic impact statement is required for this proposal by chapter 19.85 RCW.

The agency has considered whether these rule changes would create an economic impact on small businesses as defined by chapter 19.85 RCW. It has determined that there is no economic impact to small business as a result of these proposals for the following reasons: No cost or expenditure of resources; no affect on industry; and no substantive change in existing regulatory scheme.

**Hearing Location:** Best Western Lakeway Inn, 714 Lakeway Drive, Bellingham, WA 98226, on May 9, 1991, at 10:00 a.m.

**Submit Written Comments to:** Washington State Gambling Commission, 4511 Woodview Drive S.E., Olympia, WA 98504-8121, by May 8, 1991.

**Date of Intended Adoption:** May 9, 1991.

March 13, 1991  
Frank L. Miller  
Deputy Director

#### WSR 91-07-020

##### PREPROPOSAL COMMENTS BUILDING CODE COUNCIL

[Filed March 13, 1991, 4:35 p.m.]

**Subject of Possible Rule Making:** Development and possible adoption of revised building construction requirements for long-term residential care facilities. Requirements are anticipated to amend the 1991 editions of the Uniform Building Code and Uniform Fire Code.

**Persons may Comment on this Subject in the Following Ways:** Provide comments in writing, State Building Code Council, Ninth and Columbia Building, Mailstop GH-51, Olympia, Washington 98504-4151, March 13, 1991, through April 30, 1991.

**Other Information or Comments by Agency at this Time, if any:** Provide comments concerning potential building construction requirements for long-term residential care facilities; formal rule making will commence in June 1991 with public hearings in August and September 1991. Adoption will occur by November 30, 1991; contact Willy O'Neil, State Building Code Council, Ninth and Columbia Building, Mailstop GH-51, Olympia, Washington 98504-4151, (206) 586-0486.

March 13, 1991  
Gene J. Colin  
Chair

#### WSR 91-07-021 PERMANENT RULES GAMBLING COMMISSION

[Filed March 13, 1991, 4:49 p.m.]

**Date of Adoption:** March 8, 1991.

**Purpose:** Define a gambling manager; and provide requirements regarding applicant information.

**Citation of Existing Rules Affected by this Order:** Amending WAC 230-02-240 and 230-12-305.

**Statutory Authority for Adoption:** RCW 9.46.070 (7)(14).

Pursuant to notice filed as WSR 91-03-062 on January 16, 1991.

**Effective Date of Rule:** Thirty-one days after filing.

March 13, 1991  
Frank L. Miller  
Deputy Director

#### NEW SECTION

WAC 230-02-240 **GAMBLING MANAGER DEFINED.** A "gambling manager" is a person, whether compensated or not, who is responsible for operating and controlling authorized gambling activities other than bingo games, and has the authority to make decisions regarding the operation of such gambling activities. The gambling manager supervises and directs all other persons directly or indirectly involved in the conduct of such activities. A gambling manager may be: an owner; partner; officer of a corporation; or a person designated by any of the above. A gambling manager's duties include, but are not limited to the following: hiring, firing, and evaluating gambling personnel; supervising and controlling the conduct of gambling activities; preparing or supervising the preparation of gambling records; controlling cash generated by gambling activities and making bank deposits; and purchasing gambling supplies.

AMENDATORY SECTION (Amending Order 136 [167], filed 9/13/83 [4/14/87], effective 9/13/83)

WAC 230-12-305 **LICENSEE REQUIRED TO SUBMIT UPDATED DOCUMENTS OR INFORMATION.** In addition to any other requirements set forth in these rules, the persons licensed by the Commission shall be required to submit any changes in the following documents or information on file with the Commission:

(1) Articles of incorporation or by laws, or any other documents which set out the organizational structure and purposes;

(2) Internal Revenue Service tax exemption status (charitable/nonprofit organizations only);

(3) All leases, rental, consignment, franchise, or other agreements relating to gambling activities or altering the commercial stimulant business, whether oral or written; and

(4) All loans, from other than recognized financial institutions, which individually or collectively exceed a total of \$2,000.00 during any calendar year.

The new or updated documents and/or information shall be submitted to the Commission by notation on the next quarterly activity report filed, and by attaching all details concerning each transaction: Provided, that licensees not required to submit quarterly activity reports shall submit the required information no later than 60 days following the transaction(s) date.

**Reviser's note:** RCW 34.05.395 requires the use of underlining and deletion marks to indicate amendments to existing rules. The rule published above varies from its predecessor in certain respects not indicated by the use of these markings.

**Reviser's note:** The bracketed material preceding the section above was supplied by the code reviser's office.

### WSR 91-07-022

#### ATTORNEY GENERAL OPINION

Cite as: AGO 1991 No. 8

[March 11, 1991]

#### DEPARTMENT OF NATURAL RESOURCES—DEPARTMENT OF FISHERIES—TIDELANDS—PUBLIC FUNDS—CULTIVATION OF CLAMS

1. Laws of 1919, ch. 166, which was repealed in 1949, granted owners of Bush Act tidelands the right to cultivate clams in addition to oysters. Article 8, sections 5 and 7, of the Washington Constitution, prohibit gifts of public funds. Under the court's contemporary construction of article 8, sections 5 and 7, Laws of 1919, ch. 166 is not clearly unconstitutional and anyone challenging the law would have a heavy burden of establishing beyond a reasonable doubt that the law is unconstitutional.
2. Rights acquired under a statute can vest if one substantially changes position in reliance on the statute, even if it is later repealed. The repeal of Laws of 1919, ch. 166, in 1949, did not extinguish the right to cultivate clams granted by the law for those owners of Bush Act tidelands who were cultivating clams in 1949 when the act was repealed.
3. When the Legislature repealed Laws of 1919, ch. 166, it did not indicate how long any vested right to cultivate clams might continue. The Legislature may adopted legislation to eliminate or phase out whatever vested rights remain to cultivate clams, provided that the conditions under which such rights are phased out or discontinued are reasonable.

#### Requested by:

Honorable Jennifer Belcher  
State Representative, District 22  
406 John L. O'Brien Building  
Olympia, Washington 98504

**Reviser's note:** The typographical error in the above material occurred in the copy filed by the Attorney General's Office and appears in the Register pursuant to the requirements of RCW 34.08.040.

### WSR 91-07-023

#### WITHDRAWAL OF PROPOSED RULES UTILITIES AND TRANSPORTATION COMMISSION

[Filed March 14, 1991, 11:36 a.m.]

Notice of proposed rulemaking, Form CR-102, was filed January 18, 1991, under WSR 91-03-096. That notice related to mandatory cost changes for telecommunications companies, Docket No. UT-901033.

This memorandum is sent pursuant to WAC 1-21-060 as a notice of withdrawal, withdrawing the above cited rule amendment.

Paul Curl  
Secretary

### WSR 91-07-024

#### PERMANENT RULES UTILITIES AND TRANSPORTATION COMMISSION

[Order R-338, Docket No. UT-901533—Filed March 14, 1991, 11:42 a.m.]

In the matter of adopting WAC 480-09-520 relating to abbreviated proceedings for competitive classification of telecommunication companies.

This action is taken pursuant to Notice No. WSR 91-03-097 filed with the code reviser on January 18, 1991. The rule change hereinafter adopted shall taken effect pursuant to RCW 34.05.380(2).

This rule-making proceeding is brought on pursuant to RCW 80.01.040 and is intended administratively to implement these statutes.

This rule-making proceeding is in compliance with the Open Public Meetings Act (chapter 42.30 RCW), the Administrative Procedure Act (chapter 34.05 RCW), the State Register Act (chapter 34.08 RCW), the State Environmental Policy Act of 1971 (chapter 43.21C RCW) and the Regulatory Fairness Act (chapter 19.85 RCW).

Pursuant to Notice No. WSR 91-03-097 the above matter was scheduled for consideration at 9:00 a.m., Wednesday, March 6, 1991, in the Commission's Hearing Room, Second Floor, Chandler Plaza Building, 1300 South Evergreen Park Drive S.W., Olympia, Washington before Chairman Sharon L. Nelson and Commissioners Richard D. Casad and A. J. Pardini.

Under the terms of said notice, interested persons were afforded the opportunity to submit data, views, or arguments to the commission in writing prior to and orally at 9:00 a.m., Wednesday, March 6, 1991, in the commission's hearing room above noted. At the March 6, 1991, meeting the commission considered the rule change proposal. Written comments were received from William Garling for Public Counsel, Terry Vann for Washington Independent Telephone Association, Fred Logan for GTE Northwest Incorporated, and Edward Shaw for US WEST; and oral comments were made by Robert Snyder and Edward Shaw for US WEST.

The rule change affects no economic values.

In reviewing the entire record herein, it has been determined that WAC 480-09-520 should be adopted to read as set forth in Appendix A shown below and by this reference made a part hereof. WAC 480-09-520 as adopted will provide abbreviated proceedings before the commission, rather than full adjudicative proceedings, for competitive classification of telecommunications companies where there are no controversial issues or where substantially similar companies have previously been classified by the commission as competitive.

#### ORDER

WHEREFORE, IT IS ORDERED That WAC 480-09-520 as set forth in Appendix A, be adopted as a rule of the Washington Utilities and Transportation Commission to take effect pursuant to RCW 34.05.380(2).

IT IS FURTHER ORDERED That the order and the annexed rule, after first being recorded in the order register of the Washington Utilities and Transportation Commission, shall be forwarded to the code reviser for filing pursuant to chapter 34.05 RCW and chapter 1-21 WAC.

DATED at Olympia, Washington, this 13th day of March, 1991.

Washington Utilities and Transportation Commission  
Sharon L. Nelson, Chairman  
Richard D. Casad, Commissioner  
A. J. Pardini, Commissioner

#### APPENDIX "A"

#### NEW SECTION

WAC 480-09-520 FORMAL INVESTIGATION AND FACT-FINDING. (1) Pursuant to RCW 80.36.145, the commission finds that it is in the public interest to employ an abbreviated proceeding for certain petitions for competitive classification under RCW 80.36.320 and RCW 80.36.330.

(2) The commission will institute an abbreviated proceeding on its own motion or at the request of petitioner filing for competitive classification under RCW 80.36.320 or RCW 80.36.330 where it is apparent on the face of the petition that no substantial issues of controversy are presented. The commission will invoke this rule by means of a Notice of Formal Investigation and Fact-finding. The Notice will call for written requests to intervene, and advise all interested persons that no hearing is contemplated other than possible hearings for public testimony.

(3) Upon the filing of a request to intervene, the commission will take objections, if any, and determine whether the proceeding qualifies for an abbreviated proceeding. A proceeding in which an intervenor proposes to participate through written submissions and data exchanges will be presumed to fall outside the scope of this rule. At any time, by written notice, the commission may convert an abbreviated proceeding into a formal adjudicative proceeding.

(4) The procedures set forth in WAC 480-09-480 will not apply in proceedings brought under this section. Informal exchange of data is the form of discovery that will apply to proceedings authorized by this rule. If such

discovery is not sufficient to meet the needs of the parties, the proceeding will be converted to a formal adjudicative proceeding. The "Protective Order" process referenced in WAC 480-09-015 will not be available in an abbreviated proceeding. If a claim of "confidentiality" is made, the proceeding will be converted to a formal adjudicative proceeding.

(5) The formal record will be limited to written submissions by the parties. Confidential material will not be accepted. The commission will designate in the notice of investigation the number and method of rounds of written submissions necessary to develop the facts relevant to the proceeding. At a minimum, petitioners and respondents wishing to obtain classification will file one original and nineteen legible, double-sided copies of the completed petition form provided by the commission upon request, together with pre-filed testimony and exhibits supporting the petition. The party with the burden of proof will always have the opportunity to file a written reply. Upon conclusion of the investigation the commission will enter an order, containing findings of fact and conclusions of law, disposing of the petition.

#### WSR 91-07-025

#### PERMANENT RULES

#### UTILITIES AND TRANSPORTATION COMMISSION

[Order R-340, Docket No. A-900424—Filed March 14, 1991, 11:46 a.m.]

In the matter of amending WAC 480-04-100 relating to copying and service costs.

This action is taken pursuant to Notice No. WSR 91-03-098 filed with the code reviser on January 18, 1991. The rule change hereinafter adopted shall taken effect pursuant to RCW 34.05.380(2).

This rule-making proceeding is brought on pursuant to RCW 80.01.040 and is intended administratively to implement these statutes.

This rule-making proceeding is in compliance with the Open Public Meetings Act (chapter 42.30 RCW), the Administrative Procedure Act (chapter 34.05 RCW), the State Register Act (chapter 34.08 RCW), the State Environmental Policy Act of 1971 (chapter 43.21C RCW) and the Regulatory Fairness Act (chapter 19.85 RCW).

Pursuant to Notice No. WSR 91-03-098 the above matter was scheduled for consideration at 9:00 a.m., Wednesday, March 6, 1991, in the Commission's Hearing Room, Second Floor, Chandler Plaza Building, 1300 South Evergreen Park Drive S.W., Olympia, Washington, before Chairman Sharon L. Nelson and Commissioners Richard D. Casad and A. J. Pardini.

Under the terms of said notice, interested persons were afforded the opportunity to submit data, views, or arguments to the commission in writing prior to February 25, 1991, and orally at 9:00 a.m., Wednesday, March 6, 1991, in the commission's hearing room above noted. At the March 6, 1991, meeting the commission considered the rule change proposal. No oral comments were received; written comments were received from

Dean Randall on behalf of GTE Northwest Incorporated and William Garling on behalf of Public Counsel.

The rule change affects no economic values.

In reviewing the entire record herein, it has been determined that WAC 480-04-100 should be amended to read as set forth in Appendix A shown below and by this reference made a part hereof. WAC 480-04-100 as amended will more accurately reflect the cost of supplying public records and information and the type of records which are available.

#### ORDER

WHEREFORE, IT IS ORDERED That WAC 480-04-100 as set forth in Appendix A, be amended as a rule of the Washington Utilities and Transportation Commission to take effect pursuant to RCW 34.05.380(2).

IT IS FURTHER ORDERED That the order and the annexed rule, after first being recorded in the order register of the Washington Utilities and Transportation Commission, shall be forwarded to the code reviser for filing pursuant to chapter 34.05 RCW and chapter 1-21 WAC.

DATED at Olympia, Washington, this 13th day of March, 1991.

Washington Utilities and Transportation Commission  
Sharon L. Nelson, Chairman  
Richard D. Casad, Commissioner  
A. J. Pardini, Commissioner

#### APPENDIX "A"

AMENDATORY SECTION (Amending Order R-157, Cause No. TV-1429, filed 3/4/81)

WAC 480-04-100 COPYING AND SERVICE COSTS. The commission shall provide copies of information and public records upon written request.

(1) The commission shall charge a published fee ((of twelve cents per)) for each single-sided page of copy, provided that no charge shall be made for ((less than ten copies)) a photocopy of a record consisting of five single-sided pages or fewer.

(2) Except as provided in WAC 480-09-125, the base charges for services shall be as follows:

(a) Photocopies shall cost twenty cents per page.

(b) Certified copies shall cost two dollars and fifty cents per certified sheet.

(c) Telefacsimile (FAX) transmissions shall cost fifty cents per page.

(d) Computer lists or printouts shall cost fifty cents per page.

(e) Computer data copied onto floppy disks shall cost five dollars per disk.

(f) Audio tapes shall cost four dollars each.

(g) Video tapes shall cost fifteen dollars each.

(3) Sales tax, at the current rate, shall be added to the base price of each item.

#### WSR 91-07-026

#### PERMANENT RULES

#### UTILITIES AND TRANSPORTATION

#### COMMISSION

[Order R-339, Docket No. A-900425—Filed March 14, 1991, 11:48 a.m.]

In the matter of amending WAC 480-09-125 relating to failure to file sufficient copies of documents.

This action is taken pursuant to Notice No. WSR 91-03-100 filed with the code reviser on January 18, 1991. The rule change hereinafter adopted shall take effect pursuant to RCW 34.05.380(2).

This rule-making proceeding is brought on pursuant to RCW 80.01.040 and is intended administratively to implement these statutes.

This rule-making proceeding is in compliance with the Open Public Meetings Act (chapter 42.30 RCW), the Administrative Procedure Act (chapter 34.05 RCW), the State Register Act (chapter 34.08 RCW), the State Environmental Policy Act of 1971 (chapter 43.21C RCW) and the Regulatory Fairness Act (chapter 19.85 RCW).

Pursuant to Notice No. WSR 91-03-100 the above matter was scheduled for consideration at 9:00 a.m., Wednesday, March 6, 1991, in the Commission's Hearing Room, Second Floor, Chandler Plaza Building, 1300 South Evergreen Park Drive S.W., Olympia, Washington, before Chairman Sharon L. Nelson and Commissioners Richard D. Casad and A. J. Pardini.

Under the terms of said notice, interested persons were afforded the opportunity to submit data, views, or arguments to the commission in writing prior to February 25, 1991, and orally at 9:00 a.m., Wednesday, March 6, 1991, in the commission's hearing room above noted. At the March 6, 1991, meeting the commission considered the rule change proposal. Written comments were received from Dean Randall and Fred Logan on behalf of GTE Incorporated and William Garling on behalf of Public Counsel. No oral comments were made.

The rule change affects no economic values.

In reviewing the entire record herein, it has been determined that WAC 480-09-125 should be amended to read as set forth in Appendix A shown below and by this reference made a part hereof. WAC 480-09-125 as amended will set the standards for refusing a filing of documents or making the necessary copies when insufficient copies have been filed.

#### ORDER

WHEREFORE, IT IS ORDERED That WAC 480-09-125 as set forth in Appendix A, be amended as a rule of the Washington Utilities and Transportation Commission to take effect pursuant to RCW 34.05.380(2).

IT IS FURTHER ORDERED That the order and the annexed rule, after first being recorded in the order register of the Washington Utilities and Transportation Commission, shall be forwarded to the code reviser for filing pursuant to chapter 34.05 RCW and chapter 1-21 WAC.

DATED at Olympia, Washington, this 13th day of March, 1991.

Washington Utilities and Transportation Commission  
Sharon L. Nelson, Chairman  
Richard D. Casad, Commissioner  
A. J. Pardini, Commissioner

APPENDIX "A"

NEW SECTION

WAC 480-09-125 FAILURE TO FILE SUFFICIENT COPIES—COSTS OF COPYING. (1) When a person files fewer than the required number of copies of a document, the commission may reject the filing. If needed for administrative convenience, the commission will make the additional copies for distribution and processing within the commission. "Administrative convenience" means that not having access to the documents would prejudice the commission.

(2) When the commission makes copies to meet the total number required, the commission will bill the filing person at a rate of thirty cents per page, plus current sales tax. This rate compensates for the loss of the worker's attention to assigned duties, the unscheduled use of equipment, and the fully allocated cost of materials.

(3) The commission may assess a penalty against any person who, within twelve months, again fails to file the required number of copies of any document.

**WSR 91-07-027**

**PROPOSED RULES**

**PUBLIC DISCLOSURE COMMISSION**

[Filed March 14, 1991, 2:23 p.m.]

Original Notice.

Title of Rule: WAC 390-24-031 Public office fund—Establishment and use.

Purpose: Describes the use and purpose of a public office fund.

Statutory Authority for Adoption: RCW 42.17.370.

Summary: Defines a public office fund.

Reasons Supporting Proposal: The Public Disclosure Commission receives inquiries asking whether a particular fund of money created by and for employees of a public agency is a "public office fund." A clear definition of the term "public office fund" is needed.

Name of Agency Personnel Responsible for Drafting: Roselyn Marcus, Olympia, 586-1913; Implementation: Graham E. Johnson, Olympia, 3-1111; and Enforcement: Same.

Name of Proponent: Public Disclosure Commission, governmental.

Rule is not necessitated by federal law, federal or state court decision.

Explanation of Rule, its Purpose, and Anticipated Effects: The rule sets forth criteria the commission believes necessary for determining that a particular fund of money is subject to the reporting requirements of RCW 42.17.243. The rule will help answer questions about the application of RCW 42.17.243.

Proposal does not change existing rules.

No small business economic impact statement is required for this proposal by chapter 19.85 RCW.

Hearing Location: Second Floor Conference Room, Evergreen Plaza Building, FJ-42, Olympia, Washington 98504-3342, on April 23, 1991, at 9 a.m.

Submit Written Comments to: Public Disclosure Commission, 403 Evergreen Plaza Building, FJ-42, Olympia, WA 98504-3342, by April 20, 1991.

Date of Intended Adoption: April 23, 1991.

March 12, 1991

Graham E. Johnson

Executive Director

NEW SECTION

WAC 390-24-031 PUBLIC OFFICE FUND—ESTABLISHMENT AND USE. (1) Public office fund, as that term is used in RCW 42.17.243, means any fund, created by or for the benefit of any elected or appointed official required to report under RCW 42.17.240, which (a) was created for the primary purpose of defraying nonreimbursed office-related expenses for that official and members of his/her immediate family; and (b) expenditures made from the fund are primarily controlled by the official for whom the fund was created.

(2) Any contribution or expenditure from any other source for the benefit of an official or member of his/her immediate family for the primary purpose of defraying nonreimbursed office-related expenses is a contribution to that official's public office fund and shall be reported as a contribution to and/or expenditure from the official's public office fund. Any in-kind contribution shall be valued at its fair market value.

(3) If a fund, not created pursuant to RCW 42.17.243, is used both for the purposes of defraying nonreimbursed office-related expenses of an official and making other expenditures for the benefit of staff or employees of the official or agency, only the expenditures made to defray nonreimbursed office-related expenses of an official and members of his/her immediate family shall be deemed expenditures from a public office fund and shall be reported as an expenditure from the official's public office fund.

**WSR 91-07-028**

**PROPOSED RULES**

**DEPARTMENT OF LICENSING**

[Filed March 14, 1991, 4:55 p.m.]

Original Notice.

Title of Rule: New WAC 308-10-067 Public records indexing system.

Purpose: To codify the system by which the Department of Licensing indexes its public records.

Statutory Authority for Adoption: RCW 42.17.260(4).

Statute Being Implemented: RCW 42.17.260(4).

Summary: See above.

Name of Agency Personnel Responsible for Drafting, Implementation and Enforcement: Walt Fahrer, Public Disclosure Officer, Department of Licensing, Highways-Licenses Building, Olympia, Washington 98504, (206) 753-6980.

Name of Proponent: Department of Licensing, governmental.

Rule is not necessitated by federal law, federal or state court decision.

Explanation of Rule, its Purpose, and Anticipated Effects: See Purpose above.

Proposal does not change existing rules.



No small business economic impact statement is required for this proposal by chapter 19.85 RCW.

Hearing Location: 4th Floor Drivers Conference Room #1, Highways-Licenses Building, Olympia, Washington 98504, on May 1, 1991, at 9:00 a.m.

Submit Written Comments to: Walt Fahrer, Public Disclosure Officer, Department of Licensing, Highways-Licenses Building, Olympia, Washington 98504, by April 29, 1991, at 5 p.m.

Date of Intended Adoption: May 1, 1991.

March 14, 1991  
Linda M. Moran  
Assistant Attorney General

#### NEW SECTION

WAC 308-10-067 PUBLIC RECORDS INDEXING SYSTEM. (1) The department of licensing has implemented a system of indexing for identification and location of the following records:

(a) All records issued before July 1, 1990, for which the agency has maintained an index.

(b) Final orders from adjudicative proceedings entered after June 30, 1990, that contain an analysis or decision of substantial importance to the agency in carrying out its duties.

(c) Declaratory orders entered after June 30, 1990, that contain an analysis or decision of substantial importance to the agency in carrying out its duties.

(d) Interpretive statements entered after June 30, 1990.

(e) Policy statements entered after June 30, 1990.

(2) The department of licensing will maintain an index of the above-mentioned public records by departmental division and program maintaining the record, title of the record, subject of the record, and by the administrative reference number assigned to the record.

(3) The index of public records will be maintained and updated yearly by the agency. The index of records is available during regular business hours for public inspection at the agency's main office located at the Department of Licensing, 211 - 12th Avenue S.E., PB-01, Olympia, Washington 98504. Subindexes will be maintained by the departmental division and program. The public disclosure officer is responsible for updating the index yearly.

**WSR 91-07-029**  
**PERMANENT RULES**  
**DEPARTMENT OF LICENSING**  
**(Real Estate Commission)**  
[Filed March 14, 1991, 4:57 p.m.]

Date of Adoption: February 28, 1991.

Purpose: To change rule language so it is consistent with recent Real Estate Commission policy decisions.

Citation of Existing Rules Affected by this Order: Amending WAC 308-124A-430 Grading of examinations, requires examination candidate to obtain a score of 75 on each portion of the broker examination and a score of 70 on each portion of the salesperson examination effective July 31, 1991; WAC 308-124H-010 Approval of real estate courses to satisfy clock hour requirements, allows licensees to allocate mandatory continuing education credit between substantive real estate subject matter courses and business skills and management courses, effective January 1, 1992; WAC 308-124H-025 Application for course approval, designates substantive real estate subject matter course topics and allows course approval for business skills and management courses and identifies approved topic areas; and

WAC 308-124H-540 Qualifications of instructors, includes in instructor qualifications individuals selected by national or state associations with director-approved selection criteria.

Reasons Supporting These Proposals: These WAC amendments will facilitate real estate education and enhance consumer protection by supporting and encouraging quality real estate educational programs.

Statutory Authority for Adoption: RCW 18.85.040, [18.85].085, [18.85].090, and [18.85].095.

Pursuant to notice filed as WSR 91-03-047 on January 11, 1991.

Changes Other than Editing from Proposed to Adopted Version: WAC 308-124A-430 adds language making changes effective July 1, 1991.

Effective Date of Rule: Thirty-one days after filing.

March 6, 1991

Mary Faulk

Director

#### AMENDATORY SECTION (Amending Order PM 774, filed 9/30/88, effective 1/1/89)

WAC 308-124A-430 GRADING OF EXAMINATIONS. (1) A minimum scaled score of 70 (~~is required to pass~~) on each portion of the real estate salesperson examination is required to pass. The real estate salesperson examination shall consist of two portions: (a) The national portion consisting of questions that test general real estate practices and (b) the state portion consisting of questions that test on Washington licensing law and regulations effective July 1, 1991.

(2) A minimum scaled score of 75 (~~is required to pass~~) on each portion of the real estate broker examination is required to pass. The real estate broker examination shall consist of two portions: (a) The national portion consisting of questions that test general real estate brokerage practices and (b) the state portion consisting of questions that test on Washington licensing law, regulations, and the closing/settlement process effective July 1, 1991.

(3) A passing score for a portion of an examination shall be valid for a period not to exceed six months effective July 1, 1991.

#### AMENDATORY SECTION (Amending WSR 90-01-047, filed 12/14/89, effective 1/14/90)

WAC 308-124H-010 APPROVAL OF REAL ESTATE COURSES TO SATISFY CLOCK HOUR REQUIREMENTS. To satisfy a requirement for clock hours of instruction pursuant to RCW 18.85.090, 18.85-.095, 18.85.165, or 18.85.215 as applicable, a licensee or applicant for license shall submit to the department evidence of satisfactory completion of courses in a manner and on forms prescribed by the department.

(1) (~~All licensees applying for renewal of an active license on or after January 1, 1991, shall, pursuant to RCW 18.85.165, submit evidence of completion of at least thirty clock hours of instruction in a course(s) approved by the director commenced within thirty-six months of a licensee's 1991 renewal date.~~)

(2)) All licensees applying for renewal of an active license after December 31, ~~((1991))~~ 1990, shall, pursuant to RCW 18.85.165, submit evidence of completion of at least thirty clock hours of instruction in a course(s) approved by the director commenced within thirty-six months of a licensee's renewal date. A minimum of fifteen clock hours must be completed within twenty-four months of any two-year renewal date; up to fifteen clock hours of instruction beyond the thirty clock hours submitted for a previous renewal date may be carried forward to the following renewal date.

(2) To satisfy the requirement for clock hours of instruction pursuant to RCW 18.85.165, licensees shall be required to submit to the department evidence of satisfactory completion of courses of at least thirty clock hours. These clock hours may be satisfied by evidence of a minimum of twenty clock hours in courses designated by the commission as substantive real estate subject matter and not more than ten clock hours in courses designated by the commission as business skills and management courses, effective January 1, 1992.

(3) Courses previously taken for the "second renewal" requirement pursuant to RCW 18.85.095(2) may be used for continuing education if taken within thirty-six months prior to licensee's renewal date; courses taken to activate an inactive license pursuant to RCW 18.85.215(3) cannot be used to satisfy RCW 18.85.165 for continuing education; courses taken to satisfy broker's educational requirements pursuant to RCW 18.85.090(4) may be used to satisfy RCW 18.85.165 if taken within thirty-six months of a licensee's renewal date in 1991: Subsequent renewals must comply with WAC 308-124H-010(2); courses for clock hour credit pursuant to RCW 18.85.165 shall be commenced after issuance of a first license, except courses for clock hour credit pursuant to RCW 18.85.095 (1)(c) shall be commenced prior to first licensure.

(4) A licensee shall not place a license on inactive status to avoid the requirement of RCW 18.85.165. A licensee shall submit evidence of completion of clock hours pursuant to RCW 18.85.165 to reactivate a license if activation occurs within one year after the license had been placed on inactive status and the last renewal of the license had been as an inactive license.

(5) Waiver of the clock hours required under RCW 18.85.090, 18.85.095, 18.85.165, 18.85.215 shall not be considered or granted, except as provided in WAC 308-124A-425(3).

(6) Clock hour credit shall not be accepted if:

(a) The course is not approved pursuant to chapter 308-124H WAC and chapter 18.85 RCW;

(b) Clock hours for license renewal were commenced prior to the date of first licensure;

(c) The course(s) is a repeat or duplication of course(s) material for which credit had been accepted by the department the preceding renewal date; except approved courses in real estate law, real estate finance, taxation, and license law, rules and regulations may be repeated for credit;

(d) A course(s) was previously used to satisfy the requirements of RCW 18.85.095 (1)(c); except clock hour

credit taken to satisfy RCW 18.85.095 (1)(c) in 1990 may be applied to satisfy RCW 18.85.165 in 1991.

(7) Instructors shall not receive clock hour credit for teaching or course development.

**AMENDATORY SECTION** (Amending WSR 90-10-010, filed 4/20/90, effective 8/1/90)

**WAC 308-124H-025 APPLICATION FOR COURSE APPROVAL.** Courses shall meet the following requirements:

(1) Provide practical information related to the practice of real estate, and deal with substantive real estate subject matter ~~((such as, but not limited to, legal aspects of real estate, real estate principles and practices, real estate finance, appraising, and deposit receipts and earnest money agreements. Courses which will assist the licensee in improving their business skills and business management need not include substantive real estate subject matter))~~ in any of the following real estate topic areas: Fundamentals, principles/practices/essentials, law, legal aspects, brokerage management, business management, taxation, appraisal, evaluating real estate and business opportunities, property management and leasing, construction and land development, ethics and standards of practice, escrow closing/settlement practices, current trends and issues, finance, hazardous waste and other environmental issues, or;

(2) Provide practical information related to assisting licensees in improving their business skills and business management in order to enable them to better serve and protect the consumer in any of the following topic areas: Advertising, agent supervision and broker responsibility, cross cultural communication, theory and practices of relocation, and accounting for real estate offices. Have a minimum of three hours of classroom work for the student. A classroom hour is a period of fifty minutes of actual classroom or workshop instruction, exclusive of examination time;

(3) Be under the supervision of an approved instructor approved to teach the course in the classroom at all sessions and offered by an approved school provided that, if the instructional methods include the use of prerecorded audio and/or visual instructional materials, presentation shall be under the supervision of a monitor at all times and an approved instructor who shall, at a minimum, be available to respond to specific questions from students;

(4) Include a comprehensive examination(s) and answer key(s) of no fewer than three questions per clock hour with a minimum of ten questions, and a requirement of passing course grade of at least seventy percent; essay question examination keys shall identify the material to be tested and the points assigned for each question;

(5) Include textbook or instructional materials approved by the director, which shall be kept accurate and current. Course materials shall be updated no later than thirty days after the effective date of a change in statute or rules;

(6) Include in its title the phrase "real estate fundamentals," "real estate brokerage management," or "real estate law" if submitted for approval for clock hours in real estate fundamentals pursuant to WAC 308-124H-

035, real estate brokerage management pursuant to WAC 308-124H-036, or real estate law pursuant to WAC 308-124H-037. No other courses shall use these phrases in their titles;

(7) Not have a title which misleads the public as to the subject matter of the course;

(8) Be offered by a tax-supported, public vocational-technical institution, community college or any other institution of higher learning that may certify clock hours as indicated in RCW 18.85.010(9) or by a private entity approved by the director to operate as a school;

(9) Any change in course content or material other than updating for statute or rule changes, shall be submitted to the department no later than twenty days prior to the date of using the changed course content material, for approval by the director;

(10) Changes in course instructors may be made only if the substitute instructors are currently approved to teach the course pursuant to chapter ~~((308-124H))~~ 308-124H WAC;

(11) A course completed in another jurisdiction may be approved for clock hour credit if:

(a) The course was offered by a tax-supported, public vocational-technical institution, community college, or any other institution of higher learning, or by a national institution with uniform scope and quality of representation, or was approved to satisfy an education requirement for real estate licensing or renewal and offered by an entity approved to offer the course by the real estate licensing agency in that jurisdiction; and

(b) The course satisfies the requirements of subsections (1) through (5) of this section, and includes a comprehensive examination and requirement of a passing course grade of at least seventy percent; and/or

(c) If the director determines that the course substantially satisfies the requirements of the real estate fundamentals course required under RCW 18.85.095 or satisfies the requirements of the law and brokerage management courses required under RCW 18.85.090.

#### AMENDATORY SECTION (Amending WSR 90-10-010, filed 4/20/90, effective 8/1/90)

WAC 308-124H-540 QUALIFICATIONS OF INSTRUCTORS. Each instructor shall be qualified in techniques of instruction.

Instructor qualifications in techniques of instruction shall be evidenced by one of the following:

(1) One hundred fifty classroom hours as an instructor within two years preceding application in courses acceptable to the director;

(2) Possession of the professional designation, DREI, from the Real Estate Educators Association (REEA);

(3) Successful completion of an instructor training course approved by the director upon recommendation of the commission and two years fulltime experience in real estate or a related field within the five years immediately preceding the date of application;

(4) A bachelors or advanced degree in education and either two years teaching experience, or two years experience in real estate or a related field within the last five years;

(5) A current teaching certificate issued by an authorized governmental agency. The instruction must have been in a field allied to that which the instructor has applied to teach.

(6) At least ninety clock hours as an instructor in real estate within two years preceding the application;

(7) Ninety hours as an instructor at an institution of higher learning within two years preceding the application. The instruction must have been in a field allied to that which the instructor has applied to teach.

(8) ~~((Instructors selected by national organizations who have courses currently))~~ Selection by a national or state association whose selection criteria have been approved by the director.

#### WSR 91-07-030

#### PREPROPOSAL COMMENTS FOREST PRACTICES BOARD

[Filed March 15, 1991, 8:32 a.m.]

Subject of Possible Rule Making: The Forest Practices Board intends to make permanent changes to WAC 222-16-050(1), which defines those classes of forest practices that have a potential for a substantial impact on the environment.

Persons may Comment on this Subject in the Following Ways: Persons may comment on this subject in writing. Written comments should be submitted to: Edward R. Summerfield, Assistant to Chairman, Forest Practices Board, Mailstop EL-03, Olympia, Washington 98504. Written comments will be accepted until April 24, 1991.

Other Information or Comments by Agency at this Time, if any: On October 25, 1990, the Snohomish County Superior Court issued a final judgment declaring WAC 222-16-050(1) invalid as it existed on that date. *Snohomish County v. DNR*, No. 89-2-06923-5 (Snohomish Cy. Super. Ct.). On November 14, 1990, the Forest Practices Board adopted an emergency rule to replace the one declared invalid, and adopted a second emergency rule directing the Department of Natural Resources to develop a watershed screening and analysis process. The board established three task forces to develop recommendations for new permanent rule language relating to pesticide use, aesthetics, and wildlife. The task forces reported the results of their work at Forest Practices Board meetings on February 13, 1991, and March 13, 1991. The task forces have completed preliminary drafts and are continuing to receive comment and input. At its March 13, 1991, meeting, the Forest Practices Board expressed its intent that the task forces present their recommendations to the board no later than April 24, 1991. On March 13, 1991, the Forest Practices Board readopted, with modification, the two emergency rules that it had adopted on November 14, 1990. The board anticipates modifying the language in subsections (a) through (c) of emergency WAC 222-16-050(1) before proposing that rule for permanent adoption. The task forces the board established are continuing to examine those subsections and subsection (d).

The board expects to consider recommendations for permanent rule language on all subsections of WAC 222-16-050(1) at its May 8, 1991, meeting. Further information is available at the address given above.

March 14, 1991  
Brian Boyle  
Commissioner of  
Public Lands

**WSR 91-07-031**  
**PERMANENT RULES**  
**DEPARTMENT OF HEALTH**  
**(Board of Health)**

[Order 150B—Filed March 15, 1991, 10:25 a.m.]

Date of Adoption: February 13, 1991.

Purpose: These rules add volatile organic chemical monitoring requirements, MCLS, and follow-up requirements for group A public water systems.

Citation of Existing Rules Affected by this Order: Amending WAC 246-290-010, 246-290-130, 246-290-300, 246-290-310, 246-290-320, and 246-290-330.

Statutory Authority for Adoption: Chapter 43.20 RCW.

Pursuant to notice filed as WSR 90-24-071 on December 5, 1990.

Changes Other than Editing from Proposed to Adopted Version: WAC 246-290-010(7), this change clarifies that the local health officer has the same authority as the department according to a signed agreement between the two agencies; WAC 246-290-300 (8)(i), this adds two activities which have the potential to contaminate the public water system sources; WAC 246-290-310(4), this change clarifies that the State Board of Health establishes maximum contaminant levels, not the department; WAC 246-290-320 (6)(d)(iv)(B), language referring to a department hearing was placed in this section by mistake. It was referring to a different procedure related to variances, exemptions and waivers; WAC 246-290-320 (6)(i), this change is designed to assure the State Board of Health approves the methodology for determining state advisory levels as set forth in the Department of Health manual referred to in the rule; WAC 246-290-330(5), this change is meant to clarify that this subsection deals with notification procedures for volatile organic chemicals only; and WAC 246-290-330(6), this change is meant to clarify that this subsection deals with notification procedures for fluoride only.

Effective Date of Rule: Thirty-one days after filing.

February 22, 1991  
Sylvia I. Beck  
Executive Director

**AMENDATORY SECTION** (Amending Order 124B, filed 12/27/90, effective 1/31/91)

WAC 246-290-010 DEFINITIONS. (1)

Abbreviations:

- (a) kPa – kilo pascal (SI units of pressure)((:));  
(b) m – meter((:));  
(c) MCL – maximum contaminant level((:));

- (d) mg/L – milligrams per liter((:));  
(e) MID – maximum instantaneous demand((:));  
(f) mL – milliliter((:));  
(g) mm – millimeter((:));  
(h) MPN – most probable number of coliform bacteria per 100 mL((:));  
(i) NTNC – nontransient noncommunity((:));  
(j) NTU – nephelometric turbidity unit((:));  
(k) pCi/L – picocuries per liter((:));  
(l) psi – pounds per square inch((:));  
(m) SAL – state advisory level;  
(n) SOC – synthetic organic chemical;  
(o) THM – trihalomethane;  
(p) TNC – transient noncommunity((:));  
(q) ug/L – micrograms per liter((:));  
(r) umhos/cm – micromhos per centimeter((:));  
(s) VOC – volatile organic chemical; and  
(t) WFI – water facilities inventory and report form((:));

(2) "Acute" means posing an immediate risk to human health.

(3) "Composite sample" means a sample created in a certified laboratory by mixing equal parts of water from up to five different sources.

(4) "Confirmation" means to demonstrate the results of a sample to be precise by analyzing a repeat sample. Confirmation occurs when analysis results fall within plus or minus thirty percent of the original sample.

(5) "Contaminant" means ~~((any))~~ a substance present in drinking water which may adversely affect the health of the consumer ~~((and/))~~ or the aesthetic qualities of the water.

~~((+))~~ (6) "Cross-connection" means ~~((any))~~ a physical arrangement connecting a public water system, directly or indirectly, with anything other than another potable water system, and capable of contaminating the public water system.

~~((+))~~ (7) "Department" means the Washington state department of health or health officer as identified in a joint plan of operation per WAC 246-290-030(1).

~~((+))~~ (8) "Disinfection" means the use of chlorine or other agent or process ~~((approved by))~~ the department approves for ~~((the purpose of))~~ killing or inactivating microbiological organisms, including pathogenic and indicator organisms.

~~((+))~~ (9) "Distribution system" means that portion of a public water supply system which stores, transmits, pumps, and distributes water to consumers.

~~((+))~~ (10) "Duplicate (verification) sample" means a second sample collected at the same time and location as the first sample and used for verification.

(11) "Fire flow" means the rate of water flow needed to fight fires ~~((as defined by applicable codes))~~ under WAC 246-293-640 or adopted city, town, or county standards.

~~((+))~~ (12) "Guideline" means a department document ~~((intended to assist))~~ assisting the purveyor in meeting a rule requirement ~~((of a rule))~~.

~~((+))~~ (13) "Health officer" means the health officer of the city, county, city-county health department or district, or an authorized representative.

~~((11))~~ (14) "Hydraulic analysis" means the study of the water system network ~~((To evaluate))~~ evaluating water flows within the distribution system under worst case conditions ~~((;))~~ such as, maximum hourly flow plus fire flow, when required, or maximum instantaneous demand (MID), when fire flow is not required. Hydraulic analysis includes consideration of all factors affecting system energy losses.

~~((12))~~ (15) "Maximum contaminant level (MCL)" means the maximum permissible level of a contaminant in water ~~((delivered))~~ the purveyor delivers to any ~~((user of a))~~ public water system ~~((as))~~ user, measured at the locations identified ~~((in))~~ under WAC ~~((248-54-165))~~ 246-290-300, Table 4.

~~((13))~~ (16) "Maximum contaminant level violation" means a confirmed measurement above the MCL and for a duration of time, where applicable, as outlined under WAC ~~((248-54-175))~~ 246-290-310.

~~((14))~~ (17) "Maximum instantaneous demand (MID)" means the maximum rate of water use, excluding fire flow, ~~((experienced))~~ which has occurred or is expected to occur within a defined service area at ~~((any))~~ an instant in time.

~~((15))~~ (18) "Potable" means water suitable for drinking by the public.

~~((16))~~ (19) "Primary standards" means standards based on chronic or acute human health effects.

~~((17))~~ (20) "Protected ground water source" means a ground water source ~~((shown))~~ the purveyor shows to the ~~((satisfaction of the department to be))~~ department's satisfaction as protected from ~~((any))~~ potential sources of contamination on the basis of hydrogeologic data and/or satisfactory water quality history.

~~((18))~~ (21) "Public water system" ~~((refer to))~~ is defined and referenced under WAC ~~((248-54-006))~~ 246-290-020.

~~((19))~~ (22) "Purchase source" means water a purveyor purchases from a public water system not under the control of the purveyor for distribution to the purveyor's customers.

(23) "Purveyor" means ~~((any))~~ an agency or subdivision of the state or ~~((any))~~ a municipal corporation, firm, company, mutual or cooperative association, institution, partnership, or person or ~~((any))~~ other entity ~~((that owns or operates))~~ owning or operating a public water system. ~~((It))~~ Purveyor also means the authorized agent ~~((s))~~ of ~~((any))~~ such entities.

~~((20))~~ (24) "Regularly" means four hours or more per day for four days or more per week.

~~((21))~~ (25) "Repeat (confirmation) sample" means a sample collected a second time at the same location for confirmation of original analysis results.

(26) "Resident" means an individual living in a dwelling unit served by a public water system.

~~((22))~~ (27) "Seasonal source" means a public water system source used on a regular basis, but not in use more than three consecutive months within a twelve-month period.

(28) "Secondary standards" means standards based on factors other than health effects.

~~((23))~~ (29) "Service" means a connection to a public water system designed to serve a single family residence, dwelling unit, or equivalent use. ~~((If the facility has))~~ When the connection is a group home or barracks-type accommodation ~~((s))~~, three persons ~~((with))~~ shall be ~~((considered))~~ equivalent to one service.

~~((24))~~ (30) "Standard methods" means the most recently published edition of the book, titled "Standard Methods for the Examination of Water and Waste Water," jointly published by the American Public Health Association, American Water Works Association (AWWA), and Water Pollution Control Federation. This book is available through public libraries or may be ordered from AWWA, 6666 West Quincy Avenue, Denver, Colorado 80235.

~~((25))~~ (31) "State advisory level (SAL)" means a department-established value for a chemical without an existing MCL. The SAL represents a level which when exceeded, indicates the need for further assessment to determine if the chemical is an actual or potential threat to human health.

(32) "Synthetic organic chemical (SOC)" means a manufactured carbon-based chemical.

(33) "Trihalomethane (THM)" means one of a family of organic compounds, named as derivatives of methane, where three of the four hydrogen atoms in methane are each substituted by a halogen atom in the molecular structure. Trihalomethanes may occur when chlorine, a halogen, is added to water.

(34) "Verification" means to demonstrate the results of a sample to be precise by analyzing a duplicate sample. Verification occurs when analysis results fall within plus or minus thirty percent of the original sample.

(35) "Volatile organic chemical (VOC)" means a manufactured carbon-based chemical that vaporizes quickly at standard pressure and temperature.

(36) "Water facilities inventory form ~~((n))~~ (WFI)" means the department form ~~((which summarizes))~~ summarizing each public water system's characteristics.

~~((26))~~ (37) "Well field" means a group of wells ~~((owned and/))~~ one purveyor owns or ~~((controlled by one purveyor))~~ controls which:

(a) Draw from the same aquifer or aquifers as determined by comparable inorganic chemical analysis; and

(b) Discharge water through a common pipe and the common pipe shall allow for collection of a single sample before the first distribution system connection.

**AMENDATORY SECTION** (Amending Order 124B, filed 12/27/90, effective 1/31/91)

WAC 246-290-130 SOURCE APPROVAL. (1) No new, previously unapproved sources, or modification of existing sources shall be used as a public water supply without department approval. A party seeking approval shall provide the department ~~((the following))~~:

(a) A copy of the water right permit, if required, obtained from the department of ecology for the source, quantity, type, and place of use;

(b) A hydrogeologic assessment of the proposed source along with a general description of the watershed,

spring, and/or aquifer recharge area affecting the quantity or quality of flow. Seasonal variation shall also be included;

(c) For unfiltered surface water, the watershed control program identified under WAC ~~((248-54-225))~~ 246-290-450;

(d) Upstream water uses affecting either water quality or quantity;

(e) A map showing the project location and vicinity;

(f) A map depicting topography, distances to the surface water intake, well or spring from existing property lines, buildings, potential sources of contamination, ditches, drainage patterns, and any other natural or man-made features affecting the quality or quantity of water;

(g) The dimensions and location of the sanitary control area ~~((as set forth))~~ under WAC ~~((248-54-125))~~ 246-290-210;

(h) Copies of the recorded legal documents for the sanitary control area ~~((necessary to protect the source of supply))~~ under WAC 246-290-210;

(i) A copy of the on-site inspection approval made by the department or local health department representative;

(j) A copy of the water well report;

(k) ~~((Necessary))~~ Required construction documents;

(l) Well source development data ~~((to establish))~~ establishing the capacity of the source. Data shall include static water level, yield, the amount of drawdown, recovery rate~~(:))~~ and duration of pumping. Interference between existing sources and the source being tested ~~((must))~~ shall also be shown. The source shall be pump tested at no less than the maximum design rate to determine whether the well and aquifer are capable of supplying water at the rate desired and to provide information necessary to determine the proper pump settings in the well~~((, the source shall be pump tested at no less than the maximum design rate))~~. A department guideline on pump testing is available to assist purveyors;

(m) ~~((The results of))~~ An initial analysis result of ~~((the))~~ raw water quality, including as a minimum a bacteriological ~~((and))~~, complete inorganic chemical and physical analysis ~~((from each source))~~ and a VOC analysis. When source water quality is subject to variation, the department may require additional monitoring ~~((may be required by the department to define))~~ defining the range of variation. If the source being approved is for a community system, a radionuclide analysis shall also be required;

(n) Detailed information regarding ~~((all))~~ aspects of water quality addressed under WAC ~~((248-54-175))~~ 246-290-310. If treatment is planned, refer to WAC ~~((248-54-155))~~ 246-290-250(2); and

(o) Other department-required information ~~((as may be required by the department))~~. Before initiating source development or modification, the purveyor ~~((should))~~ shall contact the department ~~((in order))~~ to identify any such additional information.

(2) The department shall issue a written approval when:

(a) The purveyor submits the necessary information ~~((is submitted))~~; and

(b) The developed source provides water complying with chapter ~~((248-54))~~ 246-290 WAC.

AMENDATORY SECTION (Amending Order 124B, filed 12/27/90, effective 1/31/91)

WAC 246-290-300 MONITORING REQUIREMENTS. (1) General.

(a) The purveyor shall be responsible for satisfying ~~((all))~~ requirements of this section. The monitoring requirements in this section are minimums. The department may require additional monitoring ~~((may be required by the department))~~:

(i) When system water quality exceeds an MCL; or

(ii) When source contamination is suspected; or

(iii) Under other circumstances as identified in a departmental order.

(b) Purveyor's samples required under this section shall be collected, transported, and analyzed according to department-approved methods ~~((approved by the department))~~. The ~~((analyses shall be done by the))~~ state public health laboratory or ~~((by any other))~~ another department-certified laboratory ~~((certified by the department for))~~ shall perform the analyses ~~((to be performed))~~, except turbidity as required under WAC ~~((248-54-165))~~ 246-290-300(4) may be tested by water utility or health department personnel.

(c) When one public water system receives water from another public water system, the receiving system is only required to take bacteriological samples ~~((per))~~ as described under WAC ~~((248-54-165))~~ 246-290-300(2) and trihalomethane samples as ~~((appropriate per))~~ described under WAC ~~((248-54-165))~~ 246-290-300(5).

Subject to revision as appropriate, the department may reduce the monitoring requirement of the receiving system provided the receiving system:

(i) Has ~~((had))~~ a good water quality history;

(ii) ~~((Is operated))~~ Operates in a satisfactory manner consistent with ~~((these))~~ regulations under this chapter;

(iii) Is included in the supplying system's regular monitoring schedule; and

(iv) Is included in the service and population totals for the supplying system.

Periodic reviews of the system's sampling record may be made to determine if continued reduction is appropriate.

(d) Special purpose samples, such as check samples or samples taken to determine if disinfection following pipe repair has been sufficient, shall not count toward fulfillment of ~~((these))~~ the monitoring requirements of this chapter.

(e) ~~((All))~~ Monitoring requirements in subsections (2) ~~((through))~~, (3), (4), (5), (6), (7), and (8) of this section apply equally to systems serving resident or nonresident populations unless otherwise stated.

(2) Bacteriological.

(a) Drinking water samples shall be collected for bacteriological analysis from representative points in the distribution system at regular time intervals.

(b) The frequency for monitoring drinking water shall be determined according to the following:

(i) For community systems, the minimum number of routine samples to be analyzed is shown in Table 2;

(ii) For NTNC and TNC systems, the minimum number of routine samples to be analyzed is shown in Table 3. In the case where an activity lasts for one week or less, sampling frequency shall be as directed by the department;

(iii) For Group A water systems serving both a resident and a nonresident population, the minimum number of routine samples to be analyzed may vary from month to month. The number of samples required each month will be the higher number of samples from Table 2 and Table 3; and

(iv) For Group B water systems, the minimum number of routine samples is one every twelve months.

(c) When disinfection is practiced, the purveyor shall collect untreated (raw) water samples from each source for bacteriological analysis of total coliform in addition to the number of treated samples required. The frequency of monitoring untreated water shall be determined according to the following:

(i) For protected ground water sources, one sample every three months shall be analyzed;

(ii) For unprotected ground water sources, the number of samples analyzed shall be twenty percent of the distribution samples required each month, and in no case less than one every three months;

(iii) For surface sources with treatment including coagulation, filtration, and disinfection or other treatment process, the number of samples analyzed shall be ten percent of the distribution samples required each month, and in no case less than one every three months; and

(iv) For surface sources without coagulation and filtration treatment, the number of samples analyzed shall be twenty percent of the distribution samples required each month, and in no case less than one every three months.

TABLE 2

MINIMUM ROUTINE BACTERIOLOGICAL SAMPLING REQUIREMENTS FOR COMMUNITY SYSTEMS BASED ON THE NUMBER OF RESIDENTS

Number of Residents* Served	Minimum No. of Samples Per Month	Number of Residents Served	Minimum No. of Samples Per Month
Less than 251	1**	37,001 - 41,000	45
251 - 1,000	1	41,001 - 46,000	50
1,001 - 2,500	2	46,001 - 50,000	55
2,501 - 3,300	3	50,001 - 54,000	60
3,301 - 4,100	3	54,001 - 59,000	65
4,101 - 4,900	4	59,001 - 64,000	70
4,901 - 4,900	4	64,001 - 70,000	75
4,901 - 5,800	5	70,001 - 76,000	80
5,801 - 6,700	6	76,001 - 83,000	85
6,701 - 7,600	7	83,001 - 90,000	90
7,601 - 8,500	8	90,001 - 96,000	95
8,501 - 9,400	9	96,001 - 111,000	100
9,401 - 10,300	10	111,001 - 130,000	110
10,301 - 11,100	11	130,001 - 160,000	120
11,101 - 12,000	12	160,001 - 190,000	130
12,001 - 12,900	13	190,001 - 220,000	140
12,901 - 13,700	14	220,001 - 250,000	150
13,701 - 14,600	15	250,001 - 290,000	160
14,601 - 15,500	16	290,001 - 320,000	170
15,501 - 16,300	17	320,001 - 360,000	180
16,301 - 17,200	18	360,001 - 410,000	190
17,201 - 18,100	19	410,001 - 450,000	200
18,101 - 18,900	20	450,001 - 500,000	210
18,901 - 19,800	21	500,001 - 550,000	220
19,801 - 20,700	22	550,001 - 600,000	230
20,701 - 21,500	23	600,001 - 660,000	240
21,501 - 22,300	24	660,001 - 720,000	250
22,301 - 23,200	25	720,001 - 780,000	260
23,201 - 24,000	26	780,001 - 840,000	270
24,001 - 24,900	27	840,001 - 910,000	280
24,901 - 25,000	28	910,001 - 970,000	290

Number of Residents* Served	Minimum No. of Samples Per Month	Number of Residents Served	Minimum No. of Samples Per Month
25,001 - 28,000	30	970,001 - 1,050,000	300
28,001 - 33,000	35	1,050,001 - 1,140,000	310
33,001 - 37,000	40		

\*Does not include population of utilities wholesaled to, except as provided under WAC ((248-54-165)) 246-290-300 (1)(c)

\*\*May be reduced by the department to no less than one every three months for systems with protected ground water sources.

TABLE 3

MINIMUM ROUTINE BACTERIOLOGICAL SAMPLING REQUIREMENTS FOR NTNC AND TNC SYSTEMS BASED ON NONRESIDENT POPULATIONS

Maximum Day Population Served in Any One Month	Minimum Number Samples That Month
Less than 25	1 every 12 months
25 - 299	1 every 3 months
300 - 999	1*
1,000 - 2,499	2
2,500 - 3,499	3
3,500 - 4,999	4
5,000 - 9,999	6
10,000 - 14,999	8
15,000 - 19,999	10
20,000 - 29,999	12
30,000 - 39,999	14
40,000 - 49,999	16
50,000 - 74,999	20
75,000 - 99,999	25
100,000 or more	30

\*May be reduced by the department to one every three months for systems with protected ground water sources.

(3) Inorganic chemical and physical.

(a) The purveyor's complete inorganic chemical and physical analysis shall consist((s)) of the primary and secondary chemical and physical standards.

(i) Primary chemical and physical standards ((=)) are arsenic, barium, cadmium, chromium, fluoride, lead, mercury, nitrate (as N), selenium, silver, sodium, and turbidity.

(ii) Secondary chemical and physical standards ((=)) are chloride, color, copper, hardness, iron, manganese, specific conductivity, sulfate\*, total dissolved solids\*, and zinc.

\*Required only when specific conductivity exceeds seven hundred micromhos/centimeter.

(b) Purveyor samples taken for inorganic chemical analyses shall be collected at the source ((prior to any)) before treatment.

(c) The frequency for a purveyor's monitoring shall be according to ((the following)):

(i) Purveyors of community systems shall have one complete analysis from each surface water source every twelve months((-));

(ii) Purveyors of community systems shall have one complete analysis from each ground water source or well field every thirty-six months((-);

(iii) Purveyors of NTNC, TNC, and Group B systems shall have one initial complete analysis from each source or well field. The department may waive or reduce the minimum requirement for the initial complete analysis ((may be waived or reduced by the department)) if available information shows, to the department's satisfaction ((of the department)), that the aquifer provides water of satisfactory inorganic chemical quality((-); and

(iv) After the initial complete analysis, NTNC, TNC, and Group B systems shall have one nitrate sample analyzed from each source or well field every thirty-six months.

(d) When the purveyor provides treatment ((is provided)) for one or more inorganic chemical or physical contaminants, samples shall be taken for the specific contaminant or contaminants before and after treatment. The department shall determine the frequency ((shall be determined by the department)) of sampling.

(4) Turbidity.

(a) Purveyors of Group A water systems with surface water sources shall monitor turbidity at least once a day.

(b) The purveyor shall monitor turbidity ((shall be monitored)) at or before the entry point to the distribution system and where needed for treatment process control.

(c) The department shall determine monitoring requirements for Group B water systems ((shall be determined by the department)).

(d) The purveyor shall ensure that turbidimeters ((shall be)) are designed to meet the criteria listed under standard methods, and ((shall be)) that turbidimeters are properly operated, maintained, and calibrated at all times, based on the manufacturer's recommendations.

(5) Trihalomethanes.

(a) Purveyors of community systems serving a population of ((+0,000)) ten thousand or more and providing water treated with chlorine or other halogenated disinfectant shall monitor as follows:

(i) Ground water sources. The purveyor shall collect one sample from each treated spring, well, or well field every twelve months. This sample shall be taken at the source before treatment or at the extreme end of the distribution system. The sample shall be analyzed for maximum total trihalomethane potential (MTTP); or

(ii) Surface water sources. The purveyor shall collect four samples per treated source every three months. The



samples shall be taken within a twenty-four-hour period. The purveyor shall take one of the samples (~~collected shall be taken~~) from the extreme end of the distribution system and three samples (~~collected shall be taken~~) from representative locations in the distribution system. The samples shall be analyzed for total trihalomethanes (TTHM), the sum of trichloromethane, bromodichloromethane, dibromochloromethane, and tribromomethane. After one year of monitoring, the department may reduce the monitoring frequency to one sample every three months per treatment plant if the TTHM levels are less than 0.10 mg/L. The purveyor shall take the sample (~~shall be taken~~) at the extreme end of the distribution system; or

(iii) Purchased surface water sources. The purveyor shall collect one water sample per each purchased surface source every three months. The sample shall be taken at the extreme end of the distribution system and analyzed for TTHM.

(b) Purveyors of community systems shall monitor for TTHM when serving a population less than ten thousand and providing surface water treated with chlorine or other halogenated disinfectant (~~shall monitor for TTHM~~). The purveyor shall collect one water sample per treated source every three months for one year. The sample shall be taken at the extreme end of the distribution system and analyzed for TTHM. After the first year, the purveyor shall monitor surface water sources (~~shall be monitored~~) every thirty-six months.

(c) Purveyors of community systems shall monitor for TTHM when serving less than ten thousand people (~~that purchase~~) and purchasing surface water treated with chlorine or other halogenated disinfectant or (~~add~~) adding a halogenated disinfectant after (~~purchase, shall monitor for TTHM~~) purchase. The purveyor shall collect one water sample every three months at the extreme end of the distribution system or at a department-acceptable location (~~acceptable to the department~~). The sample shall be analyzed for TTHM. After the first year, (~~monitoring shall be~~) the purveyor shall monitor every thirty-six months.

#### (6) Pesticides.

Purveyors of community systems with surface water sources shall monitor for pesticides for which MCLs are established every thirty-six months. The purveyor shall collect the water sample (~~shall be collected~~) during the time of year (~~designated by~~) the department designates as the time when pesticide contamination is most likely to occur.

#### (7) Radionuclides.

(a) The purveyor's monitoring requirements for gross alpha particle activity, radium-226 and radium-228 (~~are~~) shall be:

(i) Community systems shall monitor once every forty-eight months. Compliance shall be based on the analysis of an annual composite of four consecutive quarterly samples or the average of the analyses of four samples obtained at quarterly intervals(~~;~~);

(ii) The purveyor may omit analysis for radium-226 and radium-228 (~~may be omitted~~) if the gross alpha particle activity is less than five pCi/L(~~;~~); and

(iii) If the results of the initial analysis are less than half of the established MCL, the department may allow compliance with the monitoring requirements (~~to be~~) based on analysis of a single sample collected every forty-eight months.

(b) The purveyor's monitoring requirements for man-made radioactivity shall be:

(i) Purveyors of community systems using surface water sources and serving more than one hundred thousand persons and other department-designated water systems (~~designated by the department~~) shall monitor for man-made radioactivity (beta particle and photon) every forty-eight months. Compliance shall be based on the analysis of a composite of four consecutive quarterly samples or the analysis of four quarterly samples(~~;~~); and

(ii) Purveyors of any water system, as directed by the department, downstream from a nuclear facility shall monitor once every three months for gross beta and iodine-131, and monitor once every twelve months for strontium-90 and tritium. The department may allow the substitution of environmental surveillance data taken in conjunction with a nuclear facility for direct monitoring of man-made radioactivity (~~after a determination~~) if the department determines that such data is applicable to a particular public water system.

#### (8) Volatile organic chemicals (VOCs).

(a) Prior to January 1, 1992, purveyors of COMMUNITY and NTNC systems shall monitor each source for all chemicals listed in Table 4. If a source is treated, VOC samples shall be collected after treatment. The department shall contact the purveyor to schedule sample collection. Purveyors shall submit VOC samples to a certified lab for analysis within ninety days of contact by the department.

TABLE 4

#### LIST 1: VOLATILE ORGANIC CHEMICALS (VOCs) WITH MCLs

Trichloroethylene  
Carbon Tetrachloride  
Vinyl Chloride<sup>1</sup>  
1,2-Dichloroethane  
Benzene  
para-Dichlorobenzene  
1,1-Dichloroethylene  
1,1,1-Trichloroethane

<sup>1</sup> Purveyors shall monitor for vinyl chloride if their source sampling has verified one or more of the following:

Trichloroethylene;  
1,2-Dichloroethane;  
1,1-Dichloroethylene;  
1,1,1-Trichloroethane;  
Chloroethane;  
trans-1,2-Dichloroethylene;  
cis-1,2-Dichloroethylene;  
1,1-Dichloroethane;  
1,1,2-Trichloroethane;

1,1,1,2-Tetrachloroethane;  
1,1,2,2-Tetrachloroethane; or  
Tetrachloroethylene.

LIST 2: VOCs WITHOUT MCLs

<u>Bromobenzene</u>	<u>p-Xylene</u>
<u>Bromomethane</u>	<u>O-Xylene</u>
<u>Chlorobenzene</u>	<u>m-Xylene</u>
<u>Chloroethane</u>	<u>Bromochloromethane</u>
<u>Chloromethane</u>	<u>n-Butylbenzene</u>
<u>o-Chlorotoluene</u>	<u>Dichlorodifluoromethane</u>
<u>p-Chlorotoluene</u>	<u>Fluorotrichloromethane</u>
<u>Dibromomethane</u>	<u>Hexachlorobutadiene</u>
<u>m-Dichlorobenzene</u>	<u>Isopropylbenzene</u>
<u>o-Dichlorobenzene</u>	<u>p-Isopropyltoluene</u>
<u>trans-1,2-Dichloroethylene</u>	<u>Naphthalene</u>
<u>cis-1,2-Dichloroethylene</u>	<u>n-Propylbenzene</u>
<u>Dichloromethane</u>	<u>Sec-butylbenzene</u>
<u>1,1-Dichloroethane</u>	<u>Tert-butylbenzene</u>
<u>1,1-Dichloropropene</u>	<u>1,2,3-Trichlorobenzene</u>
<u>1,2-Dichloropropane</u>	<u>1,2,4-Trichlorobenzene</u>
<u>1,3-Dichloropropane</u>	<u>1,2,4-Trimethylbenzene</u>
<u>1,3-Dichloropropene</u>	<u>1,3,5-Trimethylbenzene</u>
<u>2,2-Dichloropropane</u>	<u>Trihalomethanes:</u>
<u>Ethylbenzene</u>	<u>Bromodichloromethane</u>
<u>Styrene</u>	<u>Dibromochloromethane</u>
<u>1,1,2-Trichloroethane</u>	<u>Tribromomethane</u>
<u>1,1,1,2-Tetrachloroethane</u>	<u>Trichloromethane</u>
<u>1,1,2,2-Tetrachloroethane</u>	
<u>Tetrachloroethylene</u>	
<u>1,2,3-Trichloropropane</u>	
<u>Toluene</u>	

LIST 3: VOCs WITHOUT MCLs WHICH ARE REQUIRED FOR SELECTED SOURCES

<u>Ethylene dibromide (EDB)</u>	<u>1,2-Dibromo-3-Chloropropane (DBCP)</u>
---------------------------------	---

(b) During the first twelve months of VOC monitoring, purveyors shall sample surface water and ground water sources once every three months or as directed by the department. If no VOCs (exclusive of THMs) are detected in the first sample from a ground water source, the purveyor shall sample that source once more during that twelve-month period.

(c) If no VOCs (exclusive of THMs) are verified after the initial twelve months of monitoring, purveyors of COMMUNITY and NTNC water systems shall monitor each source at least once every thirty-six months.

(d) Purveyors may ask the certified lab to composite samples representing as many as five individual sources. If VOCs (exclusive of THMs) are detected in a composite sample, the lab shall analyze the duplicate sample for each source in the composite at the purveyor's expense. If duplicate samples are not available, the purveyor shall repeat sample each individual source within fourteen days of contact by the department. Analysis of all VOC samples shall occur within fourteen days of collection. The following restrictions shall apply to compositing of samples:

- (i) Samples shall not be composited in the field;
- (ii) Multiple source samples, such as samples representing well fields, shall not be composited;

(iii) Ground water sources shall not be composited with surface water sources; and

(iv) The following shall not be composited:

(A) Seasonal sources;

(B) Sources treated for the presence of synthetic organic chemicals; and

(C) Sources with synthetic organic chemicals, exclusive of THMs, detected within the last five years.

(e) Purveyors with emergency and seasonal sources shall monitor the sources when the sources are in use.

(f) If five or fewer separate sources are combined through a common pipe before entering the distribution system, and before a domestic service, the department may consider those sources as one for the purpose of sampling. The purveyor shall collect the distribution samples as directed by the department. If VOCs, exclusive of THMs, are detected, the department shall require repeat samples from each individual source.

(g) The department may require the purveyor to repeat sample for confirmation of results.

(h) The department shall not require purveyors of COMMUNITY systems serving less than two hundred fifty people and NTNC systems to monitor for the List 2 VOCs after purveyors complete the first twelve months of VOC monitoring for both List 1 and List 2 VOCs, provided no VOCs, exclusive of THMs, are detected and no changes have occurred indicating a need to take additional samples.

(i) Purveyors of COMMUNITY and NTNC systems shall monitor for List 3 VOCs if the department determines their sources are located in an area where the chemicals may have been applied, transported, handled, manufactured, or stored. The department shall notify purveyors of COMMUNITY and NTNC systems if this requirement applies.

(j) When water is purchased from another system, the department shall not require the purveyor of the purchasing system to monitor that source for VOCs. However, the department's requirement may still apply for a purveyor to monitor for trihalomethanes under subsection (5) of this section.

(k) Only samples analyzed after January 1, 1988, by a laboratory certified for VOC analysis of drinking water may be used to meet the requirements of this subsection.

(9) Other substances.

On the basis of public health concerns, ((monitoring of)) the department may require the purveyor to monitor for additional substances ((may be required by the department)).

TABLE ((4)) 5

MONITORING LOCATION

Sample Type	Sample Location
Bacteriological	From representative points in distribution system.
Complete Inorganic Chemical and Physical	From a sample point as close to the source as possible.
Nitrate	From a sample point as close to the source as possible.
Turbidity - Surface Water	From a location at or before the entry point to the distribution system.

Sample Type	Sample Location
Trihalomethanes - Surface Water	From representative points in the distribution system.
- Ground Water	From the source ((prior to)) before treatment.
Pesticides - Surface Water	From the source.
Radionuclides	From the source.
VOCs	After treatment, if any, at entry points to distribution systems.
Other Substances	As directed by the department.

**AMENDATORY SECTION** (Amending Order 124B, filed 12/27/90, effective 1/31/91)

WAC 246-290-310 MAXIMUM CONTAMINANT LEVELS (MCLS). (1) The purveyor shall be responsible for complying with the standards of water quality identified in this section.

If ~~((any))~~ a substance exceeds its maximum contaminant level (MCL), the purveyor shall take follow-up action as ~~((outlined))~~ described under WAC ~~((248-54-185))~~ 246-290-320.

(2) ~~((In))~~ When enforcing the standards ~~((set out in))~~ described under this section, the department shall ~~((seek to))~~ enforce compliance with the primary standards as its first priority.

(3) Bacteriological.

(a) Standards under subsection (3) of this section shall be considered primary standards.

(b) If any coliform bacteria are present in any sample, follow-up action as described under WAC ~~((248-54-185))~~ 246-290-320(2) shall be taken.

(c) The MCL for coliform bacteria is as follows:

(i) When the membrane filter test is used, the number of coliform bacteria shall not be greater than:

(A) One per one hundred milliliters as the average of all samples tested each month; or

(B) Four per one hundred milliliters in two or more samples when less than twenty samples are tested each month; or

(C) Four per one hundred milliliters in more than five percent of the samples when twenty or more samples are tested each month.

(ii) When the five-tube MPN method is used, coliform bacteria shall not be present in:

(A) More than ten percent of the tubes tested each month; or

(B) Three or more tubes in two or more samples when less than twenty samples are tested each month; or

(C) Three or more tubes in more than five percent of the samples when twenty or more samples are tested each month.

(iii) The department may allow systems required to take less than four samples each month to base compliance with this section on the samples taken during the three-month period consisting of the month in question and the previous two months.

(iv) Special purpose samples, such as those taken to determine if disinfection following pipe repair or replacement has been sufficient, or check samples shall not be used to determine compliance with the MCL.

(v) Samples with unsuitable test results, i.e., confluent growth, TNTC (too numerous to count), excess debris, etc., will not qualify as routine samples and will not count toward fulfillment of the monitoring requirement.

(4) Inorganic chemical and physical.

The primary and secondary MCLs are ~~((as))~~ listed in Table ~~((5))~~ 6 and ~~((6))~~ 7:

TABLE ~~((5))~~ 6

INORGANIC CHEMICAL CHARACTERISTICS

Substance	Primary MCLs (mg/L)
Arsenic (As)	0.05
Barium (Ba)	1.0
Cadmium (Cd)	0.01
Chromium (Cr)	0.05
Fluoride (F)	4.0
Lead (Pb)	0.05
Mercury (Hg)	0.002
Nitrate (as N)	10.0
Selenium (Se)	0.01
Silver (Ag)	0.05
Sodium (Na)	*

Substance	Secondary MCLs (mg/L)
Chloride (Cl)	250.0
Copper (Cu)	1.0
Fluoride (F)	2.0
Iron (Fe)	0.3
Manganese (Mn)	0.05
Sulfate (SO <sub>4</sub> )	250.0
Zinc (Zn)	5.0

Note: Although ~~((there))~~ the state board of health has not ~~((been an MCL))~~ established an MCL for sodium, there is enough public health significance connected with sodium levels to require inclusion in inorganic chemical and physical monitoring.

TABLE ~~((6))~~ 7

PHYSICAL CHARACTERISTICS

Substance	Primary MCL
Turbidity	1 NTU
Substance	Secondary MCLs
Color	15 Color Units
Hardness	None established
Specific Conductivity	700 umhos/cm
Total Dissolved Solids (TDS)	500 mg/L

(5) Turbidity.

(a) The department shall consider standards under subsection (5) of this section ~~((shall be considered))~~ primary standards.

(b) The MCLs for turbidity are ~~((as follows))~~:

(i) One NTU, based on a monthly average of the maximum daily turbidity, where the maximum daily turbidity is defined as the average of the:

(A) ~~((The average of the))~~ Highest two hourly readings over a twenty-four hour period when continuous monitoring is used; or

(B) ~~((The average of the))~~ Daily grab samples taken within one hour when daily monitoring is used.

The ~~((limit may be increased))~~ department may increase the MCL to five NTUs if the purveyor can show the source is within a controlled watershed and the source meets ~~((and))~~ the requirements under WAC ~~((248-54-125 and 248-54-225))~~ 246-290-210 and 246-290-450.

(ii) Five NTUs based on an average of the maximum daily turbidity for two consecutive days.

(6) Trihalomethanes.

(a) The department shall consider standards under subsection (6) of this section ~~((shall be considered))~~ primary standards.

(b) The MCL for total trihalomethanes (TTHM) is 0.10 mg/L. The concentrations of each of the trihalomethane compounds (trichloromethane, dibromochloromethane, bromodichloromethane, and tribromomethane) are added together to determine the TTHM level.

(c) There is no MCL for maximum total trihalomethane potential (MTTP). ~~((If))~~ When the MTTP value exceeds 0.10 mg/L, the purveyor shall follow up as ~~((outlined))~~ described under WAC ~~((248-54-185))~~ 246-290-320(5).

(7) Pesticides.

(a) The department shall consider standards under subsection (7) of this section ~~((shall be considered))~~ primary standards.

(b) The MCLs for pesticides are ~~((as follows))~~:

(i) Chlorinated hydrocarbons:

Substance	MCL (mg/L)
Endrin	0.0002 <del>((mg/L))</del>
Lindane	0.004 <del>((mg/L))</del>
Methoxychlor	0.1 <del>((mg/L))</del>
Toxaphene	0.005 <del>((mg/L))</del>

(ii) Chlorophenoxy:

Substance	MCL (mg/L)
2, 4-D	0.1 <del>((mg/L))</del>
2, 4, 5-TP Silvex	0.01 <del>((mg/L))</del>

(8) Radionuclides.

(a) The department shall consider standards under subsection (8) of this section ~~((shall be considered))~~ primary standards.

(b) The MCLs for radium-226, radium-228, and gross alpha particle radioactivity are ~~((as follows))~~:

Substance	MCL (pCi/L)
Radium-226	3 <del>((pCi/L))</del>
Combined Radium-226 and Radium-228	5 <del>((pCi/L))</del>
Gross alpha particle activity (excluding uranium)	15 <del>((pCi/L))</del>

(c) The MCL for beta particle and photon radioactivity from man-made radionuclides is ~~((that))~~: The average annual concentration shall not produce an annual dose equivalent to the total body or any internal organ greater than four millirem/year.

The department shall assume compliance with the four millirem/year dose limitation ~~((may be assumed))~~ if the average annual concentration for gross beta activity, tritium, and strontium-90 are less than 50 pCi/L, 20,000 pCi/L, and 8 pCi/L respectively ~~((, provided that if))~~. When both ~~((radionuclides))~~ tritium and strontium-90 are present, the sum of their annual dose equivalents to bone marrow shall not exceed four millirem/year.

(9) Volatile organic chemicals.

(a) The department shall consider standards under this subsection primary standards.

(b) The VOCs with MCLs are:

Substance	MCL (mg/L)
Benzene	.005
Carbon Tetrachloride	.005
1,2-Dichloroethane	.005
Trichloroethylene	.005
para-Dichlorobenzene	.075
1,1-Dichloroethylene	.007
1,1,1-Trichloroethane	.200
Vinyl Chloride	.002

(c) The department shall determine compliance with this subsection based on the running annual average of results for each sample location. The purveyor is in violation of an MCL when:

(i) The running annual average for one location is greater than the MCL (sum of all sample results in one year divided by four > MCL); or

(ii) Any one sample result causes the running annual average to exceed the MCL.

(10) The state board of health shall determine maximum contaminant levels ~~((allowable))~~ for any additional substances ~~((monitored shall be determined by the state board of health))~~.

**AMENDATORY SECTION** (Amending Order 124B, filed 12/27/90, effective 1/31/91)

WAC 246-290-320 FOLLOW-UP ACTION. (1) General.

(a) If water quality exceeds any MCLs listed ~~((in))~~ under WAC ~~((248-54-175))~~ 246-290-310, the purveyor shall notify the department and take follow-up action as described in this section.

(b) When a primary MCL violation occurs, the purveyor shall:

- (i) Notify the department within forty-eight hours;
- (ii) Notify the public according to ~~((the))~~ procedures outlined under WAC ~~((248-54-187))~~ 246-290-330;
- (iii) Determine the cause of the contamination; and
- (iv) Take corrective action as required by the department.

(c) When a secondary MCL violation occurs, the purveyor shall notify the department and take corrective action as directed by the department.

(2) Bacteriological.

(a) When coliform bacteria are present in any sample analyzed by the membrane filter method, the purveyor shall take action as follows:

(i) When the sample result is one through four per one hundred milliliters, the sample is unsatisfactory and an additional drinking water sample shall be taken to confirm the presence of coliform bacteria; or

(ii) When the sample result is greater than four per one hundred milliliters, the sample is unsatisfactory and nonconforming. The purveyor shall take action to determine and correct the cause of the contamination. Daily check samples shall continue to be collected until at least two consecutive daily check samples show less than one coliform per one hundred milliliters.

(b) When coliform bacteria are present in any sample analyzed by the five-tube MPN method, the purveyor shall take action as follows:

(i) When the sample result is one or two tubes positive, the sample is unsatisfactory and an additional drinking water sample shall be taken to confirm the presence of contamination; or

(ii) When the sample result is three or more tubes positive, the sample is unsatisfactory and nonconforming. The purveyor shall take action to determine and correct the cause of the contamination. Daily check samples shall continue to be collected until at least two consecutive daily check samples show no coliform bacteria are present.

(c) All additional samples required by this section shall be collected from the same location where the unsatisfactory or unsuitable sample was taken, except as specified by the department.

(d) All additional samples shall be submitted for analyses as soon as possible after the unsatisfactory or unsuitable results are known.

(e) When the presence of coliform bacteria in water has been confirmed by check samples, the purveyor shall notify the department within forty-eight hours.

(f) When the sample result is marked unsuitable, an additional drinking water sample shall then be submitted for analysis for each unsuitable result immediately upon notification of the unsuitable result. The additional sample shall be analyzed by the MPN testing method.

(g) The location where the daily check samples were taken to fulfill the requirements of this section shall not be eliminated from future sampling without the department's approval.

(3) Inorganic chemical and physical. When an initial analysis of ~~((any))~~ a substance exceeds the MCL, the purveyor shall ~~((take the following action))~~:

(a) For nitrate, immediately take one additional sample from the same sampling point. If the average of the two samples exceeds the MCL, a violation is confirmed; or

(b) For all other inorganic chemical and physical substances, ~~((within thirty days take))~~ collect three additional samples from the same sample point within thirty

days. If the average of all four samples exceeds the MCL, a violation is confirmed.

(4) Turbidity. When the turbidity exceeds the ~~((maximum allowable limit))~~ MCL identified under WAC ~~((248-54-175))~~ 246-290-310 for longer than one hour monitored continuously, the purveyor shall report to the department within forty-eight hours. When the results of a manual turbidity analysis exceeds the ~~((maximum allowable limit))~~ MCL, the purveyor shall collect another sample ~~((shall be collected))~~ within one hour. When the repeat sample confirms the ~~((maximum allowable limit has been))~~ MCL is exceeded, the purveyor shall notify the department.

(5) Trihalomethanes. When the average of all samples taken during any twelve-month period exceeds the MCL for total trihalomethanes, the violation is confirmed and the purveyor shall take corrective action as required by the department. ~~((If))~~ When the maximum trihalomethane potential (MTTP) result is equal to or greater than 0.10 mg/L and the result is confirmed by a ~~((check))~~ repeat sample, the ~~((system))~~ purveyor shall monitor according to WAC ~~((248-54-165))~~ 246-290-300(5) for one year or more.

(6) Volatile organic chemicals (VOCs). The purveyor shall be responsible for the following follow-up actions:

(a) After the purveyor's receipt of the first VOC analysis results from the laboratory, the purveyor shall provide notice to persons served by the system as described under WAC 246-290-330(5).

(b) When a List 1 VOC is verified at a concentration above the detection limit, the purveyor shall, at a minimum:

(i) Sample the source once every three months for at least three years; and

(ii) Make analysis results available to consumers within three months of receipt from the laboratory as described under WAC 246-290-330(5).

(c) When a List 1 VOC is verified at a concentration greater than a MCL, and the level will not cause the running annual average to exceed the MCL, the purveyor shall repeat sample the source as soon as possible. If a concentration greater than an MCL is confirmed, the purveyor shall:

(i) Notify the department within seven days of receipt of the repeat sample analysis results.

(ii) Provide consumer information per WAC 246-290-330 (5)(b).

(iii) Submit documentation to the department describing the water system's strategy for gathering and analyzing additional data and identify plans for keeping the public informed.

(iv) Sample the source a minimum of once every three months for at least three years.

(d) When the running annual average of a List 1 VOC is greater than an MCL, or one sample analysis result causes the annual average to exceed an MCL, the purveyor shall:

(i) Notify the department within seven days of receipt of analysis results.

(ii) Notify the public as described under WAC 246-290-330, including mandatory health effects language.

(iii) Submit an action plan to the department for approval addressing follow-up activities, including corrective action. The purveyor shall submit the action plan within four months of receipt of department notice that the annual average exceeds the MCL. The purveyor's action plan shall, at a minimum, contain a:

(A) Tabulation of VOC sample analysis results, including the location where VOCs were detected;

(B) Description of monitoring plans for system sources;

(C) Strategy for informing the public of monitoring results and investigations; and

(D) Description of short and long-term plans to minimize exposure and/or eliminate the source of contamination.

(iv) Implement the action plan within one year of the department's approval. The department may require the purveyor's earlier compliance if necessary to eliminate an immediate health threat or may require a revision of the action plan based upon additional sample results. The department may extend the purveyor's period of compliance when the department determines:

(A) Substantial construction is required; and

(B) The purveyor has taken all appropriate measures to protect the health of consumers served by the public water system.

If the department grants the purveyor an extension, the purveyor shall issue a notice identifying the MCL exceeded and the amount by which the repeat sample analysis results exceeded the MCL. The purveyor shall include the notice in all bills mailed to affected customers until the department determines that the purveyor complies with the MCL.

(v) Sample the source a minimum of once every three months for at least three years.

(e) When a List 2 or List 3 VOC is verified at a concentration above the detection limit, the purveyor shall:

(i) Submit the sample analysis results to the department within seven days of receipt from the laboratory; and

(ii) Sample the source a minimum of once every three months for one year and then annually thereafter during the three-month period when the highest previous measurement occurred.

(f) If the department determines that a List 2 or List 3 VOC is verified at a level greater than a state advisory level (SAL), the department shall notify the purveyor in writing. The purveyor shall repeat sample the source as soon as possible after initial department notice that a SAL has been exceeded. The purveyor shall submit the analysis results to the department within seven days of receipt from the laboratory. If any repeat sample confirms that a SAL has been exceeded, the purveyor shall:

(i) Provide consumer information per WAC 246-290-330 (5)(b);

(ii) Sample the source a minimum of once every three months for at least three years; and

(iii) Submit documentation to the department listing VOC analysis results, describing the water systems' strategy for gathering and analyzing additional data, and identifying plans for keeping the public informed.

The purveyor shall submit this information to the department within six months of the date of the first notice from the department that a SAL has been exceeded.

(g) The department may reduce the purveyor's monitoring requirement for a source detecting a List 1 VOC if, after three years of quarterly monitoring, all analysis results are less than the MCL. The purveyor's reduced monitoring frequency shall be no less than one sample per year.

(h) The department may reduce the purveyor's monitoring requirement for a source detecting a List 2 or List 3 VOC if the source has been monitored annually for at least three years, and all analysis results are less than the SAL.

(i) In establishing SAL's for List 2 and List 3 VOCs, the department shall use the most recent edition of the department document titled "Procedures And References For Determination Of State Advisory Levels For Drinking Water Contaminants" which has been approved by the state board of health. Copies are available from the department upon request.

(j) When List 1, List 2 (exclusive of THMs), or List 3 VOCs are verified in well fields, the purveyor shall repeat sample individual wells within the well field.

(k) When the sum of all trihalomethanes detected exceeds 0.100 mg/L, the purveyor shall sample within three months for total trihalomethanes as required under WAC 246-290-300(5).

(l) The department may collect samples from a water system or may require that specified quality assurance techniques be used to collect samples.

(7) The department shall determine the purveyor's follow-up action ~~((shall be determined by the department when the MCL for any additional substance is exceeded))~~ when a substance not included in these regulations is detected.

**AMENDATORY SECTION (Amending Order 124B, filed 12/27/90, effective 1/31/91)**

**WAC 246-290-330 PUBLIC NOTIFICATION.**

(1) Responsibility. The purveyor of a Group A water system shall notify the water system users ~~((and the department))~~ when the following ~~((violations))~~ occurs within the Group A system:

(a) A primary MCL violation as described under WAC ~~((248-54-175))~~ 246-290-310;

(b) ~~((Failure))~~ Failing to comply with a:

(i) Prescribed treatment technique;

(ii) Monitoring requirement under WAC ~~((248-54-165))~~ 246-290-300; ~~((and))~~ or

(iii) Testing procedure.

(c) Operating under a variance or exemption; ~~((and))~~ or

(d) ~~((Failure))~~ Failing to meet a variance or exemption schedule.

The department may also require the purveyor of a Group B water system to notify users when ~~((violations))~~ any of the conditions listed in (a) through (d) of this subsection occur within the Group B system.

(2) Content. Notices shall provide:

(a) A clear, concise, and simple explanation of the violation;

(b) Discussion of ~~((any))~~ potential adverse health effects and ~~((what))~~ any segments of the population ~~((is))~~ that may be at higher risk;

(c) Mandatory health effects information ~~((where))~~ required under WAC 246-290-330(4);

(d) A list of steps the purveyor ~~((took))~~ has taken or is planning to take to ~~((correct the violation))~~ remedy the situation;

(e) A list of steps the consumer should take ~~((until the violation is corrected))~~, including advice on seeking an alternative water supply if necessary; and

(f) The purveyor's name and phone number.

The purveyor may provide additional information ~~((may be provided by the purveyor))~~ to further explain the ~~((violation))~~ situation.

(3) Distribution.

(a) Purveyors of COMMUNITY systems in violation of a primary MCL, treatment technique or variance or exemption schedule shall provide:

(i) Newspaper notice to water system users within fourteen days of violation;

(ii) Direct mail notice or hand delivery to all permanent residences served by the system within forty-five days of the violation. The department may waive the purveyor's mail or hand delivery if the violation is corrected within forty-five days;

(iii) Notice to radio and television stations serving the area within seventy-two hours of violation of a nitrate MCL or other acute violation as determined by the department; and

(iv) Repeat mail or hand delivery every three months until the violation is corrected.

(b) Purveyors of COMMUNITY systems ~~((in violation of a monitoring requirement, testing procedure, or operating under a variance or exemption schedule))~~ shall provide newspaper notice to water system users within three months of the ~~((violation or))~~ following:

(i) Violation of a monitoring requirement or testing procedure; or

(ii) Granting of a variance or exemption.

~~((The systems))~~ Purveyors shall also provide repeat notice by mail or hand delivery to all permanent residences served by the system every three months until the ~~((violation))~~ situation is corrected or for as long as the variance or exemption remains in effect.

(c) Purveyors of NTNC and TNC systems in violation of a primary MCL, treatment technique, variance, or exemption schedule shall post a notice within fourteen days of the violation. ~~((The notice shall remain posted while the violation exists.))~~ If the violation is acute, the department shall require posting ~~((shall be required))~~ within seventy-two hours.

(d) Purveyors of NTNC and TNC systems ~~((in violation of a monitoring requirement, testing procedure, or operating under a variance or exemption schedule))~~ shall post a notice within three months of the ~~((violation or))~~:

(i) Violation of a monitoring requirement or testing procedure; or

(ii) Granting of a variance or exemption.

(e) Where there is mention of a newspaper notice in this section, ~~((posting may be substituted in the absence of a newspaper of general circulation))~~ the purveyor

may substitute a community or homeowner's association newsletter or similar periodical publication if the newsletter reaches affected consumers within the specified time.

(f) The purveyor may substitute a posted notice in the absence of a newspaper of general circulation or homeowner's association newsletter or similar periodical publication.

~~((ff))~~ (g) The purveyor shall place posted notices ~~((shall be placed))~~ in conspicuous locations and ~~((presented))~~ present the notices in a manner making ~~((the posted notices))~~ them easy to read. Notices shall remain posted until the violation is corrected or for as long as the variance or exemption remains in effect. When appropriate, notices shall be multi-lingual.

~~((g))~~ Notice to new billing units: (h) The purveyor of a community water system shall give a copy of the most recent public notice ~~((for an outstanding violation))~~ to all new billing units or new hookups before or at the time water service begins.

~~((+))~~ (i) The purveyor shall provide the department with a copy of a public notification at the time the purveyor notifies the public.

(4) Mandatory language.

(a) The purveyor shall provide specific health effects language in the notice when a violation occurs involving a:

(i) Primary VOC MCL; or

(ii) Secondary fluoride MCL.

(b) Required specific language is contained in the department guideline titled "health effects language for drinking water public notification."

(5) VOC notification procedure.

(a) Availability of results. After receipt of the first analysis results, the purveyor of a COMMUNITY or NTNC water system shall notify persons served by the system of the availability of the results and shall supply the name and telephone number of a contact person.

(i) The purveyor shall initiate notification within three months of the purveyors receipt of the first VOC analysis results. This notification is only required one time.

(ii) Notification shall occur by:

(A) Inclusion in the first set of water bills issued after receipt of the results;

(B) Newspaper notice which shall run at least one day each month for three consecutive months;

(C) Direct mail;

(D) Posting if NTNC system; or

(E) Any other method approved by the department.

(iii) Within three months of receipt of analysis results, purveyors selling water to other public water systems shall provide copies of the analysis results to the purchasing system.

(iv) Within thirty days of receipt of analysis results, purveyors purchasing water shall make results available to their customers. The purveyor's notification shall occur by the method outlined under (a)(i) of this subsection.

(b) Consumer information.

(i) The purveyor shall provide consumer information within twenty-one days of receipt of confirmation sample results when:

(A) A List 1 VOC is confirmed at a concentration greater than a MCL, and the level will not cause the running annual average to exceed the MCL; or

(B) The department determines that a List 2 or List 3 VOC is confirmed at a level greater than a SAL.

(ii) Consumer information shall include:

(A) Name and level of VOC detected;

(B) Location where the VOC was detected;

(C) Any health effects that the VOC could cause at its present concentration;

(D) Plans for follow-up activities; and

(E) Phone number to call for further information.

(iii) Consumer information shall be distributed by any of the following methods:

(A) Notice placed in the major newspaper in the affected area;

(B) Direct mail to customers;

(C) Posting if NTNC system; or

(D) Any other method approved by the department.

(6) Fluoride notification procedure.

((a)) When a secondary MCL violation occurs, the purveyor of a COMMUNITY water system shall send notice to:

((i)) (a) The department annually;

((ii) Consumers served by the system)) (b) Water system users annually; and

((iii)) (c) New billing units added while the violation exists.

((b) The notice shall include specific mandatory language available in a department guideline titled Health Effects Language For Drinking Water Public Notification.

((5)) (7) When circumstances dictate the purveyor give a broader ((and/)) or more immediate notice ((be given)) to protect public health, the department may require the purveyor's notification by whatever means necessary.

((6) When a substance does not exceed an MCL, but is measured at a department-determined level of health significance, the department may require the purveyor to notify the water system users.

((7)) (8) When the state board of health grants a public water system ((is granted)) a waiver ((by the state board of health)), the purveyor shall notify customers and new billing units or new hookups before water service begins. The purveyor shall provide a notice ((shall be provided)) annually ((with)) and send a copy ((going)) to the department.

((8)) (9) The department may give notice to the water system users as required by this section on behalf of the water purveyor. However, the purveyor remains responsible for ensuring the department's requirements are met.

## WSR 91-07-032

### PERMANENT RULES

### DEPARTMENT OF HEALTH

### (Board of Nursing)

[Order 151B—Filed March 15, 1991, 10:28 a.m.]

Date of Adoption: February 22, 1991.

Purpose: Eliminate the 90 day extension previously granted to registered nurses, for obtaining AIDS education upon interstate endorsement. Amended by emergency rule October 30, 1990.

Citation of Existing Rules Affected by this Order: Amending WAC 308-120-168 and 308-120-610.

Statutory Authority for Adoption: RCW 18.88.080 authorizes WAC 308-120-168; and RCW 70.24.270 authorizes WAC 308-120-610.

Pursuant to notice filed as WSR 90-24-073 on December 5, 1990.

Effective Date of Rule: Thirty-one days after filing.

March 11, 1991

Patricia O. Brown

Acting Executive Secretary

AMENDATORY SECTION (Amending Order PM 846, filed 6/1/89)

WAC 308-120-168 LICENSURE BY INTERSTATE ENDORSEMENT. (1) A license to practice as a registered nurse in Washington may be issued without examination provided the applicant meets all of the following requirements:

(a) The applicant has graduated and holds a degree/diploma from a state board approved school of nursing preparing candidates for licensure as a registered nurse provided such nursing program is equivalent to the minimum nursing educational standards prevailing for state board approved schools of nursing in Washington at the time of the applicant's graduation.

(i) Applicants who were licensed prior to January 1, 1953, shall have scored at least 75% on the state board examination in the state of original licensure.

(ii) Applicants licensed after January 1, 1953, but before June 1, 1982, shall have passed the state board test pool examination for registered nurse licensure with a minimum standard score of 350 in each test.

(iii) Applicants licensed after July 1, 1982, shall have passed with a minimum standard score of 1600 for the total examination.

(b) The applicant holds a valid current license to practice as a registered nurse in another state or territory.

(c) The applicant complies with the education requirements of WAC 308-120-610((; however, upon written application an applicant, who is otherwise qualified for licensure, may be licensed and have up to ninety days from the date of the issuance of such license to comply with, and submit certification of, the minimum training and education requirements of WAC 308-120-610)).

(d) The application shall be completed and notarized, the fee must be filed with the application. The fee is not refundable. A notarized copy of a valid current license shall be filed with the application.



(e) Verification of licensure by examination shall be obtained from the state or territory of original licensure. Any fee for verification required by the state or territory of original license shall be paid by the applicant.

(2) Applicants from countries outside the United States who were granted a license in another United States jurisdiction or territory prior to December 31, 1971, and who were not required to pass the state board test pool examination shall meet the following requirements:

(a) The nursing education program shall meet the minimum approved standards prevailing for schools of nursing in Washington at the time of the applicant's graduation.

(b) The applicant holds a valid current license to practice as a registered nurse in another United States jurisdiction or territory.

(c) The applicant shall submit to the board:

(i) A complete notarized application. The nonrefundable fee must be filed with the application.

(ii) Verification of original licensure obtained in the United States jurisdiction or territory.

(iii) Notarized copies of educational preparation and licensure by examination submitted directly from the country of original licensure or from the state board or territory of original United States licensure.

(iv) Verification of current nursing practice for three years prior to application for Washington licensure.

(v) Evidence to show compliance with the education requirements of WAC 308-120-610.

(d) The applicant shall meet all requirements of chapter 18.88 RCW and regulations of the board.

**AMENDATORY SECTION** (Amending Order PM 795, filed 11/9/88)

**WAC 308-120-610 AIDS EDUCATION AND TRAINING.** (1) Acceptable education and training. Effective January 1, 1989, the board will accept education and training that is consistent with the model curriculum available from the office on AIDS. Such education and training shall be a minimum of seven hours and shall include, but is not limited to, the following: Etiology and epidemiology; testing and counseling; infection control guidelines; clinical manifestations and treatment; legal and ethical issues to include confidentiality; and psychosocial issues to include special population considerations.

(2) Implementation. Effective January 1, 1989, the requirement for licensure application, renewal, or reinstatement of any license on lapsed, inactive, or disciplinary status shall include completion of AIDS education and training. All persons affected by this section shall show evidence of completion of an education and training program, which meets the requirements of subsection (1) of this section.

(3) Documentation. The licensee shall:

(a) Certify, on forms provided, that the minimum education and training has been completed after January 1, 1987, and before renewal date (~~or December 31, 1989, whichever date is earlier~~);

(b) Keep records for two years documenting attendance and description of the learning; and

(c) Be prepared to validate, through submission of these records, that education and training has taken place.

**WSR 91-07-033**  
**PERMANENT RULES**  
**DEPARTMENT OF**  
**INFORMATION SERVICES**  
 [Filed March 15, 1991, 10:42 a.m.]

Date of Adoption: March 15, 1991.

Purpose: Adopt records indexing rules required by chapter 175, Laws of 1989, and RCW 42.17.260.

Citation of Existing Rules Affected by this Order: Amending chapter 173-06 WAC, Access to public records.

Statutory Authority for Adoption: RCW 43.17.060.

Pursuant to notice filed as WSR 91-04-090 on February 6, 1991.

Effective Date of Rule: Thirty-one days after filing.

March 15, 1991

Dennis E. Jones

Acting Director

Department of Information Services

**AMENDATORY SECTION** (Amending Order 88-1, filed 10/11/88)

**WAC 143-06-130 RECORDS INDEX.** The department has available to all persons a current index which provides identifying information as to the records of the board and department. Agency records are indexed and retained as follows:

The generic index for department records is located in the office of the DIS Public Records Officer, at 1110 South Jefferson, Olympia, Washington 98504. This index lists public records as required by RCW 42.17.260, and indicates the division of the department in which they are located. Specific forms and documents are retained in the divisions as identified on the records retention schedules established by the division of state archives of the office of the secretary of state. These schedules are available to the public through the public records officer.

**WSR 91-07-034**  
**EMERGENCY RULES**  
**FOREST PRACTICES BOARD**  
 [Filed March 15, 1991, 11:17 a.m.]

Date of Adoption: March 13, 1991.

Purpose: Classify those forest practices subject to environmental review of SEPA and SEPA rules.

Citation of Existing Rules Affected by this Order: Amending WAC 222-16-050(1).

Statutory Authority for Adoption: RCW 76.09.040, 76.09.050, and 34.05.350.

Pursuant to RCW 34.05.350 the agency for good cause finds that immediate adoption, amendment, or repeal of a rule is necessary for the preservation of the public health, safety, or general welfare, and that observing the time requirements of notice and opportunity to comment upon adoption of a permanent rule would be contrary to the public interest.

Reasons for this Finding: On October 25, 1990, the Snohomish County Superior Court issued a final judgment declaring WAC 222-16-050(1) invalid as it existed on that date. *Snohomish County v. DNR*, No. 89-2-06923-5 (Snohomish Cy. Super. Ct.). On November 14, 1990, the Forest Practices Board adopted an emergency rule to replace the one declared invalid, and adopted a second emergency rule directing the Department of Natural Resources to develop a watershed screening and analysis process, WSR 90-23-041. The board established three task forces to develop recommendations for new permanent rule language relating to pesticide use, aesthetics, and wildlife. The task forces reported the results of their work at Forest Practices Board meetings on February 13, 1991, and March 13, 1991. The task forces have completed preliminary drafts and are continuing to receive comment and input. At its March 13, 1991, meeting, the Forest Practices Board: Expressed its intent that the task forces present their recommendations to the board no later than April 24, 1991; readopted, with modifications, the emergency rules it had adopted on November 14, 1990; and directed that preproposal comments for permanent rule making be solicited under RCW 34.05.310. A request for preproposal comments is being published concurrently with this notice.

Effective Date of Rule: Immediately.

March 14, 1991  
Brian Boyle  
Commissioner of  
Public Lands

*Emergency Forest Practices Rules adopted March 13, 1991*

*Effective Date: March 15, 1991*

*Expiration Date: July 13, 1991*

(New Section - Follows WAC 222-16-030)

**WAC 222-16-045 WATERSHED SCREENING AND ANALYSIS.** *The department shall study and develop a watershed screening and analysis process through consultation with the Timber-Fish-Wildlife Cooperative Monitoring, Evaluation & Research Committee (CMER) and department regional staff that is consistent with the Sustainable Forestry Roundtable (SFR) proposal and will result in environmental thresholds and decision criteria, identifying specific areas and forest practices that have the potential for substantial impact on the environment; and shall, no later than August 14, 1991, recommend rules concerning these thresholds and criteria for consideration by the board for inclusion within the Class IV-Special regulation. The thresholds and criteria should be the result of scientific analysis, and should be as clear and specific as reasonably possible.*

**AMENDATORY SECTION** (Amending Order 551, Resolution No. 88-1, filed 9/21/88)

**WAC 222-16-050 CLASSES OF FOREST PRACTICES.** *There are 4 classes of forest practices created by the act. These classes are listed below in the order most convenient for the applicant's use in determining into which class his operations fall. All forest practices (including those in Classes I and II) must be conducted in accordance with the forest practices regulations.*

(1) "**CLASS IV - SPECIAL.**" *Application to conduct forest practices involving the following circumstances requires an environmental checklist in compliance with the State Environmental Policy Act (SEPA), and SEPA guidelines, as they have been determined to have potential for a substantial impact on the environment. It may be determined that additional information or a detailed environmental statement is required before these forest practices may be conducted.*

*\*(a) Aerial application of pesticides to an "area of water supply interest" as determined according to WAC 222-38-020 (5)(i).*

*\*(b) Harvesting, road construction, site preparation or aerial application of pesticides:*

*(i) On lands known to contain a breeding pair or nest or breeding grounds of any threatened or endangered species; or*

*(ii) Within the critical habitat designated for such species by the United States Fish and Wildlife Service.*

*\*(c) Widespread use of (~~DDT~~ or a similar) a persistent insecticide.*

*(d) Harvesting, road construction, aerial application of pesticides and site preparation on all lands within the boundaries of any national park, state park or any park of a local governmental entity, except harvest of less than 5 MBF within any developed park recreation area and park managed salvage of merchantable forest products.*

*\*(e) Construction of roads, landings, rock quarries, gravel pits, borrow pits, and spoil disposal areas on slide prone areas, as defined in WAC 222-24-020(6) and field verified by the department, when such slide prone areas occur on an uninterrupted slope above (~~a Type 1, 2, 3 or 4~~) any Water Type or capital improvement of the state or its political subdivisions where there is potential for a substantial debris flow or mass failure to cause significant impact to public resources.*

*\*(f) Timber harvest on slide prone areas, field verified by the department, where soils, geological structure and local hydrology indicate that canopy removal has the potential for increasing slope instability, when such areas occur on an uninterrupted slope above any Water Type or a capital improvement of the state or its political subdivisions where there is potential for a substantial debris flow or mass failure to cause significant impact to public resources.*

*(g) Timber harvest, construction of roads, landings, rock quarries, gravel pits, borrow pits, and spoil disposal areas on snow avalanche slopes within those areas designated by the department, in consultation with department of transportation, as high avalanche hazard.*

(h) Timber harvest, construction of roads, landings, rock quarries, gravel pits, borrow pits, and spoil disposal areas on archeological or historic sites registered with the Washington state office of archaeology and historic preservation, or on sites containing evidence of Native American cairns, graves or glyptic records, as provided for in chapters 27.44 and 27.53 RCW. The department shall consult with affected Indian tribes in identifying such sites.

(2) "CLASS IV - GENERAL." Applications involving the following circumstances are "Class IV - general" forest practices unless they are listed in "Class IV - special." Upon receipt of an application, the department will determine the lead agency for purposes of compliance with the State Environmental Policy Act pursuant to WAC 197-11-924 and 197-11-938(4) and RCW 43.21C.037(2). Such applications are subject to a 30-day period for approval unless the lead agency determines a detailed statement under RCW 43.21C.030 (2)(c) is required. Upon receipt, if the department determines the application is for a proposal that will require a license from a county/city acting under the powers enumerated in RCW 76.09.240, the department shall notify the applicable county/city under WAC 197-11-924 that the department has determined according to WAC 197-11-938(4) that the county/city is the lead agency for purposes of compliance with State Environmental Policy Act.

(a) Forest practices (other than those in Class I) on lands platted after January 1, 1960, or on lands being converted to another use.

(b) Forest practices which would otherwise be Class III, but which are taking place on lands which are not to be reforested because of likelihood of future conversion to urban development. (See WAC 222-34-050.)

(3) "CLASS I." Those operations that have been determined to have no direct potential for damaging a public resource are Class I forest practices. When the conditions listed in "Class IV - Special" are not present, these operations may be commenced without notification or application.

(a) Culture and harvest of Christmas trees and seedlings.

(b) Road maintenance except: (i) Replacement of bridges and culverts across Type 1, 2, 3 or flowing Type 4 Waters; or (ii) movement of material that has a direct potential for entering Type 1, 2, 3 or flowing Type 4 Waters.

(c) Construction of landings less than 1 acre in size, if not within a shoreline area of a Type 1 Water, the riparian management zone of a Type 2 or 3 Water, or the ordinary high-water mark of a Type 4 Water.

(d) Construction of less than 600 feet of road on a sideslope of 40 percent or less if the limits of construction are not within the shoreline area of a Type 1 Water, the riparian management zone of a Type 2 or Type 3 Water, or the ordinary high-water mark of a Type 4 Water.

(e) Installation or removal of a portable water crossing structure where such installation does not take place within the shoreline area of a Type 1 Water and does

not involve disturbance of the beds or banks of any waters.

(f) Initial installation and replacement of relief culverts and other drainage control facilities not requiring a hydraulic permit.

(g) Rocking an existing road.

(h) Loading and hauling timber from landings or decks.

(i) Precommercial thinning and pruning.

(j) Tree planting and seeding.

(k) Removal of less than 5,000 board feet of timber (including live, dead and down material) for personal use (i.e., firewood, fence posts, etc.) in any 12-month period.

(l) Emergency fire control and suppression.

(m) Slash burning pursuant to a burning permit (RCW 76.04.205).

(n) Other slash control and site preparation not involving either off-road use of tractors on slopes exceeding 40 percent or off-road use of tractors within the shorelines of a Type 1 Water, the riparian management zone of any Type 2 or 3 Water, or the ordinary high-water mark of a Type 4 Water.

(o) Ground application of chemicals. (See WAC 222-38-020.)

(p) Aerial application of chemicals (except insecticides) when applied to not more than 40 contiguous acres if the application is part of a combined or cooperative project with another landowner and where the application does not take place within 100 feet of lands used for farming, or within 200 feet of a residence, unless such farmland or residence is owned by the forest landowner. Provisions of chapter 222-38 WAC shall apply.

(q) Forestry research studies and evaluation tests by an established research organization.

(4) "CLASS II." Certain forest practices have been determined to have a less than ordinary potential to damage a public resource and may be conducted as Class II forest practices: PROVIDED, That no forest practice enumerated below may be conducted as a Class II forest practice if the operation requires a hydraulic project approval (RCW 75.20.100) or is within a "shorelines of the state," or involves a bond in lieu of landowners signature (other than renewals). Such forest practices require an application. No forest practice enumerated below may be conducted as a "Class II" forest practice if it takes place on lands platted after January 1, 1960, or on lands being converted to another use. Such forest practices require a Class IV application. Class II forest practices are the following:

(a) Renewal of a prior Class II notification.

(b) Renewal of a previously approved Class III or IV forest practice application where:

(i) No modification of the uncompleted operation is proposed;

(ii) No notices to comply, stop work orders or other enforcement actions are outstanding with respect to the prior application; and

(iii) No change in the nature and extent of the forest practice is required under rules effective at the time of renewal.

(c) Any of the following if none of the operation or limits of construction takes place within the riparian management zone of a Type 2 or 3 Water, or within the ordinary highwater mark of a Type 4 Water:

- (i) Construction of advance fire trails.
- (ii) Opening a new pit of, or extending an existing pit by, less than 1 acre.
- (iii) The following operations except those involving off-road use of tractor or wheeled skidding systems on a sideslope of greater than 40 percent:
  - (A) Salvage of logging residue.
  - (B) Salvage of dead, down or dying timber if less than 40 percent of the total timber volume is removed in any 12-month period.
  - (C) West of the Cascade summit, partial cutting of 40 percent or less of the live timber volume.
  - (D) East of the Cascade summit, partial cutting of 5,000 board feet per acre or less.
  - (E) Any harvest on less than 40 acres.
  - (F) Construction of 600 or more feet of road, provided that the department shall be renotified at least 2 business days before commencement of the construction.
- (5) "CLASS III" forest practices not listed under Classes IV, I or II above are "Class III" forest practices. Among Class III forest practices are the following:
  - (a) Those requiring hydraulic project approval (RCW 75.20.100).
  - (b) Those within the shorelines of the state other than those in a Class I forest practice.
  - (c) Aerial application of insecticides, except where classified as a Class IV forest practice.
  - (d) Aerial application of chemicals (except insecticides), except where classified as Class I or IV forest practices.
  - (e) Harvest or salvage of timber except where classed as Class I, II or IV forest practices.
  - (f) All road construction and reconstruction except as listed in Classes I, II and IV forest practices.
  - (g) Opening of new pits or extensions of existing pits over 1 acre.
  - (h) Road maintenance involving:
    - (i) Replacement of bridges or culverts across Type 1, 2, 3, or flowing Type 4 Waters; or
    - (ii) Movement of material that has a direct potential for entering Type 1, 2, 3 or flowing Type 4 Waters.
  - (i) Operations involving an applicant's bond in lieu of a landowner's signature.
  - (j) Site preparation or slash abatement not listed in Classes I or IV forest practices.
  - (k) Harvesting, road construction, site preparation or aerial application of pesticides on lands which contain cultural, historic or archaeological resources which, at the time the application or notification is filed, are:
    - (i) On or are eligible for listing on the National Register of Historic Places; or
    - (ii) Have been identified to the department as being of interest to an affected Indian tribe.
  - (l) Harvesting exceeding 19 acres in a designated difficult regeneration area.
  - (m) Utilization of an alternate plan. See WAC 222-12-040.

Reviser's note: RCW 34.05.395 requires the use of underlining and deletion marks to indicate amendments to existing rules. The rule published above varies from its predecessor in certain respects not indicated by the use of these markings.

### WSR 91-07-035

#### NOTICE OF PUBLIC MEETINGS TRANSPORTATION COMMISSION

[Memorandum—March 13, 1991]

The April Washington State Transportation Commission meeting will be held on Thursday, April 18, 1991, at 9 a.m. at the Red Lion Inn at the Quay, 100 Columbia Street, Vancouver, WA. There will be subcommittee meetings on April 17, 1991.

### WSR 91-07-036

#### PROPOSED RULES DEPARTMENT OF AGRICULTURE

[Filed March 15, 1991, 11:34 a.m.]

Original Notice.

Title of Rule: Chapter 16-486 WAC, Australia and Tasmania apple quarantine.

Purpose: To repeal the quarantine which is no longer necessary.

Statutory Authority for Adoption: Chapter 17.24 RCW.

Statute Being Implemented: Chapter 17.24 RCW.

Summary: The quarantine, which became effective in March of 1973, was intended to protect the apple industry in the state of Washington from light brown apple moth (LBAM) which was being detected in fruit shipments from Australia and Tasmania. Australia and Tasmania have since put extensive inspection and certification programs into place and LBAM larvae are no longer being detected.

Reasons Supporting Proposal: Control programs in Australia and Tasmania are adequate to protect Washington's apple industry from the introduction of the light brown apple moth.

Name of Agency Personnel Responsible for Drafting, Implementation and Enforcement: William E. Brookreson, 6120 Capitol Boulevard, Tumwater, WA, (206) 586-5306.

Name of Proponent: Department of Agriculture, governmental.

Rule is not necessitated by federal law, federal or state court decision.

Explanation of Rule, its Purpose, and Anticipated Effects: The quarantine was originally implemented to prevent the introduction of light brown apple moth into Washington state, from larvae found in fruit shipments from Australia and Tasmania. Australia and Tasmania have since implemented sufficient control programs; light brown apple moth larvae are not longer found in shipments. The proposal repeals Washington state's quarantine which is no longer necessary.

Proposal Changes the Following Existing Rules: The proposed changes repeal the existing quarantine.

No small business economic impact statement is required for this proposal by chapter 19.85 RCW.

Hearing Location: Washington State University Puyallup Research and Extension Center, Administration Building, Chicon Room, 7612 Pioneer Way East, Fruitland and Pioneer, Puyallup, WA 98371-4998, on April 30, 1991, at 10:00 a.m.

Submit Written Comments to: William E. Brookreson, 406 General Administration Building, AX-41, Olympia, WA 98504, by April 30, 1991.

Date of Intended Adoption: May 15, 1991.

March 15, 1991  
William E. Brookreson  
Assistant Director

#### REPEALER

The following chapter of the Washington Administrative Code is repealed:

- WAC 16-486-001 PROMULGATION—ESTABLISHING QUARANTINE.
- WAC 16-486-010 QUARANTINE AREA.
- WAC 16-486-015 COMMODITY COVERED.
- WAC 16-486-020 REGULATION.
- WAC 16-486-025 FUMIGATION REQUIREMENTS.
- WAC 16-486-030 PROOF OF FUMIGATION.
- WAC 16-486-035 DISPOSITION OF APPLES SHIPPED IN VIOLATION OF THIS QUARANTINE.
- WAC 16-486-040 VIOLATION AND PENALTY.
- WAC 16-486-045 EFFECTIVE DATE.

**WSR 91-07-037**  
**PROPOSED RULES**  
**DEPARTMENT OF AGRICULTURE**

[Filed March 15, 1991, 11:37 a.m.]

Original Notice.

Title of Rule: Chapter 16-484 WAC, Narcissus bulb nematode quarantine.

Purpose: To repeal the quarantine which is no longer necessary.

Statutory Authority for Adoption: Chapter 17.24 RCW.

Statute Being Implemented: Chapter 17.24 RCW.

Summary: The proposal would repeal the narcissus bulb nematode quarantine.

Reasons Supporting Proposal: The proposal is put forward at industry request.

Name of Agency Personnel Responsible for Drafting, Implementation and Enforcement: William E. Brookreson, 6120 Capitol Boulevard, Tumwater, WA, (206) 586-5306.

Name of Proponent: Department of Agriculture, governmental.

Rule is not necessitated by federal law, federal or state court decision.

Explanation of Rule, its Purpose, and Anticipated Effects: The narcissus bulb nematode quarantine was enacted at industry request to regulate bulb movement for the presence of the *Tylenius dipsaci* nematode. The key

element in the process is the treatment with formalin, a chemical whose registration is being lost to the industry. At present no alternatives appear feasible. In addition, an intensive internal review and a review with the industry determined that the quarantine was no longer serving a purpose and should be repealed.

Proposal Changes the Following Existing Rules: The proposed changes repeal the existing quarantine.

No small business economic impact statement is required for this proposal by chapter 19.85 RCW.

Hearing Location: Washington State University Puyallup Research and Extension Center, Administration Building, Chicon Room, 7612 Pioneer Way East, Fruitland and Pioneer, Puyallup, WA 98371-4998, on April 30, 1991, at 11:00 a.m.

Submit Written Comments to: William E. Brookreson, 406 General Administration Building, AX-41, Olympia, WA 98504, by April 30, 1991.

Date of Intended Adoption: May 15, 1991.

March 15, 1991  
William E. Brookreson  
Assistant Director

#### REPEALER

The following chapter of the Washington Administrative Code is repealed:

- WAC 16-484-020 ESTABLISHING QUARANTINE—PROMULGATION.
- WAC 16-484-022 PROMULGATION—ESTABLISHING QUARANTINE.
- WAC 16-484-030 DEFINITIONS.
- WAC 16-484-040 CONDITIONS GOVERNING SHIPMENTS.
- WAC 16-484-050 SANITARY REQUIREMENT ON NARCISSUS BULBS GROWN WITHIN THE STATE OF WASHINGTON.
- WAC 16-484-080 CONDITIONS APPLICABLE TO GROWERS.
- WAC 16-484-090 VIOLATIONS.
- WAC 16-484-100 EFFECTIVE DATE.

**WSR 91-07-038**  
**PERMANENT RULES**  
**BOARD OF TAX APPEALS**  
[Order 91-01—Filed March 15, 1991, 12:00 p.m.]

Date of Adoption: March 15, 1991.

Purpose: Amend existing rule on conversion of hearing to conform with statute. Clarify rules on filing and appearance.

Citation of Existing Rules Affected by this Order: Amending WAC 456-09-210, 456-09-325, and 456-09-365.

Statutory Authority for Adoption: RCW 82.03.170.

Pursuant to notice filed as WSR 91-04-084 on February 6, 1991.

Effective Date of Rule: Thirty-one days after filing.

March 15, 1991  
Richard A. Virant  
Chairman

AMENDATORY SECTION (Amending Order 90-03 (WSR 90-11-105), filed 5/22/90)

WAC 456-09-210 APPEARANCE AND PRACTICE BEFORE THE BOARD—WHO MAY APPEAR. Practice before the board in formal proceedings shall be limited to the following:

- (1) Taxpayers who are natural persons representing themselves;
- (2) Attorneys at law duly qualified and entitled to practice in the courts of the state of Washington;
- (3) ~~((Attorneys at law entitled to practice before the highest court of record of any other state, if attorneys licensed in the state of Washington are permitted to appear before the courts of such other state in a representative capacity, and if not otherwise prohibited by state law;~~
- (4)) An authorized officer, partner, or full-time employee of an individual firm, association, partnership, or corporation who appears for such firm, association, partnership, or corporation; and
- (4 ((5))) Other persons permitted by law.

AMENDATORY SECTION (Amending Order 90-03 (WSR 90-11-105), filed 5/22/90)

WAC 456-09-325 DATE OF FILING—FACSIMILE. (1) Except as provided in subsection (3) of this section, the date of filing of a notice of appeal shall be the date of actual receipt by the board at its Olympia office. The board's date stamp placed thereon shall be prima facie evidence of the date of receipt.

(2) Except as provided in subsection (3) of this section, all documents may be filed with the board via facsimile machine. However, filing will not be deemed complete unless the following procedures are strictly observed:

(a) A facsimile document will only be stamped "received" by the board between the hours of 8:00 a.m. and 5:00 p.m. excluding Saturdays, Sundays, and legal holidays. Any transmission not completed before 5:00 p.m. will be stamped received on the following business day. The date and time indicated by the board's facsimile shall be prima facie evidence of the date and time of receipt of transmission.

(b) The original document must be filed with the board within ten days from the date of transmission.

(c) All transmissions are sent at the risk of the sender.

(3) In appeals pursuant to RCW 82.03.130(2) (appeal from board of equalization) the date of filing shall be the date of receipt by the county auditor or, in King County, the clerk of the county council. The date stamp placed on the notice of appeal by the auditor or clerk shall be prima facie evidence of the date of receipt.

AMENDATORY SECTION (Amending Order 89-02 (WSR 89-10-056), filed 5/2/89)

WAC 456-09-365 CONVERSION OF HEARING. (1) The assessor or taxpayer, as a party to an appeal pursuant to RCW 84.08.130(2) (appeals from the board of equalization) may, within twenty days from the date of receipt of the notice of appeal, file with the clerk of the board a notice of intention that the hearing be a

formal hearing pursuant to the Administrative Procedure Act, chapter 34.05 RCW.

(2) In appeals under RCW 82.03.190 and 82.03.130(5), except as otherwise provided in this subsection and subsection (2) of this section, the department of revenue may, within thirty ((ten)) days of receipt of the notice of appeal, file with the board a notice of its intention that the hearing be held pursuant to the Administrative Procedure Act, chapter 34.05 RCW.

(3) The parties may agree at any time before hearing, in writing, to convert the proceedings to either a formal or informal hearing.

**WSR 91-07-039****PERMANENT RULES****BOARD OF TAX APPEALS**

[Order 91-02—Filed March 15, 1991, 12:02 p.m.]

Date of Adoption: March 15, 1991.

Purpose: Amend existing rule on conversion of hearing to conform with statute. Provide rule for recording hearings at informal hearings.

Citation of Existing Rules Affected by this Order: Amending WAC 456-10-360.

Statutory Authority for Adoption: RCW 82.03.170.

Pursuant to notice filed as WSR 91-04-083 on February 6, 1991.

Effective Date of Rule: Thirty-one days after filing.

March 15, 1991

Richard A. Virant

Chairman

AMENDATORY SECTION (Amending Order 89-03 (WSR 89-10-057), filed 5/2/89)

WAC 456-10-360 CONVERSION OF HEARING. (1) The assessor or taxpayer, as a party to an appeal pursuant to RCW 84.08.130(2) (appeal from the boards of equalization) may, within twenty days from the date of receipt of the notice of appeal, file with the clerk of the board a notice of intention that the hearing be a formal hearing pursuant to the Administrative Procedure Act, chapter 34.05 RCW.

(2) In appeals under RCW 82.03.190 and 82.03.130(5), except as otherwise provided in this subsection and subsection (2) of this section, the department of revenue may, within thirty ((ten)) days of receipt of the notice of appeal, file with the board a notice of its intention that the hearing be held pursuant to the Administrative Procedure Act, chapter 34.05 RCW.

(3) The parties may agree at any time before hearing, in writing, to convert the proceedings to either a formal or informal hearing.

NEW SECTION

WAC 456-10-547 HEARINGS—REPORTING—RECORDING—RECORDING DEVICES. (1) All hearings shall be recorded by manual, electronic, or other type of recording device.

(2) Photographic and recording equipment shall be permitted at hearings; however, the presiding officer may

impose such conditions upon their use as deemed necessary to prevent disruption of the hearing, or when a statute or law limits such use.

**WSR 91-07-040**  
**PERMANENT RULES**  
**DEPARTMENT OF REVENUE**  
 [Filed March 15, 1991, 3:47 p.m.]

Date of Adoption: March 15, 1991.

Purpose: To repeal former rules which have been superseded.

Citation of Existing Rules Affected by this Order:

Repealing WAC 458-14-010, 458-14-020, 458-14-030, 458-14-040, 458-14-045, 458-14-050, 458-14-052, 458-14-055, 458-14-060, 458-14-062, 458-14-065, 458-14-070, 458-14-075, 458-14-080, 458-14-085, 458-14-086, 458-14-090, 458-14-091, 458-14-092, 458-14-094, 458-14-098, 458-14-100, 458-14-110, 458-14-115, 458-14-120, 458-14-121, 458-14-122, 458-14-125, 458-14-126, 458-14-130, 458-14-135, 458-14-140, 458-14-145, 458-14-150, 458-14-152, and 458-14-155.

Statutory Authority for Adoption: RCW 84.08.010, 84.08.070, and 84.08.200.

Pursuant to notice filed as WSR 90-18-097 on September 5, 1990.

Effective Date of Rule: Thirty-one days after filing.  
 March 15, 1990 [1991]  
 William N. Rice  
 Assistant Director

**REPEALER**

The following sections of the Chapter 458-14 Washington Administrative Code are hereby repealed:

- WAC 458-14-010 RECONVENING COUNTY BOARDS OF EQUALIZATION—BY WHOM.
- WAC 458-14-020 RECONVENING COUNTY BOARDS OF EQUALIZATION—CONTENTS OF REQUEST.
- WAC 458-14-030 CONTENT OF ORDER—LIMITATION ON WHAT COUNTY BOARD MAY CONSIDER.
- WAC 458-14-040 LIMITATIONS ON RECONVENING.
- WAC 458-14-045 RECONVENING UPON TIMELY FILED PETITION—LIMITATIONS.
- WAC 458-14-050 MEMBERSHIP.
- WAC 458-14-052 CHANGE OF VENUE.
- WAC 458-14-055 CLERK.
- WAC 458-14-060 LEGAL ADVISOR.
- WAC 458-14-062 PROPERTY TAX ADVISOR.
- WAC 458-14-065 APPRAISERS.
- WAC 458-14-070 PUBLIC NOTICE OF JULY MEETINGS.
- WAC 458-14-075 MEETINGS.
- WAC 458-14-080 ORGANIZATION OF THE BOARD.
- WAC 458-14-085 RECORD OF PROCEEDINGS—IN GENERAL.

- WAC 458-14-086 ADDITIONAL RECORD REQUIREMENTS.
- WAC 458-14-090 ASSESSMENT ROLL AND RECORDS.
- WAC 458-14-091 CERTIFICATION OF THE VALUATION OF THE ASSESSMENT ROLL BY ASSESSOR.
- WAC 458-14-092 CHANGE OF ASSESSMENT ROLLS.
- WAC 458-14-094 AVAILABILITY OF VALUATION INFORMATION.
- WAC 458-14-098 REVIEW OF VALUATION.
- WAC 458-14-100 DUTIES OF THE BOARD.
- WAC 458-14-110 NOTICE OF RAISE IN VALUATION BY THE BOARD.
- WAC 458-14-115 EXEMPT PROPERTIES.
- WAC 458-14-120 PETITIONS.
- WAC 458-14-121 ACTION ON APPEALS.
- WAC 458-14-122 APPEAL OF BOARD MEMBERS, ASSISTANTS, OR COUNTY GOVERNMENTAL AUTHORITIES.
- WAC 458-14-125 HEARING ON PETITION.
- WAC 458-14-126 HEARING EXAMINERS.
- WAC 458-14-130 ORDERS OF THE BOARD.
- WAC 458-14-135 APPEALS.
- WAC 458-14-140 RECORDS TO STATE BOARD.
- WAC 458-14-145 JUNE MEETING.
- WAC 458-14-150 NOVEMBER MEETING.
- WAC 458-14-152 MANIFEST ERRORS.
- WAC 458-14-155 DEFINITIONS.

**WSR 91-07-041**  
**PERMANENT RULES**  
**DEPARTMENT OF**  
**COMMUNITY DEVELOPMENT**  
 [Filed March 15, 1991, 4:26 p.m.]

Date of Adoption: February 5, 1991.

Purpose: To adopt minimum guidelines to assist all counties and cities statewide in classifying and designating natural resource lands and critical areas.

Citation of Existing Rules Affected by this Order: Amending chapter 365-190 WAC.

Statutory Authority for Adoption: RCW 36.70A.050.

Pursuant to notice filed as WSR 91-01-129 on December 19, 1990.

Effective Date of Rule: Thirty-one days after filing.  
 March 15, 1991  
 Chuck Clarke  
 Director

Chapter 365-190 WAC  
**MINIMUM GUIDELINES TO CLASSIFY AGRICULTURE, FOREST, MINERAL LANDS AND CRITICAL AREAS**

**PART ONE**  
**PURPOSE/AUTHORITY**

NEW SECTION

WAC 365-190-010 AUTHORITY. This chapter is established pursuant to RCW 36.70A.050.

NEW SECTION

WAC 365-190-020 PURPOSE. The intent of this chapter is to establish minimum guidelines to assist all counties and cities state-wide in classifying agricultural lands, forest lands, mineral resource lands, and critical areas. These guidelines shall be considered by counties and cities in designating these lands.

Growth management, natural resource land conservation, and critical areas protection share problems related to governmental costs and efficiency. Sprawl and the unwise development of natural resource lands or areas susceptible to natural hazards may lead to inefficient use of limited public resources, jeopardize environmental resource functions and values, subject persons and property to unsafe conditions, and affect the perceived quality of life. It is more costly to remedy the loss of natural resource lands or critical areas than to conserve and protect them from loss or degradation. The inherent economic, social, and cultural values of natural resource lands and critical areas should be considered in the development of strategies designed to conserve and protect lands.

In recognition of these common concerns, classification and designation of natural resource lands and critical areas is intended to assure the long-term conservation of natural resource lands and to preclude land uses and developments which are incompatible with critical areas. There are qualitative differences between and among natural resource lands and critical areas. Not all areas and ecosystems are critical for the same reasons. Some are critical because of the hazard they present to public health and safety, some because of the values they represent to the public welfare. In some cases, the risk posed to the public by use or development of a critical area can be mitigated or reduced by engineering or design; in other cases that risk cannot be effectively reduced except by avoidance of the critical area. Hence, classification and designation of critical areas is intended to lead counties and cities to recognize the differences among these areas, and to develop appropriate regulatory and nonregulatory actions in response.

Counties and cities required or opting to plan under the Growth Management Act of 1990 should consider the definitions and guidelines in this chapter when preparing development regulations which preclude uses and development incompatible with critical areas (see RCW 36.70A.060). Precluding incompatible uses and development does not mean a prohibition of all uses or development. Rather, it means governing changes in land uses, new activities, or development that could adversely affect critical areas. Thus for each critical area, counties and cities planning under the act should define classification schemes and prepare development regulations that govern changes in land uses and new activities by prohibiting clearly inappropriate actions and restricting, allowing, or conditioning other activities as appropriate.

It is the intent of these guidelines that critical areas designations overlay other land uses including designated natural resource lands. That is, if two or more land use designations apply to a given parcel or a portion of a parcel, both or all designations shall be made. Regarding natural resource lands, counties and cities should allow existing and ongoing resource management operations, that have long-term commercial significance, to continue. Counties and cities should encourage utilization of best management practices where existing and ongoing resource management operations that have long-term commercial significance include designated critical areas. Future operations or expansion of existing operations should be done in consideration of protecting critical areas.

## PART TWO GENERAL REQUIREMENTS

NEW SECTION

WAC 365-190-030 DEFINITIONS. (1) Agricultural land is land primarily devoted to the commercial production of horticultural, viticultural, floricultural, dairy, apiary, vegetable, or animal products or of berries, grain, hay, straw, turf, seed, Christmas trees not subject to the excise tax imposed by RCW 84.33.100 through 84.33.140, or livestock, and that has long-term commercial significance for agricultural production.

(2) Areas with a critical recharging effect on aquifers used for potable water are areas where an aquifer that is a source of drinking water is vulnerable to contamination that would affect the potability of the water.

(3) City means any city or town, including a code city.

(4) Critical areas include the following areas and ecosystems:

(a) Wetlands;

(b) Areas with a critical recharging effect on aquifers used for potable water;

(c) Fish and wildlife habitat conservation areas;

(d) Frequently flooded areas; and

(e) Geologically hazardous areas.

(5) Erosion hazard areas are those areas containing soils which, according to the United States Department of Agriculture Soil Conservation Service Soil Classification System, may experience severe to very severe erosion.

(6) Forest land is land primarily useful for growing trees, including Christmas trees subject to the excise tax imposed under RCW 84.33.100 through 84.33.140, for commercial purposes, and that has long-term commercial significance for growing trees commercially.

(7) Frequently flooded areas are lands in the floodplain subject to a one percent or greater chance of flooding in any given year. These areas include, but are not limited to, streams, rivers, lakes, coastal areas, wetlands, and the like.

(8) Geologically hazardous areas are areas that because of their susceptibility to erosion, sliding, earthquake, or other geological events, are not suited to siting



commercial, residential, or industrial development consistent with public health or safety concerns.

(9) Habitats of local importance include, a seasonal range or habitat element with which a given species has a primary association, and which, if altered, may reduce the likelihood that the species will maintain and reproduce over the long-term. These might include areas of high relative density or species richness, breeding habitat, winter range, and movement corridors. These might also include habitats that are of limited availability or high vulnerability to alteration, such as cliffs, talus, and wetlands.

(10) Landslide hazard areas are areas potentially subject to risk of mass movement due to a combination of geologic, topographic, and hydrologic factors.

(11) Long-term commercial significance includes the growing capacity, productivity, and soil composition of the land for long-term commercial production, in consideration with the land's proximity to population areas, and the possibility of more intense uses of land.

(12) Minerals include gravel, sand, and valuable metallic substances.

(13) Mine hazard areas are those areas directly underlain by, adjacent to, or affected by mine workings such as adits, tunnels, drifts, or air shafts.

(14) Mineral resource lands means lands primarily devoted to the extraction of minerals or that have known or potential long-term commercial significance for the extraction of minerals.

(15) Natural resource lands means agricultural, forest and mineral resource lands which have long-term commercial significance.

(16) Public facilities include streets, roads, highways, sidewalks, street and road lighting systems, traffic signals, domestic water systems, storm and sanitary sewer systems, parks and recreational facilities, and schools.

(17) Public services include fire protection and suppression, law enforcement, public health, education, recreation, environmental protection, and other governmental services.

(18) Seismic hazard areas are areas subject to severe risk of damage as a result of earthquake induced ground shaking, slope failure, settlement, or soil liquefaction.

(19) Species of local importance are those species that are of local concern due to their population status or their sensitivity to habitat manipulation or that are game species.

(20) Urban growth refers to growth that makes intensive use of land for the location of buildings, structures, and impermeable surfaces to such a degree as to be incompatible with the primary use of such land for the production of food, other agricultural products, or fiber, or the extraction of mineral resources. When allowed to spread over wide areas, urban growth typically requires urban governmental services. "Characterized by urban growth" refers to land having urban growth located on it, or to land located in relationship to an area with urban growth on it as to be appropriate for urban growth.

(21) Volcanic hazard areas shall include areas subject to pyroclastic flows, lava flows, and inundation by debris flows, mudflows, or related flooding resulting from volcanic activity.

(22) Wetland or wetlands means areas that are inundated or saturated by surface water or ground water at a frequency and duration sufficient to support, and that under normal circumstances do support, a prevalence of vegetation typically adapted for life in saturated soil conditions. Wetlands generally include swamps, marshes, bogs, and similar areas. Wetlands do not include those artificial wetlands intentionally created from nonwetland sites, grass-lined swales, canals, detention facilities, wastewater treatment facilities, farm ponds, and landscape amenities. However, wetlands may include those artificial wetlands intentionally created from nonwetland areas created to mitigate conversion of wetlands, if permitted by the county or city.

### PART THREE GUIDELINES

#### NEW SECTION

**WAC 365-190-040 PROCESS.** The classification and designation of natural resource lands and critical areas is an important step among several in the overall growth management process. Together these steps comprise a vision of the future, and that vision gives direction to the steps in the form of specific goals and objectives. Under the Growth Management Act, the timing of the first steps coincides with development of the larger vision through the comprehensive planning process. People are asked to take the first steps, designation and classification of natural resource lands and critical areas, before the goals, objectives, and implementing policies of the comprehensive plan are finalized. Jurisdictions planning under the Growth Management Act must also adopt interim regulations for the conservation of natural resource lands and protection of critical areas. In this way, the classification and designation help give shape to the content of the plan, and at the same time natural resource lands are conserved and critical areas are protected from incompatible development while the plan is in process.

Under the Growth Management Act, preliminary classifications and designations will be completed in 1991. Those planning under the act must also enact interim regulations to protect and conserve these lands by September 1, 1991. By July 1, 1992, counties and cities not planning under the act must bring their regulations into conformance with their comprehensive plans. By July 1, 1993, counties and cities planning under the act must adopt comprehensive plans, consistent with the goals of the act. Implementation of the plans will occur by the following year.

(1) Classification is the first step in implementing RCW 36.70A.050. It means defining categories to which natural resource lands and critical areas will be assigned.

Pursuant to RCW 36.70A.170, natural resource lands and critical areas will be designated based on the defined classifications. Designation establishes, for planning purposes: The classification scheme; the general distribution, location, and extent of the uses of land, where appropriate, for agriculture, forestry, and mineral extraction; and the general distribution, location, and extent of critical

areas. Inventories and maps can indicate designations of natural resource lands. In the circumstances where critical areas (e.g., aquifer recharge areas, wetlands, significant wildlife habitat, etc.) cannot be readily identified, these areas should be designated by performance standards or definitions, so they can be specifically identified during the processing of a permit or development authorization. Designation means, at least, formal adoption of a policy statement, and may include further legislative action. Designating inventoried lands for comprehensive planning and policy definition may be less precise than subsequent regulation of specific parcels for conservation and protection.

Classifying, inventorying, and designating lands or areas does not imply a change in a landowner's right to use his or her land under current law. Land uses are regulated on a parcel basis and innovative land use management techniques should be applied when counties and cities adopt regulations to conserve and protect designated natural resource lands and critical areas. The department of community development will provide technical assistance to counties and cities on a wide array of regulatory options and alternative land use management techniques.

These guidelines may result in critical area designations that overlay other critical area or natural resource land classifications. That is, if two or more critical area designations apply to a given parcel, or portion of a given parcel, both or all designations apply. For counties and cities required or opting to plan under chapter 36.70A RCW, reconciling these multiple designations will be the subject of local development regulations adopted pursuant to RCW 36.70A.060.

(2) Counties and cities shall involve the public in classifying and designating natural resource lands and critical areas.

(a) Public participation:

(i) Public participation should include at a minimum: Landowners; representatives of agriculture, forestry, mining, business, environmental, and community groups; tribal governments; representatives of adjacent counties and cities; and state agencies. The public participation program should include early and timely public notice of pending designations and regulations.

(ii) Counties and cities should consider using: Technical and citizen advisory committees with broad representation, press releases, news conferences, neighborhood meetings, paid advertising (e.g., newspaper, radio, T.V., transit), newsletters, and other means beyond the required normal legal advertising and public notices. Plain, understandable language should be used. The department of community development will provide technical assistance in preparing public participation plans, including: A pamphlet series, workshops, and a list of agencies available to provide help.

(b) Adoption process. Statutory and local processes already in place governing land use decisions are the minimum processes required for designation and regulation pursuant to RCW 36.70A.060 and 36.70A.170. At least these steps should be included in the process:

(i) Accept the requirements of chapter 36.70A RCW, especially definitions of agricultural lands, forest lands,

minerals, long-term commercial significance, critical areas, geologically hazardous areas, and wetlands as mandatory minimums.

(ii) Consider minimum guidelines developed by department of community development under RCW 36.70A.050.

(iii) Consider other definitions used by state and federal regulatory agencies.

(iv) Consider definitions used by the county and city and other counties and cities.

(v) Determine recommended definitions and check conformance with minimum definitions of chapter 36.70A RCW.

(vi) Adopt definitions, classifications, and standards.

(vii) Apply definitions to the land by mapping designated natural resource lands.

(viii) Establish designation amendment procedures.

(c) Intergovernmental coordination. The Growth Management Act requires coordination among communities and jurisdictions to reconcile conflicts and strive for consistent definitions, standards, and designations within regions. The minimum coordination process required under these guidelines may take one of two forms:

(i) Adjacent cities (or those with overlapping or adjacent planning areas); counties and the cities within them; and adjacent counties would provide each other and all adjacent special purpose districts and special purpose districts within them notice of their intent to classify and designate natural resource lands and critical areas within their jurisdiction. Counties or cities receiving notice may provide comments and input to the notifying jurisdiction. The notifying jurisdiction specifies a comment period prior to adoption. Within forty-five days of the jurisdiction's date of adoption of classifications or designations, affected jurisdictions are supplied a copy of the proposal. The department of community development may provide mediation services to counties and cities to help resolve disputed classifications or designations.

(ii) Adjacent jurisdictions; all the cities within a county; or all the cities and several counties may choose to cooperatively classify and designate natural resource lands and critical areas within their jurisdictions. Counties and cities by interlocal agreement would identify the definitions, classification, designation, and process that will be used to classify and designate lands within their areas. State and federal agencies or tribes may participate in the interlocal agreement or be provided a method of commenting on designations and classifications prior to adoption by jurisdictions.

Counties and/or cities may begin with the notification option ((c)(i) of this subsection) and choose to change to the interlocal agreement method ((c)(ii) of this subsection) prior to completion of the classification and designations within their jurisdictions. Approaches to intergovernmental coordination may vary between natural resource land and critical area designation. It is intended that state and federal agencies with land ownership or management responsibilities, special purpose districts, and Indian tribes with interests within the jurisdictions adopting classification and designation be consulted and their input considered in the development and adoption

of designations and classifications. The department of community development may provide mediation services to help resolve disputes between counties and cities that are using either the notification or interlocal agreement method of coordinating between jurisdictions.

(d) Mapping. Mapping should be done to identify designated natural resource lands and to identify known critical areas. Counties and cities should clearly articulate that the maps are for information or illustrative purposes only unless the map is an integral component of a regulatory scheme.

Although there is no specific requirement for inventorying or mapping either natural resource lands or critical areas, chapter 36.70A RCW requires that counties and cities planning under chapter 36.70A RCW adopt development regulations for uses adjacent to natural resource lands. Logically, the only way to regulate adjacent lands is to know where the protected lands are. Therefore, mapping natural resource lands is a practical way to make regulation effective.

For critical areas, performance standards are preferred, as any attempt to map wetlands, for example, will be too inexact for regulatory purposes. Standards will be applied upon land use application. Even so, mapping critical areas for information but not regulatory purposes, is advisable.

(e) Reporting. Chapter 36.70A RCW requires that counties and cities annually report their progress to department of community development. Department of community development will maintain a central file including examples of successful public involvement programs, interjurisdictional coordination, definitions, maps, and other materials. This file will serve as an information source for counties and cities and a planning library for state agencies and citizens.

(f) Evaluation. When counties and cities adopt a comprehensive plan, chapter 36.70A RCW requires that they evaluate their designations and development regulations to assure they are consistent with and implement the comprehensive plan. When considering changes to the designations or development regulations, counties and cities should seek interjurisdictional coordination and public participation.

(g) Designation amendment process. Land use planning is a dynamic process. Procedures for designation should provide a rational and predictable basis for accommodating change.

Land use designations must provide landowners and public service providers with the information necessary to make decisions. This includes: Determining when and where growth will occur, what services are and will be available, how they might be financed, and what type and level of land use is reasonable and/or appropriate. Resource managers need to know where and when conversions of rural land might occur in response to growth pressures and how those changes will affect resource management.

Designation changes should be based on consistency with one or more of the following criteria:

(i) Change in circumstances pertaining to the comprehensive plan or public policy.

(ii) A change in circumstances beyond the control of the landowner pertaining to the subject property.

(iii) An error in designation.

(iv) New information on natural resource land or critical area status.

(h) Use of innovative land use management techniques. Resource uses have preferred and primary status in designated natural resource lands of long-term commercial significance. Counties and cities must determine if and to what extent other uses will be allowed. If other uses are allowed, counties and cities should consider using innovative land management techniques which minimize land use incompatibilities and most effectively maintain current and future natural resource lands.

Techniques to conserve and protect agricultural, forest lands, and mineral resource lands of long-term commercial significance include the purchase or transfer of development rights, fee simple purchase of the land, less than fee simple purchase, purchase with leaseback, buffering, land trades, conservation easements or other innovations which maintain current uses and assure the conservation of these natural resource lands.

Development in and adjacent to agricultural and forest lands of long-term commercial significance shall assure the continued management of these lands for their long-term commercial uses. Counties and cities should consider the adoption of right-to-farm provisions. Covenants or easements that recognize that farming and forest activities will occur should be imposed on new development in or adjacent to agricultural or forest lands. Where buffering is used it should be on land within the development unless an alternative is mutually agreed on by adjacent landowners.

Counties and cities planning under the act should define a strategy for conserving natural resource lands and for protecting critical areas, and this strategy should integrate the use of innovative regulatory and nonregulatory techniques.

#### NEW SECTION

##### WAC 365-190-050 AGRICULTURAL LANDS.

(1) In classifying agricultural lands of long-term significance for the production of food or other agricultural products, counties and cities shall use the land-capability classification system of the United States Department of Agriculture Soil Conservation Service as defined in Agriculture Handbook No. 210. These eight classes are incorporated by the United States Department of Agriculture into map units described in published soil surveys. These categories incorporate consideration of the growing capacity, productivity and soil composition of the land. Counties and cities shall also consider the combined effects of proximity to population areas and the possibility of more intense uses of the land as indicated by:

(a) The availability of public facilities;

(b) Tax status;

(c) The availability of public services;

(d) Relationship or proximity to urban growth areas;

(e) Predominant parcel size;

(f) Land use settlement patterns and their compatibility with agricultural practices;

(g) Intensity of nearby land uses;  
 (h) History of land development permits issued nearby;

(i) Land values under alternative uses; and  
 (j) Proximity of markets.

(2) In defining categories of agricultural lands of long-term commercial significance for agricultural production, counties and cities should consider using the classification of prime and unique farmland soils as mapped by the Soil Conservation Service. If a county or city chooses to not use these categories, the rationale for that decision must be included in its next annual report to department of community development.

(3) Counties and cities may further classify additional agricultural lands of local importance. Classifying additional agricultural lands of local importance should include consultation with the board of the local conservation district and the local agriculture stabilization and conservation service committee.

These additional lands may also include bogs used to grow cranberries. Where these lands are also designated critical areas, counties and cities planning under the act must weigh the compatibility of adjacent land uses and development with the continuing need to protect the functions and values of critical areas and ecosystems.

#### NEW SECTION

WAC 365-190-060 FOREST LAND RESOURCES. In classifying forest land, counties and cities should use the private forest land grades of the department of revenue (WAC 458-40-530). This system incorporates consideration of growing capacity, productivity and soil composition of the land. Forest land of long-term commercial significance will generally have a predominance of the higher private forest land grades. However, the presence of lower private forest land grades within the areas of predominantly higher grades need not preclude designation as forest land.

Each county and city shall determine which land grade constitutes forest land of long-term commercial significance, based on local and regional physical, biological, economic, and land use considerations.

Counties and cities shall also consider the effects of proximity to population areas and the possibility of more intense uses of the land as indicated by:

(1) The availability of public services and facilities conducive to the conversion of forest land.

(2) The proximity of forest land to urban and suburban areas and rural settlements: Forest lands of long-term commercial significance are located outside the urban and suburban areas and rural settlements.

(3) The size of the parcels: Forest lands consist of predominantly large parcels.

(4) The compatibility and intensity of adjacent and nearby land use and settlement patterns with forest lands of long-term commercial significance.

(5) Property tax classification: Property is assessed as open space or forest land pursuant to chapter 84.33 or 84.34 RCW.

(6) Local economic conditions which affect the ability to manage timberlands for long-term commercial production.

(7) History of land development permits issued nearby.

#### NEW SECTION

WAC 365-190-070 MINERAL RESOURCE LANDS. (1) Counties and cities shall identify and classify aggregate and mineral resource lands from which the extraction of minerals occurs or can be anticipated. Other proposed land uses within these areas may require special attention to ensure future supply of aggregate and mineral resource material, while maintaining a balance of land uses.

(2) Classification criteria. Areas shall be classified as mineral resource lands based on geologic, environmental, and economic factors, existing land uses, and land ownership. The areas to be studied and their order of study shall be specified by counties and cities.

(a) Counties and cities should classify lands with long-term commercial significance for extracting at least the following minerals: Sand, gravel, and valuable metallic substances. Other minerals may be classified as appropriate.

(b) In classifying these areas, counties and cities should consider maps and information on location and extent of mineral deposits provided by the Washington state department of natural resources and the United States Bureau of Mines. Additionally, the department of natural resources has a detailed minerals classification system counties and cities may choose to use.

(c) Counties and cities should consider classifying known and potential mineral deposits so that access to mineral resources of long-term commercial significance is not knowingly precluded.

(d) In classifying mineral resource lands, counties and cities shall also consider the effects of proximity to population areas and the possibility of more intense uses of the land as indicated by:

(i) General land use patterns in the area;

(ii) Availability of utilities;

(iii) Availability and adequacy of water supply;

(iv) Surrounding parcel sizes and surrounding uses;

(v) Availability of public roads and other public services;

(vi) Subdivision or zoning for urban or small lots;

(vii) Accessibility and proximity to the point of use or market;

(viii) Physical and topographic characteristics of the mineral resource site;

(ix) Depth of the resource;

(x) Depth of the overburden;

(xi) Physical properties of the resource including quality and type;

(xii) Life of the resource; and

(xiii) Resource availability in the region.

#### NEW SECTION

WAC 365-190-080 CRITICAL AREAS. (1) Wetlands. The wetlands of Washington state are fragile ecosystems which serve a number of important beneficial functions. Wetlands assist in the reduction of erosion, siltation, flooding, ground and surface water pollution,

and provide wildlife, plant, and fisheries habitats. Wetlands destruction or impairment may result in increased public and private costs or property losses.

In designating wetlands for regulatory purposes, counties and cities shall use the definition of wetlands in RCW 36.70A.030(22). Counties and cities are requested and encouraged to make their actions consistent with the intent and goals of "protection of wetlands," Executive Orders 89-10 and 90-04 as they exist on September 1, 1990. Additionally, counties and cities should consider wetlands protection guidance provided by the department of ecology including the model wetlands protection ordinance.

(a) Counties and cities that do not now rate wetlands shall consider a wetlands rating system to reflect the relative function, value and uniqueness of wetlands in their jurisdictions. In developing wetlands rating systems, counties and cities should consider the following:

- (i) The Washington state four-tier wetlands rating system;
- (ii) Wetlands functions and values;
- (iii) Degree of sensitivity to disturbance;
- (iv) Rarity; and
- (v) Ability to compensate for destruction or degradation.

If a county or city chooses to not use the state four-tier wetlands rating system, the rationale for that decision must be included in its next annual report to department of community development.

(b) Counties and cities may use the National Wetlands Inventory as an information source for determining the approximate distribution and extent of wetlands. This inventory provides maps of wetland areas according to the definition of wetlands issued by the United States Department of Interior - Fish and Wildlife Service, and its wetland boundaries should be delineated for regulation consistent with the wetlands definition in RCW 36.70A.030(22).

(c) Counties and cities should consider using the methodology in the Federal Manual for Identifying and Delineating Jurisdictional Wetlands, cooperatively produced by the United States Army Corps of Engineers, United States Environmental Protection Agency, United States Department of Agriculture Soil Conservation Service, and United States Fish and Wildlife Service, that was issued in January 1989, and regulatory guidance letter 90-7 issued by the United States Corps of Engineers on November 29, 1990, for regulatory delineations.

(2) Aquifer recharge areas. Potable water is an essential life sustaining element. Much of Washington's drinking water comes from ground water supplies. Once ground water is contaminated it is difficult, costly, and sometimes impossible to clean up. Preventing contamination is necessary to avoid exorbitant costs, hardships, and potential physical harm to people.

The quality of ground water in an aquifer is inextricably linked to its recharge area. Few studies have been done on aquifers and their recharge areas in Washington state. In the cases in which aquifers and their recharge areas have been studied, affected counties

and cities should use this information as the base for classifying and designating these areas.

Where no specific studies have been done, counties and cities may use existing soil and surficial geologic information to determine where recharge areas are. To determine the threat to ground water quality, existing land use activities and their potential to lead to contamination should be evaluated.

Counties and cities shall classify recharge areas for aquifers according to the vulnerability of the aquifer. Vulnerability is the combined effect of hydrogeological susceptibility to contamination and the contamination loading potential. High vulnerability is indicated by land uses that contribute contamination that may degrade ground water, and hydrogeologic conditions that facilitate degradation. Low vulnerability is indicated by land uses that do not contribute contaminants that will degrade ground water, and by hydrogeologic conditions that do not facilitate degradation.

(a) To characterize hydrogeologic susceptibility of the recharge area to contamination, counties and cities may consider the following physical characteristics:

- (i) Depth to ground water;
- (ii) Aquifer properties such as hydraulic conductivity and gradients;
- (iii) Soil (texture, permeability, and contaminant attenuation properties);
- (iv) Characteristics of the vadose zone including permeability and attenuation properties; and
- (v) Other relevant factors.

(b) The following may be considered to evaluate the contaminant loading potential:

- (i) General land use;
- (ii) Waste disposal sites;
- (iii) Agriculture activities;
- (iv) Well logs and water quality test results; and
- (v) Other information about the potential for contamination.

(c) Classification strategy for recharge areas should be to maintain the quality of the ground water, with particular attention to recharge areas of high susceptibility. In recharge areas that are highly vulnerable, studies should be initiated to determine if ground water contamination has occurred. Classification of these areas should include consideration of the degree to which the aquifer is used as a potable water source, feasibility of protective measures to preclude further degradation, availability of treatment measures to maintain potability, and availability of alternative potable water sources.

(d) Examples of areas with a critical recharging effect on aquifers used for potable water, may include:

- (i) Sole source aquifer recharge areas designated pursuant to the Federal Safe Drinking Water Act.
- (ii) Areas established for special protection pursuant to a ground water management program, chapters 90.44, 90.48, and 90.54 RCW, and chapters 173-100 and 173-200 WAC.

(iii) Areas designated for wellhead protection pursuant to the Federal Safe Drinking Water Act.

(iv) Other areas meeting the definition of "areas with a critical recharging effect on aquifers used for potable water" in these guidelines.

(3) Frequently flooded areas. Floodplains and other areas subject to flooding perform important hydrologic functions and may present a risk to persons and property. Classifications of frequently flooded areas should include, at a minimum, the 100-year floodplain designations of the Federal Emergency Management Agency and the National Flood Insurance Program.

Counties and cities should consider the following when designating and classifying frequently flooded areas:

(a) Effects of flooding on human health and safety, and to public facilities and services;

(b) Available documentation including federal, state, and local laws, regulations, and programs, local studies and maps, and federal flood insurance programs;

(c) The future flow floodplain, defined as the channel of the stream and that portion of the adjoining floodplain that is necessary to contain and discharge the base flood flow at build out without any measurable increase in flood heights;

(d) The potential effects of tsunami, high tides with strong winds, sea level rise resulting from global climate change, and greater surface runoff caused by increasing impervious surfaces.

(4) Geologically hazardous areas.

(a) Geologically hazardous areas include areas susceptible to erosion, sliding, earthquake, or other geological events. They pose a threat to the health and safety of citizens when incompatible commercial, residential, or industrial development is sited in areas of significant hazard. Some geological hazards can be reduced or mitigated by engineering, design, or modified construction or mining practices so that risks to health and safety are acceptable. When technology cannot reduce risks to acceptable levels, building in geologically hazardous areas is best avoided. This distinction should be considered by counties and cities that do not now classify geological hazards as they develop their classification scheme.

(a) Areas that are susceptible to one or more of the following types of hazards shall be classified as a geologically hazardous area:

- (i) Erosion hazard;
- (ii) Landslide hazard;
- (iii) Seismic hazard; or

(iv) Areas subject to other geological events such as coal mine hazards and volcanic hazards including: Mass wasting, debris flows, rockfalls, and differential settlement.

(b) Counties and cities should classify geologically hazardous area as either:

- (i) Known or suspected risk;
- (ii) No risk;

(iii) Risk unknown – data are not available to determine the presence or absence of a geological hazard.

(c) Erosion hazard areas are at least those areas identified by the United States Department of Agriculture Soil Conservation Service as having a "severe" rill and inter-rill erosion hazard.

(d) Landslide hazard areas shall include areas potentially subject to landslides based on a combination of geologic, topographic, and hydrologic factors. They include any areas susceptible because of any combination of bedrock, soil, slope (gradient), slope aspect, structure,

hydrology, or other factors. Example of these may include, but are not limited to the following:

(i) Areas of historic failures, such as:

(A) Those areas delineated by the United States Department of Agriculture Soil Conservation Service as having a "severe" limitation for building site development;

(B) Those areas mapped as class u (unstable), uos (unstable old slides), and urs (unstable recent slides) in the department of ecology coastal zone atlas; or

(C) Areas designated as quaternary slumps, earthflows, mudflows, lahars, or landslides on maps published as the United States Geological Survey or department of natural resources division of geology and earth resources.

(ii) Areas with all three of the following characteristics:

(A) Slopes steeper than fifteen percent; and

(B) Hillsides intersecting geologic contacts with a relatively permeable sediment overlying a relatively impermeable sediment or bedrock; and

(C) Springs or ground water seepage;

(iii) Areas that have shown movement during the holocene epoch (from ten thousand years ago to the present) or which are underlain or covered by mass wastage debris of that epoch;

(iv) Slopes that are parallel or subparallel to planes of weakness (such as bedding planes, joint systems, and fault planes) in subsurface materials;

(v) Slopes having gradients steeper than eighty percent subject to rockfall during seismic shaking;

(vi) Areas potentially unstable as a result of rapid stream incision, stream bank erosion, and undercutting by wave action;

(vii) Areas that show evidence of, or are at risk from snow avalanches;

(viii) Areas located in a canyon or on an active alluvial fan, presently or potentially subject to inundation by debris flows or catastrophic flooding;

(ix) Any area with a slope of forty percent or steeper and with a vertical relief of ten or more feet except areas composed of consolidated rock. A slope is delineated by establishing its toe and top and measured by averaging the inclination over at least ten feet of vertical relief.

(e) Seismic hazard areas shall include areas subject to severe risk of damage as a result of earthquake induced ground shaking, slope failure, settlement, soil liquefaction, or surface faulting. One indicator of potential for future earthquake damage is a record of earthquake damage in the past. Ground shaking is the primary cause of earthquake damage in Washington. The strength of ground shaking is primarily affected by:

(i) The magnitude of an earthquake;

(ii) The distance from the source of an earthquake;

(iii) The type of thickness of geologic materials at the surface; and

(iv) The type of subsurface geologic structure.

Settlement and soil liquefaction conditions occur in areas underlain by cohesionless soils of low density, typically in association with a shallow ground water table.

(f) Other geological events:

(i) Volcanic hazard areas shall include areas subject to pyroclastic flows, lava flows, debris avalanche, inundation by debris flows, mudflows, or related flooding resulting from volcanic activity.

(ii) Mine hazard areas are those areas underlain by, adjacent to, or affected by mine workings such as adits, gangways, tunnels, drifts, or air shafts. Factors which should be considered include: Proximity to development, depth from ground surface to the mine working, and geologic material.

(5) Fish and wildlife habitat conservation areas. Fish and wildlife habitat conservation means land management for maintaining species in suitable habitats within their natural geographic distribution so that isolated subpopulations are not created. This does not mean maintaining all individuals of all species at all times, but it does mean cooperative and coordinated land use planning is critically important among counties and cities in a region. In some cases, intergovernmental cooperation and coordination may show that it is sufficient to assure that a species will usually be found in certain regions across the state.

(a) Fish and wildlife habitat conservation areas include:

(i) Areas with which endangered, threatened, and sensitive species have a primary association;

(ii) Habitats and species of local importance;

(iii) Commercial and recreational shellfish areas;

(iv) Kelp and eelgrass beds; herring and smelt spawning areas;

(v) Naturally occurring ponds under twenty acres and their submerged aquatic beds that provide fish or wildlife habitat;

(vi) Waters of the state;

(vii) Lakes, ponds, streams, and rivers planted with game fish by a governmental or tribal entity; or

(viii) State natural area preserves and natural resource conservation areas.

(b) Counties and cities may consider the following when classifying and designating these areas:

(i) Creating a system of fish and wildlife habitat with connections between larger habitat blocks and open spaces;

(ii) Level of human activity in such areas including presence of roads and level of recreation type (passive or active recreation may be appropriate for certain areas and habitats);

(iii) Protecting riparian ecosystems;

(iv) Evaluating land uses surrounding ponds and fish and wildlife habitat areas that may negatively impact these areas;

(v) Establishing buffer zones around these areas to separate incompatible uses from the habitat areas; and

(vi) Restoring of lost salmonid habitat.

(c) Sources and methods

(i) Counties and cities should classify seasonal ranges and habitat elements with which federal and state listed endangered, threatened and sensitive species have a primary association and which, if altered, may reduce the likelihood that the species will maintain and reproduce over the long term.

(ii) Counties and cities should determine which habitats and species are of local importance. Habitats and species may be further classified in terms of their relative importance.

Counties and cities may use information prepared by the Washington department of wildlife to classify and designate locally important habitats and species. Priority habitats and priority species are being identified by the department of wildlife for all lands in Washington state. While these priorities are those of the department, they and the data on which they are based may be considered by counties and cities.

(iii) Shellfish areas. All public and private tidelands or bedlands suitable for shellfish harvest shall be classified as critical areas. Counties and cities should consider both commercial and recreational shellfish areas. Counties and cities should at least consider the Washington department of health classification of commercial and recreational shellfish growing areas to determine the existing condition of these areas. Further consideration should be given to the vulnerability of these areas to contamination. Shellfish protection districts established pursuant to chapter 90.72 RCW shall be included in the classification of critical shellfish areas.

(iv) Kelp and eelgrass beds; herring and smelt spawning areas. Counties and cities shall classify kelp and eelgrass beds, identified by department of natural resources aquatic lands division and the department of ecology. Though not an inclusive inventory, locations of kelp and eelgrass beds are compiled in the Puget Sound Environmental Atlas, Volumes 1 and 2. Herring and smelt spawning times and locations are outlined in WAC 220-110-240 through 220-110-260 and the Puget Sound Environmental Atlas.

(v) Naturally occurring ponds under twenty acres and their submerged aquatic beds that provide fish or wildlife habitat.

Naturally occurring ponds do not include ponds deliberately designed and created from dry sites, such as canals, detention facilities, wastewater treatment facilities, farmponds, temporary construction ponds (of less than three years duration) and landscape amenities. However, naturally occurring ponds may include those artificial ponds intentionally created from dry areas in order to mitigate conversion of ponds, if permitted by a regulatory authority.

(vi) Waters of the state. Waters of the state are defined in Title 222 WAC, the forest practices rules and regulations. Counties and cities should use the classification system established in WAC 222-16-030 to classify waters of the state.

Counties and cities may consider the following factors when classifying waters of the state as fish and wildlife habitats:

(A) Species present which are endangered, threatened or sensitive, and other species of concern;

(B) Species present which are sensitive to habitat manipulation;

(C) Historic presence of species of local concern;

(D) Existing surrounding land uses that are incompatible with salmonid habitat;

(E) Presence and size of riparian ecosystems;



(F) Existing water rights; and  
 (G) The intermittent nature of some of the higher classes of waters of the state.

(vii) Lakes, ponds, streams, and rivers planted with game fish.

This includes game fish planted in these water bodies under the auspices of a federal, state, local, or tribal program or which supports priority fish species as identified by the department of wildlife.

(viii) State natural area preserves and natural resource conservation areas. Natural area preserves and natural resource conservation areas are defined, established, and managed by department of natural resources.

**WSR 91-07-042**  
**PROPOSED RULES**  
**GAMBLING COMMISSION**  
 [Filed March 18, 1991, 9:04 a.m.]

Continuance of WSR 91-03-062.

Title of Rule: WAC 230-04-022 Certification procedure—Information required from all applicants.

Purpose: Outlines information required from applicants for gambling licenses.

Statutory Authority for Adoption: Chapter 9.46 RCW.

Statute Being Implemented: Chapter 9.46 RCW.

Summary: Clarifies the information required from applicants for gambling licenses.

Name of Agency Personnel Responsible for Drafting and Enforcement: Frank L. Miller, Deputy Director, Lacey, 438-7640; and Implementation: Ronald O. Bailey, Director, Lacey, 438-7640.

Name of Proponent: Washington State Gambling Commission, governmental.

Rule is not necessitated by federal law, federal or state court decision.

Explanation of Rule, its Purpose, and Anticipated Effects: Clarification of requirements for applicants for gambling licenses.

Proposal Changes the Following Existing Rules: The rule seeks to clarify existing requirements.

No small business economic impact statement is required for this proposal by chapter 19.85 RCW.

The agency has considered whether this rule change would require an economic impact statement and has determined it does not. There is no economic impact to small business as a result of this rule proposal.

Hearing Location: Best Western Lakeway Inn, 714 Lakeway Drive, Bellingham, WA 98226, on May 9, 1991, at 10:00 a.m.

Submit Written Comments to: Washington State Gambling Commission, 4511 Woodview Drive S.E., Olympia, WA 98504-8121, by May 8, 1991.

Date of Intended Adoption: May 9, 1991.

March 15, 1991  
 Frank L. Miller  
 Deputy Director

**WSR 91-07-043**  
**ATTORNEY GENERAL OPINION**  
**Cite as: AGO 1991 No. 10**  
 [March 13, 1991]

COUNTIES—SHERIFF—CORONER—MOTOR VEHICLES—  
 USE OF MOTOR VEHICLES FORFEITED BY SHERIFF

RCW 69.50.505 (f)(1) provides that forfeited property may be retained for use by a law enforcement agency of the state. A coroner does not act as a law enforcement agency of the state. Therefore, a coroner is not entitled to use a motor vehicle forfeited pursuant to RCW 69.50.505 (f)(1).

Requested by:

The Honorable Andrew K. Miller  
 Benton County Prosecuting Attorney  
 Benton County Justice Center  
 7320 West Quinault  
 Kennewick, Washington 99336

**WSR 91-07-044**  
**NOTICE OF PUBLIC MEETINGS**  
**EDMONDS COMMUNITY COLLEGE**  
 [Memorandum—March 18, 1991]

Thursday, March 21, 1991  
 Lynnwood Hall, Room 424  
 4:00-7:15

The facilities for this meeting are free of mobility barriers and interpreters for deaf individuals and brailled or taped information for blind individuals will be provided upon request when adequate notice is given.

**WSR 91-07-045**  
**PROPOSED RULES**  
**WASHINGTON STATE PATROL**  
 [Order 91-001—Filed March 18, 1991, 11:33 a.m.]

Original Notice.

Title of Rule: Chapter 446-75 WAC, DNA identification.

Purpose: Implementation of RCW 43.43.752 through 43.43.759 regarding DNA identification systems and procedures.

Statutory Authority for Adoption: RCW 43.43.759.

Statute Being Implemented: RCW 43.43.752 through 43.43.759.

Summary: Implementation of rules relating to DNA identification systems and procedures including collection, analysis, storage, expungement, and use of DNA data.

Reasons Supporting Proposal: Rules are required by RCW 43.43.759 to ensure compatibility of all DNA identification systems statewide and with the Federal Bureau of Investigation; and to prohibit use of DNA data for noncriminal investigations or purposes.



Name of Agency Personnel Responsible for Drafting, Implementation and Enforcement: Lt. Robert Dale, 400 East Union, ER-14, Olympia, 753-0294.

Name of Proponent: Washington State Patrol, governmental.

Rule is not necessitated by federal law, federal or state court decision.

Explanation of Rule, its Purpose, and Anticipated Effects: To prohibit unauthorized use of DNA identification data, to implement statutory requirements, and to ensure compatibility of all systems established and procedures.

Proposal does not change existing rules.

No small business economic impact statement is required for this proposal by chapter 19.85 RCW.

Hearing Location: General Administration Building, 1st Floor Conference Room, on April 30, 1991, at 1:00 p.m.

Submit Written Comments to: Captain Bruce Bjork, Crime Lab Division, 400 East Union, ER-14, Olympia, WA 98504, by April 19, 1991.

Date of Intended Adoption: May 1, 1991.

March 18, 1991  
Ed Crawford  
Deputy Chief

Chapter 446-75 WAC  
DNA IDENTIFICATION

[NEW SECTION]

WAC 446-75-010 DEFINITIONS. (1) "DNA" wherever used in this chapter shall mean deoxyribonucleic acid.

(2) "Convicted felon" wherever used in this chapter shall mean every individual convicted on or after July 1, 1990 in a Washington superior court of a felony defined as a sex offense under RCW 9.94A.030 (29)(a) or a violent offense as defined in RCW 9.94A.030(32).

(3) "DNA identification" wherever used in this chapter shall mean the process for identifying the unique pattern to the chemical structure of the DNA contained in each cell of the human body.

**Reviser's note:** The bracketed material preceding the section above was supplied by the code reviser's office.

[NEW SECTION]

WAC 446-75-020 PURPOSE. The purpose of this chapter is to provide procedures for the operation of DNA identification systems as required by RCW 43.43.758, and to prohibit the improper use of DNA identification data as required by RCW 43.43.759.

**Reviser's note:** The bracketed material preceding the section above was supplied by the code reviser's office.

[NEW SECTION]

WAC 446-75-030 PURPOSES OF DNA IDENTIFICATION. (1) DNA identification systems as authorized by RCW 43.43 shall be used only for two purposes: (a) identification of possible suspects in criminal investigations, and (b) convicted felon identification databanking.

(2) Results from DNA identifications made in response to a criminal investigation shall not be entered into any permanent or temporary databank. Such results shall be returned to the requesting agency.

**Reviser's note:** The bracketed material preceding the section above was supplied by the code reviser's office.

[NEW SECTION]

WAC 446-75-040 DNA IDENTIFICATION SYSTEM ESTABLISHED. The DNA identification system established by the Chief of the Washington State Patrol shall be compatible with the method(s) used by the Federal Bureau of Investigation. Identification

systems established by other local law enforcement agencies shall be compatible to the current Washington State Patrol system.

**Reviser's note:** The bracketed material preceding the section above was supplied by the code reviser's office.

[NEW SECTION]

WAC 446-75-050 DNA IDENTIFICATION SYSTEM ANALYTICAL PROCEDURES. Law enforcement agencies establishing a DNA identification system shall maintain written analytical procedures necessary to complete the analyses. A copy of the analytical procedures shall be forwarded to the Chief of the Washington State Patrol to ensure compatibility with the Washington State Patrol system. The Chief shall approve or disapprove the procedures utilizing the standards set forth for DNA identification by the Federal Bureau of Investigation prior to any implementation by the submitting agency. The appeal process for any disapproval shall be in accordance with the provisions of the Administrative Procedures Act (34.04 WAC).

**Reviser's note:** The bracketed material preceding the section above was supplied by the code reviser's office.

**Reviser's note:** The typographical error in the above section occurred in the copy filed by the agency and appears in the Register pursuant to the requirements of RCW 34.08.040.

[NEW SECTION]

WAC 446-75-060 COLLECTION OF BLOOD FOR DNA DATABANK—PROCEDURES—TIME FRAME. (1) The collection, preservation, and shipment of blood samples obtained from convicted felons pursuant to RCW 43.43.754 for the convicted felon databank program shall be in conformance with the "Protocol for the Collection of Blood for the Convicted Felon DNA Program" as prepared by the Washington State Patrol Crime Laboratory Division. Copies of the current protocol may be obtained from the Washington State Patrol Crime Laboratory Division, Olympia, WA.

(a) If the convicted felon is sentenced to one year or less in jail, the blood sample will be drawn by the county no later than 30 days from the date of conviction. If the convicted felon will spend no time in jail due to time already served, probation or other sentencing by the court, the blood shall be drawn prior to release.

(b) If the convicted felon is sentenced to more than one year in jail the sample will be drawn within 30 days after transfer to the state correctional institution by the Department of Corrections.

(2) Results from DNA identifications made from blood samples obtained from convicted felons under RCW 43.43.754 shall be submitted to the Chief of the Washington State Patrol and entered into the Washington State Patrol DNA databank. Such results shall reside in the databank until expungement pursuant to WAC 446-75-070.

**Reviser's note:** The bracketed material preceding the section above was supplied by the code reviser's office.

[NEW SECTION]

WAC 446-75-070 EXPUNGEMENT OF DNA DATA. (1) A person desiring the destruction of his DNA identification data from a DNA databank shall make his request therefor on a form furnished by the Chief of the Washington State Patrol. The request shall be mailed or delivered to the Washington State Patrol Crime Laboratory Division, Olympia, WA.

(2) The request shall be completed, signed by the person whose record is sought to be expunged. The signature shall be notarized. It shall include the address of the applicant, the printed name and the address of the witness to the applicant's signature and such other information requested on the application as identifies the applicant and the offense for which the request of expungement is made.

(3) The request shall include proof that the person making the request for expungement is the same person whose DNA data is sought to be expunged. Such proof shall include a sworn statement of identity. When requested by the Patrol, fingerprints and a blood sample shall also be required from the applicant.

(4) The request shall include proof that the person making the request has no record as a convicted felon under RCW 43.43.754 or has other lawful grounds for expungement. Such proof shall include a sworn statement from the applicant, and not-guilty or released without

conviction documentation from such criminal charges. Where the finding or release is based on an order of a court, the applicant shall furnish a certified true copy of the court order.

**Reviser's note:** The bracketed material preceding the section above was supplied by the code reviser's office.

**[NEW SECTION]**

WAC 446-75-080 DNA IDENTIFICATION DATA - PROHIBITIONS. The use of any data obtained from DNA identification procedures is prohibited for any research or other purpose not related to a criminal investigation or to improving the operation of the system established by the Washington State Patrol and authorized by RCW 43.43.752 through 43.43.758.

**Reviser's note:** The bracketed material preceding the section above was supplied by the code reviser's office.

**WSR 91-07-046**

**EMERGENCY RULES**

**WASHINGTON STATE PATROL**

[Order 91-001—Filed March 18, 1991, 11:37 a.m.]

Date of Adoption: [March 18, 1991.]

Purpose: Implementation of RCW 43.43.752 through 43.43.759 regarding DNA identification systems and procedures.

Statutory Authority for Adoption: RCW 43.43.759.

Pursuant to RCW 34.05.350 the agency for good cause finds that immediate adoption, amendment, or repeal of a rule is necessary for the preservation of the public health, safety, or general welfare, and that observing the time requirements of notice and opportunity to comment upon adoption of a permanent rule would be contrary to the public interest.

Reasons for this Finding: Implementation of systems and procedures apply to persons convicted of certain offenses after July 1, 1990. Rules must be in effect immediately in order to meet statutory intent.

Effective Date of Rule: Immediately.

March 18, 1991

Ed Crawford  
Deputy Chief

*Chapter 446-75 WAC  
DNA IDENTIFICATION*

**[NEW SECTION]**

WAC 446-75-010 DEFINITIONS. (1) "DNA" wherever used in this chapter shall mean deoxyribonucleic acid.

(2) "Convicted felon" wherever used in this chapter shall mean every individual convicted on or after July 1, 1990 in a Washington superior court of a felony defined as a sex offense under RCW 9.94A.030 (29)(a) or a violent offense as defined in RCW 9.94A.030(32).

(3) "DNA identification" wherever used in this chapter shall mean the process for identifying the unique pattern to the chemical structure of the DNA contained in each cell of the human body.

**Reviser's note:** The bracketed material preceding the section above was supplied by the code reviser's office.

**[NEW SECTION]**

WAC 446-75-020 PURPOSE. The purpose of this chapter is to provide procedures for the operation of DNA identification systems as required by RCW 43.43-758, and to prohibit the improper use of DNA identification data as required by RCW 43.43.759.

**Reviser's note:** The bracketed material preceding the section above was supplied by the code reviser's office.

**[NEW SECTION]**

WAC 446-75-030 PURPOSES OF DNA IDENTIFICATION. (1) DNA identification systems as authorized by RCW 43.43 shall be used only for two purposes: (a) identification of possible suspects in criminal investigations, and (b) convicted felon identification databanking.

(2) Results from DNA identifications made in response to a criminal investigation shall not be entered into any permanent or temporary databank. Such results shall be returned to the requesting agency.

**Reviser's note:** The bracketed material preceding the section above was supplied by the code reviser's office.

**[NEW SECTION]**

WAC 446-75-040 DNA IDENTIFICATION SYSTEM ESTABLISHED. The DNA identification system established by the Chief of the Washington State Patrol shall be compatible with the method(s) used by the Federal Bureau of Investigation. Identification systems established by other local law enforcement agencies shall be compatible to the current Washington State Patrol system.

**Reviser's note:** The bracketed material preceding the section above was supplied by the code reviser's office.

**[NEW SECTION]**

WAC 446-75-050 DNA IDENTIFICATION SYSTEM ANALYTICAL PROCEDURES. Law enforcement agencies establishing a DNA identification system shall maintain written analytical procedures necessary to complete the analyses. A copy of the analytical procedures shall be forwarded to the Chief of the Washington State Patrol to ensure compatibility with the Washington State Patrol system. The Chief shall approve or disapprove the procedures utilizing the standards set forth for DNA identification by the Federal Bureau of Investigation prior to any implementation by the submitting agency. The appeal process for any disapproval shall be in accordance with the provisions of the Administrative Procedures Act (34.04 WAC).

**Reviser's note:** The bracketed material preceding the section above was supplied by the code reviser's office.

**Reviser's note:** The typographical error in the above section occurred in the copy filed by the agency and appears in the Register pursuant to the requirements of RCW 34.08.040.

**[NEW SECTION]**

WAC 446-75-060 COLLECTION OF BLOOD FOR DNA DATABANK—PROCEDURES—TIME FRAME. (1) The collection, preservation, and shipment

of blood samples obtained from convicted felons pursuant to RCW 43.43.754 for the convicted felon databank program shall be in conformance with the "Protocol for the Collection of Blood for the Convicted Felon DNA Program" as prepared by the Washington State Patrol Crime Laboratory Division. Copies of the current protocol may be obtained from the Washington State Patrol Crime Laboratory Division, Olympia, WA.

(a) If the convicted felon is sentenced to one year or less in jail, the blood sample will be drawn by the county no later than 30 days from the date of conviction. If the convicted felon will spend no time in jail due to time already served, probation or other sentencing by the court, the blood shall be drawn prior to release.

(b) If the convicted felon is sentenced to more than one year in jail the sample will be drawn within 30 days after transfer to the state correctional institution by the Department of Corrections.

(2) Results from DNA identifications made from blood samples obtained from convicted felons under RCW 43.43.754 shall be submitted to the Chief of the Washington State Patrol and entered into the Washington State Patrol DNA databank. Such results shall reside in the databank until expungement pursuant to WAC 446-75-070.

**Reviser's note:** The bracketed material preceding the section above was supplied by the code reviser's office.

**[NEW SECTION]**

WAC 446-75-070 EXPUNGEMENT OF DNA DATA. (1) A person desiring the destruction of his DNA identification data from a DNA databank shall make his request therefor on a form furnished by the Chief of the Washington State Patrol. The request shall be mailed or delivered to the Washington State Patrol Crime Laboratory Division, Olympia, WA.

(2) The request shall be completed, signed by the person whose record is sought to be expunged. The signature shall be notarized. It shall include the address of the applicant, the printed name and the address of the witness to the applicant's signature and such other information requested on the application as identifies the applicant and the offense for which the request of expungement is made.

(3) The request shall include proof that the person making the request for expungement is the same person whose DNA data is sought to be expunged. Such proof shall include a sworn statement of identity. When requested by the Patrol, fingerprints and a blood sample shall also be required from the applicant.

(4) The request shall include proof that the person making the request has no record as a convicted felon under RCW 43.43.754 or has other lawful grounds for expungement. Such proof shall include a sworn statement from the applicant, and not-guilty or released without conviction documentation from such criminal charges. Where the finding or release is based on an order of a court, the applicant shall furnish a certified true copy of the court order.

**Reviser's note:** The bracketed material preceding the section above was supplied by the code reviser's office.

**[NEW SECTION]**

WAC 446-75-080 DNA IDENTIFICATION DATA - PROHIBITIONS. The use of any data obtained from DNA identification procedures is prohibited for any research or other purpose not related to a criminal investigation or to improving the operation of the system established by the Washington State Patrol and authorized by RCW 43.43.752 through 43.43.758.

**Reviser's note:** The bracketed material preceding the section above was supplied by the code reviser's office.

**WSR 91-07-047**

**PROPOSED RULES**

**BUILDING CODE COUNCIL**

[Filed March 18, 1991, 1:14 p.m.]

**Original Notice.**

Title of rule: State-wide radon requirements and radon monitoring.

Purpose: To consider the repeal of section 502.2.1 of chapter 51-13 WAC as proposed by the Building Industry Association of Washington in accordance with RCW 34.05.330 and 34.05.340(3).

Statutory Authority for Adoption: RCW 34.05.330, 34.05.340(3), and chapter 19.27 RCW.

Statute Being Implemented: RCW 19.27.190.

Summary: To consider repealing radon monitoring requirements for new residential buildings.

Reasons Supporting Proposal: Appeal filed by the Building Industry Association of Washington in accordance with RCW 34.05.330 and 34.05.340(3).

Name of Agency Personnel Responsible for Drafting: Don Kaiser, Ninth and Columbia Building, Olympia, Washington, (206) 586-2251; Implementation: Linda Ramsey, Ninth and Columbia Building, Olympia, Washington, (206) 586-3423; and Enforcement: Local governments.

Name of Proponent: Building Industry Association of Washington, private.

Rule is not necessitated by federal law, federal or state court decision.

Explanation of Rule, its Purpose, and Anticipated Effects: Proposal, if adopted, would repeal section 502.2.1 of chapter 51-13 WAC which requires that builders provide radon monitor, installation instructions, and radon information sheets in all new residential buildings.

Proposal Changes the Following Existing Rules: Proposal would repeal existing radon monitoring requirements for new residential buildings.

No small business economic impact statement is required for this proposal by chapter 19.85 RCW.

Repeal of the rule would reduce costs to builders by \$10 to \$20 per residential unit.

Hearing Location: Spokane City Hall, West 808 Spokane Falls Boulevard, Spokane, WA 99204, (509) 456-2612, on May 10, 1991, at 9:00 a.m.

Submit Written Comments to: State Building Code Council, Ninth and Columbia Building, Olympia, Washington 98504-4151, by May 9, 1991.

Date of Intended Adoption: May 10, 1991.  
March 15, 1991  
Gene J. Colin  
Chair

**WSR 91-07-049**  
**PERMANENT RULES**  
**DEPARTMENT OF HEALTH**  
**(Board of Nursing)**

[Order 116B—Filed March 18, 1991, 2:46 p.m.]

AMENDATORY SECTION (Amending WSR 91-01-102, filed 12/18/90, effective 7/1/91)

**WAC 51-13-502 STATE-WIDE RADON REQUIREMENTS.**

**502.1: Crawlspace**

**502.1.1 General:** All crawlspaces shall comply with the requirements of this section.

**502.1.2 Ventilation:** All crawlspaces shall be ventilated as specified in section 2516 (c) of the Washington State Uniform Building Code (chapter 51-16 WAC).

If the installed ventilation in a crawlspace is less than one square foot for each three hundred square feet of crawlspace area, or if the crawlspace vents are equipped with operable louvers, a radon vent shall be installed from a point between the ground cover and soil. The radon vent shall be installed in accordance with sections 503.2.6 and 503.2.7.

**502.1.3 Crawlspace plenum systems:** In crawlspace plenum systems used for providing supply or return air for an HVAC system, aggregate, a soil gas retarder membrane and a radon vent pipe shall be installed in accordance with section 503.2.

In addition, a radon vent fan shall be installed and activated. The fan shall be located as specified in section 503.2.7. The fan shall be capable of providing at least one hundred cfm at one inch water column static pressure.

**502.2 Radon monitoring**

~~((502.2.1 Three month etched track radon monitoring: A three month etched track radon monitor, installation instructions, and radon information sheets shall be provided by the builder at the final inspection to all single family residences and to all first floor dwelling units in multi-unit structures. It is not the responsibility of the builder to administer the radon test.))~~

**WSR 91-07-048**  
**PERMANENT RULES**  
**DEPARTMENT OF HEALTH**  
[Order 132—Filed March 18, 1991, 2:41 p.m.]

Date of Adoption: February 4, 1991.  
Purpose: A housekeeping action to transfer rules to Title 246 WAC.

Citation of Existing Rules Affected by this Order: See Recodification Section below.

Statutory Authority for Adoption: RCW 43.70.040.

Pursuant to notice filed as WSR 90-22-094 on November 7, 1990.

Effective Date of Rule: Thirty-one days after filing.

February 4, 1991  
Pam Campbell Mead  
for Kristine M. Gebbie  
Secretary

RECODIFICATION SECTION

The following section is being recodified:

308-120-275 as 246-839-990

Date of Adoption: February 22, 1991.

Purpose: A housekeeping action to transfer rules to Title 246 WAC.

Citation of Existing Rules Affected by this Order: See Recodification Sections below.

Statutory Authority for Adoption: WAC 246-839-010, 246-839-020, 246-839-030, 246-839-040, 246-839-050, 246-839-060, 246-839-070, 246-839-080 and 246-839-090 is RCW 18.88.080; WAC 246-839-100 is RCW 70.24.270; WAC 246-839-110, 246-839-120, 246-839-130, 246-839-300, 246-839-310, 246-839-320, 246-839-330, 246-839-340, 246-839-350, 246-839-360, 246-839-370, 246-839-400, 246-839-410, 246-839-420, 246-839-430, 246-839-440, 246-839-450, 246-839-505, 246-839-506, 246-839-525, 246-839-530, 246-839-535, 246-839-540, 246-839-545, 246-839-550, 246-839-555, 246-839-560, 246-839-565, 246-839-570 and 246-839-575 is RCW 18.88.080; WAC 246-839-700, 246-839-710, 246-839-720, 246-839-730 and 246-839-740 is RCW 18.88.080 and 18.130.050; WAC 246-839-750, 246-839-760, 246-839-770 and 246-839-780 is RCW 18.130.050; WAC 246-839-800, 246-839-810, 246-839-820 and 246-839-830 is RCW 18.88.080; WAC 246-841-400, 246-841-410, 246-841-420, 246-841-430, 246-841-440, 246-841-450, 246-841-460, 246-841-470, 246-841-480, 246-841-490, 246-841-500 and 246-841-510 is RCW 18.88A.060; and WAC 246-842-100, 246-842-110, 246-842-120, 246-842-130, 246-842-140, 246-842-150, 246-842-160, 246-842-170, 246-842-180, 246-842-190, 246-842-200 and 246-842-210 is RCW 18.88A.060.

Pursuant to notice filed as WSR 90-24-072 on December 5, 1990.

Effective Date of Rule: Thirty-one days after filing.

March 11, 1991

Patricia O. Brown  
Acting Executive Secretary

RECODIFICATION SECTION

The following sections are being recodified as chapter 246-839 WAC:

Chapter 246-839 WAC  
Registered nurses

308-120-100 as 246-839-010

LICENSURE, RENEWAL, AND INACTIVE STATUS

308-120-170 as 246-839-020

308-120-161 as 246-839-030

308-120-162 as 246-839-040

308-120-163 as 246-839-050

308-120-164 as 246-839-060

308-120-165 as 246-839-070

308-120-166 as 246-839-080

308-120-168 as 246-839-090  
 308-120-610 as 246-839-100  
 308-120-180 as 246-839-110  
 308-120-185 as 246-839-120  
 308-120-186 as 246-839-130

**ADVANCED PRACTICE**

308-120-300 as 246-839-300  
 308-120-305 as 246-839-310  
 308-120-315 as 246-839-320  
 308-120-325 as 246-839-330  
 308-120-335 as 246-839-340  
 308-120-338 as 246-839-350  
 308-120-345 as 246-839-360  
 308-120-360 as 246-839-370  
 308-120-400 as 246-839-400  
 308-120-410 as 246-839-410  
 308-120-420 as 246-839-420  
 308-120-430 as 246-839-430  
 308-120-440 as 246-839-440  
 308-120-450 as 246-839-450

**NURSING EDUCATION**

308-120-505 as 246-839-505  
 308-120-506 as 246-839-506  
 308-120-525 as 246-839-525  
 308-120-530 as 246-839-530  
 308-120-535 as 246-839-535  
 308-120-540 as 246-839-540  
 308-120-545 as 246-839-545  
 308-120-550 as 246-839-550  
 308-120-555 as 246-839-555  
 308-120-560 as 246-839-560  
 308-120-565 as 246-839-565  
 308-120-570 as 246-839-570  
 308-120-575 as 246-839-575

**STANDARDS OF PRACTICE**

308-120-700 as 246-839-700  
 308-120-710 as 246-839-710  
 308-120-720 as 246-839-720  
 308-120-730 as 246-839-730  
 308-120-740 as 246-839-740

**SUBSTANCE ABUSE MONITORING PROGRAM**

308-120-750 as 246-839-750  
 308-120-760 as 246-839-760  
 308-120-770 as 246-839-770  
 308-120-780 as 246-839-780

**SCOPE OF PRACTICE**

308-120-800 as 246-839-800  
 308-120-270 as 246-839-810  
 308-120-620 as 246-839-820  
 308-120-810 as 246-839-830

**FEES****RECODIFICATION SECTION**

The following sections are being recodified as chapter 246-841 WAC:

**Chapter 246-841 WAC  
Nursing assistants**

308-173-210 as 246-841-400  
 308-173-220 as 246-841-410  
 308-173-230 as 246-841-420  
 308-173-240 as 246-841-430  
 308-173-245 as 246-841-440  
 308-173-250 as 246-841-450  
 308-173-255 as 246-841-460  
 308-173-260 as 246-841-470  
 308-173-265 as 246-841-480  
 308-173-270 as 246-841-490  
 308-173-275 as 246-841-500  
 308-173-280 as 246-841-510

**RECODIFICATION SECTION**

The following sections are being recodified as chapter 246-842 WAC:

**Chapter 246-842 WAC****Nursing assistants—Addendum for nursing homes**

308-121-110 as 246-842-100  
 308-121-120 as 246-842-110  
 308-121-130 as 246-842-120  
 308-121-140 as 246-842-130  
 308-121-145 as 246-842-140  
 308-121-150 as 246-842-150  
 308-121-155 as 246-842-160  
 308-121-160 as 246-842-170  
 308-121-165 as 246-842-180  
 308-121-170 as 246-842-190  
 308-121-175 as 246-842-200  
 308-121-180 as 246-842-210

**REPEALER**

The following section of the Washington Administrative Code is repealed:

WAC 308-120-365 CRN RECOGNITION AT EFFECTIVE DATE.

**WSR 91-07-050****PERMANENT RULES****DEPARTMENT OF FISHERIES**

[Order 91-12—Filed March 18, 1991, 4:40 p.m.]

Date of Adoption: March 1, 1991.

Purpose: Commercial fishing rules.

Citation of Existing Rules Affected by this Order: Amending WAC 220-44-050.

Statutory Authority for Adoption: RCW 75.08.080.

Pursuant to notice filed as WSR 91-03-152 on January 23, 1991.

Changes Other than Editing from Proposed to Adopted Version: Deletion of effective date.

Effective Date of Rule: Thirty-one days after filing.

March 13, 1991

R. Kahler Martinson  
for Joseph R. Blum  
Director

AMENDATORY SECTION (Amending Order 90-26, filed 6/21/90, effective 7/22/90)

WAC 220-44-050 COASTAL BOTTOMFISH CATCH LIMITS. It is unlawful to possess, transport through the waters of the state, or land in any Washington state port bottomfish taken from Coastal Marine Fish-Shellfish Management and Catch Reporting Areas 58B, 59A, 59B, 60A, 61, 62, or 63 in excess of the amounts or less than the minimum sizes shown below for the species indicated. All weights are in round pounds:

(1) Widow rockfish (*Sebastes entomelas*) - ~~((+5,000))~~ 10,000 pounds per vessel trip per calendar week, defined as Wednesday through the following Tuesday except that a fisherman having made a ~~((+1990))~~ 1991 declaration of intent may make one landing of not more than ~~((25,000))~~ 20,000 pounds biweekly, defined as Wednesday through the second Tuesday following. There is no limit on the number of landings of less than 3,000 pounds.

(2) Shortbelly rockfish (*Sebastes jordani*) - no maximum poundage per vessel trip; no minimum size.

(3) Pacific Ocean perch (*Sebastes alutus*) - No restriction on landing up to 1,000 pounds per vessel trip. Landings above 1,000 pounds allowed only if Pacific Ocean perch represent 20 percent or less of total weight of fish on board. Under no circumstances may a vessel land more than 3,000 pounds of Pacific Ocean perch in any one vessel trip.

(4) All other species of rockfish (includes all *Sebastes* spp. except Pacific Ocean perch, widow rockfish, shortbelly rockfish and thornyhead or idiot rockfish) - 25,000 pounds of all other species combined per vessel trip per calendar week, defined as Wednesday through the following Tuesday, of which no more than ~~((7,500))~~ 5,000 pounds may be yellowtail rockfish (*Sebastes flavidus*), except that a fisherman having made a ~~((+1990))~~ 1991 declaration of intent may make either one landing of no more than 50,000 pounds of all other species combined per vessel trip biweekly, defined as Wednesday through the second Tuesday following, of which no more than ~~((+15,000))~~ 10,000 pounds may be yellowtail rockfish, or two landings of not more than 12,500 pounds of all other species in any one calendar week of which not more than ~~((3,750))~~ 2,500 pounds in any one landing may be yellowtail rockfish. It is unlawful for any vessel to make other than one landing in excess of 3,000 pounds of other rockfish species in any calendar week, if no declaration to land other species of rockfish twice weekly has been made.

(5) Deepwater complex: Sablefish, Dover Sole and Thornyhead or Idiot Rockfish (*Sebastes* spp.) - Fishers are limited to 27,500 pounds of the deepwater complex of which no more than 7,500 pounds can be Thornyhead rockfish, per vessel trip, per calendar week, defined as Wednesday through the following Tuesday, except that a fisher having made a 1991 declaration of intent may make either one landing of no more than 55,000 pounds of the deepwater complex of which no more than 15,000 pounds can be Thornyhead rockfish, per vessel trip biweekly, defined as Wednesday through

the second Tuesday following or two landings of not more than 13,750 pounds of the deepwater complex of which no more than 3,750 pounds can be Thornyhead rockfish, in any one calendar week. If no declaration of intent to land twice weekly has been made, then it is unlawful for any vessel to make more than one landing in excess of 4,000 pounds of the deepwater complex except sablefish landings are limited to 1,000 pounds.

The following limits apply to sablefish taken under this subsection.

(a) Trawl vessels - ~~((No trip limit:))~~ No restrictions on landing up to 1,000 pounds per vessel trip. Landings above 1,000 pounds allowed only if sablefish represent 25 percent or less of the total combined round weight of the deepwater complex ~~((Sablefish, Dover Sole, Arrowtooth Flounder and Thornyhead or Idiot Rockfish))~~ on board. To convert sablefish to round weight from dressed weight multiply the dressed weight by ~~((+75))~~ 1.6. Sablefish minimum size 22 inches in length, unless dressed in which case minimum size 15.5 inches in length from the anterior insertion of the first dorsal fin to the tip of the tail. Trawl vessels are allowed an incidental sablefish catch less than the minimum size of 1,000 pounds or 25 percent of the total combined round weight of the deepwater complex, but not to exceed 5,000 pounds per trip. This undersize sablefish incidental allowance is inclusive in the trip limit for the deepwater complex.

(b) Nontrawl vessels - No trip limit. Minimum size 22 inches in length, unless dressed, in which case minimum size 15.5 inches in length from the anterior insertion of the first dorsal fin to the tip of the tail. Nontrawl vessels are allowed an incidental catch less than the minimum size of 1,500 pounds ~~((:))~~ round weight ~~((or 3% round weight of all sablefish on board, whichever is greater,))~~ per trip. To convert to round weight from dressed weight multiply the dressed weight by ~~((+75))~~ 1.6.

(6) ~~((+1990))~~ 1991 Declarations of intent - A ~~((+1990))~~ 1991 declaration must be made to make other than one vessel trip per week and land in excess of the minimum amounts as provided for in this section. The new declaration form must be completed as provided for in this subsection, and is binding for a minimum of four weeks after the first Wednesday following the declaration. The ~~((+1990))~~ 1991 declaration of intent to make other than one vessel trip per week must be mailed or delivered to the Department of Fisheries, 115 General Administration Building, Olympia, WA 98504, and must be received prior to the beginning of such fishing. The declaration of intent must contain the name and address of the fisherman, the name and registration number of the vessel, the date on which such fishing will commence and must be signed and dated by the fisherman. The fisherman may return to the one vessel trip per calendar week fishing by filing a declaration of intent to stop fishing other than once weekly with the department in the above manner once the four-week period has passed. The declaration to stop such fishing and begin one vessel trip per calendar week fishing must be received prior to the beginning of the week in which the one vessel trip per calendar week fishing will resume. The date of first landing will determine the beginning of biweekly periodicity.

((~~Biweekly periodicity will restart after a landing that occurs more than four calendar weeks after the immediate prior landing.~~)) A calendar week is defined as Wednesday through the following Tuesday.

(7) It is unlawful during unloading of the catch and prior to its being weighed or leaving the unloading facility to intermix with any other species a species or category of bottomfish having a vessel trip limit.

(8) For purposes of this section, a vessel trip is defined as having occurred upon the initiation of transfer of catch from the fishing vessel, and all fish aboard the vessel are considered part of the vessel trip limit at the initiation of transfer of catch.

**WSR 91-07-051**  
**PROPOSED RULES**  
**GAMBLING COMMISSION**  
[Filed March 19, 1991, 11:41 a.m.]

Supplemental Notice to WSR 91-07-018.

Title of Rule: WAC 230-30-075 Minimum percentage of prizes for certain gambling activity.

Purpose: To request an increase in the amount allowed to be expended for merchandise prizes in punchboard and pull tab games and lowers the mark-up allowed from 50% to 40%.

Statutory Authority for Adoption: RCW 9.46.070(11).

Statute Being Implemented: Chapter 9.46 RCW.

Summary: Allows an increase from \$300 to \$400 in the amount to be expended for merchandise prizes and lowers the mark-up allowed from 50% to 40%.

Name of Agency Personnel Responsible for Drafting and Enforcement: Frank L. Miller, Deputy Director, Lacey, 438-7640; and Implementation: Ronald O. Bailey, Director, Lacey, 438-7640.

Name of Proponent: Washington State Licensed Beverage Association, private.

Rule is not necessitated by federal law, federal or state court decision.

Explanation of Rule, its Purpose, and Anticipated Effects: The petitioner requests an increase in the amount allowed to be expended for merchandise prizes from \$300 to \$400 in order to: Meet rising costs of quality prizes; stimulate the market; and offer better prizes to the player.

Proposal Changes the Following Existing Rules: The proposed change expands the scope of an existing rule.

No small business economic impact statement is required for this proposal by chapter 19.85 RCW.

The agency has considered whether this rule change would create an economic impact on small businesses as defined by chapter 19.85 RCW. It has determined there is no economic impact to small business as a result of these proposals.

Hearing Location: Best Western Lakeway Inn, 714 Lakeway Drive, Bellingham, WA 98226, on May 9, 1991, at 10:00 a.m.

Submit Written Comments to: Washington State Gambling Commission, 4511 Woodview Drive S.E., Olympia, WA 98504-8121, by May 8, 1991.

Date of Intended Adoption: May 9, 1991.

March 19, 1991  
Sharon Tolton  
Rules Coordinator

AMENDATORY SECTION (Amending Order 154, filed 10/14/85)

WAC 230-30-075 MINIMUM PERCENTAGE OF PRIZES FOR CERTAIN GAMBLING ACTIVITIES. No operator shall put out for play and no distributor or manufacturer of punchboards and pull tabs shall sell or otherwise provide to any person in this state or for use in this state any punchboard or pull tab series that does not contain the following minimum percentage in prizes:

(1) Punchboards - a minimum of 60 percent respecting each punchboard placed out for public play.

(2) Pull tabs - a minimum of 60 percent respecting each series of pull tabs placed out for public play.

(3) For the purpose of determining the percentage of prizes offered on any punchboard, or in any pull tab series under this section, total merchandise prizes shall be computed at the amount actually paid therefor by the licensed operator plus ~~((50))~~ 40 percent of that actual cost.

(4) Single cash prized on punchboards/pull tabs shall not exceed:

(a) Two hundred in cash; or

(b) A merchandise prize, or combination merchandise prize, for which the operator has not expended more than ~~((three))~~ four hundred dollars.

(5) Multiple winners on an individual pull tab or punch shall not exceed the single cash or merchandise prize limit in (4) above.

**Reviser's note:** RCW 34.05.395 requires the use of underlining and deletion marks to indicate amendments to existing rules. The rule published above varies from its predecessor in certain respects not indicated by the use of these markings.

**WSR 91-07-052**  
**NOTICE OF PUBLIC MEETINGS**  
**HARDWOODS COMMISSION**  
[Memorandum—March 15, 1991]

There will be a meeting of the Washington State Hardwoods Commission on March 20, 1991, 10:00 a.m. until 2:00 p.m. at the O'Brien Building, Hearing Room "D", Olympia, Washington.

**WSR 91-07-053**  
**PERMANENT RULES**  
**OFFICE OF**  
**INSURANCE COMMISSIONER**  
[Order R 91-1—Filed March 19, 1991, 11:59 a.m.]

Date of Adoption: March 19, 1991.

Purpose: Repeal regulations that have become obsolete due to amendments of authorizing statutes.

Citation of Existing Rules Affected by this Order: Repealing WAC 284-44-400 and 284-46-010.

Statutory Authority for Adoption: RCW 48.02.060.

Pursuant to notice filed as WSR 91-04-057 on February 5, 1991.

Changes Other than Editing from Proposed to Adopted Version: Did not repeal WAC 284-14-010 as proposed, section remains unchanged.

Effective Date of Rule: Thirty-one days after filing.  
 March 19, 1991  
 Dick Marquardt  
 Insurance Commissioner  
 by Roger Polzin  
 Deputy Commissioner

Statutory Authority for Adoption: RCW 41.06.040 and 41.06.150.  
 Pursuant to notice filed as WSR 91-05-082 on February 20, 1991.  
 Effective Date of Rule: May 1, 1991.

March 15, 1991  
 Dee W. Henderson  
 Secretary

**REPEALER**

The following section of the Washington Administrative Code is repealed:

WAC 284-44-400 ASSESSMENTS FOR EXAMINATION COSTS.

**REPEALER**

The following section of the Washington Administrative Code is repealed:

WAC 284-46-010 ASSESSMENTS FOR EXAMINATION COSTS.

**AMENDATORY SECTION** (Amending Order 326, filed 7/25/89, effective 8/25/89)

WAC 356-18-112 SHARED LEAVE. (1) The purpose of the state leave sharing program is to permit state employees to donate vacation leave to a fellow ((permanent)) state employee who is suffering from or has a relative or household member suffering from an extraordinary or severe illness, injury, impairment, or physical or mental condition which has caused or is likely to cause the employee to take leave without pay or terminate his or her employment. An employee is eligible to request participation in the shared leave program when the employee is able to use accrued vacation leave. For purposes of the Washington state leave sharing program, the following definitions apply:

(a) "Employee" means any employee who is entitled to accrue sick leave or vacation leave and for whom accurate leave records are maintained.

((a)) (b) "Employee's relative" normally shall be limited to the employee's spouse, child, step child, grandchild, grandparent, or parent.

((b)) (c) "Household members" is defined as persons who reside in the same home who have reciprocal duties to and do provide financial support for one another. This term shall include foster children and legal wards even if they do not live in the household. The term does not include persons sharing the same general house, when the living style is primarily that of a dormitory or commune.

((c)) (d) "Severe" or "extraordinary" condition is defined as serious or extreme and/or life threatening.

(2) An employee may be eligible to receive shared leave under the following conditions:

(a) The employee's agency head determines that the employee meets the criteria described in this section.

(b) The employee is not eligible for time loss compensation under chapter 51.32 RCW. If the time loss claim is approved at a later time, all leave received shall be returned to the donors, and the employee will return any and all overpayments to the agency.

(c) The employee has abided by agency policies regarding the use of sick leave.

(d) Donated vacation leave is transferable between employees in different state agencies with the agreement of both agency heads.

(3) An employee may donate vacation leave to another employee only under the following conditions:

(a)(i) The receiving employee has exhausted, or will exhaust, his or her vacation leave, and sick leave due to an illness, injury, impairment, or physical or mental condition, which is of an extraordinary or severe nature, and involves the employee, the employee's relative or household member; and

**WSR 91-07-054**

**PROPOSED RULES**

**PERSONNEL BOARD**

[Filed March 19, 1991, 2:05 p.m.]

Continuance of WSR 91-04-046.

Title of Rule: Amending WAC 356-15-020 Work period designations.

Purpose: This rule establishes guidelines for the State Personnel Board to assign specific work period designations to each class.

Other Identifying Information: Schedule alternate work period designations.

Statutory Authority for Adoption: RCW 41.06.040.

Statute Being Implemented: RCW 41.06.150.

Hearing Location: Department of Personnel, 521 Capitol Way South, Olympia, WA 98504, on April 11, 1991, at 10:00 a.m.

Submit Written Comments to: Dorothy Gerard, P.O. Box 1789, Mailstop FE-11, Olympia, WA 98504, by April 9, 1991.

Date of Intended Adoption: April 11, 1991.

March 19, 1991

Dee W. Henderson

Secretary

**WSR 91-07-055**

**PERMANENT RULES**

**PERSONNEL BOARD**

[Order 371—Filed March 19, 1991, 2:08 p.m., effective May 1, 1991]

Date of Adoption: March 14, 1991.

Purpose: These rules describe the state leave sharing program. They also describe the reasons for extending trial service and probationary periods.

Citation of Existing Rules Affected by this Order: Amending WAC 356-18-112, 356-30-260, and 356-30-305.



(ii) The condition has caused, or is likely to cause, the employee to go on leave without pay or terminate state employment; and

(iii) The agency head permits the leave to be shared with an eligible employee.

(b) The donating employee may donate any amount of vacation leave provided the donation does not cause the employee's vacation leave balance to fall below eighty hours.

(c) Employees may not donate excess vacation leave that the donor would not be able to take due to an approaching anniversary date.

(4) The agency head shall determine the amount of donated leave an employee may receive and may only authorize an employee to use up to a maximum of two hundred sixty one days of shared leave during total state employment, except that a non-permanent employee who is eligible to use accrued vacation leave may not use shared leave beyond the earlier date of:((:))

(a) the termination date specified in the non-permanent employee's appointment letter, or

(b) nine months or 1560 non-overtime hours from date of appointment to the non-permanent position; unless extended by the director per WAC 356-30-065(4), 356-30-067(6), and 356-30-140(6).

(5) The agency head shall require the employee to submit, prior to approval or disapproval, a medical certificate from a licensed physician or health care practitioner verifying the severe or extraordinary nature and expected duration of the condition.

(6) Any donated leave may only be used by the recipient for the purposes specified in this section.

(7) The receiving employee shall be paid his or her regular rate of pay; therefore, one hour of shared leave may cover more or less than one hour of the recipient's salary. The calculation of the recipient's leave value shall be in accordance with office of financial management policies, regulations, and procedures. The dollar value of the leave is converted from the donor to the recipient. The leave received will be coded as shared leave and be maintained separately from all other leave balances.

(8) All forms of paid leave available for use by the recipient must be used prior to using shared leave.

(9) Any shared leave not used by the recipient during each incident/occurrence as determined by the agency director shall be returned to the donor(s). The shared leave remaining will be divided among the donors on a prorated basis based on the original donated value and returned at its original donor value and reinstated to each donor's vacation leave balance.

(10) All donated leave must be given voluntarily. No employee shall be coerced, threatened, intimidated, or financially induced into donating vacation leave for purposes of this program.

(11) Agencies shall maintain records which contain sufficient information to provide for legislative review.

**AMENDATORY SECTION** (Amending Order 295, filed 2/19/88, effective 4/1/88)

**WAC 356-30-260 PROBATIONARY PERIOD—PROVISIONS—STATUS OF EMPLOYEE.** (1) Employees who receive appointments to permanent positions from the open competitive register and the reemployment register shall serve a probationary period of six to twelve months as determined by the personnel board. The personnel board shall designate a probationary period of six months for all positions in a class unless they determine that job requirements of the class require a longer period (up to twelve months) to provide adequate training and/or evaluation. The personnel board shall apply the following criteria for approving probationary periods of longer than six months:

(a) The work of the majority of the positions in the class is of such a nature that performance of the full range of duties cannot be properly evaluated within six months after an appointment.

OR

(b) Work of the class is cyclical in nature and the workload cycle cannot be completed within six months after an appointment.

OR

(c) Work is of such a nature that extended formalized training is required prior to the full assumption of duties.

All positions in a class shall have the same probationary period.

(2) All persons at time of appointment shall be notified in writing by the agency of the length of their probationary period. When the probationary period for a class is increased beyond six months, the increased probationary period shall apply only to persons appointed after the effective date of the change.

(3) The probationary period will provide the appointing authority with the opportunity to observe a new employee's work, to train and aid the new employee in adjustment to the position, and to terminate any employee whose work performance fails to meet the required standards.

(4) Employees who, during their probationary period, go on leave without pay shall have their probationary period extended by the number of calendar days they are on leave without pay including any intervening non-working days.

(5) Employees shall have their probationary period extended by the number of calendar days in excess of 30 in which the employee is not at work including any intervening nonwork days if:

(a) Work is missed due to sick leave, vacation leave, military training leave, shared leave or miscellaneous leave; or

(b) Work is missed by employees of the departments of social and health services, corrections or veterans affairs due to an assault that occurred on the job and who are receiving compensation in an amount equal to full pay, as provided in chapters 72.01 and 72.09 RCW; or

(c) Work is missed due to any combination of leave identified in (5)(a) and (b) of this section which when added together exceeds 30 calendar days.

(6) Work missed during the probationary period due to holidays shall be counted as part of the required probationary period.

(7) Permanent appointment of a probationary employee shall be automatic unless the person is dismissed under provision of WAC 356-30-270.

(8) Veterans and their widows who have not remarried and are in probationary status will be granted seniority preference only within ranks of probationary employees and will not be granted preference within the ranks of the permanent employees until they acquire permanent status.

**AMENDATORY SECTION** (Amending Order 295, filed 2/19/88, effective 4/1/88)

**WAC 356-30-305 TRIAL SERVICE PERIOD—PROVISION.** (1) Employees appointed from a voluntary demotion register to a class not previously held, a promotional register, or from the inter-system employment register shall serve a trial service period of six months. The trial service period will provide the appointing authority with the opportunity to observe the employee's work and to train and aid the employee in adjustment to the position, and to revert such an employee whose work performance fails to meet required standards. Reversions shall be under the provisions of WAC 356-30-320.

(2) Employees who during their trial service period go on leave without pay shall have their trial service period extended by the number of calendar days they are on leave without pay, including any intervening nonworking days.

(3) Employees shall have their trial service period extended by the number of calendar days in excess of 30 in which the employee is not at work, including any intervening nonwork days, if:

(a) Work is missed due to sick leave, vacation leave, military training leave, shared leave or miscellaneous leave; or

(b) Work is missed by employees of the departments of social and health services, corrections or veterans affairs due to an assault that occurred on the job and who are receiving compensation in an amount equal to full pay, as provided in chapters 72.01 and 72.09 RCW; or

(c) Work is missed due to any combination of leave identified in (3)(a) and (b) of this section which when added together exceed 30 calendar days.

(4) Work missed during the trial service period due to holidays shall be counted as part of the required trial service period.

(5) When an employee is appointed to a higher class while serving in a trial service period, the trial service period for the lower class and the new trial service period for the higher class shall overlap provided that the higher and lower classes are in the same or a closely related field. The employee shall complete the terms of the original trial service period and be given permanent status in the lower class. Such employees will also be

granted the rights normally accruing to trial service for the remainder of the trial service period in the higher class.

**WSR 91-07-056**  
**PROPOSED RULES**  
**DEPARTMENT OF HEALTH**  
**(Board of Pharmacy)**

[Filed March 19, 1991, 2:50 p.m.]

Original Notice.

Title of Rule: WAC 360-20-220 Retail sale tamper resistant packaging information.

Purpose: Require every retail establishment which has nonprescription drug products accessible to the public while held for sale shall cooperate with the board's consumer awareness program to increase public knowledge of methods to detect tampered products.

Statutory Authority for Adoption: RCW 18.64.005.

Statute Being Implemented: RCW 18.64.005(7).

Summary: These rules will require retail establishments which have nonprescription drug products accessible to the public while held for sale to cooperate with the board's consumer awareness program to increase public knowledge of detecting tampered products. Retail establishments will be required to post signs and provide written information handouts.

Reasons Supporting Proposal: These rules are being proposed in response to the recent drug product tampering.

Name of Agency Personnel Responsible for Drafting, Implementation and Enforcement: D. H. Williams, 1300 Quince Street S.E., EY-20, Olympia, WA 98504, 3-6834.

Name of Proponent: Washington State Board of Pharmacy, governmental.

Rule is not necessitated by federal law, federal or state court decision.

Explanation of Rule, its Purpose, and Anticipated Effects: Rule will require every retail establishment which has nonprescription drug products accessible to the public while held for sale to cooperate with the board's consumer awareness program. Such retail establishments will display at least one sign or poster describing the importance of consumer attention to tamper resistant packaging features, provide the public with informational brochures, and designate a contact person who can respond to consumer inquiries about tamper resistant packaging. This rule is expected to increase the public knowledge of methods to detect tampered products.

Proposal does not change existing rules.

No small business economic impact statement is required for this proposal by chapter 19.85 RCW.

Hearing Location: Garden Wyndham Hotel, 18118 Pacific Highway South, Seattle, WA, on April 25, 1991, at 10:00 a.m.

Submit Written Comments to: D. H. Williams, 1300 Quince Street S.E., EY-20, Olympia, WA 98504, by April 23, 1991.

Date of Intended Adoption: April 25, 1991.

March 18, 1991  
Donald H. Williams  
Executive Director

#### NEW SECTION

WAC 360-20-220 RETAIL SALE TAMPER RESISTANT PACKAGING INFORMATION. Every retail establishment which has nonprescription drug products accessible to the public while held for sale shall cooperate with the board's consumer awareness program to increase public knowledge of methods to detect tampered products. Such retail establishment shall:

- (1) Display at least one sign or poster describing the importance of consumer attention to tamper resistant packaging features;
- (2) Provide the public with written information handouts about the steps consumers can take in protecting themselves from product tampering;
- (3) Designate a contact person who can respond to consumer inquiries about tamper resistant packaging.

**WSR 91-07-057**  
**PROPOSED RULES**  
**DEPARTMENT OF HEALTH**  
**(Hearing Aid Council)**  
[Filed March 19, 1991, 2:53 p.m.]

Original Notice.

Title of Rule: WAC 308-50-295 Defamation of competitors; and 308-50-310 Personal disclosure.

Purpose: To amend rules relating to hearing aid fitter/dispensers.

Statutory Authority for Adoption: RCW 18.35.161.

Statute Being Implemented: Chapter 18.35 RCW.

Summary: WAC 308-50-295, to amend rule to more fully describe unethical methods of competition; and WAC 308-50-310, to instruct licensees to include specific information on direct mail or other advertising initiated by the licensee.

Name of Agency Personnel Responsible for Drafting, Implementation and Enforcement: Olivia Guebara, 1300 Quince Street, Olympia, WA 98504, 753-3199.

Name of Proponent: Hearing Aid Council, governmental.

Rule is not necessitated by federal law, federal or state court decision.

Explanation of Rule, its Purpose, and Anticipated Effects: Amending WAC 308-50-295, adds an unfair practice to the existing description and will warn licensees of unethical conduct in methods of competition in the hearing aid fitting and dispensing business; and WAC 308-50-310, adds the location of the licensee's principle establishment to required disclosure and adds direct mail or other advertising to the requirement for personal disclosure. This will effect better protection for consumers.

Proposal Changes the Following Existing Rules: WAC 308-50-295, adds an unfair practice to the existing description and will warn licensees of unethical conduct in methods of competition; and WAC 308-50-310, adds the location of the licensee's principle establishment

to required disclosure and adds direct mail or other advertising to the requirement for personal disclosure.

No small business economic impact statement is required for this proposal by chapter 19.85 RCW.

The present proposed rules do not require a statement because they will have minor or negligible economic impact.

Hearing Location: Holiday Inn, 800 Rainier Avenue South, Renton, WA 98055, on May 2, 1991, at 1:30 p.m.

Submit Written Comments to: Leslie Baldwin, 1300 Quince Street S.E., Mailstop EY-16, Olympia, WA 98504, by May 1, 1991.

Date of Intended Adoption: May 2, 1991.

March 19, 1991  
Olivia S. Guebara  
for Ralph G. Lenhard  
Chairman

#### AMENDATORY SECTION (Amending Order PL 469, filed 7/3/84)

WAC 308-50-295 UNFAIR OR DECEPTIVE PRACTICES, UNETHICAL CONDUCT AND UNFAIR METHODS OF COMPETITION—DEFAMATION OF COMPETITORS OR FALSE DISPARAGEMENT OF THEIR PRODUCTS. (1) It is an unfair trade practice to defame competitors by falsely imputing to them dishonorable conduct, inability to perform contracts, questionable credit standing, or by other false representations, or falsely to disparage the products of competitors in any respect, or their testing procedures, testing equipment, business methods, selling prices, values, credit terms, policies, or services, or to knowingly intervene in any way with any contractual agreement between a competitor and his/her hearing aid purchaser, or to try to influence the purchaser to cancel the contract, or to attempt to induce the purchaser to cancel the contract by offering a lower price or by any other act of intervention.

(Note: The use of "bait" or "blind" advertisements as a means of accomplishing such defamation or false disparagement is deemed to be within the prohibitions of this rule.)

(2) Under this rule, it is an unfair trade practice for an industry member:

- (a) To display competitive products in his show window, shop, or in his advertising in such manner as falsely to disparage them; or
- (b) To represent falsely that competitors are unreliable but that the disparager is not; or
- (c) To quote prices of competitive hearing aids or devices without disclosing that they are not the present current prices, or to shown, demonstrate, or represent competitive models as being the current models when such is not the fact.

#### AMENDATORY SECTION (Amending Order PL 563, filed 11/19/85)

WAC 308-50-310 PERSONAL DISCLOSURE. A licensee who contacts a prospective purchaser away from the licensee's place of business must:

(1) When the contact is in person, present the prospective purchaser with written notice of:

- (a) His or her name, the name of his or her business firm, his or her business address and telephone number;
- (b) The number of his or her license.

(2) Telephone contact with prospective purchasers must disclose the name of the licensee, name and location of his or her ((business firm)) principal establishment and purpose of call.

(3) When the contact is through a direct mail piece or other advertising initiated by the licensee, clearly show on all promotional items the business/establishment name, the principal establishment address and telephone number, not just the address or telephone number where he/she will be on given days.

(4) A principal establishment is one which is bonded pursuant to RCW 18.35.240.

WSR 91-07-058
PROPOSED RULES
DEPARTMENT OF HEALTH
(Hearing Aid Council)
[Filed March 19, 1991, 2:56 p.m.]

Original Notice.
Title of Rule: See Recodification Section below.
Purpose: A housekeeping action to transfer rules to Title 246 WAC.
Statutory Authority for Adoption: RCW 18.35.161.
Summary: This rule action changes only the WAC numbers, not the text of the rules.
Name of Agency Personnel Responsible for Drafting, Implementation and Enforcement: Olivia Guebara, 1300 Quince Street S.E., Olympia, WA, 753-3199.
Name of Proponent: Hearing Aid Council, governmental.
Rule is not necessitated by federal law, federal or state court decision.

Explanation of Rule, its Purpose, and Anticipated Effects: The 1989 legislature created the Department of Health. This action moves the related rules to a Department of Health title. Amends title, chapter and section numbers, causing these WACs to be relocated in a new title for the Department of Health and Department of Health related boards.

Proposal Changes the Following Existing Rules: Changes numbers.

No small business economic impact statement is required for this proposal by chapter 19.85 RCW.

Hearing Location: Holiday Inn, 800 Rainier Avenue South, Renton, WA 98055, on May 2, 1991, at 1:30 p.m.

Submit Written Comments to: Leslie Baldwin, 1300 Quince Street S.E., EY-16, Olympia, WA 98504, by May 1, 1991.

Date of Intended Adoption: May 2, 1991.

March 19, 1991
Olivia S. Guebara
for Ralph G. Lenhard
Chairman

RECODIFICATION SECTION

The following sections are being recodified as chapter 246-828 WAC:

Table with 3 columns: Original WAC number, 'as', and Recodified WAC number. Includes entries for hearing aid fitters and dispensers.

Table with 3 columns: Original WAC number, 'as', and Recodified WAC number. Includes entries for hearing aid fitters and dispensers.

WSR 91-07-059
WITHDRAWAL OF PROPOSED RULES
DEPARTMENT OF HEALTH
(Hearing Aid Council)
[Filed March 19, 1991, 2:59 p.m.]

Please withdraw WSR 90-08-107 filed April 4, 1990, and WSR 90-21-048 filed October 12, 1990. The council will refile these rules for hearing.

Olivia S. Guebara
for Ralph G. Lenhard
Chair

WSR 91-07-060
PROPOSED RULES
HIGHER EDUCATION
PERSONNEL BOARD
[Filed March 20, 1991, 8:58 a.m.]

Original Notice.
Title of Rule: WAC 251-09-020 Work period designations.

Purpose: Designates work periods that positions can be assigned to.

Statutory Authority for Adoption: Chapter 28B.16 RCW.

Statute Being Implemented: RCW 28B.16.100.

Summary: Eliminates specific hourly/weekly schedule for emergency response fire officers and allows work schedules in accordance with the Federal Fair Labor Standards Act.

Reasons Supporting Proposal: Rule modification will allow the flexibility to change institution work schedules in accordance with the HEPB rules and FLSA guidelines.

Name of Agency Personnel Responsible for Drafting: Tammy Tee, 1202 Black Lake Boulevard, FT-11, Olympia, 586-0510; Implementation and Enforcement: John Spitz, Director, 1202 Black Lake Boulevard, FT-11, Olympia, 753-3730.

Name of Proponent: Washington State University and Higher Education Personnel Board staff, governmental.

Rule is not necessitated by federal law, federal or state court decision.

**Explanation of Rule, its Purpose, and Anticipated Effects:** Institutions which operate an emergency response fire department may establish work schedules for emergency response personnel. If an institution must change its way of operating relative to staffing patterns due to financial constraints or other factors, they need the flexibility to change work schedules in accordance with HEPB rules and FLSA guidelines.

**Proposal Changes the Following Existing Rules:** Allows more flexibility in setting work schedules while remaining in compliance with HEPB rules and FLSA guidelines.

No small business economic impact statement is required for this proposal by chapter 19.85 RCW.

**Hearing Location:** Terry-Lander Hall, University of Washington, Seattle, Washington, on May 2, 1991, at 10:00 a.m.

**Submit Written Comments to:** 1202 Black Lake Boulevard, FT-11, Olympia, WA 98504, by May 1, 1991.

**Date of Intended Adoption:** May 2, 1991.

March 20, 1991

John A. Spitz  
Director

**AMENDATORY SECTION** (Amending Order 108, filed 9/23/83, effective 10/24/83)

**WAC 251-09-020 WORK PERIOD DESIGNATIONS.** Each position will be assigned by the personnel officer to one of the work period designations identified below, and employees will be informed of their eligibility for overtime compensation.

(1) Scheduled work periods, within which there are three work schedules:

(a) Regular work schedule. The regular work schedule for full-time classified employees shall consist of five consecutive and uniformly scheduled eight hour days in a seven day period. Uniformly scheduled means a daily repetition of the same working hours and a weekly repetition of the same working days.

(b) Alternate work schedule. Operational necessity or employee convenience may require positions that are normally designated regular work schedule to work an alternate forty hour work schedule (other than five uniform and consecutive eight hour days in a seven day period), or as provided by the Washington state minimum wage law in conjunction with the federal law which provides for an eighty hour workweek in a fourteen day period for hospital personnel. Alternate work schedules shall be made available upon request of the director.

(c) Emergency response fire officer work schedule. Institutions which operate an emergency response fire department may establish work (~~week~~) schedules for emergency response personnel (~~which provide for a daily work shift of twenty-four hours. The weekly schedule shall provide for at least forty-eight hours, but not more than fifty-six hours, as required to meet operational requirements~~) in accordance with the provisions of 207(k) of the Federal Fair Labor Standards Act. Emergency response personnel assigned to (~~twenty-four hour~~) such schedules shall be subject to the following conditions:

(i) All rules in chapter 251-22 WAC shall apply.

(ii) Changes to the established work schedule shall be made as provided in WAC 251-09-025.

(iii) Shift differential shall not be paid.

(iv) Overtime shall be paid for work performed in excess of the scheduled daily work shift or the scheduled work (~~week~~) period. The overtime compensation shall be as provided in WAC 251-09-030 (2) and (3).

(v) Holidays shall be as provided in WAC 251-22-040 and 251-22-045. When assigned to work on a designated holiday, emergency response personnel shall receive their regular daily pay plus eight hours of holiday pay. Compensation for the eight hours of holiday time shall be at the rate of time and one-half.

(2) Nonscheduled work period. The nonscheduled work period designation applies to those positions for which the hours cannot be scheduled but which work a forty hour week and do not meet any of the other work period designations. The personnel officer shall designate positions as nonscheduled in accordance with the institution's procedure approved by the director.

(3) Excepted work period. The excepted work period designation applies to classes and positions which meet the HEPB definitions of executive, administrative, or professional employees and are assigned to salary ranges twenty-three and above. Qualifying classes will be approved by the director. Each personnel officer will be responsible for determining the positions designated "excepted" at his/her institution. The personnel officer will develop a procedure for verifying "excepted" positions which will be available for review by the director.

## WSR 91-07-061

### PROPOSED RULES DEPARTMENT OF LABOR AND INDUSTRIES [Filed March 20, 1991, 10:51 a.m.]

**Original Notice.**

**Title of Rule:** Manual of rules, classifications, rates and rating system for Washington workers' compensation insurance, chapter 296-17 WAC.

**Purpose:** Revise general reporting rules, classification plan, and corresponding base rate tables applicable to workers' compensation insurance underwritten by the Washington State Fund, Department of Labor and Industries.

**Statutory Authority for Adoption:** RCW 51.04.020(1).

**Statute Being Implemented:** RCW 51.16.035.

**Summary:** Agency proposes to establish four new risk classifications; discontinue two existing risk classifications; amend thirteen risk classification definitions; adjust base rates for the new classifications; amend four general reporting rules; and amend two experience rating base rate tables.

**Reasons Supporting Proposal:** RCW 51.16.035 requires the department to maintain actuarial solvency of the industrial insurance funds and maintain a classification plan. Adjustments to the classification and rating plan reflect changes in Washington industries and/or changes in loss experience by various industries. Revisions to general reporting rules are intended to provide greater clarity to the rules.

**Name of Agency Personnel Responsible for Drafting, Implementation and Enforcement:** Douglas Connell, Francis Romero, and Ken Woehl, 905 Plum, Olympia, 753-1434.

**Name of Proponent:** Department of Labor and Industries, governmental.

Rule is not necessitated by federal law, federal or state court decision.

**Explanation of Rule, its Purpose, and Anticipated Effects:** Revisions to the classification plan are intended to provide greater ratepayer equity. Since classifications are keyed to the nature of an employer's business and rates are based on losses sustained by industries or businesses within a given classification, the more precise the plan, the greater the equity to the policyholder (employer).

Revisions to general reporting rules are intended to clarify how the classification plan is to be administered and/or how a classification or premium calculation is to be determined. Revisions to base rates are intended to recognize recent loss (claims) experience and reported exposure (hours worked) over which those losses can be spread.

Proposal Changes the Following Existing Rules: WAC 296-17-310 General rules and instructions, amend subsection (2) of this rule to remove the word "basic" from the 5th and 7th sentence, amend subsection (7) to clarify that classifications other than basic can be found in subsection (9) and amend subsection (9) to clarify specific classifications which are not basic classifications; WAC 296-17-320 General definitions, amend subsection (3) of this rule to clarify the definition of "classification," and amend subsection (5) to clarify the definition of "exposure"; WAC 296-17-420 General inclusions, amend subsection (3) of this rule to further clarify the intent that an employer use his/her employees; WAC 296-17-440 Standard exceptions, amend subsection (3) of this rule to remove the word "basic" in the last sentence, and amend subsection (5) in paragraph (4) to include "counselors, N.O.C."; WAC 296-17-512 Classification 0306, Plumbing, amend definition to include water softening or treatment system installation and hot water heater installation, service or repair; WAC 296-17-567 Classification 2401, Paper and paper products manufacturing, amend definition to include manufacturing of counter tops, panel, spiral tubes, milk cartons and paper-mache items; WAC 296-17-579 Classification 3401, Automotive repair, amend definition to delete reference to class 0505 and add new reference class 0517; WAC 296-17-592 Classification 3508, Plastic or fiberglass manufacturing, repeal classification; WAC 296-17-59202 Classification 3510, Plastic goods extrusion, amend definition to include extrusion, rotary and liquid molding, and artificial marble manufacturing; WAC 296-17-59203 Classification 3511, Fiberglass goods manufacturing, establish a new classification for employers engaged in the manufacturing of fiberglass goods; WAC 296-17-59204 Classification 3512, Plastic goods milling, establish a new classification for employers engaged in the cutting, milling and bending of plastic; WAC 296-17-603 Classification 3707, Rubber boots and goods manufacturing, repeal classification; WAC 296-17-604 Classification 3708, Nylon products manufacturing, amend definition to add "wader, wet suit and survival suit manufacturing"; WAC 296-17-605 Classification 3801, Leather boots and goods manufacturing, amend definition to include cutting or gluing of rubber goods, the manufacturing of leather belts and rubber gaskets and seals; WAC 296-17-606 Classification 3802, Cloth goods manufacturing, amend definition to include artificial flowers manufacturing, and textile bleaching; WAC 296-17-634 Classification 4305, Garbage works, amend definition to add "tire dumps or collection centers including incidental recycle operations"; WAC 296-17-643 Classification 4802, Farm crops, amend definition to delete "vineyards including harvesting of fruits"; WAC 296-17-64905 Classification 4813, Vineyard crops, establish a new classification to cover

employers engaged in vineyard operations including to harvesting; WAC 296-17-669 Classification 5109, Heavy machinery and equipment manufacturing, amend definition to add "press roller recoating or resurfacing"; WAC 296-17-709 Classification 6405, Tire manufacturing, amend definition to include tire bumper manufacturing and tire shredding or recycle operations; WAC 296-17-71301 Classification 6410, Janitorial supply dealers, establish a new classification to cover employers engaged as janitorial supply dealers which will include outside sales and route or delivery drivers; WAC 296-17-722 Classification 6509, Boarding houses, amend definition to add "adult family homes"; WAC 296-17-753 Classification 6908, Paper goods manufacturing, amend definition to include the manufacturing of single or double ply paper products; WAC 296-17-885 Expected loss rates, amend table to add expected loss rates and D ratios for classifications 3511, 3512, 4813; and WAC 296-17-895 Industrial insurance base rates table, amend table to add base rates for new classifications 3511, 3512, 4813 and 6410.

Small Business Economic Impact Statement: This statement pertains to revisions in chapter 296-17 WAC, proposed by the Department of Labor and Industries to become effective July 1991, and is prepared to conform with sections 3(2) and 4 of the Regulatory Fairness Act (chapter 6, Laws of 1982).

Existing rules: Chapter 296-17 WAC, presently defines 292 risk classifications for purposes of reporting exposures and computing premiums for workers' compensation insurance. Base rates are established separately for accident fund and medical aid fund coverage in each risk classification within these rules, and an assessment rate for all risk classifications is prescribed for the supplemental pension. An "experience rating plan" is also established, which provides adjustment of the base industrial insurance rate by class up or down to a "merit rate" based upon past reporting experience of each individual employer. Chapter 296-17 WAC also provides optional rating plans referred to as retrospective rating. These optional rating plans are available on a elective basis to employers and industry groups and provide them with additional opportunities to reduce their worker's compensation insurance costs through accident prevention and active claims management.

Treatment of small business under existing rules: Classification definitions are keyed to the nature of an employer's business and/or employment, and are independent of business size. Once applicable classifications are determined, base rates are identical for all employers within each classification. Experience rating increases or decreases individual employer's accident fund rates, providing rate reductions for favorable past experience and rate increases for unfavorable past experience. Within the experience-rating plan, small employers with loss-free records in the rating experience period are allowed rate credits in excess of those initially computed by the rating plan based on risk size, by a maximum modification for loss-free firms of various sizes in WAC 296-17-890. During 1989 medical aid premiums became subject to experience rating under a three-year phase-in plan. Experience rating of medical aid premiums is achieved

in much the same fashion as the accident fund. Employers and industry groups (associations) wishing to further reduce their workers' compensation insurance costs can participate in optional retrospective rating plans. Dependent on the plan selected and the employers' actual losses, adjustments are made to premiums paid in; if actual losses are below expected losses for the plan selected, dividends are paid to the employer. Employers with losses which are greater than expected losses pay additional premiums within the limits as determined by their selected plans.

Effect of proposed revisions: Four new risk classifications are being proposed to be added to chapter 296-17 WAC, including corresponding expected losses and base rates applicable to the new classifications. Two risk classifications are being proposed to be discontinued. At the same time, modifications to thirteen other existing classifications are proposed. Four general reporting rules are being modified. There is no increase in administrative costs for employers to comply with these changes, since no new records or forms are required for compliance and all other requirements are unchanged.

Hearing Location: Office Building 2, OB-2, First Floor Conference Room in Olympia, located at 12th and Franklin, on May 2, 1991, at 10:00 a.m.

Submit Written Comments to: Douglas Connell, Assistant Director, Employer Services, HC-211, 905 Plum Street S.E., Olympia, WA 98504, by May 1, 1991.

Date of Intended Adoption: May 31, 1991.

March 20, 1991  
Joseph A. Dear  
Director

**AMENDATORY SECTION** (Amending Order 89-22, filed 12/1/89, effective 1/1/90)

**WAC 296-17-310 GENERAL RULES AND INSTRUCTIONS.** This section constitutes general rules and instructions for chapter 296-17 WAC.

(1) Purposes. This chapter of the Washington Administrative Code, including classifications of risk, premium rates, the experience rating plan, and all other rules contained herein governing the use thereof, is herein referred to as the manual. This manual is promulgated by the department of labor and industries pursuant to RCW 51.16.035. This manual contains a formulation of the rules and regulations providing for basic classifications, rates of premium, method of premium calculation and collection, and a rating system, consistent with recognized principles of workers' compensation insurance. This manual governs the department's underwriting of workers' compensation insurance and assessment of other monetary obligations, under the industrial insurance law of the state of Washington, Title 51 RCW.

(2) Overview. Washington law (RCW 51.16.035) requires that the department of labor and industries classify all occupations or industries by degree of hazard. To accomplish this, the department has established approximately three hundred ((basic)) classifications of risk embracing the various industries within the state (the actual number may vary from year to year). These ((basic)) classifications are set forth in WAC 296-17-501 through 296-17-779. The general principles and objectives of the basic classification system are set forth in WAC 296-17-310.

The first step in determining the appropriate classification for an employer is to determine the nature of the employer's business being insured in this state. If the department determines that an employer's business consists of a single operation or a number of separate operations which normally prevail in that business then the single enterprise rule (WAC 296-17-380) is applicable. This rule provides that the department is to assign the single basic classification which most accurately describes the employer's entire enterprise. This process begins with the search for a basic classification which specifically describes

the employer's business. If such a basic classification is found the process of assigning a basic classification is complete.

If the employers' business operation is not specifically described by any basic classification then the employer's business is to be classified as provided for in WAC 296-17-360 (assignment of classification by analogy). In classifying by analogy the department examines the process and hazard of the employer's business and compares it to that of other basic classifications with processes and hazards that are similar to those of the employer's business and assigns the most analogous classification on that basis.

In the event that a review of the employer's business operations indicates the possibility that the employer conducts more than one business within this state, a determination will be made as to whether any additional basic classifications should be assigned on the basis of the criteria set out in the multiple enterprise rule (WAC 296-17-390).

Once the employer's basic classification has been established, the department must determine whether additional classifications should be assigned to apply to specific employments within an employer's business such as the standard exception rule (WAC 296-17-440), the general exclusion rule (WAC 296-17-430), the special exception rule (WAC 296-17-441), or those indicated by the language of any applicable basic classifications that permit or require separate reporting of any operations within that business or industry or as otherwise provided by this chapter.

(3) Premium payments - quarterly reports. Each employer shall, upon such forms as prescribed by the department, prior to the last day of January, April, July and October of each year, pay to the department for the preceding calendar quarter, for the accident fund, and for the medical aid fund, a certain number of cents for each worker hour or fraction thereof worked by the worker in their employ except when the rules of this manual provide for a different method of premium computation. Provided, that in the event an employer has no employment subject to coverage under Title 51 RCW during a calendar quarter the employer shall submit to the department, according to the schedule described above, a quarterly report indicating "no payroll" or be subject to the penalties provided for in RCW 51.48.210. The director may promulgate, change and revise such rates at such times as necessary, according to the condition of the accident and medical aid funds, and assign rates as appropriate to employers who voluntarily seek coverage under the elective adoption provisions of the law.

(4) Determining accident fund premium. The amounts to be paid into the accident fund shall be determined as follows: The department shall determine a manual premium rate for each classification which shall not be inadequate, excessive or unfairly discriminatory, taking into consideration past and prospective costs in each classification and the financial condition of the accident fund as a whole.

Every employer shall pay into the accident fund at the manual premium rate unless such employer meets the requirements for the experience rating plan provided elsewhere in this manual, in which event such employer's premium rate for the accident fund shall be paid according to their experience modification as determined under the experience rating plan.

(5) Basis for determining medical aid premium. The amounts to be paid into the medical aid fund shall be determined as follows: The department shall determine a manual medical aid rate for each classification which shall not be inadequate, excessive or unfairly discriminatory, taking into consideration past and prospective costs in each classification and the financial condition of the medical aid fund as a whole.

Every employer shall pay into the medical aid fund at the manual premium rate unless such employer meets the requirements for the experience rating plan provided elsewhere in this manual, in which event such employer's premium rate for the medical aid fund shall be paid according to their experience modification as determined under the experience rating plan.

(6) All section captions or titles or catch lines used in this manual, chapter 296-17 WAC, do not constitute any part of these rules.

(7) Assignment of classifications. The classifications in this manual are all basic classifications other than the standard exception classifications which are defined in WAC 296-17-440 and those classifications specified in subsection (9) of this section. Basic classifications are used to implement the object of the classification system, which is to assign the one basic classification which best describes the business of the employer within this state. Each basic classification includes all the various types of labor found in a business unless it is specifically excluded by language contained within the classification or covered by a separate rule found elsewhere in this chapter, such as "standard exceptions" or "general exclusions." The classification procedure used



within this state is intended to classify the business undertaking of the employer and not the separate employments, occupations, or operations of individuals within a business.

In the event an employer operates a secondary business within this state, multiple basic classifications can be assigned provided that the conditions set forth in WAC 296-17-390 "multiple enterprises" have been met. However, construction or erection operations are to be assigned classifications as provided in WAC 296-17-45003 "Special construction industry rules."

(8) Classification assignment of separate legal entities. Each separate legal entity shall be assigned to the basic classification or classifications which best describe its operations within the state using the classification procedures outlined in subsections (2) and (7) of this section and WAC 296-17-45003.

(9) All operations. Each basic classification in this manual (~~other than classifications 4806, 4904, 5206, 6301, 6302, 6303, 7101, or the temporary help classifications 7104 through 7121~~) includes all the operations normally associated with the business undertaking without regard to the location(s) of such operation(s) unless an operation is specifically excluded from the manual language of the basic classification. The following classifications are not considered to be basic classifications and are limited in scope to the definition contained within each classification 4806, 4904, 5206, 6301, 6302, 6303, 7101 or the temporary help classifications 7104 through 7121.

**AMENDATORY SECTION** (Amending Order 86-18, filed 5/30/86, effective 7/1/86)

WAC 296-17-320 GENERAL DEFINITIONS. For the purpose of interpretation of this manual, chapter 296-17 WAC, the following terms shall have the meanings given below:

(1) "Workers' compensation" means the obligation imposed upon an employer by the industrial insurance laws of the state of Washington, to insure the payment of benefits prescribed by such laws.

(2) "Risk" means and includes all insured operations of one employer within the state of Washington.

(3) "Classification" means a grouping of businesses or industries having common or similar exposures without regard to the separate employments, occupations, or operations (~~comprising the employer's work force~~) normal to the business or industry.

(4) "Basic classification" shall be understood to have the same meaning as classification defined in subsection (3) of this section.

(5) "Exposure" means worker hours, worker days, payroll or other measure of the extent to which an employer's workers have been exposed to the hazards (~~of~~) found within a particular business or industry classification (~~of employment~~).

(6) "Rate" means the amount of premium for each unit of exposure. All rates are rates per worker hour except where specifically provided otherwise in this manual.

(7) "Premium" means the sum derived from the application of the rates to the exposures in each classification, after application of any duly authorized experience modification, except where the rules of this manual indicate otherwise.

(8) Unless the context indicates otherwise, the words used in this manual shall have the meanings given in Title 51 RCW.

**AMENDATORY SECTION** (Amending Order 86-18, filed 5/30/86, effective 7/1/86)

WAC 296-17-420 GENERAL INCLUSIONS. All of the basic classifications in this manual, other than standard exceptions, include certain operations which would be classified separately if they were run as separate business undertakings. These operations are referred to as general inclusions and are included in the scope of each basic classification. The following operations are included in all basic classifications unless they are specifically excluded by the language of the basic classification.

(1) Aircraft travel by employees, other than members of the flying crew.

(2) Commissaries and restaurants for the employers' employees. Provided that such operations conducted in connection with construction, erection, lumbering, or mining operations shall be assigned to Code 3905 "restaurants."

(3) Manufacture of containers, such as bags, barrels, bottles, boxes, cans, cartons, wooden pallets, or packing cases by employees of the employers for use in (~~their~~) the employer's operations.

(4) Hospitals, medical facilities, or dispensaries operated by the employers for their employees.

(5) Printing, lithography, or similar operations of the employer(s) when used exclusively for their own products.

(6) Maintenance or ordinary repair of the employer's building or equipment when performed by employees of the employer.

(7) Pick up and delivery when done by employees of the employer in connection with the business of the employer.

(8) Sales of all goods or products being manufactured by the employer.

(9) Warehousing, handling, packing, and shipping when done by an employee of the employer and done in connection with the business of the employer.

**AMENDATORY SECTION** (Amending Order 89-22, filed 12/1/89, effective 1/1/90)

WAC 296-17-440 STANDARD EXCEPTIONS. The following employments referred to as standard exceptions are to be separately rated unless these employments are specifically included within the scope of a basic classification by use of words such as "including clerical office and outside sales." (Use of the words "clerical office" will also include draftsmen and use of the words "sales personnel" will also include collectors, messengers and corporate officers.) Provided that a division of a single employee's worker hours shall not be permitted between two standard exception classifications or between a standard exception classification and a basic business classification except as provided in the general exclusion rules of this manual.

The standard exceptions are defined below:

(1) Clerical office employees are defined as those employees whose duties are confined to keeping the books or records of the employer, or conducting correspondence or who are engaged wholly in office work where such books or records are kept or where such correspondence is conducted, having no other duty of any nature in or about the employer's premises. If any clerical office employee is exposed to any operative hazard of the business, their entire worker hours shall be assigned to the highest rated classification of work to which they are exposed. The clerical office classification shall be applied only to persons as herein described who are employed exclusively in separate buildings or on separate floors of buildings or in departments on such floors which are physically separated from all other work areas of the employer by structural partitions and within which no work is performed other than clerical office duties as defined in this paragraph.

(2) Draftsmen will be considered to be clerical office employees when their duties are limited to office work only and who are engaged strictly as draftsmen in such a manner that they are not exposed to the operative hazard of the business. If any draftsman is exposed to any operative hazard of this business, their entire worker hours shall be assigned to the highest rated classification of work to which they are exposed.

(3) "Sales personnel - outside" are defined as those employees engaged in such duties away from the premises of the employer who sell or solicit new accounts or customers for the employer or who service existing accounts or customers for the employer. Provided that no employee shall be assigned to a sales classification code if their duties include delivery, even though they may also solicit or collect. Employees having delivery duties, even if they walk or use public transportation, shall be assigned to the (~~governing~~) basic classification of the employer.

(4) Messengers will be considered sales employees, provided the following conditions are met:

(a) The messenger is used solely by the employer in connection with the administration of the employer's business operation.

(b) The operation is not provided to the public as a general delivery service.

(c) The employer's basic classification does not include the standard exception classification designations.

If all the above conditions do not exist, any employee assigned such duties shall be assigned to the governing classification of the employer when multiple basic classifications are assigned or to the basic classification in the event an employer has only a single basic classification assigned.

(5) Corporate officers are defined as those employees of a corporation elected and empowered in accordance with the articles of incorporation or bylaws as officers of the corporation who are also shareholders and serve on the board of directors of the corporation and whose duties are limited to administrative, clerical office and outside sales activities for the corporations. Any corporate officer who performs any duty that relates directly to the operational activities of the business



shall be assigned to the basic classification(s) of the employer applicable to the work being performed. A corporate officer engaged exclusively in outside sales shall be assigned classification 6303. In no event however will a corporate officer be assigned the clerical office classification 4904.

With the exceptions of occupations falling within any classification that specifically includes clerical office, inside draftsmen or sales personnel, the following designated occupational classifications shall apply.

Classification 4904 clerical office employees including inside draftsmen.

Classification 6303 sales personnel, outside or away from the employers premises including collectors, counsellors, N.O.C., and messengers.

Classification 6301 automobile, truck, camper, trailer, mobile home, motorcycle and pleasure craft sales personnel.

Classification 6302 all door to door sales personnel.

Classification 7101 corporate officers.

**AMENDATORY SECTION** (Amending Order 85-33, filed 11/27/85, effective 1/1/86)

WAC 296-17-512 CLASSIFICATION 0306.

Boilers, N.O.C., installation, service or repair including boiler scaling and tank erection within buildings

Hot water heater - installation, service, or repair

Plumbing, N.O.C.

Pump installation, service or repair, N.O.C.

Sewer pipe cleaning, including Roto Rooter or similar service providers

Side sewer installation (street to house hook ups) including service or repair

Sprinkler installation - automatic

Steam pipe, boiler, etc., covering insulation

Water softening or treatment systems - installation of new equipment systems.

**AMENDATORY SECTION** (Amending Order 87-12, filed 5/29/87, effective 7/1/87)

WAC 296-17-544 CLASSIFICATION 1404.

Bus ((~~or limousine~~) companies, transit systems, contract bus driving ((~~Chauffeurs, N.O.C.~~))

Equipment escort and pilot car service

Vessels, ferries, tugs and steamboats operation, N.O.C. including dock employees - excluding maritime.

**AMENDATORY SECTION** (Amending Order 89-22, filed 12/1/89, effective 1/1/90)

WAC 296-17-567 CLASSIFICATION 2401.

((~~Paper or pulp manufacturing, wood fiber manufacturing~~

~~Corrugated and fiber board container manufacturing, including corrugating and laminating of paper~~

~~Paper coating, corrugating, laminating or oiling~~

~~Paper goods, N.O.C., manufacturing~~

~~Building and roofing paper including felt, manufacturing:))~~

Building and roofing paper including felt: Manufacturing

Corrugated and fiber board container: Manufacturing, including corrugating and laminating of paper

Paper: Coating, corrugating, laminating or oiling

Paper goods: Manufacturing, N.O.C., such as but not limited to counter tops, panels, spiral tubes, milk cartons, and paper-mache items

Paper or pulp: Manufacturing

Wood fiber: Manufacturing.

**AMENDATORY SECTION** (Amending Order 87-12, filed 5/29/87, effective 7/1/87)

WAC 296-17-57001 CLASSIFICATION 2907.

Cabinet, countertop, and fixture: Manufacturing, modifying or assembly - wood

This is a shop or plant only classification but does contemplate work being performed in an adjacent yard when operated by an employer having operations subject to this classification. This classification excludes all activities away from the shop or plant.

**AMENDATORY SECTION** (Amending Order 87-12, filed 5/29/87, effective 7/1/87)

WAC 296-17-579 CLASSIFICATION 3401.

Automobile, truck, body and fender repair shops, including painting and incidental upholstery and glass repair

Automobile, truck, mobile home, camper, and trailer sales and/or rental agency, including repair shops and canopy sales and installation by dealers subject to this classification

Automobile, truck, repair shops or garages

Automobile, truck service specialty shops including sales, installation and repair of air conditioning systems, electrical systems, cruise controls, mufflers, and sun roofs

Boat dealers, including repair shops

Marinas and boat house operations, including repair shops

This classification will include mobile home delivery and set up when done by employees of the mobile home sales agency. Contractors doing set up and delivery of mobile homes who are not employees of the mobile home sales agency will be rated under risk classification ((~~0505 (WAC 296-17-520))~~) 0517 (WAC 296-17-52109).

**AMENDATORY SECTION** (Amending WSR 90-13-018, filed 6/8/90, effective 7/9/90)

WAC 296-17-59202 CLASSIFICATION 3510.

Artificial marble: Manufacturing

Plastic goods: Manufacturing((:)) - blow molding, extrusion vacuum forming, foam molding, rotary molding, liquid molding, and injection molding

Plastic goods: Manufacturing, N.O.C.

**NEW SECTION**

WAC 296-17-59203 CLASSIFICATION 3511.

Fiberglass goods: Manufacturing, N.O.C.

**NEW SECTION**

WAC 296-17-59204 CLASSIFICATION 3512.

Plastic goods: Manufacturing - cutting, milling or bending.

**AMENDATORY SECTION** (Amending Order 87-26, filed 12/1/87, effective 1/1/88)

WAC 296-17-604 CLASSIFICATION 3708.

((~~Linoleum, oil cloth or imitation leather manufacturing~~

~~Broom and brush manufacturing, or assembly~~

~~Cordage, rope or twine manufacturing~~

~~Match manufacturing~~

~~Cotton cord or cotton twine manufacturing~~

~~Textile manufacturing, N.O.C.~~

~~Taxidermists and hide pelting~~

~~Parachutes, suspenders, fur goods and bandages manufacturing~~

~~Nylon or synthetic goods manufacturing, N.O.C.~~

~~Life preservers and canvas goods manufacturing, N.O.C.~~

~~Braid, net, plush and velvet, thread, webbing and yarn manufacturing~~

~~Spinning or weaving - natural or synthetic fibres, N.O.C.~~

~~Pillow, quilt or cushion manufacturing including stuffed animal or doll manufacturing~~

~~Mattress or box springs manufacturing - no manufacturing wire springs or excelsior~~

~~Abrasive cloth preparation~~

~~Bag or sack manufacturing or renovating - cotton, burlap, gunny, nylon, or textile~~

~~Carpet or rug manufacturing~~

~~Fire hose manufacturing from linen thread~~

~~Cotton-batting, wadding or waste manufacturing~~

~~Wool-combing or scouring~~

~~Fishing rod wrappings, manufacturing~~

~~Awning, tent, sail, flags, wind-socks or sleeping bag manufacturing:))~~

Abrasive cloth preparation

Awning, tent, sail, flag, wind sock or sleeping bag: Manufacturing

Bag or sack: Manufacturing or renovating - cotton, burlap, gunny, nylon, or textile

Braid, net, plush and velvet, thread, webbing and yarn: Manufacturing

Broom and brush: Manufacturing or assembly

Carpet or rug: Manufacturing  
Cordage, rope or twine: Manufacturing  
Cotton batting, wadding or waste: Manufacturing  
Cotton cord or cotton twine: Manufacturing  
Fire hose: Manufacturing from linen thread  
Fishing rod wrappings: Manufacturing  
Life preservers and canvas goods: Manufacturing, N.O.C.  
Linoleum, oil cloth or imitation leather: Manufacturing  
Match: Manufacturing  
Nylon or synthetic goods: Manufacturing, N.O.C.  
Parachutes, suspenders, fur goods and bandages: Manufacturing  
Pillow, quilt or cushion: Manufacturing including stuffed animal or doll manufacturing  
Spinning or weaving - natural or synthetic fibres, N.O.C.  
Taxidermists and hide pelting  
Textile: Manufacturing, N.O.C.  
Wader, wet suit, and survival suit: Manufacturing  
Wool combing or scouring.

AMENDATORY SECTION (Amending Order 85-33, filed 11/27/85, effective 1/1/86)

WAC 296-17-605 CLASSIFICATION 3801.

~~((Glove manufacturing, leather, belting manufacturing, leather goods manufacturing, N.O.C.  
 Boot or shoe manufacturing or repair, N.O.C.  
 Leather embossing  
 Shoe stock manufacturing, gasket manufacturing - not metal or asbestos:))~~  
Belting: Manufacturing - leather  
Boot or shoe: Manufacturing or repair, N.O.C.  
Gaskets or seals: Manufacturing - leather, rubber, or cork  
Glove: Manufacturing - leather  
Leather embossing  
Leather goods: Manufacturing, N.O.C.  
Shoe stock: Manufacturing  
Rubber goods: Cutting and/or gluing.

AMENDATORY SECTION (Amending Order 85-33, filed 11/27/85, effective 1/1/86)

WAC 296-17-606 CLASSIFICATION 3802.

~~((Lace, embroidery, cloth hats, umbrella and draperies manufacturing  
 Clothing or cloth goods manufacturing, N.O.C.  
 Gloves manufacturing, N.O.C.  
 Millinery manufacturing, artificial feather or flower manufacturing, N.O.C.  
 Wig making  
 Hosiery manufacturing  
 Fabric coating, impregnating or waterproofing, N.O.C., textiles bleaching, dyeing or finishing, new goods, not garments  
 Cloth printing  
 Dressmaking or tailoring:))~~  
Artificial feather or flower: Manufacturing, N.O.C.  
Clothing or cloth goods: Manufacturing, N.O.C.  
Cloth printing  
Dressmaking or tailoring  
Fabric: Coating, impregnating or waterproofing, N.O.C.  
Gloves: Manufacturing, N.O.C.  
Hosiery: Manufacturing  
Lace, embroidery, cloth hats, umbrella and draperies: Manufacturing  
Millinery: Manufacturing  
Textiles: Bleaching, dyeing, or finishing - new goods, not garments  
Wig making.

AMENDATORY SECTION (Amending WSR 90-13-018, filed 6/8/90, effective 7/9/90)

WAC 296-17-634 CLASSIFICATION 4305.

Garbage, refuse or ashes collecting  
Garbage works, landfill, reduction or incineration operations - including cashiers collecting fees from customers and incidental recycle operation conducted in connection with a landfill or garbage works operation  
Radioactive waste landfill  
Tire dumps or collection centers.

AMENDATORY SECTION (Amending Order 88-06, filed 5/31/88, effective 7/1/88)

WAC 296-17-643 CLASSIFICATION 4802.

Berry farms  
Bulb raising  
Field vegetable crops, such as bush beans, peas, sweet corn, potatoes, sugar beets, and field carrots which are mechanically harvested  
Flower or vegetable seed growing including harvesting of seeds  
Picking of forest products, N.O.C.  
~~((Vineyards including harvesting of fruit))~~  
 This classification excludes fresh fruit packing operations rated under risk classification 2104 (WAC 296-17-564); and fruit cannery or freezer operations rated under risk classification 3902 (WAC 296-17-615) unless specifically included by manual language.

NEW SECTION

WAC 296-17-64905 CLASSIFICATION 4813.

Vineyards - all operations including harvesting of fruit  
 This classification excludes fresh fruit packing operations which are to be reported separately under risk classification 2104 (WAC 296-17-564); wine making which are to be reported separately under risk classification 3702 (WAC 296-17-600); and fruit cannery, processing, or freezing operations which are to be reported separately under risk classification 3902 (WAC 296-17-615).

AMENDATORY SECTION (Amending Order 85-33, filed 11/27/85, effective 1/1/86)

WAC 296-17-669 CLASSIFICATION 5109.

Heavy arms: Manufacturing or repair  
Heavy machinery and equipment: Manufacturing or repair  
Press rollers: Recoating or resurfacing.

AMENDATORY SECTION (Amending Order 85-33, filed 11/27/85, effective 1/1/86)

WAC 296-17-709 CLASSIFICATION 6405.

Tire: Manufacturing, vulcanizing, rebuilding and/or recapping  
Tire sales and service, wholesale and retail including incidental mechanical repair work to automobiles or trucks  
Tire bumper: Manufacturing  
Tire recycle or shredding - excluding tire dump operations which are to be reported separately under risk classification 4305 (WAC 296-17-634).

NEW SECTION

WAC 296-17-71301 CLASSIFICATION 6410.

Janitorial supply dealers  
 This classification includes outside sales personnel and delivery drivers.

AMENDATORY SECTION (Amending Order 85-33, filed 11/27/85, effective 1/1/86)

WAC 296-17-722 CLASSIFICATION 6509.

~~((Boarding homes and centers, N.O.C.  
 Boarding houses  
 Foster homes  
 Fraternity houses  
 Orphanages  
 Rooming houses  
 Sorority houses:))~~  
Rooming houses  
Boarding houses  
Foster homes  
Orphanages  
Boarding homes and centers, N.O.C.  
Fraternity houses  
Sorority houses  
Adult family homes.

AMENDATORY SECTION (Amending Order 85-33, filed 11/27/85, effective 1/1/86)

WAC 296-17-753 CLASSIFICATION 6908.

Carbon paper, crepe paper, blue print paper, computer paper, calculation tape, note pad, file folder, envelope, stationery, and typewriter ribbon; Manufacturing  
 ((Envelope or stationery manufacturing))  
 Lightweight paper goods: Manufacturing such as but not limited to such single or double ply paper items as surgical gowns, towels, napkins, table or shelf covers, florist papers, tissue, and shredded packing material  
 Paper bag, abrasive paper, movers packing pads, and wallpaper: Manufacturing  
 Paper box: Manufacturing(;) - set up or folding paper boxes  
 ((Paper box manufacturing, solid paper boxes  
 Paper or plastic bag, abrasive paper and wallpaper manufacturing)).

AMENDATORY SECTION (Amending WSR 90-24-042, filed 11/30/90, effective 1/1/91)

WAC 296-17-885 TABLE III.

Expected Loss Rates and D-Ratios  
 Expected Loss Rates in Dollars Per Worker Hour  
 for Indicated Fiscal Year

CLASS	1987	1988	1989	D-RATIO
0101	0.9854	0.9200	0.9247	0.430
0102	1.1626	1.0849	1.0701	0.459
0103	1.1025	1.0310	1.0014	0.434
0104	1.1649	1.0905	1.1056	0.346
0105	0.9242	0.8624	0.8026	0.473
0106	2.4817	2.3181	2.2322	0.499
0107	0.8388	0.7834	0.8066	0.422
0108	0.8580	0.8021	0.8193	0.407
0109	2.6293	2.4566	2.4862	0.417
0201	1.5522	1.4503	1.4618	0.398
0202	1.9823	1.8609	1.8575	0.377
0206	1.4090	1.3148	1.3492	0.417
0301	0.5217	0.4861	0.4563	0.545
0302	1.4422	1.3461	1.3641	0.403
0306	0.7457	0.6960	0.6883	0.455
0307	0.6295	0.5873	0.5726	0.477
0403	0.8883	0.8301	0.8109	0.474
0502	0.8752	0.8161	0.8355	0.463
0504	1.1895	1.1107	1.0897	0.442
0506	2.9692	2.7718	2.7210	0.479
0507	2.5657	2.3908	2.2512	0.487
0508	2.9021	2.7155	2.7526	0.368
0509	1.6401	1.5357	1.5396	0.400
0510	1.1120	1.0363	0.9905	0.486
0511	0.9337	0.8695	0.8435	0.508
0512	1.2120	1.1309	1.1309	0.464
0513	0.6834	0.6367	0.5953	0.518
0514	1.0723	1.0015	0.9894	0.458
0515	1.8601	1.7359	1.7411	0.430
0516	1.5107	1.4096	1.3886	0.472
0517	1.5056	1.4068	1.4174	0.453
0518	1.2066	1.1254	1.1432	0.432
0519	1.4273	1.3308	1.3382	0.488
0601	0.4880	0.4559	0.4530	0.478
0602	0.3148	0.2936	0.2930	0.511
0603	0.6767	0.6319	0.6027	0.443
0604	0.9631	0.8996	0.8486	0.405
0606	0.2201	0.2057	0.1978	0.528
0607	0.2445	0.2285	0.2110	0.505
0608	0.2226	0.2078	0.1990	0.523
0701	1.5198	1.4186	1.4530	0.387
0803	0.2975	0.2779	0.2603	0.465
0804	0.7024	0.6562	0.6317	0.440
0901	1.5960	1.4940	1.4571	0.357
1002	0.8104	0.7555	0.7035	0.511
1003	0.4737	0.4423	0.4244	0.475
1004	0.4737	0.4423	0.4244	0.475
1005	3.4890	3.2458	2.9655	0.478
1007	0.2051	0.1915	0.1870	0.506
1101	0.4395	0.4101	0.3865	0.530
1102	0.9331	0.8699	0.8451	0.459
1103	0.3631	0.3389	0.3167	0.510
1104	0.5173	0.4834	0.4460	0.498
1106	0.1916	0.1790	0.1636	0.577
1108	0.4096	0.3828	0.3634	0.507
1109	0.6684	0.6238	0.5650	0.524
1301	0.2108	0.1973	0.2013	0.444
1303	0.1744	0.1628	0.1591	0.479
1304	0.0174	0.0163	0.0160	0.548
1305	0.2523	0.2352	0.2198	0.546
1401	0.7402	0.6938	0.6585	0.470
1404	0.5108	0.4762	0.4305	0.520
1405	0.4534	0.4232	0.3971	0.502
1501	0.3164	0.2956	0.2762	0.512
1507	0.2198	0.2054	0.1961	0.515
1701	1.3268	1.2410	1.2587	0.360
1702	1.3268	1.2410	1.2587	0.360
1703	0.3874	0.3617	0.3498	0.437
1704	0.7753	0.7249	0.6983	0.426
1801	0.8594	0.8027	0.8010	0.438
1802	0.5023	0.4689	0.4343	0.504
2002	0.5617	0.5254	0.4896	0.485
2003	0.3532	0.3300	0.3138	0.519
2004	0.6708	0.6256	0.5812	0.506
2005	0.3037	0.2843	0.2625	0.499
2007	0.3362	0.3149	0.2930	0.496
2008	0.2225	0.2079	0.1941	0.460
2101	0.4944	0.4610	0.4256	0.501
2102	0.3532	0.3300	0.3138	0.519
2104	0.3015	0.2810	0.2417	0.555
2105	0.4161	0.3889	0.3801	0.483
2106	0.3718	0.3475	0.3235	0.494
2201	0.1997	0.1863	0.1742	0.534
2202	0.4154	0.3885	0.3605	0.511
2203	0.2636	0.2457	0.2253	0.527
2401	0.4395	0.4103	0.3846	0.504
2903	0.6357	0.5930	0.5506	0.531
2904	0.5803	0.5420	0.5040	0.503
2905	0.4117	0.3841	0.3453	0.539
2906	0.4286	0.3998	0.3852	0.491
2907	0.4047	0.3772	0.3500	0.532
2908	0.7848	0.7323	0.6926	0.501
2909	0.5626	0.5251	0.4850	0.497
3101	0.5921	0.5531	0.5358	0.444
3102	0.3907	0.3654	0.3506	0.440
3103	0.3907	0.3654	0.3506	0.440
3104	0.4505	0.4224	0.4153	0.474
3105	0.7527	0.7013	0.6470	0.514
3303	0.2124	0.1986	0.1827	0.479
3304	0.6096	0.5674	0.5124	0.561
3309	0.3276	0.3071	0.2842	0.490
3401	0.3198	0.2987	0.2866	0.496
3402	0.3471	0.3239	0.3040	0.524
3403	0.1216	0.1138	0.1100	0.505
3404	0.3335	0.3111	0.2899	0.543
3405	0.2217	0.2070	0.1938	0.522
3406	0.1593	0.1491	0.1384	0.537
3407	0.2575	0.2411	0.2364	0.435
3408	0.0811	0.0758	0.0750	0.485
3409	0.1140	0.1065	0.0991	0.500
3501	0.6014	0.5620	0.5284	0.462
3503	0.1874	0.1749	0.1542	0.539
3506	0.6310	0.5896	0.5906	0.447
3508	0.3445	0.3215	0.3013	0.531
3509	0.3535	0.3287	0.3052	0.621
3510	0.3445	0.3215	0.3013	0.531
3511	0.3445	0.3215	0.3013	0.531
3512	0.3445	0.3215	0.3013	0.531
3602	0.0871	0.0815	0.0748	0.565
3603	0.4680	0.4375	0.4137	0.508
3604	1.0475	0.9786	0.9099	0.461
3605	0.3866	0.3605	0.3335	0.520
3606	0.7110	0.6647	0.6170	0.492
3701	0.2262	0.2111	0.2003	0.519

CLASS	1987	1988	1989	D-RATIO	CLASS	1987	1988	1989	D-RATIO
3702	0.3714	0.3471	0.3331	0.447	6108	0.4402	0.4103	0.3824	0.585
3707	0.3427	0.3193	0.2963	0.531	6109	0.0312	0.0292	0.0270	0.567
3708	0.2399	0.2240	0.2061	0.526	6110	0.3230	0.3013	0.2779	0.597
3801	0.1796	0.1675	0.1588	0.515	6201	0.1227	0.1149	0.1099	0.509
3802	0.1419	0.1325	0.1251	0.577	6202	0.5097	0.4771	0.4447	0.448
3808	0.2345	0.2187	0.2028	0.543	6203	0.0723	0.0677	0.0630	0.489
3901	0.1351	0.1262	0.1151	0.530	6204	0.1420	0.1328	0.1223	0.562
3902	0.4460	0.4160	0.3826	0.536	6205	0.1420	0.1328	0.1223	0.562
3903	0.9575	0.8970	0.8308	0.474	6206	0.1420	0.1328	0.1223	0.562
3905	0.1208	0.1132	0.1059	0.563	6207	0.8227	0.7701	0.7157	0.525
3906	0.3589	0.3354	0.3223	0.496	6208	0.2302	0.2151	0.1979	0.513
3909	0.2581	0.2416	0.2210	0.502	6209	0.1919	0.1798	0.1667	0.523
4002	0.5567	0.5197	0.4940	0.485	6301	0.0945	0.0885	0.0914	0.446
4101	0.1772	0.1658	0.1530	0.527	6302	0.1416	0.1327	0.1236	0.427
4103	0.2065	0.1931	0.1906	0.517	6303	0.0540	0.0506	0.0482	0.462
4107	0.0943	0.0884	0.0857	0.507	6304	0.1190	0.1115	0.1005	0.521
4108	0.1772	0.1658	0.1530	0.527	6305	0.0575	0.0538	0.0478	0.528
4109	0.1772	0.1658	0.1530	0.527	6306	0.2001	0.1870	0.1709	0.499
4201	0.2016	0.1881	0.1858	0.500	6308	0.0327	0.0306	0.0285	0.480
4301	0.7024	0.6553	0.6084	0.517	6309	0.1108	0.1036	0.0941	0.539
4302	0.5708	0.5319	0.4932	0.505	6402	0.2076	0.1937	0.1741	0.515
4303	0.2315	0.2161	0.2003	0.519	6403	0.1553	0.1451	0.1333	0.574
4304	0.5277	0.4928	0.4570	0.534	6404	0.1402	0.1309	0.1166	0.569
4305	0.9111	0.8500	0.8568	0.484	6405	0.4438	0.4143	0.3969	0.512
4401	0.4407	0.4102	0.3824	0.557	6406	0.0710	0.0665	0.0617	0.543
4402	0.6093	0.5685	0.5301	0.517	6407	0.1595	0.1491	0.1324	0.549
4404	0.5063	0.4713	0.4361	0.529	6408	0.2767	0.2591	0.2465	0.459
4501	0.1156	0.1082	0.1037	0.446	6409	0.4196	0.3938	0.3821	0.440
4502	0.0344	0.0323	0.0311	0.430	6501	0.0624	0.0581	0.0537	0.577
4504	0.0692	0.0648	0.0593	0.555	6502	0.0154	0.0144	0.0137	0.501
4601	0.5453	0.5119	0.4853	0.437	6503	0.0686	0.0644	0.0651	0.348
4802	0.3258	0.3042	0.2684	0.503	6504	0.3010	0.2817	0.2582	0.580
4803	0.3265	0.3039	0.2288	0.540	6505	0.1187	0.1109	0.1034	0.526
4804	0.4659	0.4349	0.4041	0.537	6506	0.0687	0.0644	0.0594	0.538
4805	0.3193	0.2978	0.2684	0.538	6508	0.3419	0.3195	0.2999	0.521
4806	0.0858	0.0800	0.0652	0.527	6509	0.1827	0.1710	0.1586	0.495
4808	0.4272	0.3992	0.3659	0.467	6601	0.1618	0.1514	0.1391	0.527
4809	0.2004	0.1871	0.1739	0.561	6602	0.4133	0.3857	0.3565	0.556
4810	0.1597	0.1491	0.1276	0.517	6603	0.2188	0.2045	0.1935	0.516
4811	0.2594	0.2421	0.2068	0.499	6604	0.0531	0.0496	0.0479	0.470
4812	0.4129	0.3849	0.3598	0.530	6605	0.2118	0.1977	0.1941	0.547
4813	0.3258	0.3042	0.2684	0.503	6607	0.1311	0.1224	0.1114	0.573
4901	0.0404	0.0377	0.0372	0.531	6608	0.1913	0.1784	0.1736	0.486
4902	0.0311	0.0291	0.0277	0.529	6704	0.1449	0.1355	0.1264	0.508
4903	0.0404	0.0377	0.0372	0.531	6705	0.7012	0.6555	0.5816	0.552
4904	0.0123	0.0115	0.0109	0.534	6706	0.3193	0.2990	0.2920	0.507
4905	0.2584	0.2413	0.2192	0.575	6707	1.6261	1.5183	1.4239	0.598
4906	0.0459	0.0430	0.0407	0.521	6708	3.7000	3.4899	3.3134	0.442
4907	0.0678	0.0635	0.0589	0.487	6709	0.1524	0.1427	0.1304	0.582
4908	0.1062	0.1001	0.0933	0.492	6801	0.2893	0.2705	0.2704	0.421
4909	0.1062	0.1001	0.0933	0.492	6802	0.2695	0.2521	0.2378	0.501
4910	0.2932	0.2737	0.2491	0.526	6803	1.1117	1.0404	1.0764	0.291
5001	3.3722	3.1496	3.2021	0.410	6804	0.1663	0.1556	0.1517	0.460
5002	0.4378	0.4078	0.3965	0.540	6809	2.3852	2.2431	2.1201	0.527
5003	1.1065	1.0336	1.0137	0.417	6901	0.0285	0.0272	0.0255	0.684
5004	2.7005	2.5148	2.2824	0.488	6902	0.3950	0.3689	0.3551	0.436
5101	0.5708	0.5325	0.4935	0.507	6903	5.4323	5.1028	5.1944	0.287
5103	0.7285	0.6793	0.6186	0.531	6904	0.1524	0.1425	0.1439	0.488
5106	0.5002	0.4689	0.4418	0.455	6905	0.2000	0.1873	0.1813	0.438
5108	0.5979	0.5583	0.5384	0.492	6906	0.0896	0.0855	0.0801	0.684
5109	0.3559	0.3330	0.3143	0.443	6907	1.2058	1.1245	1.0618	0.492
5201	0.2567	0.2400	0.2299	0.484	6908	0.3224	0.3003	0.2757	0.544
5204	0.9684	0.8998	0.8601	0.510	6909	0.0540	0.0506	0.0483	0.503
5206	0.3002	0.2806	0.2772	0.449	7101	0.0217	0.0203	0.0203	0.451
5207	0.1311	0.1224	0.1114	0.573	7102	2.9552	2.7846	2.6911	0.529
5208	0.7466	0.6960	0.6686	0.503	7103	0.1736	0.1621	0.1561	0.499
5209	0.5148	0.4804	0.4455	0.532	7104	0.0391	0.0366	0.0184	0.462
5301	0.0201	0.0188	0.0180	0.508	7105	0.2676	0.2495	0.0310	0.456
5305	0.0277	0.0260	0.0249	0.464	7106	0.5457	0.5086	0.1750	0.487
5306	0.0329	0.0309	0.0294	0.463	7107	1.2513	1.1725	0.1745	0.484
5307	0.2967	0.2770	0.2682	0.517	7108	2.1153	1.9707	0.1757	0.492
6103	0.0391	0.0366	0.0347	0.554	7109	5.2383	4.8932	0.2335	0.537
6104	0.2552	0.2383	0.2199	0.519	7110	0.2749	0.2563	0.2368	0.516
6105	0.1385	0.1294	0.1197	0.530	7111	0.3122	0.2907	0.2723	0.553
6107	0.0959	0.0897	0.0853	0.535	7112	0.5283	0.4925	0.4680	0.472

CLASS	1987	1988	1989	D-RATIO	Base Rates Effective January 1, 1991		
					Class	Accident Fund	Medical Aid Fund
7113	0.5568	0.5195	0.4827	0.455			
7114	0.5296	0.4938	0.4570	0.494			
7115	0.5260	0.4903	0.4545	0.472			
7116	0.5550	0.5174	0.4795	0.480			
7117	1.2579	1.1769	1.0909	0.506	0803	0.2966	0.2375
7118	2.2115	2.0627	1.9117	0.481	0804	0.7743	0.5117
7119	1.9722	1.8380	1.7022	0.484	0901	1.9242	0.9889
7120	5.1854	4.8437	4.4972	0.467	1002	0.8025	0.6541
7121	5.1846	4.8429	4.4965	0.467	1003	0.4962	0.3749
7201	0.6532	0.6068	0.5666	0.536	1004	0.4962	0.3749
7202	0.0290	0.0271	0.0258	0.484	1005	3.8685	2.1981
7203	0.1091	0.1023	0.0945	0.480	1007	0.2070	0.1794
7204	0.0000	0.0000	0.0000	0.684	1101	0.4145	0.3893
7301	0.5485	0.5113	0.4652	0.525	1102	1.0760	0.6496
7302	0.5898	0.5522	0.5226	0.552	1103	0.3480	0.3081
7307	0.8565	0.7959	0.6761	0.573	1104	0.4751	0.4476
7308	0.2039	0.1910	0.1743	0.490	1106	0.1496	0.1946
7309	0.1524	0.1427	0.1304	0.582	1108	0.3850	0.3681
					1109	0.5967	0.5773
					1301	0.2295	0.1824
					1303	0.1918	0.1344
					1304	0.0158	0.0176
					1305	0.2424	0.2151
					1401	0.6355	0.7278
					1404	0.4811	0.4104
					1405	0.4429	0.3773
					1501	0.2909	0.2821
					1507	0.2029	0.2043
					1701	1.7413	0.7666
					1702	1.7413	0.7666
					1703	0.4417	0.2689
					1704	0.8479	0.5716
					1801	1.0244	0.6016
					1802	0.4644	0.4363
					2002	0.5053	0.5075
					2003	0.3270	0.3249
					2004	0.6657	0.5342
					2005	0.2515	0.2943
					2007	0.2752	0.3341
					2008	0.2207	0.1776
					2101	0.4958	0.3812
					2102	0.3270	0.3249
					2104	0.2446	0.2605
					2105	0.4336	0.3486
					2106	0.3414	0.3279
					2201	0.1873	0.1748
					2202	0.3576	0.3919
					2203	0.2559	0.2107
					2401	0.4251	0.3701
					2903	0.5850	0.5617
					2904	0.5449	0.4980
					2905	0.3545	0.3651
					2906	0.4642	0.3273
					2907	0.3955	0.3306
					2908	0.7941	0.6345
					2909	0.5429	0.4580
					3101	0.6623	0.4288
					3102	0.4098	0.3060
					3103	0.4098	0.3060
					3104	0.4132	0.4460
					3105	0.7658	0.5697
					3303	0.1941	0.1830
					3304	0.5642	0.5054
					3309	0.2600	0.3311
					3401	0.3144	0.2786
					3402	0.3262	0.3060
					3403	0.1122	0.1161
					3404	0.3048	0.2997
					3405	0.2034	0.1991
					3406	0.1199	0.1703
					3407	0.2703	0.2128
					3408	0.0834	0.0711
					3409	0.1046	0.1006
					3501	0.6005	0.4834
					3503	0.1568	0.1649

\*Daily expected loss rate

**AMENDATORY SECTION** (Amending WSR 90-24-042, filed 11/30/90, effective 1/1/91)

WAC 296-17-895 INDUSTRIAL INSURANCE ACCIDENT FUND BASE RATES AND MEDICAL AID BASE RATES BY CLASS OF INDUSTRY. Industrial insurance accident fund and medical aid fund base rates by class of industry shall be as set forth below.

Class	Base Rates Effective January 1, 1991	
	Accident Fund	Medical Aid Fund
0101	1.1963	0.6806
0102	1.3225	0.8664
0103	1.1948	0.8453
0104	1.5032	0.6980
0105	0.9554	0.6901
0106	2.4857	2.1245
0107	1.0657	0.5652
0108	1.0529	0.6031
0109	3.2607	1.7599
0201	1.9767	0.9592
0202	2.0413	1.7329
0206	1.8773	0.8357
0301	0.5109	0.4379
0302	1.8681	0.8778
0306	0.8553	0.5514
0307	0.6859	0.4906
0403	0.9276	0.7385
0502	1.1020	0.5976
0504	1.3447	0.8784
0506	3.2648	2.3160
0507	2.7437	1.8854
0508	3.6487	1.8670
0509	1.8730	1.2442
0510	1.2157	0.8201
0511	1.0639	0.6698
0512	1.4133	0.9005
0513	0.7060	0.5235
0514	1.2089	0.8115
0515	2.2891	1.2416
0516	1.7296	1.1097
0517	1.7376	1.1542
0518	1.5331	0.7829
0519	1.6910	1.0500
0601	0.5200	0.4131
0602	0.3498	0.2542
0603	0.7414	0.4872
0604	1.1097	0.6011
0606	0.2062	0.2052
0607	0.2196	0.2180
0608	0.2213	0.1914
0701	2.1000	0.7979

Base Rates Effective January 1, 1991			Base Rates Effective January 1, 1991		
Class	Accident Fund	Medical Aid Fund	Class	Accident Fund	Medical Aid Fund
3506	0.7268	0.4767	5108	0.6175	0.4917
3508	0.3257	0.3008	5109	0.3537	0.2897
3509	0.3307	0.3126	5201	0.2527	0.2214
3510	0.3257	0.3008	5204	1.1664	0.5955
3511	0.3257	0.3008	5206	0.3302	0.2361
3512	0.3257	0.3008	5207	0.1043	0.1296
3602	0.0641	0.0932	5208	0.8053	0.5711
3603	0.4251	0.4334	5209	0.4760	0.4504
3604	1.0512	0.8141	5301	0.0175	0.0199
3605	0.3728	0.3177	5305	0.0248	0.0265
3606	0.6462	0.6302	5306	0.0299	0.0310
3701	0.2171	0.1983	5307	0.2931	0.2638
3702	0.3951	0.2853	6103	0.0304	0.0425
3707	0.3401	0.2741	6104	0.2369	0.2192
3708	0.2118	0.2172	6105	0.1238	0.1252
3801	0.1785	0.1502	6107	0.0818	0.0963
3802	0.1253	0.1371	6108	0.3876	0.4162
3808	0.2199	0.2022	6109	0.0263	0.0304
3901	0.1128	0.1274	6110	0.2650	0.3204
3902	0.4066	0.3896	6201	0.1080	0.1205
3903	0.8077	0.9127	6202	0.4747	0.4389
3905	0.0875	0.1357	6203	0.0611	0.0698
3906	0.3480	0.3181	6204	0.1135	0.1431
3909	0.2109	0.2489	6205	0.1135	0.1431
4002	0.5686	0.4478	6206	0.1135	0.1431
4101	0.1442	0.1752	6207	0.6636	0.8310
4103	0.1970	0.1988	6208	0.1967	0.2148
4107	0.0852	0.0929	6209	0.1437	0.2049
4108	0.1442	0.1752	6301	0.1053	0.0818
4109	0.1442	0.1752	6302	0.1283	0.1253
4201	0.2206	0.1622	6303	0.0489	0.0508
4301	0.6767	0.5833	6304	0.0850	0.1254
4302	0.5868	0.4293	6305	0.0379	0.0623
4303	0.2171	0.1983	6306	0.1812	0.1725
4304	0.4661	0.4862	6308	0.0318	0.0268
4305	1.0580	0.6998	6309	0.0829	0.1141
4401	0.4399	0.3558	6402	0.1828	0.1790
4402	0.5863	0.5118	6403	0.1186	0.1618
4404	0.5191	0.3829	6404	0.1082	0.1366
4501	0.1154	0.0973	6405	0.4452	0.3758
4502	0.0348	0.0288	6406	0.0543	0.0749
4504	0.0514	0.0732	6407	0.1169	0.1607
4601	0.4527	0.5496	6408	0.2522	0.2560
4802	0.2842	0.2716	6409	0.3754	0.4121
4803	0.2201	0.2588	6410	0.1040	0.1169
4804	0.4213	0.4204	6501	0.0558	0.0567
4805	0.2855	0.2732	6502	0.0134	0.0149
4806	0.0649	0.0708	6503	0.0786	0.0523
4808	0.4000	0.3536	6504	0.2105	0.3345
4809	0.1707	0.1933	6505	0.1017	0.1137
4810	0.1238	0.1417	6506	0.0531	0.0712
4811	0.2129	0.2158	6508	0.3067	0.3169
4812	0.4067	0.3395	6509	0.1585	0.1705
4813	0.2842	0.2716	6601	0.1269	0.1639
4901	0.0400	0.0373	6602	0.3608	0.3844
4902	0.0312	0.0263	6603	0.1974	0.2046
4903	0.0400	0.0373	6604	0.0540	0.0443
4904	0.0107	0.0121	6605	0.2129	0.1914
4905	0.2021	0.2587	6607	0.1043	0.1296
4906	0.0418	0.0428	6608	0.2149	0.1411
4907	0.0631	0.0586	6614	147.1050**	171.9950**
4908	0.0635	0.1324	6615	109.7640**	128.3360**
4909	0.0635	0.1324	6616	14.3370**	16.7630**
4910	0.2505	0.2690	6617	10.6490**	12.4510**
5001	4.2256	2.2446	6618	68.7350**	80.3650**
5002	0.4678	0.3543	6704	0.1223	0.1408
5003	1.2838	0.7727	6705	0.5183	0.7021
5004	2.8593	1.8177	6706	0.2880	0.3189
5101	0.5569	0.4629	6707	10.64*	13.37*
5103	0.6738	0.6111	6708	2.7390	4.2020
5106	0.4359	0.4759	6709	0.1010	0.1748

Base Rates Effective  
January 1, 1991

Class	Accident Fund	Medical Aid Fund
6801	0.3366	0.2120
6802	0.2442	0.2488
6803	1.6859	0.4081
6804	0.1687	0.1429
6809	1.5013	2.9637
6901		0.0552
6902	0.4453	0.2763
6903	6.6776	3.6229
6904	0.1616	0.1350
6905	0.1981	0.1733
6906		0.1733
6907	1.2560	0.9301
6908	0.3101	0.2628
6909	0.0475	0.0529
7101	0.0240	0.0175
7102	13.74*	31.73*
7103	0.1788	0.1429
7104	0.0164	0.0216
7105	0.0351	0.0286
7106	0.1955	0.1657
7107	0.1960	0.1641
7108	0.1927	0.1707
7109	0.2564	0.2297
7110	0.2629	0.2283
7111	0.3091	0.2584
7112	0.5797	0.3793
7113	0.5804	0.4077
7114	0.5308	0.4124
7115	0.5546	0.3777
7116	0.5702	0.4160
7117	1.0412	1.2323
7118	2.2324	1.7034
7119	2.0456	1.4557
7120	5.0268	4.2330
7121	5.0262	4.2322
7201	0.7208	0.4515
7202	0.0251	0.0282
7203	0.0835	0.1131
7204		
7301	0.5188	0.4458
7302	0.4670	0.6296
7307	0.7465	0.6666
7308	0.1663	0.1956
7309	0.1010	0.1748

\*Daily rate. The daily rate shall be paid in full on any person for any calendar day in which any duties are performed that are incidental to the profession of the worker.

\*\*These rates are calculated on a per license basis for parimutuel race tracks and are base rated.

**REPEALER**

The following sections of the Washington Administrative Code are repealed:

- WAC 296-17-592 CLASSIFICATION 3508.
- WAC 296-17-603 CLASSIFICATION 3707.

**WSR 91-07-062  
PROPOSED RULES  
SUPERINTENDENT OF  
PUBLIC INSTRUCTION**  
[Filed March 20, 1991, 11:08 a.m.]

Original Notice.  
Title of Rule: Chapter 392-160 WAC, Special service program—Transitional bilingual.

Purpose: Updating procedures for releasing students annually and listing of tests for determining initial eligibility; and technical correction of provisions governing alternative instructional programs, in order to clarify rules.

Statutory Authority for Adoption: Chapter 28A.180 RCW.

Statute Being Implemented: Chapter 28A.180 RCW.

Summary: See Purpose above.

Reasons Supporting Proposal: See Purpose above.

Name of Agency Personnel Responsible for Drafting: Richard M. Wilson, Superintendent of Public Instruction, Old Capitol Building, (206) 753-2298; Implementation: Joe Dial, Superintendent of Public Instruction, Old Capitol Building, (206) 753-2573, and Enforcement: Bridget Cullerton, Superintendent of Public Instruction, Old Capitol Building, (206) 586-6395.

Name of Proponent: Superintendent of Public Instruction, governmental.

Rule is not necessitated by federal law, federal or state court decision.

Explanation of Rule, its Purpose, and Anticipated Effects: See Purpose above.

Proposal Changes the Following Existing Rules: See Purpose above.

No small business economic impact statement is required for this proposal by chapter 19.85 RCW.

Hearing Location: Wanamaker Conference Room, Superintendent of Public Instruction, Old Capitol Building, Olympia, Washington 98504, on April 26, 1991, at 9:00 a.m.

Submit Written Comments to: Richard M. Wilson, Superintendent of Public Instruction, Legal Services, Olympia, Washington 98504, by April 23, 1991.

Date of Intended Adoption: May 3, 1991.

March 19, 1991  
Judith A. Billings  
Superintendent of  
Public Instruction

**AMENDATORY SECTION** (Amending Order 84-41, filed 10/2/84)

WAC 392-160-015 IDENTIFICATION OF ELIGIBLE STUDENTS. (1) District procedures—Identification of primary language required: Every school district board of directors shall adopt written procedures governing the identification of each student's primary language and the determination of which students with a primary language other than English are eligible students. Such procedures shall include:

(a) Provisions for the identification of a student's primary language pursuant to an interview with or a written questionnaire directed to the student and the student's parent(s) or guardian(s), or a combination of interviews and written questionnaires; and

(b) Provisions for testing students as provided for in this section, WAC 392-160-020, and 392-160-035.

(2) Deadline for determining eligibility of newly enrolled students: The primary language and eligibility of each newly enrolled student shall be established no later than the twentieth school day after the date upon which the student commences attendance at a particular school district.

(3) Newly enrolled students who speak little or no English—Determination of eligibility: The eligibility of a newly enrolled student whose eligibility is reasonably apparent by reason of:

(a) The student's ability to communicate reasonably well in his or her non-English primary language; and

(b) The student's inability to communicate in English to any practical extent as determined by an interview with the student by appropriate school district staff. No other approved test need be administered if

the professional judgment of the school personnel is that the student is eligible as defined in WAC 392-160-005(3).

(4) All other newly enrolled students—Determination of eligibility: The eligibility of all newly enrolled students:

(a) Who have a primary language other than English; and

(b) Whose eligibility is not reasonably apparent by reason of the standards established by subsection (3) shall be determined pursuant to WAC 392-160-020.

(5) Annual reassessment of all students required: Each school year each ~~((student who has previously been identified as eligible and admitted to a bilingual instruction or alternative instruction program shall be identified as eligible or ineligible each school year pursuant to the administration of a standardized test as set forth in WAC 392-160-035))~~ school in which an eligible student is enrolled shall conduct a comprehensive evaluation of the overall academic progress of the student. No student may remain in a program of transitional bilingual instruction or alternative instruction program except where the results of the evaluation indicate that lack of English proficiency is impeding the academic progress of the student in meeting grade promotion and graduation requirements and, in the case of a handicapped child, attainment of the objective in the child's individualized education program.

AMENDATORY SECTION (Amending Order 84-41, filed 10/2/84)

WAC 392-160-020 APPROVED TESTS FOR DETERMINING INITIAL ELIGIBILITY—ENGLISH PROFICIENCY SCORES. (1) Approved English proficiency tests: The following tests are approved for the purpose of annually determining the English proficiency of newly enrolled students (other than those who speak little or no English) whose primary language is other than English:

(a) Language assessment scales (LAS A&B, LAS C&D, LAS R/W, Pre-LAS);

(b) Basic inventory of natural language (BINL); ~~((and))~~

(c) Bilingual syntax measure (BSM); and

(d) Secondary level English proficiency test (SLEP).

(2) Scores which establish an English skills deficiency: In the event a student scores within the appropriate range provided by the test maker to establish such English skill deficiency, the student's English skills shall be deemed sufficiently deficient or absent to impair learning

(3) The superintendent of public instruction may approve a school district request for use of a test other than those approved for use in this section when such request is supported by evidence that:

(a) The approved tests for use identified in this section are either unsuitable, inappropriate, or impractical for use by the school district;

(b) The scores that establish English skills deficiency for the requested test correspond with the scores that establish English skills deficiency for approved tests identified in this section; and

(c) The skills being measured by the requested test correspond to the skills measured by the approved tests identified in this section.

AMENDATORY SECTION (Amending Order 84-41, filed 10/2/84)

WAC 392-160-040 ALTERNATIVE INSTRUCTIONAL PROGRAM. School districts under one or more of the following conditions may elect to provide an alternative instructional program:

(1) Necessary instructional materials are unavailable and the district has made reasonable efforts to obtain necessary materials without success;

(2) The capacity of the district's bilingual instruction program is temporarily exceeded by an unexpected increase in the enrollment of eligible students;

(3) Bilingual instruction cannot be provided affected students without substantially impairing their basic education program because of their ~~((disbursement))~~ distribution throughout many grade levels or schools, or both; or

(4) Teachers who are trained in bilingual education methods and sufficiently skilled in the non-English primary language(s) are unavailable, and the district has made reasonable attempts to obtain the services of such teachers.

**WSR 91-07-063**

**PERMANENT RULES  
SUPERINTENDENT OF  
PUBLIC INSTRUCTION**

[Order 91-05—Filed March 20, 1991, 11:14 a.m.]

Date of Adoption: March 8, 1991.

Purpose: To implement RCW 28A.310.330 through 28A.310.460 and establish budgeting procedures governing educational service districts.

Citation of Existing Rules Affected by this Order: Amending WAC 392-125-014.

Statutory Authority for Adoption: RCW 28A.310.330.

Pursuant to notice filed as WSR 91-03-050 on January 14, 1991.

Effective Date of Rule: Thirty-one days after filing.

March 19, 1991  
Judith A. Billings  
Superintendent of  
Public Instruction

NEW SECTION

WAC 392-125-014 EDUCATIONAL SERVICE DISTRICT FISCAL YEAR. The following fiscal years shall be established for educational service districts and shall apply to all governmental, proprietary, and fiduciary fund entities, including all account groups under the jurisdiction of the educational service district board of directors:

There shall be a twelve-month fiscal period of July 1, 1990, through June 30, 1991, for the 1990-1991 fiscal year.

For July and August 1991 there shall be a two-month fiscal period with a budget for this two-month period to be prepared by May 10, 1991.

For fiscal year 1991-1992 there shall be a twelve-month fiscal period beginning September 1, 1991, and ending on August 31, 1992, with a budget to be prepared by July 10, 1991.

For every fiscal year thereafter, a twelve-month fiscal period shall begin on September 1 and end on August 31 with an annual budget to be prepared by July 10th.

AMENDATORY SECTION (Amending Order 85-4, filed 7/24/85)

WAC 392-125-015 BUDGETS REQUIRED. Each educational service district shall prepare in accordance with this chapter and instructions from the superintendent of public instruction a complete general expense fund budget for each fiscal year of operation. An incomplete budget shall be considered null and void and shall not be an appropriation. ~~((The fiscal year for educational service districts commences on July 1st of one year and extends through June 30th of the following year.))~~ The annual budget shall be prepared in the format prescribed by the superintendent of public instruction pursuant to WAC 392-125-036, and shall receive all necessary approvals, and shall be filed with the proper



officials in order to constitute an official budget and appropriation for ~~((the subject))~~ each fiscal year. The superintendent may require a second or revised budget at any time the financial situation is deemed to warrant a revised budget.

AMENDATORY SECTION (Amending Order 85-4, filed 7/24/85)

WAC 392-125-020 BUDGET PREPARATION, HEARING AND ADOPTION. ~~((On or before the 1st day of May,))~~ Each educational service district shall prepare a budget for the operation of the educational service district for the ensuing fiscal year and following completion of the budget, shall publish a notice stating that the budget is completed and placed on file in the district headquarters office with copies available for any interested person or organization. The notice shall state the date, time, and place the educational service district board will meet for the purpose of fixing and adopting the budget of the district for the ensuing fiscal year. ~~((Said meeting shall occur on or before the third Friday in May.))~~ The notice shall also state that any person may appear during the meeting and be heard for or against any part of such budget. The notice shall be published once each week for two consecutive weeks following the completion of the budget in a newspaper of general circulation in the district.

An educational service district board shall secure the signature of the chairman of the superintendents' advisory committee as an indication that the budget has been reviewed by the committee. At the conclusion of the hearing which shall not exceed two days, the board of directors shall adopt the budget by resolution. After the budget has been adopted by the board at the public hearing, two certified copies shall be forwarded to the superintendent of public instruction ~~((on or before the fourth Monday in May))~~ in order that the superintendent may revise and fix the budget according to statute.

AMENDATORY SECTION (Amending Order 84-12, filed 6/13/84)

WAC 392-125-025 BUDGET APPROVAL. The superintendent of public instruction shall revise and fix the annual budget of each educational service district, establish the appropriation and return one approved copy of the budget to the district ~~((prior to the 30th day of June))~~.

NEW SECTION

WAC 392-125-026 JULY AND AUGUST 1991 BUDGET. In order to implement a change in fiscal years, a short fiscal period shall exist from July 1, 1991, through August 31, 1991.

(1) Budgets for the period July 1, 1991, through August 31, 1991, shall be prepared and adopted in the format provided by the office of the superintendent of public instruction. The budget classifications shall be in accordance with the latest revised accounting manual for

educational service districts published by the office of the superintendent of public instruction.

(2) The revenue section of said budget shall set forth the estimated revenues from all sources for said period and the probable fund balance available at the close of the 1990-1991 fiscal year.

(3) The expenditure section of said budget shall set forth by detailed items or classes the estimated expenditures for said period.

NEW SECTION

WAC 392-125-027 TIME SCHEDULE FOR JULY AND AUGUST 1991 BUDGET PROCESS. The time schedule for preparation, adoption, and filing of the July and August 1991 budget is as follows:

ON OR BEFORE	REQUIREMENT
May 10	Final date for board to prepare budget for July and August 1991. Immediately thereafter publish notice of the completion of the budget as provided in WAC 392-125-020.
14 days preceding public hearing	Copies of budget made available to interested citizens.
June 3, 1991	Final date for board in public hearing to fix and adopt the budget. (The maximum time for this hearing is two days.)
Conclusion of hearing	Board resolution to adopt budget (obtain signature of chairman of superintendents' advisory committee).
June 6, 1991	Forward two properly signed copies of budget to superintendent of public instruction.
June 28, 1991	Superintendent revises, fixes and approves budget and returns one copy to the district.

AMENDATORY SECTION (Amending Order 85-4, filed 7/24/85)

WAC 392-125-030 TIME SCHEDULE FOR FISCAL YEAR 1991-1992 BUDGET PROCESS AND FOR EVERY FISCAL YEAR THEREAFTER. The time schedule for preparation, adoption, and filing of the fiscal year 1991-1992 annual budget ~~((of an educational service district))~~ and the budget for every year thereafter is as follows: If the superintendent of public instruction deems it necessary to request a second and revised budget, the timing of the process shall be similar and shall be outlined specifically in the request.

ON OR BEFORE	REQUIREMENT
<del>((May 1))</del> <u>July 10</u>	Final date for board to prepare budget. Immediately thereafter publish notice of the completion of the budget as provided in WAC 392-125-020.
<del>((2 weeks preceding public hearing))</del> <u>July 15</u>	Copies of budget made available to interested citizens.
<del>((3rd Friday in May))</del> <u>August 1</u>	Final date for board in public hearing to fix and adopt the budget. (The maximum time for this hearing is two days.)
Conclusion of hearing	Board resolution to adopt budget (obtain signature of chairman of superintendents' advisory committee).
<del>((4th Monday in May))</del> <u>August 3</u>	Forward two properly signed copies of budget to superintendent of public instruction.
<del>((June))</del> <u>August 31</u>	Superintendent revises, fixes and approves budget and returns one copy to the district.

**AMENDATORY SECTION** (Amending Order 81-19, filed 9/4/81)

WAC 392-125-085 FINANCIAL REPORTS SUBMITTED TO SUPERINTENDENT OF PUBLIC INSTRUCTION. Within ~~((thirty))~~ ninety calendar days following the end of ~~((September, December, March, and June))~~ its fiscal year, each educational service district shall submit a financial report to the superintendent of public instruction. Said report shall be in the format specified by the superintendent of public instruction.

**WSR 91-07-064  
PROPOSED RULES  
ENGINEERS AND LAND  
SURVEYORS REGISTRATION BOARD**  
[Filed March 20, 1991, 11:29 a.m.]

Original Notice.  
Title of Rule: WAC 196-24-060 Renewals.  
Purpose: Regulation of the engineering and land surveying professions.  
Statutory Authority for Adoption: RCW 18.43.035.  
Statute Being Implemented: Chapter 18.43 RCW.

Summary: Implement a two year renewal cycle for individuals licensed as a professional engineer or land surveyor.

Reasons Supporting Proposal: Increase efficiency of the program by decreasing (50%) the number of renewal transactions each year.

Name of Agency Personnel Responsible for Drafting, Implementation and Enforcement: Alan E. Rathbun, 2424 Bristol Court S.W., Olympia, 753-3624.

Name of Proponent: Board of Registration for Professional Engineers and Land Surveyors, governmental.

Rule is not necessitated by federal law, federal or state court decision.

Explanation of Rule, its Purpose, and Anticipated Effects: Implements a two year renewal cycle for licensed individuals commencing with July 1, 1991. Additionally, this rule describes the establishment of an initial license renewal date.

Proposal Changes the Following Existing Rules: WAC 196-24-060, changes an annual renewal period to a two year renewal period. Implements this amendment through a staggered system of birthdate renewal starting with those renewals due July 1, 1991.

No small business economic impact statement is required for this proposal by chapter 19.85 RCW.

Hearing Location: Ramada Inn, Spokane International Airport, Spokane, Washington, on May 3, 1991, at 11:00 a.m.

Submit Written Comments to: Alan E. Rathbun, P.O. Box 9649, Olympia, WA 98504, by May 1, 1991.

Date of Intended Adoption: May 3, 1991.

March 19, 1991  
Alan E. Rathbun, P.E.  
Executive Director

**AMENDATORY SECTION** (Amending WSR 90-21-034, filed 10/10/90, effective 11/10/90)

WAC 196-24-060 RENEWALS ~~((FEES)).~~ (1) ~~((Renewals are issued on an annual basis.))~~ The director of the department of licensing has determined that all licenses for individuals registered as a professional engineer and/or professional land surveyor shall expire on the licensee's birth date. Renewals for individuals shall be issued for a two-year period. It shall be the licensee's responsibility to submit payment of the prescribed renewal fee to the department of licensing on or before the date of expiration.

(2) ~~((Under the staggered license renewal system the late payment penalty provision will be applied as follows:))~~ Effective with renewals due on July 1, 1991, and continuing through those due on June 30, 1992, the renewal period for engineers and land surveyors will be converted from one to two years. This conversion will be accomplished as follows:

(a) Current licensees as of July 1, 1991, with a birth date which is an even number shall initially renew for one year. All subsequent renewals shall be for a two-year period.

(b) Current licensees as of July 1, 1991, with a birth date which is an odd number shall initially renew for a two-year period. All subsequent renewals shall be for a two-year period.

(3) The initial license issued to an individual shall expire on the licensee's next birth date. However, if the licensee's next birth date is within three months of the initial date of licensure, the original license shall expire on his or her second birth date following original licensure. All subsequent renewals shall be for a two-year period.

(4) Before the expiration date of the individual's license the director of the department of licensing shall mail a notice for renewal of license to the last known address of every person holding a current license. The licensee must return such notice along with current renewal fees prior to the expiration of said license. Regardless of whether a renewal notice is received by the licensee, said license shall become invalid if

the required fee is not paid by the date of expiration. If the licensee fails to pay the prescribed renewal fees within ninety days after the expiration date of the license, then the renewal fee will be the current fee plus an amount equal to one year's renewal fee.

((3)) (5) The renewal fee for engineers, land surveyors, engineering corporations and engineering partnerships are determined by the director of the department of licensing.

**WSR 91-07-065**  
**PROPOSED RULES**  
**DEPARTMENT OF LICENSING**  
[Filed March 20, 1991, 11:31 a.m.]

**Original Notice.**

Title of Rule: WAC 196-26-020 Engineer fees; and 196-26-030 License renewals.

Purpose: Regulation of the engineering and land surveying professions.

Statutory Authority for Adoption: RCW 43.24.086 and 43.24.140.

Statute Being Implemented: Chapter 18.43 RCW.

Summary: Increase fees as required to offset the cost to regulate professions. Additionally implement a two year license renewal for engineers and land surveyor.

Reasons Supporting Proposal: State law, RCW 43.24.086, requires all costs to be recovered through collection of fees from the profession. Extension of the renewal period from one to two years will allow for more efficient operation of the program.

Name of Agency Personnel Responsible for Drafting, Implementation and Enforcement: Alan E. Rathbun, 2424 Bristol Court S.W., Olympia, 753-3634.

Name of Proponent: Department of Licensing, governmental.

Rule is not necessitated by federal law, federal or state court decision.

Explanation of Rule, its Purpose, and Anticipated Effects: The rule amends existing examination and renewal fees as required to recover the cost of regulating the professions of engineering and land surveying. This rule also implements a two year renewal cycle beginning on July 1, 1991.

Proposal Changes the Following Existing Rules: WAC 196-26-020, revise fees pertaining to engineer application (exam and reciprocity) and reexamination together with renewal fees for both engineers and land surveyors; and WAC 196-26-030, amends renewal period for individuals from one to two years. Describes how implementation will be staggered commencing July 1, 1991.

No small business economic impact statement is required for this proposal by chapter 19.85 RCW.

Hearing Location: Department of Licensing, Professional Licensing Services, 2424 Bristol Court S.W., 3rd Floor Conference Room, Olympia, WA, on April 23, 1991, at 10:00 a.m.

Submit Written Comments to: Alan E. Rathbun, P.O. Box 9649, Olympia, WA 98504, by April 22, 1991.

Date of Intended Adoption: April 23, 1991.

March 19, 1991  
Marsha Tadano Long  
Assistant Director

**AMENDATORY SECTION** (Amending WSR 90-03-028, filed 1/11/90, effective 2/11/90)

WAC 196-26-020 ENGINEER FEES. The following fees shall be charged by the professional licensing services division of the department of licensing:

Title of Fee	Fee
<b>Engineers:</b>	
Application and examination	\$ ((75-00)) 100.00
Specialty exam (structural, sanitary)	((150-00)) 175.00
Examination retake (2nd subsequent or more)	((70-00)) 90.00
Specialty exam retake (2nd subsequent or more)	((140-00)) 160.00
Reciprocity	((75-00)) 100.00
Engineer certificate (initial registration)	25.00
Replacement certificate	25.00
Exam (locally prepared) rescore	50.00
Renewal (per year)	((70-00)) 75.00
Late renewal penalty	((70-00)) 75.00
Duplicate license	15.00
<b>Engineer in training:</b>	
Application, examination and certificate	50.00
Examination retake (2nd subsequent or more)	50.00
Replacement certificate	25.00
<b>Land surveyor:</b>	
Application, examination and certificate	100.00
FLS examination retake (2nd subsequent or more)	40.00
PPLS examination retake (2nd subsequent or more)	60.00
Reciprocity	100.00
PPLS exam rescore	50.00
Renewal (per year)	((70-00)) 75.00
Late renewal penalty	((70-00)) 75.00
Replacement certificate	25.00
Duplicate license	15.00
<b>Engineer corporation:</b>	
Certificate of authorization	300.00
Renewal	175.00
Duplicate license	15.00
Replacement certificate	25.00
<b>Engineer partnership:</b>	
Certification of authorization	300.00
Renewal	175.00
Replacement certificate	25.00
Duplicate license	15.00

**AMENDATORY SECTION** (Amending WSR 90-21-033, filed 10/10/90, effective 11/10/90)

WAC 196-26-030 LICENSE RENEWALS. The licenses for those individuals registered as a professional engineer and/or a professional land surveyor shall be renewed ((annually)) every two years. The date of renewal shall be the licensee's birth date. Licensees who fail to pay the prescribed renewal fee within ninety days of the license expiration date will be subject to the late payment penalty fee as set forth in WAC 196-24-060.

Effective with renewals due on July 1, 1991, and continuing through those due on June 30, 1992, the renewal period for engineers and land surveyors will be converted from one to two years. This conversion will be accomplished as follows:

(1) Current licensees as of July 1, 1991, with a birth date which is an even number shall initially renew for one year. All subsequent renewals shall be for a two-year period.

(2) Current licensees as of July 1, 1991, with a birth date which is an odd number shall initially renew for a two-year period. All subsequent renewals shall be for a two-year period.

The initial license issued to an individual shall expire on the licensee's next birth date. However, if the licensee's next birth date is within three months of the initial date of licensure, the original license shall expire on his or her second birth date following original licensure. All subsequent renewals shall be for a two-year period.

The certificates of authorization for corporations and partnerships shall be renewed annually. The date of renewal shall be the last day of

the month of December. Failure to pay the prescribed fee by the date of expiration shall cause the certificate to become invalid.

**WSR 91-07-066**  
**PERMANENT RULES**  
**DEPARTMENT OF ECOLOGY**  
 [Order 90-58—Filed March 20, 1991, 2:56 p.m.]

Date of Adoption: March 19, 1991.

Purpose: The amendments to chapter 173-433 WAC incorporate and help implement requirements of RCW 70.94.473, [70.94.]477, [70.94.]483 and [70.94.]715, as amended by the 1990 legislature. The amendments also include a lower opacity limit for stove emissions and reflect the latest emission performance standards of the Environmental Protection Agency.

Citation of Existing Rules Affected by this Order: Amending chapter 173-433 WAC.

Statutory Authority for Adoption: Chapter 70.94 RCW.

Pursuant to notice filed as WSR 90-23-098 on November 21, 1990.

Changes Other than Editing from Proposed to Adopted Version: WAC 173-433-150(3), as proposed and printed in the state register, has been deleted. The following subsections and burn-ban matrix have been renumbered and revised accordingly.

Effective Date of Rule: Thirty-one days after filing.  
 March 19, 1991  
 Fred Olson  
 Deputy Director

Chapter 173-433 WAC  
**SOLID FUEL BURNING DEVICES** ((STAN-  
 DARDS))

**AMENDATORY SECTION** (Amending Order 90-10, filed 9/17/90, effective 10/18/90)

WAC 173-433-030 DEFINITIONS. The definitions of terms contained in chapter 173-400 WAC are incorporated by reference. Unless a different meaning is clearly required by context, the following words and phrases as used in this chapter, shall have the following meanings:

(1) "Adequate source of heat" means the ability to maintain seventy degrees Fahrenheit at a point three feet above the floor in all normally inhabited areas of a dwelling.

(2) "Certified" means that a woodstove meets emission performance standards when tested by an accredited independent laboratory and labeled according to ((EPA or DEQ)) procedures specified by the EPA in "40 CFR 60 Subpart AAA - Standards of Performance for Residential Wood Heaters" as amended through July 1, 1990.

(3) "Coal-only heater" means an enclosed, coal burning appliance capable of and intended for residential space heating, domestic water heating, or indoor cooking, which has all of the following characteristics:

(a) An opening for emptying ash which is located near the bottom or the side of the appliance;

(b) A system which admits air primarily up and through the fuel bed;

(c) A grate or other similar device for shaking or disturbing the fuel bed or power driven mechanical stoker; and

(d) The model is listed by a nationally recognized safety testing laboratory for use of coal only, except for coal ignition purposes.

~~(4) ("Dealer" means a person other than a manufacturer or a retailer who is engaged in selling solid fuel burning devices to retailers or others for resale.~~

~~(5) "DEQ" means Oregon department of environmental quality.~~

~~(6)) "EPA" means United States Environmental Protection Agency.~~

~~((7) "Impaired air quality" means a condition declared by ecology or an authority whenever:~~

~~(a) Meteorological conditions are conducive to an accumulation of air contamination concurrent with:~~

~~(i) Total suspended particulate at an ambient level of one hundred twenty-five micrograms per cubic meter measured on a twenty-four hour average; or~~

~~(ii) Particulate that is ten micron and smaller in diameter (PM10) at an ambient level of ninety micrograms per cubic meter measured on a twenty-four hour average; or~~

~~(iii) Carbon monoxide at an ambient level of eight parts of contaminant per million parts of air by volume (ppm) measured on an eight-hour average; or~~

~~(b) Air quality reaches other limits established by ecology or an authority.~~

~~(8) "Manufacturer" means any person who constructs or imports a solid fuel burning device or parts for a solid fuel burning device.~~

~~(9)) (5) "New woodstove" means a woodstove that has not been sold at retail, bargained, exchanged, or given away for the first time by the manufacturer, the manufacturer's dealer or agency, or a retailer, and has not been so used as to become what is commonly known as "second hand" within the ordinary meaning of that term.~~

~~((+0)) (6) "Nonaffected pellet stove" means that a pellet stove has an air-to-fuel ratio equal to or greater than 35.0 when tested by an accredited laboratory in accordance with methods and procedures specified by the EPA in "40 CFR 60 Appendix A, REFERENCE METHOD 28A - MEASUREMENT OF AIR TO FUEL RATIO AND MINIMUM ACHIEVABLE BURN RATES FOR WOOD-FIRED APPLIANCES" as amended through July 1, 1990.~~

~~(7) "Retailer" means any person engaged in the sale of solid fuel burning devices directly to the public. A contractor who sells dwellings with solid fuel burning devices installed or a mail order outlet which sells solid fuel burning devices directly to the public is considered to be a solid fuel burning device retailer.~~

~~((+1)) (8) "Seasoned wood" means wood of any species that has been sufficiently dried so as to contain twenty percent or less moisture by weight.~~

~~((+2)) (9) "Solid fuel burning device" (same as solid fuel heating device) means a device that burns wood,~~

coal, or any other nongaseous or nonliquid fuels, and includes any device burning any solid fuel except those prohibited by WAC 173-433-120. This also includes devices used for aesthetic or space-heating purposes in a private residence or commercial establishment, which has a heat input less than one million British thermal units per hour.

~~((+3))~~ (10) "Treated wood" means wood of any species that has been chemically impregnated, painted, or similarly modified to prevent weathering(;) and deterioration(, and damage due to insects).

~~((+4))~~ (11) "Woodstove" (same as "wood heater") means an enclosed solid fuel burning device capable of and intended for residential space heating and domestic water heating that meets ~~((all of the following criteria:~~

~~(a) For the purposes of determining qualification under "Oregon Administrative Rules, Chapter 340, Division 21 - Woodstove Certification" dated November 1984: An air-to-fuel ratio in the combustion chamber less than 30.0 during the burning of ninety percent or more of the fuel mass consumed in the low firing cycle. The low firing cycle means less than or equal to twenty-five percent of the maximum burn rate achieved with the doors closed or the minimum burn rate achievable, whichever is greater; or~~

~~(b) For the purposes of determining qualification under~~ the following criteria contained in "40 CFR 60 Subpart AAA - Standards of Performance for Residential Wood Heaters" ~~((dated February 26, 1988)) as amended through July 1, 1990:~~

~~((+i)) (a) An air-to-fuel ratio in the combustion chamber averaging less than 35.0, as determined by EPA Reference Method 28A;~~

~~((+ii)) (b) A useable firebox volume of less than twenty cubic feet;~~

~~((+iii)) (c) A minimum burn rate less than 5 kg/hr as determined by EPA Reference Method 28;~~

~~((+iv)) (d) A maximum weight of 800 kg, excluding fixtures and devices that are normally sold separately, such as flue pipe, chimney, and masonry components not integral to the appliance.~~

Any combination of parts, typically consisting of but not limited to(,); Doors, legs, flue pipe collars, brackets, bolts and other hardware, when manufactured for the purpose of being assembled, with or without additional owner supplied parts, into a woodstove, is considered a woodstove.

#### AMENDATORY SECTION (Amending Order 90-10, filed 9/17/90, effective 10/18/90)

WAC 173-433-100 EMISSION PERFORMANCE STANDARDS. ~~((+))~~ Woodstove sales. A person shall not advertise to sell, offer to sell, sell, bargain, exchange, or give away a new woodstove in Washington unless it has been tested to determine its emission performance and heating efficiency and certified and labeled in accordance with procedures and criteria specified(:

~~(a) Requirements for sale of new woodstoves in Washington after July 1, 1988;~~

~~(i) By the DEQ in "Oregon Administrative Rules, Chapter 340, Division 21 - Woodstove Certification"~~

~~dated November 1984, is adopted by reference and on file at ecology; or~~

~~(ii) By the EPA)) in "40 CFR 60 Subpart AAA - Standards of Performance for Residential Wood Heaters" ((dated February 26, 1988, is adopted by reference and on file at ecology)) as amended through July 1, 1990.~~

~~((b) Requirements for sale of new solid fuel burning devices in Washington after July 1, 1990; a person shall not advertise to sell, offer to sell, sell, bargain, exchange, or give away a new woodstove in Washington unless it has been tested to determine its emission performance and heating efficiency, certified and labeled in accordance with criteria and procedures specified by the EPA in "40 CFR 60 Subpart AAA - Standards of Performance for Residential Wood Heaters" dated February 26, 1988, and is adopted by reference and on file at ecology:~~

~~(2) Exemptions. The following solid fuel burning devices are exempt from the requirements of this section:~~

~~(a) Solid fuel burning devices sold at retail on or before July 1, 1988.~~

~~(b) Any solid fuel burning device exempted under "Oregon Administrative Rules, Chapter 340, Division 21 - Woodstove Certification" dated November 1984, bearing the appropriate labeling or written proof of exempt status furnished by the DEQ.~~

~~(c) Any solid fuel burning device exempted under "40 CFR 60 Subpart AAA - Standards of Performance for Residential Wood Heaters" as amended through July 1, 1988, section 60.530, paragraphs (a), (b), (c), (e), (f), (g), (h), or (i), bearing the appropriate labeling or exempt status furnished by the EPA.~~

~~(3) General certification procedures. A solid fuel burning device that is exempt and therefore not eligible for certification under DEQ or EPA regulations may be tested to demonstrate its emission performance in accordance with criteria and procedures no less stringent than those imposed under "40 CFR 60 Subpart AAA - Standards of Performance for Residential Wood Heaters" as amended through July 1, 1988, subject to the following conditions:~~

~~(a) All criteria and procedures shall be submitted by the applicant for review and approval by ecology prior to certification testing;~~

~~(b) Certification of the solid fuel burning device shall be granted by ecology upon approval of test results that demonstrate that the solid fuel burning device meets emission performance standards equivalent to those under "40 CFR 60 Subpart AAA - Standards of Performance for Residential Wood Heaters" as amended through July 1, 1988.~~

~~(c) The certification of a woodstove shall be valid for only the specific model, design, plans and specifications that were originally submitted, tested and approved for certification.~~

~~(4) State-wide emission performance standards. An authority shall not adopt or enforce emission performance standards for solid fuel burning devices that are more stringent than the state-wide standard.~~

~~(5) Emission performance standards for certification.~~

~~(a) A new woodstove advertised for sale, offered for sale, or sold in Washington after July 1, 1988, bearing a~~

~~DEQ certification label shall not exceed the standards for particulate matter under Section 340-21-115; "Oregon Administrative Rules, Chapter 340, Division 21 - Woodstove Certification" dated November 1984.~~

~~(b) A new woodstove advertised for sale, offered for sale, or sold in Washington after July 1, 1988, bearing an EPA certification label shall not exceed the standards for particulate matter under "40 CFR 60 Subpart AAA - Standards of Performance for Residential Wood Heaters" as amended through July 1, 1988.~~

~~(6) Labeling requirements:~~

~~(a) Woodstoves required to be labeled pursuant to subsection (1)(a)(i) of this section shall have labeling required by the DEQ in "Oregon Administrative Rules, Chapter 340, Division 21 - Woodstove Certification" dated November 1984.~~

~~(b) Woodstoves or other solid fuel burning devices required to be labeled pursuant to subsection (1)(a)(ii) or (b) of this section shall have labeling required by the EPA under "40 CFR 60 Subpart AAA - Standards of Performance for Residential Wood Heaters" dated February 26, 1988.~~

~~(7) Label alteration. A manufacturer, dealer, or retailer shall not alter either the permanent or removable label in any way from the label approved by the EPA or the DEQ.~~

~~(8) Woodstove alteration. A manufacturer, dealer, or retailer shall not remove or render inoperable any devices or components of any systems installed by the manufacturer of a woodstove for the purpose of controlling air contaminant emissions, other than for replacement or routine maintenance.~~

~~(9) Alternative testing procedure. A Washington state manufacturer who believes his solid fuel burning device, for technical reasons, should be subject to an alternative testing procedure to that established by the EPA may apply to ecology for an alternative or modified procedure. Ecology will evaluate such applications. If disapproved, the solid fuel burning device shall remain subject to the EPA testing protocol. If the application is approved, the manufacturer shall propose an alternative or modified testing procedure. If the procedure is approved by ecology, it shall be the responsibility of the manufacturer to submit the device to an accredited testing laboratory and furnish ecology with final test reports. If test results are equivalent to those required by EPA testing, Washington certification may be issued. Interim certification, for a period not to exceed sixty days, may be issued by ecology to cover the testing period. Interim certification may be renewed.))~~

AMENDATORY SECTION (Amending Order 90-10, filed 9/17/90, effective 10/18/90)

~~WAC 173-433-110 OPACITY STANDARDS. (1) ((Phase 1 opacity level. A person shall not cause or allow emission of a smoke plume from any solid fuel burning device to exceed an average of forty percent opacity for six consecutive minutes in any one-hour period.~~

~~(2) Phase 2 opacity level. After July 1, 1990,)) A person shall not cause or allow emission of a smoke plume from any solid fuel burning device to exceed an~~

average of twenty percent opacity for six consecutive minutes in any one-hour period.

~~((3)) (2) State-wide opacity standard. An authority shall not adopt or enforce an opacity level for solid fuel burning devices that is more stringent than the state-wide standard.~~

~~((4)) (3) Test method and procedures. ((EPA)) Methods and procedures specified by the EPA in "40 CFR 60 Appendix A reference method 9 - VISUAL DETERMINATION OF THE OPACITY OF EMISSIONS FROM STATIONARY SOURCES" as amended through July 1, 1990, shall be used to determine compliance with subsection((s)) (1) ((and (2))) of this section.~~

~~((5)) (4) Enforcement. Smoke visible from a chimney, flue or exhaust duct in excess of the opacity standard shall constitute prima facie evidence of unlawful operation of an applicable solid fuel burning device. This presumption may be refuted by demonstration that the smoke was not caused by an applicable solid fuel burning device. The provisions of this requirement shall:~~

~~(a) Be enforceable on a complaint basis.~~

~~(b) Not apply during the starting of a new fire for a period not to exceed twenty minutes in any four-hour period.~~

AMENDATORY SECTION (Amending Order 90-10, filed 9/17/90, effective 10/18/90)

WAC 173-433-120 PROHIBITED FUEL TYPES.

A person shall not cause or allow any of the following materials to be burned in a solid fuel burning device:

- (1) Garbage;
- (2) Treated wood;
- (3) Plastic and plastic products;
- (4) Rubber products;
- (5) Animal carcasses;
- (6) Asphaltic products;
- (7) Waste petroleum products;
- (8) Paints and chemicals; or
- (9) Any substance(;) which normally emits dense smoke or obnoxious odors other than paper to start the fire, properly seasoned fuel wood, or coal with sulfur content less than 1.0% by weight burned in a coal-only heater(, which normally emits dense smoke or obnoxious odors)).

AMENDATORY SECTION (Amending Order 90-10, filed 9/17/90, effective 10/18/90)

WAC 173-433-130 GENERAL EMISSION STANDARDS. In addition to the general applicability of chapter 173-400 WAC to all emission sources;

(1) Emissions detrimental to persons or property. No person shall cause or permit the emission of any air contaminant from ~~((any))~~ an identifiable solid fuel burning device, including any air contaminant whose emission is not otherwise prohibited by this chapter, if the air contaminant emission ((directly impacts the property of another so as to)) causes detriment to the health, safety, or welfare of a person, plant or animal, or causes damage to property or business. ~~((Direct impact means that emissions from an identifiable solid fuel burning device~~

~~are present in amounts which reasonably constitute a threat to the health, safety, or welfare of a person(s):))~~

(2) Odors. Any person who shall cause or allow the generation of any odor from any solid fuel burning device which may interfere with any other property owner's use or enjoyment of his property must use recognized good practice and procedures to reduce these odors to a reasonable minimum.

#### NEW SECTION

**WAC 173-433-140 IMPAIRED AIR QUALITY CRITERIA.** Impaired air quality shall be determined by ecology or an authority in accordance with the following criteria:

(1) "First Stage Impaired Air Quality" – the first stage indicates the presence of:

(a) Particulate matter ten microns and smaller in diameter (PM<sub>10</sub>) at or above an ambient level of seventy-five micrograms per cubic meter; or

(b) Carbon monoxide at or above an ambient level of eight parts of contaminant per million parts of air by volume (ppm).

(2) "Second Stage Impaired Air Quality" – the second stage indicates the presence of particulate matter ten microns and smaller in diameter (PM<sub>10</sub>) at or above an ambient level of one hundred five micrograms per cubic meter.

(3) On or after July 1, 1995, if an authority has geographically limited the use of solid fuel burning devices as specified under WAC 173-433-150(6), a single stage of impaired air quality will apply within the geographical area defined by the authority. A single stage of impaired air quality indicates the presence of:

(a) Particulate matter ten microns and smaller in diameter (PM<sub>10</sub>) at or above an ambient level of ninety micrograms per cubic meter; or

(b) Carbon monoxide at or above an ambient level of eight parts of contaminant ppm.

(4) Acceptable ambient air quality measurement methods.

(a) Particulate matter ten microns and smaller in diameter (PM<sub>10</sub>).

(i) Procedures specified by the EPA in "40 CFR 50, APPENDIX J – REFERENCE METHOD FOR THE DETERMINATION OF PARTICULATE MATTER AS PM<sub>10</sub> IN THE ATMOSPHERE" as amended through July 1, 1990, shall be used to gather reference ambient PM<sub>10</sub> data on a twenty-four-hour average.

(ii) More timely ambient PM<sub>10</sub> measurement methods may be utilized to evaluate air quality impairment if accepted and approved by ecology. Any alternative method for evaluating air quality impairment for the purpose of curtailing solid fuel burning device use must be done at the same location and in parallel to the reference method, and must be related to the reference method by a mathematical relationship with a correlation coefficient of no less than 0.85.

(b) Carbon monoxide (CO) must be measured on an eight-hour average in accordance with procedures specified by the EPA in "40 CFR 50, APPENDIX C – REFERENCE METHOD FOR THE DETERMINATION OF CARBON MONOXIDE IN THE ATMOSPHERE (NON-DISPURIVE INFRARED PHOTOMETRY)" as amended through July 1, 1990.

(c) All monitors used to measure PM<sub>10</sub> for evaluation of air quality impairment due to solid fuel burning device use must be sited in accordance with EPA siting criteria in or near affected residential areas.

**AMENDATORY SECTION** (Amending Order 90-10, filed 9/17/90, effective 10/18/90)

**WAC 173-433-150 CURTAILMENT.** (1) ~~((A person in a residence or commercial establishment with an adequate source of heat other than the burning of solid fuel shall not burn solid fuel in any solid fuel burning device.~~

~~(a) Whenever ecology has declared an air pollution episode for the geographical area pursuant to chapter 173-435 WAC, or~~

~~(b) Whenever ecology or an authority has declared impaired air quality for the geographical area, except when the solid fuel burning device is certified under WAC 173-433-100:))~~ Whenever ecology or an authority has declared the first stage of impaired air quality for a geographical area a person in a residence or commercial establishment within that geographical area with an adequate source of heat other than a solid fuel burning device shall not operate any solid fuel burning device, unless the solid fuel burning device is one of the following:

(a) A nonaffected pellet stove; or

(b) A woodstove certified and labeled by the EPA under "40 CFR 60 Subpart AAA – Standards of Performance for Residential Wood Heaters" as amended through July 1, 1990; or

(c) A woodstove meeting the "Oregon Department of Environmental Quality Phase 2" emissions standards contained in Subsections (2) and (3) of Section 340-21-115, and certified in accordance with "Oregon Administrative Rules, Chapter 340, Division 21 – Woodstove Certification" dated November 1984.

(2) Whenever ecology or an authority has declared the second stage of impaired air quality for a geographical area a person in a residence or commercial establishment within that geographical area with an adequate source of heat other than a solid fuel burning device shall not operate any solid fuel burning device.

(3) Whenever ecology has declared an air pollution episode at a level above forecast a person in a residence or commercial establishment within that geographical area with an adequate source of heat other than a solid fuel burning device shall not operate any solid fuel burning device.

(4) The following matrix graphically illustrates the applicability of different types of solid fuel burning devices to the provisions of subsections (1) through (3) of this section:

Burn Condition  Type of Device	Impaired Air Quality		Episode	
	First Stage	Second Stage	Forecast	Alert, Warning, or Emergency
Pellet Stove (non-affected)	OK	NO	OK	NO
EPA Certified Woodstove	OK	NO	OK	NO
DEQ Phase 2 Woodstove	OK	NO	OK	NO
EPA Exempted Device	NO	NO	OK	NO
All Other Devices	NO	NO	OK	NO

NOTES: "OK" indicates that the device may be operated  
 "NO" indicates that the device may not be operated

(5) On or after July 1, 1995, an authority may prohibit use of solid fuel burning devices within specific geographical areas:

(a) The following factors shall be considered in the exercise of this limitation:

(i) The contribution of solid fuel devices that do not meet the standards set forth in "40 CFR 60 Subpart AAA - Standards of Performance for Residential Wood Heaters" as amended through July 1, 1990, to nonattainment of national ambient air quality standards;

(ii) The population density of the applicable geographical area; and

(iii) The public health effects of the use of solid fuel devices which do not meet the standards set forth in "40 CFR 60 Subpart AAA - Standards of Performance for Residential Wood Heaters" as amended through July 1, 1990.

(b) The following solid fuel devices are exempted from this limitation:

(i) Fireplaces;

(ii) Woodstoves certified and labeled by the EPA under "40 CFR 60 Subpart AAA - Standards of Performance for Residential Wood Heaters" as amended through July 1, 1990; or

(iii) Nonaffected pellet stoves.

(c) An authority shall allow an exemption from this subsection for low-income persons who reside in the geographical area affected by this subsection.

(6) On or after July 1, 1995, whenever an authority has declared impaired air quality in accordance with criteria contained in WAC 173-433-140(3) for a geographical area defined under subsection (5) of this section, a person in a residence or commercial establishment within that geographical area shall not operate any solid fuel burning device.

((2)) (7) A person responsible for ((a)) an applicable solid fuel burning device already in operation at the time an episode is declared shall withhold new solid fuel for the duration of the episode. A person responsible for ((a)) an applicable solid fuel burning device ((that is not certified under WAC 173-433-100)) already in operation at the time impaired air quality is declared shall withhold new solid fuel for the duration of the impaired air quality. Smoke visible from a chimney, flue or exhaust duct after three hours has elapsed from the declaration of the episode or impaired air quality shall constitute prima facie evidence of unlawful operation of an

applicable solid fuel burning device. This presumption may be refuted by demonstration that the smoke was not caused by a solid fuel burning device.

((3)) (8) Ecology, authorities, health departments, fire departments, or local police forces having jurisdiction in the area may enforce compliance with the above solid fuel burning device curtailment rules after three hours has elapsed from the declaration of the episode or impaired air quality.

AMENDATORY SECTION (Amending Order 88-38, filed 1/3/89)

WAC 173-433-170 RETAIL SALES FEE. (1) A person selling a solid fuel burning device at retail shall ((impose upon the buyer a fee)) collect a fee from the buyer, pursuant to RCW 70.94.483.

(2) The fee shall be:

(a) Set at a minimum of ((five)) fifteen dollars, until January 1, ((1989, and annually)) 1991. Thereafter ((it may be adjusted upward according to increases)), ecology may annually increase the fee according to changes in the consumer price index;

(b) Applicable to all new and used solid fuel burning devices, with the exception of built-in masonry fireplaces;

(c) Collected by the retailer at the time of sale and remitted to the department of revenue in conjunction with the retail sales tax under chapter 82.08 RCW.

(3) If the ((seller should)) retailer fails to collect ((the fee herein imposed or)) and remit the fee to the department of revenue as prescribed in chapter 82.08 RCW, the ((seller)) retailer shall be personally liable to the state for the amount of the fee, with subsequent actions taken in accordance with the collection provisions of chapter 82.32 RCW.

(4) Beginning July 1, 1990, and each calendar quarter thereafter, the funds collected under RCW 70.94.483 shall be used solely for the purposes of public education and enforcement of the solid fuel burning device program. The department shall distribute the funds from the woodstove education and enforcement account as follows:

(a) Sixty-six percent of the funds shall be distributed to those local air authorities with enforcement programs, based upon the fraction of the total state population residing in the counties within their respective jurisdictions. Population figures used to establish this fraction shall be determined by the office of financial management. Where an activated local air authority does not exist or does not implement an enforcement program, or elects not to receive the funds, ecology shall retain the funds that would otherwise be distributed under this subsection; and

(b) Thirty-four percent of the funds shall be distributed to ecology for the purposes of enforcement and educating the public about:

(i) The effects of solid fuel burning device emissions upon health and air quality; and

(ii) Methods of achieving better efficiency and emission performance from solid fuel burning devices.



**WSR 91-07-067**  
**PERMANENT RULES**  
**DEPARTMENT OF HEALTH**  
**(Board of Nursing)**

[Order 152B—Filed March 20, 1991, 3:02 p.m.]

Date of Adoption: February 22, 1991.

Purpose: To redefine who qualifies for the status nursing technician, scope of function of individuals employed in that role, and responsibilities of the employer and supervising RN. Also requires nursing education programs to advise students of the rules.

Citation of Existing Rules Affected by this Order: Amending WAC 308-120-100 and 308-120-565.

Statutory Authority for Adoption: RCW 18.88.080.

Pursuant to notice filed as WSR 90-24-074 on December 5, 1990.

Changes Other than Editing from Proposed to Adopted Version: Degree of supervision for medication administration decrease to more practical level. Clause added to allow nursing students from out-of-state education programs to function in role, in response to public testimony validating need.

Effective Date of Rule: Thirty-one days after filing.

March 11, 1991

Patricia O. Brown

Acting Executive Secretary

**AMENDATORY SECTION** (Amending Order PM 795, filed 11/9/88)

WAC 308-120-100 DEFINITIONS. (1) "Board" means the Washington state board of nursing.

(2) "School" means an educational unit charged with the responsibility of preparing persons to practice as registered nurses. Three types of basic schools of nursing are distinguished by the certificate awarded to the graduate. Schools of nursing within colleges and universities award the associate degree or baccalaureate degree. Schools of nursing sponsored by a hospital award a diploma.

(3) "Provisional approval" of schools of nursing is the approval given a new school of nursing based on its proposed program prior to the admission of its first class.

(4) "Full approval" of a school of nursing is the approval given a school of nursing that meets the requirements of the law and the rules and regulations of the board.

(5) "Conditional approval" of a school of nursing is the approval given a school of nursing that has failed to meet the requirements of the law and the rules and regulations of the board, and it specifies conditions that must be met within a designated time to rectify the failure.

(6) An "unapproved school of nursing" is a school of nursing that has been removed from the list of approved schools for failure to meet the requirements of the law and the rules and regulations of the board or a school that has never been approved by the board.

(7) "Extended learning sites" refers to any area external to the parent organization selected by faculty for student learning experiences.

(8) "Faculty" means persons who are responsible for the educational program of the school of nursing and who hold faculty appointment in the school.

(9) "Nursing student" is a person currently enrolled in an approved school of nursing.

(10) The phrase "nursing aide" ((as that phrase is) used in RCW 18.88.280(3) (((the Professional Nurse Practice Act) is a nursing student who is)) shall mean a "nursing technician." "Nursing technician" is a nursing student currently enrolled in a state board of nursing approved nursing education program and employed for the purpose of giving help, assistance and support in the performance of those services which constitute the practice of registered nursing. The nursing student shall use the title "nursing technician" while employed.

~~((a) "Direction and supervision" = the nursing aide may function only under the "direction and supervision" of the licensed registered nurse. She/he may never function as an independent practitioner or in a supervisory capacity, such as, e.g., head nurse, charge nurse, supervisor, administrator, or private duty nurse. She/he shall not perform duties or functions beyond her/his educational nursing preparation, as determined by the school in which she/he is enrolled. Supervision and direction shall include, but not be limited to, the following:~~

~~(i) A delegation of duties with regard to each individual patient, which duties shall be consistent with and shall not be greater than the abilities of the nursing aide, as indicated by her/his level of educational preparation;~~

~~(ii) An awareness of the activity of the nursing aide as it occurs; and~~

~~(iii) A continuing evaluation of the performance of the nursing aide, and reassignment consistent therewith.~~

~~(b) "Responsibilities = employer and nursing aide":~~

~~(i) Employer. It is the responsibility of the employer of such a nursing aide to obtain evidence of the aide's preparation from the school of nursing in which this student is enrolled.~~

~~(ii) Nursing aide. It is the responsibility of the nursing aide to accept only those assignments which are within the limits of her/his preparation as specified by her/his school of nursing.))~~

(11) "Registered nurse" as used in these rules shall mean a nurse as defined by RCW 18.88.170.

(12) "Nurse administrator" is an individual who meets the qualifications contained in WAC 308-120-555 and who has been designated as the person primarily responsible for the direction of the program in nursing. Titles for this position may include, among others, dean, director, coordinator or chairperson.

(13) "Definition of terms appearing in RCW 18.88.280" - the terms "direction and supervision," "auxiliary services," and "minor nursing services" are defined as follows:

(a) "Minor nursing services." The techniques and procedures used by the nursing profession are extremely difficult to categorize as major or minor nursing services. The important factor with which this law is concerned is the determination of which nursing person and at what level of preparation that person may perform said technique or procedure in relation to the condition of a given

patient, and this kind of determination rests with the registered nurse.

(b) "Auxiliary services" are all those nursing services provided to patients by persons other than the registered nurse, the licensed practical nurse and the nursing student.

(c) "Direction and supervision" shall include, but not be limited to the following:

(i) Delegation of duties with regard to each individual patient, which duties shall be consistent with and shall not be greater than the abilities of the auxiliary personnel, as indicated by their level of education preparation.

(ii) An awareness of the activity of auxiliary personnel.

(iii) A continuing evaluation of the performance of the auxiliary personnel.

(iv) It is the responsibility of the auxiliary person to accept only those assignments which are within the limits of his or her preparation.

(14) "Acquired immunodeficiency syndrome" or "AIDS" means the clinical syndrome of HIV-related illnesses as defined by the board of health by rule.

(15) "Office on AIDS" means a section within the department of social and health services or any successor department with jurisdiction over public health matters as defined in chapter 70.24 RCW.

#### AMENDATORY SECTION (Amending Order PM 751, filed 7/28/88)

WAC 308-120-565 STUDENTS IN APPROVED NURSING EDUCATION PROGRAMS. (1) The approved nursing education program shall:

(a) Provide in writing policies and procedures for selection, admission, progression, graduation, withdrawal, and dismissal ((shall be consistent with the policies of the governing institution, and shall be available in written form)). These policies shall be consistent with the policies of the governing institution. Where necessary, policies specific to nursing students may be adopted if justified by the nature and purposes of the nursing program.

~~((2) Students who seek admission by transfer from another approved nursing education program, or readmission for completion of the program, shall meet the equivalent of the program's current standards required of those regularly enrolled:~~

~~(3) A system of student records shall be maintained:~~

~~(4) A statement of student rights and responsibilities shall be available in written form:))~~ (b) Maintain a system of student records.

(c) Provide a written statement of student rights and responsibilities.

(d) Require that students who seek admission by transfer from another approved nursing education program, or readmission for completion of the program, shall meet the equivalent of the program's current standards.

(2) The nursing education program shall provide the student with information on the legal definition and parameters of the nursing technician role, as in WAC 308-

120-100(10) and 246-839-840. Such information shall be provided prior to the time of completion of the first clinical course and shall clearly advise the student of their responsibilities, should they choose to be employed as a nursing technician.

#### NEW SECTION

WAC 246-839-840 NURSING TECHNICIAN. The purpose of the role of nursing technician is to provide opportunity for student nurses to gain work experience within the limits of their education, but not limited to the scope of functions of nursing assistant - certified.

(1) The nursing technician is as defined in WAC 308-120-100(10).

(2) The nursing technician shall have knowledge and understanding of the laws and rules regulating the nursing technician and shall function within the legal scope of nursing practice.

(3) The nursing technician shall be responsible and accountable for practicing within the scope and guidelines of policies defined by the employing agency.

(4) The nursing technician shall not be employed by a temporary agency.

#### NEW SECTION

WAC 246-839-850 USE OF NOMENCLATURE. (1) Any person who meets the qualifications under WAC 308-120-100(10) and 246-839-860 shall use the title nursing technician and this title shall not be abbreviated.

(2) No other person shall assume such title.

#### NEW SECTION

WAC 246-839-860 NURSING TECHNICIAN CRITERIA. To be eligible for employment as a nursing technician a student must meet the following criteria:

(1) Satisfactory completion of at least one academic term (quarter or semester) of a nursing program approved by a state board of nursing (ADN, diploma, or BSN). The term must have included a clinical component.

(2) Currently enrolled in a state board of nursing approved program will be considered to include:

All periods of regularly planned educational programs and all school scheduled vacations and holidays.

(3) The period of time of notification to the board of completion of nursing education, following graduation and application for examination, not to exceed thirty days from the date of graduation.

(4) Current enrollment will not be construed to include:

(a) Leaves of absence or withdrawal, temporary or permanent, from the nursing educational program.

(b) Students enrolled in nursing department classes who are solely enrolled in academic nonnursing supporting course-work, whether or not those courses are required for the nursing degree.

(c) Students who are awaiting the opportunity to re-enroll in nursing courses.

NEW SECTION

WAC 246-839-870 FUNCTIONS OF THE NURSING TECHNICIAN. The nursing technician:

(1) Shall function only under the supervision of the licensed registered nurse.

(2) May gather information about patients and administer care to patients.

(3) Shall not be responsible for performing the ongoing assessment, planning, implementation, and evaluation of the care of patients.

(4) Shall never function as an independent practitioner, as a team leader, charge nurse, or in a supervisory capacity.

(5) May administer medications only under the direct supervision of a registered nurse and within the limits described in this section. "Direct supervision" means that the licensed registered nurse is on the premises, is quickly and easily available, and that the patients have been assessed by the licensed registered nurse prior to the delegation of the medication duties to the nursing technician. The nursing technician shall not administer chemotherapy, blood or blood products, intravenous medications, scheduled drugs, nor carry out procedures on central lines.

There shall be written documentation from the nursing education program attesting to the nursing technician's preparation in the procedures of medication administration.

NEW SECTION

WAC 246-839-880 FUNCTIONS OF THE REGISTERED NURSE SUPERVISING THE NURSING TECHNICIAN. The licensed registered nurse:

(1) Is accountable at all times for the client's safety and well-being.

(2) Is responsible at all times for the nursing process as delineated in WAC 246-839-700 and this responsibility cannot be delegated.

(3) Shall maintain at all times an awareness of the care activities of the nursing technician and of the current assessment of the patient.

(4) Shall be available at all times to the nursing technician and shall be physically present within the health care facility.

NEW SECTION

WAC 246-839-890 RESPONSIBILITIES OF THE EMPLOYING FACILITY. The employer of the nursing technician shall:

(1) Verify the nursing technician's enrollment in a nursing education program approved by the state board of nursing in the state in which the program is located.

(2) Verify satisfactory completion of each academic term (semester or quarter) within two weeks of completion date.

(3) Obtain written documentation from the approved nursing education program of the nursing technician's current level of education preparation and his/her knowledge and skills.

(4) Assign the nursing technician to perform only to the level identified in subsection (3) of this section.

(5) Provide the nursing technician from an educational program approved by a state board of nursing other than the Washington state board of nursing with board authorized information on the legal definition and parameters of the nursing technician role, as in WAC 308-120-100(10) and 308-120-820 through 308-120-850. Such information shall be provided prior to the commencement of patient care activities by the nursing technician. The facility shall obtain written verification from the nursing technician of receipt and review of this information and the facility shall retain the written verification for a minimum of three years from the last date of employment.

(6) Advise the board of the names and addresses of the nursing technician and the name and address of the nursing education program for any and all nursing technicians employed at the facility.

(7) Identify the student nurse as a "nursing technician."

NEW SECTION

WAC 246-839-900 RESPONSIBILITIES OF THE NURSE ADMINISTRATOR. The nursing administrator or designee shall:

(1) Ensure that the nursing technician has been thoroughly oriented to the facility.

(2) Ensure that WAC 246-839-890 (3), (4), (5), (6), and (7) are accomplished prior to patient care assignments.

(3) Observe, evaluate, and document the skill level of the nursing technician in the administration of oral, IM, and subcutaneous medication and nursing care skills.

(4) Convey in writing to all facility departments the scope within which the nursing technician may practice.

(5) Provide the supervising licensed registered nurse a written job description for the nursing technician.

**WSR 91-07-068**  
**PROPOSED RULES**  
**DEPARTMENT OF**  
**SOCIAL AND HEALTH SERVICES**  
**(Public Assistance)**

[Filed March 20, 1991, 3:44 p.m.]

Original Notice.

Title of Rule: WAC 388-33-376 Advance and adequate notice—Suspension—Termination—Reduction of benefits.

Purpose: The 30 days advance time period for adverse action notices sent to clients in response to information obtained from federal computer matches results in more and higher overpayments incurred by clients. The 30 days advance notice time period also results in more staff time being spent processing public assistance benefits for clients.

Statutory Authority for Adoption: RCW 74.08.090.

Statute Being Implemented: RCW 74.08.090.

Summary: The division can reinstate the state's ten day time period, rather than using the federal 30 day time period, for adverse action notices that are sent to

clients in response to information from federal computer matches. The ten days advance time period will be reinstated by deleting all reference to the 30 days advance notice period for federal computer match information in WAC.

**Reasons Supporting Proposal:** The federal budget of the 101st Congress, second session, amends the Computer Matching and Privacy Protection Act of 1988 as of October 26, 1991, in Section 7201 of the Congressional Budget, pp H-12520/H-12697.

**Name of Agency Personnel Responsible for Drafting, Implementation and Enforcement:** Sandy Jsames, Income Assistance, 586-1516.

**Name of Proponent:** Department of Social and Health Services, governmental.

Rule is necessary because of federal law, Computer Matching and Privacy Protection Amendments of 1990.

**Explanation of Rule, its Purpose, and Anticipated Effects:** Same as above.

**Proposal Changes the Following Existing Rules:** See above.

No small business economic impact statement is required for this proposal by chapter 19.85 RCW.

**Hearing Location:** OB-2 Auditorium, 12th and Franklin, Olympia, Washington, on April 23, 1991, at 10:00 a.m.

**Submit Written Comments to:** Troyce Warner, Chief, Office of Issuances, Department of Social and Health Services, Mailstop OB-33H, Olympia, Washington 98504, by March 20, 1991.

**Date of Intended Adoption:** May 7, 1991.

March 20, 1991

Rosemary Carr

Acting Director

Administrative Services

**AMENDATORY SECTION** (Amending Order 2966, filed 4/11/90, effective 5/12/90)

WAC 388-33-376 ADVANCE AND ADEQUATE NOTICE—SUSPENSION—TERMINATION—REDUCTION OF BENEFITS. In cases of planned actions to terminate, suspend, or reduce benefits to recipients of AFDC, FIP, GA, or all medical assistance programs, the department shall give advance and adequate notice, except as provided under WAC 388-33-385, as follows:

(1) "Advance notice" means:(  
(a)) the department mails the notice at least ten days before the date of action(~~(c) or~~

(b) For actions based on information from computer matches the department conducts with federal agencies, the department mails the notice at least thirty days before the date of action)).

(2) "Adequate notice" means a written statement of the:

- (a) Action the department intends to take;
- (b) Facts relating to the decision;
- (c) Policy supporting the action; and
- (d) Recipient's right to request a fair hearing, including the circumstances under which assistance is continued if a hearing is requested.

(3) The department shall fully translate advance and adequate notice into the primary language of the limited English proficient recipient/enrollee;

(4) When advance notice of planned action is not required as provided under WAC 388-33-385, the department shall give adequate notice as provided under subsection (2) of this section; and

(5) When changes in either state or federal law require automatic grant adjustments for classes of recipients, the department shall give the recipient notice including the specific change in law.

**WSR 91-07-069**  
**PROPOSED RULES**  
**DEPARTMENT OF**  
**SOCIAL AND HEALTH SERVICES**  
**(Public Assistance)**

[Filed March 20, 1991, 3:46 p.m.]

**Original Notice.**

**Title of Rule:** WAC 388-49-310 Citizenship and alien status.

**Purpose:** Include aged, blind and disabled aliens admitted for temporary residence under section 245A of the Immigration and Nationality Act for participation in the food stamp program.

**Statutory Authority for Adoption:** RCW 74.04.050.

**Statute Being Implemented:** RCW 74.04.050.

**Summary:** WAC 388-49-310(3) is revised to remove the reference to subsection (4) dealing with eligibility of aliens legalized under section 245A of the Immigration and Nationality Act (INA). WAC 388-49-310(4) is deleted and replaced by new WAC 388-49-310 (3)(j) and (k). Subsequent subsections of WAC 388-49-310(4) are renumbered.

**Reasons Supporting Proposal:** This rule is necessary to revise food stamp regulations to reflect that aged, blind or disabled aliens admitted for temporary residence under section 245A of the Immigration and Nationality Act may participate in the food stamp program, if otherwise eligible, without meeting the five year residency requirement.

**Name of Agency Personnel Responsible for Drafting, Implementation and Enforcement:** Mike Arnaud, Food Stamp Section, 234-4918.

**Name of Proponent:** Department of Social and Health Services, governmental.

Rule is necessary because of federal law, WFS-200:FS-6-6 GEN.

**Explanation of Rule, its Purpose, and Anticipated Effects:** Same as above.

**Proposal Changes the Following Existing Rules:** See above.

No small business economic impact statement is required for this proposal by chapter 19.85 RCW.

**Hearing Location:** OB-2 Auditorium, 12th and Franklin, Olympia, Washington, on April 23, 1991, at 10:00 a.m.

**Submit Written Comments to:** Troyce Warner, Chief, Office of Issuances, Department of Social and Health Services, Mailstop OB-33H, Olympia, Washington 98504, by April 23, 1991.

**Date of Intended Adoption:** May 7, 1991.

March 20, 1991

Rosemary Carr

Acting Director

Administrative Services

**AMENDATORY SECTION** (Amending Order 2836, filed 8/2/89, effective 9/2/89)

WAC 388-49-310 CITIZENSHIP AND ALIEN STATUS. (1) The department shall require applicants to sign the application attesting to their citizenship or alien status as described under WAC 388-49-030(6).

(2) The department shall consider applicants failing to meet the requirements of subsection (1) of this section as ineligible household members under WAC 388-49-190(4), 388-49-420(5), and 388-49-480(2).

(3) ~~((Except for subsection (4) of this section;))~~ The department shall ~~((require))~~ consider the following persons ~~((participating))~~ residing in the United States eligible for participation in the food stamp program ~~((to be residents of the United States and either))~~:

- (a) A United States citizen; or
- (b) An alien lawfully admitted for permanent residence; or
- (c) An alien who:
  - (i) Entered the United States before January 1, 1972, or some later date as required by law; and
  - (ii) Has continuously maintained residency in the United States since then; and
  - (iii) Is not ineligible for citizenship but is considered to be lawfully admitted for permanent residence as a result of an exercise of discretion by the attorney general under section 249 of the Immigration and Nationality Act.

(d) An alien who qualified for entry after March 17, 1980, because of persecution or fear of persecution on account of race, religion, or political opinion under sections 203 (a)(7), 207, and 208 of the Immigration and Nationality Act; or

(e) An alien qualified for conditional entry before March 18, 1980, under former section 203 (a)(7) of the Immigration and Nationality Act; or

(f) An alien granted asylum through an exercise of discretion by the attorney general under section 208 of the Immigration and Nationality Act; or

(g) An alien lawfully present in the United States as a result of:

- (i) An exercise of discretion by the attorney general for emergent reasons or reasons deemed strictly in the public interest under section 212 (d)(5) of the Immigration and Nationality Act; or
- (ii) A grant of parole by the attorney general.

(h) An alien living within the United States for whom the attorney general withheld deportation, under section 243 of the Immigration and Nationality Act, because the attorney general judges the alien is subject to persecution because of race, religion, or political opinion; or

(i) An alien having temporary resident status as a special agricultural worker under section 210 of the Immigration and Nationality Act; or

(j) An aged, blind, or disabled alien admitted for temporary or permanent residence under section 245A of the Immigration and Nationality Act; or

(k) An alien who is not aged, blind, or disabled admitted under section 245A of the Immigration and Nationality Act when:

- (i) Temporary or permanent status has been gained; and
- (ii) A five-year period has expired.

~~(4) ((The department shall consider aliens legalized under section 245A of the Immigration and Nationality Act ineligible for five years after attaining temporary resident status except for aliens who:~~

- ~~(a) Attain permanent resident status; and~~
- ~~(b) Are aged, blind, or disabled as defined under section 1614 (a)(1) of the Social Security Act.~~

~~(5))~~ The household shall provide verification when:

- (a) Citizenship is questionable; or
  - (b) One or more of its members are aliens.
- (i) The department shall not contact the immigration and naturalization service to obtain information without the alien's written consent.

(ii) The department shall give the household failing to provide verification the option of:

- (A) Withdrawing the application; or
- (B) Participating without the alien member.

~~((6))~~ (5) An applicant shall be ineligible until:

- (a) Questionable citizenship is verified; or
- (b) Lawful alien status is verified.

~~((7))~~ (6) The department shall accept a statement under a penalty of perjury signed by a United States citizen that the applicant is a United States citizen when:

- (a) The applicant cannot produce acceptable citizenship verification; and
- (b) The household can reasonably explain why the verification is not available.

~~((8))~~ (7) The department shall notify immigration and naturalization services when any household member is ineligible because that

person is present in the United States in violation of a known deportation order of the Immigration and Nationality Act.

~~((9))~~ (8) Lawfully admitted aliens who are ineligible include:

- (a) Alien visitors(;);
- (b) Tourists(;);
- (c) Diplomats(;); and
- (d) Students with temporary status.

## WSR 91-07-070

### PROPOSED RULES

### LOTTERY COMMISSION

[Filed March 20, 1991, 4:40 p.m.]

#### Original Notice.

Title of Rule: WAC 315-11-640, 315-11-641, and 315-11-642, definitions, criteria and ticket validation requirements for Instant Game No. 64; WAC 315-11-650, 315-11-651 and 315-11-652, definitions, criteria and ticket validation requirements for Instant Game No. 65; WAC 315-11-660, 315-11-661 and 315-11-662, definitions, criteria and ticket validation requirements for Instant Game No. 66; and WAC 315-04-205, reapplication following license denial.

Purpose: To establish the game play rules and criteria for determining winners of instant games 64 (Play Day), 65 (Touchdown) and 66 (Tumbling Dice); and to establish rule regarding reapplication after license denial.

Statutory Authority for Adoption: RCW 67.70.040.

Statute Being Implemented: RCW 67.70.040.

Summary: See Purpose above.

Reasons Supporting Proposal: See Explanation of Rule below.

Name of Agency Personnel Responsible for Drafting: Jeff Burkhardt, Contracts Specialist, Olympia, 586-6583; Implementation and Enforcement: Evelyn Y. Sun, Director, Olympia, 753-3330.

Name of Proponent: Washington State Lottery Commission, governmental.

Rule is not necessitated by federal law, federal or state court decision.

Explanation of Rule, its Purpose, and Anticipated Effects: WAC 315-11-640, 315-11-641 and 315-11-642, for each game certain terms must be defined in order to provide consistency in the game play rules. The play criteria will explain how the game functions to licensed retailers and players. Rigid validation requirements are set forth which will prevent the lottery from paying out prize money on invalid tickets; WAC 315-11-650, 315-11-651 and 315-11-652, for each game certain terms must be defined in order to provide consistency in the game play rules. The play criteria will explain how the game functions to licensed retailers and players. Rigid validation requirements are set forth which will prevent the lottery from paying out prize money on invalid tickets; WAC 315-11-660, 315-11-661 and 315-11-662, for each game certain terms must be defined in order to provide consistency in the game play rules. The play criteria will explain how the game functions to licensed retailers and players. Rigid validation requirements are set forth which will prevent the lottery from paying out prize money on invalid tickets; and WAC 315-04-205,

this rule shall establish a 90-day waiting period before reapplication for a license is allowed.

Proposal does not change existing rules.

No small business economic impact statement is required for this proposal by chapter 19.85 RCW.

The lottery has considered whether this rule is subject to the Regulatory Fairness Act, chapter 19.85 RCW, and has determined that it is not for the following reasons: The rules have no economic impact on business' cost of equipment, supplies, labor or administrative costs. The rules are designed to establish rules and procedures for the playing of instant lottery games; and the rules will have a negligible impact, if any, on business because they are interpretive. They have been promulgated for the purpose of stating policy, procedure and practice and do not include requirements for forms, fees, appearances or other actions by business.

Hearing Location: Washington State Lottery, 5963 Corson Avenue, Suite 106, Seattle, WA 98108, on May 3, 1991, at 10:00 a.m.

Submit Written Comments to: Judith Giniger, Lottery, P.O. Box 9770, Olympia, WA 98504, by May 2, 1991.

Date of Intended Adoption: May 3, 1991.

March 20, 1991

Evelyn Y. Sun

Director

**NEW SECTION**

WAC 315-11-640 DEFINITIONS FOR INSTANT GAME NUMBER 64 ("PLAY DAYS"). (1) Play symbols: The following are the "play symbols": "\$1.00"; "\$2.00"; "\$3.00"; "\$4.00"; "\$8.00"; "\$12.00"; "\$16.00"; "\$20.00"; "\$24.00"; "\$40.00"; "\$500"; "\$1,000"; and "\$50,000". One of these symbols appears in each of the sixteen play spots on the front of the ticket. The sixteen play spots are divided into four separate sets of four adjoining play spots. Each set of four adjoining play spots shall be known as a playfield and covered with latex. Each ticket shall have four playfields, one in each corner of the ticket.

(2) Play Symbol Captions: The small printed characters appearing below each play symbol which verify and correspond with that play symbol. The caption is a spelling out, in full or abbreviated form of the play symbol. One and only one of these captions appears under each play symbol. For Instant Game Number 64, the captions which correspond with and verify the play symbols are:

PLAY SYMBOL	CAPTION
\$ 1.00	ONE DOL
\$ 2.00	TWO DOL
\$ 3.00	THR DOL
\$ 4.00	FOR DOL
\$ 8.00	EGT DOL
\$ 12.00	TLV DOL
\$ 16.00	SXT DOL
\$ 20.00	TWY DOL
\$ 24.00	TTF DOL
\$ 40.00	FRT DOL
\$ 500	FIVHUND
\$ 1,000	ONETHOU
\$ 50,000	FIFTHOU

(3) Validation number: The unique nine-digit random number which appears below each and every playfield on the front of the ticket and is covered by latex covering.

(4) Pack-ticket number: The eleven-digit number of the form 06400001-000 printed on the front of the ticket. The first three digits are the game identifier. The first eight digits of the pack-ticket number for Instant Game Number 64 constitute the "pack number" which starts at 06400001; the last three digits constitute the "ticket number"

which starts at 000 and continues through 199 within each pack of tickets.

(5) Retailer verification codes: Codes consisting of small letters found under the latex covering of the lower right playfield on the front of the ticket which the lottery retailer uses to verify instant winners of \$25.00 or less. For Instant Game Number 64, the retailer verification code is a three-letter code, with each letter appearing in a varying three of four locations beneath the latex covering and among the play symbols of the lower right playfield on the front of the ticket. The retailer verification codes are:

VERIFICATION CODE	PRIZE
TWO	\$ 2.00 (\$1+\$1)
THR	\$ 3.00 (\$1+\$1+)
FOR	\$ 4.00 (\$2+\$2; \$1+\$1+\$1+\$1)
EGT	\$ 8.00 (\$8; \$2+\$2+\$2+\$2; \$4+\$4)
TLV	\$ 12.00 (\$2+\$2+\$4+\$4; \$4+\$4+\$4)
SXT	\$ 16.00 (\$8+\$8)
TTF	\$ 24.00 (\$12+\$12)

(6) Pack: A set of two hundred fanfolded instant game tickets separated by perforations and packaged in plastic shrinkwrapping.

**NEW SECTION**

WAC 315-11-641 CRITERIA FOR INSTANT GAME NUMBER 64. (1) The price of each instant game ticket shall be \$2.00.

(2) Determination of prize winning tickets: An instant prize winner is determined in the following manner:

(a) The bearer of a ticket having the following play symbols in any three spots within a playfield beneath the latex covering on the front of the ticket shall win the following prize:

Three \$1.00	Play Symbols - Win	\$1.00
Three \$2.00	Play Symbols - Win	\$2.00
Three \$4.00	Play Symbols - Win	\$4.00
Three \$8.00	Play Symbols - Win	\$8.00
Three \$12.00	Play Symbols - Win	\$12.00
Three \$20.00	Play Symbols - Win	\$20.00
Three \$500	Play Symbols - Win	\$500
Three \$50,000	Play Symbols - Win	\$50,000

(b) Play symbols from one playfield may not be mixed, combined or intermingled with play symbols from another playfield.

(c) The bearer of a ticket having a winning set of symbols in more than one playfield shall win the total amount of the prizes won in each playfield.

(3) No portion of the display printing nor any extraneous matter whatever shall be usable or playable as a part of the instant game.

(4) The determination of prize winners shall be subject to the general ticket validation requirements of the lottery as set forth in WAC 315-10-070, to the particular ticket validation requirements for Instant Game Number 64 set forth in WAC 315-11-642, to the confidential validation requirements established by the director, and to the requirements stated on the back of each ticket.

(5) Notwithstanding any other provisions of these rules, the director may:

(a) Vary the length of Instant Game Number 64; and/or

(b) Vary the number of tickets sold in Instant Game Number 64 in a manner that will maintain the estimated average odds of purchasing a winning ticket.

**NEW SECTION**

WAC 315-11-642 TICKET VALIDATION REQUIREMENTS FOR INSTANT GAME NUMBER 64. (1) In addition to meeting all other requirements in these rules and regulations, to be a valid instant game ticket for Instant Game Number 64, all of the following validation requirements apply:

(a) Exactly one play symbol must appear in each of the sixteen play spots under the removable latex coverings on the front of the ticket.

(b) Each of the sixteen play symbols must have a caption below and each must agree with its caption.

(c) The display printing and the printed numbers, letters, and symbols on the ticket must be regular in every respect and correspond precisely with the specifications on file with the director. The numbers, letters, and symbols shall be printed as follows:

Play Symbols	Play Symbol Font
Captions	Caption Font
Pack-Ticket Number	Validation Font
Validation Number	Validation Font
Retail Verification Code	Validation Font

(d) Each of the play symbols and its caption, the validation number, pack-ticket number and retailer verification code must be printed in black ink.

(e) Each of the play symbols must be exactly one of those described in WAC 315-11-640(1) and each of the captions must be exactly one of those described in WAC 315-11-640(2).

(2) Any ticket not passing all the validation requirements in WAC 315-10-070 and subsection (1) of this section is invalid and ineligible for any prize.

**NEW SECTION**

WAC 315-11-650 DEFINITIONS FOR INSTANT GAME NUMBER 65 ("TOUCHDOWN"). (1) Play symbols: The following are the "play symbols": "0"; "3"; "6"; "7"; "9"; "10"; "11"; "12"; "13"; "17"; "20"; "21"; and "24". One of these symbols appears under each of the three play spots under the latex covering in the "your score" column and under each of the three play spots under the latex covering in the "their score" column in the play field on the front of the ticket.

(2) Play Symbol Captions: The small printed characters appearing below each play symbol which correspond with and verify that play symbol. The caption is a spelling out in full or in abbreviated form of the play symbol. One and only one caption appears under each play symbol. The number 1, 2 or 3 precedes each caption to indicate the location of the play symbol in Game 1, Game 2 or Game 3. For Instant Game Number 65, the play symbols and their corresponding captions are:

<u>PLAY SYMBOL</u>	<u>CAPTION</u>
0	ZRO
3	THR
6	SIX
7	SVN
9	NIN
10	TEN
11	ELV
12	TLV
13	THN
17	SVT
20	TWY
21	TTN
24	TTF

(3) Prize symbols: The following are the "prize symbols": "\$1.00"; "\$2.00"; "\$4.00"; "\$8.00"; "\$40.00"; "\$10,000". One of these prize symbols appears in the prize column of each game (row) in the play-field on the front of the ticket.

(4) Prize Symbol Captions: The small printed characters appearing below the prize symbol which verify and correspond with that prize symbol. The caption is a spelling out, in full or abbreviated form, of the prize symbol. One and only one caption appears under each prize symbol. The number 1, 2 or 3 precedes each caption to indicate the location of the caption in Game 1, Game 2 or Game 3. For Instant Game Number 65, the prize symbols and their corresponding captions are:

<u>PRIZE SYMBOL</u>	<u>CAPTION</u>
\$1.00	ONE
\$2.00	TWO
\$4.00	FOR
\$8.00	EGT
\$40.00	FORTY
\$10,000	TENTHO

(5) Validation number: The unique nine-digit random number on the front of the ticket. The number is covered by latex.

(6) Pack-ticket number: The eleven-digit number of the form 06500001-000 printed on the front of the ticket. The first three digits are the game identifier. The first eight digits of the pack-ticket number for Instant Game Number 65 constitute the "pack number" which

starts at 06500001; the last three digits constitute the "ticket number" which starts at 000 and continues through 399 within each pack of tickets.

(7) Retailer verification codes: Codes consisting of small letters found under the removable latex covering on the front of the ticket which the lottery retailer uses to verify instant winners of \$25 and less. For Instant Game Number 65, the retailer verification codes are three-letter codes, with each letter appearing in a varying three of six locations among the play symbols and prize symbols on the front of the ticket. The retailer verification codes are:

<u>VERIFICATION CODE</u>	<u>PRIZE</u>
ONE	\$ 1.00
TWO	\$ 2.00 (\$1 and \$1; \$2)
FOR	\$ 4.00 (\$1 and \$1 and \$2)
SIX	\$ 6.00 (\$2 and \$4)
EGT	\$ 8.00 (\$4 and \$2 and \$2; \$8)
SXT	\$ 16.00 (\$8 and \$4 and \$4)

(8) Pack: A set of four hundred fanfolded instant game tickets separated by perforations and packaged in a plastic bag or plastic shrinkwrapping.

**NEW SECTION**

WAC 315-11-651 CRITERIA FOR INSTANT GAME NUMBER 65. (1) The price of each instant game ticket shall be \$1.00.

(2) Determination of prize winning tickets: An instant prize winner is determined in the following manner: The bearer of a ticket having a play symbol in the "your score" column that is a larger number than the play symbol in the "their score" column in the same game (row) shall win the prize shown in the prize column for that game (row). The bearer of a ticket having winning play symbols in more than one game (row) shall win the sum of the prizes in each winning game (row). Play symbols in different games (rows) may not be combined to win a prize.

(3) No portion of the display printing nor any extraneous matter whatever shall be usable or playable as a part of the instant game.

(4) The determination of prize winners shall be subject to the general ticket validation requirements of the lottery as set forth in WAC 315-10-070, to the particular ticket validation requirements for Instant Game Number 65 set forth in WAC 315-11-652, to the confidential validation requirements established by the director, and to the requirements stated on the back of each ticket.

(5) Notwithstanding any other provisions of these rules, the director may:

(a) Vary the length of Instant Game Number 65; and/or

(b) Vary the number of tickets sold in Instant Game Number 65 in a manner that will maintain the estimated average odds of purchasing a winning ticket.

**NEW SECTION**

WAC 315-11-652 TICKET VALIDATION REQUIREMENTS FOR INSTANT GAME NUMBER 65. (1) In addition to meeting all other requirements in these rules and regulations, a valid instant game ticket for Instant Game Number 65 shall comply with all of the following validation requirements.

(a) Exactly one play symbol must appear under each of the three rub-off spots in the "your score" column and under each of the three rub-off spots in the "their score" column on the front of the ticket.

(b) Each of the six play symbols must have a caption below and each must agree with its caption.

(c) Exactly one prize symbol for each of the three games (rows) must appear under the rub-off material covering the prize column on the front of the ticket.

(d) Each of the three prize symbols must have a caption below and each must agree with its caption.

(e) The display printing and the printed numbers, letters, and symbols on the ticket must be regular in every respect and correspond precisely with the specifications on file with the director. The numbers, letters, and symbols shall be printed as follows:

Play Symbols	Play Symbol Font
Prize Symbols	Prize Symbol Font
Captions	Caption Font
Pack-Ticket Number	Validation Font
Validation Number	Validation Font
Retailer Verification Code	Validation Font

(f) Each of the play symbols and its caption, prize symbol and its caption, the validation number, pack-ticket number, and the retailer verification code must be printed in black ink.

(g) Each of the play symbols must be exactly one of those described in WAC 315-11-650(1); each of the play symbol captions must be exactly one of those described in WAC 315-11-650(2); each of the prize symbols must be exactly one of those described in WAC 315-11-650(3); and each of the prize symbol captions must be exactly one of those described in WAC 315-11-650(4).

(2) Any ticket not passing all the validation requirements in WAC 315-10-070 and subsection (1) of this section is invalid and ineligible for any prize.

**NEW SECTION**

WAC 315-11-660 DEFINITIONS FOR INSTANT GAME NUMBER 66 ("TUMBLING DICE"). (1) Play symbols: The following are the "play symbols": "1"; "2"; "3"; "4"; "5" and "6". One of these play symbols appears in each of the five play spots under the latex covering on the front of the ticket. The latex covered area shall be known as the playfield. The five play spots shall be configured with one play symbol at the top of the playfield which shall be labeled "Your Number." The other four play symbols shall appear in a horizontal row below the play symbol labeled "Your Number."

(2) Play Symbol Captions: The small printed characters appearing below each play symbol which correspond with and verify that play symbol. The caption is a spelling out, in full or abbreviated form of the play symbol. One and only one of these captions appears under each play symbol. The three-digit ticket number shall appear before each play symbol caption. For Instant Game 66, the captions which correspond with and verify the play symbols are:

PLAY SYMBOL	CAPTION
1	ONE
2	TWO
3	THR
4	FOR
5	FIV
6	SIX

(3) Prize symbols: The following are the "prize symbols": "\$1.00", "\$2.00", "\$4.00", "\$6.00", "\$12.00", "\$50.00", and "\$5,000". One of these prize symbols appears above each of the four play symbols in the horizontal row. There is no prize symbol above the play symbol labeled "Your Number."

(4) Prize Symbol Captions: The small printed characters which follow the play symbol caption and verify and correspond with that prize symbol. The prize symbol caption is a spelling out, in full or abbreviated form, of the prize symbol. For Instant Game Number 66, the prize symbol captions which correspond with and verify the prize symbols are:

PRIZE SYMBOL	CAPTION
\$1.00	ONE
\$2.00	TWO
\$4.00	FOR
\$6.00	SIX
\$12.00	TLV
\$50.00	FFTY
\$5,000	FVTH

(5) Validation number: The unique nine-digit number on the front of the ticket. The number is covered by latex.

(6) Pack-ticket number: The eleven-digit number of the form 06600001-000 printed on the front of the ticket. The first three digits are the game identifier. The first eight digits of the pack-ticket number for Instant Game Number 66 constitute the "pack number" which starts at 06600001; the last three digits constitute the "ticket number" which starts at 000 and continues through 399 within each pack of tickets.

(7) Retailer verification codes: Codes consisting of small letters found under the removable covering on the front of the ticket which the lottery retailer uses to verify instant winners of \$25.00 or less. For Instant Game Number 66, the retailer verification code is a three-letter code, with each letter appearing in a varying three of six locations beneath the removable covering and among the play symbols on the front of the ticket. The retailer verification codes are:

VERIFICATION CODE	PRIZE
ONE	\$ 1.00 (\$1)
TWO	\$ 2.00 (\$2; \$1 and \$1)
FOR	\$ 4.00 (\$2 and \$2; \$1, \$1, \$1 and \$1)
SIX	\$ 6.00 (\$4 and \$2; \$2, \$2 and \$2)
TLV	\$ 12.00 (\$12; \$6, \$4 and \$2)
EGN	\$ 18.00 (\$12 and \$6; \$12, \$4 and \$2)

(8) Pack: A set of four hundred fanfolded instant game tickets separated by perforations and packaged in a plastic bag or plastic shrinkwrapping.

**NEW SECTION**

WAC 315-11-661 CRITERIA FOR INSTANT GAME NUMBER 66. (1) The price of each instant game ticket shall be \$1.00.

(2) Determination of prize winning tickets: An instant prize winner is determined in the following manner:

(a) When one of the four play symbols in the horizontal row matches exactly the play symbol labeled "Your Number", the matching horizontal row play symbol shall be a winning play symbol, and the bearer of the ticket shall win the prize above the winning play symbol.

(b) The bearer of a ticket which has more than one winning play symbol shall win the total amount of the prizes above each winning play symbol.

(3) No portion of the display printing nor any extraneous matter whatever shall be usable or playable as a part of the instant game.

(4) The determination of prize winners shall be subject to the general ticket validation requirements of the lottery as set forth in WAC 315-10-070, to the particular ticket validation requirements for Instant Game Number 66 set forth in WAC 315-11-662, to the confidential validation requirements established by the director, and to the requirements stated on the back of each ticket.

**NEW SECTION**

WAC 315-11-662 TICKET VALIDATION REQUIREMENTS FOR INSTANT GAME NUMBER 66. (1) In addition to meeting all other requirements in these rules and regulations, to be a valid instant game ticket for Instant Game Number 66, all of the following validation requirements apply.

(a) Exactly one play symbol must appear in each of the five play spots in the playfield on the front of the ticket.

(b) Each play symbol must have a play symbol caption below it and each must agree with its caption.

(c) Each of the four play symbols in the horizontal row shall have a prize symbol above it. Each of the horizontal row play symbols shall also have a prize symbol caption following its play symbol caption.

(d) The display printing and the printed numbers, letters, and symbols on the ticket must be regular in every respect and correspond precisely with the artwork on file with the director. The numbers, letters, and symbols shall be printed as follows:

Play Symbols	Play Symbol Font
Prize Symbols	Prize Symbol Font
Captions	Caption Font
Pack-Ticket Number	Validation Font
Validation Number	Validation Font
Retailer Verification Code	Validation Font

(e) Each of the play symbols and its caption, the validation number, pack-ticket number and retailer verification code must be printed in black ink.

(f) Each of the play symbols must be exactly one of those described in WAC 315-11-660(1) and each of the play symbol captions must be exactly one of those described in WAC 315-11-660(2).

(g) Each of the prize symbols must be exactly one of those described in WAC 315-11-660(3) and each of the prize symbol captions must be exactly one of those described in WAC 315-11-660(4).

(2) Any ticket not passing all the validation requirements in WAC 315-10-070 and subsection (1) of this section is invalid and ineligible for any prize.

**NEW SECTION**

WAC 315-04-205 REAPPLICATION FOLLOWING LICENSE DENIAL OR REVOCATION. The director shall not grant a license based on reapplication less than 90 days following the agency's final order of denial or revocation under WAC 315-04-200.



## Table of WAC Sections Affected

### KEY TO TABLE

**Symbols:**

- AMD = Amendment of existing section
- A/R = Amending and recodifying a section
- DECOD = Decodification of an existing section
- NEW = New section not previously codified
- OBJEC = Notice of objection by Joint Administrative Rules Review Committee
- PREP = Preproposal comments
- RE-AD = Readoption of existing section
- RECOD = Recodification of previously codified section
- REP = Repeal of existing section
- RESCIND = Rescind previous emergency rule
- REVIEW = Review of previously adopted rule

**Suffixes:**

- P = Proposed action
- C = Continuance of previous proposal
- E = Emergency action
- S = Supplemental notice
- W = Withdrawal of proposed action
- No suffix means permanent action

This table covers the current calendar year through this issue of the Register and should be used to locate rules amended, adopted, or repealed subsequent to the publication date of the latest WAC or Supplement.

WAC # shows the section number under which an agency rule is or will be codified in the Washington Administrative Code.

WSR # shows the issue of the Washington State Register where the document may be found; the last three digits show the sequence of the document within the issue.

WAC #	WSR #	WAC #	WSR #	WAC #	WSR #
1-06-040	AMD-P 91-06-067	1-08-490	REP-P 91-06-067	16-228-164	AMD-P 91-02-106
1-08-005	REP-P 91-06-067	1-08-500	REP-P 91-06-067	16-228-164	AMD 91-06-019
1-08-007	REP-P 91-06-067	1-08-510	REP-P 91-06-067	16-230-110	REP-P 91-02-106
1-08-010	REP-P 91-06-067	1-08-520	REP-P 91-06-067	16-230-110	REP 91-06-019
1-08-030	REP-P 91-06-067	1-08-530	REP-P 91-06-067	16-230-115	REP-P 91-02-106
1-08-040	REP-P 91-06-067	1-08-540	REP-P 91-06-067	16-230-115	REP 91-06-019
1-08-050	REP-P 91-06-067	1-08-550	REP-P 91-06-067	16-230-120	REP-P 91-02-106
1-08-060	REP-P 91-06-067	1-08-560	REP-P 91-06-067	16-230-120	REP 91-06-019
1-08-070	REP-P 91-06-067	1-08-570	REP-P 91-06-067	16-230-150	AMD-P 91-04-078
1-08-080	REP-P 91-06-067	1-08-580	REP-P 91-06-067	16-230-160	AMD-P 91-04-078
1-08-090	REP-P 91-06-067	1-08-590	REP-P 91-06-067	16-230-170	AMD-P 91-04-078
1-08-100	REP-P 91-06-067	16-80-005	NEW-P 91-05-076	16-230-180	AMD-P 91-04-078
1-08-110	REP-P 91-06-067	16-80-007	NEW-P 91-05-076	16-230-190	AMD-P 91-04-078
1-08-120	REP-P 91-06-067	16-80-010	NEW-P 91-05-076	16-230-400	AMD-P 91-02-106
1-08-130	REP-P 91-06-067	16-80-015	NEW-P 91-05-076	16-230-400	AMD 91-06-019
1-08-140	REP-P 91-06-067	16-80-020	NEW-P 91-05-076	16-230-410	AMD-P 91-02-106
1-08-150	REP-P 91-06-067	16-80-025	NEW-P 91-05-076	16-230-410	AMD 91-06-019
1-08-160	REP-P 91-06-067	16-80-030	NEW-P 91-05-076	16-230-440	AMD-P 91-02-106
1-08-170	REP-P 91-06-067	16-80-035	NEW-P 91-05-076	16-230-440	AMD 91-06-019
1-08-180	REP-P 91-06-067	16-80-040	NEW-P 91-05-076	16-230-450	AMD-P 91-02-106
1-08-190	REP-P 91-06-067	16-80-045	NEW-P 91-05-076	16-230-450	AMD 91-06-019
1-08-200	REP-P 91-06-067	16-80-047	NEW-P 91-05-076	16-230-460	AMD-P 91-02-106
1-08-210	REP-P 91-06-067	16-80-050	NEW-P 91-05-076	16-230-460	AMD 91-06-019
1-08-220	REP-P 91-06-067	16-154	AMD-P 91-05-006	16-230-470	AMD-P 91-02-106
1-08-230	REP-P 91-06-067	16-154-010	AMD-P 91-05-006	16-230-470	AMD 91-06-019
1-08-240	REP-P 91-06-067	16-154-020	AMD-P 91-05-006	16-230-475	REP-P 91-02-106
1-08-250	REP-P 91-06-067	16-154-030	NEW-P 91-05-006	16-230-475	REP 91-06-019
1-08-260	REP-P 91-06-067	16-154-040	NEW-P 91-05-006	16-230-605	AMD-P 91-02-106
1-08-270	REP-P 91-06-067	16-154-050	NEW-P 91-05-006	16-230-605	AMD 91-06-019
1-08-280	REP-P 91-06-067	16-154-060	NEW-P 91-05-006	16-230-610	AMD-P 91-02-106
1-08-290	REP-P 91-06-067	16-154-070	NEW-P 91-05-006	16-230-610	AMD 91-06-019
1-08-300	REP-P 91-06-067	16-154-080	NEW-P 91-05-006	16-230-615	AMD-P 91-02-106
1-08-310	REP-P 91-06-067	16-154-090	NEW-P 91-05-006	16-230-615	AMD 91-06-019
1-08-320	REP-P 91-06-067	16-154-100	NEW-P 91-05-006	16-230-625	AMD-P 91-02-106
1-08-330	REP-P 91-06-067	16-154-110	NEW-P 91-05-006	16-230-625	AMD 91-06-019
1-08-340	REP-P 91-06-067	16-154-120	NEW-P 91-05-006	16-230-670	AMD-P 91-02-106
1-08-350	REP-P 91-06-067	16-156-005	AMD-P 91-05-006	16-230-670	AMD 91-06-019
1-08-360	REP-P 91-06-067	16-156-020	AMD-P 91-05-006	16-230-675	AMD-P 91-02-106
1-08-370	REP-P 91-06-067	16-156-035	AMD-P 91-05-006	16-230-675	AMD 91-06-019
1-08-380	REP-P 91-06-067	16-156-060	AMD-P 91-05-006	16-231-001	AMD-P 91-02-106
1-08-390	REP-P 91-06-067	16-158-120	AMD-P 91-05-006	16-231-001	AMD 91-06-019
1-08-400	REP-P 91-06-067	16-160-010	NEW 91-05-007	16-231-033	REP-P 91-02-106
1-08-410	REP-P 91-06-067	16-160-020	NEW 91-05-007	16-231-033	REP 91-06-019
1-08-420	REP-P 91-06-067	16-160-030	NEW 91-05-007	16-231-100	AMD-P 91-02-106
1-08-430	REP-P 91-06-067	16-160-040	NEW 91-05-007	16-231-100	AMD 91-06-019
1-08-440	REP-P 91-06-067	16-160-050	NEW 91-05-007	16-231-148	REP-P 91-02-106
1-08-450	REP-P 91-06-067	16-160-060	NEW 91-05-007	16-231-148	REP 91-06-019
1-08-460	REP-P 91-06-067	16-160-070	NEW 91-05-007	16-231-200	AMD-P 91-02-106
1-08-470	REP-P 91-06-067	16-160-090	NEW 91-05-007	16-231-200	AMD 91-06-019
1-08-480	REP-P 91-06-067	16-160-100	NEW 91-05-007	16-231-205	AMD-P 91-02-106

Table of WAC Sections Affected

WAC #		WSR #	WAC #		WSR #	WAC #		WSR #
16-231-205	AMD	91-06-019	16-232-100	AMD-P	91-02-106	16-482-030	REP-P	91-03-105
16-231-210	AMD-P	91-02-106	16-232-100	AMD	91-06-019	16-482-030	REP	91-07-016
16-231-210	AMD	91-06-019	16-232-105	AMD-P	91-02-106	16-482-040	REP-P	91-03-105
16-231-235	AMD-P	91-02-106	16-232-105	AMD	91-06-019	16-482-040	REP	91-07-016
16-231-235	AMD	91-06-019	16-232-110	AMD-P	91-02-106	16-484-020	REP-P	91-07-037
16-231-238	REP-P	91-02-106	16-232-110	AMD	91-06-019	16-484-022	REP-P	91-07-037
16-231-238	REP	91-06-019	16-232-120	AMD-P	91-02-106	16-484-030	REP-P	91-07-037
16-231-300	AMD-P	91-02-106	16-232-120	AMD	91-06-019	16-484-040	REP-P	91-07-037
16-231-300	AMD	91-06-019	16-232-200	AMD-P	91-02-106	16-484-050	REP-P	91-07-037
16-231-305	AMD-P	91-02-106	16-232-200	AMD	91-06-019	16-484-080	REP-P	91-07-037
16-231-305	AMD	91-06-019	16-232-205	AMD-P	91-02-106	16-484-090	REP-P	91-07-037
16-231-310	AMD-P	91-02-106	16-232-205	AMD	91-06-019	16-484-100	REP-P	91-07-037
16-231-310	AMD	91-06-019	16-232-220	AMD-P	91-02-106	16-484-200	NEW-E	91-06-035
16-231-330	AMD-P	91-02-106	16-232-220	AMD	91-06-019	16-484-205	NEW-E	91-06-035
16-231-330	AMD	91-06-019	16-232-225	AMD-P	91-02-106	16-484-210	NEW-E	91-06-035
16-231-340	AMD-P	91-02-106	16-232-225	AMD	91-06-019	16-484-220	NEW-E	91-06-035
16-231-340	AMD	91-06-019	16-232-300	AMD-P	91-02-106	16-484-230	NEW-E	91-06-035
16-231-343	REP-P	91-02-106	16-232-300	AMD	91-06-019	16-484-240	NEW-E	91-06-035
16-231-343	REP	91-06-019	16-232-305	AMD-P	91-02-106	16-484-250	NEW-E	91-06-035
16-231-400	AMD-P	91-02-106	16-232-305	AMD	91-06-019	16-484-260	NEW-E	91-06-035
16-231-400	AMD	91-06-019	16-232-315	AMD-P	91-02-106	16-486-001	REP-P	91-07-036
16-231-405	AMD-P	91-02-106	16-232-315	AMD	91-06-019	16-486-010	REP-P	91-07-036
16-231-405	AMD	91-06-019	16-232-950	REP-P	91-02-106	16-486-015	REP-P	91-07-036
16-231-410	AMD-P	91-02-106	16-232-950	REP	91-06-019	16-486-020	REP-P	91-07-036
16-231-410	AMD	91-06-019	16-316-280	AMD-P	91-04-066	16-486-025	REP-P	91-07-036
16-231-420	AMD-P	91-02-106	16-316-285	AMD-P	91-04-066	16-486-030	REP-P	91-07-036
16-231-420	AMD	91-06-019	16-316-290	AMD-P	91-04-066	16-486-035	REP-P	91-07-036
16-231-425	AMD-P	91-02-106	16-324-375	AMD-P	91-06-061	16-486-040	REP-P	91-07-036
16-231-425	AMD	91-06-019	16-324-380	AMD-P	91-06-061	16-486-045	REP-P	91-07-036
16-231-500	AMD-P	91-02-106	16-324-605	AMD-P	91-06-061	16-494-001	AMD-P	91-04-066
16-231-500	AMD	91-06-019	16-333-200	NEW-P	91-04-068	16-494-010	AMD-P	91-04-066
16-231-505	AMD-P	91-02-106	16-333-205	NEW-P	91-04-068	16-494-012	NEW-P	91-04-066
16-231-505	AMD	91-06-019	16-333-210	NEW-P	91-04-068	16-494-013	NEW-P	91-04-066
16-231-510	AMD-P	91-02-106	16-333-215	NEW-P	91-04-068	16-494-015	REP-P	91-04-066
16-231-510	AMD	91-06-019	16-333-220	NEW-P	91-04-068	16-494-020	AMD-P	91-04-066
16-231-525	AMD-P	91-02-106	16-333-225	NEW-P	91-04-068	16-494-030	AMD-P	91-04-066
16-231-525	AMD	91-06-019	16-333-230	NEW-P	91-04-068	16-494-042	AMD-P	91-04-066
16-231-530	AMD-P	91-02-106	16-333-235	NEW-P	91-04-068	16-494-043	NEW-P	91-04-066
16-231-530	AMD	91-06-019	16-333-240	NEW-P	91-04-068	16-494-044	AMD-P	91-04-066
16-231-600	AMD-P	91-02-106	16-333-245	NEW-P	91-04-068	16-494-045	NEW-P	91-04-066
16-231-600	AMD	91-06-019	16-354-005	AMD-P	91-04-067	16-494-046	NEW-P	91-04-066
16-231-605	AMD-P	91-02-106	16-354-010	AMD-P	91-04-067	16-494-047	NEW-P	91-04-066
16-231-605	AMD	91-06-019	16-354-020	AMD-P	91-04-067	16-494-062	AMD-P	91-04-066
16-231-610	AMD-P	91-02-106	16-354-030	AMD-P	91-04-067	16-494-063	NEW-P	91-04-066
16-231-610	AMD	91-06-019	16-354-040	AMD-P	91-04-067	16-494-064	NEW-P	91-04-066
16-231-615	AMD-P	91-02-106	16-354-070	AMD-P	91-04-067	16-497-001	AMD-P	91-04-067
16-231-615	AMD	91-06-019	16-354-100	AMD-P	91-04-067	16-497-005	NEW-P	91-04-067
16-231-620	AMD-P	91-02-106	16-403-141	AMD-P	91-03-093	16-497-020	AMD-P	91-04-067
16-231-620	AMD	91-06-019	16-403-141	AMD-W	91-07-015	16-497-030	AMD-P	91-04-067
16-231-700	AMD-P	91-02-106	16-470-100	AMD	91-03-115	16-497-040	AMD-P	91-04-067
16-231-700	AMD	91-06-019	16-471-010	NEW	91-03-046	16-497-050	AMD-P	91-04-067
16-231-705	AMD-P	91-02-106	16-471-015	NEW	91-03-046	16-497-060	AMD-P	91-04-067
16-231-705	AMD	91-06-019	16-471-020	NEW	91-03-046	16-528-105	NEW	91-05-065
16-231-715	AMD-P	91-02-106	16-471-030	NEW	91-03-046	16-528-110	AMD	91-05-065
16-231-715	AMD	91-06-019	16-471-040	NEW	91-03-046	16-528-150	AMD	91-05-065
16-231-720	AMD-P	91-02-106	16-471-050	NEW	91-03-046	16-528-170	NEW	91-05-065
16-231-720	AMD	91-06-019	16-471-060	NEW	91-03-046	16-603-010	NEW-P	91-04-076
16-231-800	AMD-P	91-02-106	16-471-070	NEW	91-03-046	16-752-300	AMD	91-03-045
16-231-800	AMD	91-06-019	16-471-080	NEW	91-03-046	16-752-305	AMD	91-03-045
16-231-805	AMD-P	91-02-106	16-482-001	AMD-P	91-03-105	16-752-310	RE-AD	91-03-045
16-231-805	AMD	91-06-019	16-482-001	AMD	91-07-016	16-752-315	AMD	91-03-045
16-231-825	AMD-P	91-02-106	16-482-005	NEW-P	91-03-105	16-752-320	RE-AD	91-03-045
16-231-825	AMD	91-06-019	16-482-005	NEW	91-07-016	16-752-325	REP	91-03-045
16-231-840	AMD-P	91-02-106	16-482-006	NEW-P	91-03-105	16-752-330	AMD	91-03-045
16-231-840	AMD	91-06-019	16-482-006	NEW	91-07-016	36-12	AMD-P	91-05-032
16-231-900	AMD-P	91-02-106	16-482-007	NEW-P	91-03-105	36-12-010	AMD-P	91-05-032
16-231-900	AMD	91-06-019	16-482-007	NEW	91-07-016	36-12-011	AMD-P	91-05-032
16-231-905	AMD-P	91-02-106	16-482-010	AMD-P	91-03-105	36-12-020	AMD-P	91-05-032
16-231-905	AMD	91-06-019	16-482-010	AMD	91-07-016	36-12-030	AMD-P	91-05-032
16-231-935	AMD-P	91-02-106	16-482-015	NEW-P	91-03-105	36-12-040	AMD-P	91-05-032
16-231-935	AMD	91-06-019	16-482-015	NEW	91-07-016	36-12-050	AMD-P	91-05-032
16-231-938	REP-P	91-02-106	16-482-016	NEW-P	91-03-105	36-12-060	AMD-P	91-05-032
16-231-938	REP	91-06-019	16-482-016	NEW	91-07-016	36-12-070	AMD-P	91-05-032
16-231-950	REP-P	91-02-106	16-482-017	NEW-P	91-03-105	36-12-080	AMD-P	91-05-032
16-231-950	REP	91-06-019	16-482-017	NEW	91-07-016	36-12-090	REP-P	91-05-032
16-232-001	AMD-P	91-02-106	16-482-020	AMD-P	91-03-105	36-12-100	AMD-P	91-05-032
16-232-001	AMD	91-06-019	16-482-020	AMD	91-07-016	36-12-110	AMD-P	91-05-032

**Table of WAC Sections Affected**

WAC #	WSR #	WAC #	WSR #	WAC #	WSR #
36-12-120	AMD-P 91-05-032	113-12-120	DECOD 91-05-095	132K-16-250	NEW-P 91-03-150
36-12-130	AMD-P 91-05-032	113-12-150	DECOD 91-05-095	132K-16-260	NEW-E 91-03-084
36-12-150	AMD-P 91-05-032	113-12-165	DECOD 91-05-095	132K-16-260	NEW-P 91-03-150
36-12-160	AMD-P 91-05-032	113-12-170	DECOD 91-05-095	132K-16-270	NEW-E 91-03-084
36-12-170	AMD-P 91-05-032	113-12-175	DECOD 91-05-095	132K-16-270	NEW-P 91-03-150
36-12-180	AMD-P 91-05-032	113-12-180	DECOD 91-05-095	132K-16-280	NEW-E 91-03-084
36-12-190	AMD-P 91-05-032	113-12-190	DECOD 91-05-095	132K-16-280	NEW-P 91-03-150
36-12-195	NEW-P 91-05-032	113-12-195	DECOD 91-05-095	132K-16-290	NEW-E 91-03-084
36-12-200	AMD-P 91-05-032	113-12-197	DECOD 91-05-095	132K-16-290	NEW-P 91-03-150
36-12-220	AMD-P 91-05-032	113-12-200	DECOD 91-05-095	132K-16-300	NEW-E 91-03-084
36-12-230	REP-P 91-05-032	113-12-210	DECOD 91-05-095	132K-16-300	NEW-P 91-03-150
36-12-240	AMD-P 91-05-032	113-12-220	DECOD 91-05-095	132K-16-310	NEW-E 91-03-084
36-12-250	AMD-P 91-05-032	113-12-230	DECOD 91-05-095	132K-16-310	NEW-P 91-03-150
36-12-260	AMD-P 91-05-032	113-12-300	DECOD 91-05-095	132K-16-320	NEW-E 91-03-084
36-12-270	AMD-P 91-05-032	113-12-310	DECOD 91-05-095	132K-16-320	NEW-P 91-03-150
36-12-280	AMD-P 91-05-032	113-12-320	DECOD 91-05-095	132K-16-330	NEW-E 91-03-084
36-12-290	AMD-P 91-05-032	113-12-330	DECOD 91-05-095	132K-16-330	NEW-P 91-03-150
36-12-300	AMD-P 91-05-032	113-12-340	DECOD 91-05-095	132K-16-340	NEW-E 91-03-084
36-12-310	AMD-P 91-05-032	113-12-350	DECOD 91-05-095	132K-16-340	NEW-P 91-03-150
36-12-320	AMD-P 91-05-032	114-12-011	DECOD 91-05-026	132K-16-350	NEW-E 91-03-084
36-12-330	AMD-P 91-05-032	114-12-021	DECOD 91-05-026	132K-16-350	NEW-P 91-03-150
36-12-340	AMD-P 91-05-032	114-12-031	DECOD 91-05-026	132K-16-360	NEW-E 91-03-084
36-12-350	AMD-P 91-05-032	114-12-041	DECOD 91-05-026	132K-16-360	NEW-P 91-03-150
36-12-360	AMD-P 91-05-032	114-12-115	DECOD 91-05-026	132K-16-370	NEW-E 91-03-084
36-12-365	NEW-P 91-05-032	114-12-126	DECOD 91-05-026	132K-16-370	NEW-P 91-03-150
36-12-367	NEW-P 91-05-032	114-12-132	DECOD 91-05-026	132K-16-380	NEW-E 91-03-084
36-12-370	AMD-P 91-05-032	114-12-136	DECOD 91-05-031	132K-16-380	NEW-P 91-03-150
36-12-380	REP-P 91-05-032	114-12-150	DECOD 91-05-026	132K-16-390	NEW-E 91-03-084
36-12-385	NEW-P 91-05-032	114-12-155	DECOD 91-05-026	132K-16-390	NEW-P 91-03-150
36-12-390	REP-P 91-05-032	114-12-164	DECOD 91-05-026	132K-16-400	NEW-E 91-03-084
36-12-400	AMD-P 91-05-032	114-12-170	DECOD 91-05-026	132K-16-400	NEW-P 91-03-150
36-12-410	AMD-P 91-05-032	114-12-180	DECOD 91-05-026	132K-16-410	NEW-E 91-03-084
36-12-415	NEW-P 91-05-032	114-12-190	DECOD 91-05-026	132K-16-410	NEW-P 91-03-150
36-12-420	REP-P 91-05-032	114-12-200	DECOD 91-05-026	132K-16-420	NEW-E 91-03-084
36-12-425	NEW-P 91-05-032	131-16-020	REP-E 91-06-069	132K-16-420	NEW-P 91-03-150
36-12-430	REP-P 91-05-032	131-16-021	NEW-E 91-06-069	132K-16-430	NEW-E 91-03-084
36-12-435	NEW-P 91-05-032	131-32-050	NEW-E 91-06-075	132K-16-430	NEW-P 91-03-150
36-12-440	REP-P 91-05-032	132B-120-010	AMD-P 91-05-033	132K-16-440	NEW-E 91-03-084
36-12-445	NEW-P 91-05-032	132B-120-045	NEW-P 91-05-033	132K-16-440	NEW-P 91-03-150
36-12-450	AMD-P 91-05-032	132B-120-060	AMD-P 91-05-033	132K-16-450	NEW-E 91-03-084
36-12-460	REP-P 91-05-032	132B-120-090	AMD-P 91-05-033	132K-16-450	NEW-P 91-03-150
36-12-470	REP-P 91-05-032	132B-120-100	AMD-P 91-05-033	132K-16-460	NEW-E 91-03-084
36-12-480	REP-P 91-05-032	132B-120-120	AMD-P 91-05-033	132K-16-460	NEW-P 91-03-150
51-11-0600	NEW 91-06-065	132B-120-140	AMD-P 91-05-033	132K-16-470	NEW-E 91-03-084
51-13-502	AMD-P 91-07-047	132B-120-160	AMD-P 91-05-033	132K-16-470	NEW-P 91-03-150
51-19-470	NEW-W 91-06-064	132B-120-170	AMD-P 91-05-033	132K-16-480	NEW-E 91-03-084
106-120-004	AMD 91-04-054	132B-120-180	AMD-P 91-05-033	132K-16-480	NEW-P 91-03-150
106-120-005	AMD 91-04-054	132B-120-190	AMD-P 91-05-033	132K-16-490	NEW-E 91-03-084
106-120-023	AMD 91-04-054	132K-16-110	NEW-E 91-03-084	132K-16-490	NEW-P 91-03-150
106-120-024	AMD 91-04-054	132K-16-110	NEW-P 91-03-150	132K-16-500	NEW-E 91-03-084
106-120-026	AMD 91-04-054	132K-16-120	NEW-E 91-03-084	132K-16-500	NEW-P 91-03-150
106-120-027	AMD 91-04-054	132K-16-120	NEW-P 91-03-150	132K-16-510	NEW-E 91-03-084
106-120-028	AMD 91-04-054	132K-16-130	NEW-E 91-03-084	132K-16-510	NEW-P 91-03-150
106-120-033	AMD 91-04-054	132K-16-130	NEW-P 91-03-150	132K-16-520	NEW-E 91-03-084
106-120-131	AMD 91-04-054	132K-16-140	NEW-E 91-03-084	132K-16-520	NEW-P 91-03-150
106-120-132	AMD 91-04-054	132K-16-140	NEW-P 91-03-150	132K-16-530	NEW-E 91-03-084
106-120-143	AMD 91-04-054	132K-16-150	NEW-E 91-03-084	132K-16-530	NEW-P 91-03-150
113-10-010	DECOD 91-05-095	132K-16-150	NEW-P 91-03-150	132K-16-540	NEW-E 91-03-084
113-10-020	DECOD 91-05-095	132K-16-160	NEW-E 91-03-084	132K-16-540	NEW-P 91-03-150
113-10-030	DECOD 91-05-095	132K-16-160	NEW-P 91-03-150	132K-16-550	NEW-E 91-03-084
113-10-040	DECOD 91-05-095	132K-16-170	NEW-E 91-03-084	132K-16-550	NEW-P 91-03-150
113-10-050	DECOD 91-05-095	132K-16-170	NEW-P 91-03-150	132K-16-560	NEW-E 91-03-084
113-10-060	DECOD 91-05-095	132K-16-180	NEW-E 91-03-084	132K-16-560	NEW-P 91-03-150
113-10-070	DECOD 91-05-095	132K-16-180	NEW-P 91-03-150	132S-30-036	AMD-P 91-02-101
113-10-090	DECOD 91-05-095	132K-16-190	NEW-E 91-03-084	132Y-400-010	NEW 91-05-012
113-10-100	DECOD 91-05-095	132K-16-190	NEW-P 91-03-150	132Y-400-020	NEW 91-05-012
113-10-110	DECOD 91-05-095	132K-16-200	NEW-E 91-03-084	132Y-400-030	NEW 91-05-012
113-12-010	DECOD 91-05-095	132K-16-200	NEW-P 91-03-150	132Y-400-040	NEW 91-05-012
113-12-075	DECOD 91-05-095	132K-16-210	NEW-E 91-03-084	143-06-130	AMD-P 91-04-090
113-12-080	DECOD 91-05-095	132K-16-210	NEW-P 91-03-150	143-06-130	AMD 91-07-033
113-12-085	DECOD 91-05-095	132K-16-220	NEW-E 91-03-084	154-300-005	NEW-P 91-02-098
113-12-087	DECOD 91-05-095	132K-16-220	NEW-P 91-03-150	154-300-005	NEW 91-05-084
113-12-101	DECOD 91-05-095	132K-16-230	NEW-E 91-03-084	154-300-010	NEW-P 91-02-098
113-12-101	REP-P 91-06-090	132K-16-230	NEW-P 91-03-150	154-300-010	NEW 91-05-084
113-12-103	DECOD 91-05-095	132K-16-240	NEW-E 91-03-084	154-300-020	NEW-P 91-02-098
113-12-104	DECOD 91-05-095	132K-16-240	NEW-P 91-03-150	154-300-020	NEW 91-05-084
113-12-115	DECOD 91-05-095	132K-16-250	NEW-E 91-03-084	154-300-030	NEW-P 91-02-098

Table of WAC Sections Affected

WAC #	WSR #	WAC #	WSR #	WAC #	WSR #
154-300-030	NEW 91-05-084	173-303-081	AMD 91-07-005	173-340-360	AMD 91-04-019
154-300-040	NEW-P 91-02-098	173-303-084	AMD 91-07-005	173-340-420	AMD 91-04-019
154-300-040	NEW 91-05-084	173-303-090	AMD 91-07-005	173-340-430	AMD 91-04-019
154-300-050	NEW-P 91-02-098	173-303-103	AMD 91-07-005	173-340-440	NEW 91-04-019
154-300-050	NEW 91-05-084	173-303-110	AMD 91-07-005	173-340-450	NEW 91-04-019
154-300-060	NEW-P 91-02-098	173-303-120	AMD 91-07-005	173-340-700	AMD 91-04-019
154-300-060	NEW 91-05-084	173-303-145	AMD 91-07-005	173-340-702	NEW 91-04-019
154-300-070	NEW-P 91-02-098	173-303-160	AMD 91-07-005	173-340-704	NEW 91-04-019
154-300-070	NEW 91-05-084	173-303-200	AMD 91-07-005	173-340-705	NEW 91-04-019
154-300-080	NEW-P 91-02-098	173-303-201	AMD 91-07-005	173-340-706	NEW 91-04-019
154-300-080	NEW 91-05-084	173-303-210	AMD 91-07-005	173-340-707	NEW 91-04-019
154-300-090	NEW-P 91-02-098	173-303-220	AMD 91-07-005	173-340-708	NEW 91-04-019
154-300-090	NEW 91-05-084	173-303-230	AMD 91-07-005	173-340-710	NEW 91-04-019
154-300-100	NEW-P 91-02-098	173-303-320	AMD 91-07-005	173-340-720	NEW 91-04-019
154-300-100	NEW 91-05-084	173-303-360	AMD 91-07-005	173-340-730	NEW 91-04-019
154-300-110	NEW-P 91-02-098	173-303-380	AMD 91-07-005	173-340-740	NEW 91-04-019
154-300-110	NEW 91-05-084	173-303-390	AMD 91-07-005	173-340-745	NEW 91-04-019
154-300-120	NEW-P 91-02-098	173-303-400	AMD 91-07-005	173-340-750	NEW 91-04-019
154-300-120	NEW 91-05-084	173-303-500	AMD 91-07-005	173-340-760	NEW 91-04-019
173-16-064	NEW-P 91-04-069	173-303-510	RE-AD 91-07-005	173-340-830	AMD 91-04-019
173-16-064	NEW-W 91-05-042	173-303-515	RE-AD 91-07-005	173-360-220	NEW-W 91-04-022
173-19-120	AMD-W 91-02-112	173-303-520	RE-AD 91-07-005	173-360-230	NEW-W 91-04-022
173-19-2207	AMD-P 91-03-144	173-303-525	AMD 91-07-005	173-360-620	NEW-W 91-04-022
173-19-230	AMD 91-03-145	173-303-550	AMD 91-07-005	173-400-010	AMD 91-05-064
173-19-250	AMD 91-03-149	173-303-560	RE-AD 91-07-005	173-400-020	AMD 91-05-064
173-19-280	AMD-P 91-03-141	173-303-600	AMD 91-07-005	173-400-030	AMD 91-05-064
173-19-3203	AMD 91-03-147	173-303-610	AMD 91-07-005	173-400-040	AMD 91-05-064
173-19-3205	AMD 91-03-146	173-303-620	AMD 91-07-005	173-400-050	AMD 91-05-064
173-19-3208	AMD 91-03-148	173-303-630	AMD 91-07-005	173-400-060	AMD 91-05-064
173-19-3209	AMD 91-04-070	173-303-645	AMD 91-07-005	173-400-070	AMD 91-05-064
173-19-3210	AMD 91-04-071	173-303-650	RE-AD 91-07-005	173-400-075	AMD 91-05-064
173-19-350	AMD-P 91-03-143	173-303-680	NEW 91-07-005	173-400-100	AMD 91-05-064
173-19-360	AMD 91-04-072	173-303-800	AMD 91-07-005	173-400-105	AMD 91-05-064
173-19-360	AMD-P 91-05-063	173-303-802	AMD 91-07-005	173-400-110	AMD 91-05-064
173-19-360	AMD-C 91-06-094	173-303-805	AMD 91-07-005	173-400-115	AMD 91-05-064
173-19-4205	AMD-P 91-04-079	173-303-806	AMD 91-07-005	173-400-120	AMD 91-05-064
173-160-040	AMD-E 91-04-073	173-303-807	AMD 91-07-005	173-400-131	NEW 91-05-064
173-166	AMD-C 91-02-099	173-303-808	AMD 91-07-005	173-400-136	NEW 91-05-064
173-166	AMD 91-03-081	173-303-810	AMD 91-07-005	173-400-141	NEW 91-05-064
173-166-010	AMD 91-03-081	173-303-830	AMD 91-07-005	173-400-151	NEW 91-05-064
173-166-020	AMD 91-03-081	173-303-9903	AMD 91-07-005	173-400-161	NEW 91-05-064
173-166-030	AMD 91-03-081	173-303-9904	AMD 91-07-005	173-400-171	NEW 91-05-064
173-166-040	AMD 91-03-081	173-303-9906	AMD 91-07-005	173-400-180	NEW 91-05-064
173-166-050	AMD 91-03-081	173-303-9907	AMD 91-07-005	173-400-190	NEW 91-05-064
173-166-060	AMD 91-03-081	173-305-010	REP-E 91-03-139	173-400-200	NEW 91-05-064
173-166-070	AMD 91-03-081	173-305-01001	NEW-E 91-03-139	173-400-205	NEW 91-05-064
173-166-080	NEW 91-03-081	173-305-015	REP-E 91-03-139	173-400-210	NEW 91-05-064
173-166-090	NEW 91-03-081	173-305-01501	NEW-E 91-03-139	173-400-220	NEW 91-05-064
173-166-100	NEW 91-03-081	173-305-020	REP-E 91-03-139	173-400-230	NEW 91-05-064
173-166-110	NEW 91-03-081	173-305-02001	NEW-E 91-03-139	173-400-240	NEW 91-05-064
173-166-120	NEW 91-03-081	173-305-030	REP-E 91-03-139	173-400-250	NEW 91-05-064
173-166-130	NEW 91-03-081	173-305-03001	NEW-E 91-03-139	173-400-260	NEW 91-05-064
173-166-140	NEW 91-03-081	173-305-040	REP-E 91-03-139	173-403-010	REP 91-05-064
173-204	NEW-C 91-03-094	173-305-04001	NEW-E 91-03-139	173-403-020	REP 91-05-064
173-204	NEW-C 91-06-098	173-305-050	REP-E 91-03-139	173-403-030	REP 91-05-064
173-224-015	AMD-P 91-03-080	173-305-05001	NEW-E 91-03-139	173-403-050	REP 91-05-064
173-224-030	AMD-P 91-03-080	173-305-060	REP-E 91-03-139	173-403-060	REP 91-05-064
173-224-040	AMD-P 91-03-080	173-305-06001	NEW-E 91-03-139	173-403-070	REP 91-05-064
173-224-050	AMD-P 91-03-080	173-305-070	REP-E 91-03-139	173-403-075	REP 91-05-064
173-224-090	AMD-P 91-03-080	173-305-07001	NEW-E 91-03-139	173-403-080	REP 91-05-064
173-270-010	NEW-P 91-04-091	173-305-080	REP-E 91-03-139	173-403-090	REP 91-05-064
173-270-020	NEW-P 91-04-091	173-305-090	REP-E 91-03-139	173-403-100	REP 91-05-064
173-270-030	NEW-P 91-04-091	173-331-010	NEW 91-05-020	173-403-110	REP 91-05-064
173-270-040	NEW-P 91-04-091	173-331-100	NEW 91-05-020	173-403-120	REP 91-05-064
173-270-050	NEW-P 91-04-091	173-331-200	NEW 91-05-020	173-403-130	REP 91-05-064
173-270-060	NEW-P 91-04-091	173-331-210	NEW 91-05-020	173-403-141	REP 91-05-064
173-270-070	NEW-P 91-04-091	173-331-220	NEW 91-05-020	173-403-145	REP 91-05-064
173-270-080	NEW-P 91-04-091	173-331-300	NEW 91-05-020	173-403-150	REP 91-05-064
173-270-090	NEW-P 91-04-091	173-331-400	NEW 91-05-020	173-403-160	REP 91-05-064
173-270-100	NEW-P 91-04-091	173-331-410	NEW 91-05-020	173-403-170	REP 91-05-064
173-303-016	AMD 91-07-005	173-331-500	NEW 91-05-020	173-403-180	REP 91-05-064
173-303-017	AMD 91-07-005	173-331-600	NEW 91-05-020	173-403-190	REP 91-05-064
173-303-040	AMD 91-07-005	173-340-120	AMD 91-04-019	173-405-012	AMD 91-05-064
173-303-045	AMD 91-07-005	173-340-200	AMD 91-04-019	173-405-021	AMD 91-05-064
173-303-070	AMD 91-07-005	173-340-210	AMD 91-04-019	173-405-033	AMD 91-05-064
173-303-071	AMD 91-07-005	173-340-300	AMD 91-04-019	173-405-035	AMD 91-05-064
173-303-072	AMD 91-07-005	173-340-350	AMD 91-04-019	173-405-040	AMD 91-05-064

Table of WAC Sections Affected

WAC #		WSR #	WAC #		WSR #	WAC #		WSR #
173-405-041	REP	91-05-064	180-79-236	NEW	91-05-056	212-54-075	REP-E	91-06-021
173-405-045	AMD	91-05-064	180-79-241	NEW	91-05-056	212-54-080	REP-P	91-06-020
173-405-061	AMD	91-05-064	180-85-005	AMD	91-04-016	212-54-080	REP-E	91-06-021
173-405-072	AMD	91-05-064	180-85-045	AMD	91-04-016	212-54-085	REP-P	91-06-020
173-405-077	AMD	91-05-064	180-86-100	AMD-P	91-05-024	212-54-085	REP-E	91-06-021
173-405-078	AMD	91-05-064	182-12-127	REP-P	91-04-086	212-54-090	REP-P	91-06-020
173-405-086	AMD	91-05-064	182-12-210	REP-P	91-04-086	212-54-090	REP-E	91-06-021
173-405-087	AMD	91-05-064	182-12-215	NEW-P	91-04-086	212-54-095	REP-P	91-06-020
173-405-091	AMD	91-05-064	182-16-010	NEW-P	91-04-087	212-54-095	REP-E	91-06-021
173-410-012	AMD	91-05-064	182-16-020	NEW-P	91-04-087	212-54-100	REP-P	91-06-020
173-410-021	AMD	91-05-064	182-16-030	NEW-P	91-04-087	212-54-100	REP-E	91-06-021
173-410-035	AMD	91-05-064	182-16-040	NEW-P	91-04-087	212-55-001	REP-P	91-06-020
173-410-040	AMD	91-05-064	182-16-050	NEW-P	91-04-087	212-55-001	REP-E	91-06-021
173-410-042	REP	91-05-064	182-18-005	NEW-P	91-05-079	212-55-005	REP-P	91-06-020
173-410-045	AMD	91-05-064	182-18-010	NEW-P	91-05-079	212-55-005	REP-E	91-06-021
173-410-062	AMD	91-05-064	182-18-020	NEW-P	91-05-079	212-55-010	REP-P	91-06-020
173-410-067	AMD	91-05-064	182-18-030	NEW-P	91-05-079	212-55-010	REP-E	91-06-021
173-410-071	AMD	91-05-064	182-18-040	NEW-P	91-05-079	212-55-015	REP-P	91-06-020
173-410-086	AMD	91-05-064	182-18-050	NEW-P	91-05-079	212-55-015	REP-E	91-06-021
173-410-087	AMD	91-05-064	182-18-060	NEW-P	91-05-079	212-55-020	REP-P	91-06-020
173-410-100	NEW	91-05-064	182-18-070	NEW-P	91-05-079	212-55-020	REP-E	91-06-021
173-415-010	AMD	91-05-064	182-18-080	NEW-P	91-05-079	212-55-025	REP-P	91-06-020
173-415-020	AMD	91-05-064	182-18-090	NEW-P	91-05-079	212-55-025	REP-E	91-06-021
173-415-030	AMD	91-05-064	182-18-100	NEW-P	91-05-079	212-55-030	REP-P	91-06-020
173-415-040	AMD	91-05-064	182-18-110	NEW-P	91-05-079	212-55-030	REP-E	91-06-021
173-415-041	REP	91-05-064	182-18-120	NEW-P	91-05-079	212-55-035	REP-P	91-06-020
173-415-045	AMD	91-05-064	182-18-130	NEW-P	91-05-079	212-55-035	REP-E	91-06-021
173-415-050	AMD	91-05-064	182-18-140	NEW-P	91-05-079	212-55-040	REP-P	91-06-020
173-415-051	AMD	91-05-064	182-18-150	NEW-P	91-05-079	212-55-040	REP-E	91-06-021
173-415-060	AMD	91-05-064	182-18-160	NEW-P	91-05-079	212-55-045	REP-P	91-06-020
173-415-070	AMD	91-05-064	192-12-300	AMD-E	91-03-054	212-55-045	REP-E	91-06-021
173-415-080	AMD	91-05-064	192-12-305	REP-E	91-03-054	212-55-050	REP-P	91-06-020
173-433	AMD	91-07-066	192-12-310	REP-E	91-03-054	212-55-050	REP-E	91-06-021
173-433-030	AMD	91-07-066	192-12-320	AMD-E	91-03-054	212-55-055	REP-P	91-06-020
173-433-100	AMD	91-07-066	192-12-330	AMD-E	91-03-054	212-55-055	REP-E	91-06-021
173-433-110	AMD	91-07-066	192-12-370	NEW-E	91-03-054	212-55-060	REP-P	91-06-020
173-433-120	AMD	91-07-066	196-24-060	AMD-P	91-07-064	212-55-060	REP-E	91-06-021
173-433-130	AMD	91-07-066	196-24-095	AMD-P	91-05-078	212-55-065	REP-P	91-06-020
173-433-140	NEW	91-07-066	196-24-095	AMD-C	91-06-018	212-55-065	REP-E	91-06-021
173-433-150	AMD	91-07-066	196-24-097	NEW-P	91-05-078	212-55-070	REP-P	91-06-020
173-433-170	AMD	91-07-066	196-24-097	NEW-C	91-06-018	212-55-070	REP-E	91-06-021
173-490-010	AMD	91-05-064	196-24-098	PREP	91-05-041	212-55-075	REP-P	91-06-020
173-490-020	AMD	91-05-064	196-26-020	AMD-P	91-07-065	212-55-075	REP-E	91-06-021
173-490-025	AMD	91-05-064	196-26-030	AMD-P	91-07-065	212-55-080	REP-P	91-06-020
173-490-030	AMD	91-05-064	204-53-010	NEW	91-05-019	212-55-080	REP-E	91-06-021
173-490-040	AMD	91-05-064	212-12-010	AMD-W	91-05-043	212-55-085	REP-P	91-06-020
173-490-070	REP	91-05-064	212-54-001	REP-P	91-06-020	212-55-085	REP-E	91-06-021
173-490-071	REP	91-05-064	212-54-001	REP-E	91-06-021	212-55-090	REP-P	91-06-020
173-490-080	AMD	91-05-064	212-54-005	REP-P	91-06-020	212-55-090	REP-E	91-06-021
173-490-090	AMD	91-05-064	212-54-005	REP-E	91-06-021	212-55-095	REP-P	91-06-020
173-490-120	REP	91-05-064	212-54-010	REP-P	91-06-020	212-55-095	REP-E	91-06-021
173-490-130	REP	91-05-064	212-54-010	REP-E	91-06-021	212-56A-001	NEW-P	91-06-020
173-490-135	REP	91-05-064	212-54-015	REP-P	91-06-020	212-56A-001	NEW-E	91-06-021
173-490-140	REP	91-05-064	212-54-015	REP-E	91-06-021	212-56A-005	NEW-P	91-06-020
173-490-150	REP	91-05-064	212-54-020	REP-P	91-06-020	212-56A-005	NEW-E	91-06-021
173-490-200	AMD	91-05-064	212-54-020	REP-E	91-06-021	212-56A-010	NEW-P	91-06-020
173-490-201	AMD	91-05-064	212-54-025	REP-P	91-06-020	212-56A-010	NEW-E	91-06-021
173-490-202	AMD	91-05-064	212-54-025	REP-E	91-06-021	212-56A-015	NEW-P	91-06-020
173-490-203	AMD	91-05-064	212-54-030	REP-P	91-06-020	212-56A-015	NEW-E	91-06-021
173-490-204	AMD	91-05-064	212-54-030	REP-E	91-06-021	212-56A-020	NEW-P	91-06-020
173-490-205	AMD	91-05-064	212-54-035	REP-P	91-06-020	212-56A-020	NEW-E	91-06-021
173-490-207	AMD	91-05-064	212-54-035	REP-E	91-06-021	212-56A-030	NEW-P	91-06-020
173-490-208	AMD	91-05-064	212-54-040	REP-P	91-06-020	212-56A-030	NEW-E	91-06-021
173-491-010	NEW-P	91-02-107	212-54-040	REP-E	91-06-021	212-56A-035	NEW-P	91-06-020
173-491-015	NEW-P	91-02-107	212-54-045	REP-P	91-06-020	212-56A-035	NEW-E	91-06-021
173-491-020	NEW-P	91-02-107	212-54-045	REP-E	91-06-021	212-56A-040	NEW-P	91-06-020
173-491-030	NEW-P	91-02-107	212-54-050	REP-P	91-06-020	212-56A-040	NEW-E	91-06-021
173-491-040	NEW-P	91-02-107	212-54-050	REP-E	91-06-021	212-56A-045	NEW-P	91-06-020
173-491-050	NEW-P	91-02-107	212-54-055	REP-P	91-06-020	212-56A-045	NEW-E	91-06-021
173-500-080	NEW-E	91-04-080	212-54-055	REP-E	91-06-021	212-56A-050	NEW-P	91-06-020
173-548-050	AMD-E	91-04-073	212-54-060	REP-P	91-06-020	212-56A-050	NEW-E	91-06-021
180-44-050	AMD-P	91-05-068	212-54-060	REP-E	91-06-021	212-56A-055	NEW-P	91-06-020
180-55-005	AMD	91-04-015	212-54-065	REP-P	91-06-020	212-56A-055	NEW-E	91-06-021
180-55-015	AMD	91-04-015	212-54-065	REP-E	91-06-021	212-56A-060	NEW-P	91-06-020
180-79-003	AMD	91-04-016	212-54-070	REP-P	91-06-020	212-56A-060	NEW-E	91-06-021
180-79-080	AMD	91-04-016	212-54-070	REP-E	91-06-021	212-56A-065	NEW-P	91-06-020
180-79-230	AMD	91-05-056	212-54-075	REP-P	91-06-020	212-56A-065	NEW-E	91-06-021

### Table of WAC Sections Affected

WAC #	WSR #	WAC #	WSR #	WAC #	WSR #
212-56A-070	NEW-P	91-06-020	220-56-235	AMD-P	91-03-153
212-56A-070	NEW-E	91-06-021	220-56-23500F	NEW-E	91-04-030
212-56A-075	NEW-P	91-06-020	220-56-240	AMD-P	91-03-153
212-56A-075	NEW-E	91-06-021	220-56-250	AMD-P	91-03-153
212-56A-080	NEW-P	91-06-020	220-56-282	AMD-P	91-03-153
212-56A-080	NEW-E	91-06-021	220-56-350	AMD-P	91-03-153
212-56A-085	NEW-P	91-06-020	220-56-36000W	NEW-E	91-06-057
212-56A-085	NEW-E	91-06-021	220-56-380	AMD-P	91-03-153
212-56A-090	NEW-P	91-06-020	220-57-195	AMD-P	91-03-151
212-56A-090	NEW-E	91-06-021	220-57-205	AMD-P	91-03-151
212-56A-095	NEW-P	91-06-020	220-57-210	AMD-P	91-03-151
212-56A-095	NEW-E	91-06-021	220-57-265	AMD-P	91-03-151
212-56A-100	NEW-P	91-06-020	220-57-290	AMD-P	91-03-153
212-56A-100	NEW-E	91-06-021	220-57-313	NEW-P	91-03-153
212-56A-105	NEW-P	91-06-020	220-57-340	AMD-P	91-03-153
212-56A-105	NEW-E	91-06-021	220-57-385	AMD-P	91-03-153
212-56A-110	NEW-P	91-06-020	220-57-425	AMD-P	91-03-153
212-56A-110	NEW-E	91-06-021	220-57-425	AMD-P	91-03-151
212-56A-115	NEW-P	91-06-020	220-57-430	AMD-P	91-03-151
212-56A-115	NEW-E	91-06-021	220-57-435	AMD-P	91-03-151
212-56A-120	NEW-P	91-06-020	220-57-450	AMD-P	91-03-153
212-56A-120	NEW-E	91-06-021	220-57-450	AMD-P	91-03-151
212-56A-125	NEW-P	91-06-020	220-57-455	AMD-P	91-03-151
212-56A-125	NEW-E	91-06-021	220-57-460	AMD-P	91-03-153
212-56A-130	NEW-P	91-06-020	220-57-465	AMD-P	91-03-151
212-56A-130	NEW-E	91-06-021	220-57-470	AMD-P	91-03-151
212-56A-135	NEW-P	91-06-020	220-57-490	AMD-P	91-03-151
212-56A-135	NEW-E	91-06-021	220-57-497	AMD-P	91-03-153
212-56A-140	NEW-P	91-06-020	220-57A-035	AMD-P	91-03-153
212-56A-140	NEW-E	91-06-021	220-69-260	AMD	91-05-015
220-12-020	AMD-P	91-05-102	220-69-262	AMD	91-05-015
220-16-055	REP-P	91-03-151	220-69-264	AMD	91-05-015
220-16-220	AMD-P	91-03-153	220-69-26401	AMD	91-05-015
220-16-257	AMD-P	91-03-153	222-16-045	NEW-E	91-07-034
220-20-010	AMD-P	91-03-153	222-16-050	AMD-E	91-07-034
220-20-01700A	NEW-E	91-03-108	230-02-240	NEW-P	91-03-062
220-32-05100D	REP-E	91-04-031	230-02-240	NEW	91-07-021
220-32-05100E	NEW-E	91-04-031	230-02-505	NEW-P	91-03-062
220-32-05700F	NEW-E	91-03-083	230-02-505	NEW-C	91-07-019
220-33-01000V	NEW-E	91-05-005	230-04-022	AMD-P	91-03-062
220-33-01000V	REP-E	91-05-036	230-04-022	AMD-C	91-07-042
220-33-01000W	NEW-E	91-05-036	230-04-120	AMD-P	91-03-062
220-40-030	AMD-P	91-03-153	230-04-120	AMD-C	91-07-019
220-40-031	AMD-P	91-03-153	230-04-187	NEW-P	91-03-062
220-44-050	AMD-P	91-03-152	230-04-187	NEW-C	91-07-019
220-44-050	AMD	91-07-050	230-04-190	AMD-P	91-03-062
220-48-01500E	NEW-E	91-05-037	230-04-190	AMD-C	91-07-019
220-49-063	AMD-P	91-02-108	230-04-201	AMD-P	91-03-062
220-49-063	AMD	91-05-016	230-04-201	AMD-C	91-07-019
220-52-020	AMD-P	91-05-102	230-12-100	NEW-P	91-03-062
220-52-030	AMD-P	91-05-102	230-12-100	NEW-C	91-07-019
220-52-040	AMD-P	91-05-102	230-12-305	AMD-P	91-03-062
220-52-046	AMD-P	91-05-102	230-12-305	AMD	91-07-021
220-52-060	AMD-P	91-05-102	230-20-380	AMD-C	91-03-049
220-52-069	AMD-P	91-05-102	230-20-380	AMD-W	91-05-044
220-52-071	AMD-P	91-05-102	230-20-699	REP	91-03-063
220-52-073	AMD-P	91-05-102	230-25-110	AMD-P	91-03-062
220-52-073001	REP-E	91-04-029	230-25-110	AMD-C	91-07-019
220-52-07300J	NEW-E	91-04-029	230-25-265	AMD-C	91-03-049
220-52-075	AMD-P	91-05-102	230-25-265	AMD	91-05-047
220-55-055	AMD-P	91-03-153	230-25-265	AMD	91-06-008
220-55-065	AMD-P	91-03-153	230-25-330	NEW-P	91-03-062
220-55-070	AMD-P	91-03-153	230-25-330	NEW-C	91-07-019
220-55-075	AMD-P	91-03-153	230-30-075	AMD-C	91-03-049
220-55-080	AMD-P	91-03-153	230-30-075	AMD-C	91-05-046
220-55-086	AMD-P	91-03-153	230-30-075	AMD-W	91-06-039
220-55-125	AMD-P	91-03-153	230-30-075	AMD-P	91-07-018
220-56-100	AMD-P	91-03-153	230-30-075	AMD-S	91-07-051
220-56-105	AMD-P	91-03-153	230-30-080	AMD-C	91-03-049
220-56-115	AMD-P	91-03-153	230-30-080	AMD-P	91-05-045
220-56-128	AMD-P	91-03-153	230-30-080	AMD	91-05-047
220-56-175	AMD-P	91-03-153	230-40-125	AMD-C	91-03-049
220-56-180	AMD-P	91-03-153	230-40-125	AMD	91-05-047
220-56-185	AMD-P	91-03-153	230-50-030	AMD	91-03-063
220-56-190	AMD-P	91-03-153	232-12-004	AMD-P	91-03-131
220-56-205	AMD-P	91-03-153	232-12-007	AMD-P	91-03-133
220-56-232	NEW-P	91-03-152	232-12-055	AMD-P	91-03-137
232-12-017	AMD	91-03-082	232-12-024	AMD-P	91-06-082
232-12-024	AMD-P	91-06-082	232-12-244	REP-P	91-06-081
232-12-244	NEW-P	91-06-081	232-12-245	NEW-P	91-06-081
232-12-267	AMD-P	91-06-080	232-12-831	NEW-P	91-06-083
232-12-831	NEW-P	91-06-083	232-28-022	AMD-P	91-03-130
232-28-022	AMD-P	91-03-130	232-28-215	REP-W	91-02-113
232-28-215	REP-W	91-02-113	232-28-219	REP-P	91-06-084
232-28-219	REP-P	91-06-084	232-28-220	REP-P	91-06-084
232-28-220	REP-P	91-06-084	232-28-221	REP-P	91-06-084
232-28-221	REP-P	91-06-084	232-28-222	REP-P	91-06-084
232-28-222	REP-P	91-06-084	232-28-223	REP-P	91-06-084
232-28-223	REP-P	91-06-084	232-28-224	NEW-W	91-02-113
232-28-224	NEW-W	91-02-113	232-28-225	NEW	91-06-016
232-28-225	NEW	91-06-016	232-28-226	NEW-P	91-03-138
232-28-226	NEW-P	91-03-138	232-28-226	NEW-P	91-03-138
232-28-227	NEW-P	91-03-135	232-28-227	NEW-P	91-03-135
232-28-228	NEW-P	91-03-134	232-28-229	NEW-P	91-06-086
232-28-229	NEW-P	91-06-086	232-28-230	NEW-P	91-06-087
232-28-230	NEW-P	91-06-087	232-28-231	NEW-P	91-06-085
232-28-231	NEW-P	91-06-085	232-28-61810	REP-P	91-03-136
232-28-61810	REP-P	91-03-136	232-28-61811	NEW-W	91-03-066
232-28-61811	NEW-W	91-03-066	232-28-61813	NEW	91-05-002
232-28-61813	NEW	91-05-002	232-28-61815	NEW	91-05-001
232-28-61815	NEW	91-05-001	232-28-61817	NEW-P	91-03-136
232-28-61817	NEW-P	91-03-136	232-28-713	REP	91-06-015
232-28-713	REP	91-06-015	232-28-714	NEW	91-06-015
232-28-714	NEW	91-06-015	236-12-290	AMD-P	91-04-081
236-12-290	AMD-P	91-04-081	236-12-300	AMD-P	91-04-081
236-12-300	AMD-P	91-04-081	236-100-001	NEW-P	91-05-101
236-100-001	NEW-P	91-05-101	236-100-010	NEW-P	91-05-101
236-100-010	NEW-P	91-05-101	236-100-011	NEW-P	91-05-101
236-100-011	NEW-P	91-05-101	236-100-012	NEW-P	91-05-101
236-100-012	NEW-P	91-05-101	236-100-013	NEW-P	91-05-101
236-100-013	NEW-P	91-05-101	236-100-014	NEW-P	91-05-101
236-100-014	NEW-P	91-05-101	236-100-015	NEW-P	91-05-101
236-100-015	NEW-P	91-05-101	236-100-016	NEW-P	91-05-101
240-15-005	AMD	91-02-111	240-15-005	AMD	91-02-111
240-15-010	AMD	91-02-111	240-15-010	AMD	91-02-111
240-15-015	AMD	91-02-111	240-15-020	AMD	91-02-111
240-15-020	AMD	91-02-111	240-15-025	AMD	91-02-111
240-15-025	AMD	91-02-111	240-15-030	AMD	91-02-111
240-15-030	AMD	91-02-111	240-15-035	AMD	91-02-111
246-205-001	NEW	91-04-007	246-205-001	NEW	91-04-007
246-205-001	NEW	91-04-007	246-205-010	NEW	91-04-007
246-205-010	NEW	91-04-007	246-205-020	NEW	91-04-007
246-205-020	NEW	91-04-007	246-205-030	NEW	91-04-007
246-205-030	NEW	91-04-007	246-205-040	NEW	91-04-007
246-205-040	NEW	91-04-007	246-205-050	NEW	91-04-007
246-205-050	NEW	91-04-007	246-205-060	NEW	91-04-007
246-205-060	NEW	91-04-007	246-205-070	NEW	91-04-007
246-205-070	NEW	91-04-007	246-205-080	NEW	91-04-007
246-205-080	NEW	91-04-007	246-205-090	NEW	91-04-007
246-205-090	NEW	91-04-007	246-205-100	NEW	91-04-007
246-205-100	NEW	91-04-007	246-205-110	NEW	91-04-007
246-205-110	NEW	91-04-007	246-205-120	NEW	91-04-007
246-205-120	NEW	91-04-007	246-205-990	NEW	91-04-007
246-290-010	AMD	91-07-031	246-290-010	AMD	91-07-031
246-290-010	AMD	91-07-031	246-290-130	AMD	91-07-031
246-290-130	AMD	91-07-031	246-290-300	AMD	91-07-031
246-290-300	AMD	91-07-031	246-290-310	AMD	91-07-031
246-290-310	AMD	91-07-031	246-290-320	AMD	91-07-031
246-290-320	AMD	91-07-031	246-290-330	AMD	91-07-031
246-310-500	AMD	91-05-093	246-310-500	AMD	91-05-093
246-453-001	AMD	91-05-048	246-453-001	AMD	91-05-048
246-453-001	AMD	91-05-048	246-453-010	AMD	91-05-048
246-453-010	AMD	91-05-048	246-453-020	NEW	91-05-048
246-453-020	NEW	91-05-048	246-453-030	NEW	91-05-048
246-453-030	NEW	91-05-048	246-453-040	NEW	91-05-048
246-453-040	NEW	91-05-048	246-453-050	NEW	91-05-048
246-453-050	NEW	91-05-048	246-453-060	NEW	91-05-048
246-453-060	NEW	91-05-048	246-453-070	AMD	91-05-048
246-453-070	AMD	91-05-048	246-453-080	AMD	91-05-048
246-453-080	AMD	91-05-048	246-453-085	REP	91-05-048
246-453-085	REP	91-05-048			









Table of WAC Sections Affected

WAC #	WSR #	WAC #	WSR #	WAC #	WSR #
246-924-340	NEW 91-04-021	292-10-060	NEW 91-04-060	296-22-116	AMD 91-07-008
246-924-350	RECOD 91-04-020	292-10-070	NEW 91-04-060	296-22-120	AMD 91-07-008
246-924-360	RECOD 91-04-020	296-17-310	AMD-P 91-07-061	296-22-125	AMD 91-07-008
246-924-370	RECOD 91-04-020	296-17-320	AMD-P 91-07-061	296-22-130	AMD 91-07-008
246-924-380	RECOD 91-04-020	296-17-420	AMD-P 91-07-061	296-22-132	AMD 91-07-008
246-924-390	RECOD 91-04-020	296-17-440	AMD-P 91-07-061	296-22-135	AMD 91-07-008
246-924-400	RECOD 91-04-020	296-17-512	AMD-P 91-07-061	296-22-140	AMD 91-07-008
246-924-410	RECOD 91-04-020	296-17-544	AMD-P 91-07-061	296-22-141	AMD 91-07-008
246-924-420	RECOD 91-04-020	296-17-567	AMD-P 91-07-061	296-22-146	AMD 91-07-008
246-924-430	RECOD 91-04-020	296-17-57001	AMD-P 91-07-061	296-22-147	AMD 91-07-008
246-924-440	RECOD 91-04-020	296-17-579	AMD-P 91-07-061	296-22-150	AMD 91-07-008
246-924-450	RECOD 91-04-020	296-17-592	REP-P 91-07-061	296-22-155	AMD 91-07-008
246-924-460	RECOD 91-04-020	296-17-59202	AMD-P 91-07-061	296-22-160	AMD 91-07-008
246-924-470	RECOD 91-04-020	296-17-59203	NEW-P 91-07-061	296-22-165	AMD 91-07-008
246-924-480	RECOD 91-04-020	296-17-59204	NEW-P 91-07-061	296-22-170	AMD 91-07-008
246-924-990	RECOD 91-05-028	296-17-603	REP-P 91-07-061	296-22-180	AMD 91-07-008
246-930-010	NEW-P 91-06-091	296-17-604	AMD-P 91-07-061	296-22-190	AMD 91-07-008
246-930-020	NEW-P 91-06-091	296-17-605	AMD-P 91-07-061	296-22-195	AMD 91-07-008
246-930-030	NEW-P 91-06-091	296-17-606	AMD-P 91-07-061	296-22-200	AMD 91-07-008
246-930-040	NEW-P 91-06-091	296-17-634	AMD-P 91-07-061	296-22-205	AMD-W 91-02-114
246-930-050	NEW-P 91-06-091	296-17-643	AMD-P 91-07-061	296-22-205	AMD 91-07-008
246-930-060	NEW-P 91-06-091	296-17-64905	NEW-P 91-07-061	296-22-210	AMD 91-07-008
246-930-070	NEW-P 91-06-091	296-17-669	AMD-P 91-07-061	296-22-215	AMD 91-07-008
246-930-200	NEW-P 91-06-091	296-17-709	AMD-P 91-07-061	296-22-220	AMD 91-07-008
246-930-210	NEW-P 91-06-091	296-17-71301	NEW-P 91-07-061	296-22-225	AMD 91-07-008
246-930-220	NEW-P 91-06-091	296-17-722	AMD-P 91-07-061	296-22-230	AMD 91-07-008
246-930-300	NEW-P 91-06-091	296-17-753	AMD-P 91-07-061	296-22-235	AMD 91-07-008
246-930-400	NEW-P 91-06-091	296-17-885	AMD-P 91-07-061	296-22-245	AMD 91-07-008
246-930-499	NEW-P 91-06-091	296-17-895	AMD-P 91-07-061	296-22-250	AMD 91-07-008
246-930-990	NEW-P 91-06-091	296-20-1103	AMD-P 91-03-114	296-22-255	AMD 91-07-008
246-975-160	AMD 91-06-026	296-20-200	AMD 91-07-008	296-22-260	AMD 91-07-008
246-975-180	AMD 91-06-026	296-21-013	AMD-W 91-02-114	296-22-265	AMD 91-07-008
246-975-200	AMD 91-06-026	296-21-013	AMD 91-07-008	296-22-270	AMD 91-07-008
246-975-210	AMD 91-06-026	296-21-015	AMD 91-07-008	296-22-275	AMD 91-07-008
246-975-220	AMD 91-06-026	296-21-027	AMD 91-07-008	296-22-280	AMD 91-07-008
246-975-240	AMD 91-06-026	296-21-047	AMD 91-07-008	296-22-285	AMD 91-07-008
246-975-250	AMD 91-06-026	296-21-050	AMD 91-07-008	296-22-290	AMD 91-07-008
250-44-050	AMD-E 91-04-045	296-21-0501	AMD 91-07-008	296-22-295	AMD 91-07-008
250-44-110	AMD-E 91-04-045	296-21-066	AMD 91-07-008	296-22-300	AMD 91-07-008
250-44-130	AMD-E 91-04-045	296-21-075	AMD 91-07-008	296-22-305	AMD 91-07-008
250-76	NEW-C 91-03-087	296-21-086	AMD 91-07-008	296-22-307	AMD 91-07-008
251-08-112	AMD-E 91-05-052	296-22-020	AMD 91-07-008	296-22-310	AMD 91-07-008
251-08-112	AMD-P 91-06-077	296-22-021	AMD 91-07-008	296-22-315	AMD 91-07-008
251-09-020	AMD-P 91-07-060	296-22-022	AMD 91-07-008	296-22-325	AMD 91-07-008
251-12-085	AMD-C 91-05-055	296-22-023	AMD 91-07-008	296-22-330	AMD 91-07-008
251-12-085	AMD-C 91-05-060	296-22-024	AMD 91-07-008	296-22-333	AMD 91-07-008
251-19-120	AMD-C 91-05-055	296-22-025	AMD 91-07-008	296-22-337	AMD 91-07-008
251-19-120	AMD-C 91-05-060	296-22-026	AMD 91-07-008	296-22-340	AMD 91-07-008
251-19-155	NEW-C 91-05-054	296-22-027	AMD 91-07-008	296-22-350	AMD 91-07-008
251-19-155	AMD-C 91-05-059	296-22-030	AMD 91-07-008	296-22-355	AMD 91-07-008
251-19-156	NEW-C 91-05-054	296-22-031	AMD 91-07-008	296-22-365	AMD 91-07-008
251-19-156	AMD-C 91-05-059	296-22-036	AMD 91-07-008	296-22-370	AMD 91-07-008
251-19-157	NEW-C 91-05-054	296-22-037	AMD 91-07-008	296-22-375	AMD 91-07-008
251-19-157	AMD-C 91-05-059	296-22-038	AMD 91-07-008	296-22-405	AMD 91-07-008
251-19-158	NEW-C 91-05-054	296-22-039	AMD 91-07-008	296-22-410	AMD 91-07-008
251-19-158	AMD-C 91-05-059	296-22-040	AMD 91-07-008	296-22-413	AMD 91-07-008
251-19-160	AMD-C 91-05-055	296-22-042	AMD 91-07-008	296-22-415	AMD 91-07-008
251-19-160	AMD-C 91-05-060	296-22-051	AMD 91-07-008	296-22-420	AMD 91-07-008
251-24-030	AMD-C 91-05-054	296-22-052	AMD 91-07-008	296-22-425	AMD 91-07-008
251-24-030	AMD-C 91-05-059	296-22-053	AMD-W 91-02-114	296-22-427	AMD 91-07-008
260-36-190	NEW 91-03-033	296-22-053	AMD 91-07-008	296-22-430	AMD 91-07-008
260-36-200	NEW 91-03-033	296-22-061	AMD 91-07-008	296-22-435	AMD 91-07-008
260-60-060	AMD-W 91-03-064	296-22-063	AMD 91-07-008	296-22-440	AMD 91-07-008
275-16-030	AMD-P 91-04-034	296-22-067	AMD 91-07-008	296-22-445	AMD 91-07-008
275-16-030	AMD-E 91-04-037	296-22-071	AMD 91-07-008	296-22-450	AMD 91-07-008
284-14-010	REP-P 91-04-057	296-22-073	AMD 91-07-008	296-22-455	AMD 91-07-008
284-30-600	AMD 91-03-073	296-22-079	AMD 91-07-008	296-22-465	AMD 91-07-008
284-30-610	NEW 91-03-073	296-22-082	AMD-W 91-02-114	296-22-470	AMD 91-07-008
284-44-400	REP-P 91-04-057	296-22-082	AMD 91-07-008	296-22-475	AMD 91-07-008
284-44-400	REP 91-07-053	296-22-087	AMD 91-07-008	296-23-015	AMD 91-07-008
284-46-010	REP-P 91-04-057	296-22-091	AMD 91-07-008	296-23-020	AMD 91-07-008
284-46-010	REP 91-07-053	296-22-095	AMD 91-07-008	296-23-025	AMD 91-07-008
292-10-010	NEW 91-04-060	296-22-097	AMD 91-07-008	296-23-030	AMD 91-07-008
292-10-020	NEW 91-04-060	296-22-100	AMD 91-07-008	296-23-035	AMD 91-07-008
292-10-030	NEW 91-04-060	296-22-105	AMD 91-07-008	296-23-040	AMD 91-07-008
292-10-040	NEW 91-04-060	296-22-110	AMD 91-07-008	296-23-045	AMD 91-07-008
292-10-050	NEW 91-04-060	296-22-115	AMD 91-07-008	296-23-050	AMD 91-07-008

Table of WAC Sections Affected

WAC #	WSR #	WAC #	WSR #	WAC #	WSR #
296-23-055	AMD	91-07-008	296-24-76555	AMD	91-03-044
296-23-065	AMD	91-07-008	296-24-87035	NEW	91-03-044
296-23-079	AMD	91-07-008	296-24-95611	AMD	91-03-044
296-23-07902	AMD	91-07-008	296-30-190	NEW-W	91-04-027
296-23-07903	AMD	91-07-008	296-52-417	AMD	91-03-044
296-23-07905	AMD	91-07-008	296-52-465	AMD	91-03-044
296-23-07906	AMD	91-07-008	296-52-489	AMD	91-03-044
296-23-07907	AMD-W	91-02-114	296-52-493	AMD	91-03-044
296-23-07907	AMD	91-07-008	296-52-497	AMD	91-03-044
296-23-07908	AMD	91-07-008	296-56-60073	AMD-P	91-04-077
296-23-080	AMD	91-07-008	296-56-60229	AMD-P	91-04-077
296-23-125	AMD	91-07-008	296-62-07314	AMD	91-03-044
296-23-130	AMD	91-07-008	296-62-07329	AMD	91-03-044
296-23-204	AMD	91-07-008	296-62-07515	AMD-P	91-04-077
296-23-208	AMD	91-07-008	296-62-07540	AMD-P	91-04-077
296-23-212	AMD	91-07-008	296-62-07544	AMD-P	91-04-077
296-23-216	AMD	91-07-008	296-62-07715	AMD	91-03-044
296-23-221	AMD	91-07-008	296-62-07719	AMD	91-03-044
296-23-224	AMD	91-07-008	296-62-07721	AMD	91-03-044
296-23-228	AMD	91-07-008	296-62-07725	AMD	91-03-044
296-23-231	AMD	91-07-008	296-62-07731	AMD	91-03-044
296-23-232	AMD	91-07-008	296-62-07733	AMD	91-03-044
296-23-50002	AMD	91-07-008	296-62-07755	NEW	91-03-044
296-23A-240	AMD	91-07-008	296-62-09007	AMD-P	91-04-077
296-23A-242	AMD	91-07-008	296-62-11011	AMD-P	91-04-077
296-23A-244	AMD	91-07-008	296-62-14503	AMD-P	91-04-077
296-23A-246	AMD	91-07-008	296-62-3050	AMD-P	91-04-077
296-23A-248	AMD	91-07-008	296-62-3090	AMD-P	91-04-077
296-23A-250	AMD	91-07-008	296-99-050	AMD-P	91-04-077
296-23A-252	AMD	91-07-008	296-115-005	AMD	91-03-044
296-23A-254	AMD	91-07-008	296-115-010	AMD	91-03-044
296-23A-256	AMD	91-07-008	296-115-015	AMD	91-03-044
296-23A-258	AMD	91-07-008	296-115-025	AMD	91-03-044
296-23A-260	AMD	91-07-008	296-115-035	AMD	91-03-044
296-23A-262	AMD	91-07-008	296-115-060	AMD	91-03-044
296-23A-264	AMD	91-07-008	296-115-070	AMD	91-03-044
296-23A-266	AMD	91-07-008	296-115-100	AMD	91-03-044
296-23A-268	AMD	91-07-008	296-116-185	AMD-P	91-03-075
296-23A-325	AMD	91-07-008	296-116-315	NEW	91-06-033
296-23A-330	AMD	91-07-008	296-127	AMD-C	91-03-113
296-23A-335	AMD	91-07-008	296-155-205	AMD-P	91-04-077
296-23A-340	AMD-W	91-02-114	296-155-225	REP	91-03-044
296-23A-340	AMD	91-07-008	296-155-230	REP	91-03-044
296-23A-345	AMD	91-07-008	296-155-24501	NEW	91-03-044
296-23A-350	AMD	91-07-008	296-155-24503	NEW	91-03-044
296-23A-355	AMD	91-07-008	296-155-24505	NEW	91-03-044
296-23A-360	AMD	91-07-008	296-155-24510	NEW	91-03-044
296-24-020	AMD	91-03-044	296-155-24515	NEW	91-03-044
296-24-065	AMD	91-03-044	296-155-24520	NEW	91-03-044
296-24-084	AMD	91-03-044	296-155-24521	NEW	91-03-044
296-24-11001	AMD-P	91-04-077	296-155-24525	NEW	91-03-044
296-24-11003	AMD-P	91-04-077	296-155-363	AMD-P	91-04-077
296-24-11005	AMD-P	91-04-077	296-155-36313	AMD-P	91-04-077
296-24-11007	AMD-P	91-04-077	296-155-375	AMD-P	91-04-077
296-24-11009	AMD-P	91-04-077	296-155-480	AMD	91-03-044
296-24-11011	AMD-P	91-04-077	296-155-485	AMD	91-03-044
296-24-11013	AMD-P	91-04-077	296-155-48529	AMD	91-03-044
296-24-11015	AMD-P	91-04-077	296-155-48531	AMD	91-03-044
296-24-11017	AMD-P	91-04-077	296-155-48533	AMD	91-03-044
296-24-119	AMD-P	91-04-077	296-155-500	AMD	91-03-044
296-24-12002	AMD-P	91-04-077	296-155-505	AMD	91-03-044
296-24-150	AMD	91-03-044	296-155-50501	REP	91-03-044
296-24-15001	AMD	91-03-044	296-155-50503	AMD	91-03-044
296-24-15003	AMD	91-03-044	296-155-525	AMD	91-03-044
296-24-16531	AMD	91-03-044	296-155-530	AMD	91-03-044
296-24-19505	AMD	91-03-044	296-155-620	AMD	91-03-044
296-24-19509	AMD	91-03-044	296-155-625	AMD	91-03-044
296-24-200	AMD	91-03-044	296-155-650	AMD	91-03-044
296-24-23023	AMD	91-03-044	296-155-655	AMD	91-03-044
296-24-23027	AMD	91-03-044	296-155-65505	REP	91-03-044
296-24-233	AMD-C	91-03-043	296-155-657	NEW	91-03-044
296-24-23303	NEW-C	91-03-043	296-155-660	REP	91-03-044
296-24-23533	NEW	91-03-044	296-155-66005	REP	91-03-044
296-24-450	AMD	91-03-044	296-155-66103	NEW	91-03-044
296-24-68203	AMD	91-03-044	296-155-66105	NEW	91-03-044
296-24-75009	AMD	91-03-044	296-155-66109	NEW	91-03-044
296-24-75011	AMD	91-03-044	296-155-664	NEW	91-03-044
296-155-665	REP	91-03-044	296-155-66501	REP	91-03-044
296-155-66502	REP	91-03-044	296-155-66503	REP	91-03-044
296-155-66503	REP	91-03-044	296-155-66504	REP	91-03-044
296-155-66505	REP	91-03-044	296-155-66505	REP	91-03-044
296-155-675	AMD-P	91-04-077	296-155-682	AMD	91-03-044
296-155-682	AMD	91-03-044	296-155-688	AMD	91-03-044
296-155-689	AMD	91-03-044	296-155-694	AMD-P	91-04-077
296-155-700	AMD	91-03-044	296-155-705	AMD	91-03-044
296-155-705	AMD	91-03-044	296-155-720	AMD	91-03-044
296-155-730	AMD-P	91-04-077	296-155-730	AMD-P	91-04-077
296-155-950	AMD	91-03-044	296-155-950	AMD	91-03-044
296-305-06009	AMD-P	91-04-077	296-305-110	AMD	91-03-044
296-305-110	AMD	91-03-044	296-306-260	AMD-P	91-04-077
296-306-260	AMD-P	91-04-077	296-306-265	AMD-P	91-04-077
296-306-27095	AMD-P	91-04-077	296-306-320	AMD-P	91-04-077
296-306-310	AMD-P	91-04-077	308-10-067	NEW-P	91-07-028
296-306-320	AMD-P	91-04-077	308-12-115	AMD-P	91-06-012
308-10-067	NEW-P	91-07-028	308-14-135	NEW-W	91-03-065
308-12-115	AMD-P	91-06-012	308-20-010	AMD-P	91-05-080
308-14-135	NEW-W	91-03-065	308-20-020	AMD-P	91-05-080
308-20-010	AMD-P	91-05-080	308-20-030	AMD-P	91-05-080
308-20-020	AMD-P	91-05-080	308-20-040	AMD-P	91-05-080
308-20-030	AMD-P	91-05-080	308-20-050	AMD-P	91-05-080
308-20-040	AMD-P	91-05-080	308-20-070	AMD-P	91-05-080
308-20-050	AMD-P	91-05-080	308-20-080	AMD-P	91-05-080
308-20-070	AMD-P	91-05-080	308-20-090	AMD-P	91-05-080
308-20-080	AMD-P	91-05-080	308-20-095	NEW-P	91-05-080
308-20-090	AMD-P	91-05-080	308-20-105	AMD-P	91-05-080
308-20-095	NEW-P	91-05-080	308-20-110	AMD-P	91-05-080
308-20-105	AMD-P	91-05-080	308-20-140	AMD-P	91-05-080
308-20-110	AMD-P	91-05-080	308-20-175	NEW-P	91-05-080
308-20-140	AMD-P	91-05-080	308-31-001	DECOD	91-03-095
308-20-175	NEW-P	91-05-080	308-31-010	DECOD	91-03-095
308-31-001	DECOD	91-03-095	308-31-010	AMD-P	91-05-089
308-31-010	DECOD	91-03-095	308-31-020	DECOD	91-03-095
308-31-020	DECOD	91-03-095	308-31-020	AMD-P	91-05-089
308-31-025	DECOD	91-03-095	308-31-025	DECOD	91-03-095
308-31-025	AMD-P	91-05-089	308-31-030	DECOD	91-03-095
308-31-030	DECOD	91-03-095	308-31-030	AMD-P	91-05-089
308-31-030	AMD-P	91-05-089	308-31-040	DECOD	91-03-095
308-31-040	AMD-P	91-05-089	308-31-040	AMD-P	91-05-089
308-31-050	DECOD	91-03-095	308-31-050	AMD-P	91-05-089
308-31-050	AMD-P	91-05-089	308-31-055	DECOD	91-05-029
308-31-055	DECOD	91-05-029	308-31-057	DECOD	91-03-095
308-31-057	DECOD	91-03-095	308-31-060	DECOD	91-03-095
308-31-060	DECOD	91-03-095	308-31-060	AMD-P	91-05-089
308-31-060	AMD-P	91-05-089	308-31-100	DECOD	91-03-095
308-31-100	DECOD	91-03-095	308-31-100	AMD-P	91-05-089
308-31-110	DECOD	91-03-095	308-31-110	DECOD	91-03-095
308-31-110	AMD-P	91-05-089	308-31-120	DECOD	91-03-095
308-31-120	DECOD	91-03-095	308-31-120	AMD-P	91-05-089
308-31-120	AMD-P	91-05-089	308-31-210	DECOD	91-03-095
308-31-210	DECOD	91-03-095	308-31-210	AMD-P	91-05-089
308-31-210	AMD-P	91-05-089	308-31-220	DECOD	91-03-095
308-31-220	DECOD	91-03-095	308-31-220	AMD-P	91-05-089
308-31-220	AMD-P	91-05-089	308-31-230	DECOD	91-03-095
308-31-230	DECOD	91-03-095	308-31-230	AMD-P	91-05-089
308-31-240	DECOD	91-03-095	308-31-240	DECOD	91-03-095
308-31-240	AMD-P	91-05-089	308-31-240	AMD-P	91-05-089
308-31-250	DECOD	91-03-095	308-31-250	DECOD	91-03-095
308-31-250	AMD-P	91-05-089	308-31-260	DECOD	91-03-095
308-31-260	DECOD	91-03-095	308-31-260	AMD-P	91-05-089
308-31-260	AMD-P	91-05-089	308-31-270	DECOD	91-03-095
308-31-270	DECOD	91-03-095	308-31-270	AMD-P	91-05-089
308-31-270	AMD-P	91-05-089			

Table of WAC Sections Affected

WAC #	WSR #	WAC #	WSR #	WAC #	WSR #			
308-31-280	DECOD	91-03-095	308-52-150	DECOD	91-06-030	308-53-270	DECOD	91-06-025
308-31-280	AMD-P	91-05-089	308-52-160	DECOD	91-06-030	308-53-275	DECOD	91-06-025
308-31-500	DECOD	91-03-095	308-52-165	DECOD	91-06-030	308-53-280	DECOD	91-06-025
308-31-500	AMD-P	91-05-089	308-52-190	DECOD	91-06-030	308-53-320	DECOD	91-06-025
308-31-510	DECOD	91-03-095	308-52-201	DECOD	91-06-030	308-53-330	DECOD	91-06-025
308-31-510	AMD-P	91-05-089	308-52-205	DECOD	91-06-030	308-53-340	DECOD	91-06-025
308-31-520	DECOD	91-03-095	308-52-211	DECOD	91-06-030	308-53-350	DECOD	91-06-025
308-31-520	AMD-P	91-05-089	308-52-215	DECOD	91-06-030	308-53-400	DECOD	91-06-025
308-31-530	DECOD	91-03-095	308-52-221	DECOD	91-06-030	308-54-010	DECOD	91-06-060
308-31-530	AMD-P	91-05-089	308-52-255	DECOD	91-06-030	308-54-020	DECOD	91-06-060
308-31-540	DECOD	91-03-095	308-52-260	DECOD	91-06-030	308-54-030	DECOD	91-06-060
308-31-540	AMD-P	91-05-089	308-52-260	AMD	91-06-038	308-54-040	DECOD	91-06-060
308-31-550	DECOD	91-03-095	308-52-265	DECOD	91-06-030	308-54-050	DECOD	91-06-060
308-31-550	AMD-P	91-05-089	308-52-270	DECOD	91-06-030	308-54-060	DECOD	91-06-060
308-31-560	DECOD	91-03-095	308-52-320	DECOD	91-06-030	308-54-070	DECOD	91-06-060
308-31-560	AMD-P	91-05-089	308-52-400	DECOD	91-06-030	308-54-080	DECOD	91-06-060
308-31-570	DECOD	91-03-095	308-52-405	DECOD	91-06-030	308-54-090	DECOD	91-06-060
308-31-570	AMD-P	91-05-089	308-52-406	DECOD	91-06-030	308-54-095	DECOD	91-06-060
308-42-075	AMD	91-05-004	308-52-410	DECOD	91-06-030	308-54-100	DECOD	91-06-060
308-50-010	DECOD-P	91-07-058	308-52-415	DECOD	91-06-030	308-54-110	DECOD	91-06-060
308-50-020	DECOD-P	91-07-058	308-52-420	DECOD	91-06-030	308-54-120	DECOD	91-06-060
308-50-035	DECOD-P	91-07-058	308-52-425	DECOD	91-06-030	308-54-125	DECOD	91-06-060
308-50-040	DECOD-P	91-07-058	308-52-500	DECOD	91-06-030	308-54-130	DECOD	91-06-060
308-50-090	DECOD-P	91-07-058	308-52-502	DECOD	91-06-030	308-54-150	DECOD	91-06-060
308-50-100	DECOD-P	91-07-058	308-52-504	DECOD	91-06-030	308-54-155	DECOD	91-06-060
308-50-110	DECOD-P	91-07-058	308-52-510	DECOD	91-06-030	308-54-160	DECOD	91-06-060
308-50-120	DECOD-P	91-07-058	308-52-515	DECOD	91-06-030	308-54-165	DECOD	91-06-060
308-50-130	DECOD-P	91-07-058	308-52-530	DECOD	91-06-030	308-54-170	DECOD	91-06-060
308-50-140	DECOD-P	91-07-058	308-52-540	DECOD	91-06-030	308-54-180	DECOD	91-06-060
308-50-150	DECOD-P	91-07-058	308-52-570	DECOD	91-06-030	308-54-200	DECOD	91-06-060
308-50-160	DECOD-P	91-07-058	308-52-580	DECOD	91-06-030	308-54-205	DECOD	91-06-060
308-50-170	DECOD-P	91-07-058	308-52-590	REP	91-06-027	308-54-220	DECOD	91-06-060
308-50-180	DECOD-P	91-07-058	308-52-600	DECOD	91-06-030	308-54-225	DECOD	91-06-060
308-50-190	DECOD-P	91-07-058	308-52-610	DECOD	91-06-030	308-54-230	DECOD	91-06-060
308-50-200	DECOD-P	91-07-058	308-52-620	DECOD	91-06-030	308-54-240	DECOD	91-06-060
308-50-210	DECOD-P	91-07-058	308-52-630	DECOD	91-06-030	308-54-250	DECOD	91-06-060
308-50-220	DECOD-P	91-07-058	308-52-640	DECOD	91-06-030	308-54-315	AMD-P	91-05-025
308-50-240	DECOD-P	91-07-058	308-52-650	DECOD	91-06-030	308-54-315	DECOD	91-06-058
308-50-250	DECOD-P	91-07-058	308-52-660	DECOD	91-06-030	308-54-320	DECOD	91-06-060
308-50-260	DECOD-P	91-07-058	308-52-680	DECOD	91-06-030	308-56A-090	NEW	91-03-088
308-50-270	DECOD-P	91-07-058	308-52-690	DECOD	91-06-030	308-56A-150	AMD	91-04-024
308-50-280	DECOD-P	91-07-058	308-53	DECOD-C	91-03-116	308-56A-460	AMD	91-04-025
308-50-290	DECOD-P	91-07-058	308-53-010	DECOD	91-06-025	308-57-005	NEW	91-04-026
308-50-295	AMD-P	91-07-057	308-53-020	DECOD	91-06-028	308-57-010	NEW	91-04-026
308-50-295	DECOD-P	91-07-058	308-53-030	DECOD	91-06-025	308-57-020	NEW	91-04-026
308-50-295	AMD-W	91-07-059	308-53-070	DECOD	91-06-025	308-57-030	NEW	91-04-026
308-50-310	AMD-P	91-07-057	308-53-075	DECOD	91-06-025	308-57-110	NEW	91-04-026
308-50-310	DECOD-P	91-07-058	308-53-084	DECOD	91-06-025	308-57-120	NEW	91-04-026
308-50-310	AMD-W	91-07-059	308-53-085	DECOD	91-06-025	308-57-130	NEW	91-04-026
308-50-320	DECOD-P	91-07-058	308-53-100	DECOD	91-06-025	308-57-140	NEW	91-04-026
308-50-330	DECOD-P	91-07-058	308-53-110	DECOD	91-06-025	308-57-210	NEW	91-04-026
308-50-350	DECOD-P	91-07-058	308-53-120	DECOD	91-06-025	308-57-220	NEW	91-04-026
308-50-380	DECOD-P	91-07-058	308-53-123	DECOD	91-06-025	308-57-230	NEW	91-04-026
308-50-390	DECOD-P	91-07-058	308-53-125	DECOD	91-06-025	308-57-240	NEW	91-04-026
308-50-400	DECOD-P	91-07-058	308-53-135	DECOD	91-06-025	308-57-310	NEW	91-04-026
308-50-410	DECOD-P	91-07-058	308-53-140	DECOD	91-06-025	308-57-320	NEW	91-04-026
308-50-420	DECOD-P	91-07-058	308-53-145	DECOD	91-06-025	308-57-410	NEW	91-04-026
308-50-430	DECOD-P	91-07-058	308-53-146	DECOD	91-06-025	308-57-420	NEW	91-04-026
308-50-500	DECOD-P	91-07-058	308-53-150	DECOD	91-06-025	308-57-430	NEW	91-04-026
308-52-010	DECOD	91-06-030	308-53-151	DECOD	91-06-025	308-57-440	NEW	91-04-026
308-52-030	DECOD	91-06-030	308-53-155	DECOD	91-06-025	308-58-010	AMD	91-04-025
308-52-040	DECOD	91-06-030	308-53-165	DECOD	91-06-025	308-58-020	AMD	91-04-025
308-52-100	DECOD	91-06-030	308-53-170	DECOD	91-06-025	308-66-152	AMD	91-03-019
308-52-120	DECOD	91-06-030	308-53-175	DECOD	91-06-025	308-66-156	NEW	91-03-092
308-52-132	DECOD	91-06-030	308-53-180	DECOD	91-06-025	308-77-080	REP	91-03-018
308-52-135	AMD-E	91-04-033	308-53-200	DECOD	91-06-025	308-77-100	AMD	91-03-018
308-52-135	AMD-P	91-04-055	308-53-205	DECOD	91-06-025	308-77-250	AMD	91-03-017
308-52-135	DECOD	91-06-030	308-53-210	DECOD	91-06-025	308-91-030	AMD-E	91-02-109
308-52-136	DECOD	91-06-030	308-53-215	DECOD	91-06-025	308-91-030	AMD-P	91-02-110
308-52-138	DECOD	91-06-030	308-53-220	DECOD	91-06-025	308-91-030	AMD	91-06-093
308-52-139	DECOD	91-06-030	308-53-230	DECOD	91-06-025	308-91-090	AMD-E	91-02-109
308-52-140	DECOD	91-06-030	308-53-235	DECOD	91-06-025	308-91-090	AMD-P	91-02-110
308-52-141	DECOD	91-06-030	308-53-240	DECOD	91-06-025	308-91-090	AMD	91-06-093
308-52-146	DECOD	91-06-030	308-53-245	DECOD	91-06-025	308-91-095	NEW-E	91-02-109
308-52-147	DECOD	91-06-030	308-53-250	DECOD	91-06-025	308-91-095	NEW-P	91-02-110
308-52-148	DECOD	91-06-030	308-53-260	DECOD	91-06-025	308-91-095	NEW	91-06-093
308-52-149	DECOD	91-06-030	308-53-265	DECOD	91-06-025	308-91-150	AMD-E	91-02-109

### Table of WAC Sections Affected

WAC #	WSR #	WAC #	WSR #	WAC #	WSR #			
308-91-150	AMD-P	91-02-110	308-120-810	DECOD	91-07-049	308-125-030	NEW	91-04-074
308-91-150	AMD	91-06-093	308-121-110	DECOD	91-07-049	308-125-040	NEW	91-04-074
308-93-670	NEW	91-03-089	308-121-120	DECOD	91-07-049	308-125-050	NEW	91-04-074
308-94-035	AMD-P	91-03-142	308-121-130	DECOD	91-07-049	308-125-060	NEW	91-04-074
308-96A-046	AMD	91-04-025	308-121-140	DECOD	91-07-049	308-125-070	NEW	91-04-074
308-96A-056	AMD	91-04-025	308-121-145	DECOD	91-07-049	308-125-080	NEW	91-04-074
308-96A-070	AMD	91-04-025	308-121-150	DECOD	91-07-049	308-125-090	NEW	91-04-074
308-96A-073	NEW	91-04-025	308-121-155	DECOD	91-07-049	308-125-100	NEW	91-04-074
308-96A-074	NEW	91-04-025	308-121-160	DECOD	91-07-049	308-125-110	NEW	91-04-074
308-96A-075	AMD	91-04-025	308-121-165	DECOD	91-07-049	308-125-120	NEW	91-04-074
308-96A-345	AMD	91-04-024	308-121-170	DECOD	91-07-049	308-125-130	NEW	91-04-074
308-96A-350	AMD	91-04-024	308-121-175	DECOD	91-07-049	308-125-140	NEW	91-04-074
308-96A-380	AMD	91-04-024	308-121-180	DECOD	91-07-049	308-125-150	NEW	91-04-074
308-96A-505	NEW	91-03-091	308-122-001	DECOD	91-04-020	308-125-160	NEW	91-04-074
308-96A-510	NEW	91-03-091	308-122-005	DECOD	91-04-020	308-125-170	NEW	91-04-074
308-96A-520	NEW	91-03-091	308-122-006	DECOD	91-04-020	308-125-180	NEW	91-04-074
308-96A-530	NEW	91-03-091	308-122-060	DECOD	91-04-020	308-125-190	NEW	91-04-074
308-96A-540	NEW	91-03-091	308-122-200	DECOD	91-04-020	308-125-200	NEW	91-04-074
308-96A-550	NEW	91-03-091	308-122-200	AMD	91-04-021	308-125-210	NEW	91-04-074
308-96A-560	NEW	91-03-091	308-122-211	DECOD	91-04-020	308-138-055	REP-P	91-03-117
308-120-100	DECOD	91-07-049	308-122-215	DECOD	91-04-020	308-171-001	DECOD	91-05-027
308-120-100	AMD	91-07-067	308-122-220	DECOD	91-04-020	308-171-001	AMD-P	91-05-088
308-120-161	DECOD	91-07-049	308-122-225	DECOD	91-04-020	308-171-002	DECOD	91-05-027
308-120-162	DECOD	91-07-049	308-122-230	DECOD	91-04-020	308-171-003	DECOD	91-05-027
308-120-163	DECOD	91-07-049	308-122-235	DECOD	91-04-020	308-171-010	DECOD	91-05-027
308-120-164	DECOD	91-07-049	308-122-275	DECOD	91-05-028	308-171-010	AMD-P	91-05-088
308-120-165	DECOD	91-07-049	308-122-280	DECOD	91-04-020	308-171-020	DECOD	91-05-027
308-120-166	DECOD	91-07-049	308-122-350	DECOD	91-04-020	308-171-020	AMD-P	91-05-088
308-120-168	AMD	91-07-032	308-122-360	DECOD	91-04-020	308-171-040	DECOD	91-05-027
308-120-168	DECOD	91-07-049	308-122-360	AMD	91-04-021	308-171-041	DECOD	91-05-027
308-120-170	DECOD	91-07-049	308-122-370	DECOD	91-04-020	308-171-041	AMD-P	91-05-088
308-120-180	DECOD	91-07-049	308-122-380	REP	91-04-021	308-171-045	DECOD	91-05-027
308-120-185	DECOD	91-07-049	308-122-390	REP	91-04-021	308-171-100	DECOD	91-05-027
308-120-186	DECOD	91-07-049	308-122-400	REP	91-04-021	308-171-101	DECOD	91-05-027
308-120-270	DECOD	91-07-049	308-122-410	REP	91-04-021	308-171-102	DECOD	91-05-027
308-120-275	DECOD	91-07-048	308-122-420	REP	91-04-021	308-171-103	DECOD	91-05-027
308-120-300	DECOD	91-07-049	308-122-430	DECOD	91-04-020	308-171-103	AMD-P	91-05-088
308-120-305	DECOD	91-07-049	308-122-440	DECOD	91-04-020	308-171-104	DECOD	91-05-027
308-120-315	DECOD	91-07-049	308-122-450	DECOD	91-04-020	308-171-200	DECOD	91-05-027
308-120-325	DECOD	91-07-049	308-122-500	REP	91-04-021	308-171-201	DECOD	91-05-027
308-120-335	DECOD	91-07-049	308-122-505	DECOD	91-04-020	308-171-202	DECOD	91-05-027
308-120-338	DECOD	91-07-049	308-122-510	DECOD	91-04-020	308-171-300	DECOD	91-05-027
308-120-345	DECOD	91-07-049	308-122-515	DECOD	91-04-020	308-171-301	DECOD	91-05-027
308-120-360	DECOD	91-07-049	308-122-515	AMD	91-04-021	308-171-302	DECOD	91-05-027
308-120-365	REP	91-07-049	308-122-520	DECOD	91-04-020	308-171-310	DECOD	91-05-030
308-120-400	DECOD	91-07-049	308-122-520	AMD	91-04-021	308-171-320	DECOD	91-05-027
308-120-410	DECOD	91-07-049	308-122-525	DECOD	91-04-020	308-171-330	DECOD	91-05-027
308-120-420	DECOD	91-07-049	308-122-530	DECOD	91-04-020	308-173-210	DECOD	91-07-049
308-120-430	DECOD	91-07-049	308-122-535	DECOD	91-04-020	308-173-220	DECOD	91-07-049
308-120-440	DECOD	91-07-049	308-122-540	DECOD	91-04-020	308-173-230	DECOD	91-07-049
308-120-450	DECOD	91-07-049	308-122-545	DECOD	91-04-020	308-173-240	DECOD	91-07-049
308-120-505	DECOD	91-07-049	308-122-600	DECOD	91-04-020	308-173-245	DECOD	91-07-049
308-120-506	DECOD	91-07-049	308-122-610	DECOD	91-04-020	308-173-250	DECOD	91-07-049
308-120-525	DECOD	91-07-049	308-122-620	DECOD	91-04-020	308-173-255	DECOD	91-07-049
308-120-530	DECOD	91-07-049	308-122-630	DECOD	91-04-020	308-173-260	DECOD	91-07-049
308-120-535	DECOD	91-07-049	308-122-640	DECOD	91-04-020	308-173-265	DECOD	91-07-049
308-120-540	DECOD	91-07-049	308-122-650	DECOD	91-04-020	308-173-270	DECOD	91-07-049
308-120-545	DECOD	91-07-049	308-122-660	DECOD	91-04-020	308-173-275	DECOD	91-07-049
308-120-550	DECOD	91-07-049	308-122-660	AMD	91-04-021	308-173-280	DECOD	91-07-049
308-120-555	DECOD	91-07-049	308-122-670	DECOD	91-04-020	314-16-125	AMD-P	91-05-085
308-120-560	DECOD	91-07-049	308-122-670	AMD	91-04-021	314-20-020	AMD-P	91-05-086
308-120-565	DECOD	91-07-049	308-122-680	DECOD	91-04-020	314-52-015	AMD-C	91-03-007
308-120-565	AMD	91-07-067	308-122-690	DECOD	91-04-020	314-52-015	AMD-W	91-04-085
308-120-570	DECOD	91-07-049	308-122-695	DECOD	91-04-020	315-04-205	NEW-P	91-07-070
308-120-575	DECOD	91-07-049	308-122-700	DECOD	91-04-020	315-06-120	AMD	91-03-036
308-120-610	AMD	91-07-032	308-122-710	DECOD	91-04-020	315-11-200	REP	91-03-034
308-120-620	DECOD	91-07-049	308-122-720	DECOD	91-04-020	315-11-201	REP	91-03-034
308-120-700	DECOD	91-07-049	308-124A-430	AMD-P	91-03-047	315-11-202	REP	91-03-034
308-120-710	DECOD	91-07-049	308-124A-430	AMD	91-07-029	315-11-210	REP	91-03-034
308-120-720	DECOD	91-07-049	308-124H-010	AMD-P	91-03-047	315-11-211	REP	91-03-034
308-120-730	DECOD	91-07-049	308-124H-010	AMD	91-07-029	315-11-212	REP	91-03-034
308-120-740	DECOD	91-07-049	308-124H-025	AMD-P	91-03-047	315-11-220	REP	91-03-034
308-120-750	DECOD	91-07-049	308-124H-025	AMD	91-07-029	315-11-221	REP	91-03-034
308-120-760	DECOD	91-07-049	308-124H-540	AMD-P	91-03-047	315-11-222	REP	91-03-034
308-120-770	DECOD	91-07-049	308-124H-540	AMD	91-07-029	315-11-230	REP	91-03-034
308-120-780	DECOD	91-07-049	308-125-010	NEW	91-04-074	315-11-231	REP	91-03-034
308-120-800	DECOD	91-07-049	308-125-020	NEW	91-04-074	315-11-232	REP	91-03-034

Table of WAC Sections Affected

WAC #	WSR #	WAC #	WSR #	WAC #	WSR #			
315-11-240	REP	91-03-034	315-12-145	NEW	91-03-036	360-52-120	NEW-P	91-05-092
315-11-241	REP	91-03-034	352-12-010	AMD-P	91-03-142	360-54	DECOD-W	91-06-037
315-11-242	REP	91-03-034	352-12-020	AMD-P	91-03-142	360-60	DECOD-W	91-06-037
315-11-250	REP	91-03-034	352-12-030	AMD-P	91-03-142	365-90-010	AMD	91-04-017
315-11-251	REP	91-03-034	352-32-010	AMD-P	91-03-142	365-90-020	AMD	91-04-017
315-11-252	REP	91-03-034	352-32-035	AMD-P	91-03-142	365-90-030	REP	91-04-017
315-11-260	REP	91-03-034	352-32-045	AMD-P	91-03-142	365-90-040	AMD	91-04-017
315-11-261	REP	91-03-034	352-32-200	AMD-P	91-03-140	365-90-050	REP	91-04-017
315-11-262	REP	91-03-034	352-32-200	AMD	91-07-014	365-90-070	AMD	91-04-017
315-11-270	REP	91-03-034	352-32-210	AMD-P	91-03-140	365-90-080	AMD	91-04-017
315-11-271	REP	91-03-034	352-32-210	AMD	91-07-014	365-90-090	AMD	91-04-017
315-11-272	REP	91-03-034	352-32-250	AMD-P	91-03-142	365-190-010	NEW	91-07-041
315-11-280	REP	91-03-034	352-32-252	AMD-P	91-03-142	365-190-020	NEW	91-07-041
315-11-281	REP	91-03-034	352-32-270	AMD-P	91-03-142	365-190-030	NEW	91-07-041
315-11-282	REP	91-03-034	356-06-040	AMD-C	91-03-068	365-190-040	NEW	91-07-041
315-11-290	REP	91-03-034	356-06-040	AMD-W	91-05-081	365-190-050	NEW	91-07-041
315-11-291	REP	91-03-034	356-10-050	AMD	91-03-070	365-190-060	NEW	91-07-041
315-11-292	REP	91-03-034	356-15-020	AMD-P	91-04-046	365-190-070	NEW	91-07-041
315-11-300	REP	91-03-034	356-15-020	AMD-C	91-07-054	365-190-080	NEW	91-07-041
315-11-301	REP	91-03-034	356-15-080	AMD	91-03-069	371-08	AMD-C	91-03-027
315-11-302	REP	91-03-034	356-15-130	AMD	91-05-083	371-08-001	NEW	91-03-028
315-11-310	REP	91-03-034	356-18-112	AMD-C	91-05-082	371-08-002	NEW	91-03-028
315-11-311	REP	91-03-034	356-18-112	AMD	91-07-055	371-08-005	AMD	91-03-028
315-11-312	REP	91-03-034	356-22-130	AMD	91-03-071	371-08-010	AMD	91-03-028
315-11-320	REP	91-03-034	356-22-230	AMD-C	91-03-068	371-08-015	REP	91-03-028
315-11-321	REP	91-03-034	356-22-230	AMD-W	91-05-081	371-08-020	AMD	91-03-028
315-11-322	REP	91-03-034	356-30-260	AMD-C	91-05-082	371-08-030	AMD	91-03-028
315-11-330	REP	91-03-034	356-30-260	AMD	91-07-055	371-08-031	REP	91-03-028
315-11-331	REP	91-03-034	356-30-305	AMD-C	91-05-082	371-08-032	AMD	91-03-028
315-11-332	REP	91-03-034	356-30-305	AMD	91-07-055	371-08-033	NEW	91-03-028
315-11-340	REP	91-03-034	360-08	DECOD-W	91-06-037	371-08-035	AMD	91-03-028
315-11-341	REP	91-03-034	360-10	DECOD-W	91-06-037	371-08-040	AMD	91-03-028
315-11-342	REP	91-03-034	360-10-030	AMD-P	91-05-091	371-08-045	REP	91-03-028
315-11-350	REP	91-03-034	360-10-050	AMD-P	91-05-091	371-08-065	AMD	91-03-028
315-11-351	REP	91-03-034	360-10-060	AMD-P	91-05-091	371-08-071	AMD	91-03-028
315-11-352	REP	91-03-034	360-11	DECOD-W	91-06-037	371-08-075	AMD	91-03-028
315-11-360	REP	91-03-034	360-12	DECOD-W	91-06-037	371-08-080	AMD	91-03-028
315-11-361	REP	91-03-034	360-13	DECOD-W	91-06-037	371-08-085	AMD	91-03-028
315-11-362	REP	91-03-034	360-15	DECOD-W	91-06-037	371-08-095	REP	91-03-028
315-11-370	REP	91-03-034	360-16	DECOD-W	91-06-037	371-08-100	AMD	91-03-028
315-11-371	REP	91-03-034	360-16A	DECOD-W	91-06-037	371-08-102	REP	91-03-028
315-11-372	REP	91-03-034	360-17	DECOD-W	91-06-037	371-08-104	AMD	91-03-028
315-11-380	REP	91-03-034	360-17-010	AMD-W	91-05-049	371-08-105	REP	91-03-028
315-11-381	REP	91-03-034	360-17-040	AMD-W	91-05-049	371-08-106	NEW	91-03-028
315-11-382	REP	91-03-034	360-17-070	AMD-W	91-05-049	371-08-110	REP	91-03-028
315-11-390	REP	91-03-034	360-17-075	NEW-W	91-05-049	371-08-115	REP	91-03-028
315-11-391	REP	91-03-034	360-17-095	NEW-W	91-05-049	371-08-120	REP	91-03-028
315-11-392	REP	91-03-034	360-17-100	AMD-W	91-05-049	371-08-125	AMD	91-03-028
315-11-590	AMD	91-03-036	360-18	DECOD-W	91-06-037	371-08-130	AMD	91-03-028
315-11-591	AMD	91-03-036	360-19	DECOD-W	91-06-037	371-08-131	REP	91-03-028
315-11-610	NEW	91-03-036	360-20	DECOD-W	91-06-037	371-08-132	REP	91-03-028
315-11-611	NEW	91-03-036	360-20-220	NEW-P	91-07-056	371-08-135	REP	91-03-028
315-11-611	AMD-P	91-03-112	360-21	DECOD-W	91-06-037	371-08-140	AMD	91-03-028
315-11-611	AMD	91-06-074	360-23	DECOD-W	91-06-037	371-08-144	AMD	91-03-028
315-11-612	NEW	91-03-036	360-32	DECOD-W	91-06-037	371-08-146	NEW	91-03-028
315-11-620	NEW-P	91-03-112	360-33	DECOD-W	91-06-037	371-08-147	NEW	91-03-028
315-11-620	NEW	91-06-074	360-35-010	NEW	91-04-056	371-08-148	NEW	91-03-028
315-11-621	NEW-P	91-03-112	360-35-020	NEW	91-04-056	371-08-155	AMD	91-03-028
315-11-621	NEW	91-06-074	360-35-030	NEW	91-04-056	371-08-156	AMD	91-03-028
315-11-622	NEW-P	91-03-112	360-35-040	NEW	91-04-056	371-08-160	REP	91-03-028
315-11-622	NEW	91-06-074	360-35-050	NEW	91-04-056	371-08-162	NEW	91-03-028
315-11-630	NEW-P	91-03-112	360-35-060	NEW	91-04-056	371-08-163	REP	91-03-028
315-11-630	NEW	91-06-074	360-35-070	NEW	91-04-056	371-08-165	AMD	91-03-028
315-11-631	NEW-P	91-03-112	360-35-080	NEW	91-04-056	371-08-175	REP	91-03-028
315-11-631	NEW	91-06-074	360-35-090	NEW	91-04-056	371-08-180	AMD	91-03-028
315-11-632	NEW-P	91-03-112	360-35-100	NEW	91-04-056	371-08-183	AMD	91-03-028
315-11-632	NEW	91-06-074	360-35-110	NEW	91-04-056	371-08-184	NEW	91-03-028
315-11-640	NEW-P	91-07-070	360-36	DECOD-W	91-06-037	371-08-186	AMD	91-03-028
315-11-641	NEW-P	91-07-070	360-38	DECOD-W	91-06-037	371-08-187	AMD	91-03-028
315-11-642	NEW-P	91-07-070	360-40	DECOD-W	91-06-037	371-08-188	AMD	91-03-028
315-11-650	NEW-P	91-07-070	360-44	DECOD-W	91-06-037	371-08-189	AMD	91-03-028
315-11-651	NEW-P	91-07-070	360-46	DECOD-W	91-06-037	371-08-190	REP	91-03-028
315-11-652	NEW-P	91-07-070	360-47	DECOD-W	91-06-037	371-08-195	AMD	91-03-028
315-11-660	NEW-P	91-07-070	360-48	DECOD-W	91-06-037	371-08-196	AMD	91-03-028
315-11-661	NEW-P	91-07-070	360-49	DECOD-W	91-06-037	371-08-200	AMD	91-03-028
315-11-662	NEW-P	91-07-070	360-49-050	NEW-P	91-05-090	371-08-201	REP	91-03-028
315-12-140	REP	91-03-035	360-52	DECOD-W	91-06-037	371-08-205	REP	91-03-028

### Table of WAC Sections Affected

WAC #	WSR #	WAC #	WSR #	WAC #	WSR #			
371-08-210	REP	91-03-028	388-77-500	AMD	91-05-058	388-155-010	NEW	91-04-048
371-08-215	AMD	91-03-028	388-77-515	AMD	91-04-041	388-155-020	NEW	91-04-048
371-08-220	AMD	91-03-028	388-77-520	AMD	91-05-010	388-155-040	NEW	91-04-048
371-08-230	AMD	91-03-028	388-77-515	AMD	91-05-058	388-155-050	NEW	91-04-048
371-08-240	AMD	91-03-028	388-77-520	AMD	91-04-041	388-155-060	NEW	91-04-048
371-08-245	REP	91-03-028	388-77-520	AMD	91-05-010	388-155-070	NEW	91-04-048
371-12	REP-C	91-03-027	388-77-520	AMD	91-05-058	388-155-080	NEW	91-04-048
371-12-010	REP	91-03-028	388-77-530	REP	91-04-041	388-155-090	NEW	91-04-048
371-12-020	REP	91-03-028	388-77-530	REP	91-05-010	388-155-100	NEW	91-04-048
371-12-030	REP	91-03-028	388-77-530	REP	91-05-058	388-155-110	NEW	91-04-048
371-12-040	REP	91-03-028	388-77-555	AMD	91-04-041	388-155-120	NEW	91-04-048
371-12-050	REP	91-03-028	388-77-555	AMD	91-05-010	388-155-130	NEW	91-04-048
371-12-060	REP	91-03-028	388-77-555	AMD	91-05-058	388-155-140	NEW	91-04-048
371-12-070	REP	91-03-028	388-77-600	AMD	91-04-041	388-155-150	NEW	91-04-048
371-12-080	REP	91-03-028	388-77-600	AMD	91-05-010	388-155-160	NEW	91-04-048
371-12-090	REP	91-03-028	388-77-600	AMD	91-05-058	388-155-165	NEW	91-04-048
371-12-100	REP	91-03-028	388-77-610	AMD	91-04-041	388-155-170	NEW	91-04-048
371-12-110	REP	91-03-028	388-77-610	AMD	91-05-010	388-155-180	NEW	91-04-048
371-12-120	REP	91-03-028	388-77-610	AMD	91-05-058	388-155-190	NEW	91-04-048
371-12-130	REP	91-03-028	388-77-615	AMD	91-04-041	388-155-200	NEW	91-04-048
388-11-220	AMD-P	91-06-040	388-77-615	AMD	91-05-010	388-155-210	NEW	91-04-048
388-11-220	AMD-E	91-06-048	388-77-615	AMD	91-05-058	388-155-220	NEW	91-04-048
388-14-275	AMD-P	91-06-097	388-81-030	AMD	91-07-011	388-155-230	NEW	91-04-048
388-14-385	AMD-P	91-04-002	388-82-010	AMD	91-06-003	388-155-240	NEW	91-04-048
388-14-385	AMD-E	91-04-003	388-82-140	AMD	91-07-011	388-155-250	NEW	91-04-048
388-14-415	AMD-P	91-04-002	388-83-013	AMD-P	91-06-042	388-155-260	NEW	91-04-048
388-14-415	AMD-E	91-04-003	388-83-013	AMD-E	91-06-046	388-155-270	NEW	91-04-048
388-14-435	NEW-P	91-04-002	388-83-032	AMD-P	91-06-043	388-155-280	NEW	91-04-048
388-14-435	NEW-E	91-04-003	388-83-032	AMD-E	91-06-047	388-155-290	NEW	91-04-048
388-14-440	NEW-P	91-04-002	388-83-041	NEW-P	91-05-008	388-155-295	NEW	91-04-048
388-14-440	NEW-E	91-04-003	388-83-041	NEW-E	91-05-009	388-155-310	NEW	91-04-048
388-14-445	NEW-P	91-04-002	388-83-130	AMD-P	91-06-043	388-155-320	NEW	91-04-048
388-14-445	NEW-E	91-04-003	388-83-130	AMD-E	91-06-047	388-155-330	NEW	91-04-048
388-14-450	NEW-P	91-04-002	388-84-105	AMD	91-05-011	388-155-340	NEW	91-04-048
388-14-450	NEW-E	91-04-003	388-86-00901	AMD-P	91-04-040	388-155-350	NEW	91-04-048
388-15-208	AMD-S	91-04-039	388-86-00901	AMD-E	91-04-044	388-155-360	NEW	91-04-048
388-15-209	AMD-S	91-04-039	388-87-010	AMD	91-07-011	388-155-370	NEW	91-04-048
388-15-212	AMD-S	91-04-039	388-87-070	AMD-P	91-06-044	388-155-380	NEW	91-04-048
388-15-215	AMD-S	91-04-039	388-87-070	AMD-E	91-06-049	388-155-390	NEW	91-04-048
388-15-216	AMD-S	91-04-039	388-87-070	RESCIND	91-06-056	388-155-400	NEW	91-04-048
388-24-050	AMD-E	91-04-042	388-87-072	AMD-P	91-06-044	388-155-410	NEW	91-04-048
388-24-050	AMD-P	91-04-043	388-87-072	AMD-E	91-06-049	388-155-420	NEW	91-04-048
388-28-575	AMD	91-06-007	388-87-072	RESCIND	91-06-056	388-155-430	NEW	91-04-048
388-29-125	AMD-P	91-06-041	388-92-045	AMD-P	91-05-008	388-155-440	NEW	91-04-048
388-29-125	AMD-E	91-06-045	388-92-045	AMD-E	91-05-009	388-155-450	NEW	91-04-048
388-33-376	AMD-P	91-07-068	388-95-320	AMD-P	91-05-034	388-155-460	NEW	91-04-048
388-42-150	AMD	91-06-005	388-95-320	AMD-E	91-05-035	388-155-470	NEW	91-04-048
388-44-145	AMD-C	91-03-039	388-95-337	AMD	91-07-011	388-155-480	NEW	91-04-048
388-44-145	AMD-C	91-04-047	388-95-360	AMD	91-07-011	388-155-490	NEW	91-04-048
388-44-145	AMD-C	91-06-055	388-95-380	AMD-P	91-05-008	388-155-500	NEW	91-04-048
388-49-020	AMD-P	91-05-074	388-95-380	AMD-E	91-05-009	390-20-0101	AMD-C	91-06-034
388-49-190	AMD-P	91-05-073	388-99-020	AMD	91-07-011	390-24-031	NEW-P	91-07-027
388-49-310	AMD-P	91-07-069	388-99-040	AMD-P	91-05-008	391-101-015	NEW	91-02-095
388-49-330	AMD-P	91-05-075	388-99-040	AMD-E	91-05-009	392-115-005	NEW-P	91-03-001
388-49-410	AMD-P	91-05-071	388-150-005	AMD-P	91-03-127	392-115-005	NEW	91-07-007
388-49-420	AMD-P	91-05-071	388-150-005	AMD-E	91-03-128	392-115-010	NEW-P	91-03-001
388-49-470	AMD	91-06-004	388-150-005	AMD	91-07-013	392-115-010	NEW	91-07-007
388-49-480	AMD-P	91-05-072	388-150-100	AMD-P	91-03-127	392-115-015	NEW-P	91-03-001
388-49-505	AMD-P	91-04-035	388-150-100	AMD-E	91-03-128	392-115-015	NEW	91-07-007
388-49-505	AMD-E	91-04-036	388-150-100	AMD	91-07-013	392-115-020	NEW-P	91-03-001
388-53	AMD	91-06-006	388-150-180	AMD-P	91-03-127	392-115-020	NEW	91-07-007
388-53-010	AMD	91-06-006	388-150-180	AMD-E	91-03-128	392-115-025	NEW-P	91-03-001
388-53-050	AMD	91-06-006	388-150-180	AMD	91-07-013	392-115-025	NEW	91-07-007
388-76-030	AMD-P	91-05-070	388-150-210	AMD-P	91-03-127	392-115-030	NEW-P	91-03-001
388-76-040	AMD-P	91-05-070	388-150-210	AMD-E	91-03-128	392-115-030	NEW	91-07-007
388-76-087	AMD-P	91-05-070	388-150-210	AMD	91-07-013	392-115-035	NEW-P	91-03-001
388-77-010	AMD	91-04-041	388-150-280	AMD-P	91-03-127	392-115-035	NEW	91-07-007
388-77-010	AMD	91-05-010	388-150-280	AMD-E	91-03-128	392-115-040	NEW-P	91-03-001
388-77-010	AMD	91-05-058	388-150-280	AMD	91-07-013	392-115-040	NEW	91-07-007
388-77-230	REP	91-04-041	388-150-390	AMD-P	91-03-127	392-115-045	NEW-P	91-03-001
388-77-230	REP	91-05-010	388-150-390	AMD-E	91-03-128	392-115-045	NEW	91-07-007
388-77-230	REP	91-05-058	388-150-390	AMD	91-07-013	392-115-050	NEW-P	91-03-001
388-77-320	AMD	91-04-041	388-150-450	AMD-P	91-03-127	392-115-050	NEW	91-07-007
388-77-320	AMD	91-05-010	388-150-450	AMD-E	91-03-128	392-115-055	NEW-P	91-03-001
388-77-320	AMD	91-05-058	388-150-450	AMD	91-07-013	392-115-055	NEW	91-07-007
388-77-500	AMD	91-04-041	388-155	NEW-C	91-03-038	392-115-060	NEW-P	91-03-001
388-77-500	AMD	91-05-010	388-155-005	NEW	91-04-048	392-115-060	NEW	91-07-007

**Table of WAC Sections Affected**

WAC #		WSR #	WAC #		WSR #	WAC #		WSR #
392-115-065	NEW-P	91-03-001	392-122-235	AMD	91-03-118	392-140-361	NEW	91-02-094
392-115-065	NEW	91-07-007	392-122-240	REP	91-03-118	392-140-362	NEW	91-02-094
392-115-070	NEW-P	91-03-001	392-122-245	REP	91-03-118	392-140-363	NEW	91-02-094
392-115-070	NEW	91-07-007	392-122-250	REP	91-03-118	392-140-364	NEW	91-02-094
392-115-075	NEW-P	91-03-001	392-122-270	AMD	91-03-118	392-140-365	NEW	91-02-094
392-115-075	NEW	91-07-007	392-122-600	AMD	91-03-118	392-140-366	NEW	91-02-094
392-115-080	NEW-P	91-03-001	392-122-605	AMD	91-03-118	392-140-367	NEW	91-02-094
392-115-080	NEW	91-07-007	392-122-610	AMD	91-03-118	392-140-368	NEW	91-02-094
392-115-085	NEW-P	91-03-001	392-122-700	AMD	91-03-118	392-140-369	NEW	91-02-094
392-115-085	NEW	91-07-007	392-122-800	AMD	91-03-118	392-140-370	NEW	91-02-094
392-115-090	NEW-P	91-03-001	392-122-805	AMD	91-03-118	392-140-371	NEW	91-02-094
392-115-090	NEW	91-07-007	392-122-910	NEW	91-03-118	392-140-372	NEW	91-02-094
392-115-095	NEW-P	91-03-001	392-125-014	NEW-P	91-03-050	392-140-373	NEW	91-02-094
392-115-095	NEW	91-07-007	392-125-014	NEW	91-07-063	392-140-374	NEW	91-02-094
392-115-100	NEW-P	91-03-001	392-125-015	AMD-P	91-03-050	392-140-375	NEW	91-02-094
392-115-100	NEW	91-07-007	392-125-015	AMD	91-07-063	392-140-376	NEW	91-02-094
392-115-105	NEW-P	91-03-001	392-125-020	AMD-P	91-03-050	392-140-377	NEW	91-02-094
392-115-105	NEW	91-07-007	392-125-020	AMD	91-07-063	392-140-378	NEW	91-02-094
392-115-110	NEW-P	91-03-001	392-125-025	AMD-P	91-03-050	392-140-379	NEW	91-02-094
392-115-110	NEW	91-07-007	392-125-025	AMD	91-07-063	392-140-380	NEW	91-02-094
392-115-115	NEW-P	91-03-001	392-125-026	NEW-P	91-03-050	392-140-381	NEW	91-02-094
392-115-115	NEW	91-07-007	392-125-026	NEW	91-07-063	392-140-390	NEW	91-02-094
392-115-120	NEW-P	91-03-001	392-125-027	NEW-P	91-03-050	392-140-391	NEW	91-02-094
392-115-120	NEW	91-07-007	392-125-027	NEW	91-07-063	392-140-392	NEW	91-02-094
392-115-125	NEW-P	91-03-001	392-125-030	AMD-P	91-03-050	392-140-393	NEW	91-02-094
392-115-125	NEW	91-07-007	392-125-030	AMD	91-07-063	392-145-015	AMD-P	91-03-074
392-115-130	NEW-P	91-03-001	392-125-085	AMD-P	91-03-050	392-145-015	AMD	91-06-032
392-115-130	NEW	91-07-007	392-125-085	AMD	91-07-063	392-145-030	AMD-P	91-03-074
392-115-135	NEW-P	91-03-001	392-127-700	NEW	91-03-129	392-145-030	AMD	91-06-032
392-115-135	NEW	91-07-007	392-127-703	NEW	91-03-129	392-160-015	AMD-P	91-07-062
392-115-140	NEW-P	91-03-001	392-127-705	NEW	91-03-129	392-160-020	AMD-P	91-07-062
392-115-140	NEW	91-07-007	392-127-710	NEW	91-03-129	392-160-040	AMD-P	91-07-062
392-115-145	NEW-P	91-03-001	392-127-715	NEW	91-03-129	392-202-003	AMD	91-03-119
392-115-145	NEW	91-07-007	392-127-720	NEW	91-03-129	400-12	PREP	91-05-066
392-115-150	NEW-P	91-03-001	392-127-725	NEW	91-03-129	415-100-041	NEW	91-03-013
392-115-150	NEW	91-07-007	392-127-730	NEW	91-03-129	415-100-045	NEW	91-03-013
392-115-155	NEW-P	91-03-001	392-127-735	NEW	91-03-129	415-100-051	NEW	91-03-013
392-115-155	NEW	91-07-007	392-127-740	NEW	91-03-129	415-100-055	NEW	91-03-013
392-121-108	AMD	91-02-096	392-127-745	NEW	91-03-129	415-104-201	NEW	91-03-014
392-121-133	AMD	91-02-096	392-127-750	NEW	91-03-129	415-104-205	NEW	91-03-014
392-121-136	AMD	91-02-096	392-127-755	NEW	91-03-129	415-104-211	NEW	91-03-014
392-121-182	AMD	91-02-096	392-127-760	NEW	91-03-129	415-104-215	NEW	91-03-014
392-121-184	NEW-P	91-04-088	392-127-765	NEW	91-03-129	415-108-320	NEW	91-03-015
392-121-265	AMD	91-02-097	392-127-770	NEW	91-03-129	415-108-322	NEW	91-03-015
392-121-268	AMD	91-02-097	392-127-775	NEW	91-03-129	415-108-324	NEW	91-03-015
392-121-269	NEW	91-02-097	392-127-780	NEW	91-03-129	415-108-326	NEW	91-03-015
392-121-270	AMD	91-02-097	392-127-785	NEW	91-03-129	415-112-720	NEW	91-03-016
392-121-272	AMD	91-02-097	392-127-790	NEW	91-03-129	415-112-722	NEW	91-03-016
392-121-280	AMD	91-02-097	392-127-795	NEW	91-03-129	415-112-725	NEW	91-03-016
392-121-295	AMD	91-02-097	392-127-800	NEW	91-03-129	415-112-727	NEW	91-03-016
392-121-297	REP	91-02-097	392-127-805	NEW	91-03-129	415-114-010	NEW-P	91-06-089
392-121-299	AMD	91-02-097	392-127-810	NEW	91-03-129	415-114-020	NEW-P	91-06-089
392-121-500	NEW	91-07-006	392-127-815	NEW	91-03-129	415-114-030	NEW-P	91-06-089
392-121-505	NEW	91-07-006	392-127-820	NEW	91-03-129	415-114-040	NEW-P	91-06-089
392-121-510	NEW	91-07-006	392-127-825	NEW	91-03-129	415-114-050	NEW-P	91-06-089
392-121-515	NEW	91-07-006	392-127-830	NEW	91-03-129	415-114-060	NEW-P	91-06-089
392-121-520	NEW	91-07-006	392-140-257	AMD-P	91-04-089	419-14-030	AMD-P	91-03-107
392-121-525	NEW	91-07-006	392-140-340	NEW	91-02-094	419-14-030	AMD	91-06-063
392-121-530	NEW	91-07-006	392-140-341	NEW	91-02-094	419-14-040	AMD-P	91-03-107
392-121-535	NEW	91-07-006	392-140-342	NEW	91-02-094	419-14-040	AMD	91-06-063
392-121-540	NEW	91-07-006	392-140-343	NEW	91-02-094	419-14-090	AMD-P	91-03-107
392-121-545	NEW	91-07-006	392-140-345	NEW	91-02-094	419-14-090	AMD	91-06-063
392-122-010	AMD	91-03-118	392-140-346	NEW	91-02-094	419-14-100	AMD-P	91-03-107
392-122-100	AMD	91-03-118	392-140-347	NEW	91-02-094	419-14-100	AMD	91-06-063
392-122-106	AMD	91-03-118	392-140-348	NEW	91-02-094	419-14-110	AMD-P	91-03-107
392-122-107	AMD	91-03-118	392-140-349	NEW	91-02-094	419-14-110	AMD	91-06-063
392-122-110	AMD	91-03-118	392-140-350	NEW	91-02-094	419-18-030	AMD-P	91-03-106
392-122-115	REP	91-03-118	392-140-351	NEW	91-02-094	419-18-030	AMD	91-06-062
392-122-120	AMD	91-03-118	392-140-352	NEW	91-02-094	419-18-040	AMD-P	91-03-106
392-122-125	REP	91-03-118	392-140-353	NEW	91-02-094	419-18-040	AMD	91-06-062
392-122-145	AMD	91-03-118	392-140-354	NEW	91-02-094	419-18-050	AMD-P	91-03-106
392-122-165	NEW	91-03-118	392-140-355	NEW	91-02-094	419-18-050	AMD	91-06-062
392-122-200	AMD	91-03-118	392-140-356	NEW	91-02-094	419-18-060	AMD-P	91-03-106
392-122-206	NEW	91-03-118	392-140-357	NEW	91-02-094	419-18-060	AMD	91-06-062
392-122-210	AMD	91-03-118	392-140-358	NEW	91-02-094	419-18-070	AMD-P	91-03-106
392-122-215	REP	91-03-118	392-140-359	NEW	91-02-094	419-18-070	AMD	91-06-062
392-122-230	AMD	91-03-118	392-140-360	NEW	91-02-094	434-42-900	NEW-P	91-03-125



Table of WAC Sections Affected

WAC #	WSR #	WAC #	WSR #	WAC #	WSR #			
434-42-900	NEW-E	91-03-126	446-75-020	NEW-P	91-07-045	448-13-050	NEW	91-06-022
434-42-900	REP-E	91-07-002	446-75-020	NEW-E	91-07-046	448-13-060	NEW-S	91-03-123
434-42-900	NEW-W	91-07-003	446-75-030	NEW-P	91-07-045	448-13-060	NEW	91-06-022
434-42-905	NEW-P	91-03-125	446-75-030	NEW-E	91-07-046	448-13-070	NEW-S	91-03-123
434-42-905	NEW-E	91-03-126	446-75-040	NEW-P	91-07-045	448-13-070	NEW	91-06-022
434-42-905	REP-E	91-07-002	446-75-040	NEW-E	91-07-046	448-13-080	NEW-S	91-03-123
434-42-905	NEW-W	91-07-003	446-75-050	NEW-P	91-07-045	448-13-080	NEW	91-06-022
434-42-910	NEW-P	91-03-125	446-75-050	NEW-E	91-07-046	448-13-090	NEW-S	91-03-123
434-42-910	NEW-E	91-03-126	446-75-060	NEW-P	91-07-045	448-13-090	NEW	91-06-022
434-42-910	REP-E	91-07-002	446-75-060	NEW-E	91-07-046	448-13-100	NEW-S	91-03-123
434-42-910	NEW-W	91-07-003	446-75-070	NEW-P	91-07-045	448-13-100	NEW	91-06-022
434-42-915	NEW-P	91-03-125	446-75-070	NEW-E	91-07-046	448-13-110	NEW-S	91-03-123
434-42-915	NEW-E	91-03-126	446-75-080	NEW-P	91-07-045	448-13-110	NEW	91-06-022
434-42-915	REP-E	91-07-002	446-75-080	NEW-E	91-07-046	448-13-120	NEW-S	91-03-123
434-42-915	NEW-W	91-07-003	448-12-010	REP-S	91-03-123	448-13-120	NEW	91-06-022
434-42-920	NEW-P	91-03-125	448-12-010	REP	91-06-022	448-13-130	NEW-S	91-03-123
434-42-920	NEW-E	91-03-126	448-12-015	REP-S	91-03-123	448-13-130	NEW	91-06-022
434-42-920	REP-E	91-07-002	448-12-015	REP	91-06-022	448-13-140	NEW-S	91-03-123
434-42-920	NEW-W	91-07-003	448-12-016	REP-S	91-03-123	448-13-140	NEW	91-06-022
434-42-925	NEW-P	91-03-125	448-12-016	REP	91-06-022	448-13-150	NEW-S	91-03-123
434-42-925	NEW-E	91-03-126	448-12-020	REP-S	91-03-123	448-13-150	NEW	91-06-022
434-42-925	REP-E	91-07-002	448-12-020	REP	91-06-022	448-13-160	NEW-S	91-03-123
434-42-925	NEW-W	91-07-003	448-12-030	REP-S	91-03-123	448-13-160	NEW	91-06-022
434-42-930	NEW-P	91-03-125	448-12-030	REP	91-06-022	448-13-170	NEW-S	91-03-123
434-42-930	NEW-E	91-03-126	448-12-040	REP-S	91-03-123	448-13-170	NEW	91-06-022
434-42-930	REP-E	91-07-002	448-12-040	REP	91-06-022	448-13-180	NEW-S	91-03-123
434-42-930	NEW-W	91-07-003	448-12-050	REP-S	91-03-123	448-13-180	NEW	91-06-022
434-42-935	NEW-P	91-03-125	448-12-050	REP	91-06-022	448-13-190	NEW-S	91-03-123
434-42-935	NEW-E	91-03-126	448-12-055	REP-S	91-03-123	448-13-190	NEW	91-06-022
434-42-935	REP-E	91-07-002	448-12-055	REP	91-06-022	448-13-200	NEW-S	91-03-123
434-42-935	NEW-W	91-07-003	448-12-060	REP-S	91-03-123	448-13-200	NEW	91-06-022
434-42-940	NEW-P	91-03-125	448-12-060	REP	91-06-022	448-13-210	NEW-S	91-03-123
434-42-940	NEW-E	91-03-126	448-12-070	REP-S	91-03-123	448-13-210	NEW	91-06-022
434-42-940	REP-E	91-07-002	448-12-070	REP	91-06-022	448-13-220	NEW-S	91-03-123
434-42-940	NEW-W	91-07-003	448-12-075	REP-S	91-03-123	448-13-220	NEW	91-06-022
434-42-945	NEW-P	91-03-125	448-12-075	REP	91-06-022	448-14-010	REP-P	91-03-124
434-42-945	NEW-E	91-03-126	448-12-080	REP-S	91-03-123	448-14-020	REP-P	91-03-124
434-42-945	REP-E	91-07-002	448-12-080	REP	91-06-022	448-14-030	REP-P	91-03-124
434-42-945	NEW-W	91-07-003	448-12-090	REP-S	91-03-123	448-15-010	NEW-P	91-03-124
434-42-950	NEW-P	91-03-125	448-12-090	REP	91-06-022	448-15-020	NEW-P	91-03-124
434-42-950	NEW-E	91-03-126	448-12-100	REP-S	91-03-123	448-15-030	NEW-P	91-03-124
434-42-950	REP-E	91-07-002	448-12-100	REP	91-06-022	448-15-040	NEW-P	91-03-124
434-42-950	NEW-W	91-07-003	448-12-210	REP-S	91-03-123	448-15-050	NEW-P	91-03-124
434-42-955	NEW-P	91-03-125	448-12-210	REP	91-06-022	448-15-060	NEW-P	91-03-124
434-42-955	NEW-E	91-03-126	448-12-220	REP-S	91-03-123	448-15-070	NEW-P	91-03-124
434-42-955	REP-E	91-07-002	448-12-220	REP	91-06-022	448-15-080	NEW-P	91-03-124
434-42-955	NEW-W	91-07-003	448-12-230	REP-S	91-03-123	456-09-210	AMD-P	91-04-084
434-42-960	NEW-P	91-03-125	448-12-230	REP	91-06-022	456-09-210	AMD	91-07-038
434-42-960	NEW-E	91-03-126	448-12-240	REP-S	91-03-123	456-09-325	AMD-P	91-04-084
434-42-960	REP-E	91-07-002	448-12-240	REP	91-06-022	456-09-325	AMD	91-07-038
434-42-960	NEW-W	91-07-003	448-12-250	REP-S	91-03-123	456-09-365	AMD-P	91-04-084
434-42-965	NEW-P	91-03-125	448-12-250	REP	91-06-022	456-09-365	AMD	91-07-038
434-42-965	NEW-E	91-03-126	448-12-260	REP-S	91-03-123	456-10-360	AMD-P	91-04-083
434-42-965	REP-E	91-07-002	448-12-260	REP	91-06-022	456-10-360	AMD	91-07-039
434-42-965	NEW-W	91-07-003	448-12-270	REP-S	91-03-123	456-10-547	NEW-P	91-04-083
434-42-970	NEW-P	91-03-125	448-12-270	REP	91-06-022	456-10-547	NEW	91-07-039
434-42-970	NEW-E	91-03-126	448-12-280	REP-S	91-03-123	458-14-010	REP	91-07-040
434-42-970	REP-E	91-07-002	448-12-280	REP	91-06-022	458-14-020	REP	91-07-040
434-42-970	NEW-W	91-07-003	448-12-290	REP-S	91-03-123	458-14-030	REP	91-07-040
434-42-975	NEW-P	91-03-125	448-12-290	REP	91-06-022	458-14-040	REP	91-07-040
434-42-975	NEW-E	91-03-126	448-12-300	REP-S	91-03-123	458-14-045	REP	91-07-040
434-42-975	REP-E	91-07-002	448-12-300	REP	91-06-022	458-14-050	REP	91-07-040
434-42-975	NEW-W	91-07-003	448-12-320	REP-S	91-03-123	458-14-052	REP	91-07-040
434-42-980	NEW-P	91-03-125	448-12-320	REP	91-06-022	458-14-055	REP	91-07-040
434-42-980	NEW-E	91-03-126	448-12-330	REP-S	91-03-123	458-14-060	REP	91-07-040
434-42-980	REP-E	91-07-002	448-12-330	REP	91-06-022	458-14-062	REP	91-07-040
434-42-980	NEW-W	91-07-003	448-12-340	REP-S	91-03-123	458-14-065	REP	91-07-040
434-42-985	NEW-P	91-03-125	448-12-340	REP	91-06-022	458-14-070	REP	91-07-040
434-42-985	NEW-E	91-03-126	448-13-010	NEW-S	91-03-123	458-14-075	REP	91-07-040
434-42-985	REP-E	91-07-002	448-13-010	NEW	91-06-022	458-14-080	REP	91-07-040
434-42-985	NEW-W	91-07-003	448-13-020	NEW-S	91-03-123	458-14-085	REP	91-07-040
446-65-005	NEW-E	91-06-050	448-13-020	NEW	91-06-022	458-14-086	REP	91-07-040
446-65-005	NEW	91-06-066	448-13-030	NEW-S	91-03-123	458-14-090	REP	91-07-040
446-65-010	NEW-E	91-06-050	448-13-030	NEW	91-06-022	458-14-091	REP	91-07-040
446-65-010	NEW	91-06-066	448-13-040	NEW-S	91-03-123	458-14-092	REP	91-07-040
446-75-010	NEW-P	91-07-045	448-13-040	NEW	91-06-022	458-14-094	REP	91-07-040
446-75-010	NEW-E	91-07-046	448-13-050	NEW-S	91-03-123	458-14-098	REP	91-07-040



Table of WAC Sections Affected

WAC #		WSR #	WAC #		WSR #	WAC #		WSR #
458-14-100	REP	91-07-040	460-31A-645	REP	91-04-012	460-46A-110	AMD	91-04-011
458-14-110	REP	91-07-040	460-31A-650	REP	91-04-012	463-06-010	AMD	91-03-090
458-14-115	REP	91-07-040	460-31A-655	REP	91-04-012	463-10-010	AMD	91-03-090
458-14-120	REP	91-07-040	460-31A-660	REP	91-04-012	463-14-030	AMD	91-03-090
458-14-121	REP	91-07-040	460-31A-665	REP	91-04-012	463-14-080	AMD	91-03-090
458-14-122	REP	91-07-040	460-31A-670	REP	91-04-012	463-18-020	AMD	91-03-090
458-14-125	REP	91-07-040	460-31A-675	REP	91-04-012	463-26-120	AMD	91-03-090
458-14-126	REP	91-07-040	460-31A-680	REP	91-04-012	463-26-130	AMD	91-03-090
458-14-130	REP	91-07-040	460-31A-685	REP	91-04-012	463-28-060	AMD	91-03-090
458-14-135	REP	91-07-040	460-31A-690	REP	91-04-012	463-28-080	AMD	91-03-090
458-14-140	REP	91-07-040	460-31A-695	REP	91-04-012	463-38-041	AMD	91-03-090
458-14-145	REP	91-07-040	460-31A-700	REP	91-04-012	463-38-042	AMD	91-03-090
458-14-150	REP	91-07-040	460-31A-705	REP	91-04-012	463-38-063	AMD	91-03-090
458-14-152	REP	91-07-040	460-31A-710	REP	91-04-012	463-39-130	REP	91-03-090
458-14-155	REP	91-07-040	460-31A-715	REP	91-04-012	463-39-150	AMD	91-03-090
458-20-109	PREP	91-03-057	460-31A-720	REP	91-04-012	463-42-680	NEW-P	91-03-132
458-20-110	PREP	91-03-058	460-31A-725	REP	91-04-012	463-43-060	AMD	91-03-090
458-20-126	PREP	91-04-062	460-31A-730	REP	91-04-012	463-47-060	AMD	91-03-090
458-20-151	PREP	91-04-061	460-34A-010	REP	91-04-012	463-50-030	AMD	91-03-090
458-20-163	AMD	91-05-040	460-34A-015	REP	91-04-012	463-54-070	AMD	91-03-090
458-20-227	AMD	91-05-039	460-34A-020	REP	91-04-012	463-58-030	AMD	91-03-090
458-20-237	AMD	91-05-038	460-34A-025	REP	91-04-012	468-16-010	NEW	91-04-014
458-30-262	AMD	91-04-001	460-34A-030	REP	91-04-012	468-16-020	NEW	91-04-014
458-40-660	AMD-P	91-06-052	460-34A-035	REP	91-04-012	468-16-030	NEW	91-04-014
458-40-660	AMD-E	91-06-053	460-34A-037	REP	91-04-012	468-16-040	NEW	91-04-014
460-16A-102	AMD	91-04-008	460-34A-040	REP	91-04-012	468-16-050	NEW	91-04-014
460-16A-200	NEW	91-04-008	460-34A-045	REP	91-04-012	468-16-060	NEW	91-04-014
460-16A-205	NEW	91-04-008	460-34A-050	REP	91-04-012	468-16-070	NEW	91-04-014
460-17A-030	AMD	91-04-009	460-34A-055	REP	91-04-012	468-16-080	NEW	91-04-014
460-17A-070	AMD	91-04-009	460-34A-060	REP	91-04-012	468-16-090	NEW	91-04-014
460-31A-410	REP	91-04-012	460-34A-065	REP	91-04-012	468-16-100	NEW	91-04-014
460-31A-415	REP	91-04-012	460-34A-070	REP	91-04-012	468-16-110	NEW	91-04-014
460-31A-420	REP	91-04-012	460-34A-075	REP	91-04-012	468-16-120	NEW	91-04-014
460-31A-425	REP	91-04-012	460-34A-080	REP	91-04-012	468-16-130	NEW	91-04-014
460-31A-430	REP	91-04-012	460-34A-085	REP	91-04-012	468-16-140	NEW	91-04-014
460-31A-435	REP	91-04-012	460-34A-090	REP	91-04-012	468-16-150	NEW	91-04-014
460-31A-440	REP	91-04-012	460-34A-095	REP	91-04-012	468-16-160	NEW	91-04-014
460-31A-445	REP	91-04-012	460-34A-100	REP	91-04-012	468-16-170	NEW	91-04-014
460-31A-450	REP	91-04-012	460-34A-105	REP	91-04-012	468-16-180	NEW	91-04-014
460-31A-455	REP	91-04-012	460-34A-110	REP	91-04-012	468-16-190	NEW	91-04-014
460-31A-460	REP	91-04-012	460-34A-112	REP	91-04-012	468-16-200	NEW	91-04-014
460-31A-465	REP	91-04-012	460-34A-115	REP	91-04-012	468-16-210	NEW	91-04-014
460-31A-470	REP	91-04-012	460-34A-120	REP	91-04-012	468-38-035	REP-P	91-06-078
460-31A-475	REP	91-04-012	460-34A-125	REP	91-04-012	468-38-050	AMD-P	91-06-078
460-31A-480	REP	91-04-012	460-34A-130	REP	91-04-012	468-38-190	AMD-P	91-06-079
460-31A-485	REP	91-04-012	460-34A-135	REP	91-04-012	468-38-260	AMD-P	91-06-078
460-31A-490	REP	91-04-012	460-34A-200	REP	91-04-012	468-38-370	REP-P	91-06-078
460-31A-495	REP	91-04-012	460-36A-100	REP	91-04-012	468-38-400	REP-P	91-06-078
460-31A-500	REP	91-04-012	460-36A-105	REP	91-04-012	468-38-410	REP-P	91-06-078
460-31A-505	REP	91-04-012	460-36A-110	REP	91-04-012	478-116-020	AMD-P	91-06-092
460-31A-510	REP	91-04-012	460-36A-115	REP	91-04-012	478-116-055	AMD-P	91-06-092
460-31A-515	REP	91-04-012	460-36A-120	REP	91-04-012	478-116-080	AMD-P	91-06-092
460-31A-520	REP	91-04-012	460-36A-125	REP	91-04-012	478-116-085	REP-P	91-06-092
460-31A-525	REP	91-04-012	460-36A-130	REP	91-04-012	478-116-088	NEW-P	91-06-092
460-31A-530	REP	91-04-012	460-36A-135	REP	91-04-012	478-116-090	AMD-P	91-06-092
460-31A-535	REP	91-04-012	460-36A-140	REP	91-04-012	478-116-110	AMD-P	91-06-092
460-31A-540	REP	91-04-012	460-36A-145	REP	91-04-012	478-116-130	AMD-P	91-06-092
460-31A-545	REP	91-04-012	460-36A-150	REP	91-04-012	478-116-160	AMD-P	91-06-092
460-31A-550	REP	91-04-012	460-36A-155	REP	91-04-012	478-116-210	AMD-P	91-06-092
460-31A-555	REP	91-04-012	460-36A-160	REP	91-04-012	478-116-230	AMD-P	91-06-092
460-31A-560	REP	91-04-012	460-36A-165	REP	91-04-012	478-116-240	AMD-P	91-06-092
460-31A-565	REP	91-04-012	460-36A-170	REP	91-04-012	478-116-250	AMD-P	91-06-092
460-31A-570	REP	91-04-012	460-36A-175	REP	91-04-012	478-116-260	AMD-P	91-06-092
460-31A-575	REP	91-04-012	460-36A-180	REP	91-04-012	478-116-300	AMD-P	91-06-092
460-31A-580	REP	91-04-012	460-36A-185	REP	91-04-012	478-116-360	AMD-P	91-06-092
460-31A-585	REP	91-04-012	460-36A-190	REP	91-04-012	478-116-390	AMD-P	91-06-092
460-31A-590	REP	91-04-012	460-36A-195	REP	91-04-012	478-116-450	AMD-P	91-06-092
460-31A-595	REP	91-04-012	460-42A-081	AMD	91-04-010	478-116-455	NEW-P	91-06-092
460-31A-600	REP	91-04-012	460-46A-020	AMD	91-04-011	478-116-463	NEW-P	91-06-092
460-31A-605	REP	91-04-012	460-46A-040	AMD	91-04-011	478-116-470	AMD-P	91-06-092
460-31A-610	REP	91-04-012	460-46A-050	AMD	91-04-011	478-116-520	AMD-P	91-06-092
460-31A-615	REP	91-04-012	460-46A-055	NEW	91-04-011	478-116-540	AMD-P	91-06-092
460-31A-620	REP	91-04-012	460-46A-061	NEW	91-04-011	478-116-584	AMD-P	91-06-092
460-31A-625	REP	91-04-012	460-46A-065	NEW	91-04-011	478-116-586	AMD-P	91-06-092
460-31A-630	REP	91-04-012	460-46A-071	NEW	91-04-011	478-116-588	AMD-P	91-06-092
460-31A-635	REP	91-04-012	460-46A-072	NEW	91-04-011	478-116-600	REP-P	91-06-092
460-31A-640	REP	91-04-012	460-46A-095	AMD	91-04-011	478-116-601	AMD-P	91-06-092

Table of WAC Sections Affected

WAC #	WSR #	WAC #	WSR #		
478-124-020	AMD-P	91-05-069	480-120-410	NEW	91-03-052
478-124-030	AMD-P	91-05-069	480-120-415	NEW	91-03-052
478-250-010	NEW-P	91-04-058	480-120-420	NEW	91-03-052
478-250-020	NEW-P	91-04-058	480-120-425	NEW	91-03-052
478-250-050	NEW-P	91-04-058	480-120-430	NEW	91-03-052
478-250-060	NEW-P	91-04-058	480-120-435	NEW	91-03-052
478-250-070	NEW-P	91-04-058	480-140-020	AMD-P	91-03-099
478-276-010	AMD-P	91-04-058	480-140-040	AMD-P	91-03-099
478-276-040	AMD-P	91-04-058	490-100-010	AMD-E	91-03-037
478-276-060	AMD-P	91-04-058	490-100-010	AMD-P	91-05-077
478-276-080	AMD-P	91-04-058	490-100-012	REP-E	91-03-037
478-276-100	AMD-P	91-04-058	490-100-012	REP-P	91-05-077
478-276-110	AMD-P	91-04-058	490-100-030	AMD-E	91-03-037
478-276-130	REP-P	91-04-058	490-100-030	AMD-P	91-05-077
480-04-100	AMD-P	91-03-098	490-100-035	AMD-E	91-03-037
480-04-100	AMD	91-07-025	490-100-035	AMD-P	91-05-077
480-09-015	AMD-P	91-02-105	490-100-040	AMD-E	91-03-037
480-09-015	AMD	91-06-010	490-100-040	AMD-P	91-05-077
480-09-100	AMD-P	91-02-105	490-100-050	AMD-E	91-03-037
480-09-100	AMD	91-06-010	490-100-050	AMD-P	91-05-077
480-09-120	AMD-P	91-02-105	490-100-060	AMD-E	91-03-037
480-09-120	AMD	91-06-010	490-100-060	AMD-P	91-05-077
480-09-125	NEW-P	91-03-100	490-100-070	AMD-E	91-03-037
480-09-125	NEW	91-07-026	490-100-070	AMD-P	91-05-077
480-09-440	AMD-P	91-02-105	490-100-080	AMD-E	91-03-037
480-09-440	AMD	91-06-010	490-100-080	AMD-P	91-05-077
480-09-500	AMD-P	91-02-105	490-100-090	AMD-E	91-03-037
480-09-500	AMD	91-06-010	490-100-090	AMD-P	91-05-077
480-09-510	AMD-P	91-02-105	490-100-100	AMD-E	91-03-037
480-09-510	AMD	91-06-010	490-100-100	AMD-P	91-05-077
480-09-520	NEW-P	91-03-097	490-100-105	AMD-E	91-03-037
480-09-520	NEW	91-07-024	490-100-105	AMD-P	91-05-077
480-09-610	AMD-P	91-02-105	490-100-110	AMD-E	91-03-037
480-09-610	AMD	91-06-010	490-100-110	AMD-P	91-05-077
480-09-736	AMD-P	91-02-105	490-100-120	AMD-E	91-03-037
480-09-736	AMD	91-06-010	490-100-120	AMD-P	91-05-077
480-12-030	AMD-P	91-06-009	490-100-130	AMD-E	91-03-037
480-12-033	AMD-P	91-06-009	490-100-130	AMD-P	91-05-077
480-12-315	REP	91-06-071	490-100-135	NEW-E	91-03-037
480-12-500	NEW	91-03-101	490-100-135	NEW-P	91-05-077
480-12-510	NEW	91-03-101	490-100-140	AMD-E	91-03-037
480-12-520	NEW	91-03-101	490-100-140	AMD-P	91-05-077
480-70-050	AMD	91-03-053	490-100-150	AMD-E	91-03-037
480-70-060	AMD	91-03-053	490-100-150	AMD-P	91-05-077
480-70-070	AMD	91-03-053	490-100-160	AMD-E	91-03-037
480-70-100	AMD	91-03-053	490-100-160	AMD-P	91-05-077
480-70-130	AMD	91-03-053	490-100-170	AMD-E	91-03-037
480-70-150	AMD	91-03-053	490-100-170	AMD-P	91-05-077
480-70-230	AMD	91-03-053	490-100-180	AMD-E	91-03-037
480-70-260	AMD	91-03-053	490-100-180	AMD-P	91-05-077
480-70-280	AMD	91-03-053	490-100-200	AMD-E	91-03-037
480-70-330	AMD	91-03-053	490-100-200	AMD-P	91-05-077
480-70-340	AMD	91-03-053	490-100-205	AMD-E	91-03-037
480-70-350	AMD	91-03-053	490-100-205	AMD-P	91-05-077
480-70-360	AMD	91-03-053	490-100-208	AMD-E	91-03-037
480-70-390	AMD	91-03-053	490-100-208	AMD-P	91-05-077
480-70-400	AMD	91-03-053	490-100-210	AMD-E	91-03-037
480-70-405	AMD	91-03-053	490-100-210	AMD-P	91-05-077
480-70-420	AMD	91-03-053	490-100-220	AMD-E	91-03-037
480-70-440	AMD	91-03-053	490-100-220	AMD-P	91-05-077
480-70-500	AMD	91-03-053	490-100-250	AMD-E	91-03-037
480-70-570	AMD	91-03-053	490-100-250	AMD-P	91-05-077
480-80-047	NEW-P	91-03-051	516-13-030	AMD-W	91-04-082
480-80-047	NEW-W	91-03-120	516-13-080	AMD-W	91-04-082
480-80-047	NEW-P	91-03-121			
480-80-390	AMD-P	91-03-096			
480-80-390	AMD-W	91-07-023			
480-120-021	AMD-S	91-03-122			
480-120-031	AMD-P	91-06-095			
480-120-106	AMD-S	91-03-122			
480-120-126	AMD-P	91-06-095			
480-120-136	AMD-P	91-06-095			
480-120-137	AMD-P	91-06-095			
480-120-138	AMD-S	91-03-122			
480-120-141	AMD-S	91-03-122			
480-120-400	NEW	91-03-052			
480-120-405	NEW	91-03-052			

**Subject/Agency Index**  
(Citations in **bold type** refer to material in this issue)

<b>ACCOUNTANCY, BOARD OF</b>		<b>ATTORNEY GENERAL'S OFFICE—cont.</b>	
Public records index	91-01-055	property tax payment, credit card use (1991, No. 2)	91-04-013
Superseded rules, repeal of	91-01-057	Public Disclosure Act	91-06-054
<b>AGRICULTURE, DEPARTMENT OF</b>		radioactive materials transport (1991, No. 1)	91-03-085
Apple maggot quarantine	91-01-045	small business export finance assistance center, public meetings and records (1991, No. 5)	91-05-057
Apple marketing standards	91-03-115	Rules coordinator	91-01-086
Apple moth quarantine repeal	91-03-093		
Aquaculture	<b>91-07-015</b>	<b>BELLEVEUE COMMUNITY COLLEGE</b>	
farm products identification, labeling	<b>91-07-036</b>	Meetings	91-03-061
Asparagus commission	91-04-076	<b>BLIND, WASHINGTON STATE SCHOOL FOR THE</b>	
creation, powers, and duties	91-01-104	Rules coordinator	91-02-044
Barley commission		<b>BUILDING CODE COUNCIL</b>	
producer assessment funds		Barrier-free facilities	
expenditure of	91-01-100	solicitation of preproposal comments	91-05-053
Bean seed certification standards, quarantine	91-04-066	Day care facilities for children	91-01-117
Blueberry assessments	91-01-054	Energy code	91-01-112
Chrysanthemum white rust disease		Historic buildings code	91-06-065
quarantine	91-03-046	Long-term residential care facilities, construction requirement	91-01-103
Desiccants and defoliant, rules	91-04-078	solicitation of preproposal comment	91-06-064
Fertilizers		Meetings	<b>91-07-020</b>
fertigation equipment requirements	91-01-015	Radon requirements and monitoring	91-01-101
Garlic seed certification	91-04-068	Uniform codes	<b>91-07-047</b>
Herbicides		solicitation of preproposal comments	<b>91-07-020</b>
phenoxy herbicides, use of	91-02-106	Ventilation and indoor air quality code	91-05-021
	91-06-019		91-01-102
Hops		<b>CENTRAL WASHINGTON UNIVERSITY</b>	
rootstock certification	91-04-067	Rules coordinator	91-01-049
disease quarantine	91-04-067	Student judicial code	
Narcissus bulb nematode quarantine repeal	<b>91-07-037</b>	due process for students in regard to alleged violations	91-01-013
Noxious weed control board			91-01-095
noxious weed list, additions, deletions, and changes	91-01-016		91-04-054
Organic foods		<b>CLEMENCY AND PARDONS BOARD</b>	
crop production standards	91-05-006	Meetings	91-01-027
processing certification and labeling	91-05-006		91-03-040
registration of materials			91-05-096
approved for production	91-01-116	<b>CODE REVISER'S OFFICE</b>	
	91-05-007	Rules coordinator	91-01-001
transition to organic producer certification	91-05-006	WAC amendments and repealers	91-06-067
Plum curculio quarantine	91-01-045	<b>COLUMBIA BASIN COLLEGE</b>	
Potato virus Y necrotic strain	91-06-035	Sex discrimination, grievance procedures	91-02-101
Rules coordinator	91-03-020	<b>COMMUNITY COLLEGE EDUCATION, BOARD FOR</b>	
Seed potato certification	91-06-061	Retirement annuity plan participation	91-06-069
Seed potato quarantine	91-03-105	Running start program	91-06-075
	<b>91-07-016</b>	<b>COMMUNITY DEVELOPMENT, DEPARTMENT OF</b>	
Swine		Border areas, supplemental law enforcement for	91-04-017
pseudorabies control and eradication	91-05-076	Daycare centers	91-06-020
Wheat commission		fire protection standards	91-06-021
producer assessment funds		Emergency management council meetings	91-02-023
expenditure of	91-01-099	Fire protection policy board meetings	91-03-048
	91-05-065		91-05-017
Yellow nutsedge quarantine	91-03-045	Fire protection services division fire safety standards	91-05-018
<b>ASIAN AMERICAN AFFAIRS, COMMISSION ON</b>		Homelessness, advisory council on, duties	91-06-023
Meetings	91-01-058	Land classification, guidelines for classification of agricultural, forest, mineral resource, and critical areas lands	91-01-129
<b>ATTORNEY GENERAL'S OFFICE</b>			91-01-130
Motor vehicle warranties			<b>91-07-041</b>
finances for noncompliance with arbitration decision	91-02-080		
Opinions			
apprenticeship council, authority of (1990, No. 17)	91-02-001		
Bush Act tidelands, clam cultivation (1991, No. 8)	<b>91-07-022</b>		
ecological commission, advisory role (1991, No. 4)	91-05-003		
freeholder elections, first class cities (1991, No. 3)	91-04-053		
motor vehicle, forfeited, use by state (1991, No. 10)	<b>91-07-043</b>		
property tax assistance payments (1991, No. 7)	<b>91-07-001</b>		

**Subject/Agency Index**  
(Citations in bold type refer to material in this issue)

<b>COMMUNITY DEVELOPMENT, DEPARTMENT OF</b>		<b>ECOLOGY, DEPARTMENT OF—cont.</b>	
—cont.		Medina, city of	91-01-131
Meetings	91-06-031	ocean management	91-04-069
	<b>91-07-017</b>	Ocean Shores, city of	91-03-144
Public works board		Okanogan, city of	91-03-147
meetings	91-02-003	Oroville, town of	91-03-146
Rules coordinator	91-04-006	Pierce County	91-03-143
<b>CONVENTION AND TRADE CENTER</b>		San Juan County	91-04-072
Meetings	91-01-012		91-05-063
	91-03-012		91-06-094
	91-03-041	Tonasket, town of	91-03-148
	91-05-013	Tumwater, city of	91-04-079
	91-06-036	Twisp, town of	91-04-070
	<b>91-07-009</b>	Winthrop, town of	91-04-071
<b>CORRECTIONS, DEPARTMENT OF</b>		Solid and hazardous waste management	
Rules coordinator	91-06-011	coordinated prevention grants	91-02-052
<b>CRIMINAL JUSTICE TRAINING COMMISSION</b>		Solid fuel burning devices	
Corrections academy		increase in retail sales fees	<b>91-07-066</b>
equivalency or "challenge" process	91-01-041	sale and use of	<b>91-07-066</b>
physical fitness standard for recruits	91-01-044	Solid waste disposal facilities,	
D.A.R.E. program		operator certification	91-01-093
certification and decertification of		Underground storage tanks program	91-04-022
officers	91-01-042	Waste	
Law enforcement academy		dangerous waste regulation	<b>91-07-005</b>
physical fitness standard for admission		Wastewater	
to basic academy	91-01-043	discharge permit fees	
Meetings	91-03-003	solicitation of preproposal comment	91-01-019
		system developed	91-03-080
<b>DEAF, WASHINGTON STATE SCHOOL</b>		Water	
<b>FOR THE</b>		highway runoff quality enhancement	91-04-091
Rules coordinator	91-02-045	Water resource situations strategy	91-04-080
<b>DEFERRED COMPENSATION, COMMITTEE FOR</b>		Wells	
Description	91-02-098	drilling restrictions	91-04-073
	91-05-084	<b>EDMONDS COMMUNITY COLLEGE</b>	
Public records, access to and copying of	91-02-098	Athletes, loss of eligibility for	
	91-05-084	unlawful drug use, procedure	91-05-012
<b>EASTERN WASHINGTON UNIVERSITY</b>		Meetings	91-03-110
Rules coordinator	91-02-043		91-05-050
<b>ECOLOGY, DEPARTMENT OF</b>			<b>91-07-044</b>
Air pollution		<b>EDUCATION, STATE BOARD OF</b>	
sources	91-05-064	Accreditation of schools	91-01-068
toxic air pollutants discharge,			91-01-128
control of	91-01-083	Certification	91-04-015
Aluminum plants, control and prevention		instructional specialist certificate	91-01-092
of air pollutant emissions	91-05-064		91-05-056
Batteries		internship certificate	91-01-092
vehicle battery recycling	91-05-020		91-05-056
Drought relief, emergency	91-02-099	limited certificate	91-01-092
	91-03-081		91-05-056
Gasoline vapor control requirements	91-02-107	Environmental education, interdisciplinary	
Ground water management		study of	91-01-067
general schedule	91-05-100	High school credit for courses taken by	
Island County	91-06-096	students in grades 7 and 8	91-01-066
West Snohomish County	91-03-102	Meetings	91-04-050
	91-05-099	Professional certification	
Walla Walla County	91-03-103	reprimand or certificate suspension	
	91-05-098	or revocation	91-05-024
Hazardous waste		Teacher school day requirement	91-05-068
dangerous waste regulation	<b>91-07-005</b>	Title 28A RCW, amendments to conform	
generators	91-03-139	to recodification of title	91-01-091
Kraft pulping mills, control and prevention			91-04-016
of air pollutant emissions	91-05-064	<b>EMPLOYMENT SECURITY DEPARTMENT</b>	
Model Toxics Control Act		Eligibility determination	91-03-054
cleanup, identification and investigation,		Employer notices	91-03-054
processes and standards	91-04-019	Family independent program,	
Ocean management	91-05-042	see <b>FAMILY INDEPENDENCE PROGRAM</b>	
Rules coordinator	91-03-025	Rules coordinator	91-03-055
Sediment management standards	91-01-052	<b>ENERGY FACILITY SITE EVALUATION COUNCIL</b>	
	91-03-094	Meetings	91-02-077
	91-06-098	Site restoration standards	91-03-132
Shoreline master programs		<b>ENERGY OFFICE</b>	
Chelan County	91-02-112	Terminology, revision of obsolete	
Island County	91-03-145	language	91-03-090
King County	91-03-149		
Klickitat County	91-03-141		

**Subject/Agency Index**  
(Citations in bold type refer to material in this issue)

<b>ENGINEER AND LAND SURVEYORS</b>		<b>FOREST PRACTICES BOARD—cont.</b>	
License renewals	91-07-064	Watershed screening and analysis solicitation of preproposal comment	91-07-030
<b>EVERETT COMMUNITY COLLEGE</b>		<b>GAMBLING COMMISSION</b>	
Meetings	91-02-047	Adjudicative proceedings	91-03-063
Rules coordinator	91-03-079	Amusement games, operation at regional shopping centers	91-05-047 91-06-008 91-06-039
<b>EVERGREEN STATE COLLEGE, THE</b>			
Meetings	91-02-054		
<b>FAMILY INDEPENDENCE PROGRAM</b>			
Benefits suspension, termination, or reduction advance notice	91-07-068	Fund raising events, providing food and beverages to volunteers	91-03-049 91-05-044 91-05-046 91-05-047 91-06-008 91-06-039
Child care eligibility to support employment and training	91-01-061		
Income disregard	91-05-008 91-05-009		
Management plan, implementation of second stage	91-01-062 91-04-041 91-05-058 91-05-010 91-05-008 91-05-009 91-01-060	Prizes	91-05-047 91-06-008 91-06-039 <b>91-07-018</b> <b>91-07-051</b> 91-05-045
Medical programs eligibility		Pull tab dispensing devices	
Meetings		Pull tab series, assembly, packaging, and operation	91-03-049 91-05-044 91-05-046 91-05-047 91-06-008 91-06-039 91-07-021 <b>91-07-042</b> 91-03-049 91-05-044 91-05-046 91-05-047 91-06-008 91-06-039
<b>FISHERIES, DEPARTMENT OF</b>			
<u>Commercial</u>			
bottomfish		Recreational gaming activities	
coastal bottomfish catch limits	91-01-018 91-01-023 91-01-050 91-01-094 91-03-152 <b>91-07-050</b> 91-05-037 91-05-102 91-05-102	Washington blackjack	
seasons			
crabs, seasons and areas			
crawfish, areas			
fish buyers, reporting date for fish receiving tickets	91-01-005 91-05-015 91-03-108 91-03-083 91-04-029 91-04-031		
licensing rules amended regulations		<b>GENERAL ADMINISTRATION, DEPARTMENT OF</b>	
salmon		Flood mitigation standards	
Columbia River below Bonneville, seasons	91-05-005 91-05-036 91-05-102 91-05-102 91-05-005 91-05-036	state agencies	91-05-101
sea cucumber seasons		Parking fees and payments	91-04-081
sea urchin seasons		Rules coordinator	91-03-060
shad, Columbia River harvest		Savings and loan association, division of credit union examination and supervision fees and charges	91-03-106 91-06-062
sturgeon seasons		savings and loan examination and supervision fees	91-03-107 91-06-063
Columbia River below Bonneville	91-05-005 91-05-036 91-02-108 91-05-016	<b>GOVERNOR, OFFICE OF THE</b>	
spawn on kelp auction		HIV/AIDS advisory council established	<b>91-07-004</b>
<u>Personal use</u>		Homelessness, council on	91-06-023
clams, hardshell		Low-income housing tax credit, federal, allocation of	91-02-053
areas and seasons	91-01-069 91-02-021 91-02-076	Timber export restrictions, implementation of federal legislation	91-02-111
oysters		<b>GRAYS HARBOR COLLEGE</b>	
areas and seasons	91-01-069 91-06-057 91-03-153 91-04-030 91-06-057	Athletes, loss of eligibility for unlawful drug use	91-05-033
rules amended		<b>GREEN RIVER COMMUNITY COLLEGE</b>	
salmon		Meetings	91-03-004
areas and seasons	91-03-151	<b>HARDWOODS COMMISSION</b>	
<b>FOREST PRACTICES BOARD</b>		(See <b>TRADE AND ECONOMIC DEVELOPMENT, DEPARTMENT OF</b> )	
Forest practices subject to environmental review under SEPA and SEPA rules	91-07-034 <b>91-07-012</b>	<b>HEALTH, BOARD OF</b>	
Meetings		(See <b>HEALTH, DEPARTMENT OF</b> )	
		<b>HEALTH CARE AUTHORITY</b>	
		Appeals process established	91-04-087
		Organ transplant programs, requirements	91-05-079

**Subject/Agency Index**  
(Citations in **bold type** refer to material in this issue)

<b>HEALTH CARE AUTHORITY—cont.</b>			
State employee benefits board plans, dependent parent, continued coverage on self-pay basis, qualification for	91-04-086		
<b>HEALTH, DEPARTMENT OF</b>			
Certificate of need, transfer of	91-01-075 91-05-093		
Chiropractic disciplinary board			
professional procedures	91-06-090		
rules coordinator	91-01-020		
transfer of rules to Title 246 WAC	91-05-095		
Chiropractic examining board			
rules coordinator	91-01-020		
transfer of rules to Title 246 WAC	91-05-026		
Dental disciplinary board			
discrimination prohibited as unprofessional conduct	91-03-109		
rules coordinator	91-01-020		
transfer of rules to Title 246 WAC	91-02-048		
Dental examiners, board of			
transfer of rules to Title 246 WAC	91-01-007		
Drug manufacturing or storage sites, illegal, contractor certification for decontamination of	91-04-007		
Emergency medical services			
emergency medical technicians, certification and recertification requirements	91-02-013		
training requirements	91-06-026		
Environmental Policy Act (SEPA) rules	91-02-050		
Fees	91-02-050		
Health, board of			
drug manufacturing or storage sites, illegal, contractor certification for decontamination of	91-04-007		
infants, screening for congenital disorders	91-01-032		
rules coordinator	91-01-020		
public water systems, volatile organic chemical monitoring requirements	91-07-031		
transfer of rules to Title 246 WAC	91-02-051		
Hearing aid council			
defamation of competitors	91-07-057 91-07-059		
rules coordinator	91-01-020		
personal disclosure	91-07-057 91-07-059		
transfer of rules to Title 246 WAC	91-07-058		
HIV and AIDS training and record-keeping requirements	91-06-026		
Hospital charity care, procedures, data collection, criteria for identifying indigent persons, and penalties for noncompliance	91-05-048		
Hospital pharmacy standards	91-05-049		
Massage board			
rules coordinator	91-01-020		
transfer of rules to Title 246 WAC	91-01-077		
Medical disciplinary board			
rules coordinator	91-01-020		
transfer of rules to Title 246 WAC	91-02-012		
Medical examiners, board of			
examination scores	91-01-074 91-06-038		
meetings	91-02-061		
physician assistants			
prescriptions	91-04-055		
prescription writing	91-04-033		
rules coordinator	91-01-020		
transfer of rules to Title 246 WAC	91-01-076 91-06-030		
Nursing, board of			
AIDS education requirement for nurses obtaining interstate endorsement	91-07-032		
nurse technicians, definition and function of	91-07-067		
rules coordinator	91-01-020		
<b>HEALTH, DEPARTMENT OF—cont.</b>			
transfer of rules to Title 246 WAC			91-07-049
Nursing home administrators, board of examiners for			
inactive license fee		91-05-025	
inactive license status		91-02-058 91-06-059	
rules coordinator		91-01-020	
transfer of rules to Title 246 WAC		91-02-059 91-06-060	
Nursing homes			
bed need standards		91-02-010	
Occupational therapy practice, board for educational programs		91-05-088	
licensure requirements		91-05-088	
rules coordinator		91-01-020	
transfer of rules to Title 246 WAC		91-05-027	
Opticians			
rules updating		91-05-087	
continuing education requirements		91-05-087	
Optometry board			
rules coordinator		91-01-020	
transfer of rules to Title 246 WAC		91-03-116 91-06-025	
Osteopathic medicine and surgery			
board of			
examination procedures		91-03-117	
rules coordinator		91-01-020	
substance abuse monitoring programs		91-03-117	
Pharmacy, board of			
animal control agencies, legend			
drug use regulation		91-04-056	
transfer of rules to Title 246 WAC		91-06-037	
humane societies, legend			
drug use regulation		91-04-056	
rules coordinator		91-01-020	
internship requirements		91-05-091	
nonprescription drugs, tampered products detection information		91-07-056	
prescriptions, out-of-state			
practitioners		91-05-090	
pharmacy assistant/pharmacist ratio		91-05-092	
tampered products detection information		91-07-056	
Physician assistants			
prescription writing		91-04-033	
Physical therapy licensure requirements		91-05-094	
Physical therapy, board of			
licensing fees		91-05-004	
rules coordinator		91-01-020	
transfer of rules to Title 246 WAC		91-02-011	
Podiatric medical board			
inactive license		91-05-089	
license renewals		91-05-089	
reciprocity requirements		91-05-089	
rules coordinator		91-01-020	
terminology		91-05-089	
Practical nursing board			
rules coordinator		91-01-020	
transfer of rules to Title 246 WAC		91-01-078	
Psychology, examining board of			
continuing education		91-04-021	
licensing requirements and procedures			
meetings		91-04-021 91-06-024	
rules coordinator		91-01-020	
Rules coordinator		91-01-020	
Rules, transfer to Title 246 WAC		91-03-095 91-04-020 91-05-028 91-05-029 91-05-030 91-05-031 91-06-027 91-06-028 91-06-058 91-07-048	

## Subject/Agency Index

(Citations in **bold type** refer to material in this issue)

<b>HEALTH, DEPARTMENT OF—cont.</b>		<b>LABOR AND INDUSTRIES, DEPARTMENT OF</b>	
Rural health care facilities, licensing standards	91-02-014	Agricultural safety standards	91-04-077
Sex offender treatment providers	91-06-091	Apprenticeship and training council meetings	91-04-038
Transfer of rules to Title 246 WAC	91-02-049	Boiler rules, board of meetings	91-01-107 91-03-086 91-05-062
Veterinary board of governors rules coordinator	91-01-020	Construction safety standards	91-04-077
transfer of rules to Title 246 WAC	91-02-060	Crime victim compensation repressed memory of criminal act, rights of victim with	91-01-065 91-04-027
Women, infant children program client access	91-06-029	Electrical board meetings	91-03-076
<b>HIGHER EDUCATION COORDINATING BOARD</b>		Explosives safety standards	91-01-026
American Indian endowed scholarship program	91-03-087	Firefighters safety standards	91-01-026 91-04-077
Contract issuance procedures, 1991-93	91-04-045	Grain handling facilities safety standards	91-04-077
Displaced homemaker program administration	91-01-053	Longshore, stevedore operations safety standards	91-04-077
Environmental Policy Act (SEPA) notice of action taken	91-01-124 91-01-125	Occupational health standards general standards	91-01-026 91-03-043 91-01-026
<b>HIGHER EDUCATION, JOINT CENTER FOR</b>		Passenger vessel safety standards	91-01-026
Meetings	91-03-002	Prevailing wage filing fees	91-01-017
<b>HIGHER EDUCATION PERSONNEL BOARD</b>		terms and procedures used to determine, for public works projects	91-03-113
Appointments	91-02-039 91-05-055 91-05-060	Safety and health standards general standards	91-01-026 91-03-044 91-04-077
Hearing examiners	91-02-039 91-05-055 91-05-060	Travel expenses injured workers	91-03-114
Meetings	91-02-041 91-06-014 91-02-040	Worker's compensation health care services, payment for	91-01-123 <b>91-07-008</b> 91-02-063 91-02-064 91-02-114
Rules coordinator	91-02-040	medical aid rules	
Salary reallocation	91-05-052 91-06-077 <b>91-07-060</b>	rules, classifications, rates and rating system revisions	<b>91-07-061</b>
Work period designations	<b>91-07-060</b>	<b>LEGAL FOUNDATION OF WASHINGTON</b>	
Workers' compensation return-to-work policy	91-02-038 91-05-054 91-05-059	Meetings	91-06-001
<b>HORSE RACING COMMISSION</b>		<b>LICENSING, DEPARTMENT OF</b>	
Claiming races, next start requirements, horses claimed but not processed	91-03-064	Architecture "design-build" definition	91-06-012
Owner's license, use of facsimile application and trainer as agent	91-03-033	solicitation of preproposal comment	91-02-046
<b>HUMAN RIGHTS COMMISSION</b>		Camping resorts	91-01-082
Meetings	91-01-087 91-01-088 91-02-002 91-02-035 91-02-102 91-04-063 91-04-064 91-06-072	Cosmetology, barber and manicurist rules	91-05-080
<b>INDETERMINATE SENTENCE REVIEW BOARD</b>		Court reporters, licensing requirements	91-03-065
Rules coordinator	91-03-067	Engineers and land surveyors fees	<b>91-07-065</b>
<b>INFORMATION SERVICES, DEPARTMENT OF</b>		license renewals	<b>91-07-065</b>
Public records access	91-04-090 <b>91-07-033</b>	seals solicitation of preproposal comment	91-05-041 91-05-078
<b>INSURANCE COMMISSIONER</b>		new seal required, design	91-06-018
Fees and assessments, clarification	91-04-057 <b>91-07-053</b>	use definition	91-05-078 91-06-018
Life and disability insurance, out-of-state group contracts, unfair practices	91-03-073	Funeral directors and embalmers preneed renewal fees	91-01-006
Rate standards	91-01-073	Motor vehicle excise tax rules	91-04-026
Rules coordinator	91-02-009	Motor vehicles advertising and pricing practices of dealers, prohibited practices	91-03-019
<b>INTEREST RATES</b>		certificate of inspection	91-04-024
(See inside front cover)		disclosure of vehicle owner names and addresses	91-03-088
<b>INVESTMENT BOARD</b>			
Meetings	91-02-015		
<b>JUDICIAL CONDUCT, COMMISSION ON</b>			
Public records access	91-01-126 91-04-060 91-01-002		
Rules coordinator	91-01-002		

**Subject/Agency Index**  
(Citations in bold type refer to material in this issue)

<b>LICENSING, DEPARTMENT OF—cont.</b>			
drivers' licenses			
waiver of driving test for new resident with valid license from previous home state	91-01-063		
higher education institutions license plate emblems, criteria to obtain	91-03-091		
license plates, special	91-04-025		
parking tickets outstanding, information to be supplied by jurisdiction	91-04-024		
proportional registration of fleet vehicles	91-02-109		
	91-02-110		
	91-06-093		
special license plates and emblems, criteria to obtain	91-03-091		
title, "guaranteed title" defined	91-03-092		
veterans license plate emblems	91-03-091		
	91-04-025		
Public records indexing systems	<b>91-07-028</b>		
Real estate appraiser certification	91-04-074		
Real estate commission			
course approval	91-03-047		
	<b>91-07-029</b>		
examination grading	91-03-047		
	<b>91-07-029</b>		
instructor qualifications	91-03-047		
	<b>91-07-029</b>		
meetings	91-02-078		
Rules coordinator	91-03-006		
Securities division			
cattle feeding programs	91-04-012		
commodity pools	91-04-012		
corporate limited offering exemption	91-04-011		
debt offering standards	91-04-008		
equipment programs	91-04-012		
exchange and national market system exemption from registration	91-04-010		
oil and gas programs	91-04-012		
promotional shares	91-04-008		
real estate investment trusts	91-04-012		
uniform limited offering registration (ULOR-C)	91-04-009		
Special fuel tax rules			
power tax off use	91-03-017		
	91-03-018		
Vessel registration			
owner's names and addresses, disclosure of	91-03-089		
<b>LIQUOR CONTROL BOARD</b>			
Advertising of liquor	91-03-007		
	91-04-085		
Beer			
label requirements	91-05-086		
Conduct on licensed premises, regulation	91-05-085		
<b>LOTTERY COMMISSION</b>			
Instant game number 20 through instant game number 39, repeal	91-03-034		
<u>Instant game number 59 – Lucky Draw</u>			
criteria	91-03-036		
definitions	91-03-036		
<u>Instant game number 61 – Triple Play</u>			
criteria	91-03-036		
definitions	91-03-036		
ticket validation	91-03-036		
<u>Instant game number 62 – Roulette</u>			
criteria	91-03-112		
	91-06-074		
definitions	91-03-112		
	91-06-074		
ticket validation	91-03-112		
	91-06-074		
<u>Instant game number 63 – Lucky 7's</u>			
criteria	91-03-112		
	91-06-074		
<b>LOTTERY COMMISSION—cont.</b>			
definitions		91-03-112	
		91-06-074	
ticket validation		91-03-112	
		91-06-074	
<u>Instant game number 64 – Playday</u>			
criteria		<b>91-07-070</b>	
definitions		<b>91-07-070</b>	
ticket validation		<b>91-07-070</b>	
<u>Instant game number 65 – Touchdown</u>			
criteria		<b>91-07-070</b>	
definitions		<b>91-07-070</b>	
ticket validation		<b>91-07-070</b>	
<u>Instant game number 66 – Tumbling Dice</u>			
criteria		<b>91-07-070</b>	
definitions		<b>91-07-070</b>	
ticket validation		<b>91-07-070</b>	
Prizes, payment of		91-03-036	
Public records index		91-03-035	
		91-03-036	
<b>LOWER COLUMBIA COLLEGE</b>			
Meetings		91-02-037	
		91-03-005	
<b>MARITIME COMMISSION</b>			
Assessments, rates and terms		91-02-005	
Meetings		91-02-004	
Rules coordinator		91-04-028	
<b>MINORITY AND WOMEN'S BUSINESS ENTERPRISES, OFFICE OF</b>			
Meetings		91-05-097	
<b>NATURAL RESOURCES, DEPARTMENT OF</b>			
Forest practices board			
meetings		91-02-066	
rules coordinator		91-02-065	
Geographic names, board on			
rules coordinator		91-01-106	
Natural heritage advisory council			
meetings		91-01-089	
Rules coordinator		91-01-108	
<b>OIL AND GAS CONSERVATION COMMITTEE</b>			
Meetings		91-01-072	
<b>OUTDOOR RECREATION, INTERAGENCY COMMITTEE FOR</b>			
Meetings		91-01-003	
		91-04-032	
		91-06-070	
		91-03-011	
Rules coordinator			
<b>PARKS AND RECREATION COMMISSION</b>			
Alcohol consumption in state parks, enforcement		91-03-140	
		<b>91-07-014</b>	
Fee changes		91-03-142	
Meetings		91-01-051	
Rules coordinator		91-01-084	
<b>PENINSULA COLLEGE</b>			
Meetings		91-01-009	
<b>PERSONNEL BOARD</b>			
Applications, time limits on filing of		91-02-029	
Appointment status, transfer upwards		91-02-032	
		91-03-070	
Correctional officers caring for law enforcement dogs, special pay range		91-02-025	
		91-05-083	
Examinations, waiver of minimum qualifications		91-02-034	
		91-03-071	
In-training positions		91-02-030	
Leave sharing program		91-02-024	
		91-05-082	
		<b>91-07-055</b>	
Noncompetitive service		91-02-033	
		91-03-068	
		91-05-081	



**Subject/Agency Index**  
(Citations in **bold type** refer to material in this issue)

<b>PERSONNEL BOARD—cont.</b>			
Promotional testing	91-02-028		
Public records, inspection and copying of	91-02-027		
Reexaminations	91-02-026		
Standby compensation	91-02-031		
	91-03-069		
Work period designations	91-04-046		
	<b>91-07-054</b>		
<b>PERSONNEL, DEPARTMENT OF</b>			
Registers, removal of candidate's name for cause	91-01-111		
Rules coordinator	91-02-016		
Trial service, revision for failure to perform adequately	91-01-110		
<b>PIERCE COLLEGE</b>			
Meetings	91-01-010		
	91-06-088		
Rules coordinator	91-04-049		
Student rights and responsibilities	91-03-084		
	91-03-150		
<b>PHARMACY, BOARD OF</b>			
(See <b>HEALTH, DEPARTMENT OF</b> )			
<b>PILOTAGE COMMISSIONERS, BOARD OF</b>			
Pilot applications			
qualification to take 1991 exam	91-01-090		
Pilotage rates			
Grays Harbor	91-03-075		
Retirement disbursements	91-02-062		
	91-06-033		
<b>POLLUTION CONTROL HEARINGS BOARD</b>			
Practice and procedure rules	91-03-027		
	91-03-028		
Public records	91-03-027		
	91-03-028		
<b>PRODUCTIVITY BOARD</b>			
Rules coordinator	91-03-111		
<b>PROFESSIONAL ATHLETIC COMMISSION</b>			
Boxing rules	91-05-032		
Wrestling rules	91-05-032		
<b>PUBLIC DISCLOSURE COMMISSION</b>			
Lobbyist employers, political contribution reporting form	91-06-034		
Public office fund	<b>91-07-027</b>		
<b>PUBLIC INSTRUCTION, SUPERINTENDENT OF</b>			
Absent students, reporting requirements	91-02-096		
Allocations			
procedures for allocating state moneys to school districts	91-03-118		
salary	91-02-097		
Allocations, special 1990-91			
early intervention services	91-04-089		
procedures for allocating state moneys to school districts	91-03-118		
Alternative instructional programs, eligibility	<b>91-07-062</b>		
Basic education allocation, withholding for repayment of federal moneys	<b>91-07-006</b>		
Bilingual instruction program, transitional	<b>91-07-062</b>		
Buses			
operation procedures	91-03-074		
school bus operating rules	91-06-032		
Educational service districts			
budgeting procedures	91-03-050		
	<b>91-07-063</b>		
	91-03-119		
Excellence in education awards			
Federal moneys, monetary and nonmonetary audit findings, resolution procedures	91-03-001		
	<b>91-07-007</b>		
Federal moneys, withholding from basic education allocation for repayment of	<b>91-07-006</b>		
Handicapped students, definitions and independent educational assessment of	91-01-033		
<b>PUBLIC INSTRUCTION, SUPERINTENDENT OF</b>			
—cont.			
Running start program		91-03-129	
		91-04-088	
Salary allocations		91-02-097	
Staff ratio enhancements, grades K-3		91-02-094	
Transcripts, provision to indigent persons		91-02-095	
<b>PUGET SOUND WATER QUALITY AUTHORITY</b>			
Meetings		91-01-011	
Nonpoint source pollution, local plannings solicitation of preproposal comments		91-05-066	
Rules coordinator		91-05-067	
<b>RETIREMENT SYSTEMS, DEPARTMENT OF</b>			
Actuarial tables, schedules, and factors			
law enforcement officers' and fire fighters' retirement system		91-02-019	
overdue payments, interest charges		91-06-089	
public employees' retirement system		91-02-018	
teachers' retirement system		91-02-020	
Survivor benefit options			
judicial retirement system		91-03-013	
law enforcement and firefighters		91-03-014	
public employee's retirement system		91-03-015	
teachers' retirement system		91-03-016	
<b>REVENUE, DEPARTMENT OF</b>			
Addresses of department district offices		91-01-113	
		91-05-038	
		91-04-001	
Agricultural land valuation			
Business and occupation tax			
community antenna television services, reporting of advertising income		91-01-114	
		91-05-039	
insurance companies, health insurance pool deductions to be deducted from the measure of the B&O tax		91-01-115	
		91-05-040	
real estate, lease, rental, or license to use, tax status		91-02-056	
		91-02-057	
Equalization, county boards of revised chapter relating to		<b>91-07-040</b>	
Finance charges, carrying charges, interest, and penalties			
solicitation of preproposal comment		91-03-057	
Freight and delivery charges			
solicitation of preproposal comment		91-03-058	
Medical service providers, tax reporting solicitation of preproposal comment		91-04-061	
Motor vehicle fuel and special fuel sales solicitation of preproposal comment		91-04-062	
Open Space Taxation Act rules			
agricultural land valuation		91-04-001	
Property tax			
annual ratio study		91-01-008	
Rule-making procedure			
solicitation of preproposal comment		91-04-061	
		91-04-062	
Rules coordinator		91-01-028	
Sales tax			
collection schedules		91-01-113	
Timber excise tax			
stumpage values		91-02-088	
		91-02-089	
		91-06-052	
		91-06-053	
<b>RULES COORDINATORS</b>			
Agriculture, department of		91-03-020	
Attorney general		91-01-086	
Blind, Washington State School for the		91-02-044	
Central Washington University		91-01-049	
Chiropractic disciplinary board		91-01-020	
Chiropractic examining board		91-01-020	
Code reviser		91-01-001	
Community development, department of		91-04-006	
Corrections, department of		91-06-011	

**Subject/Agency Index**  
(Citations in **bold type** refer to material in this issue)

**RULES COORDINATORS—cont.**

Deaf, Washington State School for the  
Dental disciplinary board 91-02-045  
Dental examiners, board of 91-01-020  
Eastern Washington University 91-01-020  
Ecology, department of 91-02-043  
Employment security department 91-03-025  
Everett Community College 91-03-055  
Forest practices board 91-03-079  
General administration, department of 91-02-065  
Geographic names, board on 91-03-060  
Health, board of 91-01-106  
Health, department of 91-01-020  
Hearing aids council 91-01-020  
Higher education personnel board 91-02-040  
Indeterminate sentence review board 91-03-067  
Insurance commissioner, office of 91-02-009  
Judicial conduct commission 91-01-002  
Licensing, department of 91-03-006  
Maritime commission 91-04-028  
Massage board 91-01-020  
Medical disciplinary board 91-01-020  
Medical examiners, board of 91-01-020  
Natural resources, department of 91-01-108  
Nursing, board of 91-01-020  
Nursing home administrators, board  
of examiners for 91-01-020  
Occupational therapy practice, board of 91-01-020  
Optometry board 91-01-020  
Osteopathic medicine and surgery board 91-01-020  
Outdoor recreation, interagency  
committee for 91-03-011  
Parks and recreation commission 91-01-084  
Personnel, department of 91-02-016  
Pharmacy, board of 91-01-020  
Physical therapy board 91-01-020  
Pierce College 91-04-049  
Podiatric medical board 91-01-020  
Practical nursing board 91-01-020  
Productivity board 91-03-111  
Psychology, examining board of 91-01-020  
Puget Sound water quality authority 91-05-067  
Revenue, department of 91-01-028  
Social and health services, department of 91-01-118  
Tax appeals, board of 91-02-103  
Trade and economic development,  
department of 91-03-088  
Transportation commission 91-03-078  
Transportation, department of 91-03-009  
Transportation improvement board 91-04-051  
University of Washington 91-03-056  
Veterinary board of governors 91-01-020  
Washington State University 91-05-022

**SEATTLE COMMUNITY COLLEGES**

Meetings 91-01-024  
91-03-023  
91-03-104  
91-06-068

**SECRETARY OF STATE**

Public record home and work address  
information protection for  
endangered persons 91-03-125  
91-03-126  
**91-07-002**  
**91-07-003**

**SHORELINE COMMUNITY COLLEGE**

Meetings 91-03-024

**SKAGIT VALLEY COLLEGE**

Meetings 91-01-071

**SOCIAL AND HEALTH SERVICES,  
DEPARTMENT OF**

Adult family homes  
complaints 91-05-070  
inspections 91-05-070

**SOCIAL AND HEALTH SERVICES,**

**DEPARTMENT OF—cont.**

Aid to families with dependent children  
assistance standards 91-02-072  
91-02-075  
benefits suspension, termination,  
or reduction advance notice **91-07-068**  
fifty dollars disregard payment 91-06-097  
income and resources disregard 91-02-083  
91-02-084  
91-05-008  
91-05-009  
91-06-007  
loans, when treated as income  
or resource 91-01-029  
91-01-047  
medical programs eligibility 91-05-008  
91-05-009  
overpayments, mandatory grant deductions  
to recover 91-03-039  
91-04-047  
91-06-055  
Child care  
family day care homes, licensing  
requirements 91-04-048  
Children  
institutionalized  
parent income and resources 91-05-034  
91-05-035  
Chore services program 91-04-039  
Day care  
family child day care homes  
licensing requirements 91-02-017  
91-03-038  
91-03-127  
91-03-128  
**91-07-013**  
Developmentally disabled  
adult protective services,  
eligibility for 91-01-096  
Disaster relief  
individual and family grant  
program eligibility 91-02-081  
Emergency assistance 91-01-030  
91-02-071  
Family independence program, see  
**FAMILY INDEPENDENCE PROGRAM**  
Food stamp program  
aliens eligibility **91-07-069**  
household status for temporarily  
disabled persons 91-05-074  
income exclusions 91-01-120  
91-02-067  
91-02-068  
91-02-073  
91-06-004  
91-04-035  
91-04-036  
standard utility allowance  
student participant in work study  
program, eligibility 91-05-075  
telephone standard allowance 91-04-035  
91-04-036  
work requirements 91-05-071  
91-05-072  
91-05-073  
Funeral and internment services, vendor  
payment increases 91-02-082  
91-02-085  
91-06-005  
General assistance  
benefits suspension, termination,  
or reduction advance notice **91-07-068**  
Hospitals  
inpatient and outpatient services  
payment 91-06-044  
91-06-049  
91-06-056

**Subject/Agency Index**  
(Citations in **bold type** refer to material in this issue)

<b>SOCIAL AND HEALTH SERVICES, DEPARTMENT OF—cont.</b>		<b>SOCIAL AND HEALTH SERVICES, DEPARTMENT OF—cont.</b>	
Job opportunities and basic skills training program (JOBS)	91-02-092 91-02-093 91-04-042 91-04-043	Women, infants, and children (WIC) program food vendor participation	91-01-079 91-01-119 91-01-097 91-01-098
support services	91-02-086 91-02-087	transfer of rules to Title 246 WAC	
Medicaid		<b>SOUTH PUGET SOUND COMMUNITY COLLEGE</b>	
pregnant women eligibility	91-06-043 91-06-047	Meetings	91-06-002
Medical assistance		<b>SPOKANE COMMUNITY COLLEGES</b>	
availability of resources	91-01-121	Meetings	91-02-036
benefits suspension, termination, or reduction advance notice	<b>91-07-068</b>	<b>SUPREME COURT</b>	
birth costs' collection	91-06-042 91-06-046	Admission and articulation to limited practice (Rule 18 for APR 12)	91-01-036
eligibility	91-02-069 91-02-074 91-06-003	Attorney fees	91-01-059
eligibility, community services office waiver of office interview	91-01-021 91-01-022 91-05-011	Dependents, separate cause numbers (AR3 and CrR 4.4 (c)(4))	91-01-038
hospital inpatient and outpatient payments	91-06-044 91-06-049 91-06-056	Discovery, scope and limits (CR 26(b))	91-01-040
medical care services administration	91-02-090 91-02-091 <b>91-07-011</b>	Presiding judges, more than one judge in superior court district (AR 4)	91-01-034
income levels	91-02-090 91-02-091 <b>91-07-011</b>	Trust accounts (RLD 13.4, RPC 1.14(c), RLD 1.1(j) and RLD Title 13)	91-01-037
Kitsap Physicians Service—Sound Care Plan	91-04-040 91-04-044 91-02-090 91-02-091 <b>91-07-011</b>	<b>TACOMA COMMUNITY COLLEGE</b>	
payment		Meetings	91-01-025
Pregnant women		<b>TAX APPEALS, BOARD OF</b>	
Medicaid/eligibility	91-06-043 91-06-047	Formal hearings, practice and procedure	91-04-083 91-04-084 <b>91-07-038</b> <b>91-07-039</b>
Psychiatric hospitals	91-06-041 91-06-045	Informal hearings, practice and procedure	91-04-083
Refugee assistance		Meetings	91-02-104
eligibility	91-01-122	Rules coordinator	91-02-103
Rules coordinator	91-01-118	<b>TOXICOLOGIST, STATE</b>	
Standards of assistance	91-02-072 91-02-075 91-06-041 91-06-045	Breath alcohol test program	91-03-123 91-06-022 91-03-124
State hospitals		Blood alcohol test regulations	
schedule of charges revision	91-04-034 91-04-037	<b>TRADE AND ECONOMIC DEVELOPMENT, DEPARTMENT OF</b>	
Supplemental security income, assistance standards	91-02-072 91-02-075	Business and job retention advisory committee	
Supplemental security income, state income disregard	91-05-008 91-05-009	meetings	91-03-032
medical programs eligibility	91-05-008 91-05-009	Community economic revitalization board	
supplementary programs	91-01-046	meetings	91-02-055 91-06-017
Support enforcement, office of birth costs liability	91-06-040 91-06-048	Economic development finance authority	
fifty dollars disregard payments	91-06-097	meetings	91-01-070
residential parent or payee, grievance resolution	91-04-002 91-04-003	Hardwoods commission	
Time loss payments to dependent child, recovery by office of financial recovery	91-01-031 91-01-048 91-02-070	meetings	91-01-127 91-03-026 <b>91-07-052</b> 91-03-008
		Rules coordinator	
		<b>TRAFFIC SAFETY COMMISSION</b>	
		Meetings	91-03-059
		<b>TRANSPORTATION COMMISSION</b>	
		Meetings	91-02-042 91-04-023 91-04-075 <b>91-07-035</b> 91-03-078
		Rules coordinator	
		<b>TRANSPORTATION, DEPARTMENT OF</b>	
		Contractors, prequalification of county ferry franchises, tolls and financial assistance	91-04-014
		Dishonored checks, recovery of collection costs	91-02-007
		Oversize load signs on vehicles, standards	91-06-079
		Rules coordinator	91-03-009
		Tow truck operations	91-06-078
		Traffic control devices, adoption of 1988 edition of uniform manual on (MUCTD)	91-02-008
		Urban arterial trust account monies	91-02-006

**Subject/Agency Index**  
(Citations in **bold type** refer to material in this issue)

<b>TRANSPORTATION IMPROVEMENT BOARD</b>		<b>VOCATIONAL EDUCATION, COUNCIL ON</b>	
Meetings	91-02-079	Meetings	91-04-004
	91-04-059		91-05-051
Rules coordinator	91-04-051	<b>WALLA WALLA COMMUNITY COLLEGE</b>	
<b>TREASURER</b>		Meetings	<b>91-07-010</b>
(See inside front cover)		<b>WASHINGTON INSTITUTE OF</b>	
Rules coordinator	91-03-077	<b>APPLIED TECHNOLOGY</b>	
<b>UNIVERSITY OF WASHINGTON</b>		Meetings	91-03-072
Alcohol and other prohibited substances			91-04-018
possession and use on campus or			91-05-023
at university-sponsored events			91-06-013
prohibition	91-05-069	<b>WASHINGTON STATE LIBRARY</b>	
use and possession at athletic events		Library commission	
and concerts, inspection procedures	91-01-004	meetings	91-01-014
Meetings	91-01-085		91-05-061
	91-02-100	<b>WASHINGTON STATE PATROL</b>	
	91-03-010	DNA identification systems and procedures	<b>91-07-045</b>
	91-03-021		<b>91-07-046</b>
	91-03-022	Motor helmets, exemption for operators	
	91-03-029	and riders of antique motorcycles	91-05-019
	91-03-030	Private carriers, adoption of federal	
	91-03-031	standards	91-01-105
	91-03-042		91-06-050
	91-04-005		91-06-066
	91-04-065	<b>WASHINGTON STATE UNIVERSITY</b>	
	91-05-014	Rules Coordinator	91-05-022
	91-06-073	<b>WESTERN WASHINGTON UNIVERSITY</b>	
Parking and traffic regulations	91-06-092	Bicycle traffic and parking regulation	91-04-082
Public records access	91-04-058	Parking and traffic	91-04-082
Rules coordinator	91-03-056	<b>WILDLIFE COMMISSION</b>	
<b>USURY</b>		Deleterious exotic wildlife	
(See inside front cover)		additions to list	91-03-082
<b>UTILITIES AND TRANSPORTATION COMMISSION</b>		Hunting seasons	
Budget reporting for major capital		Canada goose season, early closure	91-02-022
projects	91-03-099	snow goose season, early closure	91-01-064
Common carriers		upland game bird seasons	91-02-113
preservation of records of		<b>WILDLIFE, DEPARTMENT OF</b>	
communications	91-06-095	Coyote, classification	91-03-133
fees	91-06-009	Field identification, sex evidence	
Cost of copying and supplying public		definitions	91-06-080
records	91-03-098	Fishing	
	<b>91-07-025</b>	game fish seasons and catch limits	
Electric safety code, national	91-06-095	Cedar River	91-05-001
Extended area service routes	91-03-052	Lake Sammamish	91-05-001
Failure to file sufficient copies,		Lake Washington	91-05-001
cost of copying	91-03-100	Sammamish River	91-05-001
	<b>91-07-026</b>	Snake River	91-05-002
Interstate tariff filings, repeal of		Snoqualmie River	91-03-136
requirement	91-06-071	Tolt River	91-03-066
Log road classification	91-01-080		91-03-136
Procedures before the commission,		Forest grouse, classification	91-03-131
procedural rules	91-02-105	Game management units	91-03-130
	91-06-010	Hunting	
Recycling		blind and visually handicapped hunters	91-01-109
transportation of recovered materials	91-01-081		91-06-083
	91-03-101	firearm restriction areas	91-06-084
Solid waste collection companies	91-03-053		91-06-086
Telecommunications		hours, closure notices, and hound	
abbreviated proceedings for competitive		hunting areas	91-06-084
classification	91-03-097	hunter orange clothing requirements	91-03-137
	<b>91-07-024</b>	restrictions	91-06-081
access charges	91-03-051	Hunting seasons	
	91-03-120	bear and small game seasons,	
	91-03-121	1990-91	91-06-084
alternate operator services	91-03-122	bear 1991-92, 1992-93, 1993-94	91-03-138
mandatory cost changes	91-03-096	deerhunting seasons, 1990-91	91-06-084
	<b>91-07-023</b>	deerhunting seasons, 1991-92	91-06-087
	<b>91-07-024</b>	deerhunting seasons, opening 1991,	
	<b>91-07-024</b>	1992, and 1993	91-06-016
Uniform system of accounts	91-06-095	deer 1991-92, 1992-93, 1993-94	91-03-138
<b>VOCATIONAL EDUCATION, BOARD FOR</b>		elk	
Private vocational schools	91-01-056	seasons, opening dates, 1991,	
	91-03-037	1992, and 1993	91-06-016
	91-05-077	seasons, 1990-91	91-06-084
Meetings	91-04-052		
	91-06-076		

**Subject/Agency Index**  
(Citations in **bold type** refer to material in this issue)

<b>WILDLIFE, DEPARTMENT OF—cont.</b>	
seasons, 1991-92	91-06-087
elk 1991-92, 1992-93, 1993-94	91-03-135
general hunting seasons and rules 1991-92, 1992-93, 1993-94	91-03-134
mountain goat, sheep, moose, cougar, and lynx seasons	91-06-085
pelt sealing, river otter, cougar, lynx, and bobcat	91-06-082
special closure areas, 1991-92	91-06-086
turkey seasons	
1991 spring season	91-06-015
upland game bird seasons, opening dates, 1991, 1992, and 1993	91-06-016
Upland birds, classification	91-03-131





# WASHINGTON STATE REGISTER Subscriptions

---

To: Subscription Clerk  
WASHINGTON STATE REGISTER  
Code Reviser's Office  
Legislative Building  
Olympia, WA 98504

I would like to order \_\_\_\_\_ subscription(s) to the WASHINGTON STATE REGISTER, at an annual rate of \$161.85, sales tax included (\$150 for state agencies). Enclosed is my check or money order for \$\_\_\_\_\_. Please start my subscription with the January issue of 19\_\_\_\_\_.

NAME \_\_\_\_\_

ADDRESS \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

TELEPHONE \_\_\_\_\_

---

THE WASHINGTON STATE REGISTER, published pursuant to RCW 34.08.020, is distributed on the first and third Wednesdays of each month. The Register contains the full text of proposed, emergency, and permanently adopted rules of state agencies, executive orders of the governor, notices of public meetings of state agencies, rules of the state supreme court, summaries of attorney general opinions, and juvenile disposition standards which have been filed in the code reviser's office prior to the pertinent closing date for that issue of the Register. A cumulative table of existing sections of the Washington Administrative Code (WAC) affected by a particular agency action guides the user to the proper volume of the Register.

The code reviser's office has established an annual subscription price of \$150 for the Register, and single copies will cost \$7. Sales tax of 7.9% now applies to all sales other than to state agencies. State law requires payment in advance. To subscribe to the Register, please complete the order form above and forward it to the address indicated, accompanied by your check or money order in the amount of \$161.85 (\$150 for state agencies) payable to the code reviser's office.